1	Famotidine-associated	Famotidine-associated	B-NP	JJ	O	2	NMOD
2	delirium	delirium	I-NP	NN	O	0	ROOT
3	.	.	O	.	O	2	P

1	Famotidine	Famotidine	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	a	a	B-NP	DT	O	6	NMOD
4	histamine	histamine	I-NP	NN	O	6	NMOD
5	H2-receptor	H2-receptor	I-NP	NN	O	6	NMOD
6	antagonist	antagonist	I-NP	NN	O	2	PRD
7	used	use	B-VP	VBN	O	6	NMOD
8	in	in	B-PP	IN	O	7	VMOD
9	inpatient	inpatient	B-NP	NN	O	10	NMOD
10	settings	setting	I-NP	NNS	O	8	PMOD
11	for	for	B-PP	IN	O	7	VMOD
12	prevention	prevention	B-NP	NN	O	11	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	stress	stress	B-NP	NN	O	15	NMOD
15	ulcers	ulcer	I-NP	NNS	O	13	PMOD
16	and	and	O	CC	O	2	VMOD
17	is	be	B-VP	VBZ	O	2	VMOD
18	showing	show	I-VP	VBG	O	17	VC
19	increasing	increase	B-NP	VBG	O	20	NMOD
20	popularity	popularity	I-NP	NN	O	18	OBJ
21	because	because	B-PP	IN	O	18	VMOD
22	of	of	I-PP	IN	O	21	PMOD
23	its	its	B-NP	PRP$	O	25	NMOD
24	low	low	I-NP	JJ	O	25	NMOD
25	cost	cost	I-NP	NN	O	22	PMOD
26	.	.	O	.	O	2	P

1	Although	Although	B-SBAR	IN	O	0	ROOT
2	all	all	B-NP	DT	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	8	NMOD
5	currently	currently	I-NP	RB	O	6	AMOD
6	available	available	I-NP	JJ	O	8	NMOD
7	H2-receptor	H2-receptor	I-NP	NN	O	8	NMOD
8	antagonists	antagonist	I-NP	NNS	O	3	PMOD
9	have	have	B-VP	VBP	O	1	SBAR
10	shown	show	I-VP	VBN	O	9	VC
11	the	the	B-NP	DT	O	12	NMOD
12	propensity	propensity	I-NP	NN	O	21	NMOD
13	to	to	B-VP	TO	O	14	VMOD
14	cause	cause	I-VP	VB	O	12	NMOD
15	delirium	delirium	B-NP	NN	O	14	OBJ
16	,	,	O	,	O	12	P
17	only	only	B-NP	RB	O	12	NMOD
18	two	two	I-NP	CD	O	17	AMOD
19	previously	previously	I-NP	RB	O	17	AMOD
20	reported	report	I-NP	VBN	O	17	NMOD
21	cases	case	I-NP	NNS	O	10	OBJ
22	have	have	B-VP	VBP	O	9	VMOD
23	been	be	I-VP	VBN	O	22	VC
24	associated	associate	I-VP	VBN	O	23	VC
25	with	with	B-PP	IN	O	24	VMOD
26	famotidine	famotidine	B-NP	NN	O	25	PMOD
27	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	authors	author	I-NP	NNS	O	3	SUB
3	report	report	B-VP	VBP	O	0	ROOT
4	on	on	B-PP	IN	O	3	VMOD
5	six	six	B-NP	CD	O	6	NMOD
6	cases	case	I-NP	NNS	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	famotidine-associated	famotidine-associated	B-NP	JJ	O	9	NMOD
9	delirium	delirium	I-NP	NN	O	7	PMOD
10	in	in	B-PP	IN	O	6	NMOD
11	hospitalized	hospitalize	B-NP	VBN	O	12	NMOD
12	patients	patient	I-NP	NNS	O	10	PMOD
13	who	who	B-NP	WP	O	12	NMOD
14	cleared	clear	B-VP	VBD	O	13	SBAR
15	completely	completely	B-ADVP	RB	O	14	VMOD
16	upon	upon	B-PP	IN	O	14	VMOD
17	removal	removal	B-NP	NN	O	16	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	famotidine	famotidine	B-NP	NN	O	18	PMOD
20	.	.	O	.	O	3	P

1	Indomethacin	Indomethacin	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	hypotension	hypotension	B-NP	NN	O	2	OBJ
4	in	in	B-PP	IN	O	2	VMOD
5	sodium	sodium	B-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	volume	volume	I-NP	NN	O	9	NMOD
8	depleted	deplete	I-NP	VBN	O	9	NMOD
9	rats	rat	I-NP	NNS	O	4	PMOD
10	.	.	O	.	O	2	P

1	Late-onset	Late-onset	B-NP	JJ	O	4	NMOD
2	scleroderma	scleroderma	I-NP	NN	O	4	NMOD
3	renal	renal	I-NP	JJ	O	4	NMOD
4	crisis	crisis	I-NP	NN	O	13	NMOD
5	induced	induce	B-VP	VBN	O	4	NMOD
6	by	by	B-PP	IN	O	5	VMOD
7	tacrolimus	tacrolimus	B-NP	NN	O	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	prednisolone	prednisolone	I-NP	NN	O	6	PMOD
10	:	:	O	:	O	4	P
11	a	a	B-NP	DT	O	13	NMOD
12	case	case	I-NP	NN	O	13	NMOD
13	report	report	I-NP	NN	O	0	ROOT
14	.	.	O	.	O	13	P

1	Moderate	Moderate	B-ADJP	JJ	O	7	SUB
2	to	to	B-PP	TO	O	1	AMOD
3	high	high	B-NP	JJ	O	6	NMOD
4	dose	dose	I-NP	NN	O	6	NMOD
5	corticosteroid	corticosteroid	I-NP	NN	O	6	NMOD
6	use	use	I-NP	NN	O	2	PMOD
7	is	be	B-VP	VBZ	O	0	ROOT
8	recognized	recognize	I-VP	VBN	O	7	VC
9	as	as	B-PP	IN	O	8	VMOD
10	a	a	B-NP	DT	O	13	NMOD
11	major	major	I-NP	JJ	O	13	NMOD
12	risk	risk	I-NP	NN	O	13	NMOD
13	factor	factor	I-NP	NN	O	9	PMOD
14	for	for	B-PP	IN	O	13	NMOD
15	SRC	SRC	B-NP	NN	B-protein	14	PMOD
16	.	.	O	.	O	7	P

1	Furthermore	Furthermore	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	there	there	B-NP	EX	O	4	SUB
4	have	have	B-VP	VBP	O	0	ROOT
5	been	be	I-VP	VBN	O	4	VC
6	reports	report	B-NP	NNS	O	5	PRD
7	of	of	B-PP	IN	O	6	NMOD
8	thrombotic	thrombotic	B-NP	JJ	O	9	NMOD
9	microangiopathy	microangiopathy	I-NP	NN	O	7	PMOD
10	precipitated	precipitate	B-VP	VBN	O	9	NMOD
11	by	by	B-PP	IN	O	10	VMOD
12	cyclosporine	cyclosporine	B-NP	NN	O	11	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	patients	patient	B-NP	NNS	O	13	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	SSc	SSc	B-NP	NN	O	15	PMOD
17	.	.	O	.	O	4	P

1	In	In	B-PP	IN	O	6	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	article	article	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	6	P
5	we	we	B-NP	PRP	O	6	SUB
6	report	report	B-VP	VBP	O	0	ROOT
7	a	a	B-NP	DT	O	8	NMOD
8	patient	patient	I-NP	NN	O	6	OBJ
9	with	with	B-PP	IN	O	8	NMOD
10	SRC	SRC	B-NP	NN	B-protein	9	PMOD
11	induced	induce	B-VP	VBN	O	10	NMOD
12	by	by	B-PP	IN	O	11	VMOD
13	tacrolimus	tacrolimus	B-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	corticosteroids	corticosteroid	I-NP	NNS	O	12	PMOD
16	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	2	NMOD
2	risk	risk	I-NP	NN	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	associated	associate	B-VP	VBN	O	5	NMOD
5	factors	factor	B-NP	NNS	O	0	ROOT
6	of	of	B-PP	IN	O	5	NMOD
7	methamphetamine	methamphetamine	B-NP	NN	O	8	NMOD
8	psychosis	psychosis	I-NP	NN	O	6	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	methamphetamine-dependent	methamphetamine-dependent	B-NP	JJ	O	11	NMOD
11	patients	patient	I-NP	NNS	O	9	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	Malaysia	Malaysia	B-NP	NNP	O	12	PMOD
14	.	.	O	.	O	5	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	objective	objective	I-NP	NN	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	this	this	B-NP	DT	O	7	NMOD
7	study	study	I-NP	NN	O	5	PMOD
8	was	be	B-VP	VBD	O	1	NMOD
9	to	to	B-VP	TO	O	10	VMOD
10	determine	determine	I-VP	VB	O	8	PRD
11	the	the	B-NP	DT	O	12	NMOD
12	risk	risk	I-NP	NN	O	19	NMOD
13	of	of	B-PP	IN	O	12	NMOD
14	lifetime	lifetime	B-NP	NN	O	13	PMOD
15	and	and	O	CC	O	17	NMOD
16	current	current	B-NP	JJ	O	17	NMOD
17	methamphetamine	methamphetamine	I-NP	NN	O	19	NMOD
18	induced	induce	B-VP	VBD	O	19	NMOD
19	psychosis	psychosis	B-NP	NN	O	10	OBJ
20	in	in	B-PP	IN	O	19	NMOD
21	patients	patient	B-NP	NNS	O	20	PMOD
22	with	with	B-PP	IN	O	21	NMOD
23	methamphetamine	methamphetamine	B-NP	NN	O	24	NMOD
24	dependence	dependence	I-NP	NN	O	22	PMOD
25	.	.	O	.	O	8	P

1	The	The	B-NP	DT	O	2	NMOD
2	association	association	I-NP	NN	O	10	SUB
3	between	between	B-PP	IN	O	2	NMOD
4	psychiatric	psychiatric	B-NP	JJ	O	5	NMOD
5	co-morbidity	co-morbidity	I-NP	NN	O	9	NMOD
6	and	and	I-NP	CC	O	9	NMOD
7	methamphetamine	methamphetamine	I-NP	NN	O	9	NMOD
8	induced	induce	I-NP	VBN	O	9	NMOD
9	psychosis	psychosis	I-NP	NN	O	3	PMOD
10	was	be	B-VP	VBD	O	0	ROOT
11	also	also	I-VP	RB	O	10	VMOD
12	studied	study	I-VP	VBN	O	10	VC
13	.	.	O	.	O	10	P

1	I.	I.	B-LST	LS	O	0	ROOT
2	)	)	O	)	O	1	DEP
3	for	for	B-PP	IN	O	1	VMOD
4	methamphetamine	methamphetamine	B-NP	NN	O	5	SUB
5	induced	induce	B-VP	VBD	O	3	SBAR
6	psychosis	psychosis	B-NP	NN	O	12	NMOD
7	and	and	O	CC	O	12	NMOD
8	other	other	B-NP	JJ	O	12	NMOD
9	Axis	Axis	I-NP	NN	B-protein	12	NMOD
10	I	I	I-NP	CD	I-protein	12	NMOD
11	psychiatric	psychiatric	I-NP	JJ	O	12	NMOD
12	disorders	disorder	I-NP	NNS	O	5	OBJ
13	.	.	O	.	O	1	P

1	Co-morbid	Co-morbid	B-NP	JJ	O	4	NMOD
2	major	major	I-NP	JJ	O	4	NMOD
3	depressive	depressive	I-NP	JJ	O	4	NMOD
4	disorder	disorder	I-NP	NN	O	23	NMOD
5	(	(	O	(	O	10	DEP
6	OR=7.18	OR=7.18	B-NP	NN	O	9	NMOD
7	,	,	O	,	O	9	P
8	95	95	B-NP	CD	O	9	NMOD
9	CI=2.612-19.708	CI=2.612-19.708	I-NP	NN	O	10	DEP
10	)	)	O	)	O	4	NMOD
11	,	,	O	,	O	23	P
12	bipolar	bipolar	B-NP	JJ	O	13	NMOD
13	disorder	disorder	I-NP	NN	O	23	NMOD
14	(	(	O	(	O	19	DEP
15	OR=13.807	OR=13.807	B-NP	NN	O	18	NMOD
16	,	,	O	,	O	18	P
17	95	95	B-NP	CD	O	18	NMOD
18	CI=5.194-36.706	CI=5.194-36.706	I-NP	NN	O	19	DEP
19	)	)	O	)	O	13	NMOD
20	,	,	O	,	O	23	P
21	antisocial	antisocial	B-NP	JJ	O	23	NMOD
22	personality	personality	I-NP	NN	O	23	NMOD
23	disorder	disorder	I-NP	NN	O	33	NMOD
24	(	(	O	(	O	29	DEP
25	OR=12.619	OR=12.619	B-NP	NN	O	28	NMOD
26	,	,	O	,	O	28	P
27	95	95	B-NP	CD	O	28	NMOD
28	CI=6.702-23.759	CI=6.702-23.759	I-NP	NN	O	29	DEP
29	)	)	O	)	O	23	NMOD
30	and	and	O	CC	O	33	NMOD
31	heavy	heavy	B-NP	JJ	O	33	NMOD
32	methamphetamine	methamphetamine	I-NP	NN	O	33	NMOD
33	uses	use	I-NP	NNS	O	34	SUB
34	were	be	B-VP	VBD	O	0	ROOT
35	significantly	significantly	I-VP	RB	O	34	VMOD
36	associated	associate	I-VP	VBN	O	34	VC
37	with	with	B-PP	IN	O	36	VMOD
38	lifetime	lifetime	B-NP	NN	O	39	NMOD
39	methamphetamine	methamphetamine	I-NP	NN	O	41	NMOD
40	induced	induce	B-VP	VBD	O	39	AMOD
41	psychosis	psychosis	B-NP	NN	O	37	PMOD
42	after	after	B-SBAR	IN	O	34	VMOD
43	adjusted	adjust	B-VP	VBN	O	42	SBAR
44	for	for	B-PP	IN	O	43	VMOD
45	other	other	B-NP	JJ	O	46	NMOD
46	factors	factor	I-NP	NNS	O	44	PMOD
47	.	.	O	.	O	34	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	There	There	B-NP	EX	O	4	SUB
4	was	be	B-VP	VBD	O	1	NMOD
5	a	a	B-NP	DT	O	7	NMOD
6	high	high	I-NP	JJ	O	7	NMOD
7	risk	risk	I-NP	NN	O	4	PRD
8	of	of	B-PP	IN	O	7	NMOD
9	psychosis	psychosis	B-NP	NN	O	8	PMOD
10	in	in	B-PP	IN	O	4	VMOD
11	patients	patient	B-NP	NNS	O	10	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	methamphetamine	methamphetamine	B-NP	NN	O	14	NMOD
14	dependence	dependence	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	1	P

1	It	It	B-NP	PRP	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	associated	associate	I-VP	VBN	O	2	VC
4	with	with	B-PP	IN	O	3	VMOD
5	co-morbid	co-morbid	B-NP	JJ	O	7	NMOD
6	affective	affective	I-NP	JJ	O	7	NMOD
7	disorder	disorder	I-NP	NN	O	15	NMOD
8	,	,	O	,	O	15	P
9	antisocial	antisocial	B-NP	JJ	O	10	NMOD
10	personality	personality	I-NP	NN	O	15	NMOD
11	,	,	O	,	O	15	P
12	and	and	O	CC	O	15	NMOD
13	heavy	heavy	B-NP	JJ	O	15	NMOD
14	methamphetamine	methamphetamine	I-NP	NN	O	15	NMOD
15	use	use	I-NP	NN	O	4	PMOD
16	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	plasticity	plasticity	I-NP	NN	O	26	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	primary	primary	B-NP	JJ	O	6	NMOD
5	motor	motor	I-NP	NN	O	6	NMOD
6	cortex	cortex	I-NP	NN	O	3	PMOD
7	(	(	O	(	O	9	DEP
8	M1	M1	B-NP	NN	B-cell_line	9	DEP
9	)	)	O	)	O	6	NMOD
10	in	in	B-PP	IN	O	6	NMOD
11	patients	patient	B-NP	NNS	O	22	NMOD
12	with	with	B-PP	IN	O	11	NMOD
13	Parkinson	Parkinson	B-NP	NNP	O	14	NMOD
14	's	's	B-NP	POS	O	15	NMOD
15	disease	disease	I-NP	NN	O	12	PMOD
16	(	(	O	(	O	18	DEP
17	PD	PD	B-NP	NN	O	18	DEP
18	)	)	O	)	O	15	NMOD
19	and	and	O	CC	O	22	NMOD
20	levodopa	levodopa	B-NP	NN	O	22	NMOD
21	induced	induce	I-NP	VBN	O	22	NMOD
22	dyskinesias	dyskinesia	I-NP	NNS	O	10	PMOD
23	(	(	O	(	O	25	DEP
24	LIDs	LID	B-NP	NNS	O	25	DEP
25	)	)	O	)	O	22	NMOD
26	is	be	B-VP	VBZ	O	0	ROOT
27	severely	severely	B-ADJP	RB	O	26	VMOD
28	impaired	impaired	I-ADJP	JJ	O	26	PRD
29	.	.	O	.	O	26	P

1	The	The	B-NP	DT	O	2	NMOD
2	function	function	I-NP	NN	O	12	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	P2X3	P2X3	B-NP	NN	B-protein	5	NMOD
5	receptor	receptor	I-NP	NN	I-protein	9	NMOD
6	and	and	I-NP	CC	O	9	NMOD
7	NK1	NK1	I-NP	NN	O	9	NMOD
8	receptor	receptor	I-NP	NN	O	9	NMOD
9	antagonists	antagonist	I-NP	NNS	O	3	PMOD
10	on	on	B-PP	IN	O	2	NMOD
11	cyclophosphamide	cyclophosphamide	B-NP	NN	O	10	PMOD
12	induced	induce	B-VP	VBD	O	0	ROOT
13	cystitis	cystitis	B-NP	NN	O	12	OBJ
14	in	in	B-PP	IN	O	12	VMOD
15	rats	rat	B-NP	NNS	O	14	PMOD
16	.	.	O	.	O	12	P

1	PURPOSE	PURPOSE	B-NP	NN	O	4	NMOD
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	purpose	purpose	I-NP	NN	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	study	study	I-NP	NN	O	5	PMOD
8	is	be	B-VP	VBZ	O	0	ROOT
9	to	to	B-VP	TO	O	10	VMOD
10	explore	explore	I-VP	VB	O	8	PRD
11	the	the	B-NP	DT	O	12	NMOD
12	function	function	I-NP	NN	O	10	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	P2X3	P2X3	B-NP	NN	B-protein	18	NMOD
15	and	and	I-NP	CC	O	18	NMOD
16	NK1	NK1	I-NP	NN	O	18	NMOD
17	receptors	receptor	I-NP	NNS	O	18	NMOD
18	antagonists	antagonist	I-NP	NNS	O	13	PMOD
19	on	on	B-PP	IN	O	10	VMOD
20	cyclophosphamide	cyclophosphamide	B-NP	NN	O	25	NMOD
21	(	(	O	(	O	23	DEP
22	CYP	CYP	B-NP	NN	B-protein	23	DEP
23	)	)	O	)	O	20	NMOD
24	induced	induce	B-VP	VBD	O	25	NMOD
25	cystitis	cystitis	B-NP	NN	O	19	PMOD
26	in	in	B-PP	IN	O	25	NMOD
27	rats	rat	B-NP	NNS	O	26	PMOD
28	.	.	O	.	O	8	P

1	Spontaneous	Spontaneous	B-NP	JJ	O	3	NMOD
2	pain	pain	I-NP	NN	O	3	NMOD
3	behaviors	behavior	I-NP	NNS	O	9	SUB
4	following	follow	B-PP	VBG	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	administration	administration	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	CYP	CYP	B-NP	NN	B-protein	7	PMOD
9	were	be	B-VP	VBD	O	0	ROOT
10	observed	observe	I-VP	VBN	O	9	VC
11	.	.	O	.	O	9	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Cyclophosphamide	Cyclophosphamide	B-NP	NN	O	4	NMOD
4	treatment	treatment	I-NP	NN	O	5	SUB
5	increased	increase	B-VP	VBD	O	1	NMOD
6	the	the	B-NP	DT	O	10	NMOD
7	spontaneous	spontaneous	I-NP	JJ	O	10	NMOD
8	pain	pain	I-NP	NN	O	10	NMOD
9	behaviors	behaviors	I-NP	NN	O	10	NMOD
10	scores	score	I-NP	NNS	O	5	OBJ
11	.	.	O	.	O	1	P

1	Acute	Acute	B-NP	JJ	O	2	NMOD
2	hepatitis	hepatitis	I-NP	NN	O	11	NMOD
3	associated	associate	B-VP	VBN	O	2	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	clopidogrel	clopidogrel	B-NP	NN	O	4	PMOD
6	:	:	O	:	O	2	P
7	a	a	B-NP	DT	O	9	NMOD
8	case	case	I-NP	NN	O	9	NMOD
9	report	report	I-NP	NN	O	11	NMOD
10	and	and	O	CC	O	11	NMOD
11	review	review	B-NP	NN	O	0	ROOT
12	of	of	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	literature	literature	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	11	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	clopidogrel-related	clopidogrel-related	B-NP	JJ	O	8	NMOD
7	acute	acute	I-NP	JJ	O	8	NMOD
8	hepatitis	hepatitis	I-NP	NN	O	5	PMOD
9	.	.	O	.	O	2	P

1	Reports	Report	B-NP	NNS	O	9	SUB
2	about	about	B-PP	IN	O	1	NMOD
3	cases	case	B-NP	NNS	O	2	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	hepatotoxicity	hepatotoxicity	B-NP	NN	O	4	PMOD
6	due	due	B-ADJP	JJ	O	1	NMOD
7	to	to	B-PP	TO	O	6	AMOD
8	clopidogrel	clopidogrel	B-NP	NN	O	7	PMOD
9	are	be	B-VP	VBP	O	0	ROOT
10	increasing	increase	I-VP	VBG	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	the	the	B-NP	DT	O	15	NMOD
13	last	last	I-NP	JJ	O	15	NMOD
14	few	few	I-NP	JJ	O	15	NMOD
15	years	year	I-NP	NNS	O	11	PMOD
16	,	,	O	,	O	10	P
17	after	after	B-PP	IN	O	10	VMOD
18	the	the	B-NP	DT	O	20	NMOD
19	increased	increase	I-NP	VBN	O	20	NMOD
20	use	use	I-NP	NN	O	17	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	this	this	B-NP	DT	O	23	NMOD
23	drug	drug	I-NP	NN	O	21	PMOD
24	.	.	O	.	O	9	P

1	Bortezomib	Bortezomib	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	dexamethasone	dexamethasone	I-NP	NN	O	14	NMOD
4	as	as	B-PP	IN	O	3	NMOD
5	salvage	salvage	B-NP	NN	O	6	NMOD
6	therapy	therapy	I-NP	NN	O	4	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	patients	patient	B-NP	NNS	O	7	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	relapsed/refractory	relapsed/refractory	B-NP	NN	O	12	NMOD
11	multiple	multiple	I-NP	JJ	O	12	NMOD
12	myeloma	myeloma	I-NP	NN	O	9	PMOD
13	:	:	O	:	O	3	P
14	analysis	analysis	B-NP	NN	O	0	ROOT
15	of	of	B-PP	IN	O	14	NMOD
16	long-term	long-term	B-NP	JJ	O	18	NMOD
17	clinical	clinical	I-NP	JJ	O	18	NMOD
18	outcomes	outcome	I-NP	NNS	O	15	PMOD
19	.	.	O	.	O	14	P

1	Bortezomib	Bortezomib	B-NP	NN	O	5	NMOD
2	(	(	O	(	O	4	DEP
3	bort	bort	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	-dexamethasone	-dexamethasone	B-NP	NN	O	9	SUB
6	(	(	O	(	O	8	DEP
7	dex	dex	B-NP	NN	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	is	be	B-VP	VBZ	O	0	ROOT
10	an	an	B-NP	DT	O	12	NMOD
11	effective	effective	I-NP	JJ	O	12	NMOD
12	therapy	therapy	I-NP	NN	O	9	PRD
13	for	for	B-PP	IN	O	12	NMOD
14	relapsed/refractory	relapsed/refractory	B-NP	NN	O	19	NMOD
15	(	(	I-NP	(	O	17	DEP
16	R/R	R/R	I-NP	NN	O	17	DEP
17	)	)	I-NP	)	O	14	NMOD
18	multiple	multiple	I-NP	JJ	O	19	NMOD
19	myeloma	myeloma	I-NP	NN	O	13	PMOD
20	(	(	O	(	O	22	DEP
21	MM	MM	B-NP	NN	O	22	DEP
22	)	)	O	)	O	19	NMOD
23	.	.	O	.	O	9	P

1	This	This	B-NP	DT	O	3	NMOD
2	retrospective	retrospective	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	investigated	investigate	B-VP	VBD	O	0	ROOT
5	the	the	B-NP	DT	O	6	NMOD
6	combination	combination	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	bort	bort	B-NP	NN	O	7	PMOD
9	(	(	O	(	O	14	DEP
10	1.3	1.3	B-NP	CD	O	11	NMOD
11	mg/m	mg/m	I-NP	NN	O	14	DEP
12	(	(	O	(	O	14	DEP
13	2	2	B-NP	CD	O	14	DEP
14	)	)	O	)	O	8	NMOD
15	on	on	B-PP	IN	O	6	NMOD
16	days	day	B-NP	NNS	O	27	NMOD
17	1	1	I-NP	CD	O	16	NMOD
18	,	,	I-NP	,	O	16	P
19	4	4	I-NP	CD	O	16	NMOD
20	,	,	I-NP	,	O	16	P
21	8	8	I-NP	CD	O	16	NMOD
22	,	,	O	,	O	27	P
23	and	and	O	CC	O	27	NMOD
24	11	11	B-NP	CD	B-protein	27	NMOD
25	every	every	B-NP	DT	I-protein	27	NMOD
26	3	3	I-NP	CD	I-protein	27	NMOD
27	weeks	week	I-NP	NNS	I-protein	30	NMOD
28	)	)	O	)	O	27	NMOD
29	and	and	O	CC	O	30	NMOD
30	dex	dex	B-NP	NN	O	15	PMOD
31	(	(	O	(	O	43	DEP
32	20	20	B-NP	CD	O	33	NMOD
33	mg	mg	I-NP	NN	O	43	DEP
34	on	on	B-PP	IN	O	33	NMOD
35	the	the	B-NP	DT	O	36	NMOD
36	day	day	I-NP	NN	O	34	PMOD
37	of	of	B-PP	IN	O	36	NMOD
38	and	and	O	CC	O	37	PMOD
39	the	the	B-NP	DT	O	40	NMOD
40	day	day	I-NP	NN	O	37	PMOD
41	after	after	B-PP	IN	O	36	NMOD
42	bort	bort	B-NP	NN	O	41	PMOD
43	)	)	O	)	O	30	NMOD
44	as	as	B-PP	IN	O	30	NMOD
45	salvage	salvage	B-NP	NN	O	46	NMOD
46	treatment	treatment	I-NP	NN	O	44	PMOD
47	in	in	B-PP	IN	O	46	NMOD
48	85	85	B-NP	CD	O	49	NMOD
49	patients	patient	I-NP	NNS	O	61	NMOD
50	with	with	B-PP	IN	O	49	NMOD
51	R/R	R/R	B-NP	NN	O	52	NMOD
52	MM	MM	I-NP	NN	O	50	PMOD
53	after	after	B-PP	IN	O	49	NMOD
54	prior	prior	B-NP	JJ	O	58	NMOD
55	autologous	autologous	I-NP	JJ	O	58	NMOD
56	stem	stem	I-NP	NN	O	58	NMOD
57	cell	cell	I-NP	NN	O	58	NMOD
58	transplantation	transplantation	I-NP	NN	O	53	PMOD
59	or	or	O	CC	O	61	NMOD
60	conventional	conventional	B-NP	JJ	O	61	NMOD
61	chemotherapy	chemotherapy	I-NP	NN	O	47	PMOD
62	.	.	O	.	O	4	P

1	Pubertal	Pubertal	B-NP	JJ	O	2	NMOD
2	exposure	exposure	I-NP	NN	O	6	SUB
3	to	to	B-PP	TO	O	2	NMOD
4	Bisphenol	Bisphenol	B-NP	NN	B-protein	5	NMOD
5	A	A	I-NP	NN	I-protein	3	PMOD
6	increases	increase	B-VP	VBZ	O	0	ROOT
7	anxiety-like	anxiety-like	B-NP	JJ	O	8	NMOD
8	behavior	behavior	I-NP	NN	O	6	OBJ
9	and	and	O	CC	O	6	VMOD
10	decreases	decrease	B-VP	VBZ	O	6	VMOD
11	acetylcholinesterase	acetylcholinesterase	B-NP	NN	B-protein	12	NMOD
12	activity	activity	I-NP	NN	O	10	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	hippocampus	hippocampus	B-NP	NN	O	13	PMOD
15	in	in	B-PP	IN	O	12	NMOD
16	adult	adult	B-NP	JJ	O	18	NMOD
17	male	male	I-NP	JJ	O	18	NMOD
18	mice	mouse	I-NP	NNS	O	15	PMOD
19	.	.	O	.	O	6	P

1	Results	Result	B-NP	NNS	O	6	SUB
2	from	from	B-PP	IN	O	1	NMOD
3	our	our	B-NP	PRP$	O	5	NMOD
4	behavioral	behavioral	I-NP	JJ	O	5	NMOD
5	phenotyping	phenotyping	I-NP	NN	O	2	PMOD
6	indicated	indicate	B-VP	VBD	O	0	ROOT
7	that	that	B-SBAR	IN	O	6	VMOD
8	anxiety-like	anxiety-like	B-NP	JJ	O	9	NMOD
9	behavior	behavior	I-NP	NN	O	10	SUB
10	was	be	B-VP	VBD	O	7	SBAR
11	increased	increase	I-VP	VBN	O	10	VC
12	in	in	B-PP	IN	O	11	VMOD
13	mice	mouse	B-NP	NNS	O	12	PMOD
14	exposed	expose	B-VP	VBN	O	13	NMOD
15	to	to	B-PP	TO	O	14	VMOD
16	BPA	BPA	B-NP	NN	B-protein	15	PMOD
17	.	.	O	.	O	6	P

1	Our	Our	B-NP	PRP$	O	2	NMOD
2	findings	finding	I-NP	NNS	O	3	SUB
3	showed	show	B-VP	VBD	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	pubertal	pubertal	B-NP	JJ	O	7	NMOD
6	BPA	BPA	I-NP	NN	O	7	NMOD
7	exposure	exposure	I-NP	NN	O	8	SUB
8	increased	increase	B-VP	VBD	O	4	SBAR
9	anxiety-like	anxiety-like	B-NP	JJ	O	10	NMOD
10	behavior	behavior	I-NP	NN	O	8	OBJ
11	,	,	O	,	O	8	P
12	which	which	B-NP	WDT	O	8	VMOD
13	may	may	B-VP	MD	O	12	SBAR
14	be	be	I-VP	VB	O	13	VC
15	associated	associate	I-VP	VBN	O	14	VC
16	with	with	B-PP	IN	O	15	VMOD
17	decreased	decrease	B-NP	VBN	O	19	NMOD
18	AChE	AChE	I-NP	NN	O	19	NMOD
19	activity	activity	I-NP	NN	O	16	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	22	NMOD
22	hippocampus	hippocampus	I-NP	NN	O	20	PMOD
23	in	in	B-PP	IN	O	19	NMOD
24	adult	adult	B-NP	JJ	O	26	NMOD
25	male	male	I-NP	JJ	O	26	NMOD
26	mice	mouse	I-NP	NNS	O	23	PMOD
27	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	aim	aim	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	present	present	I-NP	JJ	O	6	NMOD
6	study	study	I-NP	NN	O	3	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	to	to	B-VP	TO	O	9	VMOD
9	investigate	investigate	I-VP	VB	O	7	PRD
10	the	the	B-NP	DT	O	12	NMOD
11	protective	protective	I-NP	JJ	O	12	NMOD
12	effect	effect	I-NP	NN	O	21	NMOD
13	of	of	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	17	NMOD
15	Solidago	Solidago	I-NP	NNP	O	17	NMOD
16	virgaurea	virgaurea	I-NP	NNP	O	17	NMOD
17	extract	extract	I-NP	NN	O	13	PMOD
18	on	on	B-PP	IN	O	12	NMOD
19	isoproterenol	isoproterenol	B-NP	NN	O	18	PMOD
20	induced	induce	B-VP	VBD	O	21	NMOD
21	cardiotoxicity	cardiotoxicity	B-NP	NN	O	9	OBJ
22	in	in	B-PP	IN	O	21	NMOD
23	rats	rat	B-NP	NNS	O	22	PMOD
24	.	.	O	.	O	7	P

1	``	``	B-NP	``	O	4	NMOD
2	Real-world	Real-world	I-NP	JJ	O	4	NMOD
3	''	''	I-NP	''	O	4	NMOD
4	data	datum	I-NP	NNS	O	31	NMOD
5	on	on	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	9	NMOD
7	efficacy	efficacy	I-NP	NN	O	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	safety	safety	I-NP	NN	O	5	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	lenalidomide	lenalidomide	B-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	dexamethasone	dexamethasone	I-NP	NN	O	10	PMOD
14	in	in	B-PP	IN	O	4	NMOD
15	patients	patient	B-NP	NNS	O	14	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	relapsed/refractory	relapsed/refractory	B-NP	NN	O	19	NMOD
18	multiple	multiple	I-NP	JJ	O	19	NMOD
19	myeloma	myeloma	I-NP	NN	O	16	PMOD
20	who	who	B-NP	WP	O	15	NMOD
21	were	be	B-VP	VBD	O	20	SBAR
22	treated	treat	I-VP	VBN	O	21	VC
23	according	accord	B-PP	VBG	O	22	VMOD
24	to	to	B-PP	TO	O	23	PMOD
25	the	the	B-NP	DT	O	28	NMOD
26	standard	standard	I-NP	JJ	O	27	AMOD
27	clinical	clinical	I-NP	JJ	O	28	NMOD
28	practice	practice	I-NP	NN	O	24	PMOD
29	:	:	O	:	O	4	P
30	a	a	B-NP	DT	O	31	NMOD
31	study	study	I-NP	NN	O	0	ROOT
32	of	of	B-PP	IN	O	31	NMOD
33	the	the	B-NP	DT	O	37	NMOD
34	Greek	Greek	I-NP	NNP	O	37	NMOD
35	Myeloma	Myeloma	I-NP	NNP	O	37	NMOD
36	Study	Study	I-NP	NNP	O	37	NMOD
37	Group	Group	I-NP	NNP	O	32	PMOD
38	.	.	O	.	O	31	P

1	Lenalidomide	Lenalidomide	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	dexamethasone	dexamethasone	I-NP	NN	O	7	SUB
4	(	(	O	(	O	6	DEP
5	RD	RD	B-NP	NN	O	6	DEP
6	)	)	O	)	O	3	NMOD
7	is	be	B-VP	VBZ	O	22	VMOD
8	a	a	B-NP	DT	O	9	NMOD
9	standard	standard	I-NP	NN	O	7	PRD
10	of	of	B-PP	IN	O	9	NMOD
11	care	care	B-NP	NN	O	10	PMOD
12	for	for	B-PP	IN	O	9	NMOD
13	relapsed/refractory	relapsed/refractory	B-NP	NN	O	15	NMOD
14	multiple	multiple	I-NP	JJ	O	15	NMOD
15	myeloma	myeloma	I-NP	NN	O	12	PMOD
16	(	(	O	(	O	18	DEP
17	RRMM	RRMM	B-NP	NN	B-protein	18	DEP
18	)	)	O	)	O	15	NMOD
19	,	,	O	,	O	22	P
20	but	but	O	CC	O	22	VMOD
21	there	there	B-NP	EX	O	22	SUB
22	is	be	B-VP	VBZ	O	0	ROOT
23	limited	limit	I-VP	VBN	O	22	VC
24	published	publish	B-NP	VBN	O	25	NMOD
25	data	datum	I-NP	NNS	O	23	OBJ
26	on	on	B-PP	IN	O	25	NMOD
27	its	its	B-NP	PRP$	O	30	NMOD
28	efficacy	efficacy	I-NP	NN	O	30	NMOD
29	and	and	I-NP	CC	O	30	NMOD
30	safety	safety	I-NP	NN	O	26	PMOD
31	in	in	B-PP	IN	O	30	NMOD
32	the	the	B-NP	DT	O	35	NMOD
33	``	``	I-NP	``	O	35	NMOD
34	real	real	I-NP	JJ	O	35	NMOD
35	world	world	I-NP	NN	O	31	PMOD
36	''	''	O	''	O	35	NMOD
37	(	(	O	(	O	39	DEP
38	RW	RW	B-NP	NN	B-protein	39	DEP
39	)	)	O	)	O	35	NMOD
40	,	,	O	,	O	25	P
41	according	accord	B-PP	VBG	O	25	NMOD
42	to	to	B-PP	TO	O	41	PMOD
43	the	the	B-NP	DT	O	45	NMOD
44	International	International	I-NP	NNP	O	45	NMOD
45	Society	Society	I-NP	NNP	O	42	PMOD
46	of	of	B-PP	IN	O	45	NMOD
47	Pharmacoeconomics	Pharmacoeconomics	B-NP	NNP	O	51	NMOD
48	and	and	I-NP	CC	O	51	NMOD
49	Outcomes	Outcomes	I-NP	NNP	O	51	NMOD
50	Research	Research	I-NP	NNP	O	51	NMOD
51	definition	definition	I-NP	NN	O	46	PMOD
52	.	.	O	.	O	22	P

1	We	We	B-NP	PRP	O	2	SUB
2	studied	study	B-VP	VBD	O	0	ROOT
3	212	212	B-NP	CD	O	5	NMOD
4	RRMM	RRMM	I-NP	NN	O	5	NMOD
5	patients	patient	I-NP	NNS	O	2	OBJ
6	who	who	B-NP	WP	O	5	NMOD
7	received	receive	B-VP	VBD	O	6	SBAR
8	RD	RD	B-NP	NN	O	7	OBJ
9	in	in	B-PP	IN	O	7	VMOD
10	RW	RW	B-NP	NN	O	9	PMOD
11	.	.	O	.	O	2	P

1	Risk	Risk	B-NP	NN	B-protein	2	NMOD
2	factors	factor	I-NP	NNS	I-protein	4	NMOD
3	and	and	O	CC	O	4	NMOD
4	predictors	predictor	B-NP	NNS	O	7	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	levodopa	levodopa	B-NP	NN	O	5	PMOD
7	induced	induce	B-VP	VBD	O	0	ROOT
8	dyskinesia	dyskinesia	B-NP	NN	O	7	OBJ
9	among	among	B-PP	IN	O	7	VMOD
10	multiethnic	multiethnic	B-NP	JJ	O	11	NMOD
11	Malaysians	Malaysian	I-NP	NNPS	O	9	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	Parkinson	Parkinson	B-NP	NNP	O	15	NMOD
14	's	's	B-NP	POS	O	15	NMOD
15	disease	disease	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	7	P

1	Chronic	Chronic	B-NP	JJ	O	4	NMOD
2	pulsatile	pulsatile	I-NP	JJ	O	4	NMOD
3	levodopa	levodopa	I-NP	NN	O	4	NMOD
4	therapy	therapy	I-NP	NN	O	12	SUB
5	for	for	B-PP	IN	O	4	NMOD
6	Parkinson	Parkinson	B-NP	NNP	O	7	NMOD
7	's	's	B-NP	POS	O	8	NMOD
8	disease	disease	I-NP	NN	O	5	PMOD
9	(	(	O	(	O	11	DEP
10	PD	PD	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	leads	lead	B-VP	VBZ	O	0	ROOT
13	to	to	B-PP	TO	O	12	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	development	development	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	motor	motor	B-NP	NN	O	18	NMOD
18	fluctuations	fluctuation	I-NP	NNS	O	20	NMOD
19	and	and	O	CC	O	20	NMOD
20	dyskinesia	dyskinesia	B-NP	NN	O	16	PMOD
21	.	.	O	.	O	12	P

1	We	We	B-NP	PRP	O	2	SUB
2	studied	study	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	6	NMOD
4	prevalence	prevalence	I-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	predictors	predictor	I-NP	NNS	O	9	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	levodopa	levodopa	B-NP	NN	O	7	PMOD
9	induced	induce	B-VP	VBD	O	2	VMOD
10	dyskinesia	dyskinesia	B-NP	NN	O	9	OBJ
11	among	among	B-PP	IN	O	9	VMOD
12	multiethnic	multiethnic	B-NP	JJ	O	14	NMOD
13	Malaysian	Malaysian	I-NP	JJ	O	14	NMOD
14	patients	patient	I-NP	NNS	O	11	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	PD	PD	B-NP	NN	O	15	PMOD
17	.	.	O	.	O	2	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	This	This	B-NP	DT	O	4	SUB
4	is	be	B-VP	VBZ	O	1	NMOD
5	a	a	B-NP	DT	O	7	NMOD
6	cross-sectional	cross-sectional	I-NP	JJ	O	7	NMOD
7	study	study	I-NP	NN	O	4	PRD
8	involving	involve	B-VP	VBG	O	7	NMOD
9	95	95	B-NP	CD	O	10	NMOD
10	patients	patient	I-NP	NNS	O	8	OBJ
11	with	with	B-PP	IN	O	10	NMOD
12	PD	PD	B-NP	NN	O	11	PMOD
13	on	on	B-PP	IN	O	10	NMOD
14	uninterrupted	uninterrupted	B-NP	JJ	O	16	NMOD
15	levodopa	levodopa	I-NP	NN	O	16	NMOD
16	therapy	therapy	I-NP	NN	O	13	PMOD
17	for	for	B-PP	IN	O	10	NMOD
18	at	at	B-NP	IN	O	21	NMOD
19	least	least	I-NP	JJS	O	18	AMOD
20	6	6	I-NP	CD	O	18	AMOD
21	months	month	I-NP	NNS	O	17	PMOD
22	.	.	O	.	O	1	P

1	Dyskinesia	Dyskinesia	B-NP	NNP	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	present	present	B-ADJP	JJ	O	2	PRD
4	in	in	B-PP	IN	O	3	AMOD
5	44	44	B-NP	CD	O	6	NMOD
6	%	%	I-NP	NN	O	4	PMOD
7	(	(	O	(	O	11	DEP
8	n	n	B-NP	NN	O	10	SUB
9	=	=	B-VP	SYM	O	10	VMOD
10	42	42	B-NP	CD	O	11	DEP
11	)	)	O	)	O	6	NMOD
12	with	with	B-PP	IN	O	6	NMOD
13	median	median	B-NP	JJ	O	15	NMOD
14	levodopa	levodopa	I-NP	NN	O	15	NMOD
15	therapy	therapy	I-NP	NN	O	12	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	3	3	B-NP	CD	O	18	NMOD
18	years	year	I-NP	NNS	O	16	PMOD
19	.	.	O	.	O	2	P

1	Patients	Patient	B-NP	NNS	O	4	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	dyskinesia	dyskinesia	B-NP	NN	O	2	PMOD
4	had	have	B-VP	VBD	O	0	ROOT
5	lower	low	B-NP	JJR	O	7	NMOD
6	onset	onset	I-NP	NN	O	7	NMOD
7	age	age	I-NP	NN	O	15	NMOD
8	(	(	O	(	O	12	DEP
9	p	p	B-NP	NN	O	11	SUB
10	<	<	O	SYM	O	11	P
11	0.001	0.001	B-NP	CD	O	12	DEP
12	)	)	O	)	O	7	NMOD
13	,	,	O	,	O	15	P
14	longer	long	B-NP	JJR	O	15	NMOD
15	duration	duration	I-NP	NN	O	27	NMOD
16	of	of	B-PP	IN	O	15	NMOD
17	levodopa	levodopa	B-NP	NN	O	18	NMOD
18	therapy	therapy	I-NP	NN	O	16	PMOD
19	(	(	O	(	O	23	DEP
20	p	p	B-NP	NN	O	22	SUB
21	<	<	O	SYM	O	22	P
22	0.001	0.001	B-NP	CD	O	23	DEP
23	)	)	O	)	O	15	NMOD
24	,	,	O	,	O	27	P
25	longer	long	B-NP	JJR	O	27	NMOD
26	disease	disease	I-NP	NN	O	27	NMOD
27	duration	duration	I-NP	NN	O	38	NMOD
28	(	(	O	(	O	32	DEP
29	p	p	B-NP	NN	O	31	SUB
30	<	<	O	SYM	O	31	P
31	0.001	0.001	B-NP	CD	O	32	DEP
32	)	)	O	)	O	27	NMOD
33	,	,	O	,	O	38	P
34	higher	high	B-NP	JJR	O	38	NMOD
35	total	total	I-NP	JJ	O	38	NMOD
36	daily	daily	I-NP	JJ	O	38	NMOD
37	levodopa	levodopa	I-NP	NN	O	38	NMOD
38	dose	dose	I-NP	NN	O	4	OBJ
39	(	(	O	(	O	43	DEP
40	p	p	B-NP	NN	O	42	SUB
41	<	<	O	SYM	O	42	VMOD
42	0.001	0.001	B-NP	CD	O	43	DEP
43	)	)	O	)	O	38	NMOD
44	,	,	O	,	O	49	P
45	and	and	O	CC	O	49	NMOD
46	higher	high	B-NP	JJR	O	49	NMOD
47	total	total	I-NP	JJ	O	49	NMOD
48	UPDRS	UPDRS	I-NP	NN	O	49	NMOD
49	scores	score	I-NP	NNS	O	4	OBJ
50	(	(	O	(	O	54	DEP
51	p	p	B-NP	NN	O	53	SUB
52	=	=	B-VP	SYM	O	53	VMOD
53	0.005	0.005	B-NP	CD	O	54	DEP
54	)	)	O	)	O	49	NMOD
55	than	than	B-PP	IN	O	49	NMOD
56	patients	patient	B-NP	NNS	O	55	PMOD
57	without	without	B-PP	IN	O	56	NMOD
58	dyskinesia	dyskinesia	B-NP	NN	O	57	PMOD
59	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	4	NMOD
2	three	three	I-NP	CD	O	4	NMOD
3	significant	significant	I-NP	JJ	O	4	NMOD
4	predictors	predictor	I-NP	NNS	O	7	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	dyskinesia	dyskinesia	B-NP	NN	O	5	PMOD
7	were	be	B-VP	VBD	O	0	ROOT
8	duration	duration	B-NP	NN	O	20	NMOD
9	of	of	B-PP	IN	O	8	NMOD
10	levodopa	levodopa	B-NP	NN	O	11	NMOD
11	therapy	therapy	I-NP	NN	O	9	PMOD
12	,	,	O	,	O	20	P
13	onset	onset	B-NP	NN	O	14	NMOD
14	age	age	I-NP	NN	O	20	NMOD
15	,	,	O	,	O	20	P
16	and	and	O	CC	O	20	NMOD
17	total	total	B-NP	JJ	O	20	NMOD
18	daily	daily	I-NP	JJ	O	20	NMOD
19	levodopa	levodopa	I-NP	NN	O	20	NMOD
20	dose	dose	I-NP	NN	O	7	PRD
21	.	.	O	.	O	7	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	prevalence	prevalence	I-NP	NN	O	7	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	levodopa	levodopa	B-NP	NN	O	5	PMOD
7	induced	induce	B-VP	VBD	O	1	NMOD
8	dyskinesia	dyskinesia	B-NP	NN	O	7	OBJ
9	in	in	B-PP	IN	O	7	VMOD
10	our	our	B-NP	PRP$	O	11	NMOD
11	patients	patient	I-NP	NNS	O	9	PMOD
12	was	be	B-VP	VBD	O	7	VMOD
13	44	44	B-NP	CD	O	14	NMOD
14	%	%	I-NP	NN	O	12	PRD
15	.	.	O	.	O	1	P

1	An	An	B-NP	DT	O	3	NMOD
2	unexpected	unexpected	I-NP	JJ	O	3	NMOD
3	diagnosis	diagnosis	I-NP	NN	O	15	NMOD
4	in	in	B-PP	IN	O	3	NMOD
5	a	a	B-NP	DT	O	7	NMOD
6	renal-transplant	renal-transplant	I-NP	JJ	O	7	NMOD
7	patient	patient	I-NP	NN	O	4	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	proteinuria	proteinuria	B-NP	NN	O	8	PMOD
10	treated	treat	B-VP	VBN	O	9	NMOD
11	with	with	B-PP	IN	O	10	VMOD
12	everolimus	everolimus	B-NP	NN	O	11	PMOD
13	:	:	O	:	O	3	P
14	AL	AL	B-NP	JJ	O	15	NMOD
15	amyloidosis	amyloidosis	I-NP	NN	O	0	ROOT
16	.	.	O	.	O	15	P

1	Proteinuria	Proteinuria	B-NP	NNP	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	an	an	B-NP	DT	O	5	NMOD
4	expected	expected	I-NP	JJ	O	5	NMOD
5	complication	complication	I-NP	NN	O	2	PRD
6	in	in	B-PP	IN	O	5	NMOD
7	transplant	transplant	B-NP	NN	O	8	NMOD
8	patients	patient	I-NP	NNS	O	6	PMOD
9	treated	treat	B-VP	VBN	O	8	NMOD
10	with	with	B-PP	IN	O	9	VMOD
11	mammalian	mammalian	B-NP	JJ	O	12	NMOD
12	target	target	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	rapamycin	rapamycin	B-NP	NN	O	15	NMOD
15	inhibitors	inhibitor	I-NP	NNS	O	13	PMOD
16	(	(	O	(	O	18	DEP
17	mTOR-i	mTOR-i	B-NP	NN	O	18	DEP
18	)	)	O	)	O	15	NMOD
19	.	.	O	.	O	2	P

1	An	An	B-NP	DT	O	2	NMOD
2	investigation	investigation	I-NP	NN	O	19	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	pattern	pattern	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	kidney	kidney	B-NP	NN	O	8	NMOD
8	injury	injury	I-NP	NN	O	6	PMOD
9	in	in	B-PP	IN	O	5	NMOD
10	HIV-positive	HIV-positive	B-NP	JJ	O	11	NMOD
11	persons	person	I-NP	NNS	O	9	PMOD
12	exposed	expose	B-VP	VBN	O	11	NMOD
13	to	to	B-VP	TO	O	14	VMOD
14	tenofovir	tenofovir	I-VP	VB	O	12	VMOD
15	disoproxil	disoproxil	B-NP	NN	O	16	NMOD
16	fumarate	fumarate	I-NP	NN	O	14	OBJ
17	:	:	O	:	O	2	P
18	an	an	B-NP	DT	O	19	NMOD
19	examination	examination	I-NP	NN	O	0	ROOT
20	of	of	B-PP	IN	O	19	NMOD
21	a	a	B-NP	DT	O	24	NMOD
22	large	large	I-NP	JJ	O	24	NMOD
23	population	population	I-NP	NN	O	24	NMOD
24	database	database	I-NP	NN	O	20	PMOD
25	(	(	O	(	O	28	DEP
26	MHRA	MHRA	B-NP	NN	B-protein	27	NMOD
27	database	database	I-NP	NN	I-protein	28	DEP
28	)	)	O	)	O	24	NMOD
29	.	.	O	.	O	19	P

1	Of	Of	B-PP	IN	O	24	VMOD
2	the	the	B-NP	DT	O	6	NMOD
3	407	407	I-NP	CD	O	6	NMOD
4	Yellow	Yellow	I-NP	NNP	O	6	NMOD
5	Card	Card	I-NP	NNP	O	6	NMOD
6	records	record	I-NP	NNS	O	7	SUB
7	analysed	analyse	B-VP	VBD	O	1	SBAR
8	,	,	O	,	O	24	P
9	106	106	B-NP	CD	O	11	NMOD
10	satisfied	satisfied	I-NP	JJ	O	11	NMOD
11	criteria	criterion	I-NP	NNS	O	19	NMOD
12	for	for	B-PP	IN	O	11	NMOD
13	TDF-related	TDF-related	B-NP	JJ	O	15	NMOD
14	kidney	kidney	I-NP	NN	O	15	NMOD
15	disease	disease	I-NP	NN	O	12	PMOD
16	,	,	O	,	O	17	P
17	of	of	B-PP	IN	O	11	NMOD
18	which	which	B-NP	WDT	O	17	PMOD
19	53	53	B-NP	CD	O	24	SUB
20	(	(	O	(	O	23	DEP
21	50	50	B-NP	CD	O	22	NMOD
22	%	%	I-NP	NN	O	23	DEP
23	)	)	O	)	O	19	NMOD
24	had	have	B-VP	VBD	O	0	ROOT
25	features	feature	B-NP	NNS	O	24	OBJ
26	of	of	B-PP	IN	O	25	NMOD
27	kidney	kidney	B-NP	NN	O	29	NMOD
28	tubular	tubular	I-NP	JJ	O	29	NMOD
29	dysfunction	dysfunction	I-NP	NN	O	36	SUB
30	,	,	O	,	O	36	P
31	35	35	B-NP	CD	O	36	SUB
32	(	(	O	(	O	35	DEP
33	33	33	B-NP	CD	O	34	NMOD
34	%	%	I-NP	NN	O	35	DEP
35	)	)	O	)	O	31	NMOD
36	were	be	B-VP	VBD	O	26	SBAR
37	found	find	I-VP	VBN	O	36	VC
38	to	to	I-VP	TO	O	39	VMOD
39	have	have	I-VP	VB	O	37	VMOD
40	features	feature	B-NP	NNS	O	39	OBJ
41	of	of	B-PP	IN	O	40	NMOD
42	glomerular	glomerular	B-NP	JJ	O	43	NMOD
43	dysfunction	dysfunction	I-NP	NN	O	41	PMOD
44	and	and	O	CC	O	50	VMOD
45	18	18	B-NP	CD	O	50	SUB
46	(	(	O	(	O	49	DEP
47	17	17	B-NP	CD	O	48	NMOD
48	%	%	I-NP	NN	O	49	DEP
49	)	)	O	)	O	45	NMOD
50	had	have	B-VP	VBD	O	43	NMOD
51	Fanconi	Fanconi	B-NP	NNP	O	52	NMOD
52	syndrome	syndrome	I-NP	NN	O	50	OBJ
53	.	.	O	.	O	24	P

1	The	The	B-NP	DT	O	2	NMOD
2	incidence	incidence	I-NP	NN	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	hospitalisation	hospitalisation	B-NP	NN	O	3	PMOD
5	for	for	B-PP	IN	O	4	NMOD
6	TDF	TDF	B-NP	NN	O	9	NMOD
7	kidney	kidney	I-NP	NN	O	9	NMOD
8	adverse	adverse	I-NP	JJ	O	9	NMOD
9	effects	effect	I-NP	NNS	O	5	PMOD
10	was	be	B-VP	VBD	O	0	ROOT
11	high	high	B-ADJP	JJ	O	10	PRD
12	,	,	O	,	O	10	P
13	particularly	particularly	B-ADVP	RB	O	10	VMOD
14	amongst	amongst	B-PP	IN	O	10	VMOD
15	patients	patient	B-NP	NNS	O	14	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	features	feature	B-NP	NNS	O	16	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	Fanconi	Fanconi	B-NP	NNP	O	20	NMOD
20	syndrome	syndrome	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	10	P

1	The	The	B-NP	DT	O	2	NMOD
2	use	use	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	thiopentone	thiopentone	B-NP	NN	O	3	PMOD
5	was	be	B-VP	VBD	O	0	ROOT
6	significantly	significantly	I-VP	RB	O	5	VMOD
7	associated	associate	I-VP	VBN	O	5	VC
8	with	with	B-PP	IN	O	7	VMOD
9	an	an	B-NP	DT	O	11	NMOD
10	eight-fold-higher	eight-fold-higher	I-NP	JJ	O	11	NMOD
11	risk	risk	I-NP	NN	O	8	PMOD
12	for	for	B-PP	IN	O	11	NMOD
13	delirium	delirium	B-NP	NN	O	12	PMOD
14	compared	compare	B-VP	VBN	O	7	VMOD
15	to	to	B-PP	TO	O	14	PMOD
16	propofol	propofol	B-NP	NN	O	15	PMOD
17	(	(	O	(	O	16	NMOD
18	57.1	57.1	B-NP	CD	O	19	NMOD
19	%	%	I-NP	NN	O	17	PMOD
20	vs.	vs.	B-PP	IN	O	19	VMOD
21	7.1	7.1	B-NP	CD	O	22	NMOD
22	%	%	I-NP	NN	O	32	NMOD
23	,	,	O	,	O	32	P
24	RR	RR	B-NP	NN	B-protein	32	NMOD
25	=	=	B-VP	SYM	I-protein	24	NMOD
26	8.0	8.0	B-NP	CD	I-protein	25	AMOD
27	,	,	O	,	O	32	P
28	X2	X2	B-NP	NN	O	32	NMOD
29	=	=	B-VP	SYM	O	28	NMOD
30	4.256	4.256	B-NP	CD	O	29	AMOD
31	;	;	O	:	O	32	P
32	df	df	B-NP	NN	O	20	PMOD
33	=	=	B-VP	SYM	O	32	NMOD
34	1	1	B-NP	CD	O	37	AMOD
35	;	;	O	:	O	37	P
36	0.05	0.05	B-NP	CD	O	37	AMOD
37	<	<	I-NP	JJR	O	33	AMOD
38	p	p	I-NP	NN	O	37	AMOD
39	<	<	I-NP	JJR	O	38	NMOD
40	0.02	0.02	I-NP	CD	O	39	AMOD
41	)	)	O	)	O	32	NMOD
42	.	.	O	.	O	5	P

1	A	A	B-NP	DT	O	4	NMOD
2	single	single	I-NP	JJ	O	4	NMOD
3	neurotoxic	neurotoxic	I-NP	JJ	O	4	NMOD
4	dose	dose	I-NP	NN	O	7	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	methamphetamine	methamphetamine	B-NP	NN	O	5	PMOD
7	induces	induce	B-VP	VBZ	O	0	ROOT
8	a	a	B-NP	DT	O	11	NMOD
9	long-lasting	long-lasting	I-NP	JJ	O	11	NMOD
10	depressive-like	depressive-like	I-NP	JJ	O	11	NMOD
11	behaviour	behaviour	I-NP	NN	O	7	OBJ
12	in	in	B-PP	IN	O	7	VMOD
13	mice	mouse	B-NP	NNS	O	12	PMOD
14	.	.	O	.	O	7	P

1	Methamphetamine	Methamphetamine	B-NP	NN	O	5	SUB
2	(	(	O	(	O	4	DEP
3	METH	METH	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	triggers	trigger	B-VP	VBZ	O	0	ROOT
6	a	a	B-NP	DT	O	7	NMOD
7	disruption	disruption	I-NP	NN	O	5	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	11	NMOD
10	monoaminergic	monoaminergic	I-NP	JJ	O	11	NMOD
11	system	system	I-NP	NN	O	14	NMOD
12	and	and	I-NP	CC	O	14	NMOD
13	METH	METH	I-NP	NN	O	14	NMOD
14	abuse	abuse	I-NP	NN	O	8	PMOD
15	leads	lead	B-VP	VBZ	O	5	VMOD
16	to	to	B-PP	TO	O	15	VMOD
17	negative	negative	B-NP	JJ	O	19	NMOD
18	emotional	emotional	I-NP	JJ	O	19	NMOD
19	states	state	I-NP	NNS	O	16	PMOD
20	including	include	B-PP	VBG	O	19	NMOD
21	depressive	depressive	B-NP	JJ	O	22	NMOD
22	symptoms	symptom	I-NP	NNS	O	20	PMOD
23	during	during	B-PP	IN	O	22	NMOD
24	drug	drug	B-NP	NN	O	25	NMOD
25	withdrawal	withdrawal	I-NP	NN	O	23	PMOD
26	.	.	O	.	O	5	P

1	However	However	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	it	it	B-NP	PRP	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	currently	currently	B-ADJP	RB	O	6	AMOD
6	unknown	unknown	I-ADJP	JJ	O	4	PRD
7	if	if	B-SBAR	IN	O	4	VMOD
8	the	the	B-NP	DT	O	11	NMOD
9	acute	acute	I-NP	JJ	O	11	NMOD
10	toxic	toxic	I-NP	JJ	O	11	NMOD
11	dosage	dosage	I-NP	NN	O	15	SUB
12	of	of	B-PP	IN	O	11	NMOD
13	METH	METH	B-NP	NN	O	12	PMOD
14	also	also	B-ADVP	RB	O	15	VMOD
15	causes	cause	B-VP	VBZ	O	7	SBAR
16	a	a	B-NP	DT	O	19	NMOD
17	long-lasting	long-lasting	I-NP	JJ	O	19	NMOD
18	depressive	depressive	I-NP	JJ	O	19	NMOD
19	phenotype	phenotype	I-NP	NN	O	23	NMOD
20	and	and	O	CC	O	23	NMOD
21	persistent	persistent	B-NP	JJ	O	23	NMOD
22	monoaminergic	monoaminergic	I-NP	JJ	O	23	NMOD
23	deficits	deficit	I-NP	NNS	O	15	OBJ
24	.	.	O	.	O	4	P

1	Thus	Thus	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	we	we	B-NP	PRP	O	5	SUB
4	now	now	B-ADVP	RB	O	5	VMOD
5	assessed	assess	B-VP	VBD	O	0	ROOT
6	the	the	B-NP	DT	O	8	NMOD
7	depressive-like	depressive-like	I-NP	JJ	O	8	NMOD
8	behaviour	behaviour	I-NP	NN	O	5	OBJ
9	in	in	B-PP	IN	O	8	NMOD
10	mice	mouse	B-NP	NNS	O	9	PMOD
11	at	at	B-PP	IN	O	5	VMOD
12	early	early	B-NP	JJ	O	15	NMOD
13	and	and	I-NP	CC	O	15	NMOD
14	long-term	long-term	I-NP	JJ	O	15	NMOD
15	periods	period	I-NP	NNS	O	11	PMOD
16	following	follow	B-PP	VBG	O	5	VMOD
17	a	a	B-NP	DT	O	21	NMOD
18	single	single	I-NP	JJ	O	21	NMOD
19	high	high	I-NP	JJ	O	21	NMOD
20	METH	METH	I-NP	NN	O	21	NMOD
21	dose	dose	I-NP	NN	O	16	PMOD
22	(	(	O	(	O	27	DEP
23	30	30	B-NP	CD	O	24	NMOD
24	mg/kg	mg/kg	I-NP	NN	O	27	DEP
25	,	,	O	,	O	24	P
26	i.p.	i.p.	B-ADVP	RB	O	24	NMOD
27	)	)	O	)	O	21	NMOD
28	.	.	O	.	O	5	P

1	This	This	B-NP	DT	O	3	NMOD
2	depressive-like	depressive-like	I-NP	JJ	O	3	NMOD
3	profile	profile	I-NP	NN	O	7	SUB
4	induced	induce	B-VP	VBN	O	3	NMOD
5	by	by	B-PP	IN	O	4	VMOD
6	METH	METH	B-NP	NN	O	5	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	accompanied	accompany	I-VP	VBN	O	7	VC
9	by	by	B-PP	IN	O	8	VMOD
10	a	a	B-NP	DT	O	12	NMOD
11	marked	marked	I-NP	JJ	O	12	NMOD
12	depletion	depletion	I-NP	NN	O	9	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	frontostriatal	frontostriatal	B-NP	JJ	O	18	NMOD
15	dopaminergic	dopaminergic	I-NP	JJ	O	18	NMOD
16	and	and	I-NP	CC	O	18	NMOD
17	serotonergic	serotonergic	I-NP	JJ	O	18	NMOD
18	neurotransmission	neurotransmission	I-NP	NN	O	13	PMOD
19	,	,	O	,	O	8	P
20	indicated	indicate	B-VP	VBN	O	8	VMOD
21	by	by	B-PP	IN	O	20	VMOD
22	a	a	B-NP	DT	O	23	NMOD
23	reduction	reduction	I-NP	NN	O	21	PMOD
24	in	in	B-PP	IN	O	23	NMOD
25	the	the	B-NP	DT	O	26	NMOD
26	levels	level	I-NP	NNS	O	24	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	dopamine	dopamine	B-NP	NN	O	37	NMOD
29	,	,	O	,	O	37	P
30	DOPAC	DOPAC	B-NP	NN	B-protein	32	NMOD
31	and	and	I-NP	CC	O	32	NMOD
32	HVA	HVA	I-NP	NN	B-protein	37	NMOD
33	,	,	O	,	O	37	P
34	tyrosine	tyrosine	B-NP	NN	B-protein	35	NMOD
35	hydroxylase	hydroxylase	I-NP	NN	I-protein	37	NMOD
36	and	and	I-NP	CC	O	37	NMOD
37	serotonin	serotonin	I-NP	NN	O	27	PMOD
38	,	,	O	,	O	8	P
39	observed	observe	B-VP	VBN	O	8	VMOD
40	at	at	B-PP	IN	O	39	VMOD
41	both	both	B-NP	CC	O	45	NMOD
42	3	3	I-NP	CD	O	45	NMOD
43	and	and	I-NP	CC	O	45	NMOD
44	49	49	I-NP	CD	O	45	NMOD
45	days	day	I-NP	NNS	O	40	PMOD
46	post-administration	post-administration	B-ADJP	JJ	O	45	NMOD
47	.	.	O	.	O	7	P

1	Linezolid	Linezolid	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	optic	optic	B-NP	JJ	O	4	NMOD
4	neuropathy	neuropathy	I-NP	NN	O	2	OBJ
5	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	progressive	progressive	B-NP	JJ	O	7	NMOD
7	loss	loss	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	vision	vision	B-NP	NN	O	8	PMOD
10	associated	associate	B-VP	VBN	O	9	NMOD
11	with	with	B-PP	IN	O	10	VMOD
12	linezolid	linezolid	B-NP	JJ	O	13	NMOD
13	therapy	therapy	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	4	NMOD
2	45-year-old	45-year-old	I-NP	JJ	O	4	NMOD
3	male	male	I-NP	JJ	O	4	NMOD
4	patient	patient	I-NP	NN	O	0	ROOT
5	who	who	B-NP	WP	O	4	NMOD
6	was	be	B-VP	VBD	O	5	SBAR
7	on	on	B-PP	IN	O	6	PRD
8	treatment	treatment	B-NP	NN	O	7	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	multiple	multiple	B-NP	JJ	O	13	NMOD
11	second-line	second-line	I-NP	JJ	O	13	NMOD
12	anti-tuberculous	anti-tuberculous	I-NP	JJ	O	13	NMOD
13	drugs	drug	I-NP	NNS	O	9	PMOD
14	including	include	B-PP	VBG	O	13	NMOD
15	linezolid	linezolid	B-NP	NN	O	17	NMOD
16	and	and	I-NP	CC	O	17	NMOD
17	ethambutol	ethambutol	I-NP	NN	O	14	PMOD
18	for	for	B-PP	IN	O	17	NMOD
19	extensively	extensively	B-NP	RB	O	20	AMOD
20	drug-resistant	drug-resistant	I-NP	JJ	O	18	PMOD
21	tuberculosis	tuberculosis	I-NP	NN	O	20	NMOD
22	(	(	O	(	O	24	DEP
23	XDR-TB	XDR-TB	B-NP	NN	B-protein	24	DEP
24	)	)	O	)	O	21	NMOD
25	presented	present	B-VP	VBN	O	20	NMOD
26	to	to	B-PP	TO	O	25	VMOD
27	us	us	B-NP	PRP	O	26	PMOD
28	with	with	B-PP	IN	O	25	VMOD
29	painless	painless	B-NP	JJ	O	31	NMOD
30	progressive	progressive	I-NP	JJ	O	31	NMOD
31	loss	loss	I-NP	NN	O	28	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	vision	vision	B-NP	NN	O	32	PMOD
34	in	in	B-PP	IN	O	31	NMOD
35	both	both	B-NP	DT	O	36	NMOD
36	eyes	eye	I-NP	NNS	O	34	PMOD
37	.	.	O	.	O	4	P

1	Ethambutol	Ethambutol	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	11	VMOD
3	toxic	toxic	B-NP	JJ	O	5	NMOD
4	optic	optic	I-NP	JJ	O	5	NMOD
5	neuropathy	neuropathy	I-NP	NN	O	6	SUB
6	was	be	B-VP	VBD	O	11	VMOD
7	suspected	suspect	I-VP	VBN	O	6	VC
8	and	and	O	CC	O	11	VMOD
9	tablet	tablet	B-NP	NN	O	10	NMOD
10	ethambutol	ethambutol	I-NP	NN	O	11	SUB
11	was	be	B-VP	VBD	O	0	ROOT
12	withdrawn	withdraw	I-VP	VBN	O	11	VC
13	.	.	O	.	O	11	P

1	Deterioration	Deterioration	B-NP	NN	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	vision	vision	B-NP	NN	O	2	PMOD
4	occurred	occur	B-VP	VBD	O	0	ROOT
5	despite	despite	B-PP	IN	O	4	VMOD
6	withdrawal	withdrawal	B-NP	NN	O	5	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	ethambutol	ethambutol	B-NP	NN	O	7	PMOD
9	.	.	O	.	O	4	P

1	Resuscitation	Resuscitation	B-NP	NN	O	0	ROOT
2	with	with	B-PP	IN	O	1	NMOD
3	lipid	lipid	B-NP	NN	O	11	SUB
4	,	,	O	,	O	11	P
5	epinephrine	epinephrine	B-NP	NN	O	11	SUB
6	,	,	O	,	O	11	P
7	or	or	O	CC	O	11	VMOD
8	both	both	O	CC	O	11	VMOD
9	in	in	B-PP	IN	O	11	VMOD
10	levobupivacaine	levobupivacaine	B-NP	NN	O	9	PMOD
11	induced	induce	B-VP	VBD	O	2	SBAR
12	cardiac	cardiac	B-NP	JJ	O	13	NMOD
13	toxicity	toxicity	I-NP	NN	O	11	OBJ
14	in	in	B-PP	IN	O	11	VMOD
15	newborn	newborn	B-NP	JJ	O	16	NMOD
16	piglets	piglet	I-NP	NNS	O	14	PMOD
17	.	.	O	.	O	1	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	6	NMOD
4	optimal	optimal	I-NP	JJ	O	6	NMOD
5	dosing	dosing	I-NP	NN	O	6	NMOD
6	regimens	regimen	I-NP	NNS	O	1	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	lipid	lipid	B-NP	NN	O	9	NMOD
9	emulsion	emulsion	I-NP	NN	O	15	SUB
10	,	,	O	,	O	15	P
11	epinephrine	epinephrine	B-NP	NN	O	15	SUB
12	,	,	O	,	O	14	P
13	or	or	O	CC	O	14	NMOD
14	both	both	O	DT	O	15	SUB
15	are	be	B-VP	VBP	O	7	SBAR
16	not	not	I-VP	RB	O	15	VMOD
17	yet	yet	I-VP	RB	O	15	VMOD
18	determined	determine	I-VP	VBN	O	15	VC
19	in	in	B-PP	IN	O	18	VMOD
20	neonates	neonate	B-NP	NNS	O	19	PMOD
21	in	in	B-PP	IN	O	20	NMOD
22	cases	case	B-NP	NNS	O	21	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	local	local	B-NP	JJ	O	27	NMOD
25	anaesthetic	anaesthetic	I-NP	JJ	O	27	NMOD
26	systemic	systemic	I-NP	JJ	O	27	NMOD
27	toxicity	toxicity	I-NP	NN	O	23	PMOD
28	(	(	O	(	O	30	DEP
29	LAST	LAST	B-NP	NN	B-protein	30	DEP
30	)	)	O	)	O	27	NMOD
31	.	.	O	.	O	1	P

1	METHODS	METHODS	B-NP	NNS	O	5	VMOD
2	:	:	O	:	O	1	P
3	Newborn	Newborn	B-NP	JJ	O	4	NMOD
4	piglets	piglet	I-NP	NNS	O	5	SUB
5	received	receive	B-VP	VBD	O	0	ROOT
6	levobupivacaine	levobupivacaine	B-NP	NN	O	5	OBJ
7	until	until	B-PP	IN	O	5	VMOD
8	cardiovascular	cardiovascular	B-NP	JJ	O	9	NMOD
9	collapse	collapse	I-NP	NN	O	10	SUB
10	occurred	occur	B-VP	VBD	O	7	SBAR
11	.	.	O	.	O	5	P

1	Incidence	Incidence	B-NP	NN	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	heparin	heparin	B-NP	NN	O	2	PMOD
4	induced	induce	B-VP	VBD	O	0	ROOT
5	thrombocytopenia	thrombocytopenia	B-NP	NN	B-protein	6	NMOD
6	type	type	I-NP	NN	I-protein	10	NMOD
7	II	II	I-NP	CD	I-protein	6	NMOD
8	and	and	O	CC	O	10	NMOD
9	postoperative	postoperative	B-NP	JJ	O	10	NMOD
10	recovery	recovery	I-NP	NN	O	4	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	platelet	platelet	B-NP	NN	O	13	NMOD
13	count	count	I-NP	NN	O	11	PMOD
14	in	in	B-PP	IN	O	13	NMOD
15	liver	liver	B-NP	NN	O	17	NMOD
16	graft	graft	I-NP	NN	O	17	NMOD
17	recipients	recipient	I-NP	NNS	O	14	PMOD
18	:	:	O	:	O	4	P
19	a	a	B-NP	DT	O	22	NMOD
20	retrospective	retrospective	I-NP	JJ	O	22	NMOD
21	cohort	cohort	I-NP	JJ	O	22	NMOD
22	analysis	analysis	I-NP	NN	O	4	VMOD
23	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	2	NMOD
2	impact	impact	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	immune-mediated	immune-mediated	B-NP	JJ	B-protein	5	NMOD
5	heparin	heparin	I-NP	NN	I-protein	3	PMOD
6	induced	induce	B-VP	VBD	O	0	ROOT
7	thrombocytopenia	thrombocytopenia	B-NP	NN	B-protein	8	NMOD
8	type	type	I-NP	NN	I-protein	6	OBJ
9	II	II	I-NP	CD	I-protein	8	NMOD
10	(	(	O	(	O	14	DEP
11	HIT	HIT	B-NP	NN	B-protein	12	NMOD
12	type	type	I-NP	NN	I-protein	14	DEP
13	II	II	I-NP	CD	I-protein	12	NMOD
14	)	)	O	)	O	8	NMOD
15	as	as	B-PP	IN	O	6	VMOD
16	a	a	B-NP	DT	O	17	NMOD
17	cause	cause	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	thrombocytopenia	thrombocytopenia	B-NP	NN	O	18	PMOD
20	after	after	B-PP	IN	O	6	VMOD
21	liver	liver	B-NP	NN	O	22	NMOD
22	transplantation	transplantation	I-NP	NN	O	20	PMOD
23	is	be	B-VP	VBZ	O	6	VMOD
24	not	not	I-VP	RB	O	23	VMOD
25	yet	yet	I-VP	RB	O	23	VMOD
26	understood	understand	I-VP	VBN	O	23	VC
27	,	,	O	,	O	26	P
28	with	with	B-SBAR	IN	O	26	VMOD
29	few	few	B-NP	JJ	O	31	NMOD
30	literature	literature	I-NP	NN	O	31	NMOD
31	citations	citation	I-NP	NNS	O	32	SUB
32	reporting	report	B-VP	VBG	O	28	PMOD
33	contradictory	contradictory	B-NP	JJ	O	34	NMOD
34	results	result	I-NP	NNS	O	32	OBJ
35	.	.	O	.	O	6	P

1	Takotsubo	Takotsubo	B-NP	NN	O	2	NMOD
2	syndrome	syndrome	I-NP	NN	O	0	ROOT
3	(	(	O	(	O	8	DEP
4	or	or	O	CC	O	8	DEP
5	apical	apical	B-NP	JJ	O	7	NMOD
6	ballooning	ballooning	I-NP	NN	O	7	NMOD
7	syndrome	syndrome	I-NP	NN	O	8	DEP
8	)	)	O	)	O	2	NMOD
9	secondary	secondary	B-ADJP	JJ	O	2	NMOD
10	to	to	B-PP	TO	O	9	AMOD
11	Zolmitriptan	Zolmitriptan	B-NP	NNP	O	10	PMOD
12	.	.	O	.	O	2	P

1	Detailed	Detailed	B-NP	JJ	O	2	NMOD
2	history	history	I-NP	NN	O	5	SUB
3	obtained	obtain	B-VP	VBN	O	2	NMOD
4	retrospectively	retrospectively	B-ADVP	RB	O	3	VMOD
5	revealed	reveal	B-VP	VBD	O	0	ROOT
6	that	that	B-SBAR	IN	O	5	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	patient	patient	I-NP	NN	O	9	SUB
9	took	take	B-VP	VBD	O	6	SBAR
10	zolmitriptan	zolmitriptan	B-NP	NN	O	9	OBJ
11	sparingly	sparingly	B-ADVP	RB	O	13	DEP
12	only	only	O	RB	O	13	DEP
13	when	when	B-ADVP	WRB	O	9	VMOD
14	she	she	B-NP	PRP	O	15	SUB
15	had	have	B-VP	VBD	O	13	SBAR
16	migraines	migraine	B-NP	NNS	O	15	OBJ
17	.	.	O	.	O	5	P

1	But	But	O	CC	O	7	VMOD
2	before	before	B-SBAR	IN	O	1	PMOD
3	this	this	B-NP	DT	O	4	NMOD
4	event	event	I-NP	NN	O	2	PMOD
5	,	,	O	,	O	7	P
6	she	she	B-NP	PRP	O	7	SUB
7	was	be	B-VP	VBD	O	0	ROOT
8	taking	take	I-VP	VBG	O	7	VC
9	zolmitriptan	zolmitriptan	B-NP	NN	O	11	NMOD
10	2-3	2-3	B-NP	CD	O	11	NMOD
11	times	time	I-NP	NNS	O	8	OBJ
12	daily	daily	B-ADVP	RB	O	13	PMOD
13	for	for	B-PP	IN	O	11	NMOD
14	several	several	B-NP	JJ	O	15	NMOD
15	days	day	I-NP	NNS	O	13	PMOD
16	because	because	B-PP	IN	O	8	VMOD
17	of	of	I-PP	IN	O	16	PMOD
18	a	a	B-NP	DT	O	21	NMOD
19	persistent	persistent	I-NP	JJ	O	21	NMOD
20	migraine	migraine	I-NP	NN	O	21	NMOD
21	headache	headache	I-NP	NN	O	16	PMOD
22	.	.	O	.	O	7	P

1	Depression	Depression	B-NP	NN	O	8	NMOD
2	,	,	O	,	O	8	P
3	impulsiveness	impulsiveness	B-NP	NN	O	8	NMOD
4	,	,	O	,	O	8	P
5	sleep	sleep	B-NP	NN	O	8	NMOD
6	,	,	O	,	O	8	P
7	and	and	O	CC	O	8	NMOD
8	memory	memory	B-NP	NN	O	0	ROOT
9	in	in	B-PP	IN	O	8	NMOD
10	past	past	B-NP	JJ	O	12	AMOD
11	and	and	I-NP	CC	O	12	AMOD
12	present	present	I-NP	JJ	O	14	NMOD
13	polydrug	polydrug	I-NP	NN	O	14	NMOD
14	users	user	I-NP	NNS	O	9	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	3	3	B-NP	CD	O	15	PMOD
17	,	,	O	,	O	18	P
18	4-methylenedioxymethamphetamine	4-methylenedioxymethamphetamine	B-NP	NN	O	16	NMOD
19	(	(	O	(	O	23	DEP
20	MDMA	MDMA	B-NP	NN	O	23	DEP
21	,	,	O	,	O	20	P
22	ecstasy	ecstasy	B-ADJP	JJ	O	20	NMOD
23	)	)	O	)	O	18	NMOD
24	.	.	O	.	O	8	P

1	Association	Association	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	common	common	B-NP	JJ	O	5	NMOD
4	genetic	genetic	I-NP	JJ	O	5	NMOD
5	variants	variant	I-NP	NNS	O	2	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	HOMER1	HOMER1	B-NP	NN	B-DNA	8	NMOD
8	gene	gene	I-NP	NN	I-DNA	6	PMOD
9	with	with	B-PP	IN	O	5	NMOD
10	levodopa	levodopa	B-NP	NN	O	12	NMOD
11	adverse	adverse	I-NP	JJ	O	12	NMOD
12	effects	effect	I-NP	NNS	O	9	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	Parkinson	Parkinson	B-NP	NNP	O	15	NMOD
15	's	's	B-NP	POS	O	17	NMOD
16	disease	disease	I-NP	NN	O	17	NMOD
17	patients	patient	I-NP	NNS	O	13	PMOD
18	.	.	O	.	O	1	P

1	Levodopa	Levodopa	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	17	VMOD
3	the	the	B-NP	DT	O	7	NMOD
4	most	most	I-NP	RBS	O	5	AMOD
5	effective	effective	I-NP	JJ	O	7	NMOD
6	symptomatic	symptomatic	I-NP	JJ	O	7	NMOD
7	therapy	therapy	I-NP	NN	O	2	PRD
8	for	for	B-PP	IN	O	7	NMOD
9	Parkinson	Parkinson	B-NP	NNP	O	11	NMOD
10	's	's	B-NP	POS	O	11	NMOD
11	disease	disease	I-NP	NN	O	8	PMOD
12	,	,	O	,	O	17	P
13	but	but	O	CC	O	16	NMOD
14	its	its	B-NP	PRP$	O	16	NMOD
15	chronic	chronic	I-NP	JJ	O	16	NMOD
16	use	use	I-NP	NN	O	17	SUB
17	could	could	B-VP	MD	O	0	ROOT
18	lead	lead	I-VP	VB	O	17	VC
19	to	to	B-PP	TO	O	18	VMOD
20	chronic	chronic	B-NP	JJ	O	22	NMOD
21	adverse	adverse	I-NP	JJ	O	22	NMOD
22	outcomes	outcome	I-NP	NNS	O	19	PMOD
23	,	,	O	,	O	22	P
24	such	such	B-PP	JJ	O	25	PMOD
25	as	as	I-PP	IN	O	22	NMOD
26	motor	motor	B-NP	NN	O	27	NMOD
27	fluctuations	fluctuation	I-NP	NNS	O	32	NMOD
28	,	,	O	,	O	32	P
29	dyskinesia	dyskinesia	B-NP	NN	O	32	NMOD
30	and	and	O	CC	O	32	NMOD
31	visual	visual	B-NP	JJ	O	32	NMOD
32	hallucinations	hallucination	I-NP	NNS	O	25	PMOD
33	.	.	O	.	O	17	P

1	Crocin	Crocin	B-NP	NN	O	2	SUB
2	reduced	reduce	B-VP	VBD	O	0	ROOT
3	inhibition	inhibition	B-NP	NN	O	9	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	ERK	ERK	B-NP	NN	B-protein	6	NMOD
6	activation	activation	I-NP	NN	O	8	NMOD
7	and	and	O	CC	O	8	NMOD
8	diazinon	diazinon	B-NP	NN	O	4	PMOD
9	induced	induce	B-VP	VBD	O	2	VMOD
10	hyperlipemia	hyperlipemia	B-NP	NN	O	9	OBJ
11	and	and	O	CC	O	9	VMOD
12	increased	increase	B-NP	VBN	O	13	NMOD
13	levels	level	I-NP	NNS	O	9	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	LDLr	LDLr	B-NP	NN	B-RNA	16	NMOD
16	transcript	transcript	I-NP	NN	I-RNA	14	PMOD
17	.	.	O	.	O	2	P

1	GEM-P	GEM-P	B-NP	NN	O	2	NMOD
2	chemotherapy	chemotherapy	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	active	active	B-ADJP	JJ	O	3	PRD
5	in	in	B-PP	IN	O	4	AMOD
6	the	the	B-NP	DT	O	7	NMOD
7	treatment	treatment	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	relapsed	relapse	B-NP	VBN	O	11	NMOD
10	Hodgkin	Hodgkin	I-NP	NN	O	11	NMOD
11	lymphoma	lymphoma	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	3	P

1	Gemcitabine	Gemcitabine	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	cisplatin	cisplatin	I-NP	NN	O	4	SUB
4	have	have	B-VP	VBP	O	0	ROOT
5	activity	activity	B-NP	NN	O	4	OBJ
6	in	in	B-PP	IN	O	4	VMOD
7	HL	HL	B-NP	NN	O	10	NMOD
8	,	,	O	,	O	10	P
9	non-overlapping	non-overlapping	B-NP	JJ	O	10	NMOD
10	toxicity	toxicity	I-NP	NN	O	6	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	first-line	first-line	B-NP	JJ	O	13	NMOD
13	chemotherapeutics	chemotherapeutic	I-NP	NNS	O	11	PMOD
14	,	,	O	,	O	4	P
15	and	and	O	CC	O	4	VMOD
16	may	may	B-VP	MD	O	4	VMOD
17	be	be	I-VP	VB	O	16	VC
18	delivered	deliver	I-VP	VBN	O	17	VC
19	in	in	B-PP	IN	O	18	VMOD
20	an	an	B-NP	DT	O	22	NMOD
21	outpatient	outpatient	I-NP	NN	O	22	NMOD
22	setting	setting	I-NP	NN	O	19	PMOD
23	.	.	O	.	O	4	P

1	In	In	B-PP	IN	O	55	VMOD
2	this	this	B-NP	DT	O	5	NMOD
3	retrospective	retrospective	I-NP	JJ	O	5	NMOD
4	single-centre	single-centre	I-NP	JJ	O	5	NMOD
5	analysis	analysis	I-NP	NN	O	1	PMOD
6	,	,	O	,	O	55	P
7	patients	patient	B-NP	NNS	O	51	NMOD
8	with	with	B-PP	IN	O	7	NMOD
9	relapsed	relapsed	B-NP	JJ	O	12	NMOD
10	or	or	I-NP	CC	O	12	NMOD
11	refractory	refractory	I-NP	JJ	O	12	NMOD
12	HL	HL	I-NP	NN	O	19	NMOD
13	treated	treat	B-VP	VBN	O	12	NMOD
14	with	with	B-PP	IN	O	13	VMOD
15	gemcitabine	gemcitabine	B-NP	NN	O	14	PMOD
16	1	1	I-NP	CD	O	15	NMOD
17	,	,	I-NP	,	O	19	P
18	000	000	I-NP	CD	O	19	NMOD
19	mg/m	mg/m	I-NP	NN	O	31	NMOD
20	(	(	O	(	O	22	DEP
21	2	2	B-NP	CD	O	22	DEP
22	)	)	O	)	O	19	NMOD
23	day	day	B-NP	NN	O	27	NMOD
24	(	(	O	(	O	26	DEP
25	D	D	B-NP	NN	O	26	DEP
26	)	)	O	)	O	23	NMOD
27	1	1	B-NP	CD	O	19	NMOD
28	,	,	O	,	O	31	P
29	D8	D8	B-NP	NN	O	31	NMOD
30	and	and	I-NP	CC	O	31	NMOD
31	D15	D15	I-NP	NN	B-protein	8	PMOD
32	;	;	O	:	O	51	P
33	methylprednisolone	methylprednisolone	B-NP	NN	O	37	NMOD
34	1	1	I-NP	CD	O	33	NMOD
35	,	,	I-NP	,	O	37	P
36	000	000	I-NP	CD	O	37	AMOD
37	mg	mg	I-NP	NN	O	38	NMOD
38	D1-5	D1-5	I-NP	NN	O	51	NMOD
39	;	;	O	:	O	51	P
40	and	and	O	CC	O	51	NMOD
41	cisplatin	cisplatin	B-NP	NN	B-protein	47	NMOD
42	100	100	I-NP	CD	I-protein	47	NMOD
43	mg/m	mg/m	I-NP	NN	I-protein	47	NMOD
44	(	(	O	(	I-protein	47	NMOD
45	2	2	B-NP	CD	I-protein	47	NMOD
46	)	)	O	)	I-protein	47	NMOD
47	D15	D15	B-NP	NN	I-protein	51	NMOD
48	,	,	O	,	O	51	P
49	every	every	B-NP	DT	O	51	NMOD
50	28	28	I-NP	CD	O	51	NMOD
51	days	day	I-NP	NNS	O	55	SUB
52	(	(	O	(	O	54	DEP
53	GEM-P	GEM-P	B-NP	NN	B-protein	54	DEP
54	)	)	O	)	O	51	NMOD
55	were	be	B-VP	VBD	O	0	ROOT
56	included	include	I-VP	VBN	O	55	VC
57	.	.	O	.	O	55	P

1	RATIONALE	RATIONALE	B-NP	NN	O	3	NMOD
2	:	:	O	:	O	1	P
3	Ecstasy	Ecstasy	B-NP	NN	O	7	SUB
4	(	(	O	(	O	6	DEP
5	MDMA	MDMA	B-NP	NN	B-protein	6	DEP
6	)	)	O	)	O	3	NMOD
7	is	be	B-VP	VBZ	O	0	ROOT
8	a	a	B-NP	DT	O	10	NMOD
9	psychostimulant	psychostimulant	I-NP	JJ	O	10	NMOD
10	drug	drug	I-NP	NN	O	7	PRD
11	which	which	B-NP	WDT	O	10	NMOD
12	is	be	B-VP	VBZ	O	11	SBAR
13	increasingly	increasingly	I-VP	RB	O	12	VMOD
14	associated	associate	I-VP	VBN	O	12	VC
15	with	with	B-PP	IN	O	14	VMOD
16	psychobiological	psychobiological	B-NP	JJ	O	17	NMOD
17	dysfunction	dysfunction	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	7	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	increases	increase	I-NP	NNS	O	9	SUB
5	in	in	B-PP	IN	O	4	NMOD
6	anxiety	anxiety	B-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	depression	depression	I-NP	NN	O	5	PMOD
9	are	be	B-VP	VBP	O	1	NMOD
10	in	in	B-PP	IN	O	9	PRD
11	line	line	B-NP	NN	O	10	PMOD
12	with	with	B-PP	IN	O	9	VMOD
13	previous	previous	B-NP	JJ	O	14	NMOD
14	observations	observation	I-NP	NNS	O	12	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	recreational	recreational	B-NP	JJ	O	18	NMOD
17	ecstasy-polydrug	ecstasy-polydrug	I-NP	JJ	O	18	NMOD
18	users	user	I-NP	NNS	O	15	PMOD
19	.	.	O	.	O	1	P

1	Ifosfamide	Ifosfamide	B-NP	NN	O	3	NMOD
2	related	related	I-NP	JJ	O	3	NMOD
3	encephalopathy	encephalopathy	I-NP	NN	O	6	NMOD
4	:	:	O	:	O	3	P
5	the	the	B-NP	DT	O	6	NMOD
6	need	need	I-NP	NN	O	0	ROOT
7	for	for	B-PP	IN	O	6	NMOD
8	a	a	B-NP	DT	O	11	NMOD
9	timely	timely	I-NP	JJ	O	11	NMOD
10	EEG	EEG	I-NP	NN	O	11	NMOD
11	evaluation	evaluation	I-NP	NN	O	7	PMOD
12	.	.	O	.	O	6	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Ifosfamide	Ifosfamide	B-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	1	NMOD
5	an	an	B-NP	DT	O	7	NMOD
6	alkylating	alkylate	I-NP	VBG	O	7	NMOD
7	agent	agent	I-NP	NN	O	4	PRD
8	useful	useful	B-ADJP	JJ	O	7	NMOD
9	in	in	B-PP	IN	O	8	AMOD
10	the	the	B-NP	DT	O	11	NMOD
11	treatment	treatment	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	a	a	B-NP	DT	O	15	NMOD
14	wide	wide	I-NP	JJ	O	15	NMOD
15	range	range	I-NP	NN	O	12	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	cancers	cancer	B-NP	NNS	O	16	PMOD
18	including	include	B-PP	VBG	O	17	NMOD
19	sarcomas	sarcoma	B-NP	NNS	O	26	NMOD
20	,	,	O	,	O	26	P
21	lymphoma	lymphoma	B-NP	NN	O	26	NMOD
22	,	,	O	,	O	26	P
23	gynecologic	gynecologic	B-NP	JJ	O	26	NMOD
24	and	and	I-NP	CC	O	26	NMOD
25	testicular	testicular	I-NP	JJ	O	26	NMOD
26	cancers	cancer	I-NP	NNS	O	18	PMOD
27	.	.	O	.	O	1	P

1	Encephalopathy	Encephalopathy	B-NP	NN	O	2	SUB
2	has	have	B-VP	VBZ	O	0	ROOT
3	been	be	I-VP	VBN	O	2	VC
4	reported	report	I-VP	VBN	O	3	VC
5	in	in	B-PP	IN	O	4	VMOD
6	10-40	10-40	B-NP	CD	O	7	NMOD
7	%	%	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	patients	patient	B-NP	NNS	O	8	PMOD
10	receiving	receive	B-VP	VBG	O	9	NMOD
11	high-dose	high-dose	B-NP	JJ	O	13	NMOD
12	IV	IV	I-NP	CD	O	13	NMOD
13	ifosfamide	ifosfamide	I-NP	NN	O	10	OBJ
14	.	.	O	.	O	2	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	highlight	highlight	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	role	role	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	electroencephalogram	electroencephalogram	B-NP	NN	O	7	PMOD
9	(	(	O	(	O	11	DEP
10	EEG	EEG	B-NP	NN	B-protein	11	DEP
11	)	)	O	)	O	8	NMOD
12	in	in	B-PP	IN	O	6	NMOD
13	the	the	B-NP	DT	O	17	NMOD
14	early	early	I-NP	JJ	O	15	NMOD
15	detection	detection	I-NP	NN	O	17	NMOD
16	and	and	I-NP	CC	O	17	NMOD
17	management	management	I-NP	NN	O	12	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	ifosfamide	ifosfamide	B-NP	NN	O	21	NMOD
20	related	related	I-NP	JJ	O	21	NMOD
21	encephalopathy	encephalopathy	I-NP	NN	O	18	PMOD
22	.	.	O	.	O	4	P

1	METHODS	METHODS	B-NP	NNS	O	5	NMOD
2	:	:	O	:	O	1	P
3	Retrospective	Retrospective	B-NP	JJ	O	5	NMOD
4	chart	chart	I-NP	NN	O	5	NMOD
5	review	review	I-NP	NN	O	12	SUB
6	including	include	B-PP	VBG	O	5	NMOD
7	clinical	clinical	B-NP	JJ	O	8	NMOD
8	data	datum	I-NP	NNS	O	11	NMOD
9	and	and	I-NP	CC	O	11	NMOD
10	EEG	EEG	I-NP	NN	O	11	NMOD
11	recordings	recording	I-NP	NNS	O	6	PMOD
12	was	be	B-VP	VBD	O	0	ROOT
13	done	do	I-VP	VBN	O	12	VC
14	on	on	B-PP	IN	O	13	VMOD
15	five	five	B-NP	CD	O	16	NMOD
16	patients	patient	I-NP	NNS	O	14	PMOD
17	,	,	O	,	O	13	P
18	admitted	admit	B-VP	VBN	O	13	VMOD
19	to	to	B-PP	TO	O	18	VMOD
20	MD	MD	B-NP	NNP	O	23	NMOD
21	Anderson	Anderson	I-NP	NNP	O	23	NMOD
22	Cancer	Cancer	I-NP	NNP	O	23	NMOD
23	Center	Center	I-NP	NNP	O	19	PMOD
24	between	between	B-PP	IN	O	23	NMOD
25	years	year	B-NP	NNS	O	24	PMOD
26	2009	2009	B-NP	CD	O	28	NMOD
27	and	and	I-NP	CC	O	28	NMOD
28	2012	2012	I-NP	CD	O	25	NMOD
29	,	,	O	,	O	23	P
30	who	who	B-NP	WP	O	23	NMOD
31	developed	develop	B-VP	VBD	O	30	SBAR
32	ifosfamide	ifosfamide	B-NP	NN	O	35	NMOD
33	related	related	I-NP	JJ	O	35	NMOD
34	acute	acute	I-NP	JJ	O	35	NMOD
35	encephalopathy	encephalopathy	I-NP	NN	O	31	OBJ
36	.	.	O	.	O	12	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	All	All	B-NP	DT	O	5	NMOD
4	five	five	I-NP	CD	O	5	NMOD
5	patients	patient	I-NP	NNS	O	6	SUB
6	experienced	experience	B-VP	VBD	O	1	NMOD
7	symptoms	symptom	B-NP	NNS	O	6	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	encephalopathy	encephalopathy	B-NP	NN	O	8	PMOD
10	soon	soon	B-ADVP	RB	O	6	VMOD
11	after	after	B-SBAR	IN	O	10	AMOD
12	(	(	O	(	O	17	DEP
13	within	within	B-PP	IN	O	17	DEP
14	12	12	B-NP	CD	O	16	NMOD
15	h-2	h-2	I-NP	NN	O	16	NMOD
16	days	day	I-NP	NNS	O	13	PMOD
17	)	)	O	)	O	19	NMOD
18	receiving	receive	B-VP	VBG	O	19	NMOD
19	ifosfamide	ifosfamide	B-NP	NN	O	11	PMOD
20	.	.	O	.	O	1	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Severity	Severity	B-NP	NN	O	8	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	ifosfamide	ifosfamide	B-NP	NN	O	7	NMOD
6	related	related	I-NP	JJ	O	7	NMOD
7	encephalopathy	encephalopathy	I-NP	NN	O	4	PMOD
8	correlates	correlate	B-VP	VBZ	O	1	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	EEG	EEG	B-NP	NN	O	11	NMOD
11	changes	change	I-NP	NNS	O	9	PMOD
12	.	.	O	.	O	1	P

1	Incidence	Incidence	B-NP	NN	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	contrast	contrast	B-NP	NN	O	2	PMOD
4	induced	induce	B-VP	VBD	O	0	ROOT
5	nephropathy	nephropathy	B-NP	NN	O	4	OBJ
6	in	in	B-PP	IN	O	4	VMOD
7	hospitalised	hospitalised	B-NP	JJ	O	8	NMOD
8	patients	patient	I-NP	NNS	O	6	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	cancer	cancer	B-NP	NN	O	9	PMOD
11	.	.	O	.	O	4	P

1	OBJECTIVES	OBJECTIVES	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	determine	determine	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	frequency	frequency	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	and	and	O	CC	O	7	PMOD
9	possible	possible	B-NP	JJ	O	10	NMOD
10	factors	factor	I-NP	NNS	O	7	PMOD
11	related	related	B-ADJP	JJ	O	10	NMOD
12	to	to	B-PP	TO	O	11	AMOD
13	contrast	contrast	B-NP	NN	O	15	NMOD
14	induced	induced	I-NP	JJ	O	15	NMOD
15	nephropathy	nephropathy	I-NP	NN	O	12	PMOD
16	(	(	O	(	O	18	DEP
17	CIN	CIN	B-NP	NN	B-protein	18	DEP
18	)	)	O	)	O	15	NMOD
19	in	in	B-PP	IN	O	15	NMOD
20	hospitalised	hospitalised	B-NP	JJ	O	21	NMOD
21	patients	patient	I-NP	NNS	O	19	PMOD
22	with	with	B-PP	IN	O	21	NMOD
23	cancer	cancer	B-NP	NN	O	22	PMOD
24	.	.	O	.	O	1	P

1	CIN	CIN	B-NP	NN	B-protein	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	significantly	significantly	B-ADJP	RB	O	4	AMOD
4	more	more	I-ADJP	JJR	O	2	PRD
5	after	after	B-PP	IN	O	2	VMOD
6	treatment	treatment	B-NP	NN	O	5	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	bevacizumab/irinotecan	bevacizumab/irinotecan	B-NP	NN	O	7	PMOD
9	(	(	O	(	O	13	DEP
10	P	P	B-NP	NN	O	12	SUB
11	=	=	B-VP	SYM	O	12	VMOD
12	0.021	0.021	B-NP	CD	O	13	DEP
13	)	)	O	)	O	2	VMOD
14	and	and	O	CC	O	2	VMOD
15	in	in	B-PP	IN	O	2	VMOD
16	patients	patient	B-NP	NNS	O	15	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	hypertension	hypertension	B-NP	NN	O	17	PMOD
19	(	(	O	(	O	23	DEP
20	P	P	B-NP	NN	O	23	DEP
21	=	=	B-VP	SYM	O	20	NMOD
22	0.044	0.044	B-NP	CD	O	21	AMOD
23	)	)	O	)	O	16	NMOD
24	.	.	O	.	O	2	P

1	Hypertension	Hypertension	B-NP	NN	O	4	NMOD
2	and	and	O	CC	O	4	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	combination	combination	I-NP	NN	O	7	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	bevacizumab/irinotecan	bevacizumab/irinotecan	B-NP	NN	O	5	PMOD
7	may	may	B-VP	MD	O	0	ROOT
8	be	be	I-VP	VB	O	7	VC
9	additional	additional	B-NP	JJ	O	11	NMOD
10	risk	risk	I-NP	NN	O	11	NMOD
11	factors	factor	I-NP	NNS	O	8	PRD
12	for	for	B-PP	IN	O	11	NMOD
13	CIN	CIN	B-NP	NN	O	14	NMOD
14	development	development	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	7	P

1	Contrast	Contrast	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	nephropathy	nephropathy	B-NP	NN	O	2	OBJ
4	(	(	O	(	O	6	DEP
5	CIN	CIN	B-NP	NN	B-protein	6	DEP
6	)	)	O	)	O	3	NMOD
7	is	be	B-VP	VBZ	O	2	VMOD
8	a	a	B-NP	DT	O	9	NMOD
9	concern	concern	I-NP	NN	O	7	PRD
10	for	for	B-PP	IN	O	9	NMOD
11	oncological	oncological	B-NP	JJ	O	12	NMOD
12	patients	patient	I-NP	NNS	O	10	PMOD
13	undergoing	undergo	B-VP	VBG	O	12	NMOD
14	CT.	CT.	B-NP	NNP	O	13	OBJ
15	.	.	O	.	O	2	P

1	Syndrome	Syndrome	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	inappropriate	inappropriate	B-NP	JJ	O	6	NMOD
4	antidiuretic	antidiuretic	I-NP	JJ	O	6	NMOD
5	hormone	hormone	I-NP	NN	O	6	NMOD
6	secretion	secretion	I-NP	NN	O	2	PMOD
7	associated	associate	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	desvenlafaxine	desvenlafaxine	B-NP	NN	O	8	PMOD
10	.	.	O	.	O	1	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	report	report	I-VP	VB	O	1	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	syndrome	syndrome	B-NP	NN	O	7	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	inappropriate	inappropriate	B-NP	JJ	O	12	NMOD
11	anti-diuretic	anti-diuretic	I-NP	JJ	O	12	NMOD
12	hormone	hormone	I-NP	NN	O	16	NMOD
13	(	(	O	(	O	15	DEP
14	SIADH	SIADH	B-NP	NN	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	secretion	secretion	B-NP	NN	O	9	PMOD
17	associated	associate	B-VP	VBN	O	16	NMOD
18	with	with	B-PP	IN	O	17	VMOD
19	desvenlafaxine	desvenlafaxine	B-NP	NN	O	18	PMOD
20	.	.	O	.	O	1	P

1	Her	Her	B-NP	PRP$	O	2	NMOD
2	medications	medication	I-NP	NNS	O	3	SUB
3	included	include	B-VP	VBD	O	8	VMOD
4	desvenlafaxine	desvenlafaxine	B-NP	NN	O	3	OBJ
5	,	,	O	,	O	8	P
6	and	and	O	CC	O	8	VMOD
7	symptoms	symptom	B-NP	NNS	O	8	SUB
8	included	include	B-VP	VBD	O	0	ROOT
9	nausea	nausea	B-NP	NN	O	13	NMOD
10	,	,	I-NP	,	O	13	P
11	anxiety	anxiety	I-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	confusion	confusion	I-NP	NN	O	8	OBJ
14	.	.	O	.	O	8	P

1	The	The	B-NP	DT	O	3	NMOD
2	serum	serum	I-NP	NN	O	3	NMOD
3	sodium	sodium	I-NP	NN	O	7	SUB
4	at	at	B-PP	IN	O	3	NMOD
5	this	this	B-NP	DT	O	6	NMOD
6	time	time	I-NP	NN	O	4	PMOD
7	was	be	B-VP	VBD	O	13	VMOD
8	120	120	B-NP	CD	O	9	NMOD
9	mmol/L	mmol/L	I-NP	NN	O	7	PRD
10	,	,	O	,	O	13	P
11	serum	serum	B-NP	NN	B-protein	12	NMOD
12	osmolality	osmolality	I-NP	NN	I-protein	13	SUB
13	was	be	B-VP	VBD	I-protein	25	NMOD
14	263	263	B-NP	CD	I-protein	15	NMOD
15	mosmol/kg	mosmol/kg	I-NP	NN	I-protein	13	PRD
16	,	,	O	,	O	25	P
17	urine	urine	B-NP	NN	O	20	NMOD
18	osmolality	osmolality	I-NP	NN	O	20	NMOD
19	410	410	I-NP	CD	O	20	NMOD
20	mosmol/kg	mosmol/kg	I-NP	NN	O	25	NMOD
21	and	and	I-NP	CC	O	25	NMOD
22	urine	urine	I-NP	NN	O	25	NMOD
23	sodium	sodium	I-NP	NN	O	25	NMOD
24	63	63	I-NP	CD	O	25	NMOD
25	mmol/L	mmol/L	I-NP	NN	O	0	ROOT
26	,	,	O	,	O	25	P
27	consistent	consistent	B-ADJP	JJ	O	25	NMOD
28	with	with	B-PP	IN	O	27	AMOD
29	a	a	B-NP	DT	O	30	NMOD
30	diagnosis	diagnosis	I-NP	NN	O	28	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	SIADH	SIADH	B-NP	NN	B-protein	31	PMOD
33	.	.	O	.	O	25	P

1	This	This	B-NP	DT	O	3	NMOD
2	case	case	I-NP	NN	O	3	NMOD
3	report	report	I-NP	NN	O	4	SUB
4	suggests	suggest	B-VP	VBZ	O	0	ROOT
5	that	that	B-SBAR	IN	O	4	VMOD
6	desvenlafaxine	desvenlafaxine	B-NP	NN	O	7	SUB
7	might	might	B-VP	MD	O	5	SBAR
8	cause	cause	I-VP	VB	O	7	VC
9	clinically	clinically	B-NP	RB	O	10	AMOD
10	significant	significant	I-NP	JJ	O	11	NMOD
11	hyponatremia	hyponatremia	I-NP	NN	O	8	OBJ
12	.	.	O	.	O	4	P

1	Oxidative	Oxidative	B-NP	JJ	O	2	NMOD
2	stress	stress	I-NP	NN	O	0	ROOT
3	on	on	B-PP	IN	O	2	NMOD
4	cardiotoxicity	cardiotoxicity	B-NP	NN	O	3	PMOD
5	after	after	B-PP	IN	O	2	NMOD
6	treatment	treatment	B-NP	NN	O	5	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	single	single	B-NP	JJ	O	11	NMOD
9	and	and	I-NP	CC	O	11	NMOD
10	multiple	multiple	I-NP	JJ	O	11	NMOD
11	doses	dose	I-NP	NNS	O	7	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	doxorubicin	doxorubicin	B-NP	NN	O	12	PMOD
14	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	mechanism	mechanism	I-NP	NN	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	doxorubicin	doxorubicin	B-NP	NN	O	9	NMOD
5	(	(	O	(	O	7	DEP
6	DOX	DOX	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	induced	induce	B-NP	VBN	O	9	NMOD
9	cardiotoxicity	cardiotoxicity	I-NP	NN	O	3	PMOD
10	remains	remain	B-VP	VBZ	O	0	ROOT
11	controversial	controversial	B-ADJP	JJ	O	10	PRD
12	.	.	O	.	O	10	P

1	Single	Single	B-NP	JJ	O	2	NMOD
2	dose	dose	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	DOX	DOX	B-NP	NN	O	3	PMOD
5	was	be	B-VP	VBD	O	0	ROOT
6	associated	associate	I-VP	VBN	O	5	VC
7	with	with	B-PP	IN	O	6	VMOD
8	increased	increase	B-NP	VBN	O	10	NMOD
9	cardiac	cardiac	I-NP	JJ	O	10	NMOD
10	disarrangement	disarrangement	I-NP	NN	O	16	NMOD
11	,	,	O	,	O	16	P
12	necrosis	necrosis	B-NP	NN	O	16	NMOD
13	,	,	O	,	O	16	P
14	and	and	O	CC	O	16	NMOD
15	DNA	DNA	B-NP	NN	O	16	NMOD
16	damage	damage	I-NP	NN	O	25	NMOD
17	(	(	O	(	O	22	DEP
18	strand	strand	B-NP	NN	O	19	NMOD
19	breaks	break	I-NP	NNS	O	22	DEP
20	(	(	O	(	O	22	DEP
21	SBs	SB	B-NP	NNS	B-protein	22	DEP
22	)	)	O	)	O	16	NMOD
23	and	and	O	CC	O	25	NMOD
24	oxidized	oxidize	B-NP	VBN	O	25	NMOD
25	pyrimidines	pyrimidine	I-NP	NNS	O	7	PMOD
26	)	)	O	)	O	6	VMOD
27	and	and	O	CC	O	6	VMOD
28	decreased	decrease	B-NP	VBN	O	29	NMOD
29	TAP	TAP	I-NP	NN	B-protein	6	VMOD
30	.	.	O	.	O	5	P

1	Our	Our	B-NP	PRP$	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	oxidative	oxidative	B-NP	JJ	O	6	NMOD
6	damage	damage	I-NP	NN	O	7	SUB
7	is	be	B-VP	VBZ	O	4	SBAR
8	associated	associate	I-VP	VBN	O	7	VC
9	with	with	B-PP	IN	O	8	VMOD
10	acute	acute	B-NP	JJ	O	11	NMOD
11	cardiotoxicity	cardiotoxicity	I-NP	NN	O	9	PMOD
12	induced	induce	B-VP	VBN	O	11	NMOD
13	by	by	B-PP	IN	O	12	VMOD
14	a	a	B-NP	DT	O	16	NMOD
15	single	single	I-NP	JJ	O	16	NMOD
16	dose	dose	I-NP	NN	O	13	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	DOX	DOX	B-NP	NN	O	17	PMOD
19	only	only	B-ADVP	RB	O	16	NMOD
20	.	.	O	.	O	3	P

1	Tacrolimus-related	Tacrolimus-related	B-NP	JJ	O	2	NMOD
2	seizure	seizure	I-NP	NN	O	10	NMOD
3	after	after	B-PP	IN	O	2	NMOD
4	pediatric	pediatric	B-NP	JJ	O	6	NMOD
5	liver	liver	I-NP	NN	O	6	NMOD
6	transplantation	transplantation	I-NP	NN	O	3	PMOD
7	--	--	O	:	O	2	P
8	a	a	B-NP	DT	O	10	NMOD
9	single-center	single-center	I-NP	JJ	O	10	NMOD
10	experience	experience	I-NP	NN	O	0	ROOT
11	.	.	O	.	O	10	P

1	Univariate	Univariate	B-NP	JJ	O	2	NMOD
2	analysis	analysis	I-NP	NN	O	3	SUB
3	showed	show	B-VP	VBD	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	the	the	B-NP	DT	O	7	NMOD
6	risk	risk	I-NP	NN	B-protein	7	NMOD
7	factors	factor	I-NP	NNS	I-protein	14	SUB
8	associated	associate	B-VP	VBN	O	7	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	seizures	seizure	B-NP	NNS	O	9	PMOD
11	after	after	B-PP	IN	O	10	NMOD
12	pediatric	pediatric	B-NP	JJ	O	13	NMOD
13	LT	LT	I-NP	NN	O	11	PMOD
14	included	include	B-VP	VBD	O	4	SBAR
15	gender	gender	B-NP	NN	O	21	NMOD
16	,	,	O	,	O	21	P
17	pediatric	pediatric	B-NP	JJ	O	21	NMOD
18	end-stage	end-stage	I-NP	NN	O	21	NMOD
19	liver	liver	I-NP	NN	O	21	NMOD
20	disease	disease	I-NP	NN	O	21	NMOD
21	score	score	I-NP	NN	O	26	NMOD
22	before	before	B-PP	IN	O	21	NMOD
23	surgery	surgery	B-NP	NN	O	22	PMOD
24	,	,	O	,	O	26	P
25	Child-Pugh	Child-Pugh	B-NP	JJ	O	26	NMOD
26	score	score	I-NP	NN	O	32	NMOD
27	before	before	B-PP	IN	O	26	NMOD
28	surgery	surgery	B-NP	NN	O	27	PMOD
29	,	,	O	,	O	32	P
30	serum	serum	B-NP	NN	B-protein	32	NMOD
31	total	total	I-NP	JJ	I-protein	32	NMOD
32	bilirubin	bilirubin	I-NP	NN	I-protein	39	NMOD
33	after	after	B-PP	IN	O	32	NMOD
34	surgery	surgery	B-NP	NN	O	33	PMOD
35	,	,	O	,	O	39	P
36	and	and	O	CC	O	39	NMOD
37	trough	trough	B-NP	NN	O	39	NMOD
38	TAC	TAC	I-NP	NN	O	39	NMOD
39	level	level	I-NP	NN	O	14	OBJ
40	.	.	O	.	O	3	P

1	Multivariate	Multivariate	B-NP	JJ	O	2	NMOD
2	analysis	analysis	I-NP	NN	O	3	SUB
3	showed	show	B-VP	VBD	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	trough	trough	B-NP	NN	O	7	NMOD
6	TAC	TAC	I-NP	NN	O	7	NMOD
7	level	level	I-NP	NN	O	8	SUB
8	was	be	B-VP	VBD	O	4	SBAR
9	the	the	B-NP	DT	O	13	NMOD
10	only	only	I-NP	RB	O	11	AMOD
11	independent	independent	I-NP	JJ	O	13	NMOD
12	risk	risk	I-NP	NN	O	13	NMOD
13	factor	factor	I-NP	NN	O	8	PRD
14	associated	associate	B-VP	VBN	O	13	NMOD
15	with	with	B-PP	IN	O	14	VMOD
16	the	the	B-NP	DT	O	17	NMOD
17	seizures	seizure	I-NP	NNS	O	15	PMOD
18	.	.	O	.	O	3	P

1	High	High	B-NP	JJ	O	4	NMOD
2	trough	trough	I-NP	NN	O	4	NMOD
3	TAC	TAC	I-NP	NN	O	4	NMOD
4	level	level	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	0	ROOT
6	the	the	B-NP	DT	O	8	NMOD
7	predominant	predominant	I-NP	JJ	O	8	NMOD
8	factor	factor	I-NP	NN	O	5	PRD
9	that	that	B-NP	WDT	O	8	NMOD
10	contributed	contribute	B-VP	VBD	O	9	SBAR
11	to	to	B-PP	TO	O	10	VMOD
12	seizures	seizure	B-NP	NNS	O	11	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	17	NMOD
15	early	early	I-NP	JJ	O	16	AMOD
16	post-operative	post-operative	I-NP	JJ	O	17	NMOD
17	period	period	I-NP	NN	O	13	PMOD
18	after	after	B-PP	IN	O	10	VMOD
19	pediatric	pediatric	B-NP	JJ	O	20	NMOD
20	LT	LT	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	5	P

1	Furthermore	Furthermore	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	apigenin	apigenin	B-NP	NN	O	4	SUB
4	did	do	B-VP	VBD	O	0	ROOT
5	not	not	I-VP	RB	O	4	VMOD
6	prevent	prevent	I-VP	VB	O	4	VC
7	the	the	B-NP	DT	O	8	NMOD
8	amnesia	amnesia	I-NP	NN	O	6	OBJ
9	induced	induce	B-VP	VBN	O	8	NMOD
10	by	by	B-PP	IN	O	9	VMOD
11	scopolamine	scopolamine	B-NP	NN	O	18	NMOD
12	(	(	O	(	O	18	NMOD
13	1mg/kg	1mg/kg	B-NP	NN	O	18	NMOD
14	,	,	O	,	O	13	P
15	i.p.	i.p.	B-ADVP	RB	O	13	NMOD
16	,	,	O	,	O	18	P
17	30	30	B-NP	CD	O	18	NMOD
18	min	min	I-NP	NN	O	10	PMOD
19	before	before	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	21	NMOD
21	acquisition	acquisition	I-NP	NN	O	19	PMOD
22	)	)	O	)	O	8	NMOD
23	.	.	O	.	O	4	P

1	We	We	B-NP	PRP	O	2	SUB
2	have	have	B-VP	VBP	O	0	ROOT
3	previously	previously	I-VP	RB	O	2	VMOD
4	reported	report	I-VP	VBN	O	2	VC
5	that	that	B-SBAR	IN	O	4	VMOD
6	CCK-8	CCK-8	B-NP	NN	B-protein	8	SUB
7	significantly	significantly	B-ADVP	RB	O	8	VMOD
8	alleviated	alleviate	B-VP	VBD	O	5	SBAR
9	morphine	morphine	B-NP	NN	O	11	NMOD
10	induced	induced	I-NP	JJ	O	11	NMOD
11	amnesia	amnesia	I-NP	NN	O	8	OBJ
12	and	and	O	CC	O	8	VMOD
13	reversed	reverse	B-VP	VBD	O	8	VMOD
14	spine	spine	B-NP	NN	O	15	NMOD
15	density	density	I-NP	NN	O	13	OBJ
16	decreases	decrease	B-VP	VBZ	O	5	DEP
17	in	in	B-PP	IN	O	16	VMOD
18	the	the	B-NP	DT	O	20	NMOD
19	CA1	CA1	I-NP	NN	B-DNA	20	NMOD
20	region	region	I-NP	NN	I-DNA	17	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	the	the	B-NP	DT	O	23	NMOD
23	hippocampus	hippocampus	I-NP	NN	O	21	PMOD
24	in	in	B-PP	IN	O	20	NMOD
25	morphine-treated	morphine-treated	B-NP	JJ	O	26	NMOD
26	animals	animal	I-NP	NNS	O	24	PMOD
27	.	.	O	.	O	2	P

1	Glial	Glial	B-NP	JJ	O	2	NMOD
2	activation	activation	I-NP	NN	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	post-synaptic	post-synaptic	B-NP	JJ	O	5	NMOD
5	neurotoxicity	neurotoxicity	I-NP	NN	O	9	NMOD
6	:	:	O	:	O	5	P
7	the	the	B-NP	DT	O	9	NMOD
8	key	key	I-NP	JJ	O	9	NMOD
9	events	event	I-NP	NNS	O	0	ROOT
10	in	in	B-PP	IN	O	9	NMOD
11	Streptozotocin	Streptozotocin	B-NP	NN	O	17	NMOD
12	(	(	O	(	O	14	DEP
13	ICV	ICV	B-NP	NN	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	induced	induce	B-VP	VBD	O	17	VMOD
16	memory	memory	B-NP	NN	O	17	NMOD
17	impairment	impairment	I-NP	NN	O	10	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	rats	rat	B-NP	NNS	O	18	PMOD
20	.	.	O	.	O	9	P

1	In	In	B-PP	IN	O	20	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	present	present	I-NP	JJ	O	4	NMOD
4	study	study	I-NP	NN	O	1	PMOD
5	the	the	B-NP	DT	O	6	NMOD
6	role	role	I-NP	NN	O	20	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	glial	glial	B-NP	JJ	O	9	NMOD
9	activation	activation	I-NP	NN	O	13	NMOD
10	and	and	O	CC	O	13	NMOD
11	post	post	B-NP	NN	O	13	NMOD
12	synaptic	synaptic	I-NP	JJ	O	13	NMOD
13	toxicity	toxicity	I-NP	NN	O	7	PMOD
14	in	in	B-PP	IN	O	6	NMOD
15	ICV	ICV	B-NP	NN	O	16	NMOD
16	Streptozotocin	Streptozotocin	I-NP	NN	O	14	PMOD
17	(	(	O	(	O	19	DEP
18	STZ	STZ	B-NP	NN	B-protein	19	DEP
19	)	)	O	)	O	16	NMOD
20	induced	induce	B-VP	VBD	O	0	ROOT
21	memory	memory	B-NP	NN	O	23	NMOD
22	impaired	impaired	I-NP	JJ	O	23	NMOD
23	rats	rat	I-NP	NNS	O	20	OBJ
24	was	be	B-VP	VBD	O	20	VMOD
25	explored	explore	I-VP	VBN	O	24	VC
26	.	.	O	.	O	20	P

1	In	In	B-PP	IN	O	0	ROOT
2	experiment	experiment	B-NP	NN	O	8	NMOD
3	set	set	B-VP	VBN	O	8	NMOD
4	up	up	B-PRT	RP	O	3	VMOD
5	1	1	B-NP	CD	O	8	NMOD
6	:	:	I-NP	SYM	O	8	NMOD
7	Memory	Memory	I-NP	NN	O	8	NMOD
8	deficit	deficit	I-NP	NN	O	9	SUB
9	was	be	B-VP	VBD	O	1	SBAR
10	found	find	I-VP	VBN	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	Morris	Morris	B-NP	NNP	O	15	NMOD
13	water	water	I-NP	NN	O	15	NMOD
14	maze	maze	I-NP	NN	O	15	NMOD
15	test	test	I-NP	NN	O	11	PMOD
16	on	on	B-PP	IN	O	15	NMOD
17	14-16	14-16	B-NP	CD	O	18	NMOD
18	days	day	I-NP	NNS	O	16	PMOD
19	after	after	B-PP	IN	O	18	NMOD
20	STZ	STZ	B-NP	NN	B-protein	26	NMOD
21	(	(	O	(	O	25	DEP
22	ICV	ICV	B-NP	NN	O	24	NMOD
23	;	;	O	:	O	24	P
24	3mg/Kg	3mg/Kg	B-NP	NN	O	25	DEP
25	)	)	O	)	O	20	NMOD
26	administration	administration	B-NP	NN	O	19	PMOD
27	.	.	O	.	O	1	P

1	STZ	STZ	B-NP	NN	B-protein	2	SUB
2	causes	cause	B-VP	VBZ	O	0	ROOT
3	increased	increase	B-NP	VBN	O	4	NMOD
4	expression	expression	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	GFAP	GFAP	B-NP	NN	B-protein	10	NMOD
7	,	,	O	,	O	10	P
8	CD11b	CD11b	B-NP	NN	B-protein	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	TNF-a	TNF-a	I-NP	NN	B-protein	5	PMOD
11	indicating	indicate	B-VP	VBG	O	4	NMOD
12	glial	glial	B-NP	JJ	O	15	NMOD
13	activation	activation	I-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	neuroinflammation	neuroinflammation	I-NP	NN	O	11	OBJ
16	.	.	O	.	O	2	P

1	STZ	STZ	B-NP	NN	B-protein	4	SUB
2	also	also	B-ADVP	RB	O	4	VMOD
3	significantly	significantly	B-VP	RB	O	2	AMOD
4	increased	increase	I-VP	VBD	O	0	ROOT
5	the	the	B-NP	DT	O	6	NMOD
6	level	level	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	ROS	ROS	B-NP	NN	O	17	SUB
9	,	,	O	,	O	17	P
10	nitrite	nitrite	B-NP	NN	O	17	SUB
11	,	,	O	,	O	17	P
12	Ca	Ca	B-NP	NN	O	17	SUB
13	(	(	O	(	O	15	DEP
14	2+	2+	B-ADJP	JJ	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	and	and	O	CC	O	17	VMOD
17	reduced	reduce	B-VP	VBD	O	7	SBAR
18	the	the	B-NP	DT	O	20	NMOD
19	mitochondrial	mitochondrial	I-NP	JJ	O	20	NMOD
20	activity	activity	I-NP	NN	O	17	OBJ
21	in	in	B-PP	IN	O	17	VMOD
22	synaptosomal	synaptosomal	B-NP	JJ	O	23	NMOD
23	preparation	preparation	I-NP	NN	O	21	PMOD
24	illustrating	illustrate	B-VP	VBG	O	23	NMOD
25	free	free	B-NP	JJ	O	27	NMOD
26	radical	radical	I-NP	NN	O	27	NMOD
27	generation	generation	I-NP	NN	O	29	NMOD
28	and	and	I-NP	CC	O	29	NMOD
29	excitotoxicity	excitotoxicity	I-NP	NN	O	24	OBJ
30	.	.	O	.	O	4	P

1	STZ	STZ	B-NP	NN	O	2	NMOD
2	treatment	treatment	I-NP	NN	O	3	SUB
3	showed	show	B-VP	VBD	O	0	ROOT
4	decrease	decrease	B-NP	NN	O	5	NMOD
5	expression	expression	I-NP	NN	O	26	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	post	post	B-NP	JJ	O	9	NMOD
8	synaptic	synaptic	I-NP	JJ	O	9	NMOD
9	markers	marker	I-NP	NNS	O	16	NMOD
10	CaMKIIa	CaMKIIa	I-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	PSD-95	PSD-95	I-NP	NN	B-protein	9	NMOD
13	,	,	O	,	O	16	P
14	while	while	B-NP	NN	O	16	NMOD
15	,	,	O	,	O	16	P
16	expression	expression	B-NP	NN	O	6	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	pre	pre	B-NP	JJ	O	20	NMOD
19	synaptic	synaptic	I-NP	JJ	O	20	NMOD
20	markers	marker	I-NP	NNS	O	17	PMOD
21	(	(	O	(	O	25	DEP
22	synaptophysin	synaptophysin	B-NP	NN	O	24	NMOD
23	and	and	O	CC	O	24	NMOD
24	SNAP-25	SNAP-25	B-NP	NN	B-protein	25	DEP
25	)	)	O	)	O	20	NMOD
26	remains	remain	B-VP	VBZ	O	3	VMOD
27	unaltered	unaltered	B-NP	JJ	O	32	NMOD
28	indicating	indicate	I-NP	VBG	O	32	NMOD
29	selective	selective	I-NP	JJ	O	32	NMOD
30	post	post	I-NP	NN	O	32	NMOD
31	synaptic	synaptic	I-NP	JJ	O	32	NMOD
32	neurotoxicity	neurotoxicity	I-NP	NN	O	26	OBJ
33	.	.	O	.	O	3	P

1	Oral	Oral	B-NP	JJ	O	2	NMOD
2	treatment	treatment	I-NP	NN	O	0	ROOT
3	with	with	B-PP	IN	O	2	NMOD
4	Memantine	Memantine	B-NP	NN	O	9	NMOD
5	(	(	O	(	O	7	DEP
6	10mg/kg	10mg/kg	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	and	and	O	CC	O	9	NMOD
9	Ibuprofen	Ibuprofen	B-NP	NN	O	3	PMOD
10	(	(	O	(	O	13	DEP
11	50	50	B-NP	CD	O	12	NMOD
12	mg/kg	mg/kg	I-NP	NN	O	13	DEP
13	)	)	O	)	O	9	NMOD
14	daily	daily	B-ADVP	RB	O	15	PMOD
15	for	for	B-PP	IN	O	2	NMOD
16	13	13	B-NP	CD	O	17	NMOD
17	days	day	I-NP	NNS	O	15	PMOD
18	attenuated	attenuate	B-VP	VBD	O	15	SBAR
19	STZ	STZ	B-NP	NN	B-protein	22	NMOD
20	induced	induced	I-NP	JJ	O	22	NMOD
21	glial	glial	I-NP	JJ	O	22	NMOD
22	activation	activation	I-NP	NN	O	18	OBJ
23	,	,	O	,	O	15	P
24	apoptotic	apoptotic	B-NP	JJ	O	26	NMOD
25	cell	cell	I-NP	NN	O	26	NMOD
26	death	death	I-NP	NN	O	30	NMOD
27	and	and	O	CC	O	30	NMOD
28	post	post	B-NP	NN	O	30	NMOD
29	synaptic	synaptic	I-NP	JJ	O	30	NMOD
30	neurotoxicity	neurotoxicity	I-NP	NN	O	15	PMOD
31	in	in	B-PP	IN	O	30	NMOD
32	rat	rat	B-NP	NN	O	33	NMOD
33	brain	brain	I-NP	NN	O	31	PMOD
34	.	.	O	.	O	2	P

1	Comparison	Comparison	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	effects	effect	B-NP	NNS	O	2	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	isotonic	isotonic	B-NP	JJ	O	7	NMOD
6	sodium	sodium	I-NP	NN	O	7	NMOD
7	chloride	chloride	I-NP	NN	O	4	PMOD
8	with	with	B-PP	IN	O	3	NMOD
9	diltiazem	diltiazem	B-NP	NN	O	8	PMOD
10	in	in	B-PP	IN	O	1	NMOD
11	prevention	prevention	B-NP	NN	O	10	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	contrast	contrast	B-NP	NN	O	15	NMOD
14	induced	induced	I-NP	JJ	O	15	NMOD
15	nephropathy	nephropathy	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	1	P

1	INTRODUCTION	INTRODUCTION	B-NP	NN	O	3	NMOD
2	AND	AND	I-NP	CC	O	3	NMOD
3	OBJECTIVE	OBJECTIVE	I-NP	NN	O	6	SUB
4	:	:	O	:	O	6	P
5	Contrast	Contrast	B-NP	NN	O	6	SUB
6	induced	induce	B-VP	VBD	O	0	ROOT
7	nephropathy	nephropathy	B-NP	NN	O	12	SUB
8	(	(	O	(	O	10	DEP
9	CIN	CIN	B-NP	NN	B-protein	10	DEP
10	)	)	O	)	O	7	NMOD
11	significantly	significantly	B-VP	RB	O	12	VMOD
12	increases	increase	I-VP	VBZ	O	6	VMOD
13	the	the	B-NP	DT	O	16	NMOD
14	morbidity	morbidity	I-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	mortality	mortality	I-NP	NN	O	12	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	patients	patient	B-NP	NNS	O	17	PMOD
19	.	.	O	.	O	6	P

1	Among	Among	B-PP	IN	O	14	VMOD
2	a	a	B-NP	DT	O	3	NMOD
3	total	total	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	60	60	B-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	4	PMOD
7	included	include	B-VP	VBN	O	6	NMOD
8	in	in	B-PP	IN	O	7	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	study	study	I-NP	NN	O	8	PMOD
11	,	,	O	,	O	14	P
12	16	16	B-NP	CD	O	13	NMOD
13	patients	patient	I-NP	NNS	O	14	SUB
14	developed	develop	B-VP	VBD	O	0	ROOT
15	acute	acute	B-NP	JJ	O	17	NMOD
16	renal	renal	I-NP	JJ	O	17	NMOD
17	failure	failure	I-NP	NN	O	14	OBJ
18	(	(	O	(	O	20	DEP
19	ARF	ARF	B-NP	NN	B-protein	20	DEP
20	)	)	O	)	O	17	NMOD
21	on	on	B-PP	IN	O	17	NMOD
22	the	the	B-NP	DT	O	24	NMOD
23	second	second	I-NP	JJ	O	24	NMOD
24	day	day	I-NP	NN	O	21	PMOD
25	after	after	B-PP	IN	O	24	NMOD
26	contrast	contrast	B-NP	NN	O	27	NMOD
27	material	material	I-NP	NN	O	25	PMOD
28	was	be	B-VP	VBD	O	14	VMOD
29	injected	inject	I-VP	VBN	O	28	VC
30	(	(	O	(	O	33	DEP
31	26.6	26.6	B-NP	CD	O	32	NMOD
32	%	%	I-NP	NN	O	33	DEP
33	)	)	O	)	O	28	VMOD
34	.	.	O	.	O	14	P

1	Neurocognitive	Neurocognitive	B-NP	JJ	O	3	AMOD
2	and	and	I-NP	CC	O	3	AMOD
3	neuroradiologic	neuroradiologic	I-NP	JJ	O	6	NMOD
4	central	central	I-NP	JJ	O	6	NMOD
5	nervous	nervous	I-NP	JJ	O	6	NMOD
6	system	system	I-NP	NN	O	8	NMOD
7	late	late	B-NP	JJ	O	8	NMOD
8	effects	effect	I-NP	NNS	O	40	NMOD
9	in	in	B-PP	IN	O	8	NMOD
10	children	child	B-NP	NNS	O	9	PMOD
11	treated	treat	B-VP	VBN	O	10	NMOD
12	on	on	B-PP	IN	O	11	VMOD
13	Pediatric	Pediatric	B-NP	NNP	O	15	NMOD
14	Oncology	Oncology	I-NP	NNP	O	15	NMOD
15	Group	Group	I-NP	NNP	O	19	NMOD
16	(	(	O	(	O	18	DEP
17	POG	POG	B-NP	NN	O	18	DEP
18	)	)	O	)	O	15	NMOD
19	P9605	P9605	B-NP	NN	O	25	NMOD
20	(	(	O	(	O	23	DEP
21	standard	standard	B-NP	JJ	O	22	NMOD
22	risk	risk	I-NP	NN	O	23	DEP
23	)	)	O	)	O	19	NMOD
24	and	and	O	CC	O	25	NMOD
25	P9201	P9201	B-NP	NN	B-protein	33	NMOD
26	(	(	O	(	O	29	DEP
27	lesser	less	B-NP	JJR	O	28	NMOD
28	risk	risk	I-NP	NN	O	29	DEP
29	)	)	I-NP	)	O	25	NMOD
30	acute	acute	I-NP	JJ	O	33	NMOD
31	lymphoblastic	lymphoblastic	I-NP	JJ	O	33	NMOD
32	leukemia	leukemia	I-NP	NN	O	33	NMOD
33	protocols	protocol	I-NP	NNS	O	12	PMOD
34	(	(	O	(	O	36	DEP
35	ACCL0131	ACCL0131	B-NP	NN	O	36	DEP
36	)	)	O	)	O	33	NMOD
37	:	:	O	:	O	8	P
38	a	a	B-NP	DT	O	40	NMOD
39	methotrexate	methotrexate	I-NP	NN	O	40	NMOD
40	consequence	consequence	I-NP	NN	O	0	ROOT
41	.	.	O	.	O	40	P

1	Concerns	Concern	B-NP	NNS	O	12	SUB
2	about	about	B-PP	IN	O	1	NMOD
3	long-term	long-term	B-NP	JJ	O	4	NMOD
4	methotrexate	methotrexate	I-NP	NN	O	8	NMOD
5	(	(	O	(	O	7	DEP
6	MTX	MTX	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	neurotoxicity	neurotoxicity	B-NP	NN	O	2	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	1990s	1990	I-NP	NNS	O	9	PMOD
12	led	lead	B-VP	VBD	O	0	ROOT
13	to	to	B-PP	TO	O	12	VMOD
14	modifications	modification	B-NP	NNS	O	13	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	intrathecal	intrathecal	O	JJ	O	26	NMOD
17	(	(	O	(	O	19	DEP
18	IT	IT	B-ADJP	JJ	O	19	DEP
19	)	)	O	)	O	16	AMOD
20	therapy	therapy	B-NP	NN	O	26	NMOD
21	,	,	O	,	O	26	P
22	leucovorin	leucovorin	B-NP	NN	O	23	NMOD
23	rescue	rescue	I-NP	NN	O	26	NMOD
24	,	,	O	,	O	26	P
25	and	and	O	CC	O	26	NMOD
26	frequency	frequency	B-NP	NN	O	15	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	systemic	systemic	B-NP	JJ	O	30	NMOD
29	MTX	MTX	I-NP	NN	O	30	NMOD
30	administration	administration	I-NP	NN	O	27	PMOD
31	in	in	B-PP	IN	O	30	NMOD
32	children	child	B-NP	NNS	O	31	PMOD
33	with	with	B-PP	IN	O	32	NMOD
34	acute	acute	B-NP	JJ	O	36	NMOD
35	lymphoblastic	lymphoblastic	I-NP	JJ	O	36	NMOD
36	leukemia	leukemia	I-NP	NN	O	33	PMOD
37	.	.	O	.	O	12	P

1	Tranexamic	Tranexamic	B-NP	JJ	O	3	NMOD
2	acid	acid	I-NP	NN	O	3	NMOD
3	overdosage	overdosage	I-NP	NN	O	4	SUB
4	induced	induce	B-VP	VBD	O	0	ROOT
5	generalized	generalize	I-VP	VBN	O	4	VC
6	seizure	seizure	B-NP	NN	O	5	OBJ
7	in	in	B-PP	IN	O	5	VMOD
8	renal	renal	B-NP	JJ	O	9	NMOD
9	failure	failure	I-NP	NN	O	7	PMOD
10	.	.	O	.	O	4	P

1	Tranexamic	Tranexamic	B-NP	JJ	O	2	NMOD
2	acid	acid	I-NP	NN	O	7	NMOD
3	(	(	O	(	O	5	DEP
4	TNA	TNA	B-NP	NN	O	5	DEP
5	)	)	O	)	O	2	NMOD
6	1	1	B-NP	CD	O	7	NMOD
7	g	g	I-NP	NN	O	9	SUB
8	8-hourly	8-hourly	B-ADVP	RB	O	9	VMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	administered	administer	I-VP	VBN	O	9	VC
11	to	to	B-PP	TO	O	14	VMOD
12	her	her	B-NP	PRP	O	14	SUB
13	to	to	B-VP	TO	O	14	VMOD
14	control	control	I-VP	VB	O	10	VMOD
15	bleeding	bleed	I-VP	VBG	O	14	VMOD
16	per	per	B-PP	IN	O	15	VMOD
17	vaginum	vaginum	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	9	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	hours	hour	I-NP	NNS	O	3	PMOD
3	after	after	B-PP	IN	O	11	VMOD
4	the	the	B-NP	DT	O	6	NMOD
5	sixth	sixth	I-NP	JJ	O	6	NMOD
6	dose	dose	I-NP	NN	O	3	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	TNA	TNA	B-NP	NN	B-protein	7	PMOD
9	,	,	O	,	O	11	P
10	she	she	B-NP	PRP	O	11	SUB
11	had	have	B-VP	VBD	O	0	ROOT
12	an	an	B-NP	DT	O	13	NMOD
13	episode	episode	I-NP	NN	O	11	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	generalized	generalize	B-NP	VBN	O	18	NMOD
16	tonic	tonic	I-NP	JJ	O	18	NMOD
17	clonic	clonic	I-NP	JJ	O	18	NMOD
18	convulsions	convulsion	I-NP	NNS	O	14	PMOD
19	.	.	O	.	O	11	P

1	Pre-treatment	Pre-treatment	B-NP	NN	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	bupivacaine	bupivacaine	B-NP	NN	O	2	PMOD
4	induced	induce	B-VP	VBD	O	0	ROOT
5	cardiovascular	cardiovascular	B-NP	JJ	O	6	NMOD
6	depression	depression	I-NP	NN	O	4	OBJ
7	using	use	B-VP	VBG	O	4	VMOD
8	different	different	B-NP	JJ	O	10	NMOD
9	lipid	lipid	I-NP	NN	O	10	NMOD
10	formulations	formulation	I-NP	NNS	O	7	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	propofol	propofol	B-NP	NN	O	11	PMOD
13	.	.	O	.	O	4	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	3	NMOD
2	:	:	O	:	O	3	P
3	Pre-treatment	Pre-treatment	B-NP	NN	O	7	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	lipid	lipid	B-NP	NN	O	6	NMOD
6	emulsions	emulsion	I-NP	NNS	O	4	PMOD
7	has	have	B-VP	VBZ	O	23	VMOD
8	been	be	I-VP	VBN	O	7	VC
9	shown	show	I-VP	VBN	O	8	VC
10	to	to	I-VP	TO	O	11	VMOD
11	increase	increase	I-VP	VB	O	9	VMOD
12	lethal	lethal	B-NP	JJ	O	13	NMOD
13	doses	dose	I-NP	NNS	O	11	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	bupivacaine	bupivacaine	B-NP	NN	O	14	PMOD
16	,	,	O	,	O	23	P
17	and	and	O	CC	O	23	VMOD
18	the	the	B-NP	DT	O	20	NMOD
19	lipid	lipid	I-NP	NN	O	20	NMOD
20	content	content	I-NP	NN	O	23	SUB
21	of	of	B-PP	IN	O	20	NMOD
22	propofol	propofol	B-NP	NN	O	21	PMOD
23	may	may	B-VP	MD	O	0	ROOT
24	alleviate	alleviate	I-VP	VB	O	23	VC
25	bupivacaine	bupivacaine	B-NP	NN	O	27	NMOD
26	induced	induced	I-NP	JJ	O	27	NMOD
27	cardiotoxicity	cardiotoxicity	I-NP	NN	O	24	OBJ
28	.	.	O	.	O	23	P

1	The	The	B-NP	DT	O	2	NMOD
2	aim	aim	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	is	be	B-VP	VBZ	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	investigate	investigate	I-VP	VB	O	6	PRD
9	the	the	B-NP	DT	O	10	NMOD
10	effects	effect	I-NP	NNS	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	propofol	propofol	B-NP	NN	O	11	PMOD
13	in	in	B-PP	IN	O	10	NMOD
14	intralipid	intralipid	B-NP	NN	O	17	NMOD
15	or	or	I-NP	CC	O	17	NMOD
16	medialipid	medialipid	I-NP	NN	O	17	NMOD
17	emulsions	emulsion	I-NP	NNS	O	13	PMOD
18	on	on	B-PP	IN	O	10	NMOD
19	bupivacaine	bupivacaine	B-NP	NN	O	21	NMOD
20	induced	induced	I-NP	JJ	O	21	NMOD
21	cardiotoxicity	cardiotoxicity	I-NP	NN	O	18	PMOD
22	.	.	O	.	O	6	P

1	We	We	B-NP	PRP	O	2	SUB
2	recorded	record	B-VP	VBD	O	0	ROOT
3	time	time	B-NP	NN	O	2	OBJ
4	to	to	B-PP	TO	O	3	NMOD
5	first	first	B-NP	JJ	O	7	NMOD
6	dysrhythmia	dysrhythmia	I-NP	NN	O	7	NMOD
7	occurrence	occurrence	I-NP	NN	O	4	PMOD
8	,	,	O	,	O	10	P
9	respective	respective	B-NP	JJ	O	10	NMOD
10	times	time	I-NP	NNS	O	3	NMOD
11	to	to	B-PP	TO	O	10	NMOD
12	25	25	B-NP	CD	O	13	NMOD
13	%	%	I-NP	NN	O	17	NMOD
14	and	and	I-NP	CC	O	17	NMOD
15	50	50	I-NP	CD	O	16	AMOD
16	%	%	I-NP	NN	O	17	NMOD
17	reduction	reduction	I-NP	NN	O	28	NMOD
18	of	of	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	21	NMOD
20	heart	heart	I-NP	NN	O	21	NMOD
21	rate	rate	I-NP	NN	O	18	PMOD
22	(	(	O	(	O	24	DEP
23	HR	HR	B-NP	NN	B-protein	24	DEP
24	)	)	O	)	O	21	NMOD
25	and	and	O	CC	O	28	NMOD
26	mean	mean	B-NP	JJ	O	28	NMOD
27	arterial	arterial	I-NP	JJ	O	28	NMOD
28	pressure	pressure	I-NP	NN	O	11	PMOD
29	,	,	O	,	O	10	NMOD
30	and	and	O	CC	O	29	PMOD
31	time	time	B-NP	NN	O	30	ROOT
32	to	to	B-PP	TO	O	31	NMOD
33	asystole	asystole	B-NP	NN	O	36	NMOD
34	and	and	O	CC	O	36	NMOD
35	total	total	B-NP	JJ	O	36	NMOD
36	amount	amount	I-NP	NN	O	32	PMOD
37	of	of	B-PP	IN	O	36	NMOD
38	bupivacaine	bupivacaine	B-NP	NN	O	39	NMOD
39	consumption	consumption	I-NP	NN	O	37	PMOD
40	.	.	O	.	O	31	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	4	VMOD
2	:	:	O	:	O	4	P
3	We	We	B-NP	PRP	O	4	SUB
4	conclude	conclude	B-VP	VBP	O	0	ROOT
5	that	that	B-SBAR	IN	O	4	VMOD
6	pre-treatment	pre-treatment	B-NP	NN	O	20	SUB
7	with	with	B-PP	IN	O	6	NMOD
8	propofol	propofol	B-NP	NN	O	7	PMOD
9	in	in	B-PP	IN	O	6	NMOD
10	intralipid	intralipid	B-NP	NN	O	9	PMOD
11	,	,	O	,	O	6	P
12	compared	compare	B-PP	VBN	O	6	NMOD
13	with	with	B-PP	IN	O	12	VMOD
14	propofol	propofol	B-NP	NN	O	13	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	medialipid	medialipid	B-NP	NN	O	18	NMOD
17	or	or	I-NP	CC	O	18	NMOD
18	saline	saline	I-NP	NN	O	15	PMOD
19	,	,	O	,	O	6	P
20	delayed	delay	B-VP	VBD	O	5	SBAR
21	the	the	B-NP	DT	O	22	NMOD
22	onset	onset	I-NP	NN	O	25	SUB
23	of	of	B-PP	IN	O	22	NMOD
24	bupivacaine	bupivacaine	B-NP	NN	O	23	PMOD
25	induced	induce	B-VP	VBD	O	20	VMOD
26	cardiotoxic	cardiotoxic	B-NP	JJ	O	27	NMOD
27	effects	effect	I-NP	NNS	O	34	NMOD
28	as	as	B-CONJP	RB	O	34	NMOD
29	well	well	I-CONJP	RB	O	28	DEP
30	as	as	I-CONJP	IN	O	28	DEP
31	reduced	reduce	B-NP	VBN	O	34	NMOD
32	plasma	plasma	I-NP	NN	O	34	NMOD
33	bupivacaine	bupivacaine	I-NP	NN	O	34	NMOD
34	levels	level	I-NP	NNS	O	25	OBJ
35	.	.	O	.	O	4	P

1	Drug-Induced	Drug-Induced	B-NP	JJ	O	4	NMOD
2	Acute	Acute	I-NP	JJ	O	4	NMOD
3	Liver	Liver	I-NP	NN	O	4	NMOD
4	Injury	Injury	I-NP	NN	O	0	ROOT
5	Within	Within	B-PP	IN	O	4	NMOD
6	12	12	B-NP	CD	O	7	NMOD
7	Hours	Hour	I-NP	NNS	O	5	PMOD
8	After	After	B-PP	IN	O	7	NMOD
9	Fluvastatin	Fluvastatin	B-NP	NN	O	10	NMOD
10	Therapy	Therapy	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	4	P

1	Although	Although	B-SBAR	IN	O	0	ROOT
2	statins	statin	B-NP	NNS	O	3	SUB
3	are	be	B-VP	VBP	O	1	SBAR
4	generally	generally	B-ADVP	RB	O	3	VMOD
5	well-tolerated	well-tolerated	B-NP	JJ	O	6	NMOD
6	drugs	drug	I-NP	NNS	O	12	SUB
7	,	,	O	,	O	12	P
8	recent	recent	B-NP	JJ	O	9	NMOD
9	cases	case	I-NP	NNS	O	12	SUB
10	of	of	B-PP	IN	O	9	NMOD
11	drug	drug	B-NP	NN	O	10	PMOD
12	induced	induce	B-VP	VBD	O	3	VMOD
13	liver	liver	B-NP	NN	O	14	NMOD
14	injury	injury	I-NP	NN	O	12	OBJ
15	associated	associate	B-VP	VBN	O	14	NMOD
16	with	with	B-PP	IN	O	15	VMOD
17	their	their	B-NP	PRP$	O	18	NMOD
18	use	use	I-NP	NN	O	16	PMOD
19	have	have	B-VP	VBP	O	12	VMOD
20	been	be	I-VP	VBN	O	19	VC
21	reported	report	I-VP	VBN	O	20	VC
22	.	.	O	.	O	1	P

1	A	A	B-NP	DT	O	4	NMOD
2	52-year-old	52-year-old	I-NP	JJ	O	4	NMOD
3	Chinese	Chinese	I-NP	JJ	O	4	NMOD
4	man	man	I-NP	NN	O	0	ROOT
5	reported	report	B-VP	VBN	O	4	NMOD
6	with	with	B-PP	IN	O	5	VMOD
7	liver	liver	B-NP	NN	O	8	NMOD
8	damage	damage	I-NP	NN	O	6	PMOD
9	,	,	O	,	O	4	P
10	which	which	B-NP	WDT	O	4	NMOD
11	appeared	appear	B-VP	VBD	O	10	SBAR
12	12	12	B-NP	CD	O	13	NMOD
13	hours	hour	I-NP	NNS	O	11	OBJ
14	after	after	B-PP	IN	O	13	NMOD
15	beginning	begin	B-VP	VBG	O	14	PMOD
16	treatment	treatment	B-NP	NN	O	15	OBJ
17	with	with	B-PP	IN	O	16	NMOD
18	fluvastatin	fluvastatin	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	4	P

1	Fluconazole	Fluconazole	B-NP	NN	O	5	NMOD
2	associated	associate	I-NP	VBN	O	5	NMOD
3	agranulocytosis	agranulocytosis	I-NP	NN	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	thrombocytopenia	thrombocytopenia	I-NP	NN	O	0	ROOT
6	.	.	O	.	O	5	P

1	CASE	CASE	B-NP	NN	B-protein	4	SUB
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	describe	describe	B-VP	VBP	O	0	ROOT
5	a	a	B-NP	DT	O	7	NMOD
6	second	second	I-NP	JJ	O	7	NMOD
7	case	case	I-NP	NN	O	4	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	fluconazole	fluconazole	B-NP	NN	O	11	NMOD
10	associated	associate	I-NP	VBN	O	11	NMOD
11	agranulocytosis	agranulocytosis	I-NP	NN	O	8	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	thrombocytopenia	thrombocytopenia	B-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	recovery	recovery	I-NP	NN	O	12	PMOD
16	upon	upon	B-PP	IN	O	7	NMOD
17	discontinuation	discontinuation	B-NP	NN	O	16	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	therapy	therapy	B-NP	NN	O	18	PMOD
20	.	.	O	.	O	4	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	25	SUB
2	:	:	O	:	O	1	P
3	According	Accord	B-PP	VBG	O	1	NMOD
4	to	to	B-PP	TO	O	3	PMOD
5	Naranjo	Naranjo	B-NP	NNP	O	6	NMOD
6	's	's	B-NP	POS	O	7	NMOD
7	algorithm	algorithm	I-NP	NN	O	4	PMOD
8	the	the	B-NP	DT	O	9	NMOD
9	likelihood	likelihood	I-NP	NN	O	3	OBJ
10	that	that	B-SBAR	IN	O	9	NMOD
11	our	our	B-NP	PRP$	O	16	NMOD
12	patient	patient	I-NP	NN	O	14	NMOD
13	's	's	B-NP	POS	O	14	NMOD
14	agranulocytosis	agranulocytosis	I-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	thrombocytopenia	thrombocytopenia	I-NP	NN	O	17	SUB
17	occurred	occur	B-VP	VBD	O	10	SBAR
18	as	as	B-PP	IN	O	17	VMOD
19	a	a	B-NP	DT	O	20	NMOD
20	result	result	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	therapy	therapy	B-NP	NN	O	21	PMOD
23	with	with	B-PP	IN	O	22	NMOD
24	fluconazole	fluconazole	B-NP	NN	O	23	PMOD
25	is	be	B-VP	VBZ	O	0	ROOT
26	probable	probable	B-ADJP	JJ	O	25	PRD
27	,	,	O	,	O	25	P
28	with	with	B-PP	IN	O	25	VMOD
29	a	a	B-NP	DT	O	30	NMOD
30	total	total	I-NP	NN	O	28	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	six	six	B-NP	CD	O	33	NMOD
33	points	point	I-NP	NNS	O	31	PMOD
34	.	.	O	.	O	25	P

1	Two-dimensional	Two-dimensional	B-NP	JJ	O	2	NMOD
2	speckle	speckle	I-NP	NN	O	0	ROOT
3	tracking	track	B-VP	VBG	O	2	NMOD
4	echocardiography	echocardiography	B-NP	NN	O	3	OBJ
5	combined	combine	B-VP	VBN	O	4	NMOD
6	with	with	B-PP	IN	O	5	VMOD
7	high-sensitive	high-sensitive	B-NP	JJ	O	10	NMOD
8	cardiac	cardiac	I-NP	JJ	O	10	NMOD
9	troponin	troponin	I-NP	NN	O	10	NMOD
10	T	T	I-NP	NN	O	6	PMOD
11	in	in	B-PP	IN	O	5	VMOD
12	early	early	B-NP	JJ	O	13	NMOD
13	detection	detection	I-NP	NN	O	15	NMOD
14	and	and	O	CC	O	15	NMOD
15	prediction	prediction	B-NP	NN	O	11	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	cardiotoxicity	cardiotoxicity	B-NP	NN	O	16	PMOD
18	during	during	B-PP	IN	O	2	NMOD
19	epirubicine-based	epirubicine-based	B-NP	JJ	O	20	NMOD
20	chemotherapy	chemotherapy	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	2	P

1	AIMS	AIMS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	investigate	investigate	I-VP	VB	O	1	NMOD
5	whether	whether	B-SBAR	IN	O	4	VMOD
6	alterations	alteration	B-NP	NNS	O	18	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	myocardial	myocardial	B-NP	JJ	O	9	NMOD
9	strain	strain	I-NP	NN	O	14	NMOD
10	and	and	O	CC	O	14	NMOD
11	high-sensitive	high-sensitive	B-NP	JJ	O	14	NMOD
12	cardiac	cardiac	I-NP	JJ	O	14	NMOD
13	troponin	troponin	I-NP	NN	O	14	NMOD
14	T	T	I-NP	NN	O	7	PMOD
15	(	(	O	(	O	17	DEP
16	cTnT	cTnT	B-NP	NN	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	could	could	B-VP	MD	O	5	SBAR
19	predict	predict	I-VP	VB	O	18	VC
20	future	future	B-NP	JJ	O	21	AMOD
21	cardiac	cardiac	I-NP	JJ	O	22	NMOD
22	dysfunction	dysfunction	I-NP	NN	O	19	OBJ
23	in	in	B-PP	IN	O	22	NMOD
24	patients	patient	B-NP	NNS	O	23	PMOD
25	after	after	B-PP	IN	O	24	NMOD
26	epirubicin	epirubicin	B-NP	NN	O	27	NMOD
27	exposure	exposure	I-NP	NN	O	25	PMOD
28	.	.	O	.	O	1	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Seventy-five	Seventy-five	B-NP	CD	O	4	NMOD
4	patients	patient	I-NP	NNS	O	11	SUB
5	with	with	B-PP	IN	O	4	NMOD
6	non-Hodgkin	non-Hodgkin	B-NP	JJ	O	7	NMOD
7	lymphoma	lymphoma	I-NP	NN	O	5	PMOD
8	treated	treat	B-VP	VBN	O	7	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	epirubicin	epirubicin	B-NP	NN	O	9	PMOD
11	were	be	B-VP	VBD	O	1	NMOD
12	studied	study	I-VP	VBN	O	11	VC
13	.	.	O	.	O	1	P

1	Prevention	Prevention	B-NP	NN	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	etomidate	etomidate	B-NP	NN	O	2	PMOD
4	induced	induce	B-VP	VBD	O	0	ROOT
5	myoclonus	myoclonus	B-NP	NN	O	4	OBJ
6	:	:	O	:	O	4	P
7	which	which	B-NP	WDT	O	4	VMOD
8	is	be	B-VP	VBZ	O	7	SBAR
9	superior	superior	B-ADJP	JJ	O	8	PRD
10	:	:	O	:	O	4	P
11	Fentanyl	Fentanyl	B-NP	NN	O	17	NMOD
12	,	,	O	,	O	17	P
13	midazolam	midazolam	B-NP	NN	O	17	NMOD
14	,	,	O	,	O	17	P
15	or	or	O	CC	O	17	NMOD
16	a	a	B-NP	DT	O	17	NMOD
17	combination	combination	I-NP	NN	O	4	VMOD
18	.	.	O	.	O	4	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	10	SUB
2	:	:	O	:	O	1	P
3	In	In	B-PP	IN	O	10	VMOD
4	this	this	B-NP	DT	O	7	NMOD
5	retrospective	retrospective	I-NP	JJ	O	7	NMOD
6	comparative	comparative	I-NP	JJ	O	7	NMOD
7	study	study	I-NP	NN	O	3	PMOD
8	,	,	O	,	O	10	P
9	we	we	B-NP	PRP	O	10	SUB
10	aimed	aim	B-VP	VBD	O	0	ROOT
11	to	to	I-VP	TO	O	12	VMOD
12	compare	compare	I-VP	VB	O	10	VMOD
13	the	the	B-NP	DT	O	14	NMOD
14	effectiveness	effectiveness	I-NP	NN	O	12	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	fentanyl	fentanyl	B-NP	NN	O	18	NMOD
17	,	,	O	,	O	18	P
18	midazolam	midazolam	B-NP	NN	O	15	PMOD
19	,	,	O	,	O	18	NMOD
20	and	and	O	CC	O	19	PMOD
21	a	a	B-NP	DT	O	22	NMOD
22	combination	combination	I-NP	NN	O	20	PRD
23	of	of	B-PP	IN	O	22	NMOD
24	fentanyl	fentanyl	B-NP	NN	O	26	NMOD
25	and	and	I-NP	CC	O	26	NMOD
26	midazolam	midazolam	I-NP	NN	O	23	PMOD
27	to	to	B-VP	TO	O	28	VMOD
28	prevent	prevent	I-VP	VB	O	22	NMOD
29	etomidate	etomidate	B-NP	NN	O	31	NMOD
30	induced	induced	I-NP	JJ	O	31	NMOD
31	myoclonus	myoclonus	I-NP	NN	O	28	OBJ
32	.	.	O	.	O	10	P

1	Myoclonic	Myoclonic	B-NP	JJ	O	2	NMOD
2	movements	movement	I-NP	NNS	O	3	SUB
3	are	be	B-VP	VBP	O	0	ROOT
4	evaluated	evaluate	I-VP	VBN	O	3	VC
5	,	,	O	,	O	4	P
6	which	which	B-NP	WDT	O	4	VMOD
7	were	be	B-VP	VBD	O	6	SBAR
8	observed	observe	I-VP	VBN	O	7	VC
9	and	and	I-VP	CC	O	8	VMOD
10	graded	grade	I-VP	VBN	O	8	VMOD
11	according	accord	B-PP	VBG	O	10	VMOD
12	to	to	B-PP	TO	O	11	PMOD
13	clinical	clinical	B-NP	JJ	O	14	NMOD
14	severity	severity	I-NP	NN	O	12	PMOD
15	during	during	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	18	NMOD
17	2	2	I-NP	CD	O	18	NMOD
18	minutes	minute	I-NP	NNS	O	15	PMOD
19	after	after	B-PP	IN	O	18	NMOD
20	etomidate	etomidate	B-NP	NN	O	21	NMOD
21	injection	injection	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	severity	severity	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	pain	pain	B-NP	NN	O	3	PMOD
5	due	due	B-ADJP	JJ	O	2	NMOD
6	to	to	B-VP	TO	O	7	VMOD
7	etomidate	etomidate	I-VP	VB	O	5	AMOD
8	injection	injection	B-NP	NN	O	20	SUB
9	,	,	O	,	O	20	P
10	mean	mean	B-NP	JJ	O	12	NMOD
11	arterial	arterial	I-NP	JJ	O	12	NMOD
12	pressure	pressure	I-NP	NN	O	20	SUB
13	,	,	O	,	O	20	P
14	heart	heart	B-NP	NN	O	15	NMOD
15	rate	rate	I-NP	NN	O	20	SUB
16	,	,	O	,	O	20	P
17	and	and	O	CC	O	20	VMOD
18	adverse	adverse	B-NP	JJ	O	19	NMOD
19	effects	effect	I-NP	NNS	O	20	SUB
20	were	be	B-VP	VBD	O	7	VMOD
21	also	also	I-VP	RB	O	20	VMOD
22	evaluated	evaluate	I-VP	VBN	O	20	VC
23	.	.	O	.	O	2	P

1	Cholestatic	Cholestatic	B-NP	JJ	O	2	NMOD
2	presentation	presentation	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	yellow	yellow	B-NP	JJ	O	6	NMOD
5	phosphorus	phosphorus	I-NP	NN	O	6	NMOD
6	poisoning	poisoning	I-NP	NN	O	3	PMOD
7	.	.	O	.	O	2	P

1	Yellow	Yellow	B-NP	JJ	O	2	NMOD
2	phosphorus	phosphorus	I-NP	NN	O	5	NMOD
3	,	,	O	,	O	5	P
4	a	a	B-NP	DT	O	5	NMOD
5	component	component	I-NP	NN	O	13	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	certain	certain	B-NP	JJ	O	6	PMOD
8	pesticide	pesticide	I-NP	NN	O	9	NMOD
9	pastes	paste	I-NP	NNS	O	7	NMOD
10	and	and	I-NP	CC	O	7	NMOD
11	fireworks	firework	I-NP	NNS	O	7	NMOD
12	,	,	O	,	O	5	P
13	is	be	B-VP	VBZ	O	0	ROOT
14	well	well	I-VP	RB	O	13	VMOD
15	known	know	I-VP	VBN	O	13	VC
16	to	to	I-VP	TO	O	17	VMOD
17	cause	cause	I-VP	VB	O	15	VMOD
18	hepatotoxicity	hepatotoxicity	B-NP	NN	O	17	OBJ
19	.	.	O	.	O	13	P

1	Poisoning	Poison	B-VP	VBG	O	6	VMOD
2	with	with	B-PP	IN	O	1	VMOD
3	yellow	yellow	B-NP	JJ	O	4	NMOD
4	phosphorus	phosphorus	I-NP	NN	O	2	PMOD
5	classically	classically	B-ADVP	RB	O	6	VMOD
6	manifests	manifest	B-VP	VBZ	O	0	ROOT
7	with	with	B-PP	IN	O	6	VMOD
8	acute	acute	B-NP	JJ	O	9	NMOD
9	hepatitis	hepatitis	I-NP	NN	O	7	PMOD
10	leading	lead	B-VP	VBG	O	9	NMOD
11	to	to	B-PP	TO	O	10	VMOD
12	acute	acute	B-NP	JJ	O	14	NMOD
13	liver	liver	I-NP	NN	O	14	NMOD
14	failure	failure	I-NP	NN	O	11	PMOD
15	which	which	B-NP	WDT	O	14	NMOD
16	may	may	B-VP	MD	O	15	SBAR
17	need	need	I-VP	VB	O	16	VC
18	liver	liver	B-NP	NN	O	19	NMOD
19	transplantation	transplantation	I-NP	NN	O	17	OBJ
20	.	.	O	.	O	6	P

1	Vasovagal	Vasovagal	B-NP	JJ	O	2	NMOD
2	syncope	syncope	I-NP	NN	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	severe	severe	B-NP	JJ	O	5	NMOD
5	bradycardia	bradycardia	I-NP	NN	O	0	ROOT
6	following	follow	B-PP	VBG	O	5	NMOD
7	intranasal	intranasal	B-NP	JJ	O	8	NMOD
8	dexmedetomidine	dexmedetomidine	I-NP	NN	O	6	PMOD
9	for	for	B-PP	IN	O	8	NMOD
10	pediatric	pediatric	B-NP	JJ	O	12	NMOD
11	procedural	procedural	I-NP	JJ	O	12	NMOD
12	sedation	sedation	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	5	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	syncope	syncope	B-NP	NN	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	bradycardia	bradycardia	I-NP	NN	O	2	OBJ
6	in	in	B-PP	IN	O	5	NMOD
7	an	an	B-NP	DT	O	9	NMOD
8	11-year-old	11-year-old	I-NP	JJ	O	9	NMOD
9	girl	girl	I-NP	NN	O	6	PMOD
10	following	follow	B-PP	VBG	O	5	NMOD
11	administration	administration	B-NP	NN	O	10	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	intranasal	intranasal	B-NP	JJ	O	14	NMOD
14	dexmedetomidine	dexmedetomidine	I-NP	NN	O	12	PMOD
15	for	for	B-PP	IN	O	11	NMOD
16	sedation	sedation	B-NP	NN	O	15	PMOD
17	for	for	B-PP	IN	O	11	NMOD
18	a	a	B-NP	DT	O	20	NMOD
19	voiding	void	I-NP	VBG	O	20	NMOD
20	cystourethrogram	cystourethrogram	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	2	P

1	Paradoxical	Paradoxical	B-NP	JJ	O	3	NMOD
2	severe	severe	I-NP	JJ	O	3	NMOD
3	agitation	agitation	I-NP	NN	O	0	ROOT
4	induced	induce	B-VP	VBN	O	3	NMOD
5	by	by	B-PP	IN	O	4	VMOD
6	add-on	add-on	B-NP	JJ	O	8	NMOD
7	high-doses	high-doses	I-NP	JJ	O	8	NMOD
8	quetiapine	quetiapine	I-NP	NN	O	5	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	schizo-affective	schizo-affective	B-NP	JJ	O	11	NMOD
11	disorder	disorder	I-NP	NN	O	9	PMOD
12	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	35-year-old	35-year-old	I-NP	JJ	O	8	NMOD
8	patient	patient	I-NP	NN	O	5	PMOD
9	suffering	suffer	B-VP	VBG	O	8	NMOD
10	from	from	B-PP	IN	O	9	VMOD
11	schizo-affective	schizo-affective	B-NP	JJ	O	12	NMOD
12	disorder	disorder	I-NP	NN	O	10	PMOD
13	since	since	B-PP	IN	O	4	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	age	age	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	19	19	B-NP	CD	O	18	NMOD
18	years	year	I-NP	NNS	O	16	PMOD
19	,	,	O	,	O	15	P
20	treated	treat	B-VP	VBN	O	15	NMOD
21	by	by	B-PP	IN	O	20	VMOD
22	a	a	B-NP	DT	O	23	NMOD
23	combination	combination	I-NP	NN	O	21	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	first-generation	first-generation	B-NP	JJ	O	26	NMOD
26	antipsychotics	antipsychotic	I-NP	NNS	O	34	NMOD
27	,	,	O	,	O	34	P
28	zuclopenthixol	zuclopenthixol	B-NP	NN	O	34	NMOD
29	(	(	O	(	O	32	DEP
30	100	100	B-NP	CD	O	31	NMOD
31	mg/day	mg/day	I-NP	NN	O	32	DEP
32	)	)	O	)	O	28	NMOD
33	and	and	O	CC	O	34	NMOD
34	lithium	lithium	B-NP	NN	O	24	PMOD
35	(	(	O	(	O	38	DEP
36	1200	1200	B-NP	CD	O	37	NMOD
37	mg/day	mg/day	I-NP	NN	O	38	DEP
38	)	)	O	)	O	34	NMOD
39	(	(	O	(	O	43	DEP
40	serum	serum	B-NP	NN	O	42	NMOD
41	lithium=0.85	lithium=0.85	I-NP	NN	O	42	NMOD
42	mEq/l	mEq/l	I-NP	NN	O	43	DEP
43	)	)	O	)	O	34	NMOD
44	.	.	O	.	O	2	P

1	Within	Within	B-PP	IN	O	20	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	48	48	I-NP	CD	O	4	NMOD
4	h	h	I-NP	NN	O	1	PMOD
5	following	follow	B-PP	VBG	O	4	NMOD
6	the	the	B-NP	DT	O	8	NMOD
7	gradual	gradual	I-NP	JJ	O	8	NMOD
8	introduction	introduction	I-NP	NN	O	5	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	quetiapine	quetiapine	B-NP	NN	O	9	PMOD
11	(	(	O	(	O	16	DEP
12	up	up	B-NP	RB	O	16	DEP
13	to	to	I-NP	TO	O	12	AMOD
14	600	600	I-NP	CD	O	12	AMOD
15	mg/day	mg/day	I-NP	NN	O	12	NMOD
16	)	)	O	)	O	8	NMOD
17	,	,	O	,	O	20	P
18	the	the	B-NP	DT	O	19	NMOD
19	patient	patient	I-NP	NN	O	20	SUB
20	presented	present	B-VP	VBD	O	0	ROOT
21	severe	severe	B-NP	JJ	O	22	NMOD
22	agitation	agitation	I-NP	NN	O	20	OBJ
23	without	without	B-PP	IN	O	20	VMOD
24	an	an	B-NP	DT	O	26	NMOD
25	environmental	environmental	I-NP	JJ	O	26	NMOD
26	explanation	explanation	I-NP	NN	O	23	PMOD
27	,	,	O	,	O	20	P
28	contrasting	contrast	B-VP	VBG	O	20	VMOD
29	with	with	B-PP	IN	O	28	VMOD
30	the	the	B-NP	DT	O	31	NMOD
31	absence	absence	I-NP	NN	O	29	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	a	a	B-NP	DT	O	34	NMOD
34	history	history	I-NP	NN	O	32	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	aggressiveness	aggressiveness	B-NP	NN	O	39	NMOD
37	or	or	I-NP	CC	O	39	NMOD
38	personality	personality	I-NP	NN	O	39	NMOD
39	disorder	disorder	I-NP	NN	O	35	PMOD
40	.	.	O	.	O	20	P

1	Antioxidant	Antioxidant	B-NP	JJ	O	2	NMOD
2	effects	effect	I-NP	NNS	O	8	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	bovine	bovine	B-NP	JJ	B-protein	5	NMOD
5	lactoferrin	lactoferrin	I-NP	NN	I-protein	3	PMOD
6	on	on	B-PP	IN	O	2	NMOD
7	dexamethasone	dexamethasone	B-NP	NN	O	6	PMOD
8	induced	induce	B-VP	VBD	O	0	ROOT
9	hypertension	hypertension	B-NP	NN	O	8	OBJ
10	in	in	B-PP	IN	O	9	NMOD
11	rat	rat	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	8	P

1	Dexamethasone-	Dexamethasone-	B-NP	NN	O	6	NMOD
2	(	(	O	(	O	4	DEP
3	Dex-	Dex-	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	induced	induce	B-NP	VBN	O	6	NMOD
6	hypertension	hypertension	I-NP	NN	O	7	SUB
7	is	be	B-VP	VBZ	O	0	ROOT
8	associated	associate	I-VP	VBN	O	7	VC
9	with	with	B-PP	IN	O	8	VMOD
10	enhanced	enhance	B-NP	VBN	O	12	NMOD
11	oxidative	oxidative	I-NP	JJ	O	12	NMOD
12	stress	stress	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	7	P

1	In	In	B-PP	IN	O	6	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	study	study	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	6	P
5	we	we	B-NP	PRP	O	6	SUB
6	investigated	investigate	B-VP	VBD	O	0	ROOT
7	the	the	B-NP	DT	O	8	NMOD
8	effect	effect	I-NP	NN	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	chronic	chronic	B-NP	JJ	O	11	NMOD
11	administration	administration	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	LF	LF	B-NP	NN	B-protein	12	PMOD
14	on	on	B-PP	IN	O	8	NMOD
15	oxidative	oxidative	B-NP	JJ	O	16	NMOD
16	stress	stress	I-NP	NN	O	18	NMOD
17	and	and	I-NP	CC	O	18	NMOD
18	hypertension	hypertension	I-NP	NN	O	14	PMOD
19	upon	upon	B-PP	IN	O	18	NMOD
20	Dex	Dex	B-NP	NN	O	21	NMOD
21	administration	administration	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	6	P

1	LF	LF	B-NP	NN	B-protein	2	SUB
2	lowered	lower	B-VP	VBD	O	11	VMOD
3	(	(	O	(	O	7	DEP
4	P	P	B-NP	NN	O	7	DEP
5	<	<	O	SYM	O	4	NMOD
6	0.01	0.01	B-NP	CD	O	5	AMOD
7	)	)	O	)	O	2	VMOD
8	and	and	O	CC	O	11	VMOD
9	dose	dose	B-NP	NN	O	11	SUB
10	dependently	dependently	B-ADVP	RB	O	11	VMOD
11	prevented	prevent	B-VP	VBD	O	0	ROOT
12	(	(	O	(	O	16	DEP
13	P	P	O	NN	O	16	DEP
14	<	<	O	SYM	O	13	NMOD
15	0.001	0.001	O	CD	O	14	AMOD
16	)	)	O	)	O	19	NMOD
17	Dex	Dex	B-NP	NN	O	18	SUB
18	induced	induce	B-VP	VBD	O	19	NMOD
19	hypertension	hypertension	B-NP	NN	O	11	OBJ
20	.	.	O	.	O	11	P

1	LF	LF	B-NP	NN	B-protein	2	SUB
2	prevented	prevent	B-VP	VBD	O	0	ROOT
3	body	body	B-NP	NN	O	5	NMOD
4	weight	weight	I-NP	NN	O	5	NMOD
5	loss	loss	I-NP	NN	O	2	OBJ
6	and	and	O	CC	O	2	VMOD
7	significantly	significantly	B-VP	RB	O	8	VMOD
8	reduced	reduce	I-VP	VBD	O	2	VMOD
9	the	the	B-NP	DT	O	12	NMOD
10	elevated	elevate	I-NP	VBN	O	12	NMOD
11	plasma	plasma	I-NP	NN	O	12	NMOD
12	H2O2	H2O2	I-NP	NN	O	8	OBJ
13	and	and	O	CC	O	8	VMOD
14	increased	increase	B-VP	VBD	O	8	VMOD
15	FRAP	FRAP	B-NP	NN	O	16	NMOD
16	values	value	I-NP	NNS	O	14	OBJ
17	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	association	association	I-NP	NN	O	15	NMOD
3	between	between	B-PP	IN	O	2	NMOD
4	tranexamic	tranexamic	B-NP	JJ	O	5	NMOD
5	acid	acid	I-NP	NN	O	8	NMOD
6	and	and	O	CC	O	8	NMOD
7	convulsive	convulsive	B-NP	JJ	O	8	NMOD
8	seizures	seizure	I-NP	NNS	O	3	PMOD
9	after	after	B-PP	IN	O	2	NMOD
10	cardiac	cardiac	B-NP	JJ	O	11	NMOD
11	surgery	surgery	I-NP	NN	O	9	PMOD
12	:	:	O	:	O	2	P
13	a	a	B-NP	DT	O	15	NMOD
14	multivariate	multivariate	I-NP	JJ	O	15	NMOD
15	analysis	analysis	I-NP	NN	O	0	ROOT
16	in	in	B-PP	IN	O	15	NMOD
17	11	11	B-NP	CD	O	19	NMOD
18	529	529	I-NP	CD	O	19	NMOD
19	patients	patient	I-NP	NNS	O	16	PMOD
20	.	.	O	.	O	15	P

1	Independent	Independent	B-NP	JJ	O	2	NMOD
2	predictors	predictor	I-NP	NNS	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	postoperative	postoperative	B-NP	JJ	O	5	NMOD
5	seizures	seizure	I-NP	NNS	O	3	PMOD
6	included	include	B-VP	VBD	O	0	ROOT
7	age	age	B-NP	NN	O	10	NMOD
8	,	,	O	,	O	10	P
9	female	female	B-NP	JJ	O	10	NMOD
10	sex	sex	I-NP	NN	O	6	OBJ
11	,	,	O	,	O	6	P
12	redo	redo	B-VP	VBP	O	6	VMOD
13	cardiac	cardiac	B-NP	JJ	O	14	NMOD
14	surgery	surgery	I-NP	NN	O	16	NMOD
15	,	,	O	,	O	16	P
16	calcification	calcification	B-NP	NN	O	12	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	ascending	ascend	B-VP	VBG	O	17	PMOD
19	aorta	aorta	B-NP	NN	O	30	NMOD
20	,	,	O	,	O	30	P
21	congestive	congestive	B-NP	JJ	O	23	NMOD
22	heart	heart	I-NP	NN	O	23	NMOD
23	failure	failure	I-NP	NN	O	30	NMOD
24	,	,	O	,	O	30	P
25	deep	deep	B-NP	JJ	O	28	NMOD
26	hypothermic	hypothermic	I-NP	JJ	O	28	NMOD
27	circulatory	circulatory	I-NP	JJ	O	28	NMOD
28	arrest	arrest	I-NP	NN	O	30	NMOD
29	,	,	O	,	O	30	P
30	duration	duration	B-NP	NN	O	18	OBJ
31	of	of	B-PP	IN	O	30	NMOD
32	aortic	aortic	B-NP	JJ	O	33	NMOD
33	cross-clamp	cross-clamp	I-NP	JJ	O	36	NMOD
34	and	and	I-NP	CC	O	36	NMOD
35	tranexamic	tranexamic	I-NP	JJ	O	36	NMOD
36	acid	acid	I-NP	NN	O	31	PMOD
37	.	.	O	.	O	6	P

1	When	When	B-ADVP	WRB	O	11	VMOD
2	tested	test	B-VP	VBN	O	1	SBAR
3	in	in	B-PP	IN	O	2	VMOD
4	a	a	B-NP	DT	O	7	NMOD
5	multivariate	multivariate	I-NP	JJ	O	7	NMOD
6	regression	regression	I-NP	NN	O	7	NMOD
7	analysis	analysis	I-NP	NN	O	3	PMOD
8	,	,	O	,	O	11	P
9	tranexamic	tranexamic	B-NP	JJ	O	10	NMOD
10	acid	acid	I-NP	NN	O	11	SUB
11	was	be	B-VP	VBD	O	0	ROOT
12	a	a	B-NP	DT	O	15	NMOD
13	strong	strong	I-NP	JJ	O	14	AMOD
14	independent	independent	I-NP	JJ	O	15	NMOD
15	predictor	predictor	I-NP	NN	O	11	PRD
16	of	of	B-PP	IN	O	15	NMOD
17	seizures	seizure	B-NP	NNS	O	16	PMOD
18	(	(	O	(	O	30	DEP
19	OR	OR	B-NP	NN	B-DNA	24	NMOD
20	14.3	14.3	I-NP	CD	I-DNA	19	NMOD
21	,	,	O	,	O	24	P
22	95	95	B-NP	CD	O	24	NMOD
23	%	%	I-NP	NN	O	24	NMOD
24	CI	CI	I-NP	NN	O	27	NMOD
25	5.5-36.7	5.5-36.7	I-NP	CD	O	24	NMOD
26	;	;	O	:	O	27	P
27	p	p	B-NP	NN	O	29	SUB
28	<	<	B-NP	SYM	O	29	VMOD
29	0.001	0.001	I-NP	CD	O	30	DEP
30	)	)	O	)	O	17	NMOD
31	.	.	O	.	O	11	P

1	Dysfunctional	Dysfunctional	B-NP	JJ	O	4	NMOD
2	overnight	overnight	I-NP	JJ	O	4	NMOD
3	memory	memory	I-NP	NN	O	4	NMOD
4	consolidation	consolidation	I-NP	NN	O	0	ROOT
5	in	in	B-PP	IN	O	4	NMOD
6	ecstasy	ecstasy	B-NP	JJ	O	7	NMOD
7	users	user	I-NP	NNS	O	5	PMOD
8	.	.	O	.	O	4	P

1	Previous	Previous	B-NP	JJ	O	2	NMOD
2	studies	study	I-NP	NNS	O	3	SUB
3	indicate	indicate	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	ecstasy	ecstasy	B-NP	JJ	O	6	NMOD
6	users	user	I-NP	NNS	O	7	SUB
7	have	have	B-VP	VBP	O	4	SBAR
8	marked	mark	I-VP	VBN	O	7	VC
9	and	and	O	CC	O	14	NMOD
10	persistent	persistent	B-NP	JJ	O	14	NMOD
11	neurocognitive	neurocognitive	I-NP	JJ	O	14	NMOD
12	and	and	I-NP	CC	O	14	NMOD
13	sleep-related	sleep-related	I-NP	JJ	O	14	NMOD
14	impairments	impairment	I-NP	NNS	O	8	OBJ
15	.	.	O	.	O	3	P

1	Ecstasy	Ecstasy	B-NP	JJ	O	2	NMOD
2	users	user	I-NP	NNS	O	3	SUB
3	demonstrated	demonstrate	B-VP	VBD	O	0	ROOT
4	impaired	impaired	B-NP	JJ	O	5	AMOD
5	overnight	overnight	I-NP	JJ	O	7	NMOD
6	memory	memory	I-NP	NN	O	7	NMOD
7	consolidation	consolidation	I-NP	NN	O	10	NMOD
8	,	,	O	,	O	10	P
9	a	a	B-NP	DT	O	10	NMOD
10	finding	finding	I-NP	NN	O	3	OBJ
11	that	that	B-NP	WDT	O	10	NMOD
12	was	be	B-VP	VBD	O	11	SBAR
13	more	more	B-ADJP	RBR	O	14	AMOD
14	pronounced	pronounced	I-ADJP	JJ	O	12	PRD
15	following	follow	B-PP	VBG	O	14	AMOD
16	associative	associative	B-NP	JJ	O	17	NMOD
17	interference	interference	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	3	P

1	Normoammonemic	Normoammonemic	B-NP	JJ	O	2	NMOD
2	encephalopathy	encephalopathy	I-NP	NN	O	9	NMOD
3	:	:	O	:	O	2	P
4	solely	solely	B-NP	RB	O	9	NMOD
5	valproate	valproate	I-NP	NN	O	9	NMOD
6	induced	induced	I-NP	JJ	O	9	NMOD
7	or	or	I-NP	CC	O	9	NMOD
8	multiple	multiple	I-NP	JJ	O	9	NMOD
9	mechanisms	mechanism	I-NP	NNS	O	0	ROOT
10	.	.	O	.	O	9	P

1	In	In	B-PP	IN	O	8	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	preceding	precede	I-NP	VBG	O	4	NMOD
4	months	month	I-NP	NNS	O	1	PMOD
5	,	,	O	,	O	8	P
6	the	the	B-NP	DT	O	7	NMOD
7	patient	patient	I-NP	NN	O	8	SUB
8	had	have	B-VP	VBD	O	0	ROOT
9	a	a	B-NP	DT	O	10	NMOD
10	number	number	I-NP	NN	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	admissions	admission	B-NP	NNS	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	transient	transient	B-NP	JJ	O	16	NMOD
15	unilateral	unilateral	I-NP	JJ	O	16	NMOD
16	hemiparesis	hemiparesis	I-NP	NN	O	13	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	facial	facial	B-NP	JJ	O	19	NMOD
19	droop	droop	I-NP	NN	O	17	PMOD
20	,	,	O	,	O	8	P
21	and	and	O	CC	O	8	VMOD
22	had	have	B-VP	VBD	O	8	VMOD
23	been	be	I-VP	VBN	O	22	VC
24	started	start	I-VP	VBN	O	23	VC
25	on	on	B-PP	IN	O	24	VMOD
26	valproate	valproate	B-NP	NN	O	25	PMOD
27	for	for	B-PP	IN	O	26	NMOD
28	presumed	presume	B-NP	VBN	O	30	NMOD
29	hemiplegic	hemiplegic	I-NP	JJ	O	30	NMOD
30	migraine	migraine	I-NP	NN	O	27	PMOD
31	.	.	O	.	O	8	P

1	EEG	EEG	B-NP	NN	B-protein	6	SUB
2	undertaken	undertake	B-VP	VBN	O	1	NMOD
3	during	during	B-PP	IN	O	2	VMOD
4	inpatient	inpatient	B-NP	NN	O	5	NMOD
5	stay	stay	I-NP	NN	O	3	PMOD
6	showed	show	B-VP	VBD	O	21	VMOD
7	changes	change	B-NP	NNS	O	20	NMOD
8	consistent	consistent	B-ADJP	JJ	O	7	NMOD
9	with	with	B-PP	IN	O	8	AMOD
10	encephalopathy	encephalopathy	B-NP	NN	O	9	PMOD
11	,	,	O	,	O	20	P
12	and	and	O	CC	O	20	NMOD
13	low	low	B-NP	JJ	O	20	NMOD
14	titre	titre	I-NP	NN	B-protein	20	NMOD
15	N-methyl-D-aspartate	N-methyl-D-aspartate	I-NP	NN	I-protein	20	NMOD
16	(	(	O	(	I-protein	20	NMOD
17	NMDA	NMDA	B-NP	NN	I-protein	20	NMOD
18	)	)	O	)	I-protein	20	NMOD
19	receptor	receptor	B-NP	NN	I-protein	20	NMOD
20	antibodies	antibody	I-NP	NNS	I-protein	21	SUB
21	were	be	B-VP	VBD	O	0	ROOT
22	present	present	B-ADJP	JJ	O	21	PRD
23	in	in	B-PP	IN	O	22	AMOD
24	this	this	B-NP	DT	O	25	NMOD
25	patient	patient	I-NP	NN	O	23	PMOD
26	.	.	O	.	O	21	P

1	Cerebellar	Cerebellar	B-NP	NN	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	oculomotor	oculomotor	I-NP	NN	O	4	NMOD
4	dysfunction	dysfunction	I-NP	NN	O	0	ROOT
5	induced	induce	B-VP	VBN	O	4	NMOD
6	by	by	B-PP	IN	O	5	VMOD
7	rapid	rapid	B-NP	JJ	O	8	NMOD
8	infusion	infusion	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	pethidine	pethidine	B-NP	NN	O	9	PMOD
11	.	.	O	.	O	4	P

1	Pethidine	Pethidine	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	an	an	B-NP	DT	O	4	NMOD
4	opioid	opioid	I-NP	NN	O	2	PRD
5	that	that	B-NP	WDT	O	4	NMOD
6	gains	gain	B-VP	VBZ	O	5	SBAR
7	its	its	B-NP	PRP$	O	8	NMOD
8	popularity	popularity	I-NP	NN	O	6	OBJ
9	for	for	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	13	NMOD
11	effective	effective	I-NP	JJ	O	13	NMOD
12	pain	pain	I-NP	NN	O	13	NMOD
13	control	control	I-NP	NN	O	9	PMOD
14	through	through	B-PP	IN	O	6	VMOD
15	acting	act	B-VP	VBG	O	14	PMOD
16	on	on	B-PP	IN	O	15	VMOD
17	the	the	B-NP	DT	O	18	NMOD
18	opioid-receptors	opioid-receptor	I-NP	NNS	B-protein	16	PMOD
19	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	19	VMOD
2	patients	patient	B-NP	NNS	O	1	PMOD
3	with	with	B-PP	IN	O	2	NMOD
4	impaired	impaired	B-NP	JJ	O	8	NMOD
5	renal	renal	I-NP	JJ	O	4	NMOD
6	and	and	I-NP	CC	O	4	NMOD
7	liver	liver	I-NP	NN	O	8	NMOD
8	function	function	I-NP	NN	O	3	PMOD
9	,	,	O	,	O	19	P
10	and	and	O	CC	O	11	NMOD
11	those	those	B-NP	DT	O	19	SUB
12	who	who	B-NP	WP	O	11	NMOD
13	need	need	B-VP	VBP	O	12	SBAR
14	long-term	long-term	B-NP	JJ	O	16	NMOD
15	pain	pain	I-NP	NN	O	16	NMOD
16	control	control	I-NP	NN	O	13	OBJ
17	,	,	O	,	O	19	P
18	pethidine	pethidine	B-NP	NN	O	19	SUB
19	may	may	B-VP	MD	O	0	ROOT
20	cause	cause	I-VP	VB	O	19	VC
21	excitatory	excitatory	B-NP	JJ	O	24	NMOD
22	central	central	I-NP	JJ	O	24	NMOD
23	nervous	nervous	I-NP	JJ	O	24	NMOD
24	system	system	I-NP	NN	O	28	NMOD
25	(	(	O	(	O	27	DEP
26	CNS	CNS	B-NP	NN	B-protein	27	DEP
27	)	)	O	)	O	24	NMOD
28	effects	effect	B-NP	NNS	O	20	OBJ
29	through	through	B-PP	IN	O	20	VMOD
30	its	its	B-NP	PRP$	O	32	NMOD
31	neurotoxic	neurotoxic	I-NP	JJ	O	32	NMOD
32	metabolite	metabolite	I-NP	NN	O	34	NMOD
33	,	,	O	,	O	34	P
34	norpethidine	norpethidine	B-NP	NN	O	29	PMOD
35	,	,	O	,	O	20	P
36	resulting	result	B-VP	VBG	O	20	VMOD
37	in	in	B-PP	IN	O	36	VMOD
38	irritability	irritability	B-NP	NN	O	41	NMOD
39	and	and	I-NP	CC	O	41	NMOD
40	seizure	seizure	I-NP	NN	O	41	NMOD
41	attack	attack	I-NP	NN	O	37	PMOD
42	.	.	O	.	O	19	P

1	Baboon	Baboon	B-NP	NN	O	2	NMOD
2	syndrome	syndrome	I-NP	NN	O	0	ROOT
3	induced	induce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	ketoconazole	ketoconazole	B-NP	NN	O	4	PMOD
6	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	4	NMOD
2	27-year-old	27-year-old	I-NP	JJ	O	4	NMOD
3	male	male	I-NP	JJ	O	4	NMOD
4	patient	patient	I-NP	NN	O	5	SUB
5	presented	present	B-VP	VBD	O	0	ROOT
6	with	with	B-PP	IN	O	5	VMOD
7	a	a	B-NP	DT	O	9	NMOD
8	maculopapular	maculopapular	I-NP	JJ	O	9	NMOD
9	eruption	eruption	I-NP	NN	O	6	PMOD
10	on	on	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	15	NMOD
12	flexural	flexural	I-NP	JJ	O	13	NMOD
13	areas	area	I-NP	NNS	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	buttocks	buttock	I-NP	NNS	O	10	PMOD
16	after	after	B-PP	IN	O	5	VMOD
17	using	use	B-VP	VBG	O	16	PMOD
18	oral	oral	B-NP	JJ	O	19	NMOD
19	ketoconazole	ketoconazole	I-NP	NN	O	17	OBJ
20	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	diagnosed	diagnose	I-VP	VBN	O	3	VC
5	with	with	B-PP	IN	O	4	VMOD
6	drug	drug	B-NP	NN	O	5	PMOD
7	induced	induce	B-VP	VBD	O	3	VMOD
8	baboon	baboon	B-NP	NN	O	9	NMOD
9	syndrome	syndrome	I-NP	NN	O	7	OBJ
10	based	base	B-VP	VBN	O	9	NMOD
11	on	on	B-PP	IN	O	10	VMOD
12	his	his	B-NP	PRP$	O	13	NMOD
13	history	history	I-NP	NN	O	11	PMOD
14	,	,	O	,	O	7	P
15	which	which	B-NP	WDT	O	7	VMOD
16	included	include	B-VP	VBD	O	15	SBAR
17	prior	prior	B-NP	JJ	O	18	NMOD
18	sensitivity	sensitivity	I-NP	NN	O	16	OBJ
19	to	to	B-PP	TO	O	18	NMOD
20	topical	topical	B-NP	JJ	O	21	NMOD
21	ketoconazole	ketoconazole	I-NP	NN	O	19	PMOD
22	,	,	O	,	O	3	P
23	a	a	B-NP	DT	O	25	NMOD
24	physical	physical	I-NP	JJ	O	25	NMOD
25	examination	examination	I-NP	NN	O	3	PRD
26	,	,	O	,	O	29	P
27	and	and	O	CC	O	29	NMOD
28	histopathological	histopathological	B-NP	JJ	O	29	NMOD
29	findings	finding	I-NP	NNS	O	3	VMOD
30	.	.	O	.	O	3	P

1	A	A	B-NP	DT	O	2	NMOD
2	Case	Case	I-NP	NNP	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	Sudden	Sudden	B-NP	NNP	O	6	NMOD
5	Cardiac	Cardiac	I-NP	NNP	O	6	NMOD
6	Death	Death	I-NP	NNP	O	3	PMOD
7	due	due	B-ADJP	JJ	O	6	NMOD
8	to	to	B-PP	TO	O	7	AMOD
9	Pilsicainide-Induced	Pilsicainide-Induced	B-NP	NNP	O	10	NMOD
10	Torsades	Torsades	I-NP	NNP	O	8	PMOD
11	de	de	I-NP	IN	O	10	NMOD
12	Pointes	Pointes	I-NP	NNP	O	11	PMOD
13	.	.	O	.	O	2	P

1	An	An	B-NP	DT	O	6	NMOD
2	84-year-old	84-year-old	I-NP	JJ	O	6	NMOD
3	male	male	I-NP	JJ	O	6	NMOD
4	received	receive	I-NP	VBN	O	6	NMOD
5	oral	oral	I-NP	JJ	O	6	NMOD
6	pilsicainide	pilsicainide	I-NP	NN	O	12	NMOD
7	,	,	O	,	O	12	P
8	a	a	B-NP	DT	O	12	NMOD
9	pure	pure	I-NP	JJ	O	12	NMOD
10	sodium	sodium	I-NP	NN	O	12	NMOD
11	channel	channel	I-NP	NN	O	12	NMOD
12	blocker	blocker	I-NP	NN	O	30	NMOD
13	with	with	B-PP	IN	O	12	NMOD
14	slow	slow	B-NP	JJ	O	16	NMOD
15	recovery	recovery	I-NP	NN	O	16	NMOD
16	kinetics	kinetic	I-NP	NNS	O	13	PMOD
17	,	,	O	,	O	12	P
18	to	to	B-VP	TO	O	19	VMOD
19	convert	convert	I-VP	VB	O	12	NMOD
20	his	his	B-NP	PRP$	O	23	NMOD
21	paroxysmal	paroxysmal	I-NP	JJ	O	23	NMOD
22	atrial	atrial	I-NP	JJ	O	23	NMOD
23	fibrillation	fibrillation	I-NP	NN	O	19	OBJ
24	to	to	B-PP	TO	O	19	VMOD
25	a	a	B-NP	DT	O	27	NMOD
26	sinus	sinus	I-NP	NN	O	27	NMOD
27	rhythm	rhythm	I-NP	NN	O	24	PMOD
28	;	;	O	:	O	12	P
29	the	the	B-NP	DT	O	30	NMOD
30	patient	patient	I-NP	NN	O	31	SUB
31	developed	develop	B-VP	VBD	O	0	ROOT
32	sudden	sudden	B-NP	JJ	O	33	AMOD
33	cardiac	cardiac	I-NP	JJ	O	36	NMOD
34	death	death	I-NP	NN	O	36	NMOD
35	two	two	B-NP	CD	O	36	NMOD
36	days	day	I-NP	NNS	O	31	OBJ
37	later	later	B-ADVP	RB	O	36	NMOD
38	.	.	O	.	O	31	P

1	Although	Although	B-SBAR	IN	O	24	VMOD
2	the	the	B-NP	DT	O	6	NMOD
3	patient	patient	I-NP	NN	O	6	NMOD
4	's	's	B-NP	POS	O	6	NMOD
5	renal	renal	I-NP	JJ	O	6	NMOD
6	function	function	I-NP	NN	O	7	SUB
7	was	be	B-VP	VBD	O	16	VMOD
8	not	not	O	RB	O	7	VMOD
9	highly	highly	B-ADJP	RB	O	10	AMOD
10	impaired	impaired	I-ADJP	JJ	O	7	PRD
11	and	and	O	CC	O	16	VMOD
12	the	the	B-NP	DT	O	13	NMOD
13	dose	dose	I-NP	NN	O	16	SUB
14	of	of	B-PP	IN	O	13	NMOD
15	pilsicainide	pilsicainide	B-NP	NN	O	14	PMOD
16	was	be	B-VP	VBD	O	1	SBAR
17	low	low	B-ADJP	JJ	O	16	PRD
18	,	,	O	,	O	24	P
19	the	the	B-NP	DT	O	21	NMOD
20	plasma	plasma	I-NP	NN	O	21	NMOD
21	concentration	concentration	I-NP	NN	O	24	SUB
22	of	of	B-PP	IN	O	21	NMOD
23	pilsicainide	pilsicainide	B-NP	NN	O	22	PMOD
24	may	may	B-VP	MD	O	0	ROOT
25	have	have	I-VP	VB	O	24	VC
26	been	be	I-VP	VBN	O	25	VC
27	high	high	B-ADJP	JJ	O	26	PRD
28	,	,	O	,	O	24	P
29	which	which	B-NP	WDT	O	24	VMOD
30	can	can	B-VP	MD	O	29	SBAR
31	produce	produce	I-VP	VB	O	30	VC
32	torsades	torsade	B-NP	NNS	O	34	NMOD
33	de	de	I-NP	IN	O	34	NMOD
34	pointes	pointe	I-NP	NNS	O	31	OBJ
35	in	in	B-PP	IN	O	31	VMOD
36	the	the	B-NP	DT	O	37	NMOD
37	octogenarian	octogenarian	I-NP	NN	O	35	PMOD
38	.	.	O	.	O	24	P

1	All-trans	All-trans	B-NP	JJ	O	3	NMOD
2	retinoic	retinoic	I-NP	JJ	O	3	NMOD
3	acid	acid	I-NP	NN	O	4	SUB
4	induced	induce	B-VP	VBD	O	0	ROOT
5	inflammatory	inflammatory	B-NP	JJ	O	6	NMOD
6	myositis	myositis	I-NP	NN	O	4	OBJ
7	in	in	B-PP	IN	O	4	VMOD
8	a	a	B-NP	DT	O	9	NMOD
9	patient	patient	I-NP	NN	O	7	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	acute	acute	B-NP	JJ	O	13	NMOD
12	promyelocytic	promyelocytic	I-NP	JJ	O	13	NMOD
13	leukemia	leukemia	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	4	P

1	All-trans	All-trans	B-NP	JJ	O	3	NMOD
2	retinoic	retinoic	I-NP	JJ	O	3	NMOD
3	acid	acid	I-NP	NN	O	9	NMOD
4	(	(	O	(	O	6	DEP
5	ATRA	ATRA	B-NP	NN	O	6	DEP
6	)	)	O	)	O	3	NMOD
7	,	,	O	,	O	9	P
8	a	a	B-NP	DT	O	9	NMOD
9	component	component	I-NP	NN	O	21	SUB
10	of	of	B-PP	IN	O	9	NMOD
11	standard	standard	B-NP	JJ	O	12	NMOD
12	therapy	therapy	I-NP	NN	O	10	PMOD
13	for	for	B-PP	IN	O	12	NMOD
14	acute	acute	B-NP	JJ	O	16	NMOD
15	promyelocytic	promyelocytic	I-NP	JJ	O	16	NMOD
16	leukemia	leukemia	I-NP	NN	O	13	PMOD
17	(	(	O	(	O	19	DEP
18	APL	APL	B-NP	NN	O	19	DEP
19	)	)	O	)	O	16	NMOD
20	,	,	O	,	O	9	P
21	is	be	B-VP	VBZ	O	0	ROOT
22	associated	associate	I-VP	VBN	O	21	VC
23	with	with	B-PP	IN	O	22	VMOD
24	potentially	potentially	B-NP	RB	O	25	AMOD
25	serious	serious	I-NP	JJ	O	27	AMOD
26	but	but	I-NP	CC	O	27	AMOD
27	treatable	treatable	I-NP	JJ	O	29	NMOD
28	adverse	adverse	I-NP	JJ	O	29	NMOD
29	effects	effect	I-NP	NNS	O	23	PMOD
30	involving	involve	B-VP	VBG	O	29	NMOD
31	numerous	numerous	B-NP	JJ	O	33	NMOD
32	organ	organ	I-NP	NN	O	33	NMOD
33	systems	system	I-NP	NNS	O	30	OBJ
34	,	,	O	,	O	33	P
35	including	include	B-PP	VBG	O	33	NMOD
36	rare	rare	B-NP	JJ	O	39	NMOD
37	skeletal	skeletal	I-NP	JJ	O	39	NMOD
38	muscle	muscle	I-NP	NN	O	39	NMOD
39	involvement	involvement	I-NP	NN	O	35	PMOD
40	.	.	O	.	O	21	P

1	Only	Only	B-NP	RB	O	3	NMOD
2	a	a	I-NP	DT	O	3	NMOD
3	handful	handful	I-NP	NN	O	8	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	cases	case	B-NP	NNS	O	4	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	ATRA	ATRA	B-NP	NN	O	6	PMOD
8	induced	induce	B-VP	VBD	O	17	VMOD
9	myositis	myositis	B-NP	NN	O	8	OBJ
10	in	in	B-PP	IN	O	8	VMOD
11	children	child	B-NP	NNS	O	10	PMOD
12	have	have	B-VP	VBP	O	8	VMOD
13	been	be	I-VP	VBN	O	12	VC
14	reported	report	I-VP	VBN	O	13	VC
15	,	,	O	,	O	17	P
16	and	and	O	CC	O	17	NMOD
17	none	none	B-NP	NN	O	0	ROOT
18	in	in	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	21	NMOD
20	radiology	radiology	I-NP	NN	O	21	NMOD
21	literature	literature	I-NP	NN	O	18	PMOD
22	.	.	O	.	O	17	P

1	Tolerability	Tolerability	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	lomustine	lomustine	B-NP	NN	O	2	PMOD
4	in	in	B-PP	IN	O	1	NMOD
5	combination	combination	B-NP	NN	O	4	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	cyclophosphamide	cyclophosphamide	B-NP	NN	O	6	PMOD
8	in	in	B-PP	IN	O	7	NMOD
9	dogs	dog	B-NP	NNS	O	8	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	lymphoma	lymphoma	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	1	P

1	This	This	B-NP	DT	O	3	NMOD
2	retrospective	retrospective	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	describes	describe	B-VP	VBZ	O	0	ROOT
5	toxicity	toxicity	B-NP	NN	O	4	OBJ
6	associated	associate	B-VP	VBN	O	5	NMOD
7	with	with	B-PP	IN	O	6	VMOD
8	a	a	B-NP	DT	O	9	NMOD
9	protocol	protocol	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	lomustine	lomustine	B-NP	NN	O	16	NMOD
12	(	(	O	(	O	14	DEP
13	CCNU	CCNU	B-NP	NN	B-protein	14	DEP
14	)	)	O	)	O	11	NMOD
15	and	and	O	CC	O	16	NMOD
16	cyclophosphamide	cyclophosphamide	B-NP	NN	O	10	PMOD
17	(	(	O	(	O	19	DEP
18	CTX	CTX	B-NP	NN	B-protein	19	DEP
19	)	)	O	)	O	16	NMOD
20	in	in	B-PP	IN	O	9	NMOD
21	dogs	dog	B-NP	NNS	O	20	PMOD
22	with	with	B-PP	IN	O	21	NMOD
23	lymphoma	lymphoma	B-NP	NN	O	22	PMOD
24	.	.	O	.	O	4	P

1	Neutropenia	Neutropenia	B-NP	NNP	O	2	SUB
2	was	be	B-VP	VBD	O	22	VMOD
3	the	the	B-NP	DT	O	6	NMOD
4	principal	principal	I-NP	JJ	O	6	NMOD
5	toxic	toxic	I-NP	JJ	O	6	NMOD
6	effect	effect	I-NP	NN	O	2	PRD
7	,	,	O	,	O	22	P
8	and	and	O	CC	O	22	VMOD
9	the	the	B-NP	DT	O	11	NMOD
10	overall	overall	I-NP	JJ	O	11	NMOD
11	frequency	frequency	I-NP	NN	O	22	SUB
12	of	of	B-PP	IN	O	11	NMOD
13	grade	grade	B-NP	NN	O	15	NMOD
14	4	4	I-NP	CD	O	15	NMOD
15	neutropenia	neutropenia	I-NP	NN	O	12	PMOD
16	after	after	B-PP	IN	O	11	NMOD
17	the	the	B-NP	DT	O	19	NMOD
18	first	first	I-NP	JJ	O	19	NMOD
19	treatment	treatment	I-NP	NN	O	16	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	CCNU/CTX	CCNU/CTX	B-NP	NN	B-protein	20	PMOD
22	was	be	B-VP	VBD	O	0	ROOT
23	30	30	B-NP	CD	O	24	NMOD
24	%	%	I-NP	NN	O	22	PRD
25	(	(	O	(	O	33	DEP
26	95	95	B-NP	CD	O	29	NMOD
27	%	%	I-NP	NN	O	29	NMOD
28	confidence	confidence	I-NP	NN	O	29	NMOD
29	interval	interval	I-NP	NN	O	32	NMOD
30	,	,	O	,	O	32	P
31	19-43	19-43	B-NP	CD	O	32	NMOD
32	%	%	I-NP	NN	O	33	DEP
33	)	)	O	)	O	24	NMOD
34	.	.	O	.	O	22	P

1	Nelarabine	Nelarabine	B-NP	NN	O	2	NMOD
2	neurotoxicity	neurotoxicity	I-NP	NN	O	11	NMOD
3	with	with	B-PP	IN	O	2	NMOD
4	concurrent	concurrent	B-NP	JJ	O	6	NMOD
5	intrathecal	intrathecal	I-NP	JJ	O	6	NMOD
6	chemotherapy	chemotherapy	I-NP	NN	O	3	PMOD
7	:	:	O	:	O	2	P
8	Case	Case	B-NP	NN	O	9	NMOD
9	report	report	I-NP	NN	O	11	NMOD
10	and	and	O	CC	O	11	NMOD
11	review	review	B-NP	NN	O	0	ROOT
12	of	of	B-PP	IN	O	11	NMOD
13	literature	literature	B-NP	NN	O	12	PMOD
14	.	.	O	.	O	11	P

1	Severe	Severe	B-NP	JJ	O	3	NMOD
2	nelarabine	nelarabine	I-NP	NN	O	3	NMOD
3	neurotoxicity	neurotoxicity	I-NP	NN	O	15	SUB
4	in	in	B-PP	IN	O	3	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	patient	patient	I-NP	NN	O	4	PMOD
7	who	who	B-NP	WP	O	6	NMOD
8	received	receive	B-VP	VBD	O	7	SBAR
9	concurrent	concurrent	B-NP	JJ	O	14	NMOD
10	intrathecal	intrathecal	I-NP	JJ	O	14	NMOD
11	(	(	O	(	O	13	DEP
12	IT	IT	B-ADJP	JJ	O	13	DEP
13	)	)	O	)	O	10	AMOD
14	chemotherapy	chemotherapy	B-NP	NN	O	8	OBJ
15	is	be	B-VP	VBZ	O	0	ROOT
16	reported	report	I-VP	VBN	O	15	VC
17	.	.	O	.	O	15	P

1	Valproate	Valproate	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	hyperammonemic	hyperammonemic	B-NP	JJ	O	4	NMOD
4	encephalopathy	encephalopathy	I-NP	NN	O	2	OBJ
5	in	in	B-PP	IN	O	2	VMOD
6	a	a	B-NP	DT	O	9	NMOD
7	renal	renal	I-NP	JJ	O	9	NMOD
8	transplanted	transplant	I-NP	VBN	O	9	NMOD
9	patient	patient	I-NP	NN	O	5	PMOD
10	.	.	O	.	O	2	P

1	Valproate	Valproate	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	hyperammonemic	hyperammonemic	B-NP	JJ	O	4	NMOD
4	encephalopathy	encephalopathy	I-NP	NN	O	5	SUB
5	is	be	B-VP	VBZ	O	2	VMOD
6	an	an	B-NP	DT	O	10	NMOD
7	uncommon	uncommon	I-NP	JJ	O	10	NMOD
8	but	but	I-NP	CC	O	10	NMOD
9	serious	serious	I-NP	JJ	O	10	NMOD
10	effect	effect	I-NP	NN	O	5	PRD
11	of	of	B-PP	IN	O	10	NMOD
12	valproate	valproate	B-NP	NN	O	13	NMOD
13	treatment	treatment	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	2	P

1	Here	Here	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	we	we	B-NP	PRP	O	4	SUB
4	describe	describe	B-VP	VBP	O	0	ROOT
5	the	the	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	a	a	B-NP	DT	O	10	NMOD
9	15-year-old	15-year-old	I-NP	JJ	O	10	NMOD
10	girl	girl	I-NP	NN	O	7	PMOD
11	who	who	B-NP	WP	O	6	NMOD
12	was	be	B-VP	VBD	O	11	SBAR
13	on	on	B-PP	IN	O	12	PRD
14	a	a	B-NP	DT	O	16	NMOD
15	long-term	long-term	I-NP	JJ	O	16	NMOD
16	therapy	therapy	I-NP	NN	O	13	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	valproate	valproate	B-NP	NN	O	17	PMOD
19	due	due	B-ADJP	JJ	O	18	NMOD
20	to	to	B-PP	TO	O	19	AMOD
21	epilepsy	epilepsy	B-NP	NN	O	20	PMOD
22	and	and	O	CC	O	4	VMOD
23	revealed	reveal	B-VP	VBD	O	4	VMOD
24	impaired	impaired	B-NP	JJ	O	25	NMOD
25	consciousness	consciousness	I-NP	NN	O	23	OBJ
26	with	with	B-PP	IN	O	25	NMOD
27	hyperammonemia	hyperammonemia	B-NP	NN	O	29	NMOD
28	12	12	B-NP	CD	O	29	NMOD
29	days	day	I-NP	NNS	O	26	PMOD
30	after	after	B-PP	IN	O	25	NMOD
31	renal	renal	B-NP	JJ	O	32	NMOD
32	transplantation	transplantation	I-NP	NN	O	30	PMOD
33	.	.	O	.	O	4	P

1	Necrotising	Necrotise	B-VP	VBG	O	0	ROOT
2	fasciitis	fasciitis	B-NP	NN	O	1	OBJ
3	after	after	B-PP	IN	O	1	VMOD
4	bortezomib	bortezomib	B-NP	NN	O	7	NMOD
5	and	and	O	CC	O	7	NMOD
6	dexamethasone-containing	dexamethasone-containing	B-NP	JJ	O	7	NMOD
7	regimen	regimen	I-NP	NN	O	3	PMOD
8	in	in	B-PP	IN	O	7	NMOD
9	an	an	B-NP	DT	O	11	NMOD
10	elderly	elderly	I-NP	JJ	O	11	NMOD
11	patient	patient	I-NP	NN	O	8	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	Waldenstrom	Waldenstrom	B-NP	NNP	O	14	NMOD
14	macroglobulinaemia	macroglobulinaemia	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	1	P

1	Bortezomib	Bortezomib	B-NP	NN	O	5	NMOD
2	and	and	O	CC	O	5	NMOD
3	high-dose	high-dose	B-NP	JJ	O	5	NMOD
4	dexamethasone-containing	dexamethasone-containing	I-NP	JJ	O	5	NMOD
5	regimens	regimen	I-NP	NNS	O	6	SUB
6	are	be	B-VP	VBP	O	0	ROOT
7	considered	consider	I-VP	VBN	O	6	VC
8	to	to	I-VP	TO	O	9	VMOD
9	be	be	I-VP	VB	O	7	VMOD
10	generally	generally	B-ADJP	RB	O	11	AMOD
11	tolerable	tolerable	I-ADJP	JJ	O	9	PRD
12	with	with	B-PP	IN	O	11	AMOD
13	few	few	B-NP	JJ	O	15	AMOD
14	severe	severe	I-NP	JJ	O	15	AMOD
15	bacterial	bacterial	I-NP	JJ	O	16	NMOD
16	infections	infection	I-NP	NNS	O	12	PMOD
17	in	in	B-PP	IN	O	16	NMOD
18	patients	patient	B-NP	NNS	O	17	PMOD
19	with	with	B-PP	IN	O	18	NMOD
20	B-cell	B-cell	B-NP	NN	O	21	NMOD
21	malignancies	malignancy	I-NP	NNS	O	19	PMOD
22	.	.	O	.	O	6	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	76-year-old	76-year-old	I-NP	JJ	O	8	NMOD
8	man	man	I-NP	NN	O	5	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	Waldenstrom	Waldenstrom	B-NP	NNP	O	11	NMOD
11	macroglobulinaemia	macroglobulinaemia	I-NP	NN	O	9	PMOD
12	who	who	B-NP	WP	O	11	NMOD
13	suffered	suffer	B-VP	VBD	O	12	SBAR
14	necrotising	necrotise	I-VP	VBG	O	13	VMOD
15	fasciitis	fasciitis	B-NP	NN	O	14	OBJ
16	without	without	B-PP	IN	O	14	VMOD
17	neutropenia	neutropenia	B-NP	NN	O	16	PMOD
18	after	after	B-PP	IN	O	13	VMOD
19	the	the	B-NP	DT	O	21	NMOD
20	combination	combination	I-NP	NN	O	21	NMOD
21	treatment	treatment	I-NP	NN	O	18	PMOD
22	with	with	B-PP	IN	O	21	NMOD
23	bortezomib	bortezomib	B-NP	NN	O	28	NMOD
24	,	,	O	,	O	28	P
25	high-dose	high-dose	B-NP	JJ	O	28	NMOD
26	dexamethasone	dexamethasone	I-NP	NN	O	28	NMOD
27	and	and	I-NP	CC	O	28	NMOD
28	rituximab	rituximab	I-NP	NN	B-protein	22	PMOD
29	.	.	O	.	O	2	P

1	An	An	B-NP	DT	O	3	NMOD
2	integrated	integrate	I-NP	VBN	O	3	NMOD
3	characterization	characterization	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	serological	serological	B-NP	JJ	O	11	NMOD
6	,	,	I-NP	,	O	11	P
7	pathological	pathological	I-NP	JJ	O	11	NMOD
8	,	,	O	,	O	11	P
9	and	and	O	CC	O	11	NMOD
10	functional	functional	B-NP	JJ	O	11	NMOD
11	events	event	I-NP	NNS	O	4	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	doxorubicin	doxorubicin	B-NP	NN	O	15	NMOD
14	induced	induced	I-NP	JJ	O	15	NMOD
15	cardiotoxicity	cardiotoxicity	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	6	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	study	study	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	6	P
5	we	we	B-NP	PRP	O	6	SUB
6	have	have	B-VP	VBP	O	0	ROOT
7	utilized	utilize	I-VP	VBN	O	6	VC
8	a	a	B-NP	DT	O	10	NMOD
9	rat	rat	I-NP	NN	O	10	NMOD
10	model	model	I-NP	NN	O	7	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	progressive	progressive	B-NP	JJ	O	13	NMOD
13	doxorubicin	doxorubicin	I-NP	NN	O	18	NMOD
14	(	(	O	(	O	16	DEP
15	DOX	DOX	B-NP	NN	O	16	DEP
16	)	)	O	)	O	13	NMOD
17	induced	induce	B-NP	VBN	O	18	NMOD
18	cardiomyopathy	cardiomyopathy	I-NP	NN	O	11	PMOD
19	,	,	O	,	O	6	P
20	applying	apply	B-VP	VBG	O	6	VMOD
21	multiple	multiple	B-NP	JJ	O	22	NMOD
22	approaches	approach	I-NP	NNS	O	20	OBJ
23	,	,	O	,	O	22	P
24	including	include	B-PP	VBG	O	22	NMOD
25	cardiac	cardiac	B-NP	JJ	O	28	NMOD
26	magnetic	magnetic	I-NP	JJ	O	28	NMOD
27	resonance	resonance	I-NP	NN	O	28	NMOD
28	imaging	imaging	I-NP	NN	O	24	PMOD
29	(	(	O	(	O	31	DEP
30	MRI	MRI	B-NP	NN	B-protein	31	DEP
31	)	)	O	)	O	28	NMOD
32	,	,	O	,	O	6	P
33	to	to	B-VP	TO	O	34	VMOD
34	provide	provide	I-VP	VB	O	6	VMOD
35	the	the	B-NP	DT	O	38	NMOD
36	most	most	I-NP	RBS	O	37	AMOD
37	comprehensive	comprehensive	I-NP	JJ	O	38	NMOD
38	characterization	characterization	I-NP	NN	O	34	OBJ
39	to	to	B-PP	TO	O	38	NMOD
40	date	date	B-NP	NN	O	39	PMOD
41	of	of	B-PP	IN	O	40	NMOD
42	the	the	B-NP	DT	O	43	NMOD
43	timecourse	timecourse	I-NP	NN	O	41	PMOD
44	of	of	B-PP	IN	O	43	NMOD
45	serological	serological	B-NP	JJ	O	51	NMOD
46	,	,	I-NP	,	O	51	P
47	pathological	pathological	I-NP	JJ	O	51	NMOD
48	,	,	O	,	O	51	P
49	and	and	O	CC	O	51	NMOD
50	functional	functional	B-NP	JJ	O	51	NMOD
51	events	event	I-NP	NNS	O	44	PMOD
52	underlying	underlie	B-VP	VBG	O	51	NMOD
53	this	this	B-NP	DT	O	54	NMOD
54	toxicity	toxicity	I-NP	NN	O	52	OBJ
55	.	.	O	.	O	6	P

1	Troponin	Troponin	B-NP	NN	O	3	NMOD
2	I	I	I-NP	CD	O	3	NMOD
3	levels	level	I-NP	NNS	O	5	SUB
4	positively	positively	B-ADVP	RB	O	5	VMOD
5	correlated	correlate	B-VP	VBD	O	0	ROOT
6	with	with	B-PP	IN	O	5	VMOD
7	delayed	delay	B-NP	VBN	O	12	NMOD
8	and	and	I-NP	CC	O	9	AMOD
9	peak	peak	I-NP	JJ	O	12	NMOD
10	gadolinium	gadolinium	I-NP	NN	O	12	NMOD
11	contrast	contrast	I-NP	NN	O	12	NMOD
12	enhancement	enhancement	I-NP	NN	O	19	NMOD
13	,	,	O	,	O	19	P
14	histopathological	histopathological	B-NP	JJ	O	15	NMOD
15	grading	grading	I-NP	NN	O	19	NMOD
16	,	,	O	,	O	19	P
17	and	and	O	CC	O	19	NMOD
18	diastolic	diastolic	B-NP	JJ	O	19	NMOD
19	dysfunction	dysfunction	I-NP	NN	O	6	PMOD
20	.	.	O	.	O	5	P

1	Intradermal	Intradermal	B-NP	JJ	O	2	NMOD
2	glutamate	glutamate	I-NP	NN	O	5	NMOD
3	and	and	I-NP	CC	O	5	NMOD
4	capsaicin	capsaicin	I-NP	NN	O	5	NMOD
5	injections	injection	I-NP	NNS	O	10	NMOD
6	:	:	O	:	O	5	P
7	intra-	intra-	B-NP	JJ	O	10	NMOD
8	and	and	I-NP	CC	O	10	NMOD
9	interindividual	interindividual	I-NP	JJ	O	10	NMOD
10	variability	variability	I-NP	NN	O	0	ROOT
11	of	of	B-PP	IN	O	10	NMOD
12	provoked	provoked	B-NP	JJ	O	13	NMOD
13	hyperalgesia	hyperalgesia	I-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	allodynia	allodynia	I-NP	NN	O	11	PMOD
16	.	.	O	.	O	10	P

1	Intradermal	Intradermal	B-NP	JJ	O	2	NMOD
2	injections	injection	I-NP	NNS	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	glutamate	glutamate	B-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	capsaicin	capsaicin	I-NP	NN	O	3	PMOD
7	are	be	B-VP	VBP	O	0	ROOT
8	attractive	attractive	B-ADJP	JJ	O	7	PRD
9	to	to	B-VP	TO	O	10	VMOD
10	use	use	I-VP	VB	O	8	AMOD
11	in	in	B-PP	IN	O	10	VMOD
12	human	human	B-NP	JJ	B-cell_type	15	NMOD
13	experimental	experimental	I-NP	JJ	I-cell_type	15	NMOD
14	pain	pain	I-NP	NN	I-cell_type	15	NMOD
15	models	model	I-NP	NNS	I-cell_type	11	PMOD
16	because	because	B-SBAR	IN	O	10	VMOD
17	hyperalgesia	hyperalgesia	B-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	allodynia	allodynia	I-NP	NN	O	20	SUB
20	mimic	mimic	B-VP	VBP	O	16	SBAR
21	isolated	isolate	I-VP	VBN	O	20	VC
22	aspects	aspect	B-NP	NNS	O	21	OBJ
23	of	of	B-PP	IN	O	22	NMOD
24	clinical	clinical	B-NP	JJ	O	26	NMOD
25	pain	pain	I-NP	NN	O	26	NMOD
26	disorders	disorder	I-NP	NNS	O	23	PMOD
27	.	.	O	.	O	7	P

1	Secondary	Secondary	B-NP	JJ	O	3	NMOD
2	pinprick	pinprick	I-NP	NN	O	3	NMOD
3	hyperalgesia	hyperalgesia	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	observed	observe	I-VP	VBN	O	4	VC
6	as	as	B-PP	IN	O	5	VMOD
7	a	a	B-NP	DT	O	9	NMOD
8	marked	marked	I-NP	JJ	O	9	NMOD
9	increase	increase	I-NP	NN	O	22	SUB
10	in	in	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	14	NMOD
12	visual	visual	I-NP	JJ	O	14	NMOD
13	analogue	analogue	I-NP	NN	O	14	NMOD
14	scale	scale	I-NP	NN	O	18	NMOD
15	(	(	O	(	O	17	DEP
16	VAS	VAS	B-NP	NN	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	response	response	B-NP	NN	O	10	PMOD
19	to	to	B-PP	TO	O	18	NMOD
20	von	von	B-NP	NNP	O	21	NMOD
21	Frey	Frey	I-NP	NNP	O	19	PMOD
22	gauges	gauge	B-VP	VBZ	O	6	SBAR
23	60	60	B-NP	CD	O	25	AMOD
24	and	and	I-NP	CC	O	25	AMOD
25	100	100	I-NP	CD	O	26	NMOD
26	g	g	I-NP	NN	O	22	OBJ
27	(	(	O	(	O	31	DEP
28	P	P	B-NP	NN	O	31	DEP
29	<	<	B-NP	SYM	O	28	NMOD
30	0.001	0.001	I-NP	CD	O	29	AMOD
31	)	)	O	)	O	22	VMOD
32	after	after	B-PP	IN	O	22	VMOD
33	glutamate	glutamate	B-NP	NN	O	34	NMOD
34	injection	injection	I-NP	NN	O	32	PMOD
35	.	.	O	.	O	4	P

1	For	For	B-PP	IN	O	7	VMOD
2	capsaicin	capsaicin	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	7	P
4	secondary	secondary	B-NP	JJ	O	6	NMOD
5	pinprick	pinprick	I-NP	NN	O	6	NMOD
6	hyperalgesia	hyperalgesia	I-NP	NN	O	7	SUB
7	was	be	B-VP	VBD	O	0	ROOT
8	detected	detect	I-VP	VBN	O	7	VC
9	with	with	B-PP	IN	O	8	VMOD
10	all	all	B-NP	DT	O	13	NMOD
11	von	von	I-NP	NNP	O	13	NMOD
12	Frey	Frey	I-NP	NNP	O	13	NMOD
13	gauges	gauge	I-NP	NNS	O	9	PMOD
14	(	(	O	(	O	18	DEP
15	P	P	B-NP	NN	O	17	SUB
16	<	<	O	SYM	O	17	VMOD
17	0.001	0.001	B-NP	CD	O	18	DEP
18	)	)	O	)	O	13	NMOD
19	.	.	O	.	O	7	P

1	Capsaicin	Capsaicin	B-NP	NN	O	2	NMOD
2	injection	injection	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	reproducible	reproducible	B-ADJP	JJ	O	3	PRD
5	for	for	B-PP	IN	O	4	AMOD
6	secondary	secondary	B-NP	JJ	O	7	NMOD
7	hyperalgesia	hyperalgesia	I-NP	NN	O	5	PMOD
8	(	(	O	(	O	12	DEP
9	ICC	ICC	B-NP	NN	O	11	NMOD
10	>	>	O	SYM	O	11	P
11	0.70	0.70	B-NP	CD	O	12	DEP
12	)	)	O	)	O	3	VMOD
13	and	and	O	CC	O	3	VMOD
14	allodynia	allodynia	B-NP	NN	O	13	PMOD
15	(	(	O	(	O	19	DEP
16	ICC	ICC	B-NP	NN	O	18	NMOD
17	>	>	O	SYM	O	18	P
18	0.71	0.71	B-NP	CD	O	19	DEP
19	)	)	O	)	O	14	NMOD
20	.	.	O	.	O	3	P

1	Treatment	Treatment	B-NP	NN	O	11	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	WT	WT	B-NP	JJ	O	4	NMOD
4	mice	mouse	I-NP	NNS	O	2	PMOD
5	with	with	B-PP	IN	O	1	NMOD
6	topical	topical	B-NP	JJ	O	10	NMOD
7	ocular	ocular	I-NP	JJ	O	9	AMOD
8	0.1	0.1	I-NP	CD	O	9	AMOD
9	%	%	I-NP	NN	O	10	NMOD
10	dexamethasone	dexamethasone	I-NP	NN	O	5	PMOD
11	led	lead	B-VP	VBD	O	0	ROOT
12	to	to	B-PP	TO	O	11	VMOD
13	elevation	elevation	B-NP	NN	O	23	AMOD
14	of	of	B-PP	IN	O	13	NMOD
15	intraocular	intraocular	B-NP	JJ	O	16	NMOD
16	pressure	pressure	I-NP	NN	O	14	PMOD
17	(	(	O	(	O	19	DEP
18	IOP	IOP	B-NP	NN	B-protein	19	DEP
19	)	)	O	)	O	16	NMOD
20	,	,	O	,	O	23	P
21	functional	functional	B-NP	JJ	O	23	AMOD
22	and	and	I-NP	CC	O	23	AMOD
23	structural	structural	I-NP	JJ	O	24	NMOD
24	loss	loss	I-NP	NN	O	12	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	retinal	retinal	B-NP	JJ	B-cell_type	28	NMOD
27	ganglion	ganglion	I-NP	NN	I-cell_type	28	NMOD
28	cells	cell	I-NP	NNS	I-cell_type	25	PMOD
29	,	,	O	,	O	11	VMOD
30	and	and	O	CC	O	32	NMOD
31	axonal	axonal	B-NP	JJ	O	32	NMOD
32	degeneration	degeneration	I-NP	NN	O	29	OBJ
33	,	,	O	,	O	34	P
34	resembling	resemble	B-VP	VBG	O	32	NMOD
35	glucocorticoid	glucocorticoid	B-NP	NN	O	37	NMOD
36	induced	induce	B-VP	VBD	O	37	NMOD
37	glaucoma	glaucoma	B-NP	NN	O	34	OBJ
38	in	in	B-PP	IN	O	37	NMOD
39	human	human	B-NP	JJ	O	40	NMOD
40	patients	patient	I-NP	NNS	O	38	PMOD
41	.	.	O	.	O	11	P

1	Furthermore	Furthermore	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	dexamethasone	dexamethasone	B-NP	NN	O	4	SUB
4	induced	induce	B-VP	VBD	O	0	ROOT
5	ocular	ocular	B-NP	JJ	O	6	NMOD
6	hypertension	hypertension	I-NP	NN	O	7	SUB
7	was	be	B-VP	VBD	O	4	VMOD
8	associated	associate	I-VP	VBN	O	7	VC
9	with	with	B-PP	IN	O	8	VMOD
10	chronic	chronic	B-NP	JJ	O	12	NMOD
11	ER	ER	I-NP	NN	O	12	NMOD
12	stress	stress	I-NP	NN	O	9	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	16	NMOD
15	trabecular	trabecular	I-NP	JJ	O	16	NMOD
16	meshwork	meshwork	I-NP	NN	O	13	PMOD
17	(	(	O	(	O	19	DEP
18	TM	TM	B-NP	NN	O	19	DEP
19	)	)	O	)	O	16	NMOD
20	.	.	O	.	O	4	P

1	Dexamethasone	Dexamethasone	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	24	VMOD
3	the	the	B-NP	DT	O	6	NMOD
4	transcriptional	transcriptional	I-NP	JJ	B-protein	6	NMOD
5	factor	factor	I-NP	NN	I-protein	6	NMOD
6	CHOP	CHOP	I-NP	NN	O	9	NMOD
7	,	,	O	,	O	9	P
8	a	a	B-NP	DT	O	9	NMOD
9	marker	marker	I-NP	NN	O	2	OBJ
10	for	for	B-PP	IN	O	9	NMOD
11	chronic	chronic	B-NP	JJ	O	13	NMOD
12	ER	ER	I-NP	NN	O	13	NMOD
13	stress	stress	I-NP	NN	O	10	PMOD
14	,	,	O	,	O	2	P
15	in	in	B-PP	IN	O	2	VMOD
16	the	the	B-NP	DT	O	19	NMOD
17	anterior	anterior	I-NP	JJ	O	19	NMOD
18	segment	segment	I-NP	NN	O	19	NMOD
19	tissues	tissue	I-NP	NNS	O	15	PMOD
20	,	,	O	,	O	24	P
21	and	and	O	CC	O	24	VMOD
22	Chop	Chop	B-NP	NN	O	23	NMOD
23	deletion	deletion	I-NP	NN	O	24	SUB
24	reduced	reduce	B-VP	VBD	O	0	ROOT
25	ER	ER	B-NP	NN	B-protein	26	NMOD
26	stress	stress	I-NP	NN	O	33	SUB
27	in	in	B-PP	IN	O	26	NMOD
28	these	these	B-NP	DT	O	29	NMOD
29	tissues	tissue	I-NP	NNS	O	27	PMOD
30	and	and	O	CC	O	33	VMOD
31	prevented	prevent	B-NP	VBN	O	32	NMOD
32	dexamethasone	dexamethasone	I-NP	NN	O	33	SUB
33	induced	induce	B-VP	VBD	O	24	VMOD
34	ocular	ocular	B-NP	JJ	O	35	NMOD
35	hypertension	hypertension	I-NP	NN	O	33	OBJ
36	.	.	O	.	O	24	P

1	Furthermore	Furthermore	B-ADVP	RB	O	13	VMOD
2	,	,	O	,	O	13	P
3	reduction	reduction	B-NP	NN	O	13	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	ER	ER	B-NP	NN	B-protein	6	NMOD
6	stress	stress	I-NP	NN	O	4	PMOD
7	in	in	B-PP	IN	O	3	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	TM	TM	I-NP	NN	O	7	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	sodium	sodium	B-NP	NN	O	12	NMOD
12	4-phenylbutyrate	4-phenylbutyrate	I-NP	NN	O	10	PMOD
13	prevented	prevent	B-VP	VBD	O	0	ROOT
14	dexamethasone	dexamethasone	B-NP	NN	O	17	NMOD
15	induced	induced	I-NP	JJ	O	17	NMOD
16	ocular	ocular	I-NP	JJ	O	17	NMOD
17	hypertension	hypertension	I-NP	NN	O	13	OBJ
18	in	in	B-PP	IN	O	17	NMOD
19	WT	WT	B-NP	JJ	O	20	NMOD
20	mice	mouse	I-NP	NNS	O	18	PMOD
21	.	.	O	.	O	13	P

1	Effects	Effect	B-NP	NNS	O	6	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	ginsenosides	ginsenoside	B-NP	NNS	O	2	PMOD
4	on	on	B-PP	IN	O	1	NMOD
5	opioid	opioid	B-NP	NN	O	4	PMOD
6	induced	induce	B-VP	VBD	O	0	ROOT
7	hyperalgesia	hyperalgesia	B-NP	NN	O	6	OBJ
8	in	in	B-PP	IN	O	6	VMOD
9	mice	mouse	B-NP	NNS	O	8	PMOD
10	.	.	O	.	O	6	P

1	In	In	B-PP	IN	O	6	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	study	study	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	6	P
5	we	we	B-NP	PRP	O	6	SUB
6	investigated	investigate	B-VP	VBD	O	0	ROOT
7	the	the	B-NP	DT	O	8	NMOD
8	effects	effect	I-NP	NNS	O	20	NMOD
9	of	of	B-PP	IN	O	8	NMOD
10	Re	Re	B-NP	NN	O	16	NMOD
11	,	,	O	,	O	16	P
12	Rg1	Rg1	B-NP	NN	B-protein	16	NMOD
13	,	,	O	,	O	16	P
14	and	and	O	CC	O	16	NMOD
15	Rb1	Rb1	B-NP	NN	O	16	NMOD
16	ginsenosides	ginsenoside	I-NP	NNS	O	9	PMOD
17	,	,	O	,	O	20	P
18	the	the	B-NP	DT	O	20	NMOD
19	bioactive	bioactive	I-NP	JJ	O	20	NMOD
20	components	component	I-NP	NNS	O	6	OBJ
21	of	of	B-PP	IN	O	20	NMOD
22	ginseng	ginseng	B-NP	NN	O	21	PMOD
23	,	,	O	,	O	20	P
24	on	on	B-PP	IN	O	20	NMOD
25	OIH	OIH	B-NP	NN	B-protein	24	PMOD
26	.	.	O	.	O	6	P

1	OIH	OIH	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	achieved	achieve	I-VP	VBN	O	2	VC
4	in	in	B-PP	IN	O	3	VMOD
5	mice	mouse	B-NP	NNS	O	4	PMOD
6	after	after	B-PP	IN	O	3	VMOD
7	subcutaneous	subcutaneous	B-NP	JJ	O	8	NMOD
8	administration	administration	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	morphine	morphine	B-NP	NN	O	9	PMOD
11	for	for	B-PP	IN	O	8	NMOD
12	7	7	B-NP	CD	O	14	NMOD
13	consecutive	consecutive	I-NP	JJ	O	14	NMOD
14	days	day	I-NP	NNS	O	11	PMOD
15	three	three	B-NP	CD	O	16	NMOD
16	times	time	I-NP	NNS	O	6	PMOD
17	per	per	B-PP	IN	O	16	NMOD
18	day	day	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	2	P

1	Re	Re	B-NP	NN	O	6	SUB
2	(	(	O	(	O	5	DEP
3	300	300	B-NP	CD	O	4	NMOD
4	mg/kg	mg/kg	I-NP	NN	O	5	DEP
5	)	)	O	)	O	1	NMOD
6	inhibited	inhibit	B-VP	VBD	O	0	ROOT
7	OIH	OIH	B-NP	NN	O	6	OBJ
8	in	in	B-PP	IN	O	6	VMOD
9	both	both	B-NP	CC	O	17	NMOD
10	the	the	I-NP	DT	O	13	NMOD
11	thermal	thermal	I-NP	JJ	O	13	NMOD
12	sensitivity	sensitivity	I-NP	NN	O	13	NMOD
13	test	test	I-NP	NN	O	17	NMOD
14	and	and	O	CC	O	17	NMOD
15	the	the	B-NP	DT	O	17	NMOD
16	acetic	acetic	I-NP	JJ	O	17	NMOD
17	acid	acid	I-NP	NN	O	18	SUB
18	induced	induce	B-VP	VBD	O	8	SBAR
19	writhing	writhe	I-VP	VBG	O	18	VC
20	test	test	B-NP	NN	O	19	OBJ
21	.	.	O	.	O	6	P

1	However	However	B-ADVP	RB	O	8	VMOD
2	,	,	O	,	O	8	P
3	the	the	B-NP	DT	O	7	NMOD
4	Rg1	Rg1	I-NP	NN	B-protein	7	NMOD
5	and	and	I-NP	CC	O	7	NMOD
6	Rb1	Rb1	I-NP	NN	O	7	NMOD
7	ginsenosides	ginsenoside	I-NP	NNS	O	8	SUB
8	failed	fail	B-VP	VBD	O	0	ROOT
9	to	to	I-VP	TO	O	10	VMOD
10	prevent	prevent	I-VP	VB	O	8	VMOD
11	OIH	OIH	B-NP	NN	O	10	OBJ
12	in	in	B-PP	IN	O	11	NMOD
13	either	either	B-NP	DT	O	14	NMOD
14	test	test	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	8	P

1	Furthermore	Furthermore	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	Rg1	Rg1	B-NP	NN	B-protein	4	SUB
4	showed	show	B-VP	VBD	O	0	ROOT
5	a	a	B-NP	DT	O	6	NMOD
6	tendency	tendency	I-NP	NN	O	4	OBJ
7	to	to	B-VP	TO	O	8	VMOD
8	aggravate	aggravate	I-VP	VB	O	6	NMOD
9	OIH	OIH	B-NP	NN	O	8	OBJ
10	in	in	B-PP	IN	O	8	VMOD
11	the	the	B-NP	DT	O	13	NMOD
12	acetic	acetic	I-NP	JJ	O	13	NMOD
13	acid	acid	I-NP	NN	O	14	SUB
14	induced	induce	B-VP	VBD	O	10	SBAR
15	writhing	writhe	I-VP	VBG	O	14	VC
16	test	test	B-NP	NN	O	15	OBJ
17	.	.	O	.	O	4	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Severe	Severe	B-NP	JJ	O	4	NMOD
4	hypotension	hypotension	I-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	bradycardia	bradycardia	I-NP	NN	O	7	SUB
7	occur	occur	B-VP	VBP	O	1	NMOD
8	at	at	B-PP	IN	O	7	VMOD
9	similar	similar	B-NP	JJ	O	10	NMOD
10	prevalence	prevalence	I-NP	NN	O	8	PMOD
11	in	in	B-PP	IN	O	7	VMOD
12	neurocritical	neurocritical	B-NP	JJ	O	14	NMOD
13	care	care	I-NP	NN	O	14	NMOD
14	patients	patient	I-NP	NNS	O	11	PMOD
15	who	who	B-NP	WP	O	14	NMOD
16	receive	receive	B-VP	VBP	O	15	SBAR
17	dexmedetomidine	dexmedetomidine	B-NP	NN	O	19	NMOD
18	or	or	I-NP	CC	O	19	NMOD
19	propofol	propofol	I-NP	NN	O	16	OBJ
20	.	.	O	.	O	1	P

1	Hydroxytyrosol	Hydroxytyrosol	B-NP	NN	O	2	SUB
2	ameliorates	ameliorate	B-VP	VBZ	O	0	ROOT
3	oxidative	oxidative	B-NP	JJ	O	4	NMOD
4	stress	stress	I-NP	NN	O	7	NMOD
5	and	and	O	CC	O	7	NMOD
6	mitochondrial	mitochondrial	B-NP	JJ	O	7	NMOD
7	dysfunction	dysfunction	I-NP	NN	O	2	OBJ
8	in	in	B-PP	IN	O	2	VMOD
9	doxorubicin	doxorubicin	B-NP	NN	O	11	NMOD
10	induced	induce	B-VP	VBD	O	11	NMOD
11	cardiotoxicity	cardiotoxicity	B-NP	NN	O	8	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	rats	rat	B-NP	NNS	O	12	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	breast	breast	B-NP	NN	O	16	NMOD
16	cancer	cancer	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	2	P

1	Oxidative	Oxidative	B-NP	JJ	O	2	NMOD
2	stress	stress	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	involved	involve	I-VP	VBN	O	3	VC
5	in	in	B-PP	IN	O	4	VMOD
6	several	several	B-NP	JJ	O	7	NMOD
7	processes	process	I-NP	NNS	O	5	PMOD
8	including	include	B-PP	VBG	O	7	NMOD
9	cancer	cancer	B-NP	NN	O	14	NMOD
10	,	,	I-NP	,	O	14	P
11	aging	aging	I-NP	NN	O	14	NMOD
12	and	and	I-NP	CC	O	14	NMOD
13	cardiovascular	cardiovascular	I-NP	JJ	O	14	NMOD
14	disease	disease	I-NP	NN	O	8	PMOD
15	,	,	O	,	O	3	P
16	and	and	O	CC	O	3	VMOD
17	has	have	B-VP	VBZ	O	3	VMOD
18	been	be	I-VP	VBN	O	17	VC
19	shown	show	I-VP	VBN	O	18	VC
20	to	to	I-VP	TO	O	21	VMOD
21	potentiate	potentiate	I-VP	VB	O	19	VMOD
22	the	the	B-NP	DT	O	24	NMOD
23	therapeutic	therapeutic	I-NP	JJ	O	24	NMOD
24	effect	effect	I-NP	NN	O	21	OBJ
25	of	of	B-PP	IN	O	24	NMOD
26	drugs	drug	B-NP	NNS	O	25	PMOD
27	such	such	B-PP	JJ	O	28	PMOD
28	as	as	I-PP	IN	O	26	NMOD
29	doxorubicin	doxorubicin	B-NP	NN	O	28	PMOD
30	.	.	O	.	O	3	P

1	Doxorubicin	Doxorubicin	B-NP	NN	O	2	SUB
2	causes	cause	B-VP	VBZ	O	0	ROOT
3	significant	significant	B-NP	JJ	O	4	NMOD
4	cardiotoxicity	cardiotoxicity	I-NP	NN	O	2	OBJ
5	characterized	characterize	B-VP	VBN	O	4	NMOD
6	by	by	B-PP	IN	O	5	VMOD
7	marked	marked	B-NP	JJ	O	8	NMOD
8	increases	increase	I-NP	NNS	O	6	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	oxidative	oxidative	B-NP	JJ	O	11	NMOD
11	stress	stress	I-NP	NN	O	14	NMOD
12	and	and	O	CC	O	14	NMOD
13	mitochondrial	mitochondrial	B-NP	JJ	O	14	NMOD
14	dysfunction	dysfunction	I-NP	NN	O	9	PMOD
15	.	.	O	.	O	2	P

1	Herein	Herein	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	we	we	B-NP	PRP	O	4	SUB
4	investigate	investigate	B-VP	VBP	O	0	ROOT
5	whether	whether	B-SBAR	IN	O	4	VMOD
6	doxorubicin-associated	doxorubicin-associated	B-NP	JJ	O	9	NMOD
7	chronic	chronic	I-NP	JJ	O	9	NMOD
8	cardiac	cardiac	I-NP	JJ	O	9	NMOD
9	toxicity	toxicity	I-NP	NN	O	10	SUB
10	can	can	B-VP	MD	O	5	SBAR
11	be	be	I-VP	VB	O	10	VC
12	ameliorated	ameliorate	I-VP	VBN	O	11	VC
13	with	with	B-PP	IN	O	12	VMOD
14	the	the	B-NP	DT	O	16	NMOD
15	antioxidant	antioxidant	I-NP	JJ	O	16	NMOD
16	hydroxytyrosol	hydroxytyrosol	I-NP	NN	O	13	PMOD
17	in	in	B-PP	IN	O	16	NMOD
18	rats	rat	B-NP	NNS	O	17	PMOD
19	with	with	B-PP	IN	O	18	NMOD
20	breast	breast	B-NP	NN	O	21	NMOD
21	cancer	cancer	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	4	P

1	Thirty-six	Thirty-six	B-NP	CD	O	2	NMOD
2	rats	rat	I-NP	NNS	O	8	SUB
3	bearing	bear	B-VP	VBG	O	2	NMOD
4	breast	breast	B-NP	NN	O	5	NMOD
5	tumors	tumor	I-NP	NNS	O	3	OBJ
6	induced	induce	B-VP	VBN	O	5	NMOD
7	chemically	chemically	B-ADVP	RB	O	6	VMOD
8	were	be	B-VP	VBD	O	0	ROOT
9	divided	divide	I-VP	VBN	O	8	VC
10	into	into	B-PP	IN	O	9	VMOD
11	4	4	B-NP	CD	O	12	NMOD
12	groups	group	I-NP	NNS	O	10	PMOD
13	:	:	O	:	O	8	P
14	control	control	B-NP	NN	O	23	NMOD
15	,	,	O	,	O	23	P
16	hydroxytyrosol	hydroxytyrosol	B-NP	NN	O	23	NMOD
17	(	(	O	(	O	21	DEP
18	0.5mg/kg	0.5mg/kg	B-NP	CD	O	21	DEP
19	,	,	O	,	O	21	P
20	5days/week	5days/week	B-ADVP	JJ	O	21	DEP
21	)	)	O	)	O	16	NMOD
22	,	,	O	,	O	23	P
23	doxorubicin	doxorubicin	B-NP	NN	O	31	NMOD
24	(	(	O	(	O	26	DEP
25	1mg/kg/week	1mg/kg/week	B-NP	NN	O	26	DEP
26	)	)	O	)	O	23	NMOD
27	,	,	O	,	O	31	P
28	and	and	O	CC	O	31	NMOD
29	doxorubicin	doxorubicin	B-NP	NN	O	31	NMOD
30	plus	plus	I-NP	CC	O	31	NMOD
31	hydroxytyrosol	hydroxytyrosol	I-NP	NN	O	8	VMOD
32	.	.	O	.	O	8	P

1	Hydroxytyrosol	Hydroxytyrosol	B-NP	NN	O	2	SUB
2	improved	improve	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	5	NMOD
4	cardiac	cardiac	I-NP	JJ	O	5	NMOD
5	disturbances	disturbance	I-NP	NNS	O	2	OBJ
6	enhanced	enhance	B-VP	VBN	O	5	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	doxorubicin	doxorubicin	B-NP	NN	O	7	PMOD
9	by	by	B-PP	IN	O	6	VMOD
10	significantly	significantly	B-VP	RB	O	11	VMOD
11	reducing	reduce	I-VP	VBG	O	9	PMOD
12	the	the	B-NP	DT	O	13	NMOD
13	percentage	percentage	I-NP	NN	O	11	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	altered	alter	B-NP	VBN	O	16	NMOD
16	mitochondria	mitochondrion	I-NP	NNS	O	19	NMOD
17	and	and	O	CC	O	19	NMOD
18	oxidative	oxidative	B-NP	JJ	O	19	NMOD
19	damage	damage	I-NP	NN	O	14	PMOD
20	.	.	O	.	O	2	P

1	Amiodarone	Amiodarone	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	myxoedema	myxoedema	B-NP	NN	O	4	NMOD
4	coma	coma	I-NP	NN	O	2	OBJ
5	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	3	NMOD
2	62-year-old	62-year-old	I-NP	JJ	O	3	NMOD
3	man	man	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	found	find	I-VP	VBN	O	4	VC
6	to	to	I-VP	TO	O	7	VMOD
7	have	have	I-VP	VB	O	5	VMOD
8	bradycardia	bradycardia	B-NP	NN	O	13	NMOD
9	,	,	I-NP	,	O	13	P
10	hypothermia	hypothermia	I-NP	NN	O	13	NMOD
11	and	and	I-NP	CC	O	13	NMOD
12	respiratory	respiratory	I-NP	JJ	O	13	NMOD
13	failure	failure	I-NP	NN	O	15	NMOD
14	3	3	B-NP	CD	O	13	NMOD
15	weeks	week	I-NP	NNS	O	7	OBJ
16	after	after	B-PP	IN	O	7	VMOD
17	initiation	initiation	B-NP	NN	O	16	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	amiodarone	amiodarone	B-NP	NN	O	20	NMOD
20	therapy	therapy	I-NP	NN	O	18	PMOD
21	for	for	B-PP	IN	O	17	NMOD
22	atrial	atrial	B-NP	JJ	O	23	NMOD
23	fibrillation	fibrillation	I-NP	NN	O	21	PMOD
24	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	4	NMOD
2	only	only	I-NP	JJ	O	4	NMOD
3	two	two	I-NP	CD	O	4	NMOD
4	cases	case	I-NP	NNS	O	7	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	amiodarone	amiodarone	B-NP	NN	O	5	PMOD
7	induced	induce	B-VP	VBD	O	0	ROOT
8	myxoedema	myxoedema	B-NP	NN	O	9	NMOD
9	coma	coma	I-NP	NN	O	7	OBJ
10	in	in	B-PP	IN	O	7	VMOD
11	the	the	B-NP	DT	O	15	NMOD
12	literature	literature	I-NP	NN	O	15	NMOD
13	report	report	I-NP	NN	O	15	NMOD
14	patient	patient	I-NP	NN	O	15	NMOD
15	death	death	I-NP	NN	O	10	PMOD
16	despite	despite	B-PP	IN	O	7	VMOD
17	supportive	supportive	B-NP	JJ	O	18	NMOD
18	therapy	therapy	I-NP	NN	O	22	NMOD
19	and	and	I-NP	CC	O	22	NMOD
20	thyroid	thyroid	I-NP	NN	O	22	NMOD
21	hormone	hormone	I-NP	NN	O	22	NMOD
22	replacement	replacement	I-NP	NN	O	16	PMOD
23	.	.	O	.	O	7	P

1	Use	Use	B-NP	NN	O	15	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	argatroban	argatroban	B-NP	JJ	O	5	AMOD
4	and	and	I-NP	CC	O	5	AMOD
5	catheter-directed	catheter-directed	I-NP	JJ	O	6	NMOD
6	thrombolysis	thrombolysis	I-NP	NN	O	2	PMOD
7	with	with	B-PP	IN	O	1	NMOD
8	alteplase	alteplase	B-NP	NN	B-protein	7	PMOD
9	in	in	B-PP	IN	O	1	NMOD
10	an	an	B-NP	DT	O	12	NMOD
11	oncology	oncology	I-NP	NN	O	12	NMOD
12	patient	patient	I-NP	NN	O	9	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	heparin	heparin	B-NP	NN	O	13	PMOD
15	induced	induce	B-VP	VBD	O	0	ROOT
16	thrombocytopenia	thrombocytopenia	B-NP	NN	O	15	OBJ
17	with	with	B-PP	IN	O	16	NMOD
18	thrombosis	thrombosis	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	15	P

1	PURPOSE	PURPOSE	B-NP	NN	O	4	NMOD
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	32	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	an	an	B-NP	DT	O	8	NMOD
7	oncology	oncology	I-NP	NN	O	8	NMOD
8	patient	patient	I-NP	NN	O	5	PMOD
9	who	who	B-NP	WP	O	8	NMOD
10	developed	develop	B-VP	VBD	O	9	SBAR
11	heparin	heparin	B-NP	NN	O	13	NMOD
12	induced	induced	I-NP	JJ	O	13	NMOD
13	thrombocytopenia	thrombocytopenia	I-NP	NN	O	10	OBJ
14	with	with	B-PP	IN	O	10	VMOD
15	thrombosis	thrombosis	B-NP	NN	O	14	PMOD
16	(	(	O	(	O	18	DEP
17	HITT	HITT	B-NP	NN	O	18	DEP
18	)	)	O	)	O	15	NMOD
19	and	and	O	CC	O	4	NMOD
20	was	be	B-VP	VBD	O	19	SBAR
21	treated	treat	I-VP	VBN	O	20	VC
22	with	with	B-PP	IN	O	21	VMOD
23	argatroban	argatroban	B-NP	JJ	O	25	AMOD
24	plus	plus	I-NP	CC	O	25	AMOD
25	catheter-directed	catheter-directed	I-NP	JJ	O	22	PMOD
26	thrombolysis	thrombolysis	I-NP	NN	O	25	NMOD
27	(	(	O	(	O	29	DEP
28	CDT	CDT	B-NP	NN	O	29	DEP
29	)	)	O	)	O	26	NMOD
30	with	with	B-PP	IN	O	21	VMOD
31	alteplase	alteplase	B-NP	NN	B-protein	30	PMOD
32	is	be	B-VP	VBZ	O	0	ROOT
33	presented	present	I-VP	VBN	O	32	VC
34	.	.	O	.	O	32	P

1	SUMMARY	SUMMARY	B-NP	NN	O	6	NMOD
2	:	:	O	:	O	1	P
3	A	A	B-NP	DT	O	6	NMOD
4	63-year-old	63-year-old	I-NP	JJ	O	6	NMOD
5	Caucasian	Caucasian	I-NP	JJ	O	6	NMOD
6	man	man	I-NP	NN	O	22	SUB
7	with	with	B-PP	IN	O	6	NMOD
8	renal	renal	B-NP	JJ	O	9	NMOD
9	amyloidosis	amyloidosis	I-NP	NN	O	7	PMOD
10	undergoing	undergo	B-VP	VBG	O	9	NMOD
11	peripheral	peripheral	B-NP	JJ	O	15	NMOD
12	blood	blood	I-NP	NN	O	15	NMOD
13	stem	stem	I-NP	NN	O	15	NMOD
14	cell	cell	I-NP	NN	O	15	NMOD
15	collection	collection	I-NP	NN	O	10	OBJ
16	for	for	B-PP	IN	O	6	NMOD
17	an	an	B-NP	DT	O	21	NMOD
18	autologous	autologous	I-NP	JJ	O	21	NMOD
19	stem	stem	I-NP	NN	O	21	NMOD
20	cell	cell	I-NP	NN	O	21	NMOD
21	transplant	transplant	I-NP	NN	O	16	PMOD
22	developed	develop	B-VP	VBD	O	0	ROOT
23	extensive	extensive	B-NP	JJ	O	24	AMOD
24	bilateral	bilateral	I-NP	JJ	O	34	NMOD
25	upper-extremity	upper-extremity	I-NP	NN	O	28	NMOD
26	deep	deep	I-NP	JJ	O	28	NMOD
27	venous	venous	I-NP	JJ	O	28	NMOD
28	thrombosis	thrombosis	I-NP	NN	O	24	NMOD
29	(	(	O	(	O	31	DEP
30	DVT	DVT	B-NP	NN	O	31	DEP
31	)	)	O	)	O	28	NMOD
32	and	and	O	CC	O	34	NMOD
33	pulmonary	pulmonary	B-NP	JJ	O	34	NMOD
34	embolism	embolism	I-NP	NN	O	22	OBJ
35	secondary	secondary	B-ADJP	JJ	O	34	NMOD
36	to	to	B-PP	TO	O	35	AMOD
37	heparin	heparin	B-NP	NN	O	39	NMOD
38	induced	induced	I-NP	JJ	O	39	NMOD
39	thrombocytopenia	thrombocytopenia	I-NP	NN	O	36	PMOD
40	.	.	O	.	O	22	P

1	The	The	B-NP	DT	O	2	NMOD
2	epistaxis	epistaxis	I-NP	NN	O	3	SUB
3	resolved	resolve	B-VP	VBD	O	11	VMOD
4	the	the	B-NP	DT	O	6	NMOD
5	next	next	I-NP	JJ	O	6	NMOD
6	day	day	I-NP	NN	O	3	OBJ
7	,	,	O	,	O	11	P
8	and	and	O	CC	O	11	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	patient	patient	I-NP	NN	O	11	SUB
11	was	be	B-VP	VBD	O	0	ROOT
12	restarted	restart	I-VP	VBN	O	11	VC
13	on	on	B-PP	IN	O	12	VMOD
14	argatroban	argatroban	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	11	P

1	Effects	Effect	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	dehydroepiandrosterone	dehydroepiandrosterone	B-NP	NN	O	2	PMOD
4	in	in	B-PP	IN	O	1	NMOD
5	amphetamine	amphetamine	B-NP	NN	O	4	PMOD
6	induced	induce	B-VP	VBD	O	4	SBAR
7	schizophrenia	schizophrenia	B-NP	NN	O	8	NMOD
8	models	model	I-NP	NNS	O	6	OBJ
9	in	in	B-PP	IN	O	6	VMOD
10	mice	mouse	B-NP	NNS	O	9	PMOD
11	.	.	O	.	O	1	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	examine	examine	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	effects	effect	I-NP	NNS	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	dehydroepiandrosterone	dehydroepiandrosterone	B-NP	NN	O	7	PMOD
9	(	(	O	(	O	11	DEP
10	DHEA	DHEA	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	on	on	B-PP	IN	O	6	NMOD
13	animal	animal	B-NP	NN	O	14	NMOD
14	models	model	I-NP	NNS	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	schizophrenia	schizophrenia	B-NP	NN	O	15	PMOD
17	.	.	O	.	O	1	P

1	Amphetamine	Amphetamine	B-NP	NN	O	7	SUB
2	(	(	O	(	O	6	DEP
3	3	3	B-NP	CD	O	5	NMOD
4	mg/kg	mg/kg	I-NP	NN	O	5	NMOD
5	ip	ip	I-NP	NN	O	6	DEP
6	)	)	O	)	O	1	NMOD
7	induced	induce	B-VP	VBD	O	33	VMOD
8	hyper	hyper	B-NP	NN	O	9	NMOD
9	locomotion	locomotion	I-NP	NN	O	24	NMOD
10	,	,	O	,	O	24	P
11	apomorphine	apomorphine	B-NP	NN	O	21	NMOD
12	(	(	O	(	O	19	DEP
13	1.5	1.5	B-NP	CD	O	14	NMOD
14	mg/kg	mg/kg	I-NP	NN	O	19	DEP
15	subcutaneously	subcutaneously	B-ADVP	RB	O	14	NMOD
16	[	[	O	(	O	18	DEP
17	sc	sc	B-NP	NN	O	18	DEP
18	]	]	O	)	O	15	AMOD
19	)	)	O	)	O	11	NMOD
20	induced	induce	B-NP	VBN	O	21	NMOD
21	climbing	climbing	I-NP	NN	O	24	NMOD
22	,	,	O	,	O	24	P
23	and	and	O	CC	O	24	NMOD
24	haloperidol	haloperidol	B-NP	NN	O	32	NMOD
25	(	(	O	(	O	29	DEP
26	1.5	1.5	B-NP	CD	O	28	NMOD
27	mg/kg	mg/kg	I-NP	NN	O	28	NMOD
28	sc	sc	I-NP	NN	O	29	DEP
29	)	)	O	)	O	24	NMOD
30	induced	induce	B-VP	VBD	O	32	NMOD
31	catalepsy	catalepsy	B-NP	NN	O	32	NMOD
32	tests	test	I-NP	NNS	O	33	SUB
33	were	be	B-VP	VBD	O	0	ROOT
34	used	use	I-VP	VBN	O	33	VC
35	as	as	B-PP	IN	O	34	VMOD
36	animal	animal	B-NP	NN	O	37	NMOD
37	models	model	I-NP	NNS	O	35	PMOD
38	of	of	B-PP	IN	O	37	NMOD
39	schizophrenia	schizophrenia	B-NP	NN	O	38	PMOD
40	.	.	O	.	O	33	P

1	There	There	B-NP	EX	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	significant	significant	I-NP	JJ	O	5	NMOD
5	difference	difference	I-NP	NN	O	13	NMOD
6	between	between	B-PP	IN	O	5	NMOD
7	groups	group	B-NP	NNS	O	6	PMOD
8	in	in	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	haloperidol	haloperidol	I-NP	NN	O	8	PMOD
11	induced	induce	B-VP	VBD	O	13	NMOD
12	catalepsy	catalepsy	B-NP	NN	O	13	NMOD
13	test	test	I-NP	NN	O	2	PRD
14	(	(	O	(	O	18	DEP
15	p	p	B-NP	NN	O	18	DEP
16	<	<	O	SYM	O	15	NMOD
17	0.05	0.05	B-NP	CD	O	16	AMOD
18	)	)	O	)	O	2	VMOD
19	.	.	O	.	O	2	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	4	VMOD
2	:	:	O	:	O	4	P
3	We	We	B-NP	PRP	O	4	SUB
4	observed	observe	B-VP	VBD	O	0	ROOT
5	that	that	B-SBAR	IN	O	4	VMOD
6	DHEA	DHEA	B-NP	NN	O	7	SUB
7	reduced	reduce	B-VP	VBD	O	5	SBAR
8	locomotor	locomotor	B-NP	NN	O	9	NMOD
9	activity	activity	I-NP	NN	O	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	increased	increase	B-NP	VBN	O	12	NMOD
12	catalepsy	catalepsy	I-NP	NN	O	7	OBJ
13	at	at	B-PP	IN	O	7	VMOD
14	both	both	B-NP	DT	O	15	NMOD
15	doses	dose	I-NP	NNS	O	13	PMOD
16	,	,	O	,	O	7	P
17	while	while	B-SBAR	IN	O	7	VMOD
18	it	it	B-NP	PRP	O	19	SUB
19	had	have	B-VP	VBD	O	17	SBAR
20	no	no	B-NP	DT	O	21	NMOD
21	effect	effect	I-NP	NN	O	19	OBJ
22	on	on	B-PP	IN	O	19	VMOD
23	climbing	climb	B-VP	VBG	O	22	PMOD
24	behavior	behavior	B-NP	NN	O	23	OBJ
25	.	.	O	.	O	4	P

1	Finally	Finally	B-ADVP	RB	O	26	VMOD
2	,	,	O	,	O	26	P
3	the	the	B-NP	DT	O	5	NMOD
4	IKr	IKr	I-NP	NN	B-protein	5	NMOD
5	blockers	blocker	I-NP	NNS	I-protein	9	NMOD
6	,	,	O	,	O	9	P
7	Terfenadine	Terfenadine	B-NP	NN	O	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	Citalopram	Citalopram	I-NP	NN	O	26	SUB
10	,	,	O	,	O	9	P
11	which	which	B-NP	WDT	O	9	NMOD
12	are	be	B-VP	VBP	O	11	SBAR
13	reported	report	I-VP	VBN	O	12	VC
14	to	to	I-VP	TO	O	15	VMOD
15	cause	cause	I-VP	VB	O	13	VMOD
16	Torsade	Torsade	B-NP	NNP	O	18	NMOD
17	de	de	I-NP	IN	O	18	NMOD
18	Pointes	Pointes	I-NP	NNP	O	15	OBJ
19	(	(	O	(	O	21	DEP
20	TdP	TdP	B-NP	NN	B-protein	21	DEP
21	)	)	O	)	O	18	NMOD
22	in	in	B-PP	IN	O	15	VMOD
23	clinical	clinical	B-NP	JJ	O	24	NMOD
24	practice	practice	I-NP	NN	O	22	PMOD
25	,	,	O	,	O	9	P
26	produced	produce	B-VP	VBD	O	0	ROOT
27	early	early	B-NP	JJ	O	28	NMOD
28	afterdepolarization	afterdepolarization	I-NP	NN	O	26	OBJ
29	(	(	O	(	O	31	DEP
30	EAD	EAD	B-NP	NN	B-protein	31	DEP
31	)	)	O	)	O	28	NMOD
32	.	.	O	.	O	26	VMOD
33	hiPS-CMs	hiPS-CM	B-NP	NNS	O	39	SUB
34	using	use	B-VP	VBG	O	33	NMOD
35	MEA	MEA	B-NP	NN	O	36	NMOD
36	system	system	I-NP	NN	O	38	NMOD
37	and	and	I-NP	CC	O	38	NMOD
38	FPDc	FPDc	I-NP	NN	B-protein	34	OBJ
39	can	can	B-VP	MD	O	32	SBAR
40	predict	predict	I-VP	VB	O	39	VC
41	the	the	B-NP	DT	O	42	NMOD
42	effects	effect	I-NP	NNS	O	40	OBJ
43	of	of	B-PP	IN	O	42	NMOD
44	drug	drug	B-NP	NN	O	45	NMOD
45	candidates	candidate	I-NP	NNS	O	43	PMOD
46	on	on	B-PP	IN	O	42	NMOD
47	QT	QT	B-NP	NN	O	48	NMOD
48	interval	interval	I-NP	NN	O	46	PMOD
49	.	.	O	.	O	26	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	S-53482	S-53482	B-NP	NN	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	S-23121	S-23121	I-NP	NN	O	6	SUB
6	are	be	B-VP	VBP	O	1	NMOD
7	N-phenylimide	N-phenylimide	B-NP	NN	O	8	NMOD
8	herbicides	herbicide	I-NP	NNS	O	6	PRD
9	and	and	O	CC	O	6	VMOD
10	produced	produce	B-VP	VBD	O	6	VMOD
11	embryolethality	embryolethality	B-NP	NN	O	26	NMOD
12	,	,	O	,	O	26	P
13	teratogenicity	teratogenicity	B-NP	NN	O	26	NMOD
14	(	(	O	(	O	22	DEP
15	mainly	mainly	B-NP	RB	O	17	AMOD
16	ventricular	ventricular	I-NP	JJ	O	17	AMOD
17	septal	septal	I-NP	JJ	O	18	NMOD
18	defects	defect	I-NP	NNS	O	21	NMOD
19	and	and	O	CC	O	21	NMOD
20	wavy	wavy	B-NP	NN	O	21	NMOD
21	ribs	rib	I-NP	NNS	O	22	DEP
22	)	)	O	)	O	13	NMOD
23	,	,	O	,	O	26	P
24	and	and	O	CC	O	26	NMOD
25	growth	growth	B-NP	NN	O	26	NMOD
26	retardation	retardation	I-NP	NN	O	10	OBJ
27	in	in	B-PP	IN	O	26	NMOD
28	rats	rat	B-NP	NNS	O	27	PMOD
29	in	in	B-PP	IN	O	26	NMOD
30	conventional	conventional	B-NP	JJ	O	34	NMOD
31	oral	oral	I-NP	JJ	O	34	NMOD
32	developmental	developmental	I-NP	JJ	O	34	NMOD
33	toxicity	toxicity	I-NP	NN	O	34	NMOD
34	studies	study	I-NP	NNS	O	29	PMOD
35	.	.	O	.	O	6	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Dermal	Dermal	B-NP	JJ	O	4	NMOD
4	exposure	exposure	I-NP	NN	O	12	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	rats	rat	B-NP	NNS	O	5	PMOD
7	to	to	B-PP	TO	O	4	NMOD
8	S-53482	S-53482	B-NP	NN	O	7	PMOD
9	at	at	B-PP	IN	O	4	NMOD
10	300	300	B-NP	CD	O	11	NMOD
11	mg/kg	mg/kg	I-NP	NN	O	9	PMOD
12	produced	produce	B-VP	VBD	O	1	NMOD
13	patterns	pattern	B-NP	NNS	O	12	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	developmental	developmental	B-NP	JJ	O	16	NMOD
16	toxicity	toxicity	I-NP	NN	O	14	PMOD
17	similar	similar	B-ADJP	JJ	O	16	NMOD
18	to	to	B-PP	TO	O	17	AMOD
19	those	those	B-NP	DT	O	18	PMOD
20	resulting	result	B-VP	VBG	O	19	NMOD
21	from	from	B-PP	IN	O	20	VMOD
22	oral	oral	B-NP	JJ	O	23	NMOD
23	exposure	exposure	I-NP	NN	O	21	PMOD
24	.	.	O	.	O	1	P

1	Dermal	Dermal	B-NP	JJ	O	2	NMOD
2	administration	administration	I-NP	NN	O	8	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	S-23121	S-23121	B-NP	NN	O	3	PMOD
5	at	at	B-PP	IN	O	2	NMOD
6	800	800	B-NP	CD	O	7	NMOD
7	mg/kg	mg/kg	I-NP	NN	O	5	PMOD
8	resulted	result	B-VP	VBD	O	0	ROOT
9	in	in	B-PP	IN	O	8	VMOD
10	an	an	B-NP	DT	O	12	NMOD
11	increased	increase	I-NP	VBN	O	12	NMOD
12	incidence	incidence	I-NP	NN	O	9	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	embryonic	embryonic	B-NP	JJ	O	15	NMOD
15	death	death	I-NP	NN	O	19	NMOD
16	and	and	O	CC	O	19	NMOD
17	ventricular	ventricular	B-NP	JJ	O	19	NMOD
18	septal	septal	I-NP	JJ	O	19	NMOD
19	defect	defect	I-NP	NN	O	13	PMOD
20	,	,	O	,	O	8	P
21	but	but	O	CC	O	8	VMOD
22	retarded	retard	B-VP	VBD	O	8	VMOD
23	fetal	fetal	B-NP	JJ	O	24	NMOD
24	growth	growth	I-NP	NN	O	25	SUB
25	was	be	B-VP	VBD	O	22	VMOD
26	not	not	I-VP	RB	O	25	VMOD
27	observed	observe	I-VP	VBN	O	25	VC
28	as	as	B-SBAR	IN	O	25	VMOD
29	it	it	B-NP	PRP	O	30	SUB
30	was	be	B-VP	VBD	O	28	SBAR
31	following	follow	I-VP	VBG	O	30	VC
32	oral	oral	B-NP	JJ	O	33	NMOD
33	exposure	exposure	I-NP	NN	O	31	OBJ
34	to	to	B-PP	TO	O	33	NMOD
35	S-23121	S-23121	B-NP	NN	B-protein	34	PMOD
36	.	.	O	.	O	8	P

1	Rates	Rate	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	Renal	Renal	B-NP	JJ	O	4	NMOD
4	Toxicity	Toxicity	I-NP	NN	O	2	PMOD
5	in	in	B-PP	IN	O	1	NMOD
6	Cancer	Cancer	B-NP	NNP	O	9	NMOD
7	Patients	Patients	I-NP	NNP	O	9	NMOD
8	Receiving	Receiving	I-NP	NNP	O	9	NMOD
9	Cisplatin	Cisplatin	I-NP	NNP	O	5	PMOD
10	With	With	B-PP	IN	O	1	NMOD
11	and	and	I-PP	CC	O	10	PMOD
12	Without	Without	I-PP	IN	O	10	PMOD
13	Mannitol	Mannitol	B-NP	NNP	O	10	PMOD
14	.	.	O	.	O	1	P

1	One	One	B-NP	CD	O	9	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	5	NMOD
4	major	major	I-NP	JJ	O	5	NMOD
5	complications	complication	I-NP	NNS	O	2	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	cisplatin	cisplatin	B-NP	NN	O	8	NMOD
8	use	use	I-NP	NN	O	6	PMOD
9	is	be	B-VP	VBZ	O	0	ROOT
10	dose-limiting	dose-limiting	B-NP	JJ	O	11	NMOD
11	nephrotoxicity	nephrotoxicity	I-NP	NN	O	9	PRD
12	.	.	O	.	O	9	P

1	There	There	B-NP	EX	O	2	SUB
2	are	be	B-VP	VBP	O	0	ROOT
3	many	many	B-NP	JJ	O	4	NMOD
4	strategies	strategy	I-NP	NNS	O	2	PRD
5	to	to	B-VP	TO	O	6	VMOD
6	prevent	prevent	I-VP	VB	O	4	NMOD
7	this	this	B-NP	DT	O	8	NMOD
8	toxicity	toxicity	I-NP	NN	O	6	OBJ
9	,	,	O	,	O	6	P
10	including	include	B-PP	VBG	O	6	VMOD
11	the	the	B-NP	DT	O	12	NMOD
12	use	use	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	mannitol	mannitol	B-NP	NN	O	13	PMOD
15	as	as	B-PP	IN	O	12	NMOD
16	a	a	B-NP	DT	O	17	NMOD
17	nephroprotectant	nephroprotectant	I-NP	NN	O	15	PMOD
18	in	in	B-PP	IN	O	12	NMOD
19	combination	combination	B-NP	NN	O	18	PMOD
20	with	with	B-PP	IN	O	19	NMOD
21	hydration	hydration	B-NP	NN	O	20	PMOD
22	.	.	O	.	O	2	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	4	VMOD
2	:	:	O	:	O	4	P
3	We	We	B-NP	PRP	O	4	SUB
4	aimed	aim	B-VP	VBD	O	0	ROOT
5	to	to	I-VP	TO	O	6	VMOD
6	evaluate	evaluate	I-VP	VB	O	4	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	rates	rate	I-NP	NNS	O	11	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	cisplatin	cisplatin	B-NP	NN	B-protein	9	PMOD
11	induced	induce	B-VP	VBD	O	6	VMOD
12	nephrotoxicity	nephrotoxicity	B-NP	NN	O	11	OBJ
13	in	in	B-PP	IN	O	12	NMOD
14	cancer	cancer	B-NP	NN	B-protein	15	NMOD
15	patients	patient	I-NP	NNS	I-protein	13	PMOD
16	receiving	receive	B-VP	VBG	I-protein	15	NMOD
17	single-agent	single-agent	B-NP	JJ	I-protein	18	NMOD
18	cisplatin	cisplatin	I-NP	NN	I-protein	16	OBJ
19	with	with	B-PP	IN	O	16	VMOD
20	and	and	I-PP	CC	O	19	PMOD
21	without	without	I-PP	IN	O	19	PMOD
22	mannitol	mannitol	B-NP	NN	O	19	PMOD
23	.	.	O	.	O	4	P

1	Data	Datum	B-NP	NNS	O	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	collected	collect	I-VP	VBN	O	2	VC
4	on	on	B-PP	IN	O	3	VMOD
5	adult	adult	B-NP	JJ	O	7	NMOD
6	cancer	cancer	I-NP	NN	O	7	NMOD
7	patients	patient	I-NP	NNS	O	4	PMOD
8	receiving	receive	B-VP	VBG	O	7	NMOD
9	single-agent	single-agent	B-NP	JJ	O	10	NMOD
10	cisplatin	cisplatin	I-NP	NN	O	8	OBJ
11	as	as	B-PP	IN	O	8	VMOD
12	an	an	B-NP	DT	O	13	NMOD
13	outpatient	outpatient	I-NP	NN	O	11	PMOD
14	from	from	B-PP	IN	O	13	NMOD
15	January	January	B-NP	NNP	O	14	PMOD
16	2011	2011	I-NP	CD	O	15	NMOD
17	to	to	B-PP	TO	O	13	NMOD
18	September	September	B-NP	NNP	O	17	PMOD
19	2012	2012	I-NP	CD	O	18	NMOD
20	.	.	O	.	O	2	P

1	RESULTS	RESULTS	B-NP	NNS	O	4	VMOD
2	:	:	O	:	O	4	P
3	We	We	B-NP	PRP	O	4	SUB
4	evaluated	evaluate	B-VP	VBD	O	16	VMOD
5	143	143	B-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	4	OBJ
7	who	who	B-NP	WP	O	6	NMOD
8	received	receive	B-VP	VBD	O	7	SBAR
9	single-agent	single-agent	B-NP	JJ	O	10	NMOD
10	cisplatin	cisplatin	I-NP	NN	O	8	OBJ
11	;	;	O	:	O	16	P
12	97.2	97.2	B-NP	CD	O	13	NMOD
13	%	%	I-NP	NN	O	16	SUB
14	of	of	B-PP	IN	O	13	NMOD
15	patients	patient	B-NP	NNS	O	14	PMOD
16	had	have	B-VP	VBD	O	0	ROOT
17	head	head	B-NP	NN	O	20	NMOD
18	and	and	I-NP	CC	O	20	NMOD
19	neck	neck	I-NP	NN	O	20	NMOD
20	cancer	cancer	I-NP	NN	O	16	OBJ
21	as	as	B-PP	IN	O	16	VMOD
22	their	their	B-NP	PRP$	O	24	NMOD
23	primary	primary	I-NP	JJ	O	24	NMOD
24	malignancy	malignancy	I-NP	NN	O	21	PMOD
25	.	.	O	.	O	16	P

1	Patients	Patient	B-NP	NNS	O	7	SUB
2	who	who	B-NP	WP	O	1	NMOD
3	did	do	B-VP	VBD	O	2	SBAR
4	not	not	I-VP	RB	O	3	VMOD
5	receive	receive	I-VP	VB	O	3	VC
6	mannitol	mannitol	B-NP	NN	O	5	OBJ
7	were	be	B-VP	VBD	O	0	ROOT
8	more	more	B-ADJP	RBR	O	9	AMOD
9	likely	likely	I-ADJP	JJ	O	7	PRD
10	to	to	B-VP	TO	O	11	VMOD
11	develop	develop	I-VP	VB	O	9	AMOD
12	nephrotoxicity	nephrotoxicity	B-NP	NN	O	11	OBJ
13	:	:	O	:	O	7	P
14	odds	odd	B-NP	NNS	O	7	VMOD
15	ratio	ratio	I-NP	NN	O	14	OBJ
16	[	[	O	(	O	18	DEP
17	OR	OR	B-NP	NN	O	18	DEP
18	]	]	O	)	O	15	NMOD
19	=	=	O	SYM	O	15	NMOD
20	2.646	2.646	B-NP	CD	O	19	AMOD
21	(	(	O	(	O	33	DEP
22	95	95	B-NP	CD	O	24	NMOD
23	%	%	I-NP	NN	O	24	NMOD
24	CI	CI	I-NP	NN	O	30	NMOD
25	=	=	B-VP	SYM	O	24	NMOD
26	1.008	1.008	B-NP	CD	O	25	AMOD
27	,	,	O	,	O	30	P
28	6.944	6.944	B-NP	CD	O	30	NMOD
29	;	;	O	:	O	30	P
30	P	P	B-NP	NN	O	33	DEP
31	=	=	B-VP	SYM	O	30	NMOD
32	0.048	0.048	B-NP	CD	O	31	AMOD
33	)	)	O	)	O	15	NMOD
34	.	.	O	.	O	7	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	12	SUB
2	:	:	O	:	O	1	P
3	When	When	B-ADVP	WRB	O	12	VMOD
4	limited	limited	B-NP	JJ	O	5	NMOD
5	quantities	quantity	I-NP	NNS	O	8	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	mannitol	mannitol	B-NP	NN	O	6	PMOD
8	are	be	B-VP	VBP	O	3	SBAR
9	available	available	B-ADJP	JJ	O	8	PRD
10	,	,	O	,	O	12	P
11	it	it	B-NP	PRP	O	12	SUB
12	should	should	B-VP	MD	O	0	ROOT
13	preferentially	preferentially	I-VP	RB	O	12	VMOD
14	be	be	I-VP	VB	O	12	VC
15	given	give	I-VP	VBN	O	14	VC
16	to	to	B-PP	TO	O	15	VMOD
17	patients	patient	B-NP	NNS	O	16	PMOD
18	at	at	B-PP	IN	O	17	NMOD
19	particularly	particularly	B-NP	RB	O	20	AMOD
20	high	high	I-NP	JJ	O	21	NMOD
21	risk	risk	I-NP	NN	O	18	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	nephrotoxicity	nephrotoxicity	B-NP	NN	O	22	PMOD
24	.	.	O	.	O	12	P

1	Metformin	Metformin	B-NP	NN	O	2	SUB
2	protects	protect	B-VP	VBZ	O	0	ROOT
3	against	against	B-PP	IN	O	2	VMOD
4	seizures	seizure	B-NP	NNS	O	3	PMOD
5	,	,	O	,	O	2	P
6	learning	learning	B-NP	NN	O	9	NMOD
7	and	and	I-NP	CC	O	9	NMOD
8	memory	memory	I-NP	NN	O	9	NMOD
9	impairments	impairment	I-NP	NNS	O	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	oxidative	oxidative	B-NP	JJ	O	12	NMOD
12	damage	damage	I-NP	NN	O	17	NMOD
13	induced	induce	B-VP	VBN	O	12	NMOD
14	by	by	B-PP	IN	O	13	VMOD
15	pentylenetetrazole	pentylenetetrazole	B-NP	NN	O	14	PMOD
16	induced	induce	B-VP	VBD	O	17	NMOD
17	kindling	kindling	B-NP	NN	O	2	OBJ
18	in	in	B-PP	IN	O	17	NMOD
19	mice	mouse	B-NP	NNS	O	18	PMOD
20	.	.	O	.	O	2	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	designed	design	I-VP	VBN	O	3	VC
5	to	to	B-VP	TO	O	6	VMOD
6	evaluate	evaluate	I-VP	VB	O	3	VMOD
7	the	the	B-NP	DT	O	9	NMOD
8	ameliorative	ameliorative	I-NP	JJ	O	9	NMOD
9	effects	effect	I-NP	NNS	O	6	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	metformin	metformin	B-NP	NN	O	10	PMOD
12	on	on	B-PP	IN	O	9	NMOD
13	seizures	seizure	B-NP	NNS	O	12	PMOD
14	,	,	O	,	O	6	P
15	cognitive	cognitive	B-NP	JJ	O	16	NMOD
16	impairment	impairment	I-NP	NN	O	18	NMOD
17	and	and	O	CC	O	18	NMOD
18	brain	brain	B-NP	NN	O	21	NMOD
19	oxidative	oxidative	I-NP	JJ	O	18	AMOD
20	stress	stress	I-NP	NN	O	21	NMOD
21	markers	marker	I-NP	NNS	O	25	SUB
22	observed	observe	B-VP	VBN	O	21	NMOD
23	in	in	B-PP	IN	O	22	VMOD
24	pentylenetetrazole	pentylenetetrazole	B-NP	NN	O	23	PMOD
25	induced	induce	B-VP	VBD	O	6	VMOD
26	kindling	kindle	B-NP	VBG	O	27	NMOD
27	animals	animal	I-NP	NNS	O	25	OBJ
28	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	found	find	B-VP	VBD	O	0	ROOT
3	that	that	B-SBAR	IN	O	2	VMOD
4	metformin	metformin	B-NP	NN	O	5	SUB
5	suppressed	suppress	B-VP	VBD	O	3	SBAR
6	the	the	B-NP	DT	O	7	NMOD
7	progression	progression	I-NP	NN	O	5	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	kindling	kindling	B-NP	NN	O	8	PMOD
10	,	,	O	,	O	5	P
11	ameliorated	ameliorate	B-VP	VBD	O	5	VMOD
12	the	the	B-NP	DT	O	14	NMOD
13	cognitive	cognitive	I-NP	JJ	O	14	NMOD
14	impairment	impairment	I-NP	NN	O	11	OBJ
15	and	and	O	CC	O	5	VMOD
16	decreased	decrease	B-VP	VBD	O	5	VMOD
17	brain	brain	B-NP	NN	O	19	NMOD
18	oxidative	oxidative	I-NP	JJ	O	19	NMOD
19	stress	stress	I-NP	NN	O	16	OBJ
20	.	.	O	.	O	2	P

1	P53	P53	B-NP	NN	B-protein	2	NMOD
2	inhibition	inhibition	I-NP	NN	O	3	SUB
3	exacerbates	exacerbate	B-VP	VBZ	O	0	ROOT
4	late-stage	late-stage	B-NP	JJ	O	6	NMOD
5	anthracycline	anthracycline	I-NP	NN	O	6	NMOD
6	cardiotoxicity	cardiotoxicity	I-NP	NN	O	3	OBJ
7	.	.	O	.	O	3	P

1	AIMS	AIMS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Doxorubicin	Doxorubicin	B-NP	NN	O	7	SUB
4	(	(	O	(	O	6	DEP
5	DOX	DOX	B-NP	NN	O	6	DEP
6	)	)	O	)	O	3	NMOD
7	is	be	B-VP	VBZ	O	1	NMOD
8	an	an	B-NP	DT	O	11	NMOD
9	effective	effective	I-NP	JJ	O	10	AMOD
10	anti-cancer	anti-cancer	I-NP	JJ	O	11	NMOD
11	therapeutic	therapeutic	I-NP	JJ	O	7	PRD
12	,	,	O	,	O	7	P
13	but	but	O	CC	O	7	VMOD
14	is	be	B-VP	VBZ	O	7	VMOD
15	associated	associate	I-VP	VBN	O	14	VC
16	with	with	B-PP	IN	O	15	VMOD
17	both	both	B-NP	CC	O	21	NMOD
18	acute	acute	I-NP	JJ	O	21	NMOD
19	and	and	I-NP	CC	O	21	NMOD
20	late-stage	late-stage	I-NP	JJ	O	21	NMOD
21	cardiotoxicity	cardiotoxicity	I-NP	NN	O	16	PMOD
22	.	.	O	.	O	1	P

1	Children	Child	B-NP	NNS	O	2	SUB
2	are	be	B-VP	VBP	O	0	ROOT
3	particularly	particularly	B-ADJP	RB	O	4	AMOD
4	sensitive	sensitive	I-ADJP	JJ	O	2	PRD
5	to	to	B-PP	TO	O	4	AMOD
6	DOX	DOX	B-NP	NN	O	9	NMOD
7	induced	induced	I-NP	JJ	O	9	NMOD
8	heart	heart	I-NP	NN	O	9	NMOD
9	failure	failure	I-NP	NN	O	5	PMOD
10	.	.	O	.	O	2	P

1	Here	Here	B-ADVP	RB	O	14	VMOD
2	,	,	O	,	O	14	P
3	the	the	B-NP	DT	O	4	NMOD
4	impact	impact	I-NP	NN	O	14	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	p53	p53	B-NP	NN	B-protein	7	NMOD
7	inhibition	inhibition	I-NP	NN	O	5	PMOD
8	on	on	B-PP	IN	O	4	NMOD
9	acute	acute	B-NP	JJ	O	8	PMOD
10	vs.	vs.	B-PP	IN	O	9	NMOD
11	late-stage	late-stage	B-NP	JJ	O	13	NMOD
12	DOX	DOX	I-NP	NN	O	13	NMOD
13	cardiotoxicity	cardiotoxicity	I-NP	NN	O	10	PMOD
14	was	be	B-VP	VBD	O	0	ROOT
15	examined	examine	I-VP	VBN	O	14	VC
16	in	in	B-PP	IN	O	15	VMOD
17	a	a	B-NP	DT	O	19	NMOD
18	juvenile	juvenile	I-NP	JJ	O	19	NMOD
19	model	model	I-NP	NN	O	16	PMOD
20	.	.	O	.	O	14	P

1	Metronidazole	Metronidazole	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	encephalopathy	encephalopathy	B-NP	NN	O	2	OBJ
4	:	:	O	:	O	2	P
5	an	an	B-NP	DT	O	7	NMOD
6	uncommon	uncommon	I-NP	JJ	O	7	NMOD
7	scenario	scenario	I-NP	NN	O	2	VMOD
8	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	present	present	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	where	where	B-ADVP	WRB	O	4	NMOD
6	a	a	B-NP	DT	O	7	NMOD
7	patient	patient	I-NP	NN	O	8	SUB
8	developed	develop	B-VP	VBD	O	5	SBAR
9	features	feature	B-NP	NNS	O	8	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	encephalopathy	encephalopathy	B-NP	NN	O	10	PMOD
12	following	follow	B-PP	VBG	O	8	VMOD
13	prolonged	prolonged	B-NP	JJ	O	15	NMOD
14	metronidazole	metronidazole	I-NP	NN	O	15	NMOD
15	intake	intake	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	2	P

1	Aconitine	Aconitine	B-NP	NN	O	5	SUB
2	induced	induce	B-VP	VBD	O	1	NMOD
3	Ca2+	Ca2+	B-NP	NN	O	4	NMOD
4	overload	overload	I-NP	NN	O	2	OBJ
5	causes	cause	B-VP	VBZ	O	0	ROOT
6	arrhythmia	arrhythmia	B-NP	NN	O	5	OBJ
7	and	and	O	CC	O	5	VMOD
8	triggers	trigger	B-VP	VBZ	O	5	VMOD
9	apoptosis	apoptosis	B-NP	NN	O	8	OBJ
10	through	through	B-PP	IN	O	8	VMOD
11	p38	p38	B-NP	NN	B-protein	14	NMOD
12	MAPK	MAPK	I-NP	NN	I-protein	14	NMOD
13	signaling	signaling	I-NP	NN	O	14	NMOD
14	pathway	pathway	I-NP	NN	O	10	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	rats	rat	B-NP	NNS	O	15	PMOD
17	.	.	O	.	O	5	P

1	Emerging	Emerge	B-NP	VBG	O	2	NMOD
2	evidence	evidence	I-NP	NN	O	3	SUB
3	indicates	indicate	B-VP	VBZ	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	voltage-dependent	voltage-dependent	B-NP	JJ	B-protein	10	NMOD
6	Na	Na	I-NP	NN	I-protein	10	NMOD
7	(	(	O	(	I-protein	9	DEP
8	+	+	O	SYM	I-protein	9	DEP
9	)	)	O	)	I-protein	10	NMOD
10	channels	channel	B-NP	NNS	I-protein	11	SUB
11	have	have	B-VP	VBP	O	4	SBAR
12	pivotal	pivotal	B-NP	JJ	O	13	NMOD
13	roles	role	I-NP	NNS	O	11	OBJ
14	in	in	B-PP	IN	O	11	VMOD
15	the	the	B-NP	DT	O	16	NMOD
16	cardiotoxicity	cardiotoxicity	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	aconitine	aconitine	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	3	P

1	However	However	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	no	no	B-NP	DT	O	4	NMOD
4	reports	report	I-NP	NNS	O	5	SUB
5	are	be	B-VP	VBP	O	0	ROOT
6	available	available	B-ADJP	JJ	O	5	PRD
7	on	on	B-PP	IN	O	6	AMOD
8	the	the	B-NP	DT	O	9	NMOD
9	role	role	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	Ca	Ca	B-NP	NN	O	10	PMOD
12	(	(	O	(	O	14	DEP
13	2+	2+	B-NP	NN	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	in	in	B-PP	IN	O	9	NMOD
16	aconitine	aconitine	B-NP	NN	O	17	NMOD
17	poisoning	poisoning	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	5	P

1	In	In	B-PP	IN	O	6	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	study	study	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	6	P
5	we	we	B-NP	PRP	O	6	SUB
6	explored	explore	B-VP	VBD	O	0	ROOT
7	the	the	B-NP	DT	O	8	NMOD
8	importance	importance	I-NP	NN	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	pathological	pathological	B-NP	JJ	O	11	NMOD
11	Ca	Ca	I-NP	NN	O	15	NMOD
12	(	(	O	(	O	14	DEP
13	2+	2+	O	JJ	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	signaling	signaling	B-NP	NN	O	9	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	aconitine	aconitine	B-NP	NN	O	18	NMOD
18	poisoning	poisoning	I-NP	NN	O	16	PMOD
19	in	in	B-ADVP	FW	O	18	NMOD
20	vitro	vitro	I-ADVP	FW	O	19	AMOD
21	and	and	O	CC	O	8	NMOD
22	in	in	B-ADVP	FW	O	21	DEP
23	vivo	vivo	I-ADVP	FW	O	22	AMOD
24	.	.	O	.	O	6	P

1	We	We	B-NP	PRP	O	2	SUB
2	found	find	B-VP	VBD	O	0	ROOT
3	that	that	B-SBAR	IN	O	2	VMOD
4	Ca	Ca	B-NP	NN	O	8	NMOD
5	(	(	O	(	O	7	DEP
6	2+	2+	O	JJ	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	overload	overload	B-NP	NN	O	9	SUB
9	lead	lead	B-VP	VBP	O	3	SBAR
10	to	to	B-PP	TO	O	9	VMOD
11	accelerated	accelerate	B-NP	VBN	O	13	NMOD
12	beating	beat	I-NP	VBG	O	13	NMOD
13	rhythm	rhythm	I-NP	NN	O	10	PMOD
14	in	in	B-PP	IN	O	13	NMOD
15	adult	adult	B-NP	JJ	B-cell_type	18	NMOD
16	rat	rat	I-NP	NN	I-cell_type	18	NMOD
17	ventricular	ventricular	I-NP	JJ	I-cell_type	18	NMOD
18	myocytes	myocyte	I-NP	NNS	I-cell_type	14	PMOD
19	and	and	O	CC	O	9	VMOD
20	caused	cause	B-VP	VBD	O	9	VMOD
21	arrhythmia	arrhythmia	B-NP	NN	O	20	OBJ
22	in	in	B-PP	IN	O	21	NMOD
23	conscious	conscious	B-ADJP	JJ	O	25	AMOD
24	freely	freely	B-VP	RB	O	25	AMOD
25	moving	move	I-VP	VBG	O	26	NMOD
26	rats	rat	B-NP	NNS	O	22	PMOD
27	.	.	O	.	O	2	P

1	To	To	B-VP	TO	O	2	VMOD
2	investigate	investigate	I-VP	VB	O	11	VMOD
3	effects	effect	B-NP	NNS	O	2	OBJ
4	of	of	B-PP	IN	O	3	NMOD
5	aconitine	aconitine	B-NP	NN	O	4	PMOD
6	on	on	B-PP	IN	O	3	NMOD
7	myocardial	myocardial	B-NP	JJ	O	8	NMOD
8	injury	injury	I-NP	NN	O	6	PMOD
9	,	,	O	,	O	11	P
10	we	we	B-NP	PRP	O	11	SUB
11	performed	perform	B-VP	VBD	O	0	ROOT
12	cytotoxicity	cytotoxicity	B-NP	NN	O	13	NMOD
13	assay	assay	I-NP	NN	O	11	OBJ
14	in	in	B-PP	IN	O	11	VMOD
15	neonatal	neonatal	B-NP	JJ	B-cell_type	18	NMOD
16	rat	rat	I-NP	NN	I-cell_type	18	NMOD
17	ventricular	ventricular	I-NP	JJ	I-cell_type	18	NMOD
18	myocytes	myocyte	I-NP	NNS	I-cell_type	14	PMOD
19	(	(	O	(	O	21	DEP
20	NRVMs	NRVM	B-NP	NNS	B-protein	21	DEP
21	)	)	O	)	O	18	NMOD
22	,	,	O	,	O	11	P
23	as	as	B-CONJP	RB	O	29	NMOD
24	well	well	I-CONJP	RB	O	23	DEP
25	as	as	I-CONJP	IN	O	23	DEP
26	measured	measure	B-NP	VBN	O	29	NMOD
27	lactate	lactate	I-NP	NN	B-protein	29	NMOD
28	dehydrogenase	dehydrogenase	I-NP	NN	I-protein	29	NMOD
29	level	level	I-NP	NN	O	11	OBJ
30	in	in	B-PP	IN	O	29	NMOD
31	the	the	B-NP	DT	O	33	NMOD
32	culture	culture	I-NP	NN	O	33	NMOD
33	medium	medium	I-NP	NN	O	30	PMOD
34	of	of	B-PP	IN	O	33	NMOD
35	NRVMs	NRVM	B-NP	NNS	B-protein	37	NMOD
36	and	and	I-NP	CC	O	37	NMOD
37	activities	activity	I-NP	NNS	O	34	PMOD
38	of	of	B-PP	IN	O	37	NMOD
39	serum	serum	B-NP	NN	B-protein	41	NMOD
40	cardiac	cardiac	I-NP	JJ	I-protein	41	NMOD
41	enzymes	enzyme	I-NP	NNS	I-protein	38	PMOD
42	in	in	B-PP	IN	O	41	NMOD
43	rats	rat	B-NP	NNS	O	42	PMOD
44	.	.	O	.	O	11	P

1	The	The	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	showed	show	B-VP	VBD	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	aconitine	aconitine	B-NP	NN	O	6	SUB
6	resulted	result	B-VP	VBD	O	4	SBAR
7	in	in	B-PP	IN	O	6	VMOD
8	myocardial	myocardial	B-NP	JJ	O	9	NMOD
9	injury	injury	I-NP	NN	O	13	NMOD
10	and	and	O	CC	O	13	NMOD
11	reduced	reduce	B-NP	VBN	O	12	NMOD
12	NRVMs	NRVM	I-NP	NNS	O	13	NMOD
13	viability	viability	I-NP	NN	O	7	PMOD
14	dose-dependently	dose-dependently	B-ADVP	RB	O	13	NMOD
15	.	.	O	.	O	3	P

1	Chronic	Chronic	B-NP	JJ	O	2	NMOD
2	treatment	treatment	I-NP	NN	O	5	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	metformin	metformin	B-NP	NN	O	3	PMOD
5	suppresses	suppress	B-VP	VBZ	O	0	ROOT
6	toll-like	toll-like	B-NP	JJ	B-protein	9	NMOD
7	receptor	receptor	I-NP	NN	I-protein	9	NMOD
8	4	4	I-NP	CD	I-protein	9	NMOD
9	signaling	signaling	I-NP	NN	O	5	OBJ
10	and	and	O	CC	O	5	VMOD
11	attenuates	attenuate	B-VP	VBZ	O	5	VMOD
12	left	left	B-NP	JJ	O	14	NMOD
13	ventricular	ventricular	I-NP	JJ	O	14	NMOD
14	dysfunction	dysfunction	I-NP	NN	O	11	OBJ
15	following	follow	B-PP	VBG	O	14	NMOD
16	myocardial	myocardial	B-NP	JJ	O	17	NMOD
17	infarction	infarction	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	5	P

1	Acute	Acute	B-NP	JJ	O	2	NMOD
2	treatment	treatment	I-NP	NN	O	5	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	metformin	metformin	B-NP	NN	O	3	PMOD
5	has	have	B-VP	VBZ	O	0	ROOT
6	a	a	B-NP	DT	O	8	NMOD
7	protective	protective	I-NP	JJ	O	8	NMOD
8	effect	effect	I-NP	NN	O	5	OBJ
9	in	in	B-PP	IN	O	5	VMOD
10	myocardial	myocardial	B-NP	JJ	O	11	NMOD
11	infarction	infarction	I-NP	NN	O	9	PMOD
12	by	by	B-PP	IN	O	5	VMOD
13	suppression	suppression	B-NP	NN	O	12	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	inflammatory	inflammatory	B-NP	JJ	O	16	NMOD
16	responses	response	I-NP	NNS	O	14	PMOD
17	due	due	B-ADJP	JJ	O	13	NMOD
18	to	to	B-PP	TO	O	17	AMOD
19	activation	activation	B-NP	NN	O	18	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	AMP-activated	AMP-activated	B-NP	JJ	B-protein	23	NMOD
22	protein	protein	I-NP	NN	I-protein	23	NMOD
23	kinase	kinase	I-NP	NN	I-protein	20	PMOD
24	(	(	O	(	O	26	DEP
25	AMPK	AMPK	B-NP	NN	B-protein	26	DEP
26	)	)	O	)	O	23	NMOD
27	.	.	O	.	O	5	P

1	In	In	B-PP	IN	O	32	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	present	present	I-NP	JJ	O	4	NMOD
4	study	study	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	32	P
6	the	the	B-NP	DT	O	7	NMOD
7	effect	effect	I-NP	NN	O	32	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	chronic	chronic	B-NP	JJ	O	10	NMOD
10	pre-treatment	pre-treatment	I-NP	NN	O	8	PMOD
11	with	with	B-PP	IN	O	7	NMOD
12	metformin	metformin	B-NP	NN	O	11	PMOD
13	on	on	B-PP	IN	O	7	NMOD
14	cardiac	cardiac	B-NP	JJ	O	15	NMOD
15	dysfunction	dysfunction	I-NP	NN	O	18	NMOD
16	and	and	I-NP	CC	O	18	NMOD
17	toll-like	toll-like	I-NP	JJ	B-protein	18	NMOD
18	receptor	receptor	I-NP	NN	I-protein	23	NMOD
19	4	4	I-NP	CD	I-protein	18	NMOD
20	(	(	O	(	O	22	DEP
21	TLR4	TLR4	B-NP	NN	B-protein	22	DEP
22	)	)	O	)	O	18	NMOD
23	activities	activity	B-NP	NNS	O	13	PMOD
24	following	follow	B-PP	VBG	O	7	NMOD
25	myocardial	myocardial	B-NP	JJ	O	26	NMOD
26	infarction	infarction	I-NP	NN	O	29	NMOD
27	and	and	O	CC	O	29	NMOD
28	their	their	B-NP	PRP$	O	29	NMOD
29	relation	relation	I-NP	NN	O	24	PMOD
30	with	with	B-PP	IN	O	29	NMOD
31	AMPK	AMPK	B-NP	NN	B-protein	30	PMOD
32	were	be	B-VP	VBD	O	0	ROOT
33	assessed	assess	I-VP	VBN	O	32	VC
34	.	.	O	.	O	32	P

1	Isoproterenol	Isoproterenol	B-NP	NN	O	5	SUB
2	(	(	O	(	O	4	DEP
3	100mg/kg	100mg/kg	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	was	be	B-VP	VBD	O	0	ROOT
6	injected	inject	I-VP	VBN	O	5	VC
7	subcutaneously	subcutaneously	B-ADVP	RB	O	6	VMOD
8	on	on	B-PP	IN	O	6	VMOD
9	the	the	B-NP	DT	O	13	NMOD
10	13th	13th	I-NP	JJ	O	13	NMOD
11	and	and	I-NP	CC	O	13	NMOD
12	14th	14th	I-NP	JJ	O	13	NMOD
13	days	day	I-NP	NNS	O	8	PMOD
14	to	to	B-VP	TO	O	15	VMOD
15	induce	induce	I-VP	VB	O	6	VMOD
16	acute	acute	B-NP	JJ	O	18	NMOD
17	myocardial	myocardial	I-NP	JJ	O	18	NMOD
18	infarction	infarction	I-NP	NN	O	15	OBJ
19	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	4	NMOD
2	left	left	I-NP	JJ	O	4	NMOD
3	ventricular	ventricular	I-NP	JJ	O	4	NMOD
4	dysfunction	dysfunction	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	0	ROOT
6	significantly	significantly	B-ADJP	RB	O	7	AMOD
7	lower	low	I-ADJP	JJR	O	5	PRD
8	in	in	B-PP	IN	O	5	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	groups	group	I-NP	NNS	O	8	PMOD
11	treated	treat	B-VP	VBN	O	10	NMOD
12	with	with	B-PP	IN	O	11	VMOD
13	25	25	B-NP	CD	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	50mg/kg	50mg/kg	I-NP	CD	O	12	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	metformin	metformin	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	5	P

1	Metfromin	Metfromin	B-NP	NN	O	3	SUB
2	markedly	markedly	B-ADVP	RB	O	3	VMOD
3	lowered	lower	B-VP	VBD	O	0	ROOT
4	isoproterenol	isoproterenol	B-NP	NN	O	6	NMOD
5	induced	induced	I-NP	JJ	O	6	NMOD
6	elevation	elevation	I-NP	NN	O	3	OBJ
7	in	in	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	levels	level	I-NP	NNS	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	TLR4	TLR4	B-NP	NN	B-RNA	12	NMOD
12	mRNA	mRNA	I-NP	NN	I-RNA	24	NMOD
13	,	,	O	,	O	24	P
14	myeloid	myeloid	B-NP	JJ	B-protein	16	NMOD
15	differentiation	differentiation	I-NP	NN	I-protein	16	NMOD
16	protein	protein	I-NP	NN	I-protein	24	NMOD
17	88	88	I-NP	CD	I-protein	16	NMOD
18	(	(	O	(	O	20	DEP
19	MyD88	MyD88	B-NP	NN	B-protein	20	DEP
20	)	)	O	)	O	16	NMOD
21	,	,	O	,	O	24	P
22	tumor	tumor	B-NP	NN	B-protein	24	NMOD
23	necrosis	necrosis	I-NP	NN	I-protein	24	NMOD
24	factor-alpha	factor-alpha	I-NP	NN	I-protein	30	NMOD
25	(	(	O	(	O	27	DEP
26	TNF-a	TNF-a	B-NP	NN	B-protein	27	DEP
27	)	)	O	)	O	24	NMOD
28	,	,	O	,	O	30	P
29	and	and	O	CC	O	30	NMOD
30	interleukin	interleukin	B-NP	NN	B-protein	10	PMOD
31	6	6	I-NP	CD	I-protein	30	NMOD
32	(	(	O	(	O	34	DEP
33	IL-6	IL-6	B-NP	NN	B-protein	34	DEP
34	)	)	O	)	O	30	NMOD
35	in	in	B-PP	IN	O	6	NMOD
36	the	the	B-NP	DT	O	38	NMOD
37	heart	heart	I-NP	NN	O	38	NMOD
38	tissues	tissue	I-NP	NNS	O	35	PMOD
39	.	.	O	.	O	3	P

1	Neuroleptic	Neuroleptic	B-NP	JJ	O	3	NMOD
2	malignant	malignant	I-NP	JJ	O	3	NMOD
3	syndrome	syndrome	I-NP	NN	O	0	ROOT
4	induced	induce	B-VP	VBN	O	3	NMOD
5	by	by	B-PP	IN	O	4	VMOD
6	combination	combination	B-NP	NN	O	7	NMOD
7	therapy	therapy	I-NP	NN	O	5	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	tetrabenazine	tetrabenazine	B-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	tiapride	tiapride	I-NP	NN	O	8	PMOD
12	in	in	B-PP	IN	O	4	VMOD
13	a	a	B-NP	DT	O	15	NMOD
14	Japanese	Japanese	I-NP	JJ	O	15	NMOD
15	patient	patient	I-NP	NN	O	12	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	Huntington	Huntington	B-NP	NNP	O	18	NMOD
18	's	's	B-NP	POS	O	19	NMOD
19	disease	disease	I-NP	NN	O	16	PMOD
20	at	at	B-PP	IN	O	15	NMOD
21	the	the	B-NP	DT	O	23	NMOD
22	terminal	terminal	I-NP	JJ	O	23	NMOD
23	stage	stage	I-NP	NN	O	20	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	recurrent	recurrent	B-NP	JJ	O	27	NMOD
26	breast	breast	I-NP	NN	O	27	NMOD
27	cancer	cancer	I-NP	NN	O	24	PMOD
28	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	3	SUB
2	herein	herein	B-ADVP	RB	O	3	VMOD
3	describe	describe	B-VP	VBP	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	case	case	I-NP	NN	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	an	an	B-NP	DT	O	10	NMOD
8	81-year-old	81-year-old	I-NP	JJ	O	10	NMOD
9	Japanese	Japanese	I-NP	JJ	O	10	NMOD
10	woman	woman	I-NP	NN	O	6	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	neuroleptic	neuroleptic	B-NP	JJ	O	14	NMOD
13	malignant	malignant	I-NP	JJ	O	14	NMOD
14	syndrome	syndrome	I-NP	NN	O	11	PMOD
15	that	that	B-NP	WDT	O	10	NMOD
16	occurred	occur	B-VP	VBD	O	15	SBAR
17	36	36	B-NP	CD	O	18	NMOD
18	days	day	I-NP	NNS	O	16	OBJ
19	after	after	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	21	NMOD
21	initiation	initiation	I-NP	NN	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	combination	combination	B-NP	NN	O	24	NMOD
24	therapy	therapy	I-NP	NN	O	22	PMOD
25	with	with	B-PP	IN	O	21	NMOD
26	tiapride	tiapride	B-NP	NN	O	32	NMOD
27	(	(	O	(	O	30	DEP
28	75	75	B-NP	CD	O	29	NMOD
29	mg/day	mg/day	I-NP	NN	O	30	DEP
30	)	)	O	)	O	26	NMOD
31	and	and	O	CC	O	32	NMOD
32	tetrabenazine	tetrabenazine	B-NP	NN	O	25	PMOD
33	(	(	O	(	O	36	DEP
34	12.5	12.5	B-NP	CD	O	35	NMOD
35	mg/day	mg/day	I-NP	NN	O	36	DEP
36	)	)	O	)	O	32	NMOD
37	for	for	B-PP	IN	O	32	NMOD
38	Huntington	Huntington	B-NP	NNP	O	40	NMOD
39	's	's	B-NP	POS	O	40	NMOD
40	disease	disease	I-NP	NN	O	37	PMOD
41	.	.	O	.	O	3	P

1	To	To	B-PP	TO	O	22	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	best	good	I-NP	JJS	O	1	VMOD
4	of	of	B-PP	IN	O	3	NMOD
5	our	our	B-NP	PRP$	O	6	NMOD
6	knowledge	knowledge	I-NP	NN	O	4	PMOD
7	,	,	O	,	O	22	P
8	the	the	B-NP	DT	O	9	NMOD
9	occurrence	occurrence	I-NP	NN	O	22	SUB
10	of	of	B-PP	IN	O	9	NMOD
11	neuroleptic	neuroleptic	B-NP	JJ	O	13	NMOD
12	malignant	malignant	I-NP	JJ	O	13	NMOD
13	syndrome	syndrome	I-NP	NN	O	10	PMOD
14	due	due	B-ADJP	JJ	O	9	NMOD
15	to	to	B-PP	TO	O	14	AMOD
16	combination	combination	B-NP	NN	O	17	NMOD
17	therapy	therapy	I-NP	NN	O	15	PMOD
18	with	with	B-PP	IN	O	17	NMOD
19	tetrabenazine	tetrabenazine	B-NP	NN	O	21	NMOD
20	and	and	I-NP	CC	O	21	NMOD
21	tiapride	tiapride	I-NP	NN	O	18	PMOD
22	has	have	B-VP	VBZ	O	0	ROOT
23	not	not	I-VP	RB	O	22	VMOD
24	been	be	I-VP	VBN	O	22	VC
25	previously	previously	I-VP	RB	O	24	VMOD
26	reported	report	I-VP	VBN	O	24	VC
27	.	.	O	.	O	22	P

1	A	A	B-NP	DT	O	3	NMOD
2	metoprolol-terbinafine	metoprolol-terbinafine	I-NP	JJ	O	3	NMOD
3	combination	combination	I-NP	NN	O	4	SUB
4	induced	induce	B-VP	VBD	O	0	ROOT
5	bradycardia	bradycardia	B-NP	NN	O	4	OBJ
6	.	.	O	.	O	4	P

1	To	To	B-VP	TO	O	2	VMOD
2	report	report	I-VP	VB	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	sinus	sinus	I-NP	NN	O	5	NMOD
5	bradycardia	bradycardia	I-NP	NN	O	2	OBJ
6	induced	induce	B-VP	VBN	O	5	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	metoprolol	metoprolol	B-NP	NN	O	12	NMOD
9	and	and	I-NP	CC	O	12	NMOD
10	terbinafine	terbinafine	I-NP	NN	O	12	NMOD
11	drug-drug	drug-drug	I-NP	NN	O	12	NMOD
12	interaction	interaction	I-NP	NN	O	15	NMOD
13	and	and	O	CC	O	15	NMOD
14	its	its	B-NP	PRP$	O	15	NMOD
15	management	management	I-NP	NN	O	7	PMOD
16	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	5	NMOD
2	63	63	I-NP	CD	O	5	NMOD
3	year-old	year-old	I-NP	JJ	O	5	NMOD
4	Caucasian	Caucasian	I-NP	JJ	O	5	NMOD
5	man	man	I-NP	NN	O	15	SUB
6	on	on	B-PP	IN	O	5	NMOD
7	metoprolol	metoprolol	B-NP	NN	O	9	AMOD
8	200	200	I-NP	CD	O	9	AMOD
9	mg/day	mg/day	I-NP	NN	O	6	PMOD
10	for	for	B-PP	IN	O	9	NMOD
11	stable	stable	B-NP	JJ	O	14	NMOD
12	coronary	coronary	I-NP	JJ	O	14	NMOD
13	artery	artery	I-NP	NN	O	14	NMOD
14	disease	disease	I-NP	NN	O	10	PMOD
15	was	be	B-VP	VBD	O	0	ROOT
16	prescribed	prescribe	I-VP	VBN	O	15	VC
17	a	a	B-NP	DT	O	19	NMOD
18	90-day	90-day	I-NP	JJ	O	19	NMOD
19	course	course	I-NP	NN	O	16	OBJ
20	of	of	B-PP	IN	O	19	NMOD
21	oral	oral	B-NP	JJ	O	22	NMOD
22	terbinafine	terbinafine	I-NP	NN	O	24	NMOD
23	250	250	I-NP	CD	O	22	NMOD
24	mg/day	mg/day	I-NP	NN	O	20	PMOD
25	for	for	B-PP	IN	O	24	NMOD
26	onychomycosis	onychomycosis	B-NP	NN	O	25	PMOD
27	.	.	O	.	O	15	P

1	On	On	B-PP	IN	O	10	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	49th	49th	I-NP	JJ	O	4	NMOD
4	day	day	I-NP	NN	O	1	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	terbinafine	terbinafine	B-NP	NN	O	7	NMOD
7	therapy	therapy	I-NP	NN	O	5	PMOD
8	,	,	O	,	O	10	P
9	he	he	B-NP	PRP	O	10	SUB
10	was	be	B-VP	VBD	O	0	ROOT
11	brought	bring	I-VP	VBN	O	10	VC
12	to	to	B-PP	TO	O	11	VMOD
13	the	the	B-NP	DT	O	15	NMOD
14	emergency	emergency	I-NP	NN	O	15	NMOD
15	room	room	I-NP	NN	O	12	PMOD
16	for	for	B-PP	IN	O	15	NMOD
17	a	a	B-NP	DT	O	18	NMOD
18	decrease	decrease	I-NP	NN	O	27	NMOD
19	of	of	B-PP	IN	O	18	NMOD
20	his	his	B-NP	PRP$	O	23	NMOD
21	global	global	I-NP	JJ	O	23	NMOD
22	health	health	I-NP	NN	O	23	NMOD
23	status	status	I-NP	NN	O	19	PMOD
24	,	,	O	,	O	27	P
25	confusion	confusion	B-NP	NN	O	27	NMOD
26	and	and	I-NP	CC	O	27	NMOD
27	falls	fall	I-NP	NNS	O	16	PMOD
28	.	.	O	.	O	10	P

1	A	A	B-NP	DT	O	2	NMOD
2	score	score	I-NP	NN	O	13	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	7	7	B-NP	CD	O	3	PMOD
5	on	on	B-PP	IN	O	2	NMOD
6	the	the	B-NP	DT	O	12	NMOD
7	Naranjo	Naranjo	I-NP	NNP	O	12	NMOD
8	adverse	adverse	I-NP	JJ	O	12	NMOD
9	drug	drug	I-NP	NN	O	12	NMOD
10	reaction	reaction	I-NP	NN	O	12	NMOD
11	probability	probability	I-NP	NN	O	12	NMOD
12	scale	scale	I-NP	NN	O	5	PMOD
13	indicates	indicate	B-VP	VBZ	O	0	ROOT
14	a	a	B-NP	DT	O	16	NMOD
15	probable	probable	I-NP	JJ	O	16	NMOD
16	relationship	relationship	I-NP	NN	O	13	OBJ
17	between	between	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	22	NMOD
19	patient	patient	I-NP	NN	O	22	NMOD
20	's	's	B-NP	POS	O	22	NMOD
21	sinus	sinus	I-NP	NN	O	22	NMOD
22	bradycardia	bradycardia	I-NP	NN	O	26	NMOD
23	and	and	O	CC	O	26	NMOD
24	the	the	B-NP	DT	O	26	NMOD
25	drug	drug	I-NP	NN	O	26	NMOD
26	interaction	interaction	I-NP	NN	O	17	PMOD
27	between	between	B-PP	IN	O	26	NMOD
28	metoprolol	metoprolol	B-NP	NN	O	30	NMOD
29	and	and	I-NP	CC	O	30	NMOD
30	terbinafine	terbinafine	I-NP	NN	O	27	PMOD
31	.	.	O	.	O	13	P

1	Optochiasmatic	Optochiasmatic	B-NP	JJ	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	peripheral	peripheral	I-NP	JJ	O	4	NMOD
4	neuropathy	neuropathy	I-NP	NN	O	0	ROOT
5	due	due	B-ADJP	JJ	O	4	NMOD
6	to	to	B-PP	TO	O	5	AMOD
7	ethambutol	ethambutol	B-NP	NN	O	8	NMOD
8	overtreatment	overtreatment	I-NP	NN	O	6	PMOD
9	.	.	O	.	O	4	P

1	Ethambutol	Ethambutol	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	known	know	I-VP	VBN	O	2	VC
4	to	to	I-VP	TO	O	5	VMOD
5	cause	cause	I-VP	VB	O	3	VMOD
6	optic	optic	B-NP	JJ	O	7	NMOD
7	neuropathy	neuropathy	I-NP	NN	O	5	OBJ
8	and	and	O	CC	O	5	VMOD
9	,	,	O	,	O	5	P
10	more	more	B-ADVP	RBR	O	11	AMOD
11	rarely	rarely	I-ADVP	RB	O	5	VMOD
12	,	,	O	,	O	2	P
13	axonal	axonal	B-NP	JJ	O	14	NMOD
14	polyneuropathy	polyneuropathy	I-NP	NN	O	2	VMOD
15	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	characterize	characterize	B-VP	VBP	O	0	ROOT
3	the	the	B-NP	DT	O	10	NMOD
4	clinical	clinical	I-NP	JJ	O	10	NMOD
5	,	,	I-NP	,	O	10	P
6	neurophysiological	neurophysiological	I-NP	JJ	O	10	NMOD
7	,	,	O	,	O	10	P
8	and	and	O	CC	O	10	NMOD
9	neuroimaging	neuroimaging	B-NP	NN	O	10	NMOD
10	findings	finding	I-NP	NNS	O	2	OBJ
11	in	in	B-PP	IN	O	2	VMOD
12	a	a	B-NP	DT	O	14	NMOD
13	72-year-old	72-year-old	I-NP	JJ	O	14	NMOD
14	man	man	I-NP	NN	O	11	PMOD
15	who	who	B-NP	WP	O	14	NMOD
16	developed	develop	B-VP	VBD	O	15	SBAR
17	visual	visual	B-NP	JJ	O	20	NMOD
18	loss	loss	I-NP	NN	O	20	NMOD
19	and	and	I-NP	CC	O	20	NMOD
20	paresthesias	paresthesia	I-NP	NNS	O	16	OBJ
21	after	after	B-PP	IN	O	20	NMOD
22	11	11	B-NP	CD	O	23	NMOD
23	weeks	week	I-NP	NNS	O	21	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	exposure	exposure	B-NP	NN	O	24	PMOD
26	to	to	B-PP	TO	O	25	NMOD
27	a	a	B-NP	DT	O	29	NMOD
28	supratherapeutic	supratherapeutic	I-NP	JJ	O	29	NMOD
29	dose	dose	I-NP	NN	O	26	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	ethambutol	ethambutol	B-NP	NN	O	30	PMOD
32	.	.	O	.	O	2	P

1	Testosterone	Testosterone	B-NP	NN	O	2	SUB
2	ameliorates	ameliorate	B-VP	VBZ	O	0	ROOT
3	streptozotocin	streptozotocin	B-NP	NN	O	6	NMOD
4	induced	induced	I-NP	JJ	O	6	NMOD
5	memory	memory	I-NP	NN	O	6	NMOD
6	impairment	impairment	I-NP	NN	O	2	OBJ
7	in	in	B-PP	IN	O	6	NMOD
8	male	male	B-NP	JJ	O	9	NMOD
9	rats	rat	I-NP	NNS	O	7	PMOD
10	.	.	O	.	O	2	P

1	AIM	AIM	B-NP	NN	O	14	SUB
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	study	study	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	effects	effect	I-NP	NNS	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	testosterone	testosterone	B-NP	NN	O	7	PMOD
9	on	on	B-PP	IN	O	6	NMOD
10	streptozotocin	streptozotocin	B-NP	NN	O	9	PMOD
11	(	(	O	(	O	13	DEP
12	STZ	STZ	B-NP	NN	B-protein	13	DEP
13	)	)	O	)	O	10	NMOD
14	induced	induce	B-VP	VBD	O	0	ROOT
15	memory	memory	B-NP	NN	O	16	NMOD
16	impairment	impairment	I-NP	NN	O	14	OBJ
17	in	in	B-PP	IN	O	14	VMOD
18	male	male	B-NP	JJ	O	19	NMOD
19	rats	rat	I-NP	NNS	O	17	PMOD
20	.	.	O	.	O	14	P

1	Administration	Administration	B-NP	NN	O	7	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	flutamide	flutamide	B-NP	NN	O	2	PMOD
4	,	,	O	,	O	7	P
5	letrozole	letrozole	B-NP	NN	O	7	NMOD
6	or	or	O	CC	O	7	NMOD
7	tamoxifen	tamoxifen	B-NP	NN	O	9	SUB
8	significantly	significantly	B-ADVP	RB	O	9	VMOD
9	impaired	impair	B-VP	VBD	O	0	ROOT
10	the	the	B-NP	DT	O	11	NMOD
11	memory	memory	I-NP	NN	O	9	OBJ
12	in	in	B-PP	IN	O	11	NMOD
13	intact	intact	B-NP	JJ	O	14	NMOD
14	rats	rat	I-NP	NNS	O	12	PMOD
15	,	,	O	,	O	9	P
16	and	and	O	CC	O	9	VMOD
17	significantly	significantly	B-VP	RB	O	9	VMOD
18	attenuated	attenuate	I-VP	VBD	O	9	VMOD
19	the	the	B-NP	DT	O	21	NMOD
20	testosterone	testosterone	I-NP	NN	O	21	NMOD
21	replacement	replacement	I-NP	NN	O	18	OBJ
22	in	in	B-PP	IN	O	18	VMOD
23	improving	improve	B-VP	VBG	O	22	PMOD
24	STZ-	STZ-	B-NP	NN	O	26	NMOD
25	and	and	I-NP	CC	O	26	NMOD
26	castration	castration	I-NP	NN	O	29	NMOD
27	induced	induce	B-VP	VBD	O	29	NMOD
28	memory	memory	B-NP	NN	O	29	NMOD
29	impairment	impairment	I-NP	NN	O	23	OBJ
30	.	.	O	.	O	9	P

1	Behavioral	Behavioral	B-NP	JJ	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	neurochemical	neurochemical	I-NP	JJ	O	4	NMOD
4	studies	study	I-NP	NNS	O	0	ROOT
5	in	in	B-PP	IN	O	4	NMOD
6	mice	mouse	B-NP	NNS	O	5	PMOD
7	pretreated	pretreate	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	garcinielliptone	garcinielliptone	B-NP	NN	O	10	NMOD
10	FC	FC	I-NP	NN	O	8	PMOD
11	in	in	B-PP	IN	O	7	VMOD
12	pilocarpine	pilocarpine	B-NP	NN	O	14	NMOD
13	induced	induce	I-NP	VBN	O	14	NMOD
14	seizures	seizure	I-NP	NNS	O	11	PMOD
15	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	aimed	aim	B-VP	VBD	O	0	ROOT
5	to	to	I-VP	TO	O	6	VMOD
6	evaluate	evaluate	I-VP	VB	O	4	VMOD
7	the	the	B-NP	DT	O	9	NMOD
8	GFC	GFC	I-NP	NN	O	9	NMOD
9	effects	effect	I-NP	NNS	O	6	OBJ
10	at	at	B-PP	IN	O	6	VMOD
11	doses	dose	B-NP	NNS	O	10	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	25	25	B-NP	CD	O	17	AMOD
14	,	,	I-NP	,	O	17	P
15	50	50	I-NP	CD	O	17	AMOD
16	or	or	I-NP	CC	O	17	AMOD
17	75	75	I-NP	CD	O	18	NMOD
18	mg/kg	mg/kg	I-NP	NN	O	12	PMOD
19	on	on	B-PP	IN	O	6	VMOD
20	seizure	seizure	B-NP	NN	O	21	NMOD
21	parameters	parameter	I-NP	NNS	O	19	PMOD
22	to	to	B-VP	TO	O	23	VMOD
23	determine	determine	I-VP	VB	O	6	VMOD
24	their	their	B-NP	PRP$	O	26	NMOD
25	anticonvulsant	anticonvulsant	I-NP	JJ	O	26	NMOD
26	activity	activity	I-NP	NN	O	29	NMOD
27	and	and	O	CC	O	29	NMOD
28	its	its	B-NP	PRP$	O	29	NMOD
29	effects	effect	I-NP	NNS	O	23	OBJ
30	on	on	B-PP	IN	O	29	NMOD
31	amino	amino	B-NP	NN	O	32	NMOD
32	acid	acid	I-NP	NN	O	46	NMOD
33	(	(	O	(	O	45	DEP
34	r-aminobutyric	r-aminobutyric	B-NP	JJ	O	35	NMOD
35	acid	acid	I-NP	NN	O	44	NMOD
36	(	(	O	(	O	38	DEP
37	GABA	GABA	B-NP	NN	B-protein	38	DEP
38	)	)	O	)	O	35	NMOD
39	,	,	O	,	O	44	P
40	glutamine	glutamine	B-NP	NN	O	44	NMOD
41	,	,	O	,	O	44	P
42	aspartate	aspartate	B-NP	NN	O	44	NMOD
43	and	and	O	CC	O	44	NMOD
44	glutathione	glutathione	B-NP	NN	O	45	DEP
45	)	)	O	)	O	32	NMOD
46	levels	level	B-NP	NNS	O	30	PMOD
47	as	as	B-CONJP	RB	O	29	NMOD
48	well	well	I-CONJP	RB	O	47	DEP
49	as	as	I-CONJP	IN	O	47	DEP
50	on	on	B-PP	IN	O	47	PMOD
51	acetylcholinesterase	acetylcholinesterase	B-NP	NN	O	55	NMOD
52	(	(	O	(	O	54	DEP
53	AChE	AChE	B-NP	NN	O	54	DEP
54	)	)	O	)	O	51	NMOD
55	activity	activity	B-NP	NN	O	50	PMOD
56	in	in	B-PP	IN	O	55	NMOD
57	mice	mouse	B-NP	NNS	O	58	NMOD
58	hippocampus	hippocampus	I-NP	NN	O	56	PMOD
59	after	after	B-PP	IN	O	58	NMOD
60	seizures	seizure	B-NP	NNS	O	59	PMOD
61	.	.	O	.	O	4	P

1	GFC	GFC	B-NP	NN	B-protein	2	SUB
2	produced	produce	B-VP	VBD	O	0	ROOT
3	an	an	B-NP	DT	O	5	NMOD
4	increased	increase	I-NP	VBN	O	5	NMOD
5	latency	latency	I-NP	NN	O	2	OBJ
6	to	to	B-PP	TO	O	5	NMOD
7	first	first	B-NP	JJ	O	8	NMOD
8	seizure	seizure	I-NP	NN	O	6	PMOD
9	,	,	O	,	O	2	P
10	at	at	B-PP	IN	O	2	VMOD
11	doses	dose	B-NP	NNS	O	29	NMOD
12	25mg/kg	25mg/kg	B-NP	CD	O	11	NMOD
13	(	(	O	(	O	18	DEP
14	20.12	20.12	B-NP	CD	O	17	NMOD
15	+	+	O	SYM	O	17	NMOD
16	2.20	2.20	B-NP	CD	O	17	NMOD
17	min	min	I-NP	NN	O	18	DEP
18	)	)	O	)	O	11	NMOD
19	,	,	O	,	O	29	P
20	50mg/kg	50mg/kg	B-NP	CD	O	29	NMOD
21	(	(	O	(	O	26	DEP
22	20.95	20.95	B-NP	CD	O	25	NMOD
23	+	+	O	SYM	O	25	NMOD
24	2.21	2.21	B-NP	CD	O	25	NMOD
25	min	min	I-NP	NN	O	26	DEP
26	)	)	O	)	O	20	NMOD
27	or	or	O	CC	O	29	NMOD
28	75	75	B-NP	CD	O	29	NMOD
29	mg/kg	mg/kg	I-NP	NN	O	10	PMOD
30	(	(	O	(	O	35	DEP
31	23.43	23.43	B-NP	CD	O	34	NMOD
32	+	+	O	SYM	O	34	NMOD
33	1.99	1.99	B-NP	CD	O	34	NMOD
34	min	min	I-NP	NN	O	35	DEP
35	)	)	O	)	O	29	NMOD
36	when	when	B-ADVP	WRB	O	2	VMOD
37	compared	compare	B-PP	VBN	O	36	SBAR
38	with	with	B-PP	IN	O	37	VMOD
39	seized	seize	B-NP	VBN	O	40	NMOD
40	mice	mouse	I-NP	NNS	O	38	PMOD
41	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	indicate	indicate	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	GFC	GFC	B-NP	NN	B-protein	6	SUB
6	can	can	B-VP	MD	O	4	SBAR
7	exert	exert	I-VP	VB	O	6	VC
8	anticonvulsant	anticonvulsant	B-NP	JJ	O	9	NMOD
9	activity	activity	I-NP	NN	O	7	OBJ
10	and	and	O	CC	O	3	VMOD
11	reduce	reduce	B-VP	VB	O	3	VMOD
12	the	the	B-NP	DT	O	13	NMOD
13	frequency	frequency	I-NP	NN	O	11	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	installation	installation	B-NP	NN	O	14	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	pilocarpine	pilocarpine	B-NP	NN	O	16	PMOD
18	induced	induce	B-VP	VBD	O	3	VMOD
19	status	status	B-NP	NN	O	20	NMOD
20	epilepticus	epilepticus	I-NP	NN	O	18	OBJ
21	,	,	O	,	O	3	P
22	as	as	B-SBAR	IN	O	3	VMOD
23	demonstrated	demonstrate	B-VP	VBN	O	22	SBAR
24	by	by	B-PP	IN	O	23	VMOD
25	increase	increase	B-NP	NN	O	32	NMOD
26	in	in	B-PP	IN	O	25	NMOD
27	latency	latency	B-NP	NN	O	26	PMOD
28	to	to	B-PP	TO	O	25	NMOD
29	first	first	B-NP	JJ	O	30	NMOD
30	seizure	seizure	I-NP	NN	O	28	PMOD
31	and	and	O	CC	O	32	NMOD
32	decrease	decrease	B-NP	NN	O	24	PMOD
33	in	in	B-PP	IN	O	32	NMOD
34	mortality	mortality	B-NP	NN	O	35	NMOD
35	rate	rate	I-NP	NN	O	33	PMOD
36	of	of	B-PP	IN	O	35	NMOD
37	animals	animal	B-NP	NNS	O	36	PMOD
38	.	.	O	.	O	3	P

1	Rhabdomyolysis	Rhabdomyolysis	B-NP	NN	O	0	ROOT
2	in	in	B-PP	IN	O	1	NMOD
3	a	a	B-NP	DT	O	8	NMOD
4	hepatitis	hepatitis	I-NP	NN	O	8	NMOD
5	C	C	I-NP	NN	O	8	NMOD
6	virus	virus	I-NP	NN	O	8	NMOD
7	infected	infected	I-NP	JJ	O	8	NMOD
8	patient	patient	I-NP	NN	O	2	PMOD
9	treated	treat	B-VP	VBN	O	8	NMOD
10	with	with	B-PP	IN	O	9	VMOD
11	telaprevir	telaprevir	B-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	simvastatin	simvastatin	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	1	P

1	A	A	B-NP	DT	O	4	NMOD
2	46-year	46-year	I-NP	JJ	O	4	NMOD
3	old	old	I-NP	JJ	O	4	NMOD
4	man	man	I-NP	NN	O	12	SUB
5	with	with	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	11	NMOD
7	chronic	chronic	I-NP	JJ	O	11	NMOD
8	hepatitis	hepatitis	I-NP	NN	O	11	NMOD
9	C	C	I-NP	NN	O	11	NMOD
10	virus	virus	I-NP	NN	O	11	NMOD
11	infection	infection	I-NP	NN	O	5	PMOD
12	received	receive	B-VP	VBD	O	0	ROOT
13	triple	triple	B-NP	JJ	O	14	NMOD
14	therapy	therapy	I-NP	NN	O	21	NMOD
15	with	with	B-PP	IN	O	14	NMOD
16	ribavirin	ribavirin	B-NP	NN	O	15	PMOD
17	,	,	O	,	O	14	P
18	pegylated	pegylate	B-NP	VBN	O	21	NMOD
19	interferon	interferon	I-NP	NN	O	21	NMOD
20	and	and	I-NP	CC	O	21	NMOD
21	telaprevir	telaprevir	I-NP	NN	O	12	OBJ
22	.	.	O	.	O	12	P

1	At	At	B-PP	IN	O	0	ROOT
2	admission	admission	B-NP	NN	O	3	NMOD
3	simvastatin	simvastatin	I-NP	NN	O	7	NMOD
4	and	and	O	CC	O	7	NMOD
5	all	all	B-NP	DT	O	7	NMOD
6	antiviral	antiviral	I-NP	JJ	O	7	NMOD
7	drugs	drug	I-NP	NNS	O	8	SUB
8	were	be	B-VP	VBD	O	1	VMOD
9	discontinued	discontinue	I-VP	VBN	O	8	VC
10	because	because	B-SBAR	IN	O	9	VMOD
11	toxicity	toxicity	B-NP	NN	O	17	SUB
12	due	due	B-PP	JJ	O	13	PMOD
13	to	to	B-PP	TO	O	11	NMOD
14	a	a	B-NP	DT	O	16	NMOD
15	drug-drug	drug-drug	I-NP	JJ	O	16	NMOD
16	interaction	interaction	I-NP	NN	O	13	PMOD
17	was	be	B-VP	VBD	O	10	SBAR
18	suspected	suspect	I-VP	VBN	O	17	VC
19	.	.	O	.	O	1	P

1	Simvastatin	Simvastatin	B-NP	NN	O	3	NMOD
2	plasma	plasma	I-NP	NN	O	3	NMOD
3	concentration	concentration	I-NP	NN	O	4	SUB
4	increased	increase	B-VP	VBD	O	0	ROOT
5	30	30	B-NP	CD	O	6	NMOD
6	times	time	I-NP	NNS	O	4	OBJ
7	in	in	B-PP	IN	O	4	VMOD
8	this	this	B-NP	DT	O	11	NMOD
9	patient	patient	I-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	statin	statin	I-NP	NN	O	7	PMOD
12	induced	induce	B-VP	VBD	O	11	NMOD
13	muscle	muscle	B-NP	NN	O	14	NMOD
14	toxicity	toxicity	I-NP	NN	O	12	OBJ
15	is	be	B-VP	VBZ	O	4	VMOD
16	related	related	B-ADJP	JJ	O	15	PRD
17	to	to	B-PP	TO	O	16	AMOD
18	the	the	B-NP	DT	O	19	NMOD
19	concentration	concentration	I-NP	NN	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	22	NMOD
22	statin	statin	I-NP	NN	O	20	PMOD
23	in	in	B-PP	IN	O	19	NMOD
24	blood	blood	B-NP	NN	O	23	PMOD
25	.	.	O	.	O	4	P

1	Combination	Combination	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	bortezomib	bortezomib	B-NP	NN	O	8	NMOD
4	,	,	O	,	O	8	P
5	thalidomide	thalidomide	B-NP	NN	O	8	NMOD
6	,	,	O	,	O	8	P
7	and	and	O	CC	O	8	NMOD
8	dexamethasone	dexamethasone	B-NP	NN	O	2	PMOD
9	(	(	O	(	O	11	DEP
10	VTD	VTD	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	as	as	B-PP	IN	O	1	NMOD
13	a	a	B-NP	DT	O	15	NMOD
14	consolidation	consolidation	I-NP	NN	O	15	NMOD
15	therapy	therapy	I-NP	NN	O	12	PMOD
16	after	after	B-PP	IN	O	15	NMOD
17	autologous	autologous	B-NP	JJ	O	20	NMOD
18	stem	stem	I-NP	NN	O	20	NMOD
19	cell	cell	I-NP	NN	O	20	NMOD
20	transplantation	transplantation	I-NP	NN	O	16	PMOD
21	for	for	B-PP	IN	O	20	NMOD
22	symptomatic	symptomatic	B-NP	JJ	O	24	NMOD
23	multiple	multiple	I-NP	JJ	O	24	NMOD
24	myeloma	myeloma	I-NP	NN	O	21	PMOD
25	in	in	B-PP	IN	O	24	NMOD
26	Japanese	Japanese	B-NP	JJ	O	27	NMOD
27	patients	patient	I-NP	NNS	O	25	PMOD
28	.	.	O	.	O	1	P

1	In	In	B-PP	IN	O	7	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	study	study	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	7	P
5	we	we	B-NP	PRP	O	7	SUB
6	retrospectively	retrospectively	B-ADVP	RB	O	7	VMOD
7	analyzed	analyze	B-VP	VBD	O	0	ROOT
8	the	the	B-NP	DT	O	11	NMOD
9	safety	safety	I-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	efficacy	efficacy	I-NP	NN	O	7	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	combination	combination	B-NP	NN	O	14	NMOD
14	regimen	regimen	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	bortezomib	bortezomib	B-NP	NN	O	21	NMOD
17	,	,	O	,	O	21	P
18	thalidomide	thalidomide	B-NP	NN	O	21	NMOD
19	,	,	O	,	O	21	P
20	and	and	O	CC	O	21	NMOD
21	dexamethasone	dexamethasone	B-NP	NN	O	15	PMOD
22	(	(	O	(	O	24	DEP
23	VTD	VTD	B-NP	NN	O	24	DEP
24	)	)	O	)	O	21	NMOD
25	as	as	B-PP	IN	O	7	VMOD
26	consolidation	consolidation	B-NP	NN	O	27	NMOD
27	therapy	therapy	I-NP	NN	O	25	PMOD
28	in	in	B-PP	IN	O	7	VMOD
29	24	24	B-NP	CD	O	31	NMOD
30	Japanese	Japanese	I-NP	JJ	O	31	NMOD
31	patients	patient	I-NP	NNS	O	28	PMOD
32	with	with	B-PP	IN	O	31	NMOD
33	newly	newly	B-NP	RB	O	34	AMOD
34	diagnosed	diagnose	I-NP	VBN	O	35	NMOD
35	MM	MM	I-NP	NN	O	32	PMOD
36	.	.	O	.	O	7	P

1	Conversion	Conversion	B-NP	NN	O	6	SUB
2	to	to	B-PP	TO	O	1	NMOD
3	sirolimus	sirolimus	B-NP	NN	O	5	NMOD
4	ameliorates	ameliorate	I-NP	NNS	O	5	NMOD
5	cyclosporine	cyclosporine	I-NP	NN	O	2	PMOD
6	induced	induce	B-VP	VBD	O	0	ROOT
7	nephropathy	nephropathy	B-NP	NN	O	6	OBJ
8	in	in	B-PP	IN	O	6	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	rat	rat	I-NP	NN	O	8	PMOD
11	:	:	O	:	O	6	VMOD
12	focus	focus	B-NP	NN	O	11	OBJ
13	on	on	B-PP	IN	O	12	NMOD
14	serum	serum	B-NP	NN	O	24	NMOD
15	,	,	O	,	O	24	P
16	urine	urine	B-NP	NN	O	24	NMOD
17	,	,	O	,	O	24	P
18	gene	gene	B-NP	NN	O	24	NMOD
19	,	,	O	,	O	24	P
20	and	and	O	CC	O	24	NMOD
21	protein	protein	B-NP	NN	O	24	NMOD
22	renal	renal	I-NP	JJ	O	24	NMOD
23	expression	expression	I-NP	NN	O	24	NMOD
24	biomarkers	biomarker	I-NP	NNS	O	13	PMOD
25	.	.	O	.	O	6	P

1	Protocols	Protocol	B-NP	NNS	O	15	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	conversion	conversion	B-NP	NN	O	2	PMOD
4	from	from	B-PP	IN	O	3	NMOD
5	cyclosporin	cyclosporin	B-NP	NN	O	6	NMOD
6	A	A	I-NP	NN	O	4	PMOD
7	(	(	O	(	O	9	DEP
8	CsA	CsA	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	to	to	B-PP	TO	O	1	NMOD
11	sirolimus	sirolimus	B-NP	NN	O	10	PMOD
12	(	(	O	(	O	14	DEP
13	SRL	SRL	B-NP	NN	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	have	have	B-VP	VBP	O	36	VMOD
16	been	be	I-VP	VBN	O	15	VC
17	widely	widely	I-VP	RB	O	18	VMOD
18	used	use	I-VP	VBN	O	16	VC
19	in	in	B-PP	IN	O	18	VMOD
20	immunotherapy	immunotherapy	B-NP	NN	O	19	PMOD
21	after	after	B-PP	IN	O	18	VMOD
22	transplantation	transplantation	B-NP	NN	O	21	PMOD
23	to	to	B-VP	TO	O	24	VMOD
24	prevent	prevent	I-VP	VB	O	18	VMOD
25	CsA	CsA	B-NP	NN	O	27	NMOD
26	induced	induced	I-NP	JJ	O	27	NMOD
27	nephropathy	nephropathy	I-NP	NN	O	24	OBJ
28	,	,	O	,	O	36	P
29	but	but	O	CC	O	36	VMOD
30	the	the	B-NP	DT	O	32	NMOD
31	molecular	molecular	I-NP	JJ	O	32	NMOD
32	mechanisms	mechanism	I-NP	NNS	O	36	SUB
33	underlying	underlie	B-VP	VBG	O	32	NMOD
34	these	these	B-NP	DT	O	35	NMOD
35	protocols	protocol	I-NP	NNS	O	33	OBJ
36	remain	remain	B-VP	VBP	O	0	ROOT
37	nuclear	nuclear	B-ADJP	JJ	O	36	PRD
38	.	.	O	.	O	36	P

1	Renal	Renal	B-NP	JJ	O	2	NMOD
2	lesions	lesion	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	0	ROOT
4	analyzed	analyze	I-VP	VBN	O	3	VC
5	in	in	B-PP	IN	O	4	VMOD
6	hematoxylin	hematoxylin	B-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	eosin	eosin	I-NP	NN	O	5	PMOD
9	,	,	O	,	O	4	P
10	periodic	periodic	B-NP	JJ	B-protein	11	NMOD
11	acid-Schiff	acid-Schiff	I-NP	NN	I-protein	17	NMOD
12	,	,	O	,	O	17	P
13	and	and	O	CC	O	17	NMOD
14	Masson	Masson	B-NP	NNP	O	15	NMOD
15	's	's	B-NP	POS	O	17	NMOD
16	trichrome	trichrome	I-NP	NN	O	17	NMOD
17	stains	stain	I-NP	NNS	O	4	VMOD
18	.	.	O	.	O	3	P

1	SRL-treated	SRL-treated	B-NP	JJ	O	2	NMOD
2	rats	rat	I-NP	NNS	O	3	SUB
3	presented	present	B-VP	VBD	O	0	ROOT
4	proteinuria	proteinuria	B-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	NGAL	NGAL	I-NP	NN	B-protein	3	OBJ
7	(	(	O	(	O	11	DEP
8	serum	serum	B-NP	NN	O	10	NMOD
9	and	and	O	CC	O	10	NMOD
10	urinary	urinary	B-ADJP	JJ	O	11	DEP
11	)	)	O	)	O	6	NMOD
12	as	as	B-PP	IN	O	3	VMOD
13	the	the	B-NP	DT	O	15	NMOD
14	best	good	I-NP	JJS	O	15	NMOD
15	markers	marker	I-NP	NNS	O	12	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	renal	renal	B-NP	JJ	O	18	NMOD
18	impairment	impairment	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	3	P

1	Short	Short	B-NP	JJ	O	3	NMOD
2	CsA	CsA	I-NP	NN	O	3	NMOD
3	treatment	treatment	I-NP	NN	O	4	SUB
4	presented	present	B-VP	VBD	O	0	ROOT
5	slight	slight	B-NP	JJ	O	8	AMOD
6	or	or	I-NP	CC	O	8	AMOD
7	even	even	I-NP	RB	O	8	AMOD
8	absent	absent	I-NP	JJ	O	10	NMOD
9	kidney	kidney	I-NP	NN	O	10	NMOD
10	lesions	lesion	I-NP	NNS	O	26	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	TGF-b	TGF-b	I-NP	NN	B-protein	26	NMOD
13	,	,	O	,	O	26	P
14	NF-	NF-	B-NP	NF-	B-protein	15	NMOD
15	kb	kb	I-NP	NN	I-protein	26	NMOD
16	,	,	O	,	O	26	P
17	mTOR	mTOR	B-NP	NN	B-protein	26	NMOD
18	,	,	O	,	O	26	P
19	PCNA	PCNA	B-NP	NN	B-protein	26	NMOD
20	,	,	O	,	O	26	P
21	TP53	TP53	B-NP	NN	B-protein	26	NMOD
22	,	,	O	,	O	26	P
23	KIM-1	KIM-1	B-NP	NN	B-protein	26	NMOD
24	,	,	O	,	O	26	P
25	and	and	O	CC	O	26	NMOD
26	CTGF	CTGF	B-NP	NN	B-protein	4	OBJ
27	as	as	B-PP	IN	O	4	VMOD
28	relevant	relevant	B-NP	JJ	O	32	NMOD
29	gene	gene	I-NP	NN	O	32	NMOD
30	and	and	I-NP	CC	O	32	NMOD
31	protein	protein	I-NP	NN	O	32	NMOD
32	changes	change	I-NP	NNS	O	27	PMOD
33	.	.	O	.	O	4	P

1	Prolonged	Prolong	B-NP	VBN	O	3	NMOD
2	CsA	CsA	I-NP	NN	O	3	NMOD
3	exposure	exposure	I-NP	NN	O	4	SUB
4	aggravated	aggravate	B-VP	VBD	O	0	ROOT
5	renal	renal	B-NP	JJ	O	6	NMOD
6	damage	damage	I-NP	NN	O	4	OBJ
7	,	,	O	,	O	4	P
8	without	without	B-PP	IN	O	4	VMOD
9	clear	clear	B-NP	JJ	O	10	NMOD
10	changes	change	I-NP	NNS	O	8	PMOD
11	on	on	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	14	NMOD
13	traditional	traditional	I-NP	JJ	B-protein	14	NMOD
14	markers	marker	I-NP	NNS	I-protein	11	PMOD
15	,	,	O	,	O	4	P
16	but	but	O	CC	O	15	PMOD
17	with	with	B-PP	IN	O	16	PRD
18	changes	change	B-NP	NNS	O	17	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	serums	serum	B-NP	NNS	O	24	NMOD
21	TGF-	TGF-	I-NP	NN	O	22	NMOD
22	b	b	I-NP	NN	O	24	NMOD
23	and	and	O	CC	O	24	NMOD
24	IL-7	IL-7	B-NP	NN	B-protein	33	NMOD
25	,	,	O	,	O	33	P
26	TBARs	TBARs	B-NP	NN	O	27	NMOD
27	clearance	clearance	I-NP	NN	O	33	NMOD
28	,	,	O	,	O	33	P
29	and	and	O	CC	O	33	NMOD
30	kidney	kidney	B-NP	NN	O	31	NMOD
31	TGF-b	TGF-b	I-NP	NN	O	33	NMOD
32	and	and	O	CC	O	33	NMOD
33	mTOR	mTOR	B-NP	NN	O	19	PMOD
34	.	.	O	.	O	16	P

1	Kinin	Kinin	B-NP	NN	O	4	NMOD
2	B2	B2	I-NP	NN	O	4	NMOD
3	receptor	receptor	I-NP	NN	O	4	NMOD
4	deletion	deletion	I-NP	NN	O	8	NMOD
5	and	and	I-NP	CC	O	8	NMOD
6	blockage	blockage	I-NP	NN	O	7	NMOD
7	ameliorates	ameliorate	I-NP	NNS	O	8	NMOD
8	cisplatin	cisplatin	I-NP	NN	O	9	SUB
9	induced	induce	B-VP	VBD	O	0	ROOT
10	acute	acute	B-NP	JJ	O	12	NMOD
11	renal	renal	I-NP	JJ	O	12	NMOD
12	injury	injury	I-NP	NN	O	9	OBJ
13	.	.	O	.	O	9	P

1	Cisplatin	Cisplatin	B-NP	NN	O	2	NMOD
2	treatment	treatment	I-NP	NN	O	3	SUB
3	has	have	B-VP	VBZ	O	14	VMOD
4	been	be	I-VP	VBN	O	3	VC
5	adopted	adopt	I-VP	VBN	O	4	VC
6	in	in	B-PP	IN	O	5	VMOD
7	some	some	B-NP	DT	O	8	NMOD
8	chemotherapies	chemotherapy	I-NP	NNS	O	6	PMOD
9	;	;	O	:	O	14	P
10	however	however	O	RB	O	14	VMOD
11	,	,	O	,	O	14	P
12	this	this	B-NP	DT	O	13	NMOD
13	drug	drug	I-NP	NN	O	14	SUB
14	can	can	B-VP	MD	O	0	ROOT
15	induce	induce	I-VP	VB	O	14	VC
16	acute	acute	B-NP	JJ	O	18	NMOD
17	kidney	kidney	I-NP	NN	O	18	NMOD
18	injury	injury	I-NP	NN	O	15	OBJ
19	due	due	B-PP	IN	O	15	VMOD
20	its	its	B-NP	PRP$	O	21	NMOD
21	ability	ability	I-NP	NN	O	19	PMOD
22	to	to	B-VP	TO	O	24	VMOD
23	negatively	negatively	I-VP	RB	O	24	VMOD
24	affect	affect	I-VP	VB	O	21	NMOD
25	renal	renal	B-NP	JJ	O	26	NMOD
26	function	function	I-NP	NN	O	24	OBJ
27	,	,	O	,	O	15	P
28	augment	augment	B-NP	NN	O	30	NMOD
29	serum	serum	I-NP	NN	O	30	NMOD
30	levels	level	I-NP	NNS	O	15	VMOD
31	of	of	B-PP	IN	O	30	NMOD
32	creatinine	creatinine	B-NP	NN	O	34	NMOD
33	and	and	I-NP	CC	O	34	NMOD
34	urea	urea	I-NP	NN	O	31	PMOD
35	,	,	O	,	O	15	P
36	increase	increase	B-VP	VBP	O	15	VMOD
37	the	the	B-NP	DT	O	41	NMOD
38	acute	acute	I-NP	JJ	O	41	NMOD
39	tubular	tubular	I-NP	JJ	O	41	NMOD
40	necrosis	necrosis	I-NP	NN	O	41	NMOD
41	score	score	I-NP	NN	O	36	OBJ
42	and	and	O	CC	O	44	NMOD
43	up-regulate	up-regulate	B-NP	JJ	O	44	NMOD
44	cytokines	cytokine	I-NP	NNS	B-protein	41	NMOD
45	(	(	O	(	O	51	DEP
46	e.g.	e.g.	B-NP	FW	O	50	NMOD
47	,	,	O	,	O	50	P
48	IL-1b	IL-1b	B-NP	NN	B-protein	50	NMOD
49	and	and	O	CC	O	50	NMOD
50	TNF-a	TNF-a	B-NP	NN	B-protein	51	DEP
51	)	)	O	)	O	41	NMOD
52	.	.	O	.	O	14	P

1	To	To	B-VP	TO	O	2	VMOD
2	examine	examine	I-VP	VB	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	role	role	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	9	NMOD
7	kinin	kinin	I-NP	NN	B-protein	9	NMOD
8	B2	B2	I-NP	NN	I-protein	9	NMOD
9	receptor	receptor	I-NP	NN	I-protein	5	PMOD
10	in	in	B-PP	IN	O	4	NMOD
11	cisplatin	cisplatin	B-NP	NN	B-protein	10	PMOD
12	induced	induce	B-VP	VBD	O	21	NMOD
13	acute	acute	B-NP	JJ	O	15	NMOD
14	kidney	kidney	I-NP	NN	O	15	NMOD
15	injury	injury	I-NP	NN	O	21	NMOD
16	,	,	O	,	O	21	P
17	kinin	kinin	B-NP	NN	O	21	NMOD
18	B2	B2	I-NP	NN	O	21	NMOD
19	receptor	receptor	I-NP	NN	O	21	NMOD
20	knockout	knockout	I-NP	NN	O	21	NMOD
21	mice	mouse	I-NP	NNS	O	22	SUB
22	were	be	B-VP	VBD	O	4	NMOD
23	challenged	challenge	I-VP	VBN	O	22	VC
24	with	with	B-PP	IN	O	23	VMOD
25	cisplatin	cisplatin	B-NP	NN	O	24	PMOD
26	.	.	O	.	O	2	P

1	Thus	Thus	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	our	our	B-NP	PRP$	O	4	NMOD
4	data	datum	I-NP	NNS	O	5	SUB
5	suggest	suggest	B-VP	VBP	O	0	ROOT
6	that	that	B-SBAR	IN	O	5	VMOD
7	the	the	B-NP	DT	O	10	NMOD
8	kinin	kinin	I-NP	NN	B-protein	10	NMOD
9	B2	B2	I-NP	NN	I-protein	10	NMOD
10	receptor	receptor	I-NP	NN	I-protein	11	SUB
11	is	be	B-VP	VBZ	O	6	SBAR
12	involved	involve	I-VP	VBN	O	11	VC
13	in	in	B-PP	IN	O	12	VMOD
14	cisplatin	cisplatin	B-NP	NN	B-protein	18	NMOD
15	induced	induce	B-VP	VBD	O	14	AMOD
16	acute	acute	B-NP	JJ	O	18	NMOD
17	kidney	kidney	I-NP	NN	O	18	NMOD
18	injury	injury	I-NP	NN	O	13	PMOD
19	by	by	B-PP	IN	O	12	VMOD
20	mediating	mediate	B-VP	VBG	O	19	PMOD
21	the	the	B-NP	DT	O	23	NMOD
22	necrotic	necrotic	I-NP	JJ	O	23	NMOD
23	process	process	I-NP	NN	O	26	NMOD
24	and	and	O	CC	O	26	NMOD
25	the	the	B-NP	DT	O	26	NMOD
26	expression	expression	I-NP	NN	O	20	OBJ
27	of	of	B-PP	IN	O	26	NMOD
28	inflammatory	inflammatory	B-NP	JJ	B-protein	29	NMOD
29	cytokines	cytokine	I-NP	NNS	I-protein	27	PMOD
30	,	,	O	,	O	20	P
31	thus	thus	B-ADVP	RB	O	32	VMOD
32	resulting	result	B-VP	VBG	O	20	VMOD
33	in	in	B-PP	IN	O	32	VMOD
34	declined	decline	B-NP	VBN	O	36	NMOD
35	renal	renal	I-NP	JJ	O	36	NMOD
36	function	function	I-NP	NN	O	33	PMOD
37	.	.	O	.	O	5	P

1	Safety	Safety	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	efficacy	efficacy	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	fluocinolone	fluocinolone	B-NP	NN	O	8	NMOD
6	acetonide	acetonide	I-NP	NN	O	8	NMOD
7	intravitreal	intravitreal	I-NP	JJ	O	8	NMOD
8	implant	implant	I-NP	NN	O	4	PMOD
9	(	(	O	(	O	12	DEP
10	0.59	0.59	B-NP	CD	O	11	NMOD
11	mg	mg	I-NP	NN	O	12	DEP
12	)	)	O	)	O	8	NMOD
13	in	in	B-PP	IN	O	3	NMOD
14	birdshot	birdshot	B-NP	NN	O	15	NMOD
15	retinochoroidopathy	retinochoroidopathy	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	3	P

1	PURPOSE	PURPOSE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	report	report	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	7	NMOD
6	treatment	treatment	I-NP	NN	O	7	NMOD
7	outcomes	outcome	I-NP	NNS	O	4	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	13	NMOD
10	fluocinolone	fluocinolone	I-NP	NN	O	13	NMOD
11	acetonide	acetonide	I-NP	NN	O	13	NMOD
12	intravitreal	intravitreal	I-NP	JJ	O	13	NMOD
13	implant	implant	I-NP	NN	O	8	PMOD
14	(	(	O	(	O	17	DEP
15	0.59	0.59	B-NP	CD	O	16	NMOD
16	mg	mg	I-NP	NN	O	17	DEP
17	)	)	O	)	O	13	NMOD
18	in	in	B-PP	IN	O	7	NMOD
19	patients	patient	B-NP	NNS	O	18	PMOD
20	with	with	B-PP	IN	O	19	NMOD
21	birdshot	birdshot	B-NP	NN	O	22	NMOD
22	retinochoroidopathy	retinochoroidopathy	I-NP	NN	O	24	NMOD
23	whose	whose	B-NP	WP$	O	24	NMOD
24	disease	disease	I-NP	NN	O	20	PMOD
25	is	be	B-VP	VBZ	O	4	VMOD
26	refractory	refractory	B-ADJP	JJ	O	28	AMOD
27	or	or	I-ADJP	CC	O	28	AMOD
28	intolerant	intolerant	I-ADJP	JJ	O	25	PRD
29	to	to	B-PP	TO	O	28	AMOD
30	conventional	conventional	B-NP	JJ	O	32	NMOD
31	immunomodulatory	immunomodulatory	I-NP	JJ	O	32	NMOD
32	therapy	therapy	I-NP	NN	O	29	PMOD
33	.	.	O	.	O	4	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	data	datum	I-NP	NNS	O	5	SUB
5	suggest	suggest	B-VP	VBP	O	1	NMOD
6	that	that	B-SBAR	IN	O	5	VMOD
7	fluocinolone	fluocinolone	B-NP	NN	O	9	NMOD
8	acetonide	acetonide	I-NP	NN	O	9	NMOD
9	implant	implant	I-NP	NN	O	14	SUB
10	(	(	O	(	O	13	DEP
11	0.59	0.59	B-NP	CD	O	12	NMOD
12	mg	mg	I-NP	NN	O	13	DEP
13	)	)	O	)	O	9	NMOD
14	helps	help	B-VP	VBZ	O	6	SBAR
15	to	to	I-VP	TO	O	16	VMOD
16	control	control	I-VP	VB	O	14	VMOD
17	inflammation	inflammation	B-NP	NN	O	16	OBJ
18	in	in	B-PP	IN	O	16	VMOD
19	otherwise	otherwise	B-NP	RB	O	20	AMOD
20	treatment-refractory	treatment-refractory	I-NP	JJ	O	21	NMOD
21	cases	case	I-NP	NNS	O	18	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	birdshot	birdshot	B-NP	NN	O	24	NMOD
24	retinochoroidopathy	retinochoroidopathy	I-NP	NN	O	22	PMOD
25	.	.	O	.	O	1	P

1	Optimal	Optimal	B-NP	JJ	O	3	NMOD
2	precurarizing	precurarize	I-NP	VBG	O	3	NMOD
3	dose	dose	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	rocuronium	rocuronium	B-NP	NN	O	4	PMOD
6	to	to	B-VP	TO	O	7	VMOD
7	decrease	decrease	I-VP	VB	O	3	NMOD
8	fasciculation	fasciculation	B-NP	NN	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	myalgia	myalgia	I-NP	NN	O	7	OBJ
11	following	follow	B-PP	VBG	O	7	VMOD
12	succinylcholine	succinylcholine	B-NP	NN	O	13	NMOD
13	administration	administration	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	3	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Succinylcholine	Succinylcholine	B-NP	NN	O	1	NMOD
4	commonly	commonly	B-ADVP	RB	O	5	VMOD
5	produces	produce	B-VP	VBZ	O	3	SBAR
6	frequent	frequent	B-NP	JJ	O	8	NMOD
7	adverse	adverse	I-NP	JJ	O	8	NMOD
8	effects	effect	I-NP	NNS	O	5	OBJ
9	,	,	O	,	O	8	P
10	including	include	B-PP	VBG	O	8	NMOD
11	muscle	muscle	B-NP	NN	O	12	NMOD
12	fasciculation	fasciculation	I-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	myalgia	myalgia	I-NP	NN	O	10	PMOD
15	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	3	NMOD
2	current	current	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	identified	identify	B-VP	VBD	O	0	ROOT
5	the	the	B-NP	DT	O	7	NMOD
6	optimal	optimal	I-NP	JJ	O	7	NMOD
7	dose	dose	I-NP	NN	O	4	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	rocuronium	rocuronium	B-NP	NN	O	8	PMOD
10	to	to	B-VP	TO	O	11	VMOD
11	prevent	prevent	I-VP	VB	O	7	NMOD
12	succinylcholine	succinylcholine	B-NP	NN	O	14	NMOD
13	induced	induced	I-NP	JJ	O	14	NMOD
14	fasciculation	fasciculation	I-NP	NN	O	11	OBJ
15	and	and	I-NP	CC	O	11	VMOD
16	myalgia	myalgia	I-NP	NN	O	11	OBJ
17	and	and	O	CC	O	4	VMOD
18	evaluated	evaluate	B-VP	VBD	O	4	VMOD
19	the	the	B-NP	DT	O	20	NMOD
20	influence	influence	I-NP	NN	O	18	OBJ
21	of	of	B-PP	IN	O	20	NMOD
22	rocuronium	rocuronium	B-NP	NN	O	21	PMOD
23	on	on	B-PP	IN	O	20	NMOD
24	the	the	B-NP	DT	O	25	NMOD
25	speed	speed	I-NP	NN	O	23	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	onset	onset	B-NP	NN	O	26	PMOD
28	produced	produce	B-VP	VBN	O	27	NMOD
29	by	by	B-PP	IN	O	28	VMOD
30	succinylcholine	succinylcholine	B-NP	NN	O	29	PMOD
31	.	.	O	.	O	4	P

1	All	All	B-NP	DT	O	2	NMOD
2	patients	patient	I-NP	NNS	O	3	SUB
3	received	receive	B-VP	VBD	O	0	ROOT
4	succinylcholine	succinylcholine	B-NP	NN	O	6	NMOD
5	1.5	1.5	I-NP	CD	O	6	NMOD
6	mg/kg	mg/kg	I-NP	NN	O	3	OBJ
7	at	at	B-PP	IN	O	3	VMOD
8	2	2	B-NP	CD	O	9	NMOD
9	minutes	minute	I-NP	NNS	O	7	PMOD
10	after	after	B-PP	IN	O	3	VMOD
11	the	the	B-NP	DT	O	12	NMOD
12	precurarization	precurarization	I-NP	NN	O	10	PMOD
13	,	,	O	,	O	3	P
14	and	and	O	CC	O	3	VMOD
15	were	be	B-VP	VBD	O	3	VMOD
16	assessed	assess	I-VP	VBN	O	15	VC
17	the	the	B-NP	DT	O	20	NMOD
18	incidence	incidence	I-NP	NN	O	20	NMOD
19	and	and	I-NP	CC	O	20	NMOD
20	severity	severity	I-NP	NN	O	16	OBJ
21	of	of	B-PP	IN	O	20	NMOD
22	fasciculations	fasciculation	B-NP	NNS	O	21	PMOD
23	,	,	O	,	O	3	P
24	while	while	B-SBAR	IN	O	3	VMOD
25	myalgia	myalgia	B-NP	NN	O	26	SUB
26	was	be	B-VP	VBD	O	24	SBAR
27	assessed	assess	I-VP	VBN	O	26	VC
28	at	at	B-PP	IN	O	27	VMOD
29	24	24	B-NP	CD	O	30	NMOD
30	hours	hour	I-NP	NNS	O	28	PMOD
31	after	after	B-PP	IN	O	30	NMOD
32	surgery	surgery	B-NP	NN	O	31	PMOD
33	.	.	O	.	O	3	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	6	NMOD
4	incidence	incidence	I-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	severity	severity	I-NP	NN	O	11	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	visible	visible	B-NP	JJ	O	10	NMOD
9	muscle	muscle	I-NP	NN	O	10	NMOD
10	fasciculation	fasciculation	I-NP	NN	O	7	PMOD
11	was	be	B-VP	VBD	O	1	NMOD
12	significantly	significantly	B-ADJP	RB	O	13	AMOD
13	less	less	I-ADJP	JJR	O	11	PRD
14	with	with	B-PP	IN	O	13	AMOD
15	increasing	increase	B-VP	VBG	O	14	PMOD
16	the	the	B-NP	DT	O	17	NMOD
17	amount	amount	I-NP	NN	O	15	OBJ
18	of	of	B-PP	IN	O	17	NMOD
19	precurarizing	precurarize	B-VP	VBG	O	18	PMOD
20	dose	dose	B-NP	NN	O	19	OBJ
21	of	of	B-PP	IN	O	20	NMOD
22	rocuronium	rocuronium	B-NP	NN	O	21	PMOD
23	(	(	O	(	O	27	DEP
24	P	P	B-NP	NN	O	26	SUB
25	<	<	O	SYM	O	26	VMOD
26	0.001	0.001	B-NP	CD	O	27	DEP
27	)	)	O	)	O	13	AMOD
28	.	.	O	.	O	11	P

1	Those	Those	B-NP	DT	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	myalgia	myalgia	B-NP	NN	O	2	PMOD
4	tend	tend	B-VP	VBP	O	20	VMOD
5	to	to	I-VP	TO	O	6	VMOD
6	decrease	decrease	I-VP	VB	O	4	VMOD
7	according	accord	B-PP	VBG	O	6	VMOD
8	to	to	B-PP	TO	O	7	PMOD
9	increasing	increase	B-VP	VBG	O	8	PMOD
10	the	the	B-NP	DT	O	11	NMOD
11	amount	amount	I-NP	NN	O	9	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	precurarizing	precurarize	B-VP	VBG	O	12	PMOD
14	dose	dose	B-NP	NN	O	13	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	rocuronium	rocuronium	B-NP	NN	O	15	PMOD
17	,	,	O	,	O	20	P
18	but	but	O	CC	O	20	VMOD
19	there	there	B-NP	EX	O	20	SUB
20	was	be	B-VP	VBD	O	0	ROOT
21	no	no	B-NP	DT	O	22	NMOD
22	significance	significance	I-NP	NN	O	20	PRD
23	(	(	O	(	O	27	DEP
24	P	P	B-NP	NN	O	27	DEP
25	=	=	B-VP	SYM	O	24	NMOD
26	0.072	0.072	B-NP	CD	O	25	AMOD
27	)	)	O	)	O	20	VMOD
28	.	.	O	.	O	20	P

1	Absence	Absence	B-NP	NN	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	PKC-alpha	PKC-alpha	B-NP	NN	B-protein	2	PMOD
4	attenuates	attenuate	B-VP	VBZ	O	0	ROOT
5	lithium	lithium	B-NP	NN	O	9	NMOD
6	induced	induced	I-NP	JJ	O	9	NMOD
7	nephrogenic	nephrogenic	I-NP	JJ	O	9	NMOD
8	diabetes	diabetes	I-NP	NN	O	9	NMOD
9	insipidus	insipidus	I-NP	NN	O	4	OBJ
10	.	.	O	.	O	4	P

1	Lithium	Lithium	B-NP	NN	O	0	ROOT
2	,	,	O	,	O	3	P
3	an	an	B-NP	DT	O	1	NMOD
4	effective	effective	I-NP	JJ	O	5	AMOD
5	antipsychotic	antipsychotic	I-NP	JJ	O	7	SUB
6	,	,	O	,	O	5	P
7	induces	induce	B-VP	VBZ	O	3	SBAR
8	nephrogenic	nephrogenic	B-NP	JJ	O	10	NMOD
9	diabetes	diabetes	I-NP	NN	O	10	NMOD
10	insipidus	insipidus	I-NP	NN	O	7	OBJ
11	(	(	O	(	O	13	DEP
12	NDI	NDI	B-NP	NN	B-protein	13	DEP
13	)	)	O	)	O	10	NMOD
14	in	in	B-PP	IN	O	7	VMOD
15	40	40	B-NP	CD	O	16	NMOD
16	%	%	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	patients	patient	B-NP	NNS	O	17	PMOD
19	.	.	O	.	O	3	P

1	Targeting	Target	B-VP	VBG	O	12	VMOD
2	an	an	B-NP	DT	O	5	NMOD
3	alternative	alternative	I-NP	JJ	O	5	NMOD
4	signaling	signaling	I-NP	NN	O	5	NMOD
5	pathway	pathway	I-NP	NN	O	1	OBJ
6	,	,	O	,	O	1	P
7	such	such	B-PP	JJ	O	8	PMOD
8	as	as	I-PP	IN	O	1	VMOD
9	PKC-mediated	PKC-mediated	B-NP	JJ	O	10	NMOD
10	signaling	signaling	I-NP	NN	O	8	PMOD
11	,	,	O	,	O	12	P
12	may	may	B-VP	MD	O	0	ROOT
13	be	be	I-VP	VB	O	12	VC
14	an	an	B-NP	DT	O	16	NMOD
15	effective	effective	I-NP	JJ	O	16	NMOD
16	method	method	I-NP	NN	O	13	PRD
17	of	of	B-PP	IN	O	16	NMOD
18	treating	treat	B-VP	VBG	O	17	PMOD
19	lithium	lithium	B-NP	NN	O	21	NMOD
20	induced	induced	I-NP	JJ	O	21	NMOD
21	polyuria	polyuria	I-NP	NN	O	18	OBJ
22	.	.	O	.	O	12	P

1	Is	Be	O	VBZ	O	0	ROOT
2	Dysguesia	Dysguesia	B-NP	NNP	O	3	NMOD
3	Going	Going	I-NP	NNP	O	1	SUB
4	to	to	B-VP	TO	O	5	VMOD
5	be	be	I-VP	VB	O	3	VMOD
6	a	a	B-NP	DT	O	7	NMOD
7	Rare	Rare	I-NP	NN	B-DNA	11	NMOD
8	or	or	O	CC	O	11	NMOD
9	a	a	B-NP	DT	O	11	NMOD
10	Common	Common	I-NP	JJ	O	11	NMOD
11	Side-effect	Side-effect	I-NP	NN	O	5	PRD
12	of	of	B-PP	IN	O	11	NMOD
13	Amlodipine	Amlodipine	B-NP	NN	O	12	PMOD
14	.	.	O	.	O	1	P

1	A	A	B-NP	DT	O	4	NMOD
2	very	very	I-NP	RB	O	3	AMOD
3	rare	rare	I-NP	JJ	O	4	NMOD
4	side-effect	side-effect	I-NP	NN	O	7	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	amlodipine	amlodipine	B-NP	NN	O	5	PMOD
7	is	be	B-VP	VBZ	O	0	ROOT
8	dysguesia	dysguesia	B-NP	NN	O	7	PRD
9	.	.	O	.	O	7	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	16	SUB
5	about	about	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	7	NMOD
7	female	female	I-NP	NN	O	5	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	essential	essential	B-NP	JJ	O	10	NMOD
10	hypertension	hypertension	I-NP	NN	O	8	PMOD
11	on	on	B-PP	IN	O	10	NMOD
12	drug	drug	B-NP	NN	O	13	NMOD
13	treatment	treatment	I-NP	NN	O	11	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	amlodipine	amlodipine	B-NP	NN	O	14	PMOD
16	developed	develop	B-VP	VBD	O	2	VMOD
17	loss	loss	B-NP	NN	O	16	OBJ
18	of	of	B-PP	IN	O	17	NMOD
19	taste	taste	B-NP	NN	O	20	NMOD
20	sensation	sensation	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	conclude	conclude	B-VP	VBP	O	0	ROOT
3	that	that	B-SBAR	IN	O	2	VMOD
4	amlodipine	amlodipine	B-NP	NN	O	5	SUB
5	can	can	B-VP	MD	O	3	SBAR
6	cause	cause	I-VP	VB	O	5	VC
7	dysguesia	dysguesia	B-NP	NN	O	6	OBJ
8	.	.	O	.	O	2	P

1	Rhabdomyolysis	Rhabdomyolysis	B-NP	NN	O	0	ROOT
2	in	in	B-PP	IN	O	1	NMOD
3	association	association	B-NP	NN	O	2	PMOD
4	with	with	B-PP	IN	O	3	NMOD
5	simvastatin	simvastatin	B-NP	NN	O	8	NMOD
6	and	and	I-NP	CC	O	8	NMOD
7	dosage	dosage	I-NP	NN	O	8	NMOD
8	increment	increment	I-NP	NN	O	4	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	clarithromycin	clarithromycin	B-NP	NN	O	9	PMOD
11	.	.	O	.	O	1	P

1	This	This	B-NP	DT	O	3	NMOD
2	particular	particular	I-NP	JJ	O	3	NMOD
3	case	case	I-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	of	of	B-PP	IN	O	4	PRD
6	interest	interest	B-NP	NN	O	5	PMOD
7	as	as	B-PP	IN	O	4	VMOD
8	rhabdomyolysis	rhabdomyolysis	B-NP	NN	O	7	PMOD
9	only	only	B-ADVP	RB	O	4	VMOD
10	occurred	occur	B-VP	VBD	O	4	VMOD
11	after	after	B-PP	IN	O	10	VMOD
12	an	an	B-NP	DT	O	13	NMOD
13	increase	increase	I-NP	NN	O	11	PMOD
14	in	in	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	dose	dose	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	clarithromycin	clarithromycin	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	4	P

1	Val204Asp	Val204Asp	B-NP	NN	O	3	SUB
2	)	)	O	)	O	1	NMOD
3	causes	cause	B-VP	VBZ	O	0	ROOT
4	loss	loss	B-NP	NN	O	3	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	activity	activity	B-NP	NN	O	9	NMOD
7	and	and	O	CC	O	9	NMOD
8	prolonged	prolonged	B-NP	JJ	O	9	NMOD
9	apnea	apnea	I-NP	NN	O	5	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	suxamethonium	suxamethonium	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	3	P

1	Butyrylcholinesterase	Butyrylcholinesterase	B-NP	NN	O	2	NMOD
2	deficiency	deficiency	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	characterized	characterize	I-VP	VBN	O	3	VC
5	by	by	B-PP	IN	O	4	VMOD
6	prolonged	prolong	B-NP	VBN	O	7	NMOD
7	apnea	apnea	I-NP	NN	O	5	PMOD
8	after	after	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	use	use	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	muscle	muscle	B-NP	NN	O	13	NMOD
13	relaxants	relaxant	I-NP	NNS	O	11	PMOD
14	(	(	O	(	O	18	DEP
15	suxamethonium	suxamethonium	B-NP	NN	O	17	NMOD
16	or	or	O	CC	O	17	NMOD
17	mivacurium	mivacurium	B-NP	NN	O	18	DEP
18	)	)	O	)	O	7	NMOD
19	in	in	B-PP	IN	O	7	NMOD
20	patients	patient	B-NP	NNS	O	19	PMOD
21	who	who	B-NP	WP	O	20	NMOD
22	have	have	B-VP	VBP	O	21	SBAR
23	mutations	mutation	B-NP	NNS	O	22	OBJ
24	in	in	B-PP	IN	O	22	VMOD
25	the	the	B-NP	DT	O	27	NMOD
26	BCHE	BCHE	I-NP	NN	B-DNA	27	NMOD
27	gene	gene	I-NP	NN	I-DNA	24	PMOD
28	.	.	O	.	O	3	P

1	Delayed	Delay	B-NP	VBN	O	2	NMOD
2	anemia	anemia	I-NP	NN	O	18	NMOD
3	after	after	B-PP	IN	O	2	NMOD
4	treatment	treatment	B-NP	NN	O	3	PMOD
5	with	with	B-PP	IN	O	4	NMOD
6	injectable	injectable	B-NP	JJ	O	7	NMOD
7	artesunate	artesunate	I-NP	NN	O	5	PMOD
8	in	in	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	11	NMOD
10	Democratic	Democratic	I-NP	JJ	O	11	NMOD
11	Republic	Republic	I-NP	NNP	O	8	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	Congo	Congo	I-NP	NNP	O	12	PMOD
15	:	:	O	:	O	2	P
16	a	a	B-NP	DT	O	18	NMOD
17	manageable	manageable	I-NP	JJ	O	18	NMOD
18	issue	issue	I-NP	NN	O	0	ROOT
19	.	.	O	.	O	18	P

1	Cases	Case	B-NP	NNS	O	6	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	delayed	delay	B-NP	VBN	O	5	NMOD
4	hemolytic	hemolytic	I-NP	JJ	O	5	NMOD
5	anemia	anemia	I-NP	NN	O	2	PMOD
6	have	have	B-VP	VBP	O	0	ROOT
7	been	be	I-VP	VBN	O	6	VC
8	described	describe	I-VP	VBN	O	7	VC
9	after	after	B-PP	IN	O	8	VMOD
10	treatment	treatment	B-NP	NN	O	9	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	injectable	injectable	B-NP	JJ	O	13	NMOD
13	artesunate	artesunate	I-NP	NN	O	11	PMOD
14	,	,	O	,	O	6	P
15	the	the	B-NP	DT	O	19	NMOD
16	current	current	I-NP	JJ	O	19	NMOD
17	World	World	I-NP	NNP	O	19	NMOD
18	Health	Health	I-NP	NNP	O	19	NMOD
19	Organization	Organization	I-NP	NNP	O	25	NMOD
20	(	(	O	(	O	22	DEP
21	WHO	WHO	B-NP	WP	O	22	DEP
22	)	)	O	)	O	19	NMOD
23	-recommended	-recommended	B-NP	JJ	O	24	AMOD
24	first-line	first-line	I-NP	JJ	O	25	NMOD
25	drug	drug	I-NP	NN	O	6	OBJ
26	for	for	B-PP	IN	O	25	NMOD
27	the	the	B-NP	DT	O	28	NMOD
28	treatment	treatment	I-NP	NN	O	26	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	severe	severe	B-NP	JJ	O	31	NMOD
31	malaria	malaria	I-NP	NN	O	29	PMOD
32	.	.	O	.	O	6	P

1	A	A	B-NP	DT	O	2	NMOD
2	total	total	I-NP	NN	O	29	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	350	350	B-NP	CD	O	5	NMOD
5	patients	patient	I-NP	NNS	O	14	NMOD
6	(	(	O	(	O	11	DEP
7	215	215	B-NP	CD	O	11	DEP
8	[	[	O	(	O	11	DEP
9	61.4	61.4	B-NP	CD	O	10	NMOD
10	%	%	I-NP	NN	O	11	DEP
11	]	]	O	)	O	5	NMOD
12	<	<	O	SYM	O	14	NMOD
13	5	5	B-NP	CD	O	14	NMOD
14	years	year	I-NP	NNS	O	3	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	age	age	B-NP	NN	O	18	NMOD
17	and	and	O	CC	O	18	NMOD
18	135	135	B-NP	CD	O	24	AMOD
19	[	[	O	(	O	22	DEP
20	38.6	38.6	B-NP	CD	O	21	NMOD
21	%	%	I-NP	NN	O	22	DEP
22	]	]	O	)	O	18	NMOD
23	>	>	O	SYM	O	24	AMOD
24	5	5	B-NP	CD	O	25	NMOD
25	years	year	I-NP	NNS	O	15	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	age	age	B-NP	NN	O	26	PMOD
28	)	)	O	)	O	2	NMOD
29	were	be	B-VP	VBD	O	0	ROOT
30	followed-up	followed-up	B-ADJP	JJ	O	29	PRD
31	after	after	B-PP	IN	O	29	VMOD
32	treatment	treatment	B-NP	NN	O	31	PMOD
33	with	with	B-PP	IN	O	32	NMOD
34	injectable	injectable	B-NP	JJ	O	35	NMOD
35	artesunate	artesunate	I-NP	NN	O	33	PMOD
36	for	for	B-PP	IN	O	35	NMOD
37	severe	severe	B-NP	JJ	O	38	NMOD
38	malaria	malaria	I-NP	NN	O	36	PMOD
39	in	in	B-PP	IN	O	38	NMOD
40	hospitals	hospital	B-NP	NNS	O	43	NMOD
41	and	and	I-NP	CC	O	43	NMOD
42	health	health	I-NP	NN	O	43	NMOD
43	centers	center	I-NP	NNS	O	39	PMOD
44	of	of	B-PP	IN	O	43	NMOD
45	the	the	B-NP	DT	O	47	NMOD
46	Democratic	Democratic	I-NP	JJ	O	47	NMOD
47	Republic	Republic	I-NP	NNP	O	44	PMOD
48	of	of	B-PP	IN	O	47	NMOD
49	the	the	B-NP	DT	O	50	NMOD
50	Congo	Congo	I-NP	NNP	O	48	PMOD
51	.	.	O	.	O	29	P

1	Regulation	Regulation	B-NP	NN	O	15	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	signal	signal	B-NP	NN	B-protein	8	NMOD
4	transducer	transducer	I-NP	NN	I-protein	8	NMOD
5	and	and	I-NP	CC	I-protein	8	NMOD
6	activator	activator	I-NP	NN	I-protein	8	NMOD
7	of	of	B-PP	IN	I-protein	8	NMOD
8	transcription	transcription	B-NP	NN	I-protein	12	NMOD
9	3	3	I-NP	CD	I-protein	8	NMOD
10	and	and	O	CC	O	12	NMOD
11	apoptotic	apoptotic	B-NP	JJ	O	12	NMOD
12	pathways	pathway	I-NP	NNS	O	2	PMOD
13	by	by	B-PP	IN	O	1	NMOD
14	betaine	betaine	B-NP	NN	O	13	PMOD
15	attenuates	attenuate	B-VP	VBZ	O	0	ROOT
16	isoproterenol	isoproterenol	B-NP	NN	O	20	NMOD
17	induced	induce	B-VP	VBD	O	20	VMOD
18	acute	acute	B-NP	JJ	O	20	NMOD
19	myocardial	myocardial	I-NP	JJ	O	20	NMOD
20	injury	injury	I-NP	NN	O	15	OBJ
21	in	in	B-PP	IN	O	20	NMOD
22	rats	rat	B-NP	NNS	O	21	PMOD
23	.	.	O	.	O	15	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	designed	design	I-VP	VBN	O	4	VC
6	to	to	B-VP	TO	O	7	VMOD
7	investigate	investigate	I-VP	VB	O	4	VMOD
8	the	the	B-NP	DT	O	10	NMOD
9	cardioprotective	cardioprotective	I-NP	JJ	O	10	NMOD
10	effects	effect	I-NP	NNS	O	7	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	betaine	betaine	B-NP	NN	O	11	PMOD
13	on	on	B-PP	IN	O	10	NMOD
14	acute	acute	B-NP	JJ	O	16	NMOD
15	myocardial	myocardial	I-NP	JJ	O	16	NMOD
16	ischemia	ischemia	I-NP	NN	O	13	PMOD
17	induced	induce	B-VP	VBN	O	16	NMOD
18	experimentally	experimentally	B-ADVP	RB	O	17	VMOD
19	in	in	B-PP	IN	O	17	VMOD
20	rats	rat	B-NP	NNS	O	19	PMOD
21	focusing	focus	B-VP	VBG	O	20	NMOD
22	on	on	B-PP	IN	O	21	VMOD
23	regulation	regulation	B-NP	NN	O	37	NMOD
24	of	of	B-PP	IN	O	23	NMOD
25	signal	signal	B-NP	NN	B-protein	30	NMOD
26	transducer	transducer	I-NP	NN	I-protein	30	NMOD
27	and	and	I-NP	CC	I-protein	30	NMOD
28	activator	activator	I-NP	NN	I-protein	30	NMOD
29	of	of	B-PP	IN	I-protein	30	NMOD
30	transcription	transcription	B-NP	NN	I-protein	24	PMOD
31	3	3	I-NP	CD	I-protein	30	NMOD
32	(	(	O	(	O	34	DEP
33	STAT3	STAT3	B-NP	NN	B-protein	34	DEP
34	)	)	O	)	O	30	NMOD
35	and	and	O	CC	O	37	NMOD
36	apoptotic	apoptotic	B-NP	JJ	O	37	NMOD
37	pathways	pathway	I-NP	NNS	O	22	PMOD
38	as	as	B-PP	IN	O	37	NMOD
39	the	the	B-NP	DT	O	41	NMOD
40	potential	potential	I-NP	JJ	O	41	NMOD
41	mechanism	mechanism	I-NP	NN	O	38	PMOD
42	underlying	underlie	B-VP	VBG	O	41	NMOD
43	the	the	B-NP	DT	O	45	NMOD
44	drug	drug	I-NP	NN	O	45	NMOD
45	effect	effect	I-NP	NN	O	42	OBJ
46	.	.	O	.	O	4	P

1	Acute	Acute	B-NP	JJ	O	4	NMOD
2	myocardial	myocardial	I-NP	JJ	O	4	NMOD
3	ischemic	ischemic	I-NP	JJ	O	4	NMOD
4	injury	injury	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	0	ROOT
6	induced	induce	I-VP	VBN	O	5	VC
7	in	in	B-PP	IN	O	6	VMOD
8	rats	rat	B-NP	NNS	O	7	PMOD
9	by	by	B-PP	IN	O	6	VMOD
10	subcutaneous	subcutaneous	B-NP	JJ	O	11	NMOD
11	injection	injection	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	isoproterenol	isoproterenol	B-NP	NN	O	12	PMOD
14	(	(	O	(	O	17	DEP
15	85	85	B-NP	CD	O	16	NMOD
16	mg/kg	mg/kg	I-NP	NN	O	17	DEP
17	)	)	O	)	O	13	NMOD
18	,	,	O	,	O	9	P
19	for	for	B-PP	IN	O	9	PMOD
20	two	two	B-NP	CD	O	22	NMOD
21	consecutive	consecutive	I-NP	JJ	O	22	NMOD
22	days	day	I-NP	NNS	O	19	PMOD
23	.	.	O	.	O	5	P

1	Oral	Oral	B-NP	JJ	O	2	NMOD
2	administration	administration	I-NP	NN	O	12	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	betaine	betaine	B-NP	NN	O	3	PMOD
5	(	(	O	(	O	10	DEP
6	200	200	B-NP	CD	O	8	AMOD
7	and	and	I-NP	CC	O	8	AMOD
8	400	400	I-NP	CD	O	9	NMOD
9	mg/kg	mg/kg	I-NP	NN	O	10	DEP
10	)	)	O	)	O	2	NMOD
11	significantly	significantly	B-ADVP	RB	O	12	VMOD
12	reduced	reduce	B-VP	VBD	O	0	ROOT
13	the	the	B-NP	DT	O	14	NMOD
14	level	level	I-NP	NN	O	12	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	cardiac	cardiac	B-NP	JJ	B-protein	18	NMOD
17	marker	marker	I-NP	NN	I-protein	18	NMOD
18	enzyme	enzyme	I-NP	NN	I-protein	15	PMOD
19	in	in	B-PP	IN	O	12	VMOD
20	the	the	B-NP	DT	O	21	NMOD
21	serum	serum	I-NP	NN	O	19	PMOD
22	and	and	O	CC	O	12	VMOD
23	prevented	prevent	B-VP	VBD	O	12	VMOD
24	left	left	B-NP	JJ	O	26	NMOD
25	ventricular	ventricular	I-NP	JJ	O	26	NMOD
26	remodeling	remodeling	I-NP	NN	O	23	OBJ
27	.	.	O	.	O	12	P

1	The	The	B-NP	DT	O	3	NMOD
2	protective	protective	I-NP	JJ	O	3	NMOD
3	role	role	I-NP	NN	O	9	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	betaine	betaine	B-NP	NN	O	4	PMOD
6	on	on	B-PP	IN	O	3	NMOD
7	myocardial	myocardial	B-NP	JJ	O	8	NMOD
8	damage	damage	I-NP	NN	O	6	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	further	further	I-VP	RBR	O	11	VMOD
11	confirmed	confirm	I-VP	VBN	O	9	VC
12	by	by	B-PP	IN	O	11	VMOD
13	histopathological	histopathological	B-NP	JJ	O	14	NMOD
14	examination	examination	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	9	P

1	Quetiapine	Quetiapine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	neutropenia	neutropenia	B-NP	NN	O	2	OBJ
4	in	in	B-PP	IN	O	2	VMOD
5	a	a	B-NP	DT	O	7	NMOD
6	bipolar	bipolar	I-NP	JJ	O	7	NMOD
7	patient	patient	I-NP	NN	O	4	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	hepatocellular	hepatocellular	B-NP	JJ	O	10	NMOD
10	carcinoma	carcinoma	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	2	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Quetiapine	Quetiapine	B-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	1	NMOD
5	a	a	B-NP	DT	O	7	NMOD
6	dibenzothiazepine	dibenzothiazepine	I-NP	NN	O	7	NMOD
7	derivative	derivative	I-NP	NN	O	4	PRD
8	,	,	O	,	O	7	P
9	similar	similar	B-ADJP	JJ	O	7	NMOD
10	to	to	B-PP	TO	O	9	AMOD
11	clozapine	clozapine	B-NP	NN	O	10	PMOD
12	,	,	O	,	O	11	P
13	which	which	B-NP	WDT	O	11	NMOD
14	has	have	B-VP	VBZ	O	13	SBAR
15	the	the	B-NP	DT	O	17	NMOD
16	highest	high	I-NP	JJS	O	17	NMOD
17	risk	risk	I-NP	NN	O	24	NMOD
18	of	of	B-PP	IN	O	17	NMOD
19	causing	cause	B-VP	VBG	O	18	PMOD
20	blood	blood	B-NP	NN	O	21	NMOD
21	dyscrasias	dyscrasia	I-NP	NNS	O	19	OBJ
22	,	,	O	,	O	24	P
23	especially	especially	B-NP	RB	O	24	NMOD
24	neutropenia	neutropenia	I-NP	NN	O	14	OBJ
25	.	.	O	.	O	1	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	16	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	a	a	B-NP	DT	O	5	NMOD
5	patient	patient	I-NP	NN	O	3	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	hepatocellular	hepatocellular	B-NP	JJ	O	8	NMOD
8	carcinoma	carcinoma	I-NP	NN	O	6	PMOD
9	that	that	B-NP	WDT	O	2	NMOD
10	developed	develop	B-VP	VBD	O	9	SBAR
11	neutropenia	neutropenia	B-NP	NN	O	10	OBJ
12	after	after	B-PP	IN	O	10	VMOD
13	treatment	treatment	B-NP	NN	O	12	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	quetiapine	quetiapine	B-NP	NN	O	14	PMOD
16	is	be	B-VP	VBZ	O	0	ROOT
17	described	describe	I-VP	VBN	O	16	VC
18	here	here	B-ADVP	RB	O	17	VMOD
19	.	.	O	.	O	16	P

1	She	She	B-NP	PRP	O	2	SUB
2	developed	develop	B-VP	VBD	O	0	ROOT
3	leucopenia	leucopenia	B-NP	NN	O	2	OBJ
4	after	after	B-PP	IN	O	2	VMOD
5	being	be	B-VP	VBG	O	4	PMOD
6	treated	treat	I-VP	VBN	O	5	VC
7	with	with	B-PP	IN	O	6	VMOD
8	quetiapine	quetiapine	B-NP	NN	O	7	PMOD
9	.	.	O	.	O	2	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Although	Although	B-SBAR	IN	O	15	VMOD
4	neutropenia	neutropenia	B-NP	NN	O	5	SUB
5	is	be	B-VP	VBZ	O	3	SBAR
6	not	not	O	RB	O	5	VMOD
7	a	a	B-NP	DT	O	10	NMOD
8	common	common	I-NP	JJ	O	10	NMOD
9	side	side	I-NP	NN	O	10	NMOD
10	effect	effect	I-NP	NN	O	5	PRD
11	of	of	B-PP	IN	O	10	NMOD
12	quetiapine	quetiapine	B-NP	NN	O	11	PMOD
13	,	,	O	,	O	15	P
14	physicians	physician	B-NP	NNS	O	15	SUB
15	should	should	B-VP	MD	O	1	NMOD
16	be	be	I-VP	VB	O	15	VC
17	cautious	cautious	B-ADJP	JJ	O	16	PRD
18	about	about	B-PP	IN	O	16	VMOD
19	its	its	B-NP	PRP$	O	24	NMOD
20	presentation	presentation	I-NP	NN	O	24	NMOD
21	and	and	I-NP	CC	O	24	NMOD
22	associated	associate	I-NP	VBN	O	24	NMOD
23	risk	risk	I-NP	NN	O	24	NMOD
24	factors	factor	I-NP	NNS	O	18	PMOD
25	.	.	O	.	O	1	P

1	Lateral	Lateral	B-NP	JJ	O	4	NMOD
2	antebrachial	antebrachial	I-NP	JJ	O	4	NMOD
3	cutaneous	cutaneous	I-NP	JJ	O	4	NMOD
4	neuropathy	neuropathy	I-NP	NN	O	0	ROOT
5	after	after	B-PP	IN	O	4	NMOD
6	steroid	steroid	B-NP	NN	O	7	NMOD
7	injection	injection	I-NP	NN	O	5	PMOD
8	at	at	B-PP	IN	O	7	NMOD
9	lateral	lateral	B-NP	JJ	O	10	NMOD
10	epicondyle	epicondyle	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	4	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	3	NMOD
2	AND	AND	I-NP	CC	O	3	NMOD
3	OBJECTIVES	OBJECTIVES	I-NP	NNS	O	0	ROOT
4	:	:	O	:	O	3	P
5	This	This	B-NP	DT	O	6	NMOD
6	report	report	I-NP	NN	O	3	OBJ
7	aimed	aim	B-VP	VBN	O	6	NMOD
8	to	to	B-VP	TO	O	9	VMOD
9	present	present	I-VP	VB	O	7	VMOD
10	a	a	B-NP	DT	O	11	NMOD
11	case	case	I-NP	NN	O	9	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	lateral	lateral	B-NP	JJ	O	16	NMOD
14	antebrachial	antebrachial	I-NP	JJ	O	16	NMOD
15	cutaneous	cutaneous	I-NP	JJ	O	16	NMOD
16	neuropathy	neuropathy	I-NP	NN	O	12	PMOD
17	(	(	O	(	O	19	DEP
18	LACNP	LACNP	B-NP	NN	B-protein	19	DEP
19	)	)	O	)	O	16	NMOD
20	that	that	B-NP	WDT	O	11	NMOD
21	occurred	occur	B-VP	VBD	O	20	SBAR
22	after	after	B-PP	IN	O	21	VMOD
23	a	a	B-NP	DT	O	25	NMOD
24	steroid	steroid	I-NP	NN	O	25	NMOD
25	injection	injection	I-NP	NN	O	22	PMOD
26	in	in	B-PP	IN	O	25	NMOD
27	the	the	B-NP	DT	O	29	NMOD
28	lateral	lateral	I-NP	JJ	O	29	NMOD
29	epicondyle	epicondyle	I-NP	NN	O	26	PMOD
30	to	to	B-VP	TO	O	31	VMOD
31	treat	treat	I-VP	VB	O	21	VMOD
32	lateral	lateral	B-NP	JJ	O	33	NMOD
33	epicondylitis	epicondylitis	I-NP	NN	O	31	OBJ
34	in	in	B-PP	IN	O	31	VMOD
35	a	a	B-NP	DT	O	37	NMOD
36	40-year-old	40-year-old	I-NP	JJ	O	37	NMOD
37	woman	woman	I-NP	NN	O	34	PMOD
38	.	.	O	.	O	3	P

1	MATERIAL	MATERIAL	B-NP	NN	O	3	NMOD
2	AND	AND	I-NP	CC	O	3	NMOD
3	METHOD	METHOD	I-NP	NN	O	8	SUB
4	:	:	O	:	O	8	P
5	A	A	B-NP	DT	O	7	NMOD
6	40-year-old	40-year-old	I-NP	JJ	O	7	NMOD
7	woman	woman	I-NP	NN	O	8	SUB
8	presented	present	B-VP	VBD	O	22	VMOD
9	with	with	B-PP	IN	O	8	VMOD
10	decreased	decrease	B-NP	VBN	O	13	NMOD
11	sensation	sensation	I-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	paresthesia	paresthesia	I-NP	NN	O	9	PMOD
14	over	over	B-PP	IN	O	8	VMOD
15	her	her	B-NP	PRP$	O	18	NMOD
16	right	right	I-NP	JJ	O	18	NMOD
17	lateral	lateral	I-NP	JJ	O	18	NMOD
18	forearm	forearm	I-NP	NN	O	14	PMOD
19	;	;	O	:	O	22	P
20	the	the	B-NP	DT	O	21	NMOD
21	paresthesia	paresthesia	I-NP	NN	O	22	SUB
22	had	have	B-VP	VBD	O	0	ROOT
23	occurred	occur	I-VP	VBN	O	22	VC
24	after	after	B-PP	IN	O	23	VMOD
25	a	a	B-NP	DT	O	27	NMOD
26	steroid	steroid	I-NP	NN	O	27	NMOD
27	injection	injection	I-NP	NN	O	24	PMOD
28	in	in	B-PP	IN	O	27	NMOD
29	the	the	B-NP	DT	O	32	NMOD
30	right	right	I-NP	JJ	O	32	NMOD
31	lateral	lateral	I-NP	JJ	O	32	NMOD
32	epicondyle	epicondyle	I-NP	NN	O	34	NMOD
33	3	3	B-NP	CD	O	32	NMOD
34	months	month	I-NP	NNS	O	28	PMOD
35	before	before	B-ADVP	RB	O	27	NMOD
36	.	.	O	.	O	22	P

1	Curcumin	Curcumin	B-NP	NN	O	2	SUB
2	prevents	prevent	B-VP	VBZ	O	0	ROOT
3	maleate	maleate	B-NP	NN	O	5	NMOD
4	induced	induced	I-NP	JJ	O	5	NMOD
5	nephrotoxicity	nephrotoxicity	I-NP	NN	O	2	OBJ
6	:	:	O	:	O	2	P
7	relation	relation	B-NP	NN	O	19	NMOD
8	to	to	B-PP	TO	O	7	NMOD
9	hemodynamic	hemodynamic	B-NP	JJ	O	10	NMOD
10	alterations	alteration	I-NP	NNS	O	8	PMOD
11	,	,	O	,	O	19	P
12	oxidative	oxidative	B-NP	JJ	O	13	NMOD
13	stress	stress	I-NP	NN	O	19	NMOD
14	,	,	O	,	O	19	P
15	mitochondrial	mitochondrial	B-NP	JJ	O	17	NMOD
16	oxygen	oxygen	I-NP	NN	O	17	NMOD
17	consumption	consumption	I-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	activity	activity	I-NP	NN	O	2	OBJ
20	of	of	B-PP	IN	O	19	NMOD
21	respiratory	respiratory	B-NP	JJ	B-protein	22	NMOD
22	complex	complex	I-NP	NN	I-protein	20	PMOD
23	I	I	I-NP	CD	I-protein	22	NMOD
24	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	4	NMOD
2	potential	potential	I-NP	JJ	O	4	NMOD
3	protective	protective	I-NP	JJ	O	4	NMOD
4	effect	effect	I-NP	NN	O	24	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	9	NMOD
7	dietary	dietary	I-NP	JJ	O	9	NMOD
8	antioxidant	antioxidant	I-NP	JJ	O	9	NMOD
9	curcumin	curcumin	I-NP	NN	O	5	PMOD
10	(	(	O	(	O	16	DEP
11	120	120	B-NP	CD	O	12	NMOD
12	mg/Kg/day	mg/Kg/day	I-NP	NN	O	16	DEP
13	for	for	B-PP	IN	O	12	NMOD
14	6	6	B-NP	CD	O	15	NMOD
15	days	day	I-NP	NNS	O	13	PMOD
16	)	)	O	)	O	9	NMOD
17	against	against	B-PP	IN	O	4	NMOD
18	the	the	B-NP	DT	O	20	NMOD
19	renal	renal	I-NP	JJ	O	20	NMOD
20	injury	injury	I-NP	NN	O	17	PMOD
21	induced	induce	B-VP	VBN	O	20	NMOD
22	by	by	B-PP	IN	O	21	VMOD
23	maleate	maleate	B-NP	NN	O	22	PMOD
24	was	be	B-VP	VBD	O	0	ROOT
25	evaluated	evaluate	I-VP	VBN	O	24	VC
26	.	.	O	.	O	24	P

1	Tubular	Tubular	B-NP	JJ	O	2	NMOD
2	proteinuria	proteinuria	I-NP	NN	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	oxidative	oxidative	B-NP	JJ	O	5	NMOD
5	stress	stress	I-NP	NN	O	6	SUB
6	were	be	B-VP	VBD	O	0	ROOT
7	induced	induce	I-VP	VBN	O	6	VC
8	by	by	B-PP	IN	O	7	VMOD
9	a	a	B-NP	DT	O	11	NMOD
10	single	single	I-NP	JJ	O	11	NMOD
11	injection	injection	I-NP	NN	O	8	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	maleate	maleate	B-NP	NN	O	12	PMOD
14	(	(	O	(	O	17	DEP
15	400	400	B-NP	CD	O	16	NMOD
16	mg/kg	mg/kg	I-NP	NN	O	17	DEP
17	)	)	O	)	O	13	NMOD
18	in	in	B-PP	IN	O	13	NMOD
19	rats	rat	B-NP	NNS	O	18	PMOD
20	.	.	O	.	O	6	P

1	Maleate	Maleate	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	renal	renal	B-NP	JJ	O	4	NMOD
4	injury	injury	I-NP	NN	O	5	SUB
5	included	include	B-VP	VBD	O	2	VMOD
6	increase	increase	B-NP	NN	O	37	NMOD
7	in	in	B-PP	IN	O	6	NMOD
8	renal	renal	B-NP	JJ	O	10	NMOD
9	vascular	vascular	I-NP	JJ	O	10	NMOD
10	resistance	resistance	I-NP	NN	O	7	PMOD
11	and	and	B-PP	CC	O	7	PMOD
12	in	in	B-PP	IN	O	7	PMOD
13	the	the	B-NP	DT	O	15	NMOD
14	urinary	urinary	I-NP	JJ	O	15	NMOD
15	excretion	excretion	I-NP	NN	O	12	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	total	total	B-NP	JJ	O	18	NMOD
18	protein	protein	I-NP	NN	O	32	NMOD
19	,	,	O	,	O	32	P
20	glucose	glucose	B-NP	NN	O	32	NMOD
21	,	,	O	,	O	32	P
22	sodium	sodium	B-NP	NN	O	32	NMOD
23	,	,	O	,	O	32	P
24	neutrophil	neutrophil	B-NP	NN	B-protein	26	NMOD
25	gelatinase-associated	gelatinase-associated	I-NP	JJ	I-protein	26	NMOD
26	lipocalin	lipocalin	I-NP	NN	I-protein	32	NMOD
27	(	(	O	(	O	29	DEP
28	NGAL	NGAL	B-NP	NN	B-protein	29	DEP
29	)	)	O	)	O	26	NMOD
30	and	and	O	CC	O	32	NMOD
31	N-acetyl	N-acetyl	B-NP	NN	B-protein	32	NMOD
32	b-D-glucosaminidase	b-D-glucosaminidase	I-NP	NN	I-protein	16	PMOD
33	(	(	O	(	O	35	DEP
34	NAG	NAG	B-NP	NN	B-protein	35	DEP
35	)	)	O	)	O	32	NMOD
36	,	,	O	,	O	37	P
37	upregulation	upregulation	B-NP	NN	O	5	OBJ
38	of	of	B-PP	IN	O	37	NMOD
39	kidney	kidney	B-NP	NN	B-protein	41	NMOD
40	injury	injury	I-NP	NN	I-protein	41	NMOD
41	molecule	molecule	I-NP	NN	I-protein	43	NMOD
42	(	(	O	(	O	43	NMOD
43	KIM	KIM	B-NP	NN	O	38	PMOD
44	)	)	O	)	O	43	NMOD
45	-1	-1	B-NP	CD	O	43	NMOD
46	,	,	O	,	O	47	P
47	decrease	decrease	B-NP	NN	O	43	NMOD
48	in	in	B-PP	IN	O	47	NMOD
49	renal	renal	B-NP	JJ	O	51	NMOD
50	blood	blood	I-NP	NN	O	51	NMOD
51	flow	flow	I-NP	NN	O	54	NMOD
52	and	and	O	CC	O	54	NMOD
53	claudin-2	claudin-2	B-NP	NN	O	54	NMOD
54	expression	expression	I-NP	NN	O	48	PMOD
55	besides	besides	B-PP	IN	O	47	NMOD
56	of	of	B-PP	IN	O	55	PMOD
57	necrosis	necrosis	B-NP	NN	O	59	NMOD
58	and	and	I-NP	CC	O	59	NMOD
59	apoptosis	apoptosis	I-NP	NN	O	56	PMOD
60	of	of	B-PP	IN	O	59	NMOD
61	tubular	tubular	B-NP	JJ	B-cell_type	62	NMOD
62	cells	cell	I-NP	NNS	I-cell_type	60	PMOD
63	on	on	B-PP	IN	O	47	NMOD
64	24	24	B-NP	CD	O	65	NMOD
65	h	h	I-NP	NN	O	63	PMOD
66	.	.	O	.	O	2	P

1	It	It	B-NP	PRP	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	concluded	conclude	I-VP	VBN	O	2	VC
4	that	that	B-SBAR	IN	O	3	VMOD
5	curcumin	curcumin	B-NP	NN	O	6	SUB
6	is	be	B-VP	VBZ	O	4	SBAR
7	able	able	B-ADJP	JJ	O	6	PRD
8	to	to	B-VP	TO	O	9	VMOD
9	attenuate	attenuate	I-VP	VB	O	7	AMOD
10	in	in	B-NP	FW	O	11	AMOD
11	vivo	vivo	I-NP	FW	O	12	NMOD
12	maleate	maleate	I-NP	NN	O	14	NMOD
13	induced	induce	B-VP	VBD	O	12	AMOD
14	nephropathy	nephropathy	B-NP	NN	O	19	NMOD
15	and	and	O	CC	O	19	NMOD
16	in	in	B-NP	FW	O	17	AMOD
17	vitro	vitro	I-NP	FW	O	19	NMOD
18	cell	cell	I-NP	NN	O	19	NMOD
19	damage	damage	I-NP	NN	O	9	OBJ
20	.	.	O	.	O	2	P

1	Incidence	Incidence	B-NP	NN	O	22	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	solid	solid	B-NP	JJ	O	4	NMOD
4	tumours	tumour	I-NP	NNS	O	2	PMOD
5	among	among	B-PP	IN	O	1	NMOD
6	pesticide	pesticide	B-NP	NN	B-protein	7	NMOD
7	applicators	applicator	I-NP	NNS	I-protein	5	PMOD
8	exposed	expose	B-VP	VBN	O	7	NMOD
9	to	to	B-PP	TO	O	8	VMOD
10	the	the	B-NP	DT	O	13	NMOD
11	organophosphate	organophosphate	I-NP	NN	O	13	NMOD
12	insecticide	insecticide	I-NP	NN	O	13	NMOD
13	diazinon	diazinon	I-NP	NN	O	9	PMOD
14	in	in	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	18	NMOD
16	Agricultural	Agricultural	I-NP	NNP	O	18	NMOD
17	Health	Health	I-NP	NNP	O	18	NMOD
18	Study	Study	I-NP	NNP	O	14	PMOD
19	:	:	O	:	O	1	P
20	an	an	B-NP	DT	O	22	NMOD
21	updated	update	I-NP	VBN	O	22	NMOD
22	analysis	analysis	I-NP	NN	O	0	ROOT
23	.	.	O	.	O	22	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	8	NMOD
2	:	:	O	:	O	1	P
3	Diazinon	Diazinon	B-NP	NNP	O	8	NMOD
4	,	,	O	,	O	8	P
5	a	a	B-NP	DT	O	8	NMOD
6	common	common	I-NP	JJ	O	8	NMOD
7	organophosphate	organophosphate	I-NP	NN	O	8	NMOD
8	insecticide	insecticide	I-NP	NN	O	13	SUB
9	with	with	B-PP	IN	O	8	NMOD
10	genotoxic	genotoxic	B-NP	JJ	O	11	NMOD
11	properties	property	I-NP	NNS	O	9	PMOD
12	,	,	O	,	O	8	P
13	was	be	B-VP	VBD	O	0	ROOT
14	previously	previously	I-VP	RB	O	13	VMOD
15	associated	associate	I-VP	VBN	O	13	VC
16	with	with	B-PP	IN	O	15	VMOD
17	lung	lung	B-NP	NN	O	18	NMOD
18	cancer	cancer	I-NP	NN	O	16	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	23	NMOD
21	Agricultural	Agricultural	I-NP	NNP	O	23	NMOD
22	Health	Health	I-NP	NNP	O	23	NMOD
23	Study	Study	I-NP	NNP	O	34	SUB
24	(	(	O	(	O	27	AMOD
25	AHS	AHS	B-NP	NNP	O	27	AMOD
26	)	)	O	)	O	27	AMOD
27	cohort	cohort	B-ADJP	JJ	O	34	VMOD
28	,	,	O	,	O	34	P
29	but	but	O	CC	O	34	VMOD
30	few	few	B-NP	JJ	O	33	NMOD
31	other	other	I-NP	JJ	O	33	NMOD
32	epidemiological	epidemiological	I-NP	JJ	O	33	NMOD
33	studies	study	I-NP	NNS	O	34	SUB
34	have	have	B-VP	VBP	O	19	SBAR
35	examined	examine	I-VP	VBN	O	34	VC
36	diazinon-associated	diazinon-associated	B-NP	JJ	O	38	NMOD
37	cancer	cancer	I-NP	NN	O	38	NMOD
38	risk	risk	I-NP	NN	O	35	OBJ
39	.	.	O	.	O	13	P

1	We	We	B-NP	PRP	O	2	SUB
2	used	use	B-VP	VBD	O	0	ROOT
3	updated	update	B-NP	VBN	O	9	NMOD
4	diazinon	diazinon	I-NP	NN	O	5	NMOD
5	exposure	exposure	I-NP	NN	O	9	NMOD
6	and	and	O	CC	O	9	NMOD
7	cancer	cancer	B-NP	NN	O	9	NMOD
8	incidence	incidence	I-NP	NN	O	9	NMOD
9	information	information	I-NP	NN	O	2	OBJ
10	to	to	B-VP	TO	O	11	VMOD
11	evaluate	evaluate	I-VP	VB	O	2	VMOD
12	solid	solid	B-NP	JJ	O	14	NMOD
13	tumour	tumour	I-NP	NN	O	14	NMOD
14	risk	risk	I-NP	NN	O	11	OBJ
15	in	in	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	AHS	AHS	I-NP	NN	B-protein	15	PMOD
18	.	.	O	.	O	2	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Male	Male	B-NP	JJ	O	5	NMOD
4	pesticide	pesticide	I-NP	NN	O	5	NMOD
5	applicators	applicator	I-NP	NNS	O	28	SUB
6	in	in	B-PP	IN	O	5	NMOD
7	Iowa	Iowa	B-NP	NNP	O	10	NMOD
8	and	and	O	CC	O	10	NMOD
9	North	North	B-NP	NNP	O	10	NMOD
10	Carolina	Carolina	I-NP	NNP	O	11	SUB
11	reported	report	B-VP	VBD	O	6	SBAR
12	lifetime	lifetime	B-NP	NN	O	14	NMOD
13	diazinon	diazinon	I-NP	NN	O	14	NMOD
14	use	use	I-NP	NN	O	11	OBJ
15	at	at	B-PP	IN	O	14	NMOD
16	enrolment	enrolment	B-NP	NN	O	21	NMOD
17	(	(	O	(	O	19	DEP
18	1993-1997	1993-1997	B-NP	CD	O	19	DEP
19	)	)	O	)	O	16	NMOD
20	and	and	O	CC	O	21	NMOD
21	follow-up	follow-up	B-NP	NN	O	15	PMOD
22	(	(	O	(	O	24	DEP
23	1998-2005	1998-2005	B-NP	CD	O	24	DEP
24	)	)	O	)	O	21	NMOD
25	;	;	O	:	O	28	P
26	cancer	cancer	B-NP	NN	O	27	NMOD
27	incidence	incidence	I-NP	NN	O	28	SUB
28	was	be	B-VP	VBD	O	1	NMOD
29	assessed	assess	I-VP	VBN	O	28	VC
30	through	through	B-PP	IN	O	29	VMOD
31	2010	2010	B-NP	CD	O	30	PMOD
32	(	(	O	(	O	35	DEP
33	North	North	B-NP	NNP	O	34	NMOD
34	Carolina	Carolina	I-NP	NNP	O	35	DEP
35	)	)	O	)	O	31	NMOD
36	/2011	/2011	B-NP	CD	O	35	PRD
37	(	(	O	(	O	39	DEP
38	Iowa	Iowa	B-NP	NN	O	39	DEP
39	)	)	O	)	O	36	NMOD
40	.	.	O	.	O	1	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	observed	observe	B-VP	VBD	O	1	NMOD
5	elevated	elevated	B-NP	JJ	O	8	NMOD
6	lung	lung	I-NP	NN	O	8	NMOD
7	cancer	cancer	I-NP	NN	O	8	NMOD
8	risks	risk	I-NP	NNS	O	4	VMOD
9	(	(	O	(	O	11	DEP
10	N=283	N=283	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	among	among	B-PP	IN	O	4	VMOD
13	applicators	applicator	B-NP	NNS	O	12	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	17	NMOD
16	greatest	great	I-NP	JJS	O	17	NMOD
17	number	number	I-NP	NN	O	14	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	LT	LT	B-NP	NN	B-protein	34	NMOD
20	(	(	O	(	O	31	DEP
21	RR=1.60	RR=1.60	B-NP	NN	O	30	NMOD
22	;	;	O	:	O	30	P
23	95	95	B-NP	CD	O	25	NMOD
24	%	%	I-NP	NN	O	25	NMOD
25	CI	CI	I-NP	NN	O	30	NMOD
26	1.11	1.11	I-NP	CD	O	28	NMOD
27	to	to	B-PP	TO	O	28	NMOD
28	2.31	2.31	B-NP	CD	O	25	NMOD
29	;	;	O	:	O	30	P
30	Ptrend=0.02	Ptrend=0.02	B-NP	NN	O	31	DEP
31	)	)	O	)	O	19	NMOD
32	and	and	O	CC	O	34	NMOD
33	IW	IW	B-NP	NN	O	34	NMOD
34	days	day	I-NP	NNS	O	18	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	diazinon	diazinon	B-NP	NN	O	37	NMOD
37	use	use	I-NP	NN	O	35	PMOD
38	(	(	O	(	O	49	DEP
39	RR=1.41	RR=1.41	B-NP	NN	O	48	NMOD
40	;	;	O	:	O	48	P
41	95	95	B-NP	CD	O	43	NMOD
42	%	%	I-NP	NN	O	43	NMOD
43	CI	CI	I-NP	NN	O	48	NMOD
44	0.98	0.98	I-NP	CD	O	46	NMOD
45	to	to	B-PP	TO	O	46	NMOD
46	2.04	2.04	B-NP	CD	O	43	NMOD
47	;	;	O	:	O	48	P
48	Ptrend=0.08	Ptrend=0.08	B-NP	NN	O	49	DEP
49	)	)	O	)	O	37	NMOD
50	.	.	O	.	O	1	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Our	Our	B-NP	PRP$	O	5	NMOD
4	updated	update	I-NP	VBN	O	5	NMOD
5	evaluation	evaluation	I-NP	NN	O	8	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	diazinon	diazinon	B-NP	NN	O	6	PMOD
8	provides	provide	B-VP	VBZ	O	1	NMOD
9	additional	additional	B-NP	JJ	O	10	NMOD
10	evidence	evidence	I-NP	NN	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	an	an	B-NP	DT	O	13	NMOD
13	association	association	I-NP	NN	O	11	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	lung	lung	B-NP	NN	B-protein	17	NMOD
16	cancer	cancer	I-NP	NN	I-protein	17	NMOD
17	risk	risk	I-NP	NN	I-protein	14	PMOD
18	.	.	O	.	O	1	P

1	Associations	Association	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	Ozone	Ozone	B-NP	NN	O	6	NMOD
4	and	and	I-NP	CC	O	6	NMOD
5	PM2.5	PM2.5	I-NP	NN	O	6	NMOD
6	Concentrations	Concentration	I-NP	NNS	O	2	PMOD
7	With	With	B-PP	IN	O	1	NMOD
8	Parkinson	Parkinson	B-NP	NNP	O	9	NMOD
9	's	's	B-NP	POS	O	10	NMOD
10	Disease	Disease	I-NP	NN	O	7	PMOD
11	Among	Among	B-PP	IN	O	1	NMOD
12	Participants	Participant	B-NP	NNPS	O	11	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	17	NMOD
15	Agricultural	Agricultural	I-NP	NNP	O	17	NMOD
16	Health	Health	I-NP	NNP	O	17	NMOD
17	Study	Study	I-NP	NNP	O	13	PMOD
18	.	.	O	.	O	1	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	5	SUB
2	:	:	O	:	O	5	P
3	This	This	B-NP	DT	O	4	NMOD
4	study	study	I-NP	NN	O	5	SUB
5	describes	describe	B-VP	VBZ	O	0	ROOT
6	associations	association	B-NP	NNS	O	5	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	ozone	ozone	B-NP	NN	O	12	NMOD
9	and	and	O	CC	O	12	NMOD
10	fine	fine	B-NP	JJ	O	12	NMOD
11	particulate	particulate	I-NP	JJ	O	12	NMOD
12	matter	matter	I-NP	NN	O	7	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	Parkinson	Parkinson	B-NP	NNP	O	15	NMOD
15	's	's	B-NP	POS	O	16	NMOD
16	disease	disease	I-NP	NN	O	13	PMOD
17	observed	observe	B-VP	VBN	O	16	NMOD
18	among	among	B-PP	IN	O	17	VMOD
19	farmers	farmer	B-NP	NNS	O	18	PMOD
20	in	in	B-PP	IN	O	19	NMOD
21	North	North	B-NP	NNP	O	22	NMOD
22	Carolina	Carolina	I-NP	NNP	O	24	NMOD
23	and	and	I-NP	CC	O	24	NMOD
24	Iowa	Iowa	I-NP	NNP	O	20	PMOD
25	.	.	O	.	O	5	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	observed	observe	B-VP	VBD	O	1	NMOD
5	positive	positive	B-NP	JJ	O	6	NMOD
6	associations	association	I-NP	NNS	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	Parkinson	Parkinson	B-NP	NNP	O	9	NMOD
9	's	's	B-NP	POS	O	10	NMOD
10	disease	disease	I-NP	NN	O	7	PMOD
11	with	with	B-PP	IN	O	6	NMOD
12	ozone	ozone	B-NP	NN	O	30	NMOD
13	(	(	O	(	O	26	DEP
14	odds	odd	B-NP	NNS	O	25	SUB
15	ratio	ratio	I-NP	NN	O	25	VMOD
16	=	=	B-VP	SYM	O	15	NMOD
17	1.39	1.39	B-NP	CD	O	16	AMOD
18	;	;	O	:	O	25	P
19	95	95	B-NP	CD	O	21	NMOD
20	%	%	I-NP	NN	O	21	NMOD
21	CI	CI	I-NP	NN	O	25	VMOD
22	:	:	O	:	O	25	P
23	0.98	0.98	B-NP	CD	O	25	AMOD
24	to	to	B-PP	TO	O	25	AMOD
25	1.98	1.98	B-NP	CD	O	26	DEP
26	)	)	O	)	O	12	NMOD
27	and	and	O	CC	O	30	NMOD
28	fine	fine	B-NP	JJ	O	30	NMOD
29	particulate	particulate	I-NP	JJ	O	30	NMOD
30	matter	matter	I-NP	NN	O	11	PMOD
31	(	(	O	(	O	44	DEP
32	odds	odd	B-NP	NNS	O	43	NMOD
33	ratio	ratio	I-NP	NN	O	43	NMOD
34	=	=	B-VP	SYM	O	33	NMOD
35	1.34	1.34	B-NP	CD	O	34	AMOD
36	;	;	O	:	O	43	P
37	95	95	B-NP	CD	O	39	NMOD
38	%	%	I-NP	NN	O	39	NMOD
39	CI	CI	I-NP	NN	O	43	VMOD
40	:	:	O	:	O	43	P
41	0.93	0.93	B-NP	CD	O	43	AMOD
42	to	to	B-PP	TO	O	43	AMOD
43	1.93	1.93	B-NP	CD	O	44	DEP
44	)	)	O	)	O	30	NMOD
45	in	in	B-PP	IN	O	30	NMOD
46	North	North	B-NP	NNP	O	47	NMOD
47	Carolina	Carolina	I-NP	NNP	O	45	PMOD
48	but	but	B-PP	CC	O	45	PMOD
49	not	not	B-PP	RB	O	50	PMOD
50	in	in	I-PP	IN	O	45	PMOD
51	Iowa	Iowa	B-NP	NNP	O	50	PMOD
52	.	.	O	.	O	1	P

1	Low	Low	B-NP	JJ	O	3	NMOD
2	functional	functional	I-NP	JJ	O	3	NMOD
3	programming	programming	I-NP	NN	O	7	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	renal	renal	B-NP	JJ	B-protein	6	NMOD
6	AT2R	AT2R	I-NP	NN	I-protein	4	PMOD
7	mediates	mediate	B-VP	VBZ	O	0	ROOT
8	the	the	B-NP	DT	O	10	NMOD
9	developmental	developmental	I-NP	JJ	O	10	NMOD
10	origin	origin	I-NP	NN	O	7	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	glomerulosclerosis	glomerulosclerosis	B-NP	NN	O	11	PMOD
13	in	in	B-PP	IN	O	7	VMOD
14	adult	adult	B-NP	JJ	O	15	NMOD
15	offspring	offspring	I-NP	NN	O	13	PMOD
16	induced	induce	B-VP	VBN	O	15	NMOD
17	by	by	B-PP	IN	O	16	VMOD
18	prenatal	prenatal	B-NP	JJ	O	20	NMOD
19	caffeine	caffeine	I-NP	NN	O	20	NMOD
20	exposure	exposure	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	7	P

1	UNASSIGNED	UNASSIGNED	B-VP	VBN	O	5	NMOD
2	:	:	O	:	O	1	P
3	Our	Our	B-NP	PRP$	O	5	NMOD
4	previous	previous	I-NP	JJ	O	5	NMOD
5	study	study	I-NP	NN	O	6	SUB
6	has	have	B-VP	VBZ	O	0	ROOT
7	indicated	indicate	I-VP	VBN	O	6	VC
8	that	that	B-SBAR	IN	O	7	VMOD
9	prenatal	prenatal	B-NP	JJ	O	11	NMOD
10	caffeine	caffeine	I-NP	NN	O	11	NMOD
11	exposure	exposure	I-NP	NN	O	15	SUB
12	(	(	O	(	O	14	DEP
13	PCE	PCE	B-NP	NN	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	could	could	B-VP	MD	O	8	SBAR
16	induce	induce	I-VP	VB	O	15	VC
17	intrauterine	intrauterine	B-NP	JJ	O	19	NMOD
18	growth	growth	I-NP	NN	O	19	NMOD
19	retardation	retardation	I-NP	NN	O	16	OBJ
20	(	(	O	(	O	22	DEP
21	IUGR	IUGR	B-NP	NN	B-protein	22	DEP
22	)	)	O	)	O	19	NMOD
23	of	of	B-PP	IN	O	19	NMOD
24	offspring	offspring	B-NP	NN	O	23	PMOD
25	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	revealed	reveal	B-VP	VBD	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	the	the	B-NP	DT	O	8	NMOD
6	adult	adult	I-NP	JJ	O	8	NMOD
7	offspring	offspring	I-NP	NN	O	8	NMOD
8	kidneys	kidney	I-NP	NNS	O	13	SUB
9	in	in	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	12	NMOD
11	PCE	PCE	I-NP	NN	O	12	NMOD
12	group	group	I-NP	NN	O	9	PMOD
13	exhibited	exhibit	B-VP	VBD	O	4	SBAR
14	glomerulosclerosis	glomerulosclerosis	B-NP	NN	O	19	NMOD
15	as	as	B-CONJP	RB	O	19	NMOD
16	well	well	I-CONJP	RB	O	15	DEP
17	as	as	I-CONJP	IN	O	15	DEP
18	interstitial	interstitial	B-NP	JJ	O	19	NMOD
19	fibrosis	fibrosis	I-NP	NN	O	13	OBJ
20	,	,	O	,	O	13	P
21	accompanied	accompany	B-VP	VBN	O	13	VMOD
22	by	by	B-PP	IN	O	21	VMOD
23	elevated	elevate	B-NP	VBN	O	24	NMOD
24	levels	level	I-NP	NNS	O	22	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	serum	serum	B-NP	NN	B-protein	27	NMOD
27	creatinine	creatinine	I-NP	NN	I-protein	30	NMOD
28	and	and	O	CC	I-protein	30	NMOD
29	urine	urine	B-NP	NN	I-protein	30	NMOD
30	protein	protein	I-NP	NN	I-protein	25	PMOD
31	.	.	O	.	O	3	P

1	1	1	B-NP	CD	O	18	NMOD
2	,	,	O	,	O	18	P
3	3-Butadiene	3-Butadiene	B-NP	NN	O	18	NMOD
4	,	,	O	,	O	18	P
5	CML	CML	B-NP	NN	O	8	NMOD
6	and	and	O	CC	O	8	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	t	t	I-NP	NN	O	18	NMOD
9	(	(	O	(	O	13	DEP
10	9	9	B-NP	CD	O	12	NMOD
11	:	:	O	SYM	O	12	P
12	22	22	O	CD	O	13	DEP
13	)	)	O	)	O	8	NMOD
14	translocation	translocation	B-NP	NN	O	8	NMOD
15	:	:	O	:	O	18	P
16	A	A	B-NP	DT	O	18	NMOD
17	reality	reality	I-NP	NN	O	18	NMOD
18	check	check	I-NP	NN	O	0	ROOT
19	.	.	O	.	O	18	P

1	UNASSIGNED	UNASSIGNED	B-VP	VBN	O	9	VMOD
2	:	:	O	:	O	1	P
3	Epidemiological	Epidemiological	B-NP	JJ	O	4	NMOD
4	studies	study	I-NP	NNS	O	9	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	1	1	B-NP	CD	O	8	NMOD
7	,	,	O	,	O	8	P
8	3-butadiene	3-butadiene	B-NP	NN	O	5	PMOD
9	have	have	B-VP	VBP	O	0	ROOT
10	suggest	suggest	I-VP	VBP	O	9	VMOD
11	that	that	B-SBAR	IN	O	10	VMOD
12	exposures	exposure	B-NP	NNS	O	15	SUB
13	to	to	B-PP	TO	O	12	NMOD
14	humans	human	B-NP	NNS	O	13	PMOD
15	are	be	B-VP	VBP	O	11	SBAR
16	associated	associate	I-VP	VBN	O	15	VC
17	with	with	B-PP	IN	O	16	VMOD
18	chronic	chronic	B-NP	JJ	O	20	NMOD
19	myeloid	myeloid	I-NP	JJ	O	20	NMOD
20	leukemia	leukemia	I-NP	NN	O	17	PMOD
21	(	(	O	(	O	23	DEP
22	CML	CML	B-NP	NN	O	23	DEP
23	)	)	O	)	O	20	NMOD
24	.	.	O	.	O	9	P

1	Cancer	Cancer	B-NP	NN	O	2	NMOD
2	incidence	incidence	I-NP	NN	O	5	NMOD
3	and	and	I-NP	CC	O	5	NMOD
4	metolachlor	metolachlor	I-NP	NN	O	5	NMOD
5	use	use	I-NP	NN	O	13	NMOD
6	in	in	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	10	NMOD
8	Agricultural	Agricultural	I-NP	NNP	O	10	NMOD
9	Health	Health	I-NP	NNP	O	10	NMOD
10	Study	Study	I-NP	NNP	O	6	PMOD
11	:	:	O	:	O	5	P
12	An	An	B-NP	DT	O	13	NMOD
13	update	update	I-NP	NN	O	0	ROOT
14	.	.	O	.	O	13	P

1	We	We	B-NP	PRP	O	2	SUB
2	evaluated	evaluate	B-VP	VBD	O	0	ROOT
3	cancer	cancer	B-NP	NN	O	4	NMOD
4	incidence	incidence	I-NP	NN	O	2	OBJ
5	through	through	B-PP	IN	O	2	VMOD
6	2010/2011	2010/2011	B-NP	CD	O	17	NMOD
7	(	(	O	(	O	9	DEP
8	NC/IA	NC/IA	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	for	for	B-PP	IN	O	6	NMOD
11	49	49	B-NP	CD	O	10	PMOD
12	,	,	O	,	O	17	P
13	616	616	B-NP	CD	O	14	NMOD
14	applicators	applicator	I-NP	NNS	O	17	NMOD
15	,	,	O	,	O	17	P
16	53	53	B-NP	CD	O	17	NMOD
17	%	%	I-NP	NN	O	20	SUB
18	of	of	B-PP	IN	O	17	NMOD
19	whom	whom	B-NP	WP	O	18	PMOD
20	reported	report	B-VP	VBD	O	5	SBAR
21	ever	ever	I-VP	RB	O	20	VMOD
22	using	use	I-VP	VBG	O	20	VMOD
23	metolachlor	metolachlor	B-NP	NN	O	22	OBJ
24	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	used	use	B-VP	VBD	O	0	ROOT
3	Poisson	Poisson	B-NP	NN	O	4	NMOD
4	regression	regression	I-NP	NN	O	2	OBJ
5	to	to	B-VP	TO	O	6	VMOD
6	evaluate	evaluate	I-VP	VB	O	2	VMOD
7	relations	relation	B-NP	NNS	O	6	OBJ
8	between	between	B-PP	IN	O	7	NMOD
9	two	two	B-NP	CD	O	10	NMOD
10	metrics	metric	I-NP	NNS	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	metolachlor	metolachlor	B-NP	NN	O	13	NMOD
13	use	use	I-NP	NN	O	24	NMOD
14	(	(	O	(	O	21	DEP
15	lifetime	lifetime	B-NP	NN	O	16	NMOD
16	days	day	I-NP	NNS	O	20	NMOD
17	,	,	O	,	O	20	P
18	intensity-weighted	intensity-weighted	B-NP	JJ	O	20	NMOD
19	lifetime	lifetime	I-NP	NN	O	20	NMOD
20	days	day	I-NP	NNS	O	21	DEP
21	)	)	O	)	O	13	NMOD
22	and	and	O	CC	O	24	NMOD
23	cancer	cancer	B-NP	NN	O	24	NMOD
24	incidence	incidence	I-NP	NN	O	11	PMOD
25	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	saw	see	B-VP	VBD	O	0	ROOT
3	no	no	B-NP	DT	O	4	NMOD
4	association	association	I-NP	NN	O	2	OBJ
5	between	between	B-PP	IN	O	4	NMOD
6	metolachlor	metolachlor	B-NP	NN	O	7	NMOD
7	use	use	I-NP	NN	O	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	incidence	incidence	I-NP	NN	O	5	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	all	all	B-NP	DT	O	12	NMOD
12	cancers	cancer	I-NP	NNS	O	28	NMOD
13	combined	combine	B-VP	VBN	O	12	NMOD
14	(	(	O	(	O	24	DEP
15	n	n	B-NP	NN	O	19	NMOD
16	=	=	B-VP	SYM	O	15	NMOD
17	5	5	B-NP	CD	O	16	AMOD
18	,	,	O	,	O	19	P
19	701	701	B-NP	CD	O	24	DEP
20	with	with	B-PP	IN	O	19	NMOD
21	a	a	B-NP	DT	O	23	NMOD
22	5-year	5-year	I-NP	JJ	O	23	NMOD
23	lag	lag	I-NP	NN	O	20	PMOD
24	)	)	O	)	O	12	NMOD
25	or	or	O	CC	O	28	NMOD
26	most	most	B-NP	RBS	O	27	AMOD
27	site-specific	site-specific	I-NP	JJ	O	28	NMOD
28	cancers	cancer	I-NP	NNS	O	10	PMOD
29	.	.	O	.	O	2	P

1	An	An	B-NP	DT	O	3	NMOD
2	earlier	early	I-NP	JJR	O	3	NMOD
3	suggestion	suggestion	I-NP	NN	O	18	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	increased	increase	B-NP	VBN	O	8	NMOD
6	lung	lung	I-NP	NN	O	8	NMOD
7	cancer	cancer	I-NP	NN	O	8	NMOD
8	risk	risk	I-NP	NN	O	4	PMOD
9	at	at	B-PP	IN	O	3	NMOD
10	high	high	B-NP	JJ	O	11	NMOD
11	levels	level	I-NP	NNS	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	metolachlor	metolachlor	B-NP	NN	O	14	NMOD
14	use	use	I-NP	NN	O	12	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	this	this	B-NP	DT	O	17	NMOD
17	cohort	cohort	I-NP	NN	O	15	PMOD
18	was	be	B-VP	VBD	O	0	ROOT
19	not	not	I-VP	RB	O	18	VMOD
20	confirmed	confirm	I-VP	VBN	O	18	VC
21	in	in	B-PP	IN	O	20	VMOD
22	this	this	B-NP	DT	O	23	NMOD
23	update	update	I-NP	NN	O	21	PMOD
24	.	.	O	.	O	18	P

1	This	This	B-NP	DT	O	2	NMOD
2	suggestion	suggestion	I-NP	NN	O	14	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	an	an	B-NP	DT	O	5	NMOD
5	association	association	I-NP	NN	O	3	PMOD
6	between	between	B-PP	IN	O	5	NMOD
7	metolachlor	metolachlor	B-NP	NN	O	10	NMOD
8	and	and	O	CC	O	10	NMOD
9	liver	liver	B-NP	NN	O	10	NMOD
10	cancer	cancer	I-NP	NN	O	6	PMOD
11	among	among	B-PP	IN	O	5	NMOD
12	pesticide	pesticide	B-NP	NN	B-protein	13	NMOD
13	applicators	applicator	I-NP	NNS	I-protein	11	PMOD
14	is	be	B-VP	VBZ	O	0	ROOT
15	a	a	B-NP	DT	O	17	NMOD
16	novel	novel	I-NP	JJ	O	17	NMOD
17	finding	finding	I-NP	NN	O	14	PRD
18	and	and	O	CC	O	14	VMOD
19	echoes	echo	B-VP	VBZ	O	14	VMOD
20	observation	observation	B-NP	NN	O	19	OBJ
21	of	of	B-PP	IN	O	20	NMOD
22	increased	increase	B-NP	VBN	O	24	NMOD
23	liver	liver	I-NP	NN	O	24	NMOD
24	neoplasms	neoplasm	I-NP	NNS	O	21	PMOD
25	in	in	B-PP	IN	O	20	NMOD
26	some	some	B-NP	DT	O	28	NMOD
27	animal	animal	I-NP	JJ	O	28	NMOD
28	studies	study	I-NP	NNS	O	25	PMOD
29	.	.	O	.	O	14	P

1	There	There	B-NP	EX	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	considerable	considerable	B-NP	JJ	O	4	NMOD
4	interest	interest	I-NP	NN	O	2	PRD
5	in	in	B-PP	IN	O	4	NMOD
6	identifying	identify	B-VP	VBG	O	5	PMOD
7	the	the	B-NP	DT	O	9	NMOD
8	molecular	molecular	I-NP	JJ	O	9	NMOD
9	mechanisms	mechanism	I-NP	NNS	O	6	OBJ
10	that	that	B-NP	WDT	O	9	NMOD
11	relate	relate	B-VP	VBP	O	10	SBAR
12	early-life	early-life	B-NP	JJ	O	14	NMOD
13	iAs	iA	I-NP	NNS	O	14	NMOD
14	exposure	exposure	I-NP	NN	O	11	OBJ
15	to	to	B-PP	TO	O	14	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	development	development	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	these	these	B-NP	DT	O	21	NMOD
20	latent	latent	I-NP	JJ	O	21	NMOD
21	diseases	disease	I-NP	NNS	O	18	PMOD
22	,	,	O	,	O	2	P
23	particularly	particularly	B-ADVP	RB	O	24	PMOD
24	in	in	B-PP	IN	O	2	VMOD
25	relationship	relationship	B-NP	NN	O	24	PMOD
26	to	to	B-PP	TO	O	25	NMOD
27	cancer	cancer	B-NP	NN	O	26	PMOD
28	.	.	O	.	O	2	P

1	OBJECTIVES	OBJECTIVES	B-NP	NNS	O	4	NMOD
2	:	:	O	:	O	1	P
3	This	This	B-NP	DT	O	4	NMOD
4	work	work	I-NP	NN	O	5	SUB
5	summarizes	summarize	B-VP	VBZ	O	0	ROOT
6	research	research	B-NP	NN	O	5	OBJ
7	on	on	B-PP	IN	O	5	VMOD
8	the	the	B-NP	DT	O	10	NMOD
9	molecular	molecular	I-NP	JJ	O	10	NMOD
10	mechanisms	mechanism	I-NP	NNS	O	7	PMOD
11	that	that	B-NP	WDT	O	10	NMOD
12	underlie	underlie	B-VP	VBP	O	11	SBAR
13	the	the	B-NP	DT	O	15	NMOD
14	increased	increase	I-NP	VBN	O	15	NMOD
15	risk	risk	I-NP	NN	O	12	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	cancer	cancer	B-NP	NN	O	18	NMOD
18	development	development	I-NP	NN	O	16	PMOD
19	in	in	B-PP	IN	O	15	NMOD
20	adulthood	adulthood	B-NP	NN	O	19	PMOD
21	that	that	B-NP	WDT	O	15	NMOD
22	is	be	B-VP	VBZ	O	21	SBAR
23	associated	associate	I-VP	VBN	O	22	VC
24	with	with	B-PP	IN	O	23	VMOD
25	early-life	early-life	B-NP	JJ	O	27	NMOD
26	iAs	iA	I-NP	NNS	O	27	NMOD
27	exposure	exposure	I-NP	NN	O	24	PMOD
28	.	.	O	.	O	5	P

1	DISCUSSION	DISCUSSION	B-NP	NN	O	4	NMOD
2	:	:	O	:	O	1	P
3	Epigenetic	Epigenetic	B-NP	JJ	O	4	NMOD
4	reprogramming	reprogramming	I-NP	NN	O	21	NMOD
5	that	that	B-NP	WDT	O	4	NMOD
6	imparts	impart	B-VP	VBZ	O	5	SBAR
7	functional	functional	B-NP	JJ	O	8	NMOD
8	changes	change	I-NP	NNS	O	6	OBJ
9	in	in	B-PP	IN	O	8	NMOD
10	gene	gene	B-NP	NN	O	11	NMOD
11	expression	expression	I-NP	NN	O	9	PMOD
12	,	,	O	,	O	21	P
13	the	the	B-NP	DT	O	14	NMOD
14	development	development	I-NP	NN	O	21	NMOD
15	of	of	B-PP	IN	O	14	NMOD
16	cancer	cancer	B-NP	NN	B-cell_type	18	NMOD
17	stem	stem	I-NP	NN	I-cell_type	18	NMOD
18	cells	cell	I-NP	NNS	I-cell_type	15	PMOD
19	,	,	O	,	O	21	P
20	and	and	O	CC	O	21	NMOD
21	immunomodulation	immunomodulation	B-NP	NN	O	22	SUB
22	are	be	B-VP	VBP	O	0	ROOT
23	plausible	plausible	B-NP	JJ	O	25	NMOD
24	underlying	underlie	I-NP	VBG	O	25	NMOD
25	mechanisms	mechanism	I-NP	NNS	O	22	PRD
26	by	by	B-PP	IN	O	25	NMOD
27	which	which	B-NP	WDT	O	26	PMOD
28	early-life	early-life	B-NP	JJ	O	30	NMOD
29	iAs	iA	I-NP	NNS	O	30	NMOD
30	exposure	exposure	I-NP	NN	O	31	SUB
31	elicits	elicit	B-VP	VBZ	O	26	SBAR
32	latent	latent	B-NP	JJ	O	33	AMOD
33	carcinogenic	carcinogenic	I-NP	JJ	O	34	NMOD
34	effects	effect	I-NP	NNS	O	31	OBJ
35	.	.	O	.	O	22	P

1	Four	Four	B-NP	CD	O	2	NMOD
2	types	type	I-NP	NNS	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	experimental	experimental	B-NP	JJ	O	5	NMOD
5	arrhythmia	arrhythmia	I-NP	NN	O	3	PMOD
6	are	be	B-VP	VBP	O	0	ROOT
7	used	use	I-VP	VBN	O	6	VC
8	--	--	O	:	O	9	P
9	with	with	B-PP	IN	O	7	VMOD
10	BaCl2	BaCl2	B-NP	NN	O	9	PMOD
11	,	,	O	,	O	9	P
12	with	with	B-PP	IN	O	11	NMOD
13	chloroform-adrenaline	chloroform-adrenaline	B-NP	NN	O	12	PMOD
14	,	,	O	,	O	12	DEP
15	with	with	B-PP	IN	O	14	VMOD
16	strophantine	strophantine	B-NP	JJ	O	17	NMOD
17	G	G	I-NP	NN	O	15	PMOD
18	and	and	B-PP	CC	O	15	PMOD
19	with	with	B-PP	IN	O	15	PMOD
20	aconitine	aconitine	B-NP	NN	O	19	PMOD
21	.	.	O	.	O	12	P

1	Myopathy	Myopathy	B-NP	NN	O	14	SUB
2	due	due	B-PP	IN	O	1	NMOD
3	to	to	B-PP	TO	O	2	PMOD
4	lack	lack	B-NP	NN	O	3	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	vitamin	vitamin	B-NP	NN	O	7	NMOD
7	E	E	I-NP	NN	O	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	myopathy	myopathy	I-NP	NN	O	5	PMOD
10	induced	induce	B-VP	VBN	O	9	NMOD
11	by	by	B-PP	IN	O	10	VMOD
12	certain	certain	B-NP	JJ	O	13	NMOD
13	viruses	virus	I-NP	NNS	O	11	PMOD
14	have	have	B-VP	VBP	O	0	ROOT
15	much	much	B-NP	JJ	O	14	OBJ
16	in	in	B-PP	IN	O	15	NMOD
17	common	common	B-ADJP	JJ	O	18	AMOD
18	anatomically	anatomically	B-ADVP	RB	O	16	PMOD
19	and	and	I-ADVP	CC	O	16	PMOD
20	pathologically	pathologically	I-ADVP	RB	O	21	PMOD
21	with	with	B-PP	IN	O	16	PMOD
22	the	the	B-NP	DT	O	24	NMOD
23	human	human	I-NP	JJ	B-protein	24	NMOD
24	form	form	I-NP	NN	I-protein	21	PMOD
25	.	.	O	.	O	14	P

1	The	The	B-NP	DT	O	2	NMOD
2	authors	author	I-NP	NNS	O	3	SUB
3	induced	induce	B-VP	VBD	O	0	ROOT
4	myodystrophy	myodystrophy	B-NP	NN	O	3	OBJ
5	in	in	B-PP	IN	O	3	VMOD
6	the	the	B-NP	DT	O	7	NMOD
7	rat	rat	I-NP	NN	O	5	PMOD
8	by	by	B-PP	IN	O	3	VMOD
9	giving	give	B-VP	VBG	O	8	PMOD
10	it	it	B-NP	PRP	O	9	OBJ
11	a	a	B-NP	DT	O	12	NMOD
12	diet	diet	I-NP	NN	O	9	OBJ
13	lacking	lack	B-VP	VBG	O	12	NMOD
14	in	in	B-PP	IN	O	13	VMOD
15	vitamin	vitamin	B-NP	NN	O	16	NMOD
16	E	E	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	3	NMOD
2	encouraging	encouraging	I-NP	JJ	O	3	NMOD
3	results	result	I-NP	NNS	O	0	ROOT
4	obtained	obtain	B-VP	VBN	O	3	NMOD
5	in	in	B-PP	IN	O	4	VMOD
6	various	various	B-NP	JJ	O	8	NMOD
7	authoratative	authoratative	I-NP	JJ	O	8	NMOD
8	departments	department	I-NP	NNS	O	5	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	myopathic	myopathic	B-NP	JJ	O	11	NMOD
11	patients	patient	I-NP	NNS	O	9	PMOD
12	by	by	B-PP	IN	O	4	VMOD
13	using	use	B-VP	VBG	O	12	PMOD
14	anabolizing	anabolize	B-NP	VBG	O	15	NMOD
15	steroids	steroid	I-NP	NNS	O	16	SUB
16	have	have	B-VP	VBP	O	13	VMOD
17	encouraged	encourage	I-VP	VBN	O	16	VC
18	the	the	B-NP	DT	O	19	NMOD
19	authors	author	I-NP	NNS	O	17	OBJ
20	to	to	B-VP	TO	O	21	VMOD
21	investigate	investigate	I-VP	VB	O	17	VMOD
22	the	the	B-NP	DT	O	24	NMOD
23	beneficial	beneficial	I-NP	JJ	O	24	NMOD
24	effects	effect	I-NP	NNS	O	21	OBJ
25	of	of	B-PP	IN	O	24	NMOD
26	one	one	B-NP	CD	O	28	NMOD
27	anabolizing	anabolize	B-VP	VBG	O	28	NMOD
28	agent	agent	B-NP	NN	O	25	PMOD
29	(	(	O	(	O	33	DEP
30	Dianabol	Dianabol	B-NP	NN	O	32	NMOD
31	,	,	O	,	O	32	P
32	CIBA	CIBA	B-NP	NN	B-protein	33	DEP
33	)	)	O	)	O	28	NMOD
34	at	at	B-PP	IN	O	21	VMOD
35	high	high	B-NP	JJ	O	36	NMOD
36	doses	dose	I-NP	NNS	O	34	PMOD
37	in	in	B-PP	IN	O	36	NMOD
38	rats	rat	B-NP	NNS	O	37	PMOD
39	rendered	render	B-VP	VBN	O	38	NMOD
40	myopathic	myopathic	B-ADJP	JJ	O	39	VMOD
41	by	by	B-PP	IN	O	40	AMOD
42	a	a	B-NP	DT	O	43	NMOD
43	diet	diet	I-NP	NN	O	41	PMOD
44	deficient	deficient	B-ADJP	JJ	O	43	NMOD
45	in	in	B-PP	IN	O	44	AMOD
46	vitamin	vitamin	B-NP	NN	O	47	NMOD
47	E	E	I-NP	NN	O	45	PMOD
48	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	baby	baby	I-NP	NN	O	3	SUB
3	showed	show	B-VP	VBD	O	0	ROOT
4	warfarin	warfarin	B-NP	NN	O	6	NMOD
5	induced	induced	I-NP	JJ	O	6	NMOD
6	embryopathy	embryopathy	I-NP	NN	O	12	NMOD
7	with	with	B-PP	IN	O	6	NMOD
8	nasal	nasal	B-NP	JJ	O	9	NMOD
9	hypoplasia	hypoplasia	I-NP	NN	O	7	PMOD
10	and	and	O	CC	O	12	NMOD
11	stippled	stipple	B-NP	VBN	O	12	NMOD
12	epiphyses	epiphysis	I-NP	NNS	O	3	OBJ
13	(	(	O	(	O	16	DEP
14	chondrodysplasia	chondrodysplasia	B-NP	NN	O	15	NMOD
15	punctata	punctata	I-NP	NN	O	16	DEP
16	)	)	O	)	O	12	NMOD
17	.	.	O	.	O	3	P

1	Isradipine	Isradipine	B-NP	NN	O	2	NMOD
2	treatment	treatment	I-NP	NN	O	0	ROOT
3	for	for	B-PP	IN	O	2	NMOD
4	hypertension	hypertension	B-NP	NN	O	3	PMOD
5	in	in	B-PP	IN	O	2	NMOD
6	general	general	B-NP	JJ	O	7	NMOD
7	practice	practice	I-NP	NN	O	5	PMOD
8	in	in	B-PP	IN	O	2	NMOD
9	Hong	Hong	B-NP	NNP	O	10	NMOD
10	Kong	Kong	I-NP	NNP	O	8	PMOD
11	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	4	NMOD
2	6-week	6-week	I-NP	JJ	O	4	NMOD
3	open	open	I-NP	JJ	O	4	NMOD
4	study	study	I-NP	NN	O	11	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	introduction	introduction	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	isradipine	isradipine	B-NP	NN	O	10	NMOD
10	treatment	treatment	I-NP	NN	O	8	PMOD
11	was	be	B-VP	VBD	O	0	ROOT
12	conducted	conduct	I-VP	VBN	O	11	VC
13	in	in	B-PP	IN	O	12	VMOD
14	general	general	B-NP	JJ	O	15	NMOD
15	practice	practice	I-NP	NN	O	13	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	Hong	Hong	B-NP	NNP	O	18	NMOD
18	Kong.	Kong.	I-NP	NNP	O	21	NMOD
19	303	303	I-NP	CD	O	18	NMOD
20	Chinese	Chinese	I-NP	JJ	O	21	NMOD
21	patients	patient	I-NP	NNS	O	16	PMOD
22	with	with	B-PP	IN	O	21	NMOD
23	mild	mild	B-ADJP	JJ	O	22	PMOD
24	to	to	B-PP	TO	O	23	NMOD
25	moderate	moderate	B-NP	JJ	O	26	NMOD
26	hypertension	hypertension	I-NP	NN	O	24	PMOD
27	entered	enter	B-VP	VBD	O	11	VMOD
28	the	the	B-NP	DT	O	29	NMOD
29	study	study	I-NP	NN	O	27	OBJ
30	.	.	O	.	O	11	P

1	The	The	B-NP	DT	O	3	NMOD
2	main	main	I-NP	JJ	O	3	NMOD
3	side-effects	side-effect	I-NP	NNS	O	4	SUB
4	were	be	B-VP	VBD	O	0	ROOT
5	headache	headache	B-NP	NN	O	11	NMOD
6	,	,	I-NP	,	O	11	P
7	dizziness	dizziness	I-NP	NN	O	11	NMOD
8	,	,	I-NP	,	O	11	P
9	palpitation	palpitation	I-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	flushing	flushing	I-NP	NN	O	14	SUB
12	and	and	O	CC	O	14	VMOD
13	these	these	B-NP	DT	O	14	SUB
14	were	be	B-VP	VBD	O	4	VMOD
15	not	not	B-ADJP	RB	O	14	VMOD
16	more	more	I-ADJP	RBR	O	17	AMOD
17	frequent	frequent	I-ADJP	JJ	O	14	PRD
18	than	than	B-SBAR	IN	O	17	AMOD
19	reported	report	B-VP	VBN	O	18	SBAR
20	in	in	B-PP	IN	O	19	VMOD
21	other	other	B-NP	JJ	O	22	NMOD
22	studies	study	I-NP	NNS	O	20	PMOD
23	with	with	B-PP	IN	O	22	NMOD
24	isradipine	isradipine	B-NP	NN	O	23	PMOD
25	or	or	B-PP	CC	O	20	PMOD
26	with	with	B-PP	IN	O	20	PMOD
27	placebo	placebo	B-NP	NN	O	26	PMOD
28	.	.	O	.	O	4	P

1	Tachyphylaxis	Tachyphylaxis	B-NP	NN	O	15	SUB
2	to	to	B-PP	TO	O	1	NMOD
3	systemic	systemic	B-ADJP	JJ	O	2	PMOD
4	but	but	I-ADJP	CC	O	3	AMOD
5	not	not	I-ADJP	RB	O	4	DEP
6	to	to	B-PP	TO	O	4	PMOD
7	airway	airway	B-NP	NN	O	8	NMOD
8	responses	response	I-NP	NNS	O	6	PMOD
9	during	during	B-PP	IN	O	1	NMOD
10	prolonged	prolonged	B-NP	JJ	O	11	NMOD
11	therapy	therapy	I-NP	NN	O	9	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	high	high	B-NP	JJ	O	14	NMOD
14	dose	dose	I-NP	NN	O	12	PMOD
15	inhaled	inhale	B-VP	VBD	O	0	ROOT
16	salbutamol	salbutamol	B-NP	NN	O	15	OBJ
17	in	in	B-PP	IN	O	16	NMOD
18	asthmatics	asthmatic	B-NP	NNS	O	17	PMOD
19	.	.	O	.	O	15	P

1	High	High	B-NP	JJ	O	2	NMOD
2	doses	dose	I-NP	NNS	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	inhaled	inhale	B-NP	VBN	O	5	NMOD
5	salbutamol	salbutamol	I-NP	NN	O	3	PMOD
6	produce	produce	B-VP	VBP	O	0	ROOT
7	substantial	substantial	B-NP	JJ	O	8	NMOD
8	improvements	improvement	I-NP	NNS	O	6	OBJ
9	in	in	B-PP	IN	O	8	NMOD
10	airway	airway	B-NP	NN	O	11	NMOD
11	response	response	I-NP	NN	O	9	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	patients	patient	B-NP	NNS	O	12	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	asthma	asthma	B-NP	NN	O	14	PMOD
16	,	,	O	,	O	6	P
17	and	and	O	CC	O	6	VMOD
18	are	be	B-VP	VBP	O	6	VMOD
19	associated	associate	I-VP	VBN	O	18	VC
20	with	with	B-PP	IN	O	19	VMOD
21	dose-dependent	dose-dependent	B-NP	JJ	O	24	NMOD
22	systemic	systemic	I-NP	JJ	O	24	NMOD
23	beta-adrenoceptor	beta-adrenoceptor	I-NP	NN	O	24	NMOD
24	responses	response	I-NP	NNS	O	20	PMOD
25	.	.	O	.	O	6	P

1	Twelve	Twelve	B-NP	CD	O	3	NMOD
2	asthmatic	asthmatic	I-NP	JJ	O	3	NMOD
3	patients	patient	I-NP	NNS	O	24	SUB
4	(	(	O	(	O	12	DEP
5	FEV1	FEV1	B-NP	NN	O	10	NMOD
6	,	,	O	,	O	10	P
7	81	81	B-NP	CD	O	9	AMOD
8	+/-	+/-	I-NP	CC	O	9	AMOD
9	4	4	I-NP	CD	O	10	NMOD
10	%	%	I-NP	NN	O	12	DEP
11	predicted	predict	B-VP	VBN	O	12	DEP
12	)	)	O	)	O	3	NMOD
13	,	,	O	,	O	3	P
14	requiring	require	B-VP	VBG	O	3	NMOD
15	only	only	B-NP	RB	O	16	AMOD
16	occasional	occasional	I-NP	JJ	O	18	NMOD
17	inhaled	inhale	I-NP	VBN	O	18	NMOD
18	beta-agonists	beta-agonist	I-NP	NNS	O	14	OBJ
19	as	as	B-PP	IN	O	14	VMOD
20	their	their	B-NP	PRP$	O	22	NMOD
21	sole	sole	I-NP	JJ	O	22	NMOD
22	therapy	therapy	I-NP	NN	O	19	PMOD
23	,	,	O	,	O	3	P
24	were	be	B-VP	VBD	O	0	ROOT
25	given	give	I-VP	VBN	O	24	VC
26	a	a	B-NP	DT	O	28	NMOD
27	14-day	14-day	I-NP	JJ	O	28	NMOD
28	treatment	treatment	I-NP	NN	O	25	OBJ
29	with	with	B-PP	IN	O	28	NMOD
30	high	high	B-NP	JJ	O	31	NMOD
31	dose	dose	I-NP	NN	O	29	PMOD
32	inhaled	inhale	B-VP	VBD	O	24	VMOD
33	salbutamol	salbutamol	B-NP	NN	O	41	NMOD
34	(	(	O	(	O	36	DEP
35	HDS	HDS	B-NP	NN	O	36	DEP
36	)	)	O	)	O	33	NMOD
37	,	,	O	,	O	41	P
38	4	4	B-NP	CD	O	41	NMOD
39	,	,	I-NP	,	O	41	P
40	000	000	I-NP	CD	O	41	NMOD
41	micrograms	microgram	I-NP	NNS	O	53	NMOD
42	daily	daily	I-NP	JJ	O	44	AMOD
43	,	,	I-NP	,	O	44	P
44	low	low	I-NP	JJ	O	45	NMOD
45	dose	dose	I-NP	NN	O	47	NMOD
46	inhaled	inhale	B-VP	VBD	O	47	NMOD
47	salbutamol	salbutamol	B-NP	NN	O	41	NMOD
48	(	(	O	(	O	50	DEP
49	LDS	LDS	B-NP	NN	B-protein	50	DEP
50	)	)	O	)	O	47	NMOD
51	,	,	O	,	O	53	P
52	800	800	B-NP	CD	O	53	NMOD
53	micrograms	microgram	I-NP	NNS	O	32	OBJ
54	daily	daily	B-ADVP	RB	O	53	NMOD
55	,	,	O	,	O	54	AMOD
56	or	or	O	CC	O	57	NMOD
57	placebo	placebo	B-NP	NN	O	55	SUB
58	(	(	O	(	O	60	DEP
59	PI	PI	B-NP	NN	O	60	DEP
60	)	)	O	)	O	57	NMOD
61	by	by	B-PP	IN	O	57	NMOD
62	metered-dose	metered-dose	B-NP	JJ	O	63	NMOD
63	inhaler	inhaler	I-NP	NN	O	61	PMOD
64	in	in	B-PP	IN	O	63	NMOD
65	a	a	B-NP	DT	O	70	NMOD
66	double-blind	double-blind	I-NP	JJ	O	68	AMOD
67	,	,	I-NP	,	O	68	P
68	randomized	randomize	I-NP	VBN	O	70	NMOD
69	crossover	crossover	I-NP	NN	O	70	NMOD
70	design	design	I-NP	NN	O	64	PMOD
71	.	.	O	.	O	24	P

1	At	At	B-PP	IN	O	40	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	end	end	I-NP	NN	O	15	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	each	each	B-NP	DT	O	7	NMOD
6	14-day	14-day	I-NP	JJ	O	7	NMOD
7	treatment	treatment	I-NP	NN	O	11	NMOD
8	,	,	O	,	O	11	P
9	a	a	B-NP	DT	O	11	NMOD
10	dose-response	dose-response	I-NP	JJ	O	11	NMOD
11	curve	curve	I-NP	NN	O	4	PMOD
12	(	(	O	(	O	14	DEP
13	DRC	DRC	B-NP	NN	B-protein	14	DEP
14	)	)	O	)	O	11	NMOD
15	was	be	B-VP	VBD	O	1	SBAR
16	performed	perform	I-VP	VBN	O	15	VC
17	,	,	O	,	O	40	P
18	and	and	O	CC	O	19	NMOD
19	airway	airway	B-NP	NN	O	40	VMOD
20	(	(	O	(	O	24	DEP
21	FEV1	FEV1	B-NP	NN	O	23	NMOD
22	,	,	O	,	O	23	P
23	FEF25-75	FEF25-75	B-NP	NN	O	24	DEP
24	)	)	O	)	O	19	NMOD
25	chronotropic	chronotropic	O	JJ	O	19	NMOD
26	(	(	O	(	O	28	DEP
27	HR	HR	B-NP	NN	B-protein	28	DEP
28	)	)	O	)	O	25	AMOD
29	,	,	O	,	O	40	P
30	tremor	tremor	B-NP	NN	O	40	SUB
31	,	,	O	,	O	40	P
32	and	and	O	CC	O	40	VMOD
33	metabolic	metabolic	B-ADJP	JJ	O	39	NMOD
34	(	(	O	(	O	38	DEP
35	K	K	B-NP	NN	O	37	NMOD
36	,	,	O	,	O	37	P
37	Glu	Glu	B-NP	NN	B-protein	38	DEP
38	)	)	O	)	O	33	AMOD
39	responses	response	B-NP	NNS	O	40	SUB
40	were	be	B-VP	VBD	O	0	ROOT
41	measured	measure	I-VP	VBN	O	40	VC
42	at	at	B-PP	IN	O	41	VMOD
43	each	each	B-NP	DT	O	44	NMOD
44	step	step	I-NP	NN	O	42	PMOD
45	(	(	O	(	O	53	DEP
46	from	from	B-PP	IN	O	53	DEP
47	100	100	B-NP	CD	O	49	AMOD
48	to	to	B-PP	TO	O	49	AMOD
49	4	4	B-NP	CD	O	52	NMOD
50	,	,	O	,	O	52	P
51	000	000	B-NP	CD	O	52	NMOD
52	micrograms	microgram	I-NP	NNS	O	46	PMOD
53	)	)	O	)	O	44	NMOD
54	.	.	O	.	O	40	P

1	Increased	Increase	B-NP	VBN	O	3	NMOD
2	anxiogenic	anxiogenic	I-NP	JJ	O	3	NMOD
3	effects	effect	I-NP	NNS	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	caffeine	caffeine	B-NP	NN	O	4	PMOD
6	in	in	B-PP	IN	O	3	NMOD
7	panic	panic	B-NP	NN	O	8	NMOD
8	disorders	disorder	I-NP	NNS	O	6	PMOD
9	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	effects	effect	I-NP	NNS	O	23	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	oral	oral	B-NP	JJ	O	5	NMOD
5	administration	administration	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	caffeine	caffeine	B-NP	NN	O	6	PMOD
8	(	(	O	(	O	11	DEP
9	10	10	B-NP	CD	O	10	NMOD
10	mg/kg	mg/kg	I-NP	NN	O	11	DEP
11	)	)	O	)	O	5	NMOD
12	on	on	B-PP	IN	O	2	NMOD
13	behavioral	behavioral	B-NP	JJ	O	14	NMOD
14	ratings	rating	I-NP	NNS	O	12	PMOD
15	,	,	O	,	O	23	P
16	somatic	somatic	B-NP	JJ	O	17	NMOD
17	symptoms	symptom	I-NP	NNS	O	23	NMOD
18	,	,	O	,	O	23	P
19	blood	blood	B-NP	NN	O	20	NMOD
20	pressure	pressure	I-NP	NN	O	23	NMOD
21	and	and	I-NP	CC	O	23	NMOD
22	plasma	plasma	I-NP	NN	O	23	NMOD
23	levels	level	I-NP	NNS	O	31	SUB
24	of	of	B-PP	IN	O	23	NMOD
25	3-methoxy-4-hydroxyphenethyleneglycol	3-methoxy-4-hydroxyphenethyleneglycol	B-NP	NN	O	30	NMOD
26	(	(	O	(	O	28	DEP
27	MHPG	MHPG	B-NP	NN	B-protein	28	DEP
28	)	)	O	)	O	25	NMOD
29	and	and	O	CC	O	30	NMOD
30	cortisol	cortisol	B-NP	NN	O	24	PMOD
31	were	be	B-VP	VBD	O	0	ROOT
32	determined	determine	I-VP	VBN	O	31	VC
33	in	in	B-PP	IN	O	32	VMOD
34	17	17	B-NP	CD	O	36	NMOD
35	healthy	healthy	I-NP	JJ	O	36	NMOD
36	subjects	subject	I-NP	NNS	O	39	NMOD
37	and	and	O	CC	O	39	NMOD
38	21	21	B-NP	CD	O	39	NMOD
39	patients	patient	I-NP	NNS	O	33	PMOD
40	meeting	meet	B-VP	VBG	O	39	NMOD
41	DSM-III	DSM-III	B-NP	NN	O	42	NMOD
42	criteria	criterion	I-NP	NNS	O	40	OBJ
43	for	for	B-PP	IN	O	42	NMOD
44	agoraphobia	agoraphobia	B-NP	NN	O	43	PMOD
45	with	with	B-PP	IN	O	44	NMOD
46	panic	panic	B-NP	JJ	O	47	NMOD
47	attacks	attack	I-NP	NNS	O	50	NMOD
48	or	or	O	CC	O	50	NMOD
49	panic	panic	B-NP	NN	O	50	NMOD
50	disorder	disorder	I-NP	NN	O	45	PMOD
51	.	.	O	.	O	31	P

1	Caffeine	Caffeine	B-NP	NN	O	2	SUB
2	produced	produce	B-VP	VBD	O	0	ROOT
3	significantly	significantly	B-NP	RB	O	4	AMOD
4	greater	great	I-NP	JJR	O	5	NMOD
5	increases	increase	I-NP	NNS	O	2	OBJ
6	in	in	B-PP	IN	O	5	NMOD
7	subject-rated	subject-rated	B-NP	JJ	O	8	NMOD
8	anxiety	anxiety	I-NP	NN	O	21	NMOD
9	,	,	O	,	O	21	P
10	nervousness	nervousness	B-NP	NN	O	21	NMOD
11	,	,	O	,	O	21	P
12	fear	fear	B-NP	NN	O	21	NMOD
13	,	,	O	,	O	21	P
14	nausea	nausea	B-NP	NN	O	21	NMOD
15	,	,	O	,	O	21	P
16	palpitations	palpitation	B-NP	NNS	O	21	NMOD
17	,	,	O	,	O	21	P
18	restlessness	restlessness	B-NP	NN	O	21	NMOD
19	,	,	O	,	O	21	P
20	and	and	O	CC	O	21	NMOD
21	tremors	tremor	B-NP	NNS	O	6	PMOD
22	in	in	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	24	NMOD
24	patients	patient	I-NP	NNS	O	22	PMOD
25	compared	compare	B-PP	VBN	O	2	VMOD
26	with	with	B-PP	IN	O	25	PMOD
27	healthy	healthy	B-NP	JJ	O	28	NMOD
28	subjects	subject	I-NP	NNS	O	26	PMOD
29	.	.	O	.	O	2	P

1	Seventy-one	Seventy-one	B-NP	CD	O	2	NMOD
2	percent	percent	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	patients	patient	I-NP	NNS	O	3	PMOD
6	reported	report	B-VP	VBD	O	0	ROOT
7	that	that	B-SBAR	IN	O	6	VMOD
8	the	the	B-NP	DT	O	10	NMOD
9	behavioral	behavioral	I-NP	JJ	O	10	NMOD
10	effects	effect	I-NP	NNS	O	13	SUB
11	of	of	B-PP	IN	O	10	NMOD
12	caffeine	caffeine	B-NP	NN	O	11	PMOD
13	were	be	B-VP	VBD	O	7	SBAR
14	similar	similar	B-ADJP	JJ	O	13	PRD
15	to	to	B-PP	TO	O	14	AMOD
16	those	those	B-NP	DT	O	15	PMOD
17	experienced	experience	B-VP	VBN	O	16	NMOD
18	during	during	B-PP	IN	O	17	VMOD
19	panic	panic	B-NP	NN	O	20	NMOD
20	attacks	attack	I-NP	NNS	O	18	PMOD
21	.	.	O	.	O	6	P

1	Because	Because	B-SBAR	IN	O	11	VMOD
2	caffeine	caffeine	B-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	1	SBAR
4	an	an	B-NP	DT	O	7	NMOD
5	adenosine	adenosine	I-NP	NN	O	7	NMOD
6	receptor	receptor	I-NP	NN	O	7	NMOD
7	antagonist	antagonist	I-NP	NN	O	3	PRD
8	,	,	O	,	O	11	P
9	these	these	B-NP	DT	O	10	NMOD
10	results	result	I-NP	NNS	O	11	SUB
11	suggest	suggest	B-VP	VBP	O	0	ROOT
12	that	that	B-SBAR	IN	O	11	VMOD
13	some	some	B-NP	DT	O	16	NMOD
14	panic	panic	I-NP	JJ	O	16	NMOD
15	disorder	disorder	I-NP	NN	O	16	NMOD
16	patients	patient	I-NP	NNS	O	17	SUB
17	may	may	B-VP	MD	O	12	SBAR
18	have	have	I-VP	VB	O	17	VC
19	abnormalities	abnormality	B-NP	NNS	O	18	OBJ
20	in	in	B-PP	IN	O	18	VMOD
21	neuronal	neuronal	B-NP	JJ	O	22	NMOD
22	systems	system	I-NP	NNS	O	20	PMOD
23	involving	involve	B-VP	VBG	O	22	NMOD
24	adenosine	adenosine	B-NP	NN	O	23	OBJ
25	.	.	O	.	O	11	P

1	In	In	B-PP	IN	O	18	VMOD
2	the	the	B-NP	DT	O	6	NMOD
3	first	first	I-NP	JJ	O	6	NMOD
4	,	,	I-NP	,	O	6	P
5	cobalt	cobalt	I-NP	NN	O	6	NMOD
6	cardiomyopathy	cardiomyopathy	I-NP	NN	O	7	SUB
7	was	be	B-VP	VBD	O	1	SBAR
8	induced	induce	I-VP	VBN	O	7	VC
9	in	in	B-PP	IN	O	8	VMOD
10	eight	eight	B-NP	CD	O	11	NMOD
11	dogs	dog	I-NP	NNS	O	9	PMOD
12	;	;	O	:	O	1	P
13	VIP	VIP	B-NP	NN	B-protein	18	SUB
14	(	(	O	(	O	17	DEP
15	by	by	B-PP	IN	O	17	DEP
16	radioimmunoassay	radioimmunoassay	B-NP	NN	O	15	PMOD
17	)	)	O	)	O	13	NMOD
18	decreased	decrease	B-VP	VBD	O	0	ROOT
19	from	from	B-PP	IN	O	18	VMOD
20	35	35	B-NP	CD	O	22	AMOD
21	+/-	+/-	I-NP	SYM	O	22	AMOD
22	11	11	I-NP	CD	O	24	NMOD
23	pg/mg	pg/mg	I-NP	NN	O	24	NMOD
24	protein	protein	I-NP	NN	O	19	PMOD
25	(	(	O	(	O	29	DEP
26	mean	mean	B-NP	NN	O	28	NMOD
27	+/-	+/-	O	SYM	O	28	NMOD
28	SD	SD	B-NP	NN	O	29	DEP
29	)	)	O	)	O	18	VMOD
30	to	to	B-PP	TO	O	18	VMOD
31	5	5	B-NP	CD	O	33	AMOD
32	+/-	+/-	I-NP	SYM	O	33	AMOD
33	4	4	I-NP	CD	O	35	NMOD
34	pg/mg	pg/mg	I-NP	NN	O	35	NMOD
35	protein	protein	I-NP	NN	O	30	PMOD
36	(	(	O	(	O	41	DEP
37	P	P	B-NP	NN	O	41	DEP
38	less	less	B-ADJP	JJR	O	37	NMOD
39	than	than	B-PP	IN	O	38	AMOD
40	0.05	0.05	B-NP	CD	O	39	PMOD
41	)	)	O	)	O	35	NMOD
42	.	.	O	.	O	18	P

1	In	In	B-PP	IN	O	11	VMOD
2	six	six	B-NP	CD	O	3	NMOD
3	dogs	dog	I-NP	NNS	O	6	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	doxorubicin	doxorubicin	B-NP	NN	O	4	PMOD
6	induced	induce	B-VP	VBD	O	1	SBAR
7	heart	heart	B-NP	NN	O	8	NMOD
8	failure	failure	I-NP	NN	O	6	OBJ
9	,	,	O	,	O	11	P
10	VIP	VIP	B-NP	NN	B-protein	11	SUB
11	decreased	decrease	B-VP	VBD	O	0	ROOT
12	from	from	B-PP	IN	O	11	VMOD
13	31	31	B-NP	CD	O	15	AMOD
14	+/-	+/-	I-NP	SYM	O	15	AMOD
15	7	7	I-NP	CD	O	12	PMOD
16	to	to	I-NP	TO	O	11	VMOD
17	11	11	I-NP	CD	O	21	NMOD
18	+/-	+/-	I-NP	SYM	O	21	NMOD
19	4	4	I-NP	CD	O	21	NMOD
20	pg/mg	pg/mg	I-NP	NN	O	21	NMOD
21	protein	protein	I-NP	NN	O	16	PMOD
22	(	(	O	(	O	27	DEP
23	P	P	B-NP	NN	O	27	DEP
24	less	less	B-ADJP	JJR	O	23	NMOD
25	than	than	B-PP	IN	O	24	AMOD
26	0.05	0.05	B-NP	CD	O	25	PMOD
27	)	)	O	)	O	21	NMOD
28	.	.	O	.	O	11	P

1	Five	Five	B-NP	CD	O	3	NMOD
2	phenotypic	phenotypic	I-NP	JJ	O	3	NMOD
3	characteristics	characteristic	I-NP	NNS	O	13	NMOD
4	--	--	O	:	O	3	P
5	locomotor	locomotor	B-NP	NN	O	6	NMOD
6	activity	activity	I-NP	NN	O	13	NMOD
7	,	,	O	,	O	13	P
8	righting	righting	B-NP	NN	O	9	NMOD
9	ability	ability	I-NP	NN	O	13	NMOD
10	,	,	O	,	O	13	P
11	clonic	clonic	B-NP	JJ	O	13	NMOD
12	seizure	seizure	I-NP	NN	O	13	NMOD
13	induction	induction	I-NP	NN	O	16	SUB
14	,	,	O	,	O	16	P
15	stress	stress	B-NP	NN	O	16	SUB
16	induced	induce	B-VP	VBD	O	0	ROOT
17	lethality	lethality	B-NP	NN	O	19	NMOD
18	,	,	O	,	O	19	P
19	death	death	B-NP	NN	O	16	OBJ
20	without	without	B-PP	IN	O	16	VMOD
21	external	external	B-NP	JJ	O	22	NMOD
22	stress	stress	I-NP	NN	O	20	PMOD
23	--	--	O	:	O	16	P
24	were	be	B-VP	VBD	O	16	VMOD
25	scored	score	I-VP	VBN	O	24	VC
26	at	at	B-PP	IN	O	25	VMOD
27	various	various	B-NP	JJ	O	29	NMOD
28	caffeine	caffeine	I-NP	NN	O	29	NMOD
29	doses	dose	I-NP	NNS	O	26	PMOD
30	in	in	B-PP	IN	O	29	NMOD
31	drug-naive	drug-naive	B-NP	JJ	O	32	NMOD
32	animals	animal	I-NP	NNS	O	30	PMOD
33	under	under	B-PP	IN	O	25	VMOD
34	empirically	empirically	B-NP	RB	O	35	AMOD
35	optimized	optimize	B-VP	VBN	O	40	NMOD
36	,	,	O	,	O	35	P
37	rigidly	rigidly	B-NP	RB	O	38	AMOD
38	constant	constant	I-NP	JJ	O	40	NMOD
39	experimental	experimental	I-NP	JJ	O	40	NMOD
40	conditions	condition	I-NP	NNS	O	33	PMOD
41	.	.	O	.	O	16	P

1	Invasive	Invasive	B-NP	JJ	O	2	NMOD
2	carcinoma	carcinoma	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	renal	renal	I-NP	JJ	O	6	NMOD
6	pelvis	pelvis	I-NP	NN	O	3	PMOD
7	following	follow	B-PP	VBG	O	2	NMOD
8	cyclophosphamide	cyclophosphamide	B-NP	NN	O	9	NMOD
9	therapy	therapy	I-NP	NN	O	7	PMOD
10	for	for	B-PP	IN	O	9	NMOD
11	nonmalignant	nonmalignant	B-NP	JJ	O	12	NMOD
12	disease	disease	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	3	NMOD
2	47-year-old	47-year-old	I-NP	JJ	O	3	NMOD
3	woman	woman	I-NP	NN	O	12	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	right	right	B-NP	JJ	O	6	NMOD
6	hydroureteronephrosis	hydroureteronephrosis	I-NP	NN	O	4	PMOD
7	due	due	B-PP	JJ	O	3	NMOD
8	to	to	B-PP	TO	O	7	AMOD
9	ureterovesical	ureterovesical	B-NP	JJ	O	11	NMOD
10	junction	junction	I-NP	NN	O	11	NMOD
11	obstruction	obstruction	I-NP	NN	O	8	PMOD
12	had	have	B-VP	VBD	O	0	ROOT
13	gross	gross	B-NP	JJ	O	14	NMOD
14	hematuria	hematuria	I-NP	NN	O	12	OBJ
15	after	after	B-PP	IN	O	12	VMOD
16	being	be	B-VP	VBG	O	15	PMOD
17	treated	treat	I-VP	VBN	O	16	VC
18	for	for	B-PP	IN	O	17	VMOD
19	five	five	B-NP	CD	O	20	NMOD
20	years	year	I-NP	NNS	O	18	PMOD
21	wtih	wtih	B-VP	VBP	O	12	VMOD
22	cyclophosphamide	cyclophosphamide	B-NP	NN	O	21	OBJ
23	for	for	B-PP	IN	O	22	NMOD
24	cerebral	cerebral	B-NP	JJ	O	25	NMOD
25	vasculitis	vasculitis	I-NP	NN	O	23	PMOD
26	.	.	O	.	O	12	P

1	Although	Although	B-SBAR	IN	O	24	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	ability	ability	I-NP	NN	O	19	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	cyclophosphamide	cyclophosphamide	B-NP	NN	O	4	PMOD
6	to	to	B-VP	TO	O	7	VMOD
7	cause	cause	I-VP	VB	O	3	NMOD
8	hemorrhagic	hemorrhagic	B-NP	JJ	O	9	NMOD
9	cystitis	cystitis	I-NP	NN	O	13	NMOD
10	and	and	O	CC	O	13	NMOD
11	urine	urine	B-NP	NN	O	13	NMOD
12	cytologic	cytologic	I-NP	JJ	O	13	NMOD
13	abnormalities	abnormality	I-NP	NNS	O	7	OBJ
14	indistinguishable	indistinguishable	B-ADJP	JJ	O	13	NMOD
15	from	from	B-PP	IN	O	14	AMOD
16	high	high	B-NP	JJ	O	18	NMOD
17	grade	grade	I-NP	NN	O	18	NMOD
18	carcinoma	carcinoma	I-NP	NN	O	15	PMOD
19	is	be	B-VP	VBZ	O	1	SBAR
20	well	well	I-VP	RB	O	19	VMOD
21	known	know	I-VP	VBN	O	19	VC
22	,	,	O	,	O	24	P
23	it	it	B-NP	PRP	O	24	SUB
24	is	be	B-VP	VBZ	O	0	ROOT
25	less	less	I-VP	RBR	O	26	AMOD
26	widely	widely	I-VP	RB	O	24	VMOD
27	appreciated	appreciate	I-VP	VBN	O	24	VC
28	that	that	B-SBAR	IN	O	27	VMOD
29	it	it	B-NP	PRP	O	30	SUB
30	is	be	B-VP	VBZ	O	28	SBAR
31	also	also	I-VP	RB	O	30	VMOD
32	associated	associate	I-VP	VBN	O	30	VC
33	with	with	B-PP	IN	O	32	VMOD
34	carcinoma	carcinoma	B-NP	NN	O	33	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	the	the	B-NP	DT	O	38	NMOD
37	urinary	urinary	I-NP	JJ	O	38	NMOD
38	tract	tract	I-NP	NN	O	35	PMOD
39	.	.	O	.	O	24	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	case	case	I-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	the	the	B-NP	DT	O	7	NMOD
6	first	first	I-NP	JJ	O	7	NMOD
7	carcinoma	carcinoma	I-NP	NN	O	4	PRD
8	of	of	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	11	NMOD
10	renal	renal	I-NP	JJ	O	11	NMOD
11	pelvis	pelvis	I-NP	NN	O	8	PMOD
12	reported	report	B-VP	VBN	O	11	NMOD
13	in	in	B-PP	IN	O	12	VMOD
14	association	association	B-NP	NN	O	13	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	cyclophosphamide	cyclophosphamide	B-NP	NN	O	17	NMOD
17	treatment	treatment	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	4	P

1	It	It	B-NP	PRP	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	the	the	B-NP	DT	O	7	NMOD
4	third	third	I-NP	JJ	O	7	NMOD
5	urinary	urinary	I-NP	JJ	O	7	NMOD
6	tract	tract	I-NP	NN	O	7	NMOD
7	cancer	cancer	I-NP	NN	O	2	PRD
8	reported	report	B-VP	VBN	O	7	NMOD
9	in	in	B-PP	IN	O	8	VMOD
10	association	association	B-NP	NN	O	9	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	cyclophosphamide	cyclophosphamide	B-NP	NN	O	13	NMOD
13	treatment	treatment	I-NP	NN	O	11	PMOD
14	for	for	B-PP	IN	O	13	NMOD
15	nonmalignant	nonmalignant	B-NP	JJ	O	16	NMOD
16	disease	disease	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	association	association	I-NP	NN	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	tumor	tumor	I-NP	NN	O	3	PMOD
6	with	with	B-PP	IN	O	2	NMOD
7	preexisting	preexist	B-VP	VBG	O	6	PMOD
8	hydroureteronephrosis	hydroureteronephrosis	B-NP	NN	O	7	OBJ
9	suggests	suggest	B-VP	VBZ	O	0	ROOT
10	that	that	B-SBAR	IN	O	9	VMOD
11	stasis	stasis	B-NP	NN	O	12	SUB
12	prolonged	prolong	B-VP	VBD	O	10	SBAR
13	and	and	I-VP	CC	O	12	VMOD
14	intensified	intensify	I-VP	VBD	O	12	VMOD
15	exposure	exposure	B-NP	NN	O	14	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	upper	upper	B-NP	JJ	O	20	NMOD
18	urinary	urinary	I-NP	JJ	O	20	NMOD
19	tract	tract	I-NP	NN	O	20	NMOD
20	epithelium	epithelium	I-NP	NN	O	16	PMOD
21	to	to	B-PP	TO	O	15	NMOD
22	cyclophosphamide	cyclophosphamide	B-NP	NN	O	21	PMOD
23	.	.	O	.	O	9	P

1	A	A	B-NP	DT	O	3	NMOD
2	pilot	pilot	I-NP	NN	O	3	NMOD
3	study	study	I-NP	NN	O	0	ROOT
4	to	to	B-VP	TO	O	5	VMOD
5	assess	assess	I-VP	VB	O	3	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	safety	safety	I-NP	NN	O	5	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	dobutamine	dobutamine	B-NP	NN	O	11	NMOD
10	stress	stress	I-NP	NN	O	11	NMOD
11	echocardiography	echocardiography	I-NP	NN	O	8	PMOD
12	in	in	B-PP	IN	O	5	VMOD
13	the	the	B-NP	DT	O	16	NMOD
14	emergency	emergency	I-NP	NN	O	16	NMOD
15	department	department	I-NP	NN	O	16	NMOD
16	evaluation	evaluation	I-NP	NN	O	12	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	cocaine-associated	cocaine-associated	B-NP	JJ	O	20	NMOD
19	chest	chest	I-NP	NN	O	20	NMOD
20	pain	pain	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	3	P

1	STUDY	STUDY	B-NP	NN	O	2	NMOD
2	OBJECTIVE	OBJECTIVE	I-NP	NN	O	0	ROOT
3	:	:	O	:	O	2	P
4	Chest	Ch	B-NP	JJS	O	5	NMOD
5	pain	pain	I-NP	NN	O	12	SUB
6	in	in	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	setting	setting	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	cocaine	cocaine	B-NP	NN	O	11	NMOD
11	use	use	I-NP	NN	O	9	PMOD
12	poses	pose	B-VP	VBZ	O	2	NMOD
13	a	a	B-NP	DT	O	15	NMOD
14	diagnostic	diagnostic	I-NP	JJ	O	15	NMOD
15	dilemma	dilemma	I-NP	NN	O	12	OBJ
16	.	.	O	.	O	12	P

1	Dobutamine	Dobutamine	B-NP	NN	O	3	NMOD
2	stress	stress	I-NP	NN	O	3	NMOD
3	echocardiography	echocardiography	I-NP	NN	O	7	SUB
4	(	(	O	(	O	6	DEP
5	DSE	DSE	B-NP	NN	B-DNA	6	DEP
6	)	)	O	)	O	3	NMOD
7	is	be	B-VP	VBZ	O	0	ROOT
8	a	a	B-NP	DT	O	13	NMOD
9	widely	widely	I-NP	RB	O	10	AMOD
10	available	available	I-NP	JJ	O	12	AMOD
11	and	and	I-NP	CC	O	12	AMOD
12	sensitive	sensitive	I-NP	JJ	O	13	NMOD
13	test	test	I-NP	NN	O	7	PRD
14	for	for	B-PP	IN	O	13	NMOD
15	evaluating	evaluate	B-VP	VBG	O	14	PMOD
16	cardiac	cardiac	B-NP	JJ	O	17	NMOD
17	ischemia	ischemia	I-NP	NN	O	15	OBJ
18	.	.	O	.	O	7	P

1	Because	Because	B-PP	IN	O	18	VMOD
2	of	of	I-PP	IN	O	1	PMOD
3	the	the	B-NP	DT	O	5	NMOD
4	theoretical	theoretical	I-NP	JJ	O	5	NMOD
5	concern	concern	I-NP	NN	O	1	PMOD
6	regarding	regard	B-VP	VBG	O	5	NMOD
7	administration	administration	B-NP	NN	O	6	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	dobutamine	dobutamine	B-NP	NN	O	8	PMOD
10	in	in	B-PP	IN	O	7	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	setting	setting	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	cocaine	cocaine	B-NP	NN	O	15	NMOD
15	use	use	I-NP	NN	O	13	PMOD
16	,	,	O	,	O	18	P
17	we	we	B-NP	PRP	O	18	SUB
18	conducted	conduct	B-VP	VBD	O	0	ROOT
19	a	a	B-NP	DT	O	21	NMOD
20	pilot	pilot	I-NP	JJ	O	21	NMOD
21	study	study	I-NP	NN	O	18	OBJ
22	to	to	B-VP	TO	O	23	VMOD
23	assess	assess	I-VP	VB	O	21	NMOD
24	the	the	B-NP	DT	O	25	NMOD
25	safety	safety	I-NP	NN	O	23	OBJ
26	of	of	B-PP	IN	O	25	NMOD
27	DSE	DSE	B-NP	NN	B-DNA	26	PMOD
28	in	in	B-PP	IN	O	25	NMOD
29	emergency	emergency	B-NP	NN	O	31	NMOD
30	department	department	I-NP	NN	O	31	NMOD
31	patients	patient	I-NP	NNS	O	28	PMOD
32	with	with	B-PP	IN	O	31	NMOD
33	cocaine-associated	cocaine-associated	B-NP	JJ	O	35	NMOD
34	chest	chest	I-NP	NN	O	35	NMOD
35	pain	pain	I-NP	NN	O	32	PMOD
36	.	.	O	.	O	18	P

1	Patients	Patient	B-NP	NNS	O	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	eligible	eligible	B-ADJP	JJ	O	2	PRD
4	for	for	B-PP	IN	O	3	AMOD
5	DSE	DSE	B-NP	NN	B-DNA	4	PMOD
6	if	if	B-SBAR	IN	O	2	VMOD
7	they	they	B-NP	PRP	O	8	SUB
8	had	have	B-VP	VBD	O	6	SBAR
9	used	use	I-VP	VBN	O	8	VC
10	cocaine	cocaine	B-NP	NN	O	9	OBJ
11	within	within	B-PP	IN	O	9	VMOD
12	24	24	B-NP	CD	O	13	NMOD
13	hours	hour	I-NP	NNS	O	11	PMOD
14	preceding	precede	B-VP	VBG	O	13	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	onset	onset	I-NP	NN	O	14	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	chest	chest	B-NP	NN	O	19	NMOD
19	pain	pain	I-NP	NN	O	17	PMOD
20	and	and	O	CC	O	2	VMOD
21	had	have	B-VP	VBD	O	2	VMOD
22	a	a	B-NP	DT	O	24	NMOD
23	normal	normal	I-NP	JJ	O	24	NMOD
24	ECG	ECG	I-NP	NN	O	28	NMOD
25	and	and	I-NP	CC	O	28	NMOD
26	tropinin	tropinin	I-NP	NN	O	28	NMOD
27	I	I	I-NP	CD	O	28	NMOD
28	level	level	I-NP	NN	O	21	OBJ
29	.	.	O	.	O	2	P

1	Patients	Patient	B-NP	NNS	O	8	SUB
2	exhibiting	exhibit	B-VP	VBG	O	1	NMOD
3	signs	sign	B-NP	NNS	O	2	OBJ
4	of	of	B-PP	IN	O	3	NMOD
5	continuing	continue	B-NP	VBG	O	7	NMOD
6	cocaine	cocaine	I-NP	NN	O	7	NMOD
7	toxicity	toxicity	I-NP	NN	O	4	PMOD
8	were	be	B-VP	VBD	O	0	ROOT
9	excluded	exclude	I-VP	VBN	O	8	VC
10	from	from	B-PP	IN	O	9	VMOD
11	the	the	B-NP	DT	O	12	NMOD
12	study	study	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	8	P

1	Amiodarone	Amiodarone	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	torsade	torsade	B-NP	FW	O	2	VMOD
4	de	de	I-NP	FW	O	5	NMOD
5	pointes	pointes	I-NP	FW	O	3	AMOD
6	during	during	B-PP	IN	O	2	VMOD
7	bladder	bladder	B-NP	NN	O	8	NMOD
8	irrigation	irrigation	I-NP	NN	O	6	PMOD
9	:	:	O	:	O	2	P
10	an	an	B-NP	DT	O	12	NMOD
11	unusual	unusual	I-NP	JJ	O	12	NMOD
12	presentation	presentation	I-NP	NN	O	16	NMOD
13	--	--	O	:	O	16	P
14	a	a	B-NP	DT	O	16	NMOD
15	case	case	I-NP	NN	O	16	NMOD
16	report	report	I-NP	NN	O	2	VMOD
17	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	authors	author	I-NP	NNS	O	3	SUB
3	present	present	B-VP	VBP	O	0	ROOT
4	a	a	B-NP	DT	O	5	NMOD
5	case	case	I-NP	NN	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	early	early	B-ADVP	JJ	O	6	PMOD
8	(	(	O	(	O	12	DEP
9	within	within	B-PP	IN	O	12	DEP
10	4	4	B-NP	CD	O	11	NMOD
11	days	day	I-NP	NNS	O	9	PMOD
12	)	)	O	)	O	7	AMOD
13	development	development	B-NP	NN	O	7	NMOD
14	of	of	B-PP	IN	O	7	NMOD
15	torsade	torsade	B-NP	FW	O	17	NMOD
16	de	de	I-NP	FW	O	17	NMOD
17	pointes	pointes	I-NP	FW	O	14	PMOD
18	(	(	O	(	O	20	DEP
19	TdP	TdP	B-NP	NN	O	20	DEP
20	)	)	O	)	O	17	NMOD
21	associated	associate	B-VP	VBN	O	17	NMOD
22	with	with	B-PP	IN	O	21	VMOD
23	oral	oral	B-NP	JJ	O	25	NMOD
24	amiodarone	amiodarone	I-NP	NN	O	25	NMOD
25	therapy	therapy	I-NP	NN	O	22	PMOD
26	.	.	O	.	O	3	P

1	Consistent	Consistent	B-ADJP	JJ	O	6	NMOD
2	with	with	B-PP	IN	O	1	AMOD
3	other	other	B-NP	JJ	O	4	NMOD
4	reports	report	I-NP	NNS	O	2	PMOD
5	this	this	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	9	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	TdP	TdP	B-NP	NN	B-protein	7	PMOD
9	occurred	occur	B-VP	VBD	O	0	ROOT
10	in	in	B-PP	IN	O	9	VMOD
11	the	the	B-NP	DT	O	12	NMOD
12	context	context	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	multiple	multiple	B-NP	JJ	O	16	NMOD
15	exacerbating	exacerbating	I-NP	JJ	B-protein	16	NMOD
16	factors	factor	I-NP	NNS	I-protein	13	PMOD
17	including	include	B-PP	VBG	O	16	NMOD
18	hypokalemia	hypokalemia	B-NP	NN	O	21	NMOD
19	and	and	I-NP	CC	O	21	NMOD
20	digoxin	digoxin	I-NP	NN	O	21	NMOD
21	excess	excess	I-NP	NN	O	17	PMOD
22	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	2	NMOD
2	authors	author	I-NP	NNS	O	3	SUB
3	speculate	speculate	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	the	the	B-NP	DT	O	8	NMOD
6	increased	increase	I-NP	VBN	O	8	NMOD
7	vagal	vagal	I-NP	JJ	O	8	NMOD
8	tone	tone	I-NP	NN	O	15	NMOD
9	during	during	B-PP	IN	O	8	NMOD
10	bladder	bladder	B-NP	NN	O	11	NMOD
11	irrigation	irrigation	I-NP	NN	O	9	PMOD
12	,	,	O	,	O	15	P
13	a	a	B-NP	DT	O	15	NMOD
14	vagal	vagal	I-NP	JJ	O	15	NMOD
15	maneuver	maneuver	I-NP	NN	O	23	SUB
16	,	,	O	,	O	15	P
17	in	in	B-PP	IN	O	15	NMOD
18	the	the	B-NP	DT	O	19	NMOD
19	context	context	I-NP	NN	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	amiodarone	amiodarone	B-NP	NN	O	22	NMOD
22	therapy	therapy	I-NP	NN	O	20	PMOD
23	resulted	result	B-VP	VBD	O	4	SBAR
24	in	in	B-PP	IN	O	23	VMOD
25	amiodarone	amiodarone	B-NP	NN	O	27	NMOD
26	induced	induced	I-NP	JJ	O	27	NMOD
27	proarrhythmia	proarrhythmia	I-NP	NN	O	24	PMOD
28	.	.	O	.	O	3	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	renal	renal	I-NP	JJ	O	3	NMOD
3	insufficiency	insufficiency	I-NP	NN	O	0	ROOT
4	after	after	B-PP	IN	O	3	NMOD
5	high-dose	high-dose	B-NP	JJ	O	6	NMOD
6	melphalan	melphalan	I-NP	NN	O	4	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	patients	patient	B-NP	NNS	O	7	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	primary	primary	B-NP	JJ	O	12	NMOD
11	systemic	systemic	I-NP	JJ	O	12	NMOD
12	amyloidosis	amyloidosis	I-NP	NN	O	9	PMOD
13	during	during	B-PP	IN	O	3	NMOD
14	stem	stem	B-NP	NN	O	16	NMOD
15	cell	cell	I-NP	NN	O	16	NMOD
16	transplantation	transplantation	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	authors	author	I-NP	NNS	O	3	SUB
3	have	have	B-VP	VBP	O	0	ROOT
4	noted	note	I-VP	VBN	O	3	VC
5	the	the	B-NP	DT	O	6	NMOD
6	development	development	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	acute	acute	B-NP	JJ	O	10	NMOD
9	renal	renal	I-NP	JJ	O	10	NMOD
10	insufficiency	insufficiency	I-NP	NN	O	7	PMOD
11	immediately	immediately	B-ADVP	RB	O	12	PMOD
12	after	after	B-PP	IN	O	4	VMOD
13	melphalan	melphalan	B-NP	NN	O	14	NMOD
14	conditioning	conditioning	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	3	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	renal	renal	I-NP	JJ	O	3	NMOD
3	insufficiency	insufficiency	I-NP	NN	O	10	SUB
4	(	(	O	(	O	6	DEP
5	ARI	ARI	B-NP	NN	O	6	DEP
6	)	)	O	)	O	3	NMOD
7	after	after	B-PP	IN	O	3	NMOD
8	high-dose	high-dose	B-NP	JJ	O	9	NMOD
9	melphalan	melphalan	I-NP	NN	O	7	PMOD
10	was	be	B-VP	VBD	O	0	ROOT
11	defined	define	I-VP	VBN	O	10	VC
12	by	by	B-PP	IN	O	11	VMOD
13	a	a	B-NP	DT	O	15	NMOD
14	minimum	minimum	I-NP	JJ	O	15	NMOD
15	increase	increase	I-NP	NN	O	12	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	0.5	0.5	B-NP	CD	O	18	NMOD
18	mg/dL	mg/dL	I-NP	NN	O	16	PMOD
19	(	(	O	(	O	22	DEP
20	44	44	B-NP	CD	O	21	NMOD
21	micromol/L	micromol/L	I-NP	NN	O	22	DEP
22	)	)	O	)	O	18	NMOD
23	in	in	B-PP	IN	O	15	NMOD
24	the	the	B-NP	DT	O	27	NMOD
25	serum	serum	I-NP	NN	O	27	NMOD
26	creatinine	creatinine	I-NP	NN	O	27	NMOD
27	level	level	I-NP	NN	O	23	PMOD
28	that	that	B-NP	WDT	O	27	NMOD
29	is	be	B-VP	VBZ	O	28	SBAR
30	greater	great	B-ADJP	JJR	O	29	VMOD
31	than	than	B-PP	IN	O	30	AMOD
32	50	50	B-NP	CD	O	33	NMOD
33	%	%	I-NP	NN	O	31	PMOD
34	of	of	B-PP	IN	O	33	NMOD
35	baseline	baseline	B-NP	NN	O	34	PMOD
36	immediately	immediately	B-ADVP	RB	O	29	VMOD
37	after	after	B-PP	IN	O	29	VMOD
38	conditioning	condition	B-VP	VBG	O	37	PMOD
39	.	.	O	.	O	10	P

1	RESULTS	RESULTS	B-NP	NNS	O	10	SUB
2	:	:	O	:	O	1	P
3	Of	Of	B-PP	IN	O	10	VMOD
4	the	the	B-NP	DT	O	6	NMOD
5	80	80	I-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	3	PMOD
7	studied	study	B-VP	VBN	O	6	NMOD
8	,	,	O	,	O	10	P
9	ARI	ARI	B-NP	NN	B-protein	10	SUB
10	developed	develop	B-VP	VBD	O	0	ROOT
11	in	in	B-PP	IN	O	10	VMOD
12	18.8	18.8	B-NP	CD	O	13	NMOD
13	%	%	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	patients	patient	I-NP	NNS	O	14	PMOD
17	after	after	B-PP	IN	O	16	NMOD
18	high-dose	high-dose	B-NP	JJ	O	19	NMOD
19	melphalan	melphalan	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	10	P

1	Patients	Patient	B-NP	NNS	O	8	SUB
2	who	who	B-NP	WP	O	1	NMOD
3	had	have	B-VP	VBD	O	2	SBAR
4	ARI	ARI	B-NP	NN	B-protein	3	OBJ
5	after	after	B-PP	IN	O	1	NMOD
6	high-dose	high-dose	B-NP	JJ	O	7	NMOD
7	melphalan	melphalan	I-NP	NN	O	5	PMOD
8	underwent	undergo	B-VP	VBD	O	0	ROOT
9	dialysis	dialysis	B-NP	NN	O	8	OBJ
10	more	more	B-ADVP	RBR	O	11	AMOD
11	often	often	I-ADVP	RB	O	8	VMOD
12	(	(	O	(	O	16	DEP
13	P	P	B-NP	NN	O	15	SUB
14	=	=	B-VP	SYM	O	15	VMOD
15	0.007	0.007	B-NP	CD	O	16	DEP
16	)	)	O	)	O	11	AMOD
17	,	,	O	,	O	8	P
18	and	and	O	CC	O	8	VMOD
19	had	have	B-VP	VBD	O	8	VMOD
20	a	a	B-NP	DT	O	23	NMOD
21	worse	worse	I-NP	JJR	O	23	NMOD
22	1-year	1-year	I-NP	JJ	O	23	NMOD
23	survival	survival	I-NP	NN	O	19	OBJ
24	(	(	O	(	O	28	DEP
25	P	P	B-NP	NN	O	28	DEP
26	=	=	B-VP	SYM	O	25	NMOD
27	0.03	0.03	B-NP	CD	O	26	AMOD
28	)	)	O	)	O	8	VMOD
29	.	.	O	.	O	8	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	timing	timing	I-NP	NN	O	9	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	renal	renal	B-NP	JJ	O	7	NMOD
7	injury	injury	I-NP	NN	O	5	PMOD
8	strongly	strongly	B-ADVP	RB	O	9	VMOD
9	suggests	suggest	B-VP	VBZ	O	1	NMOD
10	melphalan	melphalan	B-NP	NN	O	9	OBJ
11	as	as	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	14	NMOD
13	causative	causative	I-NP	JJ	O	14	NMOD
14	agent	agent	I-NP	NN	O	11	PMOD
15	.	.	O	.	O	1	P

1	Ongoing	Ongoe	B-VP	VBG	O	4	SUB
2	tubular	tubular	B-NP	JJ	O	3	NMOD
3	injury	injury	I-NP	NN	O	1	OBJ
4	may	may	B-VP	MD	O	0	ROOT
5	be	be	I-VP	VB	O	4	VC
6	a	a	B-NP	DT	O	7	NMOD
7	prerequisite	prerequisite	I-NP	NN	O	5	PRD
8	for	for	B-PP	IN	O	7	NMOD
9	renal	renal	B-NP	JJ	O	10	NMOD
10	injury	injury	I-NP	NN	O	8	PMOD
11	by	by	B-PP	IN	O	7	NMOD
12	melphalan	melphalan	B-NP	NN	O	11	PMOD
13	as	as	B-SBAR	IN	O	4	VMOD
14	evidenced	evidence	B-VP	VBN	O	13	SBAR
15	by	by	B-PP	IN	O	14	VMOD
16	the	the	B-NP	DT	O	19	NMOD
17	active	active	I-NP	JJ	O	19	NMOD
18	urinary	urinary	I-NP	JJ	O	19	NMOD
19	sediment	sediment	I-NP	NN	O	15	PMOD
20	.	.	O	.	O	4	P

1	Impaired	Impaired	B-NP	JJ	O	3	NMOD
2	fear	fear	I-NP	NN	O	3	NMOD
3	recognition	recognition	I-NP	NN	O	0	ROOT
4	in	in	B-PP	IN	O	3	NMOD
5	regular	regular	B-NP	JJ	O	8	NMOD
6	recreational	recreational	I-NP	JJ	O	8	NMOD
7	cocaine	cocaine	I-NP	NN	O	8	NMOD
8	users	user	I-NP	NNS	O	4	PMOD
9	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	3	NMOD
2	selective	selective	I-NP	JJ	O	3	NMOD
3	deficit	deficit	I-NP	NN	O	13	SUB
4	in	in	B-PP	IN	O	3	NMOD
5	fear	fear	B-NP	NN	O	7	NMOD
6	recognition	recognition	I-NP	NN	O	7	NMOD
7	accuracy	accuracy	I-NP	NN	O	4	PMOD
8	manifested	manifest	B-VP	VBN	O	7	NMOD
9	by	by	B-PP	IN	O	8	VMOD
10	the	the	B-NP	DT	O	12	NMOD
11	RC	RC	I-NP	NN	O	12	NMOD
12	group	group	I-NP	NN	O	9	PMOD
13	can	can	B-VP	MD	O	0	ROOT
14	not	not	I-VP	RB	O	13	VMOD
15	be	be	I-VP	VB	O	13	VC
16	explained	explain	I-VP	VBN	O	15	VC
17	by	by	B-PP	IN	O	16	VMOD
18	the	the	B-NP	DT	O	20	NMOD
19	subacute	subacute	I-NP	JJ	O	20	NMOD
20	effects	effect	I-NP	NNS	O	25	NMOD
21	of	of	B-PP	IN	O	20	NMOD
22	cocaine	cocaine	B-NP	NN	O	21	PMOD
23	,	,	O	,	O	25	P
24	or	or	O	CC	O	25	NMOD
25	ecstasy	ecstasy	B-NP	NN	O	17	PMOD
26	,	,	O	,	O	13	P
27	because	because	B-SBAR	IN	O	13	VMOD
28	recent	recent	B-NP	JJ	O	32	NMOD
29	and	and	I-NP	CC	O	32	NMOD
30	less	less	I-NP	RBR	O	31	AMOD
31	recent	recent	I-NP	JJ	O	32	NMOD
32	users	user	I-NP	NNS	O	39	SUB
33	of	of	B-PP	IN	O	32	NMOD
34	these	these	B-NP	DT	O	35	NMOD
35	drugs	drug	I-NP	NNS	O	33	PMOD
36	within	within	B-PP	IN	O	35	NMOD
37	this	this	B-NP	DT	O	38	NMOD
38	group	group	I-NP	NN	O	36	PMOD
39	were	be	B-VP	VBD	O	27	SBAR
40	similarly	similarly	B-ADJP	RB	O	41	AMOD
41	impaired	impaired	I-ADJP	JJ	O	39	PRD
42	.	.	O	.	O	13	P

1	Corneal	Corneal	B-NP	JJ	O	2	NMOD
2	ulcers	ulcer	I-NP	NNS	O	0	ROOT
3	associated	associate	B-VP	VBN	O	2	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	aerosolized	aerosolize	B-NP	VBN	O	8	NMOD
6	crack	crack	I-NP	NN	O	8	NMOD
7	cocaine	cocaine	I-NP	NN	O	8	NMOD
8	use	use	I-NP	NN	O	4	PMOD
9	.	.	O	.	O	2	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Four	Four	B-NP	CD	O	4	NMOD
4	patients	patient	I-NP	NNS	O	13	SUB
5	with	with	B-PP	IN	O	4	NMOD
6	corneal	corneal	B-NP	JJ	O	7	NMOD
7	ulcers	ulcer	I-NP	NNS	O	5	PMOD
8	associated	associate	B-VP	VBN	O	7	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	crack	crack	B-NP	NN	O	12	NMOD
11	cocaine	cocaine	I-NP	NN	O	12	NMOD
12	use	use	I-NP	NN	O	9	PMOD
13	were	be	B-VP	VBD	O	1	NMOD
14	reviewed	review	I-VP	VBN	O	13	VC
15	.	.	O	.	O	1	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Aerosolized	Aerosolize	B-NP	VBN	O	6	NMOD
4	crack	crack	I-NP	NN	O	6	NMOD
5	cocaine	cocaine	I-NP	NN	O	6	NMOD
6	use	use	I-NP	NN	O	7	SUB
7	can	can	B-VP	MD	O	1	NMOD
8	be	be	I-VP	VB	O	7	VC
9	associated	associate	I-VP	VBN	O	8	VC
10	with	with	B-PP	IN	O	9	VMOD
11	the	the	B-NP	DT	O	12	NMOD
12	development	development	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	corneal	corneal	B-NP	JJ	O	15	NMOD
15	ulcers	ulcer	I-NP	NNS	O	13	PMOD
16	.	.	O	.	O	1	P

1	Levetiracetam	Levetiracetam	B-NP	NN	O	0	ROOT
2	as	as	B-PP	IN	O	1	NMOD
3	an	an	B-NP	DT	O	4	NMOD
4	adjunct	adjunct	I-NP	NN	O	2	PMOD
5	to	to	B-PP	TO	O	4	NMOD
6	phenobarbital	phenobarbital	B-NP	NN	O	7	NMOD
7	treatment	treatment	I-NP	NN	O	5	PMOD
8	in	in	B-PP	IN	O	4	NMOD
9	cats	cat	B-NP	NNS	O	8	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	suspected	suspect	B-NP	VBN	O	13	NMOD
12	idiopathic	idiopathic	I-NP	JJ	O	13	NMOD
13	epilepsy	epilepsy	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	1	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	assess	assess	I-VP	VB	O	1	NMOD
5	pharmacokinetics	pharmacokinetic	B-NP	NNS	O	10	NMOD
6	,	,	O	,	O	10	P
7	efficacy	efficacy	B-NP	NN	O	10	NMOD
8	,	,	O	,	O	10	P
9	and	and	O	CC	O	10	NMOD
10	tolerability	tolerability	B-NP	NN	O	4	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	oral	oral	B-NP	JJ	O	13	NMOD
13	levetiracetam	levetiracetam	I-NP	NN	O	11	PMOD
14	administered	administer	B-VP	VBN	O	13	NMOD
15	as	as	B-PP	IN	O	14	VMOD
16	an	an	B-NP	DT	O	17	NMOD
17	adjunct	adjunct	I-NP	NN	O	15	PMOD
18	to	to	B-PP	TO	O	17	NMOD
19	phenobarbital	phenobarbital	B-NP	NN	O	20	NMOD
20	treatment	treatment	I-NP	NN	O	18	PMOD
21	in	in	B-PP	IN	O	17	NMOD
22	cats	cat	B-NP	NNS	O	21	PMOD
23	with	with	B-PP	IN	O	22	NMOD
24	poorly	poorly	B-NP	RB	O	25	AMOD
25	controlled	control	I-NP	VBN	O	28	NMOD
26	suspected	suspect	I-NP	VBN	O	28	NMOD
27	idiopathic	idiopathic	I-NP	JJ	O	28	NMOD
28	epilepsy	epilepsy	I-NP	NN	O	23	PMOD
29	.	.	O	.	O	1	P

1	ANIMALS	ANIMALS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	12	12	B-NP	CD	O	4	NMOD
4	cats	cat	I-NP	NNS	O	1	OBJ
5	suspected	suspect	B-VP	VBN	O	4	NMOD
6	to	to	I-VP	TO	O	7	VMOD
7	have	have	I-VP	VB	O	5	VMOD
8	idiopathic	idiopathic	B-NP	JJ	O	9	NMOD
9	epilepsy	epilepsy	I-NP	NN	O	7	OBJ
10	that	that	B-NP	WDT	O	9	NMOD
11	was	be	B-VP	VBD	O	10	SBAR
12	poorly	poorly	I-VP	RB	O	11	VMOD
13	controlled	control	I-VP	VBN	O	11	VC
14	with	with	B-PP	IN	O	13	VMOD
15	phenobarbital	phenobarbital	B-NP	NN	O	14	PMOD
16	or	or	O	CC	O	17	DEP
17	that	that	B-NP	WDT	O	15	NMOD
18	had	have	B-VP	VBD	O	17	SBAR
19	unacceptable	unacceptable	B-NP	JJ	O	21	NMOD
20	adverse	adverse	I-NP	JJ	O	21	NMOD
21	effects	effect	I-NP	NNS	O	18	OBJ
22	when	when	B-ADVP	WRB	O	18	VMOD
23	treated	treat	B-VP	VBN	O	22	SBAR
24	with	with	B-PP	IN	O	23	VMOD
25	phenobarbital	phenobarbital	B-NP	NN	O	24	PMOD
26	.	.	O	.	O	1	P

1	Seizure	Seizure	B-NP	NN	O	2	NMOD
2	frequencies	frequency	I-NP	NNS	O	10	SUB
3	before	before	B-PP	IN	O	2	NMOD
4	and	and	I-PP	CC	O	3	PMOD
5	after	after	I-PP	IN	O	3	PMOD
6	initiation	initiation	B-NP	NN	O	3	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	levetiracetam	levetiracetam	B-NP	NN	O	9	NMOD
9	treatment	treatment	I-NP	NN	O	7	PMOD
10	were	be	B-VP	VBD	O	16	VMOD
11	compared	compare	I-VP	VBN	O	10	VC
12	,	,	O	,	O	16	P
13	and	and	O	CC	O	16	VMOD
14	adverse	adverse	B-NP	JJ	O	15	NMOD
15	effects	effect	I-NP	NNS	O	16	SUB
16	were	be	B-VP	VBD	O	0	ROOT
17	recorded	record	I-VP	VBN	O	16	VC
18	.	.	O	.	O	16	P

1	Median	Median	B-NP	JJ	O	3	NMOD
2	seizure	seizure	I-NP	NN	O	3	NMOD
3	frequency	frequency	I-NP	NN	O	13	SUB
4	prior	prior	B-ADJP	JJ	O	3	NMOD
5	to	to	B-PP	TO	O	4	AMOD
6	treatment	treatment	B-NP	NN	O	5	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	levetiracetam	levetiracetam	B-NP	NN	O	7	PMOD
9	(	(	O	(	O	12	DEP
10	2.1	2.1	B-NP	CD	O	11	NMOD
11	seizures/mo	seizures/mo	I-NP	NN	O	12	DEP
12	)	)	O	)	O	8	NMOD
13	was	be	B-VP	VBD	O	0	ROOT
14	significantly	significantly	B-ADJP	RB	O	15	AMOD
15	higher	high	I-ADJP	JJR	O	31	NMOD
16	than	than	B-PP	IN	O	15	AMOD
17	median	median	B-NP	JJ	O	19	NMOD
18	seizure	seizure	I-NP	NN	O	19	NMOD
19	frequency	frequency	I-NP	NN	O	16	PMOD
20	after	after	B-PP	IN	O	15	AMOD
21	initiation	initiation	B-NP	NN	O	20	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	levetiracetam	levetiracetam	B-NP	NN	O	24	NMOD
24	treatment	treatment	I-NP	NN	O	22	PMOD
25	(	(	O	(	O	28	DEP
26	0.42	0.42	B-NP	CD	O	27	NMOD
27	seizures/mo	seizures/mo	I-NP	NN	O	28	DEP
28	)	)	O	)	O	15	AMOD
29	,	,	O	,	O	31	P
30	and	and	O	CC	O	31	NMOD
31	7	7	B-NP	CD	O	32	AMOD
32	of	of	B-PP	IN	O	13	VMOD
33	10	10	B-NP	CD	O	34	NMOD
34	cats	cat	I-NP	NNS	O	32	PMOD
35	were	be	B-VP	VBD	O	13	VMOD
36	classified	classify	I-VP	VBN	O	35	VC
37	as	as	B-PP	IN	O	36	VMOD
38	having	have	B-VP	VBG	O	37	PMOD
39	responded	respond	I-VP	VBN	O	38	VC
40	to	to	B-PP	TO	O	39	VMOD
41	levetiracetam	levetiracetam	B-NP	NN	O	42	NMOD
42	treatment	treatment	I-NP	NN	O	40	PMOD
43	(	(	O	(	O	54	DEP
44	ie	ie	B-NP	FW	O	54	DEP
45	,	,	O	,	O	54	P
46	reduction	reduction	B-NP	NN	O	54	DEP
47	in	in	B-PP	IN	O	46	NMOD
48	seizure	seizure	B-NP	NN	O	49	NMOD
49	frequency	frequency	I-NP	NN	O	47	PMOD
50	of	of	B-PP	IN	O	49	NMOD
51	>	>	B-NP	JJR	O	53	NMOD
52	or=50	or=50	I-NP	CD	O	53	NMOD
53	%	%	I-NP	NN	O	50	PMOD
54	)	)	O	)	O	42	NMOD
55	.	.	O	.	O	13	P

1	Bilateral	Bilateral	B-NP	JJ	O	3	NMOD
2	haemorrhagic	haemorrhagic	I-NP	JJ	O	3	NMOD
3	infarction	infarction	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	7	NMOD
6	globus	globus	I-NP	NN	O	7	NMOD
7	pallidus	pallidus	I-NP	NN	O	4	PMOD
8	after	after	B-PP	IN	O	3	NMOD
9	cocaine	cocaine	B-NP	NN	O	12	NMOD
10	and	and	I-NP	CC	O	12	NMOD
11	alcohol	alcohol	I-NP	NN	O	12	NMOD
12	intoxication	intoxication	I-NP	NN	O	8	PMOD
13	.	.	O	.	O	3	P

1	Cocaine	Cocaine	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	risk	risk	I-NP	NN	O	5	NMOD
5	factor	factor	I-NP	NN	O	2	PRD
6	for	for	B-PP	IN	O	5	NMOD
7	both	both	B-NP	CC	O	11	NMOD
8	ischemic	ischemic	I-NP	JJ	O	11	NMOD
9	and	and	I-NP	CC	O	11	NMOD
10	haemorrhagic	haemorrhagic	I-NP	JJ	O	11	NMOD
11	stroke	stroke	I-NP	NN	O	6	PMOD
12	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	present	present	B-VP	VBP	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	31-year-old	31-year-old	I-NP	JJ	O	8	NMOD
8	man	man	I-NP	NN	O	5	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	bilateral	bilateral	B-NP	JJ	O	11	NMOD
11	ischemia	ischemia	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	15	NMOD
14	globus	globus	I-NP	NN	O	15	NMOD
15	pallidus	pallidus	I-NP	NN	O	12	PMOD
16	after	after	B-PP	IN	O	11	NMOD
17	excessive	excessive	B-NP	JJ	O	18	NMOD
18	alcohol	alcohol	I-NP	NN	O	22	NMOD
19	and	and	O	CC	O	22	NMOD
20	intranasal	intranasal	B-NP	JJ	O	22	NMOD
21	cocaine	cocaine	I-NP	NN	O	22	NMOD
22	use	use	I-NP	NN	O	16	PMOD
23	.	.	O	.	O	2	P

1	Drug-related	Drug-related	B-NP	JJ	O	4	NMOD
2	globus	globus	I-NP	NN	O	4	NMOD
3	pallidus	pallidus	I-NP	NN	O	4	NMOD
4	infarctions	infarction	I-NP	NNS	O	5	SUB
5	are	be	B-VP	VBP	O	0	ROOT
6	most	most	I-VP	RBS	O	7	AMOD
7	often	often	I-VP	RB	O	5	VMOD
8	associated	associate	I-VP	VBN	O	5	VC
9	with	with	B-PP	IN	O	8	VMOD
10	heroin	heroin	B-NP	NN	O	9	PMOD
11	.	.	O	.	O	5	P

1	Bilateral	Bilateral	B-NP	JJ	O	4	NMOD
2	basal	basal	I-NP	JJ	O	4	NMOD
3	ganglia	ganglia	I-NP	NNS	O	4	NMOD
4	infarcts	infarct	I-NP	NNS	O	16	SUB
5	after	after	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	use	use	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	cocaine	cocaine	B-NP	NN	O	8	PMOD
10	,	,	O	,	O	4	P
11	without	without	B-PP	IN	O	4	NMOD
12	concurrent	concurrent	B-NP	JJ	O	14	NMOD
13	heroin	heroin	I-NP	NN	O	14	NMOD
14	use	use	I-NP	NN	O	11	PMOD
15	,	,	O	,	O	4	P
16	have	have	B-VP	VBP	O	0	ROOT
17	never	never	I-VP	RB	O	16	VMOD
18	been	be	I-VP	VBN	O	16	VC
19	reported	report	I-VP	VBN	O	18	VC
20	.	.	O	.	O	16	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	renal	renal	I-NP	JJ	O	3	NMOD
3	failure	failure	I-NP	NN	O	0	ROOT
4	after	after	B-PP	IN	O	3	NMOD
5	high-dose	high-dose	B-NP	JJ	O	7	NMOD
6	methotrexate	methotrexate	I-NP	NN	O	7	NMOD
7	therapy	therapy	I-NP	NN	O	4	PMOD
8	in	in	B-PP	IN	O	7	NMOD
9	a	a	B-NP	DT	O	10	NMOD
10	patient	patient	I-NP	NN	O	8	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	ileostomy	ileostomy	B-NP	NN	O	11	PMOD
13	.	.	O	.	O	3	P

1	High-dose	High-dose	B-NP	JJ	O	2	NMOD
2	methotrexate	methotrexate	I-NP	NN	O	6	SUB
3	(	(	O	(	O	5	DEP
4	HD-MTX	HD-MTX	B-NP	NN	B-protein	5	DEP
5	)	)	O	)	O	2	NMOD
6	is	be	B-VP	VBZ	O	0	ROOT
7	an	an	B-NP	DT	O	9	NMOD
8	important	important	I-NP	JJ	O	9	NMOD
9	treatment	treatment	I-NP	NN	O	6	PRD
10	for	for	B-PP	IN	O	9	NMOD
11	Burkitt	Burkitt	B-NP	NN	O	12	NMOD
12	lymphoma	lymphoma	I-NP	NN	O	10	PMOD
13	,	,	O	,	O	6	P
14	but	but	O	CC	O	6	VMOD
15	can	can	B-VP	MD	O	6	VMOD
16	cause	cause	I-VP	VB	O	15	VC
17	hepatic	hepatic	B-NP	JJ	O	20	NMOD
18	and	and	I-NP	CC	O	20	NMOD
19	renal	renal	I-NP	JJ	O	20	NMOD
20	toxicity	toxicity	I-NP	NN	O	16	OBJ
21	when	when	B-ADVP	WRB	O	16	VMOD
22	its	its	B-NP	PRP$	O	23	NMOD
23	clearance	clearance	I-NP	NN	O	24	SUB
24	is	be	B-VP	VBZ	O	21	SBAR
25	delayed	delay	I-VP	VBN	O	24	VC
26	.	.	O	.	O	6	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	20	VMOD
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	19	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	acute	acute	B-NP	JJ	O	8	NMOD
7	renal	renal	I-NP	JJ	O	8	NMOD
8	failure	failure	I-NP	NN	O	5	PMOD
9	after	after	B-PP	IN	O	4	NMOD
10	HD-MTX	HD-MTX	B-NP	NN	O	11	NMOD
11	therapy	therapy	I-NP	NN	O	9	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	a	a	B-NP	DT	O	14	NMOD
14	patient	patient	I-NP	NN	O	12	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	ileostomy	ileostomy	B-NP	NN	O	15	PMOD
17	,	,	O	,	O	19	P
18	The	The	B-NP	DT	O	19	NMOD
19	patient	patient	I-NP	NN	O	20	SUB
20	was	be	B-VP	VBD	O	0	ROOT
21	a	a	B-NP	DT	O	23	NMOD
22	3-year-old	3-year-old	I-NP	JJ	O	23	NMOD
23	boy	boy	I-NP	NN	O	20	PRD
24	who	who	B-NP	WP	O	23	NMOD
25	had	have	B-VP	VBD	O	24	SBAR
26	received	receive	I-VP	VBN	O	25	VC
27	a	a	B-NP	DT	O	30	NMOD
28	living-related	living-related	I-NP	JJ	O	30	NMOD
29	liver	liver	I-NP	NN	O	30	NMOD
30	transplantation	transplantation	I-NP	NN	O	26	OBJ
31	for	for	B-PP	IN	O	26	VMOD
32	congenital	congenital	B-NP	JJ	O	34	NMOD
33	biliary	biliary	I-NP	JJ	O	34	NMOD
34	atresia	atresia	I-NP	NN	O	31	PMOD
35	.	.	O	.	O	20	P

1	Subsequent	Subsequent	B-NP	JJ	O	3	NMOD
2	HD-MTX	HD-MTX	I-NP	NN	O	3	NMOD
3	therapy	therapy	I-NP	NN	O	4	SUB
4	caused	cause	B-VP	VBD	O	0	ROOT
5	acute	acute	B-NP	JJ	O	7	NMOD
6	renal	renal	I-NP	JJ	O	7	NMOD
7	failure	failure	I-NP	NN	O	4	OBJ
8	that	that	B-NP	WDT	O	7	NMOD
9	required	require	B-VP	VBD	O	8	SBAR
10	continuous	continuous	B-NP	JJ	O	11	NMOD
11	hemodialysis	hemodialysis	I-NP	NN	O	9	OBJ
12	.	.	O	.	O	4	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	In	In	B-PP	IN	O	15	VMOD
4	a	a	B-NP	DT	O	6	NMOD
5	pooled	pooled	I-NP	JJ	O	6	NMOD
6	analysis	analysis	I-NP	NN	O	3	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	1460	1460	B-NP	CD	O	9	NMOD
9	ICH	ICH	I-NP	NN	O	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	3817	3817	B-NP	CD	O	12	NMOD
12	IS/TIA	IS/TIA	I-NP	NN	O	7	PMOD
13	,	,	O	,	O	15	P
14	MB	MB	B-NP	NN	B-protein	15	SUB
15	were	be	B-VP	VBD	O	30	VMOD
16	more	more	B-ADJP	RBR	O	17	AMOD
17	frequent	frequent	I-ADJP	JJ	O	15	PRD
18	in	in	B-PP	IN	O	17	AMOD
19	ICH	ICH	B-NP	NN	O	21	NMOD
20	vs	vs	I-NP	CC	O	21	NMOD
21	IS/TIA	IS/TIA	I-NP	NN	B-protein	18	PMOD
22	in	in	B-PP	IN	O	21	NMOD
23	all	all	B-NP	DT	O	25	NMOD
24	treatment	treatment	I-NP	NN	O	25	NMOD
25	groups	group	I-NP	NNS	O	22	PMOD
26	,	,	O	,	O	30	P
27	but	but	O	CC	O	30	VMOD
28	the	the	B-NP	DT	O	29	NMOD
29	excess	excess	I-NP	NN	O	30	SUB
30	increased	increase	B-VP	VBD	O	1	NMOD
31	from	from	B-PP	IN	O	30	VMOD
32	2.8	2.8	B-NP	CD	O	31	PMOD
33	(	(	O	(	O	40	DEP
34	odds	odd	B-NP	NNS	O	35	NMOD
35	ratio	ratio	I-NP	NN	O	39	VMOD
36	;	;	O	:	O	39	P
37	range	range	B-NP	NN	O	39	NMOD
38	,	,	O	,	O	39	P
39	2.3-3.5	2.3-3.5	B-NP	CD	O	40	DEP
40	)	)	O	)	O	32	NMOD
41	in	in	B-PP	IN	O	30	VMOD
42	nonantithrombotic	nonantithrombotic	B-NP	JJ	O	43	NMOD
43	users	user	I-NP	NNS	O	41	PMOD
44	to	to	B-PP	TO	O	43	NMOD
45	5.7	5.7	B-NP	CD	O	44	PMOD
46	(	(	O	(	O	50	DEP
47	range	range	B-NP	NN	O	49	NMOD
48	,	,	O	,	O	49	P
49	3.4-9.7	3.4-9.7	B-NP	CD	O	50	DEP
50	)	)	O	)	O	45	NMOD
51	in	in	B-PP	IN	O	30	VMOD
52	antiplatelet	antiplatelet	B-NP	JJ	O	53	NMOD
53	users	user	I-NP	NNS	O	51	PMOD
54	and	and	O	CC	O	53	NMOD
55	8.0	8.0	B-NP	CD	O	54	PRD
56	(	(	O	(	O	60	DEP
57	range	range	B-NP	NN	O	59	NMOD
58	,	,	O	,	O	59	P
59	3.5-17.8	3.5-17.8	B-NP	CD	O	60	DEP
60	)	)	O	)	O	55	NMOD
61	in	in	B-PP	IN	O	55	NMOD
62	warfarin	warfarin	B-NP	NN	O	63	NMOD
63	users	user	I-NP	NNS	O	61	PMOD
64	(	(	O	(	O	67	DEP
65	P	P	B-NP	NN	O	66	NMOD
66	difference=0.01	difference=0.01	I-NP	NN	O	67	DEP
67	)	)	O	)	O	55	NMOD
68	.	.	O	.	O	1	P

1	There	There	B-NP	EX	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	also	also	B-ADVP	RB	O	2	VMOD
4	an	an	B-NP	DT	O	5	NMOD
5	excess	excess	I-NP	NN	O	2	PRD
6	of	of	B-PP	IN	O	5	NMOD
7	MB	MB	B-NP	NN	B-protein	6	PMOD
8	in	in	B-PP	IN	O	5	NMOD
9	warfarin	warfarin	B-NP	NN	O	10	NMOD
10	users	user	I-NP	NNS	O	8	PMOD
11	vs	vs	B-PP	IN	O	10	NMOD
12	nonusers	nonuser	B-NP	NNS	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	ICH	ICH	B-NP	NN	B-protein	31	NMOD
15	(	(	O	(	O	31	NMOD
16	OR	OR	B-NP	NN	O	31	NMOD
17	,	,	O	,	O	31	P
18	2.7	2.7	B-NP	CD	O	31	NMOD
19	;	;	O	:	O	31	P
20	95	95	B-NP	CD	O	22	NMOD
21	%	%	I-NP	NN	O	22	NMOD
22	CI	CI	I-NP	NN	O	31	NMOD
23	,	,	O	,	O	31	P
24	1.6-4.4	1.6-4.4	B-NP	CD	O	31	NMOD
25	;	;	O	:	O	31	P
26	P	P	B-NP	NN	O	31	NMOD
27	<	<	B-NP	SYM	O	26	NMOD
28	0.001	0.001	I-NP	CD	O	27	AMOD
29	)	)	O	)	O	26	NMOD
30	but	but	O	CC	O	31	NMOD
31	none	none	B-NP	NN	O	13	PMOD
32	in	in	B-PP	IN	O	31	NMOD
33	warfarin	warfarin	B-NP	NN	O	34	NMOD
34	users	user	I-NP	NNS	O	32	PMOD
35	with	with	B-PP	IN	O	34	NMOD
36	IS/TIA	IS/TIA	B-NP	NN	B-protein	35	PMOD
37	(	(	O	(	O	52	DEP
38	OR	OR	B-NP	NN	O	51	NMOD
39	,	,	O	,	O	51	P
40	1.3	1.3	B-NP	CD	O	51	NMOD
41	;	;	O	:	O	51	P
42	95	95	B-NP	CD	O	44	NMOD
43	%	%	I-NP	NN	O	44	NMOD
44	CI	CI	I-NP	NN	O	51	NMOD
45	,	,	O	,	O	51	P
46	0.9-1.7	0.9-1.7	B-NP	CD	O	51	NMOD
47	;	;	O	:	O	51	P
48	P=0.33	P=0.33	B-NP	NN	O	51	NMOD
49	;	;	O	:	O	51	P
50	P	P	B-NP	NN	O	51	NMOD
51	difference=0.01	difference=0.01	I-NP	NN	O	52	DEP
52	)	)	O	)	O	36	NMOD
53	.	.	O	.	O	2	P

1	Verapamil	Verapamil	B-NP	NN	O	3	NMOD
2	stimulation	stimulation	I-NP	NN	O	3	NMOD
3	test	test	I-NP	NN	O	7	NMOD
4	in	in	B-PP	IN	O	3	NMOD
5	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	4	PMOD
6	:	:	O	:	O	3	P
7	loss	loss	B-NP	NN	O	0	ROOT
8	of	of	B-PP	IN	O	7	NMOD
9	prolactin	prolactin	B-NP	NN	O	10	NMOD
10	response	response	I-NP	NN	O	8	PMOD
11	in	in	B-PP	IN	O	7	NMOD
12	anatomic	anatomic	B-NP	JJ	O	16	NMOD
13	or	or	I-NP	CC	O	16	NMOD
14	functional	functional	I-NP	JJ	O	16	NMOD
15	stalk	stalk	I-NP	NN	O	16	NMOD
16	effect	effect	I-NP	NN	O	11	PMOD
17	.	.	O	.	O	7	P

1	AIM	AIM	B-NP	NN	O	5	NMOD
2	:	:	O	:	O	1	P
3	Verapamil	Verapamil	B-NP	NN	O	5	NMOD
4	stimulation	stimulation	I-NP	NN	O	5	NMOD
5	test	test	I-NP	NN	O	6	SUB
6	was	be	B-VP	VBD	O	0	ROOT
7	previously	previously	I-VP	RB	O	6	VMOD
8	investigated	investigate	I-VP	VBN	O	6	VC
9	as	as	B-PP	IN	O	8	VMOD
10	a	a	B-NP	DT	O	11	NMOD
11	tool	tool	I-NP	NN	O	9	PMOD
12	for	for	B-PP	IN	O	11	NMOD
13	differential	differential	B-NP	JJ	O	14	NMOD
14	diagnosis	diagnosis	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	15	PMOD
17	,	,	O	,	O	9	P
18	but	but	O	CC	O	9	PMOD
19	with	with	B-PP	IN	O	9	PMOD
20	conflicting	conflict	B-VP	VBG	O	21	NMOD
21	results	result	B-NP	NNS	O	19	PMOD
22	.	.	O	.	O	6	P

1	Here	Here	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	we	we	B-NP	PRP	O	4	SUB
4	aimed	aim	B-VP	VBD	O	0	ROOT
5	to	to	I-VP	TO	O	6	VMOD
6	re-investigate	re-investigate	I-VP	VB	O	4	VMOD
7	the	the	B-NP	DT	O	9	NMOD
8	diagnostic	diagnostic	I-NP	JJ	O	9	NMOD
9	value	value	I-NP	NN	O	6	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	verapamil	verapamil	B-NP	NN	O	10	PMOD
12	in	in	B-PP	IN	O	6	VMOD
13	a	a	B-NP	DT	O	14	NMOD
14	population	population	I-NP	NN	O	12	PMOD
15	who	who	B-NP	WP	O	14	NMOD
16	were	be	B-VP	VBD	O	15	SBAR
17	all	all	O	DT	O	16	VMOD
18	screened	screen	B-VP	VBN	O	16	VC
19	for	for	B-PP	IN	O	18	VMOD
20	macroprolactinemia	macroprolactinemia	B-NP	NN	O	19	PMOD
21	.	.	O	.	O	4	P

1	Prolactin	Prolactin	B-NP	NN	O	2	NMOD
2	responses	response	I-NP	NNS	O	19	SUB
3	to	to	B-VP	TO	O	4	VMOD
4	verapamil	verapamil	I-VP	VB	O	2	NMOD
5	in	in	B-PP	IN	O	4	VMOD
6	65	65	B-NP	CD	O	8	NMOD
7	female	female	I-NP	JJ	O	8	NMOD
8	patients	patient	I-NP	NNS	O	5	PMOD
9	(	(	O	(	O	16	DEP
10	age	age	B-NP	NN	O	15	NMOD
11	:	:	O	:	O	15	P
12	29.9	29.9	B-NP	CD	O	14	AMOD
13	+/-	+/-	I-NP	CC	O	14	AMOD
14	8.1	8.1	I-NP	CD	O	15	NMOD
15	years	year	I-NP	NNS	O	16	DEP
16	)	)	O	)	O	8	NMOD
17	with	with	B-PP	IN	O	8	NMOD
18	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	17	PMOD
19	were	be	B-VP	VBD	O	0	ROOT
20	tested	test	I-VP	VBN	O	19	VC
21	in	in	B-PP	IN	O	20	VMOD
22	a	a	B-NP	DT	O	27	NMOD
23	descriptive	descriptive	I-NP	JJ	O	25	AMOD
24	,	,	I-NP	,	O	25	P
25	matched	matched	I-NP	JJ	O	27	NMOD
26	case-control	case-control	I-NP	JJ	O	27	NMOD
27	study	study	I-NP	NN	O	21	PMOD
28	.	.	O	.	O	19	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Verapamil	Verapamil	B-NP	NN	O	5	SUB
4	significantly	significantly	B-ADVP	RB	O	5	VMOD
5	increased	increase	B-VP	VBD	O	70	VMOD
6	PRL	PRL	B-NP	NN	B-protein	7	NMOD
7	levels	level	I-NP	NNS	O	5	OBJ
8	in	in	B-PP	IN	O	7	NMOD
9	healthy	healthy	B-NP	JJ	O	10	NMOD
10	controls	control	I-NP	NNS	O	32	NMOD
11	(	(	O	(	O	19	DEP
12	N.	N.	B-NP	NN	B-protein	18	NMOD
13	8	8	I-NP	CD	I-protein	12	NMOD
14	,	,	O	,	O	18	P
15	PRL	PRL	B-NP	NN	B-protein	18	NMOD
16	:	:	O	:	O	18	P
17	183	183	B-NP	CD	O	18	NMOD
18	%	%	I-NP	NN	O	19	DEP
19	)	)	O	)	O	10	NMOD
20	,	,	O	,	O	32	P
21	macroprolactinoma	macroprolactinoma	B-NP	NN	O	32	NMOD
22	(	(	O	(	O	30	DEP
23	N.	N.	B-NP	NN	B-protein	29	NMOD
24	8	8	I-NP	CD	I-protein	23	NMOD
25	,	,	O	,	O	29	P
26	PRL	PRL	B-NP	NN	B-protein	29	NMOD
27	:	:	O	:	O	29	P
28	7	7	B-NP	CD	O	29	NMOD
29	%	%	I-NP	NN	O	30	DEP
30	)	)	O	)	O	21	NMOD
31	,	,	O	,	O	32	P
32	microprolactinoma	microprolactinoma	B-NP	NN	O	43	NMOD
33	(	(	O	(	O	41	DEP
34	N.	N.	B-NP	NNP	O	40	NMOD
35	19	19	I-NP	CD	O	34	NMOD
36	,	,	O	,	O	40	P
37	PRL	PRL	B-NP	NN	B-protein	40	NMOD
38	:	:	O	:	O	40	P
39	21	21	B-NP	CD	O	40	NMOD
40	%	%	I-NP	NN	O	41	DEP
41	)	)	O	)	O	32	NMOD
42	,	,	O	,	O	43	P
43	macroprolactinemia	macroprolactinemia	B-NP	NN	O	8	PMOD
44	(	(	O	(	O	52	DEP
45	N.	N.	B-NP	NNP	O	51	NMOD
46	23	23	I-NP	CD	O	45	NMOD
47	,	,	O	,	O	51	P
48	PRL	PRL	B-NP	NN	B-protein	51	NMOD
49	:	:	O	:	O	51	P
50	126	126	B-NP	CD	O	51	NMOD
51	%	%	I-NP	NN	O	52	DEP
52	)	)	O	)	O	43	NMOD
53	,	,	O	,	O	43	P
54	but	but	B-PP	CC	O	8	PMOD
55	not	not	B-PP	RB	O	56	PMOD
56	in	in	I-PP	IN	O	8	PMOD
57	pseudoprolactinoma	pseudoprolactinoma	B-NP	NN	O	56	PMOD
58	(	(	O	(	O	66	DEP
59	N.	N.	B-NP	NN	B-protein	65	NMOD
60	8	8	I-NP	CD	I-protein	59	NMOD
61	,	,	O	,	O	65	P
62	PRL	PRL	B-NP	NN	B-protein	65	NMOD
63	:	:	O	:	O	65	P
64	0.8	0.8	B-NP	CD	O	65	NMOD
65	%	%	I-NP	NN	O	66	DEP
66	)	)	O	)	O	57	NMOD
67	,	,	O	,	O	70	P
68	and	and	O	CC	O	70	VMOD
69	risperidone	risperidone	B-NP	NN	O	70	SUB
70	induced	induce	B-VP	VBD	O	1	NMOD
71	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	70	OBJ
72	(	(	O	(	O	80	DEP
73	N.	N.	B-NP	NN	B-protein	79	NMOD
74	7	7	I-NP	CD	I-protein	73	NMOD
75	,	,	O	,	O	79	P
76	PRL	PRL	B-NP	NN	B-protein	79	NMOD
77	:	:	O	:	O	79	P
78	3	3	B-NP	CD	O	79	NMOD
79	%	%	I-NP	NN	O	80	DEP
80	)	)	O	)	O	71	NMOD
81	.	.	O	.	O	1	P

1	ROC	ROC	B-NP	NN	O	3	NMOD
2	curve	curve	I-NP	NN	O	3	NMOD
3	analysis	analysis	I-NP	NN	O	4	SUB
4	revealed	reveal	B-VP	VBD	O	0	ROOT
5	that	that	B-SBAR	IN	O	4	VMOD
6	unresponsiveness	unresponsiveness	B-NP	NN	O	21	NMOD
7	to	to	B-PP	TO	O	6	NMOD
8	verapamil	verapamil	B-NP	NN	O	7	PMOD
9	defined	define	B-VP	VBN	O	8	NMOD
10	as	as	B-PP	IN	O	9	VMOD
11	PRL	PRL	B-NP	NN	B-protein	14	NMOD
12	<	<	O	SYM	O	14	NMOD
13	7	7	B-NP	CD	O	14	NMOD
14	%	%	I-NP	NN	O	10	PMOD
15	,	,	O	,	O	21	P
16	discriminated	discriminate	B-VP	VBN	O	21	NMOD
17	anatomical	anatomical	B-NP	JJ	O	21	NMOD
18	or	or	I-NP	CC	O	21	NMOD
19	functional	functional	I-NP	JJ	O	21	NMOD
20	stalk	stalk	I-NP	NN	O	21	NMOD
21	effect	effect	I-NP	NN	O	50	SUB
22	(	(	O	(	O	44	DEP
23	sensitivity	sensitivity	B-NP	NN	O	43	NMOD
24	:	:	O	:	O	43	P
25	74	74	B-NP	CD	O	26	NMOD
26	%	%	I-NP	NN	O	43	NMOD
27	,	,	O	,	O	43	P
28	specificity	specificity	B-NP	NN	O	31	NMOD
29	:	:	O	:	O	31	P
30	73	73	B-NP	CD	O	31	NMOD
31	%	%	I-NP	NN	O	43	NMOD
32	,	,	O	,	O	43	P
33	AUC	AUC	B-NP	NN	O	35	NMOD
34	:	:	O	:	O	33	P
35	0.855+/-0.04	0.855+/-0.04	B-NP	CD	O	43	NMOD
36	,	,	O	,	O	43	P
37	P	P	B-NP	NN	O	43	NMOD
38	<	<	B-VP	SYM	O	37	NMOD
39	0.001	0.001	B-NP	CD	O	38	AMOD
40	,	,	O	,	O	43	P
41	CI	CI	B-NP	NNP	O	43	NMOD
42	:	:	O	:	O	43	P
43	0.768-0.942	0.768-0.942	B-NP	CD	O	44	DEP
44	)	)	O	)	O	21	NMOD
45	associated	associate	B-VP	VBN	O	21	NMOD
46	with	with	B-PP	IN	O	45	VMOD
47	pseudoprolactinoma	pseudoprolactinoma	B-NP	NN	O	49	NMOD
48	or	or	I-NP	CC	O	49	NMOD
49	risperidone	risperidone	I-NP	NN	O	46	PMOD
50	induced	induce	B-VP	VBD	O	5	SBAR
51	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	50	OBJ
52	,	,	O	,	O	50	P
53	respectively	respectively	B-ADVP	RB	O	50	VMOD
54	.	.	O	.	O	4	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Verapamil	Verapamil	B-NP	NN	O	4	NMOD
4	responsiveness	responsiveness	I-NP	NN	O	5	SUB
5	is	be	B-VP	VBZ	O	1	NMOD
6	not	not	O	RB	O	5	VMOD
7	a	a	B-NP	DT	O	9	NMOD
8	reliable	reliable	I-NP	JJ	O	9	NMOD
9	finding	finding	I-NP	NN	O	5	PRD
10	for	for	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	13	NMOD
12	differential	differential	I-NP	JJ	O	13	NMOD
13	diagnosis	diagnosis	I-NP	NN	O	10	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	14	PMOD
16	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	effect	effect	I-NP	NN	O	31	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	clonidine	clonidine	B-NP	NN	O	8	NMOD
5	,	,	I-NP	,	O	8	P
6	naphazoline	naphazoline	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	xylometazoline	xylometazoline	I-NP	NN	O	3	PMOD
9	on	on	B-PP	IN	O	2	NMOD
10	analgesia	analgesia	B-NP	NN	O	9	PMOD
11	induced	induce	B-VP	VBN	O	10	NMOD
12	by	by	B-PP	IN	O	11	VMOD
13	morphine	morphine	B-NP	NN	O	19	NMOD
14	,	,	I-NP	,	O	19	P
15	codeine	codeine	I-NP	NN	O	19	NMOD
16	,	,	I-NP	,	O	19	P
17	fentanyl	fentanyl	I-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	pentazocine	pentazocine	I-NP	NN	O	12	PMOD
20	,	,	B-PP	,	O	9	P
21	and	and	I-PP	CC	O	9	PMOD
22	on	on	B-PP	IN	O	9	PMOD
23	cataleptic	cataleptic	B-NP	JJ	O	24	NMOD
24	effect	effect	I-NP	NN	O	22	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	morphine	morphine	B-NP	NN	O	30	NMOD
27	,	,	I-NP	,	O	30	P
28	codine	codine	I-NP	NN	O	30	NMOD
29	and	and	I-NP	CC	O	30	NMOD
30	fentanyl	fentanyl	I-NP	NN	O	25	PMOD
31	was	be	B-VP	VBD	O	0	ROOT
32	studied	study	I-VP	VBN	O	31	VC
33	in	in	B-PP	IN	O	32	VMOD
34	rats	rat	B-NP	NNS	O	33	PMOD
35	.	.	O	.	O	31	P

1	It	It	B-NP	PRP	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	found	find	I-VP	VBN	O	2	VC
4	that	that	B-SBAR	IN	O	3	VMOD
5	three	three	B-NP	CD	O	6	NMOD
6	drugs	drug	I-NP	NNS	O	11	SUB
7	stimulating	stimulate	B-VP	VBG	O	6	NMOD
8	central	central	B-NP	JJ	B-protein	10	NMOD
9	NA	NA	I-NP	NN	I-protein	10	NMOD
10	receptors	receptor	I-NP	NNS	I-protein	7	OBJ
11	failed	fail	B-VP	VBD	O	4	SBAR
12	to	to	I-VP	TO	O	13	VMOD
13	affect	affect	I-VP	VB	O	11	VMOD
14	the	the	B-NP	DT	O	16	NMOD
15	analgesic	analgesic	I-NP	JJ	O	16	NMOD
16	ED50	ED50	I-NP	NN	O	13	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	all	all	B-NP	DT	O	20	NMOD
19	antinociceptive	antinociceptive	I-NP	JJ	O	20	NMOD
20	agents	agent	I-NP	NNS	O	17	PMOD
21	and	and	O	CC	O	23	VMOD
22	they	they	B-NP	PRP	O	23	SUB
23	enhanced	enhance	B-VP	VBD	O	11	VMOD
24	catalepsy	catalepsy	B-NP	NN	O	23	OBJ
25	induced	induce	B-VP	VBN	O	24	NMOD
26	by	by	B-PP	IN	O	25	VMOD
27	morphine	morphine	B-NP	NN	O	29	NMOD
28	and	and	I-NP	CC	O	29	NMOD
29	fentanyl	fentanyl	I-NP	NN	O	26	PMOD
30	.	.	O	.	O	2	P

1	Codeine	Codeine	B-NP	NN	O	2	NMOD
2	catalepsy	catalepsy	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	increased	increase	I-VP	VBN	O	3	VC
5	by	by	B-PP	IN	O	4	VMOD
6	clonidine	clonidine	B-NP	NN	O	5	PMOD
7	and	and	O	CC	O	4	VMOD
8	decreased	decrease	B-VP	VBN	O	4	VMOD
9	by	by	B-PP	IN	O	8	VMOD
10	naphazoline	naphazoline	B-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	xylometazoline	xylometazoline	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	3	P

1	Modification	Modification	B-NP	NN	O	0	ROOT
2	by	by	B-PP	IN	O	1	NMOD
3	propranolol	propranolol	B-NP	NN	O	2	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	cardiovascular	cardiovascular	B-NP	JJ	O	6	NMOD
6	effects	effect	I-NP	NNS	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	induced	induce	B-NP	VBN	O	9	NMOD
9	hypoglycaemia	hypoglycaemia	I-NP	NN	O	7	PMOD
10	.	.	O	.	O	1	P

1	Prevention	Prevention	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	treatment	treatment	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	endometrial	endometrial	B-NP	JJ	O	6	NMOD
6	disease	disease	I-NP	NN	O	4	PMOD
7	in	in	B-PP	IN	O	3	NMOD
8	climacteric	climacteric	B-NP	JJ	O	9	NMOD
9	women	woman	I-NP	NNS	O	7	PMOD
10	receiving	receive	B-VP	VBG	O	9	NMOD
11	oestrogen	oestrogen	B-NP	NN	O	12	NMOD
12	therapy	therapy	I-NP	NN	O	10	OBJ
13	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	3	NMOD
2	treatment	treatment	I-NP	NN	O	3	NMOD
3	regimens	regimen	I-NP	NNS	O	4	SUB
4	are	be	B-VP	VBP	O	0	ROOT
5	described	describe	I-VP	VBN	O	4	VC
6	in	in	B-PP	IN	O	5	VMOD
7	74	74	B-NP	CD	O	8	NMOD
8	patients	patient	I-NP	NNS	O	6	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	endometrial	endometrial	B-NP	JJ	O	11	NMOD
11	disease	disease	I-NP	NN	O	9	PMOD
12	among	among	B-PP	IN	O	8	NMOD
13	850	850	B-NP	CD	O	15	NMOD
14	climacteric	climacteric	I-NP	JJ	O	15	NMOD
15	women	woman	I-NP	NNS	O	12	PMOD
16	receiving	receive	B-VP	VBG	O	15	NMOD
17	oestrogen	oestrogen	B-NP	NN	O	18	NMOD
18	therapy	therapy	I-NP	NN	O	16	OBJ
19	.	.	O	.	O	4	P

1	Cystic	Cystic	B-NP	JJ	O	2	NMOD
2	hyperplasia	hyperplasia	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	associated	associate	I-VP	VBN	O	3	VC
5	with	with	B-PP	IN	O	4	VMOD
6	unopposed	unopposed	B-NP	JJ	O	8	NMOD
7	oestrogen	oestrogen	I-NP	NN	O	8	NMOD
8	therapy	therapy	I-NP	NN	O	5	PMOD
9	without	without	B-PP	IN	O	8	NMOD
10	progestagen	progestagen	B-NP	NN	O	9	PMOD
11	.	.	O	.	O	3	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	courses	course	I-NP	NNS	O	11	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	21	21	B-NP	CD	O	5	NMOD
5	days	day	I-NP	NNS	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	5	5	B-NP	CD	O	8	AMOD
8	mg	mg	I-NP	NN	O	9	NMOD
9	norethisterone	norethisterone	I-NP	NN	O	6	PMOD
10	daily	daily	B-ADVP	RB	O	11	VMOD
11	caused	cause	B-VP	VBD	O	0	ROOT
12	reversion	reversion	B-NP	NN	O	11	OBJ
13	to	to	B-PP	TO	O	12	NMOD
14	normal	normal	B-ADJP	JJ	O	13	PMOD
15	in	in	B-PP	IN	O	14	AMOD
16	all	all	B-NP	DT	O	18	NMOD
17	57	57	I-NP	CD	O	18	NMOD
18	cases	case	I-NP	NNS	O	15	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	cystic	cystic	B-NP	JJ	O	21	NMOD
21	hyperplasia	hyperplasia	I-NP	NN	O	19	PMOD
22	and	and	I-NP	CC	O	23	NMOD
23	6	6	I-NP	CD	O	15	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	the	the	B-NP	DT	O	27	NMOD
26	8	8	I-NP	CD	O	27	NMOD
27	cases	case	I-NP	NNS	O	24	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	atypical	atypical	B-NP	JJ	O	30	NMOD
30	hyperplasia.	hyperplasia.	I-NP	NN	O	32	NMOD
31	4	4	B-NP	CD	O	32	NMOD
32	cases	case	I-NP	NNS	O	28	PMOD
33	of	of	B-PP	IN	O	32	NMOD
34	endometrial	endometrial	B-NP	JJ	O	35	NMOD
35	carcinoma	carcinoma	I-NP	NN	O	39	SUB
36	referred	refer	B-VP	VBN	O	35	NMOD
37	from	from	B-PP	IN	O	36	VMOD
38	elsewhere	elsewhere	B-NP	RB	O	39	VMOD
39	demonstrated	demonstrate	B-VP	VBD	O	33	SBAR
40	the	the	B-NP	DT	O	41	NMOD
41	problems	problem	I-NP	NNS	O	51	NMOD
42	of	of	B-PP	IN	O	41	NMOD
43	inappropriate	inappropriate	B-NP	JJ	O	48	NMOD
44	and	and	I-NP	CC	O	48	NMOD
45	unsupervised	unsupervised	I-NP	JJ	O	48	NMOD
46	unopposed	unopposed	I-NP	JJ	O	48	NMOD
47	oestrogen	oestrogen	I-NP	NN	O	48	NMOD
48	therapy	therapy	I-NP	NN	O	42	PMOD
49	and	and	O	CC	O	51	NMOD
50	the	the	B-NP	DT	O	51	NMOD
51	difficulty	difficulty	I-NP	NN	O	39	OBJ
52	in	in	B-PP	IN	O	51	NMOD
53	distinguishing	distinguish	B-VP	VBG	O	52	PMOD
54	severe	severe	B-NP	JJ	O	55	NMOD
55	hyperplasia	hyperplasia	I-NP	NN	O	53	OBJ
56	from	from	B-PP	IN	O	55	NMOD
57	malignancy	malignancy	B-NP	NN	O	56	PMOD
58	.	.	O	.	O	11	P

1	Pure	Pure	B-NP	NN	O	4	NMOD
2	red	red	I-NP	JJ	O	4	NMOD
3	cell	cell	I-NP	NN	O	4	NMOD
4	aplasia	aplasia	I-NP	NN	O	9	NMOD
5	,	,	O	,	O	9	P
6	toxic	toxic	B-NP	JJ	O	7	NMOD
7	dermatitis	dermatitis	I-NP	NN	O	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	lymphadenopathy	lymphadenopathy	I-NP	NN	O	0	ROOT
10	in	in	B-PP	IN	O	9	NMOD
11	a	a	B-NP	DT	O	12	NMOD
12	patient	patient	I-NP	NN	O	10	PMOD
13	taking	take	B-VP	VBG	O	12	NMOD
14	diphenylhydantoin	diphenylhydantoin	B-NP	NN	O	13	OBJ
15	.	.	O	.	O	9	P

1	A	A	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	8	SUB
3	taking	take	B-VP	VBG	O	2	NMOD
4	diphenylhydantoin	diphenylhydantoin	B-NP	NN	O	3	OBJ
5	for	for	B-PP	IN	O	3	VMOD
6	3	3	B-NP	CD	O	7	NMOD
7	weeks	week	I-NP	NNS	O	5	PMOD
8	developed	develop	B-VP	VBD	O	0	ROOT
9	a	a	B-NP	DT	O	12	NMOD
10	generalized	generalize	I-NP	VBN	O	12	NMOD
11	skin	skin	I-NP	NN	O	12	NMOD
12	rash	rash	I-NP	NN	O	19	NMOD
13	,	,	O	,	O	19	P
14	lymphadenopathy	lymphadenopathy	B-NP	NN	O	19	NMOD
15	and	and	O	CC	O	19	NMOD
16	pure	pure	B-NP	JJ	O	19	NMOD
17	red	red	I-NP	JJ	O	19	NMOD
18	cell	cell	I-NP	NN	O	19	NMOD
19	aplasia	aplasia	I-NP	NN	O	8	OBJ
20	.	.	O	.	O	8	P

1	Skin	Skin	B-NP	NN	O	2	NMOD
2	rash	rash	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	a	a	B-NP	DT	O	6	NMOD
5	well-known	well-known	I-NP	JJ	O	6	NMOD
6	complication	complication	I-NP	NN	O	3	PRD
7	of	of	B-PP	IN	O	6	NMOD
8	diphenylhydantoin	diphenylhydantoin	B-NP	NN	O	9	NMOD
9	treatment	treatment	I-NP	NN	O	7	PMOD
10	as	as	B-SBAR	IN	O	3	VMOD
11	is	be	B-VP	VBZ	O	10	SBAR
12	benign	benign	B-NP	JJ	O	15	NMOD
13	and	and	I-NP	CC	O	15	NMOD
14	malignant	malignant	I-NP	JJ	O	15	NMOD
15	lymphadenopathy	lymphadenopathy	I-NP	NN	O	11	PRD
16	.	.	O	.	O	3	P

1	Pure	Pure	B-NP	NN	O	4	NMOD
2	red	red	I-NP	JJ	O	4	NMOD
3	cell	cell	I-NP	NN	O	4	NMOD
4	aplasia	aplasia	I-NP	NN	O	9	SUB
5	associated	associate	B-VP	VBN	O	4	NMOD
6	with	with	B-PP	IN	O	5	VMOD
7	diphenylhydantoin	diphenylhydantoin	B-NP	NN	O	8	NMOD
8	medication	medication	I-NP	NN	O	6	PMOD
9	has	have	B-VP	VBZ	O	0	ROOT
10	been	be	I-VP	VBN	O	9	VC
11	reported	report	I-VP	VBN	O	10	VC
12	in	in	B-PP	IN	O	11	VMOD
13	3	3	B-NP	CD	O	14	NMOD
14	patients	patient	I-NP	NNS	O	12	PMOD
15	.	.	O	.	O	9	P

1	Continuous	Continuous	B-NP	JJ	O	3	NMOD
2	infusion	infusion	I-NP	NN	O	3	NMOD
3	tobramycin	tobramycin	I-NP	NN	O	0	ROOT
4	combined	combine	B-VP	VBN	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	carbenicillin	carbenicillin	B-NP	NN	B-protein	5	PMOD
7	for	for	B-PP	IN	O	4	VMOD
8	infections	infection	B-NP	NNS	O	7	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	cancer	cancer	B-NP	NN	O	11	NMOD
11	patients	patient	I-NP	NNS	O	9	PMOD
12	.	.	O	.	O	3	P

1	To	To	B-VP	TO	O	2	VMOD
2	overcome	overcome	I-VP	VB	O	10	VMOD
3	the	the	B-NP	DT	O	5	NMOD
4	adverse	adverse	I-NP	JJ	O	5	NMOD
5	effects	effect	I-NP	NNS	O	2	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	neutropenia	neutropenia	B-NP	NN	O	6	PMOD
8	,	,	O	,	O	10	P
9	tobramycin	tobramycin	B-NP	NN	O	10	SUB
10	was	be	B-VP	VBD	O	0	ROOT
11	given	give	I-VP	VBN	O	10	VC
12	by	by	B-PP	IN	O	11	VMOD
13	continuous	continuous	B-NP	JJ	O	14	NMOD
14	infusion	infusion	I-NP	NN	O	12	PMOD
15	and	and	O	CC	O	11	VMOD
16	combined	combine	B-VP	VBN	O	11	VMOD
17	with	with	B-PP	IN	O	16	VMOD
18	intermittent	intermittent	B-NP	JJ	B-protein	19	NMOD
19	carbenicillin	carbenicillin	I-NP	NN	I-protein	17	PMOD
20	.	.	O	.	O	10	P

1	Major	Major	B-NP	JJ	O	2	NMOD
2	azotemia	azotemia	I-NP	NN	O	17	SUB
3	(	(	O	(	O	16	DEP
4	serum	serum	B-NP	NN	O	5	NMOD
5	creatinine	creatinine	I-NP	NN	O	16	DEP
6	greater	great	B-NP	JJR	O	5	NMOD
7	than	than	I-NP	IN	O	6	AMOD
8	2.5	2.5	I-NP	CD	O	9	NMOD
9	mg/dl	mg/dl	I-NP	NN	O	11	NMOD
10	or	or	I-NP	CC	O	11	NMOD
11	BUN	BUN	I-NP	NN	B-protein	7	PMOD
12	greater	great	B-ADJP	JJR	O	11	NMOD
13	than	than	B-PP	IN	O	12	AMOD
14	50	50	B-NP	CD	O	15	NMOD
15	mg/dl	mg/dl	I-NP	NN	O	13	PMOD
16	)	)	O	)	O	2	NMOD
17	occurred	occur	B-VP	VBD	O	0	ROOT
18	in	in	B-PP	IN	O	17	VMOD
19	only	only	B-NP	RB	O	21	NMOD
20	2	2	I-NP	CD	O	19	AMOD
21	%	%	I-NP	NN	O	18	PMOD
22	.	.	O	.	O	17	P

1	Azotemia	Azotemia	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	not	not	O	RB	O	2	VMOD
4	related	related	B-ADJP	JJ	O	2	PRD
5	to	to	B-PP	TO	O	4	AMOD
6	duration	duration	B-NP	NN	O	5	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	therapy	therapy	B-NP	NN	O	12	NMOD
9	or	or	I-NP	CC	O	12	NMOD
10	serum	serum	I-NP	NN	O	12	NMOD
11	tobramycin	tobramycin	I-NP	NN	O	12	NMOD
12	concentration	concentration	I-NP	NN	O	7	PMOD
13	.	.	O	.	O	2	P

1	Recurrent	Recurrent	B-NP	JJ	O	3	NMOD
2	subarachnoid	subarachnoid	I-NP	JJ	O	3	NMOD
3	hemorrhage	hemorrhage	I-NP	NN	O	0	ROOT
4	associated	associate	B-VP	VBN	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	aminocaproic	aminocaproic	B-NP	JJ	O	8	NMOD
7	acid	acid	I-NP	NN	O	8	NMOD
8	therapy	therapy	I-NP	NN	O	13	NMOD
9	and	and	O	CC	O	13	NMOD
10	acute	acute	B-NP	JJ	O	13	NMOD
11	renal	renal	I-NP	JJ	O	13	NMOD
12	artery	artery	I-NP	NN	O	13	NMOD
13	thrombosis	thrombosis	I-NP	NN	O	5	PMOD
14	.	.	O	.	O	3	P

1	Epsilon	Epsilon	B-NP	NN	O	3	NMOD
2	aminocaproic	aminocaproic	I-NP	JJ	O	3	NMOD
3	acid	acid	I-NP	NN	O	7	SUB
4	(	(	O	(	O	6	DEP
5	EACA	EACA	B-NP	NN	O	6	DEP
6	)	)	O	)	O	3	NMOD
7	has	have	B-VP	VBZ	O	0	ROOT
8	been	be	I-VP	VBN	O	7	VC
9	used	use	I-VP	VBN	O	8	VC
10	to	to	B-VP	TO	O	11	VMOD
11	prevent	prevent	I-VP	VB	O	7	VMOD
12	rebleeding	rebleede	B-NP	VBG	O	11	VMOD
13	in	in	B-PP	IN	O	12	VMOD
14	patients	patient	B-NP	NNS	O	13	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	subarachnoid	subarachnoid	B-NP	JJ	O	17	NMOD
17	hemorrhage	hemorrhage	I-NP	NN	O	15	PMOD
18	(	(	O	(	O	20	DEP
19	SAH	SAH	B-NP	NN	B-protein	20	DEP
20	)	)	O	)	O	17	NMOD
21	.	.	O	.	O	7	P

1	Although	Although	B-SBAR	IN	O	0	ROOT
2	this	this	B-NP	DT	O	3	NMOD
3	agent	agent	I-NP	NN	O	4	SUB
4	does	do	B-VP	VBZ	O	1	VMOD
5	decrease	decrease	I-VP	VB	O	4	VC
6	the	the	B-NP	DT	O	7	NMOD
7	frequency	frequency	I-NP	NN	O	5	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	rebleeding	rebleede	B-VP	VBG	O	13	VMOD
10	,	,	O	,	O	13	P
11	several	several	B-NP	JJ	O	12	NMOD
12	reports	report	I-NP	NNS	O	13	SUB
13	have	have	B-VP	VBP	O	8	SBAR
14	described	describe	I-VP	VBN	O	13	VC
15	thrombotic	thrombotic	B-NP	JJ	O	16	NMOD
16	complications	complication	I-NP	NNS	O	14	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	EACA	EACA	B-NP	NN	O	19	NMOD
19	therapy	therapy	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	1	P

1	These	These	B-NP	DT	O	2	NMOD
2	complications	complication	I-NP	NNS	O	3	SUB
3	have	have	B-VP	VBP	O	0	ROOT
4	included	include	I-VP	VBN	O	3	VC
5	clinical	clinical	B-NP	JJ	O	6	NMOD
6	deterioration	deterioration	I-NP	NN	O	10	NMOD
7	and	and	O	CC	O	10	NMOD
8	intracranial	intracranial	B-NP	JJ	O	10	NMOD
9	vascular	vascular	I-NP	JJ	O	10	NMOD
10	thrombosis	thrombosis	I-NP	NN	O	20	NMOD
11	in	in	B-PP	IN	O	10	NMOD
12	patients	patient	B-NP	NNS	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	SAH	SAH	B-NP	NN	O	13	PMOD
15	,	,	O	,	O	10	P
16	arteriolar	arteriolar	B-NP	JJ	O	10	NMOD
17	and	and	I-NP	CC	O	20	NMOD
18	capillary	capillary	I-NP	JJ	O	20	NMOD
19	fibrin	fibrin	I-NP	NN	O	20	NMOD
20	thrombi	thrombi	I-NP	NN	O	33	NMOD
21	in	in	B-PP	IN	O	20	NMOD
22	patients	patient	B-NP	NNS	O	21	PMOD
23	with	with	B-PP	IN	O	22	NMOD
24	fibrinolytic	fibrinolytic	B-NP	JJ	O	25	NMOD
25	syndromes	syndrome	I-NP	NNS	O	23	PMOD
26	treated	treat	B-VP	VBN	O	25	NMOD
27	with	with	B-PP	IN	O	26	VMOD
28	EACA	EACA	B-NP	NN	B-protein	27	PMOD
29	,	,	O	,	O	33	P
30	or	or	O	CC	O	33	NMOD
31	other	other	B-NP	JJ	O	33	NMOD
32	thromboembolic	thromboembolic	I-NP	JJ	O	33	NMOD
33	phenomena	phenomenon	I-NP	NNS	O	4	OBJ
34	.	.	O	.	O	3	P

1	Since	Since	B-SBAR	IN	O	15	VMOD
2	intravascular	intravascular	B-NP	JJ	O	4	NMOD
3	fibrin	fibrin	I-NP	NN	O	4	NMOD
4	thrombi	thrombi	I-NP	NN	O	5	SUB
5	are	be	B-VP	VBP	O	1	SBAR
6	often	often	I-VP	RB	O	5	VMOD
7	observed	observe	I-VP	VBN	O	5	VC
8	in	in	B-PP	IN	O	7	VMOD
9	patients	patient	B-NP	NNS	O	8	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	fibrinolytic	fibrinolytic	B-NP	JJ	O	12	NMOD
12	disorders	disorder	I-NP	NNS	O	10	PMOD
13	,	,	O	,	O	15	P
14	EACA	EACA	B-NP	NN	B-protein	15	SUB
15	should	should	B-VP	MD	O	0	ROOT
16	not	not	I-VP	RB	O	15	VMOD
17	be	be	I-VP	VB	O	15	VC
18	implicated	implicate	I-VP	VBN	O	17	VC
19	in	in	B-PP	IN	O	18	VMOD
20	the	the	B-NP	DT	O	21	NMOD
21	pathogenesis	pathogenesis	I-NP	NN	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	fibrin	fibrin	B-NP	NN	O	24	NMOD
24	thrombi	thrombi	I-NP	NN	O	22	PMOD
25	in	in	B-PP	IN	O	24	NMOD
26	patients	patient	B-NP	NNS	O	25	PMOD
27	with	with	B-PP	IN	O	26	NMOD
28	disseminated	disseminate	B-NP	VBN	O	30	NMOD
29	intravascular	intravascular	I-NP	JJ	O	30	NMOD
30	coagulation	coagulation	I-NP	NN	O	35	NMOD
31	or	or	O	CC	O	35	NMOD
32	other	other	B-NP	JJ	O	35	NMOD
33	``	``	I-NP	``	O	35	NMOD
34	consumption	consumption	I-NP	NN	O	35	NMOD
35	coagulopathies.	coagulopathies.	I-NP	NN	O	27	PMOD
36	''	''	O	''	O	35	NMOD
37	This	This	B-NP	DT	O	38	NMOD
38	report	report	I-NP	NN	O	39	SUB
39	describes	describe	B-VP	VBZ	O	18	VMOD
40	subtotal	subtotal	B-NP	JJ	O	41	NMOD
41	infarction	infarction	I-NP	NN	O	39	OBJ
42	of	of	B-PP	IN	O	41	NMOD
43	the	the	B-NP	DT	O	44	NMOD
44	kidney	kidney	I-NP	NN	O	42	PMOD
45	due	due	B-ADJP	JJ	O	41	NMOD
46	to	to	B-PP	TO	O	45	AMOD
47	thrombosis	thrombosis	B-NP	NN	O	46	PMOD
48	of	of	B-PP	IN	O	47	NMOD
49	a	a	B-NP	DT	O	52	NMOD
50	normal	normal	I-NP	JJ	O	52	NMOD
51	renal	renal	I-NP	JJ	O	52	NMOD
52	artery	artery	I-NP	NN	O	48	PMOD
53	.	.	O	.	O	15	P

1	This	This	B-NP	DT	O	2	NMOD
2	occlusion	occlusion	I-NP	NN	O	3	SUB
3	occurred	occur	B-VP	VBD	O	0	ROOT
4	after	after	B-PP	IN	O	3	VMOD
5	EACA	EACA	B-NP	NN	O	6	NMOD
6	therapy	therapy	I-NP	NN	O	4	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	a	a	B-NP	DT	O	9	NMOD
9	patient	patient	I-NP	NN	O	7	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	SAH	SAH	B-NP	NN	O	14	NMOD
12	and	and	O	CC	O	14	NMOD
13	histopathological	histopathological	B-NP	JJ	O	14	NMOD
14	documentation	documentation	I-NP	NN	O	10	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	recurrent	recurrent	B-NP	JJ	O	17	NMOD
17	SAH	SAH	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	conclude	conclude	B-VP	VBP	O	0	ROOT
3	that	that	B-SBAR	IN	O	2	VMOD
4	previously	previously	B-NP	RB	O	5	AMOD
5	reported	report	I-NP	VBN	O	16	NMOD
6	hypoglycemia	hypoglycemia	I-NP	NN	O	16	NMOD
7	,	,	O	,	O	16	P
8	hyperbilirubinemia	hyperbilirubinemia	B-NP	NN	O	16	NMOD
9	,	,	O	,	O	16	P
10	polycythemia	polycythemia	B-NP	NN	O	16	NMOD
11	,	,	O	,	O	16	P
12	neonatal	neonatal	B-NP	JJ	O	13	NMOD
13	apnea	apnea	I-NP	NN	O	16	NMOD
14	,	,	O	,	O	16	P
15	and	and	O	CC	O	16	NMOD
16	bradycardia	bradycardia	B-NP	NN	O	17	SUB
17	are	be	B-VP	VBP	O	3	SBAR
18	not	not	O	RB	O	17	VMOD
19	invariable	invariable	B-ADJP	JJ	O	17	PRD
20	and	and	O	CC	O	17	VMOD
21	can	can	B-VP	MD	O	17	VMOD
22	not	not	I-VP	RB	O	21	VMOD
23	be	be	I-VP	VB	O	21	VC
24	statistically	statistically	I-VP	RB	O	23	VMOD
25	correlated	correlate	I-VP	VBN	O	23	VC
26	with	with	B-PP	IN	O	25	VMOD
27	chronic	chronic	B-NP	JJ	O	29	NMOD
28	propranolol	propranolol	I-NP	NN	O	29	NMOD
29	therapy	therapy	I-NP	NN	O	26	PMOD
30	.	.	O	.	O	2	P

1	Use	Use	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	propranolol	propranolol	B-NP	NN	O	2	PMOD
4	in	in	B-PP	IN	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	treatment	treatment	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	idiopathic	idiopathic	B-NP	JJ	O	10	NMOD
9	orthostatic	orthostatic	I-NP	JJ	O	10	NMOD
10	hypotension	hypotension	I-NP	NN	O	7	PMOD
11	.	.	O	.	O	1	P

1	They	They	B-NP	PRP	O	3	SUB
2	all	all	O	DT	O	3	SUB
3	exhibited	exhibit	B-VP	VBD	O	0	ROOT
4	markedly	markedly	B-NP	RB	O	5	AMOD
5	reduced	reduce	I-NP	VBN	O	7	NMOD
6	plasma	plasma	I-NP	NN	O	7	NMOD
7	catecholamines	catecholamine	I-NP	NNS	O	11	NMOD
8	and	and	O	CC	O	11	NMOD
9	plasma	plasma	B-NP	NN	O	11	NMOD
10	renin	renin	I-NP	NN	B-protein	11	NMOD
11	activity	activity	I-NP	NN	O	3	OBJ
12	in	in	B-PP	IN	O	11	NMOD
13	both	both	B-NP	CC	O	17	NMOD
14	recumbent	recumbent	I-NP	JJ	O	17	NMOD
15	and	and	I-NP	CC	O	17	NMOD
16	upright	upright	I-NP	JJ	O	17	NMOD
17	positions	position	I-NP	NNS	O	12	PMOD
18	and	and	O	CC	O	3	VMOD
19	had	have	B-VP	VBD	O	3	VMOD
20	marked	mark	I-VP	VBN	O	21	NMOD
21	hypersensitivity	hypersensitivity	B-NP	NN	O	19	OBJ
22	to	to	B-PP	TO	O	21	NMOD
23	the	the	B-NP	DT	O	25	NMOD
24	pressor	pressor	I-NP	NN	O	25	NMOD
25	effects	effect	I-NP	NNS	O	22	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	infused	infuse	B-NP	VBN	O	28	NMOD
28	norepinephrine	norepinephrine	I-NP	NN	O	26	PMOD
29	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	7	VMOD
2	1	1	B-NP	CD	O	3	NMOD
3	patient	patient	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	7	P
5	marked	marked	B-NP	JJ	O	6	NMOD
6	hypertension	hypertension	I-NP	NN	O	7	SUB
7	was	be	B-VP	VBD	O	0	ROOT
8	induced	induce	I-VP	VBN	O	7	VC
9	by	by	B-PP	IN	O	8	VMOD
10	propranolol	propranolol	B-NP	NN	O	13	NMOD
11	and	and	O	CC	O	13	NMOD
12	the	the	B-NP	DT	O	13	NMOD
13	drug	drug	I-NP	NN	O	9	PMOD
14	had	have	B-VP	VBD	O	7	VMOD
15	to	to	I-VP	TO	O	16	VMOD
16	be	be	I-VP	VB	O	14	VC
17	withdrawn	withdraw	I-VP	VBN	O	16	VC
18	.	.	O	.	O	7	P

1	Bilateral	Bilateral	B-NP	JJ	O	3	NMOD
2	retinal	retinal	I-NP	JJ	O	3	NMOD
3	artery	artery	I-NP	NN	O	6	NMOD
4	and	and	I-NP	CC	O	6	NMOD
5	choriocapillaris	choriocapillaris	I-NP	NN	O	6	NMOD
6	occlusion	occlusion	I-NP	NN	O	0	ROOT
7	following	follow	B-PP	VBG	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	injection	injection	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	long-acting	long-acting	B-NP	JJ	O	13	NMOD
12	corticosteroid	corticosteroid	I-NP	NN	O	13	NMOD
13	suspensions	suspension	I-NP	NNS	O	10	PMOD
14	in	in	B-PP	IN	O	9	NMOD
15	combination	combination	B-NP	NN	O	14	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	other	other	B-NP	JJ	O	18	NMOD
18	drugs	drug	I-NP	NNS	O	16	PMOD
19	:	:	O	:	O	6	P
20	I	I	B-LST	LS	O	6	NMOD
21	.	.	O	.	O	20	P

1	Two	Two	B-NP	CD	O	3	NMOD
2	well-documented	well-documented	I-NP	JJ	O	3	NMOD
3	cases	case	I-NP	NNS	O	31	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	bilateral	bilateral	B-NP	JJ	O	7	NMOD
6	retinal	retinal	I-NP	JJ	O	7	NMOD
7	artery	artery	I-NP	NN	O	10	NMOD
8	and	and	I-NP	CC	O	10	NMOD
9	choriocapillaris	choriocapillaris	I-NP	NN	O	10	NMOD
10	occlusions	occlusion	I-NP	NNS	O	4	PMOD
11	with	with	B-PP	IN	O	3	NMOD
12	blindness	blindness	B-NP	NN	O	11	PMOD
13	following	follow	B-PP	VBG	O	3	NMOD
14	head	head	B-NP	NN	O	18	NMOD
15	and	and	I-NP	CC	O	18	NMOD
16	neck	neck	I-NP	NN	O	18	NMOD
17	soft-tissue	soft-tissue	I-NP	JJ	O	18	NMOD
18	injection	injection	I-NP	NN	O	13	PMOD
19	with	with	B-PP	IN	O	18	NMOD
20	methylprednisolone	methylprednisolone	B-NP	NN	O	21	NMOD
21	acetate	acetate	I-NP	NN	O	19	PMOD
22	in	in	B-PP	IN	O	3	NMOD
23	combination	combination	B-NP	NN	O	22	PMOD
24	with	with	B-PP	IN	O	23	NMOD
25	lidocaine	lidocaine	B-NP	NN	O	30	NMOD
26	,	,	O	,	O	30	P
27	epinephrine	epinephrine	B-NP	NN	O	30	NMOD
28	,	,	O	,	O	30	P
29	or	or	O	CC	O	30	NMOD
30	penicillin	penicillin	B-NP	NN	O	24	PMOD
31	are	be	B-VP	VBP	O	0	ROOT
32	reported	report	I-VP	VBN	O	31	VC
33	.	.	O	.	O	31	P

1	Cephalothin	Cephalothin	B-NP	NN	B-protein	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	immune	immune	B-NP	JJ	O	5	NMOD
4	hemolytic	hemolytic	I-NP	JJ	O	5	NMOD
5	anemia	anemia	I-NP	NN	O	2	OBJ
6	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	6	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	renal	renal	B-NP	JJ	O	5	NMOD
5	disease	disease	I-NP	NN	O	3	PMOD
6	developed	develop	B-VP	VBD	O	0	ROOT
7	Coombs-positive	Coombs-positive	B-NP	JJ	O	9	NMOD
8	hemolytic	hemolytic	I-NP	JJ	O	9	NMOD
9	anemia	anemia	I-NP	NN	O	6	OBJ
10	while	while	B-SBAR	IN	O	6	VMOD
11	receiving	receive	B-VP	VBG	O	10	SBAR
12	cephalothin	cephalothin	B-NP	JJ	O	13	NMOD
13	therapy	therapy	I-NP	NN	O	11	OBJ
14	.	.	O	.	O	6	P

1	Kaliuretic	Kaliuretic	B-NP	JJ	O	2	NMOD
2	effect	effect	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	L-dopa	L-dopa	B-NP	NN	O	5	NMOD
5	treatment	treatment	I-NP	NN	O	3	PMOD
6	in	in	B-PP	IN	O	2	NMOD
7	parkinsonian	parkinsonian	B-NP	JJ	O	8	NMOD
8	patients	patient	I-NP	NNS	O	6	PMOD
9	.	.	O	.	O	2	P

1	Hypokalemia	Hypokalemia	B-NP	NN	O	6	SUB
2	,	,	O	,	O	1	P
3	sometimes	sometimes	B-ADJP	RB	O	4	AMOD
4	severe	severe	I-ADJP	JJ	O	1	NMOD
5	,	,	O	,	O	1	P
6	was	be	B-VP	VBD	O	0	ROOT
7	observed	observe	I-VP	VBN	O	6	VC
8	in	in	B-PP	IN	O	7	VMOD
9	some	some	B-NP	DT	O	12	NMOD
10	L-dopa-treated	L-dopa-treated	I-NP	JJ	O	12	NMOD
11	parkinsonian	parkinsonian	I-NP	JJ	O	12	NMOD
12	patients	patient	I-NP	NNS	O	8	PMOD
13	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	2	NMOD
2	influence	influence	I-NP	NN	O	11	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	L-dopa	L-dopa	B-NP	NN	O	3	PMOD
5	on	on	B-PP	IN	O	2	NMOD
6	the	the	B-NP	DT	O	8	NMOD
7	renal	renal	I-NP	JJ	O	8	NMOD
8	excretion	excretion	I-NP	NN	O	5	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	potassium	potassium	B-NP	NN	O	9	PMOD
11	was	be	B-VP	VBD	O	0	ROOT
12	studied	study	I-VP	VBN	O	11	VC
13	in	in	B-PP	IN	O	12	VMOD
14	3	3	B-NP	CD	O	15	NMOD
15	patients	patient	I-NP	NNS	O	13	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	hypokalemia	hypokalemia	B-NP	NN	O	16	PMOD
18	and	and	O	CC	O	13	PMOD
19	in	in	B-PP	IN	O	13	PMOD
20	5	5	B-NP	CD	O	22	NMOD
21	normokalemic	normokalemic	I-NP	JJ	O	22	NMOD
22	patients	patient	I-NP	NNS	O	19	PMOD
23	by	by	B-PP	IN	O	12	VMOD
24	determination	determination	B-NP	NN	O	23	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	renal	renal	B-NP	JJ	O	28	NMOD
27	plasma	plasma	I-NP	NN	O	28	NMOD
28	flow	flow	I-NP	NN	O	44	NMOD
29	,	,	O	,	O	44	P
30	glomerular	glomerular	B-NP	JJ	O	32	NMOD
31	filtration	filtration	I-NP	NN	O	32	NMOD
32	rate	rate	I-NP	NN	O	44	NMOD
33	,	,	O	,	O	44	P
34	plasma	plasma	B-NP	NN	O	35	NMOD
35	concentration	concentration	I-NP	NN	O	44	NMOD
36	of	of	B-PP	IN	O	35	NMOD
37	potassium	potassium	B-NP	NN	O	39	NMOD
38	and	and	I-NP	CC	O	39	NMOD
39	sodium	sodium	I-NP	NN	O	36	PMOD
40	as	as	B-CONJP	RB	O	44	NMOD
41	well	well	I-CONJP	RB	O	40	DEP
42	as	as	I-CONJP	IN	O	40	DEP
43	urinary	urinary	B-NP	JJ	O	44	NMOD
44	excretion	excretion	I-NP	NN	O	25	PMOD
45	of	of	B-PP	IN	O	44	NMOD
46	potassium	potassium	B-NP	NN	O	50	NMOD
47	,	,	I-NP	,	O	50	P
48	sodium	sodium	I-NP	NN	O	50	NMOD
49	and	and	I-NP	CC	O	50	NMOD
50	aldosterone	aldosterone	I-NP	NN	O	45	PMOD
51	.	.	O	.	O	11	P

1	Phenytoin	Phenytoin	B-NP	NN	O	2	NMOD
2	encephalopathy	encephalopathy	I-NP	NN	O	9	NMOD
3	as	as	B-PP	IN	O	2	NMOD
4	probable	probable	B-NP	JJ	O	5	AMOD
5	idiosyncratic	idiosyncratic	I-NP	JJ	O	6	NMOD
6	reaction	reaction	I-NP	NN	O	3	PMOD
7	:	:	O	:	O	2	P
8	case	case	B-NP	NN	O	9	NMOD
9	report	report	I-NP	NN	O	0	ROOT
10	.	.	O	.	O	9	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	17	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	phenytoin	phenytoin	B-NP	NN	O	8	NMOD
5	(	(	O	(	O	7	DEP
6	DPH	DPH	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	encephalopathy	encephalopathy	B-NP	NN	O	3	PMOD
9	with	with	B-PP	IN	O	2	NMOD
10	increasing	increase	B-NP	VBG	O	11	NMOD
11	seizures	seizure	I-NP	NNS	O	16	NMOD
12	and	and	I-NP	CC	O	16	NMOD
13	EEG	EEG	I-NP	NN	B-protein	16	NMOD
14	and	and	I-NP	CC	O	16	NMOD
15	mental	mental	I-NP	JJ	O	16	NMOD
16	changes	change	I-NP	NNS	O	9	PMOD
17	is	be	B-VP	VBZ	O	0	ROOT
18	described	describe	I-VP	VBN	O	17	VC
19	.	.	O	.	O	17	P

1	In	In	B-PP	IN	O	8	VMOD
2	fact	fact	B-NP	NN	O	1	PMOD
3	the	the	B-NP	DT	O	4	NMOD
4	concentration	concentration	I-NP	NN	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	free	free	B-NP	JJ	O	7	NMOD
7	DPH	DPH	I-NP	NN	O	5	PMOD
8	was	be	B-VP	VBD	O	13	VMOD
9	normal	normal	B-ADJP	JJ	O	8	PRD
10	,	,	O	,	O	8	P
11	the	the	B-NP	DT	O	12	NMOD
12	patient	patient	I-NP	NN	O	13	SUB
13	presented	present	B-VP	VBD	O	24	VMOD
14	a	a	B-NP	DT	O	17	NMOD
15	retarded	retard	I-NP	VBN	O	17	NMOD
16	morbilliform	morbilliform	I-NP	NN	O	17	NMOD
17	rash	rash	I-NP	NN	O	13	OBJ
18	during	during	B-PP	IN	O	13	VMOD
19	DPH	DPH	B-NP	NN	O	20	NMOD
20	treatment	treatment	I-NP	NN	O	18	PMOD
21	,	,	O	,	O	13	P
22	the	the	B-NP	DT	O	23	NMOD
23	protidogram	protidogram	I-NP	NN	O	24	SUB
24	was	be	B-VP	VBD	O	32	VMOD
25	normal	normal	B-ADJP	JJ	O	24	PRD
26	,	,	O	,	O	32	P
27	and	and	O	CC	O	31	NMOD
28	an	an	B-NP	DT	O	31	NMOD
29	intradermic	intradermic	I-NP	JJ	O	31	NMOD
30	DPH	DPH	I-NP	NN	O	31	NMOD
31	injection	injection	I-NP	NN	O	32	SUB
32	had	have	B-VP	VBD	O	0	ROOT
33	no	no	B-NP	DT	O	35	NMOD
34	local	local	I-NP	JJ	O	35	NMOD
35	effect	effect	I-NP	NN	O	32	OBJ
36	.	.	O	.	O	32	P

1	Effects	Effect	B-NP	NNS	O	9	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	exercise	exercise	B-NP	NN	O	2	PMOD
4	on	on	B-PP	IN	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	severity	severity	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	isoproterenol	isoproterenol	B-NP	NN	O	7	PMOD
9	induced	induce	B-VP	VBD	O	0	ROOT
10	myocardial	myocardial	B-NP	JJ	O	11	NMOD
11	infarction	infarction	I-NP	NN	O	9	OBJ
12	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	2	NMOD
2	effect	effect	I-NP	NN	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	exercise	exercise	B-NP	NN	O	3	PMOD
5	on	on	B-PP	IN	O	2	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	severity	severity	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	isoproterenol	isoproterenol	B-NP	NN	O	8	PMOD
10	induced	induce	B-VP	VBD	O	0	ROOT
11	myocardial	myocardial	B-NP	JJ	O	12	NMOD
12	infarction	infarction	I-NP	NN	O	13	SUB
13	was	be	B-VP	VBD	O	10	VMOD
14	studied	study	I-VP	VBN	O	13	VC
15	in	in	B-PP	IN	O	14	VMOD
16	male	male	B-NP	JJ	O	17	NMOD
17	rats	rat	I-NP	NNS	O	15	PMOD
18	.	.	O	.	O	10	P

1	Effect	Effect	B-NP	NN	O	7	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	D-Glucarates	D-Glucarate	B-NP	NNS	O	2	PMOD
4	on	on	B-PP	IN	O	1	NMOD
5	basic	basic	B-NP	JJ	O	6	NMOD
6	antibiotic	antibiotic	I-NP	NN	O	4	PMOD
7	induced	induce	B-VP	VBD	O	0	ROOT
8	renal	renal	B-NP	JJ	O	9	NMOD
9	damage	damage	I-NP	NN	O	7	OBJ
10	in	in	B-PP	IN	O	7	VMOD
11	rats	rat	B-NP	NNS	O	10	PMOD
12	.	.	O	.	O	7	P

1	Dehydrated	Dehydrate	B-NP	VBN	O	2	NMOD
2	rats	rat	I-NP	NNS	O	4	SUB
3	regularly	regularly	B-ADVP	RB	O	4	VMOD
4	develop	develop	B-VP	VBP	O	0	ROOT
5	acute	acute	B-NP	JJ	O	7	NMOD
6	renal	renal	I-NP	JJ	O	7	NMOD
7	failure	failure	I-NP	NN	O	4	OBJ
8	following	follow	B-PP	VBG	O	7	NMOD
9	single	single	B-NP	JJ	O	10	NMOD
10	injection	injection	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	aminoglycoside	aminoglycoside	B-NP	NN	O	13	NMOD
13	antibiotics	antibiotic	I-NP	NNS	O	11	PMOD
14	combined	combine	B-VP	VBN	O	13	NMOD
15	with	with	B-PP	IN	O	14	VMOD
16	dextran	dextran	B-NP	NN	O	15	PMOD
17	or	or	B-PP	CC	O	15	PMOD
18	of	of	B-PP	IN	O	15	PMOD
19	antibiotics	antibiotic	B-NP	NNS	O	15	PMOD
20	only	only	B-ADVP	RB	O	19	NMOD
21	.	.	O	.	O	4	P

1	Oral	Oral	B-NP	JJ	O	2	NMOD
2	administration	administration	I-NP	NN	O	11	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	2	2	B-NP	CD	O	10	NMOD
5	,	,	O	,	O	10	P
6	5-di-O-acetyl-D-glucaro-1	5-di-O-acetyl-D-glucaro-1	B-NP	NN	O	10	NMOD
7	,	,	O	,	O	10	P
8	4-6	4-6	B-NP	NN	O	10	NMOD
9	,	,	O	,	O	10	P
10	3-dilactone	3-dilactone	B-NP	NN	O	3	PMOD
11	protected	protect	B-VP	VBD	O	0	ROOT
12	rats	rat	B-NP	NNS	O	11	OBJ
13	against	against	B-PP	IN	O	11	VMOD
14	renal	renal	B-NP	JJ	O	15	NMOD
15	failure	failure	I-NP	NN	O	13	PMOD
16	induced	induce	B-VP	VBN	O	15	NMOD
17	by	by	B-PP	IN	O	16	VMOD
18	kanamycin-dextran	kanamycin-dextran	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	11	P

1	D-Glucarates	D-Glucarate	B-NP	NNS	O	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	effective	effective	B-ADJP	JJ	O	2	PRD
4	against	against	B-PP	IN	O	3	AMOD
5	renal	renal	B-NP	JJ	O	6	NMOD
6	damage	damage	I-NP	NN	O	4	PMOD
7	induced	induce	B-VP	VBN	O	6	NMOD
8	by	by	B-PP	IN	O	7	VMOD
9	peptide	peptide	B-NP	NN	O	10	NMOD
10	antibiotics	antibiotic	I-NP	NNS	O	16	NMOD
11	as	as	B-CONJP	RB	O	16	NMOD
12	well	well	I-CONJP	RB	O	11	DEP
13	as	as	I-CONJP	IN	O	11	DEP
14	various	various	B-NP	JJ	O	16	NMOD
15	aminoglycoside	aminoglycoside	I-NP	NN	O	16	NMOD
16	antibitocis	antibitocis	I-NP	NN	O	8	PMOD
17	.	.	O	.	O	2	P

1	With	With	B-PP	IN	O	17	VMOD
2	a	a	B-NP	DT	O	3	NMOD
3	D-glucarate	D-glucarate	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	a	a	B-NP	DT	O	7	NMOD
6	fixed	fix	I-NP	VBN	O	7	NMOD
7	size	size	I-NP	NN	O	4	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	dose	dose	B-NP	NN	O	8	PMOD
10	,	,	O	,	O	17	P
11	approximately	approximately	B-NP	RB	O	14	NMOD
12	the	the	I-NP	DT	O	14	NMOD
13	same	same	I-NP	JJ	O	14	NMOD
14	degree	degree	I-NP	NN	O	17	SUB
15	of	of	B-PP	IN	O	14	NMOD
16	protection	protection	B-NP	NN	O	15	PMOD
17	was	be	B-VP	VBD	O	0	ROOT
18	obtained	obtain	I-VP	VBN	O	17	VC
19	against	against	B-PP	IN	O	18	VMOD
20	renal	renal	B-NP	JJ	O	21	NMOD
21	damages	damage	I-NP	NNS	O	19	PMOD
22	induced	induce	B-VP	VBN	O	21	NMOD
23	by	by	B-PP	IN	O	22	VMOD
24	different	different	B-NP	JJ	O	26	NMOD
25	basic	basic	I-NP	JJ	O	26	NMOD
26	antibiotics	antibiotic	I-NP	NNS	O	23	PMOD
27	despite	despite	B-PP	IN	O	18	VMOD
28	large	large	B-NP	JJ	O	29	NMOD
29	disparities	disparity	I-NP	NNS	O	27	PMOD
30	in	in	B-PP	IN	O	29	NMOD
31	administration	administration	B-NP	NN	O	32	NMOD
32	doses	dose	I-NP	NNS	O	30	PMOD
33	of	of	B-PP	IN	O	32	NMOD
34	different	different	B-NP	JJ	O	35	NMOD
35	antibiotics	antibiotic	I-NP	NNS	O	33	PMOD
36	.	.	O	.	O	17	P

1	D-Glucarates	D-Glucarate	B-NP	NNS	O	2	SUB
2	had	have	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	ability	ability	I-NP	NN	O	2	OBJ
5	to	to	B-VP	TO	O	6	VMOD
6	prevent	prevent	I-VP	VB	O	4	NMOD
7	renal	renal	B-NP	JJ	O	8	NMOD
8	damage	damage	I-NP	NN	O	6	OBJ
9	but	but	O	CC	O	6	VMOD
10	not	not	O	RB	O	12	VMOD
11	to	to	B-VP	TO	O	12	VMOD
12	cure	cure	I-VP	VB	O	6	VMOD
13	it	it	B-NP	PRP	O	12	OBJ
14	.	.	O	.	O	2	P

1	Rats	Rat	B-NP	NNS	O	2	SUB
2	excreted	excrete	B-VP	VBD	O	0	ROOT
3	acidic	acidic	B-NP	JJ	O	4	NMOD
4	urine	urine	I-NP	NN	O	2	OBJ
5	when	when	B-ADVP	WRB	O	2	VMOD
6	they	they	B-NP	PRP	O	7	SUB
7	were	be	B-VP	VBD	O	5	SBAR
8	spared	spar	I-VP	VBN	O	7	VC
9	from	from	B-PP	IN	O	8	VMOD
10	renal	renal	B-NP	JJ	O	11	NMOD
11	lesions	lesion	I-NP	NNS	O	9	PMOD
12	by	by	B-PP	IN	O	8	VMOD
13	monosaccharides	monosaccharide	B-NP	NNS	O	12	PMOD
14	.	.	O	.	O	2	P

1	Paraplegia	Paraplegia	B-NP	NNP	O	6	NMOD
2	following	follow	B-PP	VBG	O	1	NMOD
3	intrathecal	intrathecal	B-NP	JJ	O	4	NMOD
4	methotrexate	methotrexate	I-NP	NN	O	2	PMOD
5	:	:	O	:	O	1	P
6	report	report	B-NP	NN	O	11	NMOD
7	of	of	B-PP	IN	O	6	NMOD
8	a	a	B-NP	DT	O	9	NMOD
9	case	case	I-NP	NN	O	7	PMOD
10	and	and	I-NP	CC	O	11	NMOD
11	review	review	I-NP	NN	O	0	ROOT
12	of	of	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	literature	literature	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	11	P

1	A	A	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	12	SUB
3	who	who	B-NP	WP	O	2	NMOD
4	developed	develop	B-VP	VBD	O	3	SBAR
5	paraplegia	paraplegia	B-NP	NN	O	4	OBJ
6	following	follow	B-PP	VBG	O	4	VMOD
7	the	the	B-NP	DT	O	9	NMOD
8	intrathecal	intrathecal	I-NP	JJ	O	9	NMOD
9	instillation	instillation	I-NP	NN	O	6	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	methotrexate	methotrexate	B-NP	NN	O	10	PMOD
12	is	be	B-VP	VBZ	O	0	ROOT
13	discribed	discribe	I-VP	VBN	O	12	VC
14	.	.	O	.	O	12	P

1	The	The	B-NP	DT	O	3	NMOD
2	following	follow	I-NP	VBG	O	3	NMOD
3	factors	factor	I-NP	NNS	O	4	SUB
4	appear	appear	B-VP	VBP	O	0	ROOT
5	to	to	I-VP	TO	O	6	VMOD
6	predispose	predispose	I-VP	VB	O	4	VMOD
7	to	to	B-PP	TO	O	6	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	development	development	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	this	this	B-NP	DT	O	12	NMOD
12	complication	complication	I-NP	NN	O	10	PMOD
13	:	:	O	:	O	4	P
14	abnormal	abnormal	B-NP	JJ	O	16	NMOD
15	cerebrospinal	cerebrospinal	I-NP	JJ	O	16	NMOD
16	dynamics	dynamic	I-NP	NNS	O	4	OBJ
17	related	relate	B-VP	VBN	O	16	NMOD
18	to	to	B-PP	TO	O	17	AMOD
19	the	the	B-NP	DT	O	20	NMOD
20	presence	presence	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	central	central	B-NP	JJ	O	25	NMOD
23	nervous	nervous	I-NP	JJ	O	25	NMOD
24	system	system	I-NP	NN	O	25	NMOD
25	leukemia	leukemia	I-NP	NN	O	21	PMOD
26	,	,	O	,	O	62	P
27	and	and	O	CC	O	30	NMOD
28	epidural	epidural	B-NP	JJ	O	30	NMOD
29	cerebrospinal	cerebrospinal	I-NP	JJ	O	30	NMOD
30	leakage	leakage	I-NP	NN	O	62	NMOD
31	;	;	O	:	O	62	P
32	elevated	elevate	B-NP	VBN	O	36	NMOD
33	cerebrospinal	cerebrospinal	I-NP	JJ	O	36	NMOD
34	fluid	fluid	I-NP	NN	O	36	NMOD
35	methothexate	methothexate	I-NP	NN	O	36	NMOD
36	concentration	concentration	I-NP	NN	O	62	NMOD
37	related	relate	B-VP	VBN	O	36	NMOD
38	to	to	B-PP	TO	O	37	AMOD
39	abnormal	abnormal	B-NP	JJ	O	42	NMOD
40	cerebrospinal	cerebrospinal	I-NP	JJ	O	42	NMOD
41	fluid	fluid	I-NP	NN	O	42	NMOD
42	dynamics	dynamic	I-NP	NNS	O	38	PMOD
43	and	and	B-PP	CC	O	37	VMOD
44	to	to	B-PP	TO	O	43	PMOD
45	inappropriately	inappropriately	B-NP	RB	O	46	AMOD
46	high	high	I-NP	JJ	O	48	NMOD
47	methotrexate	methotrexate	I-NP	NN	O	48	NMOD
48	doses	dose	I-NP	NNS	O	44	PMOD
49	based	base	B-VP	VBN	O	48	NMOD
50	on	on	B-PP	IN	O	49	VMOD
51	body	body	B-NP	NN	O	54	NMOD
52	surface	surface	I-NP	NN	O	54	NMOD
53	area	area	I-NP	NN	O	54	NMOD
54	calculations	calculation	I-NP	NNS	O	50	PMOD
55	in	in	B-PP	IN	O	54	NMOD
56	older	old	B-NP	JJR	O	57	NMOD
57	children	child	I-NP	NNS	O	59	NMOD
58	and	and	I-NP	CC	O	59	NMOD
59	adults	adult	I-NP	NNS	O	55	PMOD
60	;	;	O	:	O	62	P
61	the	the	B-NP	DT	O	62	NMOD
62	presence	presence	I-NP	NN	O	4	OBJ
63	of	of	B-PP	IN	O	62	NMOD
64	neurotoxic	neurotoxic	B-NP	JJ	O	65	NMOD
65	preservatives	preservative	I-NP	NNS	O	63	PMOD
66	in	in	B-PP	IN	O	62	NMOD
67	commercially	commercially	B-NP	RB	O	68	AMOD
68	available	available	I-NP	JJ	O	66	PMOD
69	methotrexate	methotrexate	I-NP	NN	O	70	NMOD
70	preparations	preparation	I-NP	NNS	O	68	NMOD
71	and	and	I-NP	CC	O	68	NMOD
72	diluents	diluent	I-NP	NNS	O	68	NMOD
73	;	;	O	:	O	87	P
74	and	and	O	CC	O	76	NMOD
75	the	the	B-NP	DT	O	76	NMOD
76	use	use	I-NP	NN	O	87	NMOD
77	of	of	B-PP	IN	O	76	NMOD
78	methotrexate	methotrexate	B-NP	NN	O	79	NMOD
79	diluents	diluent	I-NP	NNS	O	77	PMOD
80	of	of	B-PP	IN	O	79	NMOD
81	unphysiologic	unphysiologic	B-NP	JJ	O	82	NMOD
82	pH	pH	I-NP	NN	O	80	PMOD
83	,	,	O	,	O	87	P
84	ionic	ionic	B-NP	JJ	O	85	NMOD
85	content	content	I-NP	NN	O	87	NMOD
86	and	and	I-NP	CC	O	87	NMOD
87	osmolarity	osmolarity	I-NP	NN	O	4	VMOD
88	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	2	NMOD
2	role	role	I-NP	NN	O	13	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	methotrexate	methotrexate	B-NP	NN	O	5	NMOD
5	contaminants	contaminant	I-NP	NNS	O	3	PMOD
6	,	,	O	,	O	13	P
7	local	local	B-NP	JJ	O	9	NMOD
8	folate	folate	I-NP	JJ	O	9	NMOD
9	deficiency	deficiency	I-NP	NN	O	13	NMOD
10	,	,	O	,	O	13	P
11	and	and	O	CC	O	13	NMOD
12	cranial	cranial	B-NP	JJ	O	13	NMOD
13	irradiation	irradiation	I-NP	NN	O	21	SUB
14	in	in	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	pathogenesis	pathogenesis	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	intrathecal	intrathecal	B-NP	JJ	O	20	NMOD
19	methotrexate	methotrexate	I-NP	NN	O	20	NMOD
20	toxicity	toxicity	I-NP	NN	O	17	PMOD
21	is	be	B-VP	VBZ	O	0	ROOT
22	unclear	unclear	B-ADJP	JJ	O	21	PRD
23	.	.	O	.	O	21	P

1	The	The	B-NP	DT	O	2	NMOD
2	incidence	incidence	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	neurotoxicity	neurotoxicity	B-NP	NN	O	3	PMOD
5	may	may	B-VP	MD	O	0	ROOT
6	be	be	I-VP	VB	O	5	VC
7	reduced	reduce	I-VP	VBN	O	6	VC
8	by	by	B-PP	IN	O	7	VMOD
9	employing	employ	B-VP	VBG	O	8	PMOD
10	lower	low	B-NP	JJR	O	11	NMOD
11	doses	dose	I-NP	NNS	O	9	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	methotrexate	methotrexate	B-NP	NN	O	12	PMOD
14	in	in	B-PP	IN	O	9	VMOD
15	the	the	B-NP	DT	O	16	NMOD
16	presence	presence	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	central	central	B-NP	JJ	O	21	NMOD
19	nervous	nervous	I-NP	JJ	O	21	NMOD
20	system	system	I-NP	NN	O	21	NMOD
21	leukemia	leukemia	I-NP	NN	O	17	PMOD
22	,	,	O	,	O	7	P
23	in	in	B-PP	IN	O	7	VMOD
24	older	old	B-NP	JJR	O	25	NMOD
25	children	child	I-NP	NNS	O	27	NMOD
26	and	and	I-NP	CC	O	27	NMOD
27	adults	adult	I-NP	NNS	O	23	PMOD
28	,	,	O	,	O	5	P
29	and	and	O	CC	O	5	VMOD
30	in	in	B-PP	IN	O	32	NMOD
31	the	the	B-NP	DT	O	30	PMOD
32	presence	presence	I-NP	NN	O	29	PRD
33	of	of	B-PP	IN	O	32	NMOD
34	epidural	epidural	B-NP	JJ	O	35	NMOD
35	leakage	leakage	I-NP	NN	O	33	PMOD
36	.	.	O	.	O	5	P

1	This	This	B-NP	DT	O	2	NMOD
2	response	response	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	significantly	significantly	I-VP	RB	O	3	VMOD
5	reduced	reduce	I-VP	VBN	O	3	VC
6	by	by	B-PP	IN	O	5	VMOD
7	the	the	B-NP	DT	O	12	NMOD
8	intravenous	intravenous	I-NP	JJ	O	12	NMOD
9	(	(	O	(	O	11	DEP
10	i.v.	i.v.	B-ADJP	JJ	O	11	DEP
11	)	)	O	)	O	8	AMOD
12	injection	injection	B-NP	NN	O	6	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	guanethidine	guanethidine	B-NP	NN	O	26	NMOD
15	(	(	O	(	O	18	DEP
16	5	5	B-NP	CD	O	17	NMOD
17	mg	mg	I-NP	NN	O	18	DEP
18	)	)	O	)	O	14	NMOD
19	,	,	O	,	O	26	P
20	hexamethonium	hexamethonium	B-NP	NN	O	26	NMOD
21	(	(	O	(	O	24	DEP
22	10	10	B-NP	CD	O	23	NMOD
23	mg	mg	I-NP	NN	O	24	DEP
24	)	)	O	)	O	20	NMOD
25	or	or	O	CC	O	26	NMOD
26	phentolamine	phentolamine	B-NP	NN	O	13	PMOD
27	(	(	O	(	O	30	DEP
28	5	5	B-NP	CD	O	29	NMOD
29	mg	mg	I-NP	NN	O	30	DEP
30	)	)	O	)	O	26	NMOD
31	,	,	O	,	O	3	VMOD
32	and	and	O	CC	O	31	PMOD
33	conversely	conversely	B-ADVP	RB	O	32	PRD
34	,	,	O	,	O	35	P
35	potentiated	potentiate	B-VP	VBN	O	33	AMOD
36	by	by	B-PP	IN	O	35	VMOD
37	i.v.	i.v.	B-NP	JJ	O	38	NMOD
38	desmethylimipramine	desmethylimipramine	I-NP	NN	O	36	PMOD
39	(	(	O	(	O	42	DEP
40	0.3	0.3	B-NP	CD	O	41	NMOD
41	mg	mg	I-NP	NN	O	42	DEP
42	)	)	O	)	O	38	NMOD
43	,	,	O	,	O	35	P
44	while	while	B-SBAR	IN	O	35	VMOD
45	propranolol	propranolol	B-NP	NN	O	50	NMOD
46	(	(	O	(	O	49	DEP
47	0.5	0.5	B-NP	CD	O	48	NMOD
48	mg	mg	I-NP	NN	O	49	DEP
49	)	)	O	)	O	45	NMOD
50	i.v.	i.v.	B-NP	NN	O	52	SUB
51	selectively	selectively	B-ADVP	RB	O	52	VMOD
52	inhibited	inhibit	B-VP	VBD	O	44	SBAR
53	the	the	B-NP	DT	O	54	NMOD
54	enlargement	enlargement	I-NP	NN	O	60	NMOD
55	of	of	B-PP	IN	O	54	NMOD
56	pulse	pulse	B-NP	NN	O	57	NMOD
57	pressure	pressure	I-NP	NN	O	55	PMOD
58	and	and	O	CC	O	60	NMOD
59	the	the	B-NP	DT	O	60	NMOD
60	tachycardia	tachycardia	I-NP	NN	O	52	OBJ
61	following	follow	B-PP	VBG	O	60	NMOD
62	i.c.	i.c.	B-NP	JJ	O	63	NMOD
63	carbachol	carbachol	I-NP	NN	O	61	PMOD
64	(	(	O	(	O	67	DEP
65	1	1	B-NP	CD	O	66	NMOD
66	mug	mug	I-NP	NN	O	67	DEP
67	)	)	O	)	O	63	NMOD
68	.	.	O	.	O	3	P

1	Hyperglycemic	Hyperglycemic	B-NP	JJ	O	2	NMOD
2	effect	effect	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	amino	amino	B-NP	JJ	O	5	NMOD
5	compounds	compound	I-NP	NNS	O	3	PMOD
6	structurally	structurally	B-ADJP	RB	O	7	AMOD
7	related	related	I-ADJP	JJ	O	5	NMOD
8	to	to	B-VP	TO	O	9	VMOD
9	caproate	caproate	I-VP	VB	O	7	AMOD
10	in	in	B-PP	IN	O	9	VMOD
11	rats	rat	B-NP	NNS	O	10	PMOD
12	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	chronic	chronic	I-NP	JJ	O	3	NMOD
3	feeding	feeding	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	small	small	B-NP	JJ	O	6	NMOD
6	amounts	amount	I-NP	NNS	O	4	PMOD
7	(	(	O	(	O	6	NMOD
8	0.3-3	0.3-3	B-NP	CD	O	9	NMOD
9	%	%	I-NP	NN	O	20	SUB
10	of	of	B-PP	IN	O	9	NMOD
11	diet	diet	B-NP	NN	O	12	NMOD
12	weight	weight	I-NP	NN	O	10	PMOD
13	)	)	O	)	O	10	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	certain	certain	B-NP	JJ	O	17	NMOD
16	amino	amino	I-NP	NN	O	17	NMOD
17	derivatives	derivative	I-NP	NNS	O	14	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	caproate	caproate	B-NP	NN	O	18	PMOD
20	resulted	result	B-VP	VBD	O	7	SBAR
21	in	in	B-PP	IN	O	20	VMOD
22	hyperglycemia	hyperglycemia	B-NP	NN	O	28	NMOD
23	,	,	O	,	O	28	P
24	an	an	B-NP	DT	O	28	NMOD
25	elevated	elevated	I-NP	JJ	O	28	NMOD
26	glucose	glucose	I-NP	NN	O	28	NMOD
27	tolerance	tolerance	I-NP	NN	O	28	NMOD
28	curve	curve	I-NP	NN	O	21	PMOD
29	and	and	O	CC	O	33	NMOD
30	,	,	O	,	O	33	P
31	occasionally	occasionally	B-ADVP	RB	O	33	NMOD
32	,	,	O	,	O	33	P
33	glucosuria	glucosuria	B-NP	NN	O	20	VMOD
34	.	.	O	.	O	3	P

1	Fatty	Fatty	B-NP	JJ	O	2	NMOD
2	liver	liver	I-NP	NN	O	0	ROOT
3	induced	induce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	tetracycline	tetracycline	B-NP	NN	O	4	PMOD
6	in	in	B-PP	IN	O	3	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	rat	rat	I-NP	NN	O	6	PMOD
9	.	.	O	.	O	2	P

1	Dose-response	Dose-response	B-NP	JJ	O	2	NMOD
2	relationships	relationship	I-NP	NNS	O	9	NMOD
3	,	,	O	,	O	9	P
4	biochemical	biochemical	B-NP	JJ	O	5	NMOD
5	mechanisms	mechanism	I-NP	NNS	O	9	NMOD
6	,	,	O	,	O	9	P
7	and	and	O	CC	O	9	NMOD
8	sex	sex	B-NP	NN	O	9	NMOD
9	differences	difference	I-NP	NNS	O	18	SUB
10	in	in	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	14	NMOD
12	experimental	experimental	I-NP	JJ	O	14	NMOD
13	fatty	fatty	I-NP	JJ	O	14	NMOD
14	liver	liver	I-NP	NN	O	10	PMOD
15	induced	induce	B-VP	VBN	O	14	NMOD
16	by	by	B-PP	IN	O	15	VMOD
17	tetracycline	tetracycline	B-NP	NN	O	16	PMOD
18	were	be	B-VP	VBD	O	0	ROOT
19	studied	study	I-VP	VBN	O	18	VC
20	in	in	B-PP	IN	O	19	VMOD
21	the	the	B-NP	DT	O	23	NMOD
22	intact	intact	I-NP	JJ	O	23	NMOD
23	rat	rat	I-NP	NN	O	20	PMOD
24	and	and	B-PP	CC	O	20	PMOD
25	with	with	B-PP	IN	O	20	PMOD
26	the	the	B-NP	DT	O	30	NMOD
27	isolated	isolate	I-NP	VBN	O	30	NMOD
28	perfused	perfuse	I-NP	VBN	O	30	NMOD
29	rat	rat	I-NP	NN	O	30	NMOD
30	liver	liver	I-NP	NN	O	25	PMOD
31	in	in	B-ADVP	FW	O	19	VMOD
32	vitro	vitro	I-ADVP	FW	O	31	AMOD
33	.	.	O	.	O	18	P

1	With	With	B-PP	IN	O	19	VMOD
2	provision	provision	B-NP	NN	O	1	PMOD
3	of	of	B-PP	IN	O	2	NMOD
4	adequate	adequate	B-NP	JJ	O	6	NMOD
5	oleic	oleic	I-NP	JJ	O	6	NMOD
6	acid	acid	I-NP	NN	O	3	PMOD
7	as	as	B-PP	IN	O	1	NMOD
8	a	a	B-NP	DT	O	9	NMOD
9	substrate	substrate	I-NP	NN	O	7	PMOD
10	for	for	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	14	NMOD
12	isolated	isolate	I-NP	VBN	O	14	NMOD
13	perfused	perfuse	I-NP	VBN	O	14	NMOD
14	liver	liver	I-NP	NN	O	18	NMOD
15	,	,	O	,	O	18	P
16	a	a	B-NP	DT	O	18	NMOD
17	direct	direct	I-NP	JJ	O	18	NMOD
18	relationship	relationship	I-NP	NN	O	10	PMOD
19	was	be	B-VP	VBD	O	0	ROOT
20	observed	observe	I-VP	VBN	O	19	VC
21	between	between	B-PP	IN	O	20	VMOD
22	dose	dose	B-NP	NN	O	27	NMOD
23	of	of	B-PP	IN	O	22	NMOD
24	tetracycline	tetracycline	B-NP	NN	O	23	PMOD
25	and	and	O	CC	O	27	NMOD
26	both	both	O	CC	O	27	NMOD
27	accumulation	accumulation	B-NP	NN	O	21	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	triglyceride	triglyceride	B-NP	NN	O	28	PMOD
30	in	in	B-PP	IN	O	27	NMOD
31	the	the	B-NP	DT	O	34	NMOD
32	liver	liver	I-NP	NN	O	34	NMOD
33	and	and	I-NP	CC	O	34	NMOD
34	depression	depression	I-NP	NN	O	30	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	output	output	B-NP	NN	O	35	PMOD
37	of	of	B-PP	IN	O	36	NMOD
38	triglyceride	triglyceride	B-NP	NN	O	37	PMOD
39	by	by	B-PP	IN	O	27	NMOD
40	livers	liver	B-NP	NNS	O	39	PMOD
41	from	from	B-PP	IN	O	40	NMOD
42	male	male	B-NP	JJ	O	45	NMOD
43	and	and	I-NP	CC	O	45	NMOD
44	female	female	I-NP	JJ	O	45	NMOD
45	rats	rat	I-NP	NNS	O	41	PMOD
46	.	.	O	.	O	19	P

1	However	However	B-ADVP	RB	O	13	VMOD
2	,	,	O	,	O	13	P
3	livers	liver	B-NP	NNS	O	13	SUB
4	from	from	B-PP	IN	O	3	NMOD
5	female	female	B-ADJP	JJ	O	11	NMOD
6	,	,	O	,	O	11	P
7	and	and	O	CC	O	11	NMOD
8	especially	especially	B-NP	RB	O	9	AMOD
9	pregnant	pregnant	I-NP	JJ	O	11	NMOD
10	female	female	I-NP	JJ	O	11	NMOD
11	rats	rat	I-NP	NNS	O	4	PMOD
12	,	,	O	,	O	3	P
13	were	be	B-VP	VBD	O	0	ROOT
14	strikingly	strikingly	B-ADJP	RB	O	15	AMOD
15	resistant	resistant	I-ADJP	JJ	O	13	PRD
16	to	to	B-PP	TO	O	15	AMOD
17	the	the	B-NP	DT	O	18	NMOD
18	effects	effect	I-NP	NNS	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	tetracycline	tetracycline	B-NP	NN	O	19	PMOD
21	on	on	B-PP	IN	O	18	NMOD
22	depression	depression	B-NP	NN	O	21	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	output	output	B-NP	NN	O	23	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	triglyceride	triglyceride	B-NP	NN	O	25	PMOD
27	under	under	B-PP	IN	O	15	AMOD
28	these	these	B-NP	DT	O	30	NMOD
29	experimental	experimental	I-NP	JJ	O	30	NMOD
30	conditions	condition	I-NP	NNS	O	27	PMOD
31	.	.	O	.	O	13	P

1	Fatal	Fatal	B-NP	JJ	O	2	NMOD
2	myeloencephalopathy	myeloencephalopathy	I-NP	NN	O	0	ROOT
3	due	due	B-PP	JJ	O	2	NMOD
4	to	to	B-PP	TO	O	3	AMOD
5	intrathecal	intrathecal	B-NP	JJ	O	7	NMOD
6	vincristine	vincristine	I-NP	NN	O	7	NMOD
7	administration	administration	I-NP	NN	O	4	PMOD
8	.	.	O	.	O	2	P

1	Vincristine	Vincristine	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	accidentally	accidentally	I-VP	RB	O	2	VMOD
4	given	give	I-VP	VBN	O	2	VC
5	intrathecally	intrathecally	B-ADVP	RB	O	6	PMOD
6	to	to	B-PP	TO	O	4	VMOD
7	a	a	B-NP	DT	O	8	NMOD
8	child	child	I-NP	NN	O	6	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	leukaemia	leukaemia	B-NP	NN	O	9	PMOD
11	,	,	O	,	O	4	P
12	producing	produce	B-VP	VBG	O	4	VMOD
13	sensory	sensory	B-NP	NN	O	16	NMOD
14	and	and	I-NP	CC	O	16	NMOD
15	motor	motor	I-NP	NN	O	16	NMOD
16	dysfunction	dysfunction	I-NP	NN	O	12	OBJ
17	followed	follow	B-VP	VBN	O	16	NMOD
18	by	by	B-PP	IN	O	17	VMOD
19	encephalopathy	encephalopathy	B-NP	NN	O	21	NMOD
20	and	and	I-NP	CC	O	21	NMOD
21	death	death	I-NP	NN	O	18	PMOD
22	.	.	O	.	O	2	P

1	After	After	B-PP	IN	O	0	ROOT
2	determining	determine	B-VP	VBG	O	1	PMOD
3	the	the	B-NP	DT	O	5	NMOD
4	bupivacaine	bupivacaine	I-NP	NN	O	5	NMOD
5	AD50	AD50	I-NP	NN	O	2	OBJ
6	(	(	O	(	O	5	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	concentration	concentration	I-NP	NN	O	28	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	bupivacaine	bupivacaine	B-NP	NN	O	9	PMOD
11	that	that	B-NP	WDT	O	8	NMOD
12	caused	cause	B-VP	VBD	O	11	SBAR
13	50	50	B-NP	CD	O	14	NMOD
14	%	%	I-NP	NN	O	12	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	all	all	B-NP	DT	O	21	NMOD
17	beating	beat	I-NP	VBG	O	21	NMOD
18	rat	rat	I-NP	NN	B-cell_line	21	NMOD
19	heart	heart	I-NP	NN	I-cell_line	21	NMOD
20	myocyte	myocyte	I-NP	NN	I-cell_line	21	NMOD
21	cultures	culture	I-NP	NNS	I-cell_line	15	PMOD
22	to	to	B-VP	TO	O	23	VMOD
23	become	become	I-VP	VB	O	14	NMOD
24	arrhythmic	arrhythmic	B-ADJP	JJ	O	23	PRD
25	)	)	O	)	O	23	VMOD
26	,	,	O	,	O	28	P
27	we	we	B-NP	PRP	O	28	SUB
28	determined	determine	B-VP	VBD	O	6	SBAR
29	the	the	B-NP	DT	O	30	NMOD
30	effect	effect	I-NP	NN	O	28	OBJ
31	of	of	B-PP	IN	O	30	NMOD
32	1-hour	1-hour	B-NP	JJ	O	35	NMOD
33	progesterone	progesterone	I-NP	NN	O	35	NMOD
34	HCl	HCl	I-NP	NN	O	35	NMOD
35	exposure	exposure	I-NP	NN	O	31	PMOD
36	on	on	B-PP	IN	O	30	NMOD
37	myocyte	myocyte	B-NP	NN	O	39	NMOD
38	contractile	contractile	I-NP	JJ	O	39	NMOD
39	rhythm	rhythm	I-NP	NN	O	36	PMOD
40	.	.	O	.	O	1	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	renal	renal	I-NP	JJ	O	3	NMOD
3	failure	failure	I-NP	NN	O	10	NMOD
4	occurring	occur	B-VP	VBG	O	3	NMOD
5	during	during	B-PP	IN	O	4	VMOD
6	intravenous	intravenous	B-NP	JJ	O	8	NMOD
7	desferrioxamine	desferrioxamine	I-NP	NN	O	8	NMOD
8	therapy	therapy	I-NP	NN	O	5	PMOD
9	:	:	O	:	O	3	P
10	recovery	recovery	B-NP	NN	O	0	ROOT
11	after	after	B-PP	IN	O	10	NMOD
12	haemodialysis	haemodialysis	B-NP	NN	O	11	PMOD
13	.	.	O	.	O	10	P

1	A	A	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	6	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	transfusion-dependent	transfusion-dependent	B-NP	JJ	O	5	NMOD
5	thalassemia	thalassemia	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	undergoing	undergo	I-VP	VBG	O	6	VMOD
8	home	home	B-NP	NN	O	10	NMOD
9	intravenous	intravenous	I-NP	JJ	O	10	NMOD
10	desferrioxamine	desferrioxamine	I-NP	NN	O	14	NMOD
11	(	(	O	(	O	13	DEP
12	DFX	DFX	B-NP	NN	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	treatment	treatment	B-NP	NN	O	7	OBJ
15	by	by	B-PP	IN	O	7	VMOD
16	means	mean	B-NP	NNS	O	15	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	a	a	B-NP	DT	O	21	NMOD
19	totally	totally	I-NP	RB	O	20	AMOD
20	implanted	implant	I-NP	VBN	O	21	NMOD
21	system	system	I-NP	NN	O	17	PMOD
22	because	because	B-PP	IN	O	6	VMOD
23	of	of	I-PP	IN	O	22	PMOD
24	his	his	B-NP	PRP$	O	26	NMOD
25	poor	poor	I-NP	JJ	O	26	NMOD
26	compliance	compliance	I-NP	NN	O	22	PMOD
27	with	with	B-PP	IN	O	26	NMOD
28	the	the	B-NP	DT	O	31	NMOD
29	nightly	nightly	I-NP	RB	O	30	AMOD
30	subcutaneous	subcutaneous	I-NP	JJ	O	31	NMOD
31	therapy	therapy	I-NP	NN	O	27	PMOD
32	.	.	O	.	O	6	P

1	Neuroleptic-associated	Neuroleptic-associated	B-NP	JJ	O	2	NMOD
2	hyperprolactinemia	hyperprolactinemia	I-NP	NN	O	0	ROOT
3	.	.	O	.	O	2	P

1	Six	Six	B-NP	CD	O	4	NMOD
2	stable	stable	I-NP	JJ	O	4	NMOD
3	psychiatric	psychiatric	I-NP	JJ	O	4	NMOD
4	outpatients	outpatient	I-NP	NNS	O	14	SUB
5	with	with	B-PP	IN	O	4	NMOD
6	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	amenorrhea/oligomenorrhea	amenorrhea/oligomenorrhea	I-NP	NN	O	5	PMOD
9	associated	associate	B-VP	VBN	O	4	NMOD
10	with	with	B-PP	IN	O	9	VMOD
11	their	their	B-NP	PRP$	O	13	NMOD
12	neuroleptic	neuroleptic	I-NP	JJ	O	13	NMOD
13	medications	medication	I-NP	NNS	O	10	PMOD
14	were	be	B-VP	VBD	O	0	ROOT
15	treated	treat	I-VP	VBN	O	14	VC
16	with	with	B-PP	IN	O	15	VMOD
17	bromocriptine	bromocriptine	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	14	P

1	One	One	B-NP	CD	O	2	NMOD
2	woman	woman	I-NP	NN	O	16	SUB
3	,	,	O	,	O	2	P
4	however	however	B-ADVP	RB	O	16	VMOD
5	,	,	O	,	O	16	P
6	developed	develop	B-VP	VBN	O	16	VMOD
7	worsened	worsen	B-VP	VBD	O	6	VMOD
8	psychiatric	psychiatric	B-NP	JJ	O	9	NMOD
9	symptoms	symptom	I-NP	NNS	O	7	OBJ
10	while	while	B-SBAR	IN	O	7	VMOD
11	taking	take	B-VP	VBG	O	10	SBAR
12	bromocriptine	bromocriptine	B-NP	NN	O	11	OBJ
13	,	,	O	,	O	16	P
14	and	and	O	CC	O	16	VMOD
15	it	it	B-NP	PRP	O	16	SUB
16	was	be	B-VP	VBD	O	0	ROOT
17	discontinued	discontinue	I-VP	VBN	O	16	VC
18	.	.	O	.	O	16	P

1	Ethacrynic	Ethacrynic	B-NP	JJ	O	2	NMOD
2	acid	acid	I-NP	NN	O	7	NMOD
3	induced	induce	B-VP	VBN	O	7	NMOD
4	convulsions	convulsion	B-NP	NNS	O	7	NMOD
5	and	and	O	CC	O	7	NMOD
6	brain	brain	B-NP	NN	O	7	NMOD
7	neurotransmitters	neurotransmitter	I-NP	NNS	O	0	ROOT
8	in	in	B-PP	IN	O	7	NMOD
9	mice	mouse	B-NP	NNS	O	8	PMOD
10	.	.	O	.	O	7	P

1	Intracerebroventricular	Intracerebroventricular	B-NP	JJ	O	2	NMOD
2	injection	injection	I-NP	NN	O	15	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	ethacrynic	ethacrynic	B-NP	JJ	O	5	NMOD
5	acid	acid	I-NP	NN	O	3	PMOD
6	(	(	O	(	O	14	DEP
7	50	50	B-NP	CD	O	8	AMOD
8	%	%	I-NP	NN	O	10	NMOD
9	convulsive	convulsive	I-NP	JJ	O	10	NMOD
10	dose	dose	I-NP	NN	O	13	NMOD
11	;	;	O	:	O	13	P
12	50	50	B-NP	CD	O	13	NMOD
13	micrograms/mouse	micrograms/mouse	I-NP	NN	O	14	DEP
14	)	)	O	)	O	5	NMOD
15	accelerated	accelerate	B-VP	VBD	O	0	ROOT
16	the	the	B-NP	DT	O	17	NMOD
17	synthesis/turnover	synthesis/turnover	I-NP	NN	O	15	OBJ
18	of	of	B-PP	IN	O	17	NMOD
19	5-hydroxytryptamine	5-hydroxytryptamine	B-NP	NN	O	18	PMOD
20	(	(	O	(	O	22	DEP
21	5-HT	5-HT	B-NP	NN	O	22	DEP
22	)	)	O	)	O	19	NMOD
23	but	but	O	CC	O	15	VMOD
24	suppressed	suppress	B-VP	VBD	O	15	VMOD
25	the	the	B-NP	DT	O	26	NMOD
26	synthesis	synthesis	I-NP	NN	O	31	NMOD
27	of	of	B-PP	IN	O	26	NMOD
28	gamma-aminobutyric	gamma-aminobutyric	B-NP	JJ	O	29	NMOD
29	acid	acid	I-NP	NN	O	27	PMOD
30	and	and	O	CC	O	31	NMOD
31	acetylcholine	acetylcholine	B-NP	NN	O	24	OBJ
32	in	in	B-PP	IN	O	24	VMOD
33	mouse	mouse	B-NP	NN	O	34	NMOD
34	brain	brain	I-NP	NN	O	32	PMOD
35	.	.	O	.	O	15	P

1	Recurrent	Recurrent	B-NP	JJ	O	3	NMOD
2	myocardial	myocardial	I-NP	JJ	O	3	NMOD
3	infarction	infarction	I-NP	NN	O	0	ROOT
4	in	in	B-PP	IN	O	3	NMOD
5	a	a	B-NP	DT	O	7	NMOD
6	postpartum	postpartum	I-NP	NN	O	7	NMOD
7	patient	patient	I-NP	NN	O	4	PMOD
8	receiving	receive	B-VP	VBG	O	7	NMOD
9	bromocriptine	bromocriptine	B-NP	NN	O	8	OBJ
10	.	.	O	.	O	3	P

1	Bromocriptine	Bromocriptine	B-NP	NN	O	2	SUB
2	has	have	B-VP	VBZ	O	0	ROOT
3	been	be	I-VP	VBN	O	2	VC
4	implicated	implicate	I-VP	VBN	O	3	VC
5	in	in	B-PP	IN	O	4	VMOD
6	several	several	B-NP	JJ	O	9	NMOD
7	previous	previous	I-NP	JJ	O	9	NMOD
8	case	case	I-NP	NN	O	9	NMOD
9	reports	report	I-NP	NNS	O	5	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	myocardial	myocardial	B-NP	JJ	O	12	NMOD
12	infarction	infarction	I-NP	NN	O	10	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	puerperium	puerperium	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	2	P

1	Asterixis	Asterixis	B-NP	NN	O	0	ROOT
2	induced	induce	B-VP	VBN	O	1	NMOD
3	by	by	B-PP	IN	O	2	VMOD
4	carbamazepine	carbamazepine	B-NP	NN	O	5	NMOD
5	therapy	therapy	I-NP	NN	O	3	PMOD
6	.	.	O	.	O	1	P

1	In	In	B-PP	IN	O	5	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	report	report	I-NP	NN	O	1	PMOD
4	we	we	B-NP	PRP	O	5	SUB
5	present	present	B-VP	VBP	O	0	ROOT
6	four	four	B-NP	CD	O	7	NMOD
7	patients	patient	I-NP	NNS	O	5	OBJ
8	treated	treat	B-VP	VBN	O	7	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	a	a	B-NP	DT	O	11	NMOD
11	combination	combination	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	different	different	B-NP	JJ	O	14	AMOD
14	psychotropic	psychotropic	I-NP	JJ	O	15	NMOD
15	drugs	drug	I-NP	NNS	O	12	PMOD
16	,	,	O	,	O	5	P
17	in	in	B-PP	IN	O	5	VMOD
18	whom	whom	B-NP	WP	O	19	NMOD
19	asterixis	asterixis	B-NP	NN	O	17	PMOD
20	was	be	B-VP	VBD	O	5	VMOD
21	triggered	trigger	I-VP	VBN	O	20	VC
22	either	either	O	CC	O	21	VMOD
23	by	by	B-PP	IN	O	21	VMOD
24	adding	add	B-VP	VBG	O	23	PMOD
25	carbamazepine	carbamazepine	B-NP	NN	O	24	OBJ
26	(	(	O	(	O	28	DEP
27	CBZ	CBZ	B-NP	NN	B-protein	28	DEP
28	)	)	O	)	O	25	NMOD
29	to	to	B-PP	TO	O	24	VMOD
30	a	a	B-NP	DT	O	32	NMOD
31	treatment	treatment	I-NP	NN	O	32	NMOD
32	regimen	regimen	I-NP	NN	O	29	PMOD
33	,	,	O	,	O	23	P
34	or	or	O	CC	O	23	PMOD
35	by	by	B-PP	IN	O	23	PMOD
36	increasing	increase	B-VP	VBG	O	35	PMOD
37	its	its	B-NP	PRP$	O	38	NMOD
38	dosage	dosage	I-NP	NN	O	36	OBJ
39	.	.	O	.	O	5	P

1	Pharmacodynamics	Pharmacodynamic	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	5	NMOD
4	hypotensive	hypotensive	I-NP	JJ	O	5	NMOD
5	effect	effect	I-NP	NN	O	2	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	levodopa	levodopa	B-NP	NN	O	6	PMOD
8	in	in	B-PP	IN	O	5	NMOD
9	parkinsonian	parkinsonian	B-NP	JJ	O	10	NMOD
10	patients	patient	I-NP	NNS	O	8	PMOD
11	.	.	O	.	O	1	P

1	Blood	Blood	B-NP	NN	O	3	NMOD
2	pressure	pressure	I-NP	NN	O	3	NMOD
3	effects	effect	I-NP	NNS	O	7	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	i.v.	i.v.	B-NP	JJ	O	6	NMOD
6	levodopa	levodopa	I-NP	NN	O	4	PMOD
7	were	be	B-VP	VBD	O	0	ROOT
8	examined	examine	I-VP	VBN	O	7	VC
9	in	in	B-PP	IN	O	8	VMOD
10	parkinsonian	parkinsonian	B-NP	JJ	O	11	NMOD
11	patients	patient	I-NP	NNS	O	9	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	stable	stable	B-NP	JJ	O	16	NMOD
14	and	and	I-NP	CC	O	16	NMOD
15	fluctuating	fluctuating	I-NP	JJ	O	16	NMOD
16	responses	response	I-NP	NNS	O	12	PMOD
17	to	to	B-PP	TO	O	16	NMOD
18	levodopa	levodopa	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	7	P

1	The	The	B-NP	DT	O	2	NMOD
2	magnitude	magnitude	I-NP	NN	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	hypotensive	hypotensive	I-NP	JJ	O	6	NMOD
6	effect	effect	I-NP	NN	O	3	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	levodopa	levodopa	B-NP	NN	O	7	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	concentration	concentration	B-NP	NN	O	9	PRD
11	dependent	dependent	B-ADJP	JJ	O	10	AMOD
12	and	and	O	CC	O	9	VMOD
13	was	be	B-VP	VBD	O	9	VMOD
14	fit	fit	I-VP	VBN	O	13	VC
15	to	to	B-PP	TO	O	14	VMOD
16	an	an	B-NP	DT	O	18	NMOD
17	Emax	Emax	I-NP	NN	O	18	NMOD
18	model	model	I-NP	NN	O	15	PMOD
19	in	in	B-PP	IN	O	14	VMOD
20	fluctuating	fluctuate	B-VP	VBG	O	21	NMOD
21	responders	responder	B-NP	NNS	O	19	PMOD
22	.	.	O	.	O	9	P

1	Phenylalanine	Phenylalanine	B-NP	NN	O	21	SUB
2	,	,	O	,	O	21	P
3	a	a	B-NP	DT	O	7	NMOD
4	large	large	I-NP	JJ	O	7	NMOD
5	neutral	neutral	I-NP	JJ	O	7	NMOD
6	amino	amino	I-NP	NN	O	7	NMOD
7	acid	acid	I-NP	NN	O	21	SUB
8	(	(	O	(	O	10	DEP
9	LNAA	LNAA	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	competing	compete	B-VP	VBG	O	7	NMOD
12	with	with	B-PP	IN	O	11	VMOD
13	levodopa	levodopa	B-NP	NN	O	12	PMOD
14	for	for	B-PP	IN	O	13	NMOD
15	transport	transport	B-NP	NN	O	14	PMOD
16	across	across	B-PP	IN	O	13	NMOD
17	the	the	B-NP	DT	O	19	NMOD
18	blood-brain	blood-brain	I-NP	NN	O	19	NMOD
19	barrier	barrier	I-NP	NN	O	16	PMOD
20	,	,	O	,	O	7	P
21	reduced	reduce	B-VP	VBD	O	0	ROOT
22	the	the	B-NP	DT	O	26	NMOD
23	hypotensive	hypotensive	I-NP	JJ	O	25	AMOD
24	and	and	I-NP	CC	O	25	AMOD
25	antiparkinsonian	antiparkinsonian	I-NP	JJ	O	26	NMOD
26	effects	effect	I-NP	NNS	O	21	OBJ
27	of	of	B-PP	IN	O	26	NMOD
28	levodopa	levodopa	B-NP	NN	O	27	PMOD
29	.	.	O	.	O	21	P

1	We	We	B-NP	PRP	O	2	SUB
2	conclude	conclude	B-VP	VBP	O	0	ROOT
3	that	that	B-SBAR	IN	O	2	VMOD
4	levodopa	levodopa	B-NP	NN	O	5	SUB
5	has	have	B-VP	VBZ	O	3	SBAR
6	a	a	B-NP	DT	O	9	NMOD
7	central	central	I-NP	JJ	O	9	NMOD
8	hypotensive	hypotensive	I-NP	JJ	O	9	NMOD
9	action	action	I-NP	NN	O	5	OBJ
10	that	that	B-NP	WDT	O	9	NMOD
11	parallels	parallel	B-VP	VBZ	O	10	SBAR
12	the	the	B-NP	DT	O	14	NMOD
13	motor	motor	I-NP	JJ	O	14	NMOD
14	effects	effect	I-NP	NNS	O	11	OBJ
15	in	in	B-PP	IN	O	11	VMOD
16	fluctuating	fluctuate	B-VP	VBG	O	17	NMOD
17	patients	patient	B-NP	NNS	O	15	PMOD
18	.	.	O	.	O	2	P

1	Syndrome	Syndrome	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	inappropriate	inappropriate	B-NP	JJ	O	4	NMOD
4	secretion	secretion	I-NP	NN	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	antidiuretic	antidiuretic	B-NP	JJ	O	7	NMOD
7	hormone	hormone	I-NP	NN	O	5	PMOD
8	after	after	B-PP	IN	O	1	NMOD
9	infusional	infusional	B-NP	JJ	O	10	NMOD
10	vincristine	vincristine	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	1	P

1	A	A	B-NP	DT	O	3	NMOD
2	77-year-old	77-year-old	I-NP	JJ	O	3	NMOD
3	woman	woman	I-NP	NN	O	8	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	refractory	refractory	B-NP	JJ	O	7	NMOD
6	multiple	multiple	I-NP	JJ	O	7	NMOD
7	myeloma	myeloma	I-NP	NN	O	4	PMOD
8	was	be	B-VP	VBD	O	0	ROOT
9	treated	treat	I-VP	VBN	O	8	VC
10	with	with	B-PP	IN	O	9	VMOD
11	a	a	B-NP	DT	O	15	NMOD
12	4-day	4-day	I-NP	JJ	O	15	NMOD
13	continuous	continuous	I-NP	JJ	O	15	NMOD
14	intravenous	intravenous	I-NP	JJ	O	15	NMOD
15	infusion	infusion	I-NP	NN	O	22	NMOD
16	of	of	B-PP	IN	O	15	NMOD
17	vincristine	vincristine	B-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	doxorubicin	doxorubicin	I-NP	NN	O	16	PMOD
20	and	and	O	CC	O	22	NMOD
21	4	4	B-NP	CD	O	22	NMOD
22	days	day	I-NP	NNS	O	10	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	oral	oral	B-NP	JJ	O	25	NMOD
25	dexamethasone	dexamethasone	I-NP	NN	O	23	PMOD
26	.	.	O	.	O	8	P

1	Evaluation	Evaluation	B-NP	NN	O	2	SUB
2	revealed	reveal	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	syndrome	syndrome	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	inappropriate	inappropriate	B-NP	JJ	O	7	NMOD
7	secretion	secretion	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	antidiuretic	antidiuretic	B-NP	JJ	O	10	NMOD
10	hormone	hormone	I-NP	NN	O	8	PMOD
11	,	,	O	,	O	4	P
12	which	which	B-NP	WDT	O	4	NMOD
13	was	be	B-VP	VBD	O	12	SBAR
14	attributed	attribute	I-VP	VBN	O	13	VC
15	to	to	B-PP	TO	O	14	VMOD
16	the	the	B-NP	DT	O	18	NMOD
17	vincristine	vincristine	I-NP	NN	O	18	NMOD
18	infusion	infusion	I-NP	NN	O	15	PMOD
19	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	7	VMOD
2	patients	patient	B-NP	NNS	O	1	PMOD
3	with	with	B-PP	IN	O	2	NMOD
4	atrial	atrial	B-NP	JJ	O	6	NMOD
5	fibrillation	fibrillation	I-NP	NN	O	6	NMOD
6	digoxin	digoxin	I-NP	NN	O	3	PMOD
7	is	be	B-VP	VBZ	O	0	ROOT
8	beneficial	beneficial	B-ADJP	JJ	O	7	PRD
9	for	for	B-PP	IN	O	8	AMOD
10	ventricular	ventricular	B-NP	JJ	O	12	NMOD
11	rate	rate	I-NP	NN	O	12	NMOD
12	control	control	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	7	P

1	Also	Also	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	digoxin	digoxin	B-NP	NN	O	4	SUB
4	has	have	B-VP	VBZ	O	0	ROOT
5	undesirable	undesirable	B-NP	JJ	O	6	NMOD
6	effects	effect	I-NP	NNS	O	4	OBJ
7	such	such	B-PP	JJ	O	8	PMOD
8	as	as	I-PP	IN	O	6	NMOD
9	increasing	increase	B-VP	VBG	O	11	NMOD
10	peripheral	peripheral	B-NP	JJ	O	11	NMOD
11	resistance	resistance	I-NP	NN	O	14	NMOD
12	and	and	I-NP	CC	O	14	NMOD
13	myocardial	myocardial	I-NP	JJ	O	14	NMOD
14	demands	demand	I-NP	NNS	O	8	PMOD
15	,	,	O	,	O	4	P
16	and	and	O	CC	O	4	VMOD
17	causing	cause	B-VP	VBG	O	4	VMOD
18	arrhythmias	arrhythmia	B-NP	NNS	O	17	OBJ
19	.	.	O	.	O	4	P

1	Pooled	Pool	B-NP	VBN	O	2	NMOD
2	analysis	analysis	I-NP	NN	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	effects	effect	I-NP	NNS	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	other	other	B-NP	JJ	O	9	NMOD
8	inotropic	inotropic	I-NP	JJ	O	9	NMOD
9	drugs	drug	I-NP	NNS	O	6	PMOD
10	shows	show	B-VP	VBZ	O	16	VMOD
11	an	an	B-NP	DT	O	13	NMOD
12	excess	excess	I-NP	JJ	O	13	NMOD
13	mortality	mortality	I-NP	NN	O	10	OBJ
14	and	and	O	CC	O	16	VMOD
15	there	there	B-NP	EX	O	16	SUB
16	is	be	B-VP	VBZ	O	0	ROOT
17	a	a	B-NP	DT	O	18	NMOD
18	possibility	possibility	I-NP	NN	O	16	PRD
19	that	that	B-SBAR	IN	O	18	NMOD
20	digoxin	digoxin	B-NP	NN	O	21	SUB
21	may	may	B-VP	MD	O	19	SBAR
22	increase	increase	I-VP	VB	O	21	VC
23	mortality	mortality	B-NP	NN	O	22	OBJ
24	after	after	B-PP	IN	O	22	VMOD
25	myocardial	myocardial	B-NP	JJ	O	26	NMOD
26	infarction	infarction	I-NP	NN	O	24	PMOD
27	(	(	O	(	O	29	DEP
28	MI	MI	B-NP	NN	O	29	DEP
29	)	)	O	)	O	26	NMOD
30	.	.	O	.	O	16	P

1	Intravascular	Intravascular	B-NP	JJ	O	2	NMOD
2	hemolysis	hemolysis	I-NP	NN	O	6	NMOD
3	and	and	O	CC	O	6	NMOD
4	acute	acute	B-NP	JJ	O	6	NMOD
5	renal	renal	I-NP	JJ	O	6	NMOD
6	failure	failure	I-NP	NN	O	0	ROOT
7	following	follow	B-PP	VBG	O	6	NMOD
8	intermittent	intermittent	B-NP	JJ	O	10	NMOD
9	rifampin	rifampin	I-NP	NN	O	10	NMOD
10	therapy	therapy	I-NP	NN	O	7	PMOD
11	.	.	O	.	O	6	P

1	Renal	Renal	B-NP	JJ	O	2	NMOD
2	failure	failure	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	a	a	B-NP	DT	O	6	NMOD
5	rare	rare	I-NP	JJ	O	6	NMOD
6	complication	complication	I-NP	NN	O	3	PRD
7	associated	associate	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	use	use	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	rifampin	rifampin	B-NP	NN	O	11	PMOD
13	.	.	O	.	O	3	P

1	Intravascular	Intravascular	B-NP	JJ	O	2	NMOD
2	hemolysis	hemolysis	I-NP	NN	O	11	SUB
3	leading	lead	B-VP	VBG	O	2	NMOD
4	to	to	B-PP	TO	O	3	VMOD
5	acute	acute	B-NP	JJ	O	6	AMOD
6	renal	renal	I-NP	JJ	O	7	NMOD
7	failure	failure	I-NP	NN	O	4	PMOD
8	following	follow	B-PP	VBG	O	7	NMOD
9	rifampin	rifampin	B-NP	NN	O	10	NMOD
10	therapy	therapy	I-NP	NN	O	8	PMOD
11	is	be	B-VP	VBZ	O	0	ROOT
12	extremely	extremely	B-ADJP	RB	O	13	AMOD
13	rare	rare	I-ADJP	JJ	O	11	PRD
14	.	.	O	.	O	11	P

1	Zidovudine	Zidovudine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	hepatitis	hepatitis	B-NP	NN	O	2	OBJ
4	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	15	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	acute	acute	B-NP	JJ	O	5	NMOD
5	hepatitis	hepatitis	I-NP	NN	O	3	PMOD
6	induced	induce	B-VP	VBN	O	5	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	zidovudine	zidovudine	B-NP	NN	O	7	PMOD
9	in	in	B-PP	IN	O	6	VMOD
10	a	a	B-NP	DT	O	12	NMOD
11	38-year-old	38-year-old	I-NP	JJ	O	12	NMOD
12	patient	patient	I-NP	NN	O	9	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	AIDS	AIDS	B-NP	NN	O	13	PMOD
15	is	be	B-VP	VBZ	O	0	ROOT
16	presented	present	I-VP	VBN	O	15	VC
17	.	.	O	.	O	15	P

1	Thoracic	Thoracic	B-NP	JJ	O	2	NMOD
2	hematomyelia	hematomyelia	I-NP	NN	O	11	NMOD
3	secondary	secondary	B-ADJP	JJ	O	2	NMOD
4	to	to	B-PP	TO	O	3	AMOD
5	coumadin	coumadin	B-NP	NN	O	7	NMOD
6	anticoagulant	anticoagulant	I-NP	JJ	O	7	NMOD
7	therapy	therapy	I-NP	NN	O	4	PMOD
8	:	:	O	:	O	2	P
9	a	a	B-NP	DT	O	11	NMOD
10	case	case	I-NP	NN	O	11	NMOD
11	report	report	I-NP	NN	O	0	ROOT
12	.	.	O	.	O	11	P

1	Mania	Mania	B-NP	NN	O	0	ROOT
2	associated	associate	B-VP	VBN	O	1	NMOD
3	with	with	B-PP	IN	O	2	VMOD
4	fluoxetine	fluoxetine	B-NP	NN	O	5	NMOD
5	treatment	treatment	I-NP	NN	O	3	PMOD
6	in	in	B-PP	IN	O	5	NMOD
7	adolescents	adolescent	B-NP	NNS	O	6	PMOD
8	.	.	O	.	O	1	P

1	Fluoxetine	Fluoxetine	B-NP	NN	O	7	NMOD
2	,	,	O	,	O	7	P
3	a	a	B-NP	DT	O	7	NMOD
4	selective	selective	I-NP	JJ	O	7	NMOD
5	serotonin	serotonin	I-NP	NN	O	7	NMOD
6	reuptake	reuptake	I-NP	NN	O	7	NMOD
7	inhibitor	inhibitor	I-NP	NN	O	9	SUB
8	,	,	O	,	O	7	P
9	is	be	B-VP	VBZ	O	0	ROOT
10	gaining	gain	I-VP	VBG	O	9	VC
11	increased	increase	B-NP	VBN	O	12	NMOD
12	acceptance	acceptance	I-NP	NN	O	10	OBJ
13	in	in	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	treatment	treatment	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	adolescent	adolescent	B-NP	JJ	O	18	NMOD
18	depression	depression	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	9	P

1	Generally	Generally	B-ADJP	RB	O	2	AMOD
2	safe	safe	I-ADJP	JJ	O	10	SUB
3	and	and	O	CC	O	10	VMOD
4	well	well	B-VP	RB	O	5	VMOD
5	tolerated	tolerate	I-VP	VBN	O	9	NMOD
6	by	by	B-PP	IN	O	5	VMOD
7	adults	adult	B-NP	NNS	O	6	PMOD
8	,	,	O	,	O	5	P
9	fluoxetine	fluoxetine	B-NP	NN	O	10	SUB
10	has	have	B-VP	VBZ	O	0	ROOT
11	been	be	I-VP	VBN	O	10	VC
12	reported	report	I-VP	VBN	O	11	VC
13	to	to	I-VP	TO	O	14	VMOD
14	induce	induce	I-VP	VB	O	12	VMOD
15	mania	mania	B-NP	NN	O	14	OBJ
16	.	.	O	.	O	10	P

1	The	The	B-NP	DT	O	2	NMOD
2	cases	case	I-NP	NNS	O	21	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	five	five	B-NP	CD	O	6	NMOD
5	depressed	depressed	I-NP	JJ	O	6	NMOD
6	adolescents	adolescent	I-NP	NNS	O	3	PMOD
7	,	,	O	,	O	21	P
8	14-16	14-16	B-NP	CD	O	9	NMOD
9	years	year	I-NP	NNS	O	21	SUB
10	of	of	B-PP	IN	O	9	NMOD
11	age	age	B-NP	NN	O	10	PMOD
12	,	,	O	,	O	21	P
13	who	who	B-NP	WP	O	21	VMOD
14	developed	develop	B-VP	VBD	O	13	SBAR
15	mania	mania	B-NP	NN	O	14	OBJ
16	during	during	B-PP	IN	O	14	VMOD
17	pharmacotherapy	pharmacotherapy	B-NP	NN	O	16	PMOD
18	with	with	B-PP	IN	O	17	NMOD
19	fluoxetine	fluoxetine	B-NP	NN	O	18	PMOD
20	,	,	O	,	O	21	P
21	are	be	B-VP	VBP	O	0	ROOT
22	reported	report	I-VP	VBN	O	21	VC
23	here	here	B-ADVP	RB	O	22	VMOD
24	.	.	O	.	O	21	P

1	Apparent	Apparent	B-NP	JJ	O	3	NMOD
2	risk	risk	I-NP	NN	O	3	NMOD
3	factors	factor	I-NP	NNS	O	17	SUB
4	for	for	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	development	development	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	mania	mania	B-NP	NN	O	10	NMOD
9	or	or	I-NP	CC	O	10	NMOD
10	hypomania	hypomania	I-NP	NN	O	7	PMOD
11	during	during	B-PP	IN	O	3	NMOD
12	fluoxetine	fluoxetine	B-NP	NN	O	13	NMOD
13	pharmacotherapy	pharmacotherapy	I-NP	NN	O	11	PMOD
14	in	in	B-PP	IN	O	13	NMOD
15	this	this	B-NP	DT	O	16	NMOD
16	population	population	I-NP	NN	O	14	PMOD
17	were	be	B-VP	VBD	O	0	ROOT
18	the	the	B-NP	DT	O	19	NMOD
19	combination	combination	I-NP	NN	O	36	NMOD
20	of	of	B-PP	IN	O	19	NMOD
21	attention-deficit	attention-deficit	B-NP	NN	O	23	NMOD
22	hyperactivity	hyperactivity	I-NP	NN	O	23	NMOD
23	disorder	disorder	I-NP	NN	O	26	NMOD
24	and	and	O	CC	O	26	NMOD
25	affective	affective	B-NP	JJ	O	26	NMOD
26	instability	instability	I-NP	NN	O	20	PMOD
27	;	;	O	:	O	36	P
28	major	major	B-NP	JJ	O	29	NMOD
29	depression	depression	I-NP	NN	O	36	NMOD
30	with	with	B-PP	IN	O	29	NMOD
31	psychotic	psychotic	B-NP	JJ	O	32	NMOD
32	features	feature	I-NP	NNS	O	30	PMOD
33	;	;	O	:	O	36	P
34	a	a	B-NP	DT	O	36	NMOD
35	family	family	I-NP	NN	O	36	NMOD
36	history	history	I-NP	NN	O	17	PRD
37	of	of	B-PP	IN	O	36	NMOD
38	affective	affective	B-NP	JJ	O	39	NMOD
39	disorder	disorder	I-NP	NN	O	43	NMOD
40	,	,	O	,	O	43	P
41	especially	especially	B-NP	RB	O	42	AMOD
42	bipolar	bipolar	I-NP	JJ	O	43	NMOD
43	disorder	disorder	I-NP	NN	O	37	PMOD
44	;	;	O	:	O	17	VMOD
45	and	and	O	CC	O	47	NMOD
46	a	a	B-NP	DT	O	47	NMOD
47	diagnosis	diagnosis	I-NP	NN	O	44	OBJ
48	of	of	B-PP	IN	O	47	NMOD
49	bipolar	bipolar	B-NP	JJ	O	50	NMOD
50	disorder	disorder	I-NP	NN	O	48	PMOD
51	.	.	O	.	O	17	P

1	Gemfibrozil-lovastatin	Gemfibrozil-lovastatin	B-NP	NN	O	2	NMOD
2	therapy	therapy	I-NP	NN	O	0	ROOT
3	for	for	B-PP	IN	O	2	NMOD
4	primary	primary	B-NP	JJ	O	5	NMOD
5	hyperlipoproteinemias	hyperlipoproteinemia	I-NP	NNS	O	3	PMOD
6	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	specific	specific	I-NP	JJ	O	3	NMOD
3	aim	aim	I-NP	NN	O	10	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	this	this	B-NP	DT	O	9	NMOD
6	retrospective	retrospective	I-NP	JJ	O	8	AMOD
7	,	,	I-NP	,	O	8	P
8	observational	observational	I-NP	JJ	O	9	NMOD
9	study	study	I-NP	NN	O	4	PMOD
10	was	be	B-VP	VBD	O	0	ROOT
11	to	to	B-VP	TO	O	12	VMOD
12	assess	assess	I-VP	VB	O	10	PRD
13	safety	safety	B-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	efficacy	efficacy	I-NP	NN	O	12	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	long-term	long-term	B-NP	JJ	O	26	NMOD
18	(	(	O	(	O	21	DEP
19	21	21	B-NP	CD	O	20	NMOD
20	months/patient	months/patient	I-NP	NN	O	21	DEP
21	)	)	O	)	O	17	NMOD
22	,	,	O	,	O	26	P
23	open-label	open-label	B-NP	NN	O	26	NMOD
24	,	,	O	,	O	26	P
25	gemfibrozil-lovastatin	gemfibrozil-lovastatin	B-NP	NN	O	26	NMOD
26	treatment	treatment	I-NP	NN	O	16	PMOD
27	in	in	B-PP	IN	O	26	NMOD
28	80	80	B-NP	CD	O	29	NMOD
29	patients	patient	I-NP	NNS	O	27	PMOD
30	with	with	B-PP	IN	O	29	NMOD
31	primary	primary	B-NP	JJ	O	33	NMOD
32	mixed	mixed	I-NP	JJ	O	33	NMOD
33	hyperlipidemia	hyperlipidemia	I-NP	NN	O	30	PMOD
34	(	(	O	(	O	43	DEP
35	68	68	B-NP	CD	O	36	NMOD
36	%	%	I-NP	NN	O	39	SUB
37	of	of	B-PP	IN	O	36	NMOD
38	whom	whom	B-NP	WP	O	37	PMOD
39	had	have	B-VP	VBD	O	43	DEP
40	atherosclerotic	atherosclerotic	B-NP	JJ	O	42	NMOD
41	vascular	vascular	I-NP	JJ	O	42	NMOD
42	disease	disease	I-NP	NN	O	39	OBJ
43	)	)	O	)	O	33	NMOD
44	.	.	O	.	O	10	P

1	Hepatocellular	Hepatocellular	B-NP	JJ	O	2	NMOD
2	carcinoma	carcinoma	I-NP	NN	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	Fanconi	Fanconi	B-NP	NNP	O	5	NMOD
5	's	's	B-NP	POS	O	6	NMOD
6	anemia	anemia	I-NP	NN	O	3	PMOD
7	treated	treat	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	androgen	androgen	B-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	corticosteroid	corticosteroid	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	an	an	B-NP	DT	O	6	NMOD
5	11-year-old	11-year-old	I-NP	JJ	O	6	NMOD
6	boy	boy	I-NP	NN	O	3	PMOD
7	is	be	B-VP	VBZ	O	0	ROOT
8	reported	report	I-VP	VBN	O	7	VC
9	who	who	B-NP	WP	O	8	VMOD
10	was	be	B-VP	VBD	O	9	SBAR
11	known	know	I-VP	VBN	O	10	VC
12	to	to	I-VP	TO	O	13	VMOD
13	have	have	I-VP	VB	O	11	VMOD
14	Fanconi	Fanconi	B-NP	NNP	O	15	NMOD
15	's	's	B-NP	POS	O	16	NMOD
16	anemia	anemia	I-NP	NN	O	13	OBJ
17	for	for	B-PP	IN	O	13	VMOD
18	3	3	B-NP	CD	O	19	NMOD
19	years	year	I-NP	NNS	O	17	PMOD
20	and	and	O	CC	O	7	VMOD
21	was	be	B-VP	VBD	O	7	VMOD
22	treated	treat	I-VP	VBN	O	21	VC
23	with	with	B-PP	IN	O	22	VMOD
24	androgens	androgen	B-NP	NNS	O	28	NMOD
25	,	,	I-NP	,	O	28	P
26	corticosteroids	corticosteroid	I-NP	NNS	O	28	NMOD
27	and	and	I-NP	CC	O	28	NMOD
28	transfusions	transfusion	I-NP	NNS	O	23	PMOD
29	.	.	O	.	O	7	P

1	The	The	B-NP	DT	O	4	NMOD
2	trimethaphan	trimethaphan	I-NP	NN	O	4	NMOD
3	induced	induce	I-NP	VBN	O	2	AMOD
4	hypotension	hypotension	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	32	VMOD
6	accompanied	accompany	I-VP	VBN	O	5	VC
7	by	by	B-PP	IN	O	6	VMOD
8	a	a	B-NP	DT	O	10	NMOD
9	significant	significant	I-NP	JJ	O	10	NMOD
10	bradycardia	bradycardia	I-NP	NN	O	18	NMOD
11	in	in	B-PP	IN	O	10	NMOD
12	lesioned	lesione	B-NP	VBN	O	13	NMOD
13	rats	rat	I-NP	NNS	O	11	PMOD
14	(	(	O	(	O	18	NMOD
15	-32	-32	B-NP	CD	O	17	AMOD
16	+/-	+/-	I-NP	SYM	O	17	AMOD
17	13	13	I-NP	CD	O	18	NMOD
18	beats	beat	I-NP	NNS	O	7	PMOD
19	per	per	B-PP	IN	O	18	NMOD
20	minute	minute	B-NP	NN	O	19	PMOD
21	)	)	O	)	O	18	NMOD
22	but	but	O	CC	O	32	VMOD
23	a	a	B-NP	DT	O	24	NMOD
24	tachycardia	tachycardia	I-NP	NN	O	32	NMOD
25	in	in	B-PP	IN	O	24	NMOD
26	sham	sham	B-NP	NN	O	27	NMOD
27	rats	rat	I-NP	NNS	O	25	PMOD
28	(	(	O	(	O	32	NMOD
29	+33	+33	B-NP	CD	O	31	AMOD
30	+/-	+/-	I-NP	CC	O	31	AMOD
31	12	12	I-NP	CD	O	32	NMOD
32	beats	beat	I-NP	NNS	O	38	NMOD
33	per	per	B-PP	IN	O	32	NMOD
34	minute	minute	B-NP	NN	O	33	PMOD
35	)	)	O	)	O	32	NMOD
36	1	1	B-NP	CD	O	38	NMOD
37	day	day	I-NP	NN	O	38	NMOD
38	postlesion	postlesion	I-NP	NN	O	0	ROOT
39	.	.	O	.	O	38	P

1	Damage	Damage	B-NP	NN	O	6	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	substantia	substantia	B-NP	NN	O	5	NMOD
4	nigra	nigra	I-NP	NN	O	5	NMOD
5	pars	par	I-NP	NNS	O	2	PMOD
6	reticulata	reticulata	B-VP	VBP	O	0	ROOT
7	during	during	B-PP	IN	O	6	VMOD
8	pilocarpine	pilocarpine	B-NP	NN	O	11	NMOD
9	induced	induce	B-VP	VBD	O	11	NMOD
10	status	status	B-NP	NN	O	11	NMOD
11	epilepticus	epilepticus	I-NP	NN	O	7	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	rat	rat	I-NP	NN	O	12	PMOD
15	:	:	O	:	O	24	P
16	immunohistochemical	immunohistochemical	B-NP	JJ	O	17	NMOD
17	study	study	I-NP	NN	O	24	NMOD
18	of	of	B-PP	IN	O	17	NMOD
19	neurons	neuron	B-NP	NNS	O	18	PMOD
20	,	,	O	,	O	24	P
21	astrocytes	astrocyte	B-NP	NNS	B-cell_type	24	NMOD
22	and	and	O	CC	O	24	NMOD
23	serum-protein	serum-protein	B-NP	NN	O	24	NMOD
24	extravasation	extravasation	I-NP	NN	O	6	VMOD
25	.	.	O	.	O	6	P

1	In	In	B-PP	IN	O	7	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	study	study	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	7	P
5	status	status	B-NP	NN	O	6	NMOD
6	epilepticus	epilepticus	I-NP	NN	O	7	SUB
7	was	be	B-VP	VBD	O	0	ROOT
8	induced	induce	I-VP	VBN	O	7	VC
9	by	by	B-PP	IN	O	8	VMOD
10	systemic	systemic	B-NP	JJ	O	11	NMOD
11	injection	injection	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	pilocarpine	pilocarpine	B-NP	NN	O	12	PMOD
14	in	in	B-PP	IN	O	11	NMOD
15	rats	rat	B-NP	NNS	O	14	PMOD
16	.	.	O	.	O	7	P

1	Nissl-staining	Nissl-staining	B-ADJP	JJ	O	3	NMOD
2	and	and	O	CC	O	3	NMOD
3	antibodies	antibody	B-NP	NNS	O	12	SUB
4	against	against	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	8	NMOD
6	neuron-specific	neuron-specific	I-NP	JJ	B-protein	8	NMOD
7	calcium-binding	calcium-binding	I-NP	JJ	I-protein	8	NMOD
8	protein	protein	I-NP	NN	I-protein	10	NMOD
9	,	,	O	,	O	10	P
10	parvalbumin	parvalbumin	B-NP	NN	B-protein	4	PMOD
11	,	,	O	,	O	3	P
12	served	serve	B-VP	VBD	O	0	ROOT
13	to	to	I-VP	TO	O	14	VMOD
14	detect	detect	I-VP	VB	O	12	VMOD
15	neuronal	neuronal	B-NP	JJ	O	16	NMOD
16	damage	damage	I-NP	NN	O	14	OBJ
17	in	in	B-PP	IN	O	16	NMOD
18	SNR	SNR	B-NP	NN	B-protein	17	PMOD
19	.	.	O	.	O	12	P

1	Reduced	Reduce	B-NP	VBN	O	2	NMOD
2	cardiotoxicity	cardiotoxicity	I-NP	NN	O	19	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	doxorubicin	doxorubicin	B-NP	NN	O	3	PMOD
5	given	give	B-VP	VBN	O	2	NMOD
6	in	in	B-PP	IN	O	5	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	form	form	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	N-	N-	B-NP	NN	B-protein	15	NMOD
11	(	(	O	(	I-protein	15	NMOD
12	2-hydroxypropyl	2-hydroxypropyl	B-NP	NN	I-protein	15	NMOD
13	)	)	O	)	I-protein	15	NMOD
14	methacrylamide	methacrylamide	B-NP	NN	I-protein	15	NMOD
15	conjugates	conjugate	I-NP	NNS	I-protein	9	PMOD
16	:	:	O	:	O	2	P
17	and	and	O	CC	O	19	NMOD
18	experimental	experimental	B-NP	JJ	O	19	NMOD
19	study	study	I-NP	NN	O	0	ROOT
20	in	in	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	22	NMOD
22	rat	rat	I-NP	NN	O	20	PMOD
23	.	.	O	.	O	19	P

1	A	A	B-NP	DT	O	3	NMOD
2	rat	rat	I-NP	NN	O	3	NMOD
3	model	model	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	used	use	I-VP	VBN	O	4	VC
6	to	to	B-VP	TO	O	7	VMOD
7	evaluate	evaluate	I-VP	VB	O	4	VMOD
8	the	the	B-NP	DT	O	11	NMOD
9	general	general	I-NP	JJ	O	11	NMOD
10	acute	acute	I-NP	JJ	O	11	NMOD
11	toxicity	toxicity	I-NP	NN	O	15	NMOD
12	and	and	O	CC	O	15	NMOD
13	the	the	B-NP	DT	O	15	NMOD
14	late	late	I-NP	JJ	O	15	NMOD
15	cardiotoxicity	cardiotoxicity	I-NP	NN	O	7	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	4	4	B-NP	CD	O	19	NMOD
18	mg/kg	mg/kg	I-NP	NN	O	19	NMOD
19	doxorubicin	doxorubicin	I-NP	NN	O	16	PMOD
20	(	(	O	(	O	22	DEP
21	DOX	DOX	B-NP	NN	O	22	DEP
22	)	)	O	)	O	19	NMOD
23	given	give	B-VP	VBN	O	19	NMOD
24	either	either	O	CC	O	23	VMOD
25	as	as	B-PP	IN	O	24	PMOD
26	free	free	B-NP	JJ	O	27	NMOD
27	drug	drug	I-NP	NN	O	25	PMOD
28	or	or	B-PP	CC	O	24	PMOD
29	in	in	B-PP	IN	O	24	PMOD
30	the	the	B-NP	DT	O	31	NMOD
31	form	form	I-NP	NN	O	29	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	three	three	B-NP	CD	O	43	NMOD
34	N-	N-	I-NP	NN	B-protein	43	NMOD
35	(	(	O	(	I-protein	43	NMOD
36	2-hydroxypropyl	2-hydroxypropyl	B-NP	NN	I-protein	43	NMOD
37	)	)	O	)	I-protein	43	NMOD
38	methacrylamide	methacrylamide	B-NP	NN	I-protein	43	NMOD
39	(	(	O	(	I-protein	43	NMOD
40	HPMA	HPMA	B-NP	NN	I-protein	43	NMOD
41	)	)	O	)	I-protein	43	NMOD
42	copolymer	copolymer	B-NP	NN	I-protein	43	NMOD
43	conjugates	conjugate	I-NP	NNS	I-protein	32	PMOD
44	.	.	O	.	O	4	P

1	Throughout	Throughout	B-PP	IN	O	13	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	study	study	I-NP	NN	O	1	PMOD
4	(	(	O	(	O	7	DEP
5	20	20	B-NP	CD	O	6	NMOD
6	weeks	week	I-NP	NNS	O	7	DEP
7	)	)	O	)	O	3	NMOD
8	,	,	O	,	O	13	P
9	deaths	death	B-NP	NNS	O	13	SUB
10	related	relate	B-VP	VBN	O	9	NMOD
11	to	to	B-PP	TO	O	10	AMOD
12	cardiotoxicity	cardiotoxicity	B-NP	NN	O	11	PMOD
13	were	be	B-VP	VBD	O	0	ROOT
14	observed	observe	I-VP	VBN	O	13	VC
15	only	only	B-ADVP	RB	O	16	PMOD
16	in	in	B-PP	IN	O	14	VMOD
17	animals	animal	B-NP	NNS	O	16	PMOD
18	that	that	B-NP	WDT	O	17	NMOD
19	received	receive	B-VP	VBD	O	39	VMOD
20	either	either	O	CC	O	39	VMOD
21	free	free	B-NP	JJ	O	22	NMOD
22	DOX	DOX	I-NP	NN	O	25	NMOD
23	or	or	O	CC	O	25	NMOD
24	the	the	B-NP	DT	O	25	NMOD
25	mixture	mixture	I-NP	NN	O	39	SUB
26	of	of	B-PP	IN	O	25	NMOD
27	HPMA	HPMA	B-NP	NN	O	28	NMOD
28	copolymer	copolymer	I-NP	NN	O	31	NMOD
29	and	and	O	CC	O	31	NMOD
30	free	free	B-NP	JJ	O	31	NMOD
31	DOX	DOX	I-NP	NN	O	26	PMOD
32	;	;	O	:	O	39	P
33	in	in	B-PP	IN	O	39	VMOD
34	these	these	B-NP	DT	O	35	NMOD
35	cases	case	I-NP	NNS	O	33	PMOD
36	,	,	O	,	O	39	P
37	histological	histological	B-NP	JJ	O	38	NMOD
38	investigations	investigation	I-NP	NNS	O	39	SUB
39	revealed	reveal	B-VP	VBD	O	18	SBAR
40	marked	marked	B-NP	JJ	O	41	NMOD
41	changes	change	I-NP	NNS	O	39	OBJ
42	in	in	B-PP	IN	O	41	NMOD
43	the	the	B-NP	DT	O	44	NMOD
44	heart	heart	I-NP	NN	O	42	PMOD
45	that	that	B-NP	WDT	O	41	NMOD
46	were	be	B-VP	VBD	O	45	SBAR
47	consistent	consistent	B-ADJP	JJ	O	46	PRD
48	with	with	B-PP	IN	O	47	AMOD
49	DOX	DOX	B-NP	NN	O	51	NMOD
50	induced	induced	I-NP	JJ	O	51	NMOD
51	cardiotoxicity	cardiotoxicity	I-NP	NN	O	48	PMOD
52	.	.	O	.	O	13	P

1	Topical	Topical	B-NP	JJ	O	4	NMOD
2	0.025	0.025	I-NP	CD	O	3	AMOD
3	%	%	I-NP	NN	O	4	NMOD
4	capsaicin	capsaicin	I-NP	NN	O	12	NMOD
5	in	in	B-PP	IN	O	4	NMOD
6	chronic	chronic	B-NP	JJ	O	8	NMOD
7	post-herpetic	post-herpetic	I-NP	JJ	O	8	NMOD
8	neuralgia	neuralgia	I-NP	NN	O	5	PMOD
9	:	:	O	:	O	4	P
10	efficacy	efficacy	B-NP	NN	O	4	NMOD
11	,	,	O	,	O	4	P
12	predictors	predictor	B-NP	NNS	O	17	NMOD
13	of	of	B-PP	IN	O	12	NMOD
14	response	response	B-NP	NN	O	13	PMOD
15	and	and	O	CC	O	17	NMOD
16	long-term	long-term	B-NP	JJ	O	17	NMOD
17	course	course	I-NP	NN	O	0	ROOT
18	.	.	O	.	O	17	P

1	In	In	B-SBAR	IN	O	34	VMOD
2	order	order	O	NN	O	1	DEP
3	to	to	B-VP	TO	O	4	VMOD
4	evaluate	evaluate	I-VP	VB	O	1	SBAR
5	the	the	B-NP	DT	O	6	NMOD
6	efficacy	efficacy	I-NP	NN	O	4	OBJ
7	,	,	O	,	O	34	P
8	time-course	time-course	B-NP	NN	O	12	NMOD
9	of	of	B-PP	IN	O	8	NMOD
10	action	action	B-NP	NN	O	9	PMOD
11	and	and	I-NP	CC	O	12	NMOD
12	predictors	predictor	I-NP	NNS	O	32	NMOD
13	of	of	B-PP	IN	O	12	NMOD
14	response	response	B-NP	NN	O	13	PMOD
15	to	to	B-PP	TO	O	14	NMOD
16	topical	topical	B-NP	JJ	O	17	NMOD
17	capsaicin	capsaicin	I-NP	NN	O	15	PMOD
18	,	,	O	,	O	32	P
19	39	39	B-NP	CD	O	20	NMOD
20	patients	patient	I-NP	NNS	O	32	NMOD
21	with	with	B-PP	IN	O	20	NMOD
22	chronic	chronic	B-NP	JJ	O	24	NMOD
23	post-herpetic	post-herpetic	I-NP	JJ	O	24	NMOD
24	neuralgia	neuralgia	I-NP	NN	O	21	PMOD
25	(	(	O	(	O	27	DEP
26	PHN	PHN	B-NP	NN	B-protein	27	DEP
27	)	)	O	)	O	24	NMOD
28	,	,	O	,	O	32	P
29	median	median	B-NP	JJ	O	30	NMOD
30	duration	duration	I-NP	NN	O	32	NMOD
31	24	24	B-NP	CD	O	32	NMOD
32	months	month	I-NP	NNS	O	34	SUB
33	,	,	O	,	O	34	P
34	were	be	B-VP	VBD	O	0	ROOT
35	treated	treat	I-VP	VBN	O	34	VC
36	with	with	B-PP	IN	O	35	VMOD
37	0.025	0.025	B-NP	CD	O	38	AMOD
38	%	%	I-NP	NN	O	40	NMOD
39	capsaicin	capsaicin	I-NP	NN	O	40	NMOD
40	cream	cream	I-NP	NN	O	36	PMOD
41	for	for	B-PP	IN	O	40	NMOD
42	8	8	B-NP	CD	O	43	NMOD
43	weeks	week	I-NP	NNS	O	41	PMOD
44	.	.	O	.	O	34	P

1	Nineteen	Nineteen	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	8	SUB
3	(	(	O	(	O	6	DEP
4	48.7	48.7	B-NP	CD	O	5	NMOD
5	%	%	I-NP	NN	O	6	DEP
6	)	)	O	)	O	2	NMOD
7	substantially	substantially	B-VP	RB	O	8	VMOD
8	improved	improve	I-VP	VBD	O	19	VMOD
9	after	after	B-PP	IN	O	8	VMOD
10	the	the	B-NP	DT	O	12	NMOD
11	8-week	8-week	I-NP	JJ	O	12	NMOD
12	trial	trial	I-NP	NN	O	9	PMOD
13	;	;	O	:	O	8	P
14	5	5	B-NP	CD	O	19	SUB
15	(	(	O	(	O	18	DEP
16	12.8	12.8	B-NP	CD	O	17	NMOD
17	%	%	I-NP	NN	O	18	DEP
18	)	)	O	)	O	14	NMOD
19	discontinued	discontinue	B-VP	VBD	O	45	VMOD
20	therapy	therapy	B-NP	NN	O	19	OBJ
21	due	due	B-ADJP	JJ	O	19	VMOD
22	to	to	B-PP	TO	O	21	AMOD
23	side-effects	side-effect	B-NP	NNS	O	22	PMOD
24	such	such	B-PP	JJ	O	25	PMOD
25	as	as	I-PP	IN	O	23	NMOD
26	intolerable	intolerable	B-NP	JJ	O	27	NMOD
27	capsaicin	capsaicin	I-NP	NN	O	25	PMOD
28	induced	induce	B-VP	VBD	O	19	VMOD
29	burning	burn	I-VP	VBG	O	30	NMOD
30	sensations	sensation	B-NP	NNS	O	35	NMOD
31	(	(	O	(	O	33	DEP
32	4	4	B-NP	CD	O	33	DEP
33	)	)	O	)	O	30	NMOD
34	or	or	O	CC	O	35	NMOD
35	mastitis	mastitis	B-NP	NN	O	28	OBJ
36	(	(	O	(	O	38	DEP
37	1	1	B-NP	CD	O	38	DEP
38	)	)	O	)	O	35	NMOD
39	;	;	O	:	O	19	P
40	15	15	B-NP	CD	O	45	SUB
41	(	(	O	(	O	44	DEP
42	38.5	38.5	B-NP	CD	O	43	NMOD
43	%	%	I-NP	NN	O	44	DEP
44	)	)	O	)	O	40	NMOD
45	reported	report	B-VP	VBD	O	0	ROOT
46	no	no	B-NP	DT	O	47	NMOD
47	benefit	benefit	I-NP	NN	O	45	OBJ
48	.	.	O	.	O	45	P

1	Serotonin	Serotonin	B-NP	NN	O	3	NMOD
2	reuptake	reuptake	I-NP	NN	O	3	NMOD
3	inhibitors	inhibitor	I-NP	NNS	O	11	NMOD
4	,	,	O	,	O	11	P
5	paranoia	paranoia	B-NP	NN	O	11	NMOD
6	,	,	O	,	O	11	P
7	and	and	O	CC	O	11	NMOD
8	the	the	B-NP	DT	O	11	NMOD
9	ventral	ventral	I-NP	JJ	O	11	NMOD
10	basal	basal	I-NP	JJ	O	11	NMOD
11	ganglia	ganglia	I-NP	NNS	O	0	ROOT
12	.	.	O	.	O	11	P

1	Five	Five	B-NP	CD	O	2	NMOD
2	cases	case	I-NP	NNS	O	14	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	paranoid	paranoid	B-NP	JJ	O	5	NMOD
5	exacerbation	exacerbation	I-NP	NN	O	3	PMOD
6	with	with	B-PP	IN	O	2	NMOD
7	the	the	B-NP	DT	O	10	NMOD
8	serotonin	serotonin	I-NP	NN	O	10	NMOD
9	reuptake	reuptake	I-NP	NN	O	10	NMOD
10	inhibitors	inhibitor	I-NP	NNS	O	13	NMOD
11	fluoxetine	fluoxetine	I-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	amitriptyline	amitriptyline	I-NP	NN	O	6	PMOD
14	are	be	B-VP	VBP	O	0	ROOT
15	reported	report	I-VP	VBN	O	14	VC
16	here	here	B-ADVP	RB	O	15	VMOD
17	.	.	O	.	O	14	P

1	Complicated	Complicate	B-NP	VBN	O	3	NMOD
2	depressive	depressive	I-NP	JJ	O	3	NMOD
3	disorders	disorder	I-NP	NNS	O	29	SUB
4	(	(	O	(	O	28	DEP
5	including	include	B-PP	VBG	O	28	DEP
6	atypicality	atypicality	B-NP	NN	O	5	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	course	course	B-NP	NN	O	20	NMOD
9	and	and	I-NP	CC	O	20	NMOD
10	symptomatology	symptomatology	I-NP	NN	O	20	NMOD
11	,	,	O	,	O	20	P
12	chronicity	chronicity	B-NP	NN	O	20	NMOD
13	,	,	O	,	O	20	P
14	psychosis	psychosis	B-NP	NN	O	20	NMOD
15	,	,	O	,	O	20	P
16	bipolarity	bipolarity	B-NP	NN	O	20	NMOD
17	,	,	O	,	O	20	P
18	and	and	O	CC	O	20	NMOD
19	secondary	secondary	B-NP	JJ	O	20	NMOD
20	onset	onset	I-NP	NN	O	7	PMOD
21	in	in	B-PP	IN	O	20	NMOD
22	the	the	B-NP	DT	O	23	NMOD
23	course	course	I-NP	NN	O	21	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	a	a	B-NP	DT	O	27	NMOD
26	primary	primary	I-NP	JJ	O	27	NMOD
27	psychosis	psychosis	I-NP	NN	O	24	PMOD
28	)	)	O	)	O	3	NMOD
29	may	may	B-VP	MD	O	0	ROOT
30	present	present	I-VP	VB	O	29	VC
31	particular	particular	B-NP	JJ	O	32	NMOD
32	vulnerability	vulnerability	I-NP	NN	O	30	OBJ
33	to	to	B-PP	TO	O	30	VMOD
34	paranoid	paranoid	B-NP	JJ	O	35	NMOD
35	exacerbations	exacerbation	I-NP	NNS	O	33	PMOD
36	associated	associate	B-VP	VBN	O	35	NMOD
37	with	with	B-PP	IN	O	36	VMOD
38	serotonin	serotonin	B-NP	NN	O	40	NMOD
39	reuptake	reuptake	I-NP	NN	O	40	NMOD
40	inhibitors	inhibitor	I-NP	NNS	O	37	PMOD
41	.	.	O	.	O	29	P

1	Although	Although	B-SBAR	IN	O	0	ROOT
2	the	the	B-NP	DT	O	5	NMOD
3	pharmacology	pharmacology	I-NP	NN	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	neurobiology	neurobiology	I-NP	NN	O	8	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	paranoia	paranoia	B-NP	NN	O	6	PMOD
8	remain	remain	B-VP	VBP	O	1	SBAR
9	cryptic	cryptic	B-ADJP	JJ	O	8	PRD
10	,	,	O	,	O	1	P
11	several	several	B-NP	JJ	O	12	NMOD
12	mechanisms	mechanism	I-NP	NNS	O	10	SUB
13	,	,	O	,	O	12	P
14	including	include	B-PP	VBG	O	12	NMOD
15	5HT3	5HT3	B-NP	NN	O	18	NMOD
16	receptor-mediated	receptor-mediated	I-NP	JJ	O	15	AMOD
17	dopamine	dopamine	I-NP	NN	O	18	NMOD
18	release	release	I-NP	NN	O	27	NMOD
19	,	,	O	,	O	27	P
20	beta-noradrenergic	beta-noradrenergic	B-NP	JJ	O	22	NMOD
21	receptor	receptor	I-NP	NN	O	22	NMOD
22	downregulation	downregulation	I-NP	NN	O	27	NMOD
23	,	,	O	,	O	27	P
24	or	or	O	CC	O	27	NMOD
25	GABAB	GABAB	B-NP	NN	B-protein	27	NMOD
26	receptor	receptor	I-NP	NN	I-protein	27	NMOD
27	upregulation	upregulation	I-NP	NN	O	48	SUB
28	acting	act	B-VP	VBG	O	27	NMOD
29	in	in	B-PP	IN	O	28	VMOD
30	the	the	B-NP	DT	O	31	NMOD
31	vicinity	vicinity	I-NP	NN	O	29	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	the	the	B-NP	DT	O	36	NMOD
34	ventral	ventral	I-NP	JJ	O	36	NMOD
35	basal	basal	I-NP	JJ	O	36	NMOD
36	ganglia	ganglia	I-NP	NNS	O	32	PMOD
37	(	(	O	(	O	46	DEP
38	possibly	possibly	B-ADVP	RB	O	46	DEP
39	in	in	B-PP	IN	O	38	PMOD
40	lateral	lateral	B-NP	JJ	O	45	NMOD
41	orbitofrontal	orbitofrontal	I-NP	JJ	O	45	NMOD
42	or	or	I-NP	CC	O	45	NMOD
43	anterior	anterior	I-NP	JJ	B-protein	45	NMOD
44	cingulate	cingulate	I-NP	JJ	I-protein	45	NMOD
45	circuits	circuit	I-NP	NNS	I-protein	39	PMOD
46	)	)	O	)	O	27	NMOD
47	,	,	O	,	O	27	P
48	might	might	B-VP	MD	O	14	PMOD
49	apply	apply	I-VP	VB	O	48	VC
50	to	to	B-PP	TO	O	49	VMOD
51	this	this	B-NP	DT	O	52	NMOD
52	phenomenon	phenomenon	I-NP	NN	O	50	PMOD
53	.	.	O	.	O	12	P

1	Five	Five	B-NP	CD	O	2	NMOD
2	cases	case	I-NP	NNS	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	encephalitis	encephalitis	B-NP	NN	O	3	PMOD
5	during	during	B-PP	IN	O	2	NMOD
6	treatment	treatment	B-NP	NN	O	5	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	loiasis	loiasis	B-NP	NN	O	7	PMOD
9	with	with	B-PP	IN	O	6	NMOD
10	diethylcarbamazine	diethylcarbamazine	B-NP	NN	O	9	PMOD
11	.	.	O	.	O	2	P

1	Five	Five	B-NP	CD	O	2	NMOD
2	cases	case	I-NP	NNS	O	12	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	encephalitis	encephalitis	B-NP	NN	O	3	PMOD
5	following	follow	B-PP	VBG	O	2	NMOD
6	treatment	treatment	B-NP	NN	O	5	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	diethylcarbamazine	diethylcarbamazine	B-NP	NN	O	7	PMOD
9	(	(	O	(	O	11	DEP
10	DEC	DEC	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	were	be	B-VP	VBD	O	0	ROOT
13	observed	observe	I-VP	VBN	O	12	VC
14	in	in	B-PP	IN	O	13	VMOD
15	Congolese	Congolese	B-NP	JJ	O	16	NMOD
16	patients	patient	I-NP	NNS	O	14	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	Loa	Loa	B-NP	NN	O	20	NMOD
19	loa	loa	I-NP	NN	O	20	NMOD
20	filariasis	filariasis	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	12	P

1	Delirium	Delirium	B-NP	NN	O	0	ROOT
2	in	in	B-PP	IN	O	1	NMOD
3	an	an	B-NP	DT	O	5	NMOD
4	elderly	elderly	I-NP	JJ	O	5	NMOD
5	woman	woman	I-NP	NN	O	2	PMOD
6	possibly	possibly	B-VP	RB	O	7	VMOD
7	associated	associate	I-VP	VBN	O	5	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	administration	administration	B-NP	NN	O	8	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	misoprostol	misoprostol	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	1	P

1	Misoprostol	Misoprostol	B-NP	NNP	O	2	SUB
2	has	have	B-VP	VBZ	O	0	ROOT
3	been	be	I-VP	VBN	O	2	VC
4	associated	associate	I-VP	VBN	O	3	VC
5	with	with	B-PP	IN	O	4	VMOD
6	adverse	adverse	B-NP	JJ	O	7	NMOD
7	reactions	reaction	I-NP	NNS	O	5	PMOD
8	,	,	O	,	O	7	P
9	including	include	B-PP	VBG	O	7	NMOD
10	gastrointestinal	gastrointestinal	B-NP	JJ	O	11	NMOD
11	symptoms	symptom	I-NP	NNS	O	17	NMOD
12	,	,	O	,	O	17	P
13	gynecologic	gynecologic	B-NP	JJ	O	14	NMOD
14	problems	problem	I-NP	NNS	O	17	NMOD
15	,	,	O	,	O	17	P
16	and	and	O	CC	O	17	NMOD
17	headache	headache	B-NP	NN	O	9	PMOD
18	.	.	O	.	O	2	P

1	Her	Her	B-NP	PRP$	O	2	NMOD
2	delirium	delirium	I-NP	NN	O	4	SUB
3	significantly	significantly	B-VP	RB	O	4	VMOD
4	improved	improve	I-VP	VBD	O	13	VMOD
5	after	after	B-SBAR	IN	O	4	VMOD
6	misoprostol	misoprostol	B-NP	NN	O	7	SUB
7	was	be	B-VP	VBD	O	5	SBAR
8	discontinued	discontinue	I-VP	VBN	O	7	VC
9	and	and	O	CC	O	13	VMOD
10	her	her	B-NP	PRP$	O	12	NMOD
11	mental	mental	I-NP	JJ	O	12	NMOD
12	status	status	I-NP	NN	O	13	SUB
13	returned	return	B-VP	VBD	O	0	ROOT
14	to	to	B-PP	TO	O	13	VMOD
15	normal	normal	B-NP	JJ	O	14	PMOD
16	within	within	B-PP	IN	O	13	VMOD
17	a	a	B-NP	DT	O	18	NMOD
18	week	week	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	13	P

1	There	There	B-NP	EX	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	no	no	B-NP	DT	O	4	NMOD
4	change	change	I-NP	NN	O	2	PRD
5	in	in	B-PP	IN	O	4	NMOD
6	hepatic	hepatic	B-NP	JJ	O	9	NMOD
7	tissue	tissue	I-NP	NN	O	9	NMOD
8	total	total	I-NP	JJ	O	9	NMOD
9	glutathione	glutathione	I-NP	NN	O	5	PMOD
10	following	follow	B-PP	VBG	O	9	NMOD
11	intestinal	intestinal	B-NP	JJ	O	13	NMOD
12	ischemia-reperfusion	ischemia-reperfusion	I-NP	NN	O	13	NMOD
13	injury	injury	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	2	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	renal	renal	I-NP	JJ	O	3	NMOD
3	failure	failure	I-NP	NN	O	0	ROOT
4	due	due	B-ADJP	JJ	O	3	NMOD
5	to	to	B-PP	TO	O	4	AMOD
6	rifampicin	rifampicin	B-NP	NN	O	5	PMOD
7	.	.	O	.	O	3	P

1	Severe	Severe	B-NP	JJ	O	2	NMOD
2	polyneuropathy	polyneuropathy	I-NP	NN	O	5	NMOD
3	and	and	I-NP	CC	O	5	NMOD
4	motor	motor	I-NP	NN	O	5	NMOD
5	loss	loss	I-NP	NN	O	12	NMOD
6	after	after	B-PP	IN	O	5	NMOD
7	intrathecal	intrathecal	B-NP	JJ	O	10	NMOD
8	thiotepa	thiotepa	I-NP	NN	O	10	NMOD
9	combination	combination	I-NP	NN	O	10	NMOD
10	chemotherapy	chemotherapy	I-NP	NN	O	6	PMOD
11	:	:	O	:	O	5	P
12	description	description	B-NP	NN	O	0	ROOT
13	of	of	B-PP	IN	O	12	NMOD
14	two	two	B-NP	CD	O	15	NMOD
15	cases	case	I-NP	NNS	O	13	PMOD
16	.	.	O	.	O	12	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	cases	case	I-NP	NNS	O	24	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	severe	severe	B-NP	JJ	O	7	NMOD
5	delayed	delay	I-NP	VBN	O	7	NMOD
6	neurologic	neurologic	I-NP	JJ	O	7	NMOD
7	toxicity	toxicity	I-NP	NN	O	3	PMOD
8	related	relate	B-VP	VBN	O	7	NMOD
9	to	to	B-PP	TO	O	8	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	administration	administration	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	intrathecal	intrathecal	O	JJ	O	18	NMOD
14	(	(	O	(	O	16	DEP
15	IT	IT	B-ADJP	JJ	O	16	DEP
16	)	)	O	)	O	13	AMOD
17	combination	combination	B-NP	NN	O	18	NMOD
18	chemotherapy	chemotherapy	I-NP	NN	O	12	PMOD
19	including	include	B-PP	VBG	O	18	NMOD
20	thiotepa	thiotepa	B-NP	NN	O	19	PMOD
21	(	(	O	(	O	23	DEP
22	TSPA	TSPA	B-NP	NN	B-protein	23	DEP
23	)	)	O	)	O	20	NMOD
24	are	be	B-VP	VBP	O	0	ROOT
25	presented	present	I-VP	VBN	O	24	VC
26	.	.	O	.	O	24	P

1	Neurologic	Neurologic	B-NP	JJ	O	2	NMOD
2	toxicities	toxicity	I-NP	NNS	O	3	SUB
3	have	have	B-VP	VBP	O	0	ROOT
4	been	be	I-VP	VBN	O	3	VC
5	described	describe	I-VP	VBN	O	4	VC
6	with	with	B-PP	IN	O	5	VMOD
7	IT-methotrexate	IT-methotrexate	B-NP	JJ	O	9	AMOD
8	,	,	I-NP	,	O	9	P
9	IT-cytosine	IT-cytosine	I-NP	JJ	O	6	PMOD
10	arabinoside	arabinoside	I-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	IT-TSPA	IT-TSPA	I-NP	NN	B-protein	9	NMOD
13	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	22	VMOD
2	spite	spite	B-NP	NN	O	1	PMOD
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	fact	fact	I-NP	NN	O	3	PMOD
6	that	that	B-SBAR	IN	O	5	NMOD
7	TSPA	TSPA	B-NP	NN	B-protein	8	SUB
8	is	be	B-VP	VBZ	O	6	SBAR
9	a	a	B-NP	DT	O	12	NMOD
10	useful	useful	I-NP	JJ	O	12	NMOD
11	IT	IT	I-NP	NN	O	12	NMOD
12	agent	agent	I-NP	NN	O	8	PRD
13	,	,	O	,	O	22	P
14	its	its	B-NP	PRP$	O	15	NMOD
15	combination	combination	I-NP	NN	O	22	SUB
16	with	with	B-PP	IN	O	15	NMOD
17	MTX	MTX	B-NP	NN	B-protein	21	NMOD
18	,	,	I-NP	,	O	21	P
19	ara-C	ara-C	I-NP	NN	O	21	NMOD
20	and	and	I-NP	CC	O	21	NMOD
21	radiotherapy	radiotherapy	I-NP	NN	O	16	PMOD
22	could	could	B-VP	MD	O	0	ROOT
23	cause	cause	I-VP	VB	O	22	VC
24	severe	severe	B-NP	JJ	O	25	NMOD
25	neurotoxicity	neurotoxicity	I-NP	NN	O	23	OBJ
26	.	.	O	.	O	22	P

1	Vasodilation	Vasodilation	B-NP	NN	O	9	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	large	large	B-NP	JJ	O	7	NMOD
4	and	and	I-NP	CC	O	7	NMOD
5	small	small	I-NP	JJ	O	7	NMOD
6	coronary	coronary	I-NP	JJ	O	7	NMOD
7	vessels	vessel	I-NP	NNS	O	2	PMOD
8	and	and	I-NP	CC	O	9	NMOD
9	hypotension	hypotension	I-NP	NN	O	15	SUB
10	induced	induce	B-VP	VBN	O	9	NMOD
11	by	by	B-PP	IN	O	10	VMOD
12	cromakalim	cromakalim	B-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	pinacidil	pinacidil	I-NP	NN	O	11	PMOD
15	were	be	B-VP	VBD	O	0	ROOT
16	not	not	I-VP	RB	O	15	VMOD
17	affected	affect	I-VP	VBN	O	15	VC
18	by	by	B-PP	IN	O	17	VMOD
19	prior	prior	B-NP	JJ	O	30	NMOD
20	combined	combined	I-NP	JJ	O	30	NMOD
21	beta	beta	I-NP	NN	O	30	NMOD
22	adrenergic	adrenergic	I-NP	JJ	O	21	NMOD
23	and	and	I-NP	CC	O	30	NMOD
24	muscarinic	muscarinic	I-NP	JJ	O	25	NMOD
25	receptors	receptor	I-NP	NNS	O	30	NMOD
26	blockade	blockade	I-NP	NN	O	30	NMOD
27	but	but	O	CC	O	30	NMOD
28	drug	drug	B-NP	NN	O	30	NMOD
29	induced	induce	I-NP	VBN	O	28	AMOD
30	tachycardia	tachycardia	I-NP	NN	O	18	PMOD
31	was	be	B-VP	VBD	O	17	VMOD
32	abolished	abolish	I-VP	VBN	O	31	VC
33	.	.	O	.	O	15	P

1	Mefenamic	Mefenamic	B-NP	JJ	O	2	NMOD
2	acid	acid	I-NP	NN	O	3	SUB
3	induced	induce	B-VP	VBD	O	0	ROOT
4	neutropenia	neutropenia	B-NP	NN	O	7	NMOD
5	and	and	O	CC	O	7	NMOD
6	renal	renal	B-NP	JJ	O	7	NMOD
7	failure	failure	I-NP	NN	O	3	OBJ
8	in	in	B-PP	IN	O	3	VMOD
9	elderly	elderly	B-NP	JJ	O	10	NMOD
10	females	female	I-NP	NNS	O	8	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	hypothyroidism	hypothyroidism	B-NP	NN	O	11	PMOD
13	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	mefenamic	mefenamic	B-NP	JJ	O	4	NMOD
4	acid	acid	I-NP	NN	O	5	SUB
5	induced	induce	B-VP	VBD	O	2	VMOD
6	non-oliguric	non-oliguric	B-NP	JJ	O	8	NMOD
7	renal	renal	I-NP	JJ	O	8	NMOD
8	failure	failure	I-NP	NN	O	11	NMOD
9	and	and	O	CC	O	11	NMOD
10	severe	severe	B-NP	JJ	O	11	NMOD
11	neutropenia	neutropenia	I-NP	NN	O	12	SUB
12	occurring	occur	B-VP	VBG	O	5	VMOD
13	simultaneously	simultaneously	B-ADVP	RB	O	12	VMOD
14	in	in	B-PP	IN	O	12	VMOD
15	two	two	B-NP	CD	O	17	NMOD
16	elderly	elderly	I-NP	JJ	O	17	NMOD
17	females	female	I-NP	NNS	O	14	PMOD
18	.	.	O	.	O	2	P

1	Etiology	Etiology	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	hypercalcemia	hypercalcemia	B-NP	NN	O	2	PMOD
4	in	in	B-PP	IN	O	1	NMOD
5	hemodialysis	hemodialysis	B-NP	NN	O	6	NMOD
6	patients	patient	I-NP	NNS	O	4	PMOD
7	on	on	B-PP	IN	O	6	NMOD
8	calcium	calcium	B-NP	NN	O	10	NMOD
9	carbonate	carbonate	I-NP	NN	O	10	NMOD
10	therapy	therapy	I-NP	NN	O	7	PMOD
11	.	.	O	.	O	1	P

1	Fourteen	Fourteen	B-NP	CD	O	2	AMOD
2	of	of	B-PP	IN	O	10	SUB
3	39	39	B-NP	CD	O	5	NMOD
4	dialysis	dialysis	I-NP	NN	O	5	NMOD
5	patients	patient	I-NP	NNS	O	2	NMOD
6	(	(	O	(	O	9	DEP
7	36	36	B-NP	CD	O	8	NMOD
8	%	%	I-NP	NN	O	9	DEP
9	)	)	O	)	O	5	NMOD
10	became	become	B-VP	VBD	O	0	ROOT
11	hypercalcemic	hypercalcemic	B-ADJP	JJ	O	10	PRD
12	after	after	B-PP	IN	O	11	AMOD
13	switching	switch	B-VP	VBG	O	12	PMOD
14	to	to	B-PP	TO	O	13	VMOD
15	calcium	calcium	B-NP	NN	O	16	NMOD
16	carbonate	carbonate	I-NP	NN	O	14	PMOD
17	as	as	B-PP	IN	O	13	VMOD
18	their	their	B-NP	PRP$	O	21	NMOD
19	principal	principal	I-NP	JJ	O	21	NMOD
20	phosphate	phosphate	I-NP	NN	O	21	NMOD
21	binder	binder	I-NP	NN	O	17	PMOD
22	.	.	O	.	O	10	P

1	In	In	B-SBAR	IN	O	28	VMOD
2	order	order	O	NN	O	1	DEP
3	to	to	B-VP	TO	O	4	VMOD
4	identify	identify	I-VP	VB	O	1	SBAR
5	risk	risk	B-NP	NN	B-protein	6	NMOD
6	factors	factor	I-NP	NNS	I-protein	4	OBJ
7	associated	associate	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	development	development	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	hypercalcemia	hypercalcemia	B-NP	NN	O	11	PMOD
13	,	,	O	,	O	28	P
14	indirect	indirect	B-NP	JJ	O	15	NMOD
15	parameters	parameter	I-NP	NNS	O	28	SUB
16	of	of	B-PP	IN	O	15	NMOD
17	intestinal	intestinal	B-NP	JJ	O	19	NMOD
18	calcium	calcium	I-NP	NN	O	19	NMOD
19	reabsorption	reabsorption	I-NP	NN	O	23	NMOD
20	and	and	I-NP	CC	O	23	NMOD
21	bone	bone	I-NP	NN	O	23	NMOD
22	turnover	turnover	I-NP	NN	O	23	NMOD
23	rate	rate	I-NP	NN	O	16	PMOD
24	in	in	B-PP	IN	O	15	NMOD
25	these	these	B-NP	DT	O	27	NMOD
26	14	14	I-NP	CD	O	27	NMOD
27	patients	patient	I-NP	NNS	O	24	PMOD
28	were	be	B-VP	VBD	O	0	ROOT
29	compared	compare	I-VP	VBN	O	28	VC
30	with	with	B-PP	IN	O	29	VMOD
31	results	result	B-NP	NNS	O	30	PMOD
32	in	in	B-PP	IN	O	31	NMOD
33	14	14	B-NP	CD	O	35	NMOD
34	eucalcemic	eucalcemic	I-NP	JJ	O	35	NMOD
35	patients	patient	I-NP	NNS	O	32	PMOD
36	matched	match	B-VP	VBN	O	35	NMOD
37	for	for	B-PP	IN	O	36	VMOD
38	age	age	B-NP	NN	O	40	NMOD
39	,	,	O	,	O	40	P
40	sex	sex	B-NP	NN	O	37	PMOD
41	,	,	O	,	O	49	P
42	length	length	B-NP	NN	O	49	NMOD
43	of	of	B-PP	IN	O	42	NMOD
44	time	time	B-NP	NN	O	43	PMOD
45	on	on	B-PP	IN	O	42	NMOD
46	dialysis	dialysis	B-NP	NN	O	45	PMOD
47	,	,	O	,	O	49	P
48	and	and	O	CC	O	49	NMOD
49	etiology	etiology	B-NP	NN	O	28	VMOD
50	of	of	B-PP	IN	O	49	NMOD
51	renal	renal	B-NP	JJ	O	52	NMOD
52	disease	disease	I-NP	NN	O	50	PMOD
53	.	.	O	.	O	28	P

1	In	In	B-PP	IN	O	0	ROOT
2	addition	addition	B-NP	NN	O	1	PMOD
3	to	to	B-PP	TO	O	2	NMOD
4	experiencing	experience	B-VP	VBG	O	3	PMOD
5	hypercalcemic	hypercalcemic	B-NP	JJ	O	6	NMOD
6	episodes	episode	I-NP	NNS	O	4	OBJ
7	with	with	B-PP	IN	O	6	NMOD
8	peak	peak	B-NP	JJ	O	10	NMOD
9	calcium	calcium	I-NP	NN	O	10	NMOD
10	values	value	I-NP	NNS	O	28	VMOD
11	of	of	B-PP	IN	O	10	NMOD
12	2.7	2.7	B-NP	CD	O	14	AMOD
13	to	to	I-NP	TO	O	14	AMOD
14	3.8	3.8	I-NP	CD	O	15	NMOD
15	mmol/L	mmol/L	I-NP	NN	O	11	PMOD
16	(	(	O	(	O	21	DEP
17	10.7	10.7	B-NP	CD	O	19	AMOD
18	to	to	O	TO	O	19	AMOD
19	15.0	15.0	B-NP	CD	O	20	NMOD
20	mg/dL	mg/dL	I-NP	NN	O	21	DEP
21	)	)	O	)	O	15	NMOD
22	,	,	O	,	O	28	P
23	patients	patient	B-NP	NNS	O	28	SUB
24	in	in	B-PP	IN	O	23	NMOD
25	the	the	B-NP	DT	O	27	NMOD
26	hypercalcemic	hypercalcemic	I-NP	JJ	O	27	NMOD
27	group	group	I-NP	NN	O	24	PMOD
28	exhibited	exhibit	B-VP	VBD	O	7	SBAR
29	a	a	B-NP	DT	O	31	NMOD
30	significant	significant	I-NP	JJ	O	31	NMOD
31	increase	increase	I-NP	NN	O	28	OBJ
32	in	in	B-PP	IN	O	31	NMOD
33	the	the	B-NP	DT	O	36	NMOD
34	mean	mean	I-NP	JJ	O	36	NMOD
35	calcium	calcium	I-NP	NN	O	36	NMOD
36	concentration	concentration	I-NP	NN	O	32	PMOD
37	obtained	obtain	B-VP	VBN	O	36	NMOD
38	during	during	B-PP	IN	O	37	VMOD
39	6	6	B-NP	CD	O	40	NMOD
40	months	month	I-NP	NNS	O	38	PMOD
41	before	before	B-SBAR	IN	O	28	VMOD
42	the	the	B-NP	DT	O	43	NMOD
43	switch	switch	I-NP	NN	O	41	PMOD
44	,	,	O	,	O	43	P
45	compared	compare	B-PP	VBN	O	43	NMOD
46	with	with	B-PP	IN	O	45	PMOD
47	the	the	B-NP	DT	O	49	NMOD
48	mean	mean	I-NP	JJ	O	49	NMOD
49	value	value	I-NP	NN	O	46	PMOD
50	obtained	obtain	B-VP	VBN	O	49	NMOD
51	during	during	B-PP	IN	O	50	VMOD
52	the	the	B-NP	DT	O	54	NMOD
53	7	7	I-NP	CD	O	54	NMOD
54	months	month	I-NP	NNS	O	51	PMOD
55	of	of	B-PP	IN	O	54	NMOD
56	observation	observation	B-NP	NN	O	68	NMOD
57	after	after	B-PP	IN	O	56	NMOD
58	the	the	B-NP	DT	O	59	NMOD
59	switch	switch	I-NP	NN	O	57	PMOD
60	(	(	O	(	O	68	NMOD
61	2.4	2.4	B-NP	CD	O	63	AMOD
62	+/-	+/-	I-NP	SYM	O	63	AMOD
63	0.03	0.03	I-NP	CD	O	67	AMOD
64	to	to	I-NP	TO	O	67	AMOD
65	2.5	2.5	I-NP	CD	O	67	AMOD
66	+/-	+/-	I-NP	SYM	O	67	AMOD
67	0.03	0.03	I-NP	CD	O	68	NMOD
68	mmol/L	mmol/L	I-NP	NN	O	55	PMOD
69	[	[	O	(	O	78	DEP
70	9.7	9.7	B-NP	CD	O	72	AMOD
71	+/-	+/-	I-NP	SYM	O	72	AMOD
72	0.2	0.2	I-NP	CD	O	76	AMOD
73	to	to	I-NP	TO	O	76	AMOD
74	10.2	10.2	I-NP	CD	O	76	AMOD
75	+/-	+/-	I-NP	SYM	O	76	AMOD
76	0.1	0.1	I-NP	CD	O	77	NMOD
77	mg/dL	mg/dL	I-NP	NN	O	78	DEP
78	]	]	O	)	O	1	PMOD
79	,	,	O	,	O	83	P
80	P	P	B-NP	NN	O	82	SUB
81	=	=	B-VP	SYM	O	82	VMOD
82	0.006	0.006	B-NP	CD	O	83	DEP
83	)	)	O	)	O	1	VMOD
84	.	.	O	.	O	1	P

1	Methyldopa	Methyldopa	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	hemolytic	hemolytic	B-NP	JJ	O	4	NMOD
4	anemia	anemia	I-NP	NN	O	2	OBJ
5	in	in	B-PP	IN	O	2	VMOD
6	a	a	B-NP	DT	O	10	NMOD
7	15	15	I-NP	CD	O	8	AMOD
8	year	year	I-NP	NN	O	10	NMOD
9	old	old	I-NP	JJ	O	8	AMOD
10	presenting	presenting	I-NP	NN	O	5	PMOD
11	as	as	B-PP	IN	O	2	VMOD
12	near-syncope	near-syncope	B-NP	NN	O	11	PMOD
13	.	.	O	.	O	2	P

1	Methyldopa	Methyldopa	B-NP	NN	O	2	SUB
2	causes	cause	B-VP	VBZ	O	0	ROOT
3	an	an	B-NP	DT	O	6	NMOD
4	autoimmune	autoimmune	I-NP	JJ	O	6	NMOD
5	hemolytic	hemolytic	I-NP	JJ	O	6	NMOD
6	anemia	anemia	I-NP	NN	O	2	OBJ
7	in	in	B-PP	IN	O	6	NMOD
8	a	a	B-NP	DT	O	10	NMOD
9	small	small	I-NP	JJ	O	10	NMOD
10	percentage	percentage	I-NP	NN	O	7	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	patients	patient	B-NP	NNS	O	11	PMOD
13	who	who	B-NP	WP	O	12	NMOD
14	take	take	B-VP	VBP	O	13	SBAR
15	the	the	B-NP	DT	O	16	NMOD
16	drug	drug	I-NP	NN	O	14	OBJ
17	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	7	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	methyldopa	methyldopa	B-NP	NN	O	5	PMOD
7	induced	induce	B-VP	VBD	O	2	VMOD
8	hemolytic	hemolytic	B-NP	JJ	O	9	NMOD
9	anemia	anemia	I-NP	NN	O	7	OBJ
10	in	in	B-PP	IN	O	7	VMOD
11	a	a	B-NP	DT	O	13	NMOD
12	15-year-old	15-year-old	I-NP	JJ	O	13	NMOD
13	boy	boy	I-NP	NN	O	10	PMOD
14	who	who	B-NP	WP	O	13	NMOD
15	presented	present	B-VP	VBD	O	14	SBAR
16	to	to	B-PP	TO	O	15	VMOD
17	the	the	B-NP	DT	O	19	NMOD
18	emergency	emergency	I-NP	NN	O	19	NMOD
19	department	department	I-NP	NN	O	16	PMOD
20	with	with	B-PP	IN	O	19	NMOD
21	near-syncope	near-syncope	B-NP	NN	O	20	PMOD
22	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	boy	boy	I-NP	NN	O	3	SUB
3	had	have	B-VP	VBD	O	0	ROOT
4	been	be	I-VP	VBN	O	3	VC
5	treated	treat	I-VP	VBN	O	4	VC
6	with	with	B-PP	IN	O	5	VMOD
7	intravenous	intravenous	B-NP	JJ	O	8	NMOD
8	methyldopa	methyldopa	I-NP	NN	O	6	PMOD
9	during	during	B-PP	IN	O	5	VMOD
10	a	a	B-NP	DT	O	14	NMOD
11	trauma	trauma	I-NP	NN	B-protein	14	NMOD
12	admission	admission	I-NP	NN	I-protein	14	NMOD
13	seven	seven	B-NP	CD	I-protein	14	NMOD
14	weeks	week	I-NP	NNS	I-protein	9	PMOD
15	prior	prior	B-ADVP	RB	O	16	PMOD
16	to	to	B-PP	TO	O	5	VMOD
17	presentation	presentation	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	3	NMOD
2	long-term	long-term	I-NP	JJ	O	3	NMOD
3	safety	safety	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	danazol	danazol	B-NP	NN	O	4	PMOD
6	in	in	B-PP	IN	O	3	NMOD
7	women	woman	B-NP	NNS	O	6	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	hereditary	hereditary	B-NP	JJ	O	10	NMOD
10	angioedema	angioedema	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	3	SUB
2	therefore	therefore	B-ADVP	RB	O	3	VMOD
3	investigated	investigate	B-VP	VBD	O	0	ROOT
4	the	the	B-NP	DT	O	6	NMOD
5	long-term	long-term	I-NP	JJ	O	6	NMOD
6	safety	safety	I-NP	NN	O	3	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	danazol	danazol	B-NP	NN	O	7	PMOD
9	by	by	B-PP	IN	O	3	VMOD
10	performing	perform	B-VP	VBG	O	9	PMOD
11	a	a	B-NP	DT	O	14	NMOD
12	retrospective	retrospective	I-NP	JJ	O	14	NMOD
13	chart	chart	I-NP	NN	O	14	NMOD
14	review	review	I-NP	NN	O	10	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	60	60	B-NP	CD	O	18	NMOD
17	female	female	I-NP	JJ	O	18	NMOD
18	patients	patient	I-NP	NNS	O	15	PMOD
19	with	with	B-PP	IN	O	18	NMOD
20	hereditary	hereditary	B-NP	JJ	O	21	NMOD
21	angioedema	angioedema	I-NP	NN	O	19	PMOD
22	treated	treat	B-VP	VBN	O	21	NMOD
23	with	with	B-PP	IN	O	22	VMOD
24	danazol	danazol	B-NP	NN	O	23	PMOD
25	for	for	B-PP	IN	O	22	VMOD
26	a	a	B-NP	DT	O	28	NMOD
27	continuous	continuous	I-NP	JJ	O	28	NMOD
28	period	period	I-NP	NN	O	25	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	6	6	B-NP	CD	O	31	NMOD
31	months	month	I-NP	NNS	O	29	PMOD
32	or	or	O	CC	O	10	VMOD
33	longer	long	B-ADVP	JJR	O	10	VMOD
34	.	.	O	.	O	3	P

1	Patient	Patient	B-NP	NN	O	3	NMOD
2	tolerance	tolerance	I-NP	NN	O	3	NMOD
3	study	study	I-NP	NN	O	12	NMOD
4	of	of	B-PP	IN	O	3	NMOD
5	topical	topical	B-NP	JJ	O	7	NMOD
6	chlorhexidine	chlorhexidine	I-NP	NN	O	7	NMOD
7	diphosphanilate	diphosphanilate	I-NP	NN	O	4	PMOD
8	:	:	O	:	O	3	P
9	a	a	B-NP	DT	O	12	NMOD
10	new	new	I-NP	JJ	O	12	NMOD
11	topical	topical	I-NP	JJ	O	12	NMOD
12	agent	agent	I-NP	NN	O	0	ROOT
13	for	for	B-PP	IN	O	12	NMOD
14	burns	burn	B-NP	NNS	O	13	PMOD
15	.	.	O	.	O	12	P

1	Chlorhexidine	Chlorhexidine	B-NP	NN	O	2	NMOD
2	phosphanilate	phosphanilate	I-NP	NN	O	11	NMOD
3	(	(	O	(	O	5	DEP
4	CHP	CHP	B-NP	NN	B-protein	5	DEP
5	)	)	O	)	O	2	NMOD
6	,	,	O	,	O	11	P
7	a	a	B-NP	DT	O	11	NMOD
8	new	new	I-NP	JJ	O	11	NMOD
9	broad-spectrum	broad-spectrum	I-NP	NN	O	11	NMOD
10	antimicrobial	antimicrobial	I-NP	JJ	O	11	NMOD
11	agent	agent	I-NP	NN	O	13	SUB
12	,	,	O	,	O	11	P
13	has	have	B-VP	VBZ	O	30	VMOD
14	been	be	I-VP	VBN	O	13	VC
15	evaluated	evaluate	I-VP	VBN	O	14	VC
16	as	as	B-PP	IN	O	15	VMOD
17	a	a	B-NP	DT	O	20	NMOD
18	topical	topical	I-NP	JJ	O	20	NMOD
19	burn	burn	I-NP	NN	O	20	NMOD
20	wound	wound	I-NP	NN	O	16	PMOD
21	dressing	dress	B-VP	VBG	O	20	NMOD
22	in	in	B-PP	IN	O	21	VMOD
23	cream	cream	B-NP	NN	O	24	NMOD
24	form	form	I-NP	NN	O	22	PMOD
25	,	,	O	,	O	30	P
26	but	but	O	CC	O	30	VMOD
27	preliminary	preliminary	B-NP	JJ	O	28	AMOD
28	clinical	clinical	I-NP	JJ	O	29	NMOD
29	trials	trial	I-NP	NNS	O	30	SUB
30	reported	report	B-VP	VBD	O	0	ROOT
31	that	that	B-SBAR	IN	O	30	VMOD
32	it	it	B-NP	PRP	O	33	SUB
33	was	be	B-VP	VBD	O	31	SBAR
34	painful	painful	B-ADJP	JJ	O	33	PRD
35	upon	upon	B-PP	IN	O	34	AMOD
36	application	application	B-NP	NN	O	35	PMOD
37	.	.	O	.	O	30	P

1	One	One	B-NP	CD	O	3	NMOD
2	burn	burn	I-NP	NN	O	3	NMOD
3	site	site	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	treated	treat	I-VP	VBN	O	4	VC
6	with	with	B-PP	IN	O	5	VMOD
7	each	each	B-NP	DT	O	6	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	four	four	B-NP	CD	O	12	NMOD
10	different	different	I-NP	JJ	O	12	NMOD
11	CHP	CHP	I-NP	NN	O	12	NMOD
12	concentrations	concentration	I-NP	NNS	O	8	PMOD
13	,	,	O	,	O	6	P
14	from	from	B-PP	IN	O	6	PMOD
15	0.25	0.25	B-NP	CD	O	14	PMOD
16	per	per	B-PP	IN	O	15	NMOD
17	cent	cent	B-NP	NN	O	16	PMOD
18	to	to	B-PP	TO	O	14	PMOD
19	2	2	B-NP	CD	O	18	PMOD
20	per	per	B-PP	IN	O	5	VMOD
21	cent	cent	B-NP	NN	O	20	PMOD
22	,	,	O	,	O	39	P
23	their	their	B-NP	PRP$	O	24	NMOD
24	vehicle	vehicle	I-NP	NN	O	39	NMOD
25	,	,	O	,	O	27	P
26	and	and	O	CC	O	27	NMOD
27	1	1	B-NP	CD	O	24	NMOD
28	per	per	B-PP	IN	O	24	NMOD
29	cent	cent	B-NP	NN	O	31	NMOD
30	silver	silver	I-NP	NN	O	31	NMOD
31	sulphadiazine	sulphadiazine	I-NP	NN	O	28	PMOD
32	(	(	O	(	O	34	DEP
33	AgSD	AgSD	B-NP	NN	O	34	DEP
34	)	)	O	)	O	24	NMOD
35	cream	cream	B-NP	NN	O	24	NMOD
36	,	,	O	,	O	39	P
37	an	an	B-NP	DT	O	39	NMOD
38	antimicrobial	antimicrobial	I-NP	JJ	O	39	NMOD
39	agent	agent	I-NP	NN	O	4	VMOD
40	frequently	frequently	B-VP	RB	O	41	VMOD
41	used	use	I-VP	VBN	O	39	NMOD
42	for	for	B-PP	IN	O	41	VMOD
43	topical	topical	B-NP	JJ	O	44	NMOD
44	treatment	treatment	I-NP	NN	O	42	PMOD
45	of	of	B-PP	IN	O	44	NMOD
46	burn	burn	B-NP	NN	O	47	NMOD
47	wounds	wound	I-NP	NNS	O	45	PMOD
48	.	.	O	.	O	4	P

1	There	There	B-NP	EX	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	direct	direct	I-NP	JJ	O	5	NMOD
5	relationship	relationship	I-NP	NN	O	2	PRD
6	between	between	B-PP	IN	O	2	VMOD
7	CHP	CHP	B-NP	NN	O	8	NMOD
8	concentration	concentration	I-NP	NN	O	12	NMOD
9	and	and	O	CC	O	12	NMOD
10	patients	patient	B-NP	NNS	O	11	NMOD
11	'	'	B-NP	POS	O	12	NMOD
12	ratings	rating	I-NP	NNS	O	6	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	pain	pain	B-NP	NN	O	13	PMOD
15	on	on	B-PP	IN	O	2	VMOD
16	an	an	B-NP	DT	O	18	NMOD
17	analogue	analogue	I-NP	NN	O	18	NMOD
18	scale	scale	I-NP	NN	O	15	PMOD
19	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	0.25	0.25	I-NP	CD	O	6	NMOD
3	per	per	B-PP	IN	O	2	NMOD
4	cent	cent	B-NP	NN	O	3	PMOD
5	CHP	CHP	I-NP	NN	O	6	NMOD
6	cream	cream	I-NP	NN	O	7	SUB
7	was	be	B-VP	VBD	O	21	VMOD
8	closest	closest	B-ADVP	RB	O	7	VMOD
9	to	to	B-PP	TO	O	8	AMOD
10	AgSD	AgSD	B-NP	NN	O	9	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	pain	pain	B-NP	NN	O	13	NMOD
13	tolerance	tolerance	I-NP	NN	O	11	PMOD
14	;	;	O	:	O	21	P
15	however	however	B-ADVP	RB	O	21	VMOD
16	,	,	O	,	O	21	P
17	none	none	B-NP	NN	O	21	SUB
18	of	of	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	20	NMOD
20	treatments	treatment	I-NP	NNS	O	18	PMOD
21	differed	differ	B-VP	VBD	O	0	ROOT
22	statistically	statistically	B-ADVP	RB	O	21	VMOD
23	from	from	B-PP	IN	O	21	VMOD
24	AgSD	AgSD	B-NP	NN	O	23	PMOD
25	or	or	B-PP	CC	O	23	PMOD
26	from	from	B-PP	IN	O	23	PMOD
27	each	each	B-NP	DT	O	28	NMOD
28	other	other	I-NP	JJ	O	26	PMOD
29	.	.	O	.	O	21	P

1	Dose-dependent	Dose-dependent	B-NP	JJ	O	2	NMOD
2	neurotoxicity	neurotoxicity	I-NP	NN	O	13	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	high-dose	high-dose	B-NP	JJ	O	5	NMOD
5	busulfan	busulfan	I-NP	NN	O	3	PMOD
6	in	in	B-PP	IN	O	5	NMOD
7	children	child	B-NP	NNS	O	6	PMOD
8	:	:	O	:	O	2	P
9	a	a	B-NP	DT	O	13	NMOD
10	clinical	clinical	I-NP	JJ	O	13	NMOD
11	and	and	I-NP	CC	O	13	NMOD
12	pharmacological	pharmacological	I-NP	JJ	O	13	NMOD
13	study	study	I-NP	NN	O	0	ROOT
14	.	.	O	.	O	13	P

1	Busulfan	Busulfan	B-NP	NNP	O	2	SUB
2	is	be	B-VP	VBZ	O	16	VMOD
3	known	know	I-VP	VBN	O	2	VC
4	to	to	I-VP	TO	O	5	VMOD
5	be	be	I-VP	VB	O	3	VMOD
6	neurotoxic	neurotoxic	B-ADJP	JJ	O	5	PRD
7	in	in	B-PP	IN	O	6	AMOD
8	animals	animal	B-NP	NNS	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	humans	human	I-NP	NNS	O	7	PMOD
11	,	,	O	,	O	16	P
12	but	but	O	CC	O	16	VMOD
13	its	its	B-NP	PRP$	O	15	NMOD
14	acute	acute	I-NP	JJ	O	15	NMOD
15	neurotoxicity	neurotoxicity	I-NP	NN	O	16	SUB
16	remains	remain	B-VP	VBZ	O	0	ROOT
17	poorly	poorly	B-VP	RB	O	18	VMOD
18	characterized	characterize	I-VP	VBN	O	16	VC
19	in	in	B-PP	IN	O	18	VMOD
20	children	child	B-NP	NNS	O	19	PMOD
21	.	.	O	.	O	16	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	34	VMOD
3	here	here	B-ADVP	RB	O	2	VMOD
4	a	a	B-NP	DT	O	6	NMOD
5	retrospective	retrospective	I-NP	JJ	O	6	NMOD
6	study	study	I-NP	NN	O	34	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	123	123	B-NP	CD	O	9	NMOD
9	children	child	I-NP	NNS	O	7	PMOD
10	(	(	O	(	O	16	DEP
11	median	median	B-NP	JJ	O	12	NMOD
12	age	age	I-NP	NN	O	15	NMOD
13	,	,	O	,	O	15	P
14	6.5	6.5	B-NP	CD	O	15	NMOD
15	years	year	I-NP	NNS	O	16	DEP
16	)	)	O	)	O	9	NMOD
17	receiving	receive	B-VP	VBG	O	9	NMOD
18	high-dose	high-dose	B-NP	JJ	O	19	NMOD
19	busulfan	busulfan	I-NP	NN	O	17	OBJ
20	in	in	B-PP	IN	O	19	NMOD
21	combined	combine	B-NP	VBN	O	22	NMOD
22	chemotherapy	chemotherapy	I-NP	NN	O	33	NMOD
23	before	before	B-PP	IN	O	22	NMOD
24	bone	bone	B-NP	NN	O	26	NMOD
25	marrow	marrow	I-NP	NN	O	26	NMOD
26	transplantation	transplantation	I-NP	NN	O	23	PMOD
27	for	for	B-PP	IN	O	26	NMOD
28	malignant	malignant	B-NP	JJ	O	30	NMOD
29	solid	solid	I-NP	JJ	O	30	NMOD
30	tumors	tumor	I-NP	NNS	O	27	PMOD
31	,	,	O	,	O	33	P
32	brain	brain	B-NP	NN	O	33	NMOD
33	tumors	tumor	I-NP	NNS	O	20	PMOD
34	excluded	exclude	B-VP	VBD	O	0	ROOT
35	.	.	O	.	O	34	P

1	Ninety-six	Ninety-six	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	14	VMOD
4	not	not	I-VP	RB	O	3	VMOD
5	given	give	I-VP	VBN	O	7	NMOD
6	anticonvulsive	anticonvulsive	B-NP	JJ	O	7	NMOD
7	prophylaxis	prophylaxis	I-NP	NN	O	3	PRD
8	;	;	O	:	O	3	P
9	7	7	B-NP	CD	O	14	SUB
10	(	(	O	(	O	13	DEP
11	7.5	7.5	B-NP	CD	O	12	NMOD
12	%	%	I-NP	NN	O	13	DEP
13	)	)	O	)	O	9	NMOD
14	developed	develop	B-VP	VBD	O	0	ROOT
15	seizures	seizure	B-NP	NNS	O	14	OBJ
16	during	during	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	19	NMOD
18	4	4	I-NP	CD	O	19	NMOD
19	days	day	I-NP	NNS	O	16	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	23	NMOD
22	busulfan	busulfan	I-NP	NN	O	23	NMOD
23	course	course	I-NP	NN	O	20	PMOD
24	or	or	B-PP	CC	O	16	PMOD
25	within	within	B-PP	IN	O	16	PMOD
26	24	24	B-NP	CD	O	27	NMOD
27	h	h	I-NP	NN	O	25	PMOD
28	after	after	B-PP	IN	O	27	NMOD
29	the	the	B-NP	DT	O	31	NMOD
30	last	last	I-NP	JJ	O	31	NMOD
31	dosing	dosing	I-NP	NN	O	28	PMOD
32	.	.	O	.	O	14	P

1	When	When	B-ADVP	WRB	O	12	VMOD
2	the	the	B-NP	DT	O	5	NMOD
3	total	total	I-NP	JJ	O	5	NMOD
4	busulfan	busulfan	I-NP	NN	O	5	NMOD
5	dose	dose	I-NP	NN	O	6	SUB
6	was	be	B-VP	VBD	O	1	SBAR
7	taken	take	I-VP	VBN	O	6	VC
8	into	into	B-PP	IN	O	7	VMOD
9	account	account	B-NP	NN	O	8	PMOD
10	,	,	O	,	O	12	P
11	there	there	B-NP	EX	O	12	SUB
12	was	be	B-VP	VBD	O	0	ROOT
13	a	a	B-NP	DT	O	15	NMOD
14	significant	significant	I-NP	JJ	O	15	NMOD
15	difference	difference	I-NP	NN	O	35	NMOD
16	in	in	B-PP	IN	O	15	NMOD
17	terms	term	B-NP	NNS	O	16	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	neurotoxicity	neurotoxicity	B-NP	NN	O	20	NMOD
20	incidence	incidence	I-NP	NN	O	18	PMOD
21	among	among	B-PP	IN	O	15	NMOD
22	patients	patient	B-NP	NNS	O	21	PMOD
23	under	under	B-PP	IN	O	15	NMOD
24	16	16	B-NP	CD	O	25	NMOD
25	mg/kg	mg/kg	I-NP	NN	O	23	PMOD
26	(	(	O	(	O	33	DEP
27	1	1	B-NP	CD	O	32	NMOD
28	of	of	B-PP	IN	O	27	NMOD
29	57	57	B-NP	CD	O	28	PMOD
30	,	,	O	,	O	32	P
31	1.7	1.7	B-NP	CD	O	32	NMOD
32	%	%	I-NP	NN	O	33	DEP
33	)	)	O	)	O	15	NMOD
34	and	and	O	CC	O	35	NMOD
35	patients	patient	B-NP	NNS	O	12	PRD
36	under	under	B-PP	IN	O	35	NMOD
37	600	600	B-NP	CD	O	38	NMOD
38	mg/m2	mg/m2	I-NP	NN	O	36	PMOD
39	(	(	O	(	O	46	DEP
40	6	6	B-NP	CD	O	45	NMOD
41	of	of	B-PP	IN	O	40	NMOD
42	39	39	B-NP	CD	O	41	PMOD
43	,	,	O	,	O	45	P
44	15.4	15.4	B-NP	CD	O	45	NMOD
45	%	%	I-NP	NN	O	46	DEP
46	)	)	O	)	O	35	NMOD
47	(	(	O	(	O	52	DEP
48	P	P	B-NP	NN	O	52	DEP
49	less	less	B-ADJP	JJR	O	48	NMOD
50	than	than	B-PP	IN	O	49	AMOD
51	0.02	0.02	B-NP	CD	O	50	PMOD
52	)	)	O	)	O	35	NMOD
53	.	.	O	.	O	12	P

1	Twenty-seven	Twenty-seven	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	18	VMOD
4	given	give	I-VP	VBN	O	3	VC
5	a	a	B-NP	DT	O	9	NMOD
6	600-mg/m2	600-mg/m2	I-NP	JJ	O	9	NMOD
7	busulfan	busulfan	I-NP	NN	O	9	NMOD
8	total	total	I-NP	JJ	O	9	NMOD
9	dose	dose	I-NP	NN	O	4	OBJ
10	with	with	B-PP	IN	O	9	NMOD
11	continuous	continuous	B-NP	JJ	O	13	NMOD
12	i.v.	i.v.	I-NP	JJ	O	13	NMOD
13	infusion	infusion	I-NP	NN	O	10	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	clonazepam	clonazepam	B-NP	NN	O	14	PMOD
16	;	;	O	:	O	18	P
17	none	none	B-NP	NN	O	18	SUB
18	had	have	B-VP	VBD	O	0	ROOT
19	any	any	B-NP	DT	O	21	NMOD
20	neurological	neurological	I-NP	JJ	O	21	NMOD
21	symptoms	symptom	I-NP	NNS	O	18	OBJ
22	.	.	O	.	O	18	P

1	Busulfan	Busulfan	B-NP	NN	O	2	NMOD
2	levels	level	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	38	VMOD
4	measured	measure	I-VP	VBN	O	3	VC
5	by	by	B-PP	IN	O	4	VMOD
6	a	a	B-NP	DT	O	10	NMOD
7	gas	gas	I-NP	NN	O	10	NMOD
8	chromatographic-mass	chromatographic-mass	I-NP	NN	O	10	NMOD
9	spectrometry	spectrometry	I-NP	NN	O	10	NMOD
10	assay	assay	I-NP	NN	O	5	PMOD
11	in	in	B-PP	IN	O	4	VMOD
12	the	the	B-NP	DT	O	16	NMOD
13	plasma	plasma	I-NP	NN	O	16	NMOD
14	and	and	I-NP	CC	O	16	NMOD
15	cerebrospinal	cerebrospinal	I-NP	JJ	O	16	NMOD
16	fluid	fluid	I-NP	NN	O	11	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	9	9	B-NP	CD	O	19	NMOD
19	children	child	I-NP	NNS	O	17	PMOD
20	without	without	B-PP	IN	O	16	NMOD
21	central	central	B-NP	JJ	O	24	NMOD
22	nervous	nervous	I-NP	JJ	O	24	NMOD
23	system	system	I-NP	NN	O	24	NMOD
24	disease	disease	I-NP	NN	O	20	PMOD
25	under	under	B-PP	IN	O	4	VMOD
26	600	600	B-NP	CD	O	28	NMOD
27	mg/m2	mg/m2	I-NP	NN	O	28	NMOD
28	busulfan	busulfan	I-NP	NN	O	25	PMOD
29	with	with	B-PP	IN	O	28	NMOD
30	clonazepam	clonazepam	B-NP	NN	O	29	PMOD
31	:	:	O	:	O	3	P
32	busulfan	busulfan	B-NP	NN	O	34	NMOD
33	cerebrospinal	cerebrospinal	I-NP	JJ	O	34	NMOD
34	fluid	fluid	I-NP	NN	O	37	NMOD
35	:	:	O	:	O	37	P
36	plasma	plasma	B-NP	NN	O	37	NMOD
37	ratio	ratio	I-NP	NN	O	38	SUB
38	was	be	B-VP	VBD	O	0	ROOT
39	1.39	1.39	B-NP	CD	O	38	PRD
40	.	.	O	.	O	38	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	shows	show	B-VP	VBZ	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	busulfan	busulfan	B-NP	NN	O	6	NMOD
6	neurotoxicity	neurotoxicity	I-NP	NN	O	7	SUB
7	is	be	B-VP	VBZ	O	4	SBAR
8	dose-dependent	dose-dependent	B-ADJP	JJ	O	7	PRD
9	in	in	B-PP	IN	O	8	AMOD
10	children	child	B-NP	NNS	O	9	PMOD
11	and	and	O	CC	O	7	VMOD
12	efficiently	efficiently	B-VP	RB	O	7	VMOD
13	prevented	prevent	I-VP	VBN	O	7	VC
14	by	by	B-PP	IN	O	13	VMOD
15	clonazepam	clonazepam	B-NP	NN	O	14	PMOD
16	.	.	O	.	O	3	P

1	A	A	B-NP	DT	O	3	NMOD
2	busulfan	busulfan	I-NP	JJ	O	3	NMOD
3	dose	dose	I-NP	NN	O	21	SUB
4	calculated	calculate	B-VP	VBN	O	3	NMOD
5	on	on	B-PP	IN	O	4	VMOD
6	the	the	B-NP	DT	O	7	NMOD
7	basis	basis	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	body	body	B-NP	NN	O	11	NMOD
10	surface	surface	I-NP	NN	O	11	NMOD
11	area	area	I-NP	NN	O	8	PMOD
12	,	,	O	,	O	3	P
13	resulting	result	B-VP	VBG	O	3	NMOD
14	in	in	B-PP	IN	O	13	VMOD
15	higher	high	B-NP	JJR	O	16	NMOD
16	doses	dose	I-NP	NNS	O	14	PMOD
17	in	in	B-PP	IN	O	16	NMOD
18	young	young	B-NP	JJ	O	19	NMOD
19	children	child	I-NP	NNS	O	17	PMOD
20	,	,	O	,	O	3	P
21	was	be	B-VP	VBD	O	0	ROOT
22	followed	follow	I-VP	VBN	O	21	VC
23	by	by	B-PP	IN	O	22	VMOD
24	increased	increase	B-NP	VBN	O	25	NMOD
25	neurotoxicity	neurotoxicity	I-NP	NN	O	23	PMOD
26	,	,	O	,	O	22	P
27	close	close	B-ADVP	RB	O	22	VMOD
28	to	to	B-PP	TO	O	27	AMOD
29	neurotoxicity	neurotoxicity	B-NP	NN	O	30	NMOD
30	incidence	incidence	I-NP	NN	O	28	PMOD
31	observed	observe	B-VP	VBN	O	30	NMOD
32	in	in	B-PP	IN	O	31	VMOD
33	adults	adult	B-NP	NNS	O	32	PMOD
34	.	.	O	.	O	21	P

1	Histamine	Histamine	B-NP	NN	O	2	NMOD
2	antagonists	antagonist	I-NP	NNS	O	4	NMOD
3	and	and	O	CC	O	4	NMOD
4	d-tubocurarine	d-tubocurarine	B-NP	NN	O	5	SUB
5	induced	induce	B-VP	VBD	O	0	ROOT
6	hypotension	hypotension	B-NP	NN	O	5	OBJ
7	in	in	B-PP	IN	O	5	VMOD
8	cardiac	cardiac	B-NP	JJ	O	10	NMOD
9	surgical	surgical	I-NP	JJ	O	10	NMOD
10	patients	patient	I-NP	NNS	O	7	PMOD
11	.	.	O	.	O	5	P

1	Lindane	Lindane	B-NP	NN	O	5	SUB
2	(	(	O	(	O	4	DEP
3	gamma-hexachlorocyclohexane	gamma-hexachlorocyclohexane	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	is	be	B-VP	VBZ	O	0	ROOT
6	an	an	B-NP	DT	O	8	NMOD
7	organochlorine	organochlorine	I-NP	NN	O	8	NMOD
8	insecticide	insecticide	I-NP	NN	O	5	PRD
9	with	with	B-PP	IN	O	8	NMOD
10	known	known	B-NP	JJ	O	12	NMOD
11	neurotoxic	neurotoxic	I-NP	JJ	O	12	NMOD
12	effects	effect	I-NP	NNS	O	9	PMOD
13	.	.	O	.	O	5	P

1	We	We	B-NP	PRP	O	2	SUB
2	studied	study	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	effect	effect	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	lindane	lindane	B-NP	NN	O	5	PMOD
7	(	(	O	(	O	10	DEP
8	150	150	B-NP	CD	O	9	NMOD
9	mg/kg	mg/kg	I-NP	NN	O	10	DEP
10	)	)	O	)	O	6	NMOD
11	on	on	B-PP	IN	O	4	NMOD
12	the	the	B-NP	DT	O	16	NMOD
13	GABAergic	GABAergic	I-NP	JJ	O	16	NMOD
14	and	and	I-NP	CC	O	16	NMOD
15	dopaminergic	dopaminergic	I-NP	JJ	O	16	NMOD
16	systems	system	I-NP	NNS	O	11	PMOD
17	by	by	B-PP	IN	O	2	VMOD
18	measuring	measure	B-VP	VBG	O	17	PMOD
19	the	the	B-NP	DT	O	20	NMOD
20	concentration	concentration	I-NP	NN	O	18	OBJ
21	of	of	B-PP	IN	O	20	NMOD
22	GABA	GABA	B-NP	NN	B-protein	27	NMOD
23	,	,	O	,	O	27	P
24	dopamine	dopamine	B-NP	NN	O	27	NMOD
25	and	and	O	CC	O	27	NMOD
26	its	its	B-NP	PRP$	O	27	NMOD
27	metabolites	metabolite	I-NP	NNS	O	21	PMOD
28	in	in	B-PP	IN	O	20	NMOD
29	7	7	B-NP	CD	O	31	NMOD
30	brain	brain	I-NP	NN	O	31	NMOD
31	areas	area	I-NP	NNS	O	28	PMOD
32	at	at	B-PP	IN	O	20	NMOD
33	the	the	B-NP	DT	O	34	NMOD
34	onset	onset	I-NP	NN	O	32	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	seizures	seizure	B-NP	NNS	O	35	PMOD
37	.	.	O	.	O	2	P

1	All	All	B-NP	DT	O	2	NMOD
2	animals	animal	I-NP	NNS	O	3	SUB
3	suffered	suffer	B-VP	VBD	O	0	ROOT
4	tonic	tonic	B-NP	JJ	O	5	NMOD
5	convulsions	convulsion	I-NP	NNS	O	3	OBJ
6	at	at	B-PP	IN	O	5	NMOD
7	18.3	18.3	B-NP	CD	O	9	AMOD
8	+/-	+/-	I-NP	SYM	O	9	AMOD
9	1.4	1.4	I-NP	CD	O	10	NMOD
10	min	min	I-NP	NN	O	6	PMOD
11	after	after	B-PP	IN	O	10	NMOD
12	lindane	lindane	B-NP	NN	O	13	NMOD
13	administration	administration	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	3	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	cases	case	I-NP	NNS	O	9	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	propylthiouracil-associated	propylthiouracil-associated	B-NP	JJ	O	6	NMOD
5	acute	acute	I-NP	JJ	O	6	NMOD
6	hepatitis	hepatitis	I-NP	NN	O	3	PMOD
7	,	,	O	,	O	9	P
8	one	one	B-NP	CD	O	9	NMOD
9	case	case	I-NP	NN	O	17	NMOD
10	of	of	B-PP	IN	O	9	NMOD
11	fatal	fatal	B-NP	JJ	O	14	NMOD
12	methimazole-associated	methimazole-associated	I-NP	JJ	O	14	NMOD
13	hepatocellular	hepatocellular	I-NP	JJ	O	14	NMOD
14	necrosis	necrosis	I-NP	NN	O	10	PMOD
15	and	and	O	CC	O	17	NMOD
16	one	one	B-NP	CD	O	17	NMOD
17	case	case	I-NP	NN	O	22	SUB
18	of	of	B-PP	IN	O	17	NMOD
19	propylthiouracil-associated	propylthiouracil-associated	B-NP	JJ	O	21	NMOD
20	lupus-like	lupus-like	I-NP	JJ	O	21	NMOD
21	syndrome	syndrome	I-NP	NN	O	18	PMOD
22	are	be	B-VP	VBP	O	0	ROOT
23	described	describe	I-VP	VBN	O	22	VC
24	.	.	O	.	O	22	P

1	Anticonvulsant	Anticonvulsant	B-NP	JJ	O	2	NMOD
2	actions	action	I-NP	NNS	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	MK-801	MK-801	B-NP	NN	B-protein	3	PMOD
5	on	on	B-PP	IN	O	2	NMOD
6	the	the	B-NP	DT	O	8	NMOD
7	lithium-pilocarpine	lithium-pilocarpine	I-NP	JJ	O	8	NMOD
8	model	model	I-NP	NN	O	5	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	status	status	B-NP	NN	O	11	NMOD
11	epilepticus	epilepticus	I-NP	NN	O	9	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	rats	rat	B-NP	NNS	O	12	PMOD
14	.	.	O	.	O	2	P

1	MK-801	MK-801	B-NP	NN	B-protein	10	NMOD
2	,	,	O	,	O	10	P
3	a	a	B-NP	DT	O	5	NMOD
4	noncompetitive	noncompetitive	I-NP	JJ	O	5	NMOD
5	N-methyl-D-aspartate	N-methyl-D-aspartate	I-NP	NN	O	10	NMOD
6	(	(	O	(	O	8	DEP
7	NMDA	NMDA	B-NP	NN	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	receptor	receptor	B-NP	NN	O	10	NMOD
10	antagonist	antagonist	I-NP	NN	O	12	SUB
11	,	,	O	,	O	10	P
12	was	be	B-VP	VBD	O	0	ROOT
13	tested	test	I-VP	VBN	O	12	VC
14	for	for	B-PP	IN	O	13	VMOD
15	anticonvulsant	anticonvulsant	B-NP	JJ	O	16	NMOD
16	effects	effect	I-NP	NNS	O	14	PMOD
17	in	in	B-PP	IN	O	16	NMOD
18	rats	rat	B-NP	NNS	O	17	PMOD
19	using	use	B-VP	VBG	O	16	NMOD
20	two	two	B-NP	CD	O	22	NMOD
21	seizure	seizure	I-NP	NN	O	22	NMOD
22	models	model	I-NP	NNS	O	19	OBJ
23	,	,	O	,	O	12	VMOD
24	coadministration	coadministration	B-NP	NN	O	23	OBJ
25	of	of	B-PP	IN	O	24	NMOD
26	lithium	lithium	B-NP	NN	O	30	NMOD
27	and	and	I-NP	CC	O	30	NMOD
28	pilocarpine	pilocarpine	I-NP	NN	O	30	NMOD
29	and	and	I-NP	CC	O	30	NMOD
30	administration	administration	I-NP	NN	O	25	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	a	a	B-NP	DT	O	34	NMOD
33	high	high	I-NP	JJ	O	34	NMOD
34	dose	dose	I-NP	NN	O	31	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	pilocarpine	pilocarpine	B-NP	NN	O	35	PMOD
37	alone	alone	B-ADVP	RB	O	36	NMOD
38	.	.	O	.	O	12	P

1	First	First	B-ADVP	RB	O	6	VMOD
2	,	,	O	,	O	6	P
3	pretreatment	pretreatment	B-NP	NN	O	6	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	MK-801	MK-801	B-NP	NN	B-protein	4	PMOD
6	produced	produce	B-VP	VBD	O	0	ROOT
7	an	an	B-NP	DT	O	12	NMOD
8	effective	effective	I-NP	JJ	O	10	AMOD
9	and	and	I-NP	CC	O	10	AMOD
10	dose-dependent	dose-dependent	I-NP	JJ	O	12	NMOD
11	anticonvulsant	anticonvulsant	I-NP	JJ	O	12	NMOD
12	action	action	I-NP	NN	O	6	OBJ
13	with	with	B-PP	IN	O	6	VMOD
14	the	the	B-NP	DT	O	16	NMOD
15	lithium-pilocarpine	lithium-pilocarpine	I-NP	JJ	O	16	NMOD
16	model	model	I-NP	NN	O	13	PMOD
17	but	but	B-PP	CC	O	13	PMOD
18	not	not	B-PP	RB	O	19	PMOD
19	with	with	I-PP	IN	O	13	PMOD
20	rats	rat	B-NP	NNS	O	19	PMOD
21	treated	treat	B-VP	VBN	O	20	NMOD
22	with	with	B-PP	IN	O	21	VMOD
23	pilocarpine	pilocarpine	B-NP	NN	O	22	PMOD
24	alone	alone	B-ADVP	RB	O	23	NMOD
25	,	,	O	,	O	6	P
26	suggesting	suggest	B-VP	VBG	O	6	VMOD
27	that	that	B-SBAR	IN	O	26	VMOD
28	different	different	B-NP	JJ	O	30	NMOD
29	biochemical	biochemical	I-NP	JJ	O	30	NMOD
30	mechanisms	mechanism	I-NP	NNS	O	31	SUB
31	control	control	B-VP	VBP	O	27	SBAR
32	seizures	seizure	B-NP	NNS	O	31	OBJ
33	in	in	B-PP	IN	O	32	NMOD
34	these	these	B-NP	DT	O	36	NMOD
35	two	two	I-NP	CD	O	36	NMOD
36	models	model	I-NP	NNS	O	33	PMOD
37	.	.	O	.	O	6	P

1	Second	Second	B-ADVP	RB	O	13	VMOD
2	,	,	O	,	O	13	P
3	the	the	B-NP	DT	O	5	NMOD
4	anticonvulsant	anticonvulsant	I-NP	JJ	O	5	NMOD
5	effect	effect	I-NP	NN	O	13	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	MK-801	MK-801	B-NP	NN	B-protein	6	PMOD
8	in	in	B-PP	IN	O	5	NMOD
9	the	the	B-NP	DT	O	11	NMOD
10	lithium-pilocarpine	lithium-pilocarpine	I-NP	JJ	O	11	NMOD
11	model	model	I-NP	NN	O	8	PMOD
12	only	only	B-ADVP	RB	O	13	VMOD
13	occurred	occur	B-VP	VBD	O	0	ROOT
14	after	after	B-PP	IN	O	13	VMOD
15	initial	initial	B-NP	JJ	O	16	NMOD
16	periods	period	I-NP	NNS	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	seizure	seizure	B-NP	NN	O	19	NMOD
19	activity	activity	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	13	P

1	Third	Third	B-ADVP	RB	O	25	VMOD
2	,	,	O	,	O	25	P
3	although	although	B-SBAR	IN	O	25	VMOD
4	it	it	B-NP	PRP	O	5	SUB
5	is	be	B-VP	VBZ	O	3	SBAR
6	relatively	relatively	B-ADJP	RB	O	7	AMOD
7	easy	easy	I-ADJP	JJ	O	5	PRD
8	to	to	B-VP	TO	O	9	VMOD
9	block	block	I-VP	VB	O	7	AMOD
10	seizures	seizure	B-NP	NNS	O	9	OBJ
11	induced	induce	B-VP	VBN	O	10	NMOD
12	by	by	B-PP	IN	O	11	VMOD
13	lithium	lithium	B-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	pilocarpine	pilocarpine	I-NP	NN	O	12	PMOD
16	by	by	B-PP	IN	O	11	VMOD
17	administration	administration	B-NP	NN	O	16	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	anticonvulsants	anticonvulsant	B-NP	NNS	O	18	PMOD
20	prior	prior	B-ADVP	RB	O	21	PMOD
21	to	to	B-PP	TO	O	9	VMOD
22	pilocarpine	pilocarpine	B-NP	NN	O	21	PMOD
23	,	,	O	,	O	25	P
24	it	it	B-NP	PRP	O	25	SUB
25	is	be	B-VP	VBZ	O	0	ROOT
26	more	more	B-ADJP	RBR	O	27	AMOD
27	difficult	difficult	I-ADJP	JJ	O	25	PRD
28	to	to	B-VP	TO	O	29	VMOD
29	terminate	terminate	I-VP	VB	O	27	AMOD
30	ongoing	ongoing	B-NP	JJ	O	32	NMOD
31	status	status	I-NP	NN	O	32	NMOD
32	epilepticus	epilepticus	I-NP	NN	O	29	OBJ
33	and	and	O	CC	O	29	VMOD
34	block	block	B-VP	VB	O	29	VMOD
35	the	the	B-NP	DT	O	36	NMOD
36	lethality	lethality	I-NP	NN	O	34	OBJ
37	of	of	B-PP	IN	O	36	NMOD
38	the	the	B-NP	DT	O	39	NMOD
39	seizures	seizure	I-NP	NNS	O	37	PMOD
40	.	.	O	.	O	25	P

1	Administration	Administration	B-NP	NN	O	18	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	MK-801	MK-801	B-NP	NN	O	7	NMOD
4	30	30	I-NP	CD	O	6	AMOD
5	or	or	I-NP	CC	O	6	AMOD
6	60	60	I-NP	CD	O	7	NMOD
7	min	min	I-NP	NN	O	2	PMOD
8	after	after	B-PP	IN	O	7	NMOD
9	pilocarpine	pilocarpine	B-NP	NN	O	8	PMOD
10	,	,	O	,	O	18	P
11	i.e.	i.e.	B-NP	FW	O	18	VMOD
12	,	,	O	,	O	18	P
13	during	during	B-PP	IN	O	18	VMOD
14	status	status	B-NP	NN	O	15	NMOD
15	epilepticus	epilepticus	I-NP	NN	O	13	PMOD
16	,	,	O	,	O	18	P
17	gradually	gradually	B-ADVP	RB	O	18	VMOD
18	reduced	reduce	B-VP	VBD	O	0	ROOT
19	electrical	electrical	B-NP	JJ	O	21	AMOD
20	and	and	I-NP	CC	O	21	AMOD
21	behavioral	behavioral	I-NP	JJ	O	23	NMOD
22	seizure	seizure	I-NP	NN	O	23	NMOD
23	activity	activity	I-NP	NN	O	18	OBJ
24	and	and	O	CC	O	18	VMOD
25	greatly	greatly	B-VP	RB	O	26	VMOD
26	enhanced	enhance	I-VP	VBD	O	18	VMOD
27	the	the	B-NP	DT	O	29	NMOD
28	survival	survival	I-NP	NN	O	29	NMOD
29	rate	rate	I-NP	NN	O	26	OBJ
30	.	.	O	.	O	18	P

1	These	These	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	activation	activation	B-NP	NN	O	9	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	NMDA	NMDA	B-NP	NN	B-protein	8	NMOD
8	receptors	receptor	I-NP	NNS	I-protein	6	PMOD
9	plays	play	B-VP	VBZ	O	4	SBAR
10	an	an	B-NP	DT	O	12	NMOD
11	important	important	I-NP	JJ	O	12	NMOD
12	role	role	I-NP	NN	O	9	OBJ
13	in	in	B-PP	IN	O	9	VMOD
14	status	status	B-NP	NN	O	15	NMOD
15	epilepticus	epilepticus	I-NP	NN	O	18	NMOD
16	and	and	I-NP	CC	O	18	NMOD
17	brain	brain	I-NP	NN	O	18	NMOD
18	damage	damage	I-NP	NN	O	13	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	22	NMOD
21	lithium-pilocarpine	lithium-pilocarpine	I-NP	JJ	O	22	NMOD
22	model	model	I-NP	NN	O	19	PMOD
23	.	.	O	.	O	3	P

1	Nifedipine	Nifedipine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	bradycardia	bradycardia	B-NP	NN	O	2	OBJ
4	in	in	B-PP	IN	O	2	VMOD
5	a	a	B-NP	DT	O	6	NMOD
6	patient	patient	I-NP	NN	O	4	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	autonomic	autonomic	B-NP	JJ	O	9	NMOD
9	neuropathy	neuropathy	I-NP	NN	O	7	PMOD
10	.	.	O	.	O	2	P

1	He	He	B-NP	PRP	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	found	find	I-VP	VBN	O	2	VC
4	to	to	I-VP	TO	O	5	VMOD
5	have	have	I-VP	VB	O	3	VMOD
6	atrial	atrial	B-NP	JJ	O	7	NMOD
7	flutter	flutter	I-NP	NN	O	5	OBJ
8	at	at	B-PP	IN	O	5	VMOD
9	a	a	B-NP	DT	O	11	NMOD
10	ventricular	ventricular	I-NP	JJ	O	11	NMOD
11	rate	rate	I-NP	NN	O	8	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	70/min	70/min	B-NP	NN	O	12	PMOD
14	which	which	B-NP	WDT	O	5	VMOD
15	slowed	slow	B-VP	VBD	O	14	SBAR
16	down	down	B-ADVP	RB	O	15	VMOD
17	to	to	B-PP	TO	O	15	VMOD
18	30-40/min	30-40/min	B-NP	CD	O	17	PMOD
19	when	when	B-ADVP	WRB	O	18	NMOD
20	nifedipine	nifedipine	B-NP	NN	O	19	SBAR
21	(	(	O	(	O	24	DEP
22	60	60	B-NP	CD	O	23	NMOD
23	mg	mg	I-NP	NN	O	24	DEP
24	)	)	O	)	O	20	NMOD
25	in	in	B-PP	IN	O	20	NMOD
26	3	3	B-NP	CD	O	28	NMOD
27	divided	divide	I-NP	VBN	O	28	NMOD
28	doses	dose	I-NP	NNS	O	25	PMOD
29	,	,	O	,	O	28	P
30	during	during	B-PP	IN	O	28	NMOD
31	which	which	B-NP	WDT	O	30	PMOD
32	he	he	B-NP	PRP	O	33	SUB
33	was	be	B-VP	VBD	O	30	SBAR
34	paced	pace	I-VP	VBN	O	33	VC
35	at	at	B-PP	IN	O	34	VMOD
36	a	a	B-NP	DT	O	37	NMOD
37	rate	rate	I-NP	NN	O	35	PMOD
38	of	of	B-PP	IN	O	37	NMOD
39	70/min	70/min	B-NP	NN	O	38	PMOD
40	.	.	O	.	O	2	P

1	This	This	B-NP	DT	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	inconsistent	inconsistent	B-ADJP	JJ	O	2	PRD
4	with	with	B-PP	IN	O	3	AMOD
5	the	the	B-NP	DT	O	7	NMOD
6	well-established	well-established	I-NP	JJ	O	7	NMOD
7	finding	finding	I-NP	NN	O	4	PMOD
8	that	that	B-SBAR	IN	O	7	NMOD
9	nifedipine	nifedipine	B-NP	NN	O	10	SUB
10	induces	induce	B-VP	VBZ	O	8	SBAR
11	tachycardia	tachycardia	B-NP	NN	O	10	OBJ
12	in	in	B-PP	IN	O	10	VMOD
13	normally	normally	B-NP	RB	O	14	AMOD
14	innervated	innervate	I-NP	VBN	O	15	NMOD
15	hearts	heart	I-NP	NNS	O	12	PMOD
16	.	.	O	.	O	2	P

1	Haloperidol	Haloperidol	B-NP	NN	O	2	SUB
2	failed	fail	B-VP	VBD	O	0	ROOT
3	to	to	I-VP	TO	O	4	VMOD
4	prevent	prevent	I-VP	VB	O	2	VMOD
5	amphetamine	amphetamine	B-NP	NN	O	7	NMOD
6	induced	induced	I-NP	JJ	O	7	NMOD
7	seizures	seizure	I-NP	NNS	O	4	OBJ
8	,	,	O	,	O	2	P
9	but	but	O	CC	O	2	VMOD
10	did	do	B-VP	VBD	O	2	VMOD
11	lower	low	B-ADVP	JJR	O	14	NMOD
12	the	the	B-NP	DT	O	14	NMOD
13	mortality	mortality	I-NP	NN	O	14	NMOD
14	rate	rate	I-NP	NN	O	10	OBJ
15	at	at	B-PP	IN	O	10	VMOD
16	most	most	B-NP	JJS	O	17	NMOD
17	doses	dose	I-NP	NNS	O	15	PMOD
18	tested	test	B-VP	VBN	O	17	NMOD
19	.	.	O	.	O	2	P

1	Haloperidol	Haloperidol	B-NP	NN	O	2	SUB
2	decreased	decrease	B-VP	VBD	O	22	VMOD
3	the	the	B-NP	DT	O	4	NMOD
4	incidence	incidence	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	cocaine	cocaine	B-NP	NN	O	8	NMOD
7	induced	induce	I-NP	VBN	O	8	NMOD
8	seizures	seizure	I-NP	NNS	O	5	PMOD
9	at	at	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	13	NMOD
11	two	two	I-NP	CD	O	13	NMOD
12	highest	high	I-NP	JJS	O	13	NMOD
13	doses	dose	I-NP	NNS	O	9	PMOD
14	,	,	O	,	O	22	P
15	but	but	O	CC	O	22	VMOD
16	the	the	B-NP	DT	O	17	NMOD
17	lowering	lowering	I-NP	NN	O	22	SUB
18	of	of	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	21	NMOD
20	mortality	mortality	I-NP	NN	O	21	NMOD
21	rate	rate	I-NP	NN	O	18	PMOD
22	did	do	B-VP	VBD	O	0	ROOT
23	not	not	I-VP	RB	O	22	VMOD
24	reach	reach	I-VP	VB	O	22	VC
25	statistical	statistical	B-NP	JJ	O	26	NMOD
26	significance	significance	I-NP	NN	O	24	OBJ
27	at	at	B-PP	IN	O	24	VMOD
28	any	any	B-NP	DT	O	29	NMOD
29	dose	dose	I-NP	NN	O	27	PMOD
30	.	.	O	.	O	22	P

1	These	These	B-NP	DT	O	2	NMOD
2	data	datum	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	a	a	B-NP	DT	O	6	NMOD
5	protective	protective	I-NP	JJ	O	6	NMOD
6	role	role	I-NP	NN	O	3	OBJ
7	for	for	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	12	NMOD
9	central	central	I-NP	JJ	O	12	NMOD
10	dopamine	dopamine	I-NP	NN	O	12	NMOD
11	blocker	blocker	I-NP	NN	O	12	NMOD
12	haloperidol	haloperidol	I-NP	NN	O	7	PMOD
13	against	against	B-PP	IN	O	12	NMOD
14	death	death	B-NP	NN	O	13	PMOD
15	from	from	B-PP	IN	O	14	NMOD
16	high-dose	high-dose	B-NP	JJ	O	18	NMOD
17	amphetamine	amphetamine	I-NP	NN	O	18	NMOD
18	exposure	exposure	I-NP	NN	O	15	PMOD
19	without	without	B-PP	IN	O	3	VMOD
20	reducing	reduce	B-VP	VBG	O	19	PMOD
21	the	the	B-NP	DT	O	22	NMOD
22	incidence	incidence	I-NP	NN	O	20	OBJ
23	of	of	B-PP	IN	O	22	NMOD
24	seizures	seizure	B-NP	NNS	O	23	PMOD
25	.	.	O	.	O	3	P

1	Autoradiographic	Autoradiographic	B-NP	JJ	O	2	NMOD
2	evidence	evidence	I-NP	NN	O	11	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	estrogen	estrogen	B-NP	NN	B-DNA	6	NMOD
5	binding	binding	I-NP	NN	I-DNA	6	NMOD
6	sites	site	I-NP	NNS	I-DNA	3	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	nuclei	nucleus	B-NP	NNS	O	7	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	diethylstilbesterol	diethylstilbesterol	B-NP	NN	O	9	PMOD
11	induced	induce	B-VP	VBD	O	0	ROOT
12	hamster	hamster	B-NP	NN	O	14	NMOD
13	renal	renal	I-NP	JJ	O	14	NMOD
14	carcinomas	carcinoma	I-NP	NNS	O	11	OBJ
15	.	.	O	.	O	11	P

1	Estrogen	Estrogen	B-NP	NN	B-DNA	3	NMOD
2	binding	binding	I-NP	NN	I-DNA	3	NMOD
3	sites	site	I-NP	NNS	I-DNA	4	SUB
4	were	be	B-VP	VBD	O	0	ROOT
5	demonstrated	demonstrate	I-VP	VBN	O	4	VC
6	by	by	B-PP	IN	O	5	VMOD
7	autoradiography	autoradiography	B-NP	NN	O	6	PMOD
8	in	in	B-PP	IN	O	5	VMOD
9	one	one	B-NP	CD	O	15	SUB
10	transplantable	transplantable	I-NP	JJ	O	9	NMOD
11	and	and	O	CC	O	15	VMOD
12	five	five	B-NP	CD	O	14	NMOD
13	primary	primary	I-NP	JJ	O	14	NMOD
14	diethylstilbesterol	diethylstilbesterol	I-NP	NN	O	15	SUB
15	induced	induce	B-VP	VBD	O	8	SBAR
16	renal	renal	B-NP	JJ	O	17	NMOD
17	carcinomas	carcinoma	I-NP	NNS	O	15	OBJ
18	in	in	B-PP	IN	O	17	NMOD
19	three	three	B-NP	CD	O	20	NMOD
20	hamsters	hamster	I-NP	NNS	O	18	PMOD
21	.	.	O	.	O	4	P

1	Radiolabelling	Radiolabelling	B-NP	NN	O	13	SUB
2	,	,	O	,	O	1	P
3	following	follow	B-PP	VBG	O	1	NMOD
4	the	the	B-NP	DT	O	7	NMOD
5	in	in	I-NP	FW	O	6	AMOD
6	vivo	vivo	I-NP	FW	O	7	NMOD
7	injection	injection	I-NP	NN	O	3	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	3H-17	3H-17	B-NP	NN	O	11	NMOD
10	beta	beta	I-NP	NN	O	11	NMOD
11	estradiol	estradiol	I-NP	NN	O	8	PMOD
12	,	,	O	,	O	1	P
13	was	be	B-VP	VBD	O	25	VMOD
14	increased	increase	I-VP	VBN	O	13	VC
15	only	only	B-ADVP	RB	O	16	PMOD
16	over	over	B-PP	IN	O	14	VMOD
17	the	the	B-NP	DT	O	18	NMOD
18	nuclei	nucleus	I-NP	NNS	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	tumor	tumor	B-NP	NN	B-cell_type	21	NMOD
21	cells	cell	I-NP	NNS	I-cell_type	19	PMOD
22	;	;	O	:	O	25	P
23	stereologic	stereologic	B-NP	JJ	O	24	NMOD
24	analysis	analysis	I-NP	NN	O	25	SUB
25	revealed	reveal	B-VP	VBD	O	0	ROOT
26	a	a	B-NP	DT	O	31	NMOD
27	4.5-	4.5-	I-NP	CD	O	29	AMOD
28	to	to	B-PP	TO	O	29	AMOD
29	6.7-times	6.7-time	B-NP	NNS	O	31	NMOD
30	higher	high	I-NP	JJR	O	31	NMOD
31	concentration	concentration	I-NP	NN	O	25	OBJ
32	of	of	B-PP	IN	O	31	NMOD
33	reduced	reduce	B-NP	VBN	O	35	NMOD
34	silver	silver	I-NP	NN	O	35	NMOD
35	grains	grain	I-NP	NNS	O	32	PMOD
36	over	over	B-PP	IN	O	25	VMOD
37	nuclei	nucleus	B-NP	NNS	O	36	PMOD
38	than	than	B-PP	IN	O	25	VMOD
39	cytoplasm	cytoplasm	B-NP	NN	O	38	PMOD
40	of	of	B-PP	IN	O	39	NMOD
41	these	these	B-NP	DT	O	42	NMOD
42	cells	cell	I-NP	NNS	O	40	PMOD
43	.	.	O	.	O	25	P

1	Bradycardia	Bradycardia	B-NP	NNP	O	0	ROOT
2	due	due	B-ADJP	JJ	O	1	NMOD
3	to	to	B-VP	TO	O	4	VMOD
4	biperiden	biperiden	I-VP	VB	O	2	AMOD
5	.	.	O	.	O	1	P

1	In	In	B-PP	IN	O	21	VMOD
2	a	a	B-NP	DT	O	5	NMOD
3	38-year-old	38-year-old	I-NP	JJ	O	5	NMOD
4	male	male	I-NP	JJ	O	5	NMOD
5	patient	patient	I-NP	NN	O	1	PMOD
6	suffering	suffer	B-VP	VBG	O	5	NMOD
7	from	from	B-PP	IN	O	6	VMOD
8	a	a	B-NP	DT	O	12	NMOD
9	severe	severe	I-NP	JJ	O	12	NMOD
10	postzosteric	postzosteric	I-NP	JJ	O	12	NMOD
11	trigeminal	trigeminal	I-NP	JJ	O	12	NMOD
12	neuralgia	neuralgia	I-NP	NN	O	7	PMOD
13	,	,	O	,	O	21	P
14	intravenous	intravenous	B-NP	JJ	O	15	NMOD
15	application	application	I-NP	NN	O	21	SUB
16	of	of	B-PP	IN	O	15	NMOD
17	10	10	B-NP	CD	O	18	AMOD
18	mg	mg	I-NP	NN	O	20	NMOD
19	biperiden	biperiden	I-NP	JJ	O	20	NMOD
20	lactate	lactate	I-NP	NN	O	16	PMOD
21	led	lead	B-VP	VBD	O	0	ROOT
22	to	to	B-PP	TO	O	21	VMOD
23	a	a	B-NP	DT	O	26	NMOD
24	long-lasting	long-lasting	I-NP	JJ	O	26	NMOD
25	paradoxical	paradoxical	I-NP	JJ	O	26	NMOD
26	reaction	reaction	I-NP	NN	O	22	PMOD
27	characterized	characterize	B-VP	VBN	O	26	NMOD
28	by	by	B-PP	IN	O	27	VMOD
29	considerable	considerable	B-NP	JJ	O	30	NMOD
30	bradycardia	bradycardia	I-NP	NN	O	35	NMOD
31	,	,	O	,	O	35	P
32	dysarthria	dysarthria	B-NP	NN	O	35	NMOD
33	,	,	O	,	O	35	P
34	and	and	O	CC	O	35	NMOD
35	dysphagia	dysphagia	B-NP	NN	O	28	PMOD
36	.	.	O	.	O	21	P

1	Deliberate	Deliberate	B-NP	JJ	O	2	NMOD
2	hypotension	hypotension	I-NP	NN	O	0	ROOT
3	induced	induce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	labetalol	labetalol	B-NP	NN	O	4	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	halothane	halothane	B-NP	NN	O	11	NMOD
8	,	,	I-NP	,	O	11	P
9	enflurane	enflurane	I-NP	NN	O	11	NMOD
10	or	or	I-NP	CC	O	11	NMOD
11	isoflurane	isoflurane	I-NP	NN	O	6	PMOD
12	for	for	B-PP	IN	O	11	NMOD
13	middle-ear	middle-ear	B-NP	JJ	O	14	NMOD
14	surgery	surgery	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	feasibility	feasibility	I-NP	NN	O	30	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	using	use	B-VP	VBG	O	3	PMOD
5	labetalol	labetalol	B-NP	NN	O	12	NMOD
6	,	,	O	,	O	12	P
7	an	an	B-NP	DT	O	12	NMOD
8	alpha-	alpha-	I-NP	NN	O	12	NMOD
9	and	and	I-NP	CC	O	12	NMOD
10	beta-adrenergic	beta-adrenergic	I-NP	JJ	O	12	NMOD
11	blocking	block	I-NP	VBG	O	12	NMOD
12	agent	agent	I-NP	NN	O	4	OBJ
13	,	,	O	,	O	2	P
14	as	as	B-PP	IN	O	2	NMOD
15	a	a	B-NP	DT	O	17	NMOD
16	hypotensive	hypotensive	I-NP	JJ	O	17	NMOD
17	agent	agent	I-NP	NN	O	14	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	combination	combination	B-NP	NN	O	18	PMOD
20	with	with	B-PP	IN	O	19	NMOD
21	inhalation	inhalation	B-NP	NN	O	22	NMOD
22	anaesthetics	anaesthetic	I-NP	NNS	O	20	PMOD
23	(	(	O	(	O	29	DEP
24	halothane	halothane	B-NP	NN	O	28	NMOD
25	,	,	O	,	O	28	P
26	enflurane	enflurane	B-NP	NN	O	28	NMOD
27	or	or	O	CC	O	28	NMOD
28	isoflurane	isoflurane	B-NP	NN	O	29	DEP
29	)	)	O	)	O	22	NMOD
30	was	be	B-VP	VBD	O	0	ROOT
31	studied	study	I-VP	VBN	O	30	VC
32	in	in	B-PP	IN	O	31	VMOD
33	23	23	B-NP	CD	O	35	NMOD
34	adult	adult	I-NP	JJ	O	35	NMOD
35	patients	patient	I-NP	NNS	O	32	PMOD
36	undergoing	undergo	B-VP	VBG	O	35	NMOD
37	middle-ear	middle-ear	B-NP	JJ	O	38	NMOD
38	surgery	surgery	I-NP	NN	O	36	OBJ
39	.	.	O	.	O	30	P

1	The	The	B-NP	DT	O	4	NMOD
2	mean	mean	I-NP	JJ	O	4	NMOD
3	H	H	I-NP	NN	O	4	NMOD
4	concentration	concentration	I-NP	NN	O	11	SUB
5	during	during	B-PP	IN	O	4	NMOD
6	hypotension	hypotension	B-NP	NN	O	5	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	10	NMOD
9	inspiratory	inspiratory	I-NP	JJ	O	10	NMOD
10	gas	gas	I-NP	NN	O	7	PMOD
11	was	be	B-VP	VBD	O	0	ROOT
12	0.7	0.7	B-NP	CD	O	14	AMOD
13	+/-	+/-	I-NP	SYM	O	14	AMOD
14	0.1	0.1	I-NP	CD	O	16	NMOD
15	vol	vol	I-NP	NN	O	16	NMOD
16	%	%	I-NP	NN	O	11	PRD
17	,	,	O	,	O	11	P
18	the	the	B-NP	DT	O	21	NMOD
19	mean	mean	I-NP	JJ	O	21	NMOD
20	E	E	I-NP	NN	O	21	NMOD
21	concentration	concentration	I-NP	NN	O	26	NMOD
22	1.6	1.6	I-NP	CD	O	24	AMOD
23	+/-	+/-	I-NP	SYM	O	24	AMOD
24	0.2	0.2	I-NP	CD	O	26	NMOD
25	vol	vol	I-NP	NN	O	26	NMOD
26	%	%	I-NP	NN	O	32	NMOD
27	,	,	O	,	O	32	P
28	and	and	O	CC	O	32	NMOD
29	the	the	B-NP	DT	O	32	NMOD
30	mean	mean	I-NP	JJ	O	32	NMOD
31	I	I	I-NP	CD	O	32	NMOD
32	concentration	concentration	I-NP	NN	O	37	NMOD
33	1.0	1.0	B-NP	CD	O	35	AMOD
34	+/-	+/-	I-NP	SYM	O	35	AMOD
35	0.1	0.1	I-NP	CD	O	37	NMOD
36	vol	vol	I-NP	NN	O	37	NMOD
37	%	%	I-NP	NN	O	11	VMOD
38	.	.	O	.	O	11	P

1	During	During	B-PP	IN	O	8	VMOD
2	hypotension	hypotension	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	8	P
4	the	the	B-NP	DT	O	7	NMOD
5	serum	serum	I-NP	NN	O	7	NMOD
6	creatinine	creatinine	I-NP	NN	O	7	NMOD
7	concentration	concentration	I-NP	NN	O	8	SUB
8	rose	rise	B-VP	VBD	O	0	ROOT
9	significantly	significantly	B-ADVP	RB	O	8	VMOD
10	in	in	B-PP	IN	O	8	VMOD
11	all	all	B-NP	DT	O	12	NMOD
12	groups	group	I-NP	NNS	O	10	PMOD
13	from	from	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	values	value	I-NP	NNS	O	13	PMOD
16	before	before	B-PP	IN	O	8	VMOD
17	hypotension	hypotension	B-NP	NN	O	16	PMOD
18	and	and	O	CC	O	8	VMOD
19	returned	return	B-VP	VBD	O	8	VMOD
20	postoperatively	postoperatively	B-ADVP	RB	O	19	VMOD
21	to	to	B-PP	TO	O	19	VMOD
22	the	the	B-NP	DT	O	24	NMOD
23	initial	initial	I-NP	JJ	O	24	NMOD
24	level	level	I-NP	NN	O	21	PMOD
25	in	in	B-PP	IN	O	24	NMOD
26	the	the	B-NP	DT	O	28	NMOD
27	other	other	I-NP	JJ	O	28	NMOD
28	groups	group	I-NP	NNS	O	25	PMOD
29	,	,	O	,	O	8	P
30	except	except	B-PP	IN	O	8	VMOD
31	the	the	B-NP	DT	O	33	NMOD
32	isoflurane	isoflurane	I-NP	NN	O	33	NMOD
33	group	group	I-NP	NN	O	30	PMOD
34	.	.	O	.	O	8	P

1	Convulsion	Convulsion	B-NP	NN	O	0	ROOT
2	following	follow	B-PP	VBG	O	1	NMOD
3	intravenous	intravenous	B-NP	JJ	O	5	NMOD
4	fluorescein	fluorescein	I-NP	NN	O	5	NMOD
5	angiography	angiography	I-NP	NN	O	2	PMOD
6	.	.	O	.	O	1	P

1	Tonic-clonic	Tonic-clonic	B-NP	JJ	O	2	NMOD
2	seizures	seizure	I-NP	NNS	O	3	SUB
3	followed	follow	B-VP	VBD	O	0	ROOT
4	intravenous	intravenous	B-NP	JJ	O	6	NMOD
5	fluorescein	fluorescein	I-NP	NN	O	6	NMOD
6	injection	injection	I-NP	NN	O	3	OBJ
7	for	for	B-PP	IN	O	6	NMOD
8	fundus	fundus	B-NP	NN	O	9	NMOD
9	angiography	angiography	I-NP	NN	O	7	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	a	a	B-NP	DT	O	13	NMOD
12	47-year-old	47-year-old	I-NP	JJ	O	13	NMOD
13	male	male	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	3	P

1	ACC-9653	ACC-9653	B-NP	NN	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	phenytoin	phenytoin	I-NP	NN	O	4	NMOD
4	sodium	sodium	I-NP	NN	O	5	SUB
5	have	have	B-VP	VBP	O	0	ROOT
6	equivalent	equivalent	B-NP	JJ	O	8	NMOD
7	anticonvulsant	anticonvulsant	I-NP	JJ	O	8	NMOD
8	activity	activity	I-NP	NN	O	5	OBJ
9	against	against	B-PP	IN	O	8	NMOD
10	seizures	seizure	B-NP	NNS	O	9	PMOD
11	induced	induce	B-VP	VBN	O	10	NMOD
12	by	by	B-PP	IN	O	11	VMOD
13	maximal	maximal	B-NP	JJ	O	14	NMOD
14	electroshock	electroshock	I-NP	NN	O	12	PMOD
15	(	(	O	(	O	17	DEP
16	MES	MES	B-NP	NN	B-protein	17	DEP
17	)	)	O	)	O	14	NMOD
18	in	in	B-PP	IN	O	14	NMOD
19	mice	mouse	B-NP	NNS	O	18	PMOD
20	following	follow	B-PP	VBG	O	19	NMOD
21	i.p.	i.p.	B-NP	JJ	O	27	NMOD
22	,	,	I-NP	,	O	27	P
23	oral	oral	I-NP	JJ	O	27	NMOD
24	,	,	O	,	O	27	P
25	or	or	O	CC	O	27	NMOD
26	i.v.	i.v.	B-NP	JJ	O	27	NMOD
27	administration	administration	I-NP	NN	O	20	PMOD
28	.	.	O	.	O	5	P

1	ACC-9653	ACC-9653	B-NP	NN	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	phenytoin	phenytoin	I-NP	NN	O	4	NMOD
4	sodium	sodium	I-NP	NN	O	5	SUB
5	have	have	B-VP	VBP	O	0	ROOT
6	similar	similar	B-NP	JJ	O	8	NMOD
7	antiarrhythmic	antiarrhythmic	I-NP	JJ	O	8	NMOD
8	activity	activity	I-NP	NN	O	5	OBJ
9	against	against	B-PP	IN	O	5	VMOD
10	ouabain	ouabain	B-NP	NN	O	13	NMOD
11	induced	induce	B-VP	VBD	O	10	AMOD
12	ventricular	ventricular	B-NP	JJ	O	13	NMOD
13	tachycardia	tachycardia	I-NP	NN	O	9	PMOD
14	in	in	B-PP	IN	O	5	VMOD
15	anesthetized	anesthetize	B-NP	VBN	O	16	NMOD
16	dogs	dog	I-NP	NNS	O	14	PMOD
17	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	3	NMOD
2	total	total	I-NP	JJ	O	3	NMOD
3	doses	dose	I-NP	NNS	O	19	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	ACC-9653	ACC-9653	B-NP	NN	O	8	NMOD
6	or	or	I-NP	CC	O	8	NMOD
7	phenytoin	phenytoin	I-NP	NN	O	8	NMOD
8	sodium	sodium	I-NP	NN	O	4	PMOD
9	necessary	necessary	B-ADJP	JJ	O	8	NMOD
10	to	to	B-VP	TO	O	11	VMOD
11	convert	convert	I-VP	VB	O	9	AMOD
12	the	the	B-NP	DT	O	13	NMOD
13	arrhythmia	arrhythmia	I-NP	NN	O	11	OBJ
14	to	to	B-PP	TO	O	11	VMOD
15	a	a	B-NP	DT	O	18	NMOD
16	normal	normal	I-NP	JJ	O	18	NMOD
17	sinus	sinus	I-NP	NN	O	18	NMOD
18	rhythm	rhythm	I-NP	NN	O	14	PMOD
19	were	be	B-VP	VBD	O	0	ROOT
20	24	24	B-NP	CD	O	22	AMOD
21	+/-	+/-	I-NP	SYM	O	22	AMOD
22	6	6	I-NP	CD	O	27	NMOD
23	and	and	I-NP	CC	O	27	NMOD
24	14	14	I-NP	CD	O	26	AMOD
25	+/-	+/-	I-NP	SYM	O	26	AMOD
26	3	3	I-NP	CD	O	27	NMOD
27	mg/kg	mg/kg	I-NP	NN	O	19	PRD
28	,	,	O	,	O	27	P
29	respectively	respectively	B-ADVP	RB	O	27	NMOD
30	.	.	O	.	O	19	P

1	Only	Only	B-NP	RB	O	3	NMOD
2	phenytoin	phenytoin	I-NP	NN	O	3	NMOD
3	sodium	sodium	I-NP	NN	O	4	SUB
4	displayed	display	B-VP	VBD	O	0	ROOT
5	in	in	B-NP	FW	O	6	AMOD
6	vitro	vitro	I-NP	FW	O	7	AMOD
7	antiarrhythmic	antiarrhythmic	I-NP	JJ	O	8	NMOD
8	activity	activity	I-NP	NN	O	4	OBJ
9	against	against	B-PP	IN	O	4	VMOD
10	strophanthidin	strophanthidin	B-NP	NN	B-protein	12	NMOD
11	induced	induce	I-NP	VBN	O	12	NMOD
12	arrhythmias	arrhythmia	I-NP	NNS	O	9	PMOD
13	in	in	B-PP	IN	O	4	VMOD
14	guinea	guinea	B-NP	NN	O	17	NMOD
15	pig	pig	I-NP	NN	O	17	NMOD
16	right	right	I-NP	JJ	O	17	NMOD
17	atria	atria	I-NP	NN	O	13	PMOD
18	.	.	O	.	O	4	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	toxicity	toxicity	I-NP	NN	O	3	NMOD
3	studies	study	I-NP	NNS	O	9	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	ACC-9653	ACC-9653	B-NP	NN	O	8	NMOD
6	and	and	I-NP	CC	O	8	NMOD
7	phenytoin	phenytoin	I-NP	NN	O	8	NMOD
8	sodium	sodium	I-NP	NN	O	4	PMOD
9	were	be	B-VP	VBD	O	0	ROOT
10	carried	carry	I-VP	VBN	O	9	VC
11	out	out	B-PRT	RP	O	10	VMOD
12	in	in	B-PP	IN	O	10	VMOD
13	mice	mouse	B-NP	NNS	O	20	NMOD
14	,	,	O	,	O	20	P
15	rats	rat	B-NP	NNS	O	20	NMOD
16	,	,	O	,	O	20	P
17	rabbits	rabbit	B-NP	NNS	O	20	NMOD
18	,	,	O	,	O	20	P
19	and	and	O	CC	O	20	NMOD
20	dogs	dog	B-NP	NNS	O	12	PMOD
21	by	by	B-PP	IN	O	10	VMOD
22	i.v.	i.v.	B-NP	JJ	O	28	NMOD
23	,	,	I-NP	,	O	28	P
24	i.m.	i.m.	I-NP	JJ	O	28	NMOD
25	,	,	O	,	O	28	P
26	and	and	O	CC	O	28	NMOD
27	i.p.	i.p.	B-NP	JJ	O	28	NMOD
28	routes	route	I-NP	NNS	O	21	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	administration	administration	B-NP	NN	O	29	PMOD
31	.	.	O	.	O	9	P

1	Phenytoin	Phenytoin	B-NP	NN	B-protein	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	fatal	fatal	B-NP	JJ	O	5	NMOD
4	hepatic	hepatic	I-NP	JJ	O	5	NMOD
5	injury	injury	I-NP	NN	O	2	OBJ
6	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	5	NMOD
2	61	61	I-NP	CD	O	5	NMOD
3	year	year	I-NP	NN	O	5	NMOD
4	old	old	I-NP	JJ	O	5	NMOD
5	female	female	I-NP	NN	O	6	SUB
6	developed	develop	B-VP	VBD	O	0	ROOT
7	fatal	fatal	B-NP	JJ	O	8	AMOD
8	hepatic	hepatic	I-NP	JJ	O	9	NMOD
9	failure	failure	I-NP	NN	O	6	OBJ
10	after	after	B-PP	IN	O	9	NMOD
11	phenytoin	phenytoin	B-NP	NN	O	12	NMOD
12	administration	administration	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	6	P

1	Support	Support	B-NP	NN	O	9	NMOD
2	for	for	B-PP	IN	O	1	NMOD
3	adrenaline-hypertension	adrenaline-hypertension	B-NP	NN	O	4	NMOD
4	hypothesis	hypothesis	I-NP	NN	O	2	PMOD
5	:	:	O	:	O	1	P
6	18	18	B-NP	CD	O	9	NMOD
7	hour	hour	I-NP	NN	O	9	NMOD
8	pressor	pressor	I-NP	NN	O	9	NMOD
9	effect	effect	I-NP	NN	O	0	ROOT
10	after	after	B-PP	IN	O	9	NMOD
11	6	6	B-NP	CD	O	14	NMOD
12	hours	hour	I-NP	NNS	O	14	NMOD
13	adrenaline	adrenaline	I-NP	NN	O	14	NMOD
14	infusion	infusion	I-NP	NN	O	10	PMOD
15	.	.	O	.	O	9	P

1	Effect	Effect	B-NP	NN	O	6	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	alkylxanthines	alkylxanthine	B-NP	NNS	O	2	PMOD
4	on	on	B-PP	IN	O	1	NMOD
5	gentamicin	gentamicin	B-NP	NN	O	4	PMOD
6	induced	induce	B-VP	VBD	O	0	ROOT
7	acute	acute	B-NP	JJ	O	9	NMOD
8	renal	renal	I-NP	JJ	O	9	NMOD
9	failure	failure	I-NP	NN	O	6	OBJ
10	in	in	B-PP	IN	O	6	VMOD
11	the	the	B-NP	DT	O	12	NMOD
12	rat	rat	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	6	P

1	Adenosine	Adenosine	B-NP	NN	O	2	NMOD
2	antagonists	antagonist	I-NP	NNS	O	3	SUB
3	have	have	B-VP	VBP	O	0	ROOT
4	been	be	I-VP	VBN	O	3	VC
5	previously	previously	I-VP	RB	O	4	VMOD
6	shown	show	I-VP	VBN	O	4	VC
7	to	to	I-VP	TO	O	8	VMOD
8	be	be	I-VP	VB	O	6	VMOD
9	of	of	B-PP	IN	O	8	PRD
10	benefit	benefit	B-NP	NN	O	9	PMOD
11	in	in	B-PP	IN	O	8	VMOD
12	some	some	B-NP	DT	O	16	NMOD
13	ischaemic	ischaemic	I-NP	JJ	O	16	NMOD
14	and	and	I-NP	CC	O	16	NMOD
15	nephrotoxic	nephrotoxic	I-NP	JJ	O	16	NMOD
16	models	model	I-NP	NNS	O	11	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	acute	acute	B-NP	JJ	O	20	NMOD
19	renal	renal	I-NP	JJ	O	20	NMOD
20	failure	failure	I-NP	NN	O	17	PMOD
21	(	(	O	(	O	23	DEP
22	ARF	ARF	B-NP	NN	B-protein	23	DEP
23	)	)	O	)	O	20	NMOD
24	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	23	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	present	present	I-NP	JJ	O	4	NMOD
4	study	study	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	23	P
6	the	the	B-NP	DT	O	7	NMOD
7	effects	effect	I-NP	NNS	O	23	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	three	three	B-NP	CD	O	10	NMOD
10	alkylxanthines	alkylxanthine	I-NP	NNS	O	8	PMOD
11	with	with	B-PP	IN	O	7	NMOD
12	different	different	B-NP	JJ	O	13	NMOD
13	potencies	potency	I-NP	NNS	O	11	PMOD
14	as	as	B-PP	IN	O	7	NMOD
15	adenosine	adenosine	B-NP	NN	B-cell_line	16	NMOD
16	antagonists	antagonist	I-NP	NNS	I-cell_line	21	NMOD
17	8-phenyltheophylline	8-phenyltheophylline	I-NP	NN	I-cell_line	21	NMOD
18	,	,	I-NP	,	O	21	P
19	theophylline	theophylline	I-NP	NN	O	21	NMOD
20	and	and	I-NP	CC	O	21	NMOD
21	enprofylline	enprofylline	I-NP	NN	O	14	PMOD
22	,	,	O	,	O	23	P
23	were	be	B-VP	VBD	O	0	ROOT
24	examined	examine	I-VP	VBN	O	23	VC
25	in	in	B-PP	IN	O	24	VMOD
26	rats	rat	B-NP	NNS	O	25	PMOD
27	developing	develop	B-VP	VBG	O	26	NMOD
28	acute	acute	B-NP	JJ	O	30	NMOD
29	renal	renal	I-NP	JJ	O	30	NMOD
30	failure	failure	I-NP	NN	O	27	OBJ
31	after	after	B-PP	IN	O	27	VMOD
32	4	4	B-NP	CD	O	34	NMOD
33	daily	daily	I-NP	JJ	O	34	NMOD
34	injections	injection	I-NP	NNS	O	31	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	gentamicin	gentamicin	B-NP	NN	O	35	PMOD
37	(	(	O	(	O	41	DEP
38	200	200	B-NP	CD	O	39	AMOD
39	mg	mg	I-NP	NN	O	40	NMOD
40	kg-1	kg-1	I-NP	NN	O	41	DEP
41	)	)	O	)	O	36	NMOD
42	.	.	O	.	O	23	P

1	Renal	Renal	B-NP	JJ	O	2	NMOD
2	function	function	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	assessed	assess	I-VP	VBN	O	3	VC
5	by	by	B-PP	IN	O	4	VMOD
6	biochemical	biochemical	B-NP	JJ	O	32	AMOD
7	(	(	O	(	O	12	DEP
8	plasma	plasma	B-NP	NN	O	9	NMOD
9	urea	urea	I-NP	NN	O	11	NMOD
10	and	and	O	CC	O	11	NMOD
11	creatinine	creatinine	B-NP	NN	O	12	DEP
12	)	)	O	)	O	6	NMOD
13	,	,	O	,	O	32	P
14	functional	functional	B-ADJP	JJ	O	32	AMOD
15	(	(	O	(	O	30	DEP
16	urine	urine	B-NP	NN	O	17	NMOD
17	analysis	analysis	I-NP	NN	O	22	NMOD
18	and	and	O	CC	O	22	NMOD
19	[	[	B-NP	(	O	21	DEP
20	3H	3H	I-NP	NN	O	21	DEP
21	]	]	I-NP	)	O	22	NMOD
22	inulin	inulin	I-NP	NN	O	29	NMOD
23	and	and	O	CC	O	29	NMOD
24	[	[	B-NP	(	O	26	DEP
25	14C	14C	I-NP	NN	O	26	DEP
26	]	]	I-NP	)	O	29	NMOD
27	p-aminohippuric	p-aminohippuric	I-NP	JJ	O	29	NMOD
28	acid	acid	I-NP	NN	O	29	NMOD
29	clearances	clearance	I-NP	NNS	O	30	DEP
30	)	)	O	)	O	14	NMOD
31	and	and	O	CC	O	32	AMOD
32	morphological	morphological	B-NP	JJ	O	5	PMOD
33	(	(	O	(	O	37	DEP
34	degree	degree	B-NP	NN	O	37	DEP
35	of	of	B-PP	IN	O	34	NMOD
36	necrosis	necrosis	B-NP	NN	O	35	PMOD
37	)	)	O	)	O	32	AMOD
38	indices	index	B-NP	NNS	O	32	NMOD
39	.	.	O	.	O	3	P

1	A	A	B-NP	DT	O	2	NMOD
2	total	total	I-NP	NN	O	8	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	261	261	B-NP	CD	O	7	NMOD
5	adverse	adverse	I-NP	JJ	O	6	AMOD
6	ocular	ocular	I-NP	JJ	O	7	NMOD
7	reactions	reaction	I-NP	NNS	O	3	PMOD
8	occurred	occur	B-VP	VBD	O	0	ROOT
9	in	in	B-PP	IN	O	8	VMOD
10	237	237	B-NP	CD	O	11	NMOD
11	patients	patient	I-NP	NNS	O	9	PMOD
12	who	who	B-NP	WP	O	11	NMOD
13	received	receive	B-VP	VBD	O	12	SBAR
14	isotretinoin	isotretinoin	B-NP	NN	O	13	OBJ
15	,	,	O	,	O	8	P
16	a	a	B-NP	DT	O	19	NMOD
17	commonly	commonly	I-NP	RB	O	18	AMOD
18	used	use	I-NP	VBN	O	19	NMOD
19	drug	drug	I-NP	NN	O	8	VMOD
20	in	in	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	22	NMOD
22	treatment	treatment	I-NP	NN	O	20	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	severe	severe	B-NP	JJ	O	26	NMOD
25	cystic	cystic	I-NP	JJ	O	26	NMOD
26	acne	acne	I-NP	NN	O	23	PMOD
27	.	.	O	.	O	8	P

1	Procaterol	Procaterol	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	terbutaline	terbutaline	I-NP	NN	O	0	ROOT
4	in	in	B-PP	IN	O	3	NMOD
5	bronchial	bronchial	B-NP	JJ	O	6	NMOD
6	asthma	asthma	I-NP	NN	O	4	PMOD
7	.	.	O	.	O	3	P

1	Procaterol	Procaterol	B-NP	NNP	O	7	NMOD
2	,	,	O	,	O	7	P
3	a	a	B-NP	DT	O	7	NMOD
4	new	new	I-NP	JJ	O	7	NMOD
5	beta-2	beta-2	I-NP	NN	O	7	NMOD
6	adrenoceptor	adrenoceptor	I-NP	NN	O	7	NMOD
7	stimulant	stimulant	I-NP	NN	O	9	SUB
8	,	,	O	,	O	7	P
9	was	be	B-VP	VBD	O	0	ROOT
10	studied	study	I-VP	VBN	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	a	a	B-NP	DT	O	18	NMOD
13	double-blind	double-blind	I-NP	JJ	O	17	AMOD
14	,	,	I-NP	,	O	17	P
15	placebo-controlled	placebo-controlled	I-NP	JJ	O	17	AMOD
16	,	,	I-NP	,	O	17	P
17	cross-over	cross-over	I-NP	JJ	O	18	NMOD
18	trial	trial	I-NP	NN	O	11	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	patients	patient	B-NP	NNS	O	19	PMOD
21	with	with	B-PP	IN	O	20	NMOD
22	bronchial	bronchial	B-NP	JJ	O	23	NMOD
23	asthma	asthma	I-NP	NN	O	21	PMOD
24	.	.	O	.	O	9	P

1	Both	Both	O	CC	O	5	NMOD
2	anti-asthmatic	anti-asthmatic	B-NP	JJ	O	5	NMOD
3	and	and	I-NP	CC	O	5	NMOD
4	tremorgenic	tremorgenic	I-NP	JJ	O	5	NMOD
5	effects	effect	I-NP	NNS	O	8	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	procaterol	procaterol	B-NP	NN	O	6	PMOD
8	were	be	B-VP	VBD	O	0	ROOT
9	dose-related	dose-related	B-ADJP	JJ	O	8	PRD
10	.	.	O	.	O	8	P

1	Subacute	Subacute	B-NP	JJ	O	2	NMOD
2	effects	effect	I-NP	NNS	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	propranolol	propranolol	B-NP	NN	O	6	NMOD
5	and	and	O	CC	O	6	NMOD
6	B	B	B-NP	NN	O	3	PMOD
7	24/76	24/76	I-NP	CD	O	6	NMOD
8	on	on	B-PP	IN	O	2	NMOD
9	isoproterenol	isoproterenol	B-NP	NN	O	8	PMOD
10	induced	induce	B-VP	VBD	O	0	ROOT
11	rat	rat	B-NP	NN	O	13	NMOD
12	heart	heart	I-NP	NN	O	13	NMOD
13	hypertrophy	hypertrophy	I-NP	NN	O	10	OBJ
14	in	in	B-PP	IN	O	10	VMOD
15	correlation	correlation	B-NP	NN	O	14	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	blood	blood	B-NP	NN	O	18	NMOD
18	pressure	pressure	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	10	P

1	The	The	B-NP	DT	O	2	NMOD
2	studies	study	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	0	ROOT
4	performed	perform	I-VP	VBN	O	3	VC
5	using	use	B-VP	VBG	O	3	VMOD
6	an	an	B-NP	DT	O	8	NMOD
7	experimental	experimental	I-NP	JJ	O	8	NMOD
8	model	model	I-NP	NN	O	5	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	isoproterenol	isoproterenol	B-NP	NN	O	9	PMOD
11	induced	induce	B-VP	VBD	O	5	VMOD
12	heart	heart	B-NP	NN	O	13	NMOD
13	hypertrophy	hypertrophy	I-NP	NN	O	11	OBJ
14	in	in	B-PP	IN	O	11	VMOD
15	rats	rat	B-NP	NNS	O	14	PMOD
16	.	.	O	.	O	3	P

1	It	It	B-NP	PRP	O	2	SUB
2	was	be	B-VP	VBD	O	20	VMOD
3	possible	possible	B-ADJP	JJ	O	2	PRD
4	to	to	B-VP	TO	O	5	VMOD
5	suppress	suppress	I-VP	VB	O	2	VMOD
6	the	the	B-NP	DT	O	10	NMOD
7	increased	increase	I-NP	VBN	O	10	NMOD
8	ornithine	ornithine	I-NP	NN	B-protein	10	NMOD
9	decarboxylase	decarboxylase	I-NP	NN	I-protein	10	NMOD
10	activity	activity	I-NP	NN	O	5	OBJ
11	with	with	B-PP	IN	O	10	NMOD
12	both	both	B-NP	DT	O	13	NMOD
13	beta-blockers	beta-blocker	I-NP	NNS	O	11	PMOD
14	in	in	B-PP	IN	O	5	VMOD
15	hypertrophied	hypertrophied	B-NP	JJ	O	16	NMOD
16	hearts	heart	I-NP	NNS	O	14	PMOD
17	,	,	O	,	O	20	P
18	but	but	O	CC	O	20	VMOD
19	there	there	B-NP	EX	O	20	SUB
20	was	be	B-VP	VBD	O	0	ROOT
21	no	no	B-NP	DT	O	22	NMOD
22	effect	effect	I-NP	NN	O	20	PRD
23	on	on	B-PP	IN	O	22	NMOD
24	the	the	B-NP	DT	O	26	NMOD
25	heart	heart	I-NP	NN	O	26	NMOD
26	mass	mass	I-NP	NN	O	23	PMOD
27	.	.	O	.	O	20	P

1	Neither	Neither	O	CC	O	4	NMOD
2	propranolol	propranolol	B-NP	NN	O	4	NMOD
3	nor	nor	O	CC	O	4	NMOD
4	B	B	B-NP	NN	B-protein	6	SUB
5	24/76	24/76	I-NP	CD	I-protein	4	NMOD
6	could	could	B-VP	MD	O	0	ROOT
7	stop	stop	I-VP	VB	O	6	VC
8	the	the	B-NP	DT	O	9	NMOD
9	changes	change	I-NP	NNS	O	7	OBJ
10	in	in	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	15	NMOD
12	characteristic	characteristic	I-NP	JJ	O	15	NMOD
13	myosin	myosin	I-NP	NN	O	15	NMOD
14	isoenzyme	isoenzyme	I-NP	NN	O	15	NMOD
15	pattern	pattern	I-NP	NN	O	10	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	20	NMOD
18	hypertrophied	hypertrophied	I-NP	JJ	O	20	NMOD
19	rat	rat	I-NP	NN	O	20	NMOD
20	heart	heart	I-NP	NN	O	16	PMOD
21	.	.	O	.	O	6	P

1	Comparison	Comparison	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	effect	effect	I-NP	NN	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	oxitropium	oxitropium	B-NP	NN	O	7	NMOD
7	bromide	bromide	I-NP	NN	O	5	PMOD
8	and	and	B-PP	CC	O	5	PMOD
9	of	of	B-PP	IN	O	5	PMOD
10	slow-release	slow-release	B-NP	JJ	O	11	NMOD
11	theophylline	theophylline	I-NP	NN	O	9	PMOD
12	on	on	B-PP	IN	O	1	NMOD
13	nocturnal	nocturnal	B-NP	JJ	O	14	NMOD
14	asthma	asthma	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	effects	effect	I-NP	NNS	O	22	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	a	a	B-NP	DT	O	8	NMOD
5	new	new	I-NP	JJ	O	8	NMOD
6	inhaled	inhaled	I-NP	JJ	O	8	NMOD
7	antimuscarinic	antimuscarinic	I-NP	JJ	O	8	NMOD
8	drug	drug	I-NP	NN	O	3	PMOD
9	,	,	O	,	O	22	P
10	oxitropium	oxitropium	B-NP	NN	O	11	NMOD
11	bromide	bromide	I-NP	NN	O	22	SUB
12	,	,	O	,	O	22	P
13	and	and	O	CC	O	22	VMOD
14	of	of	B-PP	IN	O	22	SUB
15	a	a	B-NP	DT	O	18	NMOD
16	slow-release	slow-release	I-NP	JJ	O	18	NMOD
17	theophylline	theophylline	I-NP	NN	O	18	NMOD
18	preparation	preparation	I-NP	NN	O	14	PMOD
19	upon	upon	B-PP	IN	O	14	PMOD
20	nocturnal	nocturnal	B-NP	JJ	O	21	NMOD
21	asthma	asthma	I-NP	NN	O	19	PMOD
22	were	be	B-VP	VBD	O	0	ROOT
23	compared	compare	I-VP	VBN	O	22	VC
24	in	in	B-PP	IN	O	23	VMOD
25	a	a	B-NP	DT	O	28	NMOD
26	placebo-controlled	placebo-controlled	I-NP	JJ	O	28	NMOD
27	double-blind	double-blind	I-NP	JJ	O	28	NMOD
28	study	study	I-NP	NN	O	24	PMOD
29	.	.	O	.	O	22	P

1	No	No	B-NP	DT	O	2	NMOD
2	subject	subject	I-NP	NN	O	3	SUB
3	reported	report	B-VP	VBD	O	0	ROOT
4	side	side	B-NP	JJ	O	5	NMOD
5	effects	effect	I-NP	NNS	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	oxitropium	oxitropium	B-NP	NN	O	6	PMOD
8	,	,	O	,	O	3	P
9	as	as	B-SBAR	IN	O	3	VMOD
10	compared	compare	B-VP	VBN	O	9	SBAR
11	to	to	B-PP	TO	O	10	VMOD
12	three	three	B-NP	CD	O	13	NMOD
13	subjects	subject	I-NP	NNS	O	11	PMOD
14	reporting	report	B-VP	VBG	O	13	NMOD
15	nausea	nausea	B-NP	NN	O	19	NMOD
16	,	,	I-NP	,	O	19	P
17	vomiting	vomiting	I-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	tremors	tremor	I-NP	NNS	O	14	OBJ
20	after	after	B-PP	IN	O	19	NMOD
21	theophylline	theophylline	B-NP	NN	O	20	PMOD
22	.	.	O	.	O	3	P

1	Penicillin	Penicillin	B-NP	NN	O	2	NMOD
2	anaphylaxis	anaphylaxis	I-NP	NN	O	0	ROOT
3	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	oral	oral	B-NP	JJ	O	6	NMOD
5	penicillin	penicillin	I-NP	NN	O	6	NMOD
6	anaphylaxis	anaphylaxis	I-NP	NN	O	3	PMOD
7	is	be	B-VP	VBZ	O	24	NMOD
8	described	describe	I-VP	VBN	O	7	VC
9	,	,	O	,	O	24	P
10	and	and	O	CC	O	24	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	terminology	terminology	I-NP	NN	O	24	NMOD
13	,	,	O	,	O	24	P
14	occurrence	occurrence	B-NP	NN	O	24	NMOD
15	,	,	O	,	O	24	P
16	clinical	clinical	B-NP	JJ	O	17	NMOD
17	manifestations	manifestation	I-NP	NNS	O	24	NMOD
18	,	,	O	,	O	24	P
19	pathogenesis	pathogenesis	B-NP	NN	O	24	NMOD
20	,	,	O	,	O	24	P
21	prevention	prevention	B-NP	NN	O	24	NMOD
22	,	,	O	,	O	24	P
23	and	and	O	CC	O	24	NMOD
24	treatment	treatment	B-NP	NN	O	27	SUB
25	of	of	B-PP	IN	O	24	NMOD
26	anaphylaxis	anaphylaxis	B-NP	NN	O	25	PMOD
27	are	be	B-VP	VBP	O	0	ROOT
28	reviewed	review	I-VP	VBN	O	27	VC
29	.	.	O	.	O	27	P

1	Reversible	Reversible	B-NP	JJ	O	3	NMOD
2	valproic	valproic	I-NP	JJ	O	3	NMOD
3	acid	acid	I-NP	NN	O	5	NMOD
4	induced	induce	B-NP	VBN	O	5	NMOD
5	dementia	dementia	I-NP	NN	O	9	NMOD
6	:	:	O	:	O	5	P
7	a	a	B-NP	DT	O	9	NMOD
8	case	case	I-NP	NN	O	9	NMOD
9	report	report	I-NP	NN	O	0	ROOT
10	.	.	O	.	O	9	P

1	Reversible	Reversible	B-NP	JJ	O	3	NMOD
2	valproic	valproic	I-NP	JJ	O	3	NMOD
3	acid	acid	I-NP	NN	O	5	NMOD
4	induced	induce	B-VP	VBN	O	5	NMOD
5	dementia	dementia	B-NP	NN	O	6	SUB
6	was	be	B-VP	VBD	O	0	ROOT
7	documented	document	I-VP	VBN	O	6	VC
8	in	in	B-PP	IN	O	7	VMOD
9	a	a	B-NP	DT	O	11	NMOD
10	21-year-old	21-year-old	I-NP	JJ	O	11	NMOD
11	man	man	I-NP	NN	O	8	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	epilepsy	epilepsy	B-NP	NN	O	12	PMOD
14	who	who	B-NP	WP	O	11	NMOD
15	had	have	B-VP	VBD	O	14	SBAR
16	a	a	B-NP	DT	O	18	NMOD
17	3-year	3-year	I-NP	JJ	O	18	NMOD
18	history	history	I-NP	NN	O	15	OBJ
19	of	of	B-PP	IN	O	18	NMOD
20	insidious	insidious	B-NP	JJ	O	22	NMOD
21	progressive	progressive	I-NP	JJ	O	22	NMOD
22	decline	decline	I-NP	NN	O	19	PMOD
23	in	in	B-PP	IN	O	22	NMOD
24	global	global	B-NP	JJ	O	26	NMOD
25	cognitive	cognitive	I-NP	JJ	O	26	NMOD
26	abilities	ability	I-NP	NNS	O	23	PMOD
27	documented	document	B-VP	VBN	O	26	NMOD
28	by	by	B-PP	IN	O	27	VMOD
29	serial	serial	B-NP	JJ	O	31	NMOD
30	neuropsychological	neuropsychological	I-NP	JJ	O	31	NMOD
31	studies	study	I-NP	NNS	O	28	PMOD
32	.	.	O	.	O	6	P

1	Reversal	Reversal	B-NP	NN	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	scopolamine	scopolamine	B-NP	NN	O	2	PMOD
4	induced	induce	B-VP	VBD	O	0	ROOT
5	amnesia	amnesia	B-NP	NN	O	4	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	passive	passive	B-NP	JJ	O	8	NMOD
8	avoidance	avoidance	I-NP	NN	O	6	PMOD
9	by	by	B-PP	IN	O	4	VMOD
10	pre-	pre-	B-NP	JJ	O	13	NMOD
11	and	and	I-NP	CC	O	13	NMOD
12	post-training	post-training	I-NP	JJ	O	13	NMOD
13	naloxone	naloxone	I-NP	NN	O	9	PMOD
14	.	.	O	.	O	4	P

1	In	In	B-PP	IN	O	16	VMOD
2	a	a	B-NP	DT	O	3	NMOD
3	series	series	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	five	five	B-NP	CD	O	6	NMOD
6	experiments	experiment	I-NP	NNS	O	4	PMOD
7	,	,	O	,	O	16	P
8	the	the	B-NP	DT	O	10	NMOD
9	modulating	modulate	I-NP	VBG	O	10	NMOD
10	role	role	I-NP	NN	O	16	SUB
11	of	of	B-PP	IN	O	10	NMOD
12	naloxone	naloxone	B-NP	NN	O	11	PMOD
13	on	on	B-PP	IN	O	10	NMOD
14	a	a	B-NP	DT	O	15	NMOD
15	scopolamine	scopolamine	I-NP	NN	O	13	PMOD
16	induced	induce	B-VP	VBD	O	0	ROOT
17	retention	retention	B-NP	NN	O	18	NMOD
18	deficit	deficit	I-NP	NN	O	16	OBJ
19	in	in	B-PP	IN	O	16	VMOD
20	a	a	B-NP	DT	O	23	NMOD
21	passive	passive	I-NP	JJ	O	23	NMOD
22	avoidance	avoidance	I-NP	NN	O	23	NMOD
23	paradigm	paradigm	I-NP	NN	O	24	SUB
24	was	be	B-VP	VBD	O	19	SBAR
25	investigated	investigate	I-VP	VBN	O	24	VC
26	in	in	B-PP	IN	O	25	VMOD
27	mice	mouse	B-NP	NNS	O	26	PMOD
28	.	.	O	.	O	16	P

1	Scopolamine	Scopolamine	B-NP	NN	O	14	SUB
2	,	,	O	,	O	14	P
3	but	but	O	CC	O	6	NMOD
4	not	not	O	RB	O	3	DEP
5	methyl	methyl	B-NP	NN	O	6	NMOD
6	scopolamine	scopolamine	I-NP	NN	O	14	SUB
7	(	(	O	(	O	12	DEP
8	1	1	B-NP	CD	O	10	AMOD
9	and	and	I-NP	CC	O	10	AMOD
10	3	3	I-NP	CD	O	11	NMOD
11	mg/kg	mg/kg	I-NP	NN	O	12	DEP
12	)	)	O	)	O	6	NMOD
13	,	,	O	,	O	6	P
14	induced	induce	B-VP	VBD	O	0	ROOT
15	an	an	B-NP	DT	O	16	NMOD
16	amnesia	amnesia	I-NP	NN	O	14	OBJ
17	as	as	B-SBAR	IN	O	14	VMOD
18	measured	measure	B-VP	VBN	O	17	SBAR
19	by	by	B-PP	IN	O	18	VMOD
20	latency	latency	B-NP	NN	O	23	NMOD
21	and	and	I-NP	CC	O	23	NMOD
22	duration	duration	I-NP	NN	O	23	NMOD
23	parameters	parameter	I-NP	NNS	O	19	PMOD
24	.	.	O	.	O	14	P

1	Naloxone	Naloxone	B-NP	NN	O	17	SUB
2	(	(	O	(	O	12	DEP
3	0.3	0.3	B-NP	CD	O	11	NMOD
4	,	,	I-NP	,	O	11	P
5	1	1	I-NP	CD	O	11	NMOD
6	,	,	I-NP	,	O	11	P
7	3	3	I-NP	CD	O	11	NMOD
8	,	,	O	,	O	11	P
9	and	and	O	CC	O	11	NMOD
10	10	10	B-NP	CD	O	11	NMOD
11	mg/kg	mg/kg	I-NP	NN	O	12	DEP
12	)	)	O	)	O	1	NMOD
13	injected	inject	B-VP	VBN	O	1	NMOD
14	prior	prior	B-ADVP	RB	O	15	PMOD
15	to	to	B-PP	TO	O	13	VMOD
16	training	training	B-NP	NN	O	15	PMOD
17	attenuated	attenuate	B-VP	VBD	O	0	ROOT
18	the	the	B-NP	DT	O	20	NMOD
19	retention	retention	I-NP	NN	O	20	NMOD
20	deficit	deficit	I-NP	NN	O	17	OBJ
21	with	with	B-PP	IN	O	17	VMOD
22	a	a	B-NP	DT	O	23	NMOD
23	peak	peak	I-NP	NN	O	21	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	activity	activity	B-NP	NN	O	24	PMOD
26	at	at	B-PP	IN	O	17	VMOD
27	3	3	B-NP	CD	O	28	NMOD
28	mg/kg	mg/kg	I-NP	NN	O	26	PMOD
29	.	.	O	.	O	17	P

1	Post-training	Post-training	B-NP	JJ	O	2	NMOD
2	administration	administration	I-NP	NN	O	18	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	naloxone	naloxone	B-NP	NN	O	3	PMOD
5	(	(	O	(	O	8	DEP
6	3	3	B-NP	CD	O	7	NMOD
7	mg/kg	mg/kg	I-NP	NN	O	8	DEP
8	)	)	O	)	O	2	NMOD
9	as	as	B-PP	IN	O	2	NMOD
10	a	a	B-NP	DT	O	11	NMOD
11	single	single	I-NP	JJ	O	9	PMOD
12	or	or	O	CC	O	9	PMOD
13	as	as	B-PP	IN	O	9	PMOD
14	a	a	B-NP	DT	O	16	NMOD
15	split	split	I-NP	JJ	O	16	NMOD
16	dose	dose	I-NP	NN	O	13	PMOD
17	also	also	B-ADVP	RB	O	18	VMOD
18	attenuated	attenuate	B-VP	VBD	O	0	ROOT
19	the	the	B-NP	DT	O	22	NMOD
20	scopolamine	scopolamine	I-NP	NN	O	22	NMOD
21	induced	induced	I-NP	JJ	O	22	NMOD
22	amnesia	amnesia	I-NP	NN	O	18	OBJ
23	.	.	O	.	O	18	P

1	Electron	Electron	B-NP	NN	O	3	NMOD
2	microscopic	microscopic	I-NP	JJ	O	3	NMOD
3	investigations	investigation	I-NP	NNS	O	7	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	cyclophosphamide	cyclophosphamide	I-NP	NN	O	4	PMOD
7	induced	induce	B-VP	VBD	O	0	ROOT
8	lesions	lesion	B-NP	NNS	O	18	NMOD
9	of	of	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	12	NMOD
11	urinary	urinary	I-NP	JJ	O	12	NMOD
12	bladder	bladder	I-NP	NN	O	9	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	rat	rat	I-NP	NN	O	13	PMOD
16	and	and	O	CC	O	18	NMOD
17	their	their	B-NP	PRP$	O	18	NMOD
18	prevention	prevention	I-NP	NN	O	7	OBJ
19	by	by	B-PP	IN	O	7	VMOD
20	mesna	mesna	B-NP	NN	O	19	PMOD
21	.	.	O	.	O	7	P

1	Fully	Fully	B-NP	RB	O	2	AMOD
2	developed	develop	I-NP	VBN	O	5	NMOD
3	cyclophosphamide	cyclophosphamide	I-NP	NN	O	5	NMOD
4	induced	induce	I-NP	VBN	O	3	AMOD
5	cystitis	cystitis	I-NP	NN	O	6	SUB
6	is	be	B-VP	VBZ	O	0	ROOT
7	characterized	characterize	I-VP	VBN	O	6	VC
8	by	by	B-PP	IN	O	7	VMOD
9	nearly	nearly	B-NP	RB	O	10	AMOD
10	complete	complete	I-NP	JJ	O	11	NMOD
11	detachment	detachment	I-NP	NN	O	18	NMOD
12	of	of	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	urothelium	urothelium	I-NP	NN	O	12	PMOD
15	,	,	O	,	O	18	P
16	severe	severe	B-NP	JJ	O	18	NMOD
17	submucosal	submucosal	I-NP	JJ	O	18	NMOD
18	edema	edema	I-NP	NN	O	8	PMOD
19	owing	owe	B-VP	VBG	O	18	NMOD
20	to	to	I-VP	TO	O	21	VMOD
21	damage	damage	I-VP	VB	O	19	VMOD
22	to	to	B-PP	TO	O	21	VMOD
23	the	the	B-NP	DT	O	29	NMOD
24	microvascular	microvascular	I-NP	JJ	O	25	NMOD
25	bed	bed	I-NP	NN	O	29	NMOD
26	and	and	O	CC	O	29	NMOD
27	focal	focal	B-NP	JJ	O	29	NMOD
28	muscle	muscle	I-NP	NN	O	29	NMOD
29	necroses	necros	I-NP	NNS	O	22	PMOD
30	.	.	O	.	O	6	P

1	Increase	Increase	B-NP	NN	O	13	NMOD
2	in	in	B-PP	IN	O	1	NMOD
3	intragastric	intragastric	B-NP	JJ	O	4	NMOD
4	pressure	pressure	I-NP	NN	O	2	PMOD
5	during	during	B-PP	IN	O	1	NMOD
6	suxamethonium	suxamethonium	B-NP	NN	O	9	NMOD
7	induced	induce	I-NP	VBN	O	9	NMOD
8	muscle	muscle	I-NP	NN	O	9	NMOD
9	fasciculations	fasciculation	I-NP	NNS	O	5	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	children	child	B-NP	NNS	O	10	PMOD
12	:	:	O	:	O	1	P
13	inhibition	inhibition	B-NP	NN	O	0	ROOT
14	by	by	B-PP	IN	O	13	NMOD
15	alfentanil	alfentanil	B-NP	NN	O	14	PMOD
16	.	.	O	.	O	13	P

1	The	The	B-NP	DT	O	4	NMOD
2	incidence	incidence	I-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	intensity	intensity	I-NP	NN	O	11	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	muscle	muscle	B-NP	NN	O	7	NMOD
7	fasciculations	fasciculation	I-NP	NNS	O	5	PMOD
8	caused	cause	B-VP	VBN	O	4	NMOD
9	by	by	B-PP	IN	O	8	VMOD
10	suxamethonium	suxamethonium	B-NP	NN	O	9	PMOD
11	were	be	B-VP	VBD	O	0	ROOT
12	significantly	significantly	B-ADJP	RB	O	13	AMOD
13	greater	great	I-ADJP	JJR	O	11	PRD
14	in	in	B-PP	IN	O	13	AMOD
15	the	the	B-NP	DT	O	16	NMOD
16	control	control	I-NP	NN	O	14	PMOD
17	than	than	B-PP	IN	O	13	AMOD
18	in	in	B-PP	IN	O	17	PMOD
19	the	the	B-NP	DT	O	21	NMOD
20	alfentanil	alfentanil	I-NP	NN	O	21	NMOD
21	group	group	I-NP	NN	O	18	PMOD
22	.	.	O	.	O	11	P

1	The	The	B-NP	DT	O	3	NMOD
2	intragastric	intragastric	I-NP	JJ	O	3	NMOD
3	pressure	pressure	I-NP	NN	O	7	SUB
4	during	during	B-PP	IN	O	3	NMOD
5	muscle	muscle	B-NP	NN	O	6	NMOD
6	fasciculations	fasciculation	I-NP	NNS	O	4	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	significantly	significantly	B-ADJP	RB	O	9	AMOD
9	higher	high	I-ADJP	JJR	O	7	PRD
10	in	in	B-PP	IN	O	9	AMOD
11	the	the	B-NP	DT	O	13	NMOD
12	control	control	I-NP	NN	O	13	NMOD
13	group	group	I-NP	NN	O	10	PMOD
14	(	(	O	(	O	23	DEP
15	16	16	B-NP	CD	O	17	NMOD
16	+/-	+/-	I-NP	CC	O	17	NMOD
17	0.7	0.7	I-NP	CD	O	22	NMOD
18	(	(	O	(	O	20	DEP
19	SEM	SEM	B-NP	NN	O	20	DEP
20	)	)	O	)	O	17	NMOD
21	cm	cm	B-NP	NN	O	22	NMOD
22	H2O	H2O	I-NP	NN	O	23	DEP
23	)	)	O	)	O	9	AMOD
24	than	than	B-PP	IN	O	9	AMOD
25	in	in	B-PP	IN	O	24	PMOD
26	the	the	B-NP	DT	O	28	NMOD
27	alfentanil	alfentanil	I-NP	NN	O	28	NMOD
28	group	group	I-NP	NN	O	25	PMOD
29	(	(	O	(	O	35	DEP
30	7.7	7.7	B-NP	CD	O	32	NMOD
31	+/-	+/-	I-NP	CC	O	32	NMOD
32	1.5	1.5	I-NP	CD	O	35	DEP
33	(	(	O	(	O	35	DEP
34	SEM	SEM	B-NP	NN	O	35	DEP
35	)	)	O	)	O	9	AMOD
36	cm	cm	B-NP	NN	O	37	NMOD
37	H2O	H2O	I-NP	NN	O	9	AMOD
38	)	)	O	)	O	7	VMOD
39	.	.	O	.	O	7	P

1	It	It	B-NP	PRP	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	concluded	conclude	I-VP	VBN	O	2	VC
4	that	that	B-SBAR	IN	O	3	VMOD
5	intragastric	intragastric	B-NP	JJ	O	6	NMOD
6	pressure	pressure	I-NP	NN	O	7	SUB
7	increases	increase	B-VP	VBZ	O	4	SBAR
8	significantly	significantly	B-ADVP	RB	O	7	VMOD
9	during	during	B-PP	IN	O	7	VMOD
10	muscle	muscle	B-NP	NN	O	11	NMOD
11	fasciculations	fasciculation	I-NP	NNS	O	9	PMOD
12	caused	cause	B-VP	VBN	O	11	NMOD
13	by	by	B-PP	IN	O	12	VMOD
14	suxamethonium	suxamethonium	B-NP	NN	O	13	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	healthy	healthy	B-NP	JJ	O	17	NMOD
17	children	child	I-NP	NNS	O	15	PMOD
18	.	.	O	.	O	2	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	insulin	insulin	I-NP	NN	O	3	NMOD
3	treatment	treatment	I-NP	NN	O	4	SUB
4	normalizes	normalize	B-VP	VBZ	O	0	ROOT
5	the	the	B-NP	DT	O	6	NMOD
6	resistance	resistance	I-NP	NN	O	4	OBJ
7	to	to	B-PP	TO	O	6	NMOD
8	the	the	B-NP	DT	O	10	NMOD
9	cardiotoxic	cardiotoxic	I-NP	JJ	O	10	NMOD
10	effect	effect	I-NP	NN	O	7	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	isoproterenol	isoproterenol	B-NP	NN	O	11	PMOD
13	in	in	B-PP	IN	O	10	NMOD
14	streptozotocin	streptozotocin	B-NP	NN	O	16	NMOD
15	diabetic	diabetic	I-NP	JJ	O	16	NMOD
16	rats	rat	I-NP	NNS	O	13	PMOD
17	.	.	O	.	O	4	P

1	A	A	B-NP	DT	O	3	NMOD
2	morphometric	morphometric	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	6	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	isoproterenol	isoproterenol	B-NP	NN	O	4	PMOD
6	induced	induce	B-VP	VBD	O	0	ROOT
7	myocardial	myocardial	B-NP	JJ	O	8	NMOD
8	fibrosis	fibrosis	I-NP	NN	O	6	OBJ
9	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	3	NMOD
2	acute	acute	I-NP	JJ	O	3	NMOD
3	effect	effect	I-NP	NN	O	28	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	insulin	insulin	B-NP	NN	B-protein	6	NMOD
6	treatment	treatment	I-NP	NN	O	4	PMOD
7	on	on	B-PP	IN	O	3	NMOD
8	the	the	B-NP	DT	O	7	PMOD
9	earlier	early	I-NP	JJR	O	8	NMOD
10	reported	report	B-VP	VBD	O	9	SBAR
11	protective	protective	B-NP	JJ	O	12	NMOD
12	effect	effect	I-NP	NN	O	10	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	streptozotocin	streptozotocin	B-NP	NN	O	15	NMOD
15	diabetes	diabete	I-NP	NNS	O	13	PMOD
16	against	against	B-PP	IN	O	12	NMOD
17	the	the	B-NP	DT	O	19	NMOD
18	cardiotoxic	cardiotoxic	I-NP	JJ	O	19	NMOD
19	effect	effect	I-NP	NN	O	16	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	high	high	B-NP	JJ	O	22	NMOD
22	doses	dose	I-NP	NNS	O	20	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	isoproterenol	isoproterenol	B-NP	NN	O	23	PMOD
25	(	(	O	(	O	27	DEP
26	ISO	ISO	B-NP	NN	O	27	DEP
27	)	)	O	)	O	24	NMOD
28	was	be	B-VP	VBD	O	0	ROOT
29	investigated	investigate	I-VP	VBN	O	28	VC
30	in	in	B-PP	IN	O	29	VMOD
31	rats	rat	B-NP	NNS	O	30	PMOD
32	.	.	O	.	O	28	P

1	Thirty	Thirty	B-NP	CD	O	3	AMOD
2	to	to	I-NP	TO	O	3	AMOD
3	135	135	I-NP	CD	O	4	NMOD
4	min	min	I-NP	NN	O	12	NMOD
5	after	after	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	injection	injection	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	crystalline	crystalline	B-NP	NN	B-protein	10	NMOD
10	insulin	insulin	I-NP	NN	I-protein	8	PMOD
11	,	,	O	,	O	12	P
12	ISO	ISO	B-NP	NN	O	13	SUB
13	was	be	B-VP	VBD	O	57	VMOD
14	given	give	I-VP	VBN	O	13	VC
15	subcutaneously	subcutaneously	B-ADVP	RB	O	17	DEP
16	and	and	O	CC	O	17	DEP
17	when	when	B-ADVP	WRB	O	14	VMOD
18	ISO	ISO	B-NP	NN	B-protein	19	SUB
19	induced	induce	B-VP	VBD	O	17	SBAR
20	fibrosis	fibrosis	B-NP	NN	O	19	OBJ
21	in	in	B-PP	IN	O	19	VMOD
22	the	the	B-NP	DT	O	23	NMOD
23	myocardium	myocardium	I-NP	NN	O	21	PMOD
24	was	be	B-VP	VBD	O	57	VMOD
25	morphometrically	morphometrically	I-VP	RB	O	24	VMOD
26	analyzed	analyze	I-VP	VBN	O	57	VMOD
27	7	7	B-NP	CD	O	28	NMOD
28	days	day	I-NP	NNS	O	57	SUB
29	later	later	B-ADVP	RB	O	57	VMOD
30	,	,	O	,	O	57	P
31	a	a	B-NP	DT	O	34	NMOD
32	highly	highly	I-NP	RB	O	33	AMOD
33	significant	significant	I-NP	JJ	O	34	NMOD
34	correlation	correlation	I-NP	NN	O	57	SUB
35	(	(	O	(	O	44	DEP
36	r	r	B-NP	NN	O	43	NMOD
37	=	=	B-VP	SYM	O	36	NMOD
38	0.83	0.83	B-NP	CD	O	37	AMOD
39	,	,	O	,	O	43	P
40	2	2	B-NP	CD	O	43	NMOD
41	p	p	I-NP	NN	O	43	SUB
42	=	=	B-VP	SYM	O	43	VMOD
43	0.006	0.006	B-NP	CD	O	44	DEP
44	)	)	O	)	O	34	NMOD
45	to	to	B-PP	TO	O	34	NMOD
46	the	the	B-NP	DT	O	47	NMOD
47	slope	slope	I-NP	NN	O	45	PMOD
48	of	of	B-PP	IN	O	47	NMOD
49	the	the	B-NP	DT	O	50	NMOD
50	fall	fall	I-NP	NN	O	48	PMOD
51	in	in	B-PP	IN	O	47	NMOD
52	blood	blood	B-NP	NN	O	53	NMOD
53	glucose	glucose	I-NP	NN	O	51	PMOD
54	after	after	B-PP	IN	O	53	NMOD
55	insulin	insulin	B-NP	NN	B-protein	56	NMOD
56	treatment	treatment	I-NP	NN	O	54	PMOD
57	appeared	appear	B-VP	VBD	O	0	ROOT
58	.	.	O	.	O	57	P

1	The	The	B-NP	DT	O	3	NMOD
2	myocardial	myocardial	I-NP	JJ	O	3	NMOD
3	content	content	I-NP	NN	O	6	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	catecholamines	catecholamine	B-NP	NNS	O	4	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	estimated	estimate	I-VP	VBN	O	6	VC
8	in	in	B-PP	IN	O	7	VMOD
9	these	these	B-NP	DT	O	13	NMOD
10	8	8	I-NP	CD	O	13	NMOD
11	day	day	I-NP	NN	O	13	NMOD
12	diabetic	diabetic	I-NP	JJ	O	13	NMOD
13	rats	rat	I-NP	NNS	O	8	PMOD
14	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	3	NMOD
2	rapid	rapid	I-NP	JJ	O	3	NMOD
3	reversion	reversion	I-NP	NN	O	7	SUB
4	after	after	B-PP	IN	O	3	NMOD
5	insulin	insulin	B-NP	NN	B-protein	6	NMOD
6	treatment	treatment	I-NP	NN	O	4	PMOD
7	excludes	exclude	B-VP	VBZ	O	0	ROOT
8	the	the	B-NP	DT	O	9	NMOD
9	possibility	possibility	I-NP	NN	O	7	OBJ
10	that	that	B-SBAR	IN	O	9	NMOD
11	streptozotocin	streptozotocin	B-NP	NN	O	14	SUB
12	in	in	B-PP	IN	O	11	NMOD
13	itself	itself	B-NP	PRP	O	12	PMOD
14	causes	cause	B-VP	VBZ	O	10	SBAR
15	the	the	B-NP	DT	O	17	NMOD
16	ISO	ISO	I-NP	NN	O	17	NMOD
17	resistance	resistance	I-NP	NN	O	19	NMOD
18	and	and	O	CC	O	19	NMOD
19	points	point	B-NP	NNS	O	14	OBJ
20	towards	towards	B-PP	IN	O	14	VMOD
21	a	a	B-NP	DT	O	24	NMOD
22	direct	direct	I-NP	JJ	O	24	NMOD
23	insulin	insulin	I-NP	NN	O	24	NMOD
24	effect	effect	I-NP	NN	O	20	PMOD
25	on	on	B-PP	IN	O	24	NMOD
26	myocardial	myocardial	B-NP	JJ	O	28	NMOD
27	catecholamine	catecholamine	I-NP	NN	O	28	NMOD
28	sensitivity	sensitivity	I-NP	NN	O	25	PMOD
29	in	in	B-PP	IN	O	28	NMOD
30	diabetic	diabetic	B-NP	JJ	O	31	NMOD
31	rats	rat	I-NP	NNS	O	29	PMOD
32	.	.	O	.	O	7	P

1	Differential	Differential	B-NP	JJ	O	2	NMOD
2	effects	effect	I-NP	NNS	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	non-steroidal	non-steroidal	B-NP	JJ	O	6	NMOD
5	anti-inflammatory	anti-inflammatory	I-NP	JJ	O	6	NMOD
6	drugs	drug	I-NP	NNS	O	3	PMOD
7	on	on	B-PP	IN	O	2	NMOD
8	seizures	seizure	B-NP	NNS	O	7	PMOD
9	produced	produce	B-VP	VBN	O	8	NMOD
10	by	by	B-PP	IN	O	9	VMOD
11	pilocarpine	pilocarpine	B-NP	NN	O	10	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	rats	rat	B-NP	NNS	O	12	PMOD
14	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	5	NMOD
2	muscarinic	muscarinic	I-NP	JJ	O	5	NMOD
3	cholinergic	cholinergic	I-NP	JJ	O	5	NMOD
4	agonist	agonist	I-NP	NN	O	5	NMOD
5	pilocarpine	pilocarpine	I-NP	NN	O	6	SUB
6	induces	induce	B-VP	VBZ	O	0	ROOT
7	in	in	B-PP	IN	O	6	VMOD
8	rats	rat	B-NP	NNS	O	12	NMOD
9	seizures	seizure	I-NP	NNS	O	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	status	status	B-NP	NN	O	12	NMOD
12	epilepticus	epilepticus	I-NP	NN	O	7	PMOD
13	followed	follow	B-VP	VBN	O	12	NMOD
14	by	by	B-PP	IN	O	13	VMOD
15	widespread	widespread	B-NP	JJ	O	16	NMOD
16	damage	damage	I-NP	NN	O	14	PMOD
17	to	to	B-PP	TO	O	16	NMOD
18	the	the	B-NP	DT	O	19	NMOD
19	forebrain	forebrain	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	designed	design	I-VP	VBN	O	4	VC
6	to	to	B-VP	TO	O	7	VMOD
7	investigate	investigate	I-VP	VB	O	4	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	effect	effect	I-NP	NN	O	7	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	5	5	B-NP	CD	O	14	NMOD
12	non-steroidal	non-steroidal	I-NP	JJ	O	14	NMOD
13	anti-inflammatory	anti-inflammatory	I-NP	JJ	O	14	NMOD
14	drugs	drug	I-NP	NNS	O	10	PMOD
15	,	,	O	,	O	7	P
16	sodium	sodium	B-NP	NN	O	17	NMOD
17	salicylate	salicylate	I-NP	NN	O	26	NMOD
18	,	,	O	,	O	26	P
19	phenylbutazone	phenylbutazone	B-NP	NN	O	26	NMOD
20	,	,	O	,	O	26	P
21	indomethacin	indomethacin	B-NP	NN	O	26	NMOD
22	,	,	O	,	O	26	P
23	ibuprofen	ibuprofen	B-NP	NN	O	26	NMOD
24	and	and	O	CC	O	26	NMOD
25	mefenamic	mefenamic	B-NP	JJ	O	26	NMOD
26	acid	acid	I-NP	NN	O	15	OBJ
27	,	,	O	,	O	26	P
28	on	on	B-PP	IN	O	26	NMOD
29	seizures	seizure	B-NP	NNS	O	28	PMOD
30	produced	produce	B-VP	VBN	O	29	NMOD
31	by	by	B-PP	IN	O	30	VMOD
32	pilocarpine	pilocarpine	B-NP	NN	O	31	PMOD
33	.	.	O	.	O	4	P

1	Indomethacin	Indomethacin	B-NP	NN	O	10	NMOD
2	,	,	O	,	O	10	P
3	1-10	1-10	B-NP	CD	O	4	NMOD
4	mg/kg	mg/kg	I-NP	NN	O	10	NMOD
5	,	,	O	,	O	10	P
6	and	and	O	CC	O	10	NMOD
7	ibuprofen	ibuprofen	B-NP	NN	O	10	NMOD
8	,	,	O	,	O	10	P
9	10-100	10-100	B-NP	CD	O	10	NMOD
10	mg/kg	mg/kg	I-NP	NN	O	12	SUB
11	,	,	O	,	O	10	P
12	failed	fail	B-VP	VBD	O	0	ROOT
13	to	to	I-VP	TO	O	14	VMOD
14	modulate	modulate	I-VP	VB	O	12	VMOD
15	seizures	seizure	B-NP	NNS	O	14	OBJ
16	produced	produce	B-VP	VBN	O	15	NMOD
17	by	by	B-PP	IN	O	16	VMOD
18	pilocarpine	pilocarpine	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	12	P

1	Mefenamic	Mefenamic	B-NP	JJ	O	2	NMOD
2	acid	acid	I-NP	NN	O	8	NMOD
3	,	,	O	,	O	8	P
4	26	26	B-NP	CD	O	8	NMOD
5	(	(	O	(	O	7	DEP
6	22-30	22-30	B-NP	CD	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	mg/kg	mg/kg	B-NP	NN	O	10	SUB
9	,	,	O	,	O	8	P
10	prevented	prevent	B-VP	VBD	O	0	ROOT
11	seizures	seizure	B-NP	NNS	O	14	NMOD
12	and	and	O	CC	O	14	NMOD
13	protected	protected	B-NP	JJ	O	14	NMOD
14	rats	rat	I-NP	NNS	O	24	NMOD
15	from	from	B-PP	IN	O	14	NMOD
16	seizure-related	seizure-related	B-NP	JJ	O	18	NMOD
17	brain	brain	I-NP	NN	O	18	NMOD
18	damage	damage	I-NP	NN	O	15	PMOD
19	induced	induce	B-VP	VBN	O	18	NMOD
20	by	by	B-PP	IN	O	19	VMOD
21	pilocarpine	pilocarpine	B-NP	NN	O	20	PMOD
22	,	,	O	,	O	24	P
23	380	380	B-NP	CD	O	24	NMOD
24	mg/kg	mg/kg	I-NP	NN	O	10	OBJ
25	.	.	O	.	O	10	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	neurologic	neurologic	I-NP	JJ	O	3	NMOD
3	dysfunction	dysfunction	I-NP	NN	O	0	ROOT
4	after	after	B-PP	IN	O	3	NMOD
5	high-dose	high-dose	B-NP	JJ	O	7	NMOD
6	etoposide	etoposide	I-NP	NN	O	7	NMOD
7	therapy	therapy	I-NP	NN	O	4	PMOD
8	for	for	B-PP	IN	O	7	NMOD
9	malignant	malignant	B-NP	JJ	O	10	NMOD
10	glioma	glioma	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	3	P

1	Etoposide	Etoposide	B-NP	NN	O	5	SUB
2	(	(	O	(	O	4	DEP
3	VP-16-213	VP-16-213	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	has	have	B-VP	VBZ	O	0	ROOT
6	been	be	I-VP	VBN	O	5	VC
7	used	use	I-VP	VBN	O	6	VC
8	in	in	B-PP	IN	O	7	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	treatment	treatment	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	many	many	B-NP	JJ	O	14	NMOD
13	solid	solid	I-NP	JJ	O	14	NMOD
14	tumors	tumor	I-NP	NNS	O	17	NMOD
15	and	and	O	CC	O	17	NMOD
16	hematologic	hematologic	B-NP	JJ	O	17	NMOD
17	malignancies	malignancy	I-NP	NNS	O	11	PMOD
18	.	.	O	.	O	5	P

1	Progressive	Progressive	B-NP	JJ	O	4	NMOD
2	bile	bile	I-NP	NN	O	4	NMOD
3	duct	duct	I-NP	NN	O	4	NMOD
4	injury	injury	I-NP	NN	O	0	ROOT
5	after	after	B-PP	IN	O	4	NMOD
6	thiabendazole	thiabendazole	B-NP	NN	O	7	NMOD
7	administration	administration	I-NP	NN	O	5	PMOD
8	.	.	O	.	O	4	P

1	A	A	B-NP	DT	O	3	NMOD
2	27-yr-old	27-yr-old	I-NP	JJ	O	3	NMOD
3	man	man	I-NP	NN	O	4	SUB
4	developed	develop	B-VP	VBD	O	0	ROOT
5	jaundice	jaundice	B-NP	NN	B-protein	7	NMOD
6	2	2	I-NP	CD	I-protein	7	NMOD
7	wk	wk	I-NP	NN	I-protein	4	OBJ
8	after	after	B-PP	IN	O	4	VMOD
9	exposure	exposure	B-NP	NN	O	8	PMOD
10	to	to	B-PP	TO	O	9	NMOD
11	thiabendazole	thiabendazole	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	4	P

1	Increasing	Increase	B-VP	VBG	O	14	SUB
2	recognition	recognition	B-NP	NN	O	1	OBJ
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	importance	importance	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	calcium	calcium	B-NP	NN	O	6	PMOD
8	in	in	B-PP	IN	O	1	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	pathogenesis	pathogenesis	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	cardiovascular	cardiovascular	B-NP	JJ	O	13	NMOD
13	disease	disease	I-NP	NN	O	11	PMOD
14	has	have	B-VP	VBZ	O	0	ROOT
15	stimulated	stimulate	I-VP	VBN	O	14	VC
16	research	research	B-NP	NN	O	15	OBJ
17	into	into	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	19	NMOD
19	use	use	I-NP	NN	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	calcium	calcium	B-NP	NN	O	22	NMOD
22	channel	channel	I-NP	NN	O	24	NMOD
23	blocking	block	B-VP	VBG	O	24	NMOD
24	agents	agent	B-NP	NNS	O	20	PMOD
25	for	for	B-PP	IN	O	19	NMOD
26	treatment	treatment	B-NP	NN	O	25	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	a	a	B-NP	DT	O	29	NMOD
29	variety	variety	I-NP	NN	O	27	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	cardiovascular	cardiovascular	B-NP	JJ	O	32	NMOD
32	diseases	disease	I-NP	NNS	O	30	PMOD
33	.	.	O	.	O	14	P

1	As	As	B-PP	IN	O	14	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	first	first	I-NP	JJ	O	4	NMOD
4	dihydropyridine	dihydropyridine	I-NP	NN	O	1	PMOD
5	available	available	B-ADJP	JJ	O	4	NMOD
6	for	for	B-PP	IN	O	5	AMOD
7	use	use	B-NP	NN	O	6	PMOD
8	in	in	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	11	NMOD
10	United	United	I-NP	NNP	O	11	NMOD
11	States	State	I-NP	NNPS	O	8	PMOD
12	,	,	O	,	O	14	P
13	nifedipine	nifedipine	B-NP	NN	O	14	SUB
14	controls	control	B-VP	VBZ	O	0	ROOT
15	angina	angina	B-NP	NN	O	17	NMOD
16	and	and	I-NP	CC	O	17	NMOD
17	hypertension	hypertension	I-NP	NN	O	14	OBJ
18	with	with	B-PP	IN	O	17	NMOD
19	minimal	minimal	B-NP	JJ	O	20	NMOD
20	depression	depression	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	cardiac	cardiac	B-NP	JJ	O	23	NMOD
23	function	function	I-NP	NN	O	21	PMOD
24	.	.	O	.	O	14	P

1	Once	Once	B-ADVP	RB	O	11	VMOD
2	or	or	O	CC	O	5	NMOD
3	twice	twice	B-NP	RB	O	5	NMOD
4	daily	daily	I-NP	RB	O	3	AMOD
5	dosage	dosage	I-NP	NN	O	11	SUB
6	possible	possible	B-ADJP	JJ	O	5	NMOD
7	with	with	B-PP	IN	O	6	AMOD
8	nitrendipine	nitrendipine	B-NP	NN	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	nisoldipine	nisoldipine	I-NP	NN	O	7	PMOD
11	offers	offer	B-VP	VBZ	O	0	ROOT
12	a	a	B-NP	DT	O	15	NMOD
13	convenient	convenient	I-NP	JJ	O	15	NMOD
14	administration	administration	I-NP	NN	O	15	NMOD
15	schedule	schedule	I-NP	NN	O	11	OBJ
16	,	,	O	,	O	15	P
17	which	which	B-NP	WDT	O	15	NMOD
18	encourages	encourage	B-VP	VBZ	O	17	SBAR
19	patient	patient	B-NP	NN	O	20	NMOD
20	compliance	compliance	I-NP	NN	O	18	OBJ
21	in	in	B-PP	IN	O	20	NMOD
22	long-term	long-term	B-NP	JJ	O	23	NMOD
23	therapy	therapy	I-NP	NN	O	21	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	hypertension	hypertension	B-NP	NN	O	24	PMOD
26	.	.	O	.	O	11	P

1	The	The	B-NP	DT	O	4	NMOD
2	coronary	coronary	I-NP	JJ	O	4	NMOD
3	vasodilating	vasodilate	I-NP	VBG	O	4	NMOD
4	properties	property	I-NP	NNS	O	7	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	nisoldipine	nisoldipine	B-NP	NN	O	5	PMOD
7	have	have	B-VP	VBP	O	0	ROOT
8	led	lead	I-VP	VBN	O	7	VC
9	to	to	B-PP	TO	O	8	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	investigation	investigation	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	this	this	B-NP	DT	O	14	NMOD
14	agent	agent	I-NP	NN	O	12	PMOD
15	for	for	B-PP	IN	O	11	NMOD
16	use	use	B-NP	NN	O	15	PMOD
17	in	in	B-PP	IN	O	16	NMOD
18	angina	angina	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	7	P

1	Selectivity	Selectivity	B-NP	NN	O	6	SUB
2	for	for	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	5	NMOD
4	cerebrovascular	cerebrovascular	I-NP	JJ	O	5	NMOD
5	bed	bed	I-NP	NN	O	2	PMOD
6	makes	make	B-VP	VBZ	O	0	ROOT
7	nimodipine	nimodipine	B-NP	NN	O	9	AMOD
8	potentially	potentially	B-ADJP	RB	O	9	AMOD
9	useful	useful	I-ADJP	JJ	O	23	NMOD
10	in	in	B-PP	IN	O	9	AMOD
11	the	the	B-NP	DT	O	12	NMOD
12	treatment	treatment	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	subarachnoid	subarachnoid	B-NP	JJ	O	15	NMOD
15	hemorrhage	hemorrhage	I-NP	NN	O	13	PMOD
16	,	,	O	,	O	23	P
17	migraine	migraine	B-NP	NN	O	18	NMOD
18	headache	headache	I-NP	NN	O	23	NMOD
19	,	,	O	,	O	23	P
20	dementia	dementia	B-NP	NN	O	23	NMOD
21	,	,	O	,	O	23	P
22	and	and	O	CC	O	23	NMOD
23	stroke	stroke	B-NP	NN	O	6	OBJ
24	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	2	NMOD
2	enhancement	enhancement	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	aminonucleoside	aminonucleoside	B-NP	NN	O	5	NMOD
5	nephrosis	nephrosis	I-NP	NN	O	3	PMOD
6	by	by	B-PP	IN	O	2	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	co-administration	co-administration	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	protamine	protamine	B-NP	NN	O	9	PMOD
11	.	.	O	.	O	2	P

1	An	An	B-NP	DT	O	3	NMOD
2	experimental	experimental	I-NP	JJ	O	3	NMOD
3	model	model	I-NP	NN	O	12	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	focal	focal	B-NP	JJ	O	8	NMOD
6	segmental	segmental	I-NP	JJ	O	8	NMOD
7	glomerular	glomerular	I-NP	JJ	O	8	NMOD
8	sclerosis	sclerosis	I-NP	NN	O	4	PMOD
9	(	(	O	(	O	11	DEP
10	FSGS	FSGS	B-NP	NN	B-protein	11	DEP
11	)	)	O	)	O	8	NMOD
12	was	be	B-VP	VBD	O	0	ROOT
13	developed	develop	I-VP	VBN	O	12	VC
14	in	in	B-PP	IN	O	13	VMOD
15	rats	rat	B-NP	NNS	O	14	PMOD
16	by	by	B-PP	IN	O	13	VMOD
17	the	the	B-NP	DT	O	19	NMOD
18	combined	combined	I-NP	JJ	O	19	NMOD
19	administration	administration	I-NP	NN	O	16	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	puromycin-aminonucleoside	puromycin-aminonucleoside	B-NP	NN	O	27	NMOD
22	(	(	O	(	O	24	DEP
23	AMNS	AMNS	B-NP	NN	B-protein	24	DEP
24	)	)	O	)	O	21	NMOD
25	and	and	O	CC	O	27	NMOD
26	protamine	protamine	B-NP	NN	O	27	NMOD
27	sulfate	sulfate	I-NP	NN	O	20	PMOD
28	(	(	O	(	O	30	DEP
29	PS	PS	B-NP	NN	O	30	DEP
30	)	)	O	)	O	27	NMOD
31	.	.	O	.	O	12	P

1	Theophylline	Theophylline	B-NP	NN	O	2	NMOD
2	neurotoxicity	neurotoxicity	I-NP	NN	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	pregnant	pregnant	B-NP	JJ	O	5	NMOD
5	rats	rat	I-NP	NNS	O	3	PMOD
6	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	purpose	purpose	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	investigation	investigation	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	determine	determine	I-VP	VB	O	6	PRD
9	whether	whether	B-SBAR	IN	O	8	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	neurotoxicity	neurotoxicity	I-NP	NN	O	14	SUB
12	of	of	B-PP	IN	O	11	NMOD
13	theophylline	theophylline	B-NP	NN	O	12	PMOD
14	is	be	B-VP	VBZ	O	9	SBAR
15	altered	alter	I-VP	VBN	O	14	VC
16	in	in	B-PP	IN	O	15	VMOD
17	advanced	advance	B-NP	VBN	O	18	NMOD
18	pregnancy	pregnancy	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	6	P

1	Sprague-Dawley	Sprague-Dawley	B-NP	JJ	O	2	NMOD
2	rats	rat	I-NP	NNS	O	17	SUB
3	that	that	B-NP	WDT	O	2	NMOD
4	were	be	B-VP	VBD	O	3	SBAR
5	20	20	B-NP	CD	O	6	NMOD
6	days	day	I-NP	NNS	O	10	NMOD
7	pregnant	pregnant	B-NP	JJ	O	10	NMOD
8	and	and	I-NP	CC	O	10	NMOD
9	nonpregnant	nonpregnant	I-NP	JJ	O	10	NMOD
10	rats	rat	I-NP	NNS	O	4	PRD
11	of	of	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	14	NMOD
13	same	same	I-NP	JJ	O	14	NMOD
14	age	age	I-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	strain	strain	I-NP	NN	O	11	PMOD
17	received	receive	B-VP	VBD	O	0	ROOT
18	infusions	infusion	B-NP	NNS	O	17	OBJ
19	of	of	B-PP	IN	O	18	NMOD
20	aminophylline	aminophylline	B-NP	NN	O	19	PMOD
21	until	until	B-PP	IN	O	17	VMOD
22	onset	onset	B-NP	NN	O	21	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	maximal	maximal	B-NP	JJ	O	25	NMOD
25	seizures	seizure	I-NP	NNS	O	23	PMOD
26	which	which	B-NP	WDT	O	25	NMOD
27	occurred	occur	B-VP	VBD	O	26	SBAR
28	after	after	B-PP	IN	O	27	VMOD
29	28	28	B-NP	CD	O	31	AMOD
30	and	and	I-NP	CC	O	31	AMOD
31	30	30	I-NP	CD	O	32	NMOD
32	minutes	minute	I-NP	NNS	O	28	PMOD
33	respectively	respectively	B-ADVP	RB	O	32	NMOD
34	.	.	O	.	O	17	P

1	Hyperkalemia	Hyperkalemia	B-NP	NN	O	0	ROOT
2	induced	induce	B-VP	VBN	O	1	NMOD
3	by	by	B-PP	IN	O	2	VMOD
4	indomethacin	indomethacin	B-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	naproxen	naproxen	I-NP	NN	O	3	PMOD
7	and	and	O	CC	O	2	VMOD
8	reversed	reverse	B-VP	VBN	O	2	VMOD
9	by	by	B-PP	IN	O	8	VMOD
10	fludrocortisone	fludrocortisone	B-NP	NN	O	9	PMOD
11	.	.	O	.	O	1	P

1	We	We	B-NP	PRP	O	2	SUB
2	have	have	B-VP	VBP	O	0	ROOT
3	described	describe	I-VP	VBN	O	2	VC
4	a	a	B-NP	DT	O	5	NMOD
5	patient	patient	I-NP	NN	O	12	NMOD
6	with	with	B-PP	IN	O	5	NMOD
7	severe	severe	B-NP	JJ	O	9	NMOD
8	rheumatoid	rheumatoid	I-NP	JJ	O	9	NMOD
9	arthritis	arthritis	I-NP	NN	O	6	PMOD
10	and	and	O	CC	O	12	NMOD
11	a	a	B-NP	DT	O	12	NMOD
12	history	history	I-NP	NN	O	3	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	mefenamic	mefenamic	B-NP	JJ	O	16	NMOD
15	acid	acid	I-NP	NN	O	16	NMOD
16	nephropathy	nephropathy	I-NP	NN	O	13	PMOD
17	in	in	B-PP	IN	O	12	NMOD
18	whom	whom	B-NP	WP	O	22	NMOD
19	hyperkalemia	hyperkalemia	B-NP	NN	O	22	NMOD
20	and	and	O	CC	O	22	NMOD
21	inappropriate	inappropriate	B-NP	JJ	O	22	NMOD
22	hypoaldosteronism	hypoaldosteronism	I-NP	NN	O	17	PMOD
23	were	be	B-VP	VBD	O	2	VMOD
24	caused	cause	I-VP	VBN	O	23	VC
25	by	by	B-PP	IN	O	24	VMOD
26	both	both	O	CC	O	29	NMOD
27	indomethacin	indomethacin	B-NP	NN	O	29	NMOD
28	and	and	I-NP	CC	O	29	NMOD
29	naproxen	naproxen	I-NP	NN	O	25	PMOD
30	,	,	O	,	O	24	P
31	without	without	B-PP	IN	O	24	VMOD
32	major	major	B-NP	JJ	O	33	NMOD
33	decline	decline	I-NP	NN	O	31	PMOD
34	in	in	B-PP	IN	O	33	NMOD
35	renal	renal	B-NP	JJ	O	36	NMOD
36	function	function	I-NP	NN	O	34	PMOD
37	.	.	O	.	O	2	P

1	It	It	B-NP	PRP	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	likely	likely	B-ADJP	JJ	O	2	PRD
4	that	that	B-SBAR	IN	O	3	AMOD
5	preexisting	preexist	B-VP	VBG	O	8	SUB
6	renal	renal	B-NP	JJ	O	7	NMOD
7	disease	disease	I-NP	NN	O	5	OBJ
8	predisposed	predispose	B-VP	VBD	O	4	SBAR
9	this	this	B-NP	DT	O	10	NMOD
10	patient	patient	I-NP	NN	O	8	OBJ
11	to	to	B-PP	TO	O	10	NMOD
12	type	type	B-NP	NN	O	16	NMOD
13	IV	IV	I-NP	CD	O	16	NMOD
14	renal	renal	I-NP	JJ	O	16	NMOD
15	tubular	tubular	I-NP	JJ	O	16	NMOD
16	acidosis	acidosis	I-NP	NN	O	11	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	prostaglandin	prostaglandin	B-NP	NN	B-protein	20	NMOD
19	synthetase	synthetase	I-NP	NN	I-protein	20	NMOD
20	inhibitors	inhibitor	I-NP	NNS	O	17	PMOD
21	.	.	O	.	O	2	P

1	Hypotension	Hypotension	B-NP	NN	O	0	ROOT
2	as	as	B-PP	IN	O	1	NMOD
3	a	a	B-NP	DT	O	4	NMOD
4	manifestation	manifestation	I-NP	NN	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	cardiotoxicity	cardiotoxicity	B-NP	NN	O	5	PMOD
7	in	in	B-PP	IN	O	1	NMOD
8	three	three	B-NP	CD	O	9	NMOD
9	patients	patient	I-NP	NNS	O	7	PMOD
10	receiving	receive	B-VP	VBG	O	9	NMOD
11	cisplatin	cisplatin	B-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	5-fluorouracil	5-fluorouracil	I-NP	NN	O	10	OBJ
14	.	.	O	.	O	1	P

1	Cardiac	Cardiac	B-NP	JJ	O	2	NMOD
2	symptoms	symptom	I-NP	NNS	O	0	ROOT
3	,	,	O	,	O	2	P
4	including	include	B-PP	VBG	O	2	NMOD
5	hypotension	hypotension	B-NP	NN	O	4	PMOD
6	,	,	O	,	O	5	P
7	developed	develop	B-VP	VBN	O	5	NMOD
8	in	in	B-PP	IN	O	7	VMOD
9	three	three	B-NP	CD	O	10	NMOD
10	patients	patient	I-NP	NNS	O	8	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	advanced	advance	B-NP	VBN	O	14	NMOD
13	colorectal	colorectal	I-NP	JJ	O	14	NMOD
14	carcinoma	carcinoma	I-NP	NN	O	11	PMOD
15	while	while	B-SBAR	IN	O	2	VMOD
16	being	be	B-VP	VBG	O	15	SBAR
17	treated	treat	I-VP	VBN	O	16	VC
18	with	with	B-PP	IN	O	17	VMOD
19	cisplatin	cisplatin	B-NP	NN	O	24	NMOD
20	(	(	O	(	O	22	DEP
21	CDDP	CDDP	B-NP	NN	B-protein	22	DEP
22	)	)	O	)	O	19	NMOD
23	and	and	O	CC	O	24	NMOD
24	5-fluorouracil	5-fluorouracil	B-NP	NN	O	18	PMOD
25	(	(	O	(	O	27	DEP
26	5-FU	5-FU	B-NP	NN	O	27	DEP
27	)	)	O	)	O	24	NMOD
28	.	.	O	.	O	2	P

1	Fatal	Fatal	B-NP	JJ	O	3	NMOD
2	aplastic	aplastic	I-NP	JJ	O	3	NMOD
3	anemia	anemia	I-NP	NN	O	0	ROOT
4	in	in	B-PP	IN	O	3	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	patient	patient	I-NP	NN	O	4	PMOD
7	treated	treat	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	carbamazepine	carbamazepine	B-NP	NN	O	8	PMOD
10	.	.	O	.	O	3	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	15	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	fatal	fatal	B-NP	JJ	O	6	NMOD
5	aplastic	aplastic	I-NP	JJ	O	6	NMOD
6	anemia	anemia	I-NP	NN	O	3	PMOD
7	due	due	B-ADJP	JJ	O	6	NMOD
8	to	to	B-PP	TO	O	7	AMOD
9	carbamazepine	carbamazepine	B-NP	NN	O	10	NMOD
10	treatment	treatment	I-NP	NN	O	8	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	an	an	B-NP	DT	O	14	NMOD
13	epileptic	epileptic	I-NP	JJ	O	14	NMOD
14	woman	woman	I-NP	NN	O	11	PMOD
15	is	be	B-VP	VBZ	O	0	ROOT
16	reported	report	I-VP	VBN	O	15	VC
17	.	.	O	.	O	15	P

1	Despite	Despite	B-PP	IN	O	13	VMOD
2	concerns	concern	B-NP	NNS	O	1	PMOD
3	of	of	B-PP	IN	O	2	NMOD
4	fatal	fatal	B-NP	JJ	O	7	NMOD
5	bone	bone	I-NP	NN	O	7	NMOD
6	marrow	marrow	I-NP	NN	O	7	NMOD
7	toxicity	toxicity	I-NP	NN	O	3	PMOD
8	due	due	B-PP	IN	O	1	PMOD
9	to	to	B-PP	TO	O	8	PMOD
10	carbamazepine	carbamazepine	B-NP	NN	O	8	PMOD
11	,	,	O	,	O	13	P
12	this	this	B-NP	DT	O	13	SUB
13	is	be	B-VP	VBZ	O	0	ROOT
14	only	only	B-NP	RB	O	16	NMOD
15	the	the	I-NP	DT	O	16	NMOD
16	fourth	fourth	I-NP	JJ	O	20	NMOD
17	documented	document	I-NP	VBN	O	20	NMOD
18	and	and	I-NP	CC	O	20	NMOD
19	published	publish	I-NP	VBN	O	20	NMOD
20	report	report	I-NP	NN	O	13	PRD
21	.	.	O	.	O	13	P

1	Participation	Participation	B-NP	NN	O	13	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	a	a	B-NP	DT	O	6	NMOD
4	bulbospinal	bulbospinal	I-NP	JJ	O	6	NMOD
5	serotonergic	serotonergic	I-NP	JJ	O	6	NMOD
6	pathway	pathway	I-NP	NN	O	2	PMOD
7	in	in	B-PP	IN	O	1	NMOD
8	the	the	B-NP	DT	O	10	NMOD
9	rat	rat	I-NP	NN	O	10	NMOD
10	brain	brain	I-NP	NN	O	7	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	clonidine	clonidine	B-NP	NN	O	11	PMOD
13	induced	induce	B-VP	VBD	O	0	ROOT
14	hypotension	hypotension	B-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	bradycardia	bradycardia	I-NP	NN	O	13	OBJ
17	.	.	O	.	O	13	P

1	The	The	B-NP	DT	O	4	NMOD
2	clonidine	clonidine	I-NP	NN	O	4	NMOD
3	induced	induce	I-NP	VBN	O	2	AMOD
4	hypotension	hypotension	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	0	ROOT
6	antagonized	antagonize	I-VP	VBN	O	5	VC
7	by	by	B-PP	IN	O	6	VMOD
8	prior	prior	B-NP	JJ	O	10	NMOD
9	spinal	spinal	I-NP	JJ	O	10	NMOD
10	transection	transection	I-NP	NN	O	7	PMOD
11	,	,	O	,	O	6	P
12	but	but	O	CC	O	6	VMOD
13	not	not	O	RB	O	15	VMOD
14	bilateral	bilateral	B-NP	JJ	O	15	NMOD
15	vagotomy	vagotomy	I-NP	NN	O	6	VMOD
16	.	.	O	.	O	5	P

1	On	On	B-PP	IN	O	10	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	other	other	I-NP	JJ	O	4	NMOD
4	hand	hand	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	10	P
6	the	the	B-NP	DT	O	9	NMOD
7	clonidine	clonidine	I-NP	NN	O	9	NMOD
8	induced	induce	I-NP	VBN	O	7	AMOD
9	bradycardia	bradycardia	I-NP	NN	O	10	SUB
10	was	be	B-VP	VBD	O	0	ROOT
11	antagonized	antagonize	I-VP	VBN	O	10	VC
12	by	by	B-PP	IN	O	11	VMOD
13	prior	prior	B-NP	JJ	O	15	NMOD
14	bilateral	bilateral	I-NP	JJ	O	15	NMOD
15	vagotomy	vagotomy	I-NP	NN	O	12	PMOD
16	,	,	O	,	O	11	P
17	but	but	O	CC	O	11	VMOD
18	not	not	O	RB	O	20	VMOD
19	spinal	spinal	B-NP	JJ	O	20	NMOD
20	transection	transection	I-NP	NN	O	11	VMOD
21	.	.	O	.	O	10	P

1	Furthermore	Furthermore	B-ADVP	RB	O	21	VMOD
2	,	,	O	,	O	21	P
3	selective	selective	B-NP	JJ	O	4	NMOD
4	destruction	destruction	I-NP	NN	O	21	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	9	NMOD
7	spinal	spinal	I-NP	JJ	O	9	NMOD
8	5-HT	5-HT	I-NP	NN	O	9	NMOD
9	nerves	nerve	I-NP	NNS	O	5	PMOD
10	,	,	O	,	O	4	P
11	produced	produce	B-VP	VBN	O	4	NMOD
12	by	by	B-PP	IN	O	11	VMOD
13	bilateral	bilateral	B-NP	JJ	O	15	NMOD
14	spinal	spinal	I-NP	JJ	O	15	NMOD
15	injection	injection	I-NP	NN	O	12	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	5	5	B-NP	CD	O	19	NMOD
18	,	,	O	,	O	19	P
19	7-dihydroxytryptamine	7-dihydroxytryptamine	B-NP	NN	O	16	PMOD
20	,	,	O	,	O	4	P
21	reduced	reduce	B-VP	VBD	O	0	ROOT
22	the	the	B-NP	DT	O	23	NMOD
23	magnitude	magnitude	I-NP	NN	O	21	OBJ
24	of	of	B-PP	IN	O	23	NMOD
25	the	the	B-NP	DT	O	26	NMOD
26	vasodepressor	vasodepressor	I-NP	NN	O	30	NMOD
27	or	or	O	CC	O	30	NMOD
28	the	the	B-NP	DT	O	30	NMOD
29	bradycardiac	bradycardiac	I-NP	JJ	O	30	NMOD
30	responses	response	I-NP	NNS	O	24	PMOD
31	to	to	B-PP	TO	O	30	NMOD
32	clonidine	clonidine	B-NP	NN	O	31	PMOD
33	microinjected	microinjecte	B-VP	VBN	O	32	NMOD
34	into	into	B-PP	IN	O	33	VMOD
35	the	the	B-NP	DT	O	36	NMOD
36	area	area	I-NP	NN	O	34	PMOD
37	near	near	B-PP	IN	O	36	NMOD
38	the	the	B-NP	DT	O	40	NMOD
39	ventrolateral	ventrolateral	I-NP	JJ	O	40	NMOD
40	surface	surface	I-NP	NN	O	37	PMOD
41	of	of	B-PP	IN	O	40	NMOD
42	the	the	B-NP	DT	O	44	NMOD
43	medulla	medulla	I-NP	NN	O	44	NMOD
44	oblongata	oblongata	I-NP	NN	O	41	PMOD
45	in	in	B-PP	IN	O	44	NMOD
46	rats	rat	B-NP	NNS	O	45	PMOD
47	.	.	O	.	O	21	P

1	The	The	B-NP	DT	O	2	NMOD
2	data	datum	I-NP	NNS	O	3	SUB
3	indicate	indicate	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	a	a	B-NP	DT	O	8	NMOD
6	bulbospinal	bulbospinal	I-NP	JJ	O	8	NMOD
7	serotonergic	serotonergic	I-NP	JJ	O	8	NMOD
8	pathway	pathway	I-NP	NN	O	9	SUB
9	is	be	B-VP	VBZ	O	4	SBAR
10	involved	involve	I-VP	VBN	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	development	development	B-NP	NN	O	15	SUB
13	of	of	B-PP	IN	O	12	NMOD
14	clonidine	clonidine	B-NP	NN	O	13	PMOD
15	induced	induce	B-VP	VBD	O	11	SBAR
16	hypotension	hypotension	B-NP	NN	O	18	NMOD
17	and	and	I-NP	CC	O	18	NMOD
18	bradycardia	bradycardia	I-NP	NN	O	15	OBJ
19	.	.	O	.	O	3	P

1	Hypertension	Hypertension	B-NP	NN	O	0	ROOT
2	in	in	B-PP	IN	O	1	NMOD
3	neuroblastoma	neuroblastoma	B-NP	NN	B-cell_type	2	PMOD
4	induced	induce	B-VP	VBN	O	3	NMOD
5	by	by	B-PP	IN	O	4	VMOD
6	imipramine	imipramine	B-NP	NN	O	5	PMOD
7	.	.	O	.	O	1	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	occurrence	occurrence	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	severe	severe	B-NP	JJ	O	7	NMOD
7	hypertension	hypertension	I-NP	NN	O	5	PMOD
8	(	(	O	(	O	12	DEP
9	blood	blood	B-NP	NN	O	10	NMOD
10	pressure	pressure	I-NP	NN	O	12	DEP
11	190/160	190/160	I-NP	CD	O	10	NMOD
12	)	)	O	)	O	7	NMOD
13	in	in	B-PP	IN	O	7	NMOD
14	a	a	B-NP	DT	O	16	NMOD
15	4-year-old	4-year-old	I-NP	JJ	O	16	NMOD
16	girl	girl	I-NP	NN	O	22	NMOD
17	with	with	B-PP	IN	O	16	NMOD
18	neuroblastoma	neuroblastoma	B-NP	NN	B-cell_type	17	PMOD
19	who	who	B-NP	WP	O	22	NMOD
20	was	be	B-VP	VBD	O	22	NMOD
21	given	give	I-VP	VBN	O	22	NMOD
22	Imipramine	Imipramine	B-NP	NN	O	13	PMOD
23	to	to	B-VP	TO	O	24	VMOD
24	control	control	I-VP	VB	O	22	NMOD
25	a	a	B-NP	DT	O	27	NMOD
26	behavior	behavior	I-NP	NN	O	27	NMOD
27	disorder	disorder	I-NP	NN	O	24	OBJ
28	.	.	O	.	O	2	P

1	Since	Since	B-SBAR	IN	O	28	VMOD
2	she	she	B-NP	PRP	O	3	SUB
3	had	have	B-VP	VBD	O	1	SBAR
4	no	no	B-NP	DT	O	7	NMOD
5	blood	blood	I-NP	NN	O	7	NMOD
6	pressure	pressure	I-NP	NN	O	7	NMOD
7	elevation	elevation	I-NP	NN	O	3	OBJ
8	at	at	B-PP	IN	O	3	VMOD
9	initial	initial	B-NP	JJ	O	10	NMOD
10	diagnosis	diagnosis	I-NP	NN	O	12	NMOD
11	and	and	O	CC	O	12	NMOD
12	none	none	B-NP	NN	O	8	PMOD
13	following	follow	B-PP	VBG	O	12	NMOD
14	discontinuation	discontinuation	B-NP	NN	O	13	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	Imipramine	Imipramine	I-NP	NN	O	15	PMOD
18	(	(	O	(	O	25	DEP
19	when	when	B-ADVP	WRB	O	25	DEP
20	she	she	B-NP	PRP	O	21	SUB
21	was	be	B-VP	VBD	O	19	SBAR
22	in	in	B-PP	IN	O	21	PRD
23	florid	florid	B-NP	JJ	O	24	NMOD
24	relapse	relapse	I-NP	NN	O	22	PMOD
25	)	)	O	)	O	12	NMOD
26	,	,	O	,	O	28	P
27	we	we	B-NP	PRP	O	28	SUB
28	believe	believe	B-VP	VBP	O	0	ROOT
29	that	that	B-SBAR	IN	O	28	VMOD
30	this	this	B-NP	DT	O	31	NMOD
31	drug	drug	I-NP	NN	O	36	NMOD
32	rather	rather	B-CONJP	RB	O	36	NMOD
33	than	than	I-CONJP	IN	O	32	DEP
34	her	her	B-NP	PRP$	O	36	NMOD
35	underlying	underlie	I-NP	VBG	O	36	NMOD
36	disease	disease	I-NP	NN	O	38	SUB
37	alone	alone	B-ADVP	RB	O	36	NMOD
38	caused	cause	B-VP	VBD	O	29	SBAR
39	her	her	B-NP	PRP$	O	40	NMOD
40	hypertension	hypertension	I-NP	NN	O	38	OBJ
41	.	.	O	.	O	28	P

1	Rechallenge	Rechallenge	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	patients	patient	B-NP	NNS	O	2	PMOD
4	who	who	B-NP	WP	O	3	NMOD
5	developed	develop	B-VP	VBD	O	4	SBAR
6	oral	oral	B-NP	JJ	O	7	NMOD
7	candidiasis	candidiasis	I-NP	NN	O	9	NMOD
8	or	or	I-NP	CC	O	9	NMOD
9	hoarseness	hoarseness	I-NP	NN	O	5	OBJ
10	with	with	B-PP	IN	O	5	VMOD
11	beclomethasone	beclomethasone	B-NP	NN	O	12	NMOD
12	dipropionate	dipropionate	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	1	P

1	Of	Of	B-PP	IN	O	0	ROOT
2	158	158	B-NP	CD	O	4	NMOD
3	asthmatic	asthmatic	I-NP	JJ	O	4	NMOD
4	patients	patient	I-NP	NNS	O	1	PMOD
5	who	who	B-NP	WP	O	4	NMOD
6	were	be	B-VP	VBD	O	5	SBAR
7	placed	place	I-VP	VBN	O	6	VC
8	on	on	B-PP	IN	O	7	VMOD
9	inhaled	inhale	B-NP	VBN	O	10	NMOD
10	beclomethasone	beclomethasone	I-NP	NN	O	17	SUB
11	,	,	O	,	O	17	P
12	15	15	B-NP	CD	O	17	SUB
13	(	(	O	(	O	16	DEP
14	9.5	9.5	B-NP	CD	O	15	NMOD
15	%	%	I-NP	NN	O	16	DEP
16	)	)	O	)	O	12	NMOD
17	developed	develop	B-VP	VBD	O	8	SBAR
18	either	either	O	CC	O	17	VMOD
19	hoarseness	hoarseness	B-NP	NN	O	25	NMOD
20	(	(	O	(	O	22	DEP
21	8	8	B-NP	CD	O	22	DEP
22	)	)	O	)	O	19	NMOD
23	,	,	O	,	O	25	P
24	oral	oral	B-NP	JJ	O	25	NMOD
25	thrush	thrush	I-NP	NN	O	18	PMOD
26	(	(	O	(	O	28	DEP
27	6	6	B-NP	CD	O	28	DEP
28	)	)	O	)	O	25	NMOD
29	,	,	O	,	O	34	P
30	or	or	O	CC	O	34	DEP
31	both	both	B-NP	DT	O	34	DEP
32	(	(	O	(	O	34	DEP
33	1	1	B-NP	CD	O	34	DEP
34	)	)	O	)	O	25	NMOD
35	.	.	O	.	O	1	P

1	We	We	B-NP	PRP	O	2	SUB
2	conclude	conclude	B-VP	VBP	O	28	VMOD
3	that	that	B-SBAR	IN	O	2	VMOD
4	patients	patient	B-NP	NNS	O	5	SUB
5	may	may	B-VP	MD	O	3	SBAR
6	be	be	I-VP	VB	O	5	VC
7	restarted	restart	I-VP	VBN	O	6	VC
8	on	on	B-PP	IN	O	7	VMOD
9	inhaled	inhale	B-NP	VBN	O	10	NMOD
10	beclomethasone	beclomethasone	I-NP	NN	O	8	PMOD
11	when	when	B-ADVP	WRB	O	7	VMOD
12	clinically	clinically	B-ADVP	RB	O	13	VMOD
13	indicated	indicate	B-VP	VBN	O	11	SBAR
14	;	;	O	:	O	28	P
15	however	however	B-ADVP	RB	O	28	VMOD
16	,	,	O	,	O	28	P
17	because	because	B-PP	IN	O	28	VMOD
18	of	of	I-PP	IN	O	17	PMOD
19	the	the	B-NP	DT	O	22	NMOD
20	high	high	I-NP	JJ	O	22	NMOD
21	recurrence	recurrence	I-NP	NN	O	22	NMOD
22	rate	rate	I-NP	NN	O	17	PMOD
23	,	,	O	,	O	28	P
24	patients	patient	B-NP	NNS	O	28	SUB
25	who	who	B-NP	WP	O	24	NMOD
26	develop	develop	B-VP	VBP	O	25	SBAR
27	hoarseness	hoarseness	B-NP	NN	O	26	OBJ
28	should	should	B-VP	MD	O	0	ROOT
29	not	not	I-VP	RB	O	28	VMOD
30	be	be	I-VP	VB	O	28	VC
31	re-challenged	re-challenged	B-ADJP	JJ	O	30	PRD
32	.	.	O	.	O	28	P

1	Cyclophosphamide	Cyclophosphamide	B-NP	NN	O	2	NMOD
2	cardiotoxicity	cardiotoxicity	I-NP	NN	O	5	NMOD
3	:	:	O	:	O	2	P
4	an	an	B-NP	DT	O	5	NMOD
5	analysis	analysis	I-NP	NN	O	0	ROOT
6	of	of	B-PP	IN	O	5	NMOD
7	dosing	dosing	B-NP	NN	O	6	PMOD
8	as	as	B-PP	IN	O	5	NMOD
9	a	a	B-NP	DT	O	11	NMOD
10	risk	risk	I-NP	NN	B-protein	11	NMOD
11	factor	factor	I-NP	NN	I-protein	8	PMOD
12	.	.	O	.	O	5	P

1	At	At	B-PP	IN	O	10	VMOD
2	these	these	B-NP	DT	O	4	NMOD
3	high	high	I-NP	JJ	O	4	NMOD
4	doses	dose	I-NP	NNS	O	1	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	CYA	CYA	B-NP	NN	O	5	PMOD
7	,	,	O	,	O	10	P
8	serious	serious	B-NP	JJ	O	9	NMOD
9	cardiotoxicity	cardiotoxicity	I-NP	NN	O	10	SUB
10	may	may	B-VP	MD	O	23	VMOD
11	occur	occur	I-VP	VB	O	10	VC
12	,	,	O	,	O	16	P
13	but	but	O	CC	O	16	NMOD
14	definitive	definitive	B-NP	JJ	O	16	NMOD
15	risk	risk	I-NP	NN	O	16	NMOD
16	factors	factor	I-NP	NNS	O	23	SUB
17	for	for	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	19	NMOD
19	development	development	I-NP	NN	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	such	such	B-NP	JJ	O	22	NMOD
22	cardiotoxicity	cardiotoxicity	I-NP	NN	O	20	PMOD
23	have	have	B-VP	VBP	O	0	ROOT
24	not	not	I-VP	RB	O	23	VMOD
25	been	be	I-VP	VBN	O	23	VC
26	described	describe	I-VP	VBN	O	25	VC
27	.	.	O	.	O	23	P

1	Since	Since	B-SBAR	IN	O	16	VMOD
2	chemotherapeutic	chemotherapeutic	B-NP	JJ	O	4	NMOD
3	agent	agent	I-NP	NN	O	4	NMOD
4	toxicity	toxicity	I-NP	NN	O	6	SUB
5	generally	generally	B-ADVP	RB	O	6	VMOD
6	correlates	correlate	B-VP	VBZ	O	1	SBAR
7	with	with	B-PP	IN	O	6	VMOD
8	dose	dose	B-NP	NN	O	7	PMOD
9	per	per	B-PP	IN	O	8	NMOD
10	body	body	B-NP	NN	O	12	NMOD
11	surface	surface	I-NP	NN	O	12	NMOD
12	area	area	I-NP	NN	O	9	PMOD
13	,	,	O	,	O	16	P
14	we	we	B-NP	PRP	O	16	SUB
15	retrospectively	retrospectively	B-ADVP	RB	O	16	VMOD
16	calculated	calculate	B-VP	VBD	O	0	ROOT
17	the	the	B-NP	DT	O	18	NMOD
18	dose	dose	I-NP	NN	O	16	OBJ
19	of	of	B-PP	IN	O	18	NMOD
20	CYA	CYA	B-NP	NN	O	19	PMOD
21	in	in	B-PP	IN	O	18	NMOD
22	patients	patient	B-NP	NNS	O	21	PMOD
23	transplanted	transplant	B-VP	VBN	O	22	NMOD
24	at	at	B-PP	IN	O	23	VMOD
25	our	our	B-NP	PRP$	O	26	NMOD
26	institution	institution	I-NP	NN	O	24	PMOD
27	to	to	B-VP	TO	O	28	VMOD
28	determine	determine	I-VP	VB	O	16	VMOD
29	whether	whether	B-SBAR	IN	O	28	VMOD
30	the	the	B-NP	DT	O	31	NMOD
31	incidence	incidence	I-NP	NN	O	35	SUB
32	of	of	B-PP	IN	O	31	NMOD
33	CYA	CYA	B-NP	NN	O	34	NMOD
34	cardiotoxicity	cardiotoxicity	I-NP	NN	O	32	PMOD
35	correlated	correlate	B-VP	VBD	O	29	SBAR
36	with	with	B-PP	IN	O	35	VMOD
37	the	the	B-NP	DT	O	38	NMOD
38	dose	dose	I-NP	NN	O	36	PMOD
39	per	per	B-PP	IN	O	38	NMOD
40	body	body	B-NP	NN	O	42	NMOD
41	surface	surface	I-NP	NN	O	42	NMOD
42	area	area	I-NP	NN	O	39	PMOD
43	.	.	O	.	O	16	P

1	Eighty	Eighty	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	18	SUB
3	who	who	B-NP	WP	O	2	NMOD
4	were	be	B-VP	VBD	O	3	SBAR
5	to	to	I-VP	TO	O	6	VMOD
6	receive	receive	I-VP	VB	O	4	VC
7	CYA	CYA	B-NP	NN	O	9	NMOD
8	50	50	I-NP	CD	O	9	NMOD
9	mg/kg/d	mg/kg/d	I-NP	NN	O	6	OBJ
10	for	for	B-PP	IN	O	9	NMOD
11	four	four	B-NP	CD	O	12	NMOD
12	days	day	I-NP	NNS	O	10	PMOD
13	as	as	B-PP	IN	O	9	NMOD
14	preparation	preparation	B-NP	NN	O	13	PMOD
15	for	for	B-PP	IN	O	14	NMOD
16	marrow	marrow	B-NP	NN	O	17	NMOD
17	grafting	grafting	I-NP	NN	O	15	PMOD
18	underwent	undergo	B-VP	VBD	O	0	ROOT
19	a	a	B-NP	DT	O	20	NMOD
20	total	total	I-NP	NN	O	18	OBJ
21	of	of	B-PP	IN	O	20	NMOD
22	84	84	B-NP	CD	O	23	NMOD
23	transplants	transplant	I-NP	NNS	O	21	PMOD
24	for	for	B-PP	IN	O	18	VMOD
25	aplastic	aplastic	B-NP	JJ	O	26	NMOD
26	anemia	anemia	I-NP	NN	O	24	PMOD
27	,	,	O	,	O	18	P
28	Wiskott-Aldrich	Wiskott-Aldrich	B-NP	JJ	O	29	NMOD
29	syndrome	syndrome	I-NP	NN	O	18	OBJ
30	,	,	O	,	O	35	P
31	or	or	O	CC	O	35	NMOD
32	severe	severe	B-NP	JJ	O	35	NMOD
33	combined	combined	I-NP	JJ	O	35	NMOD
34	immunodeficiency	immunodeficiency	I-NP	NN	O	35	NMOD
35	syndrome	syndrome	I-NP	NN	O	18	VMOD
36	.	.	O	.	O	18	P

1	Fourteen	Fourteen	B-NP	CD	O	2	AMOD
2	of	of	B-PP	IN	O	0	ROOT
3	84	84	B-NP	CD	O	2	AMOD
4	(	(	O	(	O	7	DEP
5	17	17	B-NP	CD	O	6	NMOD
6	%	%	I-NP	NN	O	7	DEP
7	)	)	O	)	O	8	NMOD
8	patients	patient	B-NP	NNS	O	2	VMOD
9	had	have	B-VP	VBD	O	8	NMOD
10	symptoms	symptom	B-NP	NNS	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	signs	sign	I-NP	NNS	O	9	OBJ
13	consistent	consistent	B-ADJP	JJ	O	12	NMOD
14	with	with	B-PP	IN	O	13	AMOD
15	CYA	CYA	B-NP	NN	O	16	NMOD
16	cardiotoxicity	cardiotoxicity	I-NP	NN	O	14	PMOD
17	within	within	B-PP	IN	O	16	NMOD
18	ten	ten	B-NP	CD	O	19	NMOD
19	days	day	I-NP	NNS	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	receiving	receive	B-VP	VBG	O	20	PMOD
22	1	1	B-NP	CD	O	24	AMOD
23	to	to	I-NP	TO	O	24	AMOD
24	4	4	I-NP	CD	O	25	NMOD
25	doses	dose	I-NP	NNS	O	21	OBJ
26	of	of	B-PP	IN	O	25	NMOD
27	CYA	CYA	B-NP	NN	O	26	PMOD
28	.	.	O	.	O	2	P

1	Cardiotoxicity	Cardiotoxicity	B-NP	NN	O	10	SUB
2	that	that	B-NP	WDT	O	1	NMOD
3	was	be	B-VP	VBD	O	2	SBAR
4	thought	think	I-VP	VBN	O	3	VC
5	to	to	I-VP	TO	O	6	VMOD
6	be	be	I-VP	VB	O	4	VMOD
7	related	relate	I-VP	VBN	O	6	VC
8	to	to	B-PP	TO	O	7	AMOD
9	CYA	CYA	B-NP	NN	B-protein	8	PMOD
10	occurred	occur	B-VP	VBD	O	0	ROOT
11	in	in	B-PP	IN	O	10	VMOD
12	1/32	1/32	B-NP	CD	O	11	PMOD
13	(	(	O	(	O	16	DEP
14	3	3	B-NP	CD	O	15	NMOD
15	%	%	I-NP	NN	O	16	DEP
16	)	)	O	)	O	12	NMOD
17	of	of	B-PP	IN	O	12	NMOD
18	patients	patient	B-NP	NNS	O	17	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	Group	Group	B-NP	NN	O	19	PMOD
21	1	1	I-NP	CD	O	20	NMOD
22	and	and	O	CC	O	11	PMOD
23	in	in	B-PP	IN	O	11	PMOD
24	13/52	13/52	B-NP	CD	O	29	NMOD
25	(	(	O	(	O	28	DEP
26	25	25	B-NP	CD	O	27	NMOD
27	%	%	I-NP	NN	O	28	DEP
28	)	)	O	)	O	24	NMOD
29	patients	patient	B-NP	NNS	O	23	PMOD
30	in	in	B-PP	IN	O	29	NMOD
31	Group	Group	B-NP	NN	O	30	PMOD
32	2	2	I-NP	CD	O	31	NMOD
33	(	(	O	(	O	38	DEP
34	P	P	B-NP	NN	O	38	DEP
35	less	less	B-ADJP	JJR	O	34	NMOD
36	than	than	B-PP	IN	O	35	AMOD
37	0.025	0.025	B-NP	CD	O	36	PMOD
38	)	)	O	)	O	29	NMOD
39	.	.	O	.	O	10	P

1	We	We	B-NP	PRP	O	2	SUB
2	conclude	conclude	B-VP	VBP	O	0	ROOT
3	that	that	B-SBAR	IN	O	19	DEP
4	the	the	B-NP	DT	O	6	NMOD
5	CYA	CYA	I-NP	NN	O	6	NMOD
6	cardiotoxicity	cardiotoxicity	I-NP	NN	O	7	SUB
7	correlates	correlate	B-VP	VBZ	O	3	SBAR
8	with	with	B-PP	IN	O	7	VMOD
9	CYA	CYA	B-NP	NN	O	10	NMOD
10	dosage	dosage	I-NP	NN	O	8	PMOD
11	as	as	B-SBAR	IN	O	7	VMOD
12	calculated	calculate	B-VP	VBN	O	11	SBAR
13	by	by	B-PP	IN	O	12	VMOD
14	body	body	B-NP	NN	O	16	NMOD
15	surface	surface	I-NP	NN	O	16	NMOD
16	area	area	I-NP	NN	O	13	PMOD
17	,	,	O	,	O	19	P
18	and	and	O	CC	O	19	DEP
19	that	that	B-SBAR	IN	O	2	VMOD
20	patients	patient	B-NP	NNS	O	26	SUB
21	with	with	B-PP	IN	O	20	NMOD
22	aplastic	aplastic	B-NP	JJ	O	23	NMOD
23	anemia	anemia	I-NP	NN	O	25	NMOD
24	and	and	I-NP	CC	O	25	NMOD
25	immunodeficiencies	immunodeficiency	I-NP	NNS	O	21	PMOD
26	can	can	B-VP	MD	O	19	SBAR
27	be	be	I-VP	VB	O	26	VC
28	effectively	effectively	I-VP	RB	O	29	VMOD
29	prepared	prepare	I-VP	VBN	O	27	VC
30	for	for	B-PP	IN	O	29	VMOD
31	bone	bone	B-NP	NN	O	32	NMOD
32	marrow	marrow	I-NP	NN	O	30	PMOD
33	grafting	graft	B-VP	VBG	O	32	NMOD
34	at	at	B-PP	IN	O	33	VMOD
35	a	a	B-NP	DT	O	37	NMOD
36	CYA	CYA	I-NP	NN	O	37	NMOD
37	dose	dose	I-NP	NN	O	34	PMOD
38	of	of	B-PP	IN	O	37	NMOD
39	1.55	1.55	B-NP	CD	O	40	NMOD
40	g/m2/d	g/m2/d	I-NP	NN	O	38	PMOD
41	for	for	B-PP	IN	O	37	NMOD
42	four	four	B-NP	CD	O	43	NMOD
43	days	day	I-NP	NNS	O	41	PMOD
44	with	with	B-PP	IN	O	43	NMOD
45	a	a	B-NP	DT	O	47	NMOD
46	lower	low	I-NP	JJR	O	47	NMOD
47	incidence	incidence	I-NP	NN	O	44	PMOD
48	of	of	B-PP	IN	O	47	NMOD
49	cardiotoxicity	cardiotoxicity	B-NP	NN	O	48	PMOD
50	than	than	B-PP	IN	O	47	NMOD
51	patients	patient	B-NP	NNS	O	54	NMOD
52	whose	whose	B-NP	WP$	O	54	NMOD
53	CYA	CYA	I-NP	NN	O	54	NMOD
54	dosage	dosage	I-NP	NN	O	50	PMOD
55	is	be	B-VP	VBZ	O	26	VMOD
56	calculated	calculate	I-VP	VBN	O	55	VC
57	based	base	B-PP	VBN	O	56	VMOD
58	on	on	B-PP	IN	O	57	PMOD
59	weight	weight	B-NP	NN	O	58	PMOD
60	.	.	O	.	O	2	P

1	Studies	Study	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	risk	risk	B-NP	NN	O	4	NMOD
4	factors	factor	I-NP	NNS	O	2	PMOD
5	for	for	B-PP	IN	O	4	NMOD
6	aminoglycoside	aminoglycoside	B-NP	NN	O	7	NMOD
7	nephrotoxicity	nephrotoxicity	I-NP	NN	O	5	PMOD
8	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	epidemiology	epidemiology	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	aminoglycoside	aminoglycoside	B-NP	NN	O	6	NMOD
5	induced	induced	I-NP	JJ	O	6	NMOD
6	nephrotoxicity	nephrotoxicity	I-NP	NN	O	3	PMOD
7	is	be	B-VP	VBZ	O	0	ROOT
8	not	not	I-VP	RB	O	7	VMOD
9	fully	fully	I-VP	RB	O	7	VMOD
10	understood	understand	I-VP	VBN	O	7	VC
11	.	.	O	.	O	7	P

1	Experimental	Experimental	B-NP	JJ	O	2	NMOD
2	studies	study	I-NP	NNS	O	7	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	healthy	healthy	B-NP	JJ	O	6	NMOD
5	human	human	I-NP	JJ	O	6	NMOD
6	volunteers	volunteer	I-NP	NNS	O	3	PMOD
7	indicate	indicate	B-VP	VBP	O	23	VMOD
8	aminoglycosides	aminoglycoside	B-NP	NNS	O	9	SUB
9	cause	cause	B-VP	VBP	O	7	VMOD
10	proximal	proximal	B-NP	JJ	O	12	NMOD
11	tubular	tubular	I-NP	JJ	O	12	NMOD
12	damage	damage	I-NP	NN	O	9	OBJ
13	in	in	B-PP	IN	O	12	NMOD
14	most	most	B-NP	JJS	O	15	NMOD
15	patients	patient	I-NP	NNS	O	13	PMOD
16	,	,	O	,	O	23	P
17	but	but	O	CC	O	23	VMOD
18	rarely	rarely	B-ADVP	RB	O	23	VMOD
19	,	,	O	,	O	23	P
20	if	if	B-SBAR	IN	O	23	VMOD
21	ever	ever	B-ADVP	RB	O	20	DEP
22	,	,	O	,	O	23	P
23	cause	cause	B-VP	VBP	O	0	ROOT
24	glomerular	glomerular	B-NP	JJ	O	27	NMOD
25	or	or	I-NP	CC	O	27	NMOD
26	tubular	tubular	I-NP	JJ	O	27	NMOD
27	dysfunction	dysfunction	I-NP	NN	O	23	OBJ
28	.	.	O	.	O	23	P

1	Clinical	Clinical	B-NP	JJ	O	2	NMOD
2	trials	trial	I-NP	NNS	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	aminoglycosides	aminoglycoside	B-NP	NNS	O	3	PMOD
5	in	in	B-PP	IN	O	4	NMOD
6	seriously	seriously	B-NP	RB	O	7	AMOD
7	ill	ill	I-NP	JJ	O	8	NMOD
8	patients	patient	I-NP	NNS	O	5	PMOD
9	indicate	indicate	B-VP	VBP	O	0	ROOT
10	that	that	B-SBAR	IN	O	27	DEP
11	the	the	B-NP	DT	O	13	NMOD
12	relative	relative	I-NP	JJ	O	13	NMOD
13	risk	risk	I-NP	NN	O	10	SBAR
14	for	for	B-PP	IN	O	13	NMOD
15	developing	develop	B-VP	VBG	O	14	SBAR
16	acute	acute	B-NP	JJ	O	18	NMOD
17	renal	renal	I-NP	JJ	O	18	NMOD
18	failure	failure	I-NP	NN	O	15	OBJ
19	during	during	B-PP	IN	O	15	VMOD
20	therapy	therapy	B-NP	NN	O	21	NMOD
21	ranges	range	I-NP	NNS	O	19	PMOD
22	from	from	B-PP	IN	O	21	NMOD
23	8	8	B-NP	CD	O	25	AMOD
24	to	to	B-PP	TO	O	25	AMOD
25	10	10	B-NP	CD	O	22	PMOD
26	and	and	O	CC	O	27	DEP
27	that	that	B-SBAR	IN	O	9	VMOD
28	the	the	B-NP	DT	O	30	NMOD
29	attributable	attributable	I-NP	JJ	O	30	NMOD
30	risk	risk	I-NP	NN	O	31	SUB
31	is	be	B-VP	VBZ	O	27	SBAR
32	70	70	B-NP	CD	O	31	PRD
33	%	%	I-NP	NN	O	32	NMOD
34	to	to	I-NP	TO	O	33	VMOD
35	80	80	I-NP	CD	O	36	NMOD
36	%	%	I-NP	NN	O	34	PMOD
37	.	.	O	.	O	9	P

1	Further	Further	B-NP	JJ	O	2	NMOD
2	analysis	analysis	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	these	these	B-NP	DT	O	5	NMOD
5	data	datum	I-NP	NNS	O	3	PMOD
6	suggests	suggest	B-VP	VBZ	O	0	ROOT
7	that	that	B-SBAR	IN	O	6	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	duration	duration	I-NP	NN	O	35	SUB
10	of	of	B-PP	IN	O	9	NMOD
11	therapy	therapy	B-NP	NN	O	10	PMOD
12	,	,	O	,	O	35	P
13	plasma	plasma	B-NP	NN	O	15	NMOD
14	aminoglycoside	aminoglycoside	I-NP	NN	O	15	NMOD
15	levels	level	I-NP	NNS	O	35	SUB
16	,	,	O	,	O	35	P
17	liver	liver	B-NP	NN	O	18	NMOD
18	disease	disease	I-NP	NN	O	27	NMOD
19	,	,	O	,	O	27	P
20	advanced	advanced	B-NP	JJ	O	21	NMOD
21	age	age	I-NP	NN	O	27	NMOD
22	,	,	O	,	O	27	P
23	high	high	B-NP	JJ	O	27	NMOD
24	initial	initial	I-NP	JJ	O	27	NMOD
25	estimated	estimate	I-NP	VBN	O	27	NMOD
26	creatinine	creatinine	I-NP	NN	O	27	NMOD
27	clearance	clearance	I-NP	NN	O	35	SUB
28	and	and	O	CC	O	35	VMOD
29	,	,	O	,	O	35	P
30	possibly	possibly	B-ADVP	RB	O	35	VMOD
31	,	,	O	,	O	35	P
32	female	female	B-NP	JJ	O	33	NMOD
33	gender	gender	I-NP	NN	O	35	SUB
34	all	all	O	DT	O	33	NMOD
35	increase	increase	B-VP	VBP	O	7	SBAR
36	the	the	B-NP	DT	O	37	NMOD
37	risk	risk	I-NP	NN	O	35	OBJ
38	for	for	B-PP	IN	O	37	NMOD
39	nephrotoxicity	nephrotoxicity	B-NP	NN	O	38	PMOD
40	.	.	O	.	O	6	P

1	Flurothyl	Flurothyl	B-NP	NN	O	3	NMOD
2	seizure	seizure	I-NP	NN	O	3	NMOD
3	thresholds	threshold	I-NP	NNS	O	19	NMOD
4	in	in	B-PP	IN	O	3	NMOD
5	mice	mouse	B-NP	NNS	O	4	PMOD
6	treated	treat	B-VP	VBN	O	5	NMOD
7	neonatally	neonatally	B-ADVP	RB	O	6	VMOD
8	with	with	B-PP	IN	O	6	VMOD
9	a	a	B-NP	DT	O	11	NMOD
10	single	single	I-NP	JJ	O	11	NMOD
11	injection	injection	I-NP	NN	O	8	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	monosodium	monosodium	B-NP	NN	O	14	NMOD
14	glutamate	glutamate	I-NP	NN	O	12	PMOD
15	(	(	O	(	O	17	DEP
16	MSG	MSG	B-NP	NN	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	:	:	O	:	O	3	P
19	evaluation	evaluation	B-NP	NN	O	0	ROOT
20	of	of	B-PP	IN	O	19	NMOD
21	experimental	experimental	B-NP	JJ	O	22	NMOD
22	parameters	parameter	I-NP	NNS	O	20	PMOD
23	in	in	B-PP	IN	O	19	NMOD
24	flurothyl	flurothyl	B-NP	NN	O	26	NMOD
25	seizure	seizure	I-NP	NN	O	26	NMOD
26	testing	testing	I-NP	NN	O	23	PMOD
27	.	.	O	.	O	19	P

1	Monosodium	Monosodium	B-NP	NN	O	2	NMOD
2	glutamate	glutamate	I-NP	NN	O	6	NMOD
3	(	(	O	(	O	5	DEP
4	MSG	MSG	B-NP	NN	O	5	DEP
5	)	)	O	)	O	2	NMOD
6	administration	administration	B-NP	NN	O	10	SUB
7	to	to	B-PP	TO	O	6	NMOD
8	neonatal	neonatal	B-NP	JJ	O	9	NMOD
9	rodents	rodent	I-NP	NNS	O	7	PMOD
10	produces	produce	B-VP	VBZ	O	0	ROOT
11	convulsions	convulsion	B-NP	NNS	O	10	OBJ
12	and	and	O	CC	O	10	VMOD
13	results	result	B-VP	VBZ	O	10	VMOD
14	in	in	B-PP	IN	O	13	VMOD
15	numerous	numerous	B-NP	JJ	O	14	PMOD
16	biochemical	biochemical	I-NP	JJ	O	15	NMOD
17	and	and	I-NP	CC	O	15	NMOD
18	behavioral	behavioral	I-NP	JJ	O	15	NMOD
19	deficits	deficit	I-NP	NNS	O	15	NMOD
20	.	.	O	.	O	10	P

1	These	These	B-NP	DT	O	2	NMOD
2	studies	study	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	0	ROOT
4	undertaken	undertake	I-VP	VBN	O	3	VC
5	to	to	B-VP	TO	O	6	VMOD
6	determine	determine	I-VP	VB	O	4	VMOD
7	if	if	B-SBAR	IN	O	6	VMOD
8	neonatal	neonatal	B-NP	JJ	O	9	NMOD
9	administration	administration	I-NP	NN	O	12	SUB
10	of	of	B-PP	IN	O	9	NMOD
11	MSG	MSG	B-NP	NN	B-protein	10	PMOD
12	produced	produce	B-VP	VBD	O	7	SBAR
13	permanent	permanent	B-NP	JJ	O	14	NMOD
14	alterations	alteration	I-NP	NNS	O	12	OBJ
15	in	in	B-PP	IN	O	12	VMOD
16	seizure	seizure	B-NP	NN	O	17	NMOD
17	susceptibility	susceptibility	I-NP	NN	O	15	PMOD
18	,	,	O	,	O	3	P
19	since	since	B-SBAR	IN	O	3	VMOD
20	previous	previous	B-NP	JJ	O	21	NMOD
21	investigations	investigation	I-NP	NNS	O	22	SUB
22	were	be	B-VP	VBD	O	19	SBAR
23	inconclusive	inconclusive	B-ADJP	JJ	O	22	PRD
24	.	.	O	.	O	3	P

1	A	A	B-NP	DT	O	6	NMOD
2	flurothyl	flurothyl	I-NP	NN	O	6	NMOD
3	ether	ether	I-NP	NN	O	6	NMOD
4	seizure	seizure	I-NP	NN	O	6	NMOD
5	screening	screening	I-NP	NN	O	6	NMOD
6	technique	technique	I-NP	NN	O	7	SUB
7	was	be	B-VP	VBD	O	0	ROOT
8	used	use	I-VP	VBN	O	7	VC
9	to	to	B-VP	TO	O	10	VMOD
10	evaluate	evaluate	I-VP	VB	O	7	VMOD
11	seizure	seizure	B-NP	NN	O	12	NMOD
12	susceptibility	susceptibility	I-NP	NN	O	10	OBJ
13	in	in	B-PP	IN	O	12	NMOD
14	adult	adult	B-NP	JJ	O	15	NMOD
15	mice	mouse	I-NP	NNS	O	13	PMOD
16	that	that	B-NP	WDT	O	12	NMOD
17	received	receive	B-VP	VBD	O	16	SBAR
18	neonatal	neonatal	B-NP	JJ	O	19	NMOD
19	injections	injection	I-NP	NNS	O	17	OBJ
20	of	of	B-PP	IN	O	19	NMOD
21	MSG	MSG	B-NP	NN	O	20	PMOD
22	(	(	O	(	O	28	DEP
23	4	4	B-NP	CD	O	24	NMOD
24	mg/g	mg/g	I-NP	NN	O	27	NMOD
25	and	and	O	CC	O	27	NMOD
26	1	1	B-NP	CD	O	27	NMOD
27	mg/g	mg/g	I-NP	NN	O	28	DEP
28	)	)	O	)	O	21	NMOD
29	.	.	O	.	O	7	P

1	MSG	MSG	B-NP	NN	O	2	NMOD
2	treatment	treatment	I-NP	NN	O	3	SUB
3	resulted	result	B-VP	VBD	O	0	ROOT
4	in	in	B-PP	IN	O	3	VMOD
5	significant	significant	B-NP	JJ	O	6	NMOD
6	reductions	reduction	I-NP	NNS	O	4	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	whole	whole	B-NP	JJ	O	10	NMOD
9	brain	brain	I-NP	NN	O	10	NMOD
10	weight	weight	I-NP	NN	O	7	PMOD
11	but	but	O	CC	O	3	VMOD
12	did	do	B-VP	VBD	O	3	VMOD
13	not	not	I-VP	RB	O	12	VMOD
14	alter	alter	I-VP	VB	O	12	VC
15	seizure	seizure	B-NP	NN	O	16	NMOD
16	threshold	threshold	I-NP	NN	O	14	OBJ
17	.	.	O	.	O	3	P

1	A	A	B-NP	DT	O	2	NMOD
2	naloxone	naloxone	I-NP	NN	O	7	NMOD
3	(	(	O	(	O	6	DEP
4	5	5	B-NP	CD	O	5	NMOD
5	mg/kg	mg/kg	I-NP	NN	O	6	DEP
6	)	)	O	)	O	2	NMOD
7	challenge	challenge	B-NP	NN	O	8	SUB
8	was	be	B-VP	VBD	O	0	ROOT
9	also	also	B-ADVP	RB	O	8	VMOD
10	ineffective	ineffective	B-ADJP	JJ	O	8	PRD
11	in	in	B-PP	IN	O	10	AMOD
12	altering	alter	B-VP	VBG	O	11	PMOD
13	the	the	B-NP	DT	O	15	NMOD
14	seizure	seizure	I-NP	NN	O	15	NMOD
15	thresholds	threshold	I-NP	NNS	O	12	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	either	either	O	CC	O	18	NMOD
18	control	control	B-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	MSG-treated	MSG-treated	B-NP	JJ	O	21	NMOD
21	mice	mouse	I-NP	NNS	O	19	PMOD
22	.	.	O	.	O	8	P

1	Flurothyl	Flurothyl	B-NP	NN	O	2	NMOD
2	ether	ether	I-NP	NN	O	3	SUB
3	produced	produce	B-VP	VBD	O	24	VMOD
4	hypothermia	hypothermia	B-NP	NN	O	3	OBJ
5	which	which	B-NP	WDT	O	4	NMOD
6	was	be	B-VP	VBD	O	5	SBAR
7	correlated	correlate	I-VP	VBN	O	6	VC
8	with	with	B-PP	IN	O	7	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	duration	duration	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	flurothyl	flurothyl	B-NP	NN	O	13	NMOD
13	exposure	exposure	I-NP	NN	O	11	PMOD
14	;	;	O	:	O	24	P
15	however	however	B-ADVP	RB	O	24	VMOD
16	,	,	O	,	O	24	P
17	the	the	B-NP	DT	O	18	NMOD
18	relationship	relationship	I-NP	NN	O	24	SUB
19	of	of	B-PP	IN	O	18	NMOD
20	hypothermia	hypothermia	B-NP	NN	O	19	PMOD
21	to	to	B-PP	TO	O	18	NMOD
22	seizure	seizure	B-NP	NN	O	23	NMOD
23	induction	induction	I-NP	NN	O	21	PMOD
24	was	be	B-VP	VBD	O	0	ROOT
25	unclear	unclear	B-ADJP	JJ	O	24	PRD
26	.	.	O	.	O	24	P

1	Susceptibility	Susceptibility	B-NP	NN	O	0	ROOT
2	to	to	B-PP	TO	O	1	NMOD
3	seizures	seizure	B-NP	NNS	O	2	PMOD
4	produced	produce	B-VP	VBN	O	3	NMOD
5	by	by	B-PP	IN	O	4	VMOD
6	pilocarpine	pilocarpine	B-NP	NN	O	5	PMOD
7	in	in	B-PP	IN	O	4	VMOD
8	rats	rat	B-NP	NNS	O	7	PMOD
9	after	after	B-PP	IN	O	4	VMOD
10	microinjection	microinjection	B-NP	NN	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	isoniazid	isoniazid	B-NP	NN	O	14	NMOD
13	or	or	I-NP	CC	O	14	NMOD
14	gamma-vinyl-GABA	gamma-vinyl-GABA	I-NP	NN	O	11	PMOD
15	into	into	B-PP	IN	O	10	NMOD
16	the	the	B-NP	DT	O	18	NMOD
17	substantia	substantia	I-NP	NN	O	18	NMOD
18	nigra	nigra	I-NP	NN	O	15	PMOD
19	.	.	O	.	O	1	P

1	Pilocarpine	Pilocarpine	B-NP	NN	O	8	SUB
2	,	,	O	,	O	1	P
3	given	give	B-VP	VBN	O	1	NMOD
4	intraperitoneally	intraperitoneally	B-ADVP	RB	O	5	PMOD
5	to	to	B-PP	TO	O	3	VMOD
6	rats	rat	B-NP	NNS	O	5	PMOD
7	,	,	O	,	O	1	P
8	reproduces	reproduce	B-VP	VBZ	O	0	ROOT
9	the	the	B-NP	DT	O	11	NMOD
10	neuropathological	neuropathological	I-NP	JJ	O	11	NMOD
11	sequelae	sequela	I-NP	NNS	O	8	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	temporal	temporal	B-NP	JJ	O	15	NMOD
14	lobe	lobe	I-NP	NN	O	15	NMOD
15	epilepsy	epilepsy	I-NP	NN	O	12	PMOD
16	and	and	O	CC	O	8	VMOD
17	provides	provide	B-VP	VBZ	O	8	VMOD
18	a	a	B-NP	DT	O	21	NMOD
19	relevant	relevant	I-NP	JJ	O	21	NMOD
20	animal	animal	I-NP	NN	O	21	NMOD
21	model	model	I-NP	NN	O	17	OBJ
22	for	for	B-PP	IN	O	21	NMOD
23	studying	study	B-VP	VBG	O	22	PMOD
24	mechanisms	mechanism	B-NP	NNS	O	23	OBJ
25	of	of	B-PP	IN	O	24	NMOD
26	buildup	buildup	B-NP	NN	O	25	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	convulsive	convulsive	B-NP	JJ	O	29	NMOD
29	activity	activity	I-NP	NN	O	31	NMOD
30	and	and	O	CC	O	31	NMOD
31	pathways	pathway	B-NP	NNS	O	27	PMOD
32	operative	operative	B-ADJP	JJ	O	31	NMOD
33	in	in	B-PP	IN	O	32	AMOD
34	the	the	B-NP	DT	O	37	NMOD
35	generalization	generalization	I-NP	NN	O	37	NMOD
36	and	and	I-NP	CC	O	37	NMOD
37	propagation	propagation	I-NP	NN	O	33	PMOD
38	of	of	B-PP	IN	O	37	NMOD
39	seizures	seizure	B-NP	NNS	O	38	PMOD
40	within	within	B-PP	IN	O	39	NMOD
41	the	the	B-NP	DT	O	42	NMOD
42	forebrain	forebrain	I-NP	NN	O	40	PMOD
43	.	.	O	.	O	8	P

1	In	In	B-PP	IN	O	34	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	present	present	I-NP	JJ	O	4	NMOD
4	study	study	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	34	P
6	the	the	B-NP	DT	O	7	NMOD
7	effects	effect	I-NP	NNS	O	34	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	manipulating	manipulate	B-VP	VBG	O	8	PMOD
10	the	the	B-NP	DT	O	11	NMOD
11	activity	activity	I-NP	NN	O	9	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	15	NMOD
14	gamma-aminobutyric	gamma-aminobutyric	I-NP	JJ	O	15	NMOD
15	acid	acid	I-NP	NN	O	21	NMOD
16	(	(	O	(	O	18	DEP
17	GABA	GABA	B-NP	NN	B-protein	18	DEP
18	)	)	O	)	O	15	NMOD
19	-mediated	-mediated	B-NP	JJ	O	21	NMOD
20	synaptic	synaptic	I-NP	JJ	O	21	NMOD
21	inhibition	inhibition	I-NP	NN	O	12	PMOD
22	within	within	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	25	NMOD
24	substantia	substantia	I-NP	NN	O	25	NMOD
25	nigra	nigra	I-NP	NN	O	22	PMOD
26	on	on	B-PP	IN	O	25	NMOD
27	seizures	seizure	B-NP	NNS	O	26	PMOD
28	produced	produce	B-VP	VBN	O	27	NMOD
29	by	by	B-PP	IN	O	28	VMOD
30	pilocarpine	pilocarpine	B-NP	NN	O	29	PMOD
31	in	in	B-PP	IN	O	30	NMOD
32	rats	rat	B-NP	NNS	O	31	PMOD
33	,	,	O	,	O	7	P
34	were	be	B-VP	VBD	O	0	ROOT
35	investigated	investigate	I-VP	VBN	O	34	VC
36	.	.	O	.	O	34	P

1	In	In	B-PP	IN	O	47	VMOD
2	animals	animal	B-NP	NNS	O	1	PMOD
3	pretreated	pretreate	B-VP	VBN	O	2	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	microinjections	microinjection	B-NP	NNS	O	4	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	isoniazid	isoniazid	B-NP	NN	O	6	PMOD
8	,	,	O	,	O	47	P
9	150	150	B-NP	CD	O	10	NMOD
10	micrograms	microgram	I-NP	NNS	O	13	NMOD
11	,	,	O	,	O	13	P
12	an	an	B-NP	DT	O	13	NMOD
13	inhibitor	inhibitor	I-NP	NN	O	47	SUB
14	of	of	B-PP	IN	O	13	NMOD
15	activity	activity	B-NP	NN	O	14	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	19	NMOD
18	GABA-synthesizing	GABA-synthesizing	I-NP	JJ	B-protein	19	NMOD
19	enzyme	enzyme	I-NP	NN	I-protein	23	NMOD
20	,	,	O	,	O	23	P
21	L-glutamic	L-glutamic	B-NP	JJ	B-protein	23	NMOD
22	acid	acid	I-NP	NN	I-protein	23	NMOD
23	decarboxylase	decarboxylase	I-NP	NN	I-protein	16	PMOD
24	,	,	O	,	O	47	P
25	into	into	B-PP	IN	O	47	VMOD
26	the	the	B-NP	DT	O	29	NMOD
27	substantia	substantia	I-NP	NN	O	29	NMOD
28	nigra	nigra	I-NP	NN	O	29	NMOD
29	pars	par	I-NP	NNS	O	25	PMOD
30	reticulata	reticulata	I-NP	NN	O	29	NMOD
31	(	(	O	(	O	33	DEP
32	SNR	SNR	B-NP	NN	B-protein	33	DEP
33	)	)	O	)	O	30	NMOD
34	,	,	O	,	O	29	P
35	bilaterally	bilaterally	B-ADVP	RB	O	29	NMOD
36	,	,	O	,	O	47	P
37	non-convulsant	non-convulsant	B-NP	JJ	O	38	NMOD
38	doses	dose	I-NP	NNS	O	45	NMOD
39	of	of	B-PP	IN	O	38	NMOD
40	pilocarpine	pilocarpine	B-NP	NN	O	39	PMOD
41	,	,	O	,	O	45	P
42	100	100	B-NP	CD	O	44	AMOD
43	and	and	I-NP	CC	O	44	AMOD
44	200	200	I-NP	CD	O	45	NMOD
45	mg/kg	mg/kg	I-NP	NN	O	47	SUB
46	,	,	O	,	O	45	P
47	resulted	result	B-VP	VBD	O	0	ROOT
48	in	in	B-PP	IN	O	47	VMOD
49	severe	severe	B-NP	JJ	O	52	NMOD
50	motor	motor	I-NP	NN	O	52	NMOD
51	limbic	limbic	I-NP	JJ	O	52	NMOD
52	seizures	seizure	I-NP	NNS	O	55	NMOD
53	and	and	O	CC	O	55	NMOD
54	status	status	B-NP	NN	O	55	NMOD
55	epilepticus	epilepticus	I-NP	NN	O	48	PMOD
56	.	.	O	.	O	47	P

1	Electroencephalographic	Electroencephalographic	B-NP	JJ	O	3	AMOD
2	and	and	I-NP	CC	O	3	AMOD
3	behavioral	behavioral	I-NP	JJ	O	4	NMOD
4	monitoring	monitoring	I-NP	NN	O	5	SUB
5	revealed	reveal	B-VP	VBD	O	0	ROOT
6	a	a	B-NP	DT	O	8	NMOD
7	profound	profound	I-NP	JJ	O	8	NMOD
8	reduction	reduction	I-NP	NN	O	5	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	threshold	threshold	I-NP	NN	O	9	PMOD
12	for	for	B-PP	IN	O	11	NMOD
13	pilocarpine	pilocarpine	B-NP	NN	O	15	NMOD
14	induced	induce	I-NP	VBN	O	15	NMOD
15	convulsions	convulsion	I-NP	NNS	O	12	PMOD
16	.	.	O	.	O	5	P

1	Morphological	Morphological	B-NP	JJ	O	2	NMOD
2	analysis	analysis	I-NP	NN	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	frontal	frontal	B-NP	JJ	O	6	NMOD
5	forebrain	forebrain	I-NP	NN	O	6	NMOD
6	sections	section	I-NP	NNS	O	3	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	light	light	B-NP	JJ	O	9	NMOD
9	microscopy	microscopy	I-NP	NN	O	7	PMOD
10	revealed	reveal	B-VP	VBD	O	0	ROOT
11	seizure-related	seizure-related	B-NP	JJ	O	12	NMOD
12	damage	damage	I-NP	NN	O	10	OBJ
13	to	to	B-PP	TO	O	12	NMOD
14	the	the	B-NP	DT	O	16	NMOD
15	hippocampal	hippocampal	I-NP	JJ	O	16	NMOD
16	formation	formation	I-NP	NN	O	28	NMOD
17	,	,	O	,	O	28	P
18	thalamus	thalamus	B-NP	NN	O	28	NMOD
19	,	,	O	,	O	28	P
20	amygdala	amygdala	B-NP	NN	O	28	NMOD
21	,	,	O	,	O	28	P
22	olfactory	olfactory	B-NP	JJ	O	23	NMOD
23	cortex	cortex	I-NP	NN	O	28	NMOD
24	,	,	O	,	O	28	P
25	substantia	substantia	B-NP	NN	O	26	NMOD
26	nigra	nigra	I-NP	NN	O	28	NMOD
27	and	and	I-NP	CC	O	28	NMOD
28	neocortex	neocortex	I-NP	NN	O	13	PMOD
29	,	,	O	,	O	28	P
30	which	which	B-NP	WDT	O	28	NMOD
31	is	be	B-VP	VBZ	O	30	SBAR
32	typically	typically	I-VP	RB	O	33	VMOD
33	observed	observe	I-VP	VBN	O	31	VC
34	with	with	B-PP	IN	O	33	VMOD
35	pilocarpine	pilocarpine	B-NP	NN	O	34	PMOD
36	in	in	B-PP	IN	O	33	VMOD
37	doses	dose	B-NP	NNS	O	36	PMOD
38	exceeding	exceed	B-VP	VBG	O	37	NMOD
39	350	350	B-NP	CD	O	40	NMOD
40	mg/kg	mg/kg	I-NP	NN	O	38	OBJ
41	.	.	O	.	O	10	P

1	Bilateral	Bilateral	B-NP	JJ	O	3	NMOD
2	intrastriatal	intrastriatal	I-NP	JJ	O	3	NMOD
3	injections	injection	I-NP	NNS	O	6	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	isoniazid	isoniazid	B-NP	NN	O	4	PMOD
6	did	do	B-VP	VBD	O	0	ROOT
7	not	not	I-VP	RB	O	6	VMOD
8	augment	augment	I-VP	VB	O	6	VC
9	seizures	seizure	B-NP	NNS	O	8	OBJ
10	produced	produce	B-VP	VBN	O	9	NMOD
11	by	by	B-PP	IN	O	10	VMOD
12	pilocarpine	pilocarpine	B-NP	NN	O	11	PMOD
13	,	,	O	,	O	6	P
14	200	200	B-NP	CD	O	15	NMOD
15	mg/kg	mg/kg	I-NP	NN	O	6	VMOD
16	.	.	O	.	O	6	P

1	Application	Application	B-NP	NN	O	27	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	an	an	B-NP	DT	O	5	NMOD
4	irreversible	irreversible	I-NP	JJ	O	5	NMOD
5	inhibitor	inhibitor	I-NP	NN	O	19	NMOD
6	of	of	B-PP	IN	O	5	NMOD
7	GABA	GABA	B-NP	NN	B-protein	8	NMOD
8	transaminase	transaminase	I-NP	NN	I-protein	6	PMOD
9	,	,	O	,	O	19	P
10	gamma-vinyl-GABA	gamma-vinyl-GABA	B-NP	NN	O	19	NMOD
11	(	(	O	(	O	16	DEP
12	D	D	B-NP	NN	O	15	NMOD
13	,	,	O	,	O	15	P
14	L-4-amino-hex-5-enoic	L-4-amino-hex-5-enoic	B-NP	JJ	O	15	NMOD
15	acid	acid	I-NP	NN	O	16	DEP
16	)	)	O	)	O	10	NMOD
17	,	,	O	,	O	19	P
18	5	5	B-NP	CD	O	19	NMOD
19	micrograms	microgram	I-NP	NNS	O	2	PMOD
20	,	,	O	,	O	1	P
21	into	into	B-PP	IN	O	1	NMOD
22	the	the	B-NP	DT	O	23	NMOD
23	SNR	SNR	I-NP	NN	B-protein	21	PMOD
24	,	,	O	,	O	23	P
25	bilaterally	bilaterally	B-ADVP	RB	O	23	NMOD
26	,	,	O	,	O	1	P
27	suppressed	suppress	B-VP	VBD	O	0	ROOT
28	the	the	B-NP	DT	O	29	NMOD
29	appearance	appearance	I-NP	NN	O	40	NMOD
30	of	of	B-PP	IN	O	29	NMOD
31	electrographic	electrographic	B-NP	JJ	O	34	NMOD
32	and	and	I-NP	CC	O	34	NMOD
33	behavioral	behavioral	I-NP	JJ	O	34	NMOD
34	seizures	seizure	I-NP	NNS	O	30	PMOD
35	produced	produce	B-VP	VBN	O	34	NMOD
36	by	by	B-PP	IN	O	35	VMOD
37	pilocarpine	pilocarpine	B-NP	NN	O	36	PMOD
38	,	,	O	,	O	40	P
39	380	380	B-NP	CD	O	40	NMOD
40	mg/kg	mg/kg	I-NP	NN	O	27	OBJ
41	.	.	O	.	O	27	P

1	Microinjections	Microinjection	B-NP	NNS	O	6	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	gamma-vinyl-GABA	gamma-vinyl-GABA	B-NP	NN	O	2	PMOD
4	,	,	O	,	O	6	P
5	5	5	B-NP	CD	O	6	NMOD
6	micrograms	microgram	I-NP	NNS	O	15	SUB
7	,	,	O	,	O	6	P
8	into	into	B-PP	IN	O	15	VMOD
9	the	the	B-NP	DT	O	11	NMOD
10	dorsal	dorsal	I-NP	JJ	O	11	NMOD
11	striatum	striatum	I-NP	NN	O	8	PMOD
12	,	,	O	,	O	8	P
13	bilaterally	bilaterally	B-ADVP	RB	O	8	PMOD
14	,	,	O	,	O	15	P
15	failed	fail	B-VP	VBD	O	0	ROOT
16	to	to	I-VP	TO	O	17	VMOD
17	prevent	prevent	I-VP	VB	O	15	VMOD
18	the	the	B-NP	DT	O	19	NMOD
19	development	development	I-NP	NN	O	17	OBJ
20	of	of	B-PP	IN	O	19	NMOD
21	convulsions	convulsion	B-NP	NNS	O	20	PMOD
22	produced	produce	B-VP	VBN	O	21	NMOD
23	by	by	B-PP	IN	O	22	VMOD
24	pilocarpine	pilocarpine	B-NP	NN	O	23	PMOD
25	,	,	O	,	O	15	P
26	380	380	B-NP	CD	O	27	NMOD
27	mg/kg	mg/kg	I-NP	NN	O	15	VMOD
28	.	.	O	.	O	15	P

1	Non-invasive	Non-invasive	B-NP	JJ	O	2	NMOD
2	detection	detection	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	coronary	coronary	B-NP	JJ	O	6	NMOD
5	artery	artery	I-NP	NN	O	6	NMOD
6	disease	disease	I-NP	NN	O	3	PMOD
7	by	by	B-PP	IN	O	2	NMOD
8	body	body	B-NP	NN	O	11	NMOD
9	surface	surface	I-NP	NN	O	11	NMOD
10	electrocardiographic	electrocardiographic	I-NP	JJ	O	11	NMOD
11	mapping	mapping	I-NP	NN	O	7	PMOD
12	after	after	B-PP	IN	O	11	NMOD
13	dipyridamole	dipyridamole	B-NP	NN	O	14	NMOD
14	infusion	infusion	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	2	P

1	Electrocardiographic	Electrocardiographic	B-NP	JJ	O	2	NMOD
2	changes	change	I-NP	NNS	O	11	SUB
3	after	after	B-PP	IN	O	2	NMOD
4	dipyridamole	dipyridamole	B-NP	NN	O	5	NMOD
5	infusion	infusion	I-NP	NN	O	3	PMOD
6	(	(	O	(	O	10	DEP
7	0.568	0.568	B-NP	CD	O	9	NMOD
8	mg/kg/4	mg/kg/4	I-NP	NN	O	9	NMOD
9	min	min	I-NP	NN	O	10	DEP
10	)	)	O	)	O	5	NMOD
11	were	be	B-VP	VBD	O	0	ROOT
12	studied	study	I-VP	VBN	O	11	VC
13	in	in	B-PP	IN	O	12	VMOD
14	41	41	B-NP	CD	O	15	NMOD
15	patients	patient	I-NP	NNS	O	13	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	coronary	coronary	B-NP	JJ	O	19	NMOD
18	artery	artery	I-NP	NN	O	19	NMOD
19	disease	disease	I-NP	NN	O	16	PMOD
20	and	and	O	CC	O	12	VMOD
21	compared	compare	B-PP	VBN	O	12	VMOD
22	with	with	B-PP	IN	O	21	PMOD
23	those	those	B-NP	DT	O	22	PMOD
24	after	after	B-PP	IN	O	23	NMOD
25	submaximal	submaximal	B-NP	JJ	O	27	NMOD
26	treadmill	treadmill	I-NP	NN	O	27	NMOD
27	exercise	exercise	I-NP	NN	O	24	PMOD
28	by	by	B-PP	IN	O	27	NMOD
29	use	use	B-NP	NN	O	28	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	the	the	B-NP	DT	O	35	NMOD
32	body	body	I-NP	NN	O	35	NMOD
33	surface	surface	I-NP	NN	O	35	NMOD
34	mapping	mapping	I-NP	NN	O	35	NMOD
35	technique	technique	I-NP	NN	O	30	PMOD
36	.	.	O	.	O	11	P

1	After	After	B-PP	IN	O	13	VMOD
2	dipyridamole	dipyridamole	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	13	P
4	ischemic	ischemic	B-NP	JJ	O	6	NMOD
5	ST-segment	ST-segment	I-NP	NN	O	6	NMOD
6	depression	depression	I-NP	NN	O	13	SUB
7	(	(	O	(	O	12	DEP
8	0.05	0.05	B-NP	CD	O	9	NMOD
9	mV	mV	I-NP	NN	O	12	DEP
10	or	or	I-NP	CC	O	11	NMOD
11	more	more	I-NP	JJR	O	9	NMOD
12	)	)	O	)	O	6	NMOD
13	was	be	B-VP	VBD	O	0	ROOT
14	observed	observe	I-VP	VBN	O	13	VC
15	in	in	B-PP	IN	O	14	VMOD
16	84	84	B-NP	CD	O	17	NMOD
17	%	%	I-NP	NN	O	24	NMOD
18	of	of	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	21	NMOD
20	non-MI	non-MI	I-NP	JJ	O	21	NMOD
21	group	group	I-NP	NN	O	18	PMOD
22	,	,	O	,	O	24	P
23	29	29	B-NP	CD	O	24	NMOD
24	%	%	I-NP	NN	O	31	NMOD
25	of	of	B-PP	IN	O	24	NMOD
26	the	the	B-NP	DT	O	28	NMOD
27	ANT-MI	ANT-MI	I-NP	NN	O	28	NMOD
28	group	group	I-NP	NN	O	25	PMOD
29	,	,	O	,	O	31	P
30	63	63	B-NP	CD	O	31	NMOD
31	%	%	I-NP	NN	O	38	NMOD
32	of	of	B-PP	IN	O	31	NMOD
33	the	the	B-NP	DT	O	35	NMOD
34	INF-MI	INF-MI	I-NP	NN	O	35	NMOD
35	group	group	I-NP	NN	O	32	PMOD
36	and	and	O	CC	O	38	NMOD
37	61	61	B-NP	CD	O	38	NMOD
38	%	%	I-NP	NN	O	15	PMOD
39	of	of	B-PP	IN	O	38	NMOD
40	the	the	B-NP	DT	O	42	NMOD
41	total	total	I-NP	JJ	O	42	NMOD
42	population	population	I-NP	NN	O	39	PMOD
43	.	.	O	.	O	13	P

1	The	The	B-NP	DT	O	2	NMOD
2	data	datum	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	the	the	B-NP	DT	O	6	NMOD
6	dipyridamole	dipyridamole	I-NP	NN	O	7	SUB
7	induced	induce	B-VP	VBD	O	4	SBAR
8	myocardial	myocardial	B-NP	JJ	O	9	NMOD
9	ischemia	ischemia	I-NP	NN	O	7	OBJ
10	is	be	B-VP	VBZ	O	7	VMOD
11	caused	cause	I-VP	VBN	O	10	VC
12	by	by	B-PP	IN	O	11	VMOD
13	the	the	B-NP	DT	O	15	NMOD
14	inhomogenous	inhomogenous	I-NP	JJ	O	15	NMOD
15	distribution	distribution	I-NP	NN	O	12	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	myocardial	myocardial	B-NP	JJ	O	19	NMOD
18	blood	blood	I-NP	NN	O	19	NMOD
19	flow	flow	I-NP	NN	O	16	PMOD
20	.	.	O	.	O	3	P

1	Bradycardia	Bradycardia	B-NP	NNP	O	0	ROOT
2	after	after	B-PP	IN	O	1	NMOD
3	high-dose	high-dose	B-NP	JJ	O	6	NMOD
4	intravenous	intravenous	I-NP	JJ	O	6	NMOD
5	methylprednisolone	methylprednisolone	I-NP	NN	O	6	NMOD
6	therapy	therapy	I-NP	NN	O	2	PMOD
7	.	.	O	.	O	1	P

1	In	In	B-PP	IN	O	34	VMOD
2	5	5	B-NP	CD	O	4	NMOD
3	consecutive	consecutive	I-NP	JJ	O	4	NMOD
4	patients	patient	I-NP	NNS	O	1	PMOD
5	with	with	B-PP	IN	O	4	NMOD
6	rheumatoid	rheumatoid	B-NP	JJ	O	7	NMOD
7	arthritis	arthritis	I-NP	NN	O	5	PMOD
8	who	who	B-NP	WP	O	4	NMOD
9	received	receive	B-VP	VBD	O	8	SBAR
10	intravenous	intravenous	B-NP	JJ	O	12	NMOD
11	high-dose	high-dose	I-NP	JJ	O	12	NMOD
12	methylprednisolone	methylprednisolone	I-NP	NN	O	16	NMOD
13	(	(	O	(	O	15	DEP
14	MP	MP	B-NP	NN	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	therapy	therapy	B-NP	NN	O	9	OBJ
17	(	(	O	(	O	27	DEP
18	1	1	B-NP	CD	O	19	NMOD
19	g	g	I-NP	NN	O	27	DEP
20	daily	daily	B-ADVP	RB	O	21	PMOD
21	for	for	B-PP	IN	O	19	NMOD
22	2	2	B-NP	CD	O	26	NMOD
23	or	or	I-NP	CC	O	26	NMOD
24	3	3	I-NP	CD	O	26	NMOD
25	consecutive	consecutive	I-NP	JJ	O	26	NMOD
26	days	day	I-NP	NNS	O	21	PMOD
27	)	)	O	)	O	4	NMOD
28	,	,	O	,	O	34	P
29	a	a	B-NP	DT	O	30	NMOD
30	decline	decline	I-NP	NN	O	34	SUB
31	in	in	B-PP	IN	O	30	NMOD
32	pulse	pulse	B-NP	NN	O	33	NMOD
33	rate	rate	I-NP	NN	O	31	PMOD
34	was	be	B-VP	VBD	O	0	ROOT
35	observed	observe	I-VP	VBN	O	34	VC
36	,	,	O	,	O	35	P
37	most	most	B-ADJP	RBS	O	38	AMOD
38	pronounced	pronounced	I-ADJP	JJ	O	35	PRD
39	on	on	B-PP	IN	O	38	AMOD
40	day	day	B-NP	NN	O	39	PMOD
41	4	4	I-NP	CD	O	40	NMOD
42	.	.	O	.	O	34	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	cases	case	I-NP	NNS	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	downbeat	downbeat	B-NP	JJ	O	5	NMOD
5	nystagmus	nystagmus	I-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	oscillopsia	oscillopsia	I-NP	NN	O	3	PMOD
8	associated	associate	B-VP	VBN	O	7	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	carbamazepine	carbamazepine	B-NP	NN	O	9	PMOD
11	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	recorded	record	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	5	NMOD
4	eye	eye	I-NP	NN	O	5	NMOD
5	movements	movement	I-NP	NNS	O	2	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	two	two	B-NP	CD	O	8	NMOD
8	patients	patient	I-NP	NNS	O	6	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	reversible	reversible	B-NP	JJ	O	12	NMOD
11	downbeat	downbeat	I-NP	JJ	O	12	NMOD
12	nystagmus	nystagmus	I-NP	NN	O	9	PMOD
13	related	relate	B-VP	VBN	O	12	NMOD
14	to	to	B-PP	TO	O	13	AMOD
15	carbamazepine	carbamazepine	B-NP	NN	O	16	NMOD
16	therapy	therapy	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	nystagmus	nystagmus	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	both	both	B-NP	DT	O	5	NMOD
5	patients	patient	I-NP	NNS	O	3	PMOD
6	resolved	resolve	B-VP	VBN	O	5	NMOD
7	after	after	B-PP	IN	O	6	VMOD
8	reduction	reduction	B-NP	NN	O	7	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	13	NMOD
11	serum	serum	I-NP	NN	O	13	NMOD
12	carbamazepine	carbamazepine	I-NP	NN	O	13	NMOD
13	levels	level	I-NP	NNS	O	9	PMOD
14	.	.	O	.	O	2	P

1	Improvement	Improvement	B-NP	NN	O	9	SUB
2	by	by	B-PP	IN	O	1	NMOD
3	denopamine	denopamine	B-NP	NN	O	2	PMOD
4	(	(	O	(	O	6	DEP
5	TA-064	TA-064	B-NP	NN	B-protein	6	DEP
6	)	)	O	)	O	3	NMOD
7	of	of	B-PP	IN	O	3	NMOD
8	pentobarbital	pentobarbital	B-NP	NN	O	7	PMOD
9	induced	induce	B-VP	VBD	O	0	ROOT
10	cardiac	cardiac	B-NP	JJ	O	11	NMOD
11	failure	failure	I-NP	NN	O	9	OBJ
12	in	in	B-PP	IN	O	9	VMOD
13	the	the	B-NP	DT	O	16	NMOD
14	dog	dog	I-NP	NN	O	16	NMOD
15	heart-lung	heart-lung	I-NP	NN	O	16	NMOD
16	preparation	preparation	I-NP	NN	O	12	PMOD
17	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	2	NMOD
2	efficacy	efficacy	I-NP	NN	O	17	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	denopamine	denopamine	B-NP	NN	O	11	NMOD
5	,	,	O	,	O	11	P
6	an	an	B-NP	DT	O	11	NMOD
7	orally	orally	I-NP	RB	O	11	NMOD
8	active	active	I-NP	JJ	O	11	NMOD
9	beta	beta	I-NP	SYM	O	11	NMOD
10	1-adrenoceptor	1-adrenoceptor	I-NP	NN	O	11	NMOD
11	agonist	agonist	I-NP	NN	O	3	PMOD
12	,	,	O	,	O	2	P
13	in	in	B-PP	IN	O	2	NMOD
14	improving	improve	B-VP	VBG	O	13	PMOD
15	cardiac	cardiac	B-NP	JJ	O	16	NMOD
16	failure	failure	I-NP	NN	O	14	OBJ
17	was	be	B-VP	VBD	O	0	ROOT
18	assessed	assess	I-VP	VBN	O	17	VC
19	in	in	B-PP	IN	O	18	VMOD
20	dog	dog	B-NP	NN	O	22	NMOD
21	heart-lung	heart-lung	I-NP	JJ	O	22	NMOD
22	preparations	preparation	I-NP	NNS	O	19	PMOD
23	.	.	O	.	O	17	P

1	No	No	B-NP	DT	O	2	NMOD
2	arrhythmias	arrhythmia	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	0	ROOT
4	induced	induce	I-VP	VBN	O	3	VC
5	by	by	B-PP	IN	O	4	VMOD
6	these	these	B-NP	DT	O	7	NMOD
7	doses	dose	I-NP	NNS	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	denopamine	denopamine	B-NP	NN	O	8	PMOD
10	.	.	O	.	O	3	P

1	Clonazepam	Clonazepam	B-NP	NN	O	2	NMOD
2	monotherapy	monotherapy	I-NP	NN	O	0	ROOT
3	for	for	B-PP	IN	O	2	NMOD
4	epilepsy	epilepsy	B-NP	NN	O	3	PMOD
5	in	in	B-PP	IN	O	4	NMOD
6	childhood	childhood	B-NP	NN	O	5	PMOD
7	.	.	O	.	O	2	P

1	Sixty	Sixty	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	19	SUB
3	(	(	O	(	O	10	DEP
4	age-range	age-range	B-NP	JJ	O	6	NMOD
5	one	one	I-NP	CD	O	6	NMOD
6	month	month	I-NP	NN	O	10	DEP
7	to	to	B-PP	TO	O	6	NMOD
8	14	14	B-NP	CD	O	9	NMOD
9	years	year	I-NP	NNS	O	7	PMOD
10	)	)	O	)	O	2	NMOD
11	with	with	B-PP	IN	O	2	NMOD
12	other	other	B-NP	JJ	O	13	NMOD
13	types	type	I-NP	NNS	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	epilepsy	epilepsy	B-NP	NN	O	14	PMOD
16	than	than	B-PP	IN	O	2	NMOD
17	infantile	infantile	B-NP	JJ	O	18	NMOD
18	spasms	spasm	I-NP	NNS	O	16	PMOD
19	were	be	B-VP	VBD	O	0	ROOT
20	treated	treat	I-VP	VBN	O	19	VC
21	with	with	B-PP	IN	O	20	VMOD
22	clonazepam	clonazepam	B-NP	NN	O	21	PMOD
23	.	.	O	.	O	19	P

1	A	A	B-NP	DT	O	4	NMOD
2	postmarketing	postmarkete	I-NP	VBG	O	4	NMOD
3	surveillance	surveillance	I-NP	NN	O	4	NMOD
4	study	study	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	0	ROOT
6	conducted	conduct	I-VP	VBN	O	5	VC
7	to	to	B-VP	TO	O	8	VMOD
8	determine	determine	I-VP	VB	O	6	VMOD
9	the	the	B-NP	DT	O	12	NMOD
10	safety	safety	I-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	efficacy	efficacy	I-NP	NN	O	8	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	a	a	B-NP	DT	O	16	NMOD
15	fixed-ratio	fixed-ratio	I-NP	JJ	O	16	NMOD
16	combination	combination	I-NP	NN	O	13	PMOD
17	containing	contain	B-VP	VBG	O	16	NMOD
18	10	10	B-NP	CD	O	19	NMOD
19	mg	mg	I-NP	NN	O	25	NMOD
20	of	of	B-PP	IN	O	19	NMOD
21	timolol	timolol	B-NP	NN	O	22	NMOD
22	maleate	maleate	I-NP	NN	O	20	PMOD
23	and	and	O	CC	O	25	NMOD
24	25	25	B-NP	CD	O	25	NMOD
25	mg	mg	I-NP	NN	O	17	OBJ
26	of	of	B-PP	IN	O	25	NMOD
27	hydrochlorothiazide	hydrochlorothiazide	B-NP	NN	O	26	PMOD
28	,	,	O	,	O	16	P
29	administered	administer	B-VP	VBN	O	16	NMOD
30	twice	twice	B-ADVP	RB	O	29	VMOD
31	daily	daily	I-ADVP	RB	O	30	AMOD
32	for	for	B-PP	IN	O	29	VMOD
33	one	one	B-NP	CD	O	34	NMOD
34	month	month	I-NP	NN	O	32	PMOD
35	to	to	B-PP	TO	O	34	NMOD
36	hypertensive	hypertensive	B-NP	JJ	O	37	NMOD
37	patients	patient	I-NP	NNS	O	35	PMOD
38	.	.	O	.	O	5	P

1	Salicylate	Salicylate	B-NP	NN	O	2	NMOD
2	nephropathy	nephropathy	I-NP	NN	O	9	NMOD
3	in	in	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	Gunn	Gunn	I-NP	NNP	O	6	NMOD
6	rat	rat	I-NP	NN	O	3	PMOD
7	:	:	O	:	O	2	P
8	potential	potential	B-NP	JJ	O	9	NMOD
9	role	role	I-NP	NN	O	0	ROOT
10	of	of	B-PP	IN	O	9	NMOD
11	prostaglandins	prostaglandin	B-NP	NNS	B-protein	10	PMOD
12	.	.	O	.	O	9	P

1	We	We	B-NP	PRP	O	2	SUB
2	examined	examine	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	5	NMOD
4	potential	potential	I-NP	JJ	O	5	NMOD
5	role	role	I-NP	NN	O	2	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	prostaglandins	prostaglandin	B-NP	NNS	B-protein	6	PMOD
8	in	in	B-PP	IN	O	5	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	development	development	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	analgesic	analgesic	B-NP	JJ	O	13	NMOD
13	nephropathy	nephropathy	I-NP	NN	O	11	PMOD
14	in	in	B-PP	IN	O	5	NMOD
15	the	the	B-NP	DT	O	17	NMOD
16	Gunn	Gunn	I-NP	NNP	O	17	NMOD
17	strain	strain	I-NP	NN	O	14	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	rat	rat	B-NP	NN	O	18	PMOD
20	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	4	NMOD
2	homozygous	homozygous	I-NP	JJ	O	4	NMOD
3	Gunn	Gunn	I-NP	NNP	O	4	NMOD
4	rats	rat	I-NP	NNS	O	5	SUB
5	have	have	B-VP	VBP	O	0	ROOT
6	unconjugated	unconjugate	I-VP	VBN	O	5	VC
7	hyperbilirubinemia	hyperbilirubinemia	B-NP	NN	O	6	OBJ
8	due	due	B-PP	IN	O	9	PMOD
9	to	to	B-PP	TO	O	6	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	absence	absence	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	glucuronyl	glucuronyl	B-NP	NN	B-protein	14	NMOD
14	transferase	transferase	I-NP	NN	I-protein	12	PMOD
15	,	,	O	,	O	5	P
16	leading	lead	B-VP	VBG	O	5	VMOD
17	to	to	B-PP	TO	O	16	VMOD
18	marked	marked	B-NP	JJ	O	20	NMOD
19	bilirubin	bilirubin	I-NP	NN	O	20	NMOD
20	deposition	deposition	I-NP	NN	O	17	PMOD
21	in	in	B-PP	IN	O	20	NMOD
22	renal	renal	B-NP	JJ	O	23	NMOD
23	medulla	medulla	I-NP	NN	O	25	NMOD
24	and	and	I-NP	CC	O	25	NMOD
25	papilla	papilla	I-NP	NN	O	21	PMOD
26	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	2	NMOD
2	changes	change	I-NP	NNS	O	7	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	renal	renal	B-NP	JJ	O	6	NMOD
5	prostaglandin	prostaglandin	I-NP	NN	O	6	NMOD
6	synthesis	synthesis	I-NP	NN	O	3	PMOD
7	were	be	B-VP	VBD	O	0	ROOT
8	accompanied	accompany	I-VP	VBN	O	7	VC
9	by	by	B-PP	IN	O	8	VMOD
10	evidence	evidence	B-NP	NN	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	renal	renal	B-NP	JJ	O	13	NMOD
13	damage	damage	I-NP	NN	O	11	PMOD
14	in	in	B-PP	IN	O	13	NMOD
15	aspirin-treated	aspirin-treated	B-NP	JJ	O	16	NMOD
16	jj	jj	I-NP	NN	O	20	NMOD
17	but	but	B-NP	CC	O	20	NMOD
18	not	not	I-NP	RB	O	17	DEP
19	jJ	jJ	B-NP	NN	O	20	NMOD
20	rats	rat	I-NP	NNS	O	14	PMOD
21	as	as	B-SBAR	IN	O	8	VMOD
22	evidenced	evidence	B-VP	VBN	O	23	NMOD
23	by	by	B-PP	IN	O	21	DEP
24	:	:	O	:	O	21	P
25	increased	increase	B-NP	VBN	O	28	NMOD
26	incidence	incidence	I-NP	NN	O	28	NMOD
27	and	and	I-NP	CC	O	28	NMOD
28	severity	severity	I-NP	NN	O	40	NMOD
29	of	of	B-PP	IN	O	28	NMOD
30	hematuria	hematuria	B-NP	NN	O	29	PMOD
31	(	(	O	(	O	36	DEP
32	p	p	B-NP	NN	O	34	SUB
33	less	less	B-ADJP	JJR	O	34	AMOD
34	than	than	B-PP	IN	O	36	DEP
35	0.01	0.01	B-NP	CD	O	34	AMOD
36	)	)	O	)	O	28	NMOD
37	;	;	O	:	O	28	P
38	increased	increase	B-NP	VBN	O	40	NMOD
39	serum	serum	I-NP	NN	O	40	NMOD
40	creatinine	creatinine	I-NP	NN	O	21	DEP
41	(	(	O	(	O	46	DEP
42	p	p	B-NP	NN	O	44	SUB
43	less	less	B-ADJP	JJR	O	44	AMOD
44	than	than	B-PP	IN	O	46	DEP
45	0.05	0.05	B-NP	CD	O	44	AMOD
46	)	)	O	)	O	40	NMOD
47	;	;	O	:	O	40	P
48	and	and	O	CC	O	40	VMOD
49	increase	increase	B-VP	VB	O	40	NMOD
50	in	in	B-PP	IN	O	49	VMOD
51	outer	outer	B-NP	JJ	O	54	NMOD
52	medullary	medullary	I-NP	JJ	O	54	NMOD
53	histopathologic	histopathologic	I-NP	JJ	O	54	NMOD
54	lesions	lesion	I-NP	NNS	O	50	PMOD
55	(	(	O	(	O	40	NMOD
56	p	p	B-NP	NN	O	55	PMOD
57	less	less	B-ADJP	JJR	O	56	NMOD
58	than	than	B-PP	IN	O	57	AMOD
59	0.005	0.005	B-NP	CD	O	58	PMOD
60	compared	compare	B-PP	VBN	O	56	NMOD
61	to	to	B-PP	TO	O	60	PMOD
62	either	either	O	CC	O	67	NMOD
63	sham-treated	sham-treated	B-NP	JJ	O	64	NMOD
64	jj	jj	I-NP	NN	O	67	NMOD
65	or	or	O	CC	O	67	NMOD
66	aspirin-treated	aspirin-treated	B-NP	JJ	O	67	NMOD
67	jJ	jJ	I-NP	NN	O	61	PMOD
68	)	)	O	)	O	67	NMOD
69	.	.	O	.	O	7	P

1	Prophylactic	Prophylactic	B-NP	JJ	O	2	NMOD
2	lidocaine	lidocaine	I-NP	NN	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	early	early	I-NP	JJ	O	6	NMOD
6	phase	phase	I-NP	NN	O	3	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	suspected	suspect	B-NP	VBN	O	10	NMOD
9	myocardial	myocardial	I-NP	JJ	O	10	NMOD
10	infarction	infarction	I-NP	NN	O	7	PMOD
11	.	.	O	.	O	2	P

1	Four	Four	B-NP	CD	O	3	AMOD
2	hundred	hundred	I-NP	CD	O	3	AMOD
3	two	two	B-NP	CD	O	4	NMOD
4	patients	patient	I-NP	NNS	O	18	SUB
5	with	with	B-PP	IN	O	4	NMOD
6	suspected	suspect	B-NP	VBN	O	8	NMOD
7	myocardial	myocardial	I-NP	JJ	O	8	NMOD
8	infarction	infarction	I-NP	NN	O	5	PMOD
9	seen	see	B-VP	VBN	O	8	NMOD
10	within	within	B-PP	IN	O	9	VMOD
11	6	6	B-NP	CD	O	12	NMOD
12	hours	hour	I-NP	NNS	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	onset	onset	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	symptoms	symptom	B-NP	NNS	O	16	PMOD
18	entered	enter	B-VP	VBD	O	0	ROOT
19	a	a	B-NP	DT	O	22	NMOD
20	double-blind	double-blind	I-NP	JJ	O	22	NMOD
21	randomized	randomize	I-NP	VBN	O	22	NMOD
22	trial	trial	I-NP	NN	O	18	OBJ
23	of	of	B-PP	IN	O	22	NMOD
24	lidocaine	lidocaine	B-NP	NN	O	23	PMOD
25	vs	vs	B-PP	IN	O	22	NMOD
26	placebo	placebo	B-NP	NN	O	25	PMOD
27	.	.	O	.	O	18	P

1	Lidocaine	Lidocaine	B-NP	NNP	O	16	SUB
2	,	,	O	,	O	1	P
3	given	give	B-PP	VBN	O	1	NMOD
4	in	in	B-PP	IN	O	3	VMOD
5	a	a	B-NP	DT	O	8	NMOD
6	300	300	I-NP	CD	O	7	AMOD
7	mg	mg	I-NP	NN	O	8	NMOD
8	dose	dose	I-NP	NN	O	4	PMOD
9	intramuscularly	intramuscularly	B-VP	RB	O	10	VMOD
10	followed	follow	I-VP	VBN	O	8	NMOD
11	by	by	B-PP	IN	O	10	VMOD
12	100	100	B-NP	CD	O	13	NMOD
13	mg	mg	I-NP	NN	O	11	PMOD
14	intravenously	intravenously	B-ADVP	RB	O	10	VMOD
15	,	,	O	,	O	1	P
16	did	do	B-VP	VBD	O	0	ROOT
17	not	not	I-VP	RB	O	16	VMOD
18	prevent	prevent	I-VP	VB	O	16	VC
19	sustained	sustained	B-NP	JJ	O	20	AMOD
20	ventricular	ventricular	I-NP	JJ	O	21	NMOD
21	tachycardia	tachycardia	I-NP	NN	O	18	OBJ
22	,	,	O	,	O	16	P
23	although	although	B-SBAR	IN	O	16	VMOD
24	there	there	B-NP	EX	O	25	SUB
25	was	be	B-VP	VBD	O	23	SBAR
26	a	a	B-NP	DT	O	28	NMOD
27	significant	significant	I-NP	JJ	O	28	NMOD
28	reduction	reduction	I-NP	NN	O	25	PRD
29	in	in	B-PP	IN	O	28	NMOD
30	the	the	B-NP	DT	O	31	NMOD
31	number	number	I-NP	NN	O	29	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	patients	patient	B-NP	NNS	O	32	PMOD
34	with	with	B-PP	IN	O	33	NMOD
35	warning	warn	B-VP	VBG	O	36	NMOD
36	arrhythmias	arrhythmia	B-NP	NNS	O	34	PMOD
37	between	between	B-PP	IN	O	36	NMOD
38	15	15	B-NP	CD	O	40	AMOD
39	and	and	I-NP	CC	O	40	AMOD
40	45	45	I-NP	CD	O	41	NMOD
41	minutes	minute	I-NP	NNS	O	37	PMOD
42	after	after	B-PP	IN	O	41	NMOD
43	the	the	B-NP	DT	O	44	NMOD
44	administration	administration	I-NP	NN	O	42	PMOD
45	of	of	B-PP	IN	O	44	NMOD
46	lidocaine	lidocaine	B-NP	NN	O	45	PMOD
47	(	(	O	(	O	52	DEP
48	p	p	B-NP	NN	O	52	DEP
49	less	less	B-ADJP	JJR	O	48	NMOD
50	than	than	B-PP	IN	O	49	AMOD
51	0.05	0.05	B-NP	CD	O	50	PMOD
52	)	)	O	)	O	41	NMOD
53	.	.	O	.	O	16	P

1	The	The	B-NP	DT	O	5	NMOD
2	average	average	I-NP	JJ	O	5	NMOD
3	plasma	plasma	I-NP	NN	O	5	NMOD
4	lidocaine	lidocaine	I-NP	NN	O	5	NMOD
5	level	level	I-NP	NN	O	7	SUB
6	10	10	B-NP	CD	O	5	NMOD
7	minutes	minute	I-NP	NNS	O	8	PMOD
8	after	after	B-PP	IN	O	16	VMOD
9	administration	administration	B-NP	NN	O	8	PMOD
10	for	for	B-PP	IN	O	9	NMOD
11	patients	patient	B-NP	NNS	O	10	PMOD
12	without	without	B-PP	IN	O	9	NMOD
13	a	a	B-NP	DT	O	15	NMOD
14	myocardial	myocardial	I-NP	JJ	O	15	NMOD
15	infarction	infarction	I-NP	NN	O	12	PMOD
16	was	be	B-VP	VBD	O	0	ROOT
17	significantly	significantly	B-ADJP	RB	O	18	AMOD
18	higher	high	I-ADJP	JJR	O	16	PRD
19	than	than	B-PP	IN	O	18	AMOD
20	that	that	B-NP	DT	O	19	PMOD
21	for	for	B-PP	IN	O	20	NMOD
22	patients	patient	B-NP	NNS	O	21	PMOD
23	with	with	B-PP	IN	O	22	NMOD
24	an	an	B-NP	DT	O	26	NMOD
25	acute	acute	I-NP	JJ	O	26	NMOD
26	infarction	infarction	I-NP	NN	O	23	PMOD
27	.	.	O	.	O	16	P

1	During	During	B-PP	IN	O	15	VMOD
2	the	the	B-NP	DT	O	5	NMOD
3	1-hour	1-hour	I-NP	JJ	O	5	NMOD
4	study	study	I-NP	NN	O	5	NMOD
5	period	period	I-NP	NN	O	1	PMOD
6	,	,	O	,	O	15	P
7	the	the	B-NP	DT	O	8	NMOD
8	incidence	incidence	I-NP	NN	O	15	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	central	central	B-NP	JJ	O	14	NMOD
11	nervous	nervous	I-NP	JJ	O	14	NMOD
12	system	system	I-NP	NN	O	14	NMOD
13	side	side	I-NP	NN	O	14	NMOD
14	effects	effect	I-NP	NNS	O	9	PMOD
15	was	be	B-VP	VBD	O	24	VMOD
16	significantly	significantly	B-ADJP	RB	O	17	AMOD
17	greater	great	I-ADJP	JJR	O	15	PRD
18	in	in	B-PP	IN	O	15	VMOD
19	the	the	B-NP	DT	O	21	NMOD
20	lidocaine	lidocaine	I-NP	NN	O	21	NMOD
21	group	group	I-NP	NN	O	18	PMOD
22	,	,	O	,	O	24	P
23	hypotension	hypotension	B-NP	NN	O	24	SUB
24	occurred	occur	B-VP	VBD	O	32	VMOD
25	in	in	B-PP	IN	O	24	VMOD
26	11	11	B-NP	CD	O	27	NMOD
27	patients	patient	I-NP	NNS	O	25	PMOD
28	,	,	O	,	O	24	P
29	nine	nine	B-NP	CD	O	32	SUB
30	of	of	B-PP	IN	O	29	NMOD
31	whom	whom	B-NP	WP	O	30	PMOD
32	had	have	B-VP	VBD	O	39	VMOD
33	received	receive	I-VP	VBN	O	34	NMOD
34	lidocaine	lidocaine	B-NP	NN	O	32	OBJ
35	,	,	O	,	O	39	P
36	and	and	O	CC	O	38	NMOD
37	four	four	B-NP	CD	O	38	NMOD
38	patients	patient	I-NP	NNS	O	39	SUB
39	died	die	B-VP	VBD	O	46	VMOD
40	from	from	B-PP	IN	O	39	VMOD
41	asystole	asystole	B-NP	NN	O	40	PMOD
42	,	,	O	,	O	39	P
43	three	three	B-NP	CD	O	46	SUB
44	of	of	B-PP	IN	O	43	NMOD
45	whom	whom	B-NP	WP	O	44	PMOD
46	had	have	B-VP	VBD	O	0	ROOT
47	had	have	I-VP	VBN	O	46	VC
48	lidocaine	lidocaine	B-NP	NN	O	47	OBJ
49	.	.	O	.	O	46	P

1	Evidence	Evidence	B-NP	NN	O	0	ROOT
2	for	for	B-PP	IN	O	1	NMOD
3	a	a	B-NP	DT	O	5	NMOD
4	cholinergic	cholinergic	I-NP	JJ	O	5	NMOD
5	role	role	I-NP	NN	O	2	PMOD
6	in	in	B-PP	IN	O	5	NMOD
7	haloperidol	haloperidol	B-NP	NN	O	9	NMOD
8	induced	induced	I-NP	JJ	O	9	NMOD
9	catalepsy	catalepsy	I-NP	NN	O	6	PMOD
10	.	.	O	.	O	1	P

1	Experiments	Experiment	B-NP	NNS	O	0	ROOT
2	in	in	B-PP	IN	O	1	NMOD
3	mice	mouse	B-NP	NNS	O	2	PMOD
4	tested	test	B-VP	VBN	O	3	NMOD
5	previous	previous	B-NP	JJ	O	6	NMOD
6	evidence	evidence	I-NP	NN	O	4	OBJ
7	that	that	B-SBAR	IN	O	6	NMOD
8	activation	activation	B-NP	NN	O	12	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	cholinergic	cholinergic	B-NP	JJ	O	11	NMOD
11	systems	system	I-NP	NNS	O	9	PMOD
12	promotes	promote	B-VP	VBZ	O	7	SBAR
13	catalepsy	catalepsy	B-NP	NN	O	12	OBJ
14	and	and	O	CC	O	15	DEP
15	that	that	B-SBAR	IN	O	1	NMOD
16	cholinergic	cholinergic	B-NP	JJ	O	17	NMOD
17	mechanisms	mechanism	I-NP	NNS	O	18	SUB
18	need	need	B-VP	VBP	O	15	SBAR
19	to	to	I-VP	TO	O	20	VMOD
20	be	be	I-VP	VB	O	18	VMOD
21	intact	intact	B-ADJP	JJ	O	20	PRD
22	for	for	B-PP	IN	O	21	AMOD
23	full	full	B-NP	JJ	O	24	NMOD
24	expression	expression	I-NP	NN	O	22	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	neuroleptic	neuroleptic	B-NP	JJ	O	28	NMOD
27	induced	induce	I-NP	VBN	O	28	NMOD
28	catalepsy	catalepsy	I-NP	NN	O	25	PMOD
29	.	.	O	.	O	1	P

1	Large	Large	B-NP	JJ	O	2	NMOD
2	doses	dose	I-NP	NNS	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	7	NMOD
5	cholinomimetic	cholinomimetic	I-NP	JJ	O	7	NMOD
6	,	,	I-NP	,	O	7	P
7	pilocarpine	pilocarpine	I-NP	NN	O	3	PMOD
8	,	,	O	,	O	2	P
9	could	could	B-VP	MD	O	0	ROOT
10	induce	induce	I-VP	VB	O	9	VC
11	catalepsy	catalepsy	B-NP	NN	B-protein	10	OBJ
12	when	when	B-ADVP	WRB	I-protein	10	VMOD
13	peripheral	peripheral	B-NP	JJ	I-protein	15	NMOD
14	cholinergic	cholinergic	I-NP	JJ	I-protein	15	NMOD
15	receptors	receptor	I-NP	NNS	I-protein	16	SUB
16	were	be	B-VP	VBD	O	12	SBAR
17	blocked	block	I-VP	VBN	O	16	VC
18	.	.	O	.	O	9	P

1	Low	Low	B-NP	JJ	O	2	NMOD
2	doses	dose	I-NP	NNS	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	pilocarpine	pilocarpine	B-NP	NN	O	3	PMOD
5	caused	cause	B-VP	VBD	O	0	ROOT
6	a	a	B-NP	DT	O	8	NMOD
7	pronounced	pronounced	I-NP	JJ	O	8	NMOD
8	enhancement	enhancement	I-NP	NN	O	5	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	catalepsy	catalepsy	I-NP	NN	O	9	PMOD
12	that	that	B-NP	WDT	O	8	NMOD
13	was	be	B-VP	VBD	O	12	SBAR
14	induced	induce	I-VP	VBN	O	13	VC
15	by	by	B-PP	IN	O	14	VMOD
16	the	the	B-NP	DT	O	18	NMOD
17	dopaminergic	dopaminergic	I-NP	JJ	O	18	NMOD
18	blocker	blocker	I-NP	NN	O	20	NMOD
19	,	,	O	,	O	20	P
20	haloperidol	haloperidol	B-NP	NN	O	15	PMOD
21	.	.	O	.	O	5	P

1	A	A	B-NP	DT	O	4	NMOD
2	muscarinic	muscarinic	I-NP	JJ	O	4	NMOD
3	receptor	receptor	I-NP	NN	O	4	NMOD
4	blocker	blocker	I-NP	NN	O	6	NMOD
5	,	,	O	,	O	6	P
6	atropine	atropine	B-NP	NN	O	8	SUB
7	,	,	O	,	O	6	P
8	disrupted	disrupt	B-VP	VBD	O	0	ROOT
9	haloperidol	haloperidol	B-NP	NN	O	11	NMOD
10	induced	induced	I-NP	JJ	O	11	NMOD
11	catalepsy	catalepsy	I-NP	NN	O	8	OBJ
12	.	.	O	.	O	8	P

1	Intracranial	Intracranial	B-NP	JJ	O	2	NMOD
2	injection	injection	I-NP	NN	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	an	an	B-NP	DT	O	6	NMOD
5	acetylcholine-synthesis	acetylcholine-synthesis	I-NP	NN	O	6	NMOD
6	inhibitor	inhibitor	I-NP	NN	O	8	NMOD
7	,	,	O	,	O	8	P
8	hemicholinium	hemicholinium	B-NP	NN	O	3	PMOD
9	,	,	O	,	O	2	P
10	prevented	prevent	B-VP	VBD	O	0	ROOT
11	the	the	B-NP	DT	O	12	NMOD
12	catalepsy	catalepsy	I-NP	NN	O	10	OBJ
13	that	that	B-NP	WDT	O	12	NMOD
14	is	be	B-VP	VBZ	O	13	SBAR
15	usually	usually	I-VP	RB	O	14	VMOD
16	induced	induce	I-VP	VBN	O	14	VC
17	by	by	B-PP	IN	O	16	VMOD
18	haloperidol	haloperidol	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	10	P

1	These	These	B-NP	DT	O	2	NMOD
2	findings	finding	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	hypothesis	hypothesis	I-NP	NN	O	3	OBJ
6	that	that	B-SBAR	IN	O	5	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	catalepsy	catalepsy	I-NP	NN	O	17	SUB
9	that	that	B-NP	WDT	O	8	NMOD
10	is	be	B-VP	VBZ	O	9	SBAR
11	produced	produce	I-VP	VBN	O	10	VC
12	by	by	B-PP	IN	O	11	VMOD
13	neuroleptics	neuroleptic	B-NP	NNS	O	12	PMOD
14	such	such	B-PP	JJ	O	15	PMOD
15	as	as	I-PP	IN	O	13	NMOD
16	haloperidol	haloperidol	B-NP	NN	O	15	PMOD
17	is	be	B-VP	VBZ	O	6	SBAR
18	actually	actually	I-VP	RB	O	17	VMOD
19	mediated	mediate	I-VP	VBN	O	17	VC
20	by	by	B-PP	IN	O	19	VMOD
21	intrinsic	intrinsic	B-NP	JJ	O	24	NMOD
22	central	central	I-NP	JJ	O	24	NMOD
23	cholinergic	cholinergic	I-NP	JJ	O	24	NMOD
24	systems	system	I-NP	NNS	O	20	PMOD
25	.	.	O	.	O	3	P

1	Cardiovascular	Cardiovascular	B-NP	JJ	O	2	NMOD
2	dysfunction	dysfunction	I-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	hypersensitivity	hypersensitivity	I-NP	NN	O	0	ROOT
5	to	to	B-PP	TO	O	4	NMOD
6	sodium	sodium	B-NP	NN	O	7	NMOD
7	pentobarbital	pentobarbital	I-NP	NN	O	5	PMOD
8	induced	induce	B-VP	VBN	O	7	NMOD
9	by	by	B-PP	IN	O	8	VMOD
10	chronic	chronic	B-NP	JJ	O	13	NMOD
11	barium	barium	I-NP	NN	O	13	NMOD
12	chloride	chloride	I-NP	NN	O	13	NMOD
13	ingestion	ingestion	I-NP	NN	O	9	PMOD
14	.	.	O	.	O	4	P

1	Barium-supplemented	Barium-supplemented	B-NP	JJ	O	4	NMOD
2	Long-Evans	Long-Evans	I-NP	JJ	O	4	NMOD
3	hooded	hooded	I-NP	JJ	O	4	NMOD
4	rats	rat	I-NP	NNS	O	5	SUB
5	were	be	B-VP	VBD	O	0	ROOT
6	characterized	characterize	I-VP	VBN	O	5	VC
7	by	by	B-PP	IN	O	6	VMOD
8	a	a	B-NP	DT	O	10	NMOD
9	persistent	persistent	I-NP	JJ	O	10	NMOD
10	hypertension	hypertension	I-NP	NN	O	7	PMOD
11	that	that	B-NP	WDT	O	10	NMOD
12	was	be	B-VP	VBD	O	11	SBAR
13	evident	evident	B-ADJP	JJ	O	12	PRD
14	after	after	B-PP	IN	O	12	VMOD
15	1	1	B-NP	CD	O	16	NMOD
16	month	month	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	barium	barium	B-NP	NN	O	26	NMOD
19	(	(	O	(	O	25	DEP
20	100	100	B-NP	CD	O	22	NMOD
21	micrograms/ml	micrograms/ml	I-NP	NN	O	22	NMOD
22	mineral	mineral	I-NP	NN	O	24	NMOD
23	fortified	fortify	B-VP	VBN	O	24	NMOD
24	water	water	B-NP	NN	O	25	DEP
25	)	)	O	)	O	18	NMOD
26	treatment	treatment	B-NP	NN	O	17	PMOD
27	.	.	O	.	O	5	P

1	Analysis	Analysis	B-NP	NN	O	16	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	in	in	B-NP	FW	O	4	AMOD
4	vivo	vivo	I-NP	FW	O	6	NMOD
5	myocardial	myocardial	I-NP	JJ	O	6	NMOD
6	excitability	excitability	I-NP	NN	O	12	NMOD
7	,	,	O	,	O	12	P
8	contractility	contractility	B-NP	NN	O	12	NMOD
9	,	,	O	,	O	12	P
10	and	and	O	CC	O	12	NMOD
11	metabolic	metabolic	B-NP	JJ	O	12	NMOD
12	characteristics	characteristic	I-NP	NNS	O	2	PMOD
13	at	at	B-PP	IN	O	1	NMOD
14	16	16	B-NP	CD	O	15	NMOD
15	months	month	I-NP	NNS	O	13	PMOD
16	revealed	reveal	B-VP	VBD	O	0	ROOT
17	other	other	B-NP	JJ	O	16	OBJ
18	significant	significant	I-NP	JJ	O	19	NMOD
19	barium	barium	I-NP	NN	O	20	SUB
20	induced	induce	B-VP	VBD	O	17	NMOD
21	disturbances	disturbance	B-NP	NNS	O	20	OBJ
22	within	within	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	25	NMOD
24	cardiovascular	cardiovascular	I-NP	JJ	O	25	NMOD
25	system	system	I-NP	NN	O	22	PMOD
26	.	.	O	.	O	16	P

1	The	The	B-NP	DT	O	4	NMOD
2	most	most	I-NP	RBS	O	3	AMOD
3	distinctive	distinctive	I-NP	JJ	O	4	NMOD
4	aspect	aspect	I-NP	NN	O	9	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	8	NMOD
7	barium	barium	I-NP	NN	O	8	NMOD
8	effect	effect	I-NP	NN	O	5	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	a	a	B-NP	DT	O	12	NMOD
11	demonstrated	demonstrate	I-NP	VBN	O	12	NMOD
12	hypersensitivity	hypersensitivity	I-NP	NN	O	9	PRD
13	of	of	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	16	NMOD
15	cardiovascular	cardiovascular	I-NP	JJ	O	16	NMOD
16	system	system	I-NP	NN	O	13	PMOD
17	to	to	B-PP	TO	O	12	NMOD
18	sodium	sodium	B-NP	NN	O	19	NMOD
19	pentobarbital	pentobarbital	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	9	P

1	Overall	Overall	B-ADVP	RB	O	26	VMOD
2	,	,	O	,	O	26	P
3	the	the	B-NP	DT	O	9	NMOD
4	altered	alter	I-NP	VBN	O	6	NMOD
5	cardiac	cardiac	I-NP	JJ	O	6	NMOD
6	contractility	contractility	I-NP	NN	O	9	NMOD
7	and	and	I-NP	CC	O	9	NMOD
8	excitability	excitability	I-NP	NN	O	9	NMOD
9	characteristics	characteristic	I-NP	NNS	O	18	NMOD
10	,	,	O	,	O	18	P
11	the	the	B-NP	DT	O	14	NMOD
12	myocardial	myocardial	I-NP	JJ	O	14	NMOD
13	metabolic	metabolic	I-NP	JJ	O	14	NMOD
14	disturbances	disturbance	I-NP	NNS	O	18	NMOD
15	,	,	O	,	O	18	P
16	and	and	O	CC	O	18	NMOD
17	the	the	B-NP	DT	O	18	NMOD
18	hypersensitivity	hypersensitivity	I-NP	NN	O	26	SUB
19	of	of	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	22	NMOD
21	cardiovascular	cardiovascular	I-NP	JJ	O	22	NMOD
22	system	system	I-NP	NN	O	19	PMOD
23	to	to	B-PP	TO	O	18	NMOD
24	sodium	sodium	B-NP	NN	O	25	NMOD
25	pentobarbital	pentobarbital	I-NP	NN	O	23	PMOD
26	suggest	suggest	B-VP	VBP	O	0	ROOT
27	the	the	B-NP	DT	O	28	NMOD
28	existence	existence	I-NP	NN	O	26	OBJ
29	of	of	B-PP	IN	O	28	NMOD
30	a	a	B-NP	DT	O	34	NMOD
31	heretofore	heretofore	I-NP	RB	O	32	AMOD
32	undescribed	undescribed	I-NP	JJ	O	34	NMOD
33	cardiomyopathic	cardiomyopathic	I-NP	JJ	O	34	NMOD
34	disorder	disorder	I-NP	NN	O	29	PMOD
35	induced	induce	B-VP	VBN	O	34	NMOD
36	by	by	B-PP	IN	O	35	VMOD
37	chronic	chronic	B-NP	JJ	O	39	NMOD
38	barium	barium	I-NP	NN	O	39	NMOD
39	exposure	exposure	I-NP	NN	O	36	PMOD
40	.	.	O	.	O	26	P

1	Propranolol	Propranolol	B-NP	NN	O	2	NMOD
2	antagonism	antagonism	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	phenylpropanolamine	phenylpropanolamine	B-NP	NN	O	6	NMOD
5	induced	induced	I-NP	JJ	O	6	NMOD
6	hypertension	hypertension	I-NP	NN	O	3	PMOD
7	.	.	O	.	O	2	P

1	Phenylpropanolamine	Phenylpropanolamine	B-NP	NN	O	5	NMOD
2	(	(	O	(	O	4	DEP
3	PPA	PPA	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	overdose	overdose	B-NP	NN	O	6	SUB
6	can	can	B-VP	MD	O	0	ROOT
7	cause	cause	I-VP	VB	O	6	VC
8	severe	severe	B-NP	JJ	O	9	NMOD
9	hypertension	hypertension	I-NP	NN	O	15	NMOD
10	,	,	O	,	O	15	P
11	intracerebral	intracerebral	B-NP	JJ	O	12	NMOD
12	hemorrhage	hemorrhage	I-NP	NN	O	15	NMOD
13	,	,	O	,	O	15	P
14	and	and	O	CC	O	15	NMOD
15	death	death	B-NP	NN	O	7	OBJ
16	.	.	O	.	O	6	P

1	We	We	B-NP	PRP	O	2	SUB
2	studied	study	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	6	NMOD
4	efficacy	efficacy	I-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	safety	safety	I-NP	NN	O	2	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	propranolol	propranolol	B-NP	NN	O	7	PMOD
9	in	in	B-PP	IN	O	6	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	treatment	treatment	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	PPA	PPA	B-NP	NN	B-protein	15	NMOD
14	induced	induced	I-NP	JJ	O	15	NMOD
15	hypertension	hypertension	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	2	P

1	Left	Leave	B-NP	VBN	O	3	NMOD
2	ventricular	ventricular	I-NP	JJ	O	3	NMOD
3	function	function	I-NP	NN	O	9	SUB
4	(	(	O	(	O	8	DEP
5	assessed	assess	B-VP	VBN	O	8	DEP
6	by	by	B-PP	IN	O	5	VMOD
7	echocardiography	echocardiography	B-NP	NN	O	6	PMOD
8	)	)	O	)	O	3	NMOD
9	showed	show	B-VP	VBD	O	0	ROOT
10	that	that	B-SBAR	IN	O	9	VMOD
11	PPA	PPA	B-NP	NN	B-protein	12	SUB
12	increased	increase	B-VP	VBD	O	10	SBAR
13	the	the	B-NP	DT	O	17	NMOD
14	stroke	stroke	I-NP	NN	O	17	NMOD
15	volume	volume	I-NP	NN	O	17	NMOD
16	30	30	B-NP	CD	O	17	NMOD
17	%	%	I-NP	NN	O	12	OBJ
18	(	(	O	(	O	28	DEP
19	from	from	B-PP	IN	O	28	DEP
20	62.5	62.5	B-NP	CD	O	22	AMOD
21	+/-	+/-	I-NP	SYM	O	22	AMOD
22	20.9	20.9	I-NP	CD	O	19	PMOD
23	to	to	I-NP	TO	O	19	PMOD
24	80.8	80.8	I-NP	CD	O	26	AMOD
25	+/-	+/-	I-NP	SYM	O	26	AMOD
26	22.4	22.4	I-NP	CD	O	23	PMOD
27	ml	ml	I-NP	NN	O	19	PMOD
28	)	)	O	)	O	17	NMOD
29	,	,	O	,	O	12	P
30	the	the	B-NP	DT	O	34	NMOD
31	ejection	ejection	I-NP	NN	O	34	NMOD
32	fraction	fraction	I-NP	NN	O	34	NMOD
33	9	9	B-NP	CD	O	34	NMOD
34	%	%	I-NP	NN	O	12	OBJ
35	(	(	O	(	O	65	DEP
36	from	from	B-PP	IN	O	54	NMOD
37	64	64	B-NP	CD	O	36	PMOD
38	%	%	I-NP	NN	O	37	NMOD
39	+/-	+/-	B-NP	SYM	O	41	AMOD
40	10	10	B-NP	CD	O	41	AMOD
41	%	%	I-NP	NN	O	48	DEP
42	to	to	I-NP	TO	O	41	NMOD
43	70	70	I-NP	CD	O	47	NMOD
44	%	%	I-NP	NN	O	47	NMOD
45	+/-	+/-	B-NP	SYM	O	47	NMOD
46	7	7	B-NP	CD	O	47	NMOD
47	%	%	I-NP	NN	O	42	PMOD
48	)	)	O	)	O	38	NMOD
49	,	,	O	,	O	36	P
50	and	and	O	CC	O	54	NMOD
51	cardiac	cardiac	B-NP	JJ	O	52	NMOD
52	output	output	I-NP	NN	O	54	NMOD
53	14	14	B-NP	CD	O	52	NMOD
54	%	%	I-NP	NN	O	65	DEP
55	(	(	O	(	O	65	DEP
56	from	from	B-PP	IN	O	64	NMOD
57	3.6	3.6	B-NP	CD	O	59	AMOD
58	+/-	+/-	I-NP	SYM	O	59	AMOD
59	0.6	0.6	I-NP	CD	O	56	PMOD
60	to	to	I-NP	TO	O	56	PMOD
61	4.1	4.1	I-NP	CD	O	63	AMOD
62	+/-	+/-	I-NP	SYM	O	63	AMOD
63	1.0	1.0	I-NP	CD	O	60	PMOD
64	L/min	L/min	I-NP	NN	O	65	DEP
65	)	)	O	)	O	34	NMOD
66	.	.	O	.	O	9	P

1	Mesangial	Mesangial	B-NP	JJ	O	2	NMOD
2	function	function	I-NP	NN	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	glomerular	glomerular	B-NP	JJ	O	5	NMOD
5	sclerosis	sclerosis	I-NP	NN	O	0	ROOT
6	in	in	B-PP	IN	O	5	NMOD
7	rats	rat	B-NP	NNS	O	6	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	aminonucleoside	aminonucleoside	B-NP	NN	O	10	NMOD
10	nephrosis	nephrosis	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	3	NMOD
2	possible	possible	I-NP	JJ	O	3	NMOD
3	relationship	relationship	I-NP	NN	O	12	SUB
4	between	between	B-PP	IN	O	3	NMOD
5	mesangial	mesangial	B-NP	JJ	O	6	NMOD
6	dysfunction	dysfunction	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	development	development	I-NP	NN	O	4	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	glomerular	glomerular	B-NP	JJ	O	11	NMOD
11	sclerosis	sclerosis	I-NP	NN	O	9	PMOD
12	was	be	B-VP	VBD	O	0	ROOT
13	studied	study	I-VP	VBN	O	12	VC
14	in	in	B-PP	IN	O	13	VMOD
15	the	the	B-NP	DT	O	17	NMOD
16	puromycin	puromycin	I-NP	NN	O	17	NMOD
17	aminonucleoside	aminonucleoside	I-NP	NN	O	21	NMOD
18	(	(	O	(	O	20	DEP
19	PAN	PAN	B-NP	NN	O	20	DEP
20	)	)	O	)	O	17	NMOD
21	model	model	B-NP	NN	O	14	PMOD
22	.	.	O	.	O	12	P

1	After	After	B-PP	IN	O	7	VMOD
2	4	4	B-NP	CD	O	3	NMOD
3	weeks	week	I-NP	NNS	O	1	PMOD
4	the	the	B-NP	DT	O	6	NMOD
5	PAN	PAN	I-NP	NN	O	6	NMOD
6	rats	rat	I-NP	NNS	O	7	SUB
7	were	be	B-VP	VBD	O	21	VMOD
8	severely	severely	B-ADJP	RB	O	7	VMOD
9	proteinuric	proteinuric	I-ADJP	JJ	O	7	PRD
10	(	(	O	(	O	16	DEP
11	190	190	B-NP	CD	O	13	AMOD
12	+/-	+/-	I-NP	SYM	O	13	AMOD
13	80	80	I-NP	CD	O	15	NMOD
14	mg/24	mg/24	I-NP	NN	O	15	NMOD
15	hr	hr	I-NP	NN	O	16	DEP
16	)	)	O	)	O	9	NMOD
17	,	,	O	,	O	21	P
18	and	and	O	CC	O	21	VMOD
19	all	all	B-NP	DT	O	20	NMOD
20	rats	rat	I-NP	NNS	O	21	SUB
21	were	be	B-VP	VBD	O	0	ROOT
22	given	give	I-VP	VBN	O	21	VC
23	colloidal	colloidal	B-NP	JJ	O	24	NMOD
24	carbon	carbon	I-NP	NN	O	22	OBJ
25	(	(	O	(	O	27	DEP
26	CC	CC	B-NP	NN	O	27	DEP
27	)	)	O	)	O	24	NMOD
28	intravenously	intravenously	B-ADVP	RB	O	24	NMOD
29	.	.	O	.	O	21	P

1	At	At	B-PP	IN	O	6	VMOD
2	5	5	B-NP	CD	O	3	NMOD
3	months	month	I-NP	NNS	O	1	PMOD
4	glomerular	glomerular	B-NP	JJ	O	5	NMOD
5	sclerosis	sclerosis	I-NP	NN	O	6	SUB
6	was	be	B-VP	VBD	O	24	VMOD
7	found	find	I-VP	VBN	O	6	VC
8	in	in	B-PP	IN	O	7	VMOD
9	7.6	7.6	B-NP	CD	O	11	AMOD
10	+/-	+/-	I-NP	SYM	O	11	AMOD
11	3.4	3.4	I-NP	CD	O	12	NMOD
12	%	%	I-NP	NN	O	8	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	glomeruli	glomeruli	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	PAN	PAN	B-NP	NN	O	18	NMOD
18	rats	rat	I-NP	NNS	O	16	PMOD
19	;	;	O	:	O	6	P
20	glomeruli	glomerulus	B-NP	NNS	O	24	SUB
21	of	of	B-PP	IN	O	20	NMOD
22	the	the	B-NP	DT	O	23	NMOD
23	controls	control	I-NP	NNS	O	21	PMOD
24	were	be	B-VP	VBD	O	0	ROOT
25	normal	normal	B-ADJP	JJ	O	24	PRD
26	.	.	O	.	O	24	P

1	Since	Since	B-SBAR	IN	O	17	VMOD
2	mesangial	mesangial	B-NP	JJ	O	4	NMOD
3	CC	CC	I-NP	NN	O	4	NMOD
4	clearance	clearance	I-NP	NN	O	8	SUB
5	from	from	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	mesangium	mesangium	I-NP	NN	O	5	PMOD
8	did	do	B-VP	VBD	O	1	SBAR
9	not	not	I-VP	RB	O	8	VMOD
10	change	change	I-VP	VB	O	8	VC
11	during	during	B-PP	IN	O	10	VMOD
12	chronic	chronic	B-NP	JJ	O	14	NMOD
13	PAN	PAN	I-NP	NN	O	14	NMOD
14	treatment	treatment	I-NP	NN	O	11	PMOD
15	,	,	O	,	O	17	P
16	we	we	B-NP	PRP	O	17	SUB
17	conclude	conclude	B-VP	VBP	O	0	ROOT
18	that	that	B-SBAR	IN	O	17	VMOD
19	this	this	B-NP	DT	O	22	NMOD
20	preferential	preferential	I-NP	JJ	O	22	NMOD
21	CC	CC	I-NP	NN	O	22	NMOD
22	localization	localization	I-NP	NN	O	26	SUB
23	within	within	B-PP	IN	O	22	NMOD
24	the	the	B-NP	DT	O	25	NMOD
25	lesions	lesion	I-NP	NNS	O	23	PMOD
26	is	be	B-VP	VBZ	O	18	SBAR
27	caused	cause	I-VP	VBN	O	26	VC
28	by	by	B-PP	IN	O	27	VMOD
29	an	an	B-NP	DT	O	32	NMOD
30	increased	increase	I-NP	VBN	O	32	NMOD
31	CC	CC	I-NP	NN	O	32	NMOD
32	uptake	uptake	I-NP	NN	O	28	PMOD
33	shortly	shortly	B-ADVP	RB	O	32	NMOD
34	after	after	B-PP	IN	O	32	NMOD
35	injection	injection	B-NP	NN	O	34	PMOD
36	in	in	B-PP	IN	O	32	NMOD
37	apparent	apparent	B-NP	JJ	O	39	NMOD
38	vulnerable	vulnerable	I-NP	JJ	O	39	NMOD
39	areas	area	I-NP	NNS	O	36	PMOD
40	where	where	B-ADVP	WRB	O	39	NMOD
41	sclerosis	sclerosis	B-NP	NN	O	42	SUB
42	will	will	B-VP	MD	O	40	SBAR
43	develop	develop	I-VP	VB	O	42	VC
44	subsequently	subsequently	B-ADVP	RB	O	43	VMOD
45	.	.	O	.	O	17	P

1	Relationship	Relationship	B-NP	NN	O	0	ROOT
2	between	between	B-PP	IN	O	1	NMOD
3	nicotine	nicotine	B-NP	NN	O	5	NMOD
4	induced	induce	I-NP	VBN	O	3	AMOD
5	seizures	seizure	I-NP	NNS	O	9	NMOD
6	and	and	O	CC	O	9	NMOD
7	hippocampal	hippocampal	B-NP	JJ	B-protein	9	NMOD
8	nicotinic	nicotinic	I-NP	JJ	I-protein	9	NMOD
9	receptors	receptor	I-NP	NNS	I-protein	2	PMOD
10	.	.	O	.	O	1	P

1	Using	Use	B-VP	VBG	O	24	SUB
2	mice	mouse	B-NP	NNS	O	1	OBJ
3	derived	derive	B-VP	VBN	O	2	NMOD
4	from	from	B-PP	IN	O	3	VMOD
5	a	a	B-NP	DT	O	7	NMOD
6	classical	classical	I-NP	JJ	O	7	NMOD
7	F2	F2	I-NP	NN	O	11	NMOD
8	and	and	O	CC	O	11	NMOD
9	backcross	backcross	B-NP	RB	O	10	AMOD
10	genetic	genetic	I-NP	JJ	O	11	NMOD
11	design	design	I-NP	NN	O	14	NMOD
12	,	,	O	,	O	14	P
13	a	a	B-NP	DT	O	14	NMOD
14	relationship	relationship	I-NP	NN	O	4	PMOD
15	between	between	B-PP	IN	O	14	NMOD
16	nicotine	nicotine	B-NP	NN	O	18	NMOD
17	induced	induce	I-NP	VBN	O	16	AMOD
18	seizures	seizure	I-NP	NNS	O	23	NMOD
19	and	and	O	CC	O	23	NMOD
20	alpha-bungarotoxin	alpha-bungarotoxin	B-NP	NN	B-protein	23	NMOD
21	nicotinic	nicotinic	I-NP	JJ	I-protein	23	NMOD
22	receptor	receptor	I-NP	NN	I-protein	23	NMOD
23	concentration	concentration	I-NP	NN	O	15	PMOD
24	was	be	B-VP	VBD	O	0	ROOT
25	found	find	I-VP	VBN	O	24	VC
26	.	.	O	.	O	24	P

1	Mice	Mouse	B-NP	NNS	O	9	SUB
2	sensitive	sensitive	B-ADJP	JJ	O	1	NMOD
3	to	to	B-PP	TO	O	2	AMOD
4	the	the	B-NP	DT	O	6	NMOD
5	convulsant	convulsant	I-NP	JJ	O	6	NMOD
6	effects	effect	I-NP	NNS	O	3	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	nicotine	nicotine	B-NP	NN	O	7	PMOD
9	had	have	B-VP	VBD	O	0	ROOT
10	greater	great	B-NP	JJR	O	12	NMOD
11	alpha-bungarotoxin	alpha-bungarotoxin	I-NP	NN	O	12	NMOD
12	binding	binding	I-NP	NN	O	9	OBJ
13	in	in	B-PP	IN	O	9	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	hippocampus	hippocampus	I-NP	NN	O	13	PMOD
16	than	than	B-PP	IN	O	15	NMOD
17	seizure	seizure	B-NP	NN	O	19	NMOD
18	insensitive	insensitive	I-NP	JJ	O	19	NMOD
19	mice	mouse	I-NP	NNS	O	16	PMOD
20	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	3	NMOD
2	binding	bind	I-NP	VBG	B-DNA	3	NMOD
3	sites	site	I-NP	NNS	I-DNA	10	SUB
4	from	from	B-PP	IN	O	3	NMOD
5	seizure	seizure	B-NP	NN	O	9	NMOD
6	sensitive	sensitive	I-NP	JJ	O	5	NMOD
7	and	and	I-NP	CC	O	5	NMOD
8	resistant	resistant	I-NP	JJ	O	9	NMOD
9	mice	mouse	I-NP	NNS	O	4	PMOD
10	were	be	B-VP	VBD	O	0	ROOT
11	equally	equally	I-VP	RB	O	10	VMOD
12	affected	affect	I-VP	VBN	O	10	VC
13	by	by	B-PP	IN	O	12	VMOD
14	treatment	treatment	B-NP	NN	O	13	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	dithiothreitol	dithiothreitol	B-NP	NN	O	20	NMOD
17	,	,	I-NP	,	O	20	P
18	trypsin	trypsin	I-NP	NN	B-protein	20	NMOD
19	or	or	I-NP	CC	O	20	NMOD
20	heat	heat	I-NP	NN	O	15	PMOD
21	.	.	O	.	O	10	P

1	The	The	B-NP	DT	O	2	NMOD
2	role	role	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	p-aminophenol	p-aminophenol	B-NP	NN	O	3	PMOD
5	in	in	B-PP	IN	O	2	NMOD
6	acetaminophen	acetaminophen	B-NP	NN	O	5	PMOD
7	induced	induce	B-VP	VBD	O	0	ROOT
8	nephrotoxicity	nephrotoxicity	B-NP	NN	O	7	OBJ
9	:	:	O	:	O	7	VMOD
10	effect	effect	B-NP	NN	O	9	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	bis	bis	B-NP	NN	O	16	NMOD
13	(	(	O	(	O	15	DEP
14	p-nitrophenyl	p-nitrophenyl	B-NP	NN	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	phosphate	phosphate	B-NP	NN	O	11	PMOD
17	on	on	B-PP	IN	O	10	NMOD
18	acetaminophen	acetaminophen	B-NP	NN	O	23	NMOD
19	and	and	I-NP	CC	O	23	NMOD
20	p-aminophenol	p-aminophenol	I-NP	NN	O	21	NMOD
21	nephrotoxicity	nephrotoxicity	I-NP	NN	O	23	NMOD
22	and	and	I-NP	CC	O	23	NMOD
23	metabolism	metabolism	I-NP	NN	O	17	PMOD
24	in	in	B-PP	IN	O	10	NMOD
25	Fischer	Fischer	B-NP	NNP	O	27	NMOD
26	344	344	I-NP	CD	O	27	NMOD
27	rats	rat	I-NP	NNS	O	24	PMOD
28	.	.	O	.	O	7	P

1	Acetaminophen	Acetaminophen	B-NP	NN	O	5	SUB
2	(	(	O	(	O	4	DEP
3	APAP	APAP	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	produces	produce	B-VP	VBZ	O	0	ROOT
6	proximal	proximal	B-NP	JJ	O	8	NMOD
7	tubular	tubular	I-NP	JJ	O	8	NMOD
8	necrosis	necrosis	I-NP	NN	O	5	OBJ
9	in	in	B-PP	IN	O	8	NMOD
10	Fischer	Fischer	B-NP	NNP	O	15	NMOD
11	344	344	I-NP	CD	O	10	NMOD
12	(	(	O	(	O	14	DEP
13	F344	F344	B-NP	NN	O	14	DEP
14	)	)	O	)	O	15	NMOD
15	rats	rat	B-NP	NNS	O	9	PMOD
16	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	2	NMOD
2	purpose	purpose	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	determine	determine	I-VP	VB	O	6	PRD
9	if	if	B-SBAR	IN	O	8	VMOD
10	PAP	PAP	B-NP	NN	O	11	NMOD
11	formation	formation	I-NP	NN	O	12	SUB
12	is	be	B-VP	VBZ	O	9	SBAR
13	a	a	B-NP	DT	O	15	NMOD
14	requisite	requisite	I-NP	JJ	O	15	NMOD
15	step	step	I-NP	NN	O	12	PRD
16	in	in	B-PP	IN	O	15	NMOD
17	APAP	APAP	B-NP	NN	B-protein	19	NMOD
18	induced	induced	I-NP	JJ	O	19	NMOD
19	nephrotoxicity	nephrotoxicity	I-NP	NN	O	16	PMOD
20	.	.	O	.	O	6	P

1	Therefore	Therefore	B-ADVP	RB	O	26	VMOD
2	,	,	O	,	O	26	P
3	the	the	B-NP	DT	O	4	NMOD
4	effect	effect	I-NP	NN	O	26	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	bis	bis	B-NP	NN	O	10	NMOD
7	(	(	O	(	O	9	DEP
8	p-nitrophenyl	p-nitrophenyl	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	phosphate	phosphate	B-NP	NN	O	17	NMOD
11	(	(	O	(	O	13	DEP
12	BNPP	BNPP	B-NP	NN	B-protein	13	DEP
13	)	)	O	)	O	10	NMOD
14	,	,	O	,	O	17	P
15	an	an	B-NP	DT	O	17	NMOD
16	acylamidase	acylamidase	I-NP	NN	O	17	NMOD
17	inhibitor	inhibitor	I-NP	NN	O	5	PMOD
18	,	,	O	,	O	17	P
19	on	on	B-PP	IN	O	4	NMOD
20	APAP	APAP	B-NP	NN	B-protein	25	NMOD
21	and	and	I-NP	CC	O	25	NMOD
22	PAP	PAP	I-NP	NN	O	23	NMOD
23	nephrotoxicity	nephrotoxicity	I-NP	NN	O	25	NMOD
24	and	and	I-NP	CC	O	25	NMOD
25	metabolism	metabolism	I-NP	NN	O	19	PMOD
26	was	be	B-VP	VBD	O	0	ROOT
27	determined	determine	I-VP	VBN	O	26	VC
28	.	.	O	.	O	26	P

1	Pretreatment	Pretreatment	B-NP	NN	O	12	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	animals	animal	B-NP	NNS	O	2	PMOD
4	with	with	B-PP	IN	O	1	NMOD
5	BNPP	BNPP	B-NP	NN	O	4	PMOD
6	prior	prior	B-ADJP	JJ	O	5	NMOD
7	to	to	B-PP	TO	O	6	AMOD
8	APAP	APAP	B-NP	NN	B-protein	11	NMOD
9	or	or	I-NP	CC	O	11	NMOD
10	PAP	PAP	I-NP	NN	O	11	NMOD
11	administration	administration	I-NP	NN	O	7	PMOD
12	resulted	result	B-VP	VBD	O	0	ROOT
13	in	in	B-PP	IN	O	12	VMOD
14	marked	marked	B-NP	JJ	O	15	NMOD
15	reduction	reduction	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	APAP	APAP	B-NP	NN	B-protein	22	NMOD
18	(	(	O	(	O	21	DEP
19	900	900	B-NP	CD	O	20	NMOD
20	mg/kg	mg/kg	I-NP	NN	O	21	DEP
21	)	)	O	)	O	17	NMOD
22	nephrotoxicity	nephrotoxicity	B-NP	NN	O	26	NMOD
23	but	but	B-NP	CC	O	26	NMOD
24	not	not	I-NP	RB	O	23	DEP
25	PAP	PAP	B-NP	NN	O	26	NMOD
26	nephrotoxicity	nephrotoxicity	I-NP	NN	O	16	PMOD
27	.	.	O	.	O	12	P

1	Therefore	Therefore	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	the	the	B-NP	DT	O	4	NMOD
4	BNPP	BNPP	I-NP	NN	B-protein	5	SUB
5	induced	induce	B-VP	VBD	O	0	ROOT
6	reduction	reduction	B-NP	NN	O	11	SUB
7	in	in	B-PP	IN	O	6	NMOD
8	APAP	APAP	B-NP	NN	B-protein	10	NMOD
9	induced	induced	I-NP	JJ	O	10	NMOD
10	nephrotoxicity	nephrotoxicity	I-NP	NN	O	7	PMOD
11	appears	appear	B-VP	VBZ	O	5	VMOD
12	to	to	I-VP	TO	O	13	VMOD
13	be	be	I-VP	VB	O	11	VMOD
14	due	due	B-PP	IN	O	15	PMOD
15	to	to	B-PP	TO	O	13	PRD
16	inhibition	inhibition	B-NP	NN	O	15	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	APAP	APAP	B-NP	NN	O	19	NMOD
19	deacetylation	deacetylation	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	5	P

1	Morphine	Morphine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	seizures	seizure	B-NP	NNS	O	2	OBJ
4	in	in	B-PP	IN	O	3	NMOD
5	newborn	newborn	B-NP	JJ	O	6	NMOD
6	infants	infant	I-NP	NNS	O	4	PMOD
7	.	.	O	.	O	2	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	neonates	neonate	I-NP	NNS	O	0	ROOT
3	suffered	suffer	B-VP	VBN	O	2	NMOD
4	from	from	B-PP	IN	O	3	VMOD
5	generalized	generalize	B-NP	VBN	O	6	NMOD
6	seizures	seizure	I-NP	NNS	O	4	PMOD
7	during	during	B-PP	IN	O	3	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	course	course	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	intravenous	intravenous	B-NP	JJ	O	13	NMOD
12	morphine	morphine	I-NP	NN	O	13	NMOD
13	sulfate	sulfate	I-NP	NN	O	10	PMOD
14	for	for	B-PP	IN	O	13	NMOD
15	post-operative	post-operative	B-NP	JJ	O	16	NMOD
16	analgesia	analgesia	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	2	P

1	They	They	B-NP	PRP	O	2	SUB
2	received	receive	B-VP	VBD	O	0	ROOT
3	morphine	morphine	B-NP	NN	O	2	OBJ
4	in	in	B-PP	IN	O	2	VMOD
5	doses	dose	B-NP	NNS	O	4	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	32	32	B-NP	CD	O	8	NMOD
8	micrograms/kg/hr	micrograms/kg/hr	I-NP	NN	O	11	NMOD
9	and	and	I-NP	CC	O	11	NMOD
10	40	40	I-NP	CD	O	11	NMOD
11	micrograms/kg/hr	micrograms/kg/hr	I-NP	NN	O	6	PMOD
12	larger	large	B-ADJP	JJR	O	5	NMOD
13	than	than	B-PP	IN	O	12	AMOD
14	a	a	B-NP	DT	O	15	NMOD
15	group	group	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	10	10	B-NP	CD	O	18	NMOD
18	neonates	neonate	I-NP	NNS	O	16	PMOD
19	who	who	B-NP	WP	O	18	NMOD
20	received	receive	B-VP	VBD	O	19	SBAR
21	6-24	6-24	B-NP	CD	O	22	NMOD
22	micrograms/kg/hr	micrograms/kg/hr	I-NP	NN	O	20	OBJ
23	and	and	O	CC	O	2	VMOD
24	had	have	B-VP	VBD	O	2	VMOD
25	no	no	B-NP	DT	O	26	NMOD
26	seizures	seizure	I-NP	NNS	O	24	OBJ
27	.	.	O	.	O	2	P

1	Other	Other	B-NP	JJ	O	3	NMOD
2	known	known	I-NP	JJ	O	3	NMOD
3	reasons	reason	I-NP	NNS	O	6	SUB
4	for	for	B-PP	IN	O	3	NMOD
5	seizures	seizure	B-NP	NNS	O	4	PMOD
6	were	be	B-VP	VBD	O	12	VMOD
7	ruled	rule	I-VP	VBN	O	6	VC
8	out	out	B-PRT	RP	O	7	VMOD
9	and	and	O	CC	O	12	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	convulsions	convulsion	I-NP	NNS	O	12	SUB
12	stopped	stop	B-VP	VBD	O	0	ROOT
13	a	a	B-NP	DT	O	15	NMOD
14	few	few	I-NP	JJ	O	15	NMOD
15	hours	hour	I-NP	NNS	O	16	PMOD
16	after	after	B-PP	IN	O	12	VMOD
17	cessation	cessation	B-NP	NN	O	16	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	morphine	morphine	B-NP	NN	O	18	PMOD
20	and	and	O	CC	O	12	VMOD
21	did	do	B-VP	VBD	O	12	VMOD
22	not	not	I-VP	RB	O	21	VMOD
23	reoccur	reoccur	I-VP	VB	O	21	VC
24	in	in	B-PP	IN	O	23	VMOD
25	the	the	B-NP	DT	O	28	NMOD
26	subsequent	subsequent	I-NP	JJ	O	28	NMOD
27	8	8	I-NP	CD	O	28	NMOD
28	months	month	I-NP	NNS	O	24	PMOD
29	.	.	O	.	O	12	P

1	Effect	Effect	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	vincristine	vincristine	B-NP	NN	O	4	NMOD
4	sulfate	sulfate	I-NP	NN	O	2	PMOD
5	on	on	B-PP	IN	O	1	NMOD
6	Pseudomonas	Pseudomonas	B-NP	NNP	O	7	NMOD
7	infections	infection	I-NP	NNS	O	5	PMOD
8	in	in	B-PP	IN	O	7	NMOD
9	monkeys	monkey	B-NP	NNS	O	8	PMOD
10	.	.	O	.	O	1	P

1	Intravenous	Intravenous	B-NP	JJ	O	4	NMOD
2	or	or	I-NP	CC	O	4	NMOD
3	intratracheal	intratracheal	I-NP	JJ	O	4	NMOD
4	inoculation	inoculation	I-NP	NN	O	13	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	2.0	2.0	B-NP	CD	O	8	AMOD
7	to	to	I-NP	TO	O	8	AMOD
8	2.5	2.5	I-NP	CD	O	9	NMOD
9	mg	mg	I-NP	NN	O	5	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	vincristine	vincristine	B-NP	NN	O	12	NMOD
12	sulfate	sulfate	I-NP	NN	O	10	PMOD
13	was	be	B-VP	VBD	O	0	ROOT
14	followed	follow	I-VP	VBN	O	13	VC
15	by	by	B-PP	IN	O	14	VMOD
16	leukopenia	leukopenia	B-NP	NN	O	15	PMOD
17	in	in	B-PP	IN	O	14	VMOD
18	4	4	B-NP	CD	O	20	AMOD
19	to	to	I-NP	TO	O	20	AMOD
20	5	5	I-NP	CD	O	21	NMOD
21	days	day	I-NP	NNS	O	17	PMOD
22	.	.	O	.	O	13	P

1	Intravenous	Intravenous	B-NP	JJ	O	2	NMOD
2	inoculation	inoculation	I-NP	NN	O	30	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	4.2	4.2	B-NP	CD	O	6	AMOD
5	x	x	I-NP	SYM	O	6	AMOD
6	10	10	I-NP	CD	O	3	PMOD
7	(	(	O	(	O	9	DEP
8	10	10	B-NP	CD	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	to	to	B-PP	TO	O	2	NMOD
11	7.8	7.8	B-NP	CD	O	21	NMOD
12	x	x	I-NP	NN	O	11	NMOD
13	10	10	B-NP	CD	O	12	NMOD
14	(	(	O	(	O	16	DEP
15	10	10	O	CD	O	16	DEP
16	)	)	O	)	O	12	NMOD
17	pyocin	pyocin	B-NP	NN	O	18	NMOD
18	type	type	I-NP	NN	O	21	NMOD
19	6	6	I-NP	CD	O	18	NMOD
20	Pseudomonas	Pseudomonas	I-NP	NN	O	21	NMOD
21	organisms	organism	I-NP	NNS	O	10	PMOD
22	in	in	B-PP	IN	O	2	NMOD
23	monkeys	monkey	B-NP	NNS	O	22	PMOD
24	given	give	B-VP	VBN	O	23	NMOD
25	vincristine	vincristine	B-NP	NN	O	26	NMOD
26	sulfate	sulfate	I-NP	NN	O	28	NMOD
27	4	4	B-NP	CD	O	28	NMOD
28	days	day	I-NP	NNS	O	24	VMOD
29	previously	previously	B-ADVP	RB	O	30	VMOD
30	resulted	result	B-VP	VBD	O	0	ROOT
31	in	in	B-PP	IN	O	30	VMOD
32	fatal	fatal	B-NP	JJ	O	33	NMOD
33	infection	infection	I-NP	NN	O	31	PMOD
34	in	in	B-PP	IN	O	33	NMOD
35	11	11	B-NP	CD	O	34	PMOD
36	of	of	B-PP	IN	O	35	NMOD
37	14	14	B-NP	CD	O	38	NMOD
38	monkeys	monkey	I-NP	NNS	O	36	PMOD
39	,	,	O	,	O	30	P
40	whereas	whereas	O	IN	O	30	VMOD
41	none	none	B-NP	NN	O	47	SUB
42	of	of	B-PP	IN	O	41	NMOD
43	four	four	B-NP	CD	O	45	NMOD
44	receiving	receive	B-VP	VBG	O	45	NMOD
45	Pseudomonas	Pseudomonas	B-NP	NNP	O	42	PMOD
46	alone	alone	B-ADVP	RB	O	45	NMOD
47	died	die	B-VP	VBD	O	40	SBAR
48	.	.	O	.	O	30	P

1	Signs	Sign	B-NP	NNS	O	7	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	FZP	FZP	B-NP	NN	O	4	NMOD
4	toxocity	toxocity	I-NP	NN	O	2	PMOD
5	in	in	B-PP	IN	O	1	NMOD
6	cats	cat	B-NP	NNS	O	5	PMOD
7	included	include	B-VP	VBD	O	0	ROOT
8	excessive	excessive	B-NP	JJ	O	9	NMOD
9	salivation	salivation	I-NP	NN	O	20	NMOD
10	,	,	O	,	O	20	P
11	extreme	extreme	B-NP	JJ	O	13	NMOD
12	apprehensive	apprehensive	I-NP	JJ	O	13	NMOD
13	behavior	behavior	I-NP	NN	O	20	NMOD
14	,	,	O	,	O	20	P
15	retching	retching	B-NP	NN	O	20	NMOD
16	,	,	O	,	O	20	P
17	muscle	muscle	B-NP	NN	O	18	NMOD
18	tremors	tremor	I-NP	NNS	O	20	NMOD
19	and	and	I-NP	CC	O	20	NMOD
20	convulsions	convulsion	I-NP	NNS	O	7	OBJ
21	.	.	O	.	O	7	P

1	As	As	B-PP	IN	O	9	VMOD
2	a	a	B-NP	DT	O	3	NMOD
3	function	function	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	dose	dose	B-NP	NN	O	4	PMOD
6	,	,	O	,	O	9	P
7	FZP	FZP	B-NP	NN	B-protein	9	SUB
8	first	first	B-ADVP	RB	O	9	VMOD
9	protected	protect	B-VP	VBD	O	0	ROOT
10	against	against	B-PP	IN	O	9	VMOD
11	convulsions	convulsion	B-NP	NNS	O	13	NMOD
12	and	and	O	CC	O	13	NMOD
13	death	death	B-NP	NN	O	10	PMOD
14	.	.	O	.	O	9	P

1	These	These	B-NP	DT	O	2	NMOD
2	doses	dose	I-NP	NNS	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	FZP	FZP	B-NP	NN	B-protein	3	PMOD
5	were	be	B-VP	VBD	O	0	ROOT
6	lower	low	B-ADJP	JJR	O	5	PRD
7	than	than	B-PP	IN	O	6	AMOD
8	those	those	B-NP	DT	O	7	PMOD
9	that	that	B-NP	WDT	O	8	NMOD
10	would	would	B-VP	MD	O	9	SBAR
11	alone	alone	I-VP	RB	O	10	VMOD
12	cause	cause	I-VP	VB	O	10	VC
13	convulsions	convulsion	B-NP	NNS	O	12	OBJ
14	.	.	O	.	O	5	P

1	We	We	B-NP	PRP	O	2	SUB
2	compared	compare	B-VP	VBD	O	24	VMOD
3	the	the	B-NP	DT	O	4	NMOD
4	effects	effect	I-NP	NNS	O	18	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	single	single	B-NP	JJ	O	7	NMOD
7	doses	dose	I-NP	NNS	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	50	50	B-NP	CD	O	10	AMOD
10	mg	mg	I-NP	NN	O	11	NMOD
11	atenolol	atenolol	I-NP	NN	O	8	PMOD
12	(	(	O	(	O	14	DEP
13	cardioselective	cardioselective	B-ADVP	JJ	O	14	DEP
14	)	)	O	)	O	7	NMOD
15	,	,	O	,	O	18	P
16	40	40	B-NP	CD	O	17	AMOD
17	mg	mg	I-NP	NN	O	18	NMOD
18	propranolol	propranolol	I-NP	NN	O	2	OBJ
19	(	(	O	(	O	21	DEP
20	nonselective	nonselective	B-ADVP	JJ	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	,	,	O	,	O	24	P
23	and	and	O	CC	O	24	NMOD
24	placebo	placebo	B-NP	NN	O	30	SUB
25	on	on	B-PP	IN	O	24	NMOD
26	both	both	O	CC	O	29	NMOD
27	exercise-	exercise-	B-NP	NN	O	29	NMOD
28	and	and	I-NP	CC	O	29	NMOD
29	isoproterenol	isoproterenol	I-NP	NN	O	25	PMOD
30	induced	induce	B-VP	VBD	O	0	ROOT
31	tachycardia	tachycardia	B-NP	NN	O	30	OBJ
32	in	in	B-PP	IN	O	30	VMOD
33	two	two	B-NP	CD	O	34	NMOD
34	experiments	experiment	I-NP	NNS	O	32	PMOD
35	involving	involve	B-VP	VBG	O	34	NMOD
36	nine	nine	B-NP	CD	O	38	NMOD
37	normal	normal	I-NP	JJ	O	38	NMOD
38	subjects	subject	I-NP	NNS	O	35	OBJ
39	.	.	O	.	O	30	P

1	The	The	B-NP	DT	O	2	NMOD
2	effects	effect	I-NP	NNS	O	6	SUB
3	on	on	B-PP	IN	O	2	NMOD
4	isoproterenol	isoproterenol	B-NP	NN	O	5	NMOD
5	tachycardia	tachycardia	I-NP	NN	O	3	PMOD
6	were	be	B-VP	VBD	O	0	ROOT
7	determined	determine	I-VP	VBN	O	6	VC
8	before	before	B-PP	IN	O	7	VMOD
9	and	and	I-PP	CC	O	8	PMOD
10	after	after	I-PP	IN	O	8	PMOD
11	atropine	atropine	B-NP	NN	O	8	PMOD
12	(	(	O	(	O	16	DEP
13	0.04	0.04	B-NP	CD	O	15	NMOD
14	mg/kg	mg/kg	I-NP	NN	O	15	NMOD
15	IV	IV	B-NP	CD	O	16	DEP
16	)	)	O	)	O	11	NMOD
17	.	.	O	.	O	6	P

1	Early	Early	B-NP	JJ	O	2	NMOD
2	infections	infection	I-NP	NNS	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	kidney	kidney	B-NP	NN	O	11	NMOD
5	,	,	O	,	O	11	P
6	heart	heart	B-NP	NN	O	11	NMOD
7	,	,	O	,	O	11	P
8	and	and	O	CC	O	11	NMOD
9	liver	liver	B-NP	NN	O	11	NMOD
10	transplant	transplant	I-NP	NN	O	11	NMOD
11	recipients	recipient	I-NP	NNS	O	3	PMOD
12	on	on	B-PP	IN	O	11	NMOD
13	cyclosporine	cyclosporine	B-NP	NN	O	12	PMOD
14	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	4	NMOD
2	randomized	randomize	I-NP	VBN	O	4	NMOD
3	Aza	Aza	I-NP	NN	O	4	NMOD
4	patients	patient	I-NP	NNS	O	5	SUB
5	had	have	B-VP	VBD	O	0	ROOT
6	more	more	B-NP	RBR	O	7	AMOD
7	overall	overall	I-NP	JJ	O	8	NMOD
8	infections	infection	I-NP	NNS	O	18	NMOD
9	(	(	O	(	O	14	DEP
10	P	P	B-NP	NN	O	12	SUB
11	less	less	B-ADJP	JJR	O	12	AMOD
12	than	than	B-PP	IN	O	14	DEP
13	0.05	0.05	B-NP	CD	O	12	AMOD
14	)	)	O	)	O	8	NMOD
15	and	and	O	CC	O	18	NMOD
16	more	more	B-NP	RBR	O	17	AMOD
17	nonviral	nonviral	I-NP	JJ	O	18	NMOD
18	infections	infection	I-NP	NNS	O	5	OBJ
19	(	(	O	(	O	24	DEP
20	P	P	B-NP	NN	O	24	DEP
21	less	less	B-ADJP	JJR	O	20	NMOD
22	than	than	B-PP	IN	O	21	AMOD
23	0.02	0.02	B-NP	CD	O	22	PMOD
24	)	)	O	)	O	18	NMOD
25	than	than	B-PP	IN	O	18	NMOD
26	the	the	B-NP	DT	O	29	NMOD
27	randomized	randomize	I-NP	VBN	O	29	NMOD
28	cyclosporine	cyclosporine	I-NP	NN	O	29	NMOD
29	patients	patient	I-NP	NNS	O	25	PMOD
30	.	.	O	.	O	5	P

1	Heart	Heart	B-NP	NN	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	liver	liver	I-NP	NN	O	4	NMOD
4	patients	patient	I-NP	NNS	O	5	SUB
5	had	have	B-VP	VBD	O	0	ROOT
6	more	more	B-NP	JJR	O	7	NMOD
7	infections	infection	I-NP	NNS	O	5	OBJ
8	than	than	B-PP	IN	O	7	NMOD
9	cyclosporine	cyclosporine	B-NP	NN	O	11	NMOD
10	renal	renal	I-NP	JJ	O	11	NMOD
11	patients	patient	I-NP	NNS	O	14	NMOD
12	but	but	O	CC	O	14	NMOD
13	fewer	few	B-NP	JJR	O	14	NMOD
14	infections	infection	I-NP	NNS	O	8	PMOD
15	than	than	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	19	NMOD
17	Aza	Aza	I-NP	NNP	O	19	NMOD
18	renal	renal	I-NP	JJ	O	19	NMOD
19	patients	patient	I-NP	NNS	O	15	PMOD
20	.	.	O	.	O	5	P

1	There	There	B-NP	EX	O	2	SUB
2	were	be	B-VP	VBD	O	17	VMOD
3	no	no	B-NP	DT	O	5	NMOD
4	infectious	infectious	I-NP	JJ	O	5	NMOD
5	deaths	death	I-NP	NNS	O	2	PRD
6	in	in	B-PP	IN	O	2	VMOD
7	renal	renal	B-NP	JJ	O	9	NMOD
8	transplant	transplant	I-NP	NN	O	9	NMOD
9	patients	patient	I-NP	NNS	O	6	PMOD
10	on	on	B-PP	IN	O	9	NMOD
11	cyclosporine	cyclosporine	B-NP	NN	O	13	NMOD
12	or	or	I-NP	CC	O	13	NMOD
13	Aza	Aza	I-NP	NN	B-protein	10	PMOD
14	,	,	O	,	O	17	P
15	but	but	O	CC	O	17	VMOD
16	infection	infection	B-NP	NN	O	17	SUB
17	played	play	B-VP	VBD	O	0	ROOT
18	a	a	B-NP	DT	O	20	NMOD
19	major	major	I-NP	JJ	O	20	NMOD
20	role	role	I-NP	NN	O	17	OBJ
21	in	in	B-PP	IN	O	17	VMOD
22	3	3	B-NP	CD	O	24	AMOD
23	out	out	I-NP	IN	O	24	AMOD
24	of	of	I-NP	IN	O	28	NMOD
25	6	6	I-NP	CD	O	24	AMOD
26	cardiac	cardiac	I-NP	JJ	O	28	NMOD
27	transplant	transplant	I-NP	NN	O	28	NMOD
28	deaths	death	I-NP	NNS	O	21	PMOD
29	and	and	O	CC	O	17	VMOD
30	in	in	B-PP	IN	O	17	VMOD
31	8	8	B-NP	CD	O	30	PMOD
32	out	out	B-PP	IN	O	17	VMOD
33	of	of	B-PP	IN	O	32	PMOD
34	9	9	B-NP	CD	O	37	NMOD
35	liver	liver	I-NP	NN	O	37	NMOD
36	transplant	transplant	I-NP	NN	O	37	NMOD
37	deaths	death	I-NP	NNS	O	33	PMOD
38	.	.	O	.	O	17	P

1	Renal	Renal	B-NP	JJ	O	2	NMOD
2	patients	patient	I-NP	NNS	O	5	SUB
3	on	on	B-PP	IN	O	2	NMOD
4	cyclosporine	cyclosporine	B-NP	NN	O	3	PMOD
5	had	have	B-VP	VBD	O	0	ROOT
6	the	the	B-NP	DT	O	8	NMOD
7	fewest	few	I-NP	JJS	O	8	NMOD
8	bacteremias	bacteremia	I-NP	NNS	O	5	OBJ
9	.	.	O	.	O	5	P

1	Pulmonary	Pulmonary	B-NP	JJ	O	2	NMOD
2	infections	infection	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	0	ROOT
4	less	less	B-ADJP	RBR	O	5	AMOD
5	common	common	I-ADJP	JJ	O	3	PRD
6	in	in	B-PP	IN	O	5	AMOD
7	cyclosporine-treated	cyclosporine-treated	B-NP	JJ	O	9	NMOD
8	renal	renal	I-NP	JJ	O	9	NMOD
9	patients	patient	I-NP	NNS	O	6	PMOD
10	than	than	B-PP	IN	O	5	AMOD
11	in	in	B-PP	IN	O	10	PMOD
12	Aza-treated	Aza-treated	B-NP	JJ	O	13	NMOD
13	patients	patient	I-NP	NNS	O	11	PMOD
14	(	(	O	(	O	19	DEP
15	P	P	B-NP	NN	O	19	DEP
16	less	less	B-ADJP	JJR	O	15	NMOD
17	than	than	B-PP	IN	O	16	AMOD
18	0.05	0.05	B-NP	CD	O	17	PMOD
19	)	)	O	)	O	13	NMOD
20	.	.	O	.	O	3	P

1	Aza	Aza	B-NP	NN	O	2	NMOD
2	patients	patient	I-NP	NNS	O	3	SUB
3	had	have	B-VP	VBD	O	24	VMOD
4	significantly	significantly	B-NP	RB	O	6	AMOD
5	more	more	I-NP	JJR	O	4	AMOD
6	staphylococcal	staphylococcal	I-NP	JJ	O	7	NMOD
7	infections	infection	I-NP	NNS	O	3	OBJ
8	than	than	B-PP	IN	O	7	NMOD
9	all	all	B-NP	DT	O	12	NMOD
10	other	other	I-NP	JJ	O	12	NMOD
11	transplant	transplant	I-NP	NN	O	12	NMOD
12	groups	group	I-NP	NNS	O	8	SBAR
13	(	(	O	(	O	18	DEP
14	P	P	B-NP	NN	O	16	SUB
15	less	less	B-ADJP	JJR	O	16	AMOD
16	than	than	B-PP	IN	O	18	DEP
17	0.005	0.005	B-NP	CD	O	16	AMOD
18	)	)	O	)	O	12	NMOD
19	,	,	O	,	O	24	P
20	and	and	O	CC	O	23	NMOD
21	systemic	systemic	B-NP	JJ	O	23	NMOD
22	fungal	fungal	I-NP	JJ	O	23	NMOD
23	infections	infection	I-NP	NNS	O	24	SUB
24	occurred	occur	B-VP	VBD	O	0	ROOT
25	only	only	B-ADVP	RB	O	26	PMOD
26	in	in	B-PP	IN	O	24	VMOD
27	the	the	B-NP	DT	O	30	NMOD
28	liver	liver	I-NP	NN	O	30	NMOD
29	transplant	transplant	I-NP	NN	O	30	NMOD
30	group	group	I-NP	NN	O	26	PMOD
31	.	.	O	.	O	24	P

1	Of	Of	B-PP	IN	O	8	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	cyclosporine	cyclosporine	I-NP	NN	O	4	NMOD
4	patients	patient	I-NP	NNS	O	1	PMOD
5	,	,	O	,	O	8	P
6	15	15	B-NP	CD	O	7	AMOD
7	%	%	I-NP	NN	O	8	SUB
8	had	have	O	VBD	O	0	ROOT
9	symptoms	symptom	B-NP	NNS	O	8	OBJ
10	related	relate	B-VP	VBN	O	9	NMOD
11	to	to	B-PP	TO	O	10	AMOD
12	CMV	CMV	B-NP	NN	O	13	NMOD
13	infection	infection	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	8	P

1	Serological	Serological	B-NP	JJ	O	2	NMOD
2	evidence	evidence	I-NP	NN	O	8	SUB
3	for	for	B-PP	IN	O	2	NMOD
4	Epstein	Epstein	B-NP	NNP	O	7	NMOD
5	Barr	Barr	I-NP	NNP	O	7	NMOD
6	Virus	Virus	I-NP	NNP	O	7	NMOD
7	infection	infection	I-NP	NN	O	3	PMOD
8	was	be	B-VP	VBD	O	0	ROOT
9	found	find	I-VP	VBN	O	8	VC
10	in	in	B-PP	IN	O	9	VMOD
11	20	20	B-NP	CD	O	12	NMOD
12	%	%	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	65	65	B-NP	CD	O	16	NMOD
15	cyclosporine	cyclosporine	I-NP	NN	O	16	NMOD
16	patients	patient	I-NP	NNS	O	13	PMOD
17	studied	study	B-VP	VBN	O	16	NMOD
18	.	.	O	.	O	8	P

1	Structure-activity	Structure-activity	B-NP	NN	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	dose-effect	dose-effect	I-NP	NN	O	4	NMOD
4	relationships	relationship	I-NP	NNS	O	0	ROOT
5	of	of	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	antagonism	antagonism	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	picrotoxin	picrotoxin	B-NP	NN	B-protein	11	NMOD
10	induced	induce	I-NP	VBN	O	11	NMOD
11	seizures	seizure	I-NP	NNS	O	8	PMOD
12	by	by	B-PP	IN	O	4	NMOD
13	cholecystokinin	cholecystokinin	B-NP	NN	B-protein	17	NMOD
14	,	,	O	,	O	17	P
15	fragments	fragment	B-NP	NNS	O	17	NMOD
16	and	and	I-NP	CC	O	17	NMOD
17	analogues	analogue	I-NP	NNS	O	12	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	cholecystokinin	cholecystokinin	B-NP	NN	B-protein	18	PMOD
20	in	in	B-PP	IN	O	4	NMOD
21	mice	mouse	B-NP	NNS	O	20	PMOD
22	.	.	O	.	O	4	P

1	Intraperitoneal	Intraperitoneal	B-NP	JJ	O	2	NMOD
2	administration	administration	I-NP	NN	O	18	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	cholecystokinin	cholecystokinin	B-NP	NN	O	7	NMOD
5	octapeptide	octapeptide	I-NP	NN	O	7	NMOD
6	sulphate	sulphate	I-NP	NN	O	7	NMOD
7	ester	ester	I-NP	NN	O	14	NMOD
8	(	(	O	(	O	10	DEP
9	CCK-8-SE	CCK-8-SE	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	and	and	O	CC	O	14	NMOD
12	nonsulphated	nonsulphated	B-NP	JJ	O	14	NMOD
13	cholecystokinin	cholecystokinin	I-NP	NN	O	14	NMOD
14	octapeptide	octapeptide	I-NP	NN	O	3	PMOD
15	(	(	O	(	O	17	DEP
16	CCK-8-NS	CCK-8-NS	B-NP	NN	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	enhanced	enhance	B-VP	VBD	O	0	ROOT
19	the	the	B-NP	DT	O	20	NMOD
20	latency	latency	I-NP	NN	O	18	OBJ
21	of	of	B-PP	IN	O	20	NMOD
22	seizures	seizure	B-NP	NNS	O	21	PMOD
23	induced	induce	B-VP	VBN	O	22	NMOD
24	by	by	B-PP	IN	O	23	VMOD
25	picrotoxin	picrotoxin	B-NP	NN	O	24	PMOD
26	in	in	B-PP	IN	O	23	VMOD
27	mice	mouse	B-NP	NNS	O	26	PMOD
28	.	.	O	.	O	18	P

1	The	The	B-NP	DT	O	3	NMOD
2	peptide	peptide	I-NP	NN	O	3	NMOD
3	CCK-5-8	CCK-5-8	I-NP	NN	O	4	SUB
4	had	have	B-VP	VBD	O	27	VMOD
5	weak	weak	B-NP	JJ	O	7	NMOD
6	anticonvulsant	anticonvulsant	I-NP	JJ	O	7	NMOD
7	activity	activity	I-NP	NN	O	4	OBJ
8	in	in	B-PP	IN	O	4	VMOD
9	comparison	comparison	B-NP	NN	O	8	PMOD
10	to	to	B-PP	TO	O	9	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	octapeptides	octapeptide	I-NP	NNS	O	10	PMOD
13	,	,	O	,	O	4	P
14	3.2	3.2	B-NP	CD	O	15	NMOD
15	mumol/kg	mumol/kg	I-NP	NN	O	4	OBJ
16	and	and	O	CC	O	24	NMOD
17	larger	large	B-NP	JJR	O	18	NMOD
18	doses	dose	I-NP	NNS	O	24	NMOD
19	of	of	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	22	NMOD
21	reference	reference	I-NP	NN	O	22	NMOD
22	drug	drug	I-NP	NN	O	19	PMOD
23	,	,	O	,	O	24	P
24	diazepam	diazepam	B-NP	NN	O	4	OBJ
25	,	,	O	,	O	4	P
26	totally	totally	B-ADVP	RB	O	27	VMOD
27	prevented	prevent	B-VP	VBD	O	0	ROOT
28	picrotoxin	picrotoxin	B-NP	NN	O	30	NMOD
29	induced	induced	I-NP	JJ	O	30	NMOD
30	seizures	seizure	I-NP	NNS	O	32	NMOD
31	and	and	I-NP	CC	O	32	NMOD
32	mortality	mortality	I-NP	NN	O	27	OBJ
33	.	.	O	.	O	27	P

1	Vasopressin	Vasopressin	B-NP	NN	B-protein	0	ROOT
2	as	as	B-PP	IN	O	1	NMOD
3	a	a	B-NP	DT	O	5	NMOD
4	possible	possible	I-NP	JJ	O	5	NMOD
5	contributor	contributor	I-NP	NN	O	2	PMOD
6	to	to	B-PP	TO	O	5	NMOD
7	hypertension	hypertension	B-NP	NN	O	6	PMOD
8	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	role	role	I-NP	NN	O	13	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	vasopressin	vasopressin	B-NP	NN	O	3	PMOD
5	as	as	B-PP	IN	O	2	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	pressor	pressor	I-NP	NN	O	8	NMOD
8	agent	agent	I-NP	NN	O	5	PMOD
9	to	to	B-PP	TO	O	8	NMOD
10	the	the	B-NP	DT	O	12	NMOD
11	hypertensive	hypertensive	I-NP	JJ	O	12	NMOD
12	process	process	I-NP	NN	O	9	PMOD
13	was	be	B-VP	VBD	O	0	ROOT
14	examined	examine	I-VP	VBN	O	13	VC
15	.	.	O	.	O	13	P

1	Vasopressin	Vasopressin	B-NP	NN	B-protein	2	SUB
2	plays	play	B-VP	VBZ	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	major	major	I-NP	JJ	O	5	NMOD
5	role	role	I-NP	NN	O	2	OBJ
6	in	in	B-PP	IN	O	2	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	pathogenesis	pathogenesis	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	DOCA-salt	DOCA-salt	B-NP	JJ	O	11	NMOD
11	hypertension	hypertension	I-NP	NN	O	9	PMOD
12	,	,	O	,	O	2	P
13	since	since	B-SBAR	IN	O	2	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	elevation	elevation	I-NP	NN	O	19	SUB
16	of	of	B-PP	IN	O	15	NMOD
17	blood	blood	B-NP	NN	O	18	NMOD
18	pressure	pressure	I-NP	NN	O	16	PMOD
19	was	be	B-VP	VBD	O	13	SBAR
20	not	not	O	RB	O	19	VMOD
21	substantial	substantial	B-ADJP	JJ	O	19	PRD
22	in	in	B-PP	IN	O	21	AMOD
23	the	the	B-NP	DT	O	24	NMOD
24	rats	rat	I-NP	NNS	O	22	PMOD
25	with	with	B-PP	IN	O	24	NMOD
26	lithium-treated	lithium-treated	B-NP	JJ	O	28	NMOD
27	diabetes	diabetes	I-NP	NN	O	28	NMOD
28	insipidus	insipidus	I-NP	NN	O	25	PMOD
29	after	after	B-PP	IN	O	28	NMOD
30	DOCA-salt	DOCA-salt	B-NP	JJ	O	31	NMOD
31	treatment	treatment	I-NP	NN	O	29	PMOD
32	.	.	O	.	O	2	P

1	Furthermore	Furthermore	B-ADVP	RB	O	8	VMOD
2	,	,	O	,	O	8	P
3	the	the	B-NP	DT	O	5	NMOD
4	pressor	pressor	I-NP	NN	O	5	NMOD
5	action	action	I-NP	NN	O	8	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	vasopressin	vasopressin	B-NP	NN	B-protein	6	PMOD
8	appears	appear	B-VP	VBZ	O	0	ROOT
9	to	to	I-VP	TO	O	10	VMOD
10	be	be	I-VP	VB	O	8	VMOD
11	important	important	B-ADJP	JJ	O	10	PRD
12	in	in	B-PP	IN	O	11	AMOD
13	the	the	B-NP	DT	O	14	NMOD
14	development	development	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	this	this	B-NP	DT	O	17	NMOD
17	model	model	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	hypertension	hypertension	B-NP	NN	O	18	PMOD
20	,	,	O	,	O	8	P
21	since	since	B-SBAR	IN	O	8	VMOD
22	the	the	B-NP	DT	O	25	NMOD
23	enhanced	enhance	I-NP	VBN	O	25	NMOD
24	pressor	pressor	I-NP	NN	O	25	NMOD
25	responsiveness	responsiveness	I-NP	NN	O	29	SUB
26	to	to	B-PP	TO	O	25	NMOD
27	the	the	B-NP	DT	O	28	NMOD
28	hormone	hormone	I-NP	NN	O	26	PMOD
29	was	be	B-VP	VBD	O	21	SBAR
30	observed	observe	I-VP	VBN	O	29	VC
31	in	in	B-PP	IN	O	30	VMOD
32	the	the	B-NP	DT	O	34	NMOD
33	initial	initial	I-NP	JJ	O	34	NMOD
34	stage	stage	I-NP	NN	O	31	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	hypertension	hypertension	B-NP	NN	O	35	PMOD
37	.	.	O	.	O	8	P

1	Increased	Increase	B-NP	VBN	O	2	NMOD
2	secretion	secretion	I-NP	NN	O	8	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	vasopressin	vasopressin	B-NP	NN	B-protein	3	PMOD
5	from	from	B-PP	IN	O	2	NMOD
6	neurohypophysis	neurohypophysis	B-NP	NN	O	5	PMOD
7	also	also	B-ADVP	RB	O	8	VMOD
8	promotes	promote	B-VP	VBZ	O	0	ROOT
9	the	the	B-NP	DT	O	10	NMOD
10	function	function	I-NP	NN	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	13	NMOD
13	hormone	hormone	I-NP	NN	O	11	PMOD
14	as	as	B-PP	IN	O	8	VMOD
15	a	a	B-NP	DT	O	17	NMOD
16	pathogenetic	pathogenetic	I-NP	JJ	B-protein	17	NMOD
17	factor	factor	I-NP	NN	I-protein	14	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	hypertension	hypertension	B-NP	NN	O	18	PMOD
20	.	.	O	.	O	8	P

1	Toxic	Toxic	B-NP	JJ	O	2	NMOD
2	hepatitis	hepatitis	I-NP	NN	O	0	ROOT
3	induced	induce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	disulfiram	disulfiram	B-NP	NN	O	4	PMOD
6	in	in	B-PP	IN	O	3	VMOD
7	a	a	B-NP	DT	O	8	NMOD
8	non-alcoholic	non-alcoholic	I-NP	JJ	O	6	PMOD
9	.	.	O	.	O	2	P

1	Atrial	Atrial	B-NP	JJ	O	2	NMOD
2	thrombosis	thrombosis	I-NP	NN	O	0	ROOT
3	involving	involve	B-VP	VBG	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	heart	heart	I-NP	NN	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	F-344	F-344	B-NP	NN	O	8	NMOD
8	rats	rat	I-NP	NNS	O	6	PMOD
9	ingesting	ingest	B-VP	VBG	O	8	NMOD
10	quinacrine	quinacrine	B-NP	NN	O	11	NMOD
11	hydrochloride	hydrochloride	I-NP	NN	O	9	OBJ
12	.	.	O	.	O	2	P

1	Rats	Rat	B-NP	NNS	O	12	SUB
2	treated	treat	B-VP	VBN	O	1	NMOD
3	with	with	B-PP	IN	O	2	VMOD
4	500	500	B-NP	CD	O	5	AMOD
5	ppm	ppm	I-NP	NN	O	7	NMOD
6	quinacrine	quinacrine	I-NP	NN	O	7	NMOD
7	hydrochloride	hydrochloride	I-NP	NN	O	3	PMOD
8	in	in	B-PP	IN	O	2	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	diet	diet	I-NP	NN	O	8	PMOD
11	all	all	O	DT	O	12	VMOD
12	developed	develop	B-VP	VBD	O	0	ROOT
13	a	a	B-NP	DT	O	15	NMOD
14	high	high	I-NP	JJ	O	15	NMOD
15	incidence	incidence	I-NP	NN	O	12	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	left	left	B-NP	JJ	O	19	NMOD
18	atrial	atrial	I-NP	JJ	O	19	NMOD
19	thrombosis	thrombosis	I-NP	NN	O	16	PMOD
20	.	.	O	.	O	12	P

1	Seventy	Seventy	B-NP	CD	O	2	NMOD
2	percent	percent	I-NP	NN	O	21	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	rats	rat	B-NP	NNS	O	3	PMOD
5	given	give	B-VP	VBN	O	4	NMOD
6	250	250	B-NP	CD	O	9	NMOD
7	ppm	ppm	I-NP	NN	O	9	NMOD
8	quinacrine	quinacrine	I-NP	NN	O	9	NMOD
9	hydrochloride	hydrochloride	I-NP	NN	O	16	NMOD
10	and	and	O	CC	O	16	NMOD
11	1	1	B-NP	CD	O	14	AMOD
12	,	,	I-NP	,	O	14	P
13	000	000	I-NP	CD	O	14	AMOD
14	ppm	ppm	I-NP	NN	O	16	NMOD
15	sodium	sodium	I-NP	NN	O	16	NMOD
16	nitrite	nitrite	I-NP	NN	O	5	OBJ
17	simultaneously	simultaneously	B-ADVP	RB	O	18	PMOD
18	in	in	B-PP	IN	O	16	NMOD
19	the	the	B-NP	DT	O	20	NMOD
20	diet	diet	I-NP	NN	O	18	PMOD
21	had	have	B-VP	VBD	O	0	ROOT
22	thrombosis	thrombosis	B-NP	NN	O	21	OBJ
23	of	of	B-PP	IN	O	22	NMOD
24	the	the	B-NP	DT	O	25	NMOD
25	atria	atria	I-NP	NN	O	23	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	the	the	B-NP	DT	O	28	NMOD
28	heart	heart	I-NP	NN	O	26	PMOD
29	,	,	O	,	O	21	P
30	while	while	B-SBAR	IN	O	21	VMOD
31	untreated	untreated	B-NP	JJ	O	33	NMOD
32	control	control	I-NP	NN	O	33	NMOD
33	rats	rat	I-NP	NNS	O	37	SUB
34	in	in	B-PP	IN	O	33	NMOD
35	this	this	B-NP	DT	O	36	NMOD
36	laboratory	laboratory	I-NP	NN	O	34	PMOD
37	did	do	B-VP	VBD	O	30	SBAR
38	not	not	I-VP	RB	O	37	VMOD
39	have	have	I-VP	VB	O	37	VC
40	atrial	atrial	B-NP	JJ	O	41	NMOD
41	thrombosis	thrombosis	I-NP	NN	O	39	OBJ
42	.	.	O	.	O	21	P

1	Alternating	Alternate	B-VP	VBG	O	0	ROOT
2	sinus	sinus	B-NP	NN	O	3	NMOD
3	rhythm	rhythm	I-NP	NN	O	7	NMOD
4	and	and	O	CC	O	7	NMOD
5	intermittent	intermittent	B-NP	JJ	O	7	NMOD
6	sinoatrial	sinoatrial	I-NP	JJ	O	7	NMOD
7	block	block	I-NP	NN	O	1	OBJ
8	induced	induce	B-VP	VBN	O	7	NMOD
9	by	by	B-PP	IN	O	8	VMOD
10	propranolol	propranolol	B-NP	NN	O	9	PMOD
11	.	.	O	.	O	1	P

1	Alternating	Alternate	B-VP	VBG	O	11	SUB
2	sinus	sinus	B-NP	NN	O	3	NMOD
3	rhythm	rhythm	I-NP	NN	O	6	NMOD
4	and	and	O	CC	O	6	NMOD
5	intermittent	intermittent	B-NP	JJ	O	6	NMOD
6	sinoatrial	sinoatrial	I-NP	JJ	O	1	OBJ
7	(	(	O	(	O	9	DEP
8	S-A	S-A	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	block	block	B-NP	NN	O	6	NMOD
11	was	be	B-VP	VBD	O	0	ROOT
12	observed	observe	I-VP	VBN	O	11	VC
13	in	in	B-PP	IN	O	12	VMOD
14	a	a	B-NP	DT	O	16	NMOD
15	57-year-old	57-year-old	I-NP	JJ	O	16	NMOD
16	woman	woman	I-NP	NN	O	13	PMOD
17	,	,	O	,	O	12	P
18	under	under	B-PP	IN	O	12	VMOD
19	treatment	treatment	B-NP	NN	O	18	PMOD
20	for	for	B-PP	IN	O	19	NMOD
21	angina	angina	B-NP	NN	O	20	PMOD
22	with	with	B-PP	IN	O	19	NMOD
23	80	80	B-NP	CD	O	24	AMOD
24	mg	mg	I-NP	NN	O	25	NMOD
25	propranolol	propranolol	I-NP	NN	O	22	PMOD
26	daily	daily	B-ADVP	RB	O	25	NMOD
27	.	.	O	.	O	11	P

1	The	The	B-NP	DT	O	3	NMOD
2	abnormal	abnormal	I-NP	JJ	O	3	NMOD
3	rhythm	rhythm	I-NP	NN	O	4	SUB
4	disappeared	disappear	B-VP	VBD	O	0	ROOT
5	with	with	B-PP	IN	O	4	VMOD
6	the	the	B-NP	DT	O	7	NMOD
7	withdrawal	withdrawal	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	propranolol	propranolol	B-NP	NN	O	8	PMOD
10	and	and	O	CC	O	4	VMOD
11	when	when	B-ADVP	WRB	O	4	VMOD
12	the	the	B-NP	DT	O	13	NMOD
13	drug	drug	I-NP	NN	O	14	SUB
14	was	be	B-VP	VBD	O	11	SBAR
15	restarted	restart	I-VP	VBN	O	14	VC
16	a	a	B-NP	DT	O	19	NMOD
17	2/1	2/1	I-NP	CD	O	19	NMOD
18	S-A	S-A	I-NP	NN	O	19	NMOD
19	block	block	I-NP	NN	O	20	SUB
20	was	be	B-VP	VBD	O	15	VMOD
21	seen	see	I-VP	VBN	O	20	VC
22	.	.	O	.	O	4	P

1	Antitumor	Antitumor	B-NP	JJ	O	2	NMOD
2	effect	effect	I-NP	NN	O	7	NMOD
3	,	,	O	,	O	7	P
4	cardiotoxicity	cardiotoxicity	B-NP	NN	O	7	NMOD
5	,	,	O	,	O	7	P
6	and	and	O	CC	O	7	NMOD
7	nephrotoxicity	nephrotoxicity	B-NP	NN	O	0	ROOT
8	of	of	B-PP	IN	O	7	NMOD
9	doxorubicin	doxorubicin	B-NP	NN	O	8	PMOD
10	in	in	B-PP	IN	O	7	NMOD
11	the	the	B-NP	DT	O	16	NMOD
12	IgM	IgM	I-NP	NN	B-protein	16	NMOD
13	solid	solid	I-NP	JJ	O	16	NMOD
14	immunocytoma-bearing	immunocytoma-bearing	I-NP	JJ	O	16	NMOD
15	LOU/M/WSL	LOU/M/WSL	I-NP	NN	O	16	NMOD
16	rat	rat	I-NP	NN	O	10	PMOD
17	.	.	O	.	O	7	P

1	Antitumor	Antitumor	B-NP	JJ	O	2	NMOD
2	activity	activity	I-NP	NN	O	7	NMOD
3	,	,	O	,	O	7	P
4	cardiotoxicity	cardiotoxicity	B-NP	NN	O	7	NMOD
5	,	,	O	,	O	7	P
6	and	and	O	CC	O	7	NMOD
7	nephrotoxicity	nephrotoxicity	B-NP	NN	O	11	SUB
8	induced	induce	B-VP	VBN	O	7	NMOD
9	by	by	B-PP	IN	O	8	VMOD
10	doxorubicin	doxorubicin	B-NP	NN	O	9	PMOD
11	were	be	B-VP	VBD	O	0	ROOT
12	studied	study	I-VP	VBN	O	11	VC
13	in	in	B-PP	IN	O	12	VMOD
14	LOU/M/WSL	LOU/M/WSL	B-NP	NN	O	16	NMOD
15	inbred	inbred	I-NP	JJ	O	16	NMOD
16	rats	rat	I-NP	NNS	O	13	PMOD
17	each	each	B-NP	DT	O	12	VMOD
18	bearing	bear	B-VP	VBG	O	17	NMOD
19	a	a	B-NP	DT	O	23	NMOD
20	transplantable	transplantable	I-NP	JJ	O	23	NMOD
21	solid	solid	I-NP	JJ	O	23	NMOD
22	IgM	IgM	I-NP	NN	B-protein	23	NMOD
23	immunocytoma	immunocytoma	I-NP	NN	O	18	OBJ
24	.	.	O	.	O	11	P

1	Animals	Animal	B-NP	NNS	O	13	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	a	a	B-NP	DT	O	4	NMOD
4	tumor	tumor	I-NP	NN	O	2	PMOD
5	(	(	O	(	O	12	DEP
6	diameter	diameter	B-NP	NN	O	11	NMOD
7	,	,	O	,	O	11	P
8	15.8	15.8	B-NP	CD	O	10	AMOD
9	+/-	+/-	I-NP	SYM	O	10	AMOD
10	3.3	3.3	I-NP	CD	O	11	NMOD
11	mm	mm	I-NP	NN	O	12	DEP
12	)	)	O	)	O	4	NMOD
13	were	be	B-VP	VBD	O	0	ROOT
14	treated	treat	I-VP	VBN	O	13	VC
15	with	with	B-PP	IN	O	14	VMOD
16	iv	iv	B-NP	NN	O	17	NMOD
17	injections	injection	I-NP	NNS	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	doxorubicin	doxorubicin	B-NP	NN	O	18	PMOD
20	on	on	B-PP	IN	O	14	VMOD
21	5	5	B-NP	CD	O	23	NMOD
22	consecutive	consecutive	I-NP	JJ	O	23	NMOD
23	days	day	I-NP	NNS	O	20	PMOD
24	,	,	O	,	O	14	P
25	followed	follow	B-VP	VBN	O	14	VMOD
26	by	by	B-PP	IN	O	25	VMOD
27	1	1	B-NP	CD	O	29	NMOD
28	weekly	weekly	I-NP	JJ	O	29	NMOD
29	injection	injection	I-NP	NN	O	26	PMOD
30	for	for	B-PP	IN	O	29	NMOD
31	7	7	B-NP	CD	O	32	NMOD
32	weeks	week	I-NP	NNS	O	30	PMOD
33	(	(	O	(	O	41	DEP
34	dose	dose	B-NP	NN	O	35	NMOD
35	range	range	I-NP	NN	O	40	NMOD
36	,	,	O	,	O	40	P
37	0.015-4.0	0.015-4.0	B-NP	CD	O	40	NMOD
38	mg/kg	mg/kg	I-NP	NN	O	40	NMOD
39	body	body	I-NP	NN	O	40	NMOD
40	wt	wt	I-NP	NN	O	41	DEP
41	)	)	O	)	O	32	NMOD
42	.	.	O	.	O	13	P

1	Tumor	Tumor	B-NP	NN	O	2	NMOD
2	regression	regression	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	observed	observe	I-VP	VBN	O	3	VC
5	with	with	B-PP	IN	O	4	VMOD
6	0.5	0.5	B-NP	CD	O	7	AMOD
7	mg	mg	I-NP	NN	O	8	NMOD
8	doxorubicin/kg	doxorubicin/kg	I-NP	NN	O	5	PMOD
9	.	.	O	.	O	3	P

1	Complete	Complete	B-NP	JJ	O	2	NMOD
2	disappearance	disappearance	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	tumor	tumor	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	induced	induce	I-VP	VBN	O	6	VC
8	with	with	B-PP	IN	O	7	VMOD
9	1.0	1.0	B-NP	CD	O	10	AMOD
10	mg	mg	I-NP	NN	O	11	NMOD
11	doxorubicin/kg	doxorubicin/kg	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	6	P

1	Histologic	Histologic	B-NP	JJ	O	2	NMOD
2	evidence	evidence	I-NP	NN	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	cardiotoxicity	cardiotoxicity	B-NP	NN	O	3	PMOD
5	scored	score	B-VP	VBN	O	4	NMOD
6	as	as	B-PP	IN	O	5	VMOD
7	grade	grade	B-NP	NN	B-DNA	6	PMOD
8	III	III	I-NP	CD	I-DNA	7	NMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	only	only	I-VP	RB	O	9	VMOD
11	observed	observe	I-VP	VBN	O	9	VC
12	at	at	B-PP	IN	O	11	VMOD
13	a	a	B-NP	DT	O	14	NMOD
14	dose	dose	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	1.0	1.0	B-NP	CD	O	17	AMOD
17	mg	mg	I-NP	NN	O	18	NMOD
18	doxorubicin/kg	doxorubicin/kg	I-NP	NN	O	15	PMOD
19	.	.	O	.	O	9	P

1	Light	Light	B-NP	NN	O	3	NMOD
2	microscopic	microscopic	I-NP	JJ	O	3	NMOD
3	evidence	evidence	I-NP	NN	O	7	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	renal	renal	B-NP	JJ	O	6	NMOD
6	damage	damage	I-NP	NN	O	4	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	seen	see	I-VP	VBN	O	7	VC
9	above	above	B-PP	IN	O	8	VMOD
10	a	a	B-NP	DT	O	11	NMOD
11	dose	dose	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	0.5	0.5	B-NP	CD	O	14	AMOD
14	mg	mg	I-NP	NN	O	15	NMOD
15	doxorubicin/kg	doxorubicin/kg	I-NP	NN	O	12	PMOD
16	,	,	O	,	O	7	P
17	which	which	B-NP	WDT	O	7	VMOD
18	resulted	result	B-VP	VBD	O	17	SBAR
19	in	in	B-PP	IN	O	18	VMOD
20	albuminuria	albuminuria	B-NP	NN	O	26	NMOD
21	and	and	O	CC	O	26	NMOD
22	very	very	B-NP	RB	O	23	AMOD
23	low	low	I-NP	JJ	O	26	NMOD
24	serum	serum	I-NP	NN	O	26	NMOD
25	albumin	albumin	I-NP	NN	O	26	NMOD
26	levels	level	I-NP	NNS	O	19	PMOD
27	.	.	O	.	O	7	P

1	Intraoperative	Intraoperative	B-NP	JJ	O	2	NMOD
2	bradycardia	bradycardia	I-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	hypotension	hypotension	I-NP	NN	O	0	ROOT
5	associated	associate	B-VP	VBN	O	4	NMOD
6	with	with	B-PP	IN	O	5	VMOD
7	timolol	timolol	B-NP	NN	O	11	NMOD
8	and	and	I-NP	CC	O	11	NMOD
9	pilocarpine	pilocarpine	I-NP	NN	O	11	NMOD
10	eye	eye	I-NP	NN	O	11	NMOD
11	drops	drop	I-NP	NNS	O	6	PMOD
12	.	.	O	.	O	4	P

1	A	A	B-NP	DT	O	3	NMOD
2	69-yr-old	69-yr-old	I-NP	JJ	O	3	NMOD
3	man	man	I-NP	NN	O	19	SUB
4	,	,	O	,	O	3	P
5	who	who	B-NP	WP	O	3	NMOD
6	was	be	B-VP	VBD	O	5	SBAR
7	concurrently	concurrently	I-VP	RB	O	6	VMOD
8	being	be	I-VP	VBG	O	6	VC
9	treated	treat	I-VP	VBN	O	8	VC
10	with	with	B-PP	IN	O	9	VMOD
11	pilocarpine	pilocarpine	B-NP	NN	O	12	NMOD
12	nitrate	nitrate	I-NP	NN	O	17	NMOD
13	and	and	O	CC	O	17	NMOD
14	timolol	timolol	B-NP	NN	O	17	NMOD
15	maleate	maleate	I-NP	NN	O	17	NMOD
16	eye	eye	I-NP	NN	O	17	NMOD
17	drops	drop	I-NP	NNS	O	10	PMOD
18	,	,	O	,	O	3	P
19	developed	develop	B-VP	VBD	O	0	ROOT
20	a	a	B-NP	DT	O	21	NMOD
21	bradycardia	bradycardia	I-NP	NN	O	19	OBJ
22	and	and	O	CC	O	19	VMOD
23	became	become	B-VP	VBD	O	19	VMOD
24	hypotensive	hypotensive	B-ADJP	JJ	O	23	PRD
25	during	during	B-PP	IN	O	24	AMOD
26	halothane	halothane	B-NP	NN	O	27	NMOD
27	anaesthesia	anaesthesia	I-NP	NN	O	25	PMOD
28	.	.	O	.	O	19	P

1	It	It	B-NP	PRP	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	postulated	postulate	I-VP	VBN	O	2	VC
4	that	that	B-SBAR	IN	O	3	VMOD
5	this	this	B-NP	DT	O	6	NMOD
6	action	action	I-NP	NN	O	7	SUB
7	may	may	B-VP	MD	O	4	SBAR
8	have	have	I-VP	VB	O	7	VC
9	been	be	I-VP	VBN	O	8	VC
10	enhanced	enhance	I-VP	VBN	O	9	VC
11	during	during	B-PP	IN	O	10	VMOD
12	halothane	halothane	B-NP	NN	O	13	NMOD
13	anaesthesia	anaesthesia	I-NP	NN	O	11	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	resultant	resultant	B-NP	JJ	O	16	NMOD
16	bradycardia	bradycardia	I-NP	NN	O	18	NMOD
17	and	and	I-NP	CC	O	18	NMOD
18	hypotension	hypotension	I-NP	NN	O	14	PMOD
19	.	.	O	.	O	2	P

1	Succinylcholine	Succinylcholine	B-NP	NN	O	2	NMOD
2	apnoea	apnoea	I-NP	NN	O	5	NMOD
3	:	:	O	:	O	2	P
4	attempted	attempt	B-NP	VBN	O	5	NMOD
5	reversal	reversal	I-NP	NN	O	0	ROOT
6	with	with	B-PP	IN	O	5	NMOD
7	anticholinesterases	anticholinesteras	B-NP	NNS	B-protein	6	PMOD
8	.	.	O	.	O	5	P

1	Anticholinesterases	Anticholinesteras	B-NP	NNS	B-protein	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	administered	administer	I-VP	VBN	O	2	VC
4	in	in	B-PP	IN	O	3	VMOD
5	an	an	B-NP	DT	O	6	NMOD
6	attempt	attempt	I-NP	NN	O	21	SUB
7	to	to	B-VP	TO	O	8	VMOD
8	antagonize	antagonize	I-VP	VB	O	21	VMOD
9	prolonged	prolonged	B-NP	JJ	O	10	AMOD
10	neuromuscular	neuromuscular	I-NP	JJ	O	11	NMOD
11	blockade	blockade	I-NP	NN	O	8	OBJ
12	following	follow	B-PP	VBG	O	11	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	administration	administration	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	succinylcholine	succinylcholine	B-NP	NN	O	15	PMOD
17	in	in	B-PP	IN	O	11	NMOD
18	a	a	B-NP	DT	O	19	NMOD
19	patient	patient	I-NP	NN	O	17	PMOD
20	later	later	B-ADVP	RB	O	21	VMOD
21	found	find	B-VP	VBD	O	4	SBAR
22	to	to	I-VP	TO	O	23	VMOD
23	be	be	I-VP	VB	O	21	VMOD
24	homozygous	homozygous	B-ADJP	JJ	O	23	PRD
25	for	for	B-PP	IN	O	24	AMOD
26	atypical	atypical	B-NP	JJ	B-protein	28	NMOD
27	plasma	plasma	I-NP	NN	I-protein	28	NMOD
28	cholinesterase	cholinesterase	I-NP	NN	I-protein	25	PMOD
29	.	.	O	.	O	2	P

1	Coronary	Coronary	B-NP	JJ	O	3	NMOD
2	blood	blood	I-NP	NN	O	3	NMOD
3	flow	flow	I-NP	NN	O	8	NMOD
4	,	,	O	,	O	8	P
5	cardiac	cardiac	B-NP	JJ	O	6	NMOD
6	work	work	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	metabolism	metabolism	I-NP	NN	O	9	SUB
9	were	be	B-VP	VBD	O	0	ROOT
10	studied	study	I-VP	VBN	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	dogs	dog	B-NP	NNS	O	11	PMOD
13	under	under	B-PP	IN	O	10	VMOD
14	sodium	sodium	B-NP	NN	O	15	NMOD
15	nitroprusside	nitroprusside	I-NP	NN	O	20	NMOD
16	(	(	O	(	O	18	DEP
17	SNP	SNP	B-NP	NN	B-protein	18	DEP
18	)	)	O	)	O	15	NMOD
19	and	and	O	CC	O	20	NMOD
20	trimetaphan	trimetaphan	B-NP	NN	O	25	NMOD
21	(	(	O	(	O	23	DEP
22	TMP	TMP	B-NP	NN	O	23	DEP
23	)	)	O	)	O	20	NMOD
24	deliberate	deliberate	B-NP	JJ	O	25	NMOD
25	hypotension	hypotension	I-NP	NN	O	13	PMOD
26	(	(	O	(	O	37	DEP
27	20	20	B-NP	CD	O	28	NMOD
28	%	%	I-NP	NN	O	34	NMOD
29	and	and	I-NP	CC	O	34	NMOD
30	40	40	I-NP	CD	O	31	NMOD
31	%	%	I-NP	NN	O	34	NMOD
32	mean	mean	I-NP	JJ	O	34	NMOD
33	pressure	pressure	I-NP	NN	O	34	NMOD
34	decrease	decrease	I-NP	NN	O	37	DEP
35	from	from	B-PP	IN	O	34	NMOD
36	baseline	baseline	B-NP	NN	O	35	PMOD
37	)	)	O	)	O	25	NMOD
38	.	.	O	.	O	9	P

1	Regarding	Regard	B-VP	VBG	O	6	SUB
2	the	the	B-NP	DT	O	3	NMOD
3	effects	effect	I-NP	NNS	O	1	OBJ
4	of	of	B-PP	IN	O	3	NMOD
5	drug	drug	B-NP	NN	O	4	PMOD
6	induced	induce	B-VP	VBD	O	27	VMOD
7	hypotension	hypotension	B-NP	NN	O	6	OBJ
8	on	on	B-PP	IN	O	6	VMOD
9	coronary	coronary	B-NP	JJ	O	11	NMOD
10	blood	blood	I-NP	NN	O	11	NMOD
11	flow	flow	I-NP	NN	O	18	NMOD
12	,	,	O	,	O	18	P
13	aortic	aortic	B-NP	JJ	O	18	NMOD
14	and	and	I-NP	CC	O	18	NMOD
15	coronary	coronary	I-NP	JJ	O	18	NMOD
16	sinus	sinus	I-NP	NN	O	18	NMOD
17	metabolic	metabolic	I-NP	JJ	O	18	NMOD
18	data	datum	I-NP	NNS	O	8	PMOD
19	(	(	O	(	O	25	DEP
20	pH	pH	B-NP	NN	O	24	NMOD
21	,	,	O	,	O	24	P
22	pO2	pO2	B-NP	NN	O	24	NMOD
23	,	,	O	,	O	24	P
24	pCO2	pCO2	B-NP	NN	O	25	DEP
25	)	)	O	)	O	18	NMOD
26	we	we	B-NP	PRP	O	27	SUB
27	could	could	B-VP	MD	O	0	ROOT
28	confirm	confirm	I-VP	VB	O	27	VC
29	that	that	B-SBAR	IN	O	28	VMOD
30	nitroprusside	nitroprusside	B-NP	NN	O	31	NMOD
31	hypotension	hypotension	I-NP	NN	O	32	SUB
32	could	could	B-VP	MD	O	29	SBAR
33	be	be	I-VP	VB	O	32	VC
34	safely	safely	I-VP	RB	O	33	VMOD
35	used	use	I-VP	VBN	O	33	VC
36	to	to	B-PP	TO	O	35	VMOD
37	30	30	B-NP	CD	O	42	NMOD
38	%	%	I-NP	NN	O	42	NMOD
39	mean	mean	I-NP	JJ	O	42	NMOD
40	blood	blood	I-NP	NN	O	42	NMOD
41	pressure	pressure	I-NP	NN	O	42	NMOD
42	decrease	decrease	I-NP	NN	O	47	NMOD
43	from	from	B-PP	IN	O	42	NMOD
44	control	control	B-NP	NN	O	43	PMOD
45	,	,	O	,	O	47	P
46	trimetaphan	trimetaphan	B-NP	NN	O	47	NMOD
47	hypotension	hypotension	I-NP	NN	O	36	PMOD
48	to	to	B-PP	TO	O	47	NMOD
49	20	20	B-NP	CD	O	54	NMOD
50	%	%	I-NP	NN	O	54	NMOD
51	mean	mean	I-NP	JJ	O	54	NMOD
52	blood	blood	I-NP	NN	O	54	NMOD
53	pressure	pressure	I-NP	NN	O	54	NMOD
54	decrease	decrease	I-NP	NN	O	48	PMOD
55	.	.	O	.	O	27	P

1	Cardiac	Cardiac	B-NP	JJ	O	2	NMOD
2	work	work	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	significantly	significantly	I-VP	RB	O	3	VMOD
5	reduced	reduce	I-VP	VBN	O	3	VC
6	during	during	B-PP	IN	O	5	VMOD
7	SNP	SNP	B-NP	NN	O	8	NMOD
8	hypotension	hypotension	I-NP	NN	O	6	PMOD
9	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	hyperactivity	hyperactivity	I-NP	NN	O	10	SUB
3	induced	induce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	D-amphetamine	D-amphetamine	B-NP	NN	O	4	PMOD
6	(	(	O	(	O	9	DEP
7	10	10	B-NP	CD	O	8	NMOD
8	mumol/kg	mumol/kg	I-NP	NN	O	9	DEP
9	)	)	O	)	O	5	NMOD
10	was	be	B-VP	VBD	O	0	ROOT
11	significantly	significantly	I-VP	RB	O	10	VMOD
12	reduced	reduce	I-VP	VBN	O	10	VC
13	by	by	B-PP	IN	O	12	VMOD
14	DSP4	DSP4	B-NP	NN	B-protein	15	NMOD
15	pretreatment	pretreatment	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	10	P

1	However	However	B-ADVP	RB	O	11	VMOD
2	,	,	O	,	O	11	P
3	the	the	B-NP	DT	O	5	NMOD
4	increased	increase	I-NP	VBN	O	5	NMOD
5	rearings	rearing	I-NP	NNS	O	10	NMOD
6	and	and	O	CC	O	10	NMOD
7	the	the	B-NP	DT	O	10	NMOD
8	amphetamine	amphetamine	I-NP	NN	O	10	NMOD
9	induced	induce	I-NP	VBN	O	10	NMOD
10	stereotypies	stereotypy	I-NP	NNS	O	11	SUB
11	were	be	B-VP	VBD	O	0	ROOT
12	not	not	I-VP	RB	O	11	VMOD
13	blocked	block	I-VP	VBN	O	11	VC
14	by	by	B-PP	IN	O	13	VMOD
15	pretreatment	pretreatment	B-NP	NN	O	14	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	DSP4	DSP4	B-NP	NN	B-protein	16	PMOD
18	.	.	O	.	O	11	P

1	The	The	B-NP	DT	O	2	NMOD
2	reduction	reduction	I-NP	NN	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	amphetamine	amphetamine	B-NP	NN	O	5	NMOD
5	hyperactivity	hyperactivity	I-NP	NN	O	3	PMOD
6	induced	induce	B-VP	VBN	O	5	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	DSP4	DSP4	B-NP	NN	B-protein	7	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	blocked	block	I-VP	VBN	O	9	VC
11	by	by	B-PP	IN	O	10	VMOD
12	pretreatment	pretreatment	B-NP	NN	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	noradrenaline-uptake	noradrenaline-uptake	I-NP	NN	O	13	PMOD
16	blocking	block	B-VP	VBG	O	15	NMOD
17	agent	agent	B-NP	NN	O	19	NMOD
18	,	,	O	,	O	19	P
19	desipramine	desipramine	B-NP	NN	O	16	OBJ
20	,	,	O	,	O	19	P
21	which	which	B-NP	WDT	O	19	NMOD
22	prevents	prevent	B-VP	VBZ	O	21	SBAR
23	the	the	B-NP	DT	O	25	NMOD
24	neurotoxic	neurotoxic	I-NP	JJ	O	25	NMOD
25	action	action	I-NP	NN	O	22	OBJ
26	of	of	B-PP	IN	O	25	NMOD
27	DSP4	DSP4	B-NP	NN	B-protein	26	PMOD
28	.	.	O	.	O	9	P

1	Accelerated	Accelerate	B-NP	VBN	O	3	NMOD
2	junctional	junctional	I-NP	JJ	O	3	NMOD
3	rhythms	rhythm	I-NP	NNS	O	0	ROOT
4	during	during	B-PP	IN	O	3	NMOD
5	oral	oral	B-NP	JJ	O	7	NMOD
6	verapamil	verapamil	I-NP	NN	O	7	NMOD
7	therapy	therapy	I-NP	NN	O	4	PMOD
8	.	.	O	.	O	3	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	examined	examine	B-VP	VBD	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	frequency	frequency	I-NP	NN	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	atrioventricular	atrioventricular	B-NP	JJ	O	11	NMOD
8	(	(	O	(	O	10	DEP
9	AV	AV	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	AMOD
11	dissociation	dissociation	B-NP	NN	O	6	PMOD
12	and	and	O	CC	O	3	VMOD
13	accelerated	accelerate	B-VP	VBD	O	3	VMOD
14	junctional	junctional	B-NP	JJ	O	15	NMOD
15	rhythms	rhythm	I-NP	NNS	O	13	OBJ
16	in	in	B-PP	IN	O	13	VMOD
17	59	59	B-NP	CD	O	18	NMOD
18	patients	patient	I-NP	NNS	O	16	PMOD
19	receiving	receive	B-VP	VBG	O	18	NMOD
20	oral	oral	B-NP	JJ	O	21	NMOD
21	verapamil	verapamil	I-NP	NN	O	19	OBJ
22	.	.	O	.	O	3	P

1	Treatment	Treatment	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	ovarian	ovarian	B-NP	JJ	O	4	NMOD
4	cancer	cancer	I-NP	NN	O	2	PMOD
5	with	with	B-PP	IN	O	1	NMOD
6	a	a	B-NP	DT	O	7	NMOD
7	combination	combination	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	cis-platinum	cis-platinum	B-NP	NN	O	15	NMOD
10	,	,	I-NP	,	O	15	P
11	adriamycin	adriamycin	I-NP	NN	O	15	NMOD
12	,	,	I-NP	,	O	15	P
13	cyclophosphamide	cyclophosphamide	I-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	hexamethylmelamine	hexamethylmelamine	I-NP	NN	O	8	PMOD
16	.	.	O	.	O	1	P

1	During	During	B-PP	IN	O	0	ROOT
2	the	the	B-NP	DT	O	6	NMOD
3	last	last	I-NP	JJ	O	6	NMOD
4	2	2	I-NP	CD	O	6	NMOD
5	1/2	1/2	I-NP	CD	O	6	NMOD
6	years	year	I-NP	NNS	O	1	PMOD
7	,	,	O	,	O	13	P
8	38	38	B-NP	CD	O	9	NMOD
9	patients	patient	I-NP	NNS	O	13	SUB
10	with	with	B-PP	IN	O	9	NMOD
11	ovarian	ovarian	B-NP	JJ	O	12	NMOD
12	cancer	cancer	I-NP	NN	O	10	PMOD
13	were	be	B-VP	VBD	O	1	VMOD
14	treated	treat	I-VP	VBN	O	13	VC
15	with	with	B-PP	IN	O	14	VMOD
16	a	a	B-NP	DT	O	17	NMOD
17	combination	combination	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	cisplatinum	cisplatinum	B-NP	NN	O	35	NMOD
20	(	(	O	(	O	22	DEP
21	CPDD	CPDD	B-NP	NN	B-protein	22	DEP
22	)	)	O	)	O	19	NMOD
23	,	,	O	,	O	35	P
24	50	50	B-NP	CD	O	25	NMOD
25	mg/m2	mg/m2	I-NP	NN	O	35	NMOD
26	,	,	O	,	O	35	P
27	adriamycin	adriamycin	B-NP	NN	O	35	NMOD
28	,	,	O	,	O	35	P
29	30	30	B-NP	CD	O	30	NMOD
30	mg/m2	mg/m2	I-NP	NN	O	35	NMOD
31	,	,	O	,	O	35	P
32	cyclophosphamide	cyclophosphamide	B-NP	NN	O	35	NMOD
33	,	,	O	,	O	35	P
34	300	300	B-NP	CD	O	35	NMOD
35	mg/m2	mg/m2	I-NP	NN	O	18	PMOD
36	,	,	O	,	O	35	P
37	on	on	B-PP	IN	O	35	NMOD
38	day	day	B-NP	NN	O	37	PMOD
39	1	1	I-NP	CD	O	38	NMOD
40	;	;	O	:	O	13	VMOD
41	and	and	O	CC	O	48	NMOD
42	hexamethylmelamine	hexamethylmelamine	B-NP	NN	O	48	NMOD
43	(	(	O	(	O	45	DEP
44	HMM	HMM	B-NP	NN	B-protein	45	DEP
45	)	)	O	)	O	42	NMOD
46	,	,	O	,	O	48	P
47	6	6	B-NP	CD	O	48	NMOD
48	mg/kg	mg/kg	I-NP	NN	O	40	OBJ
49	daily	daily	B-ADVP	RB	O	48	NMOD
50	,	,	O	,	O	49	AMOD
51	for	for	B-PP	IN	O	50	AMOD
52	14	14	B-NP	CD	O	53	NMOD
53	days	day	I-NP	NNS	O	51	PMOD
54	.	.	O	.	O	1	P

1	HMM	HMM	B-NP	NN	O	3	NMOD
2	gastrointestinal	gastrointestinal	I-NP	JJ	O	3	NMOD
3	toxicity	toxicity	I-NP	NN	O	4	SUB
4	necessitated	necessitate	B-VP	VBD	O	0	ROOT
5	discontinuation	discontinuation	B-NP	NN	O	4	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	drug	drug	I-NP	NN	O	6	PMOD
9	in	in	B-PP	IN	O	4	VMOD
10	5	5	B-NP	CD	O	11	NMOD
11	patients	patient	I-NP	NNS	O	9	PMOD
12	.	.	O	.	O	4	P

1	Propylthiouracil	Propylthiouracil	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	hepatic	hepatic	B-NP	JJ	O	4	NMOD
4	damage	damage	I-NP	NN	O	2	OBJ
5	.	.	O	.	O	2	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	cases	case	I-NP	NNS	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	propylthiouracil	propylthiouracil	B-NP	NN	O	3	PMOD
5	induced	induce	B-VP	VBD	O	0	ROOT
6	liver	liver	B-NP	NN	O	7	NMOD
7	damage	damage	I-NP	NN	O	5	OBJ
8	have	have	B-VP	VBP	O	5	VMOD
9	been	be	I-VP	VBN	O	8	VC
10	observed	observe	I-VP	VBN	O	9	VC
11	.	.	O	.	O	5	P

1	Studies	Study	B-NP	NNS	O	0	ROOT
2	on	on	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	bradycardia	bradycardia	I-NP	NN	O	2	PMOD
5	induced	induce	B-VP	VBN	O	4	NMOD
6	by	by	B-PP	IN	O	5	VMOD
7	bepridil	bepridil	B-NP	NN	O	6	PMOD
8	.	.	O	.	O	1	P

1	Bepridil	Bepridil	B-NP	NN	O	6	NMOD
2	,	,	O	,	O	6	P
3	a	a	B-NP	DT	O	6	NMOD
4	novel	novel	I-NP	JJ	O	5	AMOD
5	active	active	I-NP	JJ	O	6	NMOD
6	compound	compound	I-NP	NN	O	14	SUB
7	for	for	B-PP	IN	O	6	NMOD
8	prophylactic	prophylactic	B-NP	JJ	O	9	NMOD
9	treatment	treatment	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	anginal	anginal	B-NP	JJ	O	12	NMOD
12	attacks	attack	I-NP	NNS	O	10	PMOD
13	,	,	O	,	O	6	P
14	induced	induce	B-VP	VBD	O	0	ROOT
15	persistent	persistent	B-NP	JJ	O	16	NMOD
16	bradycardia	bradycardia	I-NP	NN	O	21	NMOD
17	and	and	O	CC	O	21	NMOD
18	a	a	B-NP	DT	O	21	NMOD
19	non-specific	non-specific	I-NP	JJ	O	21	NMOD
20	anti-tachycardial	anti-tachycardial	I-NP	JJ	O	21	NMOD
21	effect	effect	I-NP	NN	O	14	OBJ
22	,	,	O	,	O	14	P
23	the	the	B-NP	DT	O	24	NMOD
24	mechanisms	mechanism	I-NP	NNS	O	14	VMOD
25	of	of	B-PP	IN	O	24	NMOD
26	which	which	B-NP	WDT	O	25	PMOD
27	were	be	B-VP	VBD	O	25	SBAR
28	investigated	investigate	I-VP	VBN	O	27	VC
29	in	in	B-ADVP	FW	O	28	VMOD
30	vitro	vitro	I-ADVP	FW	O	29	AMOD
31	and	and	O	CC	O	29	AMOD
32	in	in	B-ADVP	FW	O	29	AMOD
33	vivo	vivo	I-ADVP	FW	O	32	AMOD
34	.	.	O	.	O	14	P

1	Hepatitis	Hepatitis	B-NP	NN	O	5	NMOD
2	and	and	I-NP	CC	O	5	NMOD
3	renal	renal	I-NP	JJ	O	5	NMOD
4	tubular	tubular	I-NP	JJ	O	5	NMOD
5	acidosis	acidosis	I-NP	NN	O	0	ROOT
6	after	after	B-PP	IN	O	5	NMOD
7	anesthesia	anesthesia	B-NP	NN	O	6	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	methoxyflurane	methoxyflurane	B-NP	NN	O	8	PMOD
10	.	.	O	.	O	5	P

1	A	A	B-NP	DT	O	3	NMOD
2	69-year-old	69-year-old	I-NP	JJ	O	3	NMOD
3	man	man	I-NP	NN	O	11	SUB
4	operated	operate	B-VP	VBN	O	3	NMOD
5	for	for	B-PP	IN	O	4	VMOD
6	acute	acute	B-NP	JJ	O	7	NMOD
7	cholecystitis	cholecystitis	I-NP	NN	O	5	PMOD
8	under	under	B-PP	IN	O	4	VMOD
9	methoxyflurane	methoxyflurane	B-NP	NN	O	10	NMOD
10	anesthesia	anesthesia	I-NP	NN	O	8	PMOD
11	developed	develop	B-VP	VBD	O	0	ROOT
12	postoperatively	postoperatively	B-ADVP	RB	O	11	VMOD
13	a	a	B-NP	DT	O	16	NMOD
14	hepatic	hepatic	I-NP	JJ	O	16	NMOD
15	insufficiency	insufficiency	I-NP	NN	O	16	NMOD
16	syndrome	syndrome	I-NP	NN	O	20	NMOD
17	and	and	O	CC	O	20	NMOD
18	renal	renal	B-NP	JJ	O	20	NMOD
19	tubular	tubular	I-NP	JJ	O	20	NMOD
20	acidosis	acidosis	I-NP	NN	O	11	VMOD
21	.	.	O	.	O	11	P

1	Pituitary	Pituitary	B-NP	JJ	O	2	NMOD
2	response	response	I-NP	NN	O	0	ROOT
3	to	to	B-PP	TO	O	2	NMOD
4	luteinizing	luteinize	B-VP	VBG	O	3	PMOD
5	hormone-releasing	hormone-releasing	B-NP	NN	O	6	NMOD
6	hormone	hormone	I-NP	NN	O	4	OBJ
7	during	during	B-PP	IN	O	4	VMOD
8	haloperidol	haloperidol	B-NP	NN	O	10	NMOD
9	induced	induced	I-NP	JJ	O	10	NMOD
10	hyperprolactinemia	hyperprolactinemia	I-NP	NN	O	7	PMOD
11	.	.	O	.	O	2	P

1	Antirifampicin	Antirifampicin	B-NP	NN	B-protein	2	NMOD
2	antibodies	antibody	I-NP	NNS	I-protein	27	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	acute	acute	B-NP	JJ	O	7	NMOD
5	rifampicin-associated	rifampicin-associated	I-NP	JJ	O	7	NMOD
6	renal	renal	I-NP	JJ	O	7	NMOD
7	failure.	failure.	I-NP	NN	O	9	NMOD
8	5	5	B-NP	CD	O	7	NMOD
9	patients	patient	I-NP	NNS	O	3	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	acute	acute	B-NP	JJ	O	13	NMOD
12	renal	renal	I-NP	JJ	O	13	NMOD
13	failure	failure	I-NP	NN	O	10	PMOD
14	(	(	O	(	O	20	DEP
15	3	3	B-NP	CD	O	20	DEP
16	with	with	B-PP	IN	O	15	NMOD
17	thrombopenia	thrombopenia	B-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	hemolysis	hemolysis	I-NP	NN	O	16	PMOD
20	)	)	O	)	O	9	NMOD
21	induced	induce	B-VP	VBN	O	2	NMOD
22	by	by	B-PP	IN	O	21	VMOD
23	the	the	B-NP	DT	O	24	NMOD
24	reintroduction	reintroduction	I-NP	NN	O	22	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	rifampicin	rifampicin	B-NP	NN	O	25	PMOD
27	are	be	B-VP	VBP	O	0	ROOT
28	described	describe	I-VP	VBN	O	27	VC
29	.	.	O	.	O	27	P

1	Cardiovascular	Cardiovascular	B-NP	JJ	O	2	NMOD
2	effects	effect	I-NP	NNS	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	hypotension	hypotension	B-NP	NN	O	3	PMOD
5	induced	induce	B-VP	VBN	O	4	NMOD
6	by	by	B-PP	IN	O	5	VMOD
7	adenosine	adenosine	B-NP	NN	O	8	NMOD
8	triphosphate	triphosphate	I-NP	NN	O	11	NMOD
9	and	and	O	CC	O	11	NMOD
10	sodium	sodium	B-NP	NN	O	11	NMOD
11	nitroprusside	nitroprusside	I-NP	NN	O	6	PMOD
12	on	on	B-PP	IN	O	5	VMOD
13	dogs	dog	B-NP	NNS	O	12	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	denervated	denervate	B-NP	VBN	O	16	NMOD
16	hearts	heart	I-NP	NNS	O	14	PMOD
17	.	.	O	.	O	2	P

1	Adenosine	Adenosine	B-NP	NN	O	2	NMOD
2	triphosphate	triphosphate	I-NP	NN	O	8	NMOD
3	(	(	O	(	O	5	DEP
4	ATP	ATP	B-NP	NN	O	5	DEP
5	)	)	O	)	O	2	NMOD
6	and	and	O	CC	O	8	NMOD
7	sodium	sodium	B-NP	NN	O	8	NMOD
8	nitroprusside	nitroprusside	I-NP	NN	O	12	SUB
9	(	(	O	(	O	11	DEP
10	SNP	SNP	B-NP	NN	B-protein	11	DEP
11	)	)	O	)	O	8	NMOD
12	are	be	B-VP	VBP	O	0	ROOT
13	administered	administer	I-VP	VBN	O	12	VC
14	to	to	B-PP	TO	O	17	VMOD
15	patients	patient	B-NP	NNS	O	17	SUB
16	to	to	B-VP	TO	O	17	VMOD
17	induce	induce	I-VP	VB	O	13	VMOD
18	and	and	I-VP	CC	O	17	VMOD
19	control	control	I-VP	VB	O	17	VMOD
20	hypotension	hypotension	B-NP	NN	O	17	VMOD
21	during	during	B-PP	IN	O	17	VMOD
22	anesthesia	anesthesia	B-NP	NN	O	21	PMOD
23	.	.	O	.	O	12	P

1	Hypotension	Hypotension	B-NP	NN	O	5	SUB
2	induced	induce	B-VP	VBN	O	1	NMOD
3	by	by	B-PP	IN	O	2	VMOD
4	ATP	ATP	B-NP	NN	O	3	PMOD
5	was	be	B-VP	VBD	O	87	VMOD
6	accompanied	accompany	I-VP	VBN	O	5	VC
7	by	by	B-PP	IN	O	6	VMOD
8	significant	significant	B-NP	JJ	O	9	NMOD
9	decreases	decrease	I-NP	NNS	O	7	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	mean	mean	B-NP	JJ	O	14	NMOD
12	pulmonary	pulmonary	I-NP	JJ	O	14	NMOD
13	arterial	arterial	I-NP	JJ	O	14	NMOD
14	pressure	pressure	I-NP	NN	O	24	NMOD
15	(	(	O	(	O	20	DEP
16	p	p	B-NP	NN	O	20	DEP
17	less	less	B-ADJP	JJR	O	16	NMOD
18	than	than	B-PP	IN	O	17	AMOD
19	0.001	0.001	B-NP	CD	O	18	PMOD
20	)	)	O	)	O	14	NMOD
21	,	,	O	,	O	24	P
22	central	central	B-NP	JJ	O	24	NMOD
23	venous	venous	I-NP	JJ	O	24	NMOD
24	pressure	pressure	I-NP	NN	O	10	PMOD
25	(	(	O	(	O	30	DEP
26	p	p	B-NP	NN	O	30	DEP
27	less	less	B-ADJP	JJR	O	26	NMOD
28	than	than	B-PP	IN	O	27	AMOD
29	0.001	0.001	B-NP	CD	O	28	PMOD
30	)	)	O	)	O	24	NMOD
31	,	,	O	,	O	5	P
32	left	leave	B-VP	VBD	O	5	VMOD
33	ventricular	ventricular	B-NP	JJ	O	35	NMOD
34	end-diastolic	end-diastolic	I-NP	JJ	O	35	NMOD
35	pressure	pressure	I-NP	NN	O	45	NMOD
36	(	(	O	(	O	41	DEP
37	p	p	B-NP	NN	O	41	DEP
38	less	less	B-ADJP	JJR	O	37	NMOD
39	than	than	B-PP	IN	O	38	AMOD
40	0.001	0.001	B-NP	CD	O	39	PMOD
41	)	)	O	)	O	35	NMOD
42	,	,	O	,	O	45	P
43	total	total	B-NP	JJ	O	45	NMOD
44	peripheral	peripheral	I-NP	JJ	O	45	NMOD
45	resistance	resistance	I-NP	NN	O	55	NMOD
46	(	(	O	(	O	51	DEP
47	p	p	B-NP	NN	O	51	DEP
48	less	less	B-ADJP	JJR	O	47	NMOD
49	than	than	B-PP	IN	O	48	AMOD
50	0.001	0.001	B-NP	CD	O	49	PMOD
51	)	)	O	)	O	45	NMOD
52	,	,	O	,	O	55	P
53	rate	rate	B-NP	NN	B-protein	55	NMOD
54	pressure	pressure	I-NP	NN	I-protein	55	NMOD
55	product	product	I-NP	NN	I-protein	66	NMOD
56	(	(	O	(	O	61	DEP
57	p	p	B-NP	NN	O	61	DEP
58	less	less	B-ADJP	JJR	O	57	NMOD
59	than	than	B-PP	IN	O	58	AMOD
60	0.001	0.001	B-NP	CD	O	59	PMOD
61	)	)	O	)	O	55	NMOD
62	,	,	O	,	O	66	P
63	total	total	B-NP	JJ	O	66	NMOD
64	body	body	I-NP	NN	O	66	NMOD
65	oxygen	oxygen	I-NP	NN	O	66	NMOD
66	consumption	consumption	I-NP	NN	O	76	NMOD
67	(	(	O	(	O	72	DEP
68	p	p	B-NP	NN	O	70	SUB
69	less	less	B-ADJP	JJR	O	70	AMOD
70	than	than	B-PP	IN	O	72	DEP
71	0.05	0.05	B-NP	CD	O	70	AMOD
72	)	)	O	)	O	66	NMOD
73	,	,	O	,	O	76	P
74	and	and	O	CC	O	76	NMOD
75	heart	heart	B-NP	NN	O	76	NMOD
76	rate	rate	I-NP	NN	O	32	OBJ
77	(	(	O	(	O	82	DEP
78	p	p	B-NP	NN	O	80	SUB
79	less	less	B-ADJP	JJR	O	80	AMOD
80	than	than	B-PP	IN	O	82	DEP
81	0.001	0.001	B-NP	CD	O	80	AMOD
82	)	)	O	)	O	76	NMOD
83	;	;	O	:	O	5	P
84	all	all	B-NP	PDT	O	86	NMOD
85	these	these	I-NP	DT	O	86	NMOD
86	variables	variable	I-NP	NNS	O	87	SUB
87	returned	return	B-VP	VBD	O	0	ROOT
88	normal	normal	B-ADJP	JJ	O	87	PRD
89	within	within	B-PP	IN	O	88	AMOD
90	30	30	B-NP	CD	O	91	NMOD
91	min	min	I-NP	NN	O	89	PMOD
92	after	after	B-PP	IN	O	91	NMOD
93	ATP	ATP	B-NP	NN	O	92	PMOD
94	was	be	B-VP	VBD	O	87	VMOD
95	stopped	stop	I-VP	VBN	O	94	VC
96	.	.	O	.	O	87	P

1	During	During	B-PP	IN	O	8	VMOD
2	hypotension	hypotension	B-NP	NN	O	1	PMOD
3	produced	produce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	SNP	SNP	B-NP	NN	O	7	NMOD
6	similar	similar	I-NP	JJ	O	7	NMOD
7	decreases	decrease	I-NP	NNS	O	4	PMOD
8	were	be	B-VP	VBD	O	0	ROOT
9	observed	observe	I-VP	VBN	O	8	VC
10	in	in	B-PP	IN	O	9	VMOD
11	mean	mean	B-NP	JJ	O	14	NMOD
12	pulmonary	pulmonary	I-NP	JJ	O	14	NMOD
13	arterial	arterial	I-NP	JJ	O	14	NMOD
14	pressure	pressure	I-NP	NN	O	24	NMOD
15	(	(	O	(	O	20	DEP
16	p	p	B-NP	NN	O	18	SUB
17	less	less	B-ADJP	JJR	O	18	AMOD
18	than	than	B-PP	IN	O	20	DEP
19	0.01	0.01	B-NP	CD	O	18	AMOD
20	)	)	O	)	O	14	NMOD
21	,	,	O	,	O	24	P
22	central	central	B-NP	JJ	O	24	NMOD
23	venous	venous	I-NP	JJ	O	24	NMOD
24	pressure	pressure	I-NP	NN	O	10	PMOD
25	(	(	O	(	O	30	DEP
26	p	p	B-NP	NN	O	30	DEP
27	less	less	B-ADJP	JJR	O	26	NMOD
28	than	than	B-PP	IN	O	27	AMOD
29	0.001	0.001	B-NP	CD	O	28	PMOD
30	)	)	O	)	O	24	NMOD
31	,	,	O	,	O	8	P
32	left	leave	B-VP	VBD	O	66	VMOD
33	ventricular	ventricular	B-NP	JJ	O	35	NMOD
34	end-diastolic	end-diastolic	I-NP	JJ	O	35	NMOD
35	pressure	pressure	I-NP	NN	O	32	OBJ
36	(	(	O	(	O	41	DEP
37	p	p	B-NP	NN	O	39	SUB
38	less	less	B-ADJP	JJR	O	39	AMOD
39	than	than	B-PP	IN	O	41	DEP
40	0.01	0.01	B-NP	CD	O	39	AMOD
41	)	)	O	)	O	32	VMOD
42	,	,	O	,	O	32	P
43	total	total	B-NP	JJ	O	45	NMOD
44	peripheral	peripheral	I-NP	JJ	O	45	NMOD
45	resistance	resistance	I-NP	NN	O	32	OBJ
46	(	(	O	(	O	51	DEP
47	p	p	B-NP	NN	O	51	DEP
48	less	less	B-ADJP	JJR	O	47	NMOD
49	than	than	B-PP	IN	O	48	AMOD
50	0.001	0.001	B-NP	CD	O	49	PMOD
51	)	)	O	)	O	32	VMOD
52	,	,	O	,	O	66	P
53	rate	rate	B-NP	NN	B-protein	55	NMOD
54	pressure	pressure	I-NP	NN	I-protein	55	NMOD
55	product	product	I-NP	NN	I-protein	66	NMOD
56	(	(	O	(	O	61	DEP
57	p	p	B-NP	NN	O	61	DEP
58	less	less	B-ADJP	JJR	O	57	NMOD
59	than	than	B-PP	IN	O	58	AMOD
60	0.001	0.001	B-NP	CD	O	59	PMOD
61	)	)	O	)	O	55	NMOD
62	,	,	O	,	O	66	P
63	and	and	O	CC	O	66	NMOD
64	oxygen	oxygen	B-NP	NN	O	66	NMOD
65	content	content	I-NP	NN	O	66	NMOD
66	difference	difference	I-NP	NN	O	8	PRD
67	between	between	B-PP	IN	O	66	NMOD
68	arterial	arterial	B-NP	JJ	O	70	AMOD
69	and	and	I-NP	CC	O	70	AMOD
70	mixed	mixed	I-NP	JJ	O	72	NMOD
71	venous	venous	I-NP	JJ	O	72	NMOD
72	blood	blood	I-NP	NN	O	67	PMOD
73	(	(	O	(	O	78	DEP
74	p	p	B-NP	NN	O	76	SUB
75	less	less	B-ADJP	JJR	O	76	AMOD
76	than	than	B-PP	IN	O	78	DEP
77	0.05	0.05	B-NP	CD	O	76	AMOD
78	)	)	O	)	O	66	NMOD
79	,	,	O	,	O	8	P
80	while	while	B-SBAR	IN	O	8	VMOD
81	heart	heart	B-NP	NN	O	82	NMOD
82	rate	rate	I-NP	NN	O	91	NMOD
83	(	(	O	(	O	88	DEP
84	p	p	B-NP	NN	O	88	DEP
85	less	less	B-ADJP	JJR	O	84	NMOD
86	than	than	B-PP	IN	O	85	AMOD
87	0.001	0.001	B-NP	CD	O	86	PMOD
88	)	)	O	)	O	82	NMOD
89	and	and	O	CC	O	91	NMOD
90	cardiac	cardiac	B-NP	JJ	O	91	NMOD
91	output	output	I-NP	NN	O	98	SUB
92	(	(	O	(	O	97	DEP
93	p	p	B-NP	NN	O	95	SUB
94	less	less	B-ADJP	JJR	O	95	AMOD
95	than	than	B-PP	IN	O	97	DEP
96	0.05	0.05	B-NP	CD	O	95	AMOD
97	)	)	O	)	O	91	NMOD
98	were	be	B-VP	VBD	O	80	SBAR
99	increased	increase	I-VP	VBN	O	98	VC
100	.	.	O	.	O	8	P

1	The	The	B-NP	DT	O	3	NMOD
2	Dimer-X	Dimer-X	I-NP	NNP	O	3	NMOD
3	group	group	I-NP	NN	O	4	SUB
4	had	have	B-VP	VBD	O	0	ROOT
5	a	a	B-NP	DT	O	7	NMOD
6	higher	high	I-NP	JJR	O	7	NMOD
7	incidence	incidence	I-NP	NN	O	4	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	nausea	nausea	B-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	dizziness	dizziness	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	3	NMOD
2	Endografine	Endografine	I-NP	NNP	O	3	NMOD
3	group	group	I-NP	NN	O	4	SUB
4	had	have	B-VP	VBD	O	0	ROOT
5	a	a	B-NP	DT	O	7	NMOD
6	higher	high	I-NP	JJR	O	7	NMOD
7	incidence	incidence	I-NP	NN	O	4	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	abdominal	abdominal	B-NP	JJ	O	10	NMOD
10	pain	pain	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	4	P

1	Post-suxamethonium	Post-suxamethonium	B-NP	JJ	O	2	NMOD
2	pains	pain	I-NP	NNS	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	Nigerian	Nigerian	B-NP	JJ	O	6	NMOD
5	surgical	surgical	I-NP	JJ	O	6	NMOD
6	patients	patient	I-NP	NNS	O	3	PMOD
7	.	.	O	.	O	2	P

1	Contrary	Contrary	B-ADVP	JJ	O	0	ROOT
2	to	to	B-PP	TO	O	1	AMOD
3	an	an	B-NP	DT	O	5	NMOD
4	earlier	early	I-NP	JJR	O	5	NMOD
5	report	report	I-NP	NN	O	2	PMOD
6	by	by	B-PP	IN	O	5	NMOD
7	Coxon	Coxon	B-NP	NNP	O	11	VMOD
8	,	,	O	,	O	11	P
9	scoline	scoline	B-NP	NN	O	10	NMOD
10	pain	pain	I-NP	NN	O	11	SUB
11	occurs	occur	B-VP	VBZ	O	6	SBAR
12	in	in	B-PP	IN	O	11	VMOD
13	African	African	B-NP	JJ	O	14	NMOD
14	negroes	negro	I-NP	NNS	O	12	PMOD
15	.	.	O	.	O	1	P

1	About	About	B-NP	RB	O	3	NMOD
2	62	62	I-NP	CD	O	1	AMOD
3	%	%	I-NP	NN	O	7	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	out-patients	out-patient	I-NP	NNS	O	4	PMOD
7	developed	develop	B-VP	VBD	O	0	ROOT
8	scoline	scoline	B-NP	NN	O	9	NMOD
9	pain	pain	I-NP	NN	O	7	OBJ
10	as	as	B-PP	IN	O	7	VMOD
11	compared	compare	B-PP	VBN	O	10	SBAR
12	with	with	B-PP	IN	O	11	VMOD
13	about	about	B-NP	RB	O	15	NMOD
14	26	26	I-NP	CD	O	13	AMOD
15	%	%	I-NP	NN	O	12	PMOD
16	among	among	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	18	NMOD
18	in-patients	in-patient	I-NP	NNS	O	16	PMOD
19	.	.	O	.	O	7	P

1	The	The	B-NP	DT	O	2	NMOD
2	abolition	abolition	I-NP	NN	O	13	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	muscle	muscle	B-NP	NN	O	5	NMOD
5	fasciculations	fasciculation	I-NP	NNS	O	3	PMOD
6	(	(	O	(	O	12	DEP
7	by	by	B-PP	IN	O	12	DEP
8	0.075mg/kg	0.075mg/kg	B-NP	CD	O	9	NMOD
9	dose	dose	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	Fazadinium	Fazadinium	B-NP	NN	O	10	PMOD
12	)	)	O	)	O	2	NMOD
13	did	do	B-VP	VBD	O	0	ROOT
14	not	not	I-VP	RB	O	13	VMOD
15	influence	influence	I-VP	VB	O	13	VC
16	the	the	B-NP	DT	O	17	NMOD
17	occurrence	occurrence	I-NP	NN	O	15	OBJ
18	of	of	B-PP	IN	O	17	NMOD
19	scoline	scoline	B-NP	NN	B-protein	20	NMOD
20	pain	pain	I-NP	NN	I-protein	18	PMOD
21	.	.	O	.	O	13	P

1	Medial	Medial	B-NP	JJ	O	2	NMOD
2	changes	change	I-NP	NNS	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	arterial	arterial	B-NP	JJ	O	5	NMOD
5	spasm	spasm	I-NP	NN	O	3	PMOD
6	induced	induce	B-VP	VBN	O	5	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	L-norepinephrine	L-norepinephrine	B-NP	NN	O	7	PMOD
9	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	17	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	media	medium	I-NP	NNS	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	7	NMOD
6	saphenous	saphenous	I-NP	JJ	O	7	NMOD
7	artery	artery	I-NP	NN	O	11	NMOD
8	and	and	O	CC	O	11	NMOD
9	its	its	B-NP	PRP$	O	11	NMOD
10	distal	distal	I-NP	JJ	O	11	NMOD
11	branch	branch	I-NP	NN	O	4	PMOD
12	,	,	O	,	O	17	P
13	vasoconstriction	vasoconstriction	B-NP	NN	O	17	SUB
14	induced	induce	B-VP	VBN	O	13	NMOD
15	by	by	B-PP	IN	O	14	VMOD
16	L-norepinephrine	L-norepinephrine	B-NP	NN	B-protein	15	PMOD
17	produced	produce	B-VP	VBD	I-protein	0	ROOT
18	many	many	B-NP	JJ	I-protein	20	NMOD
19	cell-to-cell	cell-to-cell	I-NP	JJ	I-protein	20	NMOD
20	hernias	hernia	I-NP	NNS	I-protein	17	OBJ
21	within	within	B-PP	IN	O	17	VMOD
22	15	15	B-NP	CD	O	23	NMOD
23	minutes	minute	I-NP	NNS	O	21	PMOD
24	.	.	O	.	O	17	P

1	Abnormalities	Abnormality	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	7	NMOD
4	pupil	pupil	I-NP	NN	O	7	NMOD
5	and	and	I-NP	CC	O	7	NMOD
6	visual-evoked	visual-evoked	I-NP	JJ	O	7	NMOD
7	potential	potential	I-NP	NN	O	2	PMOD
8	in	in	B-PP	IN	O	1	NMOD
9	quinine	quinine	B-NP	NN	O	10	NMOD
10	amblyopia	amblyopia	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	1	P

1	Total	Total	B-NP	JJ	O	2	NMOD
2	blindness	blindness	I-NP	NN	O	16	NMOD
3	with	with	B-PP	IN	O	2	NMOD
4	a	a	B-NP	DT	O	8	NMOD
5	transient	transient	I-NP	JJ	O	8	NMOD
6	tonic	tonic	I-NP	JJ	O	8	NMOD
7	pupillary	pupillary	I-NP	JJ	O	8	NMOD
8	response	response	I-NP	NN	O	3	PMOD
9	,	,	O	,	O	16	P
10	denervation	denervation	B-NP	NN	O	11	NMOD
11	supersensitivity	supersensitivity	I-NP	NN	O	16	NMOD
12	,	,	O	,	O	16	P
13	and	and	O	CC	O	16	NMOD
14	abnormal	abnormal	B-NP	JJ	O	16	NMOD
15	visual-evoked	visual-evoked	I-NP	JJ	O	16	NMOD
16	potentials	potential	I-NP	NNS	O	0	ROOT
17	developed	develop	B-VP	VBN	O	16	NMOD
18	in	in	B-PP	IN	O	17	VMOD
19	a	a	B-NP	DT	O	21	NMOD
20	54-year-old	54-year-old	I-NP	JJ	O	21	NMOD
21	man	man	I-NP	NN	O	18	PMOD
22	after	after	B-PP	IN	O	16	NMOD
23	the	the	B-NP	DT	O	24	NMOD
24	use	use	I-NP	NN	O	22	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	quinine	quinine	B-NP	NN	O	27	NMOD
27	sulfate	sulfate	I-NP	NN	O	25	PMOD
28	for	for	B-PP	IN	O	24	NMOD
29	leg	leg	B-NP	NN	O	30	NMOD
30	cramps	cramp	I-NP	NNS	O	28	PMOD
31	.	.	O	.	O	16	P

1	Suxamethonium	Suxamethonium	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	jaw	jaw	B-NP	NN	O	4	NMOD
4	stiffness	stiffness	I-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	myalgia	myalgia	I-NP	NN	O	2	OBJ
7	associated	associate	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	atypical	atypical	B-NP	JJ	B-protein	10	NMOD
10	cholinesterase	cholinesterase	I-NP	NN	I-protein	8	PMOD
11	:	:	O	:	O	2	P
12	case	case	B-NP	NN	O	2	VMOD
13	report	report	I-NP	NN	O	2	VMOD
14	.	.	O	.	O	2	P

1	Indomethacin	Indomethacin	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	hyperkalemia	hyperkalemia	B-NP	NN	O	2	OBJ
4	in	in	B-PP	IN	O	2	VMOD
5	three	three	B-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	4	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	gouty	gouty	B-NP	NN	O	9	NMOD
9	arthritis	arthritis	I-NP	NN	O	7	PMOD
10	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	three	three	B-NP	CD	O	4	NMOD
4	patients	patient	I-NP	NNS	O	2	OBJ
5	in	in	B-PP	IN	O	4	NMOD
6	whom	whom	B-NP	WP	O	13	NMOD
7	severe	severe	B-NP	JJ	O	9	AMOD
8	,	,	I-NP	,	O	9	P
9	life-threatening	life-threatening	I-NP	JJ	O	10	NMOD
10	hyperkalemia	hyperkalemia	I-NP	NN	O	13	NMOD
11	and	and	O	CC	O	13	NMOD
12	renal	renal	B-NP	JJ	O	13	NMOD
13	insufficiency	insufficiency	I-NP	NN	O	5	PMOD
14	developed	develop	B-VP	VBN	O	13	NMOD
15	after	after	B-PP	IN	O	14	VMOD
16	treatment	treatment	B-NP	NN	O	15	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	acute	acute	B-NP	JJ	O	20	NMOD
19	gouty	gouty	I-NP	NN	O	20	NMOD
20	arthritis	arthritis	I-NP	NN	O	17	PMOD
21	with	with	B-PP	IN	O	20	NMOD
22	indomethacin	indomethacin	B-NP	NN	O	21	PMOD
23	.	.	O	.	O	2	P

1	This	This	B-NP	DT	O	2	NMOD
2	complication	complication	I-NP	NN	O	3	SUB
3	may	may	B-VP	MD	O	0	ROOT
4	result	result	I-VP	VB	O	3	VC
5	from	from	B-PP	IN	O	4	VMOD
6	an	an	B-NP	DT	O	7	NMOD
7	inhibition	inhibition	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	prostaglandin	prostaglandin	B-NP	NN	O	10	NMOD
10	synthesis	synthesis	I-NP	NN	O	14	NMOD
11	and	and	O	CC	O	14	NMOD
12	consequent	consequent	B-NP	JJ	O	14	NMOD
13	hyporeninemic	hyporeninemic	I-NP	JJ	O	14	NMOD
14	hypoaidosteronism	hypoaidosteronism	I-NP	NN	O	8	PMOD
15	.	.	O	.	O	3	P

1	Levodopa	Levodopa	B-NP	NN	O	3	NMOD
2	induced	induced	I-NP	JJ	O	3	NMOD
3	dyskinesias	dyskinesia	I-NP	NNS	O	4	SUB
4	are	be	B-VP	VBP	O	0	ROOT
5	improved	improve	I-VP	VBN	O	4	VC
6	by	by	B-PP	IN	O	5	VMOD
7	fluoxetine	fluoxetine	B-NP	NN	O	6	PMOD
8	.	.	O	.	O	4	P

1	We	We	B-NP	PRP	O	2	SUB
2	evaluated	evaluate	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	severity	severity	I-NP	NN	O	9	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	motor	motor	B-NP	NN	O	7	NMOD
7	disability	disability	I-NP	NN	O	5	PMOD
8	and	and	I-NP	CC	O	9	NMOD
9	dyskinesias	dyskinesia	I-NP	NNS	O	2	OBJ
10	in	in	B-PP	IN	O	9	NMOD
11	seven	seven	B-NP	CD	O	13	NMOD
12	levodopa-responsive	levodopa-responsive	I-NP	JJ	O	13	NMOD
13	patients	patient	I-NP	NNS	O	10	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	Parkinson	Parkinson	B-NP	NNP	O	16	NMOD
16	's	's	B-NP	POS	O	17	NMOD
17	disease	disease	I-NP	NN	O	14	PMOD
18	after	after	B-PP	IN	O	9	NMOD
19	an	an	B-NP	DT	O	21	NMOD
20	acute	acute	I-NP	JJ	O	21	NMOD
21	challenge	challenge	I-NP	NN	O	18	PMOD
22	with	with	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	26	NMOD
24	mixed	mixed	I-NP	JJ	O	26	NMOD
25	dopamine	dopamine	I-NP	NN	O	26	NMOD
26	agonist	agonist	I-NP	NN	O	28	NMOD
27	,	,	O	,	O	28	P
28	apomorphine	apomorphine	B-NP	NN	O	22	PMOD
29	,	,	O	,	O	2	P
30	before	before	B-PP	IN	O	2	VMOD
31	and	and	I-PP	CC	O	30	PMOD
32	after	after	I-PP	IN	O	30	PMOD
33	the	the	B-NP	DT	O	34	NMOD
34	administration	administration	I-NP	NN	O	30	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	fluoxetine	fluoxetine	B-NP	NN	O	35	PMOD
37	(	(	O	(	O	43	DEP
38	20	20	B-NP	CD	O	39	NMOD
39	mg	mg	I-NP	NN	O	43	DEP
40	twice	twice	B-ADVP	RB	O	39	NMOD
41	per	per	B-PP	IN	O	39	NMOD
42	day	day	B-NP	NN	O	41	PMOD
43	)	)	O	)	O	36	NMOD
44	for	for	B-PP	IN	O	34	NMOD
45	11	11	B-NP	CD	O	47	AMOD
46	+/-	+/-	I-NP	SYM	O	47	AMOD
47	1	1	I-NP	CD	O	48	NMOD
48	days	day	I-NP	NNS	O	44	PMOD
49	.	.	O	.	O	2	P

1	After	After	B-PP	IN	O	6	VMOD
2	fluoxetine	fluoxetine	B-NP	NN	O	3	NMOD
3	treatment	treatment	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	6	P
5	there	there	B-NP	EX	O	6	SUB
6	was	be	B-VP	VBD	O	0	ROOT
7	a	a	B-NP	DT	O	11	NMOD
8	significant	significant	I-NP	JJ	O	11	NMOD
9	47	47	I-NP	CD	O	10	AMOD
10	%	%	I-NP	NN	O	11	NMOD
11	improvement	improvement	I-NP	NN	O	6	PRD
12	(	(	O	(	O	16	DEP
13	p	p	B-NP	NN	O	16	DEP
14	<	<	O	SYM	O	13	NMOD
15	0.05	0.05	B-NP	CD	O	14	AMOD
16	)	)	O	)	O	11	NMOD
17	of	of	B-PP	IN	O	11	NMOD
18	apomorphine	apomorphine	B-NP	NN	O	20	NMOD
19	induced	induce	I-NP	VBN	O	20	NMOD
20	dyskinesias	dyskinesia	I-NP	NNS	O	17	PMOD
21	without	without	B-PP	IN	O	11	NMOD
22	modification	modification	B-NP	NN	O	21	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	parkinsonian	parkinsonian	B-NP	JJ	O	26	NMOD
25	motor	motor	I-NP	NN	O	26	NMOD
26	disability	disability	I-NP	NN	O	23	PMOD
27	.	.	O	.	O	6	P

1	A	A	B-NP	DT	O	5	NMOD
2	large	large	I-NP	JJ	O	5	NMOD
3	population-based	population-based	I-NP	JJ	O	5	NMOD
4	follow-up	follow-up	I-NP	JJ	O	5	NMOD
5	study	study	I-NP	NN	O	0	ROOT
6	of	of	B-PP	IN	O	5	NMOD
7	trimethoprim-sulfamethoxazole	trimethoprim-sulfamethoxazole	B-NP	NN	O	12	NMOD
8	,	,	O	,	O	12	P
9	trimethoprim	trimethoprim	B-NP	NN	O	12	NMOD
10	,	,	O	,	O	12	P
11	and	and	O	CC	O	12	NMOD
12	cephalexin	cephalexin	B-NP	NN	O	6	PMOD
13	for	for	B-PP	IN	O	12	NMOD
14	uncommon	uncommon	B-NP	JJ	O	17	NMOD
15	serious	serious	I-NP	JJ	O	17	NMOD
16	drug	drug	I-NP	NN	O	17	NMOD
17	toxicity	toxicity	I-NP	NN	O	13	PMOD
18	.	.	O	.	O	5	P

1	We	We	B-NP	PRP	O	2	SUB
2	conducted	conduct	B-VP	VBD	O	0	ROOT
3	a	a	B-NP	DT	O	7	NMOD
4	population-based	population-based	I-NP	JJ	O	6	AMOD
5	45-day	45-day	I-NP	JJ	O	6	AMOD
6	follow-up	follow-up	I-NP	JJ	O	7	NMOD
7	study	study	I-NP	NN	O	2	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	232	232	B-NP	CD	O	12	NMOD
10	,	,	O	,	O	12	P
11	390	390	B-NP	CD	O	12	NMOD
12	people	people	I-NP	NNS	O	8	PMOD
13	who	who	B-NP	WP	O	12	NMOD
14	were	be	B-VP	VBD	O	13	SBAR
15	prescribed	prescribe	I-VP	VBN	O	14	VC
16	trimethoprim-sulfamethoxazole	trimethoprim-sulfamethoxazole	B-NP	NN	O	33	NMOD
17	(	(	O	(	O	19	DEP
18	TMP-SMZ	TMP-SMZ	B-NP	NN	B-protein	19	DEP
19	)	)	O	)	O	16	NMOD
20	,	,	O	,	O	33	P
21	266	266	B-NP	CD	O	33	NMOD
22	,	,	O	,	O	33	P
23	951	951	B-NP	CD	O	25	NMOD
24	prescribed	prescribe	I-NP	VBN	O	25	NMOD
25	trimethoprim	trimethoprim	I-NP	NN	O	33	NMOD
26	alone	alone	B-ADVP	RB	O	25	NMOD
27	,	,	O	,	O	33	P
28	and	and	O	CC	O	33	NMOD
29	196	196	B-NP	CD	O	33	NMOD
30	,	,	O	,	O	33	P
31	397	397	B-NP	CD	O	33	NMOD
32	prescribed	prescribed	I-NP	JJ	O	33	NMOD
33	cephalexin	cephalexin	I-NP	NN	O	15	OBJ
34	,	,	O	,	O	33	P
35	to	to	B-VP	TO	O	36	VMOD
36	estimate	estimate	I-VP	VB	O	33	NMOD
37	the	the	B-NP	DT	O	38	NMOD
38	risk	risk	I-NP	NN	O	36	OBJ
39	of	of	B-PP	IN	O	38	NMOD
40	serious	serious	B-NP	JJ	O	41	NMOD
41	liver	liver	I-NP	NN	O	49	NMOD
42	,	,	O	,	O	49	P
43	blood	blood	B-NP	NN	O	49	NMOD
44	,	,	O	,	O	49	P
45	skin	skin	B-NP	NN	O	49	NMOD
46	,	,	O	,	O	49	P
47	and	and	O	CC	O	49	NMOD
48	renal	renal	B-NP	JJ	O	49	NMOD
49	disorders	disorder	I-NP	NNS	O	39	PMOD
50	resulting	result	B-VP	VBG	O	49	NMOD
51	in	in	B-PP	IN	O	50	VMOD
52	referral	referral	B-NP	NN	O	54	NMOD
53	or	or	I-NP	CC	O	54	NMOD
54	hospitalization	hospitalization	I-NP	NN	O	51	PMOD
55	associated	associate	B-VP	VBN	O	54	NMOD
56	with	with	B-PP	IN	O	55	VMOD
57	these	these	B-NP	DT	O	58	NMOD
58	drugs	drug	I-NP	NNS	O	56	PMOD
59	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	risk	risk	I-NP	NN	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	clinically	clinically	B-NP	RB	O	5	AMOD
5	important	important	I-NP	JJ	O	8	NMOD
6	idiopathic	idiopathic	I-NP	JJ	O	8	NMOD
7	liver	liver	I-NP	NN	O	8	NMOD
8	disease	disease	I-NP	NN	O	3	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	similar	similar	B-ADJP	JJ	O	9	PRD
11	for	for	B-SBAR	IN	O	9	VMOD
12	persons	person	B-NP	NNS	O	13	SUB
13	prescribed	prescribe	B-VP	VBD	O	11	SBAR
14	TMP-SMZ	TMP-SMZ	B-NP	NN	B-protein	13	OBJ
15	(	(	O	(	O	19	DEP
16	5.2/100	5.2/100	B-NP	CD	O	18	NMOD
17	,	,	I-NP	,	O	18	P
18	000	000	I-NP	CD	O	19	DEP
19	)	)	O	)	O	14	NMOD
20	and	and	O	CC	O	14	NMOD
21	those	those	B-NP	DT	O	20	PMOD
22	prescribed	prescribe	I-NP	VBN	O	21	NMOD
23	trimethoprim	trimethoprim	I-NP	NN	O	22	OBJ
24	alone	alone	I-NP	RB	O	23	NMOD
25	(	(	O	(	O	29	DEP
26	3.8/100	3.8/100	B-NP	CD	O	28	NMOD
27	,	,	I-NP	,	O	28	P
28	000	000	I-NP	CD	O	29	DEP
29	)	)	O	)	O	23	NMOD
30	.	.	O	.	O	9	P

1	Only	Only	B-NP	RB	O	3	NMOD
2	five	five	I-NP	CD	O	3	NMOD
3	patients	patient	I-NP	NNS	O	4	SUB
4	experienced	experience	B-VP	VBD	O	26	VMOD
5	blood	blood	B-NP	NN	O	6	NMOD
6	disorders	disorder	I-NP	NNS	O	11	SUB
7	,	,	O	,	O	11	P
8	one	one	B-NP	CD	O	11	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	whom	whom	B-NP	WP	O	9	PMOD
11	was	be	B-VP	VBD	O	4	VMOD
12	exposed	expose	I-VP	VBN	O	11	VC
13	to	to	B-PP	TO	O	12	VMOD
14	TMP-SMZ	TMP-SMZ	B-NP	NN	B-protein	13	PMOD
15	;	;	O	:	O	26	P
16	of	of	B-PP	IN	O	26	VMOD
17	seven	seven	B-NP	CD	O	16	PMOD
18	with	with	B-PP	IN	O	17	NMOD
19	erythema	erythema	B-NP	NN	O	20	NMOD
20	multiforme	multiforme	I-NP	NN	O	23	NMOD
21	and	and	O	CC	O	23	NMOD
22	Stevens-Johnson	Stevens-Johnson	B-NP	JJ	O	23	NMOD
23	syndrome	syndrome	I-NP	NN	O	18	PMOD
24	,	,	O	,	O	26	P
25	four	four	B-NP	CD	O	26	SUB
26	were	be	B-VP	VBD	O	0	ROOT
27	exposed	expose	I-VP	VBN	O	26	VC
28	to	to	B-PP	TO	O	27	VMOD
29	TMP-SMZ	TMP-SMZ	B-NP	NN	B-protein	28	PMOD
30	.	.	O	.	O	26	P

1	The	The	B-NP	DT	O	3	NMOD
2	one	one	I-NP	CD	O	3	NMOD
3	case	case	I-NP	NN	O	8	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	toxic	toxic	B-NP	JJ	O	7	NMOD
6	epidermal	epidermal	I-NP	JJ	O	7	NMOD
7	necrolysis	necrolysis	I-NP	NN	O	4	PMOD
8	occurred	occur	B-VP	VBD	O	0	ROOT
9	in	in	B-PP	IN	O	8	VMOD
10	a	a	B-NP	DT	O	11	NMOD
11	patient	patient	I-NP	NN	O	9	PMOD
12	who	who	B-NP	WP	O	11	NMOD
13	took	take	B-VP	VBD	O	12	SBAR
14	cephalexin	cephalexin	B-NP	NN	O	13	OBJ
15	.	.	O	.	O	8	P

1	Clinical	Clinical	B-NP	JJ	O	2	NMOD
2	safety	safety	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	lidocaine	lidocaine	B-NP	NN	O	3	PMOD
5	in	in	B-PP	IN	O	2	NMOD
6	patients	patient	B-NP	NNS	O	5	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	cocaine-associated	cocaine-associated	B-NP	JJ	O	10	NMOD
9	myocardial	myocardial	I-NP	JJ	O	10	NMOD
10	infarction	infarction	I-NP	NN	O	7	PMOD
11	.	.	O	.	O	2	P

1	STUDY	STUDY	B-NP	NN	O	2	NMOD
2	OBJECTIVE	OBJECTIVE	I-NP	NN	O	15	SUB
3	:	:	O	:	O	2	P
4	To	To	B-VP	TO	O	5	VMOD
5	evaluate	evaluate	I-VP	VB	O	2	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	safety	safety	I-NP	NN	O	5	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	lidocaine	lidocaine	B-NP	NN	O	8	PMOD
10	in	in	B-PP	IN	O	7	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	setting	setting	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	cocaine	cocaine	B-NP	NN	O	13	PMOD
15	induced	induce	B-VP	VBD	O	0	ROOT
16	myocardial	myocardial	B-NP	JJ	O	17	NMOD
17	infarction	infarction	I-NP	NN	O	15	OBJ
18	(	(	O	(	O	20	DEP
19	MI	MI	B-NP	NN	O	20	DEP
20	)	)	O	)	O	17	NMOD
21	.	.	O	.	O	15	P

1	PARTICIPANTS	PARTICIPANTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Patients	Patient	B-NP	NNS	O	1	NMOD
4	with	with	B-PP	IN	O	3	NMOD
5	cocaine-associated	cocaine-associated	B-NP	JJ	O	6	NMOD
6	MI	MI	I-NP	NN	O	4	PMOD
7	who	who	B-NP	WP	O	6	NMOD
8	received	receive	B-VP	VBD	O	7	SBAR
9	lidocaine	lidocaine	B-NP	NN	O	8	OBJ
10	in	in	B-PP	IN	O	8	VMOD
11	the	the	B-NP	DT	O	13	NMOD
12	emergency	emergency	I-NP	NN	O	13	NMOD
13	department	department	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	1	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Of	Of	B-NP	IN	O	28	NMOD
4	29	29	I-NP	CD	O	5	NMOD
5	patients	patient	I-NP	NNS	O	3	PMOD
6	who	who	B-NP	WP	O	5	NMOD
7	received	receive	B-VP	VBD	O	6	SBAR
8	lidocaine	lidocaine	B-NP	NN	O	7	OBJ
9	in	in	B-PP	IN	O	7	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	setting	setting	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	cocaine-associated	cocaine-associated	B-NP	JJ	O	14	NMOD
14	MI	MI	I-NP	NN	O	12	PMOD
15	,	,	O	,	O	18	P
16	no	no	B-NP	DT	O	17	NMOD
17	patient	patient	I-NP	NN	O	18	SUB
18	died	die	B-VP	VBD	O	3	SBAR
19	;	;	O	:	O	3	P
20	exhibited	exhibit	B-NP	VBN	O	21	NMOD
21	bradydysrhythmias	bradydysrhythmia	I-NP	NNS	O	28	NMOD
22	,	,	O	,	O	28	P
23	ventricular	ventricular	B-NP	JJ	O	24	NMOD
24	tachycardia	tachycardia	I-NP	NN	O	28	NMOD
25	,	,	O	,	O	28	P
26	or	or	O	CC	O	28	NMOD
27	ventricular	ventricular	B-NP	JJ	O	28	NMOD
28	fibrillation	fibrillation	I-NP	NN	O	32	NMOD
29	;	;	O	:	O	32	P
30	or	or	O	CC	O	32	NMOD
31	experienced	experienced	B-NP	JJ	O	32	NMOD
32	seizures	seizure	I-NP	NNS	O	1	NMOD
33	after	after	B-PP	IN	O	32	NMOD
34	administration	administration	B-NP	NN	O	33	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	lidocaine	lidocaine	B-NP	NN	O	35	PMOD
37	(	(	O	(	O	48	DEP
38	95	95	B-NP	CD	O	41	NMOD
39	%	%	I-NP	NN	O	41	NMOD
40	confidence	confidence	I-NP	NN	O	41	NMOD
41	interval	interval	I-NP	NN	O	44	NMOD
42	,	,	O	,	O	44	P
43	0	0	B-NP	CD	O	44	NMOD
44	%	%	I-NP	NN	O	48	DEP
45	to	to	B-PP	TO	O	44	NMOD
46	11	11	B-NP	CD	O	47	NMOD
47	%	%	I-NP	NN	O	45	PMOD
48	)	)	O	)	O	36	NMOD
49	.	.	O	.	O	32	P

1	Paclitaxel	Paclitaxel	B-NP	NN	O	0	ROOT
2	(	(	O	(	O	1	NMOD
3	Taxol	Taxol	B-NP	NN	O	16	SUB
4	;	;	O	:	O	16	P
5	Bristol-Myers	Bristol-Myers	B-NP	NNP	O	7	NMOD
6	Squibb	Squibb	I-NP	NNP	O	7	NMOD
7	Company	Company	I-NP	NNP	O	9	NMOD
8	,	,	O	,	O	9	P
9	Princeton	Princeton	B-NP	NNP	O	11	NMOD
10	,	,	O	,	O	11	P
11	NJ	NJ	B-NP	NNP	O	16	SUB
12	)	)	O	)	O	11	DEP
13	by	by	B-PP	IN	O	11	NMOD
14	3-hour	3-hour	B-NP	JJ	O	15	NMOD
15	infusion	infusion	I-NP	NN	O	13	PMOD
16	was	be	B-VP	VBD	O	2	SBAR
17	combined	combine	I-VP	VBN	O	16	VC
18	with	with	B-PP	IN	O	17	VMOD
19	carboplatin	carboplatin	B-NP	NN	B-protein	18	PMOD
20	in	in	B-PP	IN	O	17	VMOD
21	a	a	B-NP	DT	O	24	NMOD
22	phase	phase	I-NP	NN	O	24	NMOD
23	I/II	I/II	I-NP	NN	O	24	NMOD
24	study	study	I-NP	NN	O	20	PMOD
25	directed	direct	B-VP	VBN	O	24	NMOD
26	to	to	B-PP	TO	O	25	VMOD
27	patients	patient	B-NP	NNS	O	26	PMOD
28	with	with	B-PP	IN	O	27	NMOD
29	non-small	non-small	B-NP	JJ	O	32	NMOD
30	cell	cell	I-NP	NN	O	32	NMOD
31	lung	lung	I-NP	NN	O	32	NMOD
32	cancer	cancer	I-NP	NN	O	28	PMOD
33	.	.	O	.	O	1	P

1	Toxicities	Toxicity	B-NP	NNS	O	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	compared	compare	I-VP	VBN	O	2	VC
4	with	with	B-PP	IN	O	3	VMOD
5	a	a	B-NP	DT	O	6	NMOD
6	cohort	cohort	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	patients	patient	B-NP	NNS	O	7	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	a	a	B-NP	DT	O	13	NMOD
11	phase	phase	I-NP	NN	O	13	NMOD
12	I	I	I-NP	CD	O	13	NMOD
13	trial	trial	I-NP	NN	O	9	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	paclitaxel	paclitaxel	B-NP	NN	O	14	PMOD
16	alone	alone	B-ADVP	RB	O	15	NMOD
17	at	at	B-PP	IN	O	6	NMOD
18	identical	identical	B-NP	JJ	O	20	NMOD
19	dose	dose	I-NP	NN	O	20	NMOD
20	levels	level	I-NP	NNS	O	17	PMOD
21	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	dose-dependent	dose-dependent	I-NP	JJ	O	3	NMOD
3	effect	effect	I-NP	NN	O	8	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	misoprostol	misoprostol	B-NP	NN	O	4	PMOD
6	on	on	B-PP	IN	O	3	NMOD
7	indomethacin	indomethacin	B-NP	NN	O	6	PMOD
8	induced	induce	B-VP	VBD	O	0	ROOT
9	renal	renal	B-NP	JJ	O	10	NMOD
10	dysfunction	dysfunction	I-NP	NN	O	8	OBJ
11	in	in	B-PP	IN	O	8	VMOD
12	well	well	B-NP	RB	O	13	AMOD
13	compensated	compensate	I-NP	VBN	O	14	NMOD
14	cirrhosis	cirrhosis	I-NP	NN	O	11	PMOD
15	.	.	O	.	O	8	P

1	Misoprostol	Misoprostol	B-NP	NN	O	6	SUB
2	(	(	O	(	O	5	DEP
3	200	200	B-NP	CD	O	4	NMOD
4	micrograms	microgram	I-NP	NNS	O	5	DEP
5	)	)	O	)	O	1	NMOD
6	has	have	B-VP	VBZ	O	0	ROOT
7	been	be	I-VP	VBN	O	6	VC
8	shown	show	I-VP	VBN	O	7	VC
9	to	to	I-VP	TO	O	11	VMOD
10	acutely	acutely	I-VP	RB	O	11	VMOD
11	counteract	counteract	I-VP	VB	O	8	VMOD
12	the	the	B-NP	DT	O	13	NMOD
13	indomethacin	indomethacin	I-NP	NN	O	16	NMOD
14	induced	induce	B-VP	VBD	O	13	AMOD
15	renal	renal	B-NP	JJ	O	16	NMOD
16	dysfunction	dysfunction	I-NP	NN	O	11	OBJ
17	in	in	B-PP	IN	O	11	VMOD
18	well	well	B-NP	RB	O	19	AMOD
19	compensated	compensate	I-NP	VBN	O	21	NMOD
20	cirrhotic	cirrhotic	I-NP	JJ	O	21	NMOD
21	patients	patient	I-NP	NNS	O	17	PMOD
22	.	.	O	.	O	6	P

1	Parameters	Parameter	B-NP	NNS	O	11	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	renal	renal	B-NP	JJ	O	4	NMOD
4	hemodynamics	hemodynamic	I-NP	NNS	O	10	NMOD
5	and	and	O	CC	O	10	NMOD
6	tubular	tubular	B-NP	JJ	O	7	NMOD
7	sodium	sodium	I-NP	NN	O	10	NMOD
8	and	and	O	CC	O	10	NMOD
9	water	water	B-NP	NN	O	10	NMOD
10	handling	handling	I-NP	NN	O	2	PMOD
11	were	be	B-VP	VBD	O	0	ROOT
12	assessed	assess	I-VP	VBN	O	11	VC
13	by	by	B-PP	IN	O	12	VMOD
14	clearance	clearance	B-NP	NN	O	15	NMOD
15	techniques	technique	I-NP	NNS	O	13	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	26	26	B-NP	CD	O	21	NMOD
18	well	well	I-NP	RB	O	19	AMOD
19	compensated	compensate	I-NP	VBN	O	21	NMOD
20	cirrhotic	cirrhotic	I-NP	JJ	O	21	NMOD
21	patients	patient	I-NP	NNS	O	16	PMOD
22	before	before	B-PP	IN	O	12	VMOD
23	and	and	I-PP	CC	O	22	PMOD
24	after	after	I-PP	IN	O	22	PMOD
25	an	an	B-NP	DT	O	27	NMOD
26	oral	oral	I-NP	JJ	O	27	NMOD
27	combination	combination	I-NP	NN	O	22	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	50	50	B-NP	CD	O	30	NMOD
30	mg	mg	I-NP	NN	O	35	NMOD
31	of	of	B-PP	IN	O	30	NMOD
32	indomethacin	indomethacin	B-NP	NN	O	31	PMOD
33	and	and	O	CC	O	35	NMOD
34	various	various	B-NP	JJ	O	35	NMOD
35	doses	dose	I-NP	NNS	O	28	PMOD
36	of	of	B-PP	IN	O	35	NMOD
37	misoprostol	misoprostol	B-NP	NN	O	36	PMOD
38	.	.	O	.	O	11	P

1	Increased	Increase	B-NP	VBN	O	4	NMOD
2	frequency	frequency	I-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	severity	severity	I-NP	NN	O	0	ROOT
5	of	of	B-PP	IN	O	4	NMOD
6	angio-oedema	angio-oedema	B-NP	NN	O	5	PMOD
7	related	relate	B-VP	VBN	O	6	NMOD
8	to	to	B-PP	TO	O	7	AMOD
9	long-term	long-term	B-NP	JJ	O	10	NMOD
10	therapy	therapy	I-NP	NN	O	8	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	angiotensin-converting	angiotensin-converting	B-NP	JJ	B-protein	14	NMOD
13	enzyme	enzyme	I-NP	NN	I-protein	14	NMOD
14	inhibitor	inhibitor	I-NP	NN	O	11	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	two	two	B-NP	CD	O	17	NMOD
17	patients	patient	I-NP	NNS	O	15	PMOD
18	.	.	O	.	O	4	P

1	Angiotensin-converting	Angiotensin-converting	B-NP	JJ	B-protein	2	NMOD
2	enzyme	enzyme	I-NP	NN	I-protein	6	NMOD
3	(	(	O	(	O	5	DEP
4	ACE	ACE	B-NP	NN	O	5	DEP
5	)	)	O	)	O	2	NMOD
6	inhibitors	inhibitor	B-NP	NNS	O	17	SUB
7	,	,	O	,	O	6	P
8	used	use	B-VP	VBN	O	6	NMOD
9	to	to	B-VP	TO	O	10	VMOD
10	treat	treat	I-VP	VB	O	8	VMOD
11	hypertension	hypertension	B-NP	NN	O	15	NMOD
12	and	and	O	CC	O	15	NMOD
13	congestive	congestive	B-NP	JJ	O	15	NMOD
14	heart	heart	I-NP	NN	O	15	NMOD
15	failure	failure	I-NP	NN	O	10	OBJ
16	,	,	O	,	O	6	P
17	were	be	B-VP	VBD	O	30	VMOD
18	introduced	introduce	I-VP	VBN	O	17	VC
19	in	in	B-PP	IN	O	18	VMOD
20	Europe	Europe	B-NP	NNP	O	19	PMOD
21	in	in	B-PP	IN	O	18	VMOD
22	the	the	B-NP	DT	O	23	NMOD
23	middle	middle	I-NP	NN	O	21	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	the	the	B-NP	DT	O	26	NMOD
26	eighties	eighty	I-NP	NNS	O	24	PMOD
27	,	,	O	,	O	30	P
28	and	and	O	CC	O	30	NMOD
29	the	the	B-NP	DT	O	30	NMOD
30	use	use	I-NP	NN	O	34	SUB
31	of	of	B-PP	IN	O	30	NMOD
32	these	these	B-NP	DT	O	33	NMOD
33	drugs	drug	I-NP	NNS	O	31	PMOD
34	has	have	B-VP	VBZ	O	0	ROOT
35	increased	increase	I-VP	VBN	O	34	VC
36	progressively	progressively	B-ADVP	RB	O	35	VMOD
37	.	.	O	.	O	34	P

1	Soon	Soon	B-PP	RB	O	2	DEP
2	after	after	I-PP	IN	O	13	VMOD
3	the	the	B-NP	DT	O	4	NMOD
4	introduction	introduction	I-NP	NN	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	ACE	ACE	B-NP	NN	O	7	NMOD
7	inhibitors	inhibitor	I-NP	NNS	O	5	PMOD
8	,	,	O	,	O	13	P
9	acute	acute	B-NP	JJ	O	10	NMOD
10	bouts	bout	I-NP	NNS	O	13	SUB
11	of	of	B-PP	IN	O	10	NMOD
12	angio-oedema	angio-oedema	B-NP	NN	O	11	PMOD
13	were	be	B-VP	VBD	O	0	ROOT
14	reported	report	I-VP	VBN	O	13	VC
15	in	in	B-PP	IN	O	14	VMOD
16	association	association	B-NP	NN	O	15	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	19	NMOD
19	use	use	I-NP	NN	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	these	these	B-NP	DT	O	22	NMOD
22	drugs	drug	I-NP	NNS	O	20	PMOD
23	.	.	O	.	O	13	P

1	Myoclonus	Myoclonus	B-NP	NN	O	0	ROOT
2	associated	associate	B-VP	VBN	O	1	NMOD
3	with	with	B-PP	IN	O	2	VMOD
4	lorazepam	lorazepam	B-NP	NN	O	5	NMOD
5	therapy	therapy	I-NP	NN	O	3	PMOD
6	in	in	B-PP	IN	O	5	NMOD
7	very-low-birth-weight	very-low-birth-weight	B-NP	JJ	O	8	NMOD
8	infants	infant	I-NP	NNS	O	6	PMOD
9	.	.	O	.	O	1	P

1	Three	Three	B-NP	CD	O	3	NMOD
2	young	young	I-NP	JJ	O	3	NMOD
3	infants	infant	I-NP	NNS	O	15	SUB
4	,	,	O	,	O	3	P
5	all	all	B-NP	DT	O	3	NMOD
6	of	of	B-PP	IN	O	5	NMOD
7	birth	birth	B-NP	NN	O	13	NMOD
8	weight	weight	I-NP	NN	O	13	NMOD
9	<	<	B-NP	SYM	O	13	NMOD
10	1	1	I-NP	CD	O	13	NMOD
11	,	,	I-NP	,	O	13	P
12	500	500	I-NP	CD	O	13	NMOD
13	g	g	I-NP	NN	O	6	PMOD
14	,	,	O	,	O	3	P
15	experienced	experience	B-VP	VBD	O	0	ROOT
16	myoclonus	myoclonus	B-NP	NN	O	15	OBJ
17	following	follow	B-PP	VBG	O	16	NMOD
18	the	the	B-NP	DT	O	20	NMOD
19	intravenous	intravenous	I-NP	JJ	O	20	NMOD
20	administration	administration	I-NP	NN	O	17	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	lorazepam	lorazepam	B-NP	NN	O	21	PMOD
23	.	.	O	.	O	15	P

1	Three	Three	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	3	SUB
3	had	have	B-VP	VBD	O	19	VMOD
4	acute	acute	B-NP	JJ	O	6	NMOD
5	viral	viral	I-NP	JJ	O	6	NMOD
6	myocarditis	myocarditis	I-NP	NN	O	3	OBJ
7	,	,	O	,	O	3	P
8	one	one	B-NP	CD	O	3	OBJ
9	had	have	B-VP	VBD	O	3	VMOD
10	a	a	B-NP	DT	O	11	NMOD
11	carbamazepine	carbamazepine	I-NP	NN	O	9	OBJ
12	induced	induce	B-VP	VBD	O	9	VMOD
13	acute	acute	B-NP	JJ	O	15	NMOD
14	eosinophilic	eosinophilic	I-NP	JJ	O	15	NMOD
15	myocarditis	myocarditis	I-NP	NN	O	12	OBJ
16	,	,	O	,	O	19	P
17	and	and	O	CC	O	18	NMOD
18	one	one	B-NP	CD	O	19	SUB
19	had	have	B-VP	VBD	O	0	ROOT
20	cardiac	cardiac	B-NP	JJ	O	21	NMOD
21	hemosiderosis	hemosiderosis	I-NP	NN	O	19	OBJ
22	resulting	result	B-VP	VBG	O	21	NMOD
23	in	in	B-PP	IN	O	22	VMOD
24	acute	acute	B-NP	JJ	O	26	NMOD
25	cardiogenic	cardiogenic	I-NP	JJ	O	26	NMOD
26	shock	shock	I-NP	NN	O	23	PMOD
27	.	.	O	.	O	19	P

1	Efficacy	Efficacy	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	safety	safety	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	granisetron	granisetron	B-NP	NN	O	11	NMOD
6	,	,	O	,	O	11	P
7	a	a	B-NP	DT	O	11	NMOD
8	selective	selective	I-NP	JJ	O	11	NMOD
9	5-hydroxytryptamine-3	5-hydroxytryptamine-3	I-NP	NN	O	11	NMOD
10	receptor	receptor	I-NP	NN	O	11	NMOD
11	antagonist	antagonist	I-NP	NN	O	4	PMOD
12	,	,	O	,	O	3	P
13	in	in	B-PP	IN	O	3	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	prevention	prevention	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	nausea	nausea	B-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	vomiting	vomiting	I-NP	NN	O	16	PMOD
20	induced	induce	B-VP	VBN	O	19	NMOD
21	by	by	B-PP	IN	O	20	VMOD
22	high-dose	high-dose	B-NP	JJ	B-protein	23	NMOD
23	cisplatin	cisplatin	I-NP	NN	I-protein	21	PMOD
24	.	.	O	.	O	3	P

1	PURPOSE	PURPOSE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	assess	assess	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	7	NMOD
6	antiemetic	antiemetic	I-NP	JJ	O	7	NMOD
7	effects	effect	I-NP	NNS	O	10	NMOD
8	and	and	O	CC	O	10	NMOD
9	safety	safety	B-NP	NN	O	10	NMOD
10	profile	profile	I-NP	NN	O	4	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	four	four	B-NP	CD	O	14	NMOD
13	different	different	I-NP	JJ	O	14	NMOD
14	doses	dose	I-NP	NNS	O	11	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	granisetron	granisetron	B-NP	NN	O	15	PMOD
17	(	(	O	(	O	4	VMOD
18	Kytril	Kytril	B-NP	NNP	O	42	VMOD
19	;	;	O	:	O	42	P
20	SmithKline	SmithKline	B-NP	NNP	O	21	NMOD
21	Beecham	Beecham	I-NP	NNP	O	42	SUB
22	Pharmaceuticals	Pharmaceutical	I-NP	NNPS	O	42	VMOD
23	,	,	O	,	O	42	P
24	Philadelphia	Philadelphia	B-NP	NNP	O	26	NMOD
25	,	,	O	,	O	26	P
26	PA	PA	B-NP	NNP	O	42	SUB
27	)	)	O	)	O	26	DEP
28	when	when	B-ADVP	WRB	O	42	VMOD
29	administered	administer	B-VP	VBN	O	28	SBAR
30	as	as	B-PP	IN	O	29	VMOD
31	a	a	B-NP	DT	O	33	NMOD
32	single	single	I-NP	JJ	O	33	NMOD
33	intravenous	intravenous	I-NP	JJ	O	30	PMOD
34	(	(	O	(	O	36	DEP
35	IV	IV	O	CD	O	36	DEP
36	)	)	O	)	O	33	NMOD
37	dose	dose	B-NP	NN	O	33	NMOD
38	for	for	B-PP	IN	O	33	NMOD
39	prophylaxis	prophylaxis	B-NP	NN	O	38	PMOD
40	of	of	B-PP	IN	O	39	NMOD
41	cisplatin	cisplatin	B-NP	NN	B-protein	40	PMOD
42	induced	induce	B-VP	VBD	O	17	SBAR
43	nausea	nausea	B-NP	NN	O	45	NMOD
44	and	and	I-NP	CC	O	45	NMOD
45	vomiting	vomiting	I-NP	NN	O	42	OBJ
46	.	.	O	.	O	4	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	After	After	B-PP	IN	O	1	NMOD
4	granisetron	granisetron	B-NP	NN	O	5	NMOD
5	doses	dose	I-NP	NNS	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	5	5	B-NP	CD	O	19	NMOD
8	,	,	I-NP	,	O	19	P
9	10	10	I-NP	CD	O	19	NMOD
10	,	,	I-NP	,	O	19	P
11	20	20	I-NP	CD	O	19	NMOD
12	,	,	O	,	O	19	P
13	and	and	O	CC	O	15	NMOD
14	40	40	B-NP	CD	O	15	NMOD
15	micrograms/kg	micrograms/kg	I-NP	NN	O	19	NMOD
16	,	,	O	,	O	19	P
17	a	a	B-NP	DT	O	19	NMOD
18	major	major	I-NP	JJ	O	19	NMOD
19	response	response	I-NP	NN	O	6	PMOD
20	(	(	O	(	O	19	NMOD
21	<	<	B-NP	SYM	O	23	P
22	or	or	O	CC	O	23	AMOD
23	=	=	B-VP	SYM	O	35	VMOD
24	two	two	B-NP	CD	O	23	AMOD
25	vomiting	vomit	B-VP	VBG	O	35	VMOD
26	or	or	I-VP	CC	O	25	VMOD
27	retching	retch	I-VP	VBG	O	28	NMOD
28	episodes	episode	B-NP	NNS	O	33	NMOD
29	,	,	O	,	O	33	P
30	and	and	O	CC	O	33	NMOD
31	no	no	B-NP	DT	O	33	NMOD
32	antiemetic	antiemetic	I-NP	JJ	O	33	NMOD
33	rescue	rescue	I-NP	NN	O	35	SUB
34	)	)	O	)	O	33	NMOD
35	was	be	B-VP	VBD	O	20	SBAR
36	recorded	record	I-VP	VBN	O	35	VC
37	in	in	B-PP	IN	O	36	VMOD
38	23	23	B-NP	CD	O	39	NMOD
39	%	%	I-NP	NN	O	49	NMOD
40	,	,	O	,	O	49	P
41	57	57	B-NP	CD	O	42	NMOD
42	%	%	I-NP	NN	O	49	NMOD
43	,	,	O	,	O	49	P
44	58	58	B-NP	CD	O	45	NMOD
45	%	%	I-NP	NN	O	49	NMOD
46	,	,	O	,	O	49	P
47	and	and	O	CC	O	49	NMOD
48	60	60	B-NP	CD	O	49	NMOD
49	%	%	I-NP	NN	O	37	PMOD
50	of	of	B-PP	IN	O	49	NMOD
51	patients	patient	B-NP	NNS	O	50	PMOD
52	,	,	O	,	O	36	P
53	respectively	respectively	B-ADVP	RB	O	36	VMOD
54	,	,	O	,	O	58	P
55	and	and	O	CC	O	58	NMOD
56	a	a	B-NP	DT	O	58	NMOD
57	complete	complete	I-NP	JJ	O	58	NMOD
58	response	response	I-NP	NN	O	35	VMOD
59	(	(	O	(	O	69	DEP
60	no	no	B-NP	DT	O	63	NMOD
61	vomiting	vomiting	I-NP	NN	O	63	NMOD
62	or	or	I-NP	CC	O	63	NMOD
63	retching	retching	I-NP	NN	O	68	NMOD
64	,	,	O	,	O	68	P
65	and	and	O	CC	O	68	NMOD
66	no	no	B-NP	DT	O	68	NMOD
67	antiemetic	antiemetic	I-NP	JJ	O	68	NMOD
68	rescue	rescue	I-NP	NN	O	69	DEP
69	)	)	O	)	O	58	NMOD
70	in	in	B-PP	IN	O	58	NMOD
71	18	18	B-NP	CD	O	72	NMOD
72	%	%	I-NP	NN	O	82	NMOD
73	,	,	O	,	O	82	P
74	41	41	B-NP	CD	O	75	NMOD
75	%	%	I-NP	NN	O	82	NMOD
76	,	,	O	,	O	82	P
77	40	40	B-NP	CD	O	78	NMOD
78	%	%	I-NP	NN	O	82	NMOD
79	,	,	O	,	O	82	P
80	and	and	O	CC	O	82	NMOD
81	47	47	B-NP	CD	O	82	NMOD
82	%	%	I-NP	NN	O	70	PMOD
83	of	of	B-PP	IN	O	82	NMOD
84	patients	patient	B-NP	NNS	O	83	PMOD
85	,	,	O	,	O	58	P
86	respectively	respectively	B-ADVP	RB	O	58	NMOD
87	.	.	O	.	O	1	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	11	NMOD
2	:	:	O	:	O	11	P
3	A	A	B-NP	DT	O	11	NMOD
4	single	single	I-NP	JJ	O	11	NMOD
5	10-	10-	I-NP	CD	O	11	NMOD
6	,	,	I-NP	,	O	11	P
7	20-	20-	I-NP	CD	O	11	NMOD
8	,	,	O	,	O	11	P
9	or	or	O	CC	O	11	NMOD
10	40-micrograms/kg	40-micrograms/kg	B-NP	JJ	O	11	NMOD
11	dose	dose	I-NP	NN	O	14	SUB
12	of	of	B-PP	IN	O	11	NMOD
13	granisetron	granisetron	B-NP	NN	O	12	PMOD
14	was	be	B-VP	VBD	O	0	ROOT
15	effective	effective	B-ADJP	JJ	O	14	PRD
16	in	in	B-PP	IN	O	15	AMOD
17	controlling	control	B-VP	VBG	O	16	PMOD
18	vomiting	vomit	I-VP	VBG	O	17	OBJ
19	in	in	B-PP	IN	O	18	VMOD
20	57	57	B-NP	CD	O	24	NMOD
21	%	%	I-NP	NN	O	24	NMOD
22	to	to	I-NP	TO	O	24	NMOD
23	60	60	I-NP	CD	O	24	NMOD
24	%	%	I-NP	NN	O	19	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	patients	patient	B-NP	NNS	O	25	PMOD
27	who	who	B-NP	WP	O	26	NMOD
28	received	receive	B-VP	VBD	O	27	SBAR
29	cisplatin	cisplatin	B-NP	NN	O	28	OBJ
30	at	at	B-PP	IN	O	28	VMOD
31	doses	dose	B-NP	NNS	O	30	PMOD
32	greater	great	B-ADJP	JJR	O	31	NMOD
33	than	than	B-PP	IN	O	32	AMOD
34	81	81	B-NP	CD	O	35	NMOD
35	mg/m2	mg/m2	I-NP	NN	O	33	PMOD
36	and	and	O	CC	O	14	VMOD
37	totally	totally	B-VP	RB	O	38	VMOD
38	prevented	prevent	I-VP	VBD	O	14	VMOD
39	vomiting	vomit	I-VP	VBG	O	38	VMOD
40	in	in	B-PP	IN	O	39	VMOD
41	40	40	B-NP	CD	O	45	NMOD
42	%	%	I-NP	NN	O	45	NMOD
43	to	to	I-NP	TO	O	45	NMOD
44	47	47	I-NP	CD	O	45	NMOD
45	%	%	I-NP	NN	O	40	PMOD
46	of	of	B-PP	IN	O	45	NMOD
47	patients	patient	B-NP	NNS	O	46	PMOD
48	.	.	O	.	O	14	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	report	report	I-VP	VB	O	1	NMOD
5	two	two	B-NP	CD	O	6	NMOD
6	cases	case	I-NP	NNS	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	a	a	B-NP	DT	O	11	NMOD
9	possible	possible	I-NP	JJ	O	11	NMOD
10	adverse	adverse	I-NP	JJ	O	11	NMOD
11	interaction	interaction	I-NP	NN	O	7	PMOD
12	between	between	B-PP	IN	O	11	NMOD
13	clonidine	clonidine	B-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	verapamil	verapamil	I-NP	NN	O	12	PMOD
16	resulting	result	B-VP	VBG	O	6	NMOD
17	in	in	B-PP	IN	O	16	VMOD
18	atrioventricular	atrioventricular	B-NP	JJ	O	17	PMOD
19	(	(	O	(	O	21	DEP
20	AV	AV	B-NP	NN	O	21	DEP
21	)	)	O	)	O	18	AMOD
22	block	block	B-NP	NN	O	18	NMOD
23	in	in	B-PP	IN	O	18	NMOD
24	both	both	B-NP	DT	O	28	NMOD
25	patients	patient	B-NP	NNS	O	28	NMOD
26	and	and	O	CC	O	28	NMOD
27	severe	severe	B-NP	JJ	O	28	NMOD
28	hypotension	hypotension	I-NP	NN	O	23	PMOD
29	in	in	B-PP	IN	O	16	VMOD
30	one	one	B-NP	CD	O	31	NMOD
31	patient	patient	I-NP	NN	O	29	PMOD
32	.	.	O	.	O	1	P

1	CASE	CASE	B-NP	NN	O	2	NMOD
2	SUMMARIES	SUMMARIES	I-NP	NNS	O	0	ROOT
3	:	:	O	:	O	2	P
4	A	A	B-NP	DT	O	6	NMOD
5	54-year-old	54-year-old	I-NP	JJ	O	6	NMOD
6	woman	woman	I-NP	NN	O	9	SUB
7	with	with	B-PP	IN	O	6	NMOD
8	hyperaldosteronism	hyperaldosteronism	B-NP	NN	O	7	PMOD
9	was	be	B-VP	VBD	O	2	NMOD
10	treated	treat	I-VP	VBN	O	9	VC
11	with	with	B-PP	IN	O	10	VMOD
12	verapamil	verapamil	B-NP	NN	O	14	NMOD
13	480	480	I-NP	CD	O	14	NMOD
14	mg/d	mg/d	I-NP	NN	O	18	NMOD
15	and	and	I-NP	CC	O	18	NMOD
16	spironolactone	spironolactone	I-NP	NN	O	18	NMOD
17	100	100	I-NP	CD	O	18	NMOD
18	mg/d	mg/d	I-NP	NN	O	11	PMOD
19	.	.	O	.	O	2	P

1	After	After	B-PP	IN	O	17	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	addition	addition	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	a	a	B-NP	DT	O	7	NMOD
6	minimal	minimal	I-NP	JJ	O	7	NMOD
7	dose	dose	I-NP	NN	O	4	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	clonidine	clonidine	B-NP	NN	O	8	PMOD
10	(	(	O	(	O	14	DEP
11	0.15	0.15	B-NP	CD	O	12	AMOD
12	mg	mg	I-NP	NN	O	13	NMOD
13	bid	bid	I-NP	NN	O	14	DEP
14	)	)	O	)	O	7	NMOD
15	,	,	O	,	O	17	P
16	she	she	B-NP	PRP	O	17	SUB
17	developed	develop	B-VP	VBD	O	0	ROOT
18	complete	complete	B-NP	JJ	O	20	NMOD
19	AV	AV	I-NP	NN	O	20	NMOD
20	block	block	I-NP	NN	O	23	NMOD
21	and	and	O	CC	O	23	NMOD
22	severe	severe	B-NP	JJ	O	23	NMOD
23	hypotension	hypotension	I-NP	NN	O	17	OBJ
24	,	,	O	,	O	23	P
25	which	which	B-NP	WDT	O	23	NMOD
26	resolved	resolve	B-VP	VBD	O	25	SBAR
27	upon	upon	B-PP	IN	O	26	VMOD
28	cessation	cessation	B-NP	NN	O	27	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	all	all	B-NP	DT	O	31	NMOD
31	medications	medication	I-NP	NNS	O	29	PMOD
32	.	.	O	.	O	17	P

1	After	After	B-PP	IN	O	0	ROOT
2	the	the	B-NP	DT	O	3	NMOD
3	addition	addition	I-NP	NN	O	10	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	clonidine	clonidine	B-NP	NN	O	7	NMOD
6	0.15	0.15	I-NP	CD	O	7	NMOD
7	mg	mg	I-NP	NN	O	4	PMOD
8	bid	bid	B-ADVP	RB	O	10	VMOD
9	she	she	B-NP	PRP	O	10	SUB
10	developed	develop	B-VP	VBD	O	1	SBAR
11	complete	complete	B-NP	JJ	O	13	NMOD
12	AV	AV	I-NP	NN	O	13	NMOD
13	block	block	I-NP	NN	O	10	OBJ
14	,	,	O	,	O	1	P
15	which	which	B-NP	WDT	O	1	VMOD
16	resolved	resolve	B-VP	VBD	O	15	SBAR
17	after	after	B-PP	IN	O	16	VMOD
18	all	all	B-NP	DT	O	19	NMOD
19	therapy	therapy	I-NP	NN	O	20	SUB
20	was	be	B-VP	VBD	O	17	SBAR
21	stopped	stop	I-VP	VBN	O	20	VC
22	.	.	O	.	O	1	P

1	S-312	S-312	B-NP	NN	B-protein	3	NMOD
2	,	,	O	,	O	3	P
3	S-312-d	S-312-d	B-NP	NN	O	12	NMOD
4	,	,	O	,	O	12	P
5	but	but	O	CC	O	12	NMOD
6	not	not	O	RB	O	5	DEP
7	S-312-l	S-312-l	B-NP	NN	B-protein	12	NMOD
8	,	,	O	,	O	12	P
9	L-type	L-type	B-NP	JJ	O	12	NMOD
10	calcium	calcium	I-NP	NN	O	12	NMOD
11	channel	channel	I-NP	NN	O	12	NMOD
12	antagonists	antagonist	I-NP	NNS	O	14	SUB
13	,	,	O	,	O	12	P
14	showed	show	B-VP	VBD	O	0	ROOT
15	anticonvulsant	anticonvulsant	B-NP	JJ	O	16	NMOD
16	effects	effect	I-NP	NNS	O	14	OBJ
17	on	on	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	21	NMOD
19	audiogenic	audiogenic	I-NP	JJ	O	21	NMOD
20	tonic	tonic	I-NP	JJ	O	21	NMOD
21	convulsions	convulsion	I-NP	NNS	O	17	PMOD
22	in	in	B-PP	IN	O	21	NMOD
23	DBA/2	DBA/2	B-NP	NN	O	24	NMOD
24	mice	mouse	I-NP	NNS	O	22	PMOD
25	;	;	O	:	O	49	P
26	and	and	O	CC	O	29	NMOD
27	their	their	B-NP	PRP$	O	29	NMOD
28	ED50	ED50	I-NP	NN	O	29	NMOD
29	values	value	I-NP	NNS	O	30	SUB
30	were	be	B-VP	VBD	O	49	VMOD
31	18.4	18.4	B-NP	CD	O	35	NMOD
32	(	(	O	(	O	34	DEP
33	12.8-27.1	12.8-27.1	B-NP	CD	O	34	DEP
34	)	)	O	)	O	31	NMOD
35	mg/kg	mg/kg	B-NP	NN	O	39	NMOD
36	,	,	O	,	O	35	P
37	p.o.	p.o.	B-NP	FW	O	39	NMOD
38	and	and	O	CC	O	39	NMOD
39	15.0	15.0	B-NP	CD	O	43	NMOD
40	(	(	O	(	O	42	DEP
41	10.2-23.7	10.2-23.7	B-NP	CD	O	42	DEP
42	)	)	O	)	O	39	NMOD
43	mg/kg	mg/kg	B-NP	NN	O	30	PRD
44	,	,	O	,	O	43	P
45	p.o.	p.o.	B-NP	FW	O	43	NMOD
46	,	,	O	,	O	45	P
47	respectively	respectively	B-ADVP	RB	O	45	VMOD
48	,	,	O	,	O	49	P
49	while	while	B-SBAR	IN	O	14	VMOD
50	that	that	B-NP	DT	O	53	SUB
51	of	of	B-PP	IN	O	50	NMOD
52	flunarizine	flunarizine	B-NP	NN	O	51	PMOD
53	was	be	B-VP	VBD	O	49	SBAR
54	34.0	34.0	B-NP	CD	O	58	NMOD
55	(	(	O	(	O	57	DEP
56	26.0-44.8	26.0-44.8	B-NP	CD	O	57	DEP
57	)	)	O	)	O	54	NMOD
58	mg/kg	mg/kg	B-NP	NN	O	60	NMOD
59	,	,	O	,	O	60	P
60	p.o	p.o	B-NP	NN	O	53	PRD
61	.	.	O	.	O	14	P

1	Although	Although	B-SBAR	IN	O	36	VMOD
2	moderate	moderate	B-NP	JJ	O	3	AMOD
3	anticonvulsant	anticonvulsant	I-NP	JJ	O	4	NMOD
4	effects	effect	I-NP	NNS	O	10	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	S-312-d	S-312-d	B-NP	NN	O	5	PMOD
7	in	in	B-PP	IN	O	4	NMOD
8	higher	high	B-NP	JJR	O	9	NMOD
9	doses	dose	I-NP	NNS	O	7	PMOD
10	were	be	B-VP	VBD	O	1	SBAR
11	observed	observe	I-VP	VBN	O	10	VC
12	against	against	B-PP	IN	O	11	VMOD
13	the	the	B-NP	DT	O	15	NMOD
14	clonic	clonic	I-NP	JJ	O	15	NMOD
15	convulsions	convulsion	I-NP	NNS	O	12	PMOD
16	induced	induce	B-VP	VBN	O	15	NMOD
17	by	by	B-PP	IN	O	16	VMOD
18	pentylenetetrazole	pentylenetetrazole	B-NP	NN	O	26	NMOD
19	(	(	O	(	O	24	DEP
20	85	85	B-NP	CD	O	21	NMOD
21	mg/kg	mg/kg	I-NP	NN	O	23	NMOD
22	,	,	O	,	O	23	P
23	s.c.	s.c.	B-NP	NN	O	24	DEP
24	)	)	O	)	O	18	NMOD
25	or	or	O	CC	O	26	NMOD
26	bemegride	bemegride	B-NP	NN	O	17	PMOD
27	(	(	O	(	O	32	DEP
28	40	40	B-NP	CD	O	29	NMOD
29	mg/kg	mg/kg	I-NP	NN	O	32	DEP
30	,	,	O	,	O	29	P
31	s.c.	s.c.	B-ADVP	JJ	O	29	NMOD
32	)	)	O	)	O	26	NMOD
33	,	,	O	,	O	36	P
34	no	no	B-NP	DT	O	35	NMOD
35	effects	effect	I-NP	NNS	O	36	SUB
36	were	be	B-VP	VBD	O	0	ROOT
37	observed	observe	I-VP	VBN	O	36	VC
38	in	in	B-PP	IN	O	37	VMOD
39	convulsions	convulsion	B-NP	NNS	O	38	PMOD
40	induced	induce	B-VP	VBN	O	39	NMOD
41	by	by	B-PP	IN	O	40	VMOD
42	N-methyl-D-aspartate	N-methyl-D-aspartate	B-NP	NN	O	47	NMOD
43	,	,	O	,	O	47	P
44	picrotoxin	picrotoxin	B-NP	NN	O	47	NMOD
45	,	,	O	,	O	47	P
46	or	or	O	CC	O	47	NMOD
47	electroshock	electroshock	B-NP	NN	O	41	PMOD
48	in	in	B-PP	IN	O	47	NMOD
49	Slc	Slc	B-NP	NN	O	48	PMOD
50	:	:	O	:	O	36	P
51	ddY	ddY	B-NP	NN	O	52	NMOD
52	mice	mouse	I-NP	NNS	O	36	PRD
53	.	.	O	.	O	36	P

1	Transmural	Transmural	B-NP	JJ	O	3	NMOD
2	myocardial	myocardial	I-NP	JJ	O	3	NMOD
3	infarction	infarction	I-NP	NN	O	0	ROOT
4	with	with	B-PP	IN	O	3	NMOD
5	sumatriptan	sumatriptan	B-NP	NN	O	4	PMOD
6	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	47-year-old	47-year-old	I-NP	JJ	O	5	NMOD
5	woman	woman	I-NP	NN	O	2	OBJ
6	with	with	B-PP	IN	O	5	NMOD
7	an	an	B-NP	DT	O	10	NMOD
8	acute	acute	I-NP	JJ	O	10	NMOD
9	myocardial	myocardial	I-NP	JJ	O	10	NMOD
10	infarction	infarction	I-NP	NN	O	6	PMOD
11	after	after	B-PP	IN	O	10	NMOD
12	administration	administration	B-NP	NN	O	11	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	sumatriptan	sumatriptan	B-NP	NN	O	16	NMOD
15	6	6	I-NP	CD	O	16	NMOD
16	mg	mg	I-NP	NN	O	13	PMOD
17	subcutaneously	subcutaneously	B-ADVP	RB	O	18	PMOD
18	for	for	B-PP	IN	O	2	VMOD
19	cluster	cluster	B-NP	NN	O	20	NMOD
20	headache	headache	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	2	P

1	Flumazenil	Flumazenil	B-NP	NNP	O	2	SUB
2	induces	induce	B-VP	VBZ	O	0	ROOT
3	seizures	seizure	B-NP	NNS	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	death	death	I-NP	NN	O	2	OBJ
6	in	in	B-PP	IN	O	2	VMOD
7	mixed	mix	B-NP	VBN	O	9	NMOD
8	cocaine-diazepam	cocaine-diazepam	I-NP	NN	O	9	NMOD
9	intoxications	intoxication	I-NP	NNS	O	6	PMOD
10	.	.	O	.	O	2	P

1	STUDY	STUDY	B-NP	NN	O	2	NMOD
2	HYPOTHESIS	HYPOTHESIS	I-NP	NN	O	4	NMOD
3	:	:	O	:	O	2	P
4	Administration	Administration	B-NP	NN	O	10	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	9	NMOD
7	benzodiazepine	benzodiazepine	I-NP	NN	O	9	NMOD
8	antagonist	antagonist	I-NP	NN	O	9	NMOD
9	flumazenil	flumazenil	I-NP	NN	O	5	PMOD
10	may	may	B-VP	MD	O	0	ROOT
11	unmask	unmask	I-VP	VB	O	10	VC
12	seizures	seizure	B-NP	NNS	O	11	OBJ
13	in	in	B-PP	IN	O	12	NMOD
14	mixed	mix	B-NP	VBN	O	16	NMOD
15	cocaine-benzodiazepine	cocaine-benzodiazepine	I-NP	JJ	O	16	NMOD
16	intoxication	intoxication	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	10	P

1	Mechanisms	Mechanism	B-NP	NNS	O	0	ROOT
2	for	for	B-PP	IN	O	1	NMOD
3	protective	protective	B-NP	JJ	O	4	NMOD
4	effects	effect	I-NP	NNS	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	free	free	B-NP	JJ	O	8	NMOD
7	radical	radical	I-NP	NN	O	8	NMOD
8	scavengers	scavenger	I-NP	NNS	O	5	PMOD
9	on	on	B-PP	IN	O	4	NMOD
10	gentamicin-mediated	gentamicin-mediated	B-NP	JJ	O	11	NMOD
11	nephropathy	nephropathy	I-NP	NN	O	9	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	rats	rat	B-NP	NNS	O	12	PMOD
14	.	.	O	.	O	1	P

1	Studies	Study	B-NP	NNS	O	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	performed	perform	I-VP	VBN	O	2	VC
4	to	to	B-VP	TO	O	5	VMOD
5	examine	examine	I-VP	VB	O	3	VMOD
6	the	the	B-NP	DT	O	7	NMOD
7	mechanisms	mechanism	I-NP	NNS	O	5	OBJ
8	for	for	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	11	NMOD
10	protective	protective	I-NP	JJ	O	11	NMOD
11	effects	effect	I-NP	NNS	O	8	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	free	free	B-NP	JJ	O	15	NMOD
14	radical	radical	I-NP	NN	O	15	NMOD
15	scavengers	scavenger	I-NP	NNS	O	12	PMOD
16	on	on	B-PP	IN	O	11	NMOD
17	gentamicin	gentamicin	B-NP	NN	O	22	NMOD
18	(	(	I-NP	(	O	22	NMOD
19	GM	GM	I-NP	NN	O	22	NMOD
20	)	)	I-NP	)	O	22	NMOD
21	-mediated	-mediated	I-NP	JJ	O	22	NMOD
22	nephropathy	nephropathy	I-NP	NN	O	16	PMOD
23	.	.	O	.	O	2	P

1	Administration	Administration	B-NP	NN	O	13	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	GM	GM	B-NP	NNP	O	2	PMOD
4	at	at	B-PP	IN	O	1	NMOD
5	40	40	B-NP	CD	O	6	AMOD
6	mg/kg	mg/kg	I-NP	NN	O	7	NMOD
7	sc	sc	I-NP	NN	O	4	PMOD
8	for	for	B-PP	IN	O	7	NMOD
9	13	13	B-NP	CD	O	10	NMOD
10	days	day	I-NP	NNS	O	8	PMOD
11	to	to	B-PP	TO	O	10	NMOD
12	rats	rat	B-NP	NNS	O	11	PMOD
13	induced	induce	B-VP	VBD	O	0	ROOT
14	a	a	B-NP	DT	O	16	NMOD
15	significant	significant	I-NP	JJ	O	16	NMOD
16	reduction	reduction	I-NP	NN	O	13	OBJ
17	in	in	B-PP	IN	O	16	NMOD
18	renal	renal	B-NP	JJ	O	20	NMOD
19	blood	blood	I-NP	NN	O	20	NMOD
20	flow	flow	I-NP	NN	O	26	NMOD
21	(	(	O	(	O	23	DEP
22	RBF	RBF	B-NP	NN	B-protein	23	DEP
23	)	)	O	)	O	20	NMOD
24	and	and	O	CC	O	26	NMOD
25	inulin	inulin	B-NP	NN	O	26	NMOD
26	clearance	clearance	I-NP	NN	O	17	PMOD
27	(	(	O	(	O	29	DEP
28	CIn	CIn	B-NP	NN	B-protein	29	DEP
29	)	)	O	)	O	26	NMOD
30	as	as	B-CONJP	RB	O	17	DEP
31	well	well	I-CONJP	RB	O	30	DEP
32	as	as	I-CONJP	IN	O	30	DEP
33	marked	marked	B-NP	JJ	O	35	NMOD
34	tubular	tubular	I-NP	JJ	O	35	NMOD
35	damage	damage	I-NP	NN	O	17	PMOD
36	.	.	O	.	O	13	P

1	A	A	B-NP	DT	O	3	NMOD
2	significant	significant	I-NP	JJ	O	3	NMOD
3	reduction	reduction	I-NP	NN	O	19	NMOD
4	in	in	B-PP	IN	O	3	NMOD
5	urinary	urinary	B-NP	JJ	O	6	NMOD
6	guanosine	guanosine	I-NP	NN	O	15	NMOD
7	3	3	I-NP	CD	O	6	NMOD
8	'	'	I-NP	SYM	O	6	NMOD
9	,	,	I-NP	,	O	15	P
10	5'-cyclic	5'-cyclic	I-NP	JJ	O	11	NMOD
11	monophosphate	monophosphate	I-NP	NN	O	15	NMOD
12	(	(	O	(	O	14	DEP
13	cGMP	cGMP	B-NP	NN	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	excretion	excretion	B-NP	NN	O	4	PMOD
16	and	and	O	CC	O	19	NMOD
17	a	a	B-NP	DT	O	19	NMOD
18	significant	significant	I-NP	JJ	O	19	NMOD
19	increase	increase	I-NP	NN	O	27	SUB
20	in	in	B-PP	IN	O	19	NMOD
21	renal	renal	B-NP	JJ	O	22	NMOD
22	cortical	cortical	I-NP	JJ	O	20	PMOD
23	renin	renin	I-NP	NN	B-protein	22	NMOD
24	and	and	I-NP	CC	O	22	NMOD
25	endothelin-1	endothelin-1	I-NP	NN	O	22	NMOD
26	contents	content	I-NP	NNS	O	22	NMOD
27	were	be	B-VP	VBD	O	0	ROOT
28	also	also	I-VP	RB	O	27	VMOD
29	observed	observe	I-VP	VBN	O	27	VC
30	in	in	B-PP	IN	O	29	VMOD
31	GM-mediated	GM-mediated	B-NP	JJ	O	32	NMOD
32	nephropathy	nephropathy	I-NP	NN	O	30	PMOD
33	.	.	O	.	O	27	P

1	In	In	B-PP	IN	O	6	VMOD
2	contrast	contrast	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	6	P
4	DMTU	DMTU	B-NP	NN	O	6	SUB
5	significantly	significantly	B-ADVP	RB	O	6	VMOD
6	reduced	reduce	B-VP	VBD	O	16	VMOD
7	the	the	B-NP	DT	O	9	NMOD
8	tubular	tubular	I-NP	JJ	O	9	NMOD
9	damage	damage	I-NP	NN	O	12	NMOD
10	and	and	I-NP	CC	O	12	NMOD
11	lipid	lipid	I-NP	NN	O	12	NMOD
12	peroxidation	peroxidation	I-NP	NN	O	6	OBJ
13	,	,	O	,	O	16	P
14	but	but	O	CC	O	16	VMOD
15	it	it	B-NP	PRP	O	16	SUB
16	did	do	B-VP	VBD	O	0	ROOT
17	not	not	I-VP	RB	O	16	VMOD
18	affect	affect	I-VP	VB	O	16	VC
19	renal	renal	B-NP	JJ	O	20	NMOD
20	hemodynamics	hemodynamic	I-NP	NNS	O	23	NMOD
21	and	and	O	CC	O	23	NMOD
22	vasoactive	vasoactive	B-NP	JJ	O	23	NMOD
23	substances	substance	I-NP	NNS	O	18	OBJ
24	.	.	O	.	O	16	P

1	Central	Central	B-NP	JJ	O	3	NMOD
2	cardiovascular	cardiovascular	I-NP	JJ	O	3	NMOD
3	effects	effect	I-NP	NNS	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	AVP	AVP	B-NP	NN	B-protein	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	ANP	ANP	I-NP	NN	B-protein	4	PMOD
8	in	in	B-PP	IN	O	3	NMOD
9	normotensive	normotensive	B-NP	JJ	O	13	NMOD
10	and	and	I-NP	CC	O	13	NMOD
11	spontaneously	spontaneously	I-NP	RB	O	12	AMOD
12	hypertensive	hypertensive	I-NP	JJ	O	13	NMOD
13	rats	rat	I-NP	NNS	O	8	PMOD
14	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	purpose	purpose	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	present	present	I-NP	JJ	O	6	NMOD
6	study	study	I-NP	NN	O	3	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	to	to	B-VP	TO	O	9	VMOD
9	compare	compare	I-VP	VB	O	7	PRD
10	influence	influence	B-NP	NN	O	9	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	central	central	B-NP	JJ	O	14	NMOD
13	arginine	arginine	I-NP	NN	O	14	NMOD
14	vasopressin	vasopressin	I-NP	NN	O	11	PMOD
15	(	(	O	(	O	17	DEP
16	AVP	AVP	B-NP	NN	B-protein	17	DEP
17	)	)	O	)	O	14	NMOD
18	and	and	O	CC	O	11	PMOD
19	of	of	B-PP	IN	O	11	PMOD
20	atrial	atrial	B-NP	JJ	O	22	NMOD
21	natriuretic	natriuretic	I-NP	JJ	O	22	NMOD
22	peptide	peptide	I-NP	NN	O	19	PMOD
23	(	(	O	(	O	25	DEP
24	ANP	ANP	B-NP	NN	B-protein	25	DEP
25	)	)	O	)	O	22	NMOD
26	on	on	B-PP	IN	O	10	NMOD
27	control	control	B-NP	NN	O	26	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	arterial	arterial	B-NP	JJ	O	31	NMOD
30	blood	blood	I-NP	NN	O	31	NMOD
31	pressure	pressure	I-NP	NN	O	37	NMOD
32	(	(	O	(	O	34	DEP
33	MAP	MAP	B-NP	NN	O	34	DEP
34	)	)	O	)	O	31	NMOD
35	and	and	O	CC	O	37	NMOD
36	heart	heart	B-NP	NN	O	37	NMOD
37	rate	rate	I-NP	NN	O	28	PMOD
38	(	(	O	(	O	40	DEP
39	HR	HR	B-NP	NN	O	40	DEP
40	)	)	O	)	O	37	NMOD
41	in	in	B-PP	IN	O	9	VMOD
42	normotensive	normotensive	B-NP	JJ	O	48	AMOD
43	(	(	O	(	O	45	DEP
44	WKY	WKY	B-NP	NN	O	45	DEP
45	)	)	O	)	O	42	NMOD
46	and	and	O	CC	O	48	AMOD
47	spontaneously	spontaneously	B-ADJP	RB	O	48	AMOD
48	hypertensive	hypertensive	I-ADJP	JJ	O	41	PMOD
49	(	(	O	(	O	51	DEP
50	SHR	SHR	B-NP	NN	B-protein	51	DEP
51	)	)	O	)	O	48	AMOD
52	rats	rat	B-NP	NNS	O	48	NMOD
53	.	.	O	.	O	7	P

1	Sensitivity	Sensitivity	B-NP	NN	O	19	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	cardiac	cardiac	B-NP	JJ	O	4	NMOD
4	component	component	I-NP	NN	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	baroreflex	baroreflex	B-NP	NN	O	5	PMOD
7	(	(	O	(	O	9	DEP
8	CCB	CCB	B-NP	NN	B-protein	9	DEP
9	)	)	O	)	O	6	NMOD
10	,	,	O	,	O	1	P
11	expressed	express	B-VP	VBN	O	1	NMOD
12	as	as	B-PP	IN	O	11	VMOD
13	a	a	B-NP	DT	O	14	NMOD
14	slope	slope	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	18	NMOD
17	regression	regression	I-NP	NN	O	18	NMOD
18	line	line	I-NP	NN	O	15	PMOD
19	was	be	B-VP	VBD	O	0	ROOT
20	determined	determine	I-VP	VBN	O	19	VC
21	from	from	B-PP	IN	O	20	VMOD
22	relationships	relationship	B-NP	NNS	O	21	PMOD
23	between	between	B-PP	IN	O	22	NMOD
24	systolic	systolic	B-NP	JJ	O	26	NMOD
25	arterial	arterial	I-NP	JJ	O	26	NMOD
26	pressure	pressure	I-NP	NN	O	32	NMOD
27	(	(	O	(	O	29	DEP
28	SAP	SAP	B-NP	NN	B-protein	29	DEP
29	)	)	O	)	O	26	NMOD
30	and	and	O	CC	O	32	NMOD
31	HR	HR	B-NP	NN	O	32	NMOD
32	period	period	I-NP	NN	O	23	PMOD
33	(	(	O	(	O	35	DEP
34	HRp	HRp	B-NP	NN	B-protein	35	DEP
35	)	)	O	)	O	32	NMOD
36	during	during	B-PP	IN	O	20	VMOD
37	phenylephrine	phenylephrine	B-NP	NN	O	41	SUB
38	(	(	O	(	O	40	DEP
39	Phe	Phe	B-NP	NN	O	40	DEP
40	)	)	O	)	O	37	NMOD
41	induced	induce	B-VP	VBD	O	36	SBAR
42	hypertension	hypertension	B-NP	NN	O	45	NMOD
43	and	and	O	CC	O	45	NMOD
44	sodium	sodium	B-NP	NN	O	45	NMOD
45	nitroprusside	nitroprusside	I-NP	NN	O	50	NMOD
46	(	(	O	(	O	48	DEP
47	SN	SN	B-NP	NN	O	48	DEP
48	)	)	O	)	O	45	NMOD
49	induced	induce	B-NP	VBN	O	50	NMOD
50	hypotension	hypotension	I-NP	NN	O	41	OBJ
51	.	.	O	.	O	19	P

1	CCB	CCB	B-NP	NN	B-protein	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	reduced	reduce	I-VP	VBN	O	2	VC
4	in	in	B-PP	IN	O	3	VMOD
5	WKY	WKY	B-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	SHR	SHR	I-NP	NN	B-protein	4	PMOD
8	after	after	B-PP	IN	O	3	VMOD
9	LV	LV	B-NP	NN	O	10	NMOD
10	administration	administration	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	AVP	AVP	B-NP	NN	B-protein	11	PMOD
13	during	during	B-PP	IN	O	10	NMOD
14	SN	SN	B-NP	NN	O	16	NMOD
15	induced	induced	I-NP	JJ	O	16	NMOD
16	hypotension	hypotension	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	2	P

1	Cutaneous	Cutaneous	B-NP	JJ	O	2	NMOD
2	exposure	exposure	I-NP	NN	O	13	NMOD
3	to	to	B-PP	TO	O	2	NMOD
4	warfarin-like	warfarin-like	B-NP	JJ	O	5	NMOD
5	anticoagulant	anticoagulant	I-NP	NN	O	3	PMOD
6	causing	cause	B-VP	VBG	O	2	NMOD
7	an	an	B-NP	DT	O	9	NMOD
8	intracerebral	intracerebral	I-NP	JJ	O	9	NMOD
9	hemorrhage	hemorrhage	I-NP	NN	O	6	OBJ
10	:	:	O	:	O	2	P
11	a	a	B-NP	DT	O	13	NMOD
12	case	case	I-NP	NN	O	13	NMOD
13	report	report	I-NP	NN	O	0	ROOT
14	.	.	O	.	O	13	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	11	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	intercerebral	intercerebral	B-NP	JJ	O	5	NMOD
5	hematoma	hematoma	I-NP	NN	O	3	PMOD
6	due	due	B-ADJP	JJ	O	2	NMOD
7	to	to	B-PP	TO	O	6	AMOD
8	warfarin	warfarin	B-NP	NN	O	10	NMOD
9	induced	induced	I-NP	JJ	O	8	AMOD
10	coagulopathy	coagulopathy	I-NP	NN	O	7	PMOD
11	is	be	B-VP	VBZ	O	0	ROOT
12	presented	present	I-VP	VBN	O	11	VC
13	.	.	O	.	O	11	P

1	Percutaneous	Percutaneous	B-NP	JJ	O	2	NMOD
2	absorption	absorption	I-NP	NN	O	8	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	warfarin	warfarin	B-NP	NN	O	3	PMOD
5	causing	cause	B-VP	VBG	O	4	NMOD
6	coagulopathy	coagulopathy	B-NP	NN	O	5	OBJ
7	,	,	O	,	O	2	P
8	reported	report	B-VP	VBD	O	0	ROOT
9	three	three	B-NP	CD	O	10	NMOD
10	times	time	I-NP	NNS	O	8	OBJ
11	in	in	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	13	NMOD
13	past	past	I-NP	NN	O	11	PMOD
14	,	,	O	,	O	8	P
15	is	be	B-VP	VBZ	O	8	VMOD
16	a	a	B-NP	DT	O	18	NMOD
17	significant	significant	I-NP	JJ	O	18	NMOD
18	risk	risk	I-NP	NN	O	15	PRD
19	if	if	B-SBAR	IN	O	18	NMOD
20	protective	protective	B-NP	JJ	O	21	NMOD
21	measures	measure	I-NP	NNS	O	27	SUB
22	,	,	O	,	O	21	P
23	such	such	B-PP	JJ	O	24	PMOD
24	as	as	I-PP	IN	O	21	NMOD
25	gloves	glove	B-NP	NNS	O	24	PMOD
26	,	,	O	,	O	21	P
27	are	be	B-VP	VBP	O	19	SBAR
28	not	not	I-VP	RB	O	27	VMOD
29	used	use	I-VP	VBN	O	27	VC
30	.	.	O	.	O	8	P

1	Indications	Indication	B-NP	NNS	O	4	SUB
2	for	for	B-PP	IN	O	1	NMOD
3	transplantation	transplantation	B-NP	NN	O	2	PMOD
4	were	be	B-VP	VBD	O	0	ROOT
5	idiopathic	idiopathic	B-NP	JJ	O	6	NMOD
6	cardiomyopathy	cardiomyopathy	I-NP	NN	O	23	NMOD
7	(	(	O	(	O	10	DEP
8	52	52	B-NP	CD	O	9	NMOD
9	%	%	I-NP	NN	O	10	DEP
10	)	)	O	)	O	6	NMOD
11	,	,	O	,	O	23	P
12	congenital	congenital	B-NP	JJ	O	14	NMOD
13	heart	heart	I-NP	NN	O	14	NMOD
14	disease	disease	I-NP	NN	O	23	NMOD
15	(	(	O	(	O	18	DEP
16	35	35	B-NP	CD	O	17	NMOD
17	%	%	I-NP	NN	O	18	DEP
18	)	)	O	)	O	14	NMOD
19	with	with	B-PP	IN	O	14	NMOD
20	and	and	B-PP	CC	O	19	PMOD
21	without	without	B-PP	IN	O	19	PMOD
22	prior	prior	B-NP	JJ	O	23	NMOD
23	repair	repair	I-NP	NN	O	51	NMOD
24	(	(	O	(	O	32	DEP
25	71	71	B-NP	CD	O	26	NMOD
26	%	%	I-NP	NN	O	29	NMOD
27	and	and	O	CC	O	29	NMOD
28	29	29	B-NP	CD	O	29	NMOD
29	%	%	I-NP	NN	O	32	DEP
30	,	,	O	,	O	29	P
31	respectively	respectively	B-ADVP	RB	O	29	NMOD
32	)	)	O	)	O	23	NMOD
33	,	,	O	,	O	51	P
34	hypertrophic	hypertrophic	B-NP	JJ	O	35	NMOD
35	cardiomyopathy	cardiomyopathy	I-NP	NN	O	51	NMOD
36	(	(	O	(	O	39	DEP
37	5	5	B-NP	CD	O	38	NMOD
38	%	%	I-NP	NN	O	39	DEP
39	)	)	O	)	O	35	NMOD
40	,	,	O	,	O	51	P
41	valvular	valvular	B-NP	JJ	O	43	NMOD
42	heart	heart	I-NP	NN	O	43	NMOD
43	disease	disease	I-NP	NN	O	51	NMOD
44	(	(	O	(	O	47	DEP
45	3	3	B-NP	CD	O	46	NMOD
46	%	%	I-NP	NN	O	47	DEP
47	)	)	O	)	O	43	NMOD
48	,	,	O	,	O	51	P
49	and	and	O	CC	O	51	NMOD
50	doxorubicin	doxorubicin	B-NP	NN	O	51	NMOD
51	cardiomyopathy	cardiomyopathy	I-NP	NN	O	4	PRD
52	(	(	O	(	O	55	DEP
53	5	5	B-NP	CD	O	54	NMOD
54	%	%	I-NP	NN	O	55	DEP
55	)	)	O	)	O	51	NMOD
56	.	.	O	.	O	4	P

1	Cytomegalovirus	Cytomegalovirus	B-NP	NN	O	2	NMOD
2	infections	infection	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	0	ROOT
4	treated	treat	I-VP	VBN	O	3	VC
5	successfully	successfully	B-ADVP	RB	O	4	VMOD
6	with	with	B-PP	IN	O	4	VMOD
7	ganciclovir	ganciclovir	B-NP	NN	O	6	PMOD
8	in	in	B-PP	IN	O	4	VMOD
9	11	11	B-NP	CD	O	10	NMOD
10	patients	patient	I-NP	NNS	O	8	PMOD
11	.	.	O	.	O	3	P

1	Delirium	Delirium	B-NP	NN	O	0	ROOT
2	during	during	B-PP	IN	O	1	NMOD
3	fluoxetine	fluoxetine	B-NP	NN	O	4	NMOD
4	treatment	treatment	I-NP	NN	O	2	PMOD
5	.	.	O	.	O	1	P

1	In	In	B-PP	IN	O	19	VMOD
2	some	some	B-NP	DT	O	3	NMOD
3	cases	case	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	19	P
5	a	a	B-NP	DT	O	8	NMOD
6	high	high	I-NP	JJ	O	8	NMOD
7	serum	serum	I-NP	NN	O	8	NMOD
8	concentration	concentration	I-NP	NN	O	19	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	citalopram	citalopram	B-NP	NN	O	9	PMOD
11	(	(	O	(	O	15	DEP
12	>	>	B-NP	SYM	O	14	NMOD
13	600	600	B-NP	CD	O	14	NMOD
14	nmol/L	nmol/L	I-NP	NN	O	15	DEP
15	)	)	O	)	O	8	NMOD
16	in	in	B-PP	IN	O	8	NMOD
17	elderly	elderly	B-NP	JJ	O	18	NMOD
18	patients	patient	I-NP	NNS	O	16	PMOD
19	has	have	B-VP	VBZ	O	0	ROOT
20	been	be	I-VP	VBN	O	19	VC
21	associated	associate	I-VP	VBN	O	20	VC
22	with	with	B-PP	IN	O	21	VMOD
23	increased	increase	B-NP	VBN	O	27	NMOD
24	somnolence	somnolence	I-NP	NN	O	27	NMOD
25	and	and	I-NP	CC	O	27	NMOD
26	movement	movement	I-NP	NN	O	27	NMOD
27	difficulties	difficulty	I-NP	NNS	O	22	PMOD
28	.	.	O	.	O	19	P

1	Pulmonary	Pulmonary	B-NP	JJ	O	2	NMOD
2	edema	edema	I-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	shock	shock	I-NP	NN	O	12	NMOD
5	after	after	B-PP	IN	O	4	NMOD
6	high-dose	high-dose	B-NP	JJ	O	7	NMOD
7	aracytine-C	aracytine-C	I-NP	NN	O	5	PMOD
8	for	for	B-PP	IN	O	7	NMOD
9	lymphoma	lymphoma	B-NP	NN	O	8	PMOD
10	;	;	O	:	O	12	P
11	possible	possible	B-NP	JJ	O	12	NMOD
12	role	role	I-NP	NN	O	0	ROOT
13	of	of	B-PP	IN	O	12	NMOD
14	TNF-alpha	TNF-alpha	B-NP	NN	B-protein	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	PAF	PAF	I-NP	NN	B-protein	13	PMOD
17	.	.	O	.	O	12	P

1	Four	Four	B-NP	CD	O	3	AMOD
2	out	out	I-NP	IN	O	3	AMOD
3	of	of	I-NP	IN	O	0	ROOT
4	23	23	I-NP	CD	O	3	AMOD
5	consecutive	consecutive	I-NP	JJ	O	6	NMOD
6	patients	patient	I-NP	NNS	O	16	SUB
7	treated	treat	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	high-dose	high-dose	B-NP	JJ	O	10	NMOD
10	Ara-C	Ara-C	I-NP	NN	O	8	PMOD
11	for	for	B-PP	IN	O	10	NMOD
12	lymphomas	lymphoma	B-NP	NNS	O	11	PMOD
13	in	in	B-PP	IN	O	6	NMOD
14	our	our	B-NP	PRP$	O	15	NMOD
15	institution	institution	I-NP	NN	O	13	PMOD
16	developed	develop	B-VP	VBD	O	3	VMOD
17	a	a	B-NP	DT	O	20	NMOD
18	strikingly	strikingly	I-NP	RB	O	19	AMOD
19	similar	similar	I-NP	JJ	O	20	NMOD
20	syndrome	syndrome	I-NP	NN	O	16	OBJ
21	during	during	B-PP	IN	O	16	VMOD
22	the	the	B-NP	DT	O	23	NMOD
23	perfusion	perfusion	I-NP	NN	O	21	PMOD
24	.	.	O	.	O	3	P

1	Protective	Protective	B-NP	JJ	O	2	NMOD
2	effect	effect	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	clentiazem	clentiazem	B-NP	NN	O	3	PMOD
5	against	against	B-PP	IN	O	4	NMOD
6	epinephrine	epinephrine	B-NP	NN	O	5	PMOD
7	induced	induce	B-VP	VBD	O	0	ROOT
8	cardiac	cardiac	B-NP	JJ	O	9	NMOD
9	injury	injury	I-NP	NN	O	7	OBJ
10	in	in	B-PP	IN	O	7	VMOD
11	rats	rat	B-NP	NNS	O	10	PMOD
12	.	.	O	.	O	7	P

1	We	We	B-NP	PRP	O	2	SUB
2	investigated	investigate	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	effects	effect	I-NP	NNS	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	clentiazem	clentiazem	B-NP	NN	O	13	NMOD
7	,	,	O	,	O	13	P
8	a	a	B-NP	DT	O	13	NMOD
9	1	1	I-NP	CD	O	13	NMOD
10	,	,	O	,	O	13	P
11	5-benzothiazepine	5-benzothiazepine	B-NP	JJ	O	13	NMOD
12	calcium	calcium	I-NP	NN	O	13	NMOD
13	antagonist	antagonist	I-NP	NN	O	5	PMOD
14	,	,	O	,	O	4	P
15	on	on	B-PP	IN	O	4	NMOD
16	epinephrine	epinephrine	B-NP	NN	O	15	PMOD
17	induced	induce	B-VP	VBD	O	15	SBAR
18	cardiomyopathy	cardiomyopathy	B-NP	NN	O	17	OBJ
19	in	in	B-PP	IN	O	17	VMOD
20	rats	rat	B-NP	NNS	O	19	PMOD
21	.	.	O	.	O	2	P

1	With	With	B-PP	IN	O	26	VMOD
2	2-week	2-week	B-NP	JJ	O	5	NMOD
3	chronic	chronic	I-NP	JJ	O	5	NMOD
4	epinephrine	epinephrine	I-NP	NN	O	5	NMOD
5	infusion	infusion	I-NP	NN	O	1	PMOD
6	,	,	O	,	O	26	P
7	16	16	B-NP	CD	O	8	AMOD
8	of	of	B-PP	IN	O	21	NMOD
9	30	30	B-NP	CD	O	8	AMOD
10	rats	rat	I-NP	NNS	O	8	PMOD
11	died	die	B-VP	VBD	O	8	SBAR
12	within	within	B-PP	IN	O	11	VMOD
13	4	4	B-NP	CD	O	14	NMOD
14	days	day	I-NP	NNS	O	12	PMOD
15	,	,	O	,	O	21	P
16	and	and	O	CC	O	21	NMOD
17	severe	severe	B-NP	JJ	O	19	NMOD
18	ischemic	ischemic	I-NP	JJ	O	19	NMOD
19	lesions	lesion	I-NP	NNS	O	21	NMOD
20	and	and	O	CC	O	21	NMOD
21	fibrosis	fibrosis	B-NP	NN	O	26	SUB
22	of	of	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	25	NMOD
24	left	left	I-NP	JJ	O	25	NMOD
25	ventricles	ventricle	I-NP	NNS	O	22	PMOD
26	were	be	B-VP	VBD	O	0	ROOT
27	observed	observe	I-VP	VBN	O	26	VC
28	.	.	O	.	O	26	P

1	Treatment	Treatment	B-NP	NN	O	4	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	clentiazem	clentiazem	B-NP	NN	O	2	PMOD
4	prevented	prevent	B-VP	VBD	O	0	ROOT
5	epinephrine	epinephrine	B-NP	NN	O	7	NMOD
6	induced	induced	I-NP	JJ	O	7	NMOD
7	death	death	I-NP	NN	O	4	OBJ
8	(	(	O	(	O	12	DEP
9	P	P	B-NP	NN	O	12	DEP
10	<	<	B-NP	JJR	O	9	NMOD
11	.05	.05	I-NP	CD	O	10	AMOD
12	)	)	O	)	O	7	NMOD
13	,	,	O	,	O	4	P
14	and	and	O	CC	O	4	VMOD
15	attenuated	attenuate	B-VP	VBD	O	4	VMOD
16	the	the	B-NP	DT	O	19	NMOD
17	ventricular	ventricular	I-NP	JJ	O	19	NMOD
18	ischemic	ischemic	I-NP	JJ	O	19	NMOD
19	lesions	lesion	I-NP	NNS	O	15	OBJ
20	and	and	O	CC	O	15	VMOD
21	fibrosis	fibrosis	B-NP	NN	O	20	PMOD
22	,	,	O	,	O	21	P
23	in	in	B-PP	IN	O	21	NMOD
24	a	a	B-NP	DT	O	26	NMOD
25	dose-dependent	dose-dependent	I-NP	JJ	O	26	NMOD
26	manner	manner	I-NP	NN	O	23	PMOD
27	.	.	O	.	O	4	P

1	Cocaine	Cocaine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	myocardial	myocardial	B-NP	JJ	O	4	NMOD
4	ischemia	ischemia	I-NP	NN	O	2	OBJ
5	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	myocardial	myocardial	B-NP	JJ	O	7	NMOD
7	ischemia	ischemia	I-NP	NN	O	5	PMOD
8	induced	induce	B-VP	VBN	O	7	NMOD
9	by	by	B-PP	IN	O	8	VMOD
10	cocaine	cocaine	B-NP	NN	O	9	PMOD
11	.	.	O	.	O	2	P

1	Doxorubicin	Doxorubicin	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	cardiotoxicity	cardiotoxicity	B-NP	NN	O	2	OBJ
4	monitored	monitor	B-VP	VBN	O	3	NMOD
5	by	by	B-PP	IN	O	4	VMOD
6	ECG	ECG	B-NP	NN	B-protein	5	PMOD
7	in	in	B-PP	IN	O	4	VMOD
8	freely	freely	B-ADVP	RB	O	9	AMOD
9	moving	move	B-VP	VBG	O	7	PMOD
10	mice	mouse	B-NP	NNS	O	9	OBJ
11	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	6	VMOD
2	laboratory	laboratory	B-NP	NN	O	3	NMOD
3	animals	animal	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	6	P
5	histology	histology	B-NP	NN	O	6	SUB
6	is	be	B-VP	VBZ	O	0	ROOT
7	most	most	B-ADJP	RBS	O	8	AMOD
8	commonly	commonly	I-ADJP	RB	O	6	VMOD
9	used	use	I-ADJP	VBN	O	6	VC
10	to	to	B-VP	TO	O	11	VMOD
11	study	study	I-VP	VB	O	6	VMOD
12	doxorubicin	doxorubicin	B-NP	NN	O	14	NMOD
13	induced	induced	I-NP	JJ	O	14	NMOD
14	cardiotoxicity	cardiotoxicity	I-NP	NN	O	11	OBJ
15	.	.	O	.	O	6	P

1	After	After	B-PP	IN	O	8	VMOD
2	sacrifice	sacrifice	B-NP	NN	O	1	PMOD
3	the	the	B-NP	DT	O	4	NMOD
4	hearts	heart	I-NP	NNS	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	doxorubicin-treated	doxorubicin-treated	B-NP	JJ	O	7	NMOD
7	animals	animal	I-NP	NNS	O	5	PMOD
8	were	be	B-VP	VBD	O	13	VMOD
9	enlarged	enlarge	I-VP	VBN	O	8	VC
10	and	and	O	CC	O	13	VMOD
11	the	the	B-NP	DT	O	12	NMOD
12	atria	atria	I-NP	NN	O	13	SUB
13	were	be	B-VP	VBD	O	0	ROOT
14	hypertrophic	hypertrophic	B-ADJP	JJ	O	13	PRD
15	.	.	O	.	O	13	P

1	As	As	B-SBAR	IN	O	18	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	schedule	schedule	I-NP	NN	O	4	SUB
4	exerted	exert	B-VP	VBD	O	1	SBAR
5	more	more	B-NP	JJR	O	6	NMOD
6	toxicity	toxicity	I-NP	NN	O	4	OBJ
7	than	than	B-SBAR	IN	O	4	VMOD
8	needed	need	B-VP	VBN	O	7	SBAR
9	to	to	B-VP	TO	O	10	VMOD
10	investigate	investigate	I-VP	VB	O	8	VMOD
11	protective	protective	B-NP	JJ	O	12	NMOD
12	agents	agent	I-NP	NNS	O	10	OBJ
13	,	,	O	,	O	18	P
14	the	the	B-NP	DT	O	15	NMOD
15	protection	protection	I-NP	NN	O	18	SUB
16	of	of	B-PP	IN	O	15	NMOD
17	ICRF-187	ICRF-187	B-NP	NN	B-protein	16	PMOD
18	was	be	B-VP	VBD	O	0	ROOT
19	determined	determine	I-VP	VBN	O	18	VC
20	using	use	B-VP	VBG	O	18	VMOD
21	a	a	B-NP	DT	O	23	NMOD
22	dose	dose	I-NP	NN	O	23	NMOD
23	schedule	schedule	I-NP	NN	O	20	OBJ
24	with	with	B-PP	IN	O	23	NMOD
25	lower	low	B-NP	JJR	O	26	AMOD
26	general	general	I-NP	JJ	O	27	NMOD
27	toxicity	toxicity	I-NP	NN	O	24	PMOD
28	(	(	O	(	O	43	DEP
29	6	6	B-NP	CD	O	31	NMOD
30	weekly	weekly	I-NP	JJ	O	31	NMOD
31	doses	dose	I-NP	NNS	O	43	DEP
32	of	of	B-PP	IN	O	31	NMOD
33	4	4	B-NP	CD	O	35	NMOD
34	mg/kg	mg/kg	I-NP	NN	O	35	NMOD
35	doxorubicin	doxorubicin	I-NP	NN	O	40	NMOD
36	given	give	B-VP	VBN	O	35	AMOD
37	i.v.	i.v.	B-ADJP	JJ	O	39	AMOD
38	plus	plus	O	CC	O	39	AMOD
39	2	2	B-NP	CD	O	40	NMOD
40	weeks	week	I-NP	NNS	O	32	PMOD
41	of	of	B-PP	IN	O	40	NMOD
42	observation	observation	B-NP	NN	O	41	PMOD
43	)	)	O	)	O	27	NMOD
44	.	.	O	.	O	18	P

1	Since	Since	B-SBAR	IN	O	15	VMOD
2	bupivacaine	bupivacaine	B-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	epinephrine	epinephrine	I-NP	NN	O	5	SUB
5	may	may	B-VP	MD	O	1	SBAR
6	both	both	O	DT	O	5	VMOD
7	precipitate	precipitate	B-VP	VB	O	5	VC
8	dysrhythmias	dysrhythmia	B-NP	NNS	O	7	OBJ
9	,	,	O	,	O	15	P
10	circulating	circulate	B-VP	VBG	O	11	NMOD
11	bupivacaine	bupivacaine	B-NP	NN	O	15	SUB
12	during	during	B-PP	IN	O	11	NMOD
13	regional	regional	B-NP	JJ	O	14	NMOD
14	anesthesia	anesthesia	I-NP	NN	O	12	PMOD
15	could	could	B-VP	MD	O	0	ROOT
16	potentiate	potentiate	I-VP	VB	O	15	VC
17	dysrhythmogenic	dysrhythmogenic	B-NP	JJ	O	18	NMOD
18	effects	effect	I-NP	NNS	O	16	OBJ
19	of	of	B-PP	IN	O	18	NMOD
20	epinephrine	epinephrine	B-NP	NN	O	19	PMOD
21	.	.	O	.	O	15	P

1	We	We	B-NP	PRP	O	3	SUB
2	therefore	therefore	B-ADVP	RB	O	3	VMOD
3	examined	examine	B-VP	VBD	O	0	ROOT
4	whether	whether	B-SBAR	IN	O	3	VMOD
5	bupivacaine	bupivacaine	B-NP	NN	O	6	SUB
6	alters	alter	B-VP	VBZ	O	4	SBAR
7	the	the	B-NP	DT	O	8	NMOD
8	dysrhythmogenicity	dysrhythmogenicity	I-NP	NN	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	subsequent	subsequent	B-NP	JJ	O	11	NMOD
11	administration	administration	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	epinephrine	epinephrine	B-NP	NN	O	12	PMOD
14	in	in	B-PP	IN	O	6	VMOD
15	conscious	conscious	B-NP	JJ	O	17	AMOD
16	,	,	I-NP	,	O	17	P
17	healthy	healthy	I-NP	JJ	O	18	NMOD
18	dogs	dog	I-NP	NNS	O	14	PMOD
19	and	and	B-PP	CC	O	14	PMOD
20	in	in	B-PP	IN	O	14	PMOD
21	anesthetized	anesthetize	B-NP	VBN	O	22	NMOD
22	dogs	dog	I-NP	NNS	O	20	PMOD
23	with	with	B-PP	IN	O	22	NMOD
24	myocardial	myocardial	B-NP	JJ	O	25	NMOD
25	infarction	infarction	I-NP	NN	O	23	PMOD
26	.	.	O	.	O	3	P

1	One	One	B-NP	CD	O	2	NMOD
2	day	day	I-NP	NN	O	11	NMOD
3	after	after	B-PP	IN	O	2	NMOD
4	experimental	experimental	B-NP	JJ	O	6	NMOD
5	myocardial	myocardial	I-NP	JJ	O	6	NMOD
6	infarction	infarction	I-NP	NN	O	3	PMOD
7	,	,	O	,	O	11	P
8	six	six	B-NP	CD	O	11	NMOD
9	additional	additional	I-NP	JJ	O	10	AMOD
10	halothane-anesthetized	halothane-anesthetized	I-NP	JJ	O	11	NMOD
11	dogs	dog	I-NP	NNS	O	12	SUB
12	received	receive	B-VP	VBD	O	0	ROOT
13	4	4	B-NP	CD	O	15	NMOD
14	micrograms.kg-1.min-1	micrograms.kg-1.min-1	I-NP	NN	O	15	NMOD
15	epinephrine	epinephrine	I-NP	NN	O	12	OBJ
16	until	until	B-SBAR	IN	O	12	VMOD
17	VT	VT	B-NP	NN	O	18	SUB
18	appeared	appear	B-VP	VBD	O	16	SBAR
19	.	.	O	.	O	12	P

1	Bupivacaine	Bupivacaine	B-NP	NN	O	2	SUB
2	antagonizes	antagonize	B-VP	VBZ	O	0	ROOT
3	epinephrine	epinephrine	B-NP	NN	O	4	NMOD
4	dysrhythmogenicity	dysrhythmogenicity	I-NP	NN	O	2	OBJ
5	in	in	B-PP	IN	O	4	NMOD
6	conscious	conscious	B-NP	JJ	O	7	NMOD
7	dogs	dog	I-NP	NNS	O	5	PMOD
8	susceptible	susceptible	B-ADJP	JJ	O	7	NMOD
9	to	to	B-PP	TO	O	8	AMOD
10	VT	VT	B-NP	NN	O	9	PMOD
11	and	and	O	CC	O	8	AMOD
12	in	in	B-PP	IN	O	11	PMOD
13	anesthetized	anesthetize	B-NP	VBN	O	14	NMOD
14	dogs	dog	I-NP	NNS	O	12	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	spontaneous	spontaneous	B-NP	JJ	O	18	NMOD
17	postinfarct	postinfarct	I-NP	JJ	O	18	NMOD
18	dysrhythmias	dysrhythmia	I-NP	NNS	O	15	PMOD
19	.	.	O	.	O	2	P

1	Milk-alkali	Milk-alkali	B-NP	JJ	O	2	NMOD
2	syndrome	syndrome	I-NP	NN	O	0	ROOT
3	induced	induce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	1	1	B-NP	CD	O	11	NMOD
6	,	,	I-NP	,	O	11	P
7	25	25	I-NP	CD	O	11	NMOD
8	(	(	O	(	O	10	DEP
9	OH	OH	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	2D	2D	B-NP	NN	O	4	PMOD
12	in	in	B-PP	IN	O	3	VMOD
13	a	a	B-NP	DT	O	14	NMOD
14	patient	patient	I-NP	NN	O	12	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	hypoparathyroidism	hypoparathyroidism	B-NP	NN	O	15	PMOD
17	.	.	O	.	O	2	P

1	Milk-alkali	Milk-alkali	B-NP	JJ	O	2	NMOD
2	syndrome	syndrome	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	first	first	I-VP	RB	O	3	VMOD
5	described	describe	I-VP	VBN	O	3	VC
6	70	70	B-NP	CD	O	7	NMOD
7	years	year	I-NP	NNS	O	5	OBJ
8	ago	ago	B-ADVP	RB	O	9	PMOD
9	in	in	B-PP	IN	O	7	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	context	context	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	treatment	treatment	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	peptic	peptic	B-NP	JJ	O	18	NMOD
17	ulcer	ulcer	I-NP	NN	O	18	NMOD
18	disease	disease	I-NP	NN	O	15	PMOD
19	with	with	B-PP	IN	O	14	NMOD
20	large	large	B-NP	JJ	O	21	NMOD
21	amounts	amount	I-NP	NNS	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	calcium	calcium	B-NP	NN	O	25	NMOD
24	and	and	I-NP	CC	O	25	NMOD
25	alkali	alkali	I-NP	NN	O	22	PMOD
26	.	.	O	.	O	3	P

1	Although	Although	B-SBAR	IN	O	21	VMOD
2	with	with	B-PP	IN	O	1	PMOD
3	current	current	B-NP	JJ	O	5	NMOD
4	ulcer	ulcer	I-NP	NN	O	5	NMOD
5	therapy	therapy	I-NP	NN	O	2	PMOD
6	(	(	O	(	O	14	DEP
7	H-2	H-2	B-NP	NN	O	8	NMOD
8	blockers	blocker	I-NP	NNS	O	13	NMOD
9	,	,	O	,	O	13	P
10	omeprazole	omeprazole	B-NP	NN	O	13	NMOD
11	,	,	O	,	O	13	P
12	and	and	O	CC	O	13	NMOD
13	sucralfate	sucralfate	B-NP	NN	O	14	DEP
14	)	)	O	)	O	5	NMOD
15	,	,	O	,	O	21	P
16	the	the	B-NP	DT	O	17	NMOD
17	frequency	frequency	I-NP	NN	O	21	SUB
18	of	of	B-PP	IN	O	17	NMOD
19	milk-alkali	milk-alkali	B-NP	JJ	O	20	NMOD
20	syndrome	syndrome	I-NP	NN	O	18	PMOD
21	has	have	B-VP	VBZ	O	0	ROOT
22	decreased	decrease	I-VP	VBN	O	21	VC
23	significantly	significantly	B-ADVP	RB	O	22	VMOD
24	,	,	O	,	O	22	P
25	the	the	B-NP	DT	O	27	NMOD
26	classic	classic	I-NP	JJ	O	27	NMOD
27	triad	triad	I-NP	NN	O	22	VMOD
28	of	of	B-PP	IN	O	27	NMOD
29	hypercalcemia	hypercalcemia	B-NP	NN	O	36	SUB
30	,	,	O	,	O	36	P
31	alkalosis	alkalosis	B-NP	NN	O	36	SUB
32	,	,	O	,	O	36	P
33	and	and	O	CC	O	36	VMOD
34	renal	renal	B-NP	JJ	O	35	NMOD
35	impairment	impairment	I-NP	NN	O	36	SUB
36	remains	remain	B-VP	VBZ	O	28	SBAR
37	the	the	B-NP	DT	O	38	NMOD
38	hallmark	hallmark	I-NP	NN	O	36	OBJ
39	of	of	B-PP	IN	O	38	NMOD
40	the	the	B-NP	DT	O	41	NMOD
41	syndrome	syndrome	I-NP	NN	O	39	PMOD
42	.	.	O	.	O	21	P

1	This	This	B-NP	DT	O	2	NMOD
2	article	article	I-NP	NN	O	3	SUB
3	presents	present	B-VP	VBZ	O	0	ROOT
4	a	a	B-NP	DT	O	5	NMOD
5	patient	patient	I-NP	NN	O	3	OBJ
6	with	with	B-PP	IN	O	5	NMOD
7	hypoparathyroidism	hypoparathyroidism	B-NP	NN	O	6	PMOD
8	who	who	B-NP	WP	O	5	NMOD
9	was	be	B-VP	VBD	O	8	SBAR
10	treated	treat	I-VP	VBN	O	9	VC
11	with	with	B-PP	IN	O	10	VMOD
12	calcium	calcium	B-NP	NN	O	13	NMOD
13	carbonate	carbonate	I-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	calcitriol	calcitriol	I-NP	NN	O	16	SUB
16	resulting	result	B-VP	VBG	O	11	PMOD
17	in	in	B-PP	IN	O	16	VMOD
18	two	two	B-NP	CD	O	19	NMOD
19	admissions	admission	I-NP	NNS	O	17	PMOD
20	to	to	B-PP	TO	O	19	NMOD
21	the	the	B-NP	DT	O	22	NMOD
22	hospital	hospital	I-NP	NN	O	20	PMOD
23	for	for	B-PP	IN	O	22	NMOD
24	milk-alkali	milk-alkali	B-NP	JJ	O	25	NMOD
25	syndrome	syndrome	I-NP	NN	O	23	PMOD
26	.	.	O	.	O	3	P

1	Encephalopathy	Encephalopathy	B-NP	NN	O	6	SUB
2	during	during	B-PP	IN	O	1	NMOD
3	amitriptyline	amitriptyline	B-NP	NN	O	4	NMOD
4	therapy	therapy	I-NP	NN	O	2	PMOD
5	:	:	O	:	O	1	P
6	are	be	B-VP	VBP	O	0	ROOT
7	neuroleptic	neuroleptic	B-NP	JJ	O	9	NMOD
8	malignant	malignant	I-NP	JJ	O	9	NMOD
9	syndrome	syndrome	I-NP	NN	O	14	NMOD
10	and	and	I-NP	CC	O	14	NMOD
11	serotonin	serotonin	I-NP	NN	O	14	NMOD
12	syndrome	syndrome	I-NP	NN	O	14	NMOD
13	spectrum	spectrum	I-NP	NN	O	14	NMOD
14	disorders	disorder	I-NP	NNS	O	6	PRD
15	.	.	O	.	O	6	P

1	This	This	B-NP	DT	O	2	NMOD
2	report	report	I-NP	NN	O	3	SUB
3	describes	describe	B-VP	VBZ	O	0	ROOT
4	a	a	B-NP	DT	O	5	NMOD
5	case	case	I-NP	NN	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	encephalopathy	encephalopathy	B-NP	NN	O	6	PMOD
8	developed	develop	B-VP	VBN	O	7	NMOD
9	in	in	B-PP	IN	O	8	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	course	course	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	amitriptyline	amitriptyline	B-NP	NN	O	14	NMOD
14	therapy	therapy	I-NP	NN	O	12	PMOD
15	,	,	O	,	O	3	P
16	during	during	B-PP	IN	O	3	VMOD
17	a	a	B-NP	DT	O	18	NMOD
18	remission	remission	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	unipolar	unipolar	B-NP	JJ	O	21	NMOD
21	depression	depression	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	3	P

1	Genetic	Genetic	B-NP	JJ	O	2	NMOD
2	separation	separation	I-NP	NN	O	8	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	tumor	tumor	B-NP	NN	O	5	NMOD
5	growth	growth	I-NP	NN	O	3	PMOD
6	and	and	O	CC	O	8	NMOD
7	hemorrhagic	hemorrhagic	B-NP	JJ	O	8	NMOD
8	phenotypes	phenotype	I-NP	NNS	O	0	ROOT
9	in	in	B-PP	IN	O	8	NMOD
10	an	an	B-NP	DT	O	11	NMOD
11	estrogen	estrogen	I-NP	NN	O	9	PMOD
12	induced	induce	B-VP	VBD	O	11	AMOD
13	tumor	tumor	B-NP	NN	O	11	NMOD
14	.	.	O	.	O	8	P

1	Chronic	Chronic	B-NP	JJ	O	2	NMOD
2	administration	administration	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	estrogen	estrogen	B-NP	NN	O	3	PMOD
5	to	to	B-PP	TO	O	2	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	Fischer	Fischer	I-NP	NNP	O	5	PMOD
8	344	344	I-NP	CD	O	7	NMOD
9	(	(	O	(	O	11	DEP
10	F344	F344	B-NP	NN	O	11	DEP
11	)	)	O	)	O	7	NMOD
12	rat	rat	B-NP	NN	O	13	SUB
13	induces	induce	B-VP	VBZ	O	2	NMOD
14	growth	growth	B-NP	NN	O	13	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	large	large	B-NP	JJ	O	18	AMOD
17	,	,	I-NP	,	O	18	P
18	hemorrhagic	hemorrhagic	I-NP	JJ	O	20	NMOD
19	pituitary	pituitary	I-NP	JJ	O	20	NMOD
20	tumors	tumor	I-NP	NNS	O	15	PMOD
21	.	.	O	.	O	2	P

1	Ten	Ten	B-NP	CD	O	2	NMOD
2	weeks	week	I-NP	NNS	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	diethylstilbestrol	diethylstilbestrol	B-NP	NN	O	8	NMOD
5	(	(	O	(	O	7	DEP
6	DES	DES	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	treatment	treatment	B-NP	NN	O	3	PMOD
9	caused	cause	B-VP	VBD	O	0	ROOT
10	female	female	B-NP	JJ	O	13	NMOD
11	F344	F344	I-NP	NN	O	13	NMOD
12	rat	rat	I-NP	NN	O	13	NMOD
13	pituitaries	pituitary	I-NP	NNS	O	9	OBJ
14	to	to	B-VP	TO	O	15	VMOD
15	grow	grow	I-VP	VB	O	9	VMOD
16	to	to	B-PP	TO	O	15	VMOD
17	an	an	B-NP	DT	O	18	NMOD
18	average	average	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	109.2	109.2	B-NP	CD	O	22	AMOD
21	+/-	+/-	I-NP	SYM	O	22	AMOD
22	6.3	6.3	I-NP	CD	O	23	NMOD
23	mg	mg	I-NP	NN	O	19	PMOD
24	(	(	O	(	O	28	DEP
25	mean	mean	B-NP	NN	O	27	NMOD
26	+/-	+/-	O	SYM	O	27	NMOD
27	SE	SE	B-NP	NN	O	28	DEP
28	)	)	O	)	O	15	VMOD
29	versus	versus	B-PP	IN	O	40	VMOD
30	11.3	11.3	B-NP	CD	O	32	AMOD
31	+/-	+/-	I-NP	SYM	O	32	AMOD
32	1.4	1.4	I-NP	CD	O	33	NMOD
33	mg	mg	I-NP	NN	O	29	PMOD
34	for	for	B-PP	IN	O	33	NMOD
35	untreated	untreated	B-NP	JJ	O	36	NMOD
36	rats	rat	I-NP	NNS	O	34	PMOD
37	,	,	O	,	O	29	P
38	and	and	O	CC	O	29	PMOD
39	to	to	B-VP	TO	O	40	VMOD
40	become	become	I-VP	VB	O	15	VMOD
41	highly	highly	B-ADJP	RB	O	42	AMOD
42	hemorrhagic	hemorrhagic	I-ADJP	JJ	O	40	PRD
43	.	.	O	.	O	9	P

1	However	However	B-ADVP	RB	O	8	VMOD
2	,	,	O	,	O	8	P
3	while	while	B-SBAR	IN	O	8	SUB
4	DES	DES	B-NP	NNP	O	5	SUB
5	induced	induce	B-VP	VBD	O	3	SBAR
6	pituitary	pituitary	B-NP	JJ	O	7	NMOD
7	growth	growth	I-NP	NN	O	5	OBJ
8	exhibited	exhibit	B-VP	VBD	O	17	VMOD
9	quantitative	quantitative	B-NP	JJ	O	11	AMOD
10	,	,	I-NP	,	O	11	P
11	additive	additive	I-NP	JJ	O	12	NMOD
12	inheritance	inheritance	I-NP	NN	O	16	NMOD
13	,	,	O	,	O	16	P
14	the	the	B-NP	DT	O	16	NMOD
15	hemorrhagic	hemorrhagic	I-NP	JJ	O	16	NMOD
16	phenotype	phenotype	I-NP	NN	O	17	SUB
17	exhibited	exhibit	B-VP	VBD	O	0	ROOT
18	recessive	recessive	B-NP	JJ	O	20	AMOD
19	,	,	I-NP	,	O	20	P
20	epistatic	epistatic	I-NP	JJ	O	21	NMOD
21	inheritance	inheritance	I-NP	NN	O	17	OBJ
22	.	.	O	.	O	17	P

1	Increased	Increase	B-NP	VBN	O	2	NMOD
2	expression	expression	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	neuronal	neuronal	B-NP	JJ	B-protein	7	NMOD
5	nitric	nitric	I-NP	JJ	I-protein	7	NMOD
6	oxide	oxide	I-NP	NN	I-protein	7	NMOD
7	synthase	synthase	I-NP	NN	I-protein	3	PMOD
8	in	in	B-PP	IN	O	2	NMOD
9	bladder	bladder	B-NP	NN	O	11	NMOD
10	afferent	afferent	I-NP	JJ	O	11	NMOD
11	pathways	pathway	I-NP	NNS	O	8	PMOD
12	following	follow	B-PP	VBG	O	2	NMOD
13	chronic	chronic	B-NP	JJ	O	15	NMOD
14	bladder	bladder	I-NP	NN	O	15	NMOD
15	irritation	irritation	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	2	P

1	Immunocytochemical	Immunocytochemical	B-NP	JJ	O	2	NMOD
2	techniques	technique	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	0	ROOT
4	used	use	I-VP	VBN	O	3	VC
5	to	to	B-VP	TO	O	6	VMOD
6	examine	examine	I-VP	VB	O	4	VMOD
7	alterations	alteration	B-NP	NNS	O	6	OBJ
8	in	in	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	expression	expression	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	neuronal	neuronal	B-NP	JJ	B-protein	15	NMOD
13	nitric	nitric	I-NP	JJ	I-protein	15	NMOD
14	oxide	oxide	I-NP	NN	I-protein	15	NMOD
15	synthase	synthase	I-NP	NN	I-protein	11	PMOD
16	(	(	O	(	O	18	DEP
17	NOS	NOS	B-NP	NN	B-protein	18	DEP
18	)	)	O	)	O	15	NMOD
19	in	in	B-PP	IN	O	10	NMOD
20	bladder	bladder	B-NP	NN	O	21	NMOD
21	pathways	pathway	I-NP	NNS	O	19	PMOD
22	following	follow	B-PP	VBG	O	6	VMOD
23	acute	acute	B-NP	JJ	O	26	NMOD
24	and	and	I-NP	CC	O	26	NMOD
25	chronic	chronic	I-NP	JJ	O	26	NMOD
26	irritation	irritation	I-NP	NN	O	22	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	the	the	B-NP	DT	O	30	NMOD
29	urinary	urinary	I-NP	JJ	O	30	NMOD
30	tract	tract	I-NP	NN	O	27	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	the	the	B-NP	DT	O	33	NMOD
33	rat	rat	I-NP	NN	O	31	PMOD
34	.	.	O	.	O	3	P

1	Chemical	Chemical	B-NP	JJ	O	2	NMOD
2	cystitis	cystitis	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	induced	induce	I-VP	VBN	O	3	VC
5	by	by	B-PP	IN	O	4	VMOD
6	cyclophosphamide	cyclophosphamide	B-NP	NN	O	5	PMOD
7	(	(	O	(	O	9	DEP
8	CYP	CYP	B-NP	NN	B-protein	9	DEP
9	)	)	O	)	O	6	NMOD
10	which	which	B-NP	WDT	O	6	NMOD
11	is	be	B-VP	VBZ	O	10	SBAR
12	metabolized	metabolize	I-VP	VBN	O	11	VC
13	to	to	B-PP	TO	O	12	VMOD
14	acrolein	acrolein	B-NP	NN	O	17	NMOD
15	,	,	O	,	O	17	P
16	an	an	B-NP	DT	O	17	NMOD
17	irritant	irritant	I-NP	JJ	O	13	PMOD
18	eliminated	eliminate	B-VP	VBN	O	17	NMOD
19	in	in	B-PP	IN	O	18	VMOD
20	the	the	B-NP	DT	O	21	NMOD
21	urine	urine	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	3	P

1	Effects	Effect	B-NP	NNS	O	12	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	a	a	B-NP	DT	O	6	NMOD
4	new	new	I-NP	JJ	O	6	NMOD
5	calcium	calcium	I-NP	NN	O	6	NMOD
6	antagonist	antagonist	I-NP	NN	O	8	NMOD
7	,	,	O	,	O	8	P
8	CD-832	CD-832	B-NP	NN	B-protein	2	PMOD
9	,	,	O	,	O	1	P
10	on	on	B-PP	IN	O	1	NMOD
11	isoproterenol	isoproterenol	B-NP	NN	O	10	PMOD
12	induced	induce	B-VP	VBD	O	0	ROOT
13	myocardial	myocardial	B-NP	JJ	O	14	NMOD
14	ischemia	ischemia	I-NP	NN	O	12	OBJ
15	in	in	B-PP	IN	O	12	VMOD
16	dogs	dog	B-NP	NNS	O	15	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	partial	partial	B-NP	JJ	O	20	NMOD
19	coronary	coronary	I-NP	JJ	O	20	NMOD
20	stenosis	stenosis	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	12	P

1	Effects	Effect	B-NP	NNS	O	9	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	CD-832	CD-832	B-NP	NN	B-protein	2	PMOD
4	on	on	B-PP	IN	O	1	NMOD
5	isoproterenol	isoproterenol	B-NP	NN	O	4	PMOD
6	(	(	O	(	O	8	DEP
7	ISO	ISO	B-NP	NN	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	induced	induce	B-VP	VBD	O	0	ROOT
10	myocardial	myocardial	B-NP	JJ	O	11	NMOD
11	ischemia	ischemia	I-NP	NN	O	9	OBJ
12	were	be	B-VP	VBD	O	9	VMOD
13	studied	study	I-VP	VBN	O	12	VC
14	in	in	B-PP	IN	O	13	VMOD
15	dogs	dog	B-NP	NNS	O	14	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	partial	partial	B-NP	JJ	O	19	NMOD
18	coronary	coronary	I-NP	JJ	O	19	NMOD
19	stenosis	stenosis	I-NP	NN	O	27	NMOD
20	of	of	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	25	NMOD
22	left	left	I-NP	JJ	O	25	NMOD
23	circumflex	circumflex	I-NP	NN	O	25	NMOD
24	coronary	coronary	I-NP	JJ	O	25	NMOD
25	artery	artery	I-NP	NN	O	20	PMOD
26	and	and	I-NP	CC	O	27	NMOD
27	findings	finding	I-NP	NNS	O	16	PMOD
28	were	be	B-VP	VBD	O	9	VMOD
29	compared	compare	I-VP	VBN	O	28	VC
30	with	with	B-PP	IN	O	29	VMOD
31	those	those	B-NP	DT	O	30	PMOD
32	for	for	B-PP	IN	O	31	NMOD
33	nifedipine	nifedipine	B-NP	NN	O	35	NMOD
34	or	or	I-NP	CC	O	35	NMOD
35	diltiazem	diltiazem	I-NP	NN	O	32	PMOD
36	.	.	O	.	O	9	P

1	In	In	B-PP	IN	O	19	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	presence	presence	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	coronary	coronary	B-NP	JJ	O	7	NMOD
6	artery	artery	I-NP	NN	O	7	NMOD
7	stenosis	stenosis	I-NP	NN	O	4	PMOD
8	,	,	O	,	O	19	P
9	3-min	3-min	B-NP	NN	O	10	NMOD
10	periods	period	I-NP	NNS	O	19	SUB
11	of	of	B-PP	IN	O	10	NMOD
12	intracoronary	intracoronary	B-NP	JJ	O	14	NMOD
13	ISO	ISO	I-NP	NN	O	14	NMOD
14	infusion	infusion	I-NP	NN	O	11	PMOD
15	(	(	O	(	O	18	DEP
16	10	10	B-NP	CD	O	17	NMOD
17	ng/kg/min	ng/kg/min	I-NP	NN	O	18	DEP
18	)	)	O	)	O	14	NMOD
19	increased	increase	B-VP	VBD	O	0	ROOT
20	heart	heart	B-NP	NN	O	21	NMOD
21	rate	rate	I-NP	NN	O	24	NMOD
22	and	and	O	CC	O	24	NMOD
23	maximal	maximal	B-NP	JJ	O	24	NMOD
24	rate	rate	I-NP	NN	O	19	OBJ
25	of	of	B-PP	IN	O	24	NMOD
26	left	left	B-NP	JJ	O	29	NMOD
27	ventricular	ventricular	I-NP	JJ	O	29	NMOD
28	pressure	pressure	I-NP	NN	O	29	NMOD
29	rise	rise	I-NP	NN	O	25	PMOD
30	,	,	O	,	O	19	P
31	which	which	B-NP	WDT	O	19	VMOD
32	resulted	result	B-VP	VBD	O	31	SBAR
33	in	in	B-PP	IN	O	32	VMOD
34	a	a	B-NP	DT	O	35	NMOD
35	decrease	decrease	I-NP	NN	O	33	PMOD
36	in	in	B-PP	IN	O	35	NMOD
37	percentage	percentage	B-NP	NN	O	39	NMOD
38	segmental	segmental	I-NP	JJ	O	39	NMOD
39	shortening	shortening	I-NP	NN	O	42	NMOD
40	and	and	I-NP	CC	O	42	NMOD
41	ST-segment	ST-segment	I-NP	NN	O	42	NMOD
42	elevation	elevation	I-NP	NN	O	36	PMOD
43	of	of	B-PP	IN	O	42	NMOD
44	the	the	B-NP	DT	O	46	NMOD
45	epicardial	epicardial	I-NP	JJ	O	46	NMOD
46	electrocardiogram	electrocardiogram	I-NP	NN	O	43	PMOD
47	.	.	O	.	O	19	P

1	After	After	B-PP	IN	O	49	VMOD
2	the	the	B-NP	DT	O	5	NMOD
3	control	control	I-NP	NN	O	5	NMOD
4	ISO	ISO	I-NP	NN	O	5	NMOD
5	infusion	infusion	I-NP	NN	O	8	SUB
6	with	with	B-PP	IN	O	5	NMOD
7	stenosis	stenosis	B-NP	NN	O	6	PMOD
8	was	be	B-VP	VBD	O	1	SBAR
9	performed	perform	I-VP	VBN	O	8	VC
10	,	,	O	,	O	49	P
11	equihypotensive	equihypotensive	B-NP	JJ	O	12	NMOD
12	doses	dose	I-NP	NNS	O	38	NMOD
13	of	of	B-PP	IN	O	12	NMOD
14	CD-832	CD-832	B-NP	NN	B-protein	13	PMOD
15	(	(	O	(	O	38	NMOD
16	3	3	B-NP	CD	O	18	AMOD
17	and	and	I-NP	CC	O	18	AMOD
18	10	10	I-NP	CD	O	19	NMOD
19	micrograms/kg/min	micrograms/kg/min	I-NP	NN	O	38	NMOD
20	,	,	O	,	O	38	P
21	n	n	B-NP	NN	O	38	NMOD
22	=	=	B-VP	SYM	O	21	NMOD
23	7	7	B-NP	CD	O	22	AMOD
24	)	)	O	)	O	21	NMOD
25	,	,	O	,	O	38	P
26	nifedipine	nifedipine	B-NP	NN	O	38	NMOD
27	(	(	O	(	O	38	NMOD
28	1	1	B-NP	CD	O	30	AMOD
29	and	and	I-NP	CC	O	30	AMOD
30	3	3	I-NP	CD	O	31	NMOD
31	micrograms/kg/min	micrograms/kg/min	I-NP	NN	O	38	NMOD
32	,	,	O	,	O	38	P
33	n	n	B-NP	NN	O	38	NMOD
34	=	=	B-VP	SYM	O	33	NMOD
35	9	9	B-NP	CD	O	34	AMOD
36	)	)	O	)	O	33	NMOD
37	or	or	O	CC	O	38	NMOD
38	diltiazem	diltiazem	B-NP	NN	O	49	SUB
39	(	(	O	(	O	48	DEP
40	10	10	B-NP	CD	O	42	AMOD
41	and	and	I-NP	CC	O	42	AMOD
42	30	30	I-NP	CD	O	43	NMOD
43	micrograms/kg/min	micrograms/kg/min	I-NP	NN	O	47	NMOD
44	,	,	O	,	O	47	P
45	n	n	B-NP	NN	O	47	SUB
46	=	=	B-VP	SYM	O	47	VMOD
47	7	7	B-NP	CD	O	48	DEP
48	)	)	O	)	O	38	NMOD
49	were	be	B-VP	VBD	O	0	ROOT
50	infused	infuse	I-VP	VBN	O	49	VC
51	5	5	B-NP	CD	O	52	NMOD
52	min	min	I-NP	NN	O	50	OBJ
53	before	before	B-PP	IN	O	52	NMOD
54	and	and	I-PP	CC	O	53	PMOD
55	during	during	I-PP	IN	O	53	PMOD
56	the	the	B-NP	DT	O	61	NMOD
57	second	second	I-NP	JJ	O	59	AMOD
58	and	and	I-NP	CC	O	59	AMOD
59	third	third	I-NP	JJ	O	61	NMOD
60	ISO	ISO	I-NP	NN	O	61	NMOD
61	infusion	infusion	I-NP	NN	O	53	PMOD
62	.	.	O	.	O	49	P

1	In	In	B-PP	IN	O	11	VMOD
2	contrast	contrast	B-NP	NN	O	11	SUB
3	to	to	B-PP	TO	O	11	VMOD
4	nifedipine	nifedipine	B-NP	NN	O	11	VMOD
5	,	,	O	,	O	11	P
6	CD-832	CD-832	B-NP	NN	B-protein	11	SUB
7	(	(	O	(	O	10	DEP
8	10	10	B-NP	CD	O	9	NMOD
9	micrograms/kg/min	micrograms/kg/min	I-NP	NN	O	10	DEP
10	)	)	O	)	O	6	NMOD
11	prevented	prevent	B-VP	VBD	O	0	ROOT
12	the	the	B-NP	DT	O	13	NMOD
13	decrease	decrease	I-NP	NN	O	11	OBJ
14	in	in	B-PP	IN	O	13	NMOD
15	percentage	percentage	B-NP	NN	O	17	NMOD
16	segmental	segmental	I-NP	JJ	O	17	NMOD
17	shortening	shortening	I-NP	NN	O	14	PMOD
18	from	from	B-PP	IN	O	13	NMOD
19	32	32	B-NP	CD	O	21	AMOD
20	+/-	+/-	I-NP	SYM	O	21	AMOD
21	12	12	I-NP	CD	O	22	NMOD
22	%	%	I-NP	NN	O	18	PMOD
23	to	to	B-PP	TO	O	18	PMOD
24	115	115	B-NP	CD	O	26	AMOD
25	+/-	+/-	O	SYM	O	26	AMOD
26	26	26	B-NP	CD	O	27	NMOD
27	%	%	I-NP	NN	O	23	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	the	the	B-NP	DT	O	31	NMOD
30	control	control	I-NP	NN	O	31	NMOD
31	value	value	I-NP	NN	O	39	NMOD
32	(	(	O	(	O	36	DEP
33	P	P	B-NP	NN	O	36	DEP
34	<	<	B-NP	JJR	O	33	NMOD
35	.01	.01	I-NP	CD	O	34	AMOD
36	)	)	O	)	O	31	NMOD
37	and	and	O	CC	O	39	NMOD
38	ST-segment	ST-segment	B-NP	NN	O	39	NMOD
39	elevation	elevation	I-NP	NN	O	28	PMOD
40	from	from	B-PP	IN	O	39	NMOD
41	5.6	5.6	B-NP	CD	O	43	AMOD
42	+/-	+/-	I-NP	SYM	O	43	AMOD
43	1.0	1.0	I-NP	CD	O	44	NMOD
44	mV	mV	I-NP	NN	O	40	PMOD
45	to	to	B-PP	TO	O	18	PMOD
46	1.6	1.6	B-NP	CD	O	48	AMOD
47	+/-	+/-	I-NP	SYM	O	48	AMOD
48	1.3	1.3	I-NP	CD	O	49	NMOD
49	mV	mV	I-NP	NN	O	45	PMOD
50	(	(	O	(	O	54	DEP
51	P	P	B-NP	NN	O	54	DEP
52	<	<	B-NP	JJR	O	51	NMOD
53	.01	.01	I-NP	CD	O	52	AMOD
54	)	)	O	)	O	49	NMOD
55	at	at	B-PP	IN	O	13	NMOD
56	3	3	B-NP	CD	O	57	NMOD
57	min	min	I-NP	NN	O	55	PMOD
58	after	after	B-PP	IN	O	13	NMOD
59	ISO	ISO	B-NP	NN	O	60	NMOD
60	infusion	infusion	I-NP	NN	O	58	PMOD
61	with	with	B-PP	IN	O	60	NMOD
62	stenosis	stenosis	B-NP	NN	O	61	PMOD
63	.	.	O	.	O	11	P

1	Diltiazem	Diltiazem	B-NP	NN	O	7	SUB
2	(	(	O	(	O	5	DEP
3	30	30	B-NP	CD	O	4	NMOD
4	micrograms/kg/min	micrograms/kg/min	I-NP	NN	O	5	DEP
5	)	)	O	)	O	1	NMOD
6	also	also	B-ADVP	RB	O	7	VMOD
7	prevented	prevent	B-VP	VBD	O	0	ROOT
8	the	the	B-NP	DT	O	9	NMOD
9	decrease	decrease	I-NP	NN	O	7	OBJ
10	in	in	B-PP	IN	O	9	NMOD
11	percentage	percentage	B-NP	NN	O	13	NMOD
12	segmental	segmental	I-NP	JJ	O	13	NMOD
13	shortening	shortening	I-NP	NN	O	10	PMOD
14	from	from	B-PP	IN	O	9	NMOD
15	34	34	B-NP	CD	O	17	AMOD
16	+/-	+/-	I-NP	SYM	O	17	AMOD
17	14	14	I-NP	CD	O	18	NMOD
18	%	%	I-NP	NN	O	14	PMOD
19	to	to	I-NP	TO	O	23	NMOD
20	63	63	I-NP	CD	O	22	AMOD
21	+/-	+/-	I-NP	SYM	O	22	AMOD
22	18	18	I-NP	CD	O	19	PMOD
23	%	%	I-NP	NN	O	35	NMOD
24	of	of	B-PP	IN	O	23	NMOD
25	the	the	B-NP	DT	O	27	NMOD
26	control	control	I-NP	NN	O	27	NMOD
27	value	value	I-NP	NN	O	24	PMOD
28	(	(	O	(	O	32	DEP
29	P	P	B-NP	NN	O	32	DEP
30	<	<	B-NP	JJR	O	29	NMOD
31	.05	.05	I-NP	CD	O	30	AMOD
32	)	)	O	)	O	23	NMOD
33	and	and	O	CC	O	35	NMOD
34	ST-segment	ST-segment	B-NP	NN	O	35	NMOD
35	elevation	elevation	I-NP	NN	O	14	PMOD
36	from	from	B-PP	IN	O	35	NMOD
37	4.7	4.7	B-NP	CD	O	39	AMOD
38	+/-	+/-	I-NP	SYM	O	39	AMOD
39	0.7	0.7	I-NP	CD	O	40	NMOD
40	mV	mV	I-NP	NN	O	36	PMOD
41	to	to	B-PP	TO	O	14	PMOD
42	2.1	2.1	B-NP	CD	O	44	AMOD
43	+/-	+/-	I-NP	SYM	O	44	AMOD
44	0.7	0.7	I-NP	CD	O	45	NMOD
45	mV	mV	I-NP	NN	O	41	PMOD
46	(	(	O	(	O	50	DEP
47	P	P	B-NP	NN	O	50	DEP
48	<	<	B-NP	JJR	O	47	NMOD
49	.01	.01	I-NP	CD	O	48	AMOD
50	)	)	O	)	O	45	NMOD
51	at	at	B-PP	IN	O	9	NMOD
52	3	3	B-NP	CD	O	53	NMOD
53	min	min	I-NP	NN	O	51	PMOD
54	after	after	B-PP	IN	O	9	NMOD
55	ISO	ISO	B-NP	NN	O	56	NMOD
56	infusion	infusion	I-NP	NN	O	54	PMOD
57	with	with	B-PP	IN	O	56	NMOD
58	stenosis	stenosis	B-NP	NN	O	57	PMOD
59	.	.	O	.	O	7	P

1	The	The	B-NP	DT	O	2	NMOD
2	effect	effect	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	recombinant	recombinant	B-NP	JJ	B-protein	8	NMOD
5	human	human	I-NP	JJ	I-protein	8	NMOD
6	insulin-like	insulin-like	I-NP	JJ	I-protein	8	NMOD
7	growth	growth	I-NP	NN	I-protein	8	NMOD
8	factor-I	factor-I	I-NP	NN	I-protein	3	PMOD
9	on	on	B-PP	IN	O	2	NMOD
10	chronic	chronic	B-NP	JJ	O	13	NMOD
11	puromycin	puromycin	I-NP	NN	O	13	NMOD
12	aminonucleoside	aminonucleoside	I-NP	NN	O	13	NMOD
13	nephropathy	nephropathy	I-NP	NN	O	9	PMOD
14	in	in	B-PP	IN	O	13	NMOD
15	rats	rat	B-NP	NNS	O	14	PMOD
16	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	3	SUB
2	recently	recently	B-ADVP	RB	O	3	VMOD
3	demonstrated	demonstrate	B-VP	VBD	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	recombinant	recombinant	B-NP	JJ	O	6	NMOD
6	hGH	hGH	I-NP	NN	O	7	SUB
7	exacerbates	exacerbate	B-VP	VBZ	O	4	SBAR
8	renal	renal	B-NP	JJ	O	9	NMOD
9	functional	functional	I-NP	JJ	O	11	AMOD
10	and	and	I-NP	CC	O	11	AMOD
11	structural	structural	I-NP	JJ	O	12	NMOD
12	injury	injury	I-NP	NN	O	7	OBJ
13	in	in	B-PP	IN	O	7	VMOD
14	chronic	chronic	B-NP	JJ	O	16	NMOD
15	puromycin	puromycin	I-NP	NN	O	16	NMOD
16	aminonucleoside	aminonucleoside	I-NP	NN	O	20	NMOD
17	(	(	O	(	O	19	DEP
18	PAN	PAN	B-NP	NN	O	19	DEP
19	)	)	O	)	O	16	NMOD
20	nephropathy	nephropathy	B-NP	NN	O	24	NMOD
21	,	,	O	,	O	24	P
22	an	an	B-NP	DT	O	24	NMOD
23	experimental	experimental	I-NP	JJ	O	24	NMOD
24	model	model	I-NP	NN	O	13	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	glomerular	glomerular	B-NP	JJ	O	27	NMOD
27	disease	disease	I-NP	NN	O	25	PMOD
28	.	.	O	.	O	3	P

1	Therefore	Therefore	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	we	we	B-NP	PRP	O	4	SUB
4	examined	examine	B-VP	VBD	O	0	ROOT
5	whether	whether	B-SBAR	IN	O	4	VMOD
6	recombinant	recombinant	B-NP	JJ	O	7	NMOD
7	human	human	I-NP	JJ	O	12	SUB
8	(	(	O	(	O	10	DEP
9	rh	rh	B-ADJP	JJ	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	IGF-I	IGF-I	B-NP	NN	B-protein	7	NMOD
12	is	be	B-VP	VBZ	O	5	SBAR
13	a	a	B-NP	DT	O	15	NMOD
14	safer	safe	I-NP	JJR	O	15	NMOD
15	alternative	alternative	I-NP	NN	O	12	PRD
16	for	for	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	18	NMOD
18	treatment	treatment	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	growth	growth	B-NP	NN	O	21	NMOD
21	failure	failure	I-NP	NN	O	19	PMOD
22	in	in	B-PP	IN	O	18	NMOD
23	rats	rat	B-NP	NNS	O	22	PMOD
24	with	with	B-PP	IN	O	23	NMOD
25	chronic	chronic	B-NP	JJ	O	27	NMOD
26	PAN	PAN	I-NP	NN	O	27	NMOD
27	nephropathy	nephropathy	I-NP	NN	O	24	PMOD
28	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	2	NMOD
2	glomerulopathy	glomerulopathy	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	induced	induce	I-VP	VBN	O	3	VC
5	by	by	B-PP	IN	O	4	VMOD
6	seven	seven	B-NP	CD	O	8	NMOD
7	serial	serial	I-NP	JJ	O	8	NMOD
8	injections	injection	I-NP	NNS	O	5	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	PAN	PAN	B-NP	NN	B-protein	9	PMOD
11	over	over	B-PP	IN	I-protein	4	VMOD
12	12	12	B-NP	CD	I-protein	13	NMOD
13	wk	wk	I-NP	NN	I-protein	11	PMOD
14	.	.	O	.	O	3	P

1	Urinary	Urinary	B-NP	JJ	O	3	NMOD
2	protein	protein	I-NP	NN	O	3	NMOD
3	excretion	excretion	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	unaltered	unaltered	B-ADJP	JJ	O	4	PRD
6	by	by	B-PP	IN	O	5	AMOD
7	rhIGF-I	rhIGF-I	B-NP	NN	O	8	NMOD
8	treatment	treatment	I-NP	NN	O	6	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	rats	rat	B-NP	NNS	O	9	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	chronic	chronic	B-NP	JJ	O	14	NMOD
13	PAN	PAN	I-NP	NN	O	14	NMOD
14	nephropathy	nephropathy	I-NP	NN	O	11	PMOD
15	.	.	O	.	O	4	P

1	After	After	B-PP	IN	O	8	VMOD
2	12	12	B-NP	CD	O	3	NMOD
3	wk	wk	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	8	P
5	the	the	B-NP	DT	O	7	NMOD
6	inulin	inulin	I-NP	NN	O	7	NMOD
7	clearance	clearance	I-NP	NN	O	8	SUB
8	was	be	B-VP	VBD	O	0	ROOT
9	higher	high	B-ADJP	JJR	O	22	NMOD
10	in	in	B-PP	IN	O	9	AMOD
11	rhIGF-I-treated	rhIGF-I-treated	B-NP	JJ	O	12	NMOD
12	rats	rat	I-NP	NNS	O	10	PMOD
13	,	,	O	,	O	22	P
14	0.48	0.48	B-NP	CD	O	16	AMOD
15	+/-	+/-	I-NP	SYM	O	16	AMOD
16	0.08	0.08	I-NP	CD	O	22	NMOD
17	versus	versus	B-PP	IN	O	22	NMOD
18	0.24	0.24	B-NP	CD	O	20	AMOD
19	+/-	+/-	I-NP	SYM	O	20	AMOD
20	0.06	0.06	I-NP	CD	O	22	NMOD
21	mL/min/100	mL/min/100	I-NP	NN	O	20	AMOD
22	g	g	I-NP	NN	O	8	PRD
23	of	of	B-PP	IN	O	22	NMOD
24	body	body	B-NP	NN	O	25	NMOD
25	weight	weight	I-NP	NN	O	23	PMOD
26	in	in	B-PP	IN	O	8	VMOD
27	untreated	untreated	B-NP	JJ	O	30	NMOD
28	PAN	PAN	I-NP	NN	O	30	NMOD
29	nephropathy	nephropathy	I-NP	NN	O	30	NMOD
30	animals	animal	I-NP	NNS	O	26	PMOD
31	,	,	O	,	O	8	P
32	p	p	B-NP	NN	O	8	VMOD
33	<	<	B-VP	SYM	O	32	NMOD
34	0.05	0.05	B-NP	CD	O	33	AMOD
35	.	.	O	.	O	8	P

1	The	The	B-NP	DT	O	2	NMOD
2	improvement	improvement	I-NP	NN	O	5	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	GFR	GFR	B-NP	NN	B-protein	3	PMOD
5	was	be	B-VP	VBD	O	0	ROOT
6	not	not	I-VP	RB	O	5	VMOD
7	associated	associate	I-VP	VBN	O	5	VC
8	with	with	B-PP	IN	O	7	VMOD
9	enhanced	enhance	B-NP	VBN	O	11	NMOD
10	glomerular	glomerular	I-NP	JJ	O	11	NMOD
11	hypertrophy	hypertrophy	I-NP	NN	O	15	NMOD
12	or	or	O	CC	O	15	NMOD
13	increased	increase	B-NP	VBN	O	15	NMOD
14	segmental	segmental	I-NP	JJ	O	15	NMOD
15	glomerulosclerosis	glomerulosclerosis	I-NP	NN	O	24	NMOD
16	,	,	O	,	O	24	P
17	tubulointerstitial	tubulointerstitial	B-NP	JJ	O	18	NMOD
18	injury	injury	I-NP	NN	O	24	NMOD
19	,	,	O	,	O	24	P
20	or	or	O	CC	O	24	NMOD
21	renal	renal	B-NP	JJ	O	24	NMOD
22	cortical	cortical	I-NP	JJ	O	24	NMOD
23	malondialdehyde	malondialdehyde	I-NP	NN	O	24	NMOD
24	content	content	I-NP	NN	O	8	PMOD
25	.	.	O	.	O	5	P

1	In	In	B-PP	IN	O	10	VMOD
2	rats	rat	B-NP	NNS	O	1	PMOD
3	with	with	B-PP	IN	O	2	NMOD
4	PAN	PAN	B-NP	NN	O	5	NMOD
5	nephropathy	nephropathy	I-NP	NN	O	3	PMOD
6	,	,	O	,	O	10	P
7	administration	administration	B-NP	NN	O	10	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	rhIGF-I	rhIGF-I	B-NP	NN	O	8	PMOD
10	increased	increase	B-VP	VBD	O	0	ROOT
11	IGF-I	IGF-I	B-NP	NN	B-protein	16	NMOD
12	and	and	I-NP	CC	O	16	NMOD
13	GH	GH	I-NP	NN	O	16	NMOD
14	receptor	receptor	I-NP	NN	O	16	NMOD
15	gene	gene	I-NP	NN	O	16	NMOD
16	expression	expression	I-NP	NN	O	10	OBJ
17	,	,	O	,	O	10	P
18	without	without	B-PP	IN	O	10	VMOD
19	altering	alter	B-VP	VBG	O	18	PMOD
20	the	the	B-NP	DT	O	23	NMOD
21	steady	steady	I-NP	JJ	O	23	NMOD
22	state	state	I-NP	NN	O	23	NMOD
23	level	level	I-NP	NN	O	19	OBJ
24	of	of	B-PP	IN	O	23	NMOD
25	IGF-I	IGF-I	B-NP	NN	B-RNA	27	NMOD
26	receptor	receptor	I-NP	NN	I-RNA	27	NMOD
27	mRNA	mRNA	I-NP	NN	I-RNA	24	PMOD
28	.	.	O	.	O	10	P

1	In	In	B-PP	IN	O	15	VMOD
2	normal	normal	B-NP	JJ	O	3	NMOD
3	rats	rat	I-NP	NNS	O	1	PMOD
4	with	with	B-PP	IN	O	3	NMOD
5	intact	intact	B-NP	JJ	O	6	NMOD
6	kidneys	kidney	I-NP	NNS	O	4	PMOD
7	,	,	O	,	O	15	P
8	rhIGF-I	rhIGF-I	B-NP	NN	O	9	NMOD
9	administration	administration	I-NP	NN	O	15	SUB
10	(	(	O	(	O	14	DEP
11	n	n	B-NP	NN	O	14	DEP
12	=	=	B-VP	SYM	O	11	NMOD
13	4	4	B-NP	CD	O	12	AMOD
14	)	)	O	)	O	9	NMOD
15	did	do	B-VP	VBD	O	0	ROOT
16	not	not	I-VP	RB	O	15	VMOD
17	alter	alter	I-VP	VB	O	15	VC
18	weight	weight	B-NP	NN	O	19	NMOD
19	gain	gain	I-NP	NN	O	17	OBJ
20	,	,	O	,	O	41	P
21	blood	blood	B-NP	NN	O	22	NMOD
22	pressure	pressure	I-NP	NN	O	41	NMOD
23	,	,	O	,	O	41	P
24	proteinuria	proteinuria	B-NP	NN	O	41	NMOD
25	,	,	O	,	O	41	P
26	GFR	GFR	B-NP	NN	B-protein	41	NMOD
27	,	,	O	,	O	41	P
28	glomerular	glomerular	B-NP	JJ	O	30	NMOD
29	planar	planar	I-NP	JJ	O	30	NMOD
30	area	area	I-NP	NN	O	41	NMOD
31	,	,	O	,	O	41	P
32	renal	renal	B-NP	JJ	O	35	NMOD
33	cortical	cortical	I-NP	JJ	O	35	NMOD
34	malondialdehyde	malondialdehyde	I-NP	NN	O	35	NMOD
35	content	content	I-NP	NN	O	41	NMOD
36	,	,	O	,	O	41	P
37	or	or	O	CC	O	41	NMOD
38	glomerular	glomerular	B-NP	JJ	O	41	NMOD
39	or	or	I-NP	CC	O	41	NMOD
40	tubulointerstitial	tubulointerstitial	I-NP	JJ	O	41	NMOD
41	damage	damage	I-NP	NN	O	15	OBJ
42	,	,	O	,	O	41	P
43	compared	compare	B-PP	VBN	O	41	NMOD
44	with	with	B-PP	IN	O	43	PMOD
45	untreated	untreated	B-NP	JJ	O	46	NMOD
46	animals	animal	I-NP	NNS	O	44	PMOD
47	(	(	O	(	O	51	DEP
48	n	n	B-NP	NN	O	51	DEP
49	=	=	B-VP	SYM	O	48	NMOD
50	4	4	B-NP	CD	O	49	AMOD
51	)	)	O	)	O	46	NMOD
52	.	.	O	.	O	15	P
53	rhIGF-I	rhIGF-I	B-NP	NN	O	54	NMOD
54	treatment	treatment	I-NP	NN	O	55	SUB
55	reduced	reduce	B-VP	VBD	O	15	VMOD
56	the	the	B-NP	DT	O	62	NMOD
57	steady	steady	I-NP	JJ	O	62	NMOD
58	state	state	I-NP	NN	O	62	NMOD
59	renal	renal	I-NP	JJ	O	62	NMOD
60	IGF-I	IGF-I	I-NP	NN	B-RNA	62	NMOD
61	mRNA	mRNA	I-NP	NN	I-RNA	62	NMOD
62	level	level	I-NP	NN	O	55	OBJ
63	but	but	O	CC	O	55	VMOD
64	did	do	B-VP	VBD	O	55	VMOD
65	not	not	I-VP	RB	O	64	VMOD
66	modify	modify	I-VP	VB	O	64	VC
67	gene	gene	B-NP	NN	O	68	NMOD
68	expression	expression	I-NP	NN	O	66	OBJ
69	of	of	B-PP	IN	O	68	NMOD
70	the	the	B-NP	DT	O	74	NMOD
71	IGF-I	IGF-I	I-NP	NN	B-DNA	74	NMOD
72	or	or	I-NP	CC	O	74	NMOD
73	GH	GH	I-NP	NN	B-protein	74	NMOD
74	receptors	receptor	I-NP	NNS	I-protein	69	PMOD
75	.	.	O	.	O	15	P

1	Nefiracetam	Nefiracetam	B-NP	NN	O	5	SUB
2	(	(	O	(	O	4	DEP
3	DM-9384	DM-9384	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	reverses	reverse	B-VP	VBZ	O	0	ROOT
6	apomorphine	apomorphine	B-NP	NN	O	8	NMOD
7	induced	induced	I-NP	JJ	O	8	NMOD
8	amnesia	amnesia	I-NP	NN	O	5	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	a	a	B-NP	DT	O	13	NMOD
11	passive	passive	I-NP	JJ	O	13	NMOD
12	avoidance	avoidance	I-NP	NN	O	13	NMOD
13	response	response	I-NP	NN	O	9	PMOD
14	:	:	O	:	O	5	P
15	delayed	delay	B-NP	VBN	O	16	NMOD
16	emergence	emergence	I-NP	NN	O	5	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	21	NMOD
19	memory	memory	I-NP	NN	O	21	NMOD
20	retention	retention	I-NP	NN	O	21	NMOD
21	effects	effect	I-NP	NNS	O	17	PMOD
22	.	.	O	.	O	5	P

1	Nefiracetam	Nefiracetam	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	a	a	B-NP	DT	O	6	NMOD
4	novel	novel	I-NP	JJ	O	6	NMOD
5	pyrrolidone	pyrrolidone	I-NP	NN	O	6	NMOD
6	derivative	derivative	I-NP	NN	O	2	PRD
7	which	which	B-NP	WDT	O	6	NMOD
8	attenuates	attenuate	B-VP	VBZ	O	7	SBAR
9	scopolamine	scopolamine	B-NP	NN	O	11	NMOD
10	induced	induced	I-NP	JJ	O	11	NMOD
11	learning	learning	I-NP	NN	O	15	NMOD
12	and	and	O	CC	O	15	NMOD
13	post-training	post-training	B-NP	JJ	O	15	NMOD
14	consolidation	consolidation	I-NP	NN	O	15	NMOD
15	deficits	deficit	I-NP	NNS	O	8	OBJ
16	.	.	O	.	O	2	P

1	Given	Give	B-VP	VBN	O	21	VMOD
2	that	that	B-SBAR	IN	O	1	VMOD
3	apomorphine	apomorphine	B-NP	NN	O	4	SUB
4	inhibits	inhibit	B-VP	VBZ	O	2	SBAR
5	passive	passive	B-NP	JJ	O	7	NMOD
6	avoidance	avoidance	I-NP	NN	O	7	NMOD
7	retention	retention	I-NP	NN	O	4	OBJ
8	when	when	B-ADVP	WRB	O	4	VMOD
9	given	give	B-VP	VBN	O	8	SBAR
10	during	during	B-PP	IN	O	9	VMOD
11	training	training	B-NP	NN	O	10	PMOD
12	or	or	B-PP	CC	O	10	PMOD
13	in	in	B-PP	IN	O	10	PMOD
14	a	a	B-NP	DT	O	18	NMOD
15	defined	define	I-NP	VBN	O	18	NMOD
16	10-12h	10-12h	I-NP	JJ	O	18	NMOD
17	post-training	post-training	I-NP	JJ	O	18	NMOD
18	period	period	I-NP	NN	O	13	PMOD
19	,	,	O	,	O	21	P
20	we	we	B-NP	PRP	O	21	SUB
21	evaluated	evaluate	B-VP	VBD	O	0	ROOT
22	the	the	B-NP	DT	O	23	NMOD
23	ability	ability	I-NP	NN	O	21	OBJ
24	of	of	B-PP	IN	O	23	NMOD
25	nefiracetam	nefiracetam	B-NP	NN	O	24	PMOD
26	to	to	B-VP	TO	O	27	VMOD
27	attenuate	attenuate	I-VP	VB	O	23	NMOD
28	amnesia	amnesia	B-NP	NN	O	27	OBJ
29	induced	induce	B-VP	VBN	O	28	NMOD
30	by	by	B-PP	IN	O	29	VMOD
31	dopaminergic	dopaminergic	B-NP	JJ	O	32	NMOD
32	agonism	agonism	I-NP	NN	O	30	PMOD
33	.	.	O	.	O	21	P

1	However	However	B-ADVP	RB	O	9	VMOD
2	,	,	O	,	O	9	P
3	administration	administration	B-NP	NN	O	9	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	nefiracetam	nefiracetam	B-NP	NN	O	4	PMOD
6	during	during	B-PP	IN	O	3	NMOD
7	training	training	B-NP	NN	O	6	PMOD
8	completely	completely	B-ADVP	RB	O	9	VMOD
9	reversed	reverse	B-VP	VBD	O	0	ROOT
10	the	the	B-NP	DT	O	11	NMOD
11	amnesia	amnesia	I-NP	NN	O	22	NMOD
12	induced	induce	B-VP	VBN	O	11	NMOD
13	by	by	B-PP	IN	O	12	VMOD
14	apomorphine	apomorphine	B-NP	NN	O	13	PMOD
15	at	at	B-PP	IN	O	12	VMOD
16	the	the	B-NP	DT	O	19	NMOD
17	10h	10h	I-NP	JJ	O	19	NMOD
18	post-training	post-training	I-NP	JJ	O	19	NMOD
19	time	time	I-NP	NN	O	15	PMOD
20	and	and	O	CC	O	22	NMOD
21	the	the	B-NP	DT	O	22	NMOD
22	converse	converse	I-NP	NN	O	9	OBJ
23	was	be	B-VP	VBD	O	9	VMOD
24	also	also	B-ADVP	RB	O	23	VMOD
25	true	true	B-ADJP	JJ	O	23	PRD
26	.	.	O	.	O	9	P

1	Human	Human	B-NP	JJ	O	3	NMOD
2	corticotropin-releasing	corticotropin-releasing	I-NP	NN	O	3	NMOD
3	hormone	hormone	I-NP	NN	O	6	NMOD
4	and	and	O	CC	O	6	NMOD
5	thyrotropin-releasing	thyrotropin-releasing	B-NP	NN	O	6	NMOD
6	hormone	hormone	I-NP	NN	O	7	SUB
7	modulate	modulate	B-VP	VBP	O	0	ROOT
8	the	the	B-NP	DT	O	11	NMOD
9	hypercapnic	hypercapnic	I-NP	JJ	O	11	NMOD
10	ventilatory	ventilatory	I-NP	JJ	O	11	NMOD
11	response	response	I-NP	NN	O	7	OBJ
12	in	in	B-PP	IN	O	11	NMOD
13	humans	human	B-NP	NNS	O	12	PMOD
14	.	.	O	.	O	7	P

1	Lamivudine	Lamivudine	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	effective	effective	B-ADJP	JJ	O	2	PRD
4	in	in	B-PP	IN	O	3	AMOD
5	suppressing	suppress	B-VP	VBG	O	4	PMOD
6	hepatitis	hepatitis	B-NP	NN	B-DNA	9	NMOD
7	B	B	I-NP	NN	I-DNA	9	NMOD
8	virus	virus	I-NP	NN	I-DNA	9	NMOD
9	DNA	DNA	I-NP	NN	I-DNA	5	OBJ
10	in	in	B-PP	IN	O	5	VMOD
11	Chinese	Chinese	B-NP	JJ	O	16	NMOD
12	hepatitis	hepatitis	I-NP	NN	O	16	NMOD
13	B	B	I-NP	NN	O	16	NMOD
14	surface	surface	I-NP	NN	O	16	NMOD
15	antigen	antigen	I-NP	NN	O	16	NMOD
16	carriers	carrier	I-NP	NNS	O	10	PMOD
17	:	:	O	:	O	2	P
18	a	a	B-NP	DT	O	20	NMOD
19	placebo-controlled	placebo-controlled	I-NP	JJ	O	20	NMOD
20	trial	trial	I-NP	NN	O	2	VMOD
21	.	.	O	.	O	2	P

1	Lamivudine	Lamivudine	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	a	a	B-NP	DT	O	6	NMOD
4	novel	novel	I-NP	JJ	O	6	NMOD
5	2	2	I-NP	CD	O	6	NMOD
6	'	'	I-NP	SYM	O	10	NMOD
7	,	,	O	,	O	10	P
8	3'-dideoxy	3'-dideoxy	B-NP	JJ	O	10	NMOD
9	cytosine	cytosine	I-NP	NN	O	10	NMOD
10	analogue	analogue	I-NP	NN	O	2	PRD
11	that	that	B-NP	WDT	O	10	NMOD
12	has	have	B-VP	VBZ	O	11	SBAR
13	potent	potent	B-NP	JJ	O	14	AMOD
14	inhibitory	inhibitory	I-NP	JJ	O	15	NMOD
15	effects	effect	I-NP	NNS	O	12	OBJ
16	on	on	B-PP	IN	O	12	VMOD
17	hepatitis	hepatitis	B-NP	NN	O	20	NMOD
18	B	B	I-NP	NN	O	20	NMOD
19	virus	virus	I-NP	NN	O	20	NMOD
20	replication	replication	I-NP	NN	O	16	PMOD
21	in	in	B-ADVP	FW	O	12	VMOD
22	vitro	vitro	I-ADVP	FW	O	21	AMOD
23	and	and	O	CC	O	21	AMOD
24	in	in	B-ADVP	FW	O	21	AMOD
25	vivo	vivo	I-ADVP	FW	O	24	AMOD
26	.	.	O	.	O	2	P

1	All	All	B-NP	DT	O	3	NMOD
2	36	36	I-NP	CD	O	3	NMOD
3	patients	patient	I-NP	NNS	O	6	SUB
4	receiving	receive	B-VP	VBG	O	3	NMOD
5	lamivudine	lamivudine	B-NP	NN	O	4	OBJ
6	had	have	B-VP	VBD	O	0	ROOT
7	a	a	B-NP	DT	O	8	NMOD
8	decrease	decrease	I-NP	NN	O	6	OBJ
9	in	in	B-PP	IN	O	6	VMOD
10	hepatitis	hepatitis	B-NP	NN	O	12	NMOD
11	B	B	I-NP	NN	O	12	NMOD
12	virus	virus	I-NP	NN	O	9	PMOD
13	(	(	O	(	O	15	DEP
14	HBV	HBV	B-NP	NN	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	DNA	DNA	B-NP	NN	O	17	NMOD
17	values	value	I-NP	NNS	O	9	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	>	>	B-NP	JJR	O	20	AMOD
20	90	90	I-NP	CD	O	21	NMOD
21	%	%	I-NP	NN	O	18	PMOD
22	(	(	O	(	O	29	DEP
23	P	P	B-NP	NN	O	29	DEP
24	<	<	O	SYM	O	23	NMOD
25	.001	.001	B-NP	CD	O	24	AMOD
26	compared	compare	B-PP	VBN	O	23	NMOD
27	with	with	B-PP	IN	O	26	VMOD
28	placebo	placebo	B-NP	NN	O	27	PMOD
29	)	)	O	)	O	17	NMOD
30	.	.	O	.	O	6	P

1	Population-based	Population-based	B-NP	JJ	O	2	NMOD
2	study	study	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	risk	risk	B-NP	NN	O	3	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	venous	venous	B-NP	JJ	O	7	NMOD
7	thromboembolism	thromboembolism	I-NP	NN	O	5	PMOD
8	associated	associate	B-VP	VBN	O	7	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	various	various	B-NP	JJ	O	12	NMOD
11	oral	oral	I-NP	JJ	O	12	NMOD
12	contraceptives	contraceptive	I-NP	NNS	O	9	PMOD
13	.	.	O	.	O	2	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Four	Four	B-NP	CD	O	4	NMOD
4	studies	study	I-NP	NNS	O	1	OBJ
5	published	publish	B-VP	VBN	O	4	NMOD
6	since	since	B-PP	IN	O	5	VMOD
7	December	December	B-NP	NNP	O	9	NMOD
8	,	,	O	,	O	9	P
9	1995	1995	B-NP	CD	O	11	VMOD
10	,	,	O	,	O	11	P
11	reported	report	B-VP	VBD	O	6	SBAR
12	that	that	B-SBAR	IN	O	11	VMOD
13	the	the	B-NP	DT	O	14	NMOD
14	incidence	incidence	I-NP	NN	O	21	SUB
15	of	of	B-PP	IN	O	14	NMOD
16	venous	venous	B-NP	JJ	O	17	NMOD
17	thromboembolism	thromboembolism	I-NP	NN	O	15	PMOD
18	(	(	O	(	O	20	DEP
19	VTE	VTE	B-NP	NN	O	20	DEP
20	)	)	O	)	O	17	NMOD
21	was	be	B-VP	VBD	O	12	SBAR
22	higher	high	B-ADJP	JJR	O	21	PRD
23	in	in	B-PP	IN	O	22	AMOD
24	women	woman	B-NP	NNS	O	23	PMOD
25	who	who	B-NP	WP	O	24	NMOD
26	used	use	B-VP	VBD	O	25	SBAR
27	oral	oral	B-NP	JJ	O	28	NMOD
28	contraceptives	contraceptive	I-NP	NNS	O	26	OBJ
29	(	(	O	(	O	31	DEP
30	OCs	OC	B-NP	NNS	O	31	DEP
31	)	)	O	)	O	28	NMOD
32	containing	contain	B-VP	VBG	O	28	NMOD
33	the	the	B-NP	DT	O	35	NMOD
34	third-generation	third-generation	I-NP	JJ	O	35	NMOD
35	progestagens	progestagen	I-NP	NNS	O	38	NMOD
36	gestodene	gestodene	I-NP	NN	O	38	NMOD
37	or	or	I-NP	CC	O	38	NMOD
38	desogestrel	desogestrel	I-NP	NN	O	32	OBJ
39	than	than	B-PP	IN	O	32	VMOD
40	in	in	B-PP	IN	O	39	PMOD
41	users	user	B-NP	NNS	O	40	PMOD
42	of	of	B-PP	IN	O	41	NMOD
43	OCs	OC	B-NP	NNS	B-cell_type	42	PMOD
44	containing	contain	B-VP	VBG	O	43	NMOD
45	second-generation	second-generation	B-NP	JJ	O	46	NMOD
46	progestagens	progestagen	I-NP	NNS	O	44	OBJ
47	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	aim	aim	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	our	our	B-NP	PRP$	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	re-examine	re-examine	I-VP	VB	O	6	PRD
9	the	the	B-NP	DT	O	10	NMOD
10	association	association	I-NP	NN	O	8	OBJ
11	between	between	B-PP	IN	O	10	NMOD
12	risk	risk	B-NP	NN	O	11	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	VTE	VTE	B-NP	NN	B-protein	17	NMOD
15	and	and	I-NP	CC	O	17	NMOD
16	OC	OC	I-NP	NN	O	17	NMOD
17	use	use	I-NP	NN	O	13	PMOD
18	with	with	B-PP	IN	O	12	NMOD
19	a	a	B-NP	DT	O	22	NMOD
20	different	different	I-NP	JJ	O	22	NMOD
21	study	study	I-NP	NN	O	22	NMOD
22	design	design	I-NP	NN	O	24	NMOD
23	and	and	O	CC	O	24	NMOD
24	analysis	analysis	B-NP	NN	O	18	PMOD
25	to	to	B-VP	TO	O	26	VMOD
26	avoid	avoid	I-VP	VB	O	12	NMOD
27	some	some	B-NP	DT	O	26	OBJ
28	of	of	B-PP	IN	O	27	NMOD
29	the	the	B-NP	DT	O	30	NMOD
30	bias	bias	I-NP	NN	O	28	PMOD
31	and	and	O	CC	O	26	VMOD
32	confounding	confound	B-VP	VBG	O	26	VMOD
33	of	of	B-PP	IN	O	32	VMOD
34	the	the	B-NP	DT	O	36	NMOD
35	earlier	early	I-NP	JJR	O	36	NMOD
36	studies	study	I-NP	NNS	O	33	PMOD
37	.	.	O	.	O	6	P

1	We	We	B-NP	PRP	O	2	SUB
2	did	do	B-VP	VBD	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	cohort	cohort	I-NP	JJ	O	5	NMOD
5	analysis	analysis	I-NP	NN	O	2	OBJ
6	to	to	B-VP	TO	O	7	VMOD
7	estimate	estimate	I-VP	VB	O	5	NMOD
8	and	and	I-VP	CC	O	7	VMOD
9	compare	compare	I-VP	VB	O	7	VMOD
10	incidence	incidence	B-NP	NN	O	7	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	VTE	VTE	B-NP	NN	B-protein	11	PMOD
13	in	in	B-PP	IN	O	10	NMOD
14	users	user	B-NP	NNS	O	13	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	19	NMOD
17	main	main	I-NP	JJ	O	19	NMOD
18	OC	OC	I-NP	NN	O	19	NMOD
19	preparations	preparation	I-NP	NNS	O	15	PMOD
20	,	,	O	,	O	2	VMOD
21	and	and	O	CC	O	25	NMOD
22	a	a	B-NP	DT	O	25	NMOD
23	nested	nested	I-NP	JJ	O	25	NMOD
24	case-control	case-control	I-NP	JJ	O	25	NMOD
25	study	study	I-NP	NN	O	20	OBJ
26	to	to	B-VP	TO	O	27	VMOD
27	calculate	calculate	I-VP	VB	O	25	NMOD
28	the	the	B-NP	DT	O	30	NMOD
29	odds	odd	I-NP	NNS	O	30	NMOD
30	ratios	ratio	I-NP	NNS	O	27	OBJ
31	of	of	B-PP	IN	O	30	NMOD
32	VTE	VTE	B-NP	NN	O	31	PMOD
33	associated	associate	B-VP	VBN	O	32	NMOD
34	with	with	B-PP	IN	O	33	VMOD
35	use	use	B-NP	NN	O	34	PMOD
36	of	of	B-PP	IN	O	35	NMOD
37	different	different	B-NP	JJ	O	38	NMOD
38	types	type	I-NP	NNS	O	36	PMOD
39	of	of	B-PP	IN	O	38	NMOD
40	OC	OC	B-NP	NN	O	39	PMOD
41	,	,	O	,	O	25	P
42	after	after	B-PP	IN	O	25	NMOD
43	adjustment	adjustment	B-NP	NN	O	42	PMOD
44	for	for	B-PP	IN	O	43	NMOD
45	potential	potential	B-NP	JJ	O	47	NMOD
46	confounding	confound	I-NP	VBG	O	47	NMOD
47	factors	factor	I-NP	NNS	O	44	PMOD
48	.	.	O	.	O	2	P

1	FINDINGS	FINDINGS	B-NP	NNS	O	4	NMOD
2	:	:	O	:	O	1	P
3	85	85	B-NP	CD	O	4	NMOD
4	women	woman	I-NP	NNS	O	5	SUB
5	met	meet	B-VP	VBD	O	15	VMOD
6	the	the	B-NP	DT	O	8	NMOD
7	inclusion	inclusion	I-NP	NN	O	8	NMOD
8	criteria	criterion	I-NP	NNS	O	15	SUB
9	for	for	B-PP	IN	O	8	NMOD
10	VTE	VTE	B-NP	NNP	O	12	NMOD
11	,	,	O	,	O	12	P
12	two	two	B-NP	CD	O	9	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	whom	whom	B-NP	WP	O	13	PMOD
15	were	be	B-VP	VBD	O	0	ROOT
16	users	user	B-NP	NNS	O	15	PRD
17	of	of	B-PP	IN	O	16	NMOD
18	progestagen-only	progestagen-only	B-NP	JJ	B-cell_line	19	NMOD
19	OCs	OC	I-NP	NNS	I-cell_line	17	PMOD
20	.	.	O	.	O	15	P

1	Of	Of	B-PP	IN	O	15	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	83	83	I-NP	CD	O	4	NMOD
4	cases	case	I-NP	NNS	O	1	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	VTE	VTE	B-NP	NN	O	5	PMOD
7	associated	associate	B-VP	VBN	O	4	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	use	use	B-NP	NN	O	8	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	combined	combined	B-NP	JJ	O	12	NMOD
12	OCs	OC	I-NP	NNS	O	10	PMOD
13	,	,	O	,	O	15	P
14	43	43	B-NP	CD	O	15	SUB
15	were	be	B-VP	VBD	O	0	ROOT
16	recorded	record	I-VP	VBN	O	15	VC
17	as	as	B-PP	IN	O	16	VMOD
18	deep-vein	deep-vein	B-NP	JJ	O	19	NMOD
19	thrombosis	thrombosis	I-NP	NN	O	17	PMOD
20	,	,	O	,	O	15	P
21	35	35	B-NP	CD	O	27	NMOD
22	as	as	B-PP	IN	O	21	NMOD
23	pulmonary	pulmonary	B-NP	JJ	O	24	NMOD
24	thrombosis	thrombosis	I-NP	NN	O	22	PMOD
25	,	,	O	,	O	21	P
26	and	and	O	CC	O	27	NMOD
27	five	five	B-NP	CD	O	15	VMOD
28	as	as	B-SBAR	IN	O	27	NMOD
29	venous	venous	B-NP	JJ	O	30	NMOD
30	thrombosis	thrombosis	I-NP	NN	O	33	SUB
31	not	not	B-VP	RB	O	33	VMOD
32	otherwise	otherwise	I-VP	RB	O	31	AMOD
33	specified	specify	I-VP	VBN	O	28	SBAR
34	.	.	O	.	O	15	P

1	The	The	B-NP	DT	O	3	NMOD
2	crude	crude	I-NP	JJ	O	3	NMOD
3	rate	rate	I-NP	NN	O	10	NMOD
4	of	of	B-PP	IN	O	3	NMOD
5	VTE	VTE	B-NP	NN	B-protein	4	PMOD
6	per	per	B-PP	IN	I-protein	3	NMOD
7	10	10	B-NP	CD	I-protein	6	PMOD
8	,	,	O	,	O	10	P
9	000	000	B-NP	CD	O	10	NMOD
10	woman-years	woman-year	I-NP	NNS	O	11	SUB
11	was	be	B-VP	VBD	O	0	ROOT
12	4.10	4.10	B-NP	CD	O	20	NMOD
13	in	in	B-PP	IN	O	12	NMOD
14	current	current	B-NP	JJ	O	15	NMOD
15	users	user	I-NP	NNS	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	any	any	B-NP	DT	O	18	NMOD
18	OC	OC	I-NP	NN	O	16	PMOD
19	,	,	O	,	O	20	P
20	3.10	3.10	B-NP	CD	O	28	NMOD
21	in	in	B-PP	IN	O	20	NMOD
22	users	user	B-NP	NNS	O	21	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	second-generation	second-generation	B-NP	JJ	O	25	NMOD
25	OCs	OC	I-NP	NNS	O	23	PMOD
26	,	,	O	,	O	20	P
27	and	and	O	CC	O	28	NMOD
28	4.96	4.96	B-NP	CD	O	11	PRD
29	in	in	B-PP	IN	O	28	NMOD
30	users	user	B-NP	NNS	O	29	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	third-generation	third-generation	B-NP	JJ	O	33	NMOD
33	preparations	preparation	I-NP	NNS	O	31	PMOD
34	.	.	O	.	O	11	P

1	After	After	B-PP	IN	O	19	VMOD
2	adjustment	adjustment	B-NP	NN	O	1	PMOD
3	for	for	B-PP	IN	O	2	NMOD
4	age	age	B-NP	NN	O	3	PMOD
5	,	,	O	,	O	19	P
6	the	the	B-NP	DT	O	8	NMOD
7	rate	rate	I-NP	NN	O	8	NMOD
8	ratio	ratio	I-NP	NN	O	19	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	VTE	VTE	B-NP	NN	B-protein	9	PMOD
11	in	in	B-PP	IN	O	8	NMOD
12	users	user	B-NP	NNS	O	11	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	third-generation	third-generation	B-NP	NN	O	13	PMOD
15	relative	relative	B-ADVP	JJ	O	8	NMOD
16	to	to	B-PP	TO	O	15	AMOD
17	second-generation	second-generation	B-NP	JJ	O	18	NMOD
18	OCs	OC	I-NP	NNS	O	16	PMOD
19	was	be	B-VP	VBD	O	0	ROOT
20	1.68	1.68	B-NP	CD	O	19	PRD
21	(	(	O	(	O	26	DEP
22	95	95	B-NP	CD	O	24	NMOD
23	%	%	I-NP	NN	O	24	NMOD
24	CI	CI	I-NP	NN	O	26	DEP
25	1.04-2.75	1.04-2.75	I-NP	CD	O	24	NMOD
26	)	)	O	)	O	20	NMOD
27	.	.	O	.	O	19	P

1	Logistic	Logistic	B-NP	JJ	O	2	NMOD
2	regression	regression	I-NP	NN	O	3	SUB
3	showed	show	B-VP	VBD	O	0	ROOT
4	no	no	B-NP	DT	O	6	NMOD
5	significant	significant	I-NP	JJ	O	6	NMOD
6	difference	difference	I-NP	NN	O	3	OBJ
7	in	in	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	risk	risk	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	VTE	VTE	B-NP	NN	O	10	PMOD
12	between	between	B-PP	IN	O	6	NMOD
13	users	user	B-NP	NNS	O	12	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	third-generation	third-generation	B-NP	JJ	O	18	NMOD
16	and	and	I-NP	CC	O	18	NMOD
17	second-generation	second-generation	I-NP	JJ	O	18	NMOD
18	OCs	OC	I-NP	NNS	O	14	PMOD
19	.	.	O	.	O	3	P

1	Among	Among	B-PP	IN	O	11	VMOD
2	users	user	B-NP	NNS	O	1	PMOD
3	of	of	B-PP	IN	O	2	NMOD
4	third-generation	third-generation	B-NP	JJ	O	5	NMOD
5	progestagens	progestagen	I-NP	NNS	O	3	PMOD
6	,	,	O	,	O	11	P
7	the	the	B-NP	DT	O	8	NMOD
8	risk	risk	I-NP	NN	O	11	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	VTE	VTE	B-NP	NN	B-protein	9	PMOD
11	was	be	B-VP	VBD	O	0	ROOT
12	higher	high	B-ADJP	JJR	O	11	PRD
13	in	in	B-PP	IN	O	12	AMOD
14	users	user	B-NP	NNS	O	13	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	desogestrel	desogestrel	B-NP	NN	O	15	PMOD
17	with	with	B-PP	IN	O	14	NMOD
18	20	20	B-NP	CD	O	19	AMOD
19	g	g	I-NP	NN	O	20	NMOD
20	ethinyloestradiol	ethinyloestradiol	I-NP	NN	O	17	PMOD
21	than	than	B-PP	IN	O	12	AMOD
22	in	in	B-PP	IN	O	21	PMOD
23	users	user	B-NP	NNS	O	22	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	gestodene	gestodene	B-NP	NN	O	27	NMOD
26	or	or	I-NP	CC	O	27	NMOD
27	desogestrel	desogestrel	I-NP	NN	O	24	PMOD
28	with	with	B-PP	IN	O	12	AMOD
29	30	30	B-NP	CD	O	31	NMOD
30	g	g	I-NP	NN	O	31	NMOD
31	ethinyloestradiol	ethinyloestradiol	I-NP	NN	O	28	PMOD
32	.	.	O	.	O	11	P

1	With	With	B-PP	IN	O	14	VMOD
2	all	all	B-NP	DT	O	4	NMOD
3	second-generation	second-generation	I-NP	JJ	O	4	NMOD
4	OCs	OC	I-NP	NNS	O	1	PMOD
5	as	as	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	reference	reference	I-NP	NN	O	5	PMOD
8	,	,	O	,	O	14	P
9	the	the	B-NP	DT	O	11	NMOD
10	odds	odd	I-NP	NNS	O	11	NMOD
11	ratios	ratio	I-NP	NNS	O	14	SUB
12	for	for	B-PP	IN	O	11	NMOD
13	VTE	VTE	B-NP	NNP	O	12	PMOD
14	were	be	B-VP	VBD	O	0	ROOT
15	3.49	3.49	B-NP	CD	O	14	PRD
16	(	(	O	(	O	18	DEP
17	1.21-10.12	1.21-10.12	B-NP	CD	O	18	DEP
18	)	)	O	)	O	15	NMOD
19	for	for	B-PP	IN	O	15	NMOD
20	desogestrel	desogestrel	B-NP	NN	O	24	NMOD
21	plus	plus	O	CC	O	24	NMOD
22	20	20	B-NP	CD	O	24	NMOD
23	g	g	I-NP	NN	O	24	NMOD
24	ethinyloestradiol	ethinyloestradiol	I-NP	NN	O	19	PMOD
25	and	and	O	CC	O	24	NMOD
26	1.18	1.18	B-NP	CD	O	25	PMOD
27	(	(	O	(	O	29	DEP
28	0.66-2.17	0.66-2.17	B-NP	CD	O	29	DEP
29	)	)	O	)	O	26	NMOD
30	for	for	B-PP	IN	O	26	NMOD
31	the	the	B-NP	DT	O	34	NMOD
32	other	other	I-NP	JJ	O	34	NMOD
33	third-generation	third-generation	I-NP	JJ	O	34	NMOD
34	progestagens	progestagen	I-NP	NNS	O	30	PMOD
35	.	.	O	.	O	14	P

1	MK-801	MK-801	B-NP	NN	B-protein	2	SUB
2	augments	augment	B-VP	VBZ	O	0	ROOT
3	pilocarpine	pilocarpine	B-NP	NN	O	6	NMOD
4	induced	induced	I-NP	JJ	O	6	NMOD
5	electrographic	electrographic	I-NP	JJ	O	6	NMOD
6	seizure	seizure	I-NP	NN	O	2	OBJ
7	but	but	O	CC	O	2	VMOD
8	protects	protect	B-VP	VBZ	O	2	VMOD
9	against	against	B-PP	IN	O	8	VMOD
10	brain	brain	B-NP	NN	O	11	NMOD
11	damage	damage	I-NP	NN	O	9	PMOD
12	in	in	B-PP	IN	O	8	VMOD
13	rats.	rats.	B-NP	NN	B-protein	12	PMOD
14	1	1	I-NP	CD	I-protein	13	NMOD
15	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	authors	author	I-NP	NNS	O	3	SUB
3	examined	examine	B-VP	VBD	O	0	ROOT
4	the	the	B-NP	DT	O	6	NMOD
5	anticonvulsant	anticonvulsant	I-NP	JJ	O	6	NMOD
6	effects	effect	I-NP	NNS	O	3	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	MK-801	MK-801	B-NP	NN	B-protein	7	PMOD
9	on	on	B-PP	IN	O	6	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	pilocarpine	pilocarpine	I-NP	NN	O	9	PMOD
12	induced	induce	B-VP	VBD	O	6	NMOD
13	seizure	seizure	B-NP	NN	O	14	NMOD
14	model	model	I-NP	NN	O	12	OBJ
15	.	.	O	.	O	3	P

1	Intraperitoneal	Intraperitoneal	B-NP	JJ	O	2	NMOD
2	injection	injection	I-NP	NN	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	pilocarpine	pilocarpine	B-NP	NN	O	3	PMOD
5	(	(	O	(	O	8	DEP
6	400	400	B-NP	CD	O	7	NMOD
7	mg/kg	mg/kg	I-NP	NN	O	8	DEP
8	)	)	O	)	O	4	NMOD
9	induced	induce	B-VP	VBD	O	0	ROOT
10	tonic	tonic	B-NP	JJ	O	13	NMOD
11	and	and	I-NP	CC	O	13	NMOD
12	clonic	clonic	I-NP	JJ	O	13	NMOD
13	seizure	seizure	I-NP	NN	O	9	OBJ
14	.	.	O	.	O	9	P

1	Scopolamine	Scopolamine	B-NP	NN	O	7	NMOD
2	(	(	O	(	O	5	DEP
3	10	10	B-NP	CD	O	4	NMOD
4	mg/kg	mg/kg	I-NP	NN	O	5	DEP
5	)	)	O	)	O	1	NMOD
6	and	and	O	CC	O	7	NMOD
7	pentobarbital	pentobarbital	B-NP	NN	O	12	SUB
8	(	(	O	(	O	11	DEP
9	5	5	B-NP	CD	O	10	NMOD
10	mg/kg	mg/kg	I-NP	NN	O	11	DEP
11	)	)	O	)	O	7	NMOD
12	prevented	prevent	B-VP	VBD	O	0	ROOT
13	development	development	B-NP	NN	O	12	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	pilocarpine	pilocarpine	B-NP	NN	O	14	PMOD
16	induced	induce	B-VP	VBD	O	13	NMOD
17	behavioral	behavioral	B-NP	JJ	O	18	NMOD
18	seizure	seizure	I-NP	NN	O	25	SUB
19	but	but	O	CC	O	25	VMOD
20	MK-801	MK-801	B-NP	NN	O	25	SUB
21	(	(	O	(	O	24	DEP
22	0.5	0.5	B-NP	CD	O	23	NMOD
23	mg/kg	mg/kg	I-NP	NN	O	24	DEP
24	)	)	O	)	O	20	NMOD
25	did	do	B-VP	VBD	O	16	VMOD
26	not.	not.	B-NP	NN	B-protein	25	OBJ
27	2	2	I-NP	CD	I-protein	26	NMOD
28	.	.	O	.	O	12	P

1	An	An	B-NP	DT	O	3	NMOD
2	electrical	electrical	I-NP	JJ	O	3	NMOD
3	seizure	seizure	I-NP	NN	O	8	SUB
4	measured	measure	B-VP	VBN	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	hippocampal	hippocampal	B-NP	JJ	O	7	NMOD
7	EEG	EEG	I-NP	NN	O	5	PMOD
8	appeared	appear	B-VP	VBD	O	0	ROOT
9	in	in	B-PP	IN	O	8	VMOD
10	the	the	B-NP	DT	O	12	NMOD
11	pilocarpine-treated	pilocarpine-treated	I-NP	JJ	O	12	NMOD
12	group	group	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	8	P

1	Scopolamine	Scopolamine	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	pentobarbital	pentobarbital	I-NP	NN	O	4	SUB
4	blocked	block	B-VP	VBD	O	0	ROOT
5	the	the	B-NP	DT	O	6	NMOD
6	pilocarpine	pilocarpine	I-NP	NN	O	12	NMOD
7	induced	induce	B-VP	VBD	O	12	NMOD
8	electrographic	electrographic	B-NP	JJ	O	9	NMOD
9	seizure	seizure	I-NP	NN	O	12	NMOD
10	,	,	O	,	O	12	P
11	MK-801	MK-801	B-NP	NN	O	12	NMOD
12	treatment	treatment	I-NP	NN	O	13	SUB
13	augmented	augment	B-VP	VBD	O	4	VMOD
14	the	the	B-NP	DT	O	16	NMOD
15	electrographic	electrographic	I-NP	JJ	O	16	NMOD
16	seizure	seizure	I-NP	NN	O	13	OBJ
17	induced	induce	B-VP	VBN	O	16	NMOD
18	by	by	B-PP	IN	O	17	VMOD
19	pilocarpine.	pilocarpine.	B-NP	NN	B-protein	18	PMOD
20	3	3	I-NP	CD	I-protein	19	NMOD
21	.	.	O	.	O	4	P

1	Pilocarpine	Pilocarpine	B-NP	NN	O	2	SUB
2	produced	produce	B-VP	VBD	O	0	ROOT
3	neuronal	neuronal	B-NP	JJ	O	4	NMOD
4	death	death	I-NP	NN	O	2	OBJ
5	in	in	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	hippocampus	hippocampus	I-NP	NN	O	5	PMOD
8	,	,	O	,	O	2	P
9	which	which	B-NP	WDT	O	2	VMOD
10	showed	show	B-VP	VBD	O	9	SBAR
11	pyknotic	pyknotic	B-NP	JJ	O	12	NMOD
12	changes	change	I-NP	NNS	O	10	OBJ
13	.	.	O	.	O	2	P

1	Pentobarbital	Pentobarbital	B-NP	NN	O	5	NMOD
2	,	,	I-NP	,	O	5	P
3	scopolamine	scopolamine	I-NP	NN	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	MK-801	MK-801	I-NP	NN	B-protein	6	SUB
6	protected	protect	B-VP	VBD	O	0	ROOT
7	the	the	B-NP	DT	O	9	NMOD
8	brain	brain	I-NP	NN	O	9	NMOD
9	damage	damage	I-NP	NN	O	6	OBJ
10	by	by	B-PP	IN	O	6	VMOD
11	pilocarpine	pilocarpine	B-NP	NN	O	10	PMOD
12	,	,	O	,	O	6	P
13	though	though	B-SBAR	IN	O	6	VMOD
14	in	in	B-PP	IN	O	24	VMOD
15	the	the	B-NP	DT	O	17	NMOD
16	MK-801-treated	MK-801-treated	I-NP	JJ	O	17	NMOD
17	group	group	I-NP	NN	O	14	PMOD
18	,	,	O	,	O	24	P
19	the	the	B-NP	DT	O	21	NMOD
20	pyramidal	pyramidal	I-NP	JJ	B-cell_type	21	NMOD
21	cells	cell	I-NP	NNS	I-cell_type	24	SUB
22	of	of	B-PP	IN	O	21	NMOD
23	hippocampus	hippocampus	B-NP	NN	O	22	PMOD
24	appeared	appear	B-VP	VBD	O	13	SBAR
25	darker	darker	B-ADVP	RBR	O	24	VMOD
26	than	than	B-PP	IN	O	25	AMOD
27	normal	normal	B-ADJP	JJ	O	26	SBAR
28	.	.	O	.	O	6	P

1	Paclitaxel	Paclitaxel	B-NP	NN	O	7	NMOD
2	,	,	O	,	O	7	P
3	5-fluorouracil	5-fluorouracil	B-NP	NN	O	7	NMOD
4	,	,	O	,	O	7	P
5	and	and	O	CC	O	7	NMOD
6	folinic	folinic	B-NP	JJ	O	7	NMOD
7	acid	acid	I-NP	NN	O	24	NMOD
8	in	in	B-PP	IN	O	7	NMOD
9	metastatic	metastatic	B-NP	JJ	O	11	NMOD
10	breast	breast	I-NP	NN	O	11	NMOD
11	cancer	cancer	I-NP	NN	O	8	PMOD
12	:	:	O	:	O	7	P
13	BRE-26	BRE-26	B-NP	NN	B-protein	7	NMOD
14	,	,	O	,	O	24	P
15	a	a	B-NP	DT	O	19	NMOD
16	phase	phase	I-NP	NN	O	19	NMOD
17	II	II	I-NP	CD	O	19	NMOD
18	trial.	trial.	I-NP	NN	O	19	NMOD
19	5-Fluorouracil	5-Fluorouracil	I-NP	NN	O	22	NMOD
20	plus	plus	O	CC	O	22	NMOD
21	folinic	folinic	B-NP	JJ	O	22	NMOD
22	acid	acid	I-NP	NN	O	24	NMOD
23	and	and	O	CC	O	24	NMOD
24	paclitaxel	paclitaxel	B-NP	NN	O	36	SUB
25	(	(	O	(	O	35	DEP
26	Taxol	Taxol	B-NP	NN	O	34	NMOD
27	;	;	O	:	O	34	P
28	Bristol-Myers	Bristol-Myers	B-NP	NNP	O	30	NMOD
29	Squibb	Squibb	I-NP	NNP	O	30	NMOD
30	Company	Company	I-NP	NNP	O	32	NMOD
31	,	,	O	,	O	32	P
32	Princeton	Princeton	B-NP	NNP	O	34	NMOD
33	,	,	O	,	O	34	P
34	NJ	NJ	B-NP	NNP	O	35	DEP
35	)	)	O	)	O	24	NMOD
36	are	be	B-VP	VBP	O	0	ROOT
37	effective	effective	B-NP	JJ	O	39	NMOD
38	salvage	salvage	I-NP	NN	O	39	NMOD
39	therapies	therapy	I-NP	NNS	O	36	PRD
40	for	for	B-PP	IN	O	39	NMOD
41	metastatic	metastatic	B-NP	JJ	O	44	NMOD
42	breast	breast	I-NP	NN	O	44	NMOD
43	cancer	cancer	I-NP	NN	O	44	NMOD
44	patients	patient	I-NP	NNS	O	40	PMOD
45	.	.	O	.	O	36	P

1	Paclitaxel	Paclitaxel	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	5-fluorouracil	5-fluorouracil	I-NP	NN	O	4	SUB
4	have	have	B-VP	VBP	O	0	ROOT
5	additive	additive	B-NP	JJ	O	6	NMOD
6	cytotoxicity	cytotoxicity	I-NP	NN	O	4	OBJ
7	in	in	B-PP	IN	O	4	VMOD
8	MCF-7	MCF-7	B-NP	NN	B-cell_line	10	NMOD
9	cell	cell	I-NP	NN	I-cell_line	10	NMOD
10	lines	line	I-NP	NNS	I-cell_line	7	PMOD
11	.	.	O	.	O	4	P

1	We	We	B-NP	PRP	O	2	SUB
2	performed	perform	B-VP	VBD	O	0	ROOT
3	a	a	B-NP	DT	O	6	NMOD
4	phase	phase	I-NP	NN	O	6	NMOD
5	II	II	I-NP	CD	O	6	NMOD
6	trial	trial	I-NP	NN	O	2	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	paclitaxel	paclitaxel	B-NP	NN	B-protein	10	NMOD
9	175	175	I-NP	CD	I-protein	10	NMOD
10	mg/m2	mg/m2	I-NP	NN	I-protein	7	PMOD
11	over	over	B-PP	IN	O	2	VMOD
12	3	3	B-NP	CD	O	13	NMOD
13	hours	hour	I-NP	NNS	O	11	PMOD
14	on	on	B-PP	IN	O	13	NMOD
15	day	day	B-NP	NN	B-DNA	14	PMOD
16	I	I	I-NP	CD	I-DNA	15	NMOD
17	followed	follow	B-VP	VBN	O	13	NMOD
18	by	by	B-PP	IN	O	17	VMOD
19	folinic	folinic	B-NP	JJ	B-protein	22	NMOD
20	acid	acid	I-NP	NN	I-protein	22	NMOD
21	300	300	I-NP	CD	I-protein	22	NMOD
22	mg	mg	I-NP	NN	I-protein	18	PMOD
23	over	over	B-PP	IN	I-protein	22	NMOD
24	1	1	B-NP	CD	I-protein	25	NMOD
25	hour	hour	I-NP	NN	I-protein	23	PMOD
26	before	before	B-PP	IN	I-protein	22	NMOD
27	5-fluorouracil	5-fluorouracil	B-NP	NN	I-protein	29	NMOD
28	350	350	I-NP	CD	I-protein	29	NMOD
29	mg/m2	mg/m2	I-NP	NN	I-protein	26	PMOD
30	on	on	B-PP	IN	O	17	VMOD
31	days	day	B-NP	NNS	O	30	PMOD
32	1	1	I-NP	CD	O	34	NMOD
33	to	to	I-NP	TO	O	34	NMOD
34	3	3	I-NP	CD	O	31	NMOD
35	every	every	B-NP	DT	O	37	NMOD
36	28	28	I-NP	CD	O	37	NMOD
37	days	day	I-NP	NNS	O	30	PMOD
38	(	(	O	(	O	40	DEP
39	TFL	TFL	B-NP	NN	B-protein	40	DEP
40	)	)	O	)	O	37	NMOD
41	in	in	B-PP	IN	O	37	NMOD
42	women	woman	B-NP	NNS	O	41	PMOD
43	with	with	B-PP	IN	O	42	NMOD
44	metastatic	metastatic	B-NP	JJ	O	46	NMOD
45	breast	breast	I-NP	NN	O	46	NMOD
46	cancer	cancer	I-NP	NN	O	43	PMOD
47	.	.	O	.	O	2	P

1	Analysis	Analysis	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	44	VMOD
3	reported	report	I-VP	VBN	O	2	VC
4	on	on	B-PP	IN	O	3	VMOD
5	37	37	B-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	4	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	a	a	B-NP	DT	O	9	NMOD
9	minimum	minimum	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	6	6	B-NP	CD	O	12	NMOD
12	months	month	I-NP	NNS	O	13	NMOD
13	follow-up	follow-up	B-NP	NN	O	10	PMOD
14	who	who	B-NP	WP	O	6	NMOD
15	received	receive	B-VP	VBD	O	14	SBAR
16	a	a	B-NP	DT	O	17	NMOD
17	total	total	I-NP	NN	O	15	OBJ
18	of	of	B-PP	IN	O	17	NMOD
19	192	192	B-NP	CD	O	20	NMOD
20	cycles	cycle	I-NP	NNS	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	TFL	TFL	B-NP	NN	B-protein	21	PMOD
23	:	:	O	:	O	44	P
24	nine	nine	B-NP	CD	O	25	NMOD
25	cycles	cycle	I-NP	NNS	O	30	SUB
26	(	(	O	(	O	29	DEP
27	5	5	B-NP	CD	O	28	NMOD
28	%	%	I-NP	NN	O	29	DEP
29	)	)	O	)	O	25	NMOD
30	were	be	B-VP	VBD	O	44	NMOD
31	associated	associate	I-VP	VBN	O	30	VC
32	with	with	B-PP	IN	O	31	VMOD
33	grade	grade	B-NP	NN	O	35	NMOD
34	3/4	3/4	I-NP	CD	O	35	NMOD
35	neutropenia	neutropenia	I-NP	NN	O	32	PMOD
36	requiring	require	B-VP	VBG	O	35	NMOD
37	hospitalization	hospitalization	B-NP	NN	O	36	OBJ
38	;	;	O	:	O	44	P
39	seven	seven	B-NP	CD	O	44	NMOD
40	(	(	O	(	O	43	DEP
41	4	4	B-NP	CD	O	42	NMOD
42	%	%	I-NP	NN	O	43	DEP
43	)	)	O	)	O	39	NMOD
44	cycles	cycle	B-NP	NNS	O	48	SUB
45	in	in	B-PP	IN	O	44	NMOD
46	two	two	B-NP	CD	O	47	NMOD
47	patients	patient	I-NP	NNS	O	45	PMOD
48	required	require	B-VP	VBD	O	58	VMOD
49	granulocyte	granulocyte	B-NP	NN	B-protein	51	NMOD
50	colony-stimulating	colony-stimulating	I-NP	JJ	I-protein	51	NMOD
51	factor	factor	I-NP	NN	I-protein	48	OBJ
52	due	due	B-ADJP	JJ	O	51	NMOD
53	to	to	B-PP	TO	O	52	AMOD
54	neutropenia	neutropenia	B-NP	NN	O	53	PMOD
55	;	;	O	:	O	58	P
56	no	no	B-NP	DT	O	57	NMOD
57	patient	patient	I-NP	NN	O	58	SUB
58	required	require	B-VP	VBD	O	0	ROOT
59	platelet	platelet	B-NP	NN	O	60	NMOD
60	transfusions	transfusion	I-NP	NNS	O	58	OBJ
61	.	.	O	.	O	58	P

1	Efficacy	Efficacy	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	proarrhythmia	proarrhythmia	I-NP	NN	O	10	NMOD
4	with	with	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	use	use	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	d	d	B-NP	NN	O	7	PMOD
9	,	,	O	,	O	10	P
10	l-sotalol	l-sotalol	B-NP	NN	O	0	ROOT
11	for	for	B-PP	IN	O	10	NMOD
12	sustained	sustained	B-NP	JJ	O	14	NMOD
13	ventricular	ventricular	I-NP	JJ	O	14	NMOD
14	tachyarrhythmias	tachyarrhythmia	I-NP	NNS	O	11	PMOD
15	.	.	O	.	O	10	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	4	SUB
3	prospectively	prospectively	B-ADVP	RB	O	4	VMOD
4	evaluated	evaluate	B-VP	VBD	O	20	VMOD
5	the	the	B-NP	DT	O	7	NMOD
6	clinical	clinical	I-NP	JJ	O	7	NMOD
7	efficacy	efficacy	I-NP	NN	O	10	NMOD
8	,	,	O	,	O	10	P
9	the	the	B-NP	DT	O	10	NMOD
10	incidence	incidence	I-NP	NN	O	4	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	torsades	torsade	B-NP	NNS	O	11	PMOD
13	de	de	B-PP	IN	O	12	NMOD
14	pointes	pointe	B-NP	NNS	O	13	PMOD
15	,	,	O	,	O	20	P
16	and	and	O	CC	O	20	NMOD
17	the	the	B-NP	DT	O	20	NMOD
18	presumable	presumable	I-NP	JJ	O	20	NMOD
19	risk	risk	I-NP	NN	O	20	NMOD
20	factors	factor	I-NP	NNS	O	31	NMOD
21	for	for	B-PP	IN	O	20	NMOD
22	torsades	torsade	B-NP	NNS	O	21	PMOD
23	de	de	B-PP	IN	O	22	NMOD
24	pointes	pointe	B-NP	NNS	O	23	PMOD
25	in	in	B-PP	IN	O	24	NMOD
26	patients	patient	B-NP	NNS	O	25	PMOD
27	treated	treat	B-VP	VBN	O	26	NMOD
28	with	with	B-PP	IN	O	27	VMOD
29	d	d	B-NP	NN	O	28	PMOD
30	,	,	O	,	O	31	P
31	l-sotalol	l-sotalol	B-NP	NN	O	0	ROOT
32	for	for	B-PP	IN	O	31	NMOD
33	sustained	sustained	B-NP	JJ	O	35	NMOD
34	ventricular	ventricular	I-NP	JJ	O	35	NMOD
35	tachyarrhythmias	tachyarrhythmia	I-NP	NNS	O	32	PMOD
36	.	.	O	.	O	31	P

1	Eighty-one	Eighty-one	B-NP	CD	O	3	NMOD
2	consecutive	consecutive	I-NP	JJ	O	3	NMOD
3	patients	patient	I-NP	NNS	O	25	SUB
4	(	(	O	(	O	16	DEP
5	54	54	B-NP	CD	O	12	NMOD
6	with	with	B-PP	IN	O	5	NMOD
7	coronary	coronary	B-NP	JJ	O	9	NMOD
8	artery	artery	I-NP	NN	O	9	NMOD
9	disease	disease	I-NP	NN	O	6	PMOD
10	,	,	O	,	O	12	P
11	and	and	O	CC	O	12	NMOD
12	20	20	B-NP	CD	O	16	DEP
13	with	with	B-PP	IN	O	12	NMOD
14	dilated	dilated	B-NP	JJ	O	15	NMOD
15	cardiomyopathy	cardiomyopathy	I-NP	NN	O	13	PMOD
16	)	)	O	)	O	3	NMOD
17	with	with	B-PP	IN	O	3	NMOD
18	inducible	inducible	B-NP	JJ	O	21	NMOD
19	sustained	sustained	I-NP	JJ	O	21	NMOD
20	ventricular	ventricular	I-NP	JJ	O	21	NMOD
21	tachycardia	tachycardia	I-NP	NN	O	24	NMOD
22	or	or	O	CC	O	24	NMOD
23	ventricular	ventricular	B-NP	JJ	O	24	NMOD
24	fibrillation	fibrillation	I-NP	NN	O	17	PMOD
25	received	receive	B-VP	VBD	O	0	ROOT
26	oral	oral	B-NP	JJ	O	27	NMOD
27	d	d	I-NP	NN	O	25	OBJ
28	,	,	O	,	O	29	P
29	l-sotalol	l-sotalol	B-NP	NN	O	27	NMOD
30	to	to	B-VP	TO	O	31	VMOD
31	prevent	prevent	I-VP	VB	O	29	NMOD
32	induction	induction	B-NP	NN	O	31	OBJ
33	of	of	B-PP	IN	O	32	NMOD
34	the	the	B-NP	DT	O	36	NMOD
35	ventricular	ventricular	I-NP	JJ	O	36	NMOD
36	tachyarrhythmia	tachyarrhythmia	I-NP	NN	O	33	PMOD
37	.	.	O	.	O	25	P

1	Those	Those	B-NP	DT	O	2	NMOD
2	patients	patient	I-NP	NNS	O	8	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	whom	whom	B-NP	WP	O	3	PMOD
5	d	d	B-NP	NN	O	4	NMOD
6	,	,	O	,	O	8	P
7	l-sotalol	l-sotalol	B-NP	NN	O	8	SUB
8	prevented	prevent	B-VP	VBD	O	0	ROOT
9	induction	induction	B-NP	NN	O	8	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	ventricular	ventricular	B-NP	JJ	O	12	NMOD
12	tachycardia	tachycardia	I-NP	NN	O	15	NMOD
13	or	or	O	CC	O	15	NMOD
14	ventricular	ventricular	B-NP	JJ	O	15	NMOD
15	fibrillation	fibrillation	I-NP	NN	O	10	PMOD
16	were	be	B-VP	VBD	O	8	VMOD
17	discharged	discharge	I-VP	VBN	O	16	VC
18	with	with	B-PP	IN	O	17	VMOD
19	the	the	B-NP	DT	O	20	NMOD
20	drug	drug	I-NP	NN	O	18	PMOD
21	and	and	O	CC	O	8	VMOD
22	followed	follow	B-VP	VBD	O	8	VMOD
23	up	up	B-PRT	RP	O	22	VMOD
24	on	on	B-PP	IN	O	22	VMOD
25	an	an	B-NP	DT	O	27	NMOD
26	outpatient	outpatient	I-NP	NN	O	27	NMOD
27	basis	basis	I-NP	NN	O	24	PMOD
28	for	for	B-PP	IN	O	22	VMOD
29	21	21	B-NP	CD	O	31	AMOD
30	+/-	+/-	I-NP	SYM	O	31	AMOD
31	18	18	I-NP	CD	O	32	NMOD
32	months	month	I-NP	NNS	O	28	PMOD
33	.	.	O	.	O	8	P

1	Induction	Induction	B-NP	NN	O	6	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	5	NMOD
4	ventricular	ventricular	I-NP	JJ	O	5	NMOD
5	tachyarrhythmia	tachyarrhythmia	I-NP	NN	O	2	PMOD
6	was	be	B-VP	VBD	O	24	VMOD
7	prevented	prevent	I-VP	VBN	O	6	VC
8	by	by	B-PP	IN	O	7	VMOD
9	oral	oral	B-NP	JJ	O	10	NMOD
10	d	d	I-NP	NN	O	8	PMOD
11	,	,	O	,	O	24	P
12	l-sotalol	l-sotalol	B-NP	NN	O	24	SUB
13	in	in	B-PP	IN	O	12	NMOD
14	35	35	B-NP	CD	O	19	NMOD
15	(	(	O	(	O	18	DEP
16	43	43	B-NP	CD	O	17	NMOD
17	%	%	I-NP	NN	O	18	DEP
18	)	)	O	)	O	14	NMOD
19	patients	patient	B-NP	NNS	O	13	PMOD
20	;	;	O	:	O	24	P
21	the	the	B-NP	DT	O	23	NMOD
22	ventricular	ventricular	I-NP	JJ	O	23	NMOD
23	tachyarrhythmia	tachyarrhythmia	I-NP	NN	O	24	SUB
24	remained	remain	B-VP	VBD	O	41	VMOD
25	inducible	inducible	B-ADJP	JJ	O	24	PRD
26	in	in	B-PP	IN	O	25	AMOD
27	40	40	B-NP	CD	O	26	PMOD
28	(	(	O	(	O	31	DEP
29	49	49	B-NP	CD	O	30	NMOD
30	%	%	I-NP	NN	O	31	DEP
31	)	)	O	)	O	27	NMOD
32	patients	patient	B-NP	NNS	O	27	NMOD
33	;	;	O	:	O	41	P
34	and	and	O	CC	O	40	NMOD
35	two	two	B-NP	CD	O	40	NMOD
36	(	(	O	(	O	39	DEP
37	2.5	2.5	B-NP	CD	O	38	NMOD
38	%	%	I-NP	NN	O	39	DEP
39	)	)	O	)	O	35	NMOD
40	patients	patient	B-NP	NNS	O	41	SUB
41	did	do	B-VP	VBD	O	0	ROOT
42	not	not	I-VP	RB	O	41	VMOD
43	tolerate	tolerate	I-VP	VB	O	41	VC
44	even	even	B-NP	RB	O	46	NMOD
45	40	40	I-NP	CD	O	44	AMOD
46	mg	mg	I-NP	NN	O	50	NMOD
47	of	of	B-PP	IN	O	46	NMOD
48	d	d	B-NP	NN	O	47	PMOD
49	,	,	O	,	O	50	P
50	l-sotalol	l-sotalol	B-NP	NN	O	43	OBJ
51	once	once	B-ADVP	RB	O	43	VMOD
52	daily	daily	I-ADVP	RB	O	51	AMOD
53	.	.	O	.	O	41	P

1	Four	Four	B-NP	CD	O	6	NMOD
2	(	(	O	(	O	5	DEP
3	5	5	B-NP	CD	O	4	NMOD
4	%	%	I-NP	NN	O	5	DEP
5	)	)	O	)	O	1	NMOD
6	patients	patient	B-NP	NNS	O	7	SUB
7	had	have	B-VP	VBD	O	0	ROOT
8	from	from	B-PP	IN	O	7	VMOD
9	torsades	torsade	B-NP	NNS	O	8	PMOD
10	de	de	B-PP	IN	O	9	NMOD
11	pointes	pointe	B-NP	NNS	O	10	PMOD
12	during	during	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	16	NMOD
14	initial	initial	I-NP	JJ	O	16	NMOD
15	oral	oral	I-NP	JJ	O	16	NMOD
16	treatment	treatment	I-NP	NN	O	12	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	d	d	B-NP	NN	O	20	NMOD
19	,	,	O	,	O	20	P
20	l-sotalol	l-sotalol	B-NP	NN	O	17	PMOD
21	.	.	O	.	O	7	P

1	However	However	B-ADVP	RB	O	10	VMOD
2	,	,	O	,	O	10	P
3	the	the	B-NP	DT	O	5	NMOD
4	oral	oral	I-NP	JJ	O	5	NMOD
5	dose	dose	I-NP	NN	O	9	NMOD
6	of	of	B-PP	IN	O	5	NMOD
7	d	d	B-NP	NN	O	6	PMOD
8	,	,	O	,	O	9	P
9	l-sotalol	l-sotalol	B-NP	NN	O	10	SUB
10	was	be	B-VP	VBD	O	0	ROOT
11	significantly	significantly	B-ADJP	RB	O	12	AMOD
12	lower	low	I-ADJP	JJR	O	10	PRD
13	in	in	B-PP	IN	O	10	VMOD
14	patients	patient	B-NP	NNS	O	13	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	torsades	torsade	B-NP	NNS	O	15	PMOD
17	de	de	B-PP	IN	O	16	NMOD
18	pointes	pointe	B-NP	NNS	O	17	PMOD
19	(	(	O	(	O	32	DEP
20	200	200	B-NP	CD	O	22	AMOD
21	+/-	+/-	I-NP	SYM	O	22	AMOD
22	46	46	I-NP	CD	O	29	NMOD
23	vs.	vs.	B-PP	IN	O	22	NMOD
24	328	328	B-NP	CD	O	26	AMOD
25	+/-	+/-	I-NP	SYM	O	26	AMOD
26	53	53	I-NP	CD	O	27	NMOD
27	mg/day	mg/day	I-NP	NN	O	23	PMOD
28	;	;	O	:	O	29	P
29	p	p	B-NP	NN	O	32	DEP
30	=	=	B-VP	SYM	O	29	NMOD
31	0.0017	0.0017	B-NP	CD	O	30	AMOD
32	)	)	O	)	O	14	NMOD
33	.	.	O	.	O	10	P

1	One	One	B-NP	CD	O	3	NMOD
2	female	female	I-NP	JJ	O	3	NMOD
3	patient	patient	I-NP	NN	O	8	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	stable	stable	B-NP	JJ	O	6	AMOD
6	cardiac	cardiac	I-NP	JJ	O	7	NMOD
7	disease	disease	I-NP	NN	O	4	PMOD
8	had	have	B-VP	VBD	O	0	ROOT
9	recurrent	recurrent	B-NP	JJ	O	10	NMOD
10	torsades	torsade	I-NP	NNS	O	8	OBJ
11	de	de	I-NP	IN	O	8	VMOD
12	pointes	pointe	I-NP	NNS	O	11	PMOD
13	after	after	B-PP	IN	O	12	NMOD
14	2	2	B-NP	CD	O	15	NMOD
15	years	year	I-NP	NNS	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	successful	successful	B-NP	JJ	O	18	NMOD
18	treatment	treatment	I-NP	NN	O	16	PMOD
19	with	with	B-PP	IN	O	18	NMOD
20	d	d	B-NP	NN	O	22	NMOD
21	,	,	O	,	O	22	P
22	l-sotalol	l-sotalol	B-NP	NN	O	19	PMOD
23	.	.	O	.	O	8	P

1	Torsades	Torsades	B-NP	NNP	O	4	SUB
2	de	de	I-NP	IN	O	1	NMOD
3	pointes	pointe	I-NP	NNS	O	2	PMOD
4	occurred	occur	B-VP	VBD	O	0	ROOT
5	early	early	B-ADVP	RB	O	4	VMOD
6	during	during	B-PP	IN	O	4	VMOD
7	treatment	treatment	B-NP	NN	O	6	PMOD
8	even	even	B-ADVP	RB	O	9	PMOD
9	with	with	B-PP	IN	O	7	NMOD
10	low	low	B-NP	JJ	O	11	NMOD
11	doses	dose	I-NP	NNS	O	16	NMOD
12	of	of	B-PP	IN	O	11	NMOD
13	oral	oral	B-NP	JJ	O	14	NMOD
14	d	d	I-NP	NN	O	12	PMOD
15	,	,	O	,	O	16	P
16	l-sotalol	l-sotalol	B-NP	NN	O	9	PMOD
17	.	.	O	.	O	4	P

1	Pronounced	Pronounce	B-NP	VBN	O	2	NMOD
2	changes	change	I-NP	NNS	O	25	NMOD
3	in	in	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	surface	surface	I-NP	NN	O	6	NMOD
6	ECG	ECG	I-NP	NN	O	3	PMOD
7	(	(	O	(	O	15	DEP
8	cycle	cycle	B-NP	NN	O	9	NMOD
9	length	length	I-NP	NN	O	14	NMOD
10	,	,	O	,	O	14	P
11	QT	QT	B-NP	NN	O	14	NMOD
12	,	,	O	,	O	14	P
13	and	and	O	CC	O	14	NMOD
14	QTc	QTc	B-NP	NN	B-protein	15	DEP
15	)	)	O	)	O	6	NMOD
16	in	in	B-PP	IN	O	2	NMOD
17	relation	relation	B-NP	NN	O	16	PMOD
18	to	to	B-PP	TO	O	17	NMOD
19	the	the	B-NP	DT	O	20	NMOD
20	dose	dose	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	oral	oral	B-NP	JJ	O	23	NMOD
23	d	d	I-NP	NN	O	21	PMOD
24	,	,	O	,	O	25	P
25	l-sotalol	l-sotalol	B-NP	NN	O	26	SUB
26	might	might	B-VP	MD	O	0	ROOT
27	identify	identify	I-VP	VB	O	26	VC
28	a	a	B-NP	DT	O	29	NMOD
29	subgroup	subgroup	I-NP	NN	O	27	OBJ
30	of	of	B-PP	IN	O	29	NMOD
31	patients	patient	B-NP	NNS	O	30	PMOD
32	with	with	B-PP	IN	O	31	NMOD
33	an	an	B-NP	DT	O	35	NMOD
34	increased	increase	I-NP	VBN	O	35	NMOD
35	risk	risk	I-NP	NN	O	32	PMOD
36	for	for	B-PP	IN	O	35	NMOD
37	torsades	torsade	B-NP	NNS	O	36	PMOD
38	de	de	B-PP	IN	O	37	NMOD
39	pointes	pointe	B-NP	NNS	O	38	PMOD
40	.	.	O	.	O	26	P

1	Other	Other	B-NP	JJ	O	3	NMOD
2	ECG	ECG	I-NP	NN	O	3	NMOD
3	parameters	parameter	I-NP	NNS	O	11	SUB
4	before	before	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	application	application	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	d	d	B-NP	NN	O	7	PMOD
9	,	,	O	,	O	11	P
10	l-sotalol	l-sotalol	B-NP	NN	O	11	SUB
11	did	do	B-VP	VBD	O	0	ROOT
12	not	not	I-VP	RB	O	11	VMOD
13	identify	identify	I-VP	VB	O	11	VC
14	patients	patient	B-NP	NNS	O	13	OBJ
15	at	at	B-PP	IN	O	14	NMOD
16	increased	increase	B-NP	VBN	O	17	NMOD
17	risk	risk	I-NP	NN	O	15	PMOD
18	for	for	B-PP	IN	O	14	NMOD
19	torsades	torsade	B-NP	NNS	O	18	PMOD
20	de	de	B-PP	IN	O	19	NMOD
21	pointes	pointe	B-NP	NNS	O	20	PMOD
22	.	.	O	.	O	11	P

1	Chronic	Chronic	B-NP	JJ	O	2	NMOD
2	hyperprolactinemia	hyperprolactinemia	I-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	changes	change	I-NP	NNS	O	0	ROOT
5	in	in	B-PP	IN	O	4	NMOD
6	dopamine	dopamine	B-NP	NN	O	7	NMOD
7	neurons	neuron	I-NP	NNS	O	5	PMOD
8	.	.	O	.	O	4	P

1	Hyperprolactinemia	Hyperprolactinemia	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	induced	induce	I-VP	VBN	O	2	VC
4	by	by	B-PP	IN	O	3	VMOD
5	treatment	treatment	B-NP	NN	O	4	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	haloperidol	haloperidol	B-NP	NN	O	18	NMOD
8	,	,	O	,	O	18	P
9	a	a	B-NP	DT	O	12	NMOD
10	dopamine	dopamine	I-NP	NN	O	12	NMOD
11	receptor	receptor	I-NP	NN	O	12	NMOD
12	antagonist	antagonist	I-NP	NN	O	18	NMOD
13	,	,	O	,	O	18	P
14	and	and	O	CC	O	18	NMOD
15	Palkovits	Palkovits	B-NP	NNP	O	16	NMOD
16	'	'	B-NP	POS	O	18	NMOD
17	microdissection	microdissection	I-NP	NN	O	18	NMOD
18	technique	technique	I-NP	NN	O	6	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	combination	combination	B-NP	NN	O	19	PMOD
21	with	with	B-PP	IN	O	20	NMOD
22	high-performance	high-performance	B-NP	JJ	O	24	NMOD
23	liquid	liquid	I-NP	NN	O	24	NMOD
24	chromatography	chromatography	I-NP	NN	O	21	PMOD
25	was	be	B-VP	VBD	O	2	VMOD
26	used	use	I-VP	VBN	O	25	VC
27	to	to	B-VP	TO	O	28	VMOD
28	measure	measure	I-VP	VB	O	26	VMOD
29	neurotransmitter	neurotransmitter	B-NP	NN	O	30	NMOD
30	concentrations	concentration	I-NP	NNS	O	28	OBJ
31	in	in	B-PP	IN	O	30	NMOD
32	several	several	B-NP	JJ	O	33	NMOD
33	areas	area	I-NP	NNS	O	31	PMOD
34	of	of	B-PP	IN	O	33	NMOD
35	the	the	B-NP	DT	O	36	NMOD
36	brain	brain	I-NP	NN	O	34	PMOD
37	.	.	O	.	O	2	P

1	After	After	B-PP	IN	O	19	VMOD
2	6	6	B-NP	CD	O	3	NMOD
3	months	month	I-NP	NNS	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	4	PMOD
6	,	,	O	,	O	19	P
7	dopamine	dopamine	B-NP	NN	O	11	NMOD
8	(	(	O	(	O	10	DEP
9	DA	DA	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	concentrations	concentration	B-NP	NNS	O	19	SUB
12	in	in	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	15	NMOD
14	median	median	I-NP	NN	O	15	NMOD
15	eminence	eminence	I-NP	NN	O	12	PMOD
16	(	(	O	(	O	18	DEP
17	ME	ME	B-NP	NN	O	18	DEP
18	)	)	O	)	O	15	NMOD
19	increased	increase	B-VP	VBD	O	0	ROOT
20	by	by	B-PP	IN	O	19	VMOD
21	84	84	B-NP	CD	O	22	NMOD
22	%	%	I-NP	NN	O	20	PMOD
23	over	over	B-PP	IN	O	19	VMOD
24	the	the	B-NP	DT	O	26	NMOD
25	control	control	I-NP	NN	O	26	NMOD
26	group	group	I-NP	NN	O	23	PMOD
27	.	.	O	.	O	19	P

1	Nine	Nine	B-NP	CD	O	2	NMOD
2	months	month	I-NP	NNS	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	3	PMOD
5	produced	produce	B-VP	VBD	O	0	ROOT
6	a	a	B-NP	DT	O	9	NMOD
7	50	50	I-NP	CD	O	8	AMOD
8	%	%	I-NP	NN	O	9	NMOD
9	increase	increase	I-NP	NN	O	5	OBJ
10	in	in	B-PP	IN	O	9	NMOD
11	DA	DA	B-NP	NN	O	12	NMOD
12	concentrations	concentration	I-NP	NNS	O	10	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	ME	ME	I-NP	NN	O	13	PMOD
16	over	over	B-PP	IN	O	9	NMOD
17	the	the	B-NP	DT	O	19	NMOD
18	control	control	I-NP	NN	O	19	NMOD
19	group	group	I-NP	NN	O	16	PMOD
20	.	.	O	.	O	5	P

1	However	However	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	DA	DA	B-NP	NN	O	4	NMOD
4	response	response	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	0	ROOT
6	lost	lose	I-VP	VBN	O	5	VC
7	if	if	B-SBAR	IN	O	6	VMOD
8	a	a	B-NP	DT	O	11	NMOD
9	9-month	9-month	I-NP	JJ	O	11	NMOD
10	long	long	I-NP	JJ	O	11	NMOD
11	haloperidol	haloperidol	I-NP	NN	O	13	NMOD
12	induced	induce	B-VP	VBN	O	13	NMOD
13	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	14	SUB
14	was	be	B-VP	VBD	O	7	SBAR
15	followed	follow	I-VP	VBN	O	14	VC
16	by	by	B-PP	IN	O	15	VMOD
17	a	a	B-NP	DT	O	23	NMOD
18	1	1	I-NP	CD	O	19	AMOD
19	1/2	1/2	I-NP	CD	O	22	AMOD
20	month-long	month-long	I-NP	JJ	O	22	AMOD
21	extremely	extremely	I-NP	RB	O	22	AMOD
22	high	high	I-NP	JJ	O	23	NMOD
23	increase	increase	I-NP	NN	O	16	PMOD
24	in	in	B-PP	IN	O	23	NMOD
25	serum	serum	B-NP	NN	O	27	NMOD
26	PRL	PRL	I-NP	NN	B-protein	27	NMOD
27	levels	level	I-NP	NNS	O	24	PMOD
28	produced	produce	B-VP	VBN	O	27	NMOD
29	by	by	B-PP	IN	O	28	VMOD
30	implantation	implantation	B-NP	NN	O	29	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	MMQ	MMQ	B-NP	NN	B-cell_line	33	NMOD
33	cells	cell	I-NP	NNS	I-cell_line	31	PMOD
34	under	under	B-PP	IN	O	28	VMOD
35	the	the	B-NP	DT	O	37	NMOD
36	kidney	kidney	I-NP	NN	O	37	NMOD
37	capsule	capsule	I-NP	NN	O	34	PMOD
38	.	.	O	.	O	5	P

1	There	There	B-NP	EX	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	no	no	B-NP	DT	O	4	NMOD
4	change	change	I-NP	NN	O	53	NMOD
5	in	in	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	levels	level	I-NP	NNS	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	DA	DA	B-NP	NN	O	23	NMOD
10	,	,	O	,	O	23	P
11	norepinephrine	norepinephrine	B-NP	NN	O	23	NMOD
12	(	(	O	(	O	14	DEP
13	NE	NE	B-NP	NN	B-protein	14	DEP
14	)	)	O	)	O	11	NMOD
15	,	,	O	,	O	23	P
16	serotonin	serotonin	B-NP	NN	O	23	NMOD
17	(	(	O	(	O	19	DEP
18	5-HT	5-HT	B-NP	NN	O	19	DEP
19	)	)	O	)	O	16	NMOD
20	,	,	O	,	O	23	P
21	or	or	O	CC	O	23	NMOD
22	their	their	B-NP	PRP$	O	23	NMOD
23	metabolites	metabolite	I-NP	NNS	O	34	NMOD
24	in	in	B-PP	IN	O	23	NMOD
25	the	the	B-NP	DT	O	27	NMOD
26	arcuate	arcuate	I-NP	JJ	O	27	NMOD
27	nucleus	nucleus	I-NP	NN	O	24	PMOD
28	(	(	O	(	O	30	DEP
29	AN	AN	B-NP	NN	O	30	DEP
30	)	)	O	)	O	27	NMOD
31	,	,	O	,	O	34	P
32	medial	medial	B-NP	JJ	O	34	NMOD
33	preoptic	preoptic	I-NP	JJ	O	34	NMOD
34	area	area	I-NP	NN	O	8	PMOD
35	(	(	O	(	O	37	DEP
36	MPA	MPA	B-NP	NN	B-protein	37	DEP
37	)	)	O	)	O	34	NMOD
38	,	,	O	,	O	53	P
39	caudate	caudate	B-NP	JJ	O	40	NMOD
40	putamen	putaman	I-NP	NNS	O	53	NMOD
41	(	(	O	(	O	43	DEP
42	CP	CP	B-NP	NN	B-DNA	43	DEP
43	)	)	O	)	O	40	NMOD
44	,	,	O	,	O	53	P
45	substantia	substantia	B-NP	NN	O	46	NMOD
46	nigra	nigra	I-NP	NN	O	53	NMOD
47	(	(	O	(	O	49	DEP
48	SN	SN	B-NP	NN	O	49	DEP
49	)	)	O	)	O	46	NMOD
50	,	,	O	,	O	53	P
51	and	and	O	CC	O	53	NMOD
52	zona	zona	B-NP	NN	O	53	NMOD
53	incerta	incerta	I-NP	NN	O	2	PRD
54	(	(	O	(	O	56	DEP
55	ZI	ZI	B-NP	NN	O	56	DEP
56	)	)	O	)	O	53	NMOD
57	,	,	O	,	O	2	P
58	except	except	B-PP	IN	O	2	VMOD
59	for	for	B-PP	IN	O	58	PMOD
60	a	a	B-NP	DT	O	61	NMOD
61	decrease	decrease	I-NP	NN	O	59	PMOD
62	in	in	B-PP	IN	O	61	NMOD
63	5-hydroxyindoleacetic	5-hydroxyindoleacetic	B-NP	JJ	O	64	NMOD
64	acid	acid	I-NP	NN	O	62	PMOD
65	(	(	O	(	O	67	DEP
66	5-HIAA	5-HIAA	B-NP	NN	O	67	DEP
67	)	)	O	)	O	64	NMOD
68	in	in	B-PP	IN	O	61	NMOD
69	the	the	B-NP	DT	O	70	NMOD
70	AN	AN	I-NP	NN	O	68	PMOD
71	after	after	B-PP	IN	O	61	NMOD
72	6-months	6-month	B-NP	NNS	O	71	PMOD
73	of	of	B-PP	IN	O	72	NMOD
74	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	77	NMOD
75	and	and	O	CC	O	77	NMOD
76	an	an	B-NP	DT	O	77	NMOD
77	increase	increase	I-NP	NN	O	73	PMOD
78	in	in	B-PP	IN	O	77	NMOD
79	DA	DA	B-NP	NN	O	80	NMOD
80	concentrations	concentration	I-NP	NNS	O	78	PMOD
81	in	in	B-PP	IN	O	80	NMOD
82	the	the	B-NP	DT	O	83	NMOD
83	AN	AN	I-NP	NN	O	81	PMOD
84	after	after	B-PP	IN	O	80	NMOD
85	9-months	9-month	B-NP	NNS	O	84	PMOD
86	of	of	B-PP	IN	O	85	NMOD
87	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	86	PMOD
88	.	.	O	.	O	2	P

1	This	This	B-NP	DT	O	2	NMOD
2	report	report	I-NP	NN	O	3	SUB
3	describes	describe	B-VP	VBZ	O	0	ROOT
4	unique	unique	B-NP	JJ	O	6	NMOD
5	contrast	contrast	I-NP	NN	O	6	NMOD
6	enhancement	enhancement	I-NP	NN	O	3	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	10	NMOD
9	white	white	I-NP	JJ	O	10	NMOD
10	matter	matter	I-NP	NN	O	7	PMOD
11	on	on	B-PP	IN	O	6	NMOD
12	T1-weighted	T1-weighted	B-NP	JJ	O	15	NMOD
13	magnetic	magnetic	I-NP	JJ	O	15	NMOD
14	resonance	resonance	I-NP	NN	O	15	NMOD
15	images	image	I-NP	NNS	O	11	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	two	two	B-NP	CD	O	18	NMOD
18	patients	patient	I-NP	NNS	O	16	PMOD
19	with	with	B-PP	IN	O	18	NMOD
20	disseminated	disseminate	B-NP	VBN	O	22	NMOD
21	necrotizing	necrotize	I-NP	VBG	O	22	NMOD
22	leukoencephalopathy	leukoencephalopathy	I-NP	NN	O	19	PMOD
23	,	,	O	,	O	6	P
24	which	which	B-NP	WDT	O	6	NMOD
25	developed	develop	B-VP	VBD	O	24	SBAR
26	from	from	B-PP	IN	O	25	VMOD
27	acute	acute	B-NP	JJ	O	29	NMOD
28	lymphoblastic	lymphoblastic	I-NP	JJ	O	29	NMOD
29	leukemia	leukemia	I-NP	NN	O	26	PMOD
30	treated	treat	B-VP	VBN	O	29	NMOD
31	with	with	B-PP	IN	O	30	VMOD
32	high-dose	high-dose	B-NP	JJ	O	33	NMOD
33	methotrexate	methotrexate	I-NP	NN	O	31	PMOD
34	.	.	O	.	O	3	P

1	Thrombotic	Thrombotic	B-NP	JJ	O	2	NMOD
2	complications	complication	I-NP	NNS	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	acute	acute	B-NP	JJ	O	6	NMOD
5	promyelocytic	promyelocytic	I-NP	JJ	O	6	NMOD
6	leukemia	leukemia	I-NP	NN	O	3	PMOD
7	during	during	B-PP	IN	O	2	NMOD
8	all-trans-retinoic	all-trans-retinoic	B-NP	JJ	O	10	NMOD
9	acid	acid	I-NP	NN	O	10	NMOD
10	therapy	therapy	I-NP	NN	O	7	PMOD
11	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	34	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	acute	acute	B-NP	JJ	O	6	NMOD
5	renal	renal	I-NP	JJ	O	6	NMOD
6	failure	failure	I-NP	NN	O	3	PMOD
7	,	,	O	,	O	2	P
8	due	due	B-PP	IN	O	2	NMOD
9	to	to	I-PP	TO	O	8	PMOD
10	occlusion	occlusion	B-NP	NN	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	renal	renal	B-NP	JJ	O	13	NMOD
13	vessels	vessel	I-NP	NNS	O	11	PMOD
14	in	in	B-PP	IN	O	10	NMOD
15	a	a	B-NP	DT	O	16	NMOD
16	patient	patient	I-NP	NN	O	14	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	acute	acute	B-NP	JJ	O	20	NMOD
19	promyelocytic	promyelocytic	I-NP	JJ	O	20	NMOD
20	leukemia	leukemia	I-NP	NN	O	17	PMOD
21	(	(	O	(	O	23	DEP
22	APL	APL	B-NP	NN	O	23	DEP
23	)	)	O	)	O	20	NMOD
24	treated	treat	B-VP	VBN	O	20	NMOD
25	with	with	B-PP	IN	O	24	VMOD
26	all-trans-retinoic	all-trans-retinoic	B-NP	JJ	O	27	NMOD
27	acid	acid	I-NP	NN	O	33	NMOD
28	(	(	O	(	O	30	DEP
29	ATRA	ATRA	B-NP	NN	O	30	DEP
30	)	)	O	)	O	27	NMOD
31	and	and	O	CC	O	33	NMOD
32	tranexamic	tranexamic	B-NP	JJ	O	33	NMOD
33	acid	acid	I-NP	NN	O	25	PMOD
34	has	have	B-VP	VBZ	O	0	ROOT
35	been	be	I-VP	VBN	O	34	VC
36	described	describe	I-VP	VBN	O	35	VC
37	recently	recently	B-ADVP	RB	O	36	VMOD
38	.	.	O	.	O	34	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	acute	acute	B-NP	JJ	O	8	NMOD
7	renal	renal	I-NP	JJ	O	8	NMOD
8	failure	failure	I-NP	NN	O	5	PMOD
9	in	in	B-PP	IN	O	4	NMOD
10	an	an	B-NP	DT	O	12	NMOD
11	APL	APL	I-NP	NN	O	12	NMOD
12	patient	patient	I-NP	NN	O	9	PMOD
13	treated	treat	B-VP	VBN	O	12	NMOD
14	with	with	B-PP	IN	O	13	VMOD
15	ATRA	ATRA	B-NP	NN	O	14	PMOD
16	alone	alone	B-ADVP	RB	O	15	NMOD
17	.	.	O	.	O	2	P

1	This	This	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	4	SUB
3	further	further	B-ADVP	RBR	O	4	VMOD
4	supports	support	B-VP	VBZ	O	0	ROOT
5	the	the	B-NP	DT	O	6	NMOD
6	concern	concern	I-NP	NN	O	4	OBJ
7	about	about	B-PP	IN	O	6	NMOD
8	thromboembolic	thromboembolic	B-NP	JJ	O	9	NMOD
9	complications	complication	I-NP	NNS	O	7	PMOD
10	associated	associate	B-VP	VBN	O	9	NMOD
11	with	with	B-PP	IN	O	10	VMOD
12	ATRA	ATRA	B-NP	NN	O	13	NMOD
13	therapy	therapy	I-NP	NN	O	11	PMOD
14	in	in	B-PP	IN	O	13	NMOD
15	APL	APL	B-NP	NN	O	16	NMOD
16	patients	patient	I-NP	NNS	O	14	PMOD
17	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	2	NMOD
2	patients	patient	I-NP	NNS	O	6	NMOD
3	,	,	O	,	O	6	P
4	a	a	B-NP	DT	O	6	NMOD
5	43-year-old	43-year-old	I-NP	JJ	O	6	NMOD
6	man	man	I-NP	NN	O	8	SUB
7	,	,	O	,	O	6	P
8	presented	present	B-VP	VBD	O	0	ROOT
9	all	all	B-NP	PDT	O	13	NMOD
10	the	the	I-NP	DT	O	13	NMOD
11	signs	sign	I-NP	NNS	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	symptoms	symptom	I-NP	NNS	O	8	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	APL	APL	B-NP	NN	O	14	PMOD
16	and	and	O	CC	O	8	VMOD
17	was	be	B-VP	VBD	O	8	VMOD
18	included	include	I-VP	VBN	O	17	VC
19	in	in	B-PP	IN	O	18	VMOD
20	a	a	B-NP	DT	O	22	NMOD
21	treatment	treatment	I-NP	NN	O	22	NMOD
22	protocol	protocol	I-NP	NN	O	19	PMOD
23	with	with	B-PP	IN	O	22	NMOD
24	ATRA	ATRA	B-NP	NN	O	23	PMOD
25	.	.	O	.	O	8	P

1	We	We	B-NP	PRP	O	2	SUB
2	conclude	conclude	B-VP	VBP	O	0	ROOT
3	that	that	B-SBAR	IN	O	2	VMOD
4	ATRA	ATRA	B-NP	NN	O	5	SUB
5	is	be	B-VP	VBZ	O	3	SBAR
6	a	a	B-NP	DT	O	9	NMOD
7	valid	valid	I-NP	JJ	O	8	AMOD
8	therapeutic	therapeutic	I-NP	JJ	O	9	NMOD
9	choice	choice	I-NP	NN	O	5	PRD
10	for	for	B-PP	IN	O	9	NMOD
11	patients	patient	B-NP	NNS	O	10	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	APL	APL	B-NP	NN	O	12	PMOD
14	,	,	O	,	O	5	P
15	although	although	B-SBAR	IN	O	5	VMOD
16	the	the	B-NP	DT	O	18	NMOD
17	procoagulant	procoagulant	I-NP	JJ	O	18	NMOD
18	tendency	tendency	I-NP	NN	O	19	SUB
19	is	be	B-VP	VBZ	O	15	SBAR
20	not	not	O	RB	O	19	VMOD
21	completely	completely	B-ADJP	RB	O	19	VMOD
22	corrected	correct	I-ADJP	VBN	O	19	VC
23	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	4	NMOD
2	30-year-old	30-year-old	I-NP	JJ	O	4	NMOD
3	cocaine-dependent	cocaine-dependent	I-NP	JJ	O	4	NMOD
4	man	man	I-NP	NN	O	0	ROOT
5	who	who	B-NP	WP	O	4	NMOD
6	was	be	B-VP	VBD	O	5	SBAR
7	a	a	B-NP	DT	O	8	NMOD
8	subject	subject	I-NP	NN	O	6	PRD
9	in	in	B-PP	IN	O	6	VMOD
10	a	a	B-NP	DT	O	11	NMOD
11	study	study	I-NP	NN	O	24	SUB
12	evaluating	evaluate	B-VP	VBG	O	11	NMOD
13	the	the	B-NP	DT	O	15	NMOD
14	anticraving	anticrave	I-NP	VBG	O	15	NMOD
15	efficacy	efficacy	I-NP	NN	O	12	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	20	NMOD
18	stimulant	stimulant	I-NP	JJ	O	20	NMOD
19	medication	medication	I-NP	NN	O	20	NMOD
20	diethylpropion	diethylpropion	I-NP	NN	O	16	PMOD
21	(	(	O	(	O	23	DEP
22	DEP	DEP	B-NP	NN	O	23	DEP
23	)	)	O	)	O	20	NMOD
24	became	become	B-VP	VBD	O	9	SBAR
25	manic	manic	B-ADJP	JJ	O	24	PRD
26	during	during	B-PP	IN	O	24	VMOD
27	his	his	B-NP	PRP$	O	29	NMOD
28	second	second	I-NP	JJ	O	29	NMOD
29	week	week	I-NP	NN	O	26	PMOD
30	on	on	B-PP	IN	O	24	VMOD
31	the	the	B-NP	DT	O	33	NMOD
32	study	study	I-NP	NN	O	33	NMOD
33	drug	drug	I-NP	NN	O	30	PMOD
34	.	.	O	.	O	4	P

1	Pupillometric	Pupillometric	B-NP	JJ	O	2	NMOD
2	changes	change	I-NP	NNS	O	0	ROOT
3	while	while	B-SBAR	IN	O	2	VMOD
4	on	on	B-PP	IN	O	17	VMOD
5	DEP	DEP	B-NP	NN	O	4	PMOD
6	,	,	O	,	O	17	P
7	especially	especially	B-ADVP	RB	O	8	NMOD
8	changes	change	B-NP	NNS	O	17	SUB
9	in	in	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	12	NMOD
11	total	total	I-NP	JJ	O	12	NMOD
12	power	power	I-NP	NN	O	9	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	pupillary	pupillary	B-NP	JJ	O	15	NMOD
15	oscillation	oscillation	I-NP	NN	O	13	PMOD
16	,	,	O	,	O	8	P
17	were	be	B-VP	VBD	O	3	SBAR
18	dramatically	dramatically	B-ADJP	RB	O	19	AMOD
19	different	different	I-ADJP	JJ	O	17	PRD
20	than	than	B-PP	IN	O	19	AMOD
21	those	those	B-NP	DT	O	20	PMOD
22	observed	observe	B-VP	VBN	O	21	NMOD
23	in	in	B-PP	IN	O	22	VMOD
24	the	the	B-NP	DT	O	28	NMOD
25	eight	eight	I-NP	CD	O	28	NMOD
26	other	other	I-NP	JJ	O	28	NMOD
27	study	study	I-NP	NN	O	28	NMOD
28	subjects	subject	I-NP	NNS	O	23	PMOD
29	who	who	B-NP	WP	O	28	NMOD
30	did	do	B-VP	VBD	O	29	SBAR
31	not	not	I-VP	RB	O	30	VMOD
32	become	become	I-VP	VB	O	30	VC
33	manic	manic	B-ADJP	JJ	O	32	PRD
34	.	.	O	.	O	2	P

1	Phasic	Phasic	B-NP	JJ	O	2	NMOD
2	pain	pain	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	31	VMOD
4	applied	apply	I-VP	VBN	O	3	VC
5	by	by	B-PP	IN	O	4	VMOD
6	means	mean	B-NP	NNS	O	5	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	short	short	B-NP	JJ	O	9	NMOD
9	pulses	pulse	I-NP	NNS	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	CO2	CO2	B-NP	NN	B-protein	10	PMOD
12	to	to	B-PP	TO	O	4	VMOD
13	the	the	B-NP	DT	O	15	NMOD
14	nasal	nasal	I-NP	JJ	O	15	NMOD
15	mucosa	mucosa	I-NP	NN	O	12	PMOD
16	(	(	O	(	O	26	DEP
17	stimulus	stimulus	B-NP	NN	O	20	NMOD
18	duration	duration	I-NP	NN	O	20	NMOD
19	500	500	B-NP	CD	O	20	NMOD
20	ms	ms	I-NP	NN	O	25	NMOD
21	,	,	O	,	O	25	P
22	interval	interval	B-NP	NN	O	25	NMOD
23	approximately	approximately	B-NP	RB	O	25	NMOD
24	60	60	I-NP	CD	O	23	AMOD
25	s	s	I-NP	NN	O	26	DEP
26	)	)	O	)	O	15	NMOD
27	,	,	O	,	O	31	P
28	and	and	O	CC	O	31	VMOD
29	tonic	tonic	B-NP	JJ	O	30	NMOD
30	pain	pain	I-NP	NN	O	31	SUB
31	was	be	B-VP	VBD	O	0	ROOT
32	induced	induce	I-VP	VBN	O	31	VC
33	in	in	B-PP	IN	O	32	VMOD
34	the	the	B-NP	DT	O	36	NMOD
35	nasal	nasal	I-NP	JJ	O	36	NMOD
36	cavity	cavity	I-NP	NN	O	33	PMOD
37	by	by	B-PP	IN	O	32	VMOD
38	means	mean	B-NP	NNS	O	37	PMOD
39	of	of	B-PP	IN	O	38	NMOD
40	dry	dry	B-NP	JJ	O	41	NMOD
41	air	air	I-NP	NN	O	39	PMOD
42	of	of	B-PP	IN	O	41	NMOD
43	controlled	control	B-NP	VBN	O	49	NMOD
44	temperature	temperature	I-NP	NN	O	49	NMOD
45	,	,	I-NP	,	O	49	P
46	humidity	humidity	I-NP	NN	O	49	NMOD
47	and	and	I-NP	CC	O	49	NMOD
48	flow	flow	I-NP	NN	O	49	NMOD
49	rate	rate	I-NP	NN	O	42	PMOD
50	(	(	O	(	O	62	DEP
51	22	22	B-NP	CD	O	53	NMOD
52	degrees	degree	I-NP	NNS	O	53	NMOD
53	C	C	I-NP	NN	O	56	SUB
54	,	,	O	,	O	56	P
55	0	0	B-NP	CD	O	56	AMOD
56	%	%	I-NP	NN	O	58	NMOD
57	relative	relative	I-NP	JJ	O	58	NMOD
58	humidity	humidity	I-NP	NN	O	61	NMOD
59	,	,	O	,	O	61	P
60	145	145	B-NP	CD	O	61	NMOD
61	ml.s-1	ml.s-1	I-NP	NN	O	62	DEP
62	)	)	O	)	O	41	NMOD
63	.	.	O	.	O	31	P

1	Both	Both	B-NP	DT	O	2	NMOD
2	CSSEPs	CSSEP	I-NP	NNS	O	12	SUB
3	as	as	B-PP	IN	O	2	NMOD
4	central	central	B-ADJP	JJ	O	3	PMOD
5	and	and	O	CC	O	6	NMOD
6	NMPs	NMP	B-NP	NNS	B-protein	4	NMOD
7	as	as	B-PP	IN	O	4	NMOD
8	peripheral	peripheral	B-NP	JJ	O	9	NMOD
9	correlates	correlate	I-NP	NNS	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	pain	pain	B-NP	NN	O	10	PMOD
12	were	be	B-VP	VBD	O	0	ROOT
13	obtained	obtain	I-VP	VBN	O	12	VC
14	in	in	B-PP	IN	O	13	VMOD
15	response	response	B-NP	NN	O	14	PMOD
16	to	to	B-PP	TO	O	15	NMOD
17	the	the	B-NP	DT	O	19	NMOD
18	CO2	CO2	I-NP	NN	O	19	NMOD
19	stimuli	stimulus	I-NP	NNS	O	16	PMOD
20	.	.	O	.	O	12	P

1	RESULTS	RESULTS	B-NP	NNS	O	10	VMOD
2	:	:	O	:	O	1	P
3	As	As	B-SBAR	IN	O	10	VMOD
4	described	describe	B-VP	VBN	O	3	SBAR
5	earlier	earlier	B-ADVP	RBR	O	4	VMOD
6	,	,	O	,	O	10	P
7	administration	administration	B-NP	NN	O	10	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	ibuprofen	ibuprofen	B-NP	NN	O	8	PMOD
10	was	be	B-VP	VBD	O	0	ROOT
11	followed	follow	I-VP	VBN	O	10	VC
12	by	by	B-PP	IN	O	11	VMOD
13	a	a	B-NP	DT	O	14	NMOD
14	decrease	decrease	I-NP	NN	O	12	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	tonic	tonic	B-NP	JJ	O	17	NMOD
17	pain	pain	I-NP	NN	O	15	PMOD
18	but-relative	but-relative	B-ADJP	JJ	O	17	NMOD
19	to	to	B-PP	TO	O	18	AMOD
20	placebo-an	placebo-an	B-NP	JJ	O	21	NMOD
21	increase	increase	I-NP	NN	O	19	PMOD
22	in	in	B-PP	IN	O	21	NMOD
23	correlates	correlate	B-NP	NNS	O	22	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	phasic	phasic	B-NP	JJ	O	26	NMOD
26	pain	pain	I-NP	NN	O	24	PMOD
27	,	,	O	,	O	10	P
28	indicating	indicate	B-VP	VBG	O	10	VMOD
29	a	a	B-NP	DT	O	31	NMOD
30	specific	specific	I-NP	JJ	O	31	NMOD
31	effect	effect	I-NP	NN	O	28	OBJ
32	of	of	B-PP	IN	O	31	NMOD
33	ibuprofen	ibuprofen	B-NP	NN	O	32	PMOD
34	on	on	B-PP	IN	O	31	NMOD
35	the	the	B-NP	DT	O	36	NMOD
36	interaction	interaction	I-NP	NN	O	34	PMOD
37	between	between	B-PP	IN	O	36	NMOD
38	the	the	B-NP	DT	O	40	NMOD
39	pain	pain	I-NP	NN	O	40	NMOD
40	stimuli	stimulus	I-NP	NNS	O	37	PMOD
41	under	under	B-PP	IN	O	36	NMOD
42	these	these	B-NP	DT	O	45	NMOD
43	special	special	I-NP	JJ	O	45	NMOD
44	experimental	experimental	I-NP	JJ	O	45	NMOD
45	conditions	condition	I-NP	NNS	O	41	PMOD
46	.	.	O	.	O	10	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	severe	severe	I-NP	JJ	O	3	NMOD
3	depression	depression	I-NP	NN	O	0	ROOT
4	following	follow	B-PP	VBG	O	3	NMOD
5	peri-operative	peri-operative	B-NP	JJ	O	6	NMOD
6	ondansetron	ondansetron	I-NP	NN	O	4	PMOD
7	.	.	O	.	O	3	P

1	A	A	B-NP	DT	O	3	NMOD
2	41-year-old	41-year-old	I-NP	JJ	O	3	NMOD
3	woman	woman	I-NP	NN	O	0	ROOT
4	with	with	B-PP	IN	O	3	NMOD
5	a	a	B-NP	DT	O	7	NMOD
6	strong	strong	I-NP	JJ	O	7	NMOD
7	history	history	I-NP	NN	O	4	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	postoperative	postoperative	B-NP	JJ	O	10	NMOD
10	nausea	nausea	I-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	vomiting	vomiting	I-NP	NN	O	8	PMOD
13	presented	present	B-VP	VBN	O	12	NMOD
14	for	for	B-PP	IN	O	13	VMOD
15	abdominal	abdominal	B-NP	JJ	O	16	NMOD
16	hysterectomy	hysterectomy	I-NP	NN	O	18	NMOD
17	3	3	B-NP	CD	O	16	NMOD
18	months	month	I-NP	NNS	O	14	PMOD
19	after	after	B-PP	IN	O	3	NMOD
20	a	a	B-NP	DT	O	22	NMOD
21	previous	previous	I-NP	JJ	O	22	NMOD
22	anaesthetic	anaesthetic	I-NP	NN	O	19	PMOD
23	where	where	B-ADVP	WRB	O	22	NMOD
24	ondansetron	ondansetron	B-NP	NN	O	25	NMOD
25	prophylaxis	prophylaxis	I-NP	NN	O	26	SUB
26	had	have	B-VP	VBD	O	23	SBAR
27	been	be	I-VP	VBN	O	26	VC
28	used	use	I-VP	VBN	O	27	VC
29	.	.	O	.	O	3	P

1	She	She	B-NP	PRP	O	2	SUB
2	had	have	B-VP	VBD	O	0	ROOT
3	developed	develop	I-VP	VBN	O	2	VC
4	a	a	B-NP	DT	O	9	NMOD
5	severe	severe	I-NP	JJ	O	9	NMOD
6	acute	acute	I-NP	JJ	O	9	NMOD
7	major	major	I-NP	JJ	O	9	NMOD
8	depression	depression	I-NP	NN	O	9	NMOD
9	disorder	disorder	I-NP	NN	O	3	OBJ
10	almost	almost	B-ADVP	RB	O	9	NMOD
11	immediately	immediately	I-ADVP	RB	O	10	AMOD
12	thereafter	thereafter	I-ADVP	RB	O	10	AMOD
13	,	,	O	,	O	10	P
14	possibly	possibly	B-ADJP	RB	O	10	AMOD
15	related	related	I-ADJP	JJ	O	10	AMOD
16	to	to	B-PP	TO	O	10	AMOD
17	the	the	B-NP	DT	O	18	NMOD
18	use	use	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	a	a	B-NP	DT	O	22	NMOD
21	serotonin	serotonin	I-NP	NN	O	22	NMOD
22	antagonist	antagonist	I-NP	NN	O	19	PMOD
23	.	.	O	.	O	2	P

1	Hypertensive	Hypertensive	B-NP	JJ	O	2	NMOD
2	response	response	I-NP	NN	O	0	ROOT
3	during	during	B-PP	IN	O	2	NMOD
4	dobutamine	dobutamine	B-NP	NN	O	6	NMOD
5	stress	stress	I-NP	NN	O	6	NMOD
6	echocardiography	echocardiography	I-NP	NN	O	3	PMOD
7	.	.	O	.	O	2	P

1	Among	Among	B-PP	IN	O	38	VMOD
2	3	3	B-NP	CD	O	1	PMOD
3	,	,	O	,	O	38	P
4	129	129	B-NP	CD	O	8	NMOD
5	dobutamine	dobutamine	I-NP	NN	O	8	NMOD
6	stress	stress	I-NP	NN	O	8	NMOD
7	echocardiographic	echocardiographic	I-NP	JJ	O	8	NMOD
8	studies	study	I-NP	NNS	O	12	NMOD
9	,	,	O	,	O	12	P
10	a	a	B-NP	DT	O	12	NMOD
11	hypertensive	hypertensive	I-NP	JJ	O	12	NMOD
12	response	response	I-NP	NN	O	38	SUB
13	,	,	O	,	O	12	P
14	defined	define	B-VP	VBN	O	12	NMOD
15	as	as	B-PP	IN	O	14	VMOD
16	systolic	systolic	B-NP	JJ	O	18	NMOD
17	blood	blood	I-NP	NN	O	18	NMOD
18	pressure	pressure	I-NP	NN	O	15	PMOD
19	(	(	O	(	O	21	DEP
20	BP	BP	B-NP	NN	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	>	>	B-NP	SYM	O	18	NMOD
23	or	or	O	CC	O	24	AMOD
24	=	=	B-VP	SYM	O	22	NMOD
25	220	220	B-NP	CD	O	27	NMOD
26	mm	mm	I-NP	NN	O	27	NMOD
27	Hg	Hg	I-NP	NN	O	30	NMOD
28	and/or	and/or	O	CC	O	30	NMOD
29	diastolic	diastolic	B-NP	JJ	O	30	NMOD
30	BP	BP	I-NP	NN	O	36	NMOD
31	>	>	B-VP	SYM	O	36	NMOD
32	or	or	O	CC	O	36	NMOD
33	=	=	B-VP	SYM	O	36	NMOD
34	110	110	B-NP	CD	O	36	NMOD
35	mm	mm	I-NP	NN	O	36	NMOD
36	Hg	Hg	I-NP	NN	O	24	OBJ
37	,	,	O	,	O	12	P
38	occurred	occur	B-VP	VBD	O	0	ROOT
39	in	in	B-PP	IN	O	38	VMOD
40	30	30	B-NP	CD	O	41	NMOD
41	patients	patient	I-NP	NNS	O	39	PMOD
42	(	(	O	(	O	45	DEP
43	1	1	B-NP	CD	O	44	NMOD
44	%	%	I-NP	NN	O	45	DEP
45	)	)	O	)	O	41	NMOD
46	.	.	O	.	O	38	P

1	Continuously	Continuously	B-NP	RB	O	2	AMOD
2	nebulized	nebulize	I-NP	VBN	O	3	NMOD
3	albuterol	albuterol	I-NP	NN	O	14	NMOD
4	in	in	B-PP	IN	O	3	NMOD
5	severe	severe	B-NP	JJ	O	6	NMOD
6	exacerbations	exacerbation	I-NP	NNS	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	asthma	asthma	B-NP	NN	O	7	PMOD
9	in	in	B-PP	IN	O	3	NMOD
10	adults	adult	B-NP	NNS	O	9	PMOD
11	:	:	O	:	O	3	P
12	a	a	B-NP	DT	O	14	NMOD
13	case-controlled	case-controlled	I-NP	JJ	O	14	NMOD
14	study	study	I-NP	NN	O	0	ROOT
15	.	.	O	.	O	14	P

1	A	A	B-NP	DT	O	5	NMOD
2	retrospective	retrospective	I-NP	JJ	O	4	AMOD
3	,	,	I-NP	,	O	4	P
4	case-controlled	case-controlled	I-NP	JJ	O	5	NMOD
5	analysis	analysis	I-NP	NN	O	0	ROOT
6	comparing	compare	B-VP	VBG	O	5	NMOD
7	patients	patient	B-NP	NNS	O	6	OBJ
8	admitted	admit	B-VP	VBN	O	7	NMOD
9	to	to	B-PP	TO	O	8	VMOD
10	a	a	B-NP	DT	O	14	NMOD
11	medical	medical	I-NP	JJ	O	14	NMOD
12	intensive	intensive	I-NP	JJ	O	14	NMOD
13	care	care	I-NP	NN	O	14	NMOD
14	unit	unit	I-NP	NN	O	9	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	severe	severe	B-NP	JJ	O	17	NMOD
17	exacerbations	exacerbation	I-NP	NNS	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	asthma	asthma	B-NP	NN	O	18	PMOD
20	who	who	B-NP	WP	O	17	NMOD
21	received	receive	B-VP	VBD	O	20	SBAR
22	continuously	continuously	I-VP	RB	O	23	AMOD
23	nebulized	nebulize	I-VP	VBN	O	21	VC
24	albuterol	albuterol	B-NP	NN	O	35	SUB
25	(	(	O	(	O	27	DEP
26	CNA	CNA	B-NP	NN	O	27	DEP
27	)	)	O	)	O	24	NMOD
28	versus	versus	B-PP	IN	O	24	NMOD
29	intermittent	intermittent	B-NP	JJ	O	30	NMOD
30	albuterol	albuterol	I-NP	NN	O	34	NMOD
31	(	(	O	(	O	33	DEP
32	INA	INA	B-NP	NN	O	33	DEP
33	)	)	O	)	O	30	NMOD
34	treatments	treatment	B-NP	NNS	O	28	PMOD
35	is	be	B-VP	VBZ	O	23	VMOD
36	reported	report	I-VP	VBN	O	35	VC
37	.	.	O	.	O	5	P

1	Hyperosmolar	Hyperosmolar	B-NP	JJ	O	3	NMOD
2	nonketotic	nonketotic	I-NP	JJ	O	3	NMOD
3	coma	coma	I-NP	NN	O	7	SUB
4	precipitated	precipitate	B-VP	VBN	O	3	NMOD
5	by	by	B-PP	IN	O	4	VMOD
6	lithium	lithium	B-NP	NN	O	5	PMOD
7	induced	induce	B-VP	VBD	O	0	ROOT
8	nephrogenic	nephrogenic	B-NP	JJ	O	10	NMOD
9	diabetes	diabetes	I-NP	NN	O	10	NMOD
10	insipidus	insipidus	I-NP	NN	O	7	OBJ
11	.	.	O	.	O	7	P

1	A	A	B-NP	DT	O	3	NMOD
2	45-year-old	45-year-old	I-NP	JJ	O	3	NMOD
3	man	man	I-NP	NN	O	16	SUB
4	,	,	O	,	O	3	P
5	with	with	B-PP	IN	O	3	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	10-year	10-year	I-NP	JJ	O	8	NMOD
8	history	history	I-NP	NN	O	5	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	manic	manic	B-NP	JJ	O	11	NMOD
11	depression	depression	I-NP	NN	O	9	PMOD
12	treated	treat	B-VP	VBN	O	11	NMOD
13	with	with	B-PP	IN	O	12	VMOD
14	lithium	lithium	B-NP	NN	O	13	PMOD
15	,	,	O	,	O	3	P
16	was	be	B-VP	VBD	O	0	ROOT
17	admitted	admit	I-VP	VBN	O	16	VC
18	with	with	B-PP	IN	O	17	VMOD
19	hyperosmolar	hyperosmolar	B-NP	JJ	O	21	AMOD
20	,	,	I-NP	,	O	21	P
21	nonketotic	nonketotic	I-NP	JJ	O	22	NMOD
22	coma	coma	I-NP	NN	O	18	PMOD
23	.	.	O	.	O	16	P

1	He	He	B-NP	PRP	O	2	SUB
2	gave	give	B-VP	VBD	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	five-year	five-year	I-NP	JJ	O	5	NMOD
5	history	history	I-NP	NN	O	2	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	polyuria	polyuria	B-NP	NN	O	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	polydipsia	polydipsia	I-NP	NN	O	6	PMOD
10	,	,	O	,	O	2	P
11	during	during	B-PP	IN	O	2	VMOD
12	which	which	B-NP	WDT	O	11	PMOD
13	time	time	B-NP	NN	O	14	NMOD
14	urinalysis	urinalysis	I-NP	NN	O	15	SUB
15	had	have	B-VP	VBD	O	11	SBAR
16	been	be	I-VP	VBN	O	15	VC
17	negative	negative	B-ADJP	JJ	O	16	PRD
18	for	for	B-PP	IN	O	17	AMOD
19	glucose	glucose	B-NP	NN	O	18	PMOD
20	.	.	O	.	O	2	P

1	After	After	B-PP	IN	O	7	VMOD
2	recovery	recovery	B-NP	NN	O	1	PMOD
3	from	from	B-PP	IN	O	2	NMOD
4	hyperglycaemia	hyperglycaemia	B-NP	NN	O	3	PMOD
5	,	,	O	,	O	7	P
6	he	he	B-NP	PRP	O	7	SUB
7	remained	remain	B-VP	VBD	O	18	VMOD
8	polyuric	polyuric	B-ADJP	JJ	O	7	PRD
9	despite	despite	B-PP	IN	O	8	AMOD
10	normal	normal	B-NP	JJ	O	13	NMOD
11	blood	blood	I-NP	NN	O	13	NMOD
12	glucose	glucose	I-NP	NN	O	13	NMOD
13	concentrations	concentration	I-NP	NNS	O	9	PMOD
14	;	;	O	:	O	7	P
15	water	water	B-NP	NN	O	17	NMOD
16	deprivation	deprivation	I-NP	NN	O	17	NMOD
17	testing	testing	I-NP	NN	O	18	SUB
18	indicated	indicate	B-VP	VBD	O	0	ROOT
19	nephrogenic	nephrogenic	B-NP	JJ	O	21	NMOD
20	diabetes	diabetes	I-NP	NN	O	21	NMOD
21	insipidus	insipidus	I-NP	NN	O	18	OBJ
22	,	,	O	,	O	21	P
23	likely	likely	B-ADJP	JJ	O	21	NMOD
24	to	to	B-VP	TO	O	25	VMOD
25	be	be	I-VP	VB	O	23	AMOD
26	lithium	lithium	B-NP	NN	O	25	PRD
27	induced	induce	B-VP	VBN	O	26	AMOD
28	.	.	O	.	O	18	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	12	SUB
2	:	:	O	:	O	1	P
3	In	In	B-PP	IN	O	12	VMOD
4	dogs	dog	B-NP	NNS	O	3	PMOD
5	,	,	O	,	O	12	P
6	a	a	B-NP	DT	O	8	NMOD
7	large	large	I-NP	JJ	O	8	NMOD
8	amount	amount	I-NP	NN	O	12	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	intravenous	intravenous	B-NP	JJ	O	11	NMOD
11	cocaine	cocaine	I-NP	NN	O	9	PMOD
12	causes	cause	B-VP	VBZ	O	0	ROOT
13	a	a	B-NP	DT	O	15	NMOD
14	profound	profound	I-NP	JJ	O	15	NMOD
15	deterioration	deterioration	I-NP	NN	O	26	NMOD
16	of	of	B-PP	IN	O	15	NMOD
17	left	left	B-NP	JJ	O	18	NMOD
18	ventricular	ventricular	I-NP	JJ	O	23	NMOD
19	(	(	O	(	O	21	DEP
20	LV	LV	B-NP	NN	O	21	DEP
21	)	)	I-NP	)	O	18	NMOD
22	systolic	systolic	I-NP	JJ	O	23	NMOD
23	function	function	I-NP	NN	O	16	PMOD
24	and	and	O	CC	O	26	NMOD
25	an	an	B-NP	DT	O	26	NMOD
26	increase	increase	I-NP	NN	O	12	OBJ
27	in	in	B-PP	IN	O	26	NMOD
28	LV	LV	B-NP	NN	O	30	NMOD
29	end-diastolic	end-diastolic	I-NP	JJ	O	30	NMOD
30	pressure	pressure	I-NP	NN	O	27	PMOD
31	.	.	O	.	O	12	P

1	METHODS	METHODS	B-NP	NNS	O	3	NMOD
2	AND	AND	I-NP	CC	O	3	NMOD
3	RESULTS	RESULTS	I-NP	NNS	O	0	ROOT
4	:	:	O	:	O	3	P
5	In	In	B-PP	IN	O	32	VMOD
6	20	20	B-NP	CD	O	7	NMOD
7	patients	patient	I-NP	NNS	O	5	PMOD
8	(	(	O	(	O	19	DEP
9	14	14	B-NP	CD	O	10	NMOD
10	men	man	I-NP	NNS	O	13	NMOD
11	and	and	O	CC	O	13	NMOD
12	6	6	B-NP	CD	O	13	NMOD
13	women	woman	I-NP	NNS	O	19	DEP
14	aged	age	B-ADJP	VBN	O	13	NMOD
15	39	39	B-NP	CD	O	17	AMOD
16	to	to	I-NP	TO	O	17	AMOD
17	72	72	I-NP	CD	O	18	NMOD
18	years	year	I-NP	NNS	O	14	AMOD
19	)	)	O	)	O	7	NMOD
20	referred	refer	B-VP	VBN	O	7	NMOD
21	for	for	B-PP	IN	O	20	VMOD
22	cardiac	cardiac	B-NP	JJ	O	23	NMOD
23	catheterization	catheterization	I-NP	NN	O	21	PMOD
24	for	for	B-PP	IN	O	23	NMOD
25	the	the	B-NP	DT	O	26	NMOD
26	evaluation	evaluation	I-NP	NN	O	24	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	chest	chest	B-NP	NN	O	29	NMOD
29	pain	pain	I-NP	NN	O	27	PMOD
30	,	,	O	,	O	32	P
31	we	we	B-NP	PRP	O	32	SUB
32	measured	measure	B-VP	VBD	O	55	VMOD
33	heart	heart	B-NP	NN	O	34	NMOD
34	rate	rate	I-NP	NN	O	45	NMOD
35	,	,	O	,	O	45	P
36	systemic	systemic	B-NP	JJ	O	38	NMOD
37	arterial	arterial	I-NP	JJ	O	38	NMOD
38	pressure	pressure	I-NP	NN	O	45	NMOD
39	,	,	O	,	O	45	P
40	LV	LV	B-NP	NN	O	41	NMOD
41	pressure	pressure	I-NP	NN	O	45	NMOD
42	and	and	O	CC	O	45	NMOD
43	its	its	B-NP	PRP$	O	45	NMOD
44	first	first	I-NP	JJ	O	45	NMOD
45	derivative	derivative	I-NP	NN	O	32	OBJ
46	(	(	O	(	O	48	DEP
47	dP/dt	dP/dt	B-NP	NN	O	48	DEP
48	)	)	O	)	O	45	NMOD
49	,	,	O	,	O	55	P
50	and	and	O	CC	O	55	NMOD
51	LV	LV	B-NP	NN	O	52	NMOD
52	volumes	volume	I-NP	NNS	O	55	NMOD
53	and	and	O	CC	O	55	NMOD
54	ejection	ejection	B-NP	NN	O	55	NMOD
55	fraction	fraction	I-NP	NN	O	3	OBJ
56	before	before	B-PP	IN	O	55	NMOD
57	and	and	I-PP	CC	O	56	PMOD
58	during	during	I-PP	IN	O	56	PMOD
59	the	the	B-NP	DT	O	64	NMOD
60	final	final	I-NP	JJ	O	64	NMOD
61	2	2	I-NP	CD	O	63	AMOD
62	to	to	I-NP	TO	O	63	AMOD
63	3	3	I-NP	CD	O	64	NMOD
64	minutes	minute	I-NP	NNS	O	56	PMOD
65	of	of	B-PP	IN	O	64	NMOD
66	a	a	B-NP	DT	O	69	NMOD
67	15-minute	15-minute	I-NP	JJ	O	69	NMOD
68	intracoronary	intracoronary	I-NP	JJ	O	69	NMOD
69	infusion	infusion	I-NP	NN	O	65	PMOD
70	of	of	B-PP	IN	O	69	NMOD
71	saline	saline	B-NP	NN	O	82	NMOD
72	(	(	O	(	O	77	DEP
73	n=10	n=10	B-NP	NN	O	76	NMOD
74	,	,	O	,	O	76	P
75	control	control	B-NP	JJ	O	76	NMOD
76	subjects	subject	I-NP	NNS	O	77	DEP
77	)	)	O	)	O	71	NMOD
78	or	or	O	CC	O	82	NMOD
79	cocaine	cocaine	B-NP	NN	O	82	NMOD
80	hydrochloride	hydrochloride	I-NP	NN	O	82	NMOD
81	1	1	I-NP	CD	O	82	NMOD
82	mg/min	mg/min	I-NP	NN	O	70	PMOD
83	(	(	O	(	O	85	DEP
84	n=10	n=10	B-NP	NN	B-protein	85	DEP
85	)	)	O	)	O	82	NMOD
86	.	.	O	.	O	3	P

1	Heparin	Heparin	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	thrombocytopenia	thrombocytopenia	B-NP	NN	O	11	NMOD
4	,	,	O	,	O	11	P
5	paradoxical	paradoxical	B-NP	JJ	O	6	NMOD
6	thromboembolism	thromboembolism	I-NP	NN	O	11	NMOD
7	,	,	O	,	O	11	P
8	and	and	O	CC	O	11	NMOD
9	other	other	B-NP	JJ	O	11	NMOD
10	side	side	I-NP	NN	O	11	NMOD
11	effects	effect	I-NP	NNS	O	2	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	heparin	heparin	B-NP	NN	O	14	NMOD
14	therapy	therapy	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	2	P

1	Nonopaque	Nonopaque	B-NP	JJ	O	3	NMOD
2	crystal	crystal	I-NP	JJ	O	3	NMOD
3	deposition	deposition	I-NP	NN	O	0	ROOT
4	causing	cause	B-VP	VBG	O	3	NMOD
5	ureteric	ureteric	B-NP	JJ	O	6	NMOD
6	obstruction	obstruction	I-NP	NN	O	4	OBJ
7	in	in	B-PP	IN	O	4	VMOD
8	patients	patient	B-NP	NNS	O	7	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	HIV	HIV	B-NP	NN	O	9	PMOD
11	undergoing	undergo	B-VP	VBG	O	10	NMOD
12	indinavir	indinavir	B-NP	NN	O	13	NMOD
13	therapy	therapy	I-NP	NN	O	11	OBJ
14	.	.	O	.	O	3	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	4	VMOD
2	:	:	O	:	O	4	P
3	We	We	B-NP	PRP	O	4	SUB
4	describe	describe	B-VP	VBP	O	0	ROOT
5	the	the	B-NP	DT	O	8	NMOD
6	unique	unique	I-NP	JJ	O	8	NMOD
7	CT	CT	I-NP	NN	O	8	NMOD
8	features	feature	I-NP	NNS	O	4	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	ureteric	ureteric	B-NP	JJ	O	11	NMOD
11	calculi	calculus	I-NP	NNS	O	9	PMOD
12	in	in	B-PP	IN	O	4	VMOD
13	six	six	B-NP	CD	O	15	NMOD
14	HIV-infected	HIV-infected	I-NP	JJ	O	15	NMOD
15	patients	patient	I-NP	NNS	O	12	PMOD
16	receiving	receive	B-VP	VBG	O	15	NMOD
17	indinavir	indinavir	B-NP	NN	O	16	OBJ
18	,	,	O	,	O	4	P
19	the	the	B-NP	DT	O	25	NMOD
20	most	most	I-NP	RBS	O	21	AMOD
21	commonly	commonly	I-NP	RB	O	25	NMOD
22	used	use	I-NP	VBN	O	21	AMOD
23	HIV	HIV	I-NP	NN	O	25	NMOD
24	protease	protease	I-NP	NN	O	25	NMOD
25	inhibitor	inhibitor	I-NP	NN	O	4	OBJ
26	,	,	O	,	O	25	P
27	which	which	B-NP	WDT	O	25	NMOD
28	is	be	B-VP	VBZ	O	27	SBAR
29	associated	associate	I-VP	VBN	O	28	VC
30	with	with	B-PP	IN	O	29	VMOD
31	an	an	B-NP	DT	O	33	NMOD
32	increased	increase	I-NP	VBN	O	33	NMOD
33	incidence	incidence	I-NP	NN	O	30	PMOD
34	of	of	B-PP	IN	O	33	NMOD
35	urolithiasis	urolithiasis	B-NP	NN	O	34	PMOD
36	.	.	O	.	O	4	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Ureteric	Ureteric	B-NP	JJ	O	4	NMOD
4	obstruction	obstruction	I-NP	NN	O	10	SUB
5	caused	cause	B-VP	VBN	O	4	NMOD
6	by	by	B-PP	IN	O	5	VMOD
7	precipitated	precipitate	B-NP	VBN	O	9	NMOD
8	indinavir	indinavir	I-NP	NN	O	9	NMOD
9	crystals	crystal	I-NP	NNS	O	6	PMOD
10	may	may	B-VP	MD	O	1	NMOD
11	be	be	I-VP	VB	O	10	VC
12	difficult	difficult	B-ADJP	JJ	O	11	PRD
13	to	to	B-VP	TO	O	14	VMOD
14	diagnose	diagnose	I-VP	VB	O	12	AMOD
15	with	with	B-PP	IN	O	14	VMOD
16	unenhanced	unenhanced	B-NP	JJ	O	17	NMOD
17	CT	CT	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	1	P

1	Ischemic	Ischemic	B-NP	JJ	O	2	NMOD
2	colitis	colitis	I-NP	NN	O	5	NMOD
3	and	and	I-NP	CC	O	5	NMOD
4	sumatriptan	sumatriptan	I-NP	NN	O	5	NMOD
5	use	use	I-NP	NN	O	0	ROOT
6	.	.	O	.	O	5	P

1	Cases	Case	B-NP	NNS	O	2	SUB
2	have	have	B-VP	VBP	O	0	ROOT
3	been	be	I-VP	VBN	O	2	VC
4	published	publish	I-VP	VBN	O	3	VC
5	of	of	B-PP	IN	O	4	VMOD
6	coronary	coronary	B-NP	JJ	O	7	NMOD
7	vasospasm	vasospasm	I-NP	NN	O	5	PMOD
8	,	,	O	,	O	2	P
9	myocardial	myocardial	B-NP	JJ	O	10	NMOD
10	ischemia	ischemia	I-NP	NN	O	2	OBJ
11	,	,	O	,	O	14	P
12	and	and	O	CC	O	14	NMOD
13	myocardial	myocardial	B-NP	JJ	O	14	NMOD
14	infarction	infarction	I-NP	NN	O	2	OBJ
15	occurring	occur	B-VP	VBG	O	14	NMOD
16	after	after	B-PP	IN	O	15	VMOD
17	sumatriptan	sumatriptan	B-NP	NN	O	18	NMOD
18	use	use	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	2	P

1	Pallidotomy	Pallidotomy	B-NP	NN	O	9	NMOD
2	with	with	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	5	NMOD
4	gamma	gamma	I-NP	NN	O	5	NMOD
5	knife	knife	I-NP	NN	O	2	PMOD
6	:	:	O	:	O	1	P
7	a	a	B-NP	DT	O	9	NMOD
8	positive	positive	I-NP	JJ	O	9	NMOD
9	experience.	experience.	I-NP	NN	O	11	NMOD
10	51	51	B-NP	CD	O	9	NMOD
11	patients	patient	I-NP	NNS	O	18	SUB
12	with	with	B-PP	IN	O	11	NMOD
13	medically	medically	O	RB	O	14	AMOD
14	refractory	refractory	O	JJ	O	17	NMOD
15	Parkinson	Parkinson	B-NP	NNP	O	16	NMOD
16	's	's	B-NP	POS	O	17	NMOD
17	disease	disease	I-NP	NN	O	12	PMOD
18	underwent	undergo	B-VP	VBD	O	0	ROOT
19	stereotactic	stereotactic	B-NP	JJ	O	21	NMOD
20	posteromedial	posteromedial	I-NP	JJ	O	21	NMOD
21	pallidotomy	pallidotomy	I-NP	NN	O	18	OBJ
22	between	between	B-PP	IN	O	18	VMOD
23	August	August	B-NP	NNP	O	26	NMOD
24	1993	1993	I-NP	CD	O	23	NMOD
25	and	and	O	CC	O	26	NMOD
26	February	February	B-NP	NNP	O	22	PMOD
27	1997	1997	I-NP	CD	O	26	NMOD
28	for	for	B-PP	IN	O	18	VMOD
29	treatment	treatment	B-NP	NN	O	28	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	bradykinesia	bradykinesia	B-NP	NN	O	38	NMOD
32	,	,	O	,	O	38	P
33	rigidity	rigidity	B-NP	NN	O	38	NMOD
34	,	,	O	,	O	38	P
35	and	and	O	CC	O	38	NMOD
36	L-DOPA	L-DOPA	B-NP	NN	B-protein	38	NMOD
37	induced	induce	I-NP	VBN	O	38	NMOD
38	dyskinesias	dyskinesia	I-NP	NNS	O	30	PMOD
39	.	.	O	.	O	18	P

1	Neuroleptic	Neuroleptic	B-NP	JJ	O	3	NMOD
2	malignant	malignant	I-NP	JJ	O	3	NMOD
3	syndrome	syndrome	I-NP	NN	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	methylphenidate	methylphenidate	I-NP	NN	O	0	ROOT
6	.	.	O	.	O	5	P

1	A	A	B-NP	DT	O	3	NMOD
2	1-year-old	1-year-old	I-NP	JJ	O	3	NMOD
3	female	female	I-NP	JJ	O	0	ROOT
4	presented	present	B-VP	VBN	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	neuroleptic	neuroleptic	B-NP	JJ	O	8	NMOD
7	malignant	malignant	I-NP	JJ	O	8	NMOD
8	syndrome	syndrome	I-NP	NN	O	5	PMOD
9	probably	probably	B-VP	RB	O	10	VMOD
10	caused	cause	I-VP	VBN	O	8	NMOD
11	by	by	B-PP	IN	O	10	VMOD
12	methylphenidate	methylphenidate	B-NP	NN	O	11	PMOD
13	.	.	O	.	O	3	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	shows	show	B-VP	VBZ	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	17alpha-ethinylestradiol	17alpha-ethinylestradiol	B-NP	NN	O	9	SUB
6	(	(	O	(	O	8	DEP
7	EE	EE	B-NP	NN	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	induced	induce	B-VP	VBD	O	4	SBAR
10	intrahepatic	intrahepatic	B-NP	JJ	O	11	NMOD
11	cholestasis	cholestasis	I-NP	NN	O	9	OBJ
12	in	in	B-PP	IN	O	9	VMOD
13	rats	rat	B-NP	NNS	O	12	PMOD
14	is	be	B-VP	VBZ	O	9	VMOD
15	associated	associate	I-VP	VBN	O	14	VC
16	with	with	B-PP	IN	O	15	VMOD
17	selective	selective	B-NP	JJ	O	18	NMOD
18	inhibition	inhibition	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	22	NMOD
21	neutral	neutral	I-NP	JJ	O	22	NMOD
22	pathway	pathway	I-NP	NN	O	19	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	bile	bile	B-NP	NN	O	25	NMOD
25	salt	salt	I-NP	NN	O	29	NMOD
26	(	(	O	(	O	28	DEP
27	BS	BS	B-NP	NN	O	28	DEP
28	)	)	O	)	O	25	NMOD
29	synthesis	synthesis	B-NP	NN	O	23	PMOD
30	.	.	O	.	O	3	P

1	Glibenclamide-sensitive	Glibenclamide-sensitive	B-NP	JJ	O	2	NMOD
2	hypotension	hypotension	I-NP	NN	O	0	ROOT
3	produced	produce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	helodermin	helodermin	B-NP	NN	O	4	PMOD
6	assessed	assess	B-VP	VBN	O	5	NMOD
7	in	in	B-PP	IN	O	6	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	rat	rat	I-NP	NN	O	7	PMOD
10	.	.	O	.	O	2	P

1	Helodermin	Helodermin	B-NP	NN	O	2	SUB
2	produced	produce	B-VP	VBD	O	0	ROOT
3	hypotension	hypotension	B-NP	NN	O	2	OBJ
4	in	in	B-PP	IN	O	2	VMOD
5	a	a	B-NP	DT	O	7	NMOD
6	dose-dependent	dose-dependent	I-NP	JJ	O	7	NMOD
7	manner	manner	I-NP	NN	O	4	PMOD
8	with	with	B-PP	IN	O	2	VMOD
9	approximately	approximately	B-NP	RB	O	10	AMOD
10	similar	similar	I-NP	JJ	O	13	NMOD
11	potency	potency	I-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	duration	duration	I-NP	NN	O	8	PMOD
14	to	to	B-PP	TO	O	13	NMOD
15	VIP	VIP	B-NP	NN	B-protein	14	PMOD
16	.	.	O	.	O	2	P

1	Hypotension	Hypotension	B-NP	NN	O	6	SUB
2	induced	induce	B-VP	VBN	O	1	NMOD
3	by	by	B-PP	IN	O	2	VMOD
4	both	both	B-NP	DT	O	5	NMOD
5	peptides	peptide	I-NP	NNS	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	significantly	significantly	I-VP	RB	O	6	VMOD
8	attenuated	attenuate	I-VP	VBN	O	6	VC
9	by	by	B-PP	IN	O	8	VMOD
10	glibenclamide	glibenclamide	B-NP	NN	O	9	PMOD
11	,	,	O	,	O	10	P
12	which	which	B-NP	WDT	O	10	NMOD
13	abolished	abolish	B-VP	VBD	O	12	SBAR
14	a	a	B-NP	DT	O	16	NMOD
15	levcromakalim-produced	levcromakalim-produced	I-NP	JJ	O	16	NMOD
16	decrease	decrease	I-NP	NN	O	13	OBJ
17	in	in	B-PP	IN	O	16	NMOD
18	arterial	arterial	B-NP	JJ	O	20	NMOD
19	blood	blood	I-NP	NN	O	20	NMOD
20	pressure	pressure	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	6	P

1	Oxyhemoglobin	Oxyhemoglobin	B-NP	NN	B-protein	2	SUB
2	did	do	B-VP	VBD	O	9	VMOD
3	not	not	I-VP	RB	O	2	VMOD
4	affect	affect	I-VP	VB	O	2	VC
5	helodermin	helodermin	B-NP	NN	O	7	NMOD
6	induced	induced	I-NP	JJ	O	7	NMOD
7	hypotension	hypotension	I-NP	NN	O	4	OBJ
8	,	,	O	,	O	9	P
9	whereas	whereas	O	IN	O	0	ROOT
10	it	it	B-NP	PRP	O	11	SUB
11	shortened	shorten	B-VP	VBD	O	9	VMOD
12	the	the	B-NP	DT	O	13	NMOD
13	duration	duration	I-NP	NN	O	11	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	acetylcholine	acetylcholine	B-NP	NN	O	20	NMOD
16	(	(	O	(	O	18	DEP
17	ACh	ACh	B-NP	NN	O	18	DEP
18	)	)	O	)	O	15	NMOD
19	-produced	-produced	B-NP	JJ	O	20	NMOD
20	hypotension	hypotension	I-NP	NN	O	14	PMOD
21	.	.	O	.	O	9	P

1	These	These	B-NP	DT	O	2	NMOD
2	findings	finding	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	helodermin-produced	helodermin-produced	B-NP	JJ	O	6	NMOD
6	hypotension	hypotension	I-NP	NN	O	7	SUB
7	is	be	B-VP	VBZ	O	4	SBAR
8	partly	partly	B-ADJP	RB	O	9	AMOD
9	attributable	attributable	I-ADJP	JJ	O	7	PRD
10	to	to	B-PP	TO	O	9	AMOD
11	the	the	B-NP	DT	O	12	NMOD
12	activation	activation	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	glibenclamide-sensitive	glibenclamide-sensitive	B-NP	JJ	B-protein	16	NMOD
15	K+	K+	I-NP	NN	I-protein	16	NMOD
16	channels	channel	I-NP	NNS	I-protein	13	PMOD
17	(	(	O	(	O	23	DEP
18	K	K	B-NP	NN	B-protein	22	NMOD
19	(	(	O	(	I-protein	22	NMOD
20	ATP	ATP	B-NP	NN	I-protein	22	NMOD
21	)	)	O	)	I-protein	22	NMOD
22	channels	channel	B-NP	NNS	I-protein	23	DEP
23	)	)	O	)	O	16	NMOD
24	,	,	O	,	O	16	P
25	which	which	B-NP	WDT	O	16	NMOD
26	presumably	presumably	B-ADVP	RB	O	27	VMOD
27	exist	exist	B-VP	VBP	O	25	SBAR
28	on	on	B-PP	IN	O	27	VMOD
29	arterial	arterial	B-NP	JJ	B-cell_type	32	NMOD
30	smooth	smooth	I-NP	JJ	I-cell_type	32	NMOD
31	muscle	muscle	I-NP	NN	I-cell_type	32	NMOD
32	cells	cell	I-NP	NNS	I-cell_type	28	PMOD
33	.	.	O	.	O	3	P

1	Long-term	Long-term	B-NP	JJ	O	2	NMOD
2	efficacy	efficacy	I-NP	NN	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	adverse	adverse	B-NP	JJ	O	5	NMOD
5	event	event	I-NP	NN	O	13	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	nifedipine	nifedipine	B-NP	NN	O	9	NMOD
8	sustained-release	sustained-release	I-NP	NN	O	9	NMOD
9	tablets	tablet	I-NP	NNS	O	6	PMOD
10	for	for	B-PP	IN	O	9	NMOD
11	cyclosporin	cyclosporin	B-NP	NN	O	12	NMOD
12	A	A	I-NP	NN	O	10	PMOD
13	induced	induce	B-VP	VBD	O	0	ROOT
14	hypertension	hypertension	B-NP	NN	O	13	OBJ
15	in	in	B-PP	IN	O	13	VMOD
16	patients	patient	B-NP	NNS	O	15	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	psoriasis	psoriasis	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	13	P

1	Thirteen	Thirteen	B-NP	CD	O	3	NMOD
2	psoriatic	psoriatic	I-NP	JJ	O	3	NMOD
3	patients	patient	I-NP	NNS	O	13	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	hypertension	hypertension	B-NP	NN	O	4	PMOD
6	during	during	B-PP	IN	O	3	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	course	course	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	cyclosporin	cyclosporin	B-NP	NN	O	12	NMOD
11	A	A	I-NP	NN	O	12	NMOD
12	therapy	therapy	I-NP	NN	O	9	PMOD
13	were	be	B-VP	VBD	O	0	ROOT
14	treated	treat	I-VP	VBN	O	13	VC
15	for	for	B-PP	IN	O	14	VMOD
16	25	25	B-NP	CD	O	17	NMOD
17	months	month	I-NP	NNS	O	15	PMOD
18	with	with	B-PP	IN	O	14	VMOD
19	a	a	B-NP	DT	O	22	NMOD
20	calcium	calcium	I-NP	NN	O	22	NMOD
21	channel	channel	I-NP	NN	O	22	NMOD
22	blocker	blocker	I-NP	NN	O	18	PMOD
23	,	,	O	,	O	13	VMOD
24	sustained-release	sustained-release	B-NP	JJ	O	25	NMOD
25	nifedipine	nifedipine	I-NP	NN	O	23	OBJ
26	,	,	O	,	O	25	P
27	to	to	B-VP	TO	O	28	VMOD
28	study	study	I-VP	VB	O	25	NMOD
29	the	the	B-NP	DT	O	32	NMOD
30	clinical	clinical	I-NP	JJ	O	32	NMOD
31	antihypertensive	antihypertensive	I-NP	JJ	O	32	NMOD
32	effects	effect	I-NP	NNS	O	35	NMOD
33	and	and	O	CC	O	35	NMOD
34	adverse	adverse	B-NP	JJ	O	35	NMOD
35	events	event	I-NP	NNS	O	28	OBJ
36	during	during	B-PP	IN	O	35	NMOD
37	treatment	treatment	B-NP	NN	O	36	PMOD
38	with	with	B-PP	IN	O	37	NMOD
39	both	both	B-NP	DT	O	40	NMOD
40	drugs	drug	I-NP	NNS	O	38	PMOD
41	.	.	O	.	O	13	P

1	Seven	Seven	B-NP	CD	O	6	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	5	NMOD
4	13	13	I-NP	CD	O	5	NMOD
5	patients	patient	I-NP	NNS	O	2	PMOD
6	had	have	B-VP	VBD	O	0	ROOT
7	exhibited	exhibit	I-VP	VBN	O	6	VC
8	a	a	B-NP	DT	O	11	NMOD
9	subclinical	subclinical	I-NP	JJ	O	11	NMOD
10	hypertensive	hypertensive	I-NP	JJ	O	11	NMOD
11	state	state	I-NP	NN	O	7	OBJ
12	before	before	B-PP	IN	O	7	VMOD
13	cyclosporin	cyclosporin	B-NP	NN	O	15	NMOD
14	A	A	I-NP	NN	O	15	NMOD
15	therapy	therapy	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	3	NMOD
2	adverse	adverse	I-NP	JJ	O	3	NMOD
3	events	event	I-NP	NNS	O	12	SUB
4	during	during	B-PP	IN	O	3	NMOD
5	combined	combined	B-NP	JJ	O	6	NMOD
6	therapy	therapy	I-NP	NN	O	4	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	cyclosporin	cyclosporin	B-NP	NN	O	9	NMOD
9	A	A	I-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	nifedipine	nifedipine	I-NP	NN	O	7	PMOD
12	included	include	B-VP	VBD	O	0	ROOT
13	an	an	B-NP	DT	O	14	NMOD
14	increase	increase	I-NP	NN	O	27	NMOD
15	in	in	B-PP	IN	O	14	NMOD
16	blood	blood	B-NP	NN	O	19	NMOD
17	urea	urea	I-NP	NN	O	19	NMOD
18	nitrogen	nitrogen	I-NP	NN	O	19	NMOD
19	levels	level	I-NP	NNS	O	15	PMOD
20	in	in	B-PP	IN	O	14	NMOD
21	9	9	B-NP	CD	O	20	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	25	NMOD
24	13	13	I-NP	CD	O	25	NMOD
25	patients	patient	I-NP	NNS	O	22	PMOD
26	and	and	I-NP	CC	O	27	NMOD
27	development	development	I-NP	NN	O	12	OBJ
28	of	of	B-PP	IN	O	27	NMOD
29	gingival	gingival	B-NP	JJ	O	30	NMOD
30	hyperplasia	hyperplasia	I-NP	NN	O	28	PMOD
31	in	in	B-PP	IN	O	27	NMOD
32	2	2	B-NP	CD	O	31	PMOD
33	of	of	B-PP	IN	O	32	NMOD
34	the	the	B-NP	DT	O	36	NMOD
35	13	13	I-NP	CD	O	36	NMOD
36	patients	patient	I-NP	NNS	O	33	PMOD
37	.	.	O	.	O	12	P

1	Torsade	Torsade	B-NP	FW	O	5	NMOD
2	de	de	I-NP	FW	O	3	AMOD
3	pointes	pointes	I-NP	FW	O	5	NMOD
4	ventricular	ventricular	I-NP	JJ	O	5	NMOD
5	tachycardia	tachycardia	I-NP	NN	O	0	ROOT
6	during	during	B-PP	IN	O	5	NMOD
7	low	low	B-NP	JJ	O	11	NMOD
8	dose	dose	I-NP	NN	O	11	NMOD
9	intermittent	intermittent	I-NP	JJ	O	11	NMOD
10	dobutamine	dobutamine	I-NP	NN	O	11	NMOD
11	treatment	treatment	I-NP	NN	O	6	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	a	a	B-NP	DT	O	14	NMOD
14	patient	patient	I-NP	NN	O	12	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	dilated	dilated	B-NP	JJ	O	17	NMOD
17	cardiomyopathy	cardiomyopathy	I-NP	NN	O	21	NMOD
18	and	and	O	CC	O	21	NMOD
19	congestive	congestive	B-NP	JJ	O	21	NMOD
20	heart	heart	I-NP	NN	O	21	NMOD
21	failure	failure	I-NP	NN	O	15	PMOD
22	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	2	NMOD
2	authors	author	I-NP	NNS	O	3	SUB
3	describe	describe	B-VP	VBP	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	case	case	I-NP	NN	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	a	a	B-NP	DT	O	9	NMOD
8	56-year-old	56-year-old	I-NP	JJ	O	9	NMOD
9	woman	woman	I-NP	NN	O	6	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	chronic	chronic	B-NP	JJ	O	15	NMOD
12	,	,	I-NP	,	O	15	P
13	severe	severe	I-NP	JJ	O	15	NMOD
14	heart	heart	I-NP	NN	O	15	NMOD
15	failure	failure	I-NP	NN	O	10	PMOD
16	secondary	secondary	B-ADJP	JJ	O	15	NMOD
17	to	to	B-PP	TO	O	16	AMOD
18	dilated	dilate	B-NP	VBN	O	21	NMOD
19	cardiomyopathy	cardiomyopathy	I-NP	NN	O	21	NMOD
20	and	and	I-NP	CC	O	21	NMOD
21	absence	absence	I-NP	NN	O	17	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	significant	significant	B-NP	JJ	O	24	AMOD
24	ventricular	ventricular	I-NP	JJ	O	25	NMOD
25	arrhythmias	arrhythmia	I-NP	NNS	O	22	PMOD
26	who	who	B-NP	WP	O	25	NMOD
27	developed	develop	B-VP	VBD	O	26	SBAR
28	QT	QT	B-NP	NN	O	29	NMOD
29	prolongation	prolongation	I-NP	NN	O	27	OBJ
30	and	and	O	CC	O	35	NMOD
31	torsade	torsade	B-NP	FW	O	35	NMOD
32	de	de	I-NP	FW	O	33	AMOD
33	pointes	pointes	I-NP	FW	O	35	NMOD
34	ventricular	ventricular	I-NP	JJ	O	35	NMOD
35	tachycardia	tachycardia	I-NP	NN	O	3	OBJ
36	during	during	B-PP	IN	O	3	VMOD
37	one	one	B-NP	CD	O	38	NMOD
38	cycle	cycle	I-NP	NN	O	36	PMOD
39	of	of	B-PP	IN	O	38	NMOD
40	intermittent	intermittent	B-NP	JJ	O	42	NMOD
41	low	low	I-NP	JJ	O	42	NMOD
42	dose	dose	I-NP	NN	O	49	NMOD
43	(	(	O	(	O	48	DEP
44	2.5	2.5	B-NP	CD	O	45	NMOD
45	mcg/kg	mcg/kg	I-NP	NN	O	48	DEP
46	per	per	B-PP	IN	O	45	NMOD
47	min	min	B-NP	NN	O	46	PMOD
48	)	)	O	)	O	42	NMOD
49	dobutamine	dobutamine	B-NP	NN	O	39	PMOD
50	.	.	O	.	O	3	P

1	This	This	B-NP	DT	O	2	NMOD
2	report	report	I-NP	NN	O	12	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	torsade	torsade	B-NP	FW	O	8	NMOD
5	de	de	I-NP	FW	O	6	AMOD
6	pointes	pointes	I-NP	FW	O	8	NMOD
7	ventricular	ventricular	I-NP	JJ	O	8	NMOD
8	tachycardia	tachycardia	I-NP	NN	O	3	PMOD
9	during	during	B-PP	IN	O	2	NMOD
10	intermittent	intermittent	B-NP	JJ	O	11	NMOD
11	dobutamine	dobutamine	I-NP	NN	O	9	PMOD
12	supports	support	B-VP	VBZ	O	0	ROOT
13	the	the	B-NP	DT	O	14	NMOD
14	hypothesis	hypothesis	I-NP	NN	O	12	OBJ
15	that	that	B-SBAR	IN	O	14	NMOD
16	unpredictable	unpredictable	B-NP	JJ	O	18	NMOD
17	fatal	fatal	I-NP	JJ	O	18	NMOD
18	arrhythmias	arrhythmia	I-NP	NNS	O	19	SUB
19	may	may	B-VP	MD	O	15	SBAR
20	occur	occur	I-VP	VB	O	19	VC
21	even	even	B-ADVP	RB	O	22	PMOD
22	with	with	B-PP	IN	O	20	VMOD
23	low	low	B-NP	JJ	O	24	NMOD
24	doses	dose	I-NP	NNS	O	22	PMOD
25	and	and	B-PP	CC	O	22	PMOD
26	in	in	B-PP	IN	O	22	PMOD
27	patients	patient	B-NP	NNS	O	26	PMOD
28	with	with	B-PP	IN	O	27	NMOD
29	no	no	B-NP	DT	O	30	NMOD
30	history	history	I-NP	NN	O	28	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	significant	significant	B-NP	JJ	O	34	NMOD
33	rhythm	rhythm	I-NP	NN	O	34	NMOD
34	disturbances	disturbance	I-NP	NNS	O	31	PMOD
35	.	.	O	.	O	12	P

1	Risk	Risk	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	transient	transient	B-NP	JJ	O	5	NMOD
4	hyperammonemic	hyperammonemic	I-NP	JJ	O	5	NMOD
5	encephalopathy	encephalopathy	I-NP	NN	O	2	PMOD
6	in	in	B-PP	IN	O	1	NMOD
7	cancer	cancer	B-NP	NN	O	8	NMOD
8	patients	patient	I-NP	NNS	O	6	PMOD
9	who	who	B-NP	WP	O	8	NMOD
10	received	receive	B-VP	VBD	O	9	SBAR
11	continuous	continuous	B-NP	JJ	O	12	NMOD
12	infusion	infusion	I-NP	NN	O	10	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	5-fluorouracil	5-fluorouracil	B-NP	NN	O	13	PMOD
15	with	with	B-PP	IN	O	10	VMOD
16	the	the	B-NP	DT	O	17	NMOD
17	complication	complication	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	dehydration	dehydration	B-NP	NN	O	21	NMOD
20	and	and	I-NP	CC	O	21	NMOD
21	infection	infection	I-NP	NN	O	18	PMOD
22	.	.	O	.	O	1	P

1	From	From	B-PP	IN	O	26	VMOD
2	1986	1986	B-NP	CD	O	4	AMOD
3	to	to	B-PP	TO	O	4	AMOD
4	1998	1998	B-NP	CD	O	1	PMOD
5	,	,	O	,	O	26	P
6	29	29	B-NP	CD	O	8	NMOD
7	cancer	cancer	I-NP	NN	O	8	NMOD
8	patients	patient	I-NP	NNS	O	26	SUB
9	who	who	B-NP	WP	O	8	NMOD
10	had	have	B-VP	VBD	O	9	SBAR
11	32	32	B-NP	CD	O	12	NMOD
12	episodes	episode	I-NP	NNS	O	10	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	transient	transient	B-NP	JJ	O	15	AMOD
15	hyperammonemic	hyperammonemic	I-NP	JJ	O	16	NMOD
16	encephalopathy	encephalopathy	I-NP	NN	O	13	PMOD
17	related	relate	B-VP	VBN	O	16	NMOD
18	to	to	B-PP	TO	O	17	VMOD
19	continuous	continuous	B-NP	JJ	O	20	NMOD
20	infusion	infusion	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	5-fluorouracil	5-fluorouracil	B-NP	NN	O	21	PMOD
23	(	(	O	(	O	25	DEP
24	5-FU	5-FU	B-NP	NN	O	25	DEP
25	)	)	O	)	O	22	NMOD
26	were	be	B-VP	VBD	O	0	ROOT
27	identified	identify	I-VP	VBN	O	26	VC
28	.	.	O	.	O	26	P

1	Higher	High	B-NP	JJR	O	4	NMOD
2	plasma	plasma	I-NP	NN	O	4	NMOD
3	ammonium	ammonium	I-NP	NN	O	4	NMOD
4	levels	level	I-NP	NNS	O	11	SUB
5	and	and	O	CC	O	8	NMOD
6	more	more	B-NP	RBR	O	7	AMOD
7	rapid	rapid	I-NP	JJ	O	8	NMOD
8	onset	onset	I-NP	NN	O	4	NMOD
9	of	of	B-PP	IN	O	8	NMOD
10	hyperammonemia	hyperammonemia	B-NP	NN	O	9	PMOD
11	were	be	B-VP	VBD	O	0	ROOT
12	seen	see	I-VP	VBN	O	11	VC
13	in	in	B-PP	IN	O	12	VMOD
14	18	18	B-NP	CD	O	15	NMOD
15	patients	patient	I-NP	NNS	O	13	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	bacterial	bacterial	B-NP	JJ	O	18	NMOD
18	infections	infection	I-NP	NNS	O	16	PMOD
19	(	(	O	(	O	25	DEP
20	p=0.003	p=0.003	B-NP	NN	O	22	NMOD
21	and	and	O	CC	O	22	NMOD
22	0.0006	0.0006	B-NP	CD	O	25	DEP
23	,	,	O	,	O	22	P
24	respectively	respectively	B-ADVP	RB	O	22	NMOD
25	)	)	O	)	O	18	NMOD
26	and	and	O	CC	O	13	PMOD
27	in	in	B-PP	IN	O	13	PMOD
28	nine	nine	B-NP	CD	O	29	NMOD
29	patients	patient	I-NP	NNS	O	27	PMOD
30	receiving	receive	B-VP	VBG	O	29	NMOD
31	high	high	B-NP	JJ	O	33	NMOD
32	daily	daily	I-NP	JJ	O	33	NMOD
33	doses	dose	I-NP	NNS	O	30	OBJ
34	(	(	O	(	O	39	DEP
35	2600	2600	B-NP	CD	O	37	AMOD
36	or	or	I-NP	CC	O	37	AMOD
37	1800	1800	I-NP	CD	O	38	NMOD
38	mg/m2	mg/m2	I-NP	NN	O	39	DEP
39	)	)	O	)	O	33	NMOD
40	of	of	B-PP	IN	O	33	NMOD
41	5-FU	5-FU	B-NP	NN	O	40	PMOD
42	(	(	O	(	O	49	DEP
43	p=0.0001	p=0.0001	B-NP	NN	O	45	NMOD
44	and	and	O	CC	O	45	NMOD
45	<	<	B-NP	SYM	O	49	DEP
46	0.0001	0.0001	B-NP	CD	O	45	NMOD
47	,	,	O	,	O	45	P
48	respectively	respectively	B-ADVP	RB	O	45	VMOD
49	)	)	O	)	O	29	NMOD
50	.	.	O	.	O	11	P

1	In	In	B-PP	IN	O	6	VMOD
2	conclusion	conclusion	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	6	P
4	hyperammonemic	hyperammonemic	B-NP	JJ	O	5	NMOD
5	encephalopathy	encephalopathy	I-NP	NN	O	6	SUB
6	can	can	B-VP	MD	O	0	ROOT
7	occur	occur	I-VP	VB	O	6	VC
8	in	in	B-PP	IN	O	7	VMOD
9	patients	patient	B-NP	NNS	O	8	PMOD
10	receiving	receive	B-VP	VBG	O	9	NMOD
11	continuous	continuous	B-NP	JJ	O	12	NMOD
12	infusion	infusion	I-NP	NN	O	10	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	5-FU	5-FU	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	6	P

1	In	In	B-PP	IN	O	20	VMOD
2	the	the	B-NP	DT	O	5	NMOD
3	motor	motor	I-NP	NN	O	5	NMOD
4	activity	activity	I-NP	NN	O	5	NMOD
5	test	test	I-NP	NN	O	20	SUB
6	measured	measure	B-VP	VBN	O	5	NMOD
7	with	with	B-PP	IN	O	6	VMOD
8	an	an	B-NP	DT	O	10	NMOD
9	Animex-activity	Animex-activity	I-NP	NN	O	10	NMOD
10	meter	meter	I-NP	NN	O	7	PMOD
11	neither	neither	B-PP	CC	O	7	PMOD
12	of	of	B-PP	IN	O	7	PMOD
13	the	the	B-NP	DT	O	14	NMOD
14	K	K	I-NP	NN	O	19	NMOD
15	(	(	O	(	O	17	DEP
16	+	+	O	SYM	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	-channel	-channel	B-NP	JJ	O	19	NMOD
19	blockers	blocker	I-NP	NNS	O	12	PMOD
20	affected	affect	B-VP	VBD	O	33	VMOD
21	morphine	morphine	B-NP	NN	O	23	NMOD
22	induced	induced	I-NP	JJ	O	23	NMOD
23	hypoactivity	hypoactivity	I-NP	NN	O	20	OBJ
24	,	,	O	,	O	33	P
25	but	but	O	CC	O	33	VMOD
26	both	both	O	CC	O	27	NMOD
27	K	K	B-NP	NN	O	32	NMOD
28	(	(	O	(	O	30	DEP
29	+	+	O	SYM	O	30	DEP
30	)	)	O	)	O	27	NMOD
31	-channel	-channel	B-NP	JJ	O	27	NMOD
32	blockers	blocker	I-NP	NNS	O	33	SUB
33	prevented	prevent	B-VP	VBD	O	0	ROOT
34	morphine	morphine	B-NP	NN	O	37	NMOD
35	induced	induced	I-NP	JJ	O	37	NMOD
36	secondary	secondary	I-NP	JJ	O	37	NMOD
37	hyperactivity.	hyperactivity.	I-NP	NN	O	33	OBJ
38	3	3	I-NP	CD	O	37	NMOD
39	.	.	O	.	O	33	P

1	Nociceptin/orphanin	Nociceptin/orphanin	B-NP	NN	B-protein	2	NMOD
2	FQ	FQ	I-NP	NN	I-protein	4	NMOD
3	and	and	O	CC	O	4	NMOD
4	nocistatin	nocistatin	B-NP	NN	O	0	ROOT
5	on	on	B-PP	IN	O	4	NMOD
6	learning	learning	B-NP	NN	O	9	NMOD
7	and	and	I-NP	CC	O	9	NMOD
8	memory	memory	I-NP	NN	O	9	NMOD
9	impairment	impairment	I-NP	NN	O	5	PMOD
10	induced	induce	B-VP	VBN	O	9	NMOD
11	by	by	B-PP	IN	O	10	VMOD
12	scopolamine	scopolamine	B-NP	NN	O	11	PMOD
13	in	in	B-PP	IN	O	10	VMOD
14	mice.	mice.	B-NP	NN	O	13	PMOD
15	1	1	I-NP	CD	O	14	NMOD
16	.	.	O	.	O	4	P

1	On	On	B-PP	IN	O	7	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	other	other	I-NP	JJ	O	4	NMOD
4	hand	hand	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	7	P
6	nocistatin	nocistatin	B-NP	NN	O	7	SUB
7	is	be	B-VP	VBZ	O	0	ROOT
8	recently	recently	I-VP	RB	O	7	VMOD
9	isolated	isolate	I-VP	VBN	O	7	VC
10	from	from	B-PP	IN	O	9	VMOD
11	the	the	B-NP	DT	O	13	NMOD
12	same	same	I-NP	JJ	O	13	NMOD
13	precursor	precursor	I-NP	NN	O	10	PMOD
14	as	as	B-PP	IN	O	13	NMOD
15	nociceptin	nociceptin	B-NP	NN	O	14	PMOD
16	and	and	O	CC	O	7	VMOD
17	blocks	block	B-VP	VBZ	O	7	VMOD
18	nociceptin	nociceptin	B-NP	NN	B-protein	20	NMOD
19	induced	induced	I-NP	JJ	O	20	NMOD
20	allodynia	allodynia	I-NP	NN	O	22	NMOD
21	and	and	O	CC	O	22	NMOD
22	hyperalgesia.	hyperalgesia.	B-NP	NN	O	17	OBJ
23	2	2	I-NP	CD	O	22	NMOD
24	.	.	O	.	O	7	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	designed	design	I-VP	VBN	O	4	VC
6	to	to	B-VP	TO	O	7	VMOD
7	investigate	investigate	I-VP	VB	O	5	VMOD
8	whether	whether	B-SBAR	IN	O	7	VMOD
9	nociceptin/orphanin	nociceptin/orphanin	B-NP	NN	O	10	NMOD
10	FQ	FQ	I-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	nocistatin	nocistatin	I-NP	NN	O	13	SUB
13	could	could	B-VP	MD	O	8	SBAR
14	modulate	modulate	I-VP	VB	O	13	VC
15	impairment	impairment	B-NP	NN	O	14	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	learning	learning	B-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	memory	memory	I-NP	NN	O	16	PMOD
20	induced	induce	B-VP	VBN	O	15	NMOD
21	by	by	B-PP	IN	O	20	VMOD
22	scopolamine	scopolamine	B-NP	NN	O	28	NMOD
23	,	,	O	,	O	28	P
24	a	a	B-NP	DT	O	28	NMOD
25	muscarinic	muscarinic	I-NP	JJ	O	28	NMOD
26	cholinergic	cholinergic	I-NP	JJ	O	28	NMOD
27	receptor	receptor	I-NP	NN	O	28	NMOD
28	antagonist	antagonist	I-NP	NN	O	21	PMOD
29	,	,	O	,	O	5	P
30	using	use	B-VP	VBG	O	5	VMOD
31	spontaneous	spontaneous	B-NP	JJ	O	32	NMOD
32	alternation	alternation	I-NP	NN	O	30	OBJ
33	of	of	B-PP	IN	O	32	NMOD
34	Y-maze	Y-maze	B-NP	JJ	O	40	NMOD
35	and	and	I-NP	CC	O	40	NMOD
36	step-down	step-down	I-NP	JJ	B-protein	40	NMOD
37	type	type	I-NP	NN	I-protein	40	NMOD
38	passive	passive	I-NP	JJ	I-protein	40	NMOD
39	avoidance	avoidance	I-NP	NN	I-protein	40	NMOD
40	tasks	task	I-NP	NNS	I-protein	33	PMOD
41	in	in	B-PP	IN	O	32	NMOD
42	mice.	mice.	B-NP	NN	O	41	PMOD
43	4	4	I-NP	CD	O	42	NMOD
44	.	.	O	.	O	4	P

1	Meloxicam	Meloxicam	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	liver	liver	B-NP	NN	O	4	NMOD
4	toxicity	toxicity	I-NP	NN	O	2	OBJ
5	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	female	female	I-NP	JJ	O	8	NMOD
8	patient	patient	I-NP	NN	O	5	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	rheumatoid	rheumatoid	B-NP	JJ	O	11	NMOD
11	arthritis	arthritis	I-NP	NN	O	9	PMOD
12	who	who	B-NP	WP	O	4	NMOD
13	developed	develop	B-VP	VBD	O	12	SBAR
14	acute	acute	B-NP	JJ	O	16	NMOD
15	cytolytic	cytolytic	I-NP	JJ	O	16	NMOD
16	hepatitis	hepatitis	I-NP	NN	O	13	OBJ
17	due	due	B-ADJP	JJ	O	16	NMOD
18	to	to	B-PP	TO	O	17	AMOD
19	meloxicam	meloxicam	B-NP	NN	O	18	PMOD
20	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	4	NMOD
2	acute	acute	I-NP	JJ	O	4	NMOD
3	cytolytic	cytolytic	I-NP	JJ	O	4	NMOD
4	hepatitis	hepatitis	I-NP	NN	O	5	SUB
5	occurred	occur	B-VP	VBD	O	0	ROOT
6	rapidly	rapidly	B-ADVP	RB	O	5	VMOD
7	after	after	B-SBAR	IN	O	5	VMOD
8	meloxicam	meloxicam	B-NP	NN	O	9	NMOD
9	administration	administration	I-NP	NN	O	7	PMOD
10	and	and	O	CC	O	5	VMOD
11	was	be	B-VP	VBD	O	5	VMOD
12	associated	associate	I-VP	VBN	O	11	VC
13	with	with	B-PP	IN	O	12	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	development	development	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	antinuclear	antinuclear	B-NP	JJ	B-protein	18	NMOD
18	antibodies	antibody	I-NP	NNS	I-protein	16	PMOD
19	suggesting	suggest	B-VP	VBG	O	18	NMOD
20	a	a	B-NP	DT	O	22	NMOD
21	hypersensitivity	hypersensitivity	I-NP	NN	O	22	NMOD
22	mechanism	mechanism	I-NP	NN	O	19	OBJ
23	.	.	O	.	O	5	P

1	Induction	Induction	B-NP	NN	O	18	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	apoptosis	apoptosis	B-NP	NN	O	2	PMOD
4	by	by	B-PP	IN	O	1	NMOD
5	remoxipride	remoxipride	B-NP	NN	O	6	NMOD
6	metabolites	metabolite	I-NP	NNS	O	4	PMOD
7	in	in	B-PP	IN	O	1	NMOD
8	HL60	HL60	B-NP	NN	B-cell_line	15	NMOD
9	and	and	O	CC	O	15	NMOD
10	CD34+/CD19-	CD34+/CD19-	B-NP	JJ	B-cell_type	15	NMOD
11	human	human	I-NP	JJ	I-cell_type	15	NMOD
12	bone	bone	I-NP	NN	I-cell_type	15	NMOD
13	marrow	marrow	I-NP	NN	I-cell_type	15	NMOD
14	progenitor	progenitor	I-NP	NN	I-cell_type	15	NMOD
15	cells	cell	I-NP	NNS	I-cell_type	7	PMOD
16	:	:	O	:	O	1	P
17	potential	potential	B-NP	JJ	O	18	NMOD
18	relevance	relevance	I-NP	NN	O	0	ROOT
19	to	to	B-VP	TO	O	20	VMOD
20	remoxipride	remoxipride	I-VP	VB	O	18	NMOD
21	induced	induce	B-NP	VBN	O	23	NMOD
22	aplastic	aplastic	I-NP	JJ	O	23	NMOD
23	anemia	anemia	I-NP	NN	O	20	OBJ
24	.	.	O	.	O	18	P

1	The	The	B-NP	DT	O	3	NMOD
2	antipsychotic	antipsychotic	I-NP	JJ	O	3	NMOD
3	agent	agent	I-NP	NN	O	8	NMOD
4	,	,	O	,	O	8	P
5	remoxipride	remoxipride	B-NP	NN	O	8	NMOD
6	[	[	O	(	O	8	NMOD
7	(	(	O	(	O	8	NMOD
8	S	S	B-NP	NN	O	14	NMOD
9	)	)	O	)	O	8	NMOD
10	-	-	O	HYPH	O	8	P
11	(	(	O	(	O	13	DEP
12	-	-	O	SYM	O	13	DEP
13	)	)	O	)	O	8	NMOD
14	-3-bromo-N-	-3-bromo-N-	B-NP	NN	O	19	NMOD
15	[	[	O	(	O	18	DEP
16	(	(	O	(	O	18	DEP
17	1-ethyl-2-pyrrolidinyl	1-ethyl-2-pyrrolidinyl	B-NP	NN	O	18	DEP
18	)	)	O	)	O	14	NMOD
19	methyl	methyl	B-NP	NN	O	24	NMOD
20	]	]	O	)	O	19	NMOD
21	-2	-2	B-NP	CD	O	19	NMOD
22	,	,	O	,	O	24	P
23	6-dimethoxybenz	6-dimethoxybenz	B-NP	JJ	O	24	NMOD
24	amide	amide	I-NP	NN	O	26	SUB
25	]	]	O	)	O	24	NMOD
26	has	have	B-VP	VBZ	O	0	ROOT
27	been	be	I-VP	VBN	O	26	VC
28	associated	associate	I-VP	VBN	O	27	VC
29	with	with	B-PP	IN	O	28	VMOD
30	acquired	acquire	B-NP	VBN	O	32	NMOD
31	aplastic	aplastic	I-NP	JJ	O	32	NMOD
32	anemia	anemia	I-NP	NN	O	29	PMOD
33	.	.	O	.	O	26	P

1	No	No	B-NP	DT	O	2	NMOD
2	necrosis	necrosis	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	observed	observe	I-VP	VBN	O	3	VC
5	in	in	B-PP	IN	O	4	VMOD
6	cells	cell	B-NP	NNS	O	5	PMOD
7	treated	treat	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	NCQ436	NCQ436	B-NP	NN	B-protein	11	NMOD
10	but	but	O	CC	O	11	NMOD
11	NCQ344	NCQ344	B-NP	NN	B-protein	8	PMOD
12	had	have	B-VP	VBD	O	3	VMOD
13	a	a	B-NP	DT	O	15	NMOD
14	biphasic	biphasic	I-NP	JJ	O	15	NMOD
15	effect	effect	I-NP	NN	O	12	OBJ
16	in	in	B-PP	IN	O	12	VMOD
17	both	both	B-NP	DT	O	19	NMOD
18	cell	cell	I-NP	NN	O	19	NMOD
19	types	type	I-NP	NNS	O	16	PMOD
20	,	,	O	,	O	3	P
21	inducing	induce	B-VP	VBG	O	3	VMOD
22	apoptosis	apoptosis	B-NP	NN	O	21	OBJ
23	at	at	B-PP	IN	O	21	VMOD
24	lower	low	B-NP	JJR	O	25	NMOD
25	concentrations	concentration	I-NP	NNS	O	23	PMOD
26	and	and	O	CC	O	21	VMOD
27	necrosis	necrosis	B-NP	NN	O	21	OBJ
28	at	at	B-PP	IN	O	27	NMOD
29	higher	high	B-NP	JJR	O	30	NMOD
30	concentrations	concentration	I-NP	NNS	O	28	PMOD
31	.	.	O	.	O	3	P

1	Sub-chronic	Sub-chronic	B-NP	JJ	O	2	NMOD
2	inhibition	inhibition	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	nitric-oxide	nitric-oxide	B-NP	NN	O	5	NMOD
5	synthesis	synthesis	I-NP	NN	O	3	PMOD
6	modifies	modify	B-VP	VBZ	O	0	ROOT
7	haloperidol	haloperidol	B-NP	NN	O	9	NMOD
8	induced	induced	I-NP	JJ	O	9	NMOD
9	catalepsy	catalepsy	I-NP	NN	O	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	number	number	I-NP	NN	O	6	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	NADPH-diaphorase	NADPH-diaphorase	B-NP	NN	B-protein	15	NMOD
15	neurons	neuron	I-NP	NNS	I-protein	13	PMOD
16	in	in	B-PP	IN	O	6	VMOD
17	mice	mouse	B-NP	NNS	O	16	PMOD
18	.	.	O	.	O	6	P

1	RATIONALE	RATIONALE	B-NP	NN	O	3	NMOD
2	:	:	O	:	O	1	P
3	NG-nitro-L-arginine	NG-nitro-L-arginine	B-NP	NN	O	9	NMOD
4	(	(	O	(	O	6	DEP
5	L-NOARG	L-NOARG	B-NP	NN	B-protein	6	DEP
6	)	)	O	)	O	3	NMOD
7	,	,	O	,	O	9	P
8	an	an	B-NP	DT	O	9	NMOD
9	inhibitor	inhibitor	I-NP	NN	O	17	SUB
10	of	of	B-PP	IN	O	9	NMOD
11	nitric-oxide	nitric-oxide	B-NP	NN	B-protein	12	NMOD
12	synthase	synthase	I-NP	NN	I-protein	10	PMOD
13	(	(	O	(	O	15	DEP
14	NOS	NOS	B-NP	NN	B-protein	15	DEP
15	)	)	O	)	O	12	NMOD
16	,	,	O	,	O	9	P
17	induces	induce	B-VP	VBZ	O	0	ROOT
18	catalepsy	catalepsy	B-NP	NN	O	17	OBJ
19	in	in	B-PP	IN	O	17	VMOD
20	mice	mouse	B-NP	NNS	O	19	PMOD
21	.	.	O	.	O	17	P

1	Neuroleptic	Neuroleptic	B-NP	JJ	O	2	NMOD
2	drugs	drug	I-NP	NNS	O	13	SUB
3	such	such	B-PP	JJ	O	4	PMOD
4	as	as	I-PP	IN	O	2	NMOD
5	haloperidol	haloperidol	B-NP	NN	O	4	PMOD
6	,	,	O	,	O	5	P
7	which	which	B-NP	WDT	O	5	NMOD
8	block	block	B-VP	VBP	O	7	SBAR
9	dopamine	dopamine	B-NP	NN	B-protein	10	NMOD
10	receptors	receptor	I-NP	NNS	I-protein	8	OBJ
11	,	,	O	,	O	2	P
12	also	also	B-ADVP	RB	O	13	VMOD
13	cause	cause	B-VP	VBP	O	0	ROOT
14	catalepsy	catalepsy	B-NP	NN	O	13	OBJ
15	in	in	B-PP	IN	O	14	NMOD
16	rodents	rodent	B-NP	NNS	O	15	PMOD
17	.	.	O	.	O	13	P

1	OBJECTIVES	OBJECTIVES	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	investigate	investigate	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	effects	effect	I-NP	NNS	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	subchronic	subchronic	B-NP	JJ	O	10	NMOD
9	L-NOARG	L-NOARG	I-NP	NN	O	10	NMOD
10	treatment	treatment	I-NP	NN	O	7	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	haloperidol	haloperidol	B-NP	NN	O	11	PMOD
13	induced	induce	B-VP	VBD	O	4	VMOD
14	catalepsy	catalepsy	B-NP	NN	O	17	NMOD
15	and	and	O	CC	O	17	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	number	number	I-NP	NN	O	13	OBJ
18	of	of	B-PP	IN	O	17	NMOD
19	NOS	NOS	B-NP	NN	B-protein	20	NMOD
20	neurons	neuron	I-NP	NNS	I-protein	18	PMOD
21	in	in	B-PP	IN	O	13	VMOD
22	areas	area	B-NP	NNS	O	21	PMOD
23	related	relate	B-VP	VBN	O	22	NMOD
24	to	to	B-PP	TO	O	23	AMOD
25	motor	motor	B-NP	NN	O	26	NMOD
26	control	control	I-NP	NN	O	24	PMOD
27	.	.	O	.	O	1	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	L-NOARG	L-NOARG	B-NP	NN	O	5	NMOD
4	sub-chronic	sub-chronic	I-NP	JJ	O	5	NMOD
5	administration	administration	I-NP	NN	O	6	SUB
6	produced	produce	B-VP	VBD	O	1	NMOD
7	tolerance	tolerance	B-NP	NN	O	6	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	L-NOARG	L-NOARG	B-NP	NN	B-protein	8	PMOD
10	and	and	B-PP	CC	O	8	PMOD
11	of	of	B-PP	IN	O	8	PMOD
12	haloperidol	haloperidol	B-NP	NN	O	14	NMOD
13	induced	induced	I-NP	JJ	O	14	NMOD
14	catalepsy	catalepsy	I-NP	NN	O	11	PMOD
15	.	.	O	.	O	1	P

1	Prolonged	Prolong	B-VP	VBN	O	5	VMOD
2	left	leave	B-VP	VBD	O	1	VMOD
3	ventricular	ventricular	B-NP	JJ	O	4	NMOD
4	dysfunction	dysfunction	I-NP	NN	O	2	OBJ
5	occurs	occur	B-VP	VBZ	O	0	ROOT
6	in	in	B-PP	IN	O	5	VMOD
7	patients	patient	B-NP	NNS	O	6	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	coronary	coronary	B-NP	JJ	O	11	NMOD
10	artery	artery	I-NP	NN	O	11	NMOD
11	disease	disease	I-NP	NN	O	8	PMOD
12	after	after	B-SBAR	IN	O	5	VMOD
13	both	both	O	CC	O	16	NMOD
14	dobutamine	dobutamine	B-NP	NN	O	16	NMOD
15	and	and	O	CC	O	16	NMOD
16	exercise	exercise	B-NP	NN	O	17	SUB
17	induced	induce	B-VP	VBD	O	12	SBAR
18	myocardial	myocardial	B-NP	JJ	O	19	NMOD
19	ischaemia	ischaemia	I-NP	NN	O	17	OBJ
20	.	.	O	.	O	5	P

1	DESIGN	DESIGN	B-NP	NN	O	6	NMOD
2	:	:	O	:	O	1	P
3	A	A	B-NP	DT	O	6	NMOD
4	randomised	randomise	I-NP	VBN	O	6	NMOD
5	crossover	crossover	I-NP	NN	O	6	NMOD
6	study	study	I-NP	NN	O	21	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	recovery	recovery	B-NP	NN	O	9	NMOD
9	time	time	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	systolic	systolic	B-NP	JJ	O	16	NMOD
12	and	and	I-NP	CC	O	16	NMOD
13	diastolic	diastolic	I-NP	JJ	O	14	AMOD
14	left	left	I-NP	JJ	O	16	NMOD
15	ventricular	ventricular	I-NP	JJ	O	16	NMOD
16	function	function	I-NP	NN	O	10	PMOD
17	after	after	B-PP	IN	O	16	NMOD
18	exercise	exercise	B-NP	NN	O	20	NMOD
19	and	and	I-NP	CC	O	20	NMOD
20	dobutamine	dobutamine	I-NP	NN	O	17	PMOD
21	induced	induce	B-VP	VBD	O	0	ROOT
22	ischaemia	ischaemia	B-NP	NN	O	21	OBJ
23	.	.	O	.	O	21	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	11	SUB
2	:	:	O	:	O	1	P
3	In	In	B-PP	IN	O	11	VMOD
4	patients	patient	B-NP	NNS	O	3	PMOD
5	with	with	B-PP	IN	O	4	NMOD
6	coronary	coronary	B-NP	JJ	O	8	NMOD
7	artery	artery	I-NP	NN	O	8	NMOD
8	disease	disease	I-NP	NN	O	5	PMOD
9	,	,	O	,	O	11	P
10	dobutamine	dobutamine	B-NP	NN	O	11	SUB
11	induced	induce	B-VP	VBD	O	13	VMOD
12	ischaemia	ischaemia	B-NP	NN	O	13	SUB
13	results	result	B-VP	VBZ	O	0	ROOT
14	in	in	B-PP	IN	O	13	VMOD
15	prolonged	prolong	B-NP	VBN	O	19	NMOD
16	reversible	reversible	I-NP	JJ	O	19	NMOD
17	left	left	I-NP	JJ	O	19	NMOD
18	ventricular	ventricular	I-NP	JJ	O	19	NMOD
19	dysfunction	dysfunction	I-NP	NN	O	14	PMOD
20	,	,	O	,	O	19	P
21	presumed	presume	B-VP	VBN	O	19	NMOD
22	to	to	I-VP	TO	O	23	VMOD
23	be	be	I-VP	VB	O	21	VMOD
24	myocardial	myocardial	B-ADJP	JJ	O	25	AMOD
25	stunning	stunning	B-ADJP	JJ	O	23	PRD
26	,	,	O	,	O	25	P
27	similar	similar	B-ADJP	JJ	O	25	AMOD
28	to	to	B-PP	TO	O	25	AMOD
29	that	that	B-NP	DT	O	28	PMOD
30	seen	see	B-VP	VBN	O	29	NMOD
31	after	after	B-PP	IN	O	30	VMOD
32	exercise	exercise	B-NP	NN	O	31	PMOD
33	.	.	O	.	O	13	P

1	However	However	B-ADVP	RB	O	11	VMOD
2	,	,	O	,	O	11	P
3	of	of	B-PP	IN	O	11	VMOD
4	the	the	B-NP	DT	O	5	NMOD
5	medications	medication	I-NP	NNS	O	3	PMOD
6	surveyed	survey	B-VP	VBN	O	5	NMOD
7	,	,	O	,	O	11	P
8	only	only	B-NP	RB	O	10	NMOD
9	the	the	I-NP	DT	O	10	NMOD
10	fenfluramines	fenfluramine	I-NP	NNS	O	11	SUB
11	had	have	B-VP	VBD	O	0	ROOT
12	a	a	B-NP	DT	O	15	NMOD
13	significant	significant	I-NP	JJ	O	15	NMOD
14	preferential	preferential	I-NP	JJ	O	15	NMOD
15	association	association	I-NP	NN	O	11	OBJ
16	with	with	B-PP	IN	O	15	NMOD
17	PPH	PPH	B-NP	NN	B-protein	16	PMOD
18	as	as	B-PP	IN	O	11	VMOD
19	compared	compare	B-PP	VBN	O	18	SBAR
20	with	with	B-PP	IN	O	19	VMOD
21	SPH	SPH	B-NP	NN	B-protein	20	PMOD
22	(	(	O	(	O	42	DEP
23	adjusted	adjust	B-NP	VBN	O	25	NMOD
24	odds	odd	I-NP	NNS	O	25	NMOD
25	ratio	ratio	I-NP	NN	O	41	NMOD
26	for	for	B-PP	IN	O	25	NMOD
27	use	use	B-NP	NN	O	30	NMOD
28	>	>	O	SYM	O	30	NMOD
29	6	6	B-NP	CD	O	30	NMOD
30	months	month	I-NP	NNS	O	26	PMOD
31	,	,	O	,	O	41	P
32	7.5	7.5	B-NP	CD	O	41	NMOD
33	;	;	O	:	O	41	P
34	95	95	B-NP	CD	O	37	NMOD
35	%	%	I-NP	NN	O	37	NMOD
36	confidence	confidence	I-NP	NN	O	37	NMOD
37	interval	interval	I-NP	NN	O	41	VMOD
38	,	,	O	,	O	41	P
39	1.7	1.7	B-NP	CD	O	41	AMOD
40	to	to	B-PP	TO	O	41	AMOD
41	32.4	32.4	B-NP	CD	O	42	DEP
42	)	)	O	)	O	21	NMOD
43	.	.	O	.	O	11	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	magnitude	magnitude	I-NP	NN	O	12	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	association	association	I-NP	NN	O	5	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	PPH	PPH	B-NP	NN	B-protein	8	PMOD
10	,	,	O	,	O	12	P
11	the	the	B-NP	DT	O	12	NMOD
12	increase	increase	I-NP	NN	O	23	NMOD
13	of	of	B-PP	IN	O	12	NMOD
14	association	association	B-NP	NN	O	13	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	increasing	increase	B-NP	VBG	O	17	NMOD
17	duration	duration	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	use	use	B-NP	NN	O	18	PMOD
20	,	,	O	,	O	23	P
21	and	and	O	CC	O	23	NMOD
22	the	the	B-NP	DT	O	23	NMOD
23	specificity	specificity	I-NP	NN	O	26	SUB
24	for	for	B-PP	IN	O	23	NMOD
25	fenfluramines	fenfluramine	B-NP	NNS	O	24	PMOD
26	are	be	B-VP	VBP	O	1	NMOD
27	consistent	consistent	B-ADJP	JJ	O	26	PRD
28	with	with	B-PP	IN	O	27	AMOD
29	previous	previous	B-NP	JJ	O	30	NMOD
30	studies	study	I-NP	NNS	O	28	PMOD
31	indicating	indicate	B-VP	VBG	O	30	NMOD
32	that	that	B-SBAR	IN	O	31	VMOD
33	fenfluramines	fenfluramine	B-NP	NNS	O	34	SUB
34	are	be	B-VP	VBP	O	32	SBAR
35	causally	causally	I-VP	RB	O	34	VMOD
36	related	relate	I-VP	VBN	O	34	PRD
37	to	to	B-PP	TO	O	36	AMOD
38	PPH	PPH	B-NP	NN	B-protein	37	PMOD
39	.	.	O	.	O	1	P

1	Clinical	Clinical	B-NP	JJ	O	2	NMOD
2	aspects	aspect	I-NP	NNS	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	heparin	heparin	B-NP	NN	O	3	PMOD
5	induced	induce	B-VP	VBD	O	0	ROOT
6	thrombocytopenia	thrombocytopenia	B-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	thrombosis	thrombosis	I-NP	NN	O	12	NMOD
9	and	and	O	CC	O	12	NMOD
10	other	other	B-NP	JJ	O	12	NMOD
11	side	side	I-NP	NN	O	12	NMOD
12	effects	effect	I-NP	NNS	O	5	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	heparin	heparin	B-NP	NN	O	15	NMOD
15	therapy	therapy	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	5	P

1	Heparin	Heparin	B-NP	NN	O	14	SUB
2	,	,	O	,	O	1	P
3	first	first	B-VP	RB	O	4	VMOD
4	used	use	I-VP	VBN	O	1	NMOD
5	to	to	B-VP	TO	O	6	VMOD
6	prevent	prevent	I-VP	VB	O	4	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	clotting	clotting	I-NP	NN	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	blood	blood	B-NP	NN	O	9	PMOD
11	in	in	B-ADVP	FW	O	6	VMOD
12	vitro	vitro	I-ADVP	FW	O	11	AMOD
13	,	,	O	,	O	1	P
14	has	have	B-VP	VBZ	O	0	ROOT
15	been	be	I-VP	VBN	O	14	VC
16	clinically	clinically	I-VP	RB	O	15	VMOD
17	used	use	I-VP	VBN	O	15	VC
18	to	to	B-VP	TO	O	19	VMOD
19	treat	treat	I-VP	VB	O	14	VMOD
20	thrombosis	thrombosis	B-NP	NN	O	19	OBJ
21	for	for	B-PP	IN	O	19	VMOD
22	more	more	B-NP	JJR	O	23	AMOD
23	than	than	I-NP	IN	O	25	NMOD
24	50	50	I-NP	CD	O	23	AMOD
25	years	year	I-NP	NNS	O	21	PMOD
26	.	.	O	.	O	14	P

1	Although	Although	B-SBAR	IN	O	11	VMOD
2	several	several	B-NP	JJ	O	4	AMOD
3	new	new	I-NP	JJ	O	4	AMOD
4	anticoagulant	anticoagulant	I-NP	JJ	O	5	NMOD
5	drugs	drug	I-NP	NNS	O	6	SUB
6	are	be	B-VP	VBP	O	1	SBAR
7	in	in	B-PP	IN	O	6	VMOD
8	development	development	B-NP	NN	O	7	PMOD
9	,	,	O	,	O	11	P
10	heparin	heparin	B-NP	NN	O	11	SUB
11	remains	remain	B-VP	VBZ	O	0	ROOT
12	the	the	B-NP	DT	O	13	NMOD
13	anticoagulant	anticoagulant	I-NP	NN	O	11	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	choice	choice	B-NP	NN	O	14	PMOD
16	to	to	B-VP	TO	O	17	VMOD
17	treat	treat	I-VP	VB	O	13	NMOD
18	acute	acute	B-NP	JJ	O	20	NMOD
19	thrombotic	thrombotic	I-NP	JJ	O	20	NMOD
20	episodes	episode	I-NP	NNS	O	17	OBJ
21	.	.	O	.	O	11	P

1	Bleeding	Bleeding	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	the	the	B-NP	DT	O	6	NMOD
4	primary	primary	I-NP	JJ	O	6	NMOD
5	untoward	untoward	I-NP	JJ	O	6	NMOD
6	effect	effect	I-NP	NN	O	2	PRD
7	of	of	B-PP	IN	O	6	NMOD
8	heparin	heparin	B-NP	NN	O	7	PMOD
9	.	.	O	.	O	2	P

1	Major	Major	B-NP	JJ	O	2	NMOD
2	bleeding	bleeding	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	of	of	B-PP	IN	O	3	PRD
5	primary	primary	B-NP	JJ	O	6	NMOD
6	concern	concern	I-NP	NN	O	4	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	patients	patient	B-NP	NNS	O	7	PMOD
9	receiving	receive	B-VP	VBG	O	8	NMOD
10	heparin	heparin	B-NP	NN	O	11	NMOD
11	therapy	therapy	I-NP	NN	O	9	OBJ
12	.	.	O	.	O	3	P

1	However	However	B-ADVP	RB	O	10	VMOD
2	,	,	O	,	O	10	P
3	additional	additional	B-NP	JJ	O	5	AMOD
4	important	important	I-NP	JJ	O	5	AMOD
5	untoward	untoward	I-NP	JJ	O	6	NMOD
6	effects	effect	I-NP	NNS	O	10	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	heparin	heparin	B-NP	NN	O	9	NMOD
9	therapy	therapy	I-NP	NN	O	7	PMOD
10	include	include	B-VP	VBP	O	0	ROOT
11	heparin	heparin	B-NP	NN	O	13	NMOD
12	induced	induced	I-NP	JJ	O	13	NMOD
13	thrombocytopenia	thrombocytopenia	I-NP	NN	O	24	NMOD
14	,	,	O	,	O	24	P
15	heparin-associated	heparin-associated	B-NP	JJ	O	16	NMOD
16	osteoporosis	osteoporosis	I-NP	NN	O	24	NMOD
17	,	,	O	,	O	24	P
18	eosinophilia	eosinophilia	B-NP	NN	O	24	NMOD
19	,	,	O	,	O	24	P
20	skin	skin	B-NP	NN	O	21	NMOD
21	reactions	reaction	I-NP	NNS	O	24	NMOD
22	,	,	O	,	O	24	P
23	allergic	allergic	B-NP	JJ	O	24	NMOD
24	reactions	reaction	I-NP	NNS	O	10	OBJ
25	other	other	B-ADJP	JJ	O	24	NMOD
26	than	than	B-PP	IN	O	25	AMOD
27	thrombocytopenia	thrombocytopenia	B-NP	NN	O	38	NMOD
28	,	,	O	,	O	38	P
29	alopecia	alopecia	B-NP	NN	O	38	NMOD
30	,	,	O	,	O	38	P
31	transaminasemia	transaminasemia	B-NP	NN	O	38	NMOD
32	,	,	O	,	O	38	P
33	hyperkalemia	hyperkalemia	B-NP	NN	O	38	NMOD
34	,	,	O	,	O	38	P
35	hypoaldosteronism	hypoaldosteronism	B-NP	NN	O	38	NMOD
36	,	,	O	,	O	38	P
37	and	and	O	CC	O	38	NMOD
38	priapism	priapism	B-NP	NN	O	26	PMOD
39	.	.	O	.	O	10	P

1	These	These	B-NP	DT	O	3	NMOD
2	side	side	I-NP	JJ	O	3	NMOD
3	effects	effect	I-NP	NNS	O	4	SUB
4	are	be	B-VP	VBP	O	22	VMOD
5	relatively	relatively	B-ADJP	RB	O	6	AMOD
6	rare	rare	I-ADJP	JJ	O	4	PRD
7	in	in	B-PP	IN	O	6	AMOD
8	a	a	B-NP	DT	O	10	NMOD
9	given	give	I-NP	VBN	O	10	NMOD
10	individual	individual	I-NP	NN	O	7	PMOD
11	,	,	O	,	O	22	P
12	but	but	O	CC	O	22	VMOD
13	given	give	B-PP	VBN	O	22	VMOD
14	the	the	B-NP	DT	O	17	NMOD
15	extremely	extremely	I-NP	RB	O	16	AMOD
16	widespread	widespread	I-NP	JJ	O	17	NMOD
17	use	use	I-NP	NN	O	13	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	heparin	heparin	B-NP	NN	O	18	PMOD
20	,	,	O	,	O	22	P
21	some	some	B-NP	DT	O	22	SUB
22	are	be	B-VP	VBP	O	0	ROOT
23	quite	quite	B-ADJP	RB	O	24	AMOD
24	common	common	I-ADJP	JJ	O	22	PRD
25	,	,	O	,	O	22	P
26	particularly	particularly	B-NP	RB	O	29	NMOD
27	HITT	HITT	I-NP	NN	O	29	NMOD
28	and	and	I-NP	CC	O	29	NMOD
29	osteoporosis	osteoporosis	I-NP	NN	O	22	VMOD
30	.	.	O	.	O	22	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	bilateral	bilateral	B-NP	JJ	O	6	NMOD
5	optic	optic	I-NP	JJ	O	6	NMOD
6	neuropathy	neuropathy	I-NP	NN	O	3	PMOD
7	in	in	B-PP	IN	O	2	NMOD
8	a	a	B-NP	DT	O	9	NMOD
9	patient	patient	I-NP	NN	O	7	PMOD
10	on	on	B-PP	IN	O	9	NMOD
11	tacrolimus	tacrolimus	B-NP	NN	O	15	NMOD
12	(	(	O	(	O	14	DEP
13	FK506	FK506	B-NP	NN	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	therapy	therapy	B-NP	NN	O	10	PMOD
16	after	after	B-PP	IN	O	15	NMOD
17	liver	liver	B-NP	NN	O	18	NMOD
18	transplantation	transplantation	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	2	P

1	PURPOSE	PURPOSE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	report	report	I-VP	VB	O	1	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	bilateral	bilateral	B-NP	JJ	O	10	NMOD
9	optic	optic	I-NP	JJ	O	10	NMOD
10	neuropathy	neuropathy	I-NP	NN	O	7	PMOD
11	in	in	B-PP	IN	O	6	NMOD
12	a	a	B-NP	DT	O	13	NMOD
13	patient	patient	I-NP	NN	O	11	PMOD
14	receiving	receive	B-VP	VBG	O	13	NMOD
15	tacrolimus	tacrolimus	B-NP	NN	O	14	OBJ
16	(	(	O	(	O	15	NMOD
17	FK	FK	B-NP	NN	O	16	DEP
18	506	506	I-NP	CD	O	17	NMOD
19	,	,	O	,	O	20	P
20	Prograf	Prograf	B-NP	NNP	O	29	NMOD
21	;	;	O	:	O	29	P
22	Fujisawa	Fujisawa	B-NP	NNP	O	23	NMOD
23	USA	USA	I-NP	NNP	O	29	NMOD
24	,	,	O	,	O	29	P
25	Inc	Inc	B-NP	NNP	O	27	NMOD
26	,	,	O	,	O	27	P
27	Deerfield	Deerfield	B-NP	NNP	O	29	NMOD
28	,	,	O	,	O	29	P
29	Illinois	Illinois	B-NP	NNP	O	17	DEP
30	)	)	O	)	O	29	DEP
31	for	for	B-PP	IN	O	29	NMOD
32	immunosuppression	immunosuppression	B-NP	NN	O	31	PMOD
33	after	after	B-PP	IN	O	32	NMOD
34	orthotropic	orthotropic	B-NP	JJ	O	36	NMOD
35	liver	liver	I-NP	NN	O	36	NMOD
36	transplantation	transplantation	I-NP	NN	O	33	PMOD
37	.	.	O	.	O	4	P

1	Deterioration	Deterioration	B-NP	NN	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	vision	vision	B-NP	NN	O	2	PMOD
4	occurred	occur	B-VP	VBD	O	0	ROOT
5	despite	despite	B-PP	IN	O	4	VMOD
6	discontinuation	discontinuation	B-NP	NN	O	5	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	tacrolimus	tacrolimus	I-NP	NN	O	7	PMOD
10	.	.	O	.	O	4	P

1	Recent	Recent	B-NP	JJ	O	2	NMOD
2	findings	finding	I-NP	NNS	O	17	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	a	a	B-NP	DT	O	6	NMOD
5	bipolar	bipolar	I-NP	JJ	O	6	NMOD
6	patient	patient	I-NP	NN	O	3	PMOD
7	receiving	receive	B-VP	VBG	O	6	NMOD
8	maintenance	maintenance	B-NP	NN	O	10	NMOD
9	lithium	lithium	I-NP	NN	O	10	NMOD
10	therapy	therapy	I-NP	NN	O	7	OBJ
11	who	who	B-NP	WP	O	10	NMOD
12	developed	develop	B-VP	VBD	O	11	SBAR
13	hypercalcemia	hypercalcemia	B-NP	NN	O	16	NMOD
14	and	and	O	CC	O	16	NMOD
15	severe	severe	B-NP	JJ	O	16	NMOD
16	bradyarrhythmia	bradyarrhythmia	I-NP	NN	O	12	OBJ
17	prompted	prompt	B-VP	VBD	O	0	ROOT
18	the	the	B-NP	DT	O	19	NMOD
19	authors	author	I-NP	NNS	O	21	SUB
20	to	to	B-VP	TO	O	21	VMOD
21	conduct	conduct	I-VP	VB	O	17	VMOD
22	a	a	B-NP	DT	O	24	NMOD
23	retrospective	retrospective	I-NP	JJ	O	24	NMOD
24	study	study	I-NP	NN	O	21	OBJ
25	of	of	B-PP	IN	O	24	NMOD
26	bipolar	bipolar	B-NP	JJ	O	27	NMOD
27	patients	patient	I-NP	NNS	O	25	PMOD
28	with	with	B-PP	IN	O	27	NMOD
29	lithium-associated	lithium-associated	B-NP	JJ	O	30	NMOD
30	hypercalcemia	hypercalcemia	I-NP	NN	O	28	PMOD
31	.	.	O	.	O	17	P

1	After	After	B-PP	IN	O	14	VMOD
2	eliminating	eliminate	B-VP	VBG	O	1	PMOD
3	spurious	spurious	B-NP	JJ	O	4	NMOD
4	hypercalcemias	hypercalcemia	I-NP	NNS	O	6	NMOD
5	or	or	O	CC	O	6	NMOD
6	those	those	B-NP	DT	O	2	OBJ
7	associated	associate	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	intravenous	intravenous	B-NP	JJ	O	10	NMOD
10	fluids	fluid	I-NP	NNS	O	8	PMOD
11	,	,	O	,	O	14	P
12	the	the	B-NP	DT	O	13	NMOD
13	authors	author	I-NP	NNS	O	14	SUB
14	identified	identify	B-VP	VBD	O	0	ROOT
15	18	18	B-NP	CD	O	17	NMOD
16	non-lithium-treated	non-lithium-treated	I-NP	JJ	O	17	NMOD
17	patients	patient	I-NP	NNS	O	14	OBJ
18	with	with	B-PP	IN	O	17	NMOD
19	hypercalcemias	hypercalcemia	B-NP	NNS	O	18	PMOD
20	related	relate	B-VP	VBN	O	19	NMOD
21	to	to	B-PP	TO	O	20	AMOD
22	malignancies	malignancy	B-NP	NNS	O	26	NMOD
23	and	and	O	CC	O	26	NMOD
24	other	other	B-NP	JJ	O	26	NMOD
25	medical	medical	I-NP	JJ	O	26	NMOD
26	conditions	condition	I-NP	NNS	O	33	NMOD
27	(	(	O	(	O	30	DEP
28	group	group	B-NP	NN	O	29	NMOD
29	A	A	I-NP	NN	O	30	DEP
30	)	)	O	)	O	26	NMOD
31	and	and	O	CC	O	33	NMOD
32	12	12	B-NP	CD	O	33	NMOD
33	patients	patient	I-NP	NNS	O	21	PMOD
34	with	with	B-PP	IN	O	33	NMOD
35	lithium-associated	lithium-associated	B-NP	JJ	O	36	NMOD
36	hypercalcemia	hypercalcemia	I-NP	NN	O	34	PMOD
37	(	(	O	(	O	40	DEP
38	group	group	B-NP	NN	B-protein	39	NMOD
39	B	B	I-NP	NN	I-protein	40	DEP
40	)	)	O	)	O	36	NMOD
41	.	.	O	.	O	14	P

1	Thus	Thus	B-ADVP	RB	O	6	VMOD
2	,	,	O	,	O	6	P
3	two	two	B-NP	CD	O	5	NMOD
4	control	control	I-NP	NN	O	5	NMOD
5	groups	group	I-NP	NNS	O	6	SUB
6	were	be	B-VP	VBD	O	0	ROOT
7	generated	generate	I-VP	VBN	O	6	VC
8	:	:	O	:	O	6	P
9	group	group	B-NP	NN	O	10	NMOD
10	C1	C1	I-NP	NN	O	6	PRD
11	,	,	O	,	O	10	P
12	which	which	B-NP	WDT	O	10	NMOD
13	included	include	B-VP	VBD	O	12	SBAR
14	age-	age-	B-NP	NN	O	20	NMOD
15	and	and	O	CC	O	20	NMOD
16	sex-comparable	sex-comparable	B-NP	JJ	O	20	NMOD
17	lithium-treated	lithium-treated	I-NP	JJ	O	20	NMOD
18	bipolar	bipolar	I-NP	JJ	O	20	NMOD
19	normocalcemic	normocalcemic	I-NP	JJ	O	20	NMOD
20	patients	patient	I-NP	NNS	O	13	OBJ
21	,	,	O	,	O	6	VMOD
22	and	and	O	CC	O	24	NMOD
23	group	group	B-NP	NN	B-protein	24	NMOD
24	C2	C2	I-NP	NN	I-protein	21	OBJ
25	,	,	O	,	O	24	P
26	which	which	B-NP	WDT	O	24	NMOD
27	included	include	B-VP	VBD	O	26	SBAR
28	bipolar	bipolar	B-NP	JJ	O	30	NMOD
29	normocalcemic	normocalcemic	I-NP	JJ	O	30	NMOD
30	patients	patient	I-NP	NNS	O	27	OBJ
31	treated	treat	B-VP	VBN	O	30	NMOD
32	with	with	B-PP	IN	O	31	VMOD
33	anticonvulsant	anticonvulsant	B-NP	JJ	B-protein	35	NMOD
34	mood	mood	I-NP	NN	I-protein	35	NMOD
35	stabilizers	stabilizer	I-NP	NNS	I-protein	32	PMOD
36	.	.	O	.	O	6	P

1	Attenuation	Attenuation	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	nephrotoxicity	nephrotoxicity	B-NP	NN	O	2	PMOD
4	by	by	B-PP	IN	O	1	NMOD
5	a	a	B-NP	DT	O	8	NMOD
6	novel	novel	I-NP	JJ	O	8	NMOD
7	lipid	lipid	I-NP	NN	O	8	NMOD
8	nanosphere	nanosphere	I-NP	NN	O	4	PMOD
9	(	(	O	(	O	11	DEP
10	NS-718	NS-718	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	incorporating	incorporate	B-VP	VBG	O	8	NMOD
13	amphotericin	amphotericin	B-NP	NN	O	14	NMOD
14	B	B	I-NP	NN	O	12	OBJ
15	.	.	O	.	O	1	P

1	NS-718	NS-718	B-NP	NN	B-protein	5	NMOD
2	,	,	O	,	O	5	P
3	a	a	B-NP	DT	O	5	NMOD
4	lipid	lipid	I-NP	NN	O	5	NMOD
5	nanosphere	nanosphere	I-NP	NN	O	10	SUB
6	incorporating	incorporate	B-VP	VBG	O	5	NMOD
7	amphotericin	amphotericin	B-NP	NN	O	8	NMOD
8	B	B	I-NP	NN	O	6	OBJ
9	,	,	O	,	O	5	P
10	is	be	B-VP	VBZ	O	0	ROOT
11	effective	effective	B-ADJP	JJ	O	10	PRD
12	against	against	B-PP	IN	O	11	AMOD
13	pathogenic	pathogenic	B-NP	JJ	O	14	NMOD
14	fungi	fungus	I-NP	NNS	O	12	PMOD
15	and	and	O	CC	O	10	VMOD
16	has	have	B-VP	VBZ	O	10	VMOD
17	low	low	B-NP	JJ	O	18	NMOD
18	toxicity	toxicity	I-NP	NN	O	16	OBJ
19	.	.	O	.	O	10	P

1	We	We	B-NP	PRP	O	2	SUB
2	compared	compare	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	toxicity	toxicity	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	NS-718	NS-718	B-NP	NN	B-protein	5	PMOD
7	with	with	B-PP	IN	O	4	NMOD
8	that	that	B-NP	DT	O	7	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	Fungizone	Fungizone	B-NP	NN	O	9	PMOD
11	(	(	O	(	O	17	DEP
12	amphotericin	amphotericin	B-NP	NN	O	14	NMOD
13	B-sodium	B-sodium	I-NP	NN	O	14	NMOD
14	deoxycholate	deoxycholate	I-NP	NN	O	16	NMOD
15	;	;	O	:	O	16	P
16	D-AmB	D-AmB	B-NP	NN	O	17	DEP
17	)	)	O	)	O	10	NMOD
18	in	in	B-ADVP	FW	O	2	VMOD
19	vitro	vitro	I-ADVP	FW	O	18	AMOD
20	using	use	B-VP	VBG	O	2	VMOD
21	renal	renal	B-NP	JJ	B-cell_line	23	NMOD
22	cell	cell	I-NP	NN	I-cell_line	23	NMOD
23	cultures	culture	I-NP	NNS	I-cell_line	20	OBJ
24	and	and	O	CC	O	23	NMOD
25	in	in	B-ADVP	FW	O	24	DEP
26	vivo	vivo	I-ADVP	FW	O	25	AMOD
27	by	by	B-PP	IN	O	20	VMOD
28	biochemical	biochemical	B-NP	JJ	O	29	NMOD
29	analysis	analysis	I-NP	NN	O	27	PMOD
30	,	,	O	,	O	2	P
31	histopathological	histopathological	B-NP	JJ	O	32	NMOD
32	study	study	I-NP	NN	O	2	OBJ
33	of	of	B-PP	IN	O	32	NMOD
34	the	the	B-NP	DT	O	38	NMOD
35	kidney	kidney	I-NP	NN	O	38	NMOD
36	and	and	I-NP	CC	O	38	NMOD
37	pharmacokinetic	pharmacokinetic	I-NP	JJ	O	38	NMOD
38	study	study	I-NP	NN	O	33	PMOD
39	of	of	B-PP	IN	O	38	NMOD
40	amphotericin	amphotericin	B-NP	NN	O	41	NMOD
41	B	B	I-NP	NN	O	39	PMOD
42	following	follow	B-PP	VBG	O	41	NMOD
43	intravenous	intravenous	B-NP	JJ	O	44	NMOD
44	infusion	infusion	I-NP	NN	O	42	PMOD
45	of	of	B-PP	IN	O	44	NMOD
46	the	the	B-NP	DT	O	47	NMOD
47	formulation	formulation	I-NP	NN	O	45	PMOD
48	in	in	B-PP	IN	O	44	NMOD
49	rats	rat	B-NP	NNS	O	48	PMOD
50	.	.	O	.	O	2	P

1	Histopathological	Histopathological	B-NP	JJ	O	2	NMOD
2	examination	examination	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	kidney	kidney	I-NP	NN	O	3	PMOD
6	showed	show	B-VP	VBD	O	0	ROOT
7	tubular	tubular	B-NP	JJ	O	8	NMOD
8	necrosis	necrosis	I-NP	NN	O	6	OBJ
9	in	in	B-PP	IN	O	8	NMOD
10	D-AmB-treated	D-AmB-treated	B-NP	JJ	O	11	NMOD
11	rats	rat	I-NP	NNS	O	9	PMOD
12	but	but	O	CC	O	6	VMOD
13	no	no	B-NP	DT	O	14	NMOD
14	change	change	I-NP	NN	O	12	OBJ
15	in	in	B-PP	IN	O	14	NMOD
16	NS-718-treated	NS-718-treated	B-NP	JJ	O	17	NMOD
17	rats	rat	I-NP	NNS	O	15	PMOD
18	.	.	O	.	O	6	P

1	Patterns	Pattern	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	sulfadiazine	sulfadiazine	B-NP	NN	O	5	NMOD
4	acute	acute	I-NP	JJ	O	5	NMOD
5	nephrotoxicity	nephrotoxicity	I-NP	NN	O	2	PMOD
6	.	.	O	.	O	1	P

1	Sulfadiazine	Sulfadiazine	B-NP	NN	O	3	NMOD
2	acute	acute	I-NP	JJ	O	3	NMOD
3	nephrotoxicity	nephrotoxicity	I-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	reviving	revive	I-VP	VBG	O	4	VC
6	specially	specially	B-ADVP	RB	O	5	VMOD
7	because	because	B-PP	IN	O	5	VMOD
8	of	of	I-PP	IN	O	7	PMOD
9	its	its	B-NP	PRP$	O	10	NMOD
10	use	use	I-NP	NN	O	8	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	toxoplasmosis	toxoplasmosis	B-NP	NN	O	11	PMOD
13	in	in	B-PP	IN	O	10	NMOD
14	HIV-positive	HIV-positive	B-NP	JJ	O	15	NMOD
15	patients	patient	I-NP	NNS	O	13	PMOD
16	.	.	O	.	O	4	P

1	Under	Under	B-PP	IN	O	6	VMOD
2	treatment	treatment	B-NP	NN	O	1	PMOD
3	with	with	B-PP	IN	O	2	NMOD
4	sulfadiazine	sulfadiazine	B-NP	NN	O	3	PMOD
5	they	they	B-NP	PRP	O	6	SUB
6	developed	develop	B-VP	VBD	O	0	ROOT
7	oliguria	oliguria	B-NP	NN	O	13	NMOD
8	,	,	O	,	O	13	P
9	abdominal	abdominal	B-NP	JJ	O	10	NMOD
10	pain	pain	I-NP	NN	O	13	NMOD
11	,	,	O	,	O	13	P
12	renal	renal	B-NP	JJ	O	13	NMOD
13	failure	failure	I-NP	NN	O	6	OBJ
14	and	and	O	CC	O	6	VMOD
15	showed	show	B-VP	VBD	O	6	VMOD
16	multiple	multiple	B-NP	JJ	O	18	AMOD
17	radiolucent	radiolucent	I-NP	JJ	O	18	AMOD
18	renal	renal	I-NP	JJ	O	19	NMOD
19	calculi	calculus	I-NP	NNS	O	15	OBJ
20	in	in	B-PP	IN	O	15	VMOD
21	echography	echography	B-NP	NN	O	20	PMOD
22	.	.	O	.	O	6	P

1	Downbeat	Downbeat	B-NP	NN	O	2	NMOD
2	nystagmus	nystagmus	I-NP	NN	O	0	ROOT
3	associated	associate	B-VP	VBN	O	2	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	intravenous	intravenous	B-NP	JJ	O	7	NMOD
6	patient-controlled	patient-controlled	I-NP	JJ	O	7	NMOD
7	administration	administration	I-NP	NN	O	4	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	morphine	morphine	B-NP	NN	O	8	PMOD
10	.	.	O	.	O	2	P

1	IMPLICATIONS	IMPLICATIONS	B-NP	NNS	O	4	NMOD
2	:	:	O	:	O	1	P
3	This	This	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	5	SUB
5	documents	document	B-VP	VBZ	O	0	ROOT
6	a	a	B-NP	DT	O	7	NMOD
7	patient	patient	I-NP	NN	O	5	OBJ
8	who	who	B-NP	WP	O	7	NMOD
9	developed	develop	B-VP	VBD	O	8	SBAR
10	dizziness	dizziness	B-NP	NN	O	9	OBJ
11	with	with	B-PP	IN	O	9	VMOD
12	downbeating	downbeate	B-VP	VBG	O	11	PMOD
13	nystagmus	nystagmus	B-NP	NN	O	12	OBJ
14	while	while	B-SBAR	IN	O	7	NMOD
15	receiving	receive	B-VP	VBG	O	14	SBAR
16	a	a	B-NP	DT	O	19	NMOD
17	relatively	relatively	I-NP	RB	O	18	AMOD
18	large	large	I-NP	JJ	O	19	NMOD
19	dose	dose	I-NP	NN	O	15	OBJ
20	of	of	B-PP	IN	O	19	NMOD
21	IV	IV	B-NP	CD	O	24	NMOD
22	patient-controlled	patient-controlled	I-NP	JJ	O	24	NMOD
23	analgesia	analgesia	I-NP	NN	O	24	NMOD
24	morphine	morphine	I-NP	NN	O	20	PMOD
25	.	.	O	.	O	5	P

1	Hemodynamic	Hemodynamic	B-NP	JJ	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	antiadrenergic	antiadrenergic	I-NP	JJ	O	4	NMOD
4	effects	effect	I-NP	NNS	O	0	ROOT
5	of	of	B-PP	IN	O	4	NMOD
6	dronedarone	dronedarone	B-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	amiodarone	amiodarone	I-NP	NN	O	5	PMOD
9	in	in	B-PP	IN	O	4	NMOD
10	animals	animal	B-NP	NNS	O	9	PMOD
11	with	with	B-PP	IN	O	4	NMOD
12	a	a	B-NP	DT	O	15	NMOD
13	healed	healed	I-NP	JJ	O	15	NMOD
14	myocardial	myocardial	I-NP	JJ	O	15	NMOD
15	infarction	infarction	I-NP	NN	O	11	PMOD
16	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	5	NMOD
2	hemodynamic	hemodynamic	I-NP	JJ	O	4	AMOD
3	and	and	I-NP	CC	O	4	AMOD
4	antiadrenergic	antiadrenergic	I-NP	JJ	O	5	NMOD
5	effects	effect	I-NP	NNS	O	17	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	dronedarone	dronedarone	B-NP	NN	O	11	NMOD
8	,	,	O	,	O	11	P
9	a	a	B-NP	DT	O	11	NMOD
10	noniodinated	noniodinated	I-NP	JJ	O	11	NMOD
11	compound	compound	I-NP	NN	O	6	PMOD
12	structurally	structurally	B-ADJP	RB	O	13	AMOD
13	related	related	I-ADJP	JJ	O	11	NMOD
14	to	to	B-PP	TO	O	13	AMOD
15	amiodarone	amiodarone	B-NP	NN	O	14	PMOD
16	,	,	O	,	O	5	P
17	were	be	B-VP	VBD	O	0	ROOT
18	compared	compare	I-VP	VBN	O	17	VC
19	with	with	B-PP	IN	O	18	VMOD
20	those	those	B-NP	DT	O	19	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	amiodarone	amiodarone	B-NP	NN	O	21	PMOD
23	after	after	B-PP	IN	O	22	NMOD
24	prolonged	prolonged	B-NP	JJ	O	26	NMOD
25	oral	oral	I-NP	JJ	O	26	NMOD
26	administration	administration	I-NP	NN	O	23	PMOD
27	,	,	O	,	O	19	P
28	both	both	B-PP	CC	O	19	PMOD
29	at	at	I-PP	IN	O	19	PMOD
30	rest	rest	B-NP	NN	O	29	PMOD
31	and	and	O	CC	O	19	PMOD
32	during	during	B-PP	IN	O	19	PMOD
33	sympathetic	sympathetic	B-NP	JJ	O	34	NMOD
34	stimulation	stimulation	I-NP	NN	O	32	PMOD
35	in	in	B-PP	IN	O	34	NMOD
36	conscious	conscious	B-NP	JJ	O	37	NMOD
37	dogs	dog	I-NP	NNS	O	35	PMOD
38	with	with	B-PP	IN	O	34	NMOD
39	a	a	B-NP	DT	O	42	NMOD
40	healed	healed	I-NP	JJ	O	42	NMOD
41	myocardial	myocardial	I-NP	JJ	O	42	NMOD
42	infarction	infarction	I-NP	NN	O	38	PMOD
43	.	.	O	.	O	17	P

1	Both	Both	O	CC	O	4	NMOD
2	dronedarone	dronedarone	B-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	amiodarone	amiodarone	I-NP	NN	O	6	SUB
5	significantly	significantly	B-ADVP	RB	O	6	VMOD
6	reduced	reduce	B-VP	VBD	O	18	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	exercise	exercise	I-NP	NN	O	10	NMOD
9	induced	induce	B-VP	VBD	O	10	NMOD
10	tachycardia	tachycardia	B-NP	NN	O	6	OBJ
11	and	and	O	CC	O	18	VMOD
12	,	,	O	,	O	18	P
13	at	at	B-PP	IN	O	18	VMOD
14	the	the	B-NP	DT	O	16	NMOD
15	highest	high	I-NP	JJS	O	16	NMOD
16	dose	dose	I-NP	NN	O	13	PMOD
17	,	,	O	,	O	18	P
18	decreased	decrease	B-VP	VBD	O	0	ROOT
19	the	the	B-NP	DT	O	22	NMOD
20	isoproterenol	isoproterenol	I-NP	NN	O	22	NMOD
21	induced	induced	I-NP	JJ	O	22	NMOD
22	tachycardia	tachycardia	I-NP	NN	O	18	OBJ
23	.	.	O	.	O	18	P

1	Phase	Phase	B-NP	NN	O	3	NMOD
2	2	2	I-NP	CD	O	3	NMOD
3	trial	trial	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	liposomal	liposomal	B-NP	JJ	O	6	NMOD
6	doxorubicin	doxorubicin	I-NP	NN	O	4	PMOD
7	(	(	O	(	O	13	DEP
8	40	40	B-NP	CD	O	9	NMOD
9	mg/m	mg/m	I-NP	NN	O	13	DEP
10	(	(	O	(	O	12	DEP
11	2	2	B-NP	CD	O	12	DEP
12	)	)	O	)	O	9	NMOD
13	)	)	O	)	O	3	NMOD
14	in	in	B-PP	IN	O	3	NMOD
15	platinum/paclitaxel-refractory	platinum/paclitaxel-refractory	B-NP	JJ	O	18	AMOD
16	ovarian	ovarian	I-NP	JJ	O	18	AMOD
17	and	and	I-NP	CC	O	18	AMOD
18	fallopian	fallopian	I-NP	JJ	O	20	NMOD
19	tube	tube	I-NP	NN	O	20	NMOD
20	cancers	cancer	I-NP	NNS	O	23	NMOD
21	and	and	O	CC	O	23	NMOD
22	primary	primary	B-NP	JJ	O	23	NMOD
23	carcinoma	carcinoma	I-NP	NN	O	14	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	the	the	B-NP	DT	O	26	NMOD
26	peritoneum	peritoneum	I-NP	NN	O	24	PMOD
27	.	.	O	.	O	3	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Several	Several	B-NP	JJ	O	4	NMOD
4	studies	study	I-NP	NNS	O	5	SUB
5	have	have	B-VP	VBP	O	1	NMOD
6	demonstrated	demonstrate	I-VP	VBN	O	5	VC
7	liposomal	liposomal	B-NP	JJ	O	8	NMOD
8	doxorubicin	doxorubicin	I-NP	NN	O	6	OBJ
9	(	(	O	(	O	11	DEP
10	Doxil	Doxil	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	to	to	B-VP	TO	O	13	VMOD
13	be	be	I-VP	VB	O	8	NMOD
14	an	an	B-NP	DT	O	17	NMOD
15	active	active	I-NP	JJ	O	17	NMOD
16	antineoplastic	antineoplastic	I-NP	JJ	O	17	NMOD
17	agent	agent	I-NP	NN	O	13	PRD
18	in	in	B-PP	IN	O	17	NMOD
19	platinum-resistant	platinum-resistant	B-NP	JJ	O	21	NMOD
20	ovarian	ovarian	I-NP	JJ	O	21	NMOD
21	cancer	cancer	I-NP	NN	O	18	PMOD
22	,	,	O	,	O	6	P
23	with	with	B-PP	IN	O	6	VMOD
24	dose	dose	B-NP	NN	O	23	PMOD
25	limiting	limit	B-VP	VBG	O	24	NMOD
26	toxicity	toxicity	B-NP	NN	O	42	SUB
27	of	of	B-PP	IN	O	26	NMOD
28	the	the	B-NP	DT	O	31	NMOD
29	standard	standard	I-NP	JJ	O	31	NMOD
30	dosing	dosing	I-NP	NN	O	31	NMOD
31	regimen	regimen	I-NP	NN	O	27	PMOD
32	(	(	O	(	O	41	DEP
33	50	50	B-NP	CD	O	34	NMOD
34	mg/m	mg/m	I-NP	NN	O	40	NMOD
35	(	(	O	(	O	37	DEP
36	2	2	B-NP	CD	O	37	DEP
37	)	)	O	)	O	34	NMOD
38	q	q	B-NP	NN	O	40	NMOD
39	4	4	B-NP	CD	O	40	NMOD
40	weeks	week	I-NP	NNS	O	41	DEP
41	)	)	O	)	O	31	NMOD
42	being	be	B-VP	VBG	O	25	VMOD
43	severe	severe	B-NP	JJ	O	44	NMOD
44	erythrodysesthesia	erythrodysesthesia	I-NP	NN	O	52	NMOD
45	(	(	O	(	O	50	DEP
46	``	``	O	``	O	48	NMOD
47	hand-foot	hand-foot	B-NP	JJ	O	48	NMOD
48	syndrome	syndrome	I-NP	NN	O	50	DEP
49	''	''	O	''	O	48	NMOD
50	)	)	O	)	O	44	NMOD
51	and	and	O	CC	O	52	NMOD
52	stomatitis	stomatitis	B-NP	NN	O	42	PRD
53	.	.	O	.	O	5	P

1	METHODS	METHODS	B-NP	NNS	O	3	NMOD
2	AND	AND	I-NP	CC	O	3	NMOD
3	MATERIALS	MATERIALS	I-NP	NNS	O	5	NMOD
4	:	:	O	:	O	3	P
5	Patients	Patient	B-NP	NNS	O	39	SUB
6	with	with	B-PP	IN	O	5	NMOD
7	ovarian	ovarian	B-NP	JJ	O	11	NMOD
8	or	or	I-NP	CC	O	11	NMOD
9	fallopian	fallopian	I-NP	JJ	O	11	NMOD
10	tube	tube	I-NP	NN	O	11	NMOD
11	cancers	cancer	I-NP	NNS	O	15	NMOD
12	or	or	O	CC	O	15	NMOD
13	primary	primary	B-NP	JJ	O	15	NMOD
14	peritoneal	peritoneal	I-NP	JJ	O	15	NMOD
15	carcinoma	carcinoma	I-NP	NN	O	6	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	platinum/paclitaxel-refractory	platinum/paclitaxel-refractory	B-NP	JJ	O	18	NMOD
18	disease	disease	I-NP	NN	O	23	NMOD
19	(	(	O	(	O	23	NMOD
20	stable	stable	B-NP	JJ	O	22	AMOD
21	or	or	I-NP	CC	O	22	AMOD
22	progressive	progressive	I-NP	JJ	O	23	NMOD
23	disease	disease	I-NP	NN	O	16	PMOD
24	following	follow	B-PP	VBG	O	5	NMOD
25	treatment	treatment	B-NP	NN	O	24	PMOD
26	with	with	B-PP	IN	O	25	NMOD
27	these	these	B-NP	DT	O	28	NMOD
28	agents	agent	I-NP	NNS	O	32	NMOD
29	or	or	O	CC	O	32	NMOD
30	previous	previous	B-NP	JJ	O	32	NMOD
31	objective	objective	I-NP	JJ	O	32	NMOD
32	response	response	I-NP	NN	O	35	NMOD
33	<	<	B-NP	SYM	O	35	NMOD
34	3	3	B-NP	CD	O	35	NMOD
35	months	month	I-NP	NNS	O	26	PMOD
36	in	in	B-PP	IN	O	25	NMOD
37	duration	duration	B-NP	NN	O	36	PMOD
38	)	)	O	)	O	5	NMOD
39	were	be	B-VP	VBD	O	0	ROOT
40	treated	treat	I-VP	VBN	O	39	VC
41	with	with	B-PP	IN	O	40	VMOD
42	liposomal	liposomal	B-NP	JJ	O	43	NMOD
43	doxorubicin	doxorubicin	I-NP	NN	O	41	PMOD
44	at	at	B-PP	IN	O	40	VMOD
45	a	a	B-NP	DT	O	46	NMOD
46	dose	dose	I-NP	NN	O	55	NMOD
47	of	of	B-PP	IN	O	46	NMOD
48	40	40	B-NP	CD	O	49	NMOD
49	mg/m	mg/m	I-NP	NN	O	47	PMOD
50	(	(	O	(	O	52	DEP
51	2	2	B-NP	CD	O	52	DEP
52	)	)	O	)	O	46	NMOD
53	q	q	B-NP	NN	O	55	NMOD
54	4	4	B-NP	CD	O	55	NMOD
55	weeks	week	I-NP	NNS	O	44	PMOD
56	.	.	O	.	O	39	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	This	This	B-NP	DT	O	7	NMOD
4	modified	modify	I-NP	VBN	O	7	NMOD
5	liposomal	liposomal	I-NP	JJ	O	7	NMOD
6	doxorubicin	doxorubicin	I-NP	NN	O	7	NMOD
7	regimen	regimen	I-NP	NN	O	8	SUB
8	results	result	B-VP	VBZ	O	1	NMOD
9	in	in	B-PP	IN	O	8	VMOD
10	less	less	B-NP	JJR	O	11	NMOD
11	toxicity	toxicity	I-NP	NN	O	9	PMOD
12	(	(	O	(	O	17	DEP
13	stomatitis	stomatitis	B-NP	NN	O	16	NMOD
14	,	,	O	,	O	16	P
15	hand-foot	hand-foot	B-NP	JJ	O	16	NMOD
16	syndrome	syndrome	I-NP	NN	O	17	DEP
17	)	)	O	)	O	11	NMOD
18	than	than	B-PP	IN	O	11	NMOD
19	the	the	B-NP	DT	O	23	NMOD
20	standard	standard	I-NP	JJ	O	23	NMOD
21	FDA-approved	FDA-approved	I-NP	JJ	O	23	NMOD
22	dose	dose	I-NP	NN	O	23	NMOD
23	schedule	schedule	I-NP	NN	O	18	PMOD
24	.	.	O	.	O	1	P

1	Efficacy	Efficacy	B-NP	NN	O	13	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	olanzapine	olanzapine	B-NP	NN	O	2	PMOD
4	in	in	B-PP	IN	O	1	NMOD
5	acute	acute	B-NP	JJ	O	7	NMOD
6	bipolar	bipolar	I-NP	JJ	O	7	NMOD
7	mania	mania	I-NP	NN	O	4	PMOD
8	:	:	O	:	O	1	P
9	a	a	B-NP	DT	O	13	NMOD
10	double-blind	double-blind	I-NP	JJ	O	12	AMOD
11	,	,	I-NP	,	O	12	P
12	placebo-controlled	placebo-controlled	I-NP	JJ	O	13	NMOD
13	study	study	I-NP	NN	O	0	ROOT
14	.	.	O	.	O	13	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	compared	compare	B-VP	VBD	O	1	NMOD
5	the	the	B-NP	DT	O	8	NMOD
6	efficacy	efficacy	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	safety	safety	I-NP	NN	O	4	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	olanzapine	olanzapine	B-NP	NN	O	12	NMOD
11	vs	vs	I-NP	CC	O	12	NMOD
12	placebo	placebo	I-NP	NN	O	9	PMOD
13	for	for	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	treatment	treatment	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	acute	acute	B-NP	JJ	O	19	NMOD
18	bipolar	bipolar	I-NP	JJ	O	19	NMOD
19	mania	mania	I-NP	NN	O	16	PMOD
20	.	.	O	.	O	1	P

1	A	A	B-NP	DT	O	2	NMOD
2	total	total	I-NP	NN	O	18	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	115	115	B-NP	CD	O	5	NMOD
5	patients	patient	I-NP	NNS	O	3	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	a	a	B-NP	DT	O	9	NMOD
8	DSM-IV	DSM-IV	I-NP	NN	O	9	NMOD
9	diagnosis	diagnosis	I-NP	NN	O	6	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	bipolar	bipolar	B-NP	JJ	O	12	NMOD
12	disorder	disorder	I-NP	NN	O	10	PMOD
13	,	,	O	,	O	2	P
14	manic	manic	B-ADJP	JJ	O	16	AMOD
15	or	or	I-ADJP	CC	O	16	AMOD
16	mixed	mixed	I-ADJP	JJ	O	2	NMOD
17	,	,	O	,	O	2	P
18	were	be	B-VP	VBD	O	0	ROOT
19	randomized	randomize	I-VP	VBN	O	18	VC
20	to	to	B-PP	TO	O	19	VMOD
21	olanzapine	olanzapine	B-NP	NN	O	20	PMOD
22	,	,	O	,	O	19	P
23	5	5	B-NP	CD	O	25	AMOD
24	to	to	I-NP	TO	O	25	AMOD
25	20	20	I-NP	CD	O	34	NMOD
26	mg/d	mg/d	I-NP	NN	O	34	NMOD
27	(	(	O	(	O	31	DEP
28	n	n	B-NP	NN	O	30	SUB
29	=	=	B-VP	SYM	O	30	VMOD
30	55	55	B-NP	CD	O	31	DEP
31	)	)	O	)	O	26	NMOD
32	,	,	O	,	O	34	P
33	or	or	O	CC	O	34	NMOD
34	placebo	placebo	B-NP	NN	O	19	VMOD
35	(	(	O	(	O	39	DEP
36	n	n	B-NP	NN	O	39	DEP
37	=	=	B-VP	SYM	O	36	NMOD
38	60	60	B-NP	CD	O	37	AMOD
39	)	)	O	)	O	34	NMOD
40	.	.	O	.	O	18	P

1	However	However	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	olanzapine-treated	olanzapine-treated	B-NP	JJ	O	4	NMOD
4	patients	patient	I-NP	NNS	O	5	SUB
5	had	have	B-VP	VBD	O	0	ROOT
6	a	a	B-NP	DT	O	10	NMOD
7	statistically	statistically	I-NP	RB	O	8	AMOD
8	significant	significant	I-NP	JJ	O	10	NMOD
9	greater	great	I-NP	JJR	O	10	NMOD
10	mean	mean	I-NP	NN	O	16	NMOD
11	(	(	O	(	O	14	DEP
12	+/-	+/-	B-NP	SYM	O	13	NMOD
13	SD	SD	I-NP	NN	O	14	DEP
14	)	)	O	)	O	10	NMOD
15	weight	weight	B-NP	NN	O	16	NMOD
16	gain	gain	I-NP	NN	O	5	OBJ
17	than	than	B-PP	IN	O	16	NMOD
18	placebo-treated	placebo-treated	B-NP	JJ	O	19	NMOD
19	patients	patient	I-NP	NNS	O	17	PMOD
20	(	(	O	(	O	31	DEP
21	2.1	2.1	B-NP	CD	O	23	AMOD
22	+/-	+/-	I-NP	SYM	O	23	AMOD
23	2.8	2.8	I-NP	CD	O	28	NMOD
24	vs	vs	B-PP	IN	O	28	NMOD
25	0.45	0.45	B-NP	CD	O	27	AMOD
26	+/-	+/-	I-NP	SYM	O	27	AMOD
27	2.3	2.3	I-NP	CD	O	28	NMOD
28	kg	kg	I-NP	NN	O	31	DEP
29	,	,	O	,	O	28	P
30	respectively	respectively	B-ADVP	RB	O	28	NMOD
31	)	)	O	)	O	19	NMOD
32	and	and	O	CC	O	5	VMOD
33	also	also	B-VP	RB	O	5	VMOD
34	experienced	experience	I-VP	VBD	O	5	VMOD
35	more	more	B-NP	RBR	O	36	AMOD
36	treatment-emergent	treatment-emergent	I-NP	JJ	O	37	NMOD
37	somnolence	somnolence	I-NP	NN	O	34	OBJ
38	(	(	O	(	O	44	DEP
39	21	21	B-NP	CD	O	40	NMOD
40	patients	patient	I-NP	NNS	O	44	DEP
41	[	[	O	(	O	44	DEP
42	38.2	38.2	B-NP	CD	O	43	NMOD
43	%	%	I-NP	NN	O	44	DEP
44	]	]	O	)	O	37	NMOD
45	vs	vs	B-PP	IN	O	34	VMOD
46	5	5	B-NP	CD	O	45	PMOD
47	[	[	O	(	O	50	DEP
48	8.3	8.3	B-NP	CD	O	49	NMOD
49	%	%	I-NP	NN	O	50	DEP
50	]	]	O	)	O	46	NMOD
51	,	,	O	,	O	5	P
52	respectively	respectively	B-ADVP	RB	O	5	VMOD
53	)	)	O	)	O	5	VMOD
54	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	2	NMOD
2	effect	effect	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	pupil	pupil	B-NP	NN	O	5	NMOD
5	dilation	dilation	I-NP	NN	O	3	PMOD
6	with	with	B-PP	IN	O	2	NMOD
7	tropicamide	tropicamide	B-NP	NN	O	6	PMOD
8	on	on	B-PP	IN	O	2	NMOD
9	vision	vision	B-NP	NN	O	8	PMOD
10	and	and	O	CC	O	2	DEP
11	driving	drive	B-VP	VBG	O	2	NMOD
12	simulator	simulator	B-NP	NN	O	13	NMOD
13	performance	performance	I-NP	NN	O	11	OBJ
14	.	.	O	.	O	2	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	A	A	B-NP	DT	O	4	NMOD
4	series	series	I-NP	NN	O	17	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	tests	test	B-NP	NNS	O	5	PMOD
7	on	on	B-PP	IN	O	6	NMOD
8	various	various	B-NP	JJ	O	9	NMOD
9	parameters	parameter	I-NP	NNS	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	visual	visual	B-NP	JJ	O	12	NMOD
12	function	function	I-NP	NN	O	10	PMOD
13	and	and	O	CC	O	4	DEP
14	driving	drive	B-VP	VBG	O	4	NMOD
15	simulator	simulator	B-NP	NN	O	16	NMOD
16	performance	performance	I-NP	NN	O	14	OBJ
17	were	be	B-VP	VBD	O	1	NMOD
18	performed	perform	I-VP	VBN	O	17	VC
19	on	on	B-PP	IN	O	18	VMOD
20	12	12	B-NP	CD	O	22	NMOD
21	healthy	healthy	I-NP	JJ	O	22	NMOD
22	drivers	driver	I-NP	NNS	O	19	PMOD
23	,	,	O	,	O	18	P
24	before	before	B-PP	IN	O	18	VMOD
25	and	and	I-PP	CC	O	24	PMOD
26	after	after	I-PP	IN	O	24	PMOD
27	pupil	pupil	B-NP	NN	O	28	NMOD
28	dilation	dilation	I-NP	NN	O	24	PMOD
29	using	use	B-VP	VBG	O	28	NMOD
30	guttae	gutta	B-NP	NNS	O	33	NMOD
31	tropicamide	tropicamide	I-NP	NN	O	33	NMOD
32	1	1	B-NP	CD	O	33	NMOD
33	%	%	I-NP	NN	O	29	OBJ
34	.	.	O	.	O	1	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	newborn	newborn	I-NP	JJ	O	5	NMOD
5	infant	infant	I-NP	NN	O	2	OBJ
6	with	with	B-PP	IN	O	5	NMOD
7	multiple	multiple	B-NP	JJ	O	9	NMOD
8	congenital	congenital	I-NP	JJ	O	9	NMOD
9	anomalies	anomaly	I-NP	NNS	O	6	PMOD
10	(	(	O	(	O	15	DEP
11	anotia	anotia	B-NP	NN	O	14	NMOD
12	and	and	O	CC	O	14	NMOD
13	Taussig-Bing	Taussig-Bing	B-NP	JJ	O	14	NMOD
14	malformation	malformation	I-NP	NN	O	15	DEP
15	)	)	O	)	O	9	NMOD
16	due	due	B-PP	IN	O	5	NMOD
17	to	to	B-PP	TO	O	16	PMOD
18	exposure	exposure	B-NP	NN	O	17	PMOD
19	to	to	B-PP	TO	O	18	NMOD
20	isotretinoin	isotretinoin	B-NP	NN	O	19	PMOD
21	within	within	B-PP	IN	O	20	NMOD
22	the	the	B-NP	DT	O	24	NMOD
23	first	first	I-NP	JJ	O	24	NMOD
24	trimester	trimester	I-NP	NN	O	21	PMOD
25	.	.	O	.	O	2	P

1	Effect	Effect	B-NP	NN	O	20	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	methoxamine	methoxamine	B-NP	NN	O	2	PMOD
4	on	on	B-PP	IN	O	1	NMOD
5	maximum	maximum	B-NP	JJ	O	7	NMOD
6	urethral	urethral	I-NP	JJ	O	7	NMOD
7	pressure	pressure	I-NP	NN	O	4	PMOD
8	in	in	B-PP	IN	O	7	NMOD
9	women	woman	B-NP	NNS	O	8	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	genuine	genuine	B-NP	JJ	O	13	NMOD
12	stress	stress	I-NP	NN	O	13	NMOD
13	incontinence	incontinence	I-NP	NN	O	10	PMOD
14	:	:	O	:	O	1	P
15	a	a	B-NP	DT	O	20	NMOD
16	placebo-controlled	placebo-controlled	I-NP	JJ	O	18	AMOD
17	,	,	I-NP	,	O	18	P
18	double-blind	double-blind	I-NP	JJ	O	20	NMOD
19	crossover	crossover	I-NP	NN	O	20	NMOD
20	study	study	I-NP	NN	O	0	ROOT
21	.	.	O	.	O	20	P

1	Half	Half	B-NP	NN	O	4	NMOD
2	log	log	I-NP	NN	O	4	NMOD
3	incremental	incremental	I-NP	JJ	O	4	NMOD
4	doses	dose	I-NP	NNS	O	13	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	intravenous	intravenous	B-NP	JJ	O	7	NMOD
7	methoxamine	methoxamine	I-NP	NN	O	9	NMOD
8	or	or	O	CC	O	9	NMOD
9	placebo	placebo	B-NP	NN	O	5	PMOD
10	(	(	O	(	O	12	DEP
11	saline	saline	B-NP	NN	O	12	DEP
12	)	)	O	)	O	9	NMOD
13	were	be	B-VP	VBD	O	0	ROOT
14	administered	administer	I-VP	VBN	O	13	VC
15	to	to	B-PP	TO	O	14	VMOD
16	a	a	B-NP	DT	O	17	NMOD
17	group	group	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	women	woman	B-NP	NNS	O	18	PMOD
20	with	with	B-PP	IN	O	19	NMOD
21	genuine	genuine	B-NP	JJ	O	23	NMOD
22	stress	stress	I-NP	NN	O	23	NMOD
23	incontinence	incontinence	I-NP	NN	O	20	PMOD
24	while	while	B-SBAR	IN	O	13	VMOD
25	measuring	measure	B-VP	VBG	O	24	SBAR
26	maximum	maximum	B-NP	JJ	O	28	NMOD
27	urethral	urethral	I-NP	JJ	O	28	NMOD
28	pressure	pressure	I-NP	NN	O	25	OBJ
29	(	(	O	(	O	31	DEP
30	MUP	MUP	B-NP	NN	B-protein	31	DEP
31	)	)	O	)	O	28	NMOD
32	,	,	O	,	O	42	P
33	blood	blood	B-NP	NN	O	34	NMOD
34	pressure	pressure	I-NP	NN	O	42	NMOD
35	,	,	O	,	O	42	P
36	heart	heart	B-NP	NN	O	37	NMOD
37	rate	rate	I-NP	NN	O	42	NMOD
38	,	,	O	,	O	42	P
39	and	and	O	CC	O	42	NMOD
40	symptomatic	symptomatic	B-NP	JJ	O	42	NMOD
41	side	side	I-NP	NN	O	42	NMOD
42	effects	effect	I-NP	NNS	O	13	PRD
43	.	.	O	.	O	13	P

1	Methoxamine	Methoxamine	B-NP	NN	O	2	SUB
2	evoked	evoke	B-VP	VBD	O	0	ROOT
3	non-significant	non-significant	B-NP	JJ	O	4	NMOD
4	increases	increase	I-NP	NNS	O	2	OBJ
5	in	in	B-PP	IN	O	4	NMOD
6	MUP	MUP	B-NP	NN	B-protein	10	NMOD
7	and	and	O	CC	O	10	NMOD
8	diastolic	diastolic	B-NP	JJ	O	10	NMOD
9	blood	blood	I-NP	NN	O	10	NMOD
10	pressure	pressure	I-NP	NN	O	5	PMOD
11	but	but	O	CC	O	2	VMOD
12	caused	cause	B-VP	VBD	O	2	VMOD
13	a	a	B-NP	DT	O	15	NMOD
14	significant	significant	I-NP	JJ	O	15	NMOD
15	rise	rise	I-NP	NN	O	22	NMOD
16	in	in	B-PP	IN	O	15	NMOD
17	systolic	systolic	B-NP	JJ	O	19	NMOD
18	blood	blood	I-NP	NN	O	19	NMOD
19	pressure	pressure	I-NP	NN	O	16	PMOD
20	and	and	O	CC	O	22	NMOD
21	significant	significant	B-NP	JJ	O	22	NMOD
22	fall	fall	I-NP	NN	O	12	OBJ
23	in	in	B-PP	IN	O	22	NMOD
24	heart	heart	B-NP	NN	O	25	NMOD
25	rate	rate	I-NP	NN	O	23	PMOD
26	at	at	B-PP	IN	O	12	VMOD
27	maximum	maximum	B-NP	JJ	O	28	NMOD
28	dosage	dosage	I-NP	NN	O	26	PMOD
29	.	.	O	.	O	2	P

1	Toleration	Toleration	B-NP	NN	O	16	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	high	high	B-NP	JJ	O	4	NMOD
4	doses	dose	I-NP	NNS	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	angiotensin-converting	angiotensin-converting	B-NP	JJ	O	8	NMOD
7	enzyme	enzyme	I-NP	NN	O	8	NMOD
8	inhibitors	inhibitor	I-NP	NNS	O	5	PMOD
9	in	in	B-PP	IN	O	1	NMOD
10	patients	patient	B-NP	NNS	O	9	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	chronic	chronic	B-NP	JJ	O	14	NMOD
13	heart	heart	I-NP	NN	O	14	NMOD
14	failure	failure	I-NP	NN	O	11	PMOD
15	:	:	O	:	O	1	P
16	results	result	B-NP	NNS	O	0	ROOT
17	from	from	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	20	NMOD
19	ATLAS	ATLAS	I-NP	NN	O	20	NMOD
20	trial	trial	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	16	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	29	SUB
2	:	:	O	:	O	1	P
3	Treatment	Treatment	B-NP	NN	O	11	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	angiotensin-converting	angiotensin-converting	B-NP	JJ	B-protein	6	NMOD
6	enzyme	enzyme	I-NP	NN	I-protein	10	NMOD
7	(	(	O	(	O	9	DEP
8	ACE	ACE	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	inhibitors	inhibitor	B-NP	NNS	O	4	PMOD
11	reduces	reduce	B-VP	VBZ	O	29	VMOD
12	mortality	mortality	B-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	morbidity	morbidity	I-NP	NN	O	11	OBJ
15	in	in	B-PP	IN	O	11	VMOD
16	patients	patient	B-NP	NNS	O	15	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	chronic	chronic	B-NP	JJ	O	20	NMOD
19	heart	heart	I-NP	NN	O	20	NMOD
20	failure	failure	I-NP	NN	O	17	PMOD
21	(	(	O	(	O	23	DEP
22	CHF	CHF	B-NP	NN	B-protein	23	DEP
23	)	)	O	)	O	20	NMOD
24	,	,	O	,	O	29	P
25	but	but	O	CC	O	29	VMOD
26	most	most	B-VP	JJS	O	28	NMOD
27	affected	affect	I-VP	VBN	O	28	NMOD
28	patients	patient	B-NP	NNS	O	29	SUB
29	are	be	B-VP	VBP	O	0	ROOT
30	not	not	I-VP	RB	O	29	VMOD
31	receiving	receive	I-VP	VBG	O	29	VC
32	these	these	B-NP	DT	O	33	NMOD
33	agents	agent	I-NP	NNS	O	31	OBJ
34	or	or	O	CC	O	29	VMOD
35	are	be	B-VP	VBP	O	29	VMOD
36	being	be	I-VP	VBG	O	35	VC
37	treated	treat	I-VP	VBN	O	36	VC
38	with	with	B-PP	IN	O	37	VMOD
39	doses	dose	B-NP	NNS	O	38	PMOD
40	lower	low	B-ADJP	JJR	O	39	NMOD
41	than	than	B-PP	IN	O	40	AMOD
42	those	those	B-NP	DT	O	41	PMOD
43	found	find	B-VP	VBN	O	42	NMOD
44	to	to	I-VP	TO	O	45	VMOD
45	be	be	I-VP	VB	O	43	VMOD
46	efficacious	efficacious	B-ADJP	JJ	O	45	PRD
47	in	in	B-PP	IN	O	46	AMOD
48	trials	trial	B-NP	NNS	O	47	PMOD
49	,	,	O	,	O	46	P
50	primarily	primarily	B-ADVP	RB	O	51	PMOD
51	because	because	B-PP	IN	O	46	AMOD
52	of	of	I-PP	IN	O	51	PMOD
53	concerns	concern	B-NP	NNS	O	52	PMOD
54	about	about	B-PP	IN	O	46	AMOD
55	the	the	B-NP	DT	O	58	NMOD
56	safety	safety	I-NP	NN	O	58	NMOD
57	and	and	I-NP	CC	O	58	NMOD
58	tolerability	tolerability	I-NP	NN	O	54	PMOD
59	of	of	B-PP	IN	O	58	NMOD
60	these	these	B-NP	DT	O	61	NMOD
61	agents	agent	I-NP	NNS	O	59	PMOD
62	,	,	O	,	O	58	P
63	especially	especially	B-ADVP	RB	O	64	PMOD
64	at	at	B-PP	IN	O	58	NMOD
65	the	the	B-NP	DT	O	67	NMOD
66	recommended	recommend	I-NP	VBN	O	67	NMOD
67	doses	dose	I-NP	NNS	O	64	PMOD
68	.	.	O	.	O	29	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	examines	examine	B-VP	VBZ	O	0	ROOT
5	the	the	B-NP	DT	O	8	NMOD
6	safety	safety	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	tolerability	tolerability	I-NP	NN	O	4	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	high-	high-	B-NP	JJ	O	9	PMOD
11	compared	compare	B-PP	VBN	O	4	VMOD
12	with	with	B-PP	IN	O	11	PMOD
13	low-dose	low-dose	B-NP	JJ	O	14	NMOD
14	lisinopril	lisinopril	I-NP	NN	O	12	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	CHF	CHF	B-NP	NN	B-protein	15	PMOD
17	.	.	O	.	O	4	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Of	Of	B-PP	IN	O	1	NMOD
4	405	405	B-NP	CD	O	5	NMOD
5	patients	patient	I-NP	NNS	O	3	PMOD
6	not	not	O	RB	O	8	VMOD
7	previously	previously	B-VP	RB	O	8	VMOD
8	receiving	receive	I-VP	VBG	O	1	NMOD
9	an	an	B-NP	DT	O	11	NMOD
10	ACE	ACE	I-NP	NN	O	11	NMOD
11	inhibitor	inhibitor	I-NP	NN	O	8	OBJ
12	,	,	O	,	O	1	P
13	doses	dose	B-VP	VBZ	O	1	NMOD
14	in	in	B-PP	IN	O	13	VMOD
15	only	only	B-NP	RB	O	17	NMOD
16	4.2	4.2	I-NP	CD	O	15	AMOD
17	%	%	I-NP	NN	O	14	PMOD
18	could	could	B-VP	MD	O	13	VMOD
19	not	not	I-VP	RB	O	18	VMOD
20	be	be	I-VP	VB	O	18	VC
21	titrated	titrate	I-VP	VBN	O	20	VC
22	to	to	B-PP	TO	O	21	VMOD
23	the	the	B-NP	DT	O	25	NMOD
24	medium	medium	I-NP	NN	O	25	NMOD
25	doses	dose	I-NP	NNS	O	22	PMOD
26	required	require	B-VP	VBN	O	25	NMOD
27	for	for	B-PP	IN	O	26	VMOD
28	randomization	randomization	B-NP	NN	O	27	PMOD
29	because	because	B-PP	IN	O	26	VMOD
30	of	of	I-PP	IN	O	29	PMOD
31	symptoms	symptom	B-NP	NNS	O	30	PMOD
32	possibly	possibly	B-VP	RB	O	33	VMOD
33	related	relate	I-VP	VBN	O	31	NMOD
34	to	to	B-PP	TO	O	33	AMOD
35	hypotension	hypotension	B-NP	NN	O	34	PMOD
36	(	(	O	(	O	39	DEP
37	2.0	2.0	B-NP	CD	O	38	NMOD
38	%	%	I-NP	NN	O	39	DEP
39	)	)	O	)	O	35	NMOD
40	or	or	O	CC	O	33	DEP
41	because	because	B-PP	IN	O	33	AMOD
42	of	of	I-PP	IN	O	41	PMOD
43	renal	renal	B-NP	JJ	O	44	NMOD
44	dysfunction	dysfunction	I-NP	NN	O	46	NMOD
45	or	or	O	CC	O	46	NMOD
46	hyperkalemia	hyperkalemia	B-NP	NN	O	42	PMOD
47	(	(	O	(	O	50	DEP
48	2.3	2.3	B-NP	CD	O	49	NMOD
49	%	%	I-NP	NN	O	50	DEP
50	)	)	O	)	O	46	NMOD
51	.	.	O	.	O	1	P

1	Subgroups	Subgroup	B-NP	NNS	O	39	NMOD
2	presumed	presume	B-VP	VBN	O	1	NMOD
3	to	to	I-VP	TO	O	4	VMOD
4	be	be	I-VP	VB	O	2	VMOD
5	at	at	B-PP	IN	O	4	PRD
6	higher	high	B-NP	JJR	O	7	NMOD
7	risk	risk	I-NP	NN	O	5	PMOD
8	for	for	B-PP	IN	O	7	NMOD
9	ACE	ACE	B-NP	NN	O	11	NMOD
10	inhibitor	inhibitor	I-NP	NN	O	11	NMOD
11	intolerance	intolerance	I-NP	NN	O	26	NMOD
12	(	(	O	(	O	26	NMOD
13	blood	blood	B-NP	NN	O	14	NMOD
14	pressure	pressure	I-NP	NN	O	19	NMOD
15	,	,	O	,	O	19	P
16	<	<	B-NP	SYM	O	19	NMOD
17	120	120	I-NP	CD	O	18	AMOD
18	mm	mm	I-NP	NN	O	19	NMOD
19	Hg	Hg	I-NP	NN	O	26	NMOD
20	;	;	O	:	O	26	P
21	creatinine	creatinine	B-NP	NN	O	26	NMOD
22	,	,	O	,	O	26	P
23	>	>	B-NP	SYM	O	26	NMOD
24	or	or	O	CC	O	26	NMOD
25	=132.6	=132.6	B-NP	CD	O	26	NMOD
26	micromol/L	micromol/L	I-NP	NN	O	8	PMOD
27	[	[	O	(	O	32	DEP
28	>	>	B-NP	SYM	O	31	NMOD
29	or	or	O	CC	O	31	NMOD
30	=1.5	=1.5	B-NP	CD	O	31	NMOD
31	mg/dL	mg/dL	I-NP	NN	O	32	DEP
32	]	]	O	)	O	1	NMOD
33	;	;	O	:	O	1	P
34	age	age	B-NP	NN	O	39	NMOD
35	,	,	O	,	O	39	P
36	>	>	B-NP	SYM	O	39	NMOD
37	or	or	O	CC	O	39	NMOD
38	=70	=70	B-NP	CD	O	39	NMOD
39	years	year	I-NP	NNS	O	47	SUB
40	;	;	O	:	O	47	P
41	and	and	O	CC	O	42	NMOD
42	patients	patient	B-NP	NNS	O	47	SUB
43	with	with	B-PP	IN	O	42	NMOD
44	diabetes	diabetes	B-NP	NN	O	43	PMOD
45	)	)	O	)	O	42	NMOD
46	generally	generally	B-ADVP	RB	O	47	VMOD
47	tolerated	tolerate	B-VP	VBD	O	0	ROOT
48	the	the	B-NP	DT	O	50	NMOD
49	high-dose	high-dose	I-NP	JJ	O	50	NMOD
50	strategy	strategy	I-NP	NN	O	47	OBJ
51	.	.	O	.	O	47	P

1	Cocaine	Cocaine	B-NP	NN	O	7	NMOD
2	,	,	O	,	O	7	P
3	ethanol	ethanol	B-NP	NN	O	7	NMOD
4	,	,	O	,	O	7	P
5	and	and	O	CC	O	7	NMOD
6	cocaethylene	cocaethylene	B-NP	NN	O	7	NMOD
7	cardiotoxity	cardiotoxity	I-NP	NN	O	0	ROOT
8	in	in	B-PP	IN	O	7	NMOD
9	an	an	B-NP	DT	O	11	NMOD
10	animal	animal	I-NP	NN	O	11	NMOD
11	model	model	I-NP	NN	O	8	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	cocaine	cocaine	B-NP	NN	O	16	NMOD
14	and	and	I-NP	CC	O	16	NMOD
15	ethanol	ethanol	I-NP	NN	O	16	NMOD
16	abuse	abuse	I-NP	NN	O	12	PMOD
17	.	.	O	.	O	7	P

1	Their	Their	B-NP	PRP$	O	4	NMOD
2	combined	combined	I-NP	JJ	O	4	NMOD
3	cardiac	cardiac	I-NP	JJ	O	4	NMOD
4	toxicity	toxicity	I-NP	NN	O	5	SUB
5	may	may	B-VP	MD	O	18	VMOD
6	be	be	I-VP	VB	O	5	VC
7	due	due	B-ADVP	JJ	O	8	PMOD
8	to	to	B-PP	TO	O	6	PRD
9	independent	independent	B-NP	JJ	O	10	NMOD
10	effects	effect	I-NP	NNS	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	each	each	B-NP	DT	O	13	NMOD
13	drug	drug	I-NP	NN	O	11	PMOD
14	;	;	O	:	O	18	P
15	however	however	B-ADVP	RB	O	18	VMOD
16	,	,	O	,	O	18	P
17	they	they	B-NP	PRP	O	18	SUB
18	may	may	B-VP	MD	O	0	ROOT
19	also	also	I-VP	RB	O	18	VMOD
20	be	be	I-VP	VB	O	18	VC
21	due	due	B-ADJP	JJ	O	20	PRD
22	to	to	B-PP	TO	O	21	AMOD
23	cocaethylene	cocaethylene	B-NP	NN	O	30	NMOD
24	(	(	O	(	O	26	DEP
25	CE	CE	B-NP	NN	O	26	DEP
26	)	)	O	)	O	23	NMOD
27	,	,	O	,	O	30	P
28	a	a	B-NP	DT	O	30	NMOD
29	cocaine	cocaine	I-NP	NN	O	30	NMOD
30	metabolite	metabolite	I-NP	NN	O	22	PMOD
31	formed	form	B-VP	VBN	O	30	NMOD
32	only	only	B-PP	RB	O	33	PMOD
33	in	in	I-PP	IN	O	31	VMOD
34	the	the	B-NP	DT	O	35	NMOD
35	presence	presence	I-NP	NN	O	33	PMOD
36	of	of	B-PP	IN	O	35	NMOD
37	ethanol	ethanol	B-NP	NN	O	36	PMOD
38	.	.	O	.	O	18	P

1	The	The	B-NP	DT	O	2	NMOD
2	purpose	purpose	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	delineate	delineate	I-VP	VB	O	6	PRD
9	the	the	B-NP	DT	O	10	NMOD
10	role	role	I-NP	NN	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	CE	CE	B-NP	NN	O	11	PMOD
13	in	in	B-PP	IN	O	10	NMOD
14	the	the	B-NP	DT	O	16	NMOD
15	combined	combined	I-NP	JJ	O	16	NMOD
16	cardiotoxicity	cardiotoxicity	I-NP	NN	O	13	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	cocaine	cocaine	B-NP	NN	O	20	NMOD
19	and	and	I-NP	CC	O	20	NMOD
20	ethanol	ethanol	I-NP	NN	O	17	PMOD
21	in	in	B-PP	IN	O	10	NMOD
22	a	a	B-NP	DT	O	23	NMOD
23	model	model	I-NP	NN	O	21	PMOD
24	simulating	simulate	B-VP	VBG	O	23	NMOD
25	their	their	B-NP	PRP$	O	26	NMOD
26	abuse	abuse	I-NP	NN	O	24	OBJ
27	.	.	O	.	O	6	P

1	Peak	Peak	B-NP	JJ	O	3	NMOD
2	CE	CE	I-NP	NN	O	3	NMOD
3	levels	level	I-NP	NNS	O	4	SUB
4	were	be	B-VP	VBD	O	0	ROOT
5	associated	associate	I-VP	VBN	O	4	VC
6	with	with	B-PP	IN	O	5	VMOD
7	a	a	B-NP	DT	O	9	NMOD
8	45	45	I-NP	CD	O	9	NMOD
9	%	%	I-NP	NN	O	70	NMOD
10	(	(	O	(	O	34	DEP
11	SD	SD	B-NP	NN	O	14	NMOD
12	+/-	+/-	O	SYM	O	14	NMOD
13	22	22	B-NP	CD	O	14	NMOD
14	%	%	I-NP	NN	O	26	NMOD
15	,	,	O	,	O	26	P
16	95	95	B-NP	CD	O	26	NMOD
17	%	%	I-NP	NN	O	18	NMOD
18	CI	CI	I-NP	NN	O	25	DEP
19	=	=	B-VP	SYM	O	18	NMOD
20	22	22	B-NP	CD	O	21	NMOD
21	%	%	I-NP	NN	O	19	AMOD
22	to	to	B-PP	TO	O	18	NMOD
23	69	69	B-NP	CD	O	24	NMOD
24	%	%	I-NP	NN	O	22	PMOD
25	)	)	O	)	O	16	NMOD
26	decrease	decrease	B-NP	NN	O	34	DEP
27	in	in	B-PP	IN	O	26	NMOD
28	cardiac	cardiac	B-NP	JJ	O	29	NMOD
29	output	output	I-NP	NN	O	27	PMOD
30	(	(	O	(	O	34	DEP
31	p	p	B-NP	NN	O	33	SUB
32	<	<	O	SYM	O	33	P
33	0.05	0.05	B-NP	CD	O	34	DEP
34	)	)	O	)	O	9	NMOD
35	,	,	O	,	O	70	P
36	a	a	B-NP	DT	O	38	NMOD
37	56	56	I-NP	CD	O	38	NMOD
38	%	%	I-NP	NN	O	70	NMOD
39	(	(	O	(	O	65	DEP
40	SD	SD	B-NP	NN	O	43	NMOD
41	+/-	+/-	O	SYM	O	43	NMOD
42	23	23	B-NP	CD	O	43	NMOD
43	%	%	I-NP	NN	O	55	NMOD
44	,	,	O	,	O	55	P
45	95	95	B-NP	CD	O	55	NMOD
46	%	%	I-NP	NN	O	47	NMOD
47	CI	CI	I-NP	NN	O	54	DEP
48	=	=	B-VP	SYM	O	47	NMOD
49	32	32	B-NP	CD	O	48	AMOD
50	%	%	I-NP	NN	O	49	NMOD
51	to	to	I-NP	TO	O	50	VMOD
52	80	80	I-NP	CD	O	53	NMOD
53	%	%	I-NP	NN	O	51	PMOD
54	)	)	O	)	O	45	NMOD
55	decrease	decrease	B-NP	NN	O	65	DEP
56	in	in	B-PP	IN	O	55	NMOD
57	dP/dt	dP/dt	B-NP	NN	O	56	PMOD
58	(	(	O	(	O	60	DEP
59	max	max	B-NP	NN	O	60	DEP
60	)	)	O	)	O	57	NMOD
61	(	(	O	(	O	65	DEP
62	p	p	B-NP	NN	O	65	DEP
63	<	<	B-NP	JJR	O	62	NMOD
64	.006	.006	I-NP	CD	O	63	AMOD
65	)	)	O	)	O	38	NMOD
66	,	,	O	,	O	70	P
67	and	and	O	CC	O	70	NMOD
68	a	a	B-NP	DT	O	70	NMOD
69	23	23	I-NP	CD	O	70	NMOD
70	%	%	I-NP	NN	O	87	NMOD
71	(	(	O	(	O	86	DEP
72	SD	SD	B-NP	NN	O	75	NMOD
73	+/-	+/-	O	SYM	O	75	NMOD
74	15	15	B-NP	CD	O	75	NMOD
75	%	%	I-NP	NN	O	79	NMOD
76	,	,	O	,	O	79	P
77	95	95	B-NP	CD	O	79	NMOD
78	%	%	I-NP	NN	O	79	NMOD
79	CI	CI	I-NP	NN	O	86	DEP
80	=	=	B-VP	SYM	O	79	NMOD
81	7	7	B-NP	CD	O	82	NMOD
82	%	%	I-NP	NN	O	80	AMOD
83	to	to	B-PP	TO	O	79	NMOD
84	49	49	B-NP	CD	O	85	NMOD
85	%	%	I-NP	NN	O	83	PMOD
86	)	)	O	)	O	70	NMOD
87	decrease	decrease	B-NP	NN	O	6	PMOD
88	in	in	B-PP	IN	O	87	NMOD
89	SVO	SVO	B-NP	NN	O	88	PMOD
90	(	(	O	(	O	92	DEP
91	2	2	B-NP	CD	O	92	DEP
92	)	)	O	)	O	89	NMOD
93	(	(	O	(	O	97	DEP
94	p	p	B-NP	NN	O	97	DEP
95	<	<	B-NP	JJR	O	94	NMOD
96	0.025	0.025	I-NP	CD	O	95	AMOD
97	)	)	O	)	O	87	NMOD
98	.	.	O	.	O	4	P

1	Worsening	Worsening	B-NP	NN	O	15	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	Parkinsonism	Parkinsonism	B-NP	NNP	O	2	PMOD
4	after	after	B-PP	IN	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	use	use	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	veralipride	veralipride	B-NP	NN	O	7	PMOD
9	for	for	B-PP	IN	O	6	NMOD
10	treatment	treatment	B-NP	NN	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	menopause	menopause	B-NP	NN	O	11	PMOD
13	:	:	O	:	O	1	P
14	case	case	B-NP	NN	O	15	NMOD
15	report	report	I-NP	NN	O	0	ROOT
16	.	.	O	.	O	15	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	female	female	I-NP	JJ	O	5	NMOD
5	patient	patient	I-NP	NN	O	34	NMOD
6	with	with	B-PP	IN	O	5	NMOD
7	stable	stable	B-NP	JJ	O	9	NMOD
8	Parkinson	Parkinson	I-NP	NNP	O	9	NMOD
9	's	's	B-NP	POS	O	10	NMOD
10	disease	disease	I-NP	NN	O	6	PMOD
11	who	who	B-NP	WP	O	5	NMOD
12	has	have	B-VP	VBZ	O	11	SBAR
13	shown	show	I-VP	VBN	O	12	VC
14	a	a	B-NP	DT	O	16	NMOD
15	marked	marked	I-NP	JJ	O	16	NMOD
16	worsening	worsening	I-NP	NN	O	13	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	her	her	B-NP	PRP$	O	20	NMOD
19	motor	motor	I-NP	NN	O	20	NMOD
20	functions	function	I-NP	NNS	O	17	PMOD
21	following	follow	B-PP	VBG	O	13	VMOD
22	therapy	therapy	B-NP	NN	O	21	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	menopause	menopause	B-NP	NN	O	26	NMOD
25	related	relate	B-VP	VBN	O	26	NMOD
26	symptoms	symptom	B-NP	NNS	O	23	PMOD
27	with	with	B-PP	IN	O	22	NMOD
28	veralipride	veralipride	B-NP	NN	O	27	PMOD
29	,	,	O	,	O	34	P
30	as	as	B-CONJP	RB	O	34	NMOD
31	well	well	I-CONJP	RB	O	30	DEP
32	as	as	I-CONJP	IN	O	30	DEP
33	the	the	B-NP	DT	O	34	NMOD
34	improvement	improvement	I-NP	NN	O	2	OBJ
35	of	of	B-PP	IN	O	34	NMOD
36	her	her	B-NP	PRP$	O	37	NMOD
37	symptoms	symptom	I-NP	NNS	O	35	PMOD
38	back	back	B-ADVP	RB	O	2	VMOD
39	to	to	B-PP	TO	O	38	AMOD
40	baseline	baseline	B-NP	NN	O	39	PMOD
41	after	after	B-PP	IN	O	2	VMOD
42	discontinuation	discontinuation	B-NP	NN	O	41	PMOD
43	of	of	B-PP	IN	O	42	NMOD
44	the	the	B-NP	DT	O	45	NMOD
45	drug	drug	I-NP	NN	O	43	PMOD
46	.	.	O	.	O	2	P

1	Viracept	Viracept	B-NP	JJ	O	3	AMOD
2	and	and	I-NP	CC	O	3	AMOD
3	irregular	irregular	I-NP	JJ	O	5	NMOD
4	heartbeat	heartbeat	I-NP	NN	O	5	NMOD
5	warning	warning	I-NP	NN	O	0	ROOT
6	.	.	O	.	O	5	P

1	A	A	B-NP	DT	O	2	NMOD
2	group	group	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	doctors	doctor	B-NP	NNS	O	3	PMOD
5	in	in	B-PP	IN	O	2	NMOD
6	Boston	Boston	B-NP	NNP	O	5	PMOD
7	warn	warn	B-VP	VBP	O	0	ROOT
8	that	that	B-SBAR	IN	O	7	VMOD
9	the	the	B-NP	DT	O	12	NMOD
10	protease	protease	I-NP	NN	O	12	NMOD
11	inhibitor	inhibitor	I-NP	NN	O	12	NMOD
12	Viracept	Viracept	I-NP	NN	O	13	SUB
13	may	may	B-VP	MD	O	8	SBAR
14	cause	cause	I-VP	VB	O	13	VC
15	an	an	B-NP	DT	O	18	NMOD
16	irregular	irregular	I-NP	JJ	O	18	NMOD
17	heart	heart	I-NP	NN	O	18	NMOD
18	beat	beat	I-NP	NN	O	14	OBJ
19	,	,	O	,	O	13	P
20	known	know	B-VP	VBN	O	13	VMOD
21	as	as	B-PP	IN	O	20	VMOD
22	bradycardia	bradycardia	B-NP	NN	O	21	PMOD
23	,	,	O	,	O	20	P
24	in	in	B-PP	IN	O	20	VMOD
25	people	people	B-NP	NNS	O	24	PMOD
26	with	with	B-PP	IN	O	25	NMOD
27	HIV	HIV	B-NP	NN	O	26	PMOD
28	.	.	O	.	O	7	P

1	Frequency	Frequency	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	appearance	appearance	B-NP	NN	O	2	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	myeloperoxidase-antineutrophil	myeloperoxidase-antineutrophil	B-NP	JJ	B-protein	7	NMOD
6	cytoplasmic	cytoplasmic	I-NP	JJ	I-protein	7	NMOD
7	antibody	antibody	I-NP	NN	I-protein	4	PMOD
8	(	(	O	(	O	10	DEP
9	MPO-ANCA	MPO-ANCA	B-NP	NN	B-protein	10	DEP
10	)	)	O	)	O	7	NMOD
11	in	in	B-PP	IN	O	1	NMOD
12	Graves	Graves	B-NP	NN	O	15	NMOD
13	'	'	B-NP	POS	O	15	NMOD
14	disease	disease	I-NP	NN	O	15	NMOD
15	patients	patient	I-NP	NNS	O	11	PMOD
16	treated	treat	B-VP	VBN	O	15	NMOD
17	with	with	B-PP	IN	O	16	VMOD
18	propylthiouracil	propylthiouracil	B-NP	NN	O	21	NMOD
19	and	and	O	CC	O	21	NMOD
20	the	the	B-NP	DT	O	21	NMOD
21	relationship	relationship	I-NP	NN	O	17	PMOD
22	between	between	B-PP	IN	O	21	NMOD
23	MPO-ANCA	MPO-ANCA	B-NP	NN	B-protein	26	NMOD
24	and	and	O	CC	O	26	NMOD
25	clinical	clinical	B-NP	JJ	O	26	NMOD
26	manifestations	manifestation	I-NP	NNS	O	22	PMOD
27	.	.	O	.	O	1	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	6	NMOD
2	:	:	O	:	O	1	P
3	Myeloperoxidase	Myeloperoxidase	B-NP	NN	B-protein	6	NMOD
4	antineutrophil	antineutrophil	I-NP	NN	I-protein	6	NMOD
5	cytoplasmic	cytoplasmic	I-NP	JJ	I-protein	6	NMOD
6	antibody	antibody	I-NP	NN	I-protein	11	NMOD
7	(	(	O	(	O	11	NMOD
8	MPO-ANCA	MPO-ANCA	B-NP	NN	O	11	NMOD
9	)	)	O	)	O	11	NMOD
10	-positive	-positive	B-NP	JJ	O	11	NMOD
11	vasculitis	vasculitis	I-NP	NN	O	12	SUB
12	has	have	B-VP	VBZ	O	0	ROOT
13	been	be	I-VP	VBN	O	12	VC
14	reported	report	I-VP	VBN	O	13	VC
15	in	in	B-PP	IN	O	14	VMOD
16	patients	patient	B-NP	NNS	O	15	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	Graves	Graves	B-NP	NN	O	20	NMOD
19	'	'	B-NP	POS	O	20	NMOD
20	disease	disease	I-NP	NN	O	17	PMOD
21	who	who	B-NP	WP	O	16	NMOD
22	were	be	B-VP	VBD	O	21	SBAR
23	treated	treat	I-VP	VBN	O	22	VC
24	with	with	B-PP	IN	O	23	VMOD
25	propylthiouracil	propylthiouracil	B-NP	NN	O	24	PMOD
26	(	(	O	(	O	28	DEP
27	PTU	PTU	B-NP	NN	O	28	DEP
28	)	)	O	)	O	25	NMOD
29	.	.	O	.	O	12	P

1	Nevertheless	Nevertheless	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	there	there	B-NP	EX	O	4	SUB
4	have	have	B-VP	VBP	O	0	ROOT
5	been	be	I-VP	VBN	O	4	VC
6	no	no	B-NP	DT	O	7	NMOD
7	studies	study	I-NP	NNS	O	5	OBJ
8	on	on	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	11	NMOD
10	temporal	temporal	I-NP	JJ	O	11	NMOD
11	relationship	relationship	I-NP	NN	O	8	PMOD
12	between	between	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	appearance	appearance	I-NP	NN	O	18	NMOD
15	of	of	B-PP	IN	O	14	NMOD
16	MPO-ANCA	MPO-ANCA	B-NP	NN	B-protein	15	PMOD
17	and	and	I-NP	CC	O	18	NMOD
18	vasculitis	vasculitis	I-NP	NN	O	12	PMOD
19	during	during	B-PP	IN	O	11	NMOD
20	PTU	PTU	B-NP	NN	O	21	NMOD
21	therapy	therapy	I-NP	NN	O	19	PMOD
22	,	,	O	,	O	7	P
23	or	or	O	CC	O	7	NMOD
24	on	on	B-PP	IN	O	23	DEP
25	the	the	B-NP	DT	O	26	NMOD
26	incidence	incidence	I-NP	NN	O	24	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	MPO-ANCA	MPO-ANCA	B-NP	NN	B-protein	27	PMOD
29	in	in	B-PP	IN	O	26	NMOD
30	untreated	untreated	B-NP	JJ	O	34	NMOD
31	Graves	Graves	I-NP	NN	O	34	NMOD
32	'	'	B-NP	POS	O	34	NMOD
33	disease	disease	I-NP	NN	O	34	NMOD
34	patients	patient	I-NP	NNS	O	29	PMOD
35	.	.	O	.	O	4	P

1	PATIENTS	PATIENTS	B-NP	NNS	O	4	VMOD
2	:	:	O	:	O	4	P
3	We	We	B-NP	PRP	O	4	SUB
4	investigated	investigate	B-VP	VBD	O	0	ROOT
5	102	102	B-NP	CD	O	7	NMOD
6	untreated	untreated	I-NP	JJ	O	7	NMOD
7	patients	patient	I-NP	NNS	O	4	OBJ
8	with	with	B-PP	IN	O	7	NMOD
9	hyperthyroidism	hyperthyroidism	B-NP	NN	O	8	PMOD
10	due	due	B-ADJP	JJ	O	7	NMOD
11	to	to	B-PP	TO	O	10	AMOD
12	Graves	Graves	B-NP	NN	O	14	NMOD
13	'	'	B-NP	POS	O	14	NMOD
14	disease	disease	I-NP	NN	O	11	PMOD
15	for	for	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	presence	presence	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	MPO-ANCA	MPO-ANCA	B-NP	NN	B-protein	18	PMOD
20	,	,	O	,	O	4	VMOD
21	and	and	O	CC	O	20	DEP
22	for	for	B-PP	IN	O	21	PMOD
23	the	the	B-NP	DT	O	25	NMOD
24	development	development	I-NP	NN	O	25	NMOD
25	vasculitis	vasculitis	I-NP	NN	O	22	PMOD
26	after	after	B-PP	IN	O	22	PMOD
27	starting	start	B-VP	VBG	O	26	PMOD
28	PTU	PTU	B-NP	NN	O	29	NMOD
29	therapy	therapy	I-NP	NN	O	27	OBJ
30	.	.	O	.	O	4	P

1	In	In	B-PP	IN	O	28	VMOD
2	two	two	B-NP	CD	O	1	PMOD
3	of	of	B-PP	IN	O	2	NMOD
4	them	them	B-NP	PRP	O	3	PMOD
5	,	,	O	,	O	28	P
6	the	the	B-NP	DT	O	8	NMOD
7	MPO-ANCA	MPO-ANCA	I-NP	NN	B-DNA	8	NMOD
8	titres	titre	I-NP	NNS	I-DNA	28	SUB
9	transiently	transiently	B-VP	RB	O	10	VMOD
10	increased	increase	I-VP	VBN	O	8	NMOD
11	to	to	B-PP	TO	O	10	VMOD
12	12.8	12.8	B-NP	CD	O	14	AMOD
13	and	and	I-NP	CC	O	14	AMOD
14	15.0	15.0	I-NP	CD	O	15	NMOD
15	U/ml	U/ml	I-NP	NN	O	11	PMOD
16	,	,	O	,	O	8	P
17	respectively	respectively	B-ADVP	RB	O	8	NMOD
18	,	,	O	,	O	8	P
19	despite	despite	B-PP	IN	O	8	NMOD
20	continued	continue	B-NP	VBN	O	22	NMOD
21	PTU	PTU	I-NP	NN	O	22	NMOD
22	therapy	therapy	I-NP	NN	O	19	PMOD
23	,	,	O	,	O	28	P
24	but	but	O	CC	O	28	VMOD
25	no	no	B-NP	DT	O	27	NMOD
26	vasculitic	vasculitic	I-NP	JJ	O	27	NMOD
27	disorders	disorder	I-NP	NNS	O	28	SUB
28	developed	develop	B-VP	VBD	O	0	ROOT
29	.	.	O	.	O	28	P

1	In	In	B-PP	IN	O	9	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	third	third	I-NP	JJ	O	4	NMOD
4	patient	patient	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	9	P
6	the	the	B-NP	DT	O	8	NMOD
7	MPO-ANCA	MPO-ANCA	I-NP	NN	O	8	NMOD
8	titre	titre	I-NP	NN	O	9	SUB
9	increased	increase	B-VP	VBD	O	28	VMOD
10	to	to	B-PP	TO	O	9	VMOD
11	204	204	B-NP	CD	O	12	NMOD
12	U/ml	U/ml	I-NP	NN	O	10	PMOD
13	and	and	O	CC	O	15	VMOD
14	she	she	B-NP	PRP	O	15	SUB
15	developed	develop	B-VP	VBD	O	9	VMOD
16	a	a	B-NP	DT	O	18	NMOD
17	higher	high	I-NP	JJR	O	18	NMOD
18	fever	fever	I-NP	NN	O	23	NMOD
19	,	,	O	,	O	23	P
20	oral	oral	B-NP	JJ	O	21	NMOD
21	ulcers	ulcer	I-NP	NNS	O	23	NMOD
22	and	and	O	CC	O	23	NMOD
23	polyarthralgia	polyarthralgia	B-NP	NN	O	15	OBJ
24	,	,	O	,	O	28	P
25	but	but	O	CC	O	28	VMOD
26	the	the	B-NP	DT	O	27	NMOD
27	symptoms	symptom	I-NP	NNS	O	28	SUB
28	resolved	resolve	B-VP	VBD	O	40	VMOD
29	2	2	B-NP	CD	O	30	NMOD
30	weeks	week	I-NP	NNS	O	28	OBJ
31	after	after	B-PP	IN	O	28	VMOD
32	stopping	stop	B-VP	VBG	O	31	PMOD
33	PTU	PTU	B-NP	NN	O	34	NMOD
34	therapy	therapy	I-NP	NN	O	32	OBJ
35	,	,	O	,	O	40	P
36	and	and	O	CC	O	40	VMOD
37	the	the	B-NP	DT	O	39	NMOD
38	MPO-ANCA	MPO-ANCA	I-NP	NN	O	39	NMOD
39	titre	titre	I-NP	NN	O	40	SUB
40	decreased	decrease	B-VP	VBD	O	0	ROOT
41	to	to	B-PP	TO	O	40	VMOD
42	20.7	20.7	B-NP	CD	O	43	NMOD
43	U/ml	U/ml	I-NP	NN	O	41	PMOD
44	by	by	B-PP	IN	O	40	VMOD
45	4	4	B-NP	CD	O	46	NMOD
46	months	month	I-NP	NNS	O	44	PMOD
47	after	after	B-PP	IN	O	40	VMOD
48	discontinuing	discontinue	B-VP	VBG	O	47	PMOD
49	PTU	PTU	B-NP	NN	O	48	OBJ
50	.	.	O	.	O	40	P

1	Prevalence	Prevalence	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	heart	heart	B-NP	NN	O	4	NMOD
4	disease	disease	I-NP	NN	O	2	PMOD
5	in	in	B-PP	IN	O	1	NMOD
6	asymptomatic	asymptomatic	B-NP	JJ	O	9	NMOD
7	chronic	chronic	I-NP	JJ	O	9	NMOD
8	cocaine	cocaine	I-NP	NN	O	9	NMOD
9	users	user	I-NP	NNS	O	5	PMOD
10	.	.	O	.	O	1	P

1	To	To	B-VP	TO	O	2	VMOD
2	determine	determine	I-VP	VB	O	23	VMOD
3	the	the	B-NP	DT	O	4	NMOD
4	prevalence	prevalence	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	heart	heart	B-NP	NN	O	7	NMOD
7	disease	disease	I-NP	NN	O	5	PMOD
8	in	in	B-PP	IN	O	4	NMOD
9	outpatient	outpatient	B-NP	NN	O	14	NMOD
10	young	young	I-NP	JJ	O	14	NMOD
11	asymptomatic	asymptomatic	I-NP	JJ	O	14	NMOD
12	chronic	chronic	I-NP	JJ	O	14	NMOD
13	cocaine	cocaine	I-NP	NN	O	14	NMOD
14	users	user	I-NP	NNS	O	8	PMOD
15	,	,	O	,	O	23	P
16	35	35	B-NP	CD	O	18	NMOD
17	cocaine	cocaine	I-NP	NN	O	18	NMOD
18	users	user	I-NP	NNS	O	22	NMOD
19	and	and	O	CC	O	22	NMOD
20	32	32	B-NP	CD	O	22	NMOD
21	age-matched	age-matched	I-NP	JJ	O	22	NMOD
22	controls	control	I-NP	NNS	O	23	SUB
23	underwent	undergo	B-VP	VBD	O	0	ROOT
24	resting	rest	I-VP	VBG	O	23	VC
25	and	and	O	CC	O	33	NMOD
26	exercise	exercise	B-NP	NN	O	27	NMOD
27	electrocardiography	electrocardiography	I-NP	NN	O	33	NMOD
28	(	(	O	(	O	30	DEP
29	ECG	ECG	B-NP	NN	B-protein	30	DEP
30	)	)	O	)	O	27	NMOD
31	and	and	O	CC	O	33	NMOD
32	Doppler	Doppler	B-NP	NN	O	33	NMOD
33	echocardiography	echocardiography	I-NP	NN	O	24	OBJ
34	.	.	O	.	O	23	P

1	The	The	B-NP	DT	O	3	NMOD
2	cardioprotective	cardioprotective	I-NP	JJ	O	3	NMOD
3	effect	effect	I-NP	NN	O	19	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	7	NMOD
6	ethanol	ethanol	I-NP	NN	O	7	NMOD
7	extract	extract	I-NP	NN	O	4	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	Picrorrhiza	Picrorrhiza	B-NP	NNP	O	11	NMOD
10	kurroa	kurroa	I-NP	NN	O	11	NMOD
11	rhizomes	rhizome	I-NP	NNS	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	roots	root	I-NP	NNS	O	8	PMOD
14	(	(	O	(	O	16	DEP
15	PK	PK	B-NP	NN	B-protein	16	DEP
16	)	)	O	)	O	13	NMOD
17	on	on	B-PP	IN	O	3	NMOD
18	isoproterenol	isoproterenol	B-NP	NN	O	17	PMOD
19	induced	induce	B-VP	VBD	O	0	ROOT
20	myocardial	myocardial	B-NP	JJ	O	21	NMOD
21	infarction	infarction	I-NP	NN	O	19	OBJ
22	in	in	B-PP	IN	O	19	VMOD
23	rats	rat	B-NP	NNS	O	22	PMOD
24	with	with	B-PP	IN	O	19	VMOD
25	respect	respect	B-NP	NN	O	24	PMOD
26	to	to	B-PP	TO	O	25	NMOD
27	lipid	lipid	B-NP	NN	O	28	NMOD
28	metabolism	metabolism	I-NP	NN	O	26	PMOD
29	in	in	B-PP	IN	O	28	NMOD
30	serum	serum	B-NP	NN	O	33	NMOD
31	and	and	I-NP	CC	O	33	NMOD
32	heart	heart	I-NP	NN	O	33	NMOD
33	tissue	tissue	I-NP	NN	O	29	PMOD
34	has	have	B-VP	VBZ	O	19	VMOD
35	been	be	I-VP	VBN	O	34	VC
36	investigated	investigate	I-VP	VBN	O	35	VC
37	.	.	O	.	O	19	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	This	This	B-NP	DT	O	4	NMOD
4	study	study	I-NP	NN	O	5	SUB
5	examined	examine	B-VP	VBD	O	1	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	role	role	I-NP	NN	O	5	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	phase	phase	B-NP	NN	O	12	NMOD
10	2	2	I-NP	CD	O	12	NMOD
11	early	early	I-NP	JJ	O	12	NMOD
12	afterdepolarization	afterdepolarization	I-NP	NN	O	8	PMOD
13	(	(	O	(	O	15	DEP
14	EAD	EAD	B-NP	NN	B-protein	15	DEP
15	)	)	O	)	O	12	NMOD
16	in	in	B-PP	IN	O	5	VMOD
17	producing	produce	B-VP	VBG	O	16	PMOD
18	a	a	B-NP	DT	O	19	NMOD
19	trigger	trigger	I-NP	NN	O	17	OBJ
20	to	to	B-VP	TO	O	21	VMOD
21	initiate	initiate	I-VP	VB	O	19	NMOD
22	torsade	torsade	B-NP	FW	O	24	NMOD
23	de	de	I-NP	FW	O	24	NMOD
24	pointes	pointes	I-NP	FW	O	21	VMOD
25	(	(	O	(	O	27	DEP
26	TdP	TdP	B-NP	NN	O	27	DEP
27	)	)	O	)	O	24	NMOD
28	with	with	B-PP	IN	O	24	PMOD
29	QT	QT	B-NP	NN	O	30	NMOD
30	prolongation	prolongation	I-NP	NN	O	28	PMOD
31	induced	induce	B-VP	VBN	O	30	NMOD
32	by	by	B-PP	IN	O	31	VMOD
33	dl-sotalol	dl-sotalol	B-NP	NN	O	35	NMOD
34	and	and	I-NP	CC	O	35	NMOD
35	azimilide	azimilide	I-NP	NN	O	32	PMOD
36	.	.	O	.	O	1	P

1	METHODS	METHODS	B-NP	NNS	O	3	NMOD
2	AND	AND	I-NP	CC	O	3	NMOD
3	RESULTS	RESULTS	I-NP	NNS	O	0	ROOT
4	:	:	O	:	O	3	P
5	Transmembrane	Transmembrane	B-NP	NN	O	7	NMOD
6	action	action	I-NP	NN	O	7	NMOD
7	potentials	potential	I-NP	NNS	O	15	SUB
8	from	from	B-PP	IN	O	7	NMOD
9	epicardium	epicardium	B-NP	NN	O	14	NMOD
10	,	,	O	,	O	14	P
11	midmyocardium	midmyocardium	B-NP	NN	O	14	NMOD
12	,	,	O	,	O	14	P
13	and	and	O	CC	O	14	NMOD
14	endocardium	endocardium	B-NP	NN	O	8	PMOD
15	were	be	B-VP	VBD	O	3	NMOD
16	recorded	record	I-VP	VBN	O	15	VC
17	simultaneously	simultaneously	B-ADVP	RB	O	16	VMOD
18	,	,	O	,	O	15	P
19	together	together	B-ADVP	RB	O	20	PMOD
20	with	with	B-PP	IN	O	15	VMOD
21	a	a	B-NP	DT	O	23	NMOD
22	transmural	transmural	I-NP	JJ	O	23	NMOD
23	ECG	ECG	I-NP	NN	O	20	PMOD
24	,	,	O	,	O	15	P
25	in	in	B-PP	IN	O	15	VMOD
26	arterially	arterially	B-NP	RB	O	27	AMOD
27	perfused	perfuse	I-NP	VBN	O	30	NMOD
28	canine	canine	I-NP	NN	O	30	NMOD
29	and	and	I-NP	CC	O	30	NMOD
30	rabbit	rabbit	I-NP	NN	O	31	SUB
31	left	leave	B-VP	VBD	O	36	VMOD
32	ventricular	ventricular	B-NP	JJ	O	34	NMOD
33	preparations.	preparations.	I-NP	JJ	O	34	NMOD
34	dl-Sotalol	dl-Sotalol	I-NP	NN	O	31	OBJ
35	preferentially	preferentially	B-ADVP	RB	O	36	VMOD
36	prolonged	prolong	B-VP	VBD	O	25	SBAR
37	action	action	B-NP	NN	O	39	NMOD
38	potential	potential	I-NP	NN	O	39	NMOD
39	duration	duration	I-NP	NN	O	36	OBJ
40	(	(	O	(	O	42	DEP
41	APD	APD	B-NP	NN	O	42	DEP
42	)	)	O	)	O	39	NMOD
43	in	in	B-PP	IN	O	39	NMOD
44	M	M	B-NP	NN	B-cell_line	45	NMOD
45	cells	cell	I-NP	NNS	I-cell_line	43	PMOD
46	dose-dependently	dose-dependently	B-ADVP	RB	O	36	VMOD
47	(	(	O	(	O	52	DEP
48	1	1	B-NP	CD	O	50	AMOD
49	to	to	O	TO	O	50	AMOD
50	100	100	B-NP	CD	O	51	NMOD
51	micromol/L	micromol/L	I-NP	NN	O	52	DEP
52	)	)	O	)	O	46	AMOD
53	,	,	O	,	O	36	P
54	leading	lead	B-VP	VBG	O	36	VMOD
55	to	to	B-PP	TO	O	54	VMOD
56	QT	QT	B-NP	NN	O	57	NMOD
57	prolongation	prolongation	I-NP	NN	O	60	NMOD
58	and	and	O	CC	O	60	NMOD
59	an	an	B-NP	DT	O	60	NMOD
60	increase	increase	I-NP	NN	O	55	PMOD
61	in	in	B-PP	IN	O	60	NMOD
62	TDR	TDR	B-NP	NN	B-protein	61	PMOD
63	.	.	O	.	O	3	P

1	Although	Although	B-SBAR	IN	O	15	VMOD
2	both	both	O	CC	O	5	NMOD
3	dl-sotalol	dl-sotalol	B-NP	NN	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	azimilide	azimilide	I-NP	NN	O	7	SUB
6	rarely	rarely	B-ADVP	RB	O	7	VMOD
7	induced	induce	B-VP	VBD	O	1	SBAR
8	EADs	EAD	B-NP	NNS	B-protein	7	OBJ
9	in	in	B-PP	IN	O	7	VMOD
10	canine	canine	B-NP	JJ	O	12	NMOD
11	left	left	I-NP	JJ	O	12	NMOD
12	ventricles	ventricle	I-NP	NNS	O	9	PMOD
13	,	,	O	,	O	15	P
14	they	they	B-NP	PRP	O	15	SUB
15	produced	produce	B-VP	VBD	O	0	ROOT
16	frequent	frequent	B-NP	JJ	O	17	NMOD
17	EADs	EAD	I-NP	NNS	O	15	OBJ
18	in	in	B-PP	IN	O	15	VMOD
19	rabbits	rabbit	B-NP	NNS	O	18	PMOD
20	,	,	O	,	O	15	P
21	in	in	B-PP	IN	O	15	VMOD
22	which	which	B-NP	WDT	O	21	PMOD
23	more	more	B-NP	RBR	O	24	AMOD
24	pronounced	pronounced	I-NP	JJ	O	26	NMOD
25	QT	QT	I-NP	NN	O	26	NMOD
26	prolongation	prolongation	I-NP	NN	O	27	SUB
27	was	be	B-VP	VBD	O	21	SBAR
28	seen	see	I-VP	VBN	O	27	VC
29	.	.	O	.	O	15	P

1	An	An	B-NP	DT	O	2	NMOD
2	increase	increase	I-NP	NN	O	7	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	TDR	TDR	B-NP	NN	B-protein	3	PMOD
5	by	by	B-PP	IN	O	2	NMOD
6	dl-sotalol	dl-sotalol	B-NP	NN	O	5	PMOD
7	facilitated	facilitate	B-VP	VBD	O	0	ROOT
8	transmural	transmural	B-NP	JJ	O	9	NMOD
9	propagation	propagation	I-NP	NN	O	7	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	EADs	EAD	B-NP	NNS	B-protein	10	PMOD
12	that	that	B-NP	WDT	O	11	NMOD
13	initiated	initiate	B-VP	VBD	O	12	SBAR
14	multiple	multiple	B-NP	JJ	O	15	NMOD
15	episodes	episode	I-NP	NNS	O	13	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	spontaneous	spontaneous	B-NP	JJ	O	18	NMOD
18	TdP	TdP	I-NP	NN	O	16	PMOD
19	in	in	B-PP	IN	O	15	NMOD
20	3	3	B-NP	CD	O	21	AMOD
21	of	of	B-PP	IN	O	25	NMOD
22	6	6	B-NP	CD	O	21	AMOD
23	rabbit	rabbit	I-NP	NN	O	25	NMOD
24	left	left	I-NP	JJ	O	25	NMOD
25	ventricles	ventricle	I-NP	NNS	O	19	PMOD
26	.	.	O	.	O	7	P

1	Prenatal	Prenatal	B-NP	JJ	O	3	NMOD
2	cocaine	cocaine	I-NP	NN	O	3	NMOD
3	exposure	exposure	I-NP	NN	O	7	NMOD
4	and	and	O	CC	O	7	NMOD
5	cranial	cranial	B-NP	JJ	O	7	NMOD
6	sonographic	sonographic	I-NP	JJ	O	7	NMOD
7	findings	finding	I-NP	NNS	O	0	ROOT
8	in	in	B-PP	IN	O	7	NMOD
9	preterm	preterm	B-NP	JJ	O	10	NMOD
10	infants	infant	I-NP	NNS	O	8	PMOD
11	.	.	O	.	O	7	P

1	PURPOSE	PURPOSE	B-NP	NN	O	5	NMOD
2	:	:	O	:	O	1	P
3	Prenatal	Prenatal	B-NP	JJ	O	5	NMOD
4	cocaine	cocaine	I-NP	NN	O	5	NMOD
5	exposure	exposure	I-NP	NN	O	6	SUB
6	has	have	B-VP	VBZ	O	0	ROOT
7	been	be	I-VP	VBN	O	6	VC
8	linked	link	I-VP	VBN	O	7	VC
9	with	with	B-PP	IN	O	8	VMOD
10	subependymal	subependymal	B-NP	JJ	O	11	NMOD
11	hemorrhage	hemorrhage	I-NP	NN	O	14	NMOD
12	and	and	O	CC	O	14	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	formation	formation	I-NP	NN	O	9	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	cysts	cyst	B-NP	NNS	O	15	PMOD
17	that	that	B-NP	WDT	O	16	NMOD
18	are	be	B-VP	VBP	O	17	SBAR
19	detectable	detectable	B-ADJP	JJ	O	18	PRD
20	on	on	B-PP	IN	O	19	AMOD
21	cranial	cranial	B-NP	JJ	O	22	NMOD
22	sonography	sonography	I-NP	NN	O	20	PMOD
23	in	in	B-PP	IN	O	22	NMOD
24	neonates	neonate	B-NP	NNS	O	23	PMOD
25	born	bear	B-VP	VBN	O	24	NMOD
26	at	at	B-PP	IN	O	25	VMOD
27	term	term	B-NP	NN	O	26	PMOD
28	.	.	O	.	O	6	P

1	We	We	B-NP	PRP	O	2	SUB
2	sought	seek	B-VP	VBD	O	0	ROOT
3	to	to	I-VP	TO	O	4	VMOD
4	determine	determine	I-VP	VB	O	2	VMOD
5	if	if	B-SBAR	IN	O	4	VMOD
6	prenatal	prenatal	B-NP	JJ	O	8	NMOD
7	cocaine	cocaine	I-NP	NN	O	8	NMOD
8	exposure	exposure	I-NP	NN	O	9	SUB
9	increases	increase	B-VP	VBZ	O	5	SBAR
10	the	the	B-NP	DT	O	11	NMOD
11	incidence	incidence	I-NP	NN	O	9	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	subependymal	subependymal	B-NP	JJ	O	14	NMOD
14	cysts	cyst	I-NP	NNS	O	12	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	preterm	preterm	B-NP	JJ	O	17	NMOD
17	infants	infant	I-NP	NNS	O	15	PMOD
18	.	.	O	.	O	2	P

1	Infants	Infant	B-NP	NNS	O	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	assigned	assign	I-VP	VBN	O	2	VC
4	to	to	B-PP	TO	O	3	VMOD
5	the	the	B-NP	DT	O	7	NMOD
6	cocaine-exposed	cocaine-exposed	I-NP	JJ	O	7	NMOD
7	group	group	I-NP	NN	O	4	PMOD
8	if	if	B-SBAR	IN	O	20	DEP
9	there	there	B-NP	EX	O	10	SUB
10	was	be	B-VP	VBD	O	8	SBAR
11	a	a	B-NP	DT	O	13	NMOD
12	maternal	maternal	I-NP	JJ	O	13	NMOD
13	history	history	I-NP	NN	O	10	PRD
14	of	of	B-PP	IN	O	13	NMOD
15	cocaine	cocaine	B-NP	NN	O	16	NMOD
16	abuse	abuse	I-NP	NN	O	14	PMOD
17	during	during	B-PP	IN	O	10	VMOD
18	pregnancy	pregnancy	B-NP	NN	O	17	PMOD
19	or	or	O	CC	O	20	DEP
20	if	if	B-SBAR	IN	O	3	VMOD
21	maternal	maternal	B-NP	JJ	O	23	AMOD
22	or	or	I-NP	CC	O	23	AMOD
23	neonatal	neonatal	I-NP	JJ	O	26	NMOD
24	urine	urine	I-NP	NN	O	26	NMOD
25	toxicology	toxicology	I-NP	NN	O	26	NMOD
26	results	result	I-NP	NNS	O	27	SUB
27	were	be	B-VP	VBD	O	20	SBAR
28	positive	positive	B-ADJP	JJ	O	27	PRD
29	at	at	B-PP	IN	O	28	AMOD
30	the	the	B-NP	DT	O	31	NMOD
31	time	time	I-NP	NN	O	29	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	delivery	delivery	B-NP	NN	O	32	PMOD
34	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	incidence	incidence	I-NP	NN	O	12	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	subependymal	subependymal	B-NP	JJ	O	5	NMOD
5	cysts	cyst	I-NP	NNS	O	3	PMOD
6	in	in	B-PP	IN	O	5	NMOD
7	infants	infant	B-NP	NNS	O	6	PMOD
8	exposed	expose	B-VP	VBN	O	7	NMOD
9	to	to	B-PP	TO	O	8	VMOD
10	cocaine	cocaine	B-NP	NN	O	9	PMOD
11	prenatally	prenatally	B-ADVP	RB	O	12	VMOD
12	was	be	B-VP	VBD	O	0	ROOT
13	44	44	B-NP	CD	O	14	NMOD
14	%	%	I-NP	NN	O	12	PRD
15	(	(	O	(	O	19	DEP
16	8	8	B-NP	CD	O	17	AMOD
17	of	of	B-PP	IN	O	19	DEP
18	18	18	B-NP	CD	O	17	AMOD
19	)	)	O	)	O	14	NMOD
20	compared	compare	B-PP	VBN	O	12	VMOD
21	with	with	B-PP	IN	O	20	VMOD
22	8	8	B-NP	CD	O	23	NMOD
23	%	%	I-NP	NN	O	21	PMOD
24	(	(	O	(	O	28	DEP
25	8	8	B-NP	CD	O	26	AMOD
26	of	of	B-PP	IN	O	28	DEP
27	99	99	B-NP	CD	O	26	AMOD
28	)	)	O	)	O	23	NMOD
29	in	in	B-PP	IN	O	23	NMOD
30	the	the	B-NP	DT	O	32	NMOD
31	unexposed	unexposed	I-NP	JJ	O	32	NMOD
32	group	group	I-NP	NN	O	29	PMOD
33	(	(	O	(	O	37	DEP
34	p	p	B-NP	NN	O	37	DEP
35	<	<	O	SYM	O	34	NMOD
36	0.01	0.01	B-NP	CD	O	35	AMOD
37	)	)	O	)	O	12	VMOD
38	.	.	O	.	O	12	P

1	Thalidomide	Thalidomide	B-NP	NN	O	2	NMOD
2	neuropathy	neuropathy	I-NP	NN	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	patients	patient	B-NP	NNS	O	3	PMOD
5	treated	treat	B-VP	VBN	O	4	NMOD
6	for	for	B-PP	IN	O	5	VMOD
7	metastatic	metastatic	B-NP	JJ	O	9	NMOD
8	prostate	prostate	I-NP	NN	O	9	NMOD
9	cancer	cancer	I-NP	NN	O	6	PMOD
10	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	3	SUB
2	prospectively	prospectively	B-ADVP	RB	O	3	VMOD
3	evaluated	evaluate	B-VP	VBD	O	0	ROOT
4	thalidomide	thalidomide	B-NP	NN	O	6	NMOD
5	induced	induced	I-NP	JJ	O	6	NMOD
6	neuropathy	neuropathy	I-NP	NN	O	3	OBJ
7	using	use	B-VP	VBG	O	6	NMOD
8	electrodiagnostic	electrodiagnostic	B-NP	JJ	O	9	NMOD
9	studies	study	I-NP	NNS	O	7	OBJ
10	.	.	O	.	O	3	P

1	Sixty-seven	Sixty-seven	B-NP	CD	O	2	NMOD
2	men	man	I-NP	NNS	O	15	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	metastatic	metastatic	B-NP	JJ	O	7	NMOD
5	androgen-independent	androgen-independent	I-NP	JJ	O	7	NMOD
6	prostate	prostate	I-NP	NN	O	7	NMOD
7	cancer	cancer	I-NP	NN	O	3	PMOD
8	in	in	B-PP	IN	O	2	NMOD
9	an	an	B-NP	DT	O	11	NMOD
10	open-label	open-label	I-NP	JJ	O	11	NMOD
11	trial	trial	I-NP	NN	O	8	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	oral	oral	B-NP	JJ	O	14	NMOD
14	thalidomide	thalidomide	I-NP	NN	O	12	PMOD
15	underwent	undergo	B-VP	VBD	O	0	ROOT
16	neurologic	neurologic	B-NP	JJ	O	17	NMOD
17	examinations	examination	I-NP	NNS	O	21	NMOD
18	and	and	O	CC	O	21	NMOD
19	nerve	nerve	B-NP	NN	O	21	NMOD
20	conduction	conduction	I-NP	NN	O	21	NMOD
21	studies	study	I-NP	NNS	O	15	OBJ
22	(	(	O	(	O	24	DEP
23	NCS	NCS	B-NP	NNS	B-cell_type	24	DEP
24	)	)	O	)	O	21	NMOD
25	prior	prior	B-ADJP	JJ	O	15	VMOD
26	to	to	B-PP	TO	O	25	AMOD
27	and	and	B-PP	CC	O	26	PMOD
28	at	at	I-PP	IN	O	30	NMOD
29	3-month	3-month	B-NP	JJ	O	30	NMOD
30	intervals	interval	I-NP	NNS	O	26	PMOD
31	during	during	B-PP	IN	O	30	NMOD
32	treatment	treatment	B-NP	NN	O	31	PMOD
33	.	.	O	.	O	15	P

1	Neuropathy	Neuropathy	B-NP	NN	O	2	SUB
2	may	may	B-VP	MD	O	0	ROOT
3	thus	thus	I-VP	RB	O	2	VMOD
4	be	be	I-VP	VB	O	2	VC
5	a	a	B-NP	DT	O	7	NMOD
6	common	common	I-NP	JJ	O	7	NMOD
7	complication	complication	I-NP	NN	O	4	PRD
8	of	of	B-PP	IN	O	7	NMOD
9	thalidomide	thalidomide	B-NP	NN	O	8	PMOD
10	in	in	B-PP	IN	O	7	NMOD
11	older	old	B-NP	JJR	O	12	NMOD
12	patients	patient	I-NP	NNS	O	10	PMOD
13	.	.	O	.	O	2	P

1	Overexpression	Overexpression	B-NP	NN	O	5	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	copper/zinc-superoxide	copper/zinc-superoxide	B-NP	NN	B-protein	4	NMOD
4	dismutase	dismutase	I-NP	NN	I-protein	2	PMOD
5	protects	protect	B-VP	VBZ	O	0	ROOT
6	from	from	B-PP	IN	O	5	VMOD
7	kanamycin	kanamycin	B-NP	NN	O	6	PMOD
8	induced	induce	B-VP	VBD	O	5	VMOD
9	hearing	hearing	B-NP	NN	O	10	NMOD
10	loss	loss	I-NP	NN	O	8	OBJ
11	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	2	NMOD
2	participation	participation	I-NP	NN	O	11	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	reactive	reactive	B-NP	JJ	O	6	NMOD
5	oxygen	oxygen	I-NP	NN	O	6	NMOD
6	species	specie	I-NP	NNS	O	3	PMOD
7	in	in	B-PP	IN	O	2	NMOD
8	aminoglycoside	aminoglycoside	B-NP	NN	O	10	NMOD
9	induced	induced	I-NP	JJ	O	10	NMOD
10	ototoxicity	ototoxicity	I-NP	NN	O	7	PMOD
11	has	have	B-VP	VBZ	O	0	ROOT
12	been	be	I-VP	VBN	O	11	VC
13	deduced	deduce	I-VP	VBN	O	12	VC
14	from	from	B-PP	IN	O	13	VMOD
15	observations	observation	B-NP	NNS	O	14	PMOD
16	that	that	B-SBAR	IN	O	28	DEP
17	aminoglycoside-iron	aminoglycoside-iron	B-NP	NN	B-protein	18	NMOD
18	complexes	complex	I-NP	NNS	I-protein	19	SUB
19	catalyze	catalyze	B-VP	VBP	O	16	SBAR
20	the	the	B-NP	DT	O	21	NMOD
21	formation	formation	I-NP	NN	O	19	OBJ
22	of	of	B-PP	IN	O	21	NMOD
23	superoxide	superoxide	B-NP	NN	O	24	NMOD
24	radicals	radical	I-NP	NNS	O	22	PMOD
25	in	in	B-ADVP	FW	O	19	VMOD
26	vitro	vitro	I-ADVP	FW	O	25	AMOD
27	and	and	O	CC	O	28	DEP
28	that	that	B-SBAR	IN	O	15	NMOD
29	antioxidants	antioxidant	B-NP	NNS	O	30	SUB
30	attenuate	attenuate	B-VP	VBP	O	28	SBAR
31	ototoxicity	ototoxicity	B-NP	NN	O	30	OBJ
32	in	in	B-ADVP	FW	O	30	VMOD
33	vivo	vivo	I-ADVP	FW	O	32	AMOD
34	.	.	O	.	O	11	P

1	We	We	B-NP	PRP	O	3	SUB
2	therefore	therefore	B-ADVP	RB	O	3	VMOD
3	hypothesized	hypothesize	B-VP	VBD	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	overexpression	overexpression	B-NP	NN	O	12	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	Cu/Zn-superoxide	Cu/Zn-superoxide	B-NP	NN	B-protein	8	NMOD
8	dismutase	dismutase	I-NP	NN	I-protein	6	PMOD
9	(	(	O	(	O	11	DEP
10	h-SOD1	h-SOD1	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	should	should	B-VP	MD	O	4	SBAR
13	protect	protect	I-VP	VB	O	12	VC
14	transgenic	transgenic	B-NP	JJ	O	15	NMOD
15	mice	mouse	I-NP	NNS	O	13	OBJ
16	from	from	B-PP	IN	O	13	VMOD
17	ototoxicity	ototoxicity	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	3	P

1	Prednisone	Prednisone	B-NP	NN	O	2	SUB
2	induces	induce	B-VP	VBZ	O	0	ROOT
3	anxiety	anxiety	B-NP	NN	O	7	NMOD
4	and	and	O	CC	O	7	NMOD
5	glial	glial	B-NP	JJ	O	7	NMOD
6	cerebral	cerebral	I-NP	JJ	O	7	NMOD
7	changes	change	I-NP	NNS	O	2	OBJ
8	in	in	B-PP	IN	O	2	VMOD
9	rats	rat	B-NP	NNS	O	8	PMOD
10	.	.	O	.	O	2	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	assess	assess	I-VP	VB	O	1	NMOD
5	whether	whether	B-SBAR	IN	O	4	VMOD
6	prednisone	prednisone	B-NP	NN	O	10	SUB
7	(	(	O	(	O	9	DEP
8	PDN	PDN	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	produces	produce	B-VP	VBZ	O	5	SBAR
11	anxiety	anxiety	B-NP	NN	O	15	NMOD
12	and/or	and/or	O	CC	O	15	NMOD
13	cerebral	cerebral	B-NP	JJ	O	15	NMOD
14	glial	glial	I-NP	JJ	O	15	NMOD
15	changes	change	I-NP	NNS	O	10	OBJ
16	in	in	B-PP	IN	O	10	VMOD
17	rats	rat	B-NP	NNS	O	16	PMOD
18	.	.	O	.	O	4	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Anxiety	Anxiety	B-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	1	NMOD
5	documented	document	I-VP	VBN	O	4	VC
6	in	in	B-PP	IN	O	5	VMOD
7	both	both	B-NP	DT	O	8	NMOD
8	groups	group	I-NP	NNS	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	PDN	PDN	B-NP	NN	O	12	NMOD
11	treated	treat	B-NP	VBN	O	12	NMOD
12	rats	rat	I-NP	NNS	O	9	PMOD
13	compared	compare	B-PP	VBN	O	5	VMOD
14	with	with	B-PP	IN	O	13	PMOD
15	controls	control	B-NP	NNS	O	14	PMOD
16	.	.	O	.	O	1	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Subacute	Subacute	B-NP	JJ	O	4	NMOD
4	exposure	exposure	I-NP	NN	O	7	SUB
5	to	to	B-PP	TO	O	4	NMOD
6	PDN	PDN	B-NP	NN	B-protein	5	PMOD
7	induced	induce	B-VP	VBD	O	1	NMOD
8	anxiety	anxiety	B-NP	NN	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	reactivity	reactivity	I-NP	NN	O	7	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	microglia	microglia	B-NP	NNS	B-cell_type	11	PMOD
13	.	.	O	.	O	7	P

1	Phase	Phase	B-NP	NN	O	3	NMOD
2	II	II	I-NP	CD	O	3	NMOD
3	study	study	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	carboplatin	carboplatin	B-NP	NN	B-protein	8	NMOD
6	and	and	O	CC	O	8	NMOD
7	liposomal	liposomal	B-NP	JJ	O	8	NMOD
8	doxorubicin	doxorubicin	I-NP	NN	O	4	PMOD
9	in	in	B-PP	IN	O	3	NMOD
10	patients	patient	B-NP	NNS	O	9	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	recurrent	recurrent	B-NP	JJ	O	15	NMOD
13	squamous	squamous	I-NP	JJ	O	15	NMOD
14	cell	cell	I-NP	NN	O	15	NMOD
15	carcinoma	carcinoma	I-NP	NN	O	11	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	18	NMOD
18	cervix	cervix	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	3	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	activity	activity	I-NP	NN	O	13	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	combination	combination	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	carboplatin	carboplatin	B-NP	NN	B-protein	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	liposomal	liposomal	B-NP	JJ	O	12	NMOD
12	doxorubicin	doxorubicin	I-NP	NN	O	8	PMOD
13	was	be	B-VP	VBD	O	1	NMOD
14	tested	test	I-VP	VBN	O	13	VC
15	in	in	B-PP	IN	O	14	VMOD
16	a	a	B-NP	DT	O	19	NMOD
17	Phase	Phase	I-NP	NN	O	19	NMOD
18	II	II	I-NP	CD	O	19	NMOD
19	study	study	I-NP	NN	O	15	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	patients	patient	B-NP	NNS	O	20	PMOD
22	with	with	B-PP	IN	O	21	NMOD
23	recurrent	recurrent	B-NP	JJ	O	25	NMOD
24	cervical	cervical	I-NP	JJ	O	25	NMOD
25	carcinoma	carcinoma	I-NP	NN	O	22	PMOD
26	.	.	O	.	O	13	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	combination	combination	I-NP	NN	O	1	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	carboplatin	carboplatin	B-NP	NN	B-protein	8	NMOD
7	(	(	O	(	O	8	NMOD
8	area	area	B-NP	NN	O	5	PMOD
9	under	under	B-PP	IN	O	4	NMOD
10	the	the	B-NP	DT	O	12	NMOD
11	concentration	concentration	I-NP	NN	O	12	NMOD
12	curve	curve	I-NP	NN	O	17	NMOD
13	[	[	O	(	O	15	DEP
14	AUC	AUC	B-NP	NN	O	15	DEP
15	]	]	O	)	O	12	NMOD
16	,	,	O	,	O	17	P
17	5	5	B-NP	CD	O	21	NMOD
18	)	)	O	)	O	17	NMOD
19	and	and	O	CC	O	21	NMOD
20	liposomal	liposomal	B-NP	JJ	O	21	NMOD
21	doxorubicin	doxorubicin	I-NP	NN	O	9	PMOD
22	(	(	O	(	O	4	NMOD
23	Doxil	Doxil	B-NP	NNP	O	26	NMOD
24	;	;	O	:	O	23	P
25	starting	start	B-NP	VBG	O	26	NMOD
26	dose	dose	I-NP	NN	O	34	SUB
27	,	,	O	,	O	34	P
28	40	40	B-NP	CD	O	29	NMOD
29	mg/m	mg/m	I-NP	NN	O	34	SUB
30	(	(	O	(	O	32	DEP
31	2	2	B-NP	CD	O	32	DEP
32	)	)	O	)	O	29	NMOD
33	)	)	O	)	O	29	NMOD
34	was	be	B-VP	VBD	O	22	SBAR
35	administered	administer	I-VP	VBN	O	34	VC
36	intravenously	intravenously	B-NP	RB	O	39	NMOD
37	every	every	I-NP	DT	O	39	NMOD
38	28	28	I-NP	CD	O	39	NMOD
39	days	day	I-NP	NNS	O	35	OBJ
40	to	to	B-PP	TO	O	35	VMOD
41	37	37	B-NP	CD	O	42	NMOD
42	patients	patient	I-NP	NNS	O	40	PMOD
43	with	with	B-PP	IN	O	42	NMOD
44	recurrent	recurrent	B-NP	JJ	O	48	NMOD
45	squamous	squamous	I-NP	JJ	O	48	NMOD
46	cell	cell	I-NP	NN	O	48	NMOD
47	cervical	cervical	I-NP	JJ	O	48	NMOD
48	carcinoma	carcinoma	I-NP	NN	O	43	PMOD
49	to	to	B-VP	TO	O	50	VMOD
50	determine	determine	I-VP	VB	O	42	NMOD
51	antitumor	antitumor	B-NP	JJ	O	52	NMOD
52	activity	activity	I-NP	NN	O	55	NMOD
53	and	and	I-NP	CC	O	55	NMOD
54	toxicity	toxicity	I-NP	NN	O	55	NMOD
55	profile	profile	I-NP	NN	O	50	OBJ
56	.	.	O	.	O	1	P

1	Cotrimoxazole	Cotrimoxazole	B-NP	NN	O	6	NMOD
2	,	,	O	,	O	6	P
3	metronidazole	metronidazole	B-NP	NN	O	6	NMOD
4	,	,	O	,	O	6	P
5	and	and	O	CC	O	6	NMOD
6	erythromycin	erythromycin	B-NP	NN	O	7	SUB
7	were	be	B-VP	VBD	O	0	ROOT
8	involved	involve	I-VP	VBN	O	7	VC
9	in	in	B-PP	IN	O	8	VMOD
10	15	15	B-NP	CD	O	11	SUB
11	reported	report	B-VP	VBD	O	13	NMOD
12	manic	manic	B-NP	JJ	O	13	NMOD
13	episodes	episode	I-NP	NNS	O	9	PMOD
14	.	.	O	.	O	7	P

1	Cases	Case	B-NP	NNS	O	6	SUB
2	reported	report	B-VP	VBN	O	1	NMOD
3	by	by	B-PP	IN	O	2	VMOD
4	the	the	B-NP	DT	O	5	NMOD
5	FDA	FDA	I-NP	NNP	O	3	PMOD
6	showed	show	B-VP	VBD	O	0	ROOT
7	clarithromycin	clarithromycin	B-NP	NN	O	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	ciprofloxacin	ciprofloxacin	I-NP	NN	O	6	OBJ
10	to	to	B-VP	TO	O	11	VMOD
11	be	be	I-VP	VB	O	9	NMOD
12	the	the	B-NP	DT	O	11	PRD
13	most	most	I-NP	RBS	O	14	AMOD
14	frequently	frequently	I-NP	RB	O	12	AMOD
15	associated	associate	I-NP	VBN	O	14	NMOD
16	with	with	B-PP	IN	O	15	VMOD
17	the	the	B-NP	DT	O	18	NMOD
18	development	development	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	mania	mania	B-NP	NN	O	19	PMOD
21	.	.	O	.	O	6	P

1	Levodopa	Levodopa	B-NP	NNP	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	ocular	ocular	B-NP	JJ	O	4	NMOD
4	dyskinesias	dyskinesia	I-NP	NNS	O	2	OBJ
5	in	in	B-PP	IN	O	2	VMOD
6	Parkinson	Parkinson	B-NP	NNP	O	8	NMOD
7	's	's	B-NP	POS	O	8	NMOD
8	disease	disease	I-NP	NN	O	5	PMOD
9	.	.	O	.	O	2	P

1	Levodopa	Levodopa	B-NP	NNP	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	ocular	ocular	B-NP	JJ	O	4	NMOD
4	dyskinesias	dyskinesia	I-NP	NNS	O	2	OBJ
5	are	be	B-VP	VBP	O	2	VMOD
6	very	very	B-ADJP	RB	O	7	AMOD
7	uncommon	uncommon	I-ADJP	JJ	O	5	PRD
8	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	2	NMOD
2	comparison	comparison	I-NP	NN	O	21	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	glyceryl	glyceryl	B-NP	NN	O	5	NMOD
5	trinitrate	trinitrate	I-NP	NN	O	3	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	diclofenac	diclofenac	B-NP	NN	O	6	PMOD
8	for	for	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	treatment	treatment	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	primary	primary	B-NP	JJ	O	13	NMOD
13	dysmenorrhea	dysmenorrhea	I-NP	NN	O	11	PMOD
14	:	:	O	:	O	2	P
15	an	an	B-NP	DT	O	21	NMOD
16	open	open	I-NP	JJ	O	20	AMOD
17	,	,	I-NP	,	O	20	P
18	randomized	randomize	I-NP	VBN	O	20	AMOD
19	,	,	I-NP	,	O	20	P
20	cross-over	cross-over	I-NP	JJ	O	21	NMOD
21	trial	trial	I-NP	NN	O	0	ROOT
22	.	.	O	.	O	21	P

1	Primary	Primary	B-NP	JJ	O	2	NMOD
2	dysmenorrhea	dysmenorrhea	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	22	VMOD
4	a	a	B-NP	DT	O	5	NMOD
5	syndrome	syndrome	I-NP	NN	O	3	PRD
6	characterized	characterize	B-VP	VBN	O	5	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	painful	painful	B-NP	JJ	O	10	NMOD
9	uterine	uterine	I-NP	JJ	O	10	NMOD
10	contractility	contractility	I-NP	NN	O	7	PMOD
11	caused	cause	B-VP	VBN	O	10	NMOD
12	by	by	B-PP	IN	O	11	VMOD
13	a	a	B-NP	DT	O	14	NMOD
14	hypersecretion	hypersecretion	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	endometrial	endometrial	B-NP	JJ	O	17	NMOD
17	prostaglandins	prostaglandin	I-NP	NNS	O	15	PMOD
18	;	;	O	:	O	22	P
19	non-steroidal	non-steroidal	B-NP	JJ	O	21	NMOD
20	anti-inflammatory	anti-inflammatory	I-NP	JJ	O	21	NMOD
21	drugs	drug	I-NP	NNS	O	22	SUB
22	are	be	B-VP	VBP	O	0	ROOT
23	the	the	B-NP	DT	O	25	NMOD
24	first	first	I-NP	JJ	O	25	NMOD
25	choice	choice	I-NP	NN	O	22	PRD
26	for	for	B-PP	IN	O	25	NMOD
27	its	its	B-NP	PRP$	O	28	NMOD
28	treatment	treatment	I-NP	NN	O	26	PMOD
29	.	.	O	.	O	22	P

1	The	The	B-NP	DT	O	2	NMOD
2	aim	aim	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	present	present	I-NP	JJ	O	6	NMOD
6	study	study	I-NP	NN	O	3	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	to	to	B-VP	TO	O	9	VMOD
9	determine	determine	I-VP	VB	O	7	PRD
10	the	the	B-NP	DT	O	11	NMOD
11	efficacy	efficacy	I-NP	NN	O	9	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	glyceryl	glyceryl	B-NP	NN	O	14	NMOD
14	trinitrate	trinitrate	I-NP	NN	O	21	NMOD
15	(	(	O	(	O	17	DEP
16	GTN	GTN	B-NP	NN	B-protein	17	DEP
17	)	)	O	)	O	14	NMOD
18	,	,	O	,	O	21	P
19	an	an	B-NP	DT	O	21	NMOD
20	NO	NO	I-NP	NN	O	21	NMOD
21	donor	donor	I-NP	NN	O	12	PMOD
22	,	,	O	,	O	21	P
23	in	in	B-PP	IN	O	21	NMOD
24	the	the	B-NP	DT	O	25	NMOD
25	resolution	resolution	I-NP	NN	O	23	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	primary	primary	B-NP	JJ	O	28	NMOD
28	dysmenorrhea	dysmenorrhea	I-NP	NN	O	26	PMOD
29	in	in	B-PP	IN	O	11	NMOD
30	comparison	comparison	B-NP	NN	O	29	PMOD
31	with	with	B-PP	IN	O	30	NMOD
32	diclofenac	diclofenac	B-NP	NN	O	31	PMOD
33	(	(	O	(	O	35	DEP
34	DCF	DCF	B-NP	NN	B-protein	35	DEP
35	)	)	O	)	O	32	NMOD
36	.	.	O	.	O	7	P

1	However	However	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	DCF	DCF	B-NP	NN	B-protein	4	SUB
4	continued	continue	B-VP	VBD	O	16	VMOD
5	to	to	I-VP	TO	O	6	VMOD
6	be	be	I-VP	VB	O	4	VMOD
7	effective	effective	B-ADJP	JJ	O	6	PRD
8	in	in	B-PP	IN	O	7	AMOD
9	reducing	reduce	B-VP	VBG	O	8	PMOD
10	pelvic	pelvic	B-NP	JJ	O	11	NMOD
11	pain	pain	I-NP	NN	O	9	OBJ
12	for	for	B-PP	IN	O	11	NMOD
13	two	two	B-NP	CD	O	14	NMOD
14	hours	hour	I-NP	NNS	O	12	PMOD
15	,	,	O	,	O	16	P
16	whereas	whereas	O	IN	O	0	ROOT
17	GTN	GTN	B-NP	NN	B-DNA	18	NMOD
18	scores	score	I-NP	NNS	I-DNA	19	SUB
19	remained	remain	B-VP	VBD	O	16	VMOD
20	more	more	B-ADVP	RBR	O	23	AMOD
21	or	or	I-ADVP	CC	O	20	AMOD
22	less	less	B-ADJP	RBR	O	23	AMOD
23	stable	stable	I-ADJP	JJ	O	19	PRD
24	after	after	B-PP	IN	O	19	VMOD
25	30	30	B-NP	CD	O	26	NMOD
26	min	min	I-NP	NN	O	24	PMOD
27	and	and	O	CC	O	19	VMOD
28	significantly	significantly	B-ADJP	RB	O	29	AMOD
29	higher	high	I-ADJP	JJR	O	19	VMOD
30	than	than	B-PP	IN	O	29	AMOD
31	those	those	B-NP	DT	O	30	PMOD
32	for	for	B-PP	IN	O	31	NMOD
33	DFC	DFC	B-NP	NN	O	32	PMOD
34	(	(	O	(	O	70	DEP
35	after	after	B-PP	IN	O	69	NMOD
36	one	one	B-NP	CD	O	37	NMOD
37	hour	hour	I-NP	NN	O	35	PMOD
38	:	:	O	:	O	35	P
39	GTN	GTN	B-NP	NN	B-protein	43	NMOD
40	,	,	O	,	O	43	P
41	-12.8	-12.8	B-NP	CD	O	43	AMOD
42	+/-	+/-	I-NP	CC	O	43	AMOD
43	17.9	17.9	I-NP	CD	O	69	NMOD
44	;	;	O	:	O	69	P
45	DFC	DFC	B-NP	NN	O	49	NMOD
46	,	,	O	,	O	49	P
47	-18.9	-18.9	B-NP	CD	O	49	NMOD
48	+/-	+/-	I-NP	CC	O	49	NMOD
49	16.6	16.6	I-NP	CD	O	59	NMOD
50	and	and	O	CC	O	49	NMOD
51	after	after	B-PP	IN	O	50	PMOD
52	two	two	B-NP	CD	O	53	NMOD
53	hours	hour	I-NP	NNS	O	51	PMOD
54	:	:	O	:	O	59	P
55	GTN	GTN	B-NP	NN	B-protein	59	SUB
56	,	,	O	,	O	59	P
57	-23.7	-23.7	B-NP	CD	O	59	AMOD
58	+/-	+/-	I-NP	CC	O	59	AMOD
59	20.5	20.5	I-NP	CD	O	69	NMOD
60	;	;	O	:	O	69	P
61	DFC	DFC	B-NP	NN	O	69	SUB
62	,	,	O	,	O	69	P
63	-59.7	-59.7	B-NP	CD	O	65	AMOD
64	+/-	+/-	I-NP	SYM	O	65	AMOD
65	17.9	17.9	I-NP	CD	O	69	NMOD
66	,	,	O	,	O	69	P
67	p	p	B-NP	NN	O	69	SUB
68	=	=	B-VP	SYM	O	69	VMOD
69	0.0001	0.0001	B-NP	CD	O	70	DEP
70	)	)	O	)	O	29	AMOD
71	.	.	O	.	O	16	P

1	Headache	Headache	B-NP	PRP	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	significantly	significantly	I-VP	RB	O	2	VMOD
4	increased	increase	I-VP	VBN	O	2	VC
5	by	by	B-PP	IN	O	4	VMOD
6	GTN	GTN	B-NP	NN	B-protein	5	PMOD
7	but	but	B-PP	CC	O	5	PMOD
8	not	not	B-PP	RB	O	9	PMOD
9	by	by	I-PP	IN	O	5	PMOD
10	DCF	DCF	B-NP	NN	B-protein	9	PMOD
11	.	.	O	.	O	2	P

1	Eight	Eight	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	3	SUB
3	stopped	stop	B-VP	VBD	O	0	ROOT
4	using	use	I-VP	VBG	O	3	VMOD
5	GTN	GTN	B-NP	NN	B-protein	4	OBJ
6	because	because	B-SBAR	IN	O	4	VMOD
7	headache	headache	B-NP	NN	O	14	SUB
8	--	--	O	:	O	7	P
9	attributed	attribute	B-VP	VBN	O	7	NMOD
10	to	to	B-PP	TO	O	9	VMOD
11	its	its	B-NP	PRP$	O	12	NMOD
12	use	use	I-NP	NN	O	10	PMOD
13	--	--	O	:	O	7	P
14	became	become	B-VP	VBD	O	6	SBAR
15	intolerable	intolerable	B-ADJP	JJ	O	14	PRD
16	.	.	O	.	O	3	P

1	Temocapril	Temocapril	B-NP	NNP	O	7	NMOD
2	,	,	O	,	O	7	P
3	a	a	B-NP	DT	O	7	NMOD
4	long-acting	long-acting	I-NP	JJ	O	7	NMOD
5	non-SH	non-SH	I-NP	JJ	O	7	NMOD
6	group	group	I-NP	NN	O	7	NMOD
7	angiotensin	angiotensin	I-NP	NN	O	12	SUB
8	converting	convert	B-VP	VBG	O	7	NMOD
9	enzyme	enzyme	B-NP	NN	O	10	NMOD
10	inhibitor	inhibitor	I-NP	NN	O	8	OBJ
11	,	,	O	,	O	7	P
12	modulates	modulate	B-VP	VBZ	O	0	ROOT
13	glomerular	glomerular	B-NP	JJ	O	14	NMOD
14	injury	injury	I-NP	NN	O	12	OBJ
15	in	in	B-PP	IN	O	14	NMOD
16	chronic	chronic	B-NP	JJ	O	19	NMOD
17	puromycin	puromycin	I-NP	NN	O	19	NMOD
18	aminonucleoside	aminonucleoside	I-NP	NN	O	19	NMOD
19	nephrosis	nephrosis	I-NP	NN	O	15	PMOD
20	.	.	O	.	O	12	P

1	The	The	B-NP	DT	O	2	NMOD
2	purpose	purpose	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	present	present	I-NP	JJ	O	6	NMOD
6	study	study	I-NP	NN	O	3	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	to	to	B-VP	TO	O	9	VMOD
9	determine	determine	I-VP	VB	O	7	PRD
10	whether	whether	B-SBAR	IN	O	9	VMOD
11	chronic	chronic	B-NP	JJ	O	12	NMOD
12	administration	administration	I-NP	NN	O	22	NMOD
13	of	of	B-PP	IN	O	12	NMOD
14	temocapril	temocapril	B-NP	NN	O	13	PMOD
15	,	,	O	,	O	22	P
16	a	a	B-NP	DT	O	22	NMOD
17	long-acting	long-acting	I-NP	JJ	B-protein	22	NMOD
18	non-SH	non-SH	I-NP	JJ	I-protein	22	NMOD
19	group	group	I-NP	NN	I-protein	22	NMOD
20	angiotensin	angiotensin	I-NP	NN	I-protein	22	NMOD
21	converting	convert	B-VP	VBG	I-protein	22	NMOD
22	enzyme	enzyme	B-NP	NN	I-protein	26	NMOD
23	(	(	O	(	O	25	DEP
24	ACE	ACE	B-NP	NN	O	25	DEP
25	)	)	O	)	O	22	NMOD
26	inhibitor	inhibitor	B-NP	NN	O	31	SUB
27	,	,	O	,	O	26	P
28	reduced	reduce	B-VP	VBN	O	26	NMOD
29	proteinuria	proteinuria	B-NP	NN	O	28	VMOD
30	,	,	O	,	O	26	P
31	inhibited	inhibit	B-VP	VBD	O	10	SBAR
32	glomerular	glomerular	B-NP	JJ	O	33	NMOD
33	hypertrophy	hypertrophy	I-NP	NN	O	31	OBJ
34	and	and	O	CC	O	31	VMOD
35	prevented	prevent	B-VP	VBD	O	31	VMOD
36	glomerulosclerosis	glomerulosclerosis	B-NP	NN	O	35	OBJ
37	in	in	B-PP	IN	O	36	NMOD
38	chronic	chronic	B-NP	JJ	O	40	NMOD
39	puromycin	puromycin	I-NP	NN	O	40	NMOD
40	aminonucleoside	aminonucleoside	I-NP	NN	O	47	NMOD
41	(	(	O	(	O	43	DEP
42	PAN	PAN	B-NP	NN	O	43	DEP
43	)	)	O	)	O	40	NMOD
44	-	-	O	HYPH	O	47	P
45	induced	induce	B-NP	VBN	O	47	NMOD
46	nephrotic	nephrotic	I-NP	JJ	O	47	NMOD
47	rats	rat	I-NP	NNS	O	37	PMOD
48	.	.	O	.	O	7	P

1	Nephrosis	Nephrosis	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	induced	induce	I-VP	VBN	O	2	VC
4	by	by	B-PP	IN	O	3	VMOD
5	injection	injection	B-NP	NN	O	4	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	PAN	PAN	B-NP	NN	B-protein	6	PMOD
8	(	(	O	(	O	12	DEP
9	15mg/100g	15mg/100g	B-NP	NN	O	11	NMOD
10	body	body	I-NP	NN	O	11	NMOD
11	weight	weight	I-NP	NN	O	12	DEP
12	)	)	O	)	O	7	NMOD
13	in	in	B-PP	IN	O	5	NMOD
14	male	male	B-NP	JJ	O	15	NMOD
15	Sprague-Dawley	Sprague-Dawley	I-NP	NNP	O	19	NMOD
16	(	(	O	(	O	19	NMOD
17	SD	SD	B-NP	NNP	O	19	NMOD
18	)	)	O	)	O	19	NMOD
19	rats	rat	B-NP	NNS	O	13	PMOD
20	.	.	O	.	O	2	P

1	Temocapril	Temocapril	B-NP	NNP	O	2	SUB
2	did	do	B-VP	VBD	O	12	VMOD
3	not	not	I-VP	RB	O	2	VMOD
4	attenuate	attenuate	I-VP	VB	O	2	VC
5	proteinuria	proteinuria	B-NP	NN	O	4	OBJ
6	at	at	B-PP	IN	O	5	NMOD
7	8	8	B-NP	CD	O	8	NMOD
8	days	day	I-NP	NNS	O	6	PMOD
9	,	,	O	,	O	12	P
10	but	but	O	CC	O	12	VMOD
11	it	it	B-NP	PRP	O	12	SUB
12	did	do	B-VP	VBD	O	0	ROOT
13	markedly	markedly	B-ADJP	RB	O	14	AMOD
14	lower	low	I-ADJP	JJR	O	12	PRD
15	it	it	B-NP	PRP	O	14	AMOD
16	from	from	B-PP	IN	O	15	NMOD
17	weeks	week	B-NP	NNS	O	16	PMOD
18	4	4	B-NP	CD	O	20	NMOD
19	to	to	B-PP	TO	O	20	NMOD
20	20	20	B-NP	CD	O	17	NMOD
21	.	.	O	.	O	12	P

1	The	The	B-NP	DT	O	3	NMOD
2	glomerulosclerosis	glomerulosclerosis	I-NP	NN	O	3	NMOD
3	index	index	I-NP	NN	O	7	SUB
4	(	(	O	(	O	6	DEP
5	GSI	GSI	B-NP	NN	O	6	DEP
6	)	)	O	)	O	3	NMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	6.21	6.21	B-NP	CD	O	9	NMOD
9	%	%	I-NP	NN	O	16	NMOD
10	at	at	B-PP	IN	O	9	NMOD
11	4	4	B-NP	CD	O	12	NMOD
12	weeks	week	I-NP	NNS	O	10	PMOD
13	and	and	O	CC	O	16	NMOD
14	respectively	respectively	B-NP	RB	O	16	NMOD
15	25.35	25.35	I-NP	CD	O	16	NMOD
16	%	%	I-NP	NN	O	19	NMOD
17	and	and	O	CC	O	19	NMOD
18	30.49	30.49	B-NP	CD	O	19	NMOD
19	%	%	I-NP	NN	O	7	PRD
20	at	at	B-PP	IN	O	19	NMOD
21	14	14	B-NP	CD	O	23	AMOD
22	and	and	I-NP	CC	O	23	AMOD
23	20	20	I-NP	CD	O	24	NMOD
24	weeks	week	I-NP	NNS	O	20	PMOD
25	in	in	B-PP	IN	O	7	VMOD
26	the	the	B-NP	DT	O	28	NMOD
27	PAN	PAN	I-NP	NN	B-protein	28	NMOD
28	group	group	I-NP	NN	I-protein	25	PMOD
29	.	.	O	.	O	7	P

1	Pulmonary	Pulmonary	B-NP	JJ	O	2	NMOD
2	hypertension	hypertension	I-NP	NN	O	0	ROOT
3	after	after	B-PP	IN	O	2	NMOD
4	ibuprofen	ibuprofen	B-NP	NN	O	5	NMOD
5	prophylaxis	prophylaxis	I-NP	NN	O	3	PMOD
6	in	in	B-PP	IN	O	5	NMOD
7	very	very	B-NP	RB	O	8	AMOD
8	preterm	preterm	I-NP	JJ	O	9	NMOD
9	infants	infant	I-NP	NNS	O	6	PMOD
10	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	three	three	B-NP	CD	O	4	NMOD
4	cases	case	I-NP	NNS	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	severe	severe	B-NP	JJ	O	7	NMOD
7	hypoxaemia	hypoxaemia	I-NP	NN	O	5	PMOD
8	after	after	B-PP	IN	O	4	NMOD
9	ibuprofen	ibuprofen	B-NP	NN	O	10	NMOD
10	administration	administration	I-NP	NN	O	8	PMOD
11	during	during	B-PP	IN	O	2	VMOD
12	a	a	B-NP	DT	O	15	NMOD
13	randomised	randomise	I-NP	VBN	O	15	NMOD
14	controlled	control	I-NP	VBN	O	15	NMOD
15	trial	trial	I-NP	NN	O	11	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	prophylactic	prophylactic	B-NP	JJ	O	18	NMOD
18	treatment	treatment	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	patent	patent	B-NP	NN	O	22	NMOD
21	ductus	ductus	I-NP	NN	O	22	NMOD
22	arteriosus	arteriosus	I-NP	NN	O	19	PMOD
23	with	with	B-PP	IN	O	18	NMOD
24	ibuprofen	ibuprofen	B-NP	NN	O	23	PMOD
25	in	in	B-PP	IN	O	15	NMOD
26	premature	premature	B-NP	JJ	O	27	NMOD
27	infants	infant	I-NP	NNS	O	25	PMOD
28	born	bear	B-VP	VBN	O	27	NMOD
29	at	at	B-PP	IN	O	28	VMOD
30	less	less	B-NP	JJR	O	31	AMOD
31	than	than	I-NP	IN	O	33	NMOD
32	28	28	I-NP	CD	O	31	AMOD
33	weeks	week	I-NP	NNS	O	29	PMOD
34	of	of	B-PP	IN	O	33	NMOD
35	gestation	gestation	B-NP	NN	O	34	PMOD
36	.	.	O	.	O	2	P

1	Hypoxaemia	Hypoxaemia	B-NP	NN	O	2	SUB
2	resolved	resolve	B-VP	VBD	O	0	ROOT
3	quickly	quickly	B-ADVP	RB	O	2	VMOD
4	on	on	B-PP	IN	O	2	VMOD
5	inhaled	inhale	B-NP	VBN	O	8	NMOD
6	nitric	nitric	I-NP	JJ	O	8	NMOD
7	oxide	oxide	I-NP	NN	O	8	NMOD
8	therapy	therapy	I-NP	NN	O	4	PMOD
9	.	.	O	.	O	2	P

1	Hyponatremia	Hyponatremia	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	syndrome	syndrome	I-NP	NN	O	16	NMOD
4	of	of	B-PP	IN	O	3	NMOD
5	inappropriate	inappropriate	B-NP	JJ	O	7	NMOD
6	anti-diuretic	anti-diuretic	I-NP	JJ	O	7	NMOD
7	hormone	hormone	I-NP	NN	O	4	PMOD
8	reported	report	B-VP	VBN	O	7	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	use	use	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	Vincristine	Vincristine	B-NP	NN	O	12	PMOD
14	:	:	O	:	O	3	P
15	an	an	B-NP	DT	O	16	NMOD
16	over-representation	over-representation	I-NP	NN	O	0	ROOT
17	of	of	B-PP	IN	O	16	NMOD
18	Asians	Asian	B-NP	NNPS	O	17	PMOD
19	.	.	O	.	O	16	P

1	PURPOSE	PURPOSE	B-NP	NN	O	5	NMOD
2	:	:	O	:	O	1	P
3	This	This	B-NP	DT	O	5	NMOD
4	retrospective	retrospective	I-NP	JJ	O	5	NMOD
5	study	study	I-NP	NN	O	6	SUB
6	used	use	B-VP	VBD	O	0	ROOT
7	a	a	B-NP	DT	O	10	NMOD
8	pharmaceutical	pharmaceutical	I-NP	JJ	O	10	NMOD
9	company	company	I-NP	NN	O	10	NMOD
10	's	's	B-NP	POS	O	13	NMOD
11	global	global	I-NP	JJ	O	13	NMOD
12	safety	safety	I-NP	NN	O	13	NMOD
13	database	database	I-NP	NN	O	6	OBJ
14	to	to	B-VP	TO	O	15	VMOD
15	determine	determine	I-VP	VB	O	6	VMOD
16	the	the	B-NP	DT	O	18	NMOD
17	reporting	reporting	I-NP	NN	O	18	NMOD
18	rate	rate	I-NP	NN	O	15	OBJ
19	of	of	B-PP	IN	O	18	NMOD
20	hyponatremia	hyponatremia	B-NP	NN	O	22	NMOD
21	and/or	and/or	O	CC	O	22	NMOD
22	syndrome	syndrome	B-NP	NN	O	19	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	inappropriate	inappropriate	B-NP	JJ	O	25	NMOD
25	secretion	secretion	I-NP	NN	O	23	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	anti-diuretic	anti-diuretic	B-NP	JJ	O	28	NMOD
28	hormone	hormone	I-NP	NN	O	26	PMOD
29	(	(	O	(	O	31	DEP
30	SIADH	SIADH	B-NP	NN	O	31	DEP
31	)	)	O	)	O	28	NMOD
32	among	among	B-PP	IN	O	18	NMOD
33	vincristine-treated	vincristine-treated	B-NP	JJ	O	34	NMOD
34	patients	patient	I-NP	NNS	O	32	PMOD
35	and	and	O	CC	O	15	VMOD
36	to	to	B-VP	TO	O	37	VMOD
37	explore	explore	I-VP	VB	O	15	VMOD
38	the	the	B-NP	DT	O	39	NMOD
39	possibility	possibility	I-NP	NN	O	37	OBJ
40	of	of	B-PP	IN	O	39	NMOD
41	at-risk	at-risk	B-NP	JJ	O	43	NMOD
42	population	population	I-NP	NN	O	43	NMOD
43	subgroups	subgroup	I-NP	NNS	O	40	PMOD
44	.	.	O	.	O	6	P

1	METHOD	METHOD	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	searched	search	B-VP	VBD	O	1	NMOD
5	the	the	B-NP	DT	O	7	NMOD
6	Eli	Eli	I-NP	NNP	O	7	NMOD
7	Lilly	Lilly	I-NP	NNP	O	14	NMOD
8	and	and	O	CC	O	14	NMOD
9	Company	Company	B-NP	NNP	O	10	NMOD
10	's	's	B-NP	POS	O	14	NMOD
11	computerized	computerized	I-NP	JJ	O	14	NMOD
12	adverse	adverse	I-NP	JJ	O	14	NMOD
13	event	event	I-NP	NN	O	14	NMOD
14	database	database	I-NP	NN	O	4	OBJ
15	for	for	B-PP	IN	O	14	NMOD
16	all	all	B-NP	DT	O	18	NMOD
17	reported	report	I-NP	VBN	O	18	NMOD
18	cases	case	I-NP	NNS	O	15	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	hyponatremia	hyponatremia	B-NP	NN	O	22	NMOD
21	and/or	and/or	I-NP	CC	O	22	NMOD
22	SIADH	SIADH	I-NP	NN	B-protein	19	PMOD
23	as	as	B-PP	IN	O	4	VMOD
24	of	of	B-PP	IN	O	23	PMOD
25	1	1	B-NP	CD	O	27	NMOD
26	November	November	I-NP	NNP	O	27	NMOD
27	1999	1999	I-NP	CD	O	24	PMOD
28	that	that	B-NP	WDT	O	27	NMOD
29	had	have	B-VP	VBD	O	28	SBAR
30	been	be	I-VP	VBN	O	29	VC
31	reported	report	I-VP	VBN	O	30	VC
32	during	during	B-PP	IN	O	31	VMOD
33	the	the	B-NP	DT	O	34	NMOD
34	use	use	I-NP	NN	O	32	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	vincristine	vincristine	B-NP	NN	O	35	PMOD
37	.	.	O	.	O	1	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	A	A	B-NP	DT	O	4	NMOD
4	total	total	I-NP	NN	O	16	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	76	76	B-NP	CD	O	7	NMOD
7	cases	case	I-NP	NNS	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	hyponatremia	hyponatremia	B-NP	NN	O	11	NMOD
10	and/or	and/or	I-NP	CC	O	11	NMOD
11	SIADH	SIADH	I-NP	NN	B-protein	8	PMOD
12	associated	associate	B-VP	VBN	O	7	NMOD
13	with	with	B-PP	IN	O	12	VMOD
14	vincristine	vincristine	B-NP	NN	O	15	NMOD
15	use	use	I-NP	NN	O	13	PMOD
16	were	be	B-VP	VBD	O	1	NMOD
17	identified	identify	I-VP	VBN	O	16	VC
18	.	.	O	.	O	1	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Our	Our	B-NP	PRP$	O	4	NMOD
4	data	datum	I-NP	NNS	O	5	SUB
5	suggest	suggest	B-VP	VBP	O	1	NMOD
6	that	that	B-SBAR	IN	O	5	VMOD
7	Asian	Asian	B-NP	JJ	O	8	NMOD
8	patients	patient	I-NP	NNS	O	9	SUB
9	may	may	B-VP	MD	O	6	SBAR
10	be	be	I-VP	VB	O	9	VC
11	at	at	B-PP	IN	O	10	PRD
12	increased	increase	B-NP	VBN	O	13	NMOD
13	risk	risk	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	hyponatremia	hyponatremia	B-NP	NN	O	17	NMOD
16	and/or	and/or	I-NP	CC	O	17	NMOD
17	SIADH	SIADH	I-NP	NN	B-protein	14	PMOD
18	associated	associate	B-VP	VBN	O	17	NMOD
19	with	with	B-PP	IN	O	18	VMOD
20	vincristine	vincristine	B-NP	NN	O	21	NMOD
21	use	use	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	1	P

1	Delayed	Delay	B-NP	VBN	O	2	NMOD
2	toxicity	toxicity	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	cyclophosphamide	cyclophosphamide	B-NP	NN	O	3	PMOD
5	on	on	B-PP	IN	O	2	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	bladder	bladder	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	DBA/2	DBA/2	B-NP	NN	B-protein	13	NMOD
10	and	and	I-NP	CC	O	13	NMOD
11	C57BL/6	C57BL/6	I-NP	NN	O	13	NMOD
12	female	female	I-NP	JJ	O	13	NMOD
13	mouse	mouse	I-NP	NN	O	8	PMOD
14	.	.	O	.	O	2	P

1	Early	Early	B-NP	JJ	O	3	NMOD
2	CY	CY	I-NP	NN	O	3	NMOD
3	toxicity	toxicity	I-NP	NN	O	4	SUB
4	caused	cause	B-VP	VBD	O	0	ROOT
5	a	a	B-NP	DT	O	8	NMOD
6	typical	typical	I-NP	JJ	O	8	NMOD
7	haemorrhagic	haemorrhagic	I-NP	JJ	O	8	NMOD
8	cystitis	cystitis	I-NP	NN	O	4	OBJ
9	in	in	B-PP	IN	O	4	VMOD
10	both	both	B-NP	DT	O	11	NMOD
11	strains	strain	I-NP	NNS	O	9	PMOD
12	that	that	B-NP	WDT	O	11	NMOD
13	was	be	B-VP	VBD	O	12	SBAR
14	completely	completely	I-VP	RB	O	13	VMOD
15	repaired	repair	I-VP	VBN	O	13	VC
16	in	in	B-PP	IN	O	15	VMOD
17	about	about	B-NP	RB	O	19	NMOD
18	7-10	7-10	I-NP	CD	O	17	AMOD
19	days	day	I-NP	NNS	O	16	PMOD
20	.	.	O	.	O	4	P

1	After	After	B-PP	IN	O	0	ROOT
2	30	30	B-NP	CD	O	3	NMOD
3	days	day	I-NP	NNS	O	14	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	CY	CY	B-NP	NN	O	6	AMOD
6	injection	injection	I-NP	NN	O	9	AMOD
7	ulcerous	ulcerous	I-NP	JJ	O	9	AMOD
8	and	and	I-NP	CC	O	9	AMOD
9	non-ulcerous	non-ulcerous	I-NP	JJ	O	10	NMOD
10	forms	form	I-NP	NNS	O	4	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	chronic	chronic	B-NP	JJ	O	13	NMOD
13	cystitis	cystitis	I-NP	NN	O	11	PMOD
14	appeared	appear	B-VP	VBD	O	1	PMOD
15	in	in	B-PP	IN	O	14	VMOD
16	86	86	B-NP	CD	O	17	NMOD
17	%	%	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	DBA/2	DBA/2	B-NP	NN	O	20	NMOD
20	mice	mouse	I-NP	NNS	O	18	PMOD
21	but	but	O	CC	O	1	VMOD
22	only	only	B-PP	RB	O	23	PMOD
23	in	in	I-PP	IN	O	1	PMOD
24	4	4	B-NP	CD	O	25	NMOD
25	%	%	I-NP	NN	O	23	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	C57BL/6	C57BL/6	B-NP	NN	O	28	NMOD
28	mice	mouse	I-NP	NNS	O	26	PMOD
29	.	.	O	.	O	1	P

1	These	These	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	indicate	indicate	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	delayed	delay	B-NP	VBN	O	6	NMOD
6	toxicity	toxicity	I-NP	NN	O	13	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	CY	CY	B-NP	NN	O	7	PMOD
9	in	in	B-PP	IN	O	6	NMOD
10	female	female	B-NP	JJ	O	12	NMOD
11	DBA/2	DBA/2	I-NP	NN	O	12	NMOD
12	mice	mouse	I-NP	NNS	O	9	PMOD
13	causes	cause	B-VP	VBZ	O	4	SBAR
14	a	a	B-NP	DT	O	16	NMOD
15	bladder	bladder	I-NP	NN	O	16	NMOD
16	pathology	pathology	I-NP	NN	O	13	OBJ
17	that	that	B-NP	WDT	O	16	NMOD
18	is	be	B-VP	VBZ	O	17	SBAR
19	not	not	I-VP	RB	O	18	VMOD
20	observed	observe	I-VP	VBN	O	18	VC
21	in	in	B-PP	IN	O	20	VMOD
22	C57BL/6	C57BL/6	B-NP	NN	O	23	NMOD
23	mice	mouse	I-NP	NNS	O	21	PMOD
24	.	.	O	.	O	3	P

1	High-dose	High-dose	B-NP	JJ	O	5	NMOD
2	5-fluorouracil	5-fluorouracil	I-NP	NN	O	5	NMOD
3	/	/	B-VP	SYM	O	5	NMOD
4	folinic	folinic	B-NP	JJ	O	5	NMOD
5	acid	acid	I-NP	NN	O	0	ROOT
6	in	in	B-PP	IN	O	5	NMOD
7	combination	combination	B-NP	NN	O	6	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	three-weekly	three-weekly	B-NP	JJ	O	11	NMOD
10	mitomycin	mitomycin	I-NP	NN	O	11	NMOD
11	C	C	I-NP	NN	O	8	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	treatment	treatment	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	advanced	advance	B-NP	VBN	O	18	NMOD
17	gastric	gastric	I-NP	JJ	O	18	NMOD
18	cancer	cancer	I-NP	NN	O	15	PMOD
19	.	.	O	.	O	5	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	6	NMOD
4	24-hour	24-hour	I-NP	JJ	O	6	NMOD
5	continuous	continuous	I-NP	JJ	O	6	NMOD
6	infusion	infusion	I-NP	NN	O	33	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	5-fluorouracil	5-fluorouracil	B-NP	NN	O	14	NMOD
9	(	(	O	(	O	11	DEP
10	5-FU	5-FU	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	and	and	O	CC	O	14	NMOD
13	folinic	folinic	B-NP	JJ	O	14	NMOD
14	acid	acid	I-NP	NN	O	7	PMOD
15	(	(	O	(	O	17	DEP
16	FA	FA	B-NP	NN	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	as	as	B-PP	IN	O	6	NMOD
19	part	part	B-NP	NN	O	18	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	several	several	B-NP	JJ	O	25	NMOD
22	new	new	I-NP	JJ	O	25	NMOD
23	multidrug	multidrug	I-NP	JJ	O	25	NMOD
24	chemotherapy	chemotherapy	I-NP	NN	O	25	NMOD
25	regimens	regimen	I-NP	NNS	O	20	PMOD
26	in	in	B-PP	IN	O	6	NMOD
27	advanced	advance	B-NP	VBN	O	29	NMOD
28	gastric	gastric	I-NP	JJ	O	29	NMOD
29	cancer	cancer	I-NP	NN	O	26	PMOD
30	(	(	O	(	O	32	DEP
31	AGC	AGC	B-NP	NN	O	32	DEP
32	)	)	O	)	O	29	NMOD
33	has	have	B-VP	VBZ	O	1	NMOD
34	shown	show	I-VP	VBN	O	33	VC
35	to	to	I-VP	TO	O	36	VMOD
36	be	be	I-VP	VB	O	34	VMOD
37	effective	effective	B-ADJP	JJ	O	36	PRD
38	,	,	O	,	O	34	P
39	with	with	B-PP	IN	O	34	VMOD
40	low	low	B-NP	JJ	O	41	NMOD
41	toxicity	toxicity	I-NP	NN	O	39	PMOD
42	.	.	O	.	O	33	P

1	In	In	B-PP	IN	O	20	VMOD
2	a	a	B-NP	DT	O	6	NMOD
3	previous	previous	I-NP	JJ	O	6	NMOD
4	phase	phase	I-NP	NN	O	6	NMOD
5	II	II	I-NP	CD	O	6	NMOD
6	study	study	I-NP	NN	O	1	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	3-weekly	3-weekly	B-NP	JJ	O	10	NMOD
9	bolus	bolus	I-NP	NN	O	10	NMOD
10	5-FU	5-FU	I-NP	NN	O	15	NMOD
11	,	,	O	,	O	15	P
12	FA	FA	B-NP	NN	B-protein	15	NMOD
13	and	and	O	CC	O	15	NMOD
14	mitomycin	mitomycin	B-NP	NN	O	15	NMOD
15	C	C	I-NP	NN	O	7	PMOD
16	(	(	O	(	O	18	DEP
17	MMC	MMC	B-NP	NN	O	18	DEP
18	)	)	O	)	O	15	NMOD
19	we	we	B-NP	PRP	O	20	SUB
20	found	find	B-VP	VBD	O	0	ROOT
21	a	a	B-NP	DT	O	27	NMOD
22	low	low	I-NP	JJ	O	24	NMOD
23	toxicity	toxicity	I-NP	NN	O	24	NMOD
24	rate	rate	I-NP	NN	O	27	NMOD
25	and	and	I-NP	CC	O	27	NMOD
26	response	response	I-NP	NN	O	27	NMOD
27	rates	rate	I-NP	NNS	O	20	OBJ
28	comparable	comparable	B-ADJP	JJ	O	27	NMOD
29	to	to	B-PP	TO	O	28	AMOD
30	those	those	B-NP	DT	O	29	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	regimens	regimen	B-NP	NNS	O	31	PMOD
33	such	such	B-PP	JJ	O	34	PMOD
34	as	as	I-PP	IN	O	32	NMOD
35	ELF	ELF	B-NP	NN	B-protein	39	NMOD
36	,	,	I-NP	,	O	39	P
37	FAM	FAM	I-NP	NN	O	39	NMOD
38	or	or	I-NP	CC	O	39	NMOD
39	FAMTX	FAMTX	I-NP	NN	B-protein	34	PMOD
40	,	,	O	,	O	46	P
41	and	and	O	CC	O	46	NMOD
42	a	a	B-NP	DT	O	46	NMOD
43	promising	promising	I-NP	JJ	O	46	NMOD
44	median	median	I-NP	JJ	O	46	NMOD
45	overall	overall	I-NP	JJ	O	46	NMOD
46	survival	survival	I-NP	NN	O	20	VMOD
47	.	.	O	.	O	20	P

1	PATIENTS	PATIENTS	B-NP	NNS	O	3	NMOD
2	AND	AND	I-NP	CC	O	3	NMOD
3	METHODS	METHODS	I-NP	NNS	O	14	SUB
4	:	:	O	:	O	3	P
5	From	From	B-PP	IN	O	14	VMOD
6	February	February	B-NP	NNP	O	12	NMOD
7	,	,	O	,	O	12	P
8	1998	1998	B-NP	CD	O	10	NMOD
9	to	to	B-PP	TO	O	10	NMOD
10	September	September	B-NP	NNP	O	12	NMOD
11	,	,	O	,	O	12	P
12	2000	2000	B-NP	CD	O	5	PMOD
13	we	we	B-NP	PRP	O	14	SUB
14	recruited	recruit	B-VP	VBD	O	0	ROOT
15	33	33	B-NP	CD	O	16	NMOD
16	patients	patient	I-NP	NNS	O	14	OBJ
17	with	with	B-PP	IN	O	14	VMOD
18	AGC	AGC	B-NP	NN	O	17	PMOD
19	to	to	B-VP	TO	O	20	VMOD
20	receive	receive	I-VP	VB	O	14	VMOD
21	weekly	weekly	B-NP	JJ	O	23	NMOD
22	24-hour	24-hour	I-NP	JJ	O	23	NMOD
23	5-FU	5-FU	I-NP	NN	O	20	OBJ
24	2	2	I-NP	CD	O	23	NMOD
25	,	,	O	,	O	14	P
26	600	600	B-NP	CD	O	27	NMOD
27	mg/m	mg/m	I-NP	NN	O	14	VMOD
28	(	(	O	(	O	30	DEP
29	2	2	B-NP	CD	O	30	DEP
30	)	)	O	)	O	27	NMOD
31	preceded	precede	B-VP	VBN	O	27	NMOD
32	by	by	B-PP	IN	O	31	VMOD
33	2-hour	2-hour	B-NP	JJ	O	36	NMOD
34	FA	FA	I-NP	NN	O	36	NMOD
35	500	500	I-NP	CD	O	36	NMOD
36	mg/m	mg/m	I-NP	NN	O	32	PMOD
37	(	(	O	(	O	39	DEP
38	2	2	B-NP	CD	O	39	DEP
39	)	)	O	)	O	36	NMOD
40	for	for	B-PP	IN	O	36	NMOD
41	6	6	B-NP	CD	O	42	NMOD
42	weeks	week	I-NP	NNS	O	40	PMOD
43	,	,	O	,	O	27	P
44	followed	follow	B-VP	VBN	O	27	NMOD
45	by	by	B-PP	IN	O	44	VMOD
46	a	a	B-NP	DT	O	49	NMOD
47	2-week	2-week	I-NP	JJ	O	49	NMOD
48	rest	rest	I-NP	NN	O	49	NMOD
49	period	period	I-NP	NN	O	45	PMOD
50	.	.	O	.	O	14	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	High-dose	High-dose	B-NP	JJ	O	4	NMOD
4	5-FU/FA/MMC	5-FU/FA/MMC	I-NP	NN	O	5	SUB
5	is	be	B-VP	VBZ	O	1	NMOD
6	an	an	B-NP	DT	O	11	NMOD
7	effective	effective	I-NP	JJ	O	9	AMOD
8	and	and	I-NP	CC	O	9	AMOD
9	well-tolerated	well-tolerated	I-NP	JJ	O	11	NMOD
10	outpatient	outpatient	I-NP	NN	O	11	NMOD
11	regimen	regimen	I-NP	NN	O	5	PRD
12	for	for	B-PP	IN	O	11	NMOD
13	AGC	AGC	B-NP	NN	O	12	PMOD
14	(	(	O	(	O	20	DEP
15	objective	objective	B-NP	JJ	O	17	NMOD
16	response	response	I-NP	NN	O	17	NMOD
17	rate	rate	I-NP	NN	O	19	NMOD
18	54.6	54.6	B-NP	CD	O	19	NMOD
19	%	%	I-NP	NN	O	20	DEP
20	)	)	O	)	O	13	NMOD
21	.	.	O	.	O	1	P

1	Persistent	Persistent	B-NP	JJ	O	3	NMOD
2	sterile	sterile	I-NP	JJ	O	3	NMOD
3	leukocyturia	leukocyturia	I-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	associated	associate	I-VP	VBN	O	4	VC
6	with	with	B-PP	IN	O	5	VMOD
7	impaired	impaired	B-NP	JJ	O	9	NMOD
8	renal	renal	I-NP	JJ	O	9	NMOD
9	function	function	I-NP	NN	O	6	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	human	human	B-NP	JJ	O	16	NMOD
12	immunodeficiency	immunodeficiency	I-NP	NN	O	16	NMOD
13	virus	virus	I-NP	NN	O	16	NMOD
14	type	type	I-NP	NN	O	16	NMOD
15	1-infected	1-infected	I-NP	JJ	O	16	NMOD
16	children	child	I-NP	NNS	O	10	PMOD
17	treated	treat	B-VP	VBN	O	16	NMOD
18	with	with	B-PP	IN	O	17	VMOD
19	indinavir	indinavir	B-NP	NN	O	18	PMOD
20	.	.	O	.	O	4	P

1	DESIGN	DESIGN	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	A	A	B-NP	DT	O	5	NMOD
4	prospective	prospective	I-NP	JJ	O	5	NMOD
5	study	study	I-NP	NN	O	1	OBJ
6	to	to	B-VP	TO	O	7	VMOD
7	monitor	monitor	I-VP	VB	O	5	NMOD
8	indinavir-related	indinavir-related	B-NP	JJ	O	9	NMOD
9	nephrotoxicity	nephrotoxicity	I-NP	NN	O	7	OBJ
10	in	in	B-PP	IN	O	7	VMOD
11	a	a	B-NP	DT	O	12	NMOD
12	cohort	cohort	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	30	30	B-NP	CD	O	20	NMOD
15	human	human	I-NP	JJ	O	20	NMOD
16	immunodeficiency	immunodeficiency	I-NP	NN	O	20	NMOD
17	virus	virus	I-NP	NN	O	20	NMOD
18	type	type	I-NP	NN	O	20	NMOD
19	1-infected	1-infected	I-NP	JJ	O	20	NMOD
20	children	child	I-NP	NNS	O	13	PMOD
21	treated	treat	B-VP	VBN	O	20	NMOD
22	with	with	B-PP	IN	O	21	VMOD
23	indinavir	indinavir	B-NP	NN	O	22	PMOD
24	.	.	O	.	O	1	P

1	Persistent	Persistent	B-NP	JJ	O	3	NMOD
2	sterile	sterile	I-NP	JJ	O	3	NMOD
3	leukocyturia	leukocyturia	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	frequently	frequently	I-VP	RB	O	4	VMOD
6	associated	associate	I-VP	VBN	O	4	VC
7	with	with	B-PP	IN	O	6	VMOD
8	a	a	B-NP	DT	O	10	NMOD
9	mild	mild	I-NP	JJ	O	10	NMOD
10	increase	increase	I-NP	NN	O	7	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	15	NMOD
13	urine	urine	I-NP	NN	O	15	NMOD
14	albumin/creatinine	albumin/creatinine	I-NP	NN	O	15	NMOD
15	ratio	ratio	I-NP	NN	O	11	PMOD
16	and	and	B-PP	CC	O	7	PMOD
17	by	by	B-PP	IN	O	7	PMOD
18	microscopic	microscopic	B-NP	JJ	O	19	NMOD
19	hematuria	hematuria	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	4	P

1	Children	Child	B-NP	NNS	O	8	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	persistent	persistent	B-NP	JJ	O	5	NMOD
4	sterile	sterile	I-NP	JJ	O	5	NMOD
5	leukocyturia	leukocyturia	I-NP	NN	O	2	PMOD
6	more	more	B-ADVP	RBR	O	7	AMOD
7	frequently	frequently	I-ADVP	RB	O	8	VMOD
8	had	have	B-VP	VBD	O	0	ROOT
9	serum	serum	B-NP	NN	O	11	NMOD
10	creatinine	creatinine	I-NP	NN	O	11	NMOD
11	levels	level	I-NP	NNS	O	8	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	50	50	B-NP	CD	O	14	NMOD
14	%	%	I-NP	NN	O	12	PMOD
15	above	above	B-PP	IN	O	8	VMOD
16	normal	normal	B-ADJP	JJ	O	15	PMOD
17	than	than	B-PP	IN	O	16	AMOD
18	those	those	B-NP	DT	O	19	NMOD
19	children	child	I-NP	NNS	O	17	PMOD
20	without	without	B-PP	IN	O	19	NMOD
21	persistent	persistent	B-NP	JJ	O	23	NMOD
22	sterile	sterile	I-NP	JJ	O	23	NMOD
23	leukocyturia	leukocyturia	I-NP	NN	O	20	PMOD
24	.	.	O	.	O	8	P

1	A	A	B-NP	DT	O	4	NMOD
2	higher	high	I-NP	JJR	O	4	NMOD
3	cumulative	cumulative	I-NP	JJ	O	4	NMOD
4	incidence	incidence	I-NP	NN	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	persistent	persistent	B-NP	JJ	O	7	NMOD
7	leukocyturia	leukocyturia	I-NP	NN	O	5	PMOD
8	was	be	B-VP	VBD	O	0	ROOT
9	found	find	I-VP	VBN	O	8	VC
10	in	in	B-PP	IN	O	9	VMOD
11	children	child	B-NP	NNS	O	27	NMOD
12	with	with	B-PP	IN	O	11	NMOD
13	an	an	B-NP	DT	O	14	NMOD
14	area	area	I-NP	NN	O	12	PMOD
15	under	under	B-PP	IN	O	11	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	curve	curve	I-NP	NN	O	15	PMOD
18	>	>	B-NP	JJR	O	22	NMOD
19	19	19	I-NP	CD	O	22	NMOD
20	mg/L	mg/L	I-NP	NN	O	22	NMOD
21	x	x	B-NP	SYM	O	22	NMOD
22	h	h	I-NP	NN	O	27	NMOD
23	or	or	O	CC	O	27	NMOD
24	a	a	B-NP	DT	O	27	NMOD
25	peak	peak	I-NP	JJ	O	27	NMOD
26	serum	serum	I-NP	NN	O	27	NMOD
27	level	level	I-NP	NN	O	10	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	indinavir	indinavir	B-NP	NN	O	32	NMOD
30	>	>	O	SYM	O	32	NMOD
31	12	12	B-NP	CD	O	32	NMOD
32	mg/L	mg/L	I-NP	NN	O	28	PMOD
33	.	.	O	.	O	8	P

1	In	In	B-PP	IN	O	6	VMOD
2	4	4	B-NP	CD	O	3	NMOD
3	children	child	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	6	P
5	indinavir	indinavir	B-NP	NN	O	6	SUB
6	was	be	B-VP	VBD	O	0	ROOT
7	discontinued	discontinue	I-VP	VBN	O	6	VC
8	because	because	B-PP	IN	O	7	VMOD
9	of	of	I-PP	IN	O	8	PMOD
10	nephrotoxicity	nephrotoxicity	B-NP	NN	O	9	PMOD
11	.	.	O	.	O	6	P

1	Subsequently	Subsequently	B-ADVP	RB	O	7	VMOD
2	,	,	O	,	O	7	P
3	the	the	B-NP	DT	O	6	NMOD
4	serum	serum	I-NP	NN	O	6	NMOD
5	creatinine	creatinine	I-NP	NN	O	6	NMOD
6	levels	level	I-NP	NNS	O	7	SUB
7	decreased	decrease	B-VP	VBD	O	20	VMOD
8	,	,	O	,	O	7	P
9	the	the	B-NP	DT	O	12	NMOD
10	urine	urine	I-NP	NN	O	12	NMOD
11	albumin/creatinine	albumin/creatinine	I-NP	NN	O	12	NMOD
12	ratios	ratio	I-NP	NNS	O	13	SUB
13	returned	return	B-VP	VBD	O	7	VMOD
14	to	to	B-PP	TO	O	13	VMOD
15	zero	zero	B-NP	CD	O	14	PMOD
16	,	,	O	,	O	20	P
17	and	and	O	CC	O	20	VMOD
18	the	the	B-NP	DT	O	19	NMOD
19	leukocyturia	leukocyturia	I-NP	NN	O	20	SUB
20	disappeared	disappear	B-VP	VBD	O	0	ROOT
21	within	within	B-PP	IN	O	20	VMOD
22	3	3	B-NP	CD	O	23	NMOD
23	months	month	I-NP	NNS	O	21	PMOD
24	.	.	O	.	O	20	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Children	Child	B-NP	NNS	O	7	SUB
4	treated	treat	B-VP	VBN	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	indinavir	indinavir	B-NP	NN	O	5	PMOD
7	have	have	B-VP	VBP	O	1	NMOD
8	a	a	B-NP	DT	O	11	NMOD
9	high	high	I-NP	JJ	O	11	NMOD
10	cumulative	cumulative	I-NP	JJ	O	11	NMOD
11	incidence	incidence	I-NP	NN	O	7	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	persistent	persistent	B-NP	JJ	O	15	NMOD
14	sterile	sterile	I-NP	JJ	O	15	NMOD
15	leukocyturia	leukocyturia	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	1	P

1	Children	Child	B-NP	NNS	O	8	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	persistent	persistent	B-NP	JJ	O	5	NMOD
4	sterile	sterile	I-NP	JJ	O	5	NMOD
5	leukocyturia	leukocyturia	I-NP	NN	O	2	PMOD
6	more	more	B-ADVP	RBR	O	7	AMOD
7	frequently	frequently	I-ADVP	RB	O	8	VMOD
8	had	have	B-VP	VBD	O	0	ROOT
9	an	an	B-NP	DT	O	10	NMOD
10	increase	increase	I-NP	NN	O	8	OBJ
11	in	in	B-PP	IN	O	10	NMOD
12	serum	serum	B-NP	NN	O	14	NMOD
13	creatinine	creatinine	I-NP	NN	O	14	NMOD
14	levels	level	I-NP	NNS	O	11	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	>	>	B-NP	SYM	O	18	NMOD
17	50	50	B-NP	CD	O	18	NMOD
18	%	%	I-NP	NN	O	15	PMOD
19	above	above	B-PP	IN	O	10	NMOD
20	normal	normal	B-ADJP	JJ	O	19	PMOD
21	.	.	O	.	O	8	P

1	Utility	Utility	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	troponin	troponin	B-NP	NN	B-DNA	2	PMOD
4	I	I	I-NP	CD	I-DNA	3	NMOD
5	in	in	B-PP	IN	O	1	NMOD
6	patients	patient	B-NP	NNS	O	5	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	cocaine-associated	cocaine-associated	B-NP	JJ	O	10	NMOD
9	chest	chest	I-NP	NN	O	10	NMOD
10	pain	pain	I-NP	NN	O	7	PMOD
11	.	.	O	.	O	1	P

1	Baseline	Baseline	B-NP	NN	O	3	NMOD
2	electrocardiogram	electrocardiogram	I-NP	NN	O	3	NMOD
3	abnormalities	abnormality	I-NP	NNS	O	6	NMOD
4	and	and	O	CC	O	6	NMOD
5	market	market	B-NP	NN	O	6	NMOD
6	elevations	elevation	I-NP	NNS	O	12	SUB
7	not	not	B-VP	RB	O	8	VMOD
8	associated	associate	I-VP	VBN	O	6	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	myocardial	myocardial	B-NP	JJ	O	11	NMOD
11	necrosis	necrosis	I-NP	NN	O	9	PMOD
12	make	make	B-VP	VBP	O	0	ROOT
13	accurate	accurate	B-NP	JJ	O	14	NMOD
14	diagnosis	diagnosis	I-NP	NN	O	12	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	myocardial	myocardial	B-NP	JJ	O	17	NMOD
17	infarction	infarction	I-NP	NN	O	15	PMOD
18	(	(	O	(	O	20	DEP
19	MI	MI	B-NP	NN	O	20	DEP
20	)	)	O	)	O	17	NMOD
21	difficult	difficult	B-ADJP	JJ	O	17	NMOD
22	in	in	B-PP	IN	O	21	AMOD
23	patients	patient	B-NP	NNS	O	22	PMOD
24	with	with	B-PP	IN	O	23	NMOD
25	cocaine-associated	cocaine-associated	B-NP	JJ	O	27	NMOD
26	chest	chest	I-NP	NN	O	27	NMOD
27	pain	pain	I-NP	NN	O	24	PMOD
28	.	.	O	.	O	12	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	assess	assess	I-VP	VB	O	1	NMOD
5	outcomes	outcome	B-NP	NNS	O	4	OBJ
6	based	base	B-PP	VBN	O	5	NMOD
7	on	on	B-PP	IN	O	6	PMOD
8	troponin	troponin	B-NP	NN	O	9	NMOD
9	positivity	positivity	I-NP	NN	O	7	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	patients	patient	B-NP	NNS	O	10	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	cocaine	cocaine	B-NP	NN	O	15	NMOD
14	chest	chest	I-NP	NN	O	15	NMOD
15	pain	pain	I-NP	NN	O	12	PMOD
16	admitted	admit	B-VP	VBN	O	15	NMOD
17	for	for	B-PP	IN	O	16	VMOD
18	exclusion	exclusion	B-NP	NN	O	17	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	MI	MI	B-NP	NN	O	19	PMOD
21	.	.	O	.	O	1	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Outcomes	Outcome	B-NP	NNS	O	4	SUB
4	were	be	B-VP	VBD	O	1	NMOD
5	examined	examine	I-VP	VBN	O	4	VC
6	in	in	B-PP	IN	O	5	VMOD
7	patients	patient	B-NP	NNS	O	6	PMOD
8	admitted	admit	B-VP	VBN	O	7	NMOD
9	for	for	B-PP	IN	O	8	VMOD
10	possible	possible	B-NP	JJ	O	11	NMOD
11	MI	MI	I-NP	NN	O	9	PMOD
12	after	after	B-PP	IN	O	11	NMOD
13	cocaine	cocaine	B-NP	NN	O	14	NMOD
14	use	use	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	1	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	interstitial	interstitial	I-NP	JJ	O	3	NMOD
3	nephritis	nephritis	I-NP	NN	O	0	ROOT
4	due	due	B-ADJP	JJ	O	3	NMOD
5	to	to	B-PP	TO	O	4	AMOD
6	nicergoline	nicergoline	B-NP	NN	O	5	PMOD
7	(	(	O	(	O	9	DEP
8	Sermion	Sermion	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	acute	acute	B-NP	JJ	O	8	NMOD
7	interstitial	interstitial	I-NP	JJ	O	8	NMOD
8	nephritis	nephritis	I-NP	NN	O	5	PMOD
9	(	(	O	(	O	11	DEP
10	AIN	AIN	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	due	due	B-PP	IN	O	4	NMOD
13	to	to	B-PP	TO	O	12	PMOD
14	nicergoline	nicergoline	B-NP	NN	O	13	PMOD
15	(	(	O	(	O	17	DEP
16	Sermion	Sermion	B-NP	NN	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	.	.	O	.	O	2	P

1	Before	Before	B-PP	IN	O	5	VMOD
2	admission	admission	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	5	P
4	he	he	B-NP	PRP	O	5	SUB
5	had	have	B-VP	VBD	O	0	ROOT
6	been	be	I-VP	VBN	O	5	VC
7	taking	take	I-VP	VBG	O	6	VC
8	nicergoline	nicergoline	B-NP	NN	O	11	NMOD
9	and	and	I-NP	CC	O	11	NMOD
10	bendazac	bendazac	I-NP	NN	O	11	NMOD
11	lysine	lysine	I-NP	NN	O	7	OBJ
12	due	due	B-ADJP	JJ	O	11	NMOD
13	to	to	B-PP	TO	O	12	AMOD
14	retinal	retinal	B-NP	JJ	O	16	NMOD
15	vein	vein	I-NP	NN	O	16	NMOD
16	occlusion	occlusion	I-NP	NN	O	13	PMOD
17	at	at	B-PP	IN	O	16	NMOD
18	ophthalmologic	ophthalmologic	B-NP	JJ	O	19	NMOD
19	department	department	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	5	P

1	A	A	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	10	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	chronic	chronic	B-NP	JJ	O	6	NMOD
5	renal	renal	I-NP	JJ	O	6	NMOD
6	failure	failure	I-NP	NN	O	3	PMOD
7	(	(	O	(	O	9	DEP
8	CRF	CRF	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	developed	develop	B-VP	VBD	O	0	ROOT
11	neuroleptic	neuroleptic	B-NP	JJ	O	13	NMOD
12	malignant	malignant	I-NP	JJ	O	13	NMOD
13	syndrome	syndrome	I-NP	NN	O	10	OBJ
14	(	(	O	(	O	16	DEP
15	NMS	NMS	B-NP	NN	O	16	DEP
16	)	)	O	)	O	13	NMOD
17	after	after	B-PP	IN	O	10	VMOD
18	administration	administration	B-NP	NN	O	17	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	risperidone	risperidone	B-NP	NN	O	22	NMOD
21	and	and	I-NP	CC	O	22	NMOD
22	levomepromazine	levomepromazine	I-NP	NN	O	19	PMOD
23	.	.	O	.	O	10	P

1	Adrenaline	Adrenaline	B-NP	NN	O	3	NMOD
2	induced	induced	I-NP	JJ	O	3	NMOD
3	hypertension	hypertension	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	used	use	I-VP	VBN	O	4	VC
6	to	to	B-VP	TO	O	7	VMOD
7	destroy	destroy	I-VP	VB	O	4	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	BBB	BBB	I-NP	NN	B-protein	7	OBJ
10	,	,	O	,	O	9	P
11	which	which	B-NP	WDT	O	9	NMOD
12	was	be	B-VP	VBD	O	11	SBAR
13	evaluated	evaluate	I-VP	VBN	O	12	VC
14	using	use	I-VP	VBG	O	13	VMOD
15	triphenyltetrazolium	triphenyltetrazolium	B-NP	NN	O	19	NMOD
16	(	(	O	(	O	18	DEP
17	TTC	TTC	B-NP	NN	O	18	DEP
18	)	)	O	)	O	15	NMOD
19	staining	staining	B-NP	NN	O	14	OBJ
20	of	of	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	23	NMOD
22	brain	brain	I-NP	NN	O	23	NMOD
23	slices	slice	I-NP	NNS	O	20	PMOD
24	just	just	B-ADVP	RB	O	25	PMOD
25	after	after	B-PP	IN	O	13	VMOD
26	giving	give	B-VP	VBG	O	25	PMOD
27	adrenaline	adrenaline	B-NP	NN	O	26	OBJ
28	for	for	B-PP	IN	O	26	VMOD
29	30	30	B-NP	CD	O	30	NMOD
30	s	s	I-NP	NN	O	28	PMOD
31	.	.	O	.	O	4	P

1	Carvedilol	Carvedilol	B-NP	NN	O	2	SUB
2	protects	protect	B-VP	VBZ	O	0	ROOT
3	against	against	B-PP	IN	O	2	VMOD
4	doxorubicin	doxorubicin	B-NP	NN	O	3	PMOD
5	induced	induce	B-VP	VBD	O	2	VMOD
6	mitochondrial	mitochondrial	B-NP	JJ	O	7	NMOD
7	cardiomyopathy	cardiomyopathy	I-NP	NN	O	5	OBJ
8	.	.	O	.	O	2	P

1	Several	Several	B-NP	JJ	O	3	NMOD
2	cytopathic	cytopathic	I-NP	JJ	O	3	NMOD
3	mechanisms	mechanism	I-NP	NNS	O	4	SUB
4	have	have	B-VP	VBP	O	0	ROOT
5	been	be	I-VP	VBN	O	4	VC
6	suggested	suggest	I-VP	VBN	O	5	VC
7	to	to	I-VP	TO	O	8	VMOD
8	mediate	mediate	I-VP	VB	O	6	VMOD
9	the	the	B-NP	DT	O	14	NMOD
10	dose-limiting	dose-limiting	I-NP	NN	O	13	AMOD
11	cumulative	cumulative	I-NP	JJ	O	13	AMOD
12	and	and	I-NP	CC	O	13	AMOD
13	irreversible	irreversible	I-NP	JJ	O	14	NMOD
14	cardiomyopathy	cardiomyopathy	I-NP	NN	O	8	OBJ
15	caused	cause	B-VP	VBN	O	14	NMOD
16	by	by	B-PP	IN	O	15	VMOD
17	doxorubicin	doxorubicin	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	2	NMOD
2	objective	objective	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	investigation	investigation	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	test	test	I-VP	VB	O	6	PRD
9	the	the	B-NP	DT	O	10	NMOD
10	hypothesis	hypothesis	I-NP	NN	O	8	OBJ
11	that	that	B-NP	IN	O	10	NMOD
12	carvedilol	carvedilol	B-NP	NN	O	18	NMOD
13	,	,	O	,	O	18	P
14	a	a	B-NP	DT	O	18	NMOD
15	nonselective	nonselective	I-NP	JJ	O	18	NMOD
16	beta-adrenergic	beta-adrenergic	I-NP	JJ	O	18	NMOD
17	receptor	receptor	I-NP	NN	O	18	NMOD
18	antagonist	antagonist	I-NP	NN	O	24	SUB
19	with	with	B-PP	IN	O	18	NMOD
20	potent	potent	B-NP	JJ	O	21	AMOD
21	antioxidant	antioxidant	I-NP	JJ	O	22	NMOD
22	properties	property	I-NP	NNS	O	19	PMOD
23	,	,	O	,	O	18	P
24	protects	protect	B-VP	VBZ	O	11	SBAR
25	against	against	B-PP	IN	O	24	VMOD
26	the	the	B-NP	DT	O	32	NMOD
27	cardiac	cardiac	I-NP	JJ	O	29	AMOD
28	and	and	I-NP	CC	O	29	AMOD
29	hepatic	hepatic	I-NP	JJ	O	32	NMOD
30	mitochondrial	mitochondrial	I-NP	JJ	O	32	NMOD
31	bioenergetic	bioenergetic	I-NP	JJ	O	32	NMOD
32	dysfunction	dysfunction	I-NP	NN	O	25	PMOD
33	associated	associate	B-VP	VBN	O	32	NMOD
34	with	with	B-PP	IN	O	33	VMOD
35	subchronic	subchronic	B-NP	JJ	O	37	NMOD
36	doxorubicin	doxorubicin	I-NP	NN	O	37	NMOD
37	toxicity	toxicity	I-NP	NN	O	34	PMOD
38	.	.	O	.	O	6	P

1	Cocaine	Cocaine	B-NP	NN	O	3	NMOD
2	induced	induce	B-VP	VBD	O	3	NMOD
3	hyperactivity	hyperactivity	B-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	more	more	B-ADJP	RBR	O	4	VMOD
6	influenced	influence	I-ADJP	VBN	O	4	VC
7	by	by	B-PP	IN	O	6	VMOD
8	adenosine	adenosine	B-NP	NN	B-protein	10	NMOD
9	receptor	receptor	I-NP	NN	I-protein	10	NMOD
10	agonists	agonist	I-NP	NNS	O	7	PMOD
11	than	than	B-PP	IN	O	10	NMOD
12	amphetamine	amphetamine	B-NP	NN	O	14	NMOD
13	induced	induced	I-NP	JJ	O	14	NMOD
14	hyperactivity	hyperactivity	I-NP	NN	O	11	PMOD
15	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	2	NMOD
2	influence	influence	I-NP	NN	O	14	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	adenosine	adenosine	B-NP	NN	B-protein	6	NMOD
5	receptor	receptor	I-NP	NN	I-protein	6	NMOD
6	agonists	agonist	I-NP	NNS	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	antagonists	antagonist	I-NP	NNS	O	3	PMOD
9	on	on	B-PP	IN	O	2	NMOD
10	cocaine-and	cocaine-and	B-NP	NN	O	11	NMOD
11	amphetamine	amphetamine	I-NP	NN	O	13	NMOD
12	induced	induce	B-NP	VBN	O	13	NMOD
13	hyperactivity	hyperactivity	I-NP	NN	O	9	PMOD
14	was	be	B-VP	VBD	O	0	ROOT
15	examined	examine	I-VP	VBN	O	14	VC
16	in	in	B-PP	IN	O	15	VMOD
17	mice	mouse	B-NP	NNS	O	16	PMOD
18	.	.	O	.	O	14	P

1	All	All	B-NP	DT	O	4	NMOD
2	adenosine	adenosine	I-NP	NN	O	4	NMOD
3	receptor	receptor	I-NP	NN	O	4	NMOD
4	agonists	agonist	I-NP	NNS	O	6	SUB
5	significantly	significantly	B-ADVP	RB	O	6	VMOD
6	decreased	decrease	B-VP	VBD	O	16	VMOD
7	the	the	B-NP	DT	O	9	NMOD
8	locomotor	locomotor	I-NP	NN	O	9	NMOD
9	activity	activity	I-NP	NN	O	6	OBJ
10	in	in	B-PP	IN	O	6	VMOD
11	mice	mouse	B-NP	NNS	O	10	PMOD
12	,	,	O	,	O	16	P
13	and	and	O	CC	O	16	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	effects	effect	I-NP	NNS	O	16	SUB
16	were	be	B-VP	VBD	O	0	ROOT
17	dose-dependent	dose-dependent	B-ADJP	JJ	O	16	PRD
18	.	.	O	.	O	16	P

1	Similarly	Similarly	B-ADVP	RB	O	7	VMOD
2	,	,	O	,	O	7	P
3	all	all	B-NP	DT	O	6	NMOD
4	adenosine	adenosine	I-NP	NN	O	6	NMOD
5	receptor	receptor	I-NP	NN	O	6	NMOD
6	agonists	agonist	I-NP	NNS	O	7	SUB
7	decreased	decrease	B-VP	VBD	O	0	ROOT
8	amphetamine	amphetamine	B-NP	NN	O	10	NMOD
9	induced	induced	I-NP	JJ	O	10	NMOD
10	hyperactivity	hyperactivity	I-NP	NN	O	7	OBJ
11	,	,	O	,	O	7	P
12	but	but	O	CC	O	11	PMOD
13	at	at	B-PP	IN	O	12	PRD
14	the	the	B-NP	DT	O	16	NMOD
15	higher	high	I-NP	JJR	O	16	NMOD
16	doses	dose	I-NP	NNS	O	13	PMOD
17	than	than	B-PP	IN	O	13	PMOD
18	those	those	B-NP	DT	O	17	PMOD
19	which	which	B-NP	WDT	O	18	NMOD
20	were	be	B-VP	VBD	O	19	SBAR
21	active	active	B-ADJP	JJ	O	20	PRD
22	in	in	B-PP	IN	O	20	VMOD
23	cocaine	cocaine	B-NP	NN	O	25	NMOD
24	induced	induced	I-NP	JJ	O	25	NMOD
25	hyperactivity	hyperactivity	I-NP	NN	O	22	PMOD
26	.	.	O	.	O	12	P

1	Amiodarone	Amiodarone	B-NP	NN	O	4	NMOD
2	and	and	O	CC	O	4	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	risk	risk	I-NP	NN	O	0	ROOT
5	of	of	B-PP	IN	O	4	NMOD
6	bradyarrhythmia	bradyarrhythmia	B-NP	NN	O	5	PMOD
7	requiring	require	B-VP	VBG	O	6	NMOD
8	permanent	permanent	B-NP	JJ	O	9	NMOD
9	pacemaker	pacemaker	I-NP	NN	O	7	OBJ
10	in	in	B-PP	IN	O	9	NMOD
11	elderly	elderly	B-NP	JJ	O	12	NMOD
12	patients	patient	I-NP	NNS	O	10	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	atrial	atrial	B-NP	JJ	O	15	NMOD
15	fibrillation	fibrillation	I-NP	NN	O	19	NMOD
16	and	and	O	CC	O	19	NMOD
17	prior	prior	B-NP	JJ	O	19	NMOD
18	myocardial	myocardial	I-NP	JJ	O	19	NMOD
19	infarction	infarction	I-NP	NN	O	13	PMOD
20	.	.	O	.	O	4	P

1	OBJECTIVES	OBJECTIVES	B-NP	NNS	O	8	VMOD
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	aim	aim	I-NP	NN	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	this	this	B-NP	DT	O	7	NMOD
7	study	study	I-NP	NN	O	5	PMOD
8	was	be	B-VP	VBD	O	0	ROOT
9	to	to	B-VP	TO	O	10	VMOD
10	determine	determine	I-VP	VB	O	8	PRD
11	whether	whether	B-SBAR	IN	O	10	VMOD
12	the	the	B-NP	DT	O	13	NMOD
13	use	use	I-NP	NN	O	24	SUB
14	of	of	B-PP	IN	O	13	NMOD
15	amiodarone	amiodarone	B-NP	NN	O	14	PMOD
16	in	in	B-PP	IN	O	13	NMOD
17	patients	patient	B-NP	NNS	O	16	PMOD
18	with	with	B-PP	IN	O	17	NMOD
19	atrial	atrial	B-NP	JJ	O	20	NMOD
20	fibrillation	fibrillation	I-NP	NN	O	18	PMOD
21	(	(	O	(	O	23	DEP
22	AF	AF	B-NP	NN	O	23	DEP
23	)	)	O	)	O	20	NMOD
24	increases	increase	B-VP	VBZ	O	11	SBAR
25	the	the	B-NP	DT	O	26	NMOD
26	risk	risk	I-NP	NN	O	24	OBJ
27	of	of	B-PP	IN	O	26	NMOD
28	bradyarrhythmia	bradyarrhythmia	B-NP	NN	O	27	PMOD
29	requiring	require	B-VP	VBG	O	28	NMOD
30	a	a	B-NP	DT	O	32	NMOD
31	permanent	permanent	I-NP	JJ	O	32	NMOD
32	pacemaker	pacemaker	I-NP	NN	O	29	OBJ
33	.	.	O	.	O	8	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Reports	Report	B-NP	NNS	O	10	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	severe	severe	B-NP	JJ	O	6	NMOD
6	bradyarrhythmia	bradyarrhythmia	I-NP	NN	O	4	PMOD
7	during	during	B-PP	IN	O	3	NMOD
8	amiodarone	amiodarone	B-NP	NN	O	9	NMOD
9	therapy	therapy	I-NP	NN	O	7	PMOD
10	are	be	B-VP	VBP	O	1	NMOD
11	infrequent	infrequent	B-ADJP	JJ	O	13	AMOD
12	and	and	O	CC	O	13	AMOD
13	limited	limited	B-ADJP	JJ	O	10	PRD
14	to	to	B-PP	TO	O	13	AMOD
15	studies	study	B-NP	NNS	O	14	PMOD
16	assessing	assess	B-VP	VBG	O	15	NMOD
17	the	the	B-NP	DT	O	19	NMOD
18	therapy	therapy	I-NP	NN	O	19	NMOD
19	's	's	B-NP	POS	O	20	NMOD
20	use	use	I-NP	NN	O	16	OBJ
21	in	in	B-PP	IN	O	20	NMOD
22	the	the	B-NP	DT	O	23	NMOD
23	management	management	I-NP	NN	O	21	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	patients	patient	B-NP	NNS	O	24	PMOD
26	with	with	B-PP	IN	O	25	NMOD
27	ventricular	ventricular	B-NP	JJ	O	28	NMOD
28	arrhythmias	arrhythmia	I-NP	NNS	O	26	PMOD
29	.	.	O	.	O	1	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	This	This	B-NP	DT	O	4	NMOD
4	study	study	I-NP	NN	O	5	SUB
5	suggests	suggest	B-VP	VBZ	O	1	NMOD
6	that	that	B-SBAR	IN	O	5	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	use	use	I-NP	NN	O	19	NMOD
9	of	of	B-PP	IN	O	8	NMOD
10	amiodarone	amiodarone	B-NP	NN	O	9	PMOD
11	in	in	B-PP	IN	O	8	NMOD
12	elderly	elderly	B-NP	JJ	O	13	NMOD
13	patients	patient	I-NP	NNS	O	11	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	AF	AF	B-NP	NN	O	14	PMOD
16	and	and	O	CC	O	19	NMOD
17	a	a	B-NP	DT	O	19	NMOD
18	previous	previous	I-NP	JJ	O	19	NMOD
19	MI	MI	I-NP	NN	O	20	SUB
20	increases	increase	B-VP	VBZ	O	6	SBAR
21	the	the	B-NP	DT	O	22	NMOD
22	risk	risk	I-NP	NN	O	20	OBJ
23	of	of	B-PP	IN	O	22	NMOD
24	bradyarrhythmia	bradyarrhythmia	B-NP	NN	O	23	PMOD
25	requiring	require	B-VP	VBG	O	24	NMOD
26	a	a	B-NP	DT	O	28	NMOD
27	permanent	permanent	I-NP	JJ	O	28	NMOD
28	pacemaker	pacemaker	I-NP	NN	O	25	OBJ
29	.	.	O	.	O	1	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	4	VMOD
2	:	:	O	:	O	1	P
3	Indomethacin	Indomethacin	B-NP	NN	O	4	SUB
4	resulted	result	B-VP	VBD	O	0	ROOT
5	in	in	B-PP	IN	O	4	VMOD
6	histopathologic	histopathologic	B-NP	JJ	O	7	NMOD
7	findings	finding	I-NP	NNS	O	5	PMOD
8	typical	typical	B-ADJP	JJ	O	7	NMOD
9	of	of	B-PP	IN	O	8	AMOD
10	interstitial	interstitial	B-NP	JJ	O	11	NMOD
11	cystitis	cystitis	I-NP	NN	O	9	PMOD
12	,	,	O	,	O	7	P
13	such	such	B-PP	JJ	O	14	PMOD
14	as	as	I-PP	IN	O	7	NMOD
15	leaky	leaky	B-NP	JJ	O	17	NMOD
16	bladder	bladder	I-NP	NN	O	17	NMOD
17	epithelium	epithelium	I-NP	NN	O	20	NMOD
18	and	and	O	CC	O	20	NMOD
19	mucosal	mucosal	B-NP	JJ	O	20	NMOD
20	mastocytosis	mastocytosis	I-NP	NN	O	14	PMOD
21	.	.	O	.	O	4	P

1	An	An	B-NP	DT	O	5	NMOD
2	open-label	open-label	I-NP	JJ	O	5	NMOD
3	phase	phase	I-NP	NN	O	5	NMOD
4	II	II	I-NP	CD	O	5	NMOD
5	study	study	I-NP	NN	O	0	ROOT
6	of	of	B-PP	IN	O	5	NMOD
7	low-dose	low-dose	B-NP	JJ	O	8	NMOD
8	thalidomide	thalidomide	I-NP	NN	O	6	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	androgen-independent	androgen-independent	B-NP	JJ	O	12	NMOD
11	prostate	prostate	I-NP	NN	O	12	NMOD
12	cancer	cancer	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	3	NMOD
2	antiangiogenic	antiangiogenic	I-NP	JJ	O	3	NMOD
3	effects	effect	I-NP	NNS	O	6	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	thalidomide	thalidomide	B-NP	NN	O	4	PMOD
6	have	have	B-VP	VBP	O	0	ROOT
7	been	be	I-VP	VBN	O	6	VC
8	assessed	assess	I-VP	VBN	O	7	VC
9	in	in	B-PP	IN	O	8	VMOD
10	clinical	clinical	B-NP	JJ	O	11	NMOD
11	trials	trial	I-NP	NNS	O	9	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	patients	patient	B-NP	NNS	O	12	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	various	various	B-NP	JJ	O	14	PMOD
16	solid	solid	I-NP	JJ	O	15	NMOD
17	and	and	I-NP	CC	O	15	NMOD
18	haematological	haematological	I-NP	JJ	O	15	NMOD
19	malignancies	malignancy	I-NP	NNS	O	15	NMOD
20	.	.	O	.	O	6	P

1	We	We	B-NP	PRP	O	2	SUB
2	undertook	undertake	B-VP	VBD	O	0	ROOT
3	an	an	B-NP	DT	O	5	NMOD
4	open-label	open-label	I-NP	JJ	O	5	NMOD
5	study	study	I-NP	NN	O	2	OBJ
6	using	use	B-VP	VBG	O	2	VMOD
7	thalidomide	thalidomide	B-NP	IN	O	6	VMOD
8	100	100	I-NP	CD	O	9	NMOD
9	mg	mg	I-NP	NN	O	7	PMOD
10	once	once	B-ADVP	RB	O	2	VMOD
11	daily	daily	I-ADVP	RB	O	10	AMOD
12	for	for	B-PP	IN	O	10	AMOD
13	up	up	B-NP	RB	O	16	NMOD
14	to	to	I-NP	TO	O	13	AMOD
15	6	6	I-NP	CD	O	13	AMOD
16	months	month	I-NP	NNS	O	12	PMOD
17	in	in	B-PP	IN	O	16	NMOD
18	20	20	B-NP	CD	O	19	NMOD
19	men	man	I-NP	NNS	O	17	PMOD
20	with	with	B-PP	IN	O	19	NMOD
21	androgen-independent	androgen-independent	B-NP	JJ	O	23	NMOD
22	prostate	prostate	I-NP	NN	O	23	NMOD
23	cancer	cancer	I-NP	NN	O	20	PMOD
24	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	17	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	seven	seven	I-NP	CD	O	4	NMOD
4	men	man	I-NP	NNS	O	1	PMOD
5	who	who	B-NP	WP	O	4	NMOD
6	completed	complete	B-VP	VBD	O	5	SBAR
7	six	six	B-NP	CD	O	8	NMOD
8	months	month	I-NP	NNS	O	6	OBJ
9	on	on	B-PP	IN	O	8	NMOD
10	thalidomide	thalidomide	B-NP	NN	O	9	PMOD
11	,	,	O	,	O	17	P
12	subclinical	subclinical	B-NP	JJ	O	13	NMOD
13	evidence	evidence	I-NP	NN	O	17	SUB
14	of	of	B-PP	IN	O	13	NMOD
15	peripheral	peripheral	B-NP	JJ	O	16	NMOD
16	neuropathy	neuropathy	I-NP	NN	O	14	PMOD
17	was	be	B-VP	VBD	O	0	ROOT
18	found	find	I-VP	VBN	O	17	VC
19	in	in	B-PP	IN	O	18	VMOD
20	four	four	B-NP	CD	O	19	PMOD
21	before	before	B-PP	IN	O	20	NMOD
22	treatment	treatment	B-NP	NN	O	21	PMOD
23	,	,	O	,	O	17	VMOD
24	but	but	O	CC	O	23	VMOD
25	in	in	B-PP	IN	O	24	DEP
26	all	all	B-NP	DT	O	27	NMOD
27	seven	seven	I-NP	CD	O	25	PMOD
28	at	at	B-PP	IN	O	25	PMOD
29	repeat	repeat	B-NP	NN	O	30	NMOD
30	testing	testing	I-NP	NN	O	25	PMOD
31	.	.	O	.	O	17	P

1	Central	Central	B-NP	JJ	O	4	NMOD
2	nervous	nervous	I-NP	JJ	O	4	NMOD
3	system	system	I-NP	NN	O	4	NMOD
4	toxicity	toxicity	I-NP	NN	O	16	NMOD
5	following	follow	B-PP	VBG	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	administration	administration	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	levobupivacaine	levobupivacaine	B-NP	NN	O	8	PMOD
10	for	for	B-PP	IN	O	7	NMOD
11	lumbar	lumbar	B-NP	NN	O	13	NMOD
12	plexus	plexus	I-NP	NN	O	13	NMOD
13	block	block	I-NP	NN	O	10	PMOD
14	:	:	O	:	O	4	P
15	A	A	B-NP	DT	O	16	NMOD
16	report	report	I-NP	NN	O	0	ROOT
17	of	of	B-PP	IN	O	16	NMOD
18	two	two	B-NP	CD	O	19	NMOD
19	cases	case	I-NP	NNS	O	17	PMOD
20	.	.	O	.	O	16	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	2	2	B-NP	CD	O	4	NMOD
4	cases	case	I-NP	NNS	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	grand	grand	B-NP	JJ	O	8	NMOD
7	mal	mal	I-NP	JJ	O	8	NMOD
8	seizures	seizure	I-NP	NNS	O	5	PMOD
9	following	follow	B-PP	VBG	O	2	VMOD
10	accidental	accidental	B-NP	JJ	O	12	NMOD
11	intravascular	intravascular	I-NP	JJ	O	12	NMOD
12	injection	injection	I-NP	NN	O	9	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	levobupivacaine	levobupivacaine	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	2	P

1	Immediately	Immediately	B-ADVP	RB	O	16	VMOD
2	after	after	B-PP	IN	O	1	PMOD
3	the	the	B-NP	DT	O	4	NMOD
4	administration	administration	I-NP	NN	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	levobupivacaine	levobupivacaine	B-NP	NN	O	8	NMOD
7	0.5	0.5	B-NP	CD	O	8	NMOD
8	%	%	I-NP	NN	O	5	PMOD
9	with	with	B-PP	IN	O	4	NMOD
10	epinephrine	epinephrine	B-NP	NN	O	12	NMOD
11	2.5	2.5	I-NP	CD	O	12	NMOD
12	microgram/mL	microgram/mL	I-NP	NN	O	9	PMOD
13	,	,	O	,	O	16	P
14	the	the	B-NP	DT	O	15	NMOD
15	patients	patient	I-NP	NNS	O	16	SUB
16	developed	develop	B-VP	VBD	O	0	ROOT
17	grand	grand	B-NP	JJ	O	19	NMOD
18	mal	mal	I-NP	JJ	O	19	NMOD
19	seizures	seizure	I-NP	NNS	O	16	OBJ
20	,	,	O	,	O	19	P
21	despite	despite	B-PP	IN	O	19	NMOD
22	negative	negative	B-NP	JJ	O	23	NMOD
23	aspiration	aspiration	I-NP	NN	O	29	NMOD
24	for	for	B-PP	IN	O	23	NMOD
25	blood	blood	B-NP	NN	O	24	PMOD
26	and	and	O	CC	O	29	NMOD
27	no	no	B-NP	DT	O	29	NMOD
28	clinical	clinical	I-NP	JJ	O	29	NMOD
29	signs	sign	I-NP	NNS	O	21	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	intravenous	intravenous	B-NP	JJ	O	33	NMOD
32	epinephrine	epinephrine	I-NP	NN	O	33	NMOD
33	administration	administration	I-NP	NN	O	30	PMOD
34	.	.	O	.	O	16	P

1	The	The	B-NP	DT	O	2	NMOD
2	seizures	seizure	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	0	ROOT
4	successfully	successfully	I-VP	RB	O	3	VMOD
5	treated	treat	I-VP	VBN	O	3	VC
6	with	with	B-PP	IN	O	5	VMOD
7	sodium	sodium	B-NP	NN	O	8	NMOD
8	thiopental	thiopental	I-NP	NN	O	6	PMOD
9	in	in	B-PP	IN	O	5	VMOD
10	addition	addition	B-NP	NN	O	9	PMOD
11	to	to	B-PP	TO	O	10	NMOD
12	succinylcholine	succinylcholine	B-NP	NN	O	11	PMOD
13	in	in	B-PP	IN	O	5	VMOD
14	1	1	B-NP	CD	O	15	NMOD
15	patient	patient	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	3	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Although	Although	B-SBAR	IN	O	26	VMOD
4	levobupivacaine	levobupivacaine	B-NP	NN	O	5	SUB
5	may	may	B-VP	MD	O	3	SBAR
6	have	have	I-VP	VB	O	5	VC
7	a	a	B-NP	DT	O	11	NMOD
8	safer	safe	I-NP	JJR	O	11	NMOD
9	cardiac	cardiac	I-NP	JJ	O	11	NMOD
10	toxicity	toxicity	I-NP	NN	O	11	NMOD
11	profile	profile	I-NP	NN	O	6	OBJ
12	than	than	B-PP	IN	O	6	VMOD
13	racemic	racemic	B-NP	JJ	O	14	NMOD
14	bupivacaine	bupivacaine	I-NP	NN	O	12	PMOD
15	,	,	O	,	O	26	P
16	if	if	B-SBAR	IN	O	26	VMOD
17	adequate	adequate	B-NP	JJ	O	18	NMOD
18	amounts	amount	I-NP	NNS	O	21	SUB
19	of	of	B-PP	IN	O	18	NMOD
20	levobupivacaine	levobupivacaine	B-NP	NN	O	19	PMOD
21	reach	reach	B-VP	VBP	O	16	SBAR
22	the	the	B-NP	DT	O	23	NMOD
23	circulation	circulation	I-NP	NN	O	21	OBJ
24	,	,	O	,	O	26	P
25	it	it	B-NP	PRP	O	26	SUB
26	will	will	B-VP	MD	O	1	NMOD
27	result	result	I-VP	VB	O	26	VC
28	in	in	B-PP	IN	O	27	VMOD
29	convulsions	convulsion	B-NP	NNS	O	28	PMOD
30	.	.	O	.	O	1	P

1	Myotonia	Myotonia	B-NP	NN	B-protein	2	NMOD
2	congenita	congenita	I-NP	NN	I-protein	6	SUB
3	(	(	O	(	O	5	DEP
4	MC	MC	B-NP	NN	O	5	DEP
5	)	)	O	)	O	2	NMOD
6	is	be	B-VP	VBZ	O	0	ROOT
7	caused	cause	I-VP	VBN	O	6	VC
8	by	by	B-PP	IN	O	7	VMOD
9	a	a	B-NP	DT	O	10	NMOD
10	defect	defect	I-NP	NN	O	8	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	17	NMOD
13	skeletal	skeletal	I-NP	JJ	O	17	NMOD
14	muscle	muscle	I-NP	NN	O	17	NMOD
15	chloride	chloride	I-NP	NN	O	17	NMOD
16	channel	channel	I-NP	NN	O	17	NMOD
17	function	function	I-NP	NN	O	11	PMOD
18	,	,	O	,	O	10	P
19	which	which	B-NP	WDT	O	10	NMOD
20	may	may	B-VP	MD	O	19	SBAR
21	cause	cause	I-VP	VB	O	20	VC
22	sustained	sustained	B-NP	JJ	O	24	NMOD
23	membrane	membrane	I-NP	NN	O	24	NMOD
24	depolarisation	depolarisation	I-NP	NN	O	21	OBJ
25	.	.	O	.	O	6	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	7	NMOD
4	previously	previously	I-NP	RB	O	5	AMOD
5	healthy	healthy	I-NP	JJ	O	7	NMOD
6	32-year-old	32-year-old	I-NP	JJ	O	7	NMOD
7	woman	woman	I-NP	NN	O	2	OBJ
8	who	who	B-NP	WP	O	7	NMOD
9	developed	develop	B-VP	VBD	O	8	SBAR
10	a	a	B-NP	DT	O	13	NMOD
11	life-threatening	life-threatening	I-NP	JJ	O	13	NMOD
12	muscle	muscle	I-NP	NN	O	13	NMOD
13	spasm	spasm	I-NP	NN	O	17	NMOD
14	and	and	O	CC	O	17	NMOD
15	secondary	secondary	B-NP	JJ	O	17	NMOD
16	ventilation	ventilation	I-NP	NN	O	17	NMOD
17	difficulties	difficulty	I-NP	NNS	O	9	OBJ
18	following	follow	B-PP	VBG	O	17	NMOD
19	a	a	B-NP	DT	O	21	NMOD
20	preoperative	preoperative	I-NP	JJ	O	21	NMOD
21	injection	injection	I-NP	NN	O	18	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	suxamethonium	suxamethonium	B-NP	NN	O	22	PMOD
24	.	.	O	.	O	2	P

1	Here	Here	B-ADVP	RB	O	3	VMOD
2	we	we	B-NP	PRP	O	3	SUB
3	sought	seek	B-VP	VBD	O	0	ROOT
4	to	to	I-VP	TO	O	5	VMOD
5	generate	generate	I-VP	VB	O	3	VMOD
6	information	information	B-NP	NN	O	5	OBJ
7	with	with	B-PP	IN	O	5	VMOD
8	regard	regard	B-NP	NN	O	7	PMOD
9	to	to	B-PP	TO	O	8	NMOD
10	the	the	B-NP	DT	O	12	NMOD
11	interictal	interictal	I-NP	JJ	O	12	NMOD
12	period	period	I-NP	NN	O	9	PMOD
13	in	in	B-PP	IN	O	8	NMOD
14	animals	animal	B-NP	NNS	O	13	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	pilocarpine	pilocarpine	B-NP	NN	O	18	NMOD
17	induced	induced	I-NP	JJ	O	18	NMOD
18	epilepsy	epilepsy	I-NP	NN	O	15	PMOD
19	.	.	O	.	O	3	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	5	NMOD
4	hyperventilation	hyperventilation	I-NP	NN	O	5	NMOD
5	maneuver	maneuver	I-NP	NN	O	6	SUB
6	caused	cause	B-VP	VBD	O	1	NMOD
7	a	a	B-NP	DT	O	8	NMOD
8	decrease	decrease	I-NP	NN	O	6	OBJ
9	in	in	B-PP	IN	O	8	NMOD
10	spontaneous	spontaneous	B-NP	JJ	O	11	NMOD
11	ventilation	ventilation	I-NP	NN	O	9	PMOD
12	in	in	B-PP	IN	O	8	NMOD
13	pilocarpine-treated	pilocarpine-treated	B-NP	JJ	O	16	NMOD
14	and	and	I-NP	CC	O	16	NMOD
15	control	control	I-NP	NN	O	16	NMOD
16	rats	rat	I-NP	NNS	O	12	PMOD
17	.	.	O	.	O	1	P

1	Increased	Increase	B-NP	VBN	O	4	NMOD
2	serum	serum	I-NP	NN	O	4	NMOD
3	soluble	soluble	I-NP	JJ	O	4	NMOD
4	Fas	Fas	I-NP	NN	B-protein	0	ROOT
5	in	in	B-PP	IN	O	4	NMOD
6	patients	patient	B-NP	NNS	O	5	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	acute	acute	B-NP	JJ	O	10	NMOD
9	liver	liver	I-NP	NN	O	10	NMOD
10	failure	failure	I-NP	NN	O	7	PMOD
11	due	due	B-PP	IN	O	4	NMOD
12	to	to	B-PP	TO	O	11	PMOD
13	paracetamol	paracetamol	B-NP	NN	O	14	NMOD
14	overdose	overdose	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	4	P

1	Levels	Level	B-NP	NNS	O	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	significantly	significantly	B-ADJP	RB	O	4	AMOD
4	greater	great	I-ADJP	JJR	O	2	PRD
5	in	in	B-PP	IN	O	4	AMOD
6	patients	patient	B-NP	NNS	O	5	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	acute	acute	B-NP	JJ	O	10	NMOD
9	liver	liver	I-NP	NN	O	10	NMOD
10	failure	failure	I-NP	NN	O	7	PMOD
11	due	due	B-PP	IN	O	4	AMOD
12	to	to	B-PP	TO	O	11	PMOD
13	paracetamol	paracetamol	B-NP	NN	O	14	NMOD
14	overdose	overdose	I-NP	NN	O	11	PMOD
15	(	(	O	(	O	29	DEP
16	median	median	B-NP	NN	O	28	NMOD
17	,	,	O	,	O	19	P
18	28.7	28.7	B-NP	CD	O	19	NMOD
19	U/mL	U/mL	I-NP	NNP	O	28	NMOD
20	;	;	O	:	O	28	P
21	range	range	B-NP	NN	O	28	NMOD
22	,	,	O	,	O	28	P
23	12.8-52.7	12.8-52.7	B-NP	CD	O	24	NMOD
24	U/mL	U/mL	I-NP	NN	O	28	NMOD
25	,	,	O	,	O	28	P
26	n	n	B-NP	NN	O	28	SUB
27	=	=	B-VP	SYM	O	28	VMOD
28	17	17	B-NP	CD	O	29	DEP
29	)	)	O	)	O	4	AMOD
30	than	than	B-PP	IN	O	4	AMOD
31	those	those	B-NP	DT	O	30	PMOD
32	due	due	B-PP	JJ	O	31	NMOD
33	to	to	B-PP	TO	O	32	AMOD
34	non-A	non-A	B-ADJP	JJ	O	33	PMOD
35	to	to	B-PP	TO	O	34	AMOD
36	E	E	B-NP	NN	O	37	NMOD
37	hepatitis	hepatitis	I-NP	NN	O	35	PMOD
38	(	(	O	(	O	56	DEP
39	median	median	B-NP	NN	O	53	NMOD
40	,	,	O	,	O	42	P
41	12.5	12.5	B-NP	CD	O	42	NMOD
42	U/mL	U/mL	I-NP	NNP	O	53	NMOD
43	;	;	O	:	O	53	P
44	range	range	B-NP	NN	O	53	NMOD
45	,	,	O	,	O	53	P
46	6.9-46.0	6.9-46.0	B-NP	CD	O	47	NMOD
47	U/mL	U/mL	I-NP	NN	O	53	NMOD
48	,	,	O	,	O	53	P
49	n	n	B-NP	NN	O	53	NMOD
50	=	=	B-VP	SYM	O	49	NMOD
51	7	7	B-NP	CD	O	50	AMOD
52	,	,	O	,	O	53	P
53	P	P	B-NP	NN	O	56	DEP
54	<	<	B-NP	SYM	O	53	NMOD
55	0.01	0.01	I-NP	CD	O	54	AMOD
56	)	)	O	)	O	37	NMOD
57	.	.	O	.	O	2	P

1	METHOD	METHOD	B-NP	NN	O	4	NMOD
2	:	:	O	:	O	1	P
3	Twenty-three	Twenty-three	B-NP	CD	O	4	NMOD
4	patients	patient	I-NP	NNS	O	31	SUB
5	suffering	suffer	B-VP	VBG	O	4	NMOD
6	from	from	B-PP	IN	O	5	VMOD
7	severe	severe	B-NP	JJ	O	10	NMOD
8	Parkinson	Parkinson	I-NP	NNP	O	9	NMOD
9	's	's	B-NP	POS	O	10	NMOD
10	disease	disease	I-NP	NN	O	6	PMOD
11	(	(	O	(	O	19	DEP
12	Stages	Stage	B-NP	NNS	O	19	DEP
13	III-V	III-V	B-NP	CD	O	12	NMOD
14	on	on	B-PP	IN	O	12	NMOD
15	Hoehn	Hoehn	B-NP	NNP	O	18	NMOD
16	and	and	I-NP	CC	O	18	NMOD
17	Yahr	Yahr	I-NP	NNP	O	18	NMOD
18	scale	scale	I-NP	NN	O	14	PMOD
19	)	)	O	)	O	4	NMOD
20	and	and	O	CC	O	31	VMOD
21	,	,	O	,	O	31	P
22	particularly	particularly	B-ADVP	RB	O	31	VMOD
23	bradykinesia	bradykinesia	B-NP	NN	O	31	SUB
24	,	,	O	,	O	31	P
25	rigidity	rigidity	B-NP	NN	O	31	SUB
26	,	,	O	,	O	31	P
27	and	and	O	CC	O	31	VMOD
28	levodopa	levodopa	B-NP	NN	O	30	NMOD
29	induced	induce	I-NP	VBN	O	30	NMOD
30	dyskinesias	dyskinesia	I-NP	NNS	O	31	SUB
31	underwent	undergo	B-VP	VBD	O	0	ROOT
32	bilateral	bilateral	B-NP	JJ	O	33	NMOD
33	implantation	implantation	I-NP	NN	O	31	OBJ
34	of	of	B-PP	IN	O	33	NMOD
35	electrodes	electrode	B-NP	NNS	O	34	PMOD
36	in	in	B-PP	IN	O	31	VMOD
37	the	the	B-NP	DT	O	38	NMOD
38	STN	STN	I-NP	NN	B-protein	36	PMOD
39	.	.	O	.	O	31	P

1	Ocular	Ocular	B-NP	JJ	O	3	NMOD
2	motility	motility	I-NP	NN	O	3	NMOD
3	changes	change	I-NP	NNS	O	0	ROOT
4	after	after	B-PP	IN	O	3	NMOD
5	subtenon	subtenon	B-NP	NN	O	7	NMOD
6	carboplatin	carboplatin	I-NP	NN	O	7	NMOD
7	chemotherapy	chemotherapy	I-NP	NN	O	4	PMOD
8	for	for	B-PP	IN	O	7	NMOD
9	retinoblastoma	retinoblastoma	B-NP	NN	O	8	PMOD
10	.	.	O	.	O	3	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Focal	Focal	B-NP	JJ	O	6	NMOD
4	subtenon	subtenon	I-NP	NN	O	6	NMOD
5	carboplatin	carboplatin	I-NP	NN	O	6	NMOD
6	injections	injection	I-NP	NNS	O	7	SUB
7	have	have	B-VP	VBP	O	1	NMOD
8	recently	recently	I-VP	RB	O	7	VMOD
9	been	be	I-VP	VBN	O	7	VC
10	used	use	I-VP	VBN	O	9	VC
11	as	as	B-PP	IN	O	10	VMOD
12	a	a	B-NP	DT	O	15	NMOD
13	presumably	presumably	I-NP	RB	O	14	AMOD
14	toxicity-free	toxicity-free	I-NP	JJ	O	15	NMOD
15	adjunct	adjunct	I-NP	NN	O	11	PMOD
16	to	to	B-PP	TO	O	15	NMOD
17	systemic	systemic	B-NP	JJ	O	18	NMOD
18	chemotherapy	chemotherapy	I-NP	NN	O	16	PMOD
19	for	for	B-PP	IN	O	15	NMOD
20	intraocular	intraocular	B-NP	JJ	O	21	NMOD
21	retinoblastoma	retinoblastoma	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	7	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	report	report	I-VP	VB	O	1	NMOD
5	our	our	B-NP	PRP$	O	7	NMOD
6	clinical	clinical	I-NP	JJ	O	7	NMOD
7	experience	experience	I-NP	NN	O	4	OBJ
8	with	with	B-PP	IN	O	7	NMOD
9	abnormal	abnormal	B-NP	JJ	O	11	NMOD
10	ocular	ocular	I-NP	JJ	O	11	NMOD
11	motility	motility	I-NP	NN	O	8	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	patients	patient	B-NP	NNS	O	12	PMOD
14	treated	treat	B-VP	VBN	O	13	NMOD
15	with	with	B-PP	IN	O	14	VMOD
16	subtenon	subtenon	B-NP	NN	O	18	NMOD
17	carboplatin	carboplatin	I-NP	NN	O	18	NMOD
18	chemotherapy	chemotherapy	I-NP	NN	O	15	PMOD
19	.	.	O	.	O	1	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	noted	note	B-VP	VBD	O	1	NMOD
5	abnormal	abnormal	B-NP	JJ	O	7	NMOD
6	ocular	ocular	I-NP	JJ	O	7	NMOD
7	motility	motility	I-NP	NN	O	4	OBJ
8	in	in	B-PP	IN	O	4	VMOD
9	10	10	B-NP	CD	O	11	NMOD
10	consecutive	consecutive	I-NP	JJ	O	11	NMOD
11	patients	patient	I-NP	NNS	O	8	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	retinoblastoma	retinoblastoma	B-NP	NN	B-protein	12	PMOD
14	who	who	B-NP	WP	I-protein	11	NMOD
15	had	have	B-VP	VBD	I-protein	14	SBAR
16	received	receive	I-VP	VBN	I-protein	18	NMOD
17	subtenon	subtenon	B-NP	NN	I-protein	18	NMOD
18	carboplatin	carboplatin	I-NP	NN	I-protein	15	OBJ
19	.	.	O	.	O	1	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Limitation	Limitation	B-NP	NN	O	7	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	ocular	ocular	B-NP	JJ	O	6	NMOD
6	motility	motility	I-NP	NN	O	4	PMOD
7	was	be	B-VP	VBD	O	1	NMOD
8	detected	detect	I-VP	VBN	O	7	VC
9	in	in	B-PP	IN	O	8	VMOD
10	all	all	B-NP	DT	O	12	NMOD
11	12	12	I-NP	CD	O	12	NMOD
12	eyes	eye	I-NP	NNS	O	9	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	10	10	B-NP	CD	O	15	NMOD
15	patients	patient	I-NP	NNS	O	13	PMOD
16	treated	treat	B-VP	VBN	O	15	NMOD
17	for	for	B-PP	IN	O	16	VMOD
18	intraocular	intraocular	B-NP	JJ	O	19	NMOD
19	retinoblastoma	retinoblastoma	I-NP	NN	O	17	PMOD
20	with	with	B-PP	IN	O	9	PMOD
21	1	1	B-NP	CD	O	23	AMOD
22	to	to	I-NP	TO	O	23	AMOD
23	6	6	I-NP	CD	O	24	NMOD
24	injections	injection	I-NP	NNS	O	20	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	subtenon	subtenon	B-NP	NN	O	27	NMOD
27	carboplatin	carboplatin	I-NP	NN	O	25	PMOD
28	as	as	B-PP	IN	O	8	VMOD
29	part	part	B-NP	NN	O	28	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	multimodality	multimodality	B-NP	JJ	O	32	NMOD
32	therapy	therapy	I-NP	NN	O	30	PMOD
33	.	.	O	.	O	1	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Subtenon	Subtenon	B-NP	NN	O	5	NMOD
4	carboplatin	carboplatin	I-NP	NN	O	5	NMOD
5	chemotherapy	chemotherapy	I-NP	NN	O	6	SUB
6	is	be	B-VP	VBZ	O	1	NMOD
7	associated	associate	I-VP	VBN	O	6	VC
8	with	with	B-PP	IN	O	7	VMOD
9	significant	significant	B-NP	JJ	O	10	NMOD
10	fibrosis	fibrosis	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	orbital	orbital	B-NP	JJ	O	14	NMOD
13	soft	soft	I-NP	JJ	O	14	NMOD
14	tissues	tissue	I-NP	NNS	O	11	PMOD
15	,	,	O	,	O	6	P
16	leading	lead	B-VP	VBG	O	6	VMOD
17	to	to	B-PP	TO	O	16	VMOD
18	mechanical	mechanical	B-NP	JJ	O	19	NMOD
19	restriction	restriction	I-NP	NN	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	eye	eye	B-NP	NN	O	22	NMOD
22	movements	movement	I-NP	NNS	O	20	PMOD
23	and	and	O	CC	O	16	VMOD
24	making	make	B-VP	VBG	O	16	VMOD
25	subsequent	subsequent	B-NP	JJ	O	26	AMOD
26	enucleation	enucleation	I-NP	NN	O	24	VMOD
27	difficult	difficult	B-ADJP	JJ	O	26	AMOD
28	.	.	O	.	O	1	P

1	Ethambutol	Ethambutol	B-NP	NN	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	optic	optic	I-NP	JJ	O	4	NMOD
4	neuropathy	neuropathy	I-NP	NN	O	0	ROOT
5	.	.	O	.	O	4	P

1	PURPOSE	PURPOSE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	demonstrate	demonstrate	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	association	association	I-NP	NN	O	4	OBJ
7	between	between	B-PP	IN	O	6	NMOD
8	ethambutol	ethambutol	B-NP	NN	O	11	NMOD
9	and	and	O	CC	O	11	NMOD
10	optic	optic	B-NP	JJ	O	11	NMOD
11	neuropathy	neuropathy	I-NP	NN	O	7	PMOD
12	.	.	O	.	O	1	P

1	METHOD	METHOD	B-NP	NN	O	4	NMOD
2	:	:	O	:	O	1	P
3	Thirteen	Thirteen	B-NP	CD	O	4	NMOD
4	patients	patient	I-NP	NNS	O	29	SUB
5	who	who	B-NP	WP	O	4	NMOD
6	developed	develop	B-VP	VBD	O	5	SBAR
7	optic	optic	B-NP	JJ	O	8	NMOD
8	neuropathy	neuropathy	I-NP	NN	O	6	OBJ
9	after	after	B-PP	IN	O	6	VMOD
10	being	be	B-VP	VBG	O	9	PMOD
11	treated	treat	I-VP	VBN	O	10	NMOD
12	with	with	B-PP	IN	O	11	VMOD
13	ethambutol	ethambutol	B-NP	NN	O	12	PMOD
14	for	for	B-PP	IN	O	11	VMOD
15	tuberculosis	tuberculosis	B-NP	NN	O	14	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	21	NMOD
18	lung	lung	I-NP	NN	O	21	NMOD
19	or	or	I-NP	CC	O	21	NMOD
20	lymph	lymph	I-NP	NN	O	21	NMOD
21	node	node	I-NP	NN	O	16	PMOD
22	at	at	B-PP	IN	O	11	VMOD
23	Siriraj	Siriraj	B-NP	NNP	O	24	NMOD
24	Hospital	Hospital	I-NP	NNP	O	22	PMOD
25	between	between	B-PP	IN	O	22	PMOD
26	1997	1997	B-NP	CD	O	28	NMOD
27	and	and	I-NP	CC	O	28	NMOD
28	2001	2001	I-NP	CD	O	25	PMOD
29	were	be	B-VP	VBD	O	0	ROOT
30	retrospectively	retrospectively	I-VP	RB	O	29	VMOD
31	reviewed	review	I-VP	VBN	O	29	VC
32	.	.	O	.	O	29	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	All	All	B-NP	DT	O	4	NMOD
4	patients	patient	I-NP	NNS	O	5	SUB
5	had	have	B-VP	VBD	O	1	NMOD
6	optic	optic	B-NP	JJ	O	7	NMOD
7	neuropathy	neuropathy	I-NP	NN	O	5	OBJ
8	between	between	B-PP	IN	O	5	VMOD
9	1	1	B-NP	CD	O	11	AMOD
10	to	to	I-NP	TO	O	11	AMOD
11	6	6	I-NP	CD	O	12	NMOD
12	months	month	I-NP	NNS	O	8	PMOD
13	(	(	O	(	O	18	DEP
14	mean	mean	B-NP	NN	O	18	DEP
15	=	=	B-VP	SYM	O	14	NMOD
16	2.9	2.9	B-NP	CD	O	17	NMOD
17	months	month	I-NP	NNS	O	15	AMOD
18	)	)	O	)	O	12	NMOD
19	after	after	B-PP	IN	O	5	VMOD
20	starting	start	B-VP	VBG	O	19	PMOD
21	ethambutol	ethambutol	B-NP	NN	O	22	NMOD
22	therapy	therapy	I-NP	NN	O	20	OBJ
23	at	at	B-PP	IN	O	22	NMOD
24	a	a	B-NP	DT	O	25	NMOD
25	dosage	dosage	I-NP	NN	O	23	PMOD
26	ranging	range	B-VP	VBG	O	25	NMOD
27	from	from	B-PP	IN	O	31	NMOD
28	13	13	B-NP	CD	O	27	PMOD
29	to	to	I-NP	TO	O	27	AMOD
30	20	20	I-NP	CD	O	27	AMOD
31	mg/kg/day	mg/kg/day	I-NP	NN	O	26	OBJ
32	(	(	O	(	O	37	DEP
33	mean	mean	B-NP	NN	O	37	DEP
34	=	=	B-VP	SYM	O	33	NMOD
35	17	17	B-NP	CD	O	36	NMOD
36	mg/kg/day	mg/kg/day	I-NP	NN	O	34	AMOD
37	)	)	O	)	O	5	VMOD
38	.	.	O	.	O	1	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	8	VMOD
2	:	:	O	:	O	8	P
3	Early	Early	B-NP	JJ	O	4	NMOD
4	recognition	recognition	I-NP	NN	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	optic	optic	B-NP	JJ	O	7	NMOD
7	neuropathy	neuropathy	I-NP	NN	O	5	PMOD
8	should	should	B-VP	MD	O	0	ROOT
9	be	be	I-VP	VB	O	8	VC
10	considered	consider	I-VP	VBN	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	patients	patient	B-NP	NNS	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	ethambutol	ethambutol	B-NP	NN	O	15	NMOD
15	therapy	therapy	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	8	P

1	Treatment	Treatment	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	compensatory	compensatory	B-NP	JJ	O	5	NMOD
4	gustatory	gustatory	I-NP	JJ	O	5	NMOD
5	hyperhidrosis	hyperhidrosis	I-NP	NN	O	2	PMOD
6	with	with	B-PP	IN	O	1	NMOD
7	topical	topical	B-NP	JJ	O	8	NMOD
8	glycopyrrolate	glycopyrrolate	I-NP	NN	O	6	PMOD
9	.	.	O	.	O	1	P

1	After	After	B-PP	IN	O	9	VMOD
2	applying	apply	B-VP	VBG	O	1	PMOD
3	topical	topical	B-NP	JJ	O	4	NMOD
4	glycopyrrolate	glycopyrrolate	I-NP	NN	O	2	OBJ
5	,	,	O	,	O	9	P
6	the	the	B-NP	DT	O	8	NMOD
7	subjective	subjective	I-NP	JJ	O	8	NMOD
8	effect	effect	I-NP	NN	O	9	SUB
9	was	be	B-VP	VBD	O	0	ROOT
10	excellent	excellent	B-ADJP	JJ	O	9	PRD
11	(	(	O	(	O	10	AMOD
12	no	no	B-NP	DT	O	13	NMOD
13	sweating	sweating	I-NP	NN	O	11	PMOD
14	after	after	B-PP	IN	O	13	NMOD
15	eating	eat	B-VP	VBG	O	14	PMOD
16	hot	hot	B-NP	JJ	O	18	NMOD
17	spicy	spicy	I-NP	NN	O	18	NMOD
18	food	food	I-NP	NN	O	15	OBJ
19	)	)	O	)	O	18	NMOD
20	in	in	B-PP	IN	O	15	VMOD
21	10	10	B-NP	CD	O	22	NMOD
22	patients	patient	I-NP	NNS	O	20	PMOD
23	(	(	O	(	O	26	DEP
24	77	77	B-NP	CD	O	25	NMOD
25	%	%	I-NP	NN	O	26	DEP
26	)	)	O	)	O	22	NMOD
27	,	,	O	,	O	13	P
28	and	and	O	CC	O	27	PMOD
29	fair	fair	B-ADJP	JJ	O	28	PRD
30	(	(	O	(	O	34	DEP
31	clearly	clearly	B-VP	RB	O	32	AMOD
32	reduced	reduce	I-VP	VBN	O	33	NMOD
33	sweating	sweating	B-NP	NN	O	34	DEP
34	)	)	O	)	O	29	AMOD
35	in	in	B-PP	IN	O	29	AMOD
36	3	3	B-NP	CD	O	37	NMOD
37	patients	patient	I-NP	NNS	O	35	PMOD
38	(	(	O	(	O	41	DEP
39	23	23	B-NP	CD	O	40	NMOD
40	%	%	I-NP	NN	O	41	DEP
41	)	)	O	)	O	37	NMOD
42	.	.	O	.	O	9	P

1	Adverse	Adverse	B-NP	JJ	O	2	NMOD
2	effects	effect	I-NP	NNS	O	3	SUB
3	included	include	B-VP	VBD	O	0	ROOT
4	a	a	B-NP	DT	O	7	NMOD
5	mildly	mildly	I-NP	RB	O	6	AMOD
6	dry	dry	I-NP	JJ	O	7	NMOD
7	mouth	mouth	I-NP	NN	O	11	NMOD
8	and	and	O	CC	O	11	NMOD
9	a	a	B-NP	DT	O	11	NMOD
10	sore	sore	I-NP	JJ	O	11	NMOD
11	throat	throat	I-NP	NN	O	23	NMOD
12	in	in	B-PP	IN	O	11	NMOD
13	2	2	B-NP	CD	O	14	NMOD
14	patients	patient	I-NP	NNS	O	12	PMOD
15	(	(	O	(	O	19	DEP
16	2	2	B-NP	CD	O	17	AMOD
17	%	%	I-NP	NN	O	18	NMOD
18	glycopyrrolate	glycopyrrolate	I-NP	NN	O	19	DEP
19	)	)	O	)	O	11	NMOD
20	,	,	O	,	O	23	P
21	a	a	B-NP	DT	O	23	NMOD
22	light	light	I-NP	JJ	O	23	NMOD
23	headache	headache	I-NP	NN	O	3	OBJ
24	in	in	B-PP	IN	O	23	NMOD
25	1	1	B-NP	CD	O	26	NMOD
26	patient	patient	I-NP	NN	O	24	PMOD
27	(	(	O	(	O	31	DEP
28	1.5	1.5	B-NP	CD	O	29	AMOD
29	%	%	I-NP	NN	O	30	NMOD
30	glycopyrrolate	glycopyrrolate	I-NP	NN	O	31	DEP
31	)	)	O	)	O	23	NMOD
32	.	.	O	.	O	3	P

1	Pain	Pain	B-NP	NN	B-protein	15	NMOD
2	on	on	B-PP	IN	O	1	NMOD
3	injection	injection	B-NP	NN	O	2	PMOD
4	(	(	O	(	O	15	NMOD
5	80	80	B-NP	CD	O	8	NMOD
6	vs.	vs.	I-NP	IN	O	8	NMOD
7	20	20	B-NP	CD	O	8	NMOD
8	%	%	I-NP	NN	O	15	NMOD
9	,	,	O	,	O	15	P
10	p	p	B-NP	NN	O	15	NMOD
11	<	<	B-NP	SYM	O	10	NMOD
12	0.01	0.01	I-NP	CD	O	11	AMOD
13	)	)	O	)	O	10	NMOD
14	and	and	O	CC	O	15	NMOD
15	thrombophlebitis	thrombophlebitis	B-NP	NN	O	0	ROOT
16	(	(	O	(	O	15	NMOD
17	93.3	93.3	B-NP	CD	O	20	NMOD
18	vs.	vs.	B-PP	IN	O	20	NMOD
19	6.6	6.6	B-NP	CD	O	20	NMOD
20	%	%	I-NP	NN	O	26	SUB
21	,	,	O	,	O	26	P
22	p	p	B-NP	NN	O	26	SUB
23	<	<	B-NP	SYM	O	22	NMOD
24	0.001	0.001	I-NP	CD	O	23	AMOD
25	)	)	O	)	O	22	NMOD
26	occurred	occur	B-VP	VBD	O	16	SBAR
27	more	more	B-ADVP	RBR	O	28	AMOD
28	frequently	frequently	I-ADVP	RB	O	26	VMOD
29	with	with	B-PP	IN	O	26	VMOD
30	AM149	AM149	B-NP	NN	O	29	PMOD
31	than	than	B-PP	IN	O	26	VMOD
32	with	with	B-PP	IN	O	31	PMOD
33	Disoprivan	Disoprivan	B-NP	NNP	O	32	PMOD
34	.	.	O	.	O	15	P

1	In	In	B-SBAR	IN	O	13	VMOD
2	order	order	O	NN	O	1	DEP
3	to	to	B-VP	TO	O	4	VMOD
4	quantify	quantify	I-VP	VB	O	1	SBAR
5	the	the	B-NP	DT	O	6	NMOD
6	incidence	incidence	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	these	these	B-NP	DT	O	10	NMOD
9	cardiac	cardiac	I-NP	JJ	O	10	NMOD
10	events	event	I-NP	NNS	O	7	PMOD
11	,	,	O	,	O	13	P
12	we	we	B-NP	PRP	O	13	SUB
13	performed	perform	B-VP	VBD	O	0	ROOT
14	a	a	B-NP	DT	O	15	NMOD
15	meta-analysis	meta-analysis	I-NP	NN	O	13	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	clinical	clinical	B-NP	JJ	O	18	NMOD
18	trials	trial	I-NP	NNS	O	16	PMOD
19	comparing	compare	B-VP	VBG	O	18	NMOD
20	VNR	VNR	B-NP	NN	B-protein	19	OBJ
21	with	with	B-PP	IN	O	19	VMOD
22	other	other	B-NP	JJ	O	24	NMOD
23	chemotherapeutic	chemotherapeutic	I-NP	JJ	O	24	NMOD
24	agents	agent	I-NP	NNS	O	21	PMOD
25	in	in	B-PP	IN	O	24	NMOD
26	the	the	B-NP	DT	O	27	NMOD
27	treatment	treatment	I-NP	NN	O	25	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	various	various	B-NP	JJ	O	30	NMOD
30	malignancies	malignancy	I-NP	NNS	O	28	PMOD
31	.	.	O	.	O	13	P

1	Randomized	Randomize	B-VP	VBN	O	0	ROOT
2	clinical	clinical	B-NP	JJ	O	3	NMOD
3	trials	trial	I-NP	NNS	O	1	OBJ
4	comparing	compare	B-VP	VBG	O	3	NMOD
5	VNR	VNR	B-NP	NN	B-protein	4	OBJ
6	with	with	B-PP	IN	O	4	VMOD
7	other	other	B-NP	JJ	O	8	NMOD
8	drugs	drug	I-NP	NNS	O	6	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	treatment	treatment	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	cancer	cancer	B-NP	NN	O	12	PMOD
14	were	be	B-VP	VBD	O	1	VMOD
15	searched	search	I-VP	VBN	O	14	VC
16	in	in	B-PP	IN	O	15	VMOD
17	Medline	Medline	B-NP	NN	O	24	NMOD
18	,	,	O	,	O	24	P
19	Embase	Embase	B-NP	NN	B-protein	24	NMOD
20	,	,	O	,	O	24	P
21	Evidence-based	Evidence-based	B-NP	JJ	B-protein	24	NMOD
22	Medicine	Medicine	I-NP	NNP	I-protein	24	NMOD
23	Reviews	Reviews	I-NP	NNP	I-protein	24	NMOD
24	databases	database	I-NP	NNS	I-protein	28	NMOD
25	and	and	O	CC	O	28	NMOD
26	the	the	B-NP	DT	O	28	NMOD
27	Cochrane	Cochrane	I-NP	NN	O	28	NMOD
28	library	library	I-NP	NN	O	16	PMOD
29	from	from	B-PP	IN	O	28	NMOD
30	1987	1987	B-NP	CD	O	29	PMOD
31	to	to	B-PP	TO	O	29	PMOD
32	2002	2002	B-NP	CD	O	31	PMOD
33	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	risk	risk	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	VNR	VNR	B-NP	NN	B-protein	6	NMOD
5	cardiac	cardiac	I-NP	JJ	O	6	NMOD
6	events	event	I-NP	NNS	O	3	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	similar	similar	B-ADJP	JJ	O	7	PRD
9	to	to	B-PP	TO	O	8	AMOD
10	vindesine	vindesine	B-NP	NN	O	17	NMOD
11	(	(	O	(	O	13	DEP
12	VDS	VDS	B-NP	NN	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	and	and	O	CC	O	17	NMOD
15	other	other	B-NP	JJ	O	17	NMOD
16	cardiotoxic	cardiotoxic	I-NP	JJ	O	17	NMOD
17	drugs	drug	I-NP	NNS	O	9	PMOD
18	[	[	O	(	O	29	DEP
19	fluorouracil	fluorouracil	B-NP	NN	O	28	NMOD
20	,	,	O	,	O	28	P
21	anthracyclines	anthracycline	B-NP	NNS	O	28	NMOD
22	,	,	O	,	O	28	P
23	gemcitabine	gemcitabine	B-NP	NN	O	28	NMOD
24	(	(	O	(	O	26	DEP
25	GEM	GEM	B-NP	NN	O	26	DEP
26	)	)	O	)	O	28	NMOD
27	em	em	B-NP	NN	O	28	NMOD
28	leader	leader	I-NP	NN	O	29	DEP
29	]	]	O	)	O	7	VMOD
30	.	.	O	.	O	7	P

1	We	We	B-NP	PRP	O	2	SUB
2	present	present	B-VP	VBP	O	0	ROOT
3	magnetic	magnetic	B-NP	JJ	O	6	NMOD
4	resonance	resonance	I-NP	NN	O	6	NMOD
5	imaging	imaging	I-NP	NN	O	6	NMOD
6	findings	finding	I-NP	NNS	O	2	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	a	a	B-NP	DT	O	10	NMOD
9	5-year-old	5-year-old	I-NP	JJ	O	10	NMOD
10	girl	girl	I-NP	NN	O	7	PMOD
11	who	who	B-NP	WP	O	10	NMOD
12	had	have	B-VP	VBD	O	11	SBAR
13	a	a	B-NP	DT	O	18	NMOD
14	rapidly	rapidly	I-NP	RB	O	15	AMOD
15	installing	instal	I-NP	VBG	O	18	NMOD
16	hemolytic	hemolytic	I-NP	JJ	O	18	NMOD
17	anemia	anemia	I-NP	NN	O	18	NMOD
18	crisis	crisis	I-NP	NN	O	12	OBJ
19	induced	induce	B-VP	VBN	O	18	NMOD
20	by	by	B-PP	IN	O	19	VMOD
21	trimethoprim-sulfomethoxazole	trimethoprim-sulfomethoxazole	B-NP	NN	O	20	PMOD
22	,	,	O	,	O	2	P
23	resulting	result	B-VP	VBG	O	2	VMOD
24	in	in	B-PP	IN	O	23	VMOD
25	cerebral	cerebral	B-NP	JJ	O	26	NMOD
26	anoxia	anoxia	I-NP	NN	O	24	PMOD
27	leading	lead	B-VP	VBG	O	26	NMOD
28	to	to	B-PP	TO	O	27	VMOD
29	permanent	permanent	B-NP	JJ	O	30	NMOD
30	damage	damage	I-NP	NN	O	28	PMOD
31	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	natural	natural	I-NP	JJ	O	3	NMOD
3	history	history	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	Vigabatrin	Vigabatrin	B-NP	NN	O	9	NMOD
6	associated	associated	I-NP	JJ	O	9	NMOD
7	visual	visual	I-NP	JJ	O	9	NMOD
8	field	field	I-NP	NN	O	9	NMOD
9	defects	defect	I-NP	NNS	O	4	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	patients	patient	B-NP	NNS	O	10	PMOD
12	electing	elect	B-VP	VBG	O	11	NMOD
13	to	to	I-VP	TO	O	14	VMOD
14	continue	continue	I-VP	VB	O	12	VMOD
15	their	their	B-NP	PRP$	O	16	NMOD
16	medication	medication	I-NP	NN	O	14	OBJ
17	.	.	O	.	O	3	P

1	PURPOSE	PURPOSE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	determine	determine	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	7	NMOD
6	natural	natural	I-NP	JJ	O	7	NMOD
7	history	history	I-NP	NN	O	4	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	visual	visual	B-NP	JJ	O	11	NMOD
10	field	field	I-NP	NN	O	11	NMOD
11	defects	defect	I-NP	NNS	O	8	PMOD
12	in	in	B-PP	IN	O	7	NMOD
13	a	a	B-NP	DT	O	14	NMOD
14	group	group	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	patients	patient	B-NP	NNS	O	15	PMOD
17	known	know	B-VP	VBN	O	16	NMOD
18	to	to	I-VP	TO	O	19	VMOD
19	have	have	I-VP	VB	O	17	VMOD
20	Vigabatrin-associated	Vigabatrin-associated	B-NP	JJ	O	21	NMOD
21	changes	change	I-NP	NNS	O	19	OBJ
22	who	who	B-NP	WP	O	21	NMOD
23	elected	elect	B-VP	VBD	O	22	SBAR
24	to	to	I-VP	TO	O	25	VMOD
25	continue	continue	I-VP	VB	O	23	VMOD
26	the	the	B-NP	DT	O	27	NMOD
27	medication	medication	I-NP	NN	O	25	OBJ
28	because	because	B-PP	IN	O	25	VMOD
29	of	of	I-PP	IN	O	28	PMOD
30	good	good	B-NP	JJ	O	32	NMOD
31	seizure	seizure	I-NP	NN	O	32	NMOD
32	control	control	I-NP	NN	O	29	PMOD
33	.	.	O	.	O	4	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Established	Establish	B-NP	VBN	O	6	NMOD
4	visual	visual	I-NP	JJ	O	6	NMOD
5	field	field	I-NP	NN	O	6	NMOD
6	defects	defect	I-NP	NNS	O	14	SUB
7	presumed	presume	B-VP	VBN	O	14	VMOD
8	to	to	I-VP	TO	O	9	VMOD
9	be	be	I-VP	VB	O	14	VMOD
10	due	due	B-PP	IN	O	14	VMOD
11	to	to	B-PP	TO	O	10	PMOD
12	Vigabatrin	Vigabatrin	B-NP	NN	O	13	NMOD
13	therapy	therapy	I-NP	NN	O	14	SUB
14	did	do	B-VP	VBD	O	1	NMOD
15	not	not	I-VP	RB	O	14	VMOD
16	usually	usually	I-VP	RB	O	14	VMOD
17	progress	progress	I-VP	VBP	O	14	VMOD
18	in	in	B-PP	IN	O	17	VMOD
19	spite	spite	B-NP	NN	O	18	PMOD
20	of	of	B-PP	IN	O	18	PMOD
21	continuing	continue	B-NP	VBG	O	22	NMOD
22	use	use	I-NP	NN	O	18	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	the	the	B-NP	DT	O	25	NMOD
25	medication	medication	I-NP	NN	O	23	PMOD
26	.	.	O	.	O	1	P

1	Induction	Induction	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	rosaceiform	rosaceiform	B-NP	JJ	O	4	NMOD
4	dermatitis	dermatitis	I-NP	NN	O	2	PMOD
5	during	during	B-PP	IN	O	1	NMOD
6	treatment	treatment	B-NP	NN	O	5	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	facial	facial	B-NP	JJ	O	10	NMOD
9	inflammatory	inflammatory	I-NP	JJ	O	10	NMOD
10	dermatoses	dermatos	I-NP	NNS	O	7	PMOD
11	with	with	B-PP	IN	O	6	NMOD
12	tacrolimus	tacrolimus	B-NP	NN	O	13	NMOD
13	ointment	ointment	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	1	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Tacrolimus	Tacrolimus	B-NP	NN	O	4	NMOD
4	ointment	ointment	I-NP	NN	O	5	SUB
5	is	be	B-VP	VBZ	O	22	VMOD
6	increasingly	increasingly	I-VP	RB	O	5	VMOD
7	used	use	I-VP	VBN	O	5	VC
8	for	for	B-PP	IN	O	7	VMOD
9	anti-inflammatory	anti-inflammatory	B-NP	JJ	O	10	NMOD
10	treatment	treatment	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	sensitive	sensitive	B-NP	JJ	O	13	NMOD
13	areas	area	I-NP	NNS	O	11	PMOD
14	such	such	B-PP	JJ	O	15	PMOD
15	as	as	I-PP	IN	O	13	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	face	face	I-NP	NN	O	15	PMOD
18	,	,	O	,	O	22	P
19	and	and	O	CC	O	22	VMOD
20	recent	recent	B-NP	JJ	O	21	NMOD
21	observations	observation	I-NP	NNS	O	22	SUB
22	indicate	indicate	B-VP	VBP	O	1	NMOD
23	that	that	B-SBAR	IN	O	22	VMOD
24	the	the	B-NP	DT	O	25	NMOD
25	treatment	treatment	I-NP	NN	O	26	SUB
26	is	be	B-VP	VBZ	O	23	SBAR
27	effective	effective	B-ADJP	JJ	O	26	PRD
28	in	in	B-PP	IN	O	27	AMOD
29	steroid-aggravated	steroid-aggravated	B-NP	JJ	O	30	NMOD
30	rosacea	rosacea	I-NP	NN	O	33	NMOD
31	and	and	O	CC	O	33	NMOD
32	perioral	perioral	B-NP	JJ	O	33	NMOD
33	dermatitis	dermatitis	I-NP	NN	O	28	PMOD
34	.	.	O	.	O	1	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	on	on	B-PP	IN	O	2	VMOD
4	rosaceiform	rosaceiform	B-NP	NN	O	5	NMOD
5	dermatitis	dermatitis	I-NP	NN	O	3	PMOD
6	as	as	B-PP	IN	O	5	NMOD
7	a	a	B-NP	DT	O	8	NMOD
8	complication	complication	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	treatment	treatment	B-NP	NN	O	9	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	tacrolimus	tacrolimus	B-NP	NN	O	13	NMOD
13	ointment	ointment	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	2	P

1	OBSERVATIONS	OBSERVATIONS	B-NP	NNS	O	5	NMOD
2	:	:	O	:	O	1	P
3	Six	Six	B-NP	CD	O	5	NMOD
4	adult	adult	I-NP	JJ	O	5	NMOD
5	patients	patient	I-NP	NNS	O	10	SUB
6	with	with	B-PP	IN	O	5	NMOD
7	inflammatory	inflammatory	B-NP	JJ	O	9	NMOD
8	facial	facial	I-NP	JJ	O	9	NMOD
9	dermatoses	dermatos	I-NP	NNS	O	6	PMOD
10	were	be	B-VP	VBD	O	0	ROOT
11	treated	treat	I-VP	VBN	O	10	VC
12	with	with	B-PP	IN	O	11	VMOD
13	tacrolimus	tacrolimus	B-NP	NN	O	14	NMOD
14	ointment	ointment	I-NP	NN	O	12	PMOD
15	because	because	B-PP	IN	O	11	VMOD
16	of	of	I-PP	IN	O	15	PMOD
17	the	the	B-NP	DT	O	18	NMOD
18	ineffectiveness	ineffectiveness	I-NP	NN	O	15	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	standard	standard	B-NP	JJ	O	21	NMOD
21	treatments	treatment	I-NP	NNS	O	19	PMOD
22	.	.	O	.	O	10	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Our	Our	B-NP	PRP$	O	4	NMOD
4	observations	observation	I-NP	NNS	O	5	SUB
5	suggest	suggest	B-VP	VBP	O	1	NMOD
6	that	that	B-SBAR	IN	O	5	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	spectrum	spectrum	I-NP	NN	O	20	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	rosaceiform	rosaceiform	B-NP	JJ	O	11	NMOD
11	dermatitis	dermatitis	I-NP	NN	O	9	PMOD
12	as	as	B-PP	IN	O	8	NMOD
13	a	a	B-NP	DT	O	14	NMOD
14	complication	complication	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	treatment	treatment	B-NP	NN	O	15	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	tacrolimus	tacrolimus	B-NP	NN	O	19	NMOD
19	ointment	ointment	I-NP	NN	O	17	PMOD
20	is	be	B-VP	VBZ	O	6	SBAR
21	heterogeneous	heterogeneous	B-ADJP	JJ	O	20	PRD
22	.	.	O	.	O	1	P

1	We	We	B-NP	PRP	O	2	SUB
2	visualize	visualize	B-VP	VBP	O	0	ROOT
3	,	,	O	,	O	2	P
4	for	for	B-PP	IN	O	2	VMOD
5	the	the	B-NP	DT	O	7	NMOD
6	first	first	I-NP	JJ	O	7	NMOD
7	time	time	I-NP	NN	O	4	PMOD
8	,	,	O	,	O	2	P
9	the	the	B-NP	DT	O	10	NMOD
10	profile	profile	I-NP	NN	O	2	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	structural	structural	B-NP	JJ	O	13	NMOD
13	deficits	deficit	I-NP	NNS	O	11	PMOD
14	in	in	B-PP	IN	O	10	NMOD
15	the	the	B-NP	DT	O	17	NMOD
16	human	human	I-NP	JJ	O	17	NMOD
17	brain	brain	I-NP	NN	O	14	PMOD
18	associated	associate	B-VP	VBN	O	17	NMOD
19	with	with	B-PP	IN	O	18	VMOD
20	chronic	chronic	B-NP	JJ	O	21	NMOD
21	methamphetamine	methamphetamine	I-NP	NN	O	25	NMOD
22	(	(	O	(	O	24	DEP
23	MA	MA	B-NP	NN	O	24	DEP
24	)	)	O	)	O	21	NMOD
25	abuse	abuse	B-NP	NN	O	19	PMOD
26	.	.	O	.	O	2	P

1	Studies	Study	B-NP	NNS	O	10	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	human	human	B-NP	JJ	O	4	NMOD
4	subjects	subject	I-NP	NNS	O	2	PMOD
5	who	who	B-NP	WP	O	4	NMOD
6	have	have	B-VP	VBP	O	5	SBAR
7	used	use	I-VP	VBN	O	6	VC
8	MA	MA	B-NP	NN	O	7	OBJ
9	chronically	chronically	B-ADVP	RB	O	7	VMOD
10	have	have	B-VP	VBP	O	0	ROOT
11	revealed	reveal	I-VP	VBN	O	10	VC
12	deficits	deficit	B-NP	NNS	O	21	NMOD
13	in	in	B-PP	IN	O	12	NMOD
14	dopaminergic	dopaminergic	B-NP	JJ	O	17	NMOD
15	and	and	I-NP	CC	O	17	NMOD
16	serotonergic	serotonergic	I-NP	JJ	O	17	NMOD
17	systems	system	I-NP	NNS	O	13	PMOD
18	and	and	O	CC	O	21	NMOD
19	cerebral	cerebral	B-NP	JJ	O	21	NMOD
20	metabolic	metabolic	I-NP	JJ	O	21	NMOD
21	abnormalities	abnormality	I-NP	NNS	O	11	OBJ
22	.	.	O	.	O	10	P

1	Using	Use	B-VP	VBG	O	15	VMOD
2	magnetic	magnetic	B-NP	JJ	O	4	NMOD
3	resonance	resonance	I-NP	NN	O	4	NMOD
4	imaging	imaging	I-NP	NN	O	12	NMOD
5	(	(	O	(	O	7	DEP
6	MRI	MRI	B-NP	NN	B-protein	7	DEP
7	)	)	O	)	O	4	NMOD
8	and	and	O	CC	O	12	NMOD
9	new	new	B-NP	JJ	O	12	NMOD
10	computational	computational	I-NP	JJ	O	12	NMOD
11	brain-mapping	brain-mapping	I-NP	JJ	O	12	NMOD
12	techniques	technique	I-NP	NNS	O	1	OBJ
13	,	,	O	,	O	15	P
14	we	we	B-NP	PRP	O	15	SUB
15	determined	determine	B-VP	VBD	O	0	ROOT
16	the	the	B-NP	DT	O	17	NMOD
17	pattern	pattern	I-NP	NN	O	15	OBJ
18	of	of	B-PP	IN	O	17	NMOD
19	structural	structural	B-NP	JJ	O	21	NMOD
20	brain	brain	I-NP	NN	O	21	NMOD
21	alterations	alteration	I-NP	NNS	O	18	PMOD
22	associated	associate	B-VP	VBN	O	21	NMOD
23	with	with	B-PP	IN	O	22	VMOD
24	chronic	chronic	B-NP	JJ	O	26	NMOD
25	MA	MA	I-NP	JJ	O	26	NMOD
26	abuse	abuse	I-NP	NN	O	23	PMOD
27	in	in	B-PP	IN	O	26	NMOD
28	human	human	B-NP	JJ	O	29	NMOD
29	subjects	subject	I-NP	NNS	O	27	PMOD
30	and	and	O	CC	O	15	VMOD
31	related	relate	B-VP	VBN	O	15	VMOD
32	these	these	B-NP	DT	O	33	NMOD
33	deficits	deficit	I-NP	NNS	O	31	OBJ
34	to	to	B-PP	TO	O	31	AMOD
35	cognitive	cognitive	B-NP	JJ	O	36	NMOD
36	impairment	impairment	I-NP	NN	O	34	PMOD
37	.	.	O	.	O	15	P

1	We	We	B-NP	PRP	O	2	SUB
2	used	use	B-VP	VBD	O	0	ROOT
3	high-resolution	high-resolution	B-NP	JJ	O	4	NMOD
4	MRI	MRI	I-NP	NN	O	9	NMOD
5	and	and	O	CC	O	9	NMOD
6	surface-based	surface-based	B-NP	JJ	O	9	NMOD
7	computational	computational	I-NP	JJ	O	9	NMOD
8	image	image	I-NP	NN	O	9	NMOD
9	analyses	analysis	I-NP	NNS	O	2	OBJ
10	to	to	B-VP	TO	O	11	VMOD
11	map	map	I-VP	VB	O	2	VMOD
12	regional	regional	B-NP	JJ	O	13	NMOD
13	abnormalities	abnormality	I-NP	NNS	O	11	OBJ
14	in	in	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	cortex	cortex	I-NP	NN	O	24	NMOD
17	,	,	O	,	O	24	P
18	hippocampus	hippocampus	B-NP	NN	O	24	NMOD
19	,	,	O	,	O	24	P
20	white	white	B-NP	JJ	O	21	NMOD
21	matter	matter	I-NP	NN	O	24	NMOD
22	,	,	O	,	O	24	P
23	and	and	O	CC	O	24	NMOD
24	ventricles	ventricle	B-NP	NNS	O	14	PMOD
25	in	in	B-PP	IN	O	24	NMOD
26	22	22	B-NP	CD	O	28	NMOD
27	human	human	I-NP	JJ	O	28	NMOD
28	subjects	subject	I-NP	NNS	O	25	PMOD
29	who	who	B-NP	WP	O	28	NMOD
30	used	use	B-VP	VBD	O	29	SBAR
31	MA	MA	B-ADJP	JJ	O	37	NMOD
32	and	and	O	CC	O	37	NMOD
33	21	21	B-NP	CD	O	37	NMOD
34	age-matched	age-matched	I-NP	JJ	O	36	AMOD
35	,	,	I-NP	,	O	36	P
36	healthy	healthy	I-NP	JJ	O	37	NMOD
37	controls	control	I-NP	NNS	O	30	OBJ
38	.	.	O	.	O	2	P

1	On	On	B-PP	IN	O	6	VMOD
2	average	average	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	6	P
4	MA	MA	B-NP	JJ	O	5	NMOD
5	abusers	abuser	I-NP	NNS	O	6	SUB
6	had	have	B-VP	VBD	O	0	ROOT
7	7.8	7.8	B-NP	CD	O	8	NMOD
8	%	%	I-NP	NN	O	11	NMOD
9	smaller	small	B-NP	JJR	O	11	NMOD
10	hippocampal	hippocampal	I-NP	JJ	O	11	NMOD
11	volumes	volume	I-NP	NNS	O	35	NMOD
12	than	than	B-PP	IN	O	11	NMOD
13	control	control	B-NP	JJ	O	14	NMOD
14	subjects	subject	I-NP	NNS	O	12	PMOD
15	(	(	O	(	O	31	DEP
16	p	p	B-NP	NN	O	20	SUB
17	<	<	O	SYM	O	16	NMOD
18	0.01	0.01	B-NP	CD	O	17	AMOD
19	;	;	O	:	O	16	P
20	left	leave	B-VP	VBN	O	31	DEP
21	,	,	O	,	O	29	P
22	p	p	B-NP	NN	O	29	NMOD
23	=	=	B-VP	SYM	O	22	NMOD
24	0.01	0.01	B-NP	CD	O	23	AMOD
25	;	;	O	:	O	29	P
26	right	right	B-NP	NN	O	29	NMOD
27	,	,	O	,	O	29	P
28	p	p	B-NP	NN	O	29	NMOD
29	<	<	B-NP	SYM	O	20	VMOD
30	0.05	0.05	I-NP	CD	O	29	PRD
31	)	)	O	)	O	11	NMOD
32	and	and	O	CC	O	35	NMOD
33	significant	significant	B-NP	JJ	O	35	NMOD
34	white-matter	white-matter	I-NP	JJ	O	35	NMOD
35	hypertrophy	hypertrophy	I-NP	NN	O	6	OBJ
36	(	(	O	(	O	43	DEP
37	7.0	7.0	B-NP	CD	O	38	NMOD
38	%	%	I-NP	NN	O	40	NMOD
39	;	;	O	:	O	40	P
40	p	p	B-NP	NN	O	43	DEP
41	<	<	B-NP	SYM	O	40	NMOD
42	0.01	0.01	I-NP	CD	O	41	AMOD
43	)	)	O	)	O	35	NMOD
44	.	.	O	.	O	6	P

1	MRI-based	MRI-based	B-NP	JJ	O	2	NMOD
2	maps	map	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	chronic	chronic	B-NP	JJ	O	7	NMOD
6	methamphetamine	methamphetamine	I-NP	NN	O	7	NMOD
7	abuse	abuse	I-NP	NN	O	8	SUB
8	causes	cause	B-VP	VBZ	O	4	SBAR
9	a	a	B-NP	DT	O	11	NMOD
10	selective	selective	I-NP	JJ	O	11	NMOD
11	pattern	pattern	I-NP	NN	O	8	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	cerebral	cerebral	B-NP	JJ	O	14	NMOD
14	deterioration	deterioration	I-NP	NN	O	12	PMOD
15	that	that	B-NP	WDT	O	14	NMOD
16	contributes	contribute	B-VP	VBZ	O	15	SBAR
17	to	to	B-PP	TO	O	16	VMOD
18	impaired	impaired	B-NP	JJ	O	20	NMOD
19	memory	memory	I-NP	NN	O	20	NMOD
20	performance	performance	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	3	P

1	Amiodarone	Amiodarone	B-NP	NN	O	9	NMOD
2	,	,	O	,	O	9	P
3	an	an	B-NP	DT	O	9	NMOD
4	efficacious	efficacious	I-NP	JJ	O	9	NMOD
5	and	and	I-NP	CC	O	9	NMOD
6	widely	widely	I-NP	RB	O	7	AMOD
7	used	use	I-NP	VBN	O	9	NMOD
8	antiarrhythmic	antiarrhythmic	I-NP	JJ	O	9	NMOD
9	agent	agent	I-NP	NN	O	11	SUB
10	,	,	O	,	O	9	P
11	has	have	B-VP	VBZ	O	0	ROOT
12	been	be	I-VP	VBN	O	11	VC
13	reported	report	I-VP	VBN	O	12	VC
14	to	to	I-VP	TO	O	15	VMOD
15	cause	cause	I-VP	VB	O	13	VMOD
16	hepatotoxicity	hepatotoxicity	B-NP	NN	O	15	OBJ
17	in	in	B-PP	IN	O	15	VMOD
18	some	some	B-NP	DT	O	19	NMOD
19	patients	patient	I-NP	NNS	O	17	PMOD
20	.	.	O	.	O	11	P

1	Amiodarone	Amiodarone	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	13	VMOD
3	hepatomegaly	hepatomegaly	B-ADVP	RB	O	2	VMOD
4	,	,	O	,	O	2	P
5	hepatocyte	hepatocyte	B-NP	NN	O	8	NMOD
6	microvesicular	microvesicular	I-NP	JJ	O	8	NMOD
7	lipid	lipid	I-NP	NN	O	8	NMOD
8	accumulation	accumulation	I-NP	NN	O	2	OBJ
9	,	,	O	,	O	13	P
10	and	and	O	CC	O	13	NMOD
11	a	a	B-NP	DT	O	13	NMOD
12	significant	significant	I-NP	JJ	O	13	NMOD
13	decrease	decrease	I-NP	NN	O	0	ROOT
14	in	in	B-PP	IN	O	13	NMOD
15	serum	serum	B-NP	NN	O	16	NMOD
16	triglycerides	triglyceride	I-NP	NNS	O	18	NMOD
17	and	and	O	CC	O	18	NMOD
18	glucose	glucose	B-NP	NN	O	14	PMOD
19	.	.	O	.	O	13	P

1	The	The	B-NP	DT	O	2	NMOD
2	absence	absence	I-NP	NN	O	11	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	induction	induction	B-NP	NN	O	3	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	these	these	B-NP	DT	O	7	NMOD
7	genes	gene	I-NP	NNS	O	5	PMOD
8	as	as	B-CONJP	RB	O	11	NMOD
9	well	well	I-CONJP	RB	O	8	DEP
10	as	as	I-CONJP	IN	O	8	DEP
11	hepatomegaly	hepatomegaly	B-NP	NN	O	18	NMOD
12	in	in	B-PP	IN	O	11	NMOD
13	PPARalpha	PPARalpha	B-NP	NN	B-protein	14	NMOD
14	knockout	knockout	I-NP	NN	O	12	PMOD
15	[	[	O	(	O	17	DEP
16	PPARalpha-/-	PPARalpha-/-	O	JJ	O	17	DEP
17	]	]	O	)	O	11	NMOD
18	mice	mouse	B-NP	NNS	O	19	SUB
19	indicated	indicate	B-VP	VBD	O	0	ROOT
20	that	that	B-SBAR	IN	O	19	VMOD
21	the	the	B-NP	DT	O	22	NMOD
22	effects	effect	I-NP	NNS	O	25	SUB
23	of	of	B-PP	IN	O	22	NMOD
24	amiodarone	amiodarone	B-NP	NN	O	23	PMOD
25	were	be	B-VP	VBD	O	20	SBAR
26	dependent	dependent	B-ADJP	JJ	O	25	PRD
27	upon	upon	B-PP	IN	O	26	AMOD
28	the	the	B-NP	DT	O	29	NMOD
29	presence	presence	I-NP	NN	O	27	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	a	a	B-NP	DT	O	34	NMOD
32	functional	functional	I-NP	JJ	B-DNA	34	NMOD
33	PPARalpha	PPARalpha	I-NP	NN	I-DNA	34	NMOD
34	gene	gene	I-NP	NN	I-DNA	30	PMOD
35	.	.	O	.	O	19	P

1	Compared	Compare	B-PP	VBN	O	12	VMOD
2	to	to	B-PP	TO	O	1	PMOD
3	wild-type	wild-type	B-NP	JJ	O	4	NMOD
4	mice	mouse	I-NP	NNS	O	2	PMOD
5	,	,	O	,	O	12	P
6	treatment	treatment	B-NP	NN	O	12	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	PPARalpha-/-	PPARalpha-/-	B-NP	JJ	O	9	NMOD
9	mice	mouse	I-NP	NNS	O	7	PMOD
10	with	with	B-PP	IN	O	6	NMOD
11	amiodarone	amiodarone	B-NP	NN	O	10	PMOD
12	resulted	result	B-VP	VBD	O	0	ROOT
13	in	in	B-PP	IN	O	12	VMOD
14	an	an	B-NP	DT	O	18	NMOD
15	increased	increase	I-NP	VBN	O	18	NMOD
16	rate	rate	I-NP	NN	O	18	NMOD
17	and	and	I-NP	CC	O	18	NMOD
18	extent	extent	I-NP	NN	O	13	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	total	total	B-NP	JJ	O	23	NMOD
21	body	body	I-NP	NN	O	23	NMOD
22	weight	weight	I-NP	NN	O	23	NMOD
23	loss	loss	I-NP	NN	O	19	PMOD
24	.	.	O	.	O	12	P

1	The	The	B-NP	DT	O	2	NMOD
2	inability	inability	I-NP	NN	O	20	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	amiodarone	amiodarone	B-NP	NN	O	3	PMOD
5	to	to	B-VP	TO	O	7	VMOD
6	directly	directly	I-VP	RB	O	7	VMOD
7	activate	activate	I-VP	VB	O	2	NMOD
8	either	either	O	CC	O	12	NMOD
9	human	human	O	JJ	O	12	NMOD
10	or	or	O	CC	O	12	NMOD
11	mouse	mouse	B-NP	NN	B-protein	12	NMOD
12	PPARalpha	PPARalpha	I-NP	NN	I-protein	7	OBJ
13	transiently	transiently	B-VP	RB	O	7	VMOD
14	expressed	express	I-VP	VBN	O	7	VC
15	in	in	B-PP	IN	O	14	VMOD
16	human	human	B-NP	JJ	B-cell_line	19	NMOD
17	HepG2	HepG2	I-NP	NN	I-cell_line	19	NMOD
18	hepatoma	hepatoma	I-NP	NN	I-cell_line	19	NMOD
19	cells	cell	I-NP	NNS	I-cell_line	15	PMOD
20	indicates	indicate	B-VP	VBZ	O	0	ROOT
21	that	that	B-SBAR	IN	O	20	VMOD
22	the	the	B-NP	DT	O	23	NMOD
23	effects	effect	I-NP	NNS	O	32	SUB
24	of	of	B-PP	IN	O	23	NMOD
25	amiodarone	amiodarone	B-NP	NN	O	24	PMOD
26	on	on	B-PP	IN	O	23	NMOD
27	the	the	B-NP	DT	O	28	NMOD
28	function	function	I-NP	NN	O	26	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	this	this	B-NP	DT	O	31	NMOD
31	receptor	receptor	I-NP	NN	O	29	PMOD
32	were	be	B-VP	VBD	O	21	SBAR
33	indirect	indirect	B-ADJP	JJ	O	32	PRD
34	.	.	O	.	O	20	P

1	Niacin	Niacin	B-NP	NN	B-protein	2	NMOD
2	extended-release/lovastatin	extended-release/lovastatin	I-NP	NN	I-protein	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	a	a	B-NP	DT	O	7	NMOD
5	new	new	I-NP	JJ	O	7	NMOD
6	combination	combination	I-NP	NN	O	7	NMOD
7	product	product	I-NP	NN	O	3	PRD
8	approved	approve	B-VP	VBN	O	7	NMOD
9	for	for	B-PP	IN	O	8	VMOD
10	treatment	treatment	B-NP	NN	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	primary	primary	B-NP	JJ	O	13	NMOD
13	hypercholesterolemia	hypercholesterolemia	I-NP	NN	O	16	NMOD
14	and	and	O	CC	O	16	NMOD
15	mixed	mixed	B-NP	JJ	O	16	NMOD
16	dyslipidemia	dyslipidemia	I-NP	NN	O	11	PMOD
17	.	.	O	.	O	3	P

1	Patients	Patient	B-NP	NNS	O	3	SUB
2	also	also	B-ADVP	RB	O	3	VMOD
3	received	receive	B-VP	VBD	O	0	ROOT
4	dietary	dietary	B-NP	JJ	O	5	NMOD
5	counseling	counseling	I-NP	NN	O	8	NMOD
6	,	,	O	,	O	8	P
7	educational	educational	B-NP	JJ	O	8	NMOD
8	materials	material	I-NP	NNS	O	3	OBJ
9	,	,	O	,	O	3	P
10	and	and	O	CC	O	3	VMOD
11	reminders	reminder	B-VP	VBZ	O	3	VMOD
12	to	to	I-VP	TO	O	13	VMOD
13	call	call	I-VP	VB	O	11	VMOD
14	a	a	B-NP	DT	O	16	NMOD
15	toll-free	toll-free	I-NP	JJ	O	16	NMOD
16	number	number	I-NP	NN	O	13	OBJ
17	that	that	B-NP	WDT	O	16	NMOD
18	provided	provide	B-VP	VBD	O	17	SBAR
19	further	further	B-NP	JJ	O	20	NMOD
20	education	education	I-NP	NN	O	18	OBJ
21	about	about	B-PP	IN	O	20	NMOD
22	dyslipidemia	dyslipidemia	B-NP	NN	O	25	NMOD
23	and	and	I-NP	CC	O	25	NMOD
24	niacin	niacin	I-NP	NN	B-protein	25	NMOD
25	extended-release/lovastatin	extended-release/lovastatin	I-NP	NN	I-protein	21	PMOD
26	.	.	O	.	O	3	P

1	An	An	B-NP	DT	O	2	NMOD
2	increase	increase	I-NP	NN	O	12	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	creatine	creatine	B-NP	NN	B-protein	5	NMOD
5	phosphokinase	phosphokinase	I-NP	NN	I-protein	3	PMOD
6	to	to	B-PP	TO	O	2	NMOD
7	>	>	B-NP	SYM	O	9	AMOD
8	5	5	B-NP	CD	O	9	AMOD
9	times	time	I-NP	NNS	O	6	PMOD
10	the	the	I-NP	DT	O	12	NMOD
11	upper	upper	I-NP	JJ	O	12	NMOD
12	limit	limit	I-NP	NN	O	15	SUB
13	of	of	B-PP	IN	O	12	NMOD
14	normal	normal	B-NP	JJ	O	13	PMOD
15	occurred	occur	B-VP	VBD	O	29	VMOD
16	in	in	B-PP	IN	O	15	VMOD
17	0.24	0.24	B-NP	CD	O	18	NMOD
18	%	%	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	patients	patient	B-NP	NNS	O	19	PMOD
21	,	,	O	,	O	24	P
22	and	and	O	CC	O	24	NMOD
23	no	no	B-NP	DT	O	24	NMOD
24	cases	case	I-NP	NNS	O	29	SUB
25	of	of	B-PP	IN	O	24	NMOD
26	drug	drug	B-NP	NN	O	28	NMOD
27	induced	induce	I-NP	VBN	O	28	NMOD
28	myopathy	myopathy	I-NP	NN	O	25	PMOD
29	were	be	B-VP	VBD	O	0	ROOT
30	observed	observe	I-VP	VBN	O	29	VC
31	.	.	O	.	O	29	P

1	Protective	Protective	B-NP	JJ	O	2	NMOD
2	effect	effect	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	Terminalia	Terminalia	B-NP	NNP	O	5	NMOD
5	chebula	chebula	I-NP	NN	O	3	PMOD
6	against	against	B-PP	IN	O	5	NMOD
7	experimental	experimental	B-NP	JJ	O	9	NMOD
8	myocardial	myocardial	I-NP	JJ	O	9	NMOD
9	injury	injury	I-NP	NN	O	6	PMOD
10	induced	induce	B-VP	VBN	O	9	NMOD
11	by	by	B-PP	IN	O	10	VMOD
12	isoproterenol	isoproterenol	B-NP	NN	O	11	PMOD
13	.	.	O	.	O	2	P

1	Cardioprotective	Cardioprotective	B-NP	JJ	O	2	NMOD
2	effect	effect	I-NP	NN	O	16	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	ethanolic	ethanolic	B-NP	JJ	O	5	NMOD
5	extract	extract	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	Terminalia	Terminalia	B-NP	NNP	O	9	NMOD
8	chebula	chebula	I-NP	NN	O	9	NMOD
9	fruits	fruit	I-NP	NNS	O	6	PMOD
10	(	(	O	(	O	15	DEP
11	500	500	B-NP	CD	O	14	NMOD
12	mg/kg	mg/kg	I-NP	NN	O	14	NMOD
13	body	body	I-NP	NN	O	14	NMOD
14	wt	wt	I-NP	NN	O	15	DEP
15	)	)	O	)	O	9	NMOD
16	was	be	B-VP	VBD	O	0	ROOT
17	examined	examine	I-VP	VBN	O	16	VC
18	in	in	B-PP	IN	O	17	VMOD
19	isoproterenol	isoproterenol	B-NP	NN	O	26	SUB
20	(	(	O	(	O	25	DEP
21	200	200	B-NP	CD	O	24	NMOD
22	mg/kg	mg/kg	I-NP	NN	O	24	NMOD
23	body	body	I-NP	NN	O	24	NMOD
24	wt	wt	I-NP	NN	O	25	DEP
25	)	)	O	)	O	19	NMOD
26	induced	induce	B-VP	VBD	O	18	SBAR
27	myocardial	myocardial	B-NP	JJ	O	28	NMOD
28	damage	damage	I-NP	NN	O	26	OBJ
29	in	in	B-PP	IN	O	26	VMOD
30	rats	rat	B-NP	NNS	O	29	PMOD
31	.	.	O	.	O	16	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	postoperative	postoperative	B-NP	JJ	O	5	NMOD
5	anxiety	anxiety	I-NP	NN	O	3	PMOD
6	due	due	B-PP	JJ	O	2	NMOD
7	to	to	B-PP	TO	O	6	AMOD
8	low	low	B-NP	JJ	O	10	NMOD
9	dose	dose	I-NP	NN	O	10	NMOD
10	droperidol	droperidol	I-NP	NN	O	7	PMOD
11	used	use	B-VP	VBN	O	10	NMOD
12	with	with	B-PP	IN	O	11	VMOD
13	patient-controlled	patient-controlled	B-NP	JJ	O	14	NMOD
14	analgesia	analgesia	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	diagnosis	diagnosis	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	droperidol	droperidol	B-NP	NN	O	3	PMOD
5	induced	induce	B-VP	VBD	O	0	ROOT
6	psychological	psychological	B-NP	JJ	O	7	NMOD
7	disturbance	disturbance	I-NP	NN	O	8	SUB
8	was	be	B-VP	VBD	O	5	VMOD
9	not	not	I-VP	RB	O	8	VMOD
10	made	make	I-VP	VBN	O	8	VC
11	straight	straight	B-ADVP	RB	O	10	VMOD
12	away	away	I-ADVP	RB	O	11	AMOD
13	although	although	B-SBAR	IN	O	10	VMOD
14	on	on	B-PP	IN	O	20	VMOD
15	subsequent	subsequent	B-NP	JJ	O	16	NMOD
16	close	close	I-NP	NN	O	14	PMOD
17	questioning	question	B-VP	VBG	O	16	NMOD
18	the	the	B-NP	DT	O	19	NMOD
19	patient	patient	I-NP	NN	O	17	OBJ
20	gave	give	B-VP	VBD	O	13	SBAR
21	a	a	B-NP	DT	O	24	NMOD
22	very	very	I-NP	RB	O	23	AMOD
23	clear	clear	I-NP	JJ	O	24	NMOD
24	history	history	I-NP	NN	O	20	OBJ
25	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	3	NMOD
2	nursing	nursing	I-NP	NN	O	3	NMOD
3	staff	staff	I-NP	NN	O	16	SUB
4	,	,	O	,	O	3	P
5	by	by	B-PP	IN	O	3	NMOD
6	reviewing	review	B-VP	VBG	O	5	PMOD
7	the	the	B-NP	DT	O	11	NMOD
8	patient	patient	I-NP	NN	O	11	NMOD
9	's	's	B-NP	POS	O	11	NMOD
10	health	health	I-NP	NN	O	11	NMOD
11	history	history	I-NP	NN	O	6	OBJ
12	with	with	B-PP	IN	O	6	VMOD
13	his	his	B-NP	PRP$	O	14	NMOD
14	family	family	I-NP	NN	O	12	PMOD
15	,	,	O	,	O	3	P
16	discovered	discover	B-VP	VBD	O	0	ROOT
17	a	a	B-NP	DT	O	18	NMOD
18	history	history	I-NP	NN	O	16	OBJ
19	of	of	B-PP	IN	O	18	NMOD
20	polydipsia	polydipsia	B-NP	NN	O	24	NMOD
21	and	and	O	CC	O	24	NMOD
22	long-standing	long-standing	B-NP	JJ	O	24	NMOD
23	lithium	lithium	I-NP	NN	O	24	NMOD
24	use	use	I-NP	NN	O	19	PMOD
25	.	.	O	.	O	16	P

1	Lithium	Lithium	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	implicated	implicate	I-VP	VBN	O	2	VC
4	in	in	B-PP	IN	O	3	VMOD
5	drug	drug	B-NP	NN	O	4	PMOD
6	induced	induce	B-VP	VBD	O	5	NMOD
7	nephrogenic	nephrogenic	B-NP	JJ	O	8	NMOD
8	DI	DI	I-NP	NN	O	6	OBJ
9	,	,	O	,	O	2	VMOD
10	and	and	O	CC	O	9	VMOD
11	because	because	B-SBAR	IN	O	10	DEP
12	the	the	B-NP	DT	O	13	NMOD
13	patient	patient	I-NP	NN	O	14	SUB
14	had	have	B-VP	VBD	O	11	SBAR
15	not	not	I-VP	RB	O	14	VMOD
16	received	receive	I-VP	VBN	O	14	VC
17	lithium	lithium	B-NP	NN	O	16	OBJ
18	since	since	B-PP	IN	O	16	VMOD
19	being	be	B-VP	VBG	O	27	VMOD
20	admitted	admit	I-VP	VBN	O	19	VC
21	to	to	B-PP	TO	O	20	VMOD
22	the	the	B-NP	DT	O	23	NMOD
23	hospital	hospital	I-NP	NN	O	21	PMOD
24	,	,	O	,	O	27	P
25	his	his	B-NP	PRP$	O	26	NMOD
26	treatment	treatment	I-NP	NN	O	27	SUB
27	changed	change	B-VP	VBD	O	18	SBAR
28	to	to	I-VP	TO	O	29	VMOD
29	focus	focus	I-VP	VB	O	27	VMOD
30	on	on	B-PP	IN	O	29	VMOD
31	nephrogenic	nephrogenic	B-NP	JJ	O	32	NMOD
32	DI	DI	I-NP	NNP	O	30	PMOD
33	.	.	O	.	O	2	P

1	By	By	B-PP	IN	O	23	VMOD
2	combining	combine	B-VP	VBG	O	1	PMOD
3	information	information	B-NP	NN	O	2	OBJ
4	from	from	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	7	NMOD
6	patient	patient	I-NP	NN	O	7	NMOD
7	history	history	I-NP	NN	O	4	PMOD
8	,	,	O	,	O	23	P
9	the	the	B-NP	DT	O	11	NMOD
10	physical	physical	I-NP	JJ	O	11	NMOD
11	examination	examination	I-NP	NN	O	17	NMOD
12	,	,	O	,	O	17	P
13	and	and	O	CC	O	17	NMOD
14	radiologic	radiologic	B-NP	JJ	O	17	NMOD
15	and	and	I-NP	CC	O	17	NMOD
16	laboratory	laboratory	I-NP	JJ	O	17	NMOD
17	studies	study	I-NP	NNS	O	22	NMOD
18	,	,	O	,	O	22	P
19	the	the	B-NP	DT	O	22	NMOD
20	critical	critical	I-NP	JJ	O	22	NMOD
21	care	care	I-NP	NN	O	22	NMOD
22	team	team	I-NP	NN	O	23	SUB
23	demonstrated	demonstrate	B-VP	VBD	O	0	ROOT
24	that	that	B-SBAR	IN	O	23	VMOD
25	the	the	B-NP	DT	O	26	NMOD
26	patient	patient	I-NP	NN	O	27	SUB
27	had	have	B-VP	VBD	O	24	SBAR
28	been	be	I-VP	VBN	O	27	VC
29	self-treating	self-treate	I-VP	VBG	O	28	VMOD
30	his	his	B-NP	PRP$	O	31	NMOD
31	lithium	lithium	I-NP	NN	O	29	OBJ
32	induced	induce	B-VP	VBD	O	31	AMOD
33	nephrogenic	nephrogenic	B-NP	JJ	O	31	AMOD
34	DI	DI	I-NP	NN	O	31	NMOD
35	and	and	O	CC	O	27	VMOD
36	developed	develop	B-VP	VBD	O	27	VMOD
37	neurogenic	neurogenic	B-NP	JJ	O	38	NMOD
38	DI	DI	I-NP	NN	O	36	OBJ
39	secondary	secondary	B-ADJP	JJ	O	38	NMOD
40	to	to	B-PP	TO	O	39	AMOD
41	brain	brain	B-NP	NN	O	42	NMOD
42	trauma	trauma	I-NP	NN	O	40	PMOD
43	.	.	O	.	O	23	P

1	Factors	Factor	B-NP	NNS	O	0	ROOT
2	contributing	contribute	B-VP	VBG	O	1	NMOD
3	to	to	B-PP	TO	O	2	VMOD
4	ribavirin	ribavirin	B-NP	NN	O	6	NMOD
5	induced	induced	I-NP	JJ	O	6	NMOD
6	anemia	anemia	I-NP	NN	O	3	PMOD
7	.	.	O	.	O	1	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	3	NMOD
2	AND	AND	I-NP	CC	O	3	NMOD
3	AIM	AIM	I-NP	NN	O	9	NMOD
4	:	:	O	:	O	9	P
5	Interferon	Interferon	B-NP	NN	B-protein	9	NMOD
6	and	and	I-NP	CC	O	9	NMOD
7	ribavirin	ribavirin	I-NP	NN	O	9	NMOD
8	combination	combination	I-NP	NN	O	9	NMOD
9	therapy	therapy	I-NP	NN	O	14	SUB
10	for	for	B-PP	IN	O	9	NMOD
11	chronic	chronic	B-NP	JJ	O	13	NMOD
12	hepatitis	hepatitis	I-NP	NN	O	13	NMOD
13	C	C	I-NP	NN	O	10	PMOD
14	produces	produce	B-VP	VBZ	O	0	ROOT
15	hemolytic	hemolytic	B-NP	JJ	O	16	NMOD
16	anemia	anemia	I-NP	NN	O	14	OBJ
17	.	.	O	.	O	14	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	conducted	conduct	I-VP	VBN	O	3	VC
5	to	to	I-VP	TO	O	6	VMOD
6	identify	identify	I-VP	VB	O	4	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	factors	factor	I-NP	NNS	O	6	OBJ
9	contributing	contribute	B-VP	VBG	O	8	NMOD
10	to	to	B-PP	TO	O	9	VMOD
11	ribavirin	ribavirin	B-NP	NN	O	13	NMOD
12	induced	induced	I-NP	JJ	O	13	NMOD
13	anemia	anemia	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	3	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Eighty-eight	Eighty-eight	B-NP	CD	O	4	NMOD
4	patients	patient	I-NP	NNS	O	38	SUB
5	with	with	B-PP	IN	O	4	NMOD
6	chronic	chronic	B-NP	JJ	O	8	NMOD
7	hepatitis	hepatitis	I-NP	NN	O	8	NMOD
8	C	C	I-NP	NN	O	5	PMOD
9	who	who	B-NP	WP	O	4	NMOD
10	received	receive	B-VP	VBD	O	9	SBAR
11	interferon-alpha-2b	interferon-alpha-2b	B-NP	NN	B-protein	10	OBJ
12	at	at	B-PP	IN	O	10	VMOD
13	a	a	B-NP	DT	O	14	NMOD
14	dose	dose	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	6	6	B-NP	CD	O	17	NMOD
17	MU	MU	I-NP	NN	O	15	PMOD
18	administered	administer	B-VP	VBN	O	14	NMOD
19	intramuscularly	intramuscularly	B-ADVP	RB	O	18	VMOD
20	for	for	B-PP	IN	O	18	VMOD
21	24	24	B-NP	CD	O	22	NMOD
22	weeks	week	I-NP	NNS	O	20	PMOD
23	in	in	B-PP	IN	O	18	VMOD
24	combination	combination	B-NP	NN	O	23	PMOD
25	with	with	B-PP	IN	O	24	NMOD
26	ribavirin	ribavirin	B-NP	NN	O	25	PMOD
27	administered	administer	B-VP	VBN	O	26	NMOD
28	orally	orally	B-ADVP	RB	O	27	VMOD
29	at	at	B-PP	IN	O	27	VMOD
30	a	a	B-NP	DT	O	31	NMOD
31	dose	dose	I-NP	NN	O	37	NMOD
32	of	of	B-PP	IN	O	31	NMOD
33	600	600	B-NP	CD	O	34	NMOD
34	mg	mg	I-NP	NN	O	32	PMOD
35	or	or	O	CC	O	37	NMOD
36	800	800	B-NP	CD	O	37	NMOD
37	mg	mg	I-NP	NN	O	29	PMOD
38	participated	participate	B-VP	VBD	O	1	NMOD
39	in	in	B-PP	IN	O	38	VMOD
40	the	the	B-NP	DT	O	41	NMOD
41	study	study	I-NP	NN	O	39	PMOD
42	.	.	O	.	O	1	P

1	A	A	B-NP	DT	O	3	NMOD
2	hemoglobin	hemoglobin	I-NP	NN	B-protein	3	NMOD
3	concentration	concentration	I-NP	NN	O	8	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	<	<	B-NP	SYM	O	7	NMOD
6	10	10	I-NP	CD	O	7	NMOD
7	g/dL	g/dL	I-NP	NN	O	4	PMOD
8	was	be	B-VP	VBD	O	0	ROOT
9	defined	define	I-VP	VBN	O	8	VC
10	as	as	B-PP	IN	O	9	VMOD
11	ribavirin	ribavirin	B-NP	NN	O	13	NMOD
12	induced	induced	I-NP	JJ	O	13	NMOD
13	anemia	anemia	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	8	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Ribavirin	Ribavirin	B-NP	NN	O	5	NMOD
4	induced	induced	I-NP	JJ	O	5	NMOD
5	anemia	anemia	I-NP	NN	O	6	SUB
6	occurred	occur	B-VP	VBD	O	1	NMOD
7	in	in	B-PP	IN	O	6	VMOD
8	18	18	B-NP	CD	O	13	NMOD
9	(	(	O	(	O	12	DEP
10	20.5	20.5	B-NP	CD	O	11	NMOD
11	%	%	I-NP	NN	O	12	DEP
12	)	)	O	)	O	8	NMOD
13	patients	patient	B-NP	NNS	O	7	PMOD
14	during	during	B-PP	IN	O	13	NMOD
15	treatment	treatment	B-NP	NN	O	14	PMOD
16	.	.	O	.	O	1	P

1	Oxidative	Oxidative	B-NP	JJ	O	2	NMOD
2	damage	damage	I-NP	NN	O	3	SUB
3	precedes	precede	B-VP	VBZ	O	0	ROOT
4	nitrative	nitrative	B-NP	JJ	O	5	NMOD
5	damage	damage	I-NP	NN	O	3	OBJ
6	in	in	B-PP	IN	O	3	VMOD
7	adriamycin	adriamycin	B-NP	NN	O	8	SUB
8	induced	induce	B-VP	VBD	O	6	SBAR
9	cardiac	cardiac	B-NP	JJ	O	11	NMOD
10	mitochondrial	mitochondrial	I-NP	JJ	O	11	NMOD
11	injury	injury	I-NP	NN	O	8	OBJ
12	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	purpose	purpose	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	present	present	I-NP	JJ	O	6	NMOD
6	study	study	I-NP	NN	O	3	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	to	to	B-VP	TO	O	9	VMOD
9	determine	determine	I-VP	VB	O	7	PRD
10	if	if	B-SBAR	IN	O	9	VMOD
11	elevated	elevated	B-NP	JJ	O	13	NMOD
12	reactive	reactive	I-NP	JJ	O	13	NMOD
13	oxygen	oxygen	I-NP	NN	O	18	NMOD
14	(	(	O	(	O	16	DEP
15	ROS	ROS	B-NP	NN	O	16	DEP
16	)	)	O	)	O	13	NMOD
17	/nitrogen	/nitrogen	B-NP	NN	O	18	NMOD
18	species	specie	I-NP	NNS	O	22	SUB
19	(	(	O	(	O	21	DEP
20	RNS	RNS	B-NP	NN	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	reported	report	B-VP	VBD	O	10	SBAR
23	to	to	I-VP	TO	O	24	VMOD
24	be	be	I-VP	VB	O	22	VMOD
25	present	present	B-ADJP	JJ	O	24	PRD
26	in	in	B-PP	IN	O	25	AMOD
27	adriamycin	adriamycin	B-NP	NN	O	31	SUB
28	(	(	O	(	O	30	DEP
29	ADR	ADR	B-NP	NN	B-protein	30	DEP
30	)	)	O	)	O	27	NMOD
31	induced	induce	B-VP	VBD	O	26	SBAR
32	cardiotoxicity	cardiotoxicity	B-NP	NN	O	31	OBJ
33	actually	actually	B-ADVP	RB	O	31	VMOD
34	resulted	result	B-VP	VBD	O	31	VMOD
35	in	in	B-PP	IN	O	34	VMOD
36	cardiomyocyte	cardiomyocyte	B-NP	NN	O	38	NMOD
37	oxidative/nitrative	oxidative/nitrative	I-NP	JJ	O	38	NMOD
38	damage	damage	I-NP	NN	O	35	PMOD
39	,	,	O	,	O	31	P
40	and	and	O	CC	O	31	VMOD
41	to	to	B-VP	TO	O	43	VMOD
42	quantitatively	quantitatively	I-VP	RB	O	43	VMOD
43	determine	determine	I-VP	VB	O	31	VMOD
44	the	the	B-NP	DT	O	46	NMOD
45	time	time	I-NP	NN	O	46	NMOD
46	course	course	I-NP	NN	O	49	NMOD
47	and	and	O	CC	O	49	NMOD
48	subcellular	subcellular	B-NP	JJ	O	49	NMOD
49	localization	localization	I-NP	NN	O	43	OBJ
50	of	of	B-PP	IN	O	49	NMOD
51	these	these	B-NP	DT	O	54	NMOD
52	postulated	postulate	I-NP	VBN	O	54	NMOD
53	damage	damage	I-NP	NN	O	54	NMOD
54	products	product	I-NP	NNS	O	50	PMOD
55	using	use	B-VP	VBG	O	43	VMOD
56	an	an	B-NP	DT	O	59	NMOD
57	in	in	I-NP	FW	O	58	AMOD
58	vivo	vivo	I-NP	FW	O	59	NMOD
59	approach	approach	I-NP	NN	O	55	OBJ
60	.	.	O	.	O	7	P

1	Our	Our	B-NP	PRP$	O	2	NMOD
2	data	datum	I-NP	NNS	O	3	SUB
3	showed	show	B-VP	VBD	O	0	ROOT
4	ADR	ADR	B-NP	NN	B-protein	7	NMOD
5	induced	induced	I-NP	JJ	O	7	NMOD
6	4HNE-protein	4HNE-protein	I-NP	NN	O	7	NMOD
7	adducts	adduct	I-NP	NNS	O	3	OBJ
8	in	in	B-PP	IN	O	7	NMOD
9	mitochondria	mitochondrion	B-NP	NNS	O	8	PMOD
10	at	at	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	14	NMOD
12	same	same	I-NP	JJ	O	14	NMOD
13	time	time	I-NP	NN	O	14	NMOD
14	point	point	I-NP	NN	O	10	PMOD
15	as	as	B-PP	IN	O	3	VMOD
16	when	when	B-ADVP	WRB	O	15	PMOD
17	mitochondrial	mitochondrial	B-NP	JJ	O	18	NMOD
18	injury	injury	I-NP	NN	O	20	SUB
19	initially	initially	B-ADVP	RB	O	20	VMOD
20	appeared	appear	B-VP	VBD	O	16	SBAR
21	.	.	O	.	O	3	P

1	Sotalol	Sotalol	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	coronary	coronary	B-NP	JJ	O	4	NMOD
4	spasm	spasm	I-NP	NN	O	2	OBJ
5	in	in	B-PP	IN	O	2	VMOD
6	a	a	B-NP	DT	O	7	NMOD
7	patient	patient	I-NP	NN	O	5	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	dilated	dilated	B-NP	JJ	O	10	NMOD
10	cardiomyopathy	cardiomyopathy	I-NP	NN	O	8	PMOD
11	associated	associate	B-VP	VBN	O	10	NMOD
12	with	with	B-PP	IN	O	11	VMOD
13	sustained	sustained	B-NP	JJ	O	15	NMOD
14	ventricular	ventricular	I-NP	JJ	O	15	NMOD
15	tachycardia	tachycardia	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	2	P

1	After	After	B-SBAR	IN	O	0	ROOT
2	the	the	B-NP	DT	O	3	NMOD
3	administration	administration	I-NP	NN	O	9	NMOD
4	of	of	B-PP	IN	O	3	NMOD
5	nifekalant	nifekalant	B-NP	JJ	O	6	NMOD
6	hydrochloride	hydrochloride	I-NP	NN	O	4	PMOD
7	,	,	O	,	O	9	P
8	sustained	sustained	B-NP	JJ	O	9	NMOD
9	VT	VT	I-NP	NN	O	10	SUB
10	was	be	B-VP	VBD	O	1	SBAR
11	terminated	terminate	I-VP	VBN	O	10	VC
12	.	.	O	.	O	1	P

1	An	An	B-NP	DT	O	5	NMOD
2	alternate	alternate	I-NP	JJ	O	5	NMOD
3	class	class	I-NP	NN	O	5	NMOD
4	III	III	I-NP	CD	O	5	NMOD
5	agent	agent	I-NP	NN	O	7	NMOD
6	,	,	O	,	O	7	P
7	sotalol	sotalol	B-NP	NN	O	9	SUB
8	,	,	O	,	O	7	P
9	was	be	B-VP	VBD	O	0	ROOT
10	also	also	B-ADVP	RB	O	9	VMOD
11	effective	effective	B-ADJP	JJ	O	9	PRD
12	for	for	B-PP	IN	O	11	AMOD
13	the	the	B-NP	DT	O	14	NMOD
14	prevention	prevention	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	VT	VT	B-NP	NN	O	15	PMOD
17	.	.	O	.	O	9	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	effect	effect	I-NP	NN	O	13	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	pretreatment	pretreatment	B-NP	NN	O	5	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	trazodone	trazodone	B-NP	NN	O	7	PMOD
9	on	on	B-PP	IN	O	4	NMOD
10	dexamphetamine-	dexamphetamine-	B-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	apomorphine	apomorphine	I-NP	NN	O	9	PMOD
13	induced	induce	B-VP	VBD	O	1	NMOD
14	oral	oral	B-NP	JJ	O	15	NMOD
15	stereotypies	stereotypy	I-NP	NNS	O	13	OBJ
16	,	,	O	,	O	15	P
17	on	on	B-PP	IN	O	15	NMOD
18	catalepsy	catalepsy	B-NP	NN	O	17	PMOD
19	induced	induce	B-VP	VBN	O	18	NMOD
20	by	by	B-PP	IN	O	19	VMOD
21	haloperidol	haloperidol	B-NP	NN	O	23	NMOD
22	and	and	I-NP	CC	O	23	NMOD
23	apomorphine	apomorphine	I-NP	NN	O	20	PMOD
24	(	(	O	(	O	29	DEP
25	0.05	0.05	B-NP	CD	O	26	NMOD
26	mg/kg	mg/kg	I-NP	NN	O	29	DEP
27	,	,	O	,	O	26	P
28	i.p.	i.p.	B-ADVP	RB	O	26	NMOD
29	)	)	O	)	O	23	NMOD
30	,	,	O	,	O	13	P
31	on	on	B-PP	IN	O	13	VMOD
32	ergometrine	ergometrine	B-NP	NN	O	36	NMOD
33	induced	induce	B-VP	VBD	O	32	AMOD
34	wet	wet	B-NP	JJ	O	36	NMOD
35	dog	dog	I-NP	NN	O	36	NMOD
36	shake	shake	I-NP	NN	O	45	NMOD
37	(	(	O	(	O	39	DEP
38	WDS	WDS	B-NP	NN	O	39	DEP
39	)	)	O	)	O	36	NMOD
40	behavior	behavior	B-NP	NN	O	36	NMOD
41	and	and	I-NP	CC	O	42	NMOD
42	fluoxetine	fluoxetine	I-NP	NN	O	45	NMOD
43	induced	induce	B-VP	VBD	O	45	NMOD
44	penile	penile	B-NP	JJ	O	45	NMOD
45	erections	erection	I-NP	NNS	O	31	PMOD
46	was	be	B-VP	VBD	O	13	VMOD
47	studied	study	I-VP	VBN	O	46	VC
48	in	in	B-PP	IN	O	47	VMOD
49	rats	rat	B-NP	NNS	O	48	PMOD
50	.	.	O	.	O	1	P

1	We	We	B-NP	PRP	O	3	SUB
2	also	also	B-ADVP	RB	O	3	VMOD
3	investigated	investigate	B-VP	VBD	O	0	ROOT
4	whether	whether	B-SBAR	IN	O	3	VMOD
5	trazodone	trazodone	B-NP	NN	O	6	SUB
6	induces	induce	B-VP	VBZ	O	4	SBAR
7	catalepsy	catalepsy	B-NP	NN	O	6	OBJ
8	in	in	B-PP	IN	O	6	VMOD
9	rats	rat	B-NP	NNS	O	8	PMOD
10	.	.	O	.	O	3	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Trazodone	Trazodone	B-NP	NN	O	1	NMOD
4	at	at	B-PP	IN	O	3	NMOD
5	2.5-20	2.5-20	B-NP	CD	O	6	NMOD
6	mg/kg	mg/kg	I-NP	NN	O	4	PMOD
7	i.p.	i.p.	B-ADVP	RB	O	8	VMOD
8	did	do	B-VP	VBD	O	1	NMOD
9	not	not	I-VP	RB	O	8	VMOD
10	induce	induce	I-VP	VB	O	8	VC
11	catalepsy	catalepsy	B-NP	NN	O	10	OBJ
12	,	,	O	,	O	8	P
13	and	and	O	CC	O	8	VMOD
14	did	do	B-VP	VBD	O	8	VMOD
15	not	not	I-VP	RB	O	14	VMOD
16	antagonize	antagonize	I-VP	VB	O	14	VC
17	apomorphine	apomorphine	B-NP	NN	O	24	NMOD
18	(	(	O	(	O	23	DEP
19	1.5	1.5	B-NP	CD	O	21	AMOD
20	and	and	I-NP	CC	O	21	AMOD
21	3	3	I-NP	CD	O	22	NMOD
22	mg/kg	mg/kg	I-NP	NN	O	23	DEP
23	)	)	O	)	O	17	NMOD
24	stereotypy	stereotypy	B-NP	NN	O	26	NMOD
25	and	and	O	CC	O	26	NMOD
26	apomorphine	apomorphine	B-NP	NN	O	32	NMOD
27	(	(	O	(	O	30	DEP
28	0.05	0.05	B-NP	CD	O	29	NMOD
29	mg/kg	mg/kg	I-NP	NN	O	30	DEP
30	)	)	O	)	O	26	NMOD
31	induced	induce	B-NP	VBN	O	32	NMOD
32	catalepsy	catalepsy	I-NP	NN	O	16	OBJ
33	.	.	O	.	O	1	P

1	However	However	B-ADVP	RB	O	13	VMOD
2	,	,	O	,	O	13	P
3	pretreatment	pretreatment	B-NP	NN	O	13	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	5	5	B-NP	CD	O	9	AMOD
6	,	,	I-NP	,	O	9	P
7	10	10	I-NP	CD	O	9	AMOD
8	and	and	I-NP	CC	O	9	AMOD
9	20	20	I-NP	CD	O	12	NMOD
10	mg/kg	mg/kg	I-NP	NN	O	12	NMOD
11	i.p.	i.p.	I-NP	JJ	O	12	NMOD
12	trazodone	trazodone	I-NP	NN	O	4	PMOD
13	enhanced	enhance	B-VP	VBD	O	0	ROOT
14	dexamphetamine	dexamphetamine	B-NP	NN	O	15	NMOD
15	stereotypy	stereotypy	I-NP	NN	O	13	OBJ
16	,	,	O	,	O	13	P
17	and	and	O	CC	O	13	VMOD
18	antagonized	antagonize	B-VP	VBD	O	13	VMOD
19	haloperidol	haloperidol	B-NP	NN	O	20	NMOD
20	catalepsy	catalepsy	I-NP	NN	O	18	OBJ
21	,	,	O	,	O	13	P
22	ergometrine	ergometrine	B-NP	NN	O	30	NMOD
23	induced	induce	B-VP	VBD	O	30	NMOD
24	WDS	WDS	B-NP	NN	O	25	NMOD
25	behavior	behavior	I-NP	NN	O	30	NMOD
26	and	and	O	CC	O	27	NMOD
27	fluoxetine	fluoxetine	B-NP	NN	O	30	NMOD
28	induced	induce	B-VP	VBD	O	30	NMOD
29	penile	penile	B-NP	JJ	O	30	NMOD
30	erections	erection	I-NP	NNS	O	13	VMOD
31	.	.	O	.	O	13	P

1	Trazodone	Trazodone	B-NP	NN	O	10	SUB
2	at	at	B-PP	IN	O	1	NMOD
3	30	30	B-NP	CD	O	7	AMOD
4	,	,	I-NP	,	O	7	P
5	40	40	I-NP	CD	O	7	AMOD
6	and	and	I-NP	CC	O	7	AMOD
7	50	50	I-NP	CD	O	8	NMOD
8	mg/kg	mg/kg	I-NP	NN	O	2	PMOD
9	i.p.	i.p.	B-ADVP	RB	O	10	VMOD
10	induced	induce	B-VP	VBD	O	0	ROOT
11	catalepsy	catalepsy	B-NP	NN	O	10	OBJ
12	and	and	O	CC	O	10	VMOD
13	antagonized	antagonize	B-VP	VBD	O	10	VMOD
14	apomorphine	apomorphine	B-NP	NN	O	17	NMOD
15	and	and	I-NP	CC	O	17	NMOD
16	dexamphetamine	dexamphetamine	I-NP	NN	O	17	NMOD
17	stereotypies	stereotypy	I-NP	NNS	O	13	OBJ
18	.	.	O	.	O	10	P

1	The	The	B-NP	DT	O	2	NMOD
2	aim	aim	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	characterize	characterize	I-VP	VB	O	6	PRD
9	the	the	B-NP	DT	O	11	NMOD
10	oropharyngeal	oropharyngeal	I-NP	JJ	O	11	NMOD
11	dynamics	dynamic	I-NP	NNS	O	8	OBJ
12	in	in	B-PP	IN	O	11	NMOD
13	PD	PD	B-NP	NN	O	14	NMOD
14	patients	patient	I-NP	NNS	O	12	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	and	and	I-PP	CC	O	15	PMOD
17	without	without	I-PP	IN	O	15	PMOD
18	levodopa	levodopa	B-NP	NN	O	20	NMOD
19	induced	induced	I-NP	JJ	O	20	NMOD
20	dyskinesia	dyskinesia	I-NP	NN	O	15	PMOD
21	.	.	O	.	O	6	P

1	In	In	B-PP	IN	O	0	ROOT
2	the	the	B-NP	DT	O	4	NMOD
3	current	current	I-NP	JJ	O	4	NMOD
4	study	study	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	1	VMOD
6	dyskinetic	dyskinetic	B-NP	JJ	O	7	NMOD
7	patients	patient	I-NP	NNS	O	5	NMOD
8	performed	perform	B-VP	VBN	O	7	NMOD
9	better	well	B-ADVP	RBR	O	8	VMOD
10	in	in	B-PP	IN	O	8	VMOD
11	swallowing	swallow	B-VP	VBG	O	12	NMOD
12	function	function	B-NP	NN	O	10	PMOD
13	,	,	O	,	O	7	P
14	which	which	B-NP	WDT	O	7	NMOD
15	could	could	B-VP	MD	O	14	SBAR
16	be	be	I-VP	VB	O	15	VC
17	explained	explain	I-VP	VBN	O	16	VC
18	on	on	B-PP	IN	O	17	VMOD
19	the	the	B-NP	DT	O	20	NMOD
20	basis	basis	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	a	a	B-NP	DT	O	25	NMOD
23	greater	great	I-NP	JJR	O	25	NMOD
24	levodopa	levodopa	I-NP	NN	O	25	NMOD
25	dose	dose	I-NP	NN	O	21	PMOD
26	.	.	O	.	O	7	P

1	Inhibition	Inhibition	B-NP	NN	O	6	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	nuclear	nuclear	B-NP	JJ	B-protein	5	NMOD
4	factor-kappaB	factor-kappaB	I-NP	NN	I-protein	5	NMOD
5	activation	activation	I-NP	NN	O	2	PMOD
6	attenuates	attenuate	B-VP	VBZ	O	0	ROOT
7	tubulointerstitial	tubulointerstitial	B-NP	JJ	O	8	NMOD
8	nephritis	nephritis	I-NP	NN	O	6	OBJ
9	induced	induce	B-VP	VBN	O	8	NMOD
10	by	by	B-PP	IN	O	9	VMOD
11	gentamicin	gentamicin	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	6	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Animals	Animal	B-NP	NNS	O	7	SUB
4	treated	treat	B-VP	VBN	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	gentamicin	gentamicin	B-NP	NN	O	5	PMOD
7	can	can	B-VP	MD	O	1	NMOD
8	show	show	I-VP	VB	O	7	VC
9	residual	residual	B-NP	JJ	O	10	NMOD
10	areas	area	I-NP	NNS	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	interstitial	interstitial	B-NP	JJ	O	13	NMOD
13	fibrosis	fibrosis	I-NP	NN	O	11	PMOD
14	in	in	B-PP	IN	O	8	VMOD
15	the	the	B-NP	DT	O	17	NMOD
16	renal	renal	I-NP	JJ	O	17	NMOD
17	cortex	cortex	I-NP	NN	O	14	PMOD
18	.	.	O	.	O	1	P

1	Glucose	Glucose	B-NP	NN	O	2	NMOD
2	metabolism	metabolism	I-NP	NN	O	19	NMOD
3	in	in	B-PP	IN	O	2	NMOD
4	patients	patient	B-NP	NNS	O	3	PMOD
5	with	with	B-PP	IN	O	4	NMOD
6	schizophrenia	schizophrenia	B-NP	NN	O	5	PMOD
7	treated	treat	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	atypical	atypical	B-NP	JJ	O	11	NMOD
10	antipsychotic	antipsychotic	I-NP	JJ	O	11	NMOD
11	agents	agent	I-NP	NNS	O	8	PMOD
12	:	:	O	:	O	2	P
13	a	a	B-NP	DT	O	19	NMOD
14	frequently	frequently	I-NP	RB	O	15	AMOD
15	sampled	sample	I-NP	VBN	O	19	NMOD
16	intravenous	intravenous	I-NP	JJ	O	19	NMOD
17	glucose	glucose	I-NP	NN	O	19	NMOD
18	tolerance	tolerance	I-NP	NN	O	19	NMOD
19	test	test	I-NP	NN	O	23	NMOD
20	and	and	O	CC	O	23	NMOD
21	minimal	minimal	B-NP	JJ	O	23	NMOD
22	model	model	I-NP	NN	O	23	NMOD
23	analysis	analysis	I-NP	NN	O	0	ROOT
24	.	.	O	.	O	23	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	25	VMOD
2	:	:	O	:	O	1	P
3	While	While	B-SBAR	IN	O	25	VMOD
4	the	the	B-NP	DT	O	5	NMOD
5	incidence	incidence	I-NP	NN	O	10	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	new-onset	new-onset	B-NP	JJ	O	9	NMOD
8	diabetes	diabetes	I-NP	NN	O	9	NMOD
9	mellitus	mellitus	I-NP	NN	O	6	PMOD
10	may	may	B-VP	MD	O	3	SBAR
11	be	be	I-VP	VB	O	10	VC
12	increasing	increase	I-VP	VBG	O	11	VC
13	in	in	B-PP	IN	O	12	VMOD
14	patients	patient	B-NP	NNS	O	13	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	schizophrenia	schizophrenia	B-NP	NN	O	15	PMOD
17	treated	treat	B-VP	VBN	O	16	NMOD
18	with	with	B-PP	IN	O	17	VMOD
19	certain	certain	B-NP	JJ	O	22	NMOD
20	atypical	atypical	I-NP	JJ	O	22	NMOD
21	antipsychotic	antipsychotic	I-NP	JJ	O	22	NMOD
22	agents	agent	I-NP	NNS	O	18	PMOD
23	,	,	O	,	O	25	P
24	it	it	B-NP	PRP	O	25	SUB
25	remains	remain	B-VP	VBZ	O	0	ROOT
26	unclear	unclear	B-ADJP	JJ	O	25	PRD
27	whether	whether	B-SBAR	IN	O	25	VMOD
28	atypical	atypical	B-NP	JJ	O	29	NMOD
29	agents	agent	I-NP	NNS	O	30	SUB
30	are	be	B-VP	VBP	O	27	SBAR
31	directly	directly	I-VP	RB	O	30	VMOD
32	affecting	affect	I-VP	VBG	O	30	VMOD
33	glucose	glucose	B-NP	NN	O	34	NMOD
34	metabolism	metabolism	I-NP	NN	O	32	OBJ
35	or	or	O	CC	O	30	VMOD
36	simply	simply	B-VP	RB	O	37	VMOD
37	increasing	increase	I-VP	VBG	O	40	NMOD
38	known	know	B-NP	VBN	O	40	NMOD
39	risk	risk	I-NP	NN	O	40	NMOD
40	factors	factor	I-NP	NNS	O	30	VMOD
41	for	for	B-PP	IN	O	40	NMOD
42	diabetes	diabete	B-NP	NNS	O	41	PMOD
43	.	.	O	.	O	25	P

1	DESIGN	DESIGN	B-NP	NN	O	5	NMOD
2	:	:	O	:	O	1	P
3	A	A	B-NP	DT	O	5	NMOD
4	cross-sectional	cross-sectional	I-NP	JJ	O	5	NMOD
5	design	design	I-NP	NN	O	10	NMOD
6	in	in	B-PP	IN	O	5	NMOD
7	stable	stable	B-NP	JJ	O	6	PMOD
8	,	,	O	,	O	5	P
9	treated	treat	B-VP	VBN	O	10	NMOD
10	patients	patient	B-NP	NNS	O	0	ROOT
11	with	with	B-PP	IN	O	10	NMOD
12	schizophrenia	schizophrenia	B-NP	NN	O	11	PMOD
13	evaluated	evaluate	B-VP	VBN	O	12	NMOD
14	using	use	B-VP	VBG	O	10	NMOD
15	a	a	B-NP	DT	O	21	NMOD
16	frequently	frequently	I-NP	RB	O	17	AMOD
17	sampled	sample	I-NP	VBN	O	21	NMOD
18	intravenous	intravenous	I-NP	JJ	O	21	NMOD
19	glucose	glucose	I-NP	NN	O	21	NMOD
20	tolerance	tolerance	I-NP	NN	O	21	NMOD
21	test	test	I-NP	NN	O	27	NMOD
22	and	and	O	CC	O	27	NMOD
23	the	the	B-NP	DT	O	27	NMOD
24	Bergman	Bergman	I-NP	NNP	O	27	NMOD
25	minimal	minimal	I-NP	JJ	O	27	NMOD
26	model	model	I-NP	NN	O	27	NMOD
27	analysis	analysis	I-NP	NN	O	14	OBJ
28	.	.	O	.	O	10	P

1	Thirty-six	Thirty-six	B-NP	CD	O	3	NMOD
2	nonobese	nonobese	I-NP	JJ	O	3	NMOD
3	subjects	subject	I-NP	NNS	O	26	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	schizophrenia	schizophrenia	B-NP	NN	O	8	NMOD
6	or	or	O	CC	O	8	NMOD
7	schizoaffective	schizoaffective	B-NP	JJ	O	8	NMOD
8	disorder	disorder	I-NP	NN	O	4	PMOD
9	,	,	O	,	O	8	P
10	matched	match	B-VP	VBN	O	8	NMOD
11	by	by	B-PP	IN	O	10	VMOD
12	body	body	B-NP	NN	O	14	NMOD
13	mass	mass	I-NP	NN	O	14	NMOD
14	index	index	I-NP	NN	O	11	PMOD
15	and	and	O	CC	O	10	VMOD
16	treated	treat	B-VP	VBN	O	10	VMOD
17	with	with	B-PP	IN	O	16	VMOD
18	either	either	O	CC	O	24	NMOD
19	clozapine	clozapine	B-NP	NN	O	24	NMOD
20	,	,	O	,	O	24	P
21	olanzapine	olanzapine	B-NP	NN	O	24	NMOD
22	,	,	O	,	O	24	P
23	or	or	O	CC	O	24	NMOD
24	risperidone	risperidone	B-NP	NN	O	17	PMOD
25	,	,	O	,	O	3	P
26	were	be	B-VP	VBD	O	0	ROOT
27	included	include	I-VP	VBN	O	26	VC
28	in	in	B-PP	IN	O	27	VMOD
29	the	the	B-NP	DT	O	30	NMOD
30	analysis	analysis	I-NP	NN	O	28	PMOD
31	.	.	O	.	O	26	P

1	MAIN	MAIN	B-NP	NNP	O	3	NMOD
2	OUTCOME	OUTCOME	I-NP	NNP	O	3	NMOD
3	MEASURES	MEASURES	I-NP	NNP	O	20	NMOD
4	:	:	O	:	O	3	P
5	Fasting	Fast	B-VP	VBG	O	3	NMOD
6	plasma	plasma	B-NP	NN	O	7	NMOD
7	glucose	glucose	I-NP	NN	O	5	OBJ
8	and	and	O	CC	O	5	VMOD
9	fasting	fast	B-VP	VBG	O	5	VMOD
10	serum	serum	B-NP	NN	B-protein	12	NMOD
11	insulin	insulin	I-NP	NN	I-protein	12	NMOD
12	levels	level	I-NP	NNS	O	9	OBJ
13	,	,	O	,	O	20	P
14	insulin	insulin	B-NP	NN	O	16	NMOD
15	sensitivity	sensitivity	I-NP	NN	O	16	NMOD
16	index	index	I-NP	NN	O	20	NMOD
17	,	,	O	,	O	20	P
18	homeostasis	homeostasis	B-NP	NN	O	20	NMOD
19	model	model	I-NP	NN	O	20	NMOD
20	assessment	assessment	I-NP	NN	O	27	NMOD
21	of	of	B-PP	IN	O	20	NMOD
22	insulin	insulin	B-NP	NN	B-protein	23	NMOD
23	resistance	resistance	I-NP	NN	O	21	PMOD
24	,	,	O	,	O	27	P
25	and	and	O	CC	O	27	NMOD
26	glucose	glucose	B-NP	NN	O	27	NMOD
27	effectiveness	effectiveness	I-NP	NN	O	0	ROOT
28	.	.	O	.	O	27	P

1	There	There	B-NP	EX	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	significant	significant	I-NP	JJ	O	5	NMOD
5	difference	difference	I-NP	NN	O	2	PRD
6	in	in	B-PP	IN	O	5	NMOD
7	insulin	insulin	B-NP	NN	O	9	NMOD
8	sensitivity	sensitivity	I-NP	NN	O	9	NMOD
9	index	index	I-NP	NN	O	6	PMOD
10	among	among	B-PP	IN	O	9	NMOD
11	groups	group	B-NP	NNS	O	10	PMOD
12	(	(	O	(	O	5	NMOD
13	F	F	B-NP	NN	O	38	NMOD
14	(	(	O	(	O	16	DEP
15	33	33	B-NP	CD	O	16	DEP
16	)	)	O	)	O	13	NMOD
17	=	=	B-VP	SYM	O	13	NMOD
18	10.66	10.66	B-NP	CD	O	17	AMOD
19	;	;	O	:	O	38	P
20	P	P	B-NP	NN	O	38	NMOD
21	<	<	B-NP	JJR	O	20	NMOD
22	.001	.001	I-NP	CD	O	21	AMOD
23	)	)	O	)	O	20	NMOD
24	(	(	O	(	O	30	DEP
25	clozapine	clozapine	B-NP	NN	O	29	NMOD
26	<	<	B-NP	SYM	O	29	NMOD
27	olanzapine	olanzapine	I-NP	NN	O	29	NMOD
28	<	<	I-NP	SYM	O	29	NMOD
29	risperidone	risperidone	I-NP	NN	O	30	DEP
30	)	)	O	)	O	20	NMOD
31	,	,	O	,	O	20	P
32	with	with	B-PP	IN	O	20	NMOD
33	subjects	subject	B-NP	NNS	O	32	PMOD
34	who	who	B-NP	WP	O	20	NMOD
35	received	receive	B-VP	VBD	O	34	SBAR
36	clozapine	clozapine	B-NP	NN	O	35	OBJ
37	and	and	I-NP	CC	O	38	NMOD
38	olanzapine	olanzapine	I-NP	NN	O	12	PMOD
39	exhibiting	exhibit	B-VP	VBG	O	38	NMOD
40	significant	significant	B-NP	JJ	O	42	NMOD
41	insulin	insulin	I-NP	NN	O	42	NMOD
42	resistance	resistance	I-NP	NN	O	39	OBJ
43	compared	compare	B-PP	VBN	O	38	NMOD
44	with	with	B-PP	IN	O	43	PMOD
45	subjects	subject	B-NP	NNS	O	44	PMOD
46	who	who	B-NP	WP	O	45	NMOD
47	were	be	B-VP	VBD	O	46	SBAR
48	treated	treat	I-VP	VBN	O	47	VC
49	with	with	B-PP	IN	O	48	VMOD
50	risperidone	risperidone	B-NP	NN	O	49	PMOD
51	(	(	O	(	O	50	NMOD
52	clozapine	clozapine	B-NP	NN	O	54	NMOD
53	vs	vs	O	CC	O	54	NMOD
54	risperidone	risperidone	B-NP	NN	O	56	NMOD
55	,	,	O	,	O	56	P
56	t	t	B-NP	NN	O	51	PMOD
57	(	(	O	(	O	56	NMOD
58	33	33	B-NP	CD	O	56	NMOD
59	)	)	O	)	O	56	NMOD
60	=	=	B-VP	SYM	O	61	VMOD
61	-4.29	-4.29	B-NP	CD	O	56	NMOD
62	;	;	O	:	O	56	P
63	P	P	B-NP	NN	O	56	NMOD
64	<	<	B-ADJP	SYM	O	63	NMOD
65	.001	.001	B-NP	CD	O	64	AMOD
66	;	;	O	:	O	86	P
67	olanzapine	olanzapine	B-NP	NN	O	86	DEP
68	vs	vs	B-PP	IN	O	67	NMOD
69	risperidone	risperidone	B-NP	NN	O	78	NMOD
70	,	,	O	,	O	78	P
71	t	t	B-NP	NN	O	78	NMOD
72	(	(	O	(	O	71	NMOD
73	33	33	B-NP	CD	O	71	NMOD
74	)	)	O	)	O	71	NMOD
75	=	=	B-VP	SYM	O	76	VMOD
76	-3.62	-3.62	B-NP	CD	O	71	NMOD
77	;	;	O	:	O	78	P
78	P	P	B-NP	NN	O	68	PMOD
79	=	=	B-VP	SYM	O	78	NMOD
80	.001	.001	B-NP	CD	O	79	AMOD
81	[	[	O	(	O	85	DEP
82	P	P	B-NP	NN	O	83	SUB
83	<	<	B-NP	JJR	O	85	DEP
84	.001	.001	I-NP	CD	O	83	NMOD
85	]	]	O	)	O	67	NMOD
86	)	)	O	)	O	56	NMOD
87	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	4	NMOD
2	homeostasis	homeostasis	I-NP	NN	O	4	NMOD
3	model	model	I-NP	NN	O	4	NMOD
4	assessment	assessment	I-NP	NN	O	9	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	insulin	insulin	B-NP	NN	B-protein	7	NMOD
7	resistance	resistance	I-NP	NN	O	5	PMOD
8	also	also	B-ADVP	RB	O	9	VMOD
9	differed	differ	B-VP	VBD	O	0	ROOT
10	significantly	significantly	B-ADVP	RB	O	9	VMOD
11	among	among	B-PP	IN	O	9	VMOD
12	groups	group	B-NP	NNS	O	11	PMOD
13	(	(	O	(	O	24	DEP
14	F	F	B-NP	NN	O	21	NMOD
15	(	(	O	(	O	17	DEP
16	33	33	B-NP	CD	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	=	=	B-VP	SYM	O	19	VMOD
19	4.92	4.92	B-NP	CD	O	21	NMOD
20	;	;	O	:	O	21	P
21	P	P	B-NP	NN	O	24	DEP
22	=	=	B-VP	SYM	O	21	NMOD
23	.01	.01	B-NP	CD	O	22	AMOD
24	)	)	O	)	O	9	VMOD
25	(	(	O	(	O	31	DEP
26	clozapine	clozapine	B-NP	NN	O	30	NMOD
27	>	>	B-NP	SYM	O	30	NMOD
28	olanzapine	olanzapine	I-NP	NN	O	30	NMOD
29	>	>	I-NP	SYM	O	30	NMOD
30	risperidone	risperidone	I-NP	NN	O	31	DEP
31	)	)	O	)	O	9	VMOD
32	(	(	O	(	O	9	VMOD
33	clozapine	clozapine	B-NP	NN	O	35	NMOD
34	vs	vs	O	CC	O	35	NMOD
35	risperidone	risperidone	B-NP	NN	O	44	NMOD
36	,	,	O	,	O	44	P
37	t	t	B-NP	NN	O	44	NMOD
38	(	(	O	(	O	37	NMOD
39	33	33	B-NP	CD	O	37	NMOD
40	)	)	O	)	O	37	NMOD
41	=	=	B-VP	SYM	O	42	VMOD
42	2.94	2.94	B-NP	CD	O	37	NMOD
43	;	;	O	:	O	44	P
44	P	P	B-NP	NN	O	32	PMOD
45	=	=	B-VP	SYM	O	44	NMOD
46	.006	.006	B-NP	CD	O	45	AMOD
47	;	;	O	:	O	44	NMOD
48	olanzapine	olanzapine	B-NP	NN	O	47	PMOD
49	vs	vs	B-PP	IN	O	48	NMOD
50	risperidone	risperidone	B-NP	NN	O	59	NMOD
51	,	,	O	,	O	59	P
52	t	t	B-NP	NN	O	59	NMOD
53	(	(	O	(	O	52	NMOD
54	33	33	B-NP	CD	O	52	NMOD
55	)	)	O	)	O	52	NMOD
56	=	=	B-VP	SYM	O	57	VMOD
57	2.42	2.42	B-NP	CD	O	52	NMOD
58	;	;	O	:	O	59	P
59	P	P	B-NP	NN	O	49	PMOD
60	=	=	B-VP	SYM	O	59	NMOD
61	.02	.02	B-NP	CD	O	60	AMOD
62	)	)	O	)	O	59	NMOD
63	.	.	O	.	O	9	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Both	Both	O	CC	O	8	NMOD
4	nonobese	nonobese	B-NP	JJ	O	5	NMOD
5	clozapine-	clozapine-	I-NP	NN	O	8	NMOD
6	and	and	O	CC	O	8	NMOD
7	olanzapine-treated	olanzapine-treated	B-NP	JJ	O	8	NMOD
8	groups	group	I-NP	NNS	O	9	SUB
9	displayed	display	B-VP	VBD	O	1	NMOD
10	significant	significant	B-NP	JJ	O	12	NMOD
11	insulin	insulin	I-NP	NN	O	12	NMOD
12	resistance	resistance	I-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	impairment	impairment	I-NP	NN	O	9	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	glucose	glucose	B-NP	NN	O	17	NMOD
17	effectiveness	effectiveness	I-NP	NN	O	15	PMOD
18	compared	compare	B-PP	VBN	O	9	VMOD
19	with	with	B-PP	IN	O	18	PMOD
20	risperidone-treated	risperidone-treated	B-NP	JJ	O	21	NMOD
21	subjects	subject	I-NP	NNS	O	19	PMOD
22	.	.	O	.	O	1	P

1	Focal	Focal	B-NP	JJ	O	3	NMOD
2	cerebral	cerebral	I-NP	JJ	O	3	NMOD
3	ischemia	ischemia	I-NP	NN	O	7	NMOD
4	in	in	B-PP	IN	O	3	NMOD
5	rats	rat	B-NP	NNS	O	4	PMOD
6	:	:	O	:	O	3	P
7	effect	effect	B-NP	NN	O	10	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	phenylephrine	phenylephrine	B-NP	NN	O	8	PMOD
10	induced	induce	B-VP	VBD	O	0	ROOT
11	hypertension	hypertension	B-NP	NN	O	10	OBJ
12	during	during	B-PP	IN	O	10	VMOD
13	reperfusion	reperfusion	B-NP	NN	O	12	PMOD
14	.	.	O	.	O	10	P

1	After	After	B-PP	IN	O	19	VMOD
2	180	180	B-NP	CD	O	3	NMOD
3	min	min	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	temporary	temporary	B-NP	JJ	O	9	NMOD
6	middle	middle	I-NP	JJ	O	9	NMOD
7	cerebral	cerebral	I-NP	JJ	O	9	NMOD
8	artery	artery	I-NP	NN	O	9	NMOD
9	occlusion	occlusion	I-NP	NN	O	4	PMOD
10	in	in	B-PP	IN	O	3	NMOD
11	spontaneously	spontaneously	B-NP	RB	O	12	AMOD
12	hypertensive	hypertensive	I-NP	JJ	O	13	NMOD
13	rats	rat	I-NP	NNS	O	10	PMOD
14	,	,	O	,	O	19	P
15	the	the	B-NP	DT	O	16	NMOD
16	effect	effect	I-NP	NN	O	19	SUB
17	of	of	B-PP	IN	O	16	NMOD
18	phenylephrine	phenylephrine	B-NP	NN	O	17	PMOD
19	induced	induce	B-VP	VBD	O	29	VMOD
20	hypertension	hypertension	B-NP	NN	O	29	SUB
21	on	on	B-PP	IN	O	20	NMOD
22	ischemic	ischemic	B-NP	JJ	O	24	NMOD
23	brain	brain	I-NP	NN	O	24	NMOD
24	injury	injury	I-NP	NN	O	28	NMOD
25	and	and	I-NP	CC	O	28	NMOD
26	blood-brain	blood-brain	I-NP	NN	O	28	NMOD
27	barrier	barrier	I-NP	NN	O	28	NMOD
28	permeability	permeability	I-NP	NN	O	21	PMOD
29	was	be	B-VP	VBD	O	0	ROOT
30	determined	determine	I-VP	VBN	O	29	VC
31	.	.	O	.	O	29	P

1	Part	Part	B-NP	NNP	O	2	NMOD
2	A	A	I-NP	NNP	O	12	SUB
3	,	,	O	,	O	2	P
4	for	for	B-PP	IN	O	2	NMOD
5	eight	eight	B-NP	CD	O	6	NMOD
6	rats	rat	I-NP	NNS	O	4	PMOD
7	in	in	B-PP	IN	O	2	NMOD
8	each	each	B-NP	DT	O	11	NMOD
9	group	group	I-NP	NN	O	11	NMOD
10	brain	brain	I-NP	NN	O	11	NMOD
11	injury	injury	I-NP	NN	O	7	PMOD
12	was	be	B-VP	VBD	O	0	ROOT
13	evaluated	evaluate	I-VP	VBN	O	12	VC
14	by	by	B-PP	IN	O	13	VMOD
15	staining	stain	B-VP	VBG	O	14	PMOD
16	tissue	tissue	B-NP	NN	O	15	OBJ
17	using	use	B-VP	VBG	O	15	VMOD
18	2	2	B-NP	CD	O	25	NMOD
19	,	,	I-NP	,	O	25	P
20	3	3	I-NP	CD	O	25	NMOD
21	,	,	I-NP	,	O	25	P
22	5-triphenyltetrazolium	5-triphenyltetrazolium	I-NP	NN	O	23	NMOD
23	chloride	chloride	I-NP	NN	O	25	NMOD
24	and	and	I-NP	CC	O	25	NMOD
25	edema	edema	I-NP	NN	O	17	OBJ
26	was	be	B-VP	VBD	O	12	VMOD
27	evaluated	evaluate	I-VP	VBN	O	26	VC
28	by	by	B-PP	IN	O	27	VMOD
29	microgravimetry	microgravimetry	B-NP	NN	O	28	PMOD
30	.	.	O	.	O	12	P

1	Evans	Evans	B-NP	NNP	O	2	NMOD
2	Blue	Blue	I-NP	NNP	O	10	SUB
3	(	(	O	(	O	9	DEP
4	mug	mug	B-NP	NN	O	5	NMOD
5	g-1	g-1	I-NP	NN	O	9	DEP
6	of	of	B-PP	IN	O	5	NMOD
7	brain	brain	B-NP	NN	O	8	NMOD
8	tissue	tissue	I-NP	NN	O	6	PMOD
9	)	)	O	)	O	2	NMOD
10	was	be	B-VP	VBD	O	0	ROOT
11	greater	great	B-ADJP	JJR	O	10	PRD
12	in	in	B-PP	IN	O	11	AMOD
13	the	the	B-NP	DT	O	15	NMOD
14	90/HTN	90/HTN	I-NP	NN	O	15	NMOD
15	group	group	I-NP	NN	O	12	PMOD
16	(	(	O	(	O	20	DEP
17	24.4	24.4	B-NP	CD	O	19	NMOD
18	+/-	+/-	I-NP	CC	O	19	NMOD
19	6.0	6.0	I-NP	CD	O	20	DEP
20	)	)	O	)	O	11	AMOD
21	versus	versus	B-PP	IN	O	11	AMOD
22	the	the	B-NP	DT	O	24	NMOD
23	control	control	I-NP	NN	O	24	NMOD
24	group	group	I-NP	NN	O	21	PMOD
25	(	(	O	(	O	29	DEP
26	12.3	12.3	B-NP	CD	O	28	NMOD
27	+/-	+/-	I-NP	CC	O	28	NMOD
28	4.1	4.1	I-NP	CD	O	29	DEP
29	)	)	O	)	O	24	NMOD
30	,	,	O	,	O	24	P
31	which	which	B-NP	WDT	O	24	NMOD
32	was	be	B-VP	VBD	O	31	SBAR
33	in	in	B-PP	IN	O	32	PRD
34	turn	turn	B-NP	NN	O	33	PMOD
35	greater	great	B-ADJP	JJR	O	34	NMOD
36	than	than	B-PP	IN	O	35	AMOD
37	the	the	B-NP	DT	O	39	NMOD
38	15/HTN	15/HTN	I-NP	NN	O	39	NMOD
39	group	group	I-NP	NN	O	36	PMOD
40	(	(	O	(	O	44	DEP
41	7.3	7.3	B-NP	CD	O	43	AMOD
42	+/-	+/-	I-NP	CC	O	43	AMOD
43	3.2	3.2	I-NP	CD	O	44	DEP
44	)	)	O	)	O	39	NMOD
45	.	.	O	.	O	10	P

1	People	People	B-NP	NNS	O	12	NMOD
2	aged	age	B-VP	VBN	O	1	NMOD
3	over	over	B-PP	IN	O	2	VMOD
4	75	75	B-NP	CD	O	3	PMOD
5	in	in	B-PP	IN	O	4	NMOD
6	atrial	atrial	B-NP	JJ	O	7	NMOD
7	fibrillation	fibrillation	I-NP	NN	O	5	PMOD
8	on	on	B-PP	IN	O	7	NMOD
9	warfarin	warfarin	B-NP	NN	O	8	PMOD
10	:	:	O	:	O	1	P
11	the	the	B-NP	DT	O	12	NMOD
12	rate	rate	I-NP	NN	O	17	NMOD
13	of	of	B-PP	IN	O	12	NMOD
14	major	major	B-NP	JJ	O	15	NMOD
15	hemorrhage	hemorrhage	I-NP	NN	O	13	PMOD
16	and	and	I-NP	CC	O	17	NMOD
17	stroke	stroke	I-NP	NN	O	0	ROOT
18	in	in	B-PP	IN	O	17	NMOD
19	more	more	B-NP	JJR	O	20	AMOD
20	than	than	I-NP	IN	O	22	NMOD
21	500	500	I-NP	CD	O	20	AMOD
22	patient-years	patient-year	I-NP	NNS	O	18	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	follow-up	follow-up	B-NP	NN	O	23	PMOD
25	.	.	O	.	O	17	P

1	OBJECTIVES	OBJECTIVES	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	determine	determine	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	incidence	incidence	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	major	major	B-NP	JJ	O	9	NMOD
9	hemorrhage	hemorrhage	I-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	stroke	stroke	I-NP	NN	O	7	PMOD
12	in	in	B-PP	IN	O	6	NMOD
13	people	people	B-NP	NNS	O	12	PMOD
14	aged	age	B-VP	VBN	O	13	NMOD
15	76	76	B-NP	CD	O	17	AMOD
16	and	and	O	CC	O	17	AMOD
17	older	old	B-ADJP	JJR	O	14	VMOD
18	with	with	B-PP	IN	O	17	AMOD
19	atrial	atrial	B-NP	JJ	O	20	NMOD
20	fibrillation	fibrillation	I-NP	NN	O	18	PMOD
21	on	on	B-PP	IN	O	17	AMOD
22	adjusted-dose	adjusted-dose	B-NP	JJ	O	23	NMOD
23	warfarin	warfarin	I-NP	NN	O	21	PMOD
24	who	who	B-NP	WP	O	23	NMOD
25	had	have	B-VP	VBD	O	24	SBAR
26	been	be	I-VP	VBN	O	25	VC
27	recently	recently	I-VP	RB	O	26	VMOD
28	been	be	I-VP	VBN	O	26	VC
29	admitted	admit	I-VP	VBN	O	28	VC
30	to	to	B-PP	TO	O	29	VMOD
31	hospital	hospital	B-NP	NN	O	30	PMOD
32	.	.	O	.	O	1	P

1	PARTICIPANTS	PARTICIPANTS	B-NP	NNS	O	6	NMOD
2	:	:	O	:	O	1	P
3	Two	Two	B-NP	CD	O	5	AMOD
4	hundred	hundred	I-NP	CD	O	5	AMOD
5	thirty-five	thirty-five	I-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	0	ROOT
7	aged	age	B-ADJP	VBN	O	6	NMOD
8	76	76	B-NP	CD	O	34	SUB
9	and	and	O	CC	O	34	VMOD
10	older	old	B-ADJP	JJR	O	34	SUB
11	admitted	admit	B-VP	VBN	O	10	NMOD
12	to	to	B-PP	TO	O	11	VMOD
13	a	a	B-NP	DT	O	16	NMOD
14	major	major	I-NP	JJ	O	16	NMOD
15	healthcare	healthcare	I-NP	NN	O	16	NMOD
16	network	network	I-NP	NN	O	12	PMOD
17	between	between	B-PP	IN	O	16	NMOD
18	July	July	B-NP	NNP	O	24	NMOD
19	1	1	I-NP	CD	O	18	NMOD
20	,	,	I-NP	,	O	18	P
21	2001	2001	I-NP	CD	O	18	NMOD
22	,	,	O	,	O	18	P
23	and	and	O	CC	O	24	NMOD
24	June	June	B-NP	NNP	O	17	PMOD
25	30	30	I-NP	CD	O	24	NMOD
26	,	,	I-NP	,	O	24	P
27	2002	2002	I-NP	CD	O	24	NMOD
28	,	,	O	,	O	24	P
29	with	with	B-PP	IN	O	24	NMOD
30	atrial	atrial	B-NP	JJ	O	31	NMOD
31	fibrillation	fibrillation	I-NP	NN	O	29	PMOD
32	on	on	B-PP	IN	O	16	NMOD
33	warfarin	warfarin	B-NP	NN	O	32	PMOD
34	were	be	B-VP	VBD	O	7	VMOD
35	enrolled	enrol	I-VP	VBN	O	34	VC
36	.	.	O	.	O	6	P

1	MEASUREMENTS	MEASUREMENTS	B-NP	NNS	O	3	NMOD
2	:	:	O	:	O	1	P
3	Information	Information	B-NP	NN	O	0	ROOT
4	regarding	regard	B-PP	VBG	O	3	NMOD
5	major	major	B-NP	JJ	O	7	NMOD
6	bleeding	bleed	I-NP	VBG	O	7	NMOD
7	episodes	episode	I-NP	NNS	O	14	VMOD
8	,	,	O	,	O	14	P
9	strokes	stroke	B-NP	NNS	O	14	VMOD
10	,	,	O	,	O	14	P
11	and	and	O	CC	O	14	VMOD
12	warfarin	warfarin	B-NP	NN	O	13	NMOD
13	use	use	I-NP	NN	O	14	SUB
14	was	be	B-VP	VBD	O	4	SBAR
15	obtained	obtain	I-VP	VBN	O	14	VC
16	from	from	B-PP	IN	O	15	VMOD
17	patients	patient	B-NP	NNS	O	26	NMOD
18	,	,	O	,	O	26	P
19	relatives	relative	B-NP	NNS	O	26	NMOD
20	,	,	O	,	O	26	P
21	primary	primary	B-NP	JJ	O	22	NMOD
22	physicians	physician	I-NP	NNS	O	26	NMOD
23	,	,	O	,	O	26	P
24	and	and	O	CC	O	26	NMOD
25	medical	medical	B-NP	JJ	O	26	NMOD
26	records	record	I-NP	NNS	O	16	PMOD
27	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	4	NMOD
2	annual	annual	I-NP	JJ	O	4	NMOD
3	stroke	stroke	I-NP	NN	O	4	NMOD
4	rate	rate	I-NP	NN	O	9	SUB
5	after	after	B-PP	IN	O	4	NMOD
6	initiation	initiation	B-NP	NN	O	5	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	warfarin	warfarin	B-NP	NN	O	7	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	2.6	2.6	B-NP	CD	O	11	NMOD
11	%	%	I-NP	NN	O	9	PRD
12	.	.	O	.	O	9	P

1	Safety	Safety	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	celecoxib	celecoxib	B-NP	NN	O	2	PMOD
4	in	in	B-PP	IN	O	1	NMOD
5	patients	patient	B-NP	NNS	O	4	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	adverse	adverse	B-NP	JJ	O	9	NMOD
8	skin	skin	I-NP	NN	O	9	NMOD
9	reactions	reaction	I-NP	NNS	O	6	PMOD
10	to	to	B-PP	TO	O	5	NMOD
11	acetaminophen	acetaminophen	B-NP	NN	O	16	NMOD
12	(	(	O	(	O	14	DEP
13	paracetamol	paracetamol	B-NP	NN	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	and	and	O	CC	O	16	NMOD
16	nimesulide	nimesulide	B-NP	NN	O	10	PMOD
17	associated	associate	B-VP	VBN	O	16	NMOD
18	or	or	O	CC	O	17	VMOD
19	not	not	O	RB	O	20	PMOD
20	with	with	B-PP	IN	O	17	VMOD
21	common	common	B-NP	JJ	O	24	NMOD
22	non-steroidal	non-steroidal	I-NP	JJ	O	24	NMOD
23	anti-inflammatory	anti-inflammatory	I-NP	JJ	O	24	NMOD
24	drugs	drug	I-NP	NNS	O	20	PMOD
25	.	.	O	.	O	1	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	evaluated	evaluate	B-VP	VBD	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	tolerability	tolerability	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	CE	CE	B-NP	NN	O	7	PMOD
9	in	in	B-PP	IN	O	6	NMOD
10	a	a	B-NP	DT	O	11	NMOD
11	group	group	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	patients	patient	B-NP	NNS	O	12	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	documented	document	B-NP	VBN	O	16	NMOD
16	history	history	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	adverse	adverse	B-NP	JJ	O	20	NMOD
19	cutaneous	cutaneous	I-NP	JJ	O	20	NMOD
20	reactions	reaction	I-NP	NNS	O	17	PMOD
21	to	to	B-PP	TO	O	11	NMOD
22	P	P	B-NP	NN	O	24	NMOD
23	and	and	I-NP	CC	O	24	NMOD
24	N	N	I-NP	NN	O	21	PMOD
25	associated	associate	B-VP	VBN	O	24	NMOD
26	or	or	O	CC	O	25	VMOD
27	not	not	O	RB	O	25	VMOD
28	to	to	B-PP	TO	O	27	PMOD
29	classic	classic	B-NP	JJ	O	30	NMOD
30	NSAIDs	NSAID	I-NP	NNS	O	28	PMOD
31	.	.	O	.	O	1	P

1	METHODS	METHODS	B-NP	NNS	O	4	VMOD
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	studied	study	B-VP	VBD	O	0	ROOT
5	9	9	B-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	4	OBJ
7	with	with	B-PP	IN	O	6	NMOD
8	hypersensitivity	hypersensitivity	B-NP	NN	O	7	PMOD
9	to	to	B-PP	TO	O	8	NMOD
10	P	P	B-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	N	N	I-NP	NN	O	9	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	or	or	B-PP	CC	O	13	PMOD
15	without	without	B-PP	IN	O	13	PMOD
16	associated	associated	B-NP	JJ	O	17	NMOD
17	reactions	reaction	I-NP	NNS	O	13	PMOD
18	to	to	B-PP	TO	O	17	NMOD
19	classic	classic	B-NP	JJ	O	20	NMOD
20	NSAIDs	NSAID	I-NP	NNS	O	18	PMOD
21	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	2	NMOD
2	diagnosis	diagnosis	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	P	P	B-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	N	N	I-NP	NN	O	3	PMOD
7	induced	induce	B-VP	VBD	O	10	VMOD
8	skin	skin	B-NP	NN	O	9	NMOD
9	reactions	reaction	I-NP	NNS	O	10	SUB
10	was	be	B-VP	VBD	O	0	ROOT
11	based	base	I-VP	VBN	O	10	VC
12	in	in	B-NP	FW	O	13	AMOD
13	vivo	vivo	I-NP	FW	O	14	NMOD
14	challenge	challenge	I-NP	NN	O	11	OBJ
15	.	.	O	.	O	10	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	6	NMOD
2	:	:	O	:	O	1	P
3	Only	Only	B-NP	RB	O	6	NMOD
4	one	one	I-NP	CD	O	3	AMOD
5	hypersensitivity	hypersensitivity	I-NP	NN	O	6	NMOD
6	reaction	reaction	I-NP	NN	O	9	SUB
7	to	to	B-PP	TO	O	6	NMOD
8	CE	CE	B-NP	NN	O	7	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	documented	document	I-VP	VBN	O	18	NMOD
11	among	among	B-PP	IN	O	10	VMOD
12	9	9	B-NP	CD	O	13	NMOD
13	P	P	I-NP	NN	O	11	PMOD
14	and	and	O	CC	O	10	VMOD
15	N-highly	N-highly	B-ADVP	RB	O	10	VMOD
16	NSAIDs	NSAID	B-NP	NNS	O	18	NMOD
17	intolerant	intolerant	B-NP	JJ	O	18	NMOD
18	patients	patient	I-NP	NNS	O	9	PRD
19	.	.	O	.	O	9	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Studies	Study	B-NP	NNS	O	30	SUB
4	on	on	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	association	association	I-NP	NN	O	4	PMOD
7	between	between	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	10	NMOD
9	long-term	long-term	I-NP	JJ	O	10	NMOD
10	use	use	I-NP	NN	O	26	NMOD
11	of	of	B-PP	IN	O	10	NMOD
12	aspirin	aspirin	B-NP	NN	O	19	NMOD
13	and	and	O	CC	O	19	NMOD
14	other	other	B-NP	JJ	O	19	NMOD
15	analgesic	analgesic	I-NP	JJ	O	19	NMOD
16	and	and	I-NP	CC	O	19	NMOD
17	nonsteroidal	nonsteroidal	I-NP	JJ	O	19	NMOD
18	anti-inflammatory	anti-inflammatory	I-NP	JJ	O	19	NMOD
19	drugs	drug	I-NP	NNS	O	11	PMOD
20	(	(	O	(	O	22	DEP
21	NSAIDs	NSAID	B-NP	NNS	O	22	DEP
22	)	)	O	)	O	19	NMOD
23	and	and	O	CC	O	26	NMOD
24	end-stage	end-stage	B-NP	JJ	O	26	NMOD
25	renal	renal	I-NP	JJ	O	26	NMOD
26	disease	disease	I-NP	NN	O	7	PMOD
27	(	(	O	(	O	29	DEP
28	ESRD	ESRD	B-NP	NN	O	29	DEP
29	)	)	O	)	O	26	NMOD
30	have	have	B-VP	VBP	O	1	NMOD
31	given	give	I-VP	VBN	O	30	VC
32	conflicting	conflict	I-VP	VBG	O	33	NMOD
33	results	result	B-NP	NNS	O	31	OBJ
34	.	.	O	.	O	30	P

1	The	The	B-NP	DT	O	2	NMOD
2	risk	risk	I-NP	NN	O	8	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	ESRD	ESRD	B-NP	NN	O	3	PMOD
5	associated	associate	B-VP	VBN	O	4	NMOD
6	with	with	B-PP	IN	O	5	VMOD
7	aspirin	aspirin	B-NP	NN	O	6	PMOD
8	was	be	B-VP	VBD	O	21	VMOD
9	related	relate	I-VP	VBN	O	8	PRD
10	to	to	B-PP	TO	O	9	AMOD
11	the	the	B-NP	DT	O	13	NMOD
12	cumulated	cumulate	I-NP	VBN	O	13	NMOD
13	dose	dose	I-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	duration	duration	I-NP	NN	O	10	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	use	use	B-NP	NN	O	16	PMOD
18	,	,	O	,	O	21	P
19	and	and	O	CC	O	21	VMOD
20	it	it	B-NP	PRP	O	21	SUB
21	was	be	B-VP	VBD	O	0	ROOT
22	particularly	particularly	B-ADJP	RB	O	23	AMOD
23	high	high	I-ADJP	JJ	O	21	PRD
24	among	among	B-PP	IN	O	23	AMOD
25	the	the	B-NP	DT	O	26	NMOD
26	subset	subset	I-NP	NN	O	24	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	patients	patient	B-NP	NNS	O	27	PMOD
29	with	with	B-PP	IN	O	28	NMOD
30	vascular	vascular	B-NP	JJ	O	31	NMOD
31	nephropathy	nephropathy	I-NP	NN	O	29	PMOD
32	as	as	B-PP	IN	O	23	AMOD
33	underlying	underlie	B-VP	VBG	O	34	NMOD
34	disease	disease	B-NP	NN	O	32	PMOD
35	[	[	O	(	O	40	DEP
36	2.35	2.35	B-NP	CD	O	40	DEP
37	(	(	O	(	O	39	DEP
38	1.17-4.72	1.17-4.72	B-NP	CD	O	39	DEP
39	)	)	O	)	O	36	NMOD
40	]	]	O	)	O	21	VMOD
41	.	.	O	.	O	21	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	cases	case	I-NP	NNS	O	8	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	amisulpride	amisulpride	B-NP	NN	O	5	NMOD
5	overdose	overdose	I-NP	NN	O	3	PMOD
6	:	:	O	:	O	2	P
7	a	a	B-NP	DT	O	8	NMOD
8	cause	cause	I-NP	NN	O	0	ROOT
9	for	for	B-PP	IN	O	8	NMOD
10	prolonged	prolonged	B-NP	JJ	O	12	NMOD
11	QT	QT	I-NP	NN	O	12	NMOD
12	syndrome	syndrome	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	8	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	cases	case	I-NP	NNS	O	17	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	deliberate	deliberate	B-NP	JJ	O	5	NMOD
5	self-poisoning	self-poisoning	I-NP	NN	O	3	PMOD
6	with	with	B-PP	IN	O	2	NMOD
7	5	5	B-NP	CD	O	8	NMOD
8	g	g	I-NP	NN	O	11	NMOD
9	and	and	O	CC	O	11	NMOD
10	3.6	3.6	B-NP	CD	O	11	NMOD
11	g	g	I-NP	NN	O	6	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	amisulpride	amisulpride	B-NP	NN	O	12	PMOD
14	,	,	O	,	O	2	P
15	respectively	respectively	B-ADVP	RB	O	2	NMOD
16	,	,	O	,	O	2	P
17	are	be	B-VP	VBP	O	0	ROOT
18	reported	report	I-VP	VBN	O	17	VC
19	.	.	O	.	O	17	P

1	Growth-associated	Growth-associated	B-NP	JJ	B-protein	2	NMOD
2	protein	protein	I-NP	NN	I-protein	4	NMOD
3	43	43	I-NP	CD	I-protein	2	NMOD
4	expression	expression	I-NP	NN	O	0	ROOT
5	in	in	B-PP	IN	O	4	NMOD
6	hippocampal	hippocampal	B-NP	JJ	O	8	NMOD
7	molecular	molecular	I-NP	JJ	O	8	NMOD
8	layer	layer	I-NP	NN	O	5	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	chronic	chronic	B-NP	JJ	O	12	NMOD
11	epileptic	epileptic	I-NP	JJ	O	12	NMOD
12	rats	rat	I-NP	NNS	O	9	PMOD
13	treated	treat	B-VP	VBN	O	12	NMOD
14	with	with	B-PP	IN	O	13	VMOD
15	cycloheximide	cycloheximide	B-NP	NN	O	14	PMOD
16	.	.	O	.	O	4	P

1	To	To	B-VP	TO	O	2	VMOD
2	investigate	investigate	I-VP	VB	O	14	VMOD
3	how	how	B-ADVP	WRB	O	2	VMOD
4	GAP43	GAP43	B-NP	NN	B-protein	5	NMOD
5	expression	expression	I-NP	NN	O	9	SUB
6	(	(	O	(	O	8	DEP
7	GAP43-ir	GAP43-ir	B-NP	NN	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	correlates	correlate	B-VP	VBZ	O	3	SBAR
10	with	with	B-PP	IN	O	9	VMOD
11	MFS	MFS	B-NP	NN	B-protein	10	PMOD
12	,	,	O	,	O	14	P
13	we	we	B-NP	PRP	O	14	SUB
14	assessed	assess	B-VP	VBD	O	0	ROOT
15	the	the	B-NP	DT	O	16	NMOD
16	intensity	intensity	I-NP	NN	O	21	NMOD
17	(	(	O	(	O	19	DEP
18	densitometry	densitometry	B-NP	NN	O	19	DEP
19	)	)	O	)	O	16	NMOD
20	and	and	O	CC	O	21	NMOD
21	extension	extension	B-NP	NN	O	14	OBJ
22	(	(	O	(	O	24	DEP
23	width	width	B-NP	NN	O	24	DEP
24	)	)	O	)	O	21	NMOD
25	of	of	B-PP	IN	O	21	NMOD
26	GAP43-ir	GAP43-ir	B-NP	NN	B-protein	25	PMOD
27	in	in	B-PP	IN	O	21	NMOD
28	the	the	B-NP	DT	O	31	NMOD
29	inner	inner	I-NP	JJ	O	31	NMOD
30	molecular	molecular	I-NP	JJ	O	31	NMOD
31	layer	layer	I-NP	NN	O	27	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	the	the	B-NP	DT	O	35	NMOD
34	dentate	dentate	I-NP	NN	O	35	NMOD
35	gyrus	gyrus	I-NP	NN	O	32	PMOD
36	(	(	O	(	O	38	DEP
37	IML	IML	B-NP	NN	O	38	DEP
38	)	)	O	)	O	35	NMOD
39	of	of	B-PP	IN	O	35	NMOD
40	rats	rat	B-NP	NNS	O	39	PMOD
41	subject	subject	B-ADJP	JJ	O	40	NMOD
42	to	to	B-PP	TO	O	41	AMOD
43	status	status	B-NP	NN	B-protein	44	NMOD
44	epilepticus	epilepticus	I-NP	NN	I-protein	42	PMOD
45	induced	induce	B-VP	VBN	O	44	NMOD
46	by	by	B-PP	IN	O	45	VMOD
47	pilocarpine	pilocarpine	B-NP	NN	O	46	PMOD
48	(	(	O	(	O	50	DEP
49	Pilo	Pilo	B-NP	NN	B-protein	50	DEP
50	)	)	O	)	O	47	NMOD
51	,	,	O	,	O	21	P
52	previously	previously	B-VP	RB	O	53	VMOD
53	injected	inject	I-VP	VBN	O	21	NMOD
54	or	or	O	CC	O	53	VMOD
55	not	not	O	RB	O	56	PMOD
56	with	with	B-PP	IN	O	53	VMOD
57	cycloheximide	cycloheximide	B-NP	NN	O	56	PMOD
58	(	(	O	(	O	60	DEP
59	CHX	CHX	B-NP	NN	B-protein	60	DEP
60	)	)	O	)	O	57	NMOD
61	,	,	O	,	O	57	P
62	which	which	B-NP	WDT	O	57	NMOD
63	has	have	B-VP	VBZ	O	62	SBAR
64	been	be	I-VP	VBN	O	63	VC
65	shown	show	I-VP	VBN	O	64	VC
66	to	to	I-VP	TO	O	67	VMOD
67	inhibit	inhibit	I-VP	VB	O	65	VMOD
68	MFS	MFS	B-NP	NN	B-protein	67	OBJ
69	.	.	O	.	O	14	P

1	OBJECTIVES	OBJECTIVES	B-NP	NNS	O	5	NMOD
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	5	NMOD
4	present	present	I-NP	JJ	O	5	NMOD
5	study	study	I-NP	NN	O	6	SUB
6	investigates	investigate	B-VP	VBZ	O	0	ROOT
7	the	the	B-NP	DT	O	8	NMOD
8	effects	effect	I-NP	NNS	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	nicotine	nicotine	B-NP	NN	O	9	PMOD
11	on	on	B-PP	IN	O	8	NMOD
12	anxiety	anxiety	B-NP	NN	O	11	PMOD
13	induced	induce	B-VP	VBN	O	12	NMOD
14	by	by	B-PP	IN	O	13	VMOD
15	caffeine	caffeine	B-NP	NN	O	21	NMOD
16	and	and	O	CC	O	21	NMOD
17	another	another	B-NP	DT	O	19	NMOD
18	anxiogenic	anxiogenic	I-NP	JJ	O	19	NMOD
19	drug	drug	I-NP	NN	O	21	NMOD
20	,	,	O	,	O	21	P
21	pentylenetetrazole	pentylenetetrazole	B-NP	NN	O	14	PMOD
22	,	,	O	,	O	11	P
23	in	in	B-PP	IN	O	11	PMOD
24	mice	mouse	B-NP	NNS	O	23	PMOD
25	.	.	O	.	O	6	P

1	Nicotine	Nicotine	B-NP	NN	O	6	NMOD
2	(	(	O	(	O	5	DEP
3	0.25	0.25	B-NP	CD	O	4	NMOD
4	mg/kg	mg/kg	I-NP	NN	O	5	DEP
5	)	)	O	)	O	1	NMOD
6	pretreatment	pretreatment	B-NP	NN	O	7	SUB
7	blocked	block	B-VP	VBD	O	0	ROOT
8	the	the	B-NP	DT	O	9	NMOD
9	caffeine-	caffeine-	I-NP	NN	O	14	NMOD
10	but	but	B-NP	CC	O	12	NMOD
11	not	not	I-NP	RB	O	10	DEP
12	pentylenetetrazole	pentylenetetrazole	B-NP	NN	O	14	NMOD
13	induced	induce	B-VP	VBD	O	14	NMOD
14	anxiety	anxiety	B-NP	NN	O	7	OBJ
15	.	.	O	.	O	7	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Our	Our	B-NP	PRP$	O	4	NMOD
4	results	result	I-NP	NNS	O	5	SUB
5	suggest	suggest	B-VP	VBP	O	1	NMOD
6	that	that	B-SBAR	IN	O	5	VMOD
7	the	the	B-NP	DT	O	9	NMOD
8	antagonistic	antagonistic	I-NP	JJ	O	9	NMOD
9	effect	effect	I-NP	NN	O	16	SUB
10	of	of	B-PP	IN	O	9	NMOD
11	nicotine	nicotine	B-NP	NN	O	10	PMOD
12	on	on	B-PP	IN	O	9	NMOD
13	caffeine	caffeine	B-NP	NN	O	15	NMOD
14	induced	induced	I-NP	JJ	O	15	NMOD
15	anxiety	anxiety	I-NP	NN	O	12	PMOD
16	is	be	B-VP	VBZ	O	6	SBAR
17	specific	specific	B-ADJP	JJ	O	16	PRD
18	to	to	B-PP	TO	O	17	AMOD
19	caffeine	caffeine	B-NP	NN	O	18	PMOD
20	,	,	O	,	O	16	P
21	instead	instead	B-PP	RB	O	22	PMOD
22	of	of	I-PP	IN	O	16	VMOD
23	a	a	B-NP	DT	O	26	NMOD
24	non-specific	non-specific	I-NP	JJ	O	26	NMOD
25	anxiolytic	anxiolytic	I-NP	JJ	O	26	NMOD
26	effect	effect	I-NP	NN	O	22	PMOD
27	.	.	O	.	O	1	P

1	Long-term	Long-term	B-NP	JJ	O	3	NMOD
2	oestrogen-only	oestrogen-only	I-NP	JJ	O	3	NMOD
3	HT	HT	I-NP	NN	O	6	SUB
4	also	also	B-ADVP	RB	O	6	VMOD
5	significantly	significantly	B-VP	RB	O	4	AMOD
6	increased	increase	I-VP	VBD	O	0	ROOT
7	the	the	B-NP	DT	O	8	NMOD
8	risk	risk	I-NP	NN	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	stroke	stroke	B-NP	NN	O	13	NMOD
11	and	and	I-NP	CC	O	13	NMOD
12	gallbladder	gallbladder	I-NP	NN	O	13	NMOD
13	disease	disease	I-NP	NN	O	9	PMOD
14	.	.	O	.	O	6	P

1	Factors	Factor	B-NP	NNS	O	10	SUB
2	associated	associate	B-VP	VBN	O	1	NMOD
3	with	with	B-PP	IN	O	2	VMOD
4	the	the	B-NP	DT	O	5	NMOD
5	development	development	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	fulminant	fulminant	B-NP	JJ	O	9	NMOD
8	hepatic	hepatic	I-NP	JJ	O	9	NMOD
9	failure	failure	I-NP	NN	O	6	PMOD
10	were	be	B-VP	VBD	O	0	ROOT
11	female	female	B-NP	JJ	O	12	NMOD
12	sex	sex	I-NP	NN	O	10	PRD
13	(	(	O	(	O	12	NMOD
14	OR	OR	B-NP	NN	O	20	NMOD
15	=	=	B-VP	SYM	O	14	NMOD
16	25	25	B-NP	CD	O	15	AMOD
17	;	;	O	:	O	20	P
18	95	95	B-NP	CD	O	20	NMOD
19	%	%	I-NP	NN	O	20	NMOD
20	CI	CI	I-NP	NN	O	13	PMOD
21	:	:	O	:	O	22	P
22	4.1-151	4.1-151	B-NP	CD	O	20	NMOD
23	;	;	O	:	O	22	NMOD
24	P	P	B-NP	NN	O	30	NMOD
25	<	<	B-NP	JJR	O	24	NMOD
26	.0001	.0001	I-NP	CD	O	25	AMOD
27	)	)	O	)	O	24	NMOD
28	,	,	O	,	O	30	P
29	hepatocellular	hepatocellular	B-NP	JJ	O	30	NMOD
30	damage	damage	I-NP	NN	O	23	PMOD
31	(	(	O	(	O	67	DEP
32	OR	OR	B-NP	NN	O	52	NMOD
33	=	=	B-VP	SYM	O	32	NMOD
34	7.9	7.9	B-NP	CD	O	33	AMOD
35	;	;	O	:	O	52	P
36	95	95	B-NP	CD	O	38	NMOD
37	%	%	I-NP	NN	O	38	NMOD
38	CI	CI	I-NP	NN	O	52	NMOD
39	:	:	O	:	O	52	P
40	1.6-37	1.6-37	B-NP	CD	O	52	NMOD
41	;	;	O	:	O	52	P
42	P	P	B-NP	NN	O	52	NMOD
43	<	<	B-NP	JJR	O	42	NMOD
44	.009	.009	I-NP	CD	O	43	AMOD
45	)	)	O	)	O	42	NMOD
46	,	,	O	,	O	52	P
47	and	and	O	CC	O	52	NMOD
48	higher	high	B-NP	JJR	O	52	NMOD
49	baseline	baseline	I-NP	NN	O	52	NMOD
50	plasma	plasma	I-NP	NN	O	52	NMOD
51	bilirubin	bilirubin	I-NP	NN	O	52	NMOD
52	value	value	I-NP	NN	O	67	DEP
53	(	(	O	(	O	67	DEP
54	OR	OR	B-NP	NN	O	67	DEP
55	=	=	B-VP	SYM	O	54	NMOD
56	1.15	1.15	B-NP	CD	O	55	AMOD
57	;	;	O	:	O	67	P
58	95	95	B-NP	CD	O	60	NMOD
59	%	%	I-NP	NN	O	60	NMOD
60	CI	CI	I-NP	NN	O	67	DEP
61	:	:	O	:	O	67	P
62	1.09-1.22	1.09-1.22	B-NP	CD	O	67	DEP
63	;	;	O	:	O	67	P
64	P	P	B-NP	NN	O	67	DEP
65	<	<	B-NP	JJR	O	64	NMOD
66	.0001	.0001	I-NP	CD	O	65	AMOD
67	)	)	O	)	O	30	NMOD
68	.	.	O	.	O	10	P

1	Morphological	Morphological	B-NP	JJ	O	2	NMOD
2	evaluation	evaluation	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	effect	effect	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	d-ribose	d-ribose	B-NP	NN	O	6	PMOD
8	on	on	B-PP	IN	O	5	NMOD
9	adriamycin-evoked	adriamycin-evoked	B-NP	JJ	O	10	NMOD
10	cardiotoxicity	cardiotoxicity	I-NP	NN	O	8	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	rats	rat	B-NP	NNS	O	11	PMOD
13	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	influence	influence	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	d-ribose	d-ribose	B-NP	NN	O	3	PMOD
5	on	on	B-PP	IN	O	2	NMOD
6	adriamycin	adriamycin	B-NP	NN	O	5	PMOD
7	induced	induce	B-VP	VBD	O	0	ROOT
8	myocardiopathy	myocardiopathy	B-NP	NN	O	7	OBJ
9	in	in	B-PP	IN	O	7	VMOD
10	rats	rat	B-NP	NNS	O	9	PMOD
11	was	be	B-VP	VBD	O	7	VMOD
12	studied	study	I-VP	VBN	O	11	VC
13	.	.	O	.	O	7	P

1	Adriamycin	Adriamycin	B-NP	NN	O	9	SUB
2	in	in	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	5	NMOD
4	cumulative	cumulative	I-NP	JJ	O	5	NMOD
5	dose	dose	I-NP	NN	O	2	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	25	25	B-NP	CD	O	8	NMOD
8	mg/kg	mg/kg	I-NP	NN	O	6	PMOD
9	evoked	evoke	B-VP	VBD	O	0	ROOT
10	fully	fully	B-NP	RB	O	11	AMOD
11	developed	develop	I-NP	VBN	O	13	NMOD
12	cardiac	cardiac	I-NP	JJ	O	13	NMOD
13	toxicity	toxicity	I-NP	NN	O	9	OBJ
14	.	.	O	.	O	9	P

1	In	In	B-NP	FW	O	2	AMOD
2	vivo	vivo	I-NP	FW	O	3	NMOD
3	evidences	evidence	I-NP	NNS	O	14	SUB
4	suggesting	suggest	B-VP	VBG	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	role	role	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	oxidative	oxidative	B-NP	JJ	O	9	NMOD
9	stress	stress	I-NP	NN	O	7	PMOD
10	in	in	B-PP	IN	O	6	NMOD
11	pathogenesis	pathogenesis	B-NP	NN	O	10	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	vancomycin	vancomycin	B-NP	NN	O	12	PMOD
14	induced	induce	B-VP	VBD	O	0	ROOT
15	nephrotoxicity	nephrotoxicity	B-NP	NN	O	14	OBJ
16	:	:	O	:	O	14	P
17	protection	protection	B-NP	NN	O	14	VMOD
18	by	by	B-PP	IN	O	14	VMOD
19	erdosteine	erdosteine	B-NP	NN	O	18	PMOD
20	.	.	O	.	O	14	P

1	The	The	B-NP	DT	O	2	NMOD
2	aims	aim	I-NP	NNS	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	were	be	B-VP	VBD	O	0	ROOT
7	to	to	I-VP	TO	O	8	VMOD
8	examine	examine	I-VP	VB	O	6	PRD
9	vancomycin	vancomycin	B-NP	NN	O	13	SUB
10	(	(	O	(	O	12	DEP
11	VCM	VCM	B-NP	NN	O	12	DEP
12	)	)	O	)	O	9	NMOD
13	induced	induce	B-VP	VBD	O	8	VMOD
14	oxidative	oxidative	B-NP	JJ	O	15	NMOD
15	stress	stress	I-NP	NN	O	13	OBJ
16	that	that	B-NP	WDT	O	15	NMOD
17	promotes	promote	B-VP	VBZ	O	16	SBAR
18	production	production	B-NP	NN	O	17	OBJ
19	of	of	B-PP	IN	O	18	NMOD
20	reactive	reactive	B-NP	JJ	O	22	NMOD
21	oxygen	oxygen	I-NP	NN	O	22	NMOD
22	species	specie	I-NP	NNS	O	19	PMOD
23	(	(	O	(	O	25	DEP
24	ROS	ROS	B-NP	NNS	O	25	DEP
25	)	)	O	)	O	22	NMOD
26	and	and	O	CC	O	28	VMOD
27	to	to	B-VP	TO	O	28	VMOD
28	investigate	investigate	I-VP	VB	O	16	SBAR
29	the	the	B-NP	DT	O	30	NMOD
30	role	role	I-NP	NN	O	28	OBJ
31	of	of	B-PP	IN	O	30	NMOD
32	erdosteine	erdosteine	B-NP	NN	O	36	NMOD
33	,	,	O	,	O	36	P
34	an	an	B-NP	DT	O	36	NMOD
35	expectorant	expectorant	I-NP	JJ	O	36	NMOD
36	agent	agent	I-NP	NN	O	31	PMOD
37	,	,	O	,	O	36	P
38	which	which	B-NP	WDT	O	36	NMOD
39	has	have	B-VP	VBZ	O	38	SBAR
40	also	also	B-ADVP	RB	O	39	VMOD
41	antioxidant	antioxidant	B-NP	JJ	O	42	NMOD
42	properties	property	I-NP	NNS	O	39	OBJ
43	,	,	O	,	O	13	P
44	on	on	B-PP	IN	O	13	VMOD
45	kidney	kidney	B-NP	NN	O	46	NMOD
46	tissue	tissue	I-NP	NN	O	44	PMOD
47	against	against	B-PP	IN	O	46	NMOD
48	the	the	B-NP	DT	O	50	NMOD
49	possible	possible	I-NP	JJ	O	50	NMOD
50	VCM	VCM	I-NP	NN	B-protein	47	PMOD
51	induced	induce	B-VP	VBD	O	13	VMOD
52	renal	renal	B-NP	JJ	O	53	NMOD
53	impairment	impairment	I-NP	NN	O	51	OBJ
54	in	in	B-PP	IN	O	51	VMOD
55	rats	rat	B-NP	NNS	O	54	PMOD
56	.	.	O	.	O	6	P

1	VCM	VCM	B-NP	NN	O	2	NMOD
2	administration	administration	I-NP	NN	O	7	SUB
3	to	to	B-PP	TO	O	2	NMOD
4	control	control	B-NP	NN	O	5	NMOD
5	rats	rat	I-NP	NNS	O	3	PMOD
6	significantly	significantly	B-ADVP	RB	O	7	VMOD
7	increased	increase	B-VP	VBD	O	0	ROOT
8	renal	renal	B-NP	JJ	O	9	NMOD
9	malondialdehyde	malondialdehyde	I-NP	NN	O	15	NMOD
10	(	(	O	(	O	12	DEP
11	MDA	MDA	B-NP	NN	B-protein	12	DEP
12	)	)	O	)	O	9	NMOD
13	and	and	O	CC	O	15	NMOD
14	urinary	urinary	B-NP	JJ	B-protein	15	NMOD
15	N-acetyl-beta-d-glucosaminidase	N-acetyl-beta-d-glucosaminidase	I-NP	NN	I-protein	20	NMOD
16	(	(	O	(	O	20	NMOD
17	NAG	NAG	B-NP	NN	B-protein	20	NMOD
18	,	,	O	,	O	20	P
19	a	a	B-NP	DT	O	20	NMOD
20	marker	marker	I-NP	NN	O	26	NMOD
21	of	of	B-PP	IN	O	20	NMOD
22	renal	renal	B-NP	JJ	O	24	NMOD
23	tubular	tubular	I-NP	JJ	O	24	NMOD
24	injury	injury	I-NP	NN	O	21	PMOD
25	)	)	O	)	O	20	NMOD
26	excretion	excretion	B-NP	NN	O	7	OBJ
27	but	but	O	CC	O	7	VMOD
28	decreased	decrease	B-VP	VBD	O	7	VMOD
29	superoxide	superoxide	B-NP	NN	B-protein	30	NMOD
30	dismutase	dismutase	I-NP	NN	I-protein	35	NMOD
31	(	(	O	(	O	33	DEP
32	SOD	SOD	B-NP	NN	B-protein	33	DEP
33	)	)	O	)	O	30	NMOD
34	and	and	O	CC	O	35	NMOD
35	catalase	catalase	B-NP	NN	B-protein	39	NMOD
36	(	(	O	(	O	38	DEP
37	CAT	CAT	B-NP	NN	B-protein	38	DEP
38	)	)	O	)	O	35	NMOD
39	activities	activity	B-NP	NNS	O	28	OBJ
40	.	.	O	.	O	7	P

1	Erdosteine	Erdosteine	B-NP	NN	O	2	SUB
2	showed	show	B-VP	VBD	O	0	ROOT
3	histopathological	histopathological	B-NP	JJ	O	4	NMOD
4	protection	protection	I-NP	NN	O	2	OBJ
5	against	against	B-PP	IN	O	4	NMOD
6	VCM	VCM	B-NP	NN	B-protein	8	NMOD
7	induced	induced	I-NP	JJ	O	8	NMOD
8	nephrotoxicity	nephrotoxicity	I-NP	NN	O	5	PMOD
9	.	.	O	.	O	2	P

1	There	There	B-NP	EX	O	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	significant	significant	I-NP	JJ	O	5	NMOD
5	dilatation	dilatation	I-NP	NN	O	20	NMOD
6	of	of	B-PP	IN	O	5	NMOD
7	tubular	tubular	B-NP	JJ	O	8	NMOD
8	lumens	lumen	I-NP	NNS	O	6	PMOD
9	,	,	O	,	O	20	P
10	extensive	extensive	B-NP	JJ	O	13	NMOD
11	epithelial	epithelial	I-NP	JJ	O	13	NMOD
12	cell	cell	I-NP	NN	O	13	NMOD
13	vacuolization	vacuolization	I-NP	NN	O	20	NMOD
14	,	,	O	,	O	20	P
15	atrophy	atrophy	B-NP	NN	O	20	NMOD
16	,	,	O	,	O	20	P
17	desquamation	desquamation	B-NP	NN	O	20	NMOD
18	,	,	O	,	O	20	P
19	and	and	O	CC	O	20	NMOD
20	necrosis	necrosis	B-NP	NN	O	2	PRD
21	in	in	B-PP	IN	O	20	NMOD
22	VCM-treated	VCM-treated	B-NP	JJ	B-protein	23	NMOD
23	rats	rat	I-NP	NNS	I-protein	21	PMOD
24	more	more	B-ADVP	RBR	O	20	NMOD
25	than	than	B-PP	IN	O	24	AMOD
26	those	those	B-NP	DT	O	33	NMOD
27	of	of	B-PP	IN	O	26	NMOD
28	the	the	B-NP	DT	O	29	NMOD
29	control	control	I-NP	NN	O	27	PMOD
30	and	and	O	CC	O	33	NMOD
31	the	the	B-NP	DT	O	33	NMOD
32	erdosteine	erdosteine	I-NP	NN	O	33	NMOD
33	groups	group	I-NP	NNS	O	25	SBAR
34	.	.	O	.	O	2	P

1	Does	Does	B-NP	NNP	O	2	NMOD
2	domperidone	domperidone	I-NP	NN	O	3	SUB
3	potentiate	potentiate	B-VP	VBP	O	0	ROOT
4	mirtazapine-associated	mirtazapine-associated	B-NP	JJ	O	7	NMOD
5	restless	restless	I-NP	JJ	O	7	NMOD
6	legs	leg	I-NP	NNS	O	7	NMOD
7	syndrome	syndrome	I-NP	NN	O	3	OBJ
8	.	.	O	.	O	3	P

1	For	For	B-PP	IN	O	8	VMOD
2	example	example	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	8	P
4	the	the	B-NP	DT	O	5	NMOD
5	symptoms	symptom	I-NP	NNS	O	8	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	RLS	RLS	B-NP	NN	B-protein	6	PMOD
8	can	can	B-VP	MD	O	18	VMOD
9	be	be	I-VP	VB	O	8	VC
10	dramatically	dramatically	I-VP	RB	O	9	VMOD
11	improved	improve	I-VP	VBN	O	9	VC
12	by	by	B-PP	IN	O	11	VMOD
13	levodopa	levodopa	B-NP	NN	O	16	NMOD
14	and	and	I-NP	CC	O	16	NMOD
15	dopamine	dopamine	I-NP	NN	O	16	NMOD
16	agonists	agonist	I-NP	NNS	O	12	PMOD
17	,	,	O	,	O	18	P
18	whereas	whereas	O	IN	O	0	ROOT
19	central	central	B-NP	JJ	O	23	NMOD
20	dopamine	dopamine	I-NP	NN	O	23	NMOD
21	D2	D2	I-NP	NN	O	23	NMOD
22	receptor	receptor	I-NP	NN	O	23	NMOD
23	antagonists	antagonist	I-NP	NNS	O	24	SUB
24	can	can	B-VP	MD	O	18	VMOD
25	induce	induce	I-VP	VB	O	24	VC
26	or	or	I-VP	CC	O	25	VMOD
27	aggravate	aggravate	I-VP	VB	O	25	VMOD
28	RLS	RLS	B-NP	NN	O	29	NMOD
29	symptoms	symptom	I-NP	NNS	O	27	OBJ
30	.	.	O	.	O	18	P

1	To	To	B-PP	TO	O	6	VMOD
2	our	our	B-NP	PRP$	O	3	NMOD
3	knowledge	knowledge	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	6	P
5	there	there	B-NP	EX	O	6	SUB
6	is	be	B-VP	VBZ	O	0	ROOT
7	no	no	B-NP	DT	O	9	NMOD
8	previous	previous	I-NP	JJ	O	9	NMOD
9	report	report	I-NP	NN	O	6	PRD
10	regarding	regard	B-VP	VBG	O	9	NMOD
11	whether	whether	B-SBAR	IN	O	10	VMOD
12	domperidone	domperidone	B-NP	NN	O	19	NMOD
13	,	,	O	,	O	19	P
14	a	a	B-NP	DT	O	19	NMOD
15	peripheral	peripheral	I-NP	JJ	B-protein	19	NMOD
16	dopamine	dopamine	I-NP	NN	I-protein	19	NMOD
17	D2	D2	I-NP	NN	I-protein	19	NMOD
18	receptor	receptor	I-NP	NN	I-protein	19	NMOD
19	antagonist	antagonist	I-NP	NN	O	21	SUB
20	,	,	O	,	O	19	P
21	can	can	B-VP	MD	O	11	SBAR
22	also	also	I-VP	RB	O	21	VMOD
23	induce	induce	I-VP	VB	O	21	VC
24	or	or	I-VP	CC	O	23	VMOD
25	aggravate	aggravate	I-VP	VB	O	23	VMOD
26	symptoms	symptom	B-NP	NNS	O	25	OBJ
27	of	of	B-PP	IN	O	26	NMOD
28	RLS	RLS	B-NP	NN	B-protein	27	PMOD
29	.	.	O	.	O	6	P

1	Mirtazapine	Mirtazapine	B-NP	NNP	O	9	NMOD
2	,	,	O	,	O	9	P
3	the	the	B-NP	DT	O	9	NMOD
4	first	first	I-NP	JJ	O	7	AMOD
5	noradrenergic	noradrenergic	I-NP	JJ	O	7	AMOD
6	and	and	I-NP	CC	O	7	AMOD
7	specific	specific	I-NP	JJ	O	9	NMOD
8	serotonergic	serotonergic	I-NP	JJ	O	9	NMOD
9	antidepressant	antidepressant	I-NP	NN	O	14	SUB
10	(	(	O	(	O	12	DEP
11	NaSSA	NaSSA	B-NP	NN	B-protein	12	DEP
12	)	)	O	)	O	9	NMOD
13	,	,	O	,	O	9	P
14	has	have	B-VP	VBZ	O	0	ROOT
15	been	be	I-VP	VBN	O	14	VC
16	associated	associate	I-VP	VBN	O	15	VC
17	with	with	B-PP	IN	O	16	VMOD
18	RLS	RLS	B-NP	NN	B-protein	17	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	several	several	B-NP	JJ	O	22	NMOD
21	recent	recent	I-NP	JJ	O	22	NMOD
22	publications	publication	I-NP	NNS	O	19	PMOD
23	.	.	O	.	O	14	P

1	The	The	B-NP	DT	O	2	NMOD
2	authors	author	I-NP	NNS	O	3	SUB
3	report	report	B-VP	VBP	O	0	ROOT
4	here	here	B-ADVP	RB	O	3	VMOD
5	a	a	B-NP	DT	O	8	NMOD
6	depressed	depressed	I-NP	JJ	O	8	NMOD
7	patient	patient	I-NP	NN	O	8	NMOD
8	comorbid	comorbid	I-NP	NN	O	3	OBJ
9	with	with	B-PP	IN	O	8	NMOD
10	postprandial	postprandial	B-NP	JJ	O	11	NMOD
11	dyspepsia	dyspepsia	I-NP	NN	O	9	PMOD
12	who	who	B-NP	WP	O	11	NMOD
13	developed	develop	B-VP	VBD	O	12	SBAR
14	RLS	RLS	B-NP	NN	B-protein	13	OBJ
15	after	after	B-SBAR	IN	O	13	VMOD
16	mirtazapine	mirtazapine	B-NP	NN	O	17	SUB
17	had	have	B-VP	VBD	O	15	SBAR
18	been	be	I-VP	VBN	O	17	VC
19	added	add	I-VP	VBN	O	18	VC
20	to	to	B-PP	TO	O	19	VMOD
21	his	his	B-NP	PRP$	O	23	NMOD
22	domperidone	domperidone	I-NP	NN	O	23	NMOD
23	therapy	therapy	I-NP	NN	O	20	PMOD
24	.	.	O	.	O	3	P

1	Our	Our	B-NP	PRP$	O	2	NMOD
2	patient	patient	I-NP	NN	O	3	SUB
3	started	start	B-VP	VBD	O	22	VMOD
4	to	to	I-VP	TO	O	5	VMOD
5	have	have	I-VP	VB	O	3	VMOD
6	symptoms	symptom	B-NP	NNS	O	5	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	RLS	RLS	B-NP	NN	B-protein	7	PMOD
9	only	only	B-ADVP	RB	O	10	DEP
10	after	after	B-SBAR	IN	O	5	VMOD
11	he	he	B-NP	PRP	O	12	SUB
12	had	have	B-VP	VBD	O	10	SBAR
13	been	be	I-VP	VBN	O	12	VC
14	treated	treat	I-VP	VBN	O	13	VC
15	with	with	B-PP	IN	O	14	VMOD
16	mirtazapine	mirtazapine	B-NP	NN	O	15	PMOD
17	,	,	O	,	O	22	P
18	and	and	O	CC	O	21	NMOD
19	his	his	B-NP	PRP$	O	21	NMOD
20	RLS	RLS	I-NP	NN	O	21	NMOD
21	symptoms	symptom	I-NP	NNS	O	22	SUB
22	resolved	resolve	B-VP	VBD	O	0	ROOT
23	completely	completely	B-ADVP	RB	O	22	VMOD
24	upon	upon	B-PP	IN	O	22	VMOD
25	discontinuation	discontinuation	B-NP	NN	O	24	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	his	his	B-NP	PRP$	O	28	NMOD
28	mirtazapine	mirtazapine	I-NP	NN	O	26	PMOD
29	.	.	O	.	O	22	P

1	Such	Such	B-NP	PDT	O	4	NMOD
2	a	a	I-NP	DT	O	4	NMOD
3	temporal	temporal	I-NP	JJ	O	4	NMOD
4	relationship	relationship	I-NP	NN	O	18	SUB
5	between	between	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	use	use	I-NP	NN	O	12	NMOD
8	of	of	B-PP	IN	O	7	NMOD
9	mirtazapine	mirtazapine	B-NP	NN	O	8	PMOD
10	and	and	O	CC	O	12	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	symptoms	symptom	I-NP	NNS	O	5	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	RLS	RLS	B-NP	NN	B-protein	13	PMOD
15	in	in	B-PP	IN	O	4	NMOD
16	our	our	B-NP	PRP$	O	17	NMOD
17	patient	patient	I-NP	NN	O	15	PMOD
18	did	do	B-VP	VBD	O	0	ROOT
19	not	not	I-VP	RB	O	18	VMOD
20	support	support	I-VP	VB	O	18	VC
21	a	a	B-NP	DT	O	23	NMOD
22	potentiating	potentiating	I-NP	NN	O	23	NMOD
23	effect	effect	I-NP	NN	O	20	OBJ
24	of	of	B-PP	IN	O	23	NMOD
25	domperione	domperione	B-NP	NN	O	24	PMOD
26	on	on	B-PP	IN	O	23	NMOD
27	mirtazapine-associated	mirtazapine-associated	B-NP	JJ	O	28	NMOD
28	RLS	RLS	I-NP	NN	O	26	PMOD
29	.	.	O	.	O	18	P

1	MATERIALS	MATERIALS	B-NP	NNS	O	3	NMOD
2	AND	AND	I-NP	CC	O	3	NMOD
3	METHODS	METHODS	I-NP	NNS	O	11	SUB
4	:	:	O	:	O	3	P
5	We	We	B-NP	PRP	O	6	SUB
6	studied	study	B-VP	VBD	O	3	NMOD
7	with	with	B-PP	IN	O	6	VMOD
8	a	a	B-NP	DT	O	10	NMOD
9	2.5	2.5	I-NP	CD	O	10	NMOD
10	years	year	I-NP	NNS	O	7	PMOD
11	follow-up	follow-up	B-VP	VBP	O	0	ROOT
12	the	the	B-NP	DT	O	13	NMOD
13	changes	change	I-NP	NNS	O	11	OBJ
14	in	in	B-PP	IN	O	13	NMOD
15	plasma	plasma	B-NP	NN	O	16	NMOD
16	cholesterols	cholesterol	I-NP	NNS	O	44	NMOD
17	(	(	O	(	O	19	DEP
18	C	C	B-NP	NN	O	19	DEP
19	)	)	O	)	O	16	NMOD
20	,	,	O	,	O	44	P
21	triglycerides	triglyceride	B-NP	NNS	O	44	NMOD
22	(	(	O	(	O	24	DEP
23	TG	TG	B-NP	NN	B-protein	24	DEP
24	)	)	O	)	O	21	NMOD
25	,	,	O	,	O	44	P
26	lipoproteins	lipoprotein	B-NP	NNS	O	44	NMOD
27	(	(	O	(	O	29	DEP
28	LP	LP	B-NP	NN	O	29	DEP
29	)	)	O	)	O	26	NMOD
30	,	,	O	,	O	44	P
31	and	and	O	CC	O	32	NMOD
32	apolipoproteins	apolipoprotein	B-NP	NNS	B-protein	36	NMOD
33	(	(	O	(	O	35	DEP
34	Apo	Apo	B-NP	NN	B-protein	35	DEP
35	)	)	O	)	O	32	NMOD
36	B-100	B-100	B-NP	NN	O	44	NMOD
37	,	,	O	,	O	44	P
38	A-I	A-I	B-NP	NN	O	44	NMOD
39	,	,	O	,	O	44	P
40	and	and	O	CC	O	44	NMOD
41	A-II	A-II	B-NP	NN	B-protein	44	NMOD
42	pro	pro	I-NP	FW	O	44	NMOD
43	fi	fi	I-NP	FW	O	44	NMOD
44	les	le	I-NP	NNS	O	14	PMOD
45	in	in	B-PP	IN	O	44	NMOD
46	24	24	B-NP	CD	O	47	NMOD
47	patients	patient	I-NP	NNS	O	45	PMOD
48	of	of	B-PP	IN	O	47	NMOD
49	mean	mean	B-NP	JJ	O	50	NMOD
50	age	age	I-NP	NN	O	52	NMOD
51	60	60	B-NP	CD	O	50	NMOD
52	years	year	I-NP	NNS	O	48	PMOD
53	with	with	B-PP	IN	O	47	NMOD
54	low	low	B-NP	JJ	O	57	NMOD
55	risk	risk	I-NP	NN	O	57	NMOD
56	prostate	prostate	I-NP	NN	O	57	NMOD
57	cancer	cancer	I-NP	NN	O	53	PMOD
58	(	(	O	(	O	67	DEP
59	stage	stage	B-NP	NN	O	61	NMOD
60	:	:	O	:	O	59	P
61	T1cN0M0	T1cN0M0	B-NP	NN	O	64	NMOD
62	,	,	O	,	O	64	P
63	Gleason	Gleason	B-NP	NN	O	64	NMOD
64	score	score	I-NP	NN	O	66	NMOD
65	:	:	O	:	O	66	P
66	2-5	2-5	B-NP	CD	O	67	DEP
67	)	)	O	)	O	57	NMOD
68	during	during	B-PP	IN	O	11	VMOD
69	treatment	treatment	B-NP	NN	O	68	PMOD
70	with	with	B-PP	IN	O	69	NMOD
71	cyproterone	cyproterone	B-NP	NN	O	72	NMOD
72	acetate	acetate	I-NP	NN	O	70	PMOD
73	(	(	O	(	O	75	DEP
74	CPA	CPA	B-NP	NN	O	75	DEP
75	)	)	O	)	O	72	NMOD
76	without	without	B-PP	IN	O	69	NMOD
77	surgical	surgical	B-NP	JJ	O	78	NMOD
78	management	management	I-NP	NN	O	81	NMOD
79	or	or	I-NP	CC	O	81	NMOD
80	radiation	radiation	I-NP	NN	O	81	NMOD
81	therapy	therapy	I-NP	NN	O	76	PMOD
82	.	.	O	.	O	11	P

1	After	After	B-PP	IN	O	16	VMOD
2	a	a	B-NP	DT	O	3	NMOD
3	period	period	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	2.5	2.5	B-NP	CD	O	6	NMOD
6	years	year	I-NP	NNS	O	4	PMOD
7	on	on	B-PP	IN	O	3	NMOD
8	CPA	CPA	B-NP	NN	B-protein	9	NMOD
9	treatment	treatment	I-NP	NN	O	7	PMOD
10	,	,	O	,	O	16	P
11	four	four	B-NP	CD	O	12	NMOD
12	patients	patient	I-NP	NNS	O	16	SUB
13	out	out	B-PP	IN	O	12	NMOD
14	of	of	B-PP	IN	O	13	PMOD
15	twenty-four	twenty-four	B-NP	CD	O	14	PMOD
16	were	be	B-VP	VBD	O	0	ROOT
17	found	find	I-VP	VBN	O	16	VC
18	to	to	I-VP	TO	O	19	VMOD
19	be	be	I-VP	VB	O	17	VMOD
20	affected	affect	I-VP	VBN	O	19	VC
21	by	by	B-PP	IN	O	20	VMOD
22	coronary	coronary	B-NP	JJ	O	24	NMOD
23	heart	heart	I-NP	NN	O	24	NMOD
24	disease	disease	I-NP	NN	O	21	PMOD
25	.	.	O	.	O	16	P

1	5-Fluorouracil	5-Fluorouracil	B-NP	NN	O	2	NMOD
2	cardiotoxicity	cardiotoxicity	I-NP	NN	O	0	ROOT
3	induced	induce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	alpha-fluoro-beta-alanine	alpha-fluoro-beta-alanine	B-NP	NN	O	4	PMOD
6	.	.	O	.	O	2	P

1	Cardiotoxicity	Cardiotoxicity	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	rare	rare	I-NP	JJ	O	5	NMOD
5	complication	complication	I-NP	NN	O	2	PRD
6	occurring	occur	B-VP	VBG	O	5	NMOD
7	during	during	B-PP	IN	O	6	VMOD
8	5-fluorouracil	5-fluorouracil	B-NP	NN	O	12	NMOD
9	(	(	O	(	O	11	DEP
10	5-FU	5-FU	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	treatment	treatment	B-NP	NN	O	7	PMOD
13	for	for	B-PP	IN	O	12	NMOD
14	malignancies	malignancy	B-NP	NNS	O	13	PMOD
15	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	3	SUB
2	herein	herein	B-ADVP	RB	O	3	VMOD
3	report	report	B-VP	VBP	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	case	case	I-NP	NN	O	12	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	a	a	B-NP	DT	O	9	NMOD
8	70-year-old	70-year-old	I-NP	JJ	O	9	NMOD
9	man	man	I-NP	NN	O	6	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	5-FU	5-FU	B-NP	NN	O	10	PMOD
12	induced	induce	B-VP	VBD	O	3	VMOD
13	cardiotoxicity	cardiotoxicity	B-NP	NN	O	12	OBJ
14	,	,	O	,	O	13	P
15	in	in	B-PP	IN	O	13	NMOD
16	whom	whom	B-NP	WP	O	15	PMOD
17	a	a	B-NP	DT	O	20	NMOD
18	high	high	I-NP	JJ	O	20	NMOD
19	serum	serum	I-NP	NN	O	20	NMOD
20	level	level	I-NP	NN	O	15	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	alpha-fluoro-beta-alanine	alpha-fluoro-beta-alanine	B-NP	NN	O	21	PMOD
23	(	(	O	(	O	25	DEP
24	FBAL	FBAL	B-NP	NN	O	25	DEP
25	)	)	O	)	O	22	NMOD
26	was	be	B-VP	VBD	O	12	VMOD
27	observed	observe	I-VP	VBN	O	26	VC
28	.	.	O	.	O	3	P

1	After	After	B-PP	IN	O	6	VMOD
2	admission	admission	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	6	P
4	the	the	B-NP	DT	O	5	NMOD
5	patient	patient	I-NP	NN	O	6	SUB
6	received	receive	B-VP	VBD	O	0	ROOT
7	a	a	B-NP	DT	O	10	NMOD
8	continuous	continuous	I-NP	JJ	O	10	NMOD
9	intravenous	intravenous	I-NP	JJ	O	10	NMOD
10	infusion	infusion	I-NP	NN	O	6	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	5-FU	5-FU	B-NP	NN	O	11	PMOD
13	(	(	O	(	O	16	DEP
14	1000	1000	B-NP	CD	O	15	NMOD
15	mg/day	mg/day	I-NP	NN	O	16	DEP
16	)	)	O	)	O	12	NMOD
17	,	,	O	,	O	6	P
18	during	during	B-PP	IN	O	6	VMOD
19	which	which	B-NP	WDT	O	18	PMOD
20	precordial	precordial	B-NP	JJ	O	21	NMOD
21	pain	pain	I-NP	NN	O	27	SUB
22	with	with	B-PP	IN	O	21	NMOD
23	right	right	B-NP	JJ	O	26	NMOD
24	bundle	bundle	I-NP	NN	O	26	NMOD
25	branch	branch	I-NP	NN	O	26	NMOD
26	block	block	I-NP	NN	O	22	PMOD
27	occurred	occur	B-VP	VBD	O	18	SBAR
28	concomitantly	concomitantly	B-ADVP	RB	O	27	VMOD
29	with	with	B-PP	IN	O	27	VMOD
30	a	a	B-NP	DT	O	34	NMOD
31	high	high	I-NP	JJ	O	34	NMOD
32	serum	serum	I-NP	NN	O	34	NMOD
33	FBAL	FBAL	I-NP	NN	O	34	NMOD
34	concentration	concentration	I-NP	NN	O	29	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	1955	1955	B-NP	CD	O	37	NMOD
37	ng/ml	ng/ml	I-NP	NN	O	35	PMOD
38	.	.	O	.	O	6	P

1	Both	Both	O	CC	O	8	NMOD
2	the	the	B-NP	DT	O	4	NMOD
3	precordial	precordial	I-NP	JJ	O	4	NMOD
4	pain	pain	I-NP	NN	O	8	NMOD
5	and	and	O	CC	O	8	NMOD
6	the	the	B-NP	DT	O	8	NMOD
7	electrocardiographic	electrocardiographic	I-NP	JJ	O	8	NMOD
8	changes	change	I-NP	NNS	O	9	SUB
9	disappeared	disappear	B-VP	VBD	O	0	ROOT
10	spontaneously	spontaneously	B-ADVP	RB	O	9	VMOD
11	after	after	B-SBAR	IN	O	9	VMOD
12	the	the	B-NP	DT	O	13	NMOD
13	discontinuation	discontinuation	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	5-FU	5-FU	B-NP	NN	O	14	PMOD
16	.	.	O	.	O	9	P

1	As	As	B-SBAR	IN	O	23	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	precordial	precordial	I-NP	JJ	O	4	NMOD
4	pain	pain	I-NP	NN	O	8	SUB
5	in	in	B-PP	IN	O	4	NMOD
6	this	this	B-NP	DT	O	7	NMOD
7	patient	patient	I-NP	NN	O	5	PMOD
8	was	be	B-VP	VBD	O	1	SBAR
9	considered	consider	I-VP	VBN	O	8	VC
10	to	to	I-VP	TO	O	11	VMOD
11	have	have	I-VP	VB	O	9	VMOD
12	been	be	I-VP	VBN	O	11	VC
13	due	due	B-ADJP	JJ	O	14	PMOD
14	to	to	B-PP	TO	O	12	PRD
15	5-FU	5-FU	B-NP	NN	O	17	NMOD
16	induced	induced	I-NP	JJ	O	17	NMOD
17	cardiotoxicity	cardiotoxicity	I-NP	NN	O	14	PMOD
18	,	,	O	,	O	23	P
19	the	the	B-NP	DT	O	20	NMOD
20	administration	administration	I-NP	NN	O	23	SUB
21	of	of	B-PP	IN	O	20	NMOD
22	5-FU	5-FU	B-NP	NN	O	21	PMOD
23	was	be	B-VP	VBD	O	0	ROOT
24	abandoned	abandon	I-VP	VBN	O	23	VC
25	.	.	O	.	O	23	P

1	The	The	B-NP	DT	O	2	NMOD
2	experience	experience	I-NP	NN	O	15	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	case	case	I-NP	NN	O	3	PMOD
6	,	,	O	,	O	2	P
7	together	together	B-ADVP	RB	O	8	PMOD
8	with	with	B-PP	IN	O	2	NMOD
9	a	a	B-NP	DT	O	10	NMOD
10	review	review	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	13	NMOD
13	literature	literature	I-NP	NN	O	11	PMOD
14	,	,	O	,	O	2	P
15	suggests	suggest	B-VP	VBZ	O	0	ROOT
16	that	that	B-SBAR	IN	O	15	VMOD
17	FBAL	FBAL	B-NP	NN	B-protein	18	SUB
18	is	be	B-VP	VBZ	O	16	SBAR
19	related	relate	I-VP	VBN	O	18	PRD
20	to	to	B-PP	TO	O	19	AMOD
21	5-FU	5-FU	B-NP	NN	O	23	NMOD
22	induced	induced	I-NP	JJ	O	23	NMOD
23	cardiotoxicity	cardiotoxicity	I-NP	NN	O	20	PMOD
24	.	.	O	.	O	15	P

1	The	The	B-NP	DT	O	2	NMOD
2	influence	influence	I-NP	NN	O	17	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	time	time	I-NP	NN	O	6	NMOD
6	interval	interval	I-NP	NN	O	3	PMOD
7	between	between	B-PP	IN	O	6	NMOD
8	monoHER	monoHER	B-NP	NN	O	11	NMOD
9	and	and	I-NP	CC	O	11	NMOD
10	doxorubicin	doxorubicin	I-NP	NN	O	11	NMOD
11	administration	administration	I-NP	NN	O	7	PMOD
12	on	on	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	protection	protection	I-NP	NN	O	12	PMOD
15	against	against	B-PP	IN	O	14	NMOD
16	doxorubicin	doxorubicin	B-NP	NN	O	15	PMOD
17	induced	induce	B-VP	VBD	O	0	ROOT
18	cardiotoxicity	cardiotoxicity	B-NP	NN	O	17	OBJ
19	in	in	B-PP	IN	O	17	VMOD
20	mice	mouse	B-NP	NNS	O	19	PMOD
21	.	.	O	.	O	17	P

1	PURPOSE	PURPOSE	B-NP	NN	O	14	SUB
2	:	:	O	:	O	1	P
3	Despite	Despite	B-PP	IN	O	14	VMOD
4	its	its	B-NP	PRP$	O	6	NMOD
5	well-known	well-known	I-NP	JJ	O	6	NMOD
6	cardiotoxicity	cardiotoxicity	I-NP	NN	O	3	PMOD
7	,	,	O	,	O	14	P
8	the	the	B-NP	DT	O	10	NMOD
9	anthracyclin	anthracyclin	I-NP	NN	O	10	NMOD
10	doxorubicin	doxorubicin	I-NP	NN	O	14	SUB
11	(	(	O	(	O	13	DEP
12	DOX	DOX	B-NP	NN	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	continues	continue	B-VP	VBZ	O	0	ROOT
15	to	to	I-VP	TO	O	16	VMOD
16	be	be	I-VP	VB	O	14	VMOD
17	an	an	B-NP	DT	O	23	NMOD
18	effective	effective	I-NP	JJ	O	21	AMOD
19	and	and	I-NP	CC	O	21	AMOD
20	widely	widely	I-NP	RB	O	21	AMOD
21	used	use	I-NP	VBN	O	23	NMOD
22	chemotherapeutic	chemotherapeutic	I-NP	JJ	O	23	NMOD
23	agent	agent	I-NP	NN	O	16	PRD
24	.	.	O	.	O	14	P

1	DOX	DOX	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	6	VMOD
3	cardiac	cardiac	B-NP	JJ	O	4	NMOD
4	damage	damage	I-NP	NN	O	2	OBJ
5	presumably	presumably	B-ADVP	RB	O	6	VMOD
6	results	result	B-VP	VBZ	O	0	ROOT
7	from	from	B-PP	IN	O	6	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	formation	formation	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	free	free	B-NP	JJ	O	12	NMOD
12	radicals	radical	I-NP	NNS	O	10	PMOD
13	by	by	B-PP	IN	O	9	NMOD
14	DOX	DOX	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	4	NMOD
2	semisynthetic	semisynthetic	I-NP	JJ	O	4	NMOD
3	flavonoid	flavonoid	I-NP	NN	O	4	NMOD
4	monohydroxyethylrutoside	monohydroxyethylrutoside	I-NP	NN	O	8	SUB
5	(	(	O	(	O	7	DEP
6	monoHER	monoHER	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	showed	show	B-VP	VBD	O	0	ROOT
9	cardioprotection	cardioprotection	B-NP	NN	O	8	OBJ
10	against	against	B-PP	IN	O	9	NMOD
11	DOX	DOX	B-NP	NN	B-protein	10	PMOD
12	induced	induce	B-VP	VBD	O	9	NMOD
13	cardiotoxicity	cardiotoxicity	B-NP	NN	O	12	OBJ
14	through	through	B-PP	IN	O	12	VMOD
15	its	its	B-NP	PRP$	O	21	NMOD
16	radical	radical	I-NP	JJ	O	17	NMOD
17	scavenging	scavenging	I-NP	NN	O	21	NMOD
18	and	and	I-NP	CC	O	21	NMOD
19	iron	iron	I-NP	NN	O	21	NMOD
20	chelating	chelating	I-NP	NN	O	21	NMOD
21	properties	property	I-NP	NNS	O	14	PMOD
22	.	.	O	.	O	8	P

1	Microscopic	Microscopic	B-NP	JJ	O	2	NMOD
2	evaluation	evaluation	I-NP	NN	O	3	SUB
3	revealed	reveal	B-VP	VBD	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	treatment	treatment	B-NP	NN	O	9	SUB
6	with	with	B-PP	IN	O	5	NMOD
7	DOX	DOX	B-NP	NN	O	6	PMOD
8	alone	alone	B-ADVP	RB	O	7	NMOD
9	induced	induce	B-VP	VBD	O	4	SBAR
10	significant	significant	B-NP	JJ	O	12	NMOD
11	cardiac	cardiac	I-NP	JJ	O	12	NMOD
12	damage	damage	I-NP	NN	O	9	OBJ
13	in	in	B-PP	IN	O	19	NMOD
14	comparison	comparison	B-NP	NN	O	13	PMOD
15	to	to	B-PP	TO	O	13	PMOD
16	the	the	B-NP	DT	O	19	NMOD
17	saline	saline	I-NP	NN	O	19	NMOD
18	control	control	I-NP	NN	O	19	NMOD
19	group	group	I-NP	NN	O	9	OBJ
20	(	(	O	(	O	24	DEP
21	P	P	B-NP	NN	O	23	SUB
22	<	<	O	SYM	O	23	VMOD
23	0.001	0.001	B-NP	CD	O	24	DEP
24	)	)	O	)	O	19	NMOD
25	.	.	O	.	O	3	P

1	Clinical	Clinical	B-NP	JJ	O	2	NMOD
2	evaluation	evaluation	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	adverse	adverse	B-NP	JJ	O	5	NMOD
5	effects	effect	I-NP	NNS	O	3	PMOD
6	during	during	B-PP	IN	O	2	NMOD
7	bepridil	bepridil	B-NP	NN	O	8	NMOD
8	administration	administration	I-NP	NN	O	6	PMOD
9	for	for	B-PP	IN	O	8	NMOD
10	atrial	atrial	B-NP	JJ	O	13	NMOD
11	fibrillation	fibrillation	I-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	flutter	flutter	I-NP	NN	O	9	PMOD
14	.	.	O	.	O	2	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Bepridil	Bepridil	B-NP	NN	O	4	NMOD
4	hydrochloride	hydrochloride	I-NP	NN	O	8	SUB
5	(	(	O	(	O	7	DEP
6	Bpd	Bpd	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	has	have	B-VP	VBZ	O	1	NMOD
9	attracted	attract	I-VP	VBN	O	8	VC
10	attention	attention	B-NP	NN	O	9	OBJ
11	as	as	B-PP	IN	O	9	VMOD
12	an	an	B-NP	DT	O	14	NMOD
13	effective	effective	I-NP	JJ	O	14	NMOD
14	drug	drug	I-NP	NN	O	11	PMOD
15	for	for	B-PP	IN	O	14	NMOD
16	atrial	atrial	B-NP	JJ	O	17	NMOD
17	fibrillation	fibrillation	I-NP	NN	O	23	NMOD
18	(	(	O	(	O	20	DEP
19	AF	AF	B-NP	NN	O	20	DEP
20	)	)	O	)	O	17	NMOD
21	and	and	O	CC	O	23	NMOD
22	atrial	atrial	B-NP	JJ	O	23	NMOD
23	flutter	flutter	I-NP	NN	O	15	PMOD
24	(	(	O	(	O	26	DEP
25	AFL	AFL	B-NP	NN	O	26	DEP
26	)	)	O	)	O	23	NMOD
27	.	.	O	.	O	8	P

1	Bpd	Bpd	B-NP	NN	B-protein	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	administered	administer	I-VP	VBN	O	2	VC
4	to	to	B-PP	TO	O	3	VMOD
5	459	459	B-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	4	PMOD
7	(	(	O	(	O	14	DEP
8	361	361	B-NP	CD	O	9	NMOD
9	males	male	I-NP	NNS	O	14	DEP
10	,	,	O	,	O	14	P
11	63+/-12	63+/-12	B-NP	CD	O	12	NMOD
12	years	year	I-NP	NNS	O	14	DEP
13	old	old	B-ADJP	JJ	O	12	NMOD
14	)	)	O	)	O	6	NMOD
15	comprising	comprise	B-VP	VBG	O	6	NMOD
16	378	378	B-NP	CD	O	17	NMOD
17	AF	AF	I-NP	NN	O	21	NMOD
18	and	and	O	CC	O	21	NMOD
19	81	81	B-NP	CD	O	21	NMOD
20	AFL	AFL	I-NP	NN	O	21	NMOD
21	cases	case	I-NP	NNS	O	15	OBJ
22	.	.	O	.	O	2	P

1	Enhanced	Enhance	B-NP	VBN	O	2	NMOD
2	isoproterenol	isoproterenol	I-NP	NN	O	3	SUB
3	induced	induce	B-VP	VBD	O	0	ROOT
4	cardiac	cardiac	B-NP	JJ	O	5	NMOD
5	hypertrophy	hypertrophy	I-NP	NN	O	3	OBJ
6	in	in	B-PP	IN	O	3	VMOD
7	transgenic	transgenic	B-NP	JJ	O	8	NMOD
8	rats	rat	I-NP	NNS	O	6	PMOD
9	with	with	B-PP	IN	O	3	VMOD
10	low	low	B-NP	JJ	O	12	NMOD
11	brain	brain	I-NP	NN	O	12	NMOD
12	angiotensinogen	angiotensinogen	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	3	P

1	LV	LV	B-NP	NN	O	2	NMOD
2	hypertrophy	hypertrophy	I-NP	NN	O	7	SUB
3	induced	induce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	Iso	Iso	B-NP	NN	B-protein	6	NMOD
6	treatment	treatment	I-NP	NN	O	4	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	significantly	significantly	B-ADJP	RB	O	9	AMOD
9	higher	high	I-ADJP	JJR	O	7	PRD
10	in	in	B-PP	IN	O	9	AMOD
11	TGR	TGR	B-NP	NN	B-protein	10	PMOD
12	than	than	B-PP	IN	O	9	AMOD
13	in	in	B-PP	IN	O	12	PMOD
14	SD	SD	B-NP	NN	O	15	NMOD
15	rats	rat	I-NP	NNS	O	13	PMOD
16	(	(	O	(	O	34	DEP
17	in	in	B-PP	IN	O	34	DEP
18	g	g	B-NP	NN	O	23	NMOD
19	LV	LV	I-NP	NN	O	23	NMOD
20	wt/100	wt/100	I-NP	CD	O	23	NMOD
21	g	g	I-NP	NN	O	23	NMOD
22	body	body	I-NP	NN	O	23	NMOD
23	wt	wt	I-NP	NN	O	17	PMOD
24	,	,	O	,	O	34	P
25	0.28	0.28	B-NP	CD	O	27	AMOD
26	+/-	+/-	I-NP	SYM	O	27	AMOD
27	0.004	0.004	I-NP	CD	O	31	NMOD
28	vs.	vs.	B-PP	IN	O	31	NMOD
29	0.24	0.24	B-NP	CD	O	31	NMOD
30	+/-	+/-	I-NP	SYM	O	31	NMOD
31	0.004	0.004	I-NP	CD	O	34	DEP
32	,	,	O	,	O	34	P
33	respectively	respectively	B-ADVP	RB	O	34	DEP
34	)	)	O	)	O	9	AMOD
35	.	.	O	.	O	7	P

1	Drug	Drug	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	long	long	B-ADVP	RB	O	2	VMOD
4	QT	QT	B-NP	NN	O	5	NMOD
5	syndrome	syndrome	I-NP	NN	O	2	OBJ
6	in	in	B-PP	IN	O	2	VMOD
7	injection	injection	B-NP	NN	O	9	NMOD
8	drug	drug	I-NP	NN	O	9	NMOD
9	users	user	I-NP	NNS	O	6	PMOD
10	receiving	receive	B-VP	VBG	O	9	NMOD
11	methadone	methadone	B-NP	NN	O	10	OBJ
12	:	:	O	:	O	2	VMOD
13	high	high	B-NP	JJ	O	14	NMOD
14	frequency	frequency	I-NP	NN	O	12	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	hospitalized	hospitalize	B-NP	VBN	O	17	NMOD
17	patients	patient	I-NP	NNS	O	20	NMOD
18	and	and	O	CC	O	20	NMOD
19	risk	risk	B-NP	NN	O	20	NMOD
20	factors	factor	I-NP	NNS	O	15	PMOD
21	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	29	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	inpatient	inpatient	I-NP	NN	O	4	NMOD
4	setting	setting	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	29	P
6	the	the	B-NP	DT	O	7	NMOD
7	frequency	frequency	I-NP	NN	O	22	NMOD
8	of	of	B-PP	IN	O	7	NMOD
9	QT	QT	B-NP	NN	O	11	NMOD
10	interval	interval	I-NP	NN	O	11	NMOD
11	prolongation	prolongation	I-NP	NN	O	8	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	methadone	methadone	B-NP	NN	O	14	NMOD
14	treatment	treatment	I-NP	NN	O	12	PMOD
15	,	,	O	,	O	22	P
16	its	its	B-NP	PRP$	O	18	NMOD
17	dose	dose	I-NP	NN	O	18	NMOD
18	dependence	dependence	I-NP	NN	O	22	NMOD
19	,	,	O	,	O	22	P
20	and	and	O	CC	O	22	NMOD
21	the	the	B-NP	DT	O	22	NMOD
22	importance	importance	I-NP	NN	O	29	SUB
23	of	of	B-PP	IN	O	22	NMOD
24	cofactors	cofactor	B-NP	NNS	B-protein	23	PMOD
25	such	such	B-PP	JJ	O	26	PMOD
26	as	as	I-PP	IN	O	24	NMOD
27	drug-drug	drug-drug	B-NP	JJ	O	28	NMOD
28	interactions	interaction	I-NP	NNS	O	26	PMOD
29	remain	remain	B-VP	VBP	O	0	ROOT
30	unknown	unknown	B-ADJP	JJ	O	29	PRD
31	.	.	O	.	O	29	P

1	In	In	B-PP	IN	O	15	VMOD
2	addition	addition	B-NP	NN	O	1	PMOD
3	to	to	B-PP	TO	O	2	NMOD
4	methadone	methadone	B-NP	NN	O	5	NMOD
5	dose	dose	I-NP	NN	O	3	PMOD
6	,	,	O	,	O	15	P
7	15	15	B-NP	CD	O	15	SUB
8	demographic	demographic	I-NP	JJ	O	15	VMOD
9	,	,	I-NP	,	O	15	P
10	biological	biological	I-NP	JJ	O	15	VMOD
11	,	,	O	,	O	15	P
12	and	and	O	CC	O	15	VMOD
13	pharmacological	pharmacological	B-NP	JJ	O	14	NMOD
14	variables	variable	I-NP	NNS	O	15	SUB
15	were	be	B-VP	VBD	O	0	ROOT
16	considered	consider	I-VP	VBN	O	15	VC
17	as	as	B-PP	IN	O	16	VMOD
18	potential	potential	B-NP	JJ	O	20	NMOD
19	risk	risk	I-NP	NN	O	20	NMOD
20	factors	factor	I-NP	NNS	O	17	PMOD
21	for	for	B-PP	IN	O	20	NMOD
22	QT	QT	B-NP	NN	O	23	NMOD
23	prolongation	prolongation	I-NP	NN	O	21	PMOD
24	.	.	O	.	O	15	P

1	Six	Six	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	11	SUB
3	(	(	O	(	O	6	DEP
4	3.6	3.6	B-NP	CD	O	5	NMOD
5	%	%	I-NP	NN	O	6	DEP
6	)	)	O	)	O	2	NMOD
7	in	in	B-PP	IN	O	2	NMOD
8	the	the	B-NP	DT	O	10	NMOD
9	methadone	methadone	I-NP	NN	O	10	NMOD
10	group	group	I-NP	NN	O	7	PMOD
11	presented	present	B-VP	VBD	O	0	ROOT
12	torsades	torsade	B-NP	NNS	O	11	OBJ
13	de	de	B-PP	IN	O	11	VMOD
14	pointes	pointe	B-NP	NNS	O	13	PMOD
15	.	.	O	.	O	11	P

1	Multivariate	Multivariate	B-NP	JJ	O	3	NMOD
2	regression	regression	I-NP	NN	O	3	NMOD
3	analysis	analysis	I-NP	NN	O	4	SUB
4	allowed	allow	B-VP	VBD	O	0	ROOT
5	attribution	attribution	B-NP	NN	O	4	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	31.8	31.8	B-NP	CD	O	8	NMOD
8	%	%	I-NP	NN	O	27	NMOD
9	of	of	B-PP	IN	O	8	NMOD
10	QTc	QTc	B-NP	NN	O	11	NMOD
11	variability	variability	I-NP	NN	O	9	PMOD
12	to	to	B-PP	TO	O	11	NMOD
13	methadone	methadone	B-NP	NN	O	14	NMOD
14	dose	dose	I-NP	NN	O	12	PMOD
15	,	,	O	,	O	27	P
16	cytochrome	cytochrome	B-NP	NN	B-protein	20	NMOD
17	P-450	P-450	I-NP	NN	I-protein	20	NMOD
18	3A4	3A4	I-NP	NN	I-protein	20	NMOD
19	drug-drug	drug-drug	I-NP	NN	O	20	NMOD
20	interactions	interaction	I-NP	NNS	O	27	NMOD
21	,	,	O	,	O	27	P
22	hypokalemia	hypokalemia	B-NP	NN	O	27	NMOD
23	,	,	O	,	O	27	P
24	and	and	O	CC	O	27	NMOD
25	altered	alter	B-VP	VBD	O	27	NMOD
26	liver	liver	B-NP	NN	O	27	NMOD
27	function	function	I-NP	NN	O	6	PMOD
28	.	.	O	.	O	4	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	QT	QT	B-NP	NN	O	5	NMOD
4	interval	interval	I-NP	NN	O	5	NMOD
5	prolongation	prolongation	I-NP	NN	O	16	SUB
6	in	in	B-PP	IN	O	5	NMOD
7	methadone	methadone	B-NP	NN	O	9	NMOD
8	maintenance	maintenance	I-NP	NN	O	9	NMOD
9	patients	patient	I-NP	NNS	O	6	PMOD
10	hospitalized	hospitalize	B-VP	VBN	O	9	NMOD
11	in	in	B-PP	IN	O	10	VMOD
12	a	a	B-NP	DT	O	15	NMOD
13	tertiary	tertiary	I-NP	JJ	O	15	NMOD
14	care	care	I-NP	NN	O	15	NMOD
15	center	center	I-NP	NN	O	11	PMOD
16	is	be	B-VP	VBZ	O	1	NMOD
17	a	a	B-NP	DT	O	19	NMOD
18	frequent	frequent	I-NP	JJ	O	19	NMOD
19	finding	finding	I-NP	NN	O	16	PRD
20	.	.	O	.	O	1	P

1	Methadone	Methadone	B-NP	NN	O	2	NMOD
2	dose	dose	I-NP	NN	O	4	NMOD
3	,	,	O	,	O	4	P
4	presence	presence	B-NP	NN	O	16	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	cytochrome	cytochrome	B-NP	NN	B-protein	9	NMOD
7	P-450	P-450	I-NP	NN	I-protein	9	NMOD
8	3A4	3A4	I-NP	NN	I-protein	9	NMOD
9	inhibitors	inhibitor	I-NP	NNS	O	5	PMOD
10	,	,	O	,	O	16	P
11	potassium	potassium	B-NP	NN	O	12	NMOD
12	level	level	I-NP	NN	O	16	NMOD
13	,	,	O	,	O	16	P
14	and	and	O	CC	O	16	NMOD
15	liver	liver	B-NP	NN	O	16	NMOD
16	function	function	I-NP	NN	O	17	SUB
17	contribute	contribute	B-VP	VBP	O	0	ROOT
18	to	to	B-PP	TO	O	17	VMOD
19	QT	QT	B-NP	NN	O	20	NMOD
20	prolongation	prolongation	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	17	P

1	Mechanisms	Mechanism	B-NP	NNS	O	13	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	hypertension	hypertension	B-NP	NN	O	2	PMOD
4	induced	induce	B-VP	VBN	O	3	NMOD
5	by	by	B-PP	IN	O	4	VMOD
6	nitric	nitric	B-NP	JJ	O	7	NMOD
7	oxide	oxide	I-NP	NN	O	11	NMOD
8	(	(	O	(	O	10	DEP
9	NO	NO	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	deficiency	deficiency	B-NP	NN	O	5	PMOD
12	:	:	O	:	O	1	P
13	focus	focus	B-NP	NN	O	0	ROOT
14	on	on	B-PP	IN	O	13	NMOD
15	venous	venous	B-NP	JJ	O	16	NMOD
16	function	function	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	13	P

1	Loss	Loss	B-NP	NN	O	12	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	endothelial	endothelial	B-NP	JJ	O	6	NMOD
4	cell-derived	cell-derived	I-NP	JJ	O	6	NMOD
5	nitric	nitric	I-NP	JJ	O	6	NMOD
6	oxide	oxide	I-NP	NN	O	2	PMOD
7	(	(	O	(	O	9	DEP
8	NO	NO	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	in	in	B-PP	IN	O	1	NMOD
11	hypertension	hypertension	B-NP	NN	O	10	PMOD
12	is	be	B-VP	VBZ	O	0	ROOT
13	a	a	B-NP	DT	O	14	NMOD
14	hallmark	hallmark	I-NP	NN	O	12	PRD
15	of	of	B-PP	IN	O	14	NMOD
16	arterial	arterial	B-NP	JJ	O	17	NMOD
17	dysfunction	dysfunction	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	12	P

1	Experimental	Experimental	B-NP	JJ	O	2	NMOD
2	hypertension	hypertension	I-NP	NN	O	12	SUB
3	created	create	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	the	the	B-NP	DT	O	6	NMOD
6	removal	removal	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	NO	NO	B-NP	NN	O	7	PMOD
9	,	,	O	,	O	12	P
10	however	however	B-ADVP	RB	O	12	VMOD
11	,	,	O	,	O	12	P
12	involves	involve	B-VP	VBZ	O	0	ROOT
13	mechanisms	mechanism	B-NP	NNS	O	12	OBJ
14	in	in	B-PP	IN	O	13	NMOD
15	addition	addition	B-NP	NN	O	14	PMOD
16	to	to	B-PP	TO	O	15	NMOD
17	decreased	decrease	B-NP	VBN	O	20	NMOD
18	arterial	arterial	I-NP	JJ	O	20	NMOD
19	vasodilator	vasodilator	I-NP	NN	O	20	NMOD
20	activity	activity	I-NP	NN	O	16	PMOD
21	.	.	O	.	O	12	P

1	We	We	B-NP	PRP	O	2	SUB
2	hypothesized	hypothesize	B-VP	VBD	O	0	ROOT
3	that	that	B-SBAR	IN	O	2	VMOD
4	increased	increase	B-NP	VBN	O	11	NMOD
5	venous	venous	I-NP	JJ	O	7	NMOD
6	smooth	smooth	I-NP	JJ	O	7	NMOD
7	muscle	muscle	I-NP	NN	O	11	NMOD
8	(	(	O	(	O	10	DEP
9	venomotor	venomotor	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	tone	tone	B-NP	NN	O	12	SUB
12	plays	play	B-VP	VBZ	O	3	SBAR
13	a	a	B-NP	DT	O	14	NMOD
14	role	role	I-NP	NN	O	12	OBJ
15	in	in	B-PP	IN	O	12	VMOD
16	Nomega-nitro-L-arginine	Nomega-nitro-L-arginine	B-NP	NN	O	20	NMOD
17	(	(	O	(	O	19	DEP
18	LNNA	LNNA	B-NP	NN	O	19	DEP
19	)	)	O	)	O	16	NMOD
20	hypertension	hypertension	B-NP	NN	O	15	PMOD
21	through	through	B-PP	IN	O	20	NMOD
22	these	these	B-NP	DT	O	23	NMOD
23	mechanisms	mechanism	I-NP	NNS	O	21	PMOD
24	.	.	O	.	O	2	P

1	Mean	Mean	B-NP	JJ	O	4	NMOD
2	circulatory	circulatory	I-NP	JJ	O	4	NMOD
3	filling	filling	I-NP	NN	O	4	NMOD
4	pressure	pressure	I-NP	NN	O	9	NMOD
5	,	,	O	,	O	9	P
6	an	an	B-NP	DT	O	9	NMOD
7	in	in	I-NP	FW	O	8	AMOD
8	vivo	vivo	I-NP	FW	O	9	NMOD
9	measure	measure	I-NP	NN	O	14	SUB
10	of	of	B-PP	IN	O	9	NMOD
11	venomotor	venomotor	B-NP	NN	O	12	NMOD
12	tone	tone	I-NP	NN	O	10	PMOD
13	,	,	O	,	O	9	P
14	was	be	B-VP	VBD	O	0	ROOT
15	not	not	I-VP	RB	O	14	VMOD
16	elevated	elevate	I-VP	VBN	O	14	VC
17	in	in	B-PP	IN	O	16	VMOD
18	LNNA	LNNA	B-NP	NN	O	19	NMOD
19	hypertension	hypertension	I-NP	NN	O	17	PMOD
20	at	at	B-PP	IN	O	19	NMOD
21	1	1	B-NP	CD	O	23	AMOD
22	or	or	I-NP	CC	O	23	AMOD
23	2	2	I-NP	CD	O	24	NMOD
24	weeks	week	I-NP	NNS	O	20	PMOD
25	after	after	B-PP	IN	O	19	NMOD
26	LNNA	LNNA	B-NP	NN	B-protein	25	PMOD
27	.	.	O	.	O	14	P

1	Similarly	Similarly	B-ADVP	RB	O	7	VMOD
2	,	,	O	,	O	7	P
3	ganglionic	ganglionic	B-NP	JJ	O	4	NMOD
4	blockade	blockade	I-NP	NN	O	7	SUB
5	with	with	B-PP	IN	O	4	NMOD
6	hexamethonium	hexamethonium	B-NP	NN	O	5	PMOD
7	caused	cause	B-VP	VBD	O	0	ROOT
8	a	a	B-NP	DT	O	11	NMOD
9	significantly	significantly	I-NP	RB	O	10	AMOD
10	greater	great	I-NP	JJR	O	11	NMOD
11	fall	fall	I-NP	NN	O	7	OBJ
12	in	in	B-PP	IN	O	11	NMOD
13	LNNA	LNNA	B-NP	NN	O	15	NMOD
14	hypertensive	hypertensive	I-NP	JJ	O	15	NMOD
15	rats	rat	I-NP	NNS	O	12	PMOD
16	(	(	O	(	O	22	DEP
17	76	76	B-NP	CD	O	19	AMOD
18	+/-	+/-	I-NP	SYM	O	19	AMOD
19	9	9	I-NP	CD	O	21	NMOD
20	mm	mm	I-NP	NN	O	21	NMOD
21	Hg	Hg	I-NP	NN	O	22	DEP
22	)	)	O	)	O	11	NMOD
23	compared	compare	B-PP	VBN	O	11	NMOD
24	with	with	B-PP	IN	O	23	PMOD
25	control	control	B-NP	NN	O	26	NMOD
26	rats	rat	I-NP	NNS	O	24	PMOD
27	(	(	O	(	O	33	DEP
28	35	35	B-NP	CD	O	30	AMOD
29	+/-	+/-	I-NP	SYM	O	30	AMOD
30	10	10	I-NP	CD	O	32	NMOD
31	mm	mm	I-NP	NN	O	32	NMOD
32	Hg	Hg	I-NP	NN	O	33	DEP
33	)	)	O	)	O	26	NMOD
34	.	.	O	.	O	7	P

1	Association	Association	B-NP	NN	O	6	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	DRD2	DRD2	B-NP	NN	B-DNA	4	NMOD
4	polymorphisms	polymorphism	I-NP	NNS	I-DNA	2	PMOD
5	and	and	O	CC	O	6	NMOD
6	chlorpromazine	chlorpromazine	B-NP	NN	O	7	SUB
7	induced	induce	B-VP	VBD	O	0	ROOT
8	extrapyramidal	extrapyramidal	B-NP	JJ	O	9	NMOD
9	syndrome	syndrome	I-NP	NN	O	7	OBJ
10	in	in	B-PP	IN	O	7	VMOD
11	Chinese	Chinese	B-NP	JJ	O	13	NMOD
12	schizophrenic	schizophrenic	I-NP	JJ	O	13	NMOD
13	patients	patient	I-NP	NNS	O	10	PMOD
14	.	.	O	.	O	7	P

1	In	In	B-PP	IN	O	6	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	study	study	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	6	P
5	we	we	B-NP	PRP	O	6	SUB
6	evaluate	evaluate	B-VP	VBP	O	0	ROOT
7	the	the	B-NP	DT	O	9	NMOD
8	role	role	I-NP	NN	O	9	NMOD
9	DRD2	DRD2	I-NP	NN	B-protein	10	SUB
10	plays	play	B-VP	VBZ	O	6	VMOD
11	in	in	B-PP	IN	O	10	VMOD
12	chlorpromazine	chlorpromazine	B-NP	NN	O	14	NMOD
13	induced	induce	B-VP	VBD	O	12	AMOD
14	EPS	EPS	B-NP	NN	B-protein	11	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	schizophrenic	schizophrenic	B-NP	JJ	O	17	NMOD
17	patients	patient	I-NP	NNS	O	15	PMOD
18	.	.	O	.	O	6	P

1	METHODS	METHODS	B-NP	NNS	O	4	VMOD
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	identified	identify	B-VP	VBD	O	0	ROOT
5	seven	seven	B-NP	CD	O	6	NMOD
6	SNP	SNP	I-NP	NN	O	4	OBJ
7	(	(	O	(	O	11	DEP
8	single	single	B-NP	JJ	O	10	NMOD
9	nucleotide	nucleotide	I-NP	NN	O	10	NMOD
10	polymorphism	polymorphism	I-NP	NN	O	11	DEP
11	)	)	O	)	O	6	NMOD
12	(	(	O	(	O	28	DEP
13	-141Cins	-141Cin	B-NP	NNS	O	27	NMOD
14	>	>	O	SYM	O	27	NMOD
15	del	del	B-NP	NN	O	27	NMOD
16	,	,	O	,	O	27	P
17	TaqIB	TaqIB	B-NP	NN	B-protein	27	NMOD
18	,	,	O	,	O	27	P
19	TaqID	TaqID	B-NP	NN	O	27	NMOD
20	,	,	O	,	O	27	P
21	Ser311Cys	Ser311Cys	B-NP	NN	O	27	NMOD
22	,	,	O	,	O	27	P
23	rs6275	rs6275	B-NP	NN	O	27	NMOD
24	,	,	O	,	O	27	P
25	rs6277	rs6277	B-NP	NN	O	27	NMOD
26	and	and	O	CC	O	27	NMOD
27	TaqIA	TaqIA	B-NP	NN	B-protein	28	DEP
28	)	)	O	)	O	6	NMOD
29	in	in	B-PP	IN	O	6	NMOD
30	the	the	B-NP	DT	O	32	NMOD
31	DRD2	DRD2	I-NP	NN	B-DNA	32	NMOD
32	gene	gene	I-NP	NN	I-DNA	29	PMOD
33	in	in	B-PP	IN	O	4	VMOD
34	146	146	B-NP	CD	O	36	NMOD
35	schizophrenic	schizophrenic	I-NP	JJ	O	36	NMOD
36	inpatients	inpatient	I-NP	NNS	O	33	PMOD
37	(	(	O	(	O	50	DEP
38	59	59	B-NP	CD	O	42	NMOD
39	with	with	B-PP	IN	O	38	NMOD
40	EPS	EPS	B-NP	NN	B-protein	39	PMOD
41	and	and	O	CC	O	42	NMOD
42	87	87	B-NP	CD	O	50	DEP
43	without	without	B-PP	IN	O	42	NMOD
44	EPS	EPS	B-NP	NN	B-protein	43	PMOD
45	according	accord	B-PP	VBG	O	42	NMOD
46	to	to	B-PP	TO	O	45	PMOD
47	the	the	B-NP	DT	O	49	NMOD
48	Simpson-Angus	Simpson-Angus	I-NP	NNP	O	49	NMOD
49	Scale	Scale	I-NP	NNP	O	46	PMOD
50	)	)	O	)	O	4	VMOD
51	treated	treat	B-VP	VBN	O	4	VMOD
52	with	with	B-PP	IN	O	51	VMOD
53	chlorpromazine	chlorpromazine	B-NP	NN	B-protein	52	PMOD
54	after	after	B-PP	IN	I-protein	51	VMOD
55	8	8	B-NP	CD	I-protein	56	NMOD
56	weeks	week	I-NP	NNS	I-protein	54	PMOD
57	.	.	O	.	O	4	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Our	Our	B-NP	PRP$	O	4	NMOD
4	results	result	I-NP	NNS	O	5	SUB
5	did	do	B-VP	VBD	O	1	NMOD
6	not	not	I-VP	RB	O	5	VMOD
7	lend	lend	I-VP	VB	O	5	VC
8	strong	strong	B-NP	JJ	O	9	NMOD
9	support	support	I-NP	NN	O	7	OBJ
10	to	to	B-PP	TO	O	7	VMOD
11	the	the	B-NP	DT	O	12	NMOD
12	view	view	I-NP	NN	O	10	PMOD
13	that	that	B-SBAR	IN	O	12	NMOD
14	the	the	B-NP	DT	O	16	NMOD
15	genetic	genetic	I-NP	JJ	O	16	NMOD
16	variation	variation	I-NP	NN	O	21	SUB
17	of	of	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	20	NMOD
19	DRD2	DRD2	I-NP	NN	B-DNA	20	NMOD
20	gene	gene	I-NP	NN	I-DNA	17	PMOD
21	plays	play	B-VP	VBZ	O	13	SBAR
22	a	a	B-NP	DT	O	24	NMOD
23	major	major	I-NP	JJ	O	24	NMOD
24	role	role	I-NP	NN	O	21	OBJ
25	in	in	B-PP	IN	O	21	VMOD
26	the	the	B-NP	DT	O	30	NMOD
27	individually	individually	I-NP	RB	O	28	AMOD
28	variable	variable	I-NP	JJ	O	30	NMOD
29	adverse	adverse	I-NP	JJ	O	30	NMOD
30	effect	effect	I-NP	NN	O	25	PMOD
31	induced	induce	B-VP	VBN	O	30	NMOD
32	by	by	B-PP	IN	O	31	VMOD
33	chlorpromazine	chlorpromazine	B-NP	NN	O	32	PMOD
34	,	,	O	,	O	21	P
35	at	at	B-ADVP	IN	O	21	VMOD
36	least	least	I-ADVP	JJS	O	35	AMOD
37	in	in	B-PP	IN	O	35	PMOD
38	Chinese	Chinese	B-NP	JJ	O	39	NMOD
39	patients	patient	I-NP	NNS	O	37	PMOD
40	with	with	B-PP	IN	O	39	NMOD
41	schizophrenia	schizophrenia	B-NP	NN	O	40	PMOD
42	.	.	O	.	O	1	P

1	Physical	Physical	B-NP	JJ	O	2	NMOD
2	training	training	I-NP	NN	O	3	SUB
3	decreases	decrease	B-VP	VBZ	O	8	VMOD
4	susceptibility	susceptibility	B-NP	NN	O	8	SUB
5	to	to	B-PP	TO	O	4	NMOD
6	subsequent	subsequent	B-NP	JJ	O	7	NMOD
7	pilocarpine	pilocarpine	I-NP	NN	O	5	PMOD
8	induced	induce	B-VP	VBD	O	0	ROOT
9	seizures	seizure	B-NP	NNS	O	8	OBJ
10	in	in	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	rat	rat	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	8	P

1	Thereafter	Thereafter	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	seizures	seizure	B-NP	NNS	O	4	SUB
4	were	be	B-VP	VBD	O	0	ROOT
5	induced	induce	I-VP	VBN	O	4	VC
6	by	by	B-PP	IN	O	5	VMOD
7	pilocarpine	pilocarpine	B-NP	NN	O	8	NMOD
8	injections	injection	I-NP	NNS	O	6	PMOD
9	in	in	B-PP	IN	O	5	VMOD
10	trained	trained	B-NP	JJ	O	12	AMOD
11	and	and	I-NP	CC	O	12	AMOD
12	non-trained	non-trained	I-NP	JJ	O	14	NMOD
13	control	control	I-NP	NN	O	14	NMOD
14	groups	group	I-NP	NNS	O	9	PMOD
15	.	.	O	.	O	4	P

1	Administration	Administration	B-NP	NN	O	7	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	6	NMOD
4	dopamine	dopamine	I-NP	NN	O	6	NMOD
5	precursor	precursor	I-NP	NN	O	6	NMOD
6	levodopa	levodopa	I-NP	NN	O	2	PMOD
7	enhances	enhance	B-VP	VBZ	O	0	ROOT
8	learning	learning	B-NP	NN	O	7	OBJ
9	in	in	B-PP	IN	O	8	NMOD
10	healthy	healthy	B-NP	JJ	O	11	NMOD
11	subjects	subject	I-NP	NNS	O	14	NMOD
12	and	and	O	CC	O	14	NMOD
13	stroke	stroke	B-NP	NN	O	14	NMOD
14	patients	patient	I-NP	NNS	O	9	PMOD
15	.	.	O	.	O	7	P

1	The	The	B-NP	DT	O	3	NMOD
2	dopamine	dopamine	I-NP	NN	O	3	NMOD
3	agonist	agonist	I-NP	NN	O	5	SUB
4	significantly	significantly	B-ADVP	RB	O	5	VMOD
5	impaired	impair	B-VP	VBD	O	0	ROOT
6	novel	novel	B-NP	JJ	O	8	NMOD
7	word	word	I-NP	NN	O	8	NMOD
8	learning	learning	I-NP	NN	O	5	OBJ
9	compared	compare	B-VP	VBN	O	8	NMOD
10	to	to	B-PP	TO	O	9	VMOD
11	placebo	placebo	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	5	P

1	Minocycline	Minocycline	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	vasculitis	vasculitis	B-NP	NN	O	2	OBJ
4	fulfilling	fulfil	B-VP	VBG	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	criteria	criterion	I-NP	NNS	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	polyarteritis	polyarteritis	B-NP	NN	O	9	NMOD
9	nodosa	nodosa	I-NP	NN	O	7	PMOD
10	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	3	NMOD
2	47-year-old	47-year-old	I-NP	JJ	O	3	NMOD
3	man	man	I-NP	NN	O	12	SUB
4	who	who	B-NP	WP	O	3	NMOD
5	had	have	B-VP	VBD	O	4	SBAR
6	been	be	I-VP	VBN	O	5	VC
7	taking	take	I-VP	VBG	O	6	VC
8	minocycline	minocycline	B-NP	NN	O	7	OBJ
9	for	for	B-PP	IN	O	8	NMOD
10	palmoplantar	palmoplantar	B-NP	JJ	O	11	NMOD
11	pustulosis	pustulosis	I-NP	NN	O	9	PMOD
12	developed	develop	B-VP	VBD	O	0	ROOT
13	fever	fever	B-NP	NN	O	21	NMOD
14	,	,	O	,	O	21	P
15	myalgias	myalgia	B-NP	NNS	O	21	NMOD
16	,	,	O	,	O	21	P
17	polyneuropathy	polyneuropathy	B-NP	NN	O	21	NMOD
18	,	,	O	,	O	21	P
19	and	and	O	CC	O	21	NMOD
20	testicular	testicular	B-NP	JJ	B-protein	21	NMOD
21	pain	pain	I-NP	NN	I-protein	12	OBJ
22	,	,	O	,	O	21	P
23	with	with	B-PP	IN	O	21	NMOD
24	elevated	elevated	B-NP	JJ	O	26	NMOD
25	C-reactive	C-reactive	I-NP	JJ	B-protein	26	NMOD
26	protein	protein	I-NP	NN	I-protein	23	PMOD
27	(	(	O	(	O	29	DEP
28	CRP	CRP	B-NP	NN	B-protein	29	DEP
29	)	)	O	)	O	26	NMOD
30	.	.	O	.	O	12	P

1	To	To	B-PP	TO	O	6	VMOD
2	our	our	B-NP	PRP$	O	3	NMOD
3	knowledge	knowledge	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	6	P
5	this	this	B-NP	DT	O	6	SUB
6	is	be	B-VP	VBZ	O	12	VMOD
7	the	the	B-NP	DT	O	9	NMOD
8	second	second	I-NP	JJ	O	9	NMOD
9	case	case	I-NP	NN	O	12	SUB
10	of	of	B-PP	IN	O	9	NMOD
11	minocycline	minocycline	B-NP	NN	O	10	PMOD
12	induced	induce	B-VP	VBD	O	0	ROOT
13	vasculitis	vasculitis	B-NP	NN	O	12	OBJ
14	satisfying	satisfy	B-VP	VBG	O	13	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	criteria	criterion	I-NP	NNS	O	14	OBJ
17	.	.	O	.	O	12	P

1	Intramuscular	Intramuscular	B-NP	JJ	B-protein	5	NMOD
2	hepatitis	hepatitis	I-NP	NN	I-protein	5	NMOD
3	B	B	I-NP	NN	I-protein	5	NMOD
4	immune	immune	I-NP	JJ	I-protein	5	NMOD
5	globulin	globulin	I-NP	NN	I-protein	0	ROOT
6	combined	combine	B-VP	VBN	O	5	NMOD
7	with	with	B-PP	IN	O	6	VMOD
8	lamivudine	lamivudine	B-NP	NN	O	7	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	prevention	prevention	B-NP	NN	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	hepatitis	hepatitis	B-NP	NN	O	14	NMOD
13	B	B	I-NP	NN	O	14	NMOD
14	recurrence	recurrence	I-NP	NN	O	11	PMOD
15	after	after	B-PP	IN	O	14	NMOD
16	liver	liver	B-NP	NN	O	17	NMOD
17	transplantation	transplantation	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	5	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Combined	Combine	B-NP	VBN	O	7	NMOD
4	hepatitis	hepatitis	I-NP	NN	B-protein	7	NMOD
5	B	B	I-NP	NN	I-protein	7	NMOD
6	immune	immune	I-NP	JJ	I-protein	7	NMOD
7	globulin	globulin	I-NP	NN	I-protein	12	NMOD
8	(	(	O	(	O	10	DEP
9	HBIg	HBIg	B-NP	NN	B-protein	10	DEP
10	)	)	O	)	O	7	NMOD
11	and	and	O	CC	O	12	NMOD
12	lamivudine	lamivudine	B-NP	NN	O	24	SUB
13	in	in	B-PP	IN	O	12	NMOD
14	prophylaxis	prophylaxis	B-NP	NN	O	13	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	recurrence	recurrence	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	hepatitis	hepatitis	B-NP	NN	O	20	NMOD
20	B	B	I-NP	NN	O	18	PMOD
21	after	after	B-PP	IN	O	17	NMOD
22	liver	liver	B-NP	NN	O	23	NMOD
23	transplantation	transplantation	I-NP	NN	O	21	PMOD
24	has	have	B-VP	VBZ	O	1	NMOD
25	significantly	significantly	I-VP	RB	O	24	VMOD
26	improved	improve	I-VP	VBN	O	24	VC
27	the	the	B-NP	DT	O	28	NMOD
28	survival	survival	I-NP	NN	O	26	OBJ
29	of	of	B-PP	IN	O	28	NMOD
30	HBsAg	HBsAg	B-NP	NN	B-protein	32	NMOD
31	positive	positive	I-NP	JJ	O	32	NMOD
32	patients	patient	I-NP	NNS	O	29	PMOD
33	.	.	O	.	O	24	P

1	Anticonvulsant	Anticonvulsant	B-NP	JJ	O	2	NMOD
2	effect	effect	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	eslicarbazepine	eslicarbazepine	B-NP	NN	O	5	NMOD
5	acetate	acetate	I-NP	NN	O	3	PMOD
6	(	(	O	(	O	9	DEP
7	BIA	BIA	B-NP	NN	O	9	DEP
8	2-093	2-093	I-NP	CD	O	7	NMOD
9	)	)	O	)	O	5	NMOD
10	on	on	B-PP	IN	O	2	NMOD
11	seizures	seizure	B-NP	NNS	O	10	PMOD
12	induced	induce	B-VP	VBN	O	11	NMOD
13	by	by	B-PP	IN	O	12	VMOD
14	microperfusion	microperfusion	B-NP	NN	O	13	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	picrotoxin	picrotoxin	B-NP	NN	B-protein	15	PMOD
17	in	in	B-PP	IN	O	14	NMOD
18	the	the	B-NP	DT	O	19	NMOD
19	hippocampus	hippocampus	I-NP	NN	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	freely	freely	B-ADVP	RB	O	22	AMOD
22	moving	move	B-VP	VBG	O	20	PMOD
23	rats	rat	B-NP	NNS	O	22	OBJ
24	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	have	have	B-VP	VBP	O	0	ROOT
3	studied	study	I-VP	VBN	O	2	VC
4	the	the	B-NP	DT	O	5	NMOD
5	effects	effect	I-NP	NNS	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	oral	oral	B-NP	JJ	O	8	NMOD
8	treatment	treatment	I-NP	NN	O	6	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	eslicarbazepine	eslicarbazepine	B-NP	NN	O	11	NMOD
11	acetate	acetate	I-NP	NN	O	9	PMOD
12	on	on	B-PP	IN	O	5	NMOD
13	a	a	B-NP	DT	O	15	NMOD
14	whole-animal	whole-animal	I-NP	JJ	O	15	NMOD
15	model	model	I-NP	NN	O	12	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	which	which	B-NP	WDT	O	16	PMOD
18	partial	partial	B-NP	JJ	O	19	NMOD
19	seizures	seizure	I-NP	NNS	O	20	SUB
20	can	can	B-VP	MD	O	16	SBAR
21	be	be	I-VP	VB	O	20	VC
22	elicited	elicit	I-VP	VBN	O	21	VC
23	repeatedly	repeatedly	B-ADVP	RB	O	22	VMOD
24	on	on	B-PP	IN	O	22	VMOD
25	different	different	B-NP	JJ	O	26	NMOD
26	days	day	I-NP	NNS	O	24	PMOD
27	without	without	B-PP	IN	O	26	NMOD
28	changes	change	B-NP	NNS	O	27	PMOD
29	in	in	B-PP	IN	O	28	NMOD
30	threshold	threshold	B-NP	NN	O	33	NMOD
31	or	or	I-NP	CC	O	33	NMOD
32	seizure	seizure	I-NP	NN	O	33	NMOD
33	patterns	pattern	I-NP	NNS	O	29	PMOD
34	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	16	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	animals	animal	I-NP	NNS	O	1	PMOD
4	treated	treat	B-VP	VBN	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	threshold	threshold	B-NP	NN	O	7	NMOD
7	doses	dose	I-NP	NNS	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	picrotoxin	picrotoxin	B-NP	NN	O	8	PMOD
10	,	,	O	,	O	16	P
11	the	the	B-NP	DT	O	13	NMOD
12	average	average	I-NP	JJ	O	13	NMOD
13	number	number	I-NP	NN	O	16	SUB
14	of	of	B-PP	IN	O	13	NMOD
15	seizures	seizure	B-NP	NNS	O	14	PMOD
16	was	be	B-VP	VBD	O	23	VMOD
17	2.3+/-1.2	2.3+/-1.2	B-NP	CD	O	16	PRD
18	,	,	O	,	O	23	P
19	and	and	O	CC	O	23	VMOD
20	average	average	B-NP	JJ	O	22	NMOD
21	seizure	seizure	I-NP	NN	O	22	NMOD
22	duration	duration	I-NP	NN	O	23	SUB
23	was	be	B-VP	VBD	O	0	ROOT
24	39.5+/-8.4s	39.5+/-8.4	B-NP	NNS	O	23	PRD
25	.	.	O	.	O	23	P

1	Pre-treatment	Pre-treatment	B-NP	NN	O	12	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	a	a	B-NP	DT	O	4	NMOD
4	dose	dose	I-NP	NN	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	30	30	B-NP	CD	O	8	NMOD
7	mg/kg	mg/kg	I-NP	NN	O	8	NMOD
8	2h	2h	I-NP	NN	O	5	PMOD
9	before	before	B-PP	IN	O	1	NMOD
10	picrotoxin	picrotoxin	B-NP	NN	O	11	NMOD
11	microperfusion	microperfusion	I-NP	NN	O	9	PMOD
12	prevented	prevent	B-VP	VBD	O	0	ROOT
13	seizures	seizure	B-NP	NNS	O	12	OBJ
14	in	in	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	17	NMOD
16	75	75	I-NP	CD	O	17	NMOD
17	%	%	I-NP	NN	O	14	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	20	NMOD
20	rats	rat	I-NP	NNS	O	18	PMOD
21	.	.	O	.	O	12	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	renal	renal	I-NP	JJ	O	3	NMOD
3	failure	failure	I-NP	NN	O	0	ROOT
4	associated	associate	B-VP	VBN	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	prolonged	prolonged	B-NP	JJ	O	7	NMOD
7	intake	intake	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	slimming	slimme	B-VP	VBG	O	8	PMOD
10	pills	pill	B-NP	NNS	O	9	OBJ
11	containing	contain	B-VP	VBG	O	10	NMOD
12	anthraquinones	anthraquinone	B-NP	NNS	O	11	OBJ
13	.	.	O	.	O	3	P

1	Nephropathy	Nephropathy	B-NP	NN	O	6	SUB
2	caused	cause	B-VP	VBN	O	1	NMOD
3	by	by	B-PP	IN	O	2	VMOD
4	Chinese	Chinese	B-NP	JJ	B-protein	5	NMOD
5	herbs	herb	I-NP	NNS	I-protein	3	PMOD
6	has	have	B-VP	VBZ	O	0	ROOT
7	previously	previously	I-VP	RB	O	6	VMOD
8	been	be	I-VP	VBN	O	6	VC
9	reported	report	I-VP	VBN	O	8	VC
10	,	,	O	,	O	6	P
11	usually	usually	B-ADVP	RB	O	12	VMOD
12	involving	involve	B-VP	VBG	O	6	VMOD
13	the	the	B-NP	DT	O	14	NMOD
14	use	use	I-NP	NN	O	12	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	aristolochic	aristolochic	B-NP	JJ	O	17	NMOD
17	acids	acid	I-NP	NNS	O	15	PMOD
18	.	.	O	.	O	6	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	23-year-old	23-year-old	I-NP	JJ	O	5	NMOD
5	woman	woman	I-NP	NN	O	2	OBJ
6	who	who	B-NP	WP	O	5	NMOD
7	developed	develop	B-VP	VBD	O	6	SBAR
8	acute	acute	B-NP	JJ	O	10	NMOD
9	renal	renal	I-NP	JJ	O	10	NMOD
10	failure	failure	I-NP	NN	O	7	OBJ
11	following	follow	B-PP	VBG	O	7	VMOD
12	prolonged	prolong	B-NP	VBN	O	13	NMOD
13	use	use	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	a	a	B-NP	DT	O	20	NMOD
16	proprietary	proprietary	I-NP	JJ	O	19	AMOD
17	Chinese	Chinese	I-NP	JJ	O	19	AMOD
18	herbal	herbal	I-NP	JJ	O	19	AMOD
19	slimming	slimming	I-NP	JJ	O	20	NMOD
20	pill	pill	I-NP	NN	O	14	PMOD
21	that	that	B-NP	WDT	O	20	NMOD
22	contained	contain	B-VP	VBD	O	21	SBAR
23	anthraquinone	anthraquinone	B-NP	NN	O	24	NMOD
24	derivatives	derivative	I-NP	NNS	O	22	OBJ
25	,	,	O	,	O	24	P
26	extracted	extract	B-VP	VBN	O	24	NMOD
27	from	from	B-PP	IN	O	26	VMOD
28	Rhizoma	Rhizoma	B-NP	NNP	O	29	NMOD
29	Rhei	Rhei	I-NP	NNP	O	27	PMOD
30	(	(	O	(	O	32	DEP
31	rhubarb	rhubarb	B-NP	NN	O	32	DEP
32	)	)	O	)	O	29	NMOD
33	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	renal	renal	I-NP	JJ	O	3	NMOD
3	injury	injury	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	probably	probably	I-VP	RB	O	4	VMOD
6	aggravated	aggravate	I-VP	VBN	O	4	VC
7	by	by	B-PP	IN	O	6	VMOD
8	the	the	B-NP	DT	O	10	NMOD
9	concomitant	concomitant	I-NP	JJ	O	10	NMOD
10	intake	intake	I-NP	NN	O	17	NMOD
11	of	of	B-PP	IN	O	10	NMOD
12	a	a	B-NP	DT	O	15	NMOD
13	non-steroidal	non-steroidal	I-NP	JJ	O	15	NMOD
14	anti-inflammatory	anti-inflammatory	I-NP	JJ	O	15	NMOD
15	drug	drug	I-NP	NN	O	11	PMOD
16	,	,	O	,	O	17	P
17	diclofenac	diclofenac	B-NP	NN	O	7	PMOD
18	.	.	O	.	O	4	P

1	Chloroacetaldehyde	Chloroacetaldehyde	B-NP	NN	O	8	NMOD
2	as	as	B-PP	IN	O	1	NMOD
3	a	a	B-NP	DT	O	5	NMOD
4	sulfhydryl	sulfhydryl	I-NP	NN	O	5	NMOD
5	reagent	reagent	I-NP	NN	O	2	PMOD
6	:	:	O	:	O	1	P
7	the	the	B-NP	DT	O	8	NMOD
8	role	role	I-NP	NN	O	0	ROOT
9	of	of	B-PP	IN	O	8	NMOD
10	critical	critical	B-NP	JJ	O	12	NMOD
11	thiol	thiol	I-NP	NN	O	12	NMOD
12	groups	group	I-NP	NNS	O	9	PMOD
13	in	in	B-PP	IN	O	8	NMOD
14	ifosfamide	ifosfamide	B-NP	NN	O	15	NMOD
15	nephropathy	nephropathy	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	8	P

1	Chloroacetaldehyde	Chloroacetaldehyde	B-NP	NN	O	5	SUB
2	(	(	O	(	O	4	DEP
3	CAA	CAA	B-NP	NN	B-protein	4	DEP
4	)	)	O	)	O	1	NMOD
5	is	be	B-VP	VBZ	O	0	ROOT
6	a	a	B-NP	DT	O	7	NMOD
7	metabolite	metabolite	I-NP	NN	O	5	PRD
8	of	of	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	12	NMOD
10	alkylating	alkylate	I-NP	VBG	O	12	NMOD
11	agent	agent	I-NP	NN	O	12	NMOD
12	ifosfamide	ifosfamide	I-NP	NN	O	8	PMOD
13	(	(	O	(	O	15	DEP
14	IFO	IFO	B-NP	NN	B-protein	15	DEP
15	)	)	O	)	O	12	NMOD
16	and	and	O	CC	O	18	AMOD
17	putatively	putatively	B-ADJP	RB	O	18	AMOD
18	responsible	responsible	I-ADJP	JJ	O	7	NMOD
19	for	for	B-PP	IN	O	18	AMOD
20	renal	renal	B-NP	JJ	O	21	NMOD
21	damage	damage	I-NP	NN	O	19	PMOD
22	following	follow	B-PP	VBG	O	21	NMOD
23	anti-tumor	anti-tumor	B-NP	JJ	O	24	NMOD
24	therapy	therapy	I-NP	NN	O	22	PMOD
25	with	with	B-PP	IN	O	24	NMOD
26	IFO	IFO	B-NP	NN	B-protein	25	PMOD
27	.	.	O	.	O	5	P

1	Toxicity	Toxicity	B-NP	NN	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	CAA	CAA	B-NP	NN	B-protein	2	PMOD
4	was	be	B-VP	VBD	O	0	ROOT
5	determined	determine	I-VP	VBN	O	4	VC
6	by	by	B-PP	IN	O	5	VMOD
7	protein	protein	B-NP	NN	O	8	NMOD
8	content	content	I-NP	NN	O	22	NMOD
9	,	,	O	,	O	22	P
10	cell	cell	B-NP	NN	O	11	NMOD
11	number	number	I-NP	NN	O	22	NMOD
12	,	,	O	,	O	22	P
13	LDH	LDH	B-NP	NN	O	14	NMOD
14	release	release	I-NP	NN	O	22	NMOD
15	,	,	O	,	O	22	P
16	trypan	trypan	B-NP	NN	O	19	NMOD
17	blue	blue	I-NP	JJ	O	19	NMOD
18	exclusion	exclusion	I-NP	NN	O	19	NMOD
19	assay	assay	I-NP	NN	O	22	NMOD
20	and	and	O	CC	O	22	NMOD
21	caspase-3	caspase-3	B-NP	NN	B-protein	22	NMOD
22	activity	activity	I-NP	NN	O	6	PMOD
23	.	.	O	.	O	4	P

1	CAA	CAA	B-NP	NN	B-protein	2	SUB
2	reduced	reduce	B-VP	VBD	O	0	ROOT
3	hRPTEC	hRPTEC	B-NP	NN	O	5	NMOD
4	cell	cell	I-NP	NN	O	5	NMOD
5	number	number	I-NP	NN	O	7	NMOD
6	and	and	O	CC	O	7	NMOD
7	protein	protein	B-NP	NN	O	2	OBJ
8	,	,	O	,	O	2	P
9	induced	induce	B-VP	VBD	O	2	VMOD
10	a	a	B-NP	DT	O	11	NMOD
11	loss	loss	I-NP	NN	O	18	NMOD
12	in	in	B-PP	IN	O	11	NMOD
13	free	free	B-NP	JJ	O	15	NMOD
14	intracellular	intracellular	I-NP	JJ	O	15	NMOD
15	thiols	thiol	I-NP	NNS	O	12	PMOD
16	and	and	O	CC	O	18	NMOD
17	an	an	B-NP	DT	O	18	NMOD
18	increase	increase	I-NP	NN	O	9	OBJ
19	in	in	B-PP	IN	O	18	NMOD
20	necrosis	necrosis	B-NP	NN	O	21	NMOD
21	markers	marker	I-NP	NNS	O	19	PMOD
22	.	.	O	.	O	2	P

1	Acidification	Acidification	B-NP	NN	O	13	SUB
2	,	,	O	,	O	1	P
3	which	which	B-NP	WDT	O	1	NMOD
4	slowed	slow	B-VP	VBD	O	3	SBAR
5	the	the	B-NP	DT	O	6	NMOD
6	reaction	reaction	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	CAA	CAA	B-NP	NN	B-protein	7	PMOD
9	with	with	B-PP	IN	O	6	NMOD
10	thiol	thiol	B-NP	NN	O	11	NMOD
11	donors	donor	I-NP	NNS	O	9	PMOD
12	,	,	O	,	O	1	P
13	could	could	B-VP	MD	O	28	NMOD
14	also	also	I-VP	RB	O	13	VMOD
15	attenuate	attenuate	I-VP	VB	O	13	VC
16	effects	effect	B-NP	NNS	O	15	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	CAA	CAA	B-NP	NN	B-protein	17	PMOD
19	on	on	B-PP	IN	O	16	NMOD
20	necrosis	necrosis	B-NP	NN	O	21	NMOD
21	markers	marker	I-NP	NNS	O	19	PMOD
22	,	,	O	,	O	28	P
23	thiol	thiol	B-NP	NN	O	24	NMOD
24	depletion	depletion	I-NP	NN	O	28	NMOD
25	and	and	I-NP	CC	O	28	NMOD
26	cysteine	cysteine	I-NP	NN	B-protein	27	NMOD
27	protease	protease	I-NP	NN	I-protein	28	NMOD
28	inhibition	inhibition	I-NP	NN	O	0	ROOT
29	in	in	B-PP	IN	O	28	NMOD
30	living	live	B-VP	VBG	B-cell_type	31	NMOD
31	cells	cell	B-NP	NNS	I-cell_type	29	PMOD
32	.	.	O	.	O	28	P

1	Thus	Thus	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	CAA	CAA	B-NP	NN	B-protein	5	SUB
4	directly	directly	B-ADVP	RB	O	5	VMOD
5	reacts	react	B-VP	VBZ	O	0	ROOT
6	with	with	B-PP	IN	O	5	VMOD
7	cellular	cellular	B-NP	JJ	B-protein	8	NMOD
8	protein	protein	I-NP	NN	I-protein	11	NMOD
9	and	and	O	CC	O	11	NMOD
10	non-protein	non-protein	B-NP	JJ	O	11	NMOD
11	thiols	thiol	I-NP	NNS	O	6	PMOD
12	,	,	O	,	O	5	P
13	mediating	mediate	B-VP	VBG	O	5	VMOD
14	its	its	B-NP	PRP$	O	15	NMOD
15	toxicity	toxicity	I-NP	NN	O	13	OBJ
16	on	on	B-PP	IN	O	15	NMOD
17	hRPTEC	hRPTEC	B-NP	NN	B-cell_type	16	PMOD
18	.	.	O	.	O	5	P

1	Stereological	Stereological	B-NP	JJ	O	2	NMOD
2	methods	method	I-NP	NNS	O	3	SUB
3	reveal	reveal	B-VP	VBP	O	0	ROOT
4	the	the	B-NP	DT	O	8	NMOD
5	robust	robust	I-NP	JJ	O	8	NMOD
6	size	size	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	stability	stability	I-NP	NN	O	3	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	ectopic	ectopic	B-NP	JJ	B-cell_type	13	NMOD
11	hilar	hilar	I-NP	JJ	I-cell_type	13	NMOD
12	granule	granule	I-NP	NN	I-cell_type	13	NMOD
13	cells	cell	I-NP	NNS	I-cell_type	9	PMOD
14	after	after	B-SBAR	IN	O	8	NMOD
15	pilocarpine	pilocarpine	B-NP	NN	O	16	SUB
16	induced	induce	B-VP	VBD	O	14	SBAR
17	status	status	B-NP	NN	O	18	NMOD
18	epilepticus	epilepticus	I-NP	NN	O	16	OBJ
19	in	in	B-PP	IN	O	16	VMOD
20	the	the	B-NP	DT	O	22	NMOD
21	adult	adult	I-NP	JJ	O	22	NMOD
22	rat	rat	I-NP	NN	O	19	PMOD
23	.	.	O	.	O	3	P

1	To	To	B-VP	TO	O	2	VMOD
2	quantify	quantify	I-VP	VB	O	14	VMOD
3	this	this	B-NP	DT	O	4	NMOD
4	population	population	I-NP	NN	O	2	OBJ
5	,	,	O	,	O	14	P
6	the	the	B-NP	DT	O	8	NMOD
7	total	total	I-NP	JJ	O	8	NMOD
8	number	number	I-NP	NN	O	14	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	ectopic	ectopic	B-NP	JJ	B-cell_type	13	NMOD
11	hilar	hilar	I-NP	JJ	I-cell_type	13	NMOD
12	granule	granule	I-NP	NN	I-cell_type	13	NMOD
13	cells	cell	I-NP	NNS	I-cell_type	9	PMOD
14	was	be	B-VP	VBD	O	0	ROOT
15	estimated	estimate	I-VP	VBN	O	14	VC
16	using	use	B-VP	VBG	O	15	VMOD
17	unbiased	unbiased	B-NP	JJ	O	18	NMOD
18	stereology	stereology	I-NP	NN	O	16	OBJ
19	at	at	B-PP	IN	O	18	NMOD
20	different	different	B-NP	JJ	O	21	NMOD
21	times	time	I-NP	NNS	O	19	PMOD
22	after	after	B-SBAR	IN	O	16	VMOD
23	pilocarpine	pilocarpine	B-NP	NN	O	24	SUB
24	induced	induce	B-VP	VBD	O	22	SBAR
25	status	status	B-NP	NN	O	26	NMOD
26	epilepticus	epilepticus	I-NP	NN	O	24	OBJ
27	.	.	O	.	O	14	P

1	A	A	B-NP	DT	O	5	NMOD
2	prospective	prospective	I-NP	JJ	O	4	AMOD
3	,	,	I-NP	,	O	4	P
4	open-label	open-label	I-NP	JJ	O	5	NMOD
5	trial	trial	I-NP	NN	O	0	ROOT
6	of	of	B-PP	IN	O	5	NMOD
7	galantamine	galantamine	B-NP	NN	O	6	PMOD
8	in	in	B-PP	IN	O	5	NMOD
9	autistic	autistic	B-NP	JJ	O	10	NMOD
10	disorder	disorder	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	2	NMOD
2	purpose	purpose	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	assess	assess	I-VP	VB	O	6	PRD
9	the	the	B-NP	DT	O	10	NMOD
10	use	use	I-NP	NN	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	galantamine	galantamine	B-NP	NN	O	20	NMOD
13	,	,	O	,	O	20	P
14	an	an	B-NP	DT	O	16	NMOD
15	acetylcholinesterase	acetylcholinesterase	I-NP	NN	O	16	NMOD
16	inhibitor	inhibitor	I-NP	NN	O	20	NMOD
17	and	and	O	CC	O	20	NMOD
18	nicotinic	nicotinic	B-NP	JJ	O	20	NMOD
19	receptor	receptor	I-NP	NN	O	20	NMOD
20	modulator	modulator	I-NP	NN	O	11	PMOD
21	,	,	O	,	O	8	P
22	in	in	B-PP	IN	O	8	VMOD
23	the	the	B-NP	DT	O	24	NMOD
24	treatment	treatment	I-NP	NN	O	22	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	interfering	interfere	B-VP	VBG	O	27	NMOD
27	behaviors	behavior	B-NP	NNS	O	25	PMOD
28	in	in	B-PP	IN	O	27	NMOD
29	children	child	B-NP	NNS	O	28	PMOD
30	with	with	B-PP	IN	O	29	NMOD
31	autism	autism	B-NP	NN	O	30	PMOD
32	.	.	O	.	O	6	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Thirteen	Thirteen	B-NP	CD	O	5	NMOD
4	medication-free	medication-free	I-NP	JJ	O	5	NMOD
5	children	child	I-NP	NNS	O	1	NMOD
6	with	with	B-PP	IN	O	5	NMOD
7	autism	autism	B-NP	NN	O	6	PMOD
8	(	(	O	(	O	16	DEP
9	mean	mean	B-NP	JJ	O	10	NMOD
10	age	age	I-NP	NN	O	15	NMOD
11	,	,	O	,	O	15	P
12	8.8	8.8	B-NP	CD	O	14	AMOD
13	+/-	+/-	I-NP	CC	O	14	AMOD
14	3.5	3.5	I-NP	CD	O	15	NMOD
15	years	year	I-NP	NNS	O	16	DEP
16	)	)	O	)	O	7	NMOD
17	participated	participate	B-VP	VBN	O	7	NMOD
18	in	in	B-PP	IN	O	17	VMOD
19	a	a	B-NP	DT	O	23	NMOD
20	12-week	12-week	I-NP	JJ	O	22	AMOD
21	,	,	I-NP	,	O	22	P
22	open-label	open-label	I-NP	JJ	O	23	NMOD
23	trial	trial	I-NP	NN	O	18	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	galantamine	galantamine	B-NP	NN	O	24	PMOD
26	.	.	O	.	O	5	P

1	Overall	Overall	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	galantamine	galantamine	B-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	well-tolerated	well-tolerated	B-ADJP	JJ	O	4	PRD
6	,	,	O	,	O	4	P
7	with	with	B-PP	IN	O	4	VMOD
8	no	no	B-NP	DT	O	11	NMOD
9	significant	significant	I-NP	JJ	O	10	AMOD
10	adverse	adverse	I-NP	JJ	O	11	NMOD
11	effects	effect	I-NP	NNS	O	7	PMOD
12	apart	apart	B-ADVP	RB	O	11	NMOD
13	from	from	B-PP	IN	O	12	AMOD
14	headaches	headache	B-NP	NNS	O	13	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	one	one	B-NP	CD	O	17	NMOD
17	patient	patient	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	4	P

1	Randomized	Randomize	B-NP	VBN	O	2	NMOD
2	comparison	comparison	I-NP	NN	O	15	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	olanzapine	olanzapine	B-NP	NN	O	6	NMOD
5	versus	versus	I-NP	CC	O	6	NMOD
6	risperidone	risperidone	I-NP	NN	O	3	PMOD
7	for	for	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	treatment	treatment	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	first-episode	first-episode	B-NP	JJ	O	12	NMOD
12	schizophrenia	schizophrenia	I-NP	NN	O	10	PMOD
13	:	:	O	:	O	2	P
14	4-month	4-month	B-NP	JJ	O	15	NMOD
15	outcomes	outcome	I-NP	NNS	O	0	ROOT
16	.	.	O	.	O	15	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	4	NMOD
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	authors	author	I-NP	NNS	O	5	SUB
5	compared	compare	B-VP	VBD	O	0	ROOT
6	4-month	4-month	B-NP	JJ	O	8	NMOD
7	treatment	treatment	I-NP	NN	O	8	NMOD
8	outcomes	outcome	I-NP	NNS	O	5	OBJ
9	for	for	B-PP	IN	O	8	NMOD
10	olanzapine	olanzapine	B-NP	NN	O	12	NMOD
11	versus	versus	O	CC	O	12	NMOD
12	risperidone	risperidone	B-NP	NN	O	9	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	patients	patient	B-NP	NNS	O	13	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	first-episode	first-episode	B-NP	JJ	O	19	NMOD
17	schizophrenia	schizophrenia	I-NP	NN	O	19	NMOD
18	spectrum	spectrum	I-NP	NN	O	19	NMOD
19	disorders	disorder	I-NP	NNS	O	15	PMOD
20	.	.	O	.	O	5	P

1	METHOD	METHOD	B-NP	NN	O	6	NMOD
2	:	:	O	:	O	1	P
3	One	One	B-NP	CD	O	5	AMOD
4	hundred	hundred	I-NP	CD	O	5	AMOD
5	twelve	twelve	I-NP	CD	O	6	NMOD
6	subjects	subject	I-NP	NNS	O	38	NMOD
7	(	(	O	(	O	20	DEP
8	70	70	B-NP	CD	O	9	AMOD
9	%	%	I-NP	NN	O	10	NMOD
10	male	male	I-NP	NN	O	20	DEP
11	;	;	O	:	O	20	P
12	mean	mean	B-NP	JJ	O	14	NMOD
13	age=23.3	age=23.3	I-NP	NN	O	14	NMOD
14	years	year	I-NP	NNS	O	20	DEP
15	[	[	O	(	O	19	DEP
16	SD	SD	B-NP	NN	O	18	SUB
17	=	=	B-VP	SYM	O	18	VMOD
18	5.1	5.1	B-NP	CD	O	19	DEP
19	]	]	O	)	O	14	NMOD
20	)	)	O	)	O	6	NMOD
21	with	with	B-PP	IN	O	6	NMOD
22	first-episode	first-episode	B-NP	JJ	O	23	NMOD
23	schizophrenia	schizophrenia	I-NP	NN	O	21	PMOD
24	(	(	O	(	O	27	DEP
25	75	75	B-NP	CD	O	26	NMOD
26	%	%	I-NP	NN	O	27	DEP
27	)	)	O	)	O	23	NMOD
28	,	,	O	,	O	38	P
29	schizophreniform	schizophreniform	B-NP	NN	O	30	NMOD
30	disorder	disorder	I-NP	NN	O	38	NMOD
31	(	(	O	(	O	34	DEP
32	17	17	B-NP	CD	O	33	NMOD
33	%	%	I-NP	NN	O	34	DEP
34	)	)	O	)	O	30	NMOD
35	,	,	O	,	O	38	P
36	or	or	O	CC	O	38	NMOD
37	schizoaffective	schizoaffective	B-NP	JJ	O	38	NMOD
38	disorder	disorder	I-NP	NN	O	43	SUB
39	(	(	O	(	O	42	DEP
40	8	8	B-NP	CD	O	41	NMOD
41	%	%	I-NP	NN	O	42	DEP
42	)	)	O	)	O	38	NMOD
43	were	be	B-VP	VBD	O	0	ROOT
44	randomly	randomly	I-VP	RB	O	43	VMOD
45	assigned	assign	I-VP	VBN	O	43	VC
46	to	to	B-PP	TO	O	45	VMOD
47	treatment	treatment	B-NP	NN	O	46	PMOD
48	with	with	B-PP	IN	O	47	NMOD
49	olanzapine	olanzapine	B-NP	NN	O	55	NMOD
50	(	(	O	(	O	53	DEP
51	2.5-20	2.5-20	B-NP	CD	O	52	NMOD
52	mg/day	mg/day	I-NP	NN	O	53	DEP
53	)	)	O	)	O	49	NMOD
54	or	or	O	CC	O	55	NMOD
55	risperidone	risperidone	B-NP	NN	O	48	PMOD
56	(	(	O	(	O	59	DEP
57	1-6	1-6	B-NP	CD	O	58	NMOD
58	mg/day	mg/day	I-NP	NN	O	59	DEP
59	)	)	O	)	O	55	NMOD
60	.	.	O	.	O	43	P

1	Extrapyramidal	Extrapyramidal	B-NP	JJ	O	4	NMOD
2	symptom	symptom	I-NP	NN	O	4	NMOD
3	severity	severity	I-NP	NN	O	4	NMOD
4	scores	score	I-NP	NNS	O	5	SUB
5	were	be	B-VP	VBD	O	0	ROOT
6	1.4	1.4	B-NP	CD	O	5	PRD
7	(	(	O	(	O	11	DEP
8	95	95	B-NP	CD	O	10	NMOD
9	%	%	I-NP	NN	O	10	NMOD
10	CI=1.2-1.6	CI=1.2-1.6	I-NP	NN	O	11	DEP
11	)	)	O	)	O	6	NMOD
12	with	with	B-PP	IN	O	6	NMOD
13	risperidone	risperidone	B-NP	NN	O	15	NMOD
14	and	and	O	CC	O	15	NMOD
15	1.2	1.2	B-NP	CD	O	12	PMOD
16	(	(	O	(	O	20	DEP
17	95	95	B-NP	CD	O	19	NMOD
18	%	%	I-NP	NN	O	19	NMOD
19	CI=1.0-1.4	CI=1.0-1.4	I-NP	NN	O	20	DEP
20	)	)	O	)	O	15	NMOD
21	with	with	B-PP	IN	O	15	NMOD
22	olanzapine	olanzapine	B-NP	NN	O	21	PMOD
23	.	.	O	.	O	5	P

1	Significantly	Significantly	B-NP	RB	O	2	AMOD
2	more	more	I-NP	JJR	O	4	NMOD
3	weight	weight	I-NP	NN	O	4	NMOD
4	gain	gain	I-NP	NN	O	5	SUB
5	occurred	occur	B-VP	VBD	O	23	VMOD
6	with	with	B-PP	IN	O	5	VMOD
7	olanzapine	olanzapine	B-NP	NN	O	6	PMOD
8	than	than	B-PP	IN	O	5	VMOD
9	with	with	B-PP	IN	O	8	PMOD
10	risperidone	risperidone	B-NP	NN	O	9	PMOD
11	:	:	O	:	O	5	P
12	the	the	B-NP	DT	O	13	NMOD
13	increase	increase	I-NP	NN	O	23	SUB
14	in	in	B-PP	IN	O	13	NMOD
15	weight	weight	B-NP	NN	O	14	PMOD
16	at	at	B-PP	IN	O	13	NMOD
17	4	4	B-NP	CD	O	18	NMOD
18	months	month	I-NP	NNS	O	16	PMOD
19	relative	relative	B-ADJP	JJ	O	13	NMOD
20	to	to	B-PP	TO	O	19	AMOD
21	baseline	baseline	B-NP	NN	O	22	NMOD
22	weight	weight	I-NP	NN	O	20	PMOD
23	was	be	B-VP	VBD	O	0	ROOT
24	17.3	17.3	B-NP	CD	O	25	NMOD
25	%	%	I-NP	NN	O	23	PRD
26	(	(	O	(	O	33	DEP
27	95	95	B-NP	CD	O	32	NMOD
28	%	%	I-NP	NN	O	32	NMOD
29	CI=14.2	CI=14.2	I-NP	NN	O	32	NMOD
30	%	%	I-NP	NN	O	32	NMOD
31	-20.5	-20.5	B-NP	CD	O	32	NMOD
32	%	%	I-NP	NN	O	33	DEP
33	)	)	O	)	O	25	NMOD
34	with	with	B-PP	IN	O	25	NMOD
35	olanzapine	olanzapine	B-NP	NN	O	38	NMOD
36	and	and	O	CC	O	38	NMOD
37	11.3	11.3	B-NP	CD	O	38	NMOD
38	%	%	I-NP	NN	O	34	PMOD
39	(	(	O	(	O	46	DEP
40	95	95	B-NP	CD	O	45	NMOD
41	%	%	I-NP	NN	O	45	NMOD
42	CI=8.4	CI=8.4	I-NP	NN	O	45	NMOD
43	%	%	I-NP	NN	O	45	NMOD
44	-14.3	-14.3	B-NP	CD	O	45	NMOD
45	%	%	I-NP	NN	O	46	DEP
46	)	)	O	)	O	38	NMOD
47	with	with	B-PP	IN	O	38	NMOD
48	risperidone	risperidone	B-NP	NN	O	47	PMOD
49	.	.	O	.	O	23	P

1	Early	Early	B-NP	RB	O	2	AMOD
2	paracentral	paracentral	I-NP	JJ	O	5	NMOD
3	visual	visual	I-NP	JJ	O	5	NMOD
4	field	field	I-NP	NN	O	5	NMOD
5	loss	loss	I-NP	NN	O	0	ROOT
6	in	in	B-PP	IN	O	5	NMOD
7	patients	patient	B-NP	NNS	O	6	PMOD
8	taking	take	B-VP	VBG	O	7	NMOD
9	hydroxychloroquine	hydroxychloroquine	B-NP	NN	O	8	OBJ
10	.	.	O	.	O	5	P

1	Thirty-five	Thirty-five	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	7	SUB
3	(	(	O	(	O	6	DEP
4	13.4	13.4	B-NP	CD	O	5	NMOD
5	%	%	I-NP	NN	O	6	DEP
6	)	)	O	)	O	2	NMOD
7	had	have	B-VP	VBD	O	0	ROOT
8	visual	visual	B-NP	JJ	O	10	NMOD
9	field	field	I-NP	NN	O	10	NMOD
10	abnormalities	abnormality	I-NP	NNS	O	7	OBJ
11	,	,	O	,	O	10	P
12	which	which	B-NP	WDT	O	10	NMOD
13	were	be	B-VP	VBD	O	12	SBAR
14	attributed	attribute	I-VP	VBN	O	13	VC
15	to	to	B-PP	TO	O	14	VMOD
16	hydroxychloroquine	hydroxychloroquine	B-NP	NN	O	17	NMOD
17	treatment	treatment	I-NP	NN	O	15	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	4	4	B-NP	CD	O	20	NMOD
20	patients	patient	I-NP	NNS	O	18	PMOD
21	(	(	O	(	O	24	DEP
22	1.5	1.5	B-NP	CD	O	23	NMOD
23	%	%	I-NP	NN	O	24	DEP
24	)	)	O	)	O	20	NMOD
25	.	.	O	.	O	7	P

1	Peri-operative	Peri-operative	B-NP	JJ	O	3	NMOD
2	atrioventricular	atrioventricular	I-NP	JJ	O	3	NMOD
3	block	block	I-NP	NN	O	0	ROOT
4	as	as	B-PP	IN	O	3	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	result	result	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	chemotherapy	chemotherapy	B-NP	NN	O	7	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	epirubicin	epirubicin	B-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	paclitaxel	paclitaxel	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	3	P

1	OBJECTIVES	OBJECTIVES	B-NP	NNS	O	4	NMOD
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	risk	risk	I-NP	NN	O	15	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	acute	acute	B-NP	JJ	O	8	NMOD
7	myocardial	myocardial	I-NP	JJ	O	8	NMOD
8	infarction	infarction	I-NP	NN	O	5	PMOD
9	(	(	O	(	O	11	DEP
10	AMI	AMI	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	with	with	B-PP	IN	O	8	NMOD
13	COX-2	COX-2	B-NP	NN	B-protein	14	NMOD
14	inhibitors	inhibitor	I-NP	NNS	O	12	PMOD
15	may	may	B-VP	MD	O	0	ROOT
16	offset	offset	I-VP	VB	O	15	VC
17	their	their	B-NP	PRP$	O	22	NMOD
18	gastrointestinal	gastrointestinal	I-NP	JJ	O	22	NMOD
19	(	(	O	(	O	21	DEP
20	GI	GI	B-NP	NN	O	21	DEP
21	)	)	O	)	O	18	AMOD
22	benefit	benefit	B-NP	NN	O	16	OBJ
23	compared	compare	B-PP	VBN	O	16	VMOD
24	with	with	B-PP	IN	O	23	PMOD
25	non-selective	non-selective	B-NP	JJ	O	24	PMOD
26	(	(	O	(	O	34	DEP
27	NS	NS	B-NP	NN	O	31	NMOD
28	)	)	O	)	O	31	NMOD
29	non-steroidal	non-steroidal	B-NP	JJ	O	31	NMOD
30	anti-inflammatory	anti-inflammatory	I-NP	JJ	O	31	NMOD
31	drugs	drug	I-NP	NNS	O	34	DEP
32	(	(	O	(	O	34	DEP
33	NSAIDs	NSAID	B-NP	NNS	O	34	DEP
34	)	)	O	)	O	25	NMOD
35	.	.	O	.	O	15	P

1	We	We	B-NP	PRP	O	2	SUB
2	aimed	aim	B-VP	VBD	O	0	ROOT
3	to	to	I-VP	TO	O	4	VMOD
4	compare	compare	I-VP	VB	O	2	VMOD
5	the	the	B-NP	DT	O	6	NMOD
6	risks	risk	I-NP	NNS	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	hospitalization	hospitalization	B-NP	NN	O	7	PMOD
9	for	for	B-PP	IN	O	8	NMOD
10	AMI	AMI	B-NP	NN	B-protein	13	NMOD
11	and	and	I-NP	CC	O	13	NMOD
12	GI	GI	I-NP	NN	O	13	NMOD
13	bleeding	bleeding	I-NP	NN	O	9	PMOD
14	among	among	B-PP	IN	O	4	VMOD
15	elderly	elderly	B-NP	JJ	O	16	NMOD
16	patients	patient	I-NP	NNS	O	14	PMOD
17	using	use	B-VP	VBG	O	2	VMOD
18	COX-2	COX-2	B-NP	NN	B-protein	19	NMOD
19	inhibitors	inhibitor	I-NP	NNS	O	23	NMOD
20	,	,	O	,	O	23	P
21	NS-NSAIDs	NS-NSAID	B-NP	NNS	O	23	NMOD
22	and	and	O	CC	O	23	NMOD
23	acetaminophen	acetaminophen	B-NP	NN	O	17	OBJ
24	.	.	O	.	O	2	P

1	Among	Among	B-PP	IN	O	29	VMOD
2	non-users	non-user	B-NP	NNS	O	1	PMOD
3	of	of	B-PP	IN	O	2	NMOD
4	aspirin	aspirin	B-NP	NN	O	3	PMOD
5	,	,	O	,	O	29	P
6	the	the	B-NP	DT	O	9	NMOD
7	adjusted	adjust	I-NP	VBN	O	9	NMOD
8	hazard	hazard	I-NP	NN	O	9	NMOD
9	ratios	ratio	I-NP	NNS	O	29	SUB
10	(	(	O	(	O	15	DEP
11	95	95	B-NP	CD	O	14	NMOD
12	%	%	I-NP	NN	O	14	NMOD
13	confidence	confidence	I-NP	NN	O	14	NMOD
14	interval	interval	I-NP	NN	O	15	DEP
15	)	)	O	)	O	9	NMOD
16	of	of	B-PP	IN	O	9	NMOD
17	hospitalization	hospitalization	B-NP	NN	O	16	PMOD
18	for	for	B-PP	IN	O	9	NMOD
19	AMI/GI	AMI/GI	B-NP	NN	B-protein	18	PMOD
20	vs	vs	B-PP	IN	O	9	NMOD
21	the	the	B-NP	DT	O	22	NMOD
22	acetaminophen	acetaminophen	I-NP	NN	O	28	NMOD
23	(	(	O	(	O	27	DEP
24	with	with	B-PP	IN	O	27	DEP
25	no	no	B-NP	DT	O	26	NMOD
26	aspirin	aspirin	I-NP	NN	O	24	PMOD
27	)	)	O	)	O	22	NMOD
28	group	group	B-NP	NN	O	20	PMOD
29	were	be	B-VP	VBD	O	0	ROOT
30	:	:	O	:	O	29	P
31	rofecoxib	rofecoxib	B-NP	NN	O	63	NMOD
32	1.27	1.27	I-NP	CD	O	31	NMOD
33	(	(	O	(	O	37	DEP
34	1.13	1.13	B-NP	CD	O	36	NMOD
35	,	,	I-NP	,	O	36	P
36	1.42	1.42	I-NP	CD	O	37	DEP
37	)	)	O	)	O	31	NMOD
38	,	,	O	,	O	63	P
39	celecoxib	celecoxib	B-NP	NN	O	63	NMOD
40	0.93	0.93	I-NP	CD	O	39	NMOD
41	(	(	O	(	O	45	DEP
42	0.83	0.83	B-NP	CD	O	44	NMOD
43	,	,	I-NP	,	O	44	P
44	1.03	1.03	I-NP	CD	O	45	DEP
45	)	)	O	)	O	39	NMOD
46	,	,	O	,	O	63	P
47	naproxen	naproxen	B-NP	NN	O	63	NMOD
48	1.59	1.59	I-NP	CD	O	47	NMOD
49	(	(	O	(	O	53	DEP
50	1.31	1.31	B-NP	CD	O	52	NMOD
51	,	,	I-NP	,	O	52	P
52	1.93	1.93	I-NP	CD	O	53	DEP
53	)	)	O	)	O	47	NMOD
54	,	,	O	,	O	63	P
55	diclofenac	diclofenac	B-NP	NN	O	63	NMOD
56	1.17	1.17	I-NP	CD	O	55	NMOD
57	(	(	O	(	O	61	DEP
58	0.99	0.99	B-NP	CD	O	60	NMOD
59	,	,	I-NP	,	O	60	P
60	1.38	1.38	I-NP	CD	O	61	DEP
61	)	)	O	)	O	55	NMOD
62	and	and	O	CC	O	63	NMOD
63	ibuprofen	ibuprofen	B-NP	NN	O	29	VMOD
64	1.05	1.05	I-NP	CD	O	63	NMOD
65	(	(	O	(	O	69	DEP
66	0.74	0.74	B-NP	CD	O	68	NMOD
67	,	,	I-NP	,	O	68	P
68	1.51	1.51	I-NP	CD	O	69	DEP
69	)	)	O	)	O	63	NMOD
70	.	.	O	.	O	29	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	8	NMOD
2	:	:	O	:	O	1	P
3	Among	Among	B-PP	IN	O	1	NMOD
4	non-users	non-user	B-NP	NNS	O	3	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	aspirin	aspirin	B-NP	NN	O	5	PMOD
7	,	,	O	,	O	8	P
8	naproxen	naproxen	B-NP	NN	O	9	SUB
9	seemed	seem	B-VP	VBD	O	0	ROOT
10	to	to	I-VP	TO	O	11	VMOD
11	carry	carry	I-VP	VB	O	9	VMOD
12	the	the	B-NP	DT	O	14	NMOD
13	highest	high	I-NP	JJS	O	14	NMOD
14	risk	risk	I-NP	NN	O	11	OBJ
15	for	for	B-PP	IN	O	14	NMOD
16	AMI/GI	AMI/GI	B-NP	NN	O	17	NMOD
17	bleeding	bleeding	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	3	NMOD
2	AMI/GI	AMI/GI	I-NP	NN	O	3	NMOD
3	toxicity	toxicity	I-NP	NN	O	6	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	celecoxib	celecoxib	B-NP	NN	O	4	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	similar	similar	B-ADJP	JJ	O	6	PRD
8	to	to	B-PP	TO	O	7	AMOD
9	that	that	B-NP	DT	O	8	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	acetaminophen	acetaminophen	B-NP	NN	O	10	PMOD
12	and	and	O	CC	O	6	VMOD
13	seemed	seem	B-VP	VBD	O	6	VMOD
14	to	to	I-VP	TO	O	15	VMOD
15	be	be	I-VP	VB	O	13	VMOD
16	better	good	B-ADJP	JJR	O	15	PRD
17	than	than	B-PP	IN	O	16	AMOD
18	those	those	B-NP	DT	O	17	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	rofecoxib	rofecoxib	B-NP	NN	O	22	NMOD
21	and	and	I-NP	CC	O	22	NMOD
22	NS-NSAIDs	NS-NSAID	I-NP	NNS	O	19	PMOD
23	.	.	O	.	O	6	P

1	Quinine	Quinine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	arrhythmia	arrhythmia	B-NP	NN	O	2	OBJ
4	in	in	B-PP	IN	O	2	VMOD
5	a	a	B-NP	DT	O	6	NMOD
6	patient	patient	I-NP	NN	O	4	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	severe	severe	B-NP	JJ	O	9	NMOD
9	malaria	malaria	I-NP	NN	O	7	PMOD
10	.	.	O	.	O	2	P

1	It	It	B-NP	PRP	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	reported	report	I-VP	VBN	O	2	VC
4	that	that	B-SBAR	IN	O	3	VMOD
5	there	there	B-NP	EX	O	6	SUB
6	was	be	B-VP	VBD	O	4	SBAR
7	a	a	B-NP	DT	O	8	NMOD
8	case	case	I-NP	NN	O	6	PRD
9	of	of	B-PP	IN	O	8	NMOD
10	severe	severe	B-NP	JJ	O	12	NMOD
11	malaria	malaria	I-NP	NN	O	12	NMOD
12	patient	patient	I-NP	NN	O	9	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	jaundice	jaundice	B-NP	NN	O	13	PMOD
15	who	who	B-NP	WP	O	8	NMOD
16	presented	present	B-VP	VBD	O	15	SBAR
17	with	with	B-PP	IN	O	16	VMOD
18	arrhythmia	arrhythmia	B-NP	NN	O	17	PMOD
19	(	(	O	(	O	23	DEP
20	premature	premature	B-NP	JJ	O	22	NMOD
21	ventricular	ventricular	I-NP	JJ	O	22	NMOD
22	contraction	contraction	I-NP	NN	O	23	DEP
23	)	)	O	)	O	18	NMOD
24	while	while	B-SBAR	IN	O	16	VMOD
25	getting	get	B-VP	VBG	O	28	SUB
26	quinine	quinine	B-NP	NN	O	27	NMOD
27	infusion	infusion	I-NP	NN	O	25	OBJ
28	was	be	B-VP	VBD	O	24	SBAR
29	reported	report	I-VP	VBN	O	28	VC
30	.	.	O	.	O	2	P

1	On	On	B-PP	IN	O	6	VMOD
2	admission	admission	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	6	P
4	laboratory	laboratory	B-NP	NN	O	5	NMOD
5	examination	examination	I-NP	NN	O	6	SUB
6	showed	show	B-VP	VBD	O	32	VMOD
7	Plasmodium	Plasmodium	B-NP	NN	O	8	NMOD
8	falciparum	falciparum	I-NP	NN	O	16	NMOD
9	(	(	O	(	O	11	DEP
10	++++	++++	B-NP	SYM	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	,	,	O	,	O	16	P
13	total	total	B-NP	JJ	O	16	NMOD
14	bilirubin	bilirubin	I-NP	NN	O	16	NMOD
15	8.25	8.25	I-NP	CD	O	16	NMOD
16	mg/dL	mg/dL	I-NP	NN	O	6	OBJ
17	,	,	O	,	O	6	P
18	conjugated	conjugate	B-VP	VBD	O	6	VMOD
19	bilirubin	bilirubin	B-NP	NN	O	21	NMOD
20	4.36	4.36	I-NP	CD	O	21	NMOD
21	mg/dL	mg/dL	I-NP	NN	O	18	OBJ
22	,	,	O	,	O	6	P
23	unconjugated	unconjugated	B-NP	JJ	O	26	NMOD
24	bilirubin	bilirubin	I-NP	NN	O	26	NMOD
25	3.89	3.89	I-NP	CD	O	26	NMOD
26	mg/dL	mg/dL	I-NP	NN	O	31	NMOD
27	,	,	O	,	O	31	P
28	potassium	potassium	B-NP	NN	O	31	NMOD
29	3.52	3.52	I-NP	CD	O	31	NMOD
30	meq/L	meq/L	I-NP	NN	O	31	NMOD
31	Patient	Patient	I-NP	NN	O	32	SUB
32	was	be	B-VP	VBD	O	0	ROOT
33	diagnosed	diagnose	I-VP	VBN	O	32	VC
34	as	as	B-PP	IN	O	33	VMOD
35	severe	severe	B-NP	JJ	O	36	NMOD
36	malaria	malaria	I-NP	NN	O	34	PMOD
37	with	with	B-PP	IN	O	36	NMOD
38	jaundice	jaundice	B-NP	NN	O	37	PMOD
39	and	and	O	CC	O	32	VMOD
40	got	get	B-VP	VBD	O	32	VMOD
41	quinine	quinine	B-NP	NN	O	42	NMOD
42	infusion	infusion	I-NP	NN	O	40	OBJ
43	in	in	B-PP	IN	O	42	NMOD
44	dextrose	dextrose	B-NP	NN	O	46	AMOD
45	5	5	B-NP	CD	O	46	AMOD
46	%	%	I-NP	NN	O	49	NMOD
47	500	500	B-NP	CD	O	49	NMOD
48	mg/8	mg/8	I-NP	NN	O	49	NMOD
49	hour	hour	I-NP	NN	O	43	PMOD
50	.	.	O	.	O	32	P

1	After	After	B-PP	IN	O	9	VMOD
2	30	30	B-NP	CD	O	3	NMOD
3	hours	hour	I-NP	NNS	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	quinine	quinine	B-NP	NN	O	6	NMOD
6	infusion	infusion	I-NP	NN	O	4	PMOD
7	the	the	B-NP	DT	O	8	NMOD
8	patient	patient	I-NP	NN	O	9	SUB
9	felt	feel	B-VP	VBD	O	0	ROOT
10	palpitation	palpitation	B-NP	NN	O	12	NMOD
11	and	and	O	CC	O	12	NMOD
12	electrocardiography	electrocardiography	B-NP	NN	O	16	NMOD
13	(	(	O	(	O	15	DEP
14	ECG	ECG	B-NP	NN	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	recording	recording	B-NP	NN	O	17	SUB
17	showed	show	B-VP	VBD	O	9	VMOD
18	premature	premature	B-NP	JJ	O	20	NMOD
19	ventricular	ventricular	I-NP	JJ	O	20	NMOD
20	contraction	contraction	I-NP	NN	O	38	NMOD
21	(	(	O	(	O	23	DEP
22	PVC	PVC	B-NP	NN	O	23	DEP
23	)	)	O	)	O	20	NMOD
24	>	>	O	SYM	O	26	NMOD
25	5	5	B-NP	CD	O	26	NMOD
26	x/minute	x/minute	I-NP	NN	O	31	NMOD
27	,	,	O	,	O	31	P
28	trigemini	trigemini	B-NP	NN	O	31	NMOD
29	,	,	O	,	O	31	P
30	constant	constant	B-NP	JJ	O	31	NMOD
31	type	type	I-NP	NN	O	38	NMOD
32	--	--	O	:	O	38	P
33	sinoatrial	sinoatrial	B-NP	JJ	O	34	NMOD
34	block	block	I-NP	NN	O	38	NMOD
35	,	,	O	,	O	38	P
36	positive	positive	B-NP	JJ	O	38	NMOD
37	U	U	I-NP	NN	O	38	NMOD
38	wave	wave	I-NP	NN	O	17	OBJ
39	.	.	O	.	O	9	P

1	Three	Three	B-NP	CD	O	2	NMOD
2	hours	hour	I-NP	NNS	O	5	NMOD
3	later	later	B-ADVP	RB	O	5	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	patient	patient	I-NP	NN	O	6	SUB
6	felt	feel	B-VP	VBD	O	30	VMOD
7	better	well	B-ADVP	RBR	O	6	VMOD
8	,	,	O	,	O	6	P
9	the	the	B-NP	DT	O	10	NMOD
10	frequency	frequency	I-NP	NN	O	13	SUB
11	of	of	B-PP	IN	O	10	NMOD
12	PVC	PVC	B-NP	NN	B-protein	11	PMOD
13	reduced	reduce	B-VP	VBD	O	30	VMOD
14	to	to	B-PP	TO	O	13	VMOD
15	4	4	B-NP	CD	O	17	AMOD
16	-	-	I-NP	HYPH	O	17	P
17	5	5	I-NP	CD	O	18	NMOD
18	x/minute	x/minute	I-NP	NN	O	14	PMOD
19	and	and	B-PP	CC	O	13	VMOD
20	on	on	B-PP	IN	O	13	VMOD
21	the	the	B-NP	DT	O	24	NMOD
22	third	third	I-NP	JJ	O	24	NMOD
23	day	day	I-NP	NN	O	24	NMOD
24	ECG	ECG	I-NP	NN	O	25	SUB
25	was	be	B-VP	VBD	O	20	SBAR
26	normal	normal	B-ADJP	JJ	O	25	PRD
27	,	,	O	,	O	30	P
28	potassium	potassium	B-NP	NN	O	29	NMOD
29	level	level	I-NP	NN	O	30	SUB
30	was	be	B-VP	VBD	O	0	ROOT
31	3.34	3.34	B-NP	CD	O	32	NMOD
32	meq/L	meq/L	I-NP	NN	O	30	PRD
33	.	.	O	.	O	30	P

1	Quinine	Quinine	B-NP	NN	O	6	SUB
2	,	,	O	,	O	1	P
3	like	like	B-PP	IN	O	6	VMOD
4	quinidine	quinidine	B-NP	NN	O	3	PMOD
5	,	,	O	,	O	6	P
6	is	be	B-VP	VBZ	O	0	ROOT
7	a	a	B-NP	DT	O	9	NMOD
8	chincona	chincona	I-NP	NN	O	9	NMOD
9	alkaloid	alkaloid	I-NP	NN	O	6	PRD
10	that	that	B-NP	WDT	O	9	NMOD
11	has	have	B-VP	VBZ	O	10	SBAR
12	anti-arrhythmic	anti-arrhythmic	B-NP	JJ	O	13	NMOD
13	property	property	I-NP	NN	O	11	OBJ
14	,	,	O	,	O	6	P
15	although	although	B-SBAR	IN	O	6	VMOD
16	it	it	B-NP	PRP	O	18	SUB
17	also	also	B-ADVP	RB	O	18	VMOD
18	pro-arrhythmic	pro-arrhythmic	B-ADJP	JJ	O	15	SBAR
19	that	that	B-NP	WDT	O	18	NMOD
20	can	can	B-VP	MD	O	19	SBAR
21	cause	cause	I-VP	VB	O	20	VC
22	various	various	B-NP	JJ	O	23	NMOD
23	arrhythmias	arrhythmia	I-NP	NNS	O	21	OBJ
24	,	,	O	,	O	23	P
25	including	include	B-PP	VBG	O	23	NMOD
26	severe	severe	B-NP	JJ	O	27	NMOD
27	arrhythmia	arrhythmia	I-NP	NN	O	25	PMOD
28	such	such	B-PP	JJ	O	29	PMOD
29	as	as	I-PP	IN	O	27	NMOD
30	multiple	multiple	B-NP	JJ	O	31	NMOD
31	PVC	PVC	I-NP	NN	O	29	PMOD
32	.	.	O	.	O	6	P

1	Penicillamine-related	Penicillamine-related	B-NP	JJ	O	3	NMOD
2	lichenoid	lichenoid	I-NP	NN	O	3	NMOD
3	dermatitis	dermatitis	I-NP	NN	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	utility	utility	I-NP	NN	O	21	NMOD
6	of	of	B-PP	IN	O	5	NMOD
7	zinc	zinc	B-NP	NN	O	8	NMOD
8	acetate	acetate	I-NP	NN	O	6	PMOD
9	in	in	B-PP	IN	O	5	NMOD
10	a	a	B-NP	DT	O	13	NMOD
11	Wilson	Wilson	I-NP	NNP	O	13	NMOD
12	disease	disease	I-NP	NN	O	13	NMOD
13	patient	patient	I-NP	NN	O	9	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	hepatic	hepatic	B-NP	JJ	O	16	NMOD
16	presentation	presentation	I-NP	NN	O	14	PMOD
17	,	,	O	,	O	21	P
18	anxiety	anxiety	B-NP	NN	O	21	NMOD
19	and	and	I-NP	CC	O	21	NMOD
20	SPECT	SPECT	I-NP	NN	O	21	NMOD
21	abnormalities	abnormality	I-NP	NNS	O	0	ROOT
22	.	.	O	.	O	21	P

1	Wilson	Wilson	B-NP	NNP	O	2	NMOD
2	's	's	B-NP	POS	O	3	NMOD
3	disease	disease	I-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	an	an	B-NP	DT	O	8	NMOD
6	autosomal	autosomal	I-NP	JJ	O	8	NMOD
7	recessive	recessive	I-NP	JJ	O	8	NMOD
8	disorder	disorder	I-NP	NN	O	4	PRD
9	of	of	B-PP	IN	O	8	NMOD
10	hepatic	hepatic	B-NP	JJ	O	12	NMOD
11	copper	copper	I-NP	NN	O	12	NMOD
12	metabolism	metabolism	I-NP	NN	O	9	PMOD
13	with	with	B-PP	IN	O	8	NMOD
14	consequent	consequent	B-NP	JJ	O	16	NMOD
15	copper	copper	I-NP	NN	O	16	NMOD
16	accumulation	accumulation	I-NP	NN	O	18	NMOD
17	and	and	I-NP	CC	O	18	NMOD
18	toxicity	toxicity	I-NP	NN	O	13	PMOD
19	in	in	B-PP	IN	O	4	VMOD
20	many	many	B-NP	JJ	O	21	NMOD
21	tissues	tissue	I-NP	NNS	O	29	NMOD
22	and	and	O	CC	O	29	NMOD
23	consequent	consequent	B-NP	JJ	O	24	NMOD
24	hepatic	hepatic	I-NP	JJ	O	29	NMOD
25	,	,	I-NP	,	O	29	P
26	neurologic	neurologic	I-NP	JJ	O	29	NMOD
27	and	and	I-NP	CC	O	29	NMOD
28	psychiatric	psychiatric	I-NP	JJ	O	29	NMOD
29	disorders	disorder	I-NP	NNS	O	19	PMOD
30	.	.	O	.	O	4	P

1	During	During	B-PP	IN	O	9	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	follow-up	follow-up	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	our	our	B-NP	PRP$	O	6	NMOD
6	patient	patient	I-NP	NN	O	4	PMOD
7	,	,	O	,	O	9	P
8	penicillamine	penicillamine	B-NP	NN	O	9	SUB
9	was	be	B-VP	VBD	O	22	VMOD
10	interrupted	interrupt	I-VP	VBN	O	9	VC
11	after	after	B-PP	IN	O	10	VMOD
12	the	the	B-NP	DT	O	13	NMOD
13	appearance	appearance	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	a	a	B-NP	DT	O	17	NMOD
16	lichenoid	lichenoid	I-NP	JJ	O	17	NMOD
17	dermatitis	dermatitis	I-NP	NN	O	14	PMOD
18	,	,	O	,	O	22	P
19	and	and	O	CC	O	22	VMOD
20	zinc	zinc	B-NP	NN	O	21	NMOD
21	acetate	acetate	I-NP	NN	O	22	SUB
22	permitted	permit	B-VP	VBD	O	0	ROOT
23	to	to	I-VP	TO	O	24	VMOD
24	continue	continue	I-VP	VB	O	22	VMOD
25	the	the	B-NP	DT	O	27	NMOD
26	successful	successful	I-NP	JJ	O	27	NMOD
27	treatment	treatment	I-NP	NN	O	24	OBJ
28	of	of	B-PP	IN	O	27	NMOD
29	the	the	B-NP	DT	O	30	NMOD
30	patient	patient	I-NP	NN	O	28	PMOD
31	without	without	B-PP	IN	O	27	NMOD
32	side-effects	side-effect	B-NP	NNS	O	31	PMOD
33	.	.	O	.	O	22	P

1	In	In	B-PP	IN	O	9	VMOD
2	our	our	B-NP	PRP$	O	3	NMOD
3	case	case	I-NP	NN	O	1	PMOD
4	the	the	B-NP	DT	O	5	NMOD
5	therapy	therapy	I-NP	NN	O	9	SUB
6	with	with	B-PP	IN	O	5	NMOD
7	zinc	zinc	B-NP	NN	O	8	NMOD
8	acetate	acetate	I-NP	NN	O	6	PMOD
9	represented	represent	B-VP	VBD	O	0	ROOT
10	an	an	B-NP	DT	O	12	NMOD
11	effective	effective	I-NP	JJ	O	12	NMOD
12	treatment	treatment	I-NP	NN	O	9	OBJ
13	for	for	B-PP	IN	O	12	NMOD
14	a	a	B-NP	DT	O	18	NMOD
15	Wilson	Wilson	I-NP	NNP	O	16	NMOD
16	's	's	B-NP	POS	O	18	NMOD
17	disease	disease	I-NP	NN	O	18	NMOD
18	patient	patient	I-NP	NN	O	13	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	which	which	B-NP	WDT	O	19	PMOD
21	penicillamine-related	penicillamine-related	B-NP	JJ	O	23	NMOD
22	side	side	I-NP	NN	O	23	NMOD
23	effects	effect	I-NP	NNS	O	24	SUB
24	appeared	appear	B-VP	VBD	O	19	SBAR
25	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	2	NMOD
2	safety	safety	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	zinc	zinc	I-NP	NN	O	6	NMOD
6	acetate	acetate	I-NP	NN	O	3	PMOD
7	allowed	allow	B-VP	VBD	O	0	ROOT
8	us	us	B-NP	PRP	O	10	SUB
9	to	to	B-VP	TO	O	10	VMOD
10	avoid	avoid	I-VP	VB	O	7	VMOD
11	other	other	B-NP	JJ	O	15	NMOD
12	potentially	potentially	I-NP	RB	O	15	NMOD
13	toxic	toxic	I-NP	JJ	O	15	NMOD
14	chelating	chelate	I-NP	VBG	O	15	NMOD
15	drugs	drug	I-NP	NNS	O	10	OBJ
16	;	;	O	:	O	19	P
17	this	this	B-NP	DT	O	18	NMOD
18	observation	observation	I-NP	NN	O	19	SUB
19	is	be	B-VP	VBZ	O	7	VMOD
20	in	in	B-PP	IN	O	19	PRD
21	line	line	B-NP	NN	O	20	PMOD
22	with	with	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	25	NMOD
24	growing	grow	I-NP	VBG	O	25	NMOD
25	evidence	evidence	I-NP	NN	O	22	PMOD
26	on	on	B-PP	IN	O	25	NMOD
27	the	the	B-NP	DT	O	28	NMOD
28	efficacy	efficacy	I-NP	NN	O	26	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	the	the	B-NP	DT	O	31	NMOD
31	drug	drug	I-NP	NN	O	29	PMOD
32	in	in	B-PP	IN	O	28	NMOD
33	the	the	B-NP	DT	O	34	NMOD
34	treatment	treatment	I-NP	NN	O	32	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	Wilson	Wilson	B-NP	NNP	O	38	NMOD
37	's	's	B-NP	POS	O	38	NMOD
38	disease	disease	I-NP	NN	O	35	PMOD
39	.	.	O	.	O	7	P

1	Since	Since	B-SBAR	IN	O	19	VMOD
2	most	most	B-NP	JJS	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	Wilson	Wilson	B-NP	NNP	O	5	NMOD
5	's	's	B-NP	POS	O	8	NMOD
6	disease	disease	I-NP	NN	O	8	NMOD
7	penicillamine-treated	penicillamine-treated	B-NP	JJ	O	8	NMOD
8	patients	patient	I-NP	NNS	O	3	PMOD
9	do	do	B-VP	VBP	O	1	SBAR
10	not	not	I-VP	RB	O	9	VMOD
11	seem	seem	I-VP	VB	O	9	VC
12	to	to	I-VP	TO	O	13	VMOD
13	develop	develop	I-VP	VB	O	11	VMOD
14	this	this	B-NP	DT	O	16	NMOD
15	skin	skin	I-NP	NN	O	16	NMOD
16	lesion	lesion	I-NP	NN	O	13	OBJ
17	,	,	O	,	O	19	P
18	it	it	B-NP	PRP	O	19	SUB
19	could	could	B-VP	MD	O	0	ROOT
20	be	be	I-VP	VB	O	19	VC
21	conceivable	conceivable	B-ADJP	JJ	O	20	PRD
22	that	that	B-SBAR	IN	O	20	VMOD
23	a	a	B-NP	DT	O	26	NMOD
24	specific	specific	I-NP	JJ	O	26	NMOD
25	genetic	genetic	I-NP	JJ	O	26	NMOD
26	factor	factor	I-NP	NN	O	27	SUB
27	is	be	B-VP	VBZ	O	22	SBAR
28	involved	involve	I-VP	VBN	O	27	VC
29	in	in	B-PP	IN	O	28	VMOD
30	drug	drug	B-NP	NN	O	31	NMOD
31	response	response	I-NP	NN	O	29	PMOD
32	.	.	O	.	O	19	P

1	A	A	B-NP	DT	O	3	NMOD
2	dramatic	dramatic	I-NP	JJ	O	3	NMOD
3	drop	drop	I-NP	NN	O	0	ROOT
4	in	in	B-PP	IN	O	3	NMOD
5	blood	blood	B-NP	NN	O	6	NMOD
6	pressure	pressure	I-NP	NN	O	4	PMOD
7	following	follow	B-PP	VBG	O	3	NMOD
8	prehospital	prehospital	B-NP	NN	O	10	NMOD
9	GTN	GTN	I-NP	NN	O	10	NMOD
10	administration	administration	I-NP	NN	O	7	PMOD
11	.	.	O	.	O	3	P

1	Several	Several	B-NP	JJ	O	2	NMOD
2	minutes	minute	I-NP	NNS	O	3	PMOD
3	after	after	B-PP	IN	O	8	VMOD
4	the	the	B-NP	DT	O	5	NMOD
5	GTN	GTN	I-NP	NN	O	3	PMOD
6	the	the	B-NP	DT	O	7	NMOD
7	patient	patient	I-NP	NN	O	8	SUB
8	experienced	experience	B-VP	VBD	O	0	ROOT
9	a	a	B-NP	DT	O	11	NMOD
10	sudden	sudden	I-NP	JJ	O	11	NMOD
11	drop	drop	I-NP	NN	O	8	OBJ
12	in	in	B-PP	IN	O	8	VMOD
13	blood	blood	B-NP	NN	O	14	NMOD
14	pressure	pressure	I-NP	NN	O	17	NMOD
15	and	and	I-NP	CC	O	17	NMOD
16	heart	heart	I-NP	NN	O	17	NMOD
17	rate	rate	I-NP	NN	O	12	PMOD
18	,	,	O	,	O	8	P
19	this	this	B-NP	DT	O	8	VMOD
20	was	be	B-VP	VBD	O	8	VMOD
21	rectified	rectify	I-VP	VBN	O	20	VC
22	by	by	B-PP	IN	O	21	VMOD
23	atropine	atropine	B-NP	NN	O	24	NMOD
24	sulphate	sulphate	I-NP	NN	O	28	NMOD
25	and	and	O	CC	O	28	NMOD
26	a	a	B-NP	DT	O	28	NMOD
27	fluid	fluid	I-NP	NN	O	28	NMOD
28	challenge	challenge	I-NP	NN	O	22	PMOD
29	.	.	O	.	O	8	P

1	Acute	Acute	B-NP	JJ	O	2	NMOD
2	encephalopathy	encephalopathy	I-NP	NN	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	cerebral	cerebral	B-NP	JJ	O	5	NMOD
5	vasospasm	vasospasm	I-NP	NN	O	0	ROOT
6	after	after	B-PP	IN	O	5	NMOD
7	multiagent	multiagent	B-NP	JJ	O	8	NMOD
8	chemotherapy	chemotherapy	I-NP	NN	O	6	PMOD
9	including	include	B-PP	VBG	O	8	NMOD
10	PEG-asparaginase	PEG-asparaginase	B-NP	NN	B-protein	13	NMOD
11	and	and	O	CC	O	13	NMOD
12	intrathecal	intrathecal	B-NP	JJ	O	13	NMOD
13	cytarabine	cytarabine	I-NP	NN	O	9	PMOD
14	for	for	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	treatment	treatment	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	acute	acute	B-NP	JJ	O	20	NMOD
19	lymphoblastic	lymphoblastic	I-NP	JJ	O	20	NMOD
20	leukemia	leukemia	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	3	SUB
3	developed	develop	B-VP	VBD	O	0	ROOT
4	acute	acute	B-NP	JJ	O	5	NMOD
5	encephalopathy	encephalopathy	I-NP	NN	O	3	OBJ
6	evidenced	evidence	B-VP	VBN	O	5	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	behavioral	behavioral	B-NP	JJ	O	9	NMOD
9	changes	change	I-NP	NNS	O	20	NMOD
10	,	,	O	,	O	20	P
11	aphasia	aphasia	B-NP	NN	O	20	NMOD
12	,	,	O	,	O	20	P
13	incontinence	incontinence	B-NP	NN	O	20	NMOD
14	,	,	O	,	O	20	P
15	visual	visual	B-NP	JJ	O	16	NMOD
16	hallucinations	hallucination	I-NP	NNS	O	20	NMOD
17	,	,	O	,	O	20	P
18	and	and	O	CC	O	20	NMOD
19	right-sided	right-sided	B-NP	JJ	O	20	NMOD
20	weakness	weakness	I-NP	NN	O	7	PMOD
21	with	with	B-PP	IN	O	20	NMOD
22	diffuse	diffuse	B-NP	JJ	O	23	AMOD
23	cerebral	cerebral	I-NP	JJ	O	24	NMOD
24	vasospasm	vasospasm	I-NP	NN	O	21	PMOD
25	on	on	B-PP	IN	O	20	NMOD
26	magnetic	magnetic	B-NP	JJ	O	28	NMOD
27	resonance	resonance	I-NP	NN	O	28	NMOD
28	angiography	angiography	I-NP	NN	O	25	PMOD
29	after	after	B-SBAR	IN	O	28	NMOD
30	the	the	B-NP	DT	O	31	NMOD
31	administration	administration	I-NP	NN	O	29	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	intrathecal	intrathecal	B-NP	JJ	O	34	NMOD
34	cytarabine	cytarabine	I-NP	NN	O	32	PMOD
35	.	.	O	.	O	3	P

1	Comparison	Comparison	B-NP	NN	O	19	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	valsartan/hydrochlorothiazide	valsartan/hydrochlorothiazide	B-NP	NN	O	5	NMOD
4	combination	combination	I-NP	NN	O	5	NMOD
5	therapy	therapy	I-NP	NN	O	2	PMOD
6	at	at	B-PP	IN	O	1	NMOD
7	doses	dose	B-NP	NNS	O	11	NMOD
8	up	up	B-NP	RB	O	11	NMOD
9	to	to	I-NP	TO	O	8	AMOD
10	320/25	320/25	I-NP	CD	O	8	AMOD
11	mg	mg	I-NP	NN	O	6	PMOD
12	versus	versus	B-PP	IN	O	11	NMOD
13	monotherapy	monotherapy	B-NP	NN	O	12	PMOD
14	:	:	O	:	O	1	P
15	a	a	B-NP	DT	O	19	NMOD
16	double-blind	double-blind	I-NP	JJ	O	18	AMOD
17	,	,	I-NP	,	O	18	P
18	placebo-controlled	placebo-controlled	I-NP	JJ	O	19	NMOD
19	study	study	I-NP	NN	O	0	ROOT
20	followed	follow	B-VP	VBN	O	19	NMOD
21	by	by	B-PP	IN	O	20	VMOD
22	long-term	long-term	B-NP	JJ	O	24	NMOD
23	combination	combination	I-NP	NN	O	24	NMOD
24	therapy	therapy	I-NP	NN	O	21	PMOD
25	in	in	B-PP	IN	O	24	NMOD
26	hypertensive	hypertensive	B-NP	JJ	O	27	NMOD
27	adults	adult	I-NP	NNS	O	25	PMOD
28	.	.	O	.	O	19	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	5	VMOD
2	:	:	O	:	O	5	P
3	This	This	B-NP	DT	O	4	NMOD
4	study	study	I-NP	NN	O	5	SUB
5	investigated	investigate	B-VP	VBD	O	0	ROOT
6	the	the	B-NP	DT	O	9	NMOD
7	efficacy	efficacy	I-NP	NN	O	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	tolerability	tolerability	I-NP	NN	O	5	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	valsartan	valsartan	B-NP	NN	O	16	NMOD
12	(	(	O	(	O	14	DEP
13	VAL	VAL	B-NP	NN	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	or	or	O	CC	O	16	NMOD
16	hydrochlorothiazide	hydrochlorothiazide	B-NP	NN	O	20	NMOD
17	(	(	O	(	O	19	DEP
18	HCTZ	HCTZ	B-NP	NN	B-protein	19	DEP
19	)	)	O	)	O	16	NMOD
20	-monotherapy	-monotherapy	B-NP	NN	O	23	NMOD
21	and	and	O	CC	O	23	NMOD
22	higher-dose	higher-dose	B-NP	JJ	O	23	NMOD
23	combinations	combination	I-NP	NNS	O	10	PMOD
24	in	in	B-PP	IN	O	23	NMOD
25	patients	patient	B-NP	NNS	O	24	PMOD
26	with	with	B-PP	IN	O	25	NMOD
27	essential	essential	B-NP	JJ	O	28	NMOD
28	hypertension	hypertension	I-NP	NN	O	26	PMOD
29	.	.	O	.	O	5	P

1	Patients	Patient	B-NP	NNS	O	25	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	essential	essential	B-NP	JJ	O	4	NMOD
4	hypertension	hypertension	I-NP	NN	O	2	PMOD
5	(	(	O	(	O	24	DEP
6	mean	mean	B-NP	NN	O	23	NMOD
7	sitting	sit	B-VP	VBG	O	6	NMOD
8	diastolic	diastolic	B-NP	JJ	O	9	NMOD
9	BP	BP	I-NP	NN	O	7	OBJ
10	[	[	O	(	O	12	DEP
11	MSDBP	MSDBP	B-NP	NN	B-protein	12	DEP
12	]	]	O	)	O	9	NMOD
13	,	,	O	,	O	23	P
14	>	>	B-NP	JJR	O	16	AMOD
15	or	or	I-NP	CC	O	16	AMOD
16	=95	=95	I-NP	CD	O	18	NMOD
17	mm	mm	I-NP	NN	O	18	NMOD
18	Hg	Hg	I-NP	NN	O	23	NMOD
19	and	and	O	CC	O	23	NMOD
20	<	<	B-NP	SYM	O	23	NMOD
21	110	110	I-NP	CD	O	23	NMOD
22	mm	mm	I-NP	NN	O	23	NMOD
23	Hg	Hg	I-NP	NN	O	24	DEP
24	)	)	O	)	O	4	NMOD
25	were	be	B-VP	VBD	O	0	ROOT
26	randomized	randomize	I-VP	VBN	O	25	VC
27	to	to	B-PP	TO	O	26	VMOD
28	1	1	B-NP	CD	O	29	AMOD
29	of	of	B-PP	IN	O	27	PMOD
30	8	8	B-NP	CD	O	32	NMOD
31	treatment	treatment	I-NP	NN	O	32	NMOD
32	groups	group	I-NP	NNS	O	29	PMOD
33	:	:	O	:	O	25	P
34	VAL	VAL	B-NP	NN	O	38	NMOD
35	160	160	B-NP	CD	O	37	AMOD
36	or	or	I-NP	CC	O	37	AMOD
37	320	320	I-NP	CD	O	38	NMOD
38	mg	mg	I-NP	NN	O	56	NMOD
39	;	;	O	:	O	56	P
40	HCTZ	HCTZ	B-NP	NN	B-cell_line	44	NMOD
41	12.5	12.5	I-NP	CD	I-cell_line	43	AMOD
42	or	or	I-NP	CC	O	43	AMOD
43	25	25	I-NP	CD	O	44	NMOD
44	mg	mg	I-NP	NN	O	56	NMOD
45	;	;	O	:	O	56	P
46	VAL/HCTZ	VAL/HCTZ	B-NP	NN	O	53	NMOD
47	160/12.5	160/12.5	I-NP	CD	O	53	NMOD
48	,	,	I-NP	,	O	53	P
49	320/12.5	320/12.5	I-NP	CD	O	53	NMOD
50	,	,	O	,	O	53	P
51	or	or	O	CC	O	53	NMOD
52	320/25	320/25	B-NP	CD	O	53	NMOD
53	mg	mg	I-NP	NN	O	56	NMOD
54	;	;	O	:	O	56	P
55	or	or	O	CC	O	56	NMOD
56	placebo	placebo	B-NP	NN	O	25	VMOD
57	.	.	O	.	O	25	P

1	The	The	B-NP	DT	O	2	NMOD
2	incidence	incidence	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	hypokalemia	hypokalemia	B-NP	NN	O	3	PMOD
5	was	be	B-VP	VBD	O	0	ROOT
6	lower	low	B-ADJP	JJR	O	5	PRD
7	with	with	B-PP	IN	O	6	AMOD
8	VAL/HCTZ	VAL/HCTZ	B-NP	NN	O	9	NMOD
9	combinations	combination	I-NP	NNS	O	7	PMOD
10	(	(	O	(	O	15	DEP
11	1.8	1.8	B-NP	CD	O	14	NMOD
12	%	%	I-NP	NN	O	14	NMOD
13	-6.1	-6.1	B-NP	CD	O	14	NMOD
14	%	%	I-NP	NN	O	15	DEP
15	)	)	O	)	O	5	VMOD
16	than	than	B-PP	IN	O	5	VMOD
17	with	with	B-PP	IN	O	16	PMOD
18	HCTZ	HCTZ	B-NP	NN	O	19	NMOD
19	monotherapies	monotherapy	I-NP	NNS	O	17	PMOD
20	(	(	O	(	O	25	DEP
21	7.1	7.1	B-NP	CD	O	24	NMOD
22	%	%	I-NP	NN	O	24	NMOD
23	-13.3	-13.3	B-NP	CD	O	24	NMOD
24	%	%	I-NP	NN	O	25	DEP
25	)	)	O	)	O	19	NMOD
26	.	.	O	.	O	5	P

1	Succimer	Succimer	B-NP	NN	O	2	NMOD
2	chelation	chelation	I-NP	NN	O	3	SUB
3	improves	improve	B-VP	VBZ	O	0	ROOT
4	learning	learning	B-NP	NN	O	10	NMOD
5	,	,	O	,	O	10	P
6	attention	attention	B-NP	NN	O	10	NMOD
7	,	,	O	,	O	10	P
8	and	and	O	CC	O	10	NMOD
9	arousal	arousal	B-NP	JJ	O	10	NMOD
10	regulation	regulation	I-NP	NN	O	3	OBJ
11	in	in	B-PP	IN	O	10	NMOD
12	lead-exposed	lead-exposed	B-NP	JJ	O	13	NMOD
13	rats	rat	I-NP	NNS	O	11	PMOD
14	but	but	O	CC	O	3	VMOD
15	produces	produce	B-VP	VBZ	O	3	VMOD
16	lasting	last	I-VP	VBG	O	15	VC
17	cognitive	cognitive	B-NP	JJ	O	18	NMOD
18	impairment	impairment	I-NP	NN	O	16	OBJ
19	in	in	B-PP	IN	O	16	VMOD
20	the	the	B-NP	DT	O	21	NMOD
21	absence	absence	I-NP	NN	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	lead	lead	B-NP	NN	O	24	NMOD
24	exposure	exposure	I-NP	NN	O	22	PMOD
25	.	.	O	.	O	3	P

1	OBJECTIVES	OBJECTIVES	B-NP	NNS	O	6	SUB
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	5	NMOD
4	present	present	I-NP	JJ	O	5	NMOD
5	study	study	I-NP	NN	O	6	SUB
6	was	be	B-VP	VBD	O	0	ROOT
7	designed	design	I-VP	VBN	O	6	VC
8	to	to	B-VP	TO	O	9	VMOD
9	answer	answer	I-VP	VB	O	7	VMOD
10	these	these	B-NP	DT	O	11	NMOD
11	questions	question	I-NP	NNS	O	9	OBJ
12	,	,	O	,	O	9	P
13	using	use	B-VP	VBG	O	9	VMOD
14	a	a	B-NP	DT	O	16	NMOD
15	rodent	rodent	I-NP	NN	O	16	NMOD
16	model	model	I-NP	NN	O	13	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	early	early	B-NP	JJ	O	21	NMOD
19	childhood	childhood	I-NP	NN	O	21	NMOD
20	Pb	Pb	I-NP	NN	O	21	NMOD
21	exposure	exposure	I-NP	NN	O	23	NMOD
22	and	and	O	CC	O	23	NMOD
23	treatment	treatment	B-NP	NN	O	17	PMOD
24	with	with	B-PP	IN	O	23	NMOD
25	succimer	succimer	B-NP	NN	O	31	NMOD
26	,	,	O	,	O	31	P
27	a	a	B-NP	DT	O	31	NMOD
28	widely	widely	I-NP	RB	O	29	AMOD
29	used	use	I-NP	VBN	O	31	NMOD
30	chelating	chelate	I-NP	VBG	O	31	NMOD
31	agent	agent	I-NP	NN	O	24	PMOD
32	for	for	B-PP	IN	O	31	NMOD
33	the	the	B-NP	DT	O	34	NMOD
34	treatment	treatment	I-NP	NN	O	32	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	Pb	Pb	B-NP	NN	O	37	NMOD
37	poisoning	poisoning	I-NP	NN	O	35	PMOD
38	.	.	O	.	O	6	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Pb	Pb	B-NP	NN	O	4	NMOD
4	exposure	exposure	I-NP	NN	O	5	SUB
5	produced	produce	B-VP	VBD	O	1	NMOD
6	lasting	last	I-VP	VBG	O	7	NMOD
7	impairments	impairment	B-NP	NNS	O	5	OBJ
8	in	in	B-PP	IN	O	7	NMOD
9	learning	learning	B-NP	NN	O	18	NMOD
10	,	,	O	,	O	18	P
11	attention	attention	B-NP	NN	O	18	NMOD
12	,	,	O	,	O	18	P
13	inhibitory	inhibitory	B-NP	JJ	O	14	NMOD
14	control	control	I-NP	NN	O	18	NMOD
15	,	,	O	,	O	18	P
16	and	and	O	CC	O	18	NMOD
17	arousal	arousal	B-NP	JJ	O	18	NMOD
18	regulation	regulation	I-NP	NN	O	8	PMOD
19	,	,	O	,	O	5	P
20	paralleling	parallel	B-VP	VBG	O	5	VMOD
21	the	the	B-NP	DT	O	22	NMOD
22	areas	area	I-NP	NNS	O	20	OBJ
23	of	of	B-PP	IN	O	22	NMOD
24	dysfunction	dysfunction	B-NP	NN	O	23	PMOD
25	seen	see	B-VP	VBN	O	24	NMOD
26	in	in	B-PP	IN	O	25	VMOD
27	Pb-exposed	Pb-exposed	B-NP	JJ	O	28	NMOD
28	children	child	I-NP	NNS	O	26	PMOD
29	.	.	O	.	O	1	P

1	In	In	B-PP	IN	O	0	ROOT
2	contrast	contrast	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	1	VMOD
4	succimer	succimer	B-NP	NN	O	5	NMOD
5	treatment	treatment	I-NP	NN	O	3	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	rats	rat	B-NP	NNS	O	6	PMOD
8	not	not	B-VP	RB	O	10	VMOD
9	previously	previously	I-VP	RB	O	8	AMOD
10	exposed	expose	I-VP	VBN	O	5	NMOD
11	to	to	B-PP	TO	O	10	VMOD
12	Pb	Pb	B-NP	NN	O	11	PMOD
13	produced	produce	B-VP	VBD	O	10	VMOD
14	lasting	lasting	B-NP	JJ	O	16	AMOD
15	and	and	I-NP	CC	O	16	AMOD
16	pervasive	pervasive	I-NP	JJ	O	20	NMOD
17	cognitive	cognitive	I-NP	JJ	O	20	NMOD
18	and	and	I-NP	CC	O	20	NMOD
19	affective	affective	I-NP	JJ	O	20	NMOD
20	dysfunction	dysfunction	I-NP	NN	O	13	OBJ
21	comparable	comparable	B-ADJP	JJ	O	20	NMOD
22	in	in	B-PP	IN	O	21	AMOD
23	magnitude	magnitude	B-NP	NN	O	22	PMOD
24	to	to	B-PP	TO	O	21	AMOD
25	that	that	B-NP	DT	O	24	PMOD
26	produced	produce	B-VP	VBN	O	25	NMOD
27	by	by	B-PP	IN	O	26	VMOD
28	the	the	B-NP	DT	O	32	NMOD
29	higher	high	I-NP	JJR	O	32	NMOD
30	Pb	Pb	I-NP	NN	O	32	NMOD
31	exposure	exposure	I-NP	NN	O	32	NMOD
32	regimen	regimen	I-NP	NN	O	27	PMOD
33	.	.	O	.	O	5	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	These	These	B-NP	DT	O	4	SUB
4	are	be	B-VP	VBP	O	1	NMOD
5	the	the	B-NP	DT	O	7	NMOD
6	first	first	I-NP	JJ	O	7	NMOD
7	data	datum	I-NP	NNS	O	4	PRD
8	,	,	O	,	O	7	P
9	to	to	B-PP	TO	O	7	NMOD
10	our	our	B-NP	PRP$	O	11	NMOD
11	knowledge	knowledge	I-NP	NN	O	9	PMOD
12	,	,	O	,	O	4	P
13	to	to	B-VP	TO	O	14	VMOD
14	show	show	I-VP	VB	O	4	VMOD
15	that	that	B-SBAR	IN	O	14	VMOD
16	treatment	treatment	B-NP	NN	O	21	SUB
17	with	with	B-PP	IN	O	16	NMOD
18	any	any	B-NP	DT	O	20	NMOD
19	chelating	chelate	I-NP	VBG	O	20	NMOD
20	agent	agent	I-NP	NN	O	17	PMOD
21	can	can	B-VP	MD	O	15	SBAR
22	alleviate	alleviate	I-VP	VB	O	21	VC
23	cognitive	cognitive	B-NP	JJ	O	24	NMOD
24	deficits	deficit	I-NP	NNS	O	22	OBJ
25	due	due	B-ADJP	JJ	O	24	NMOD
26	to	to	B-PP	TO	O	25	AMOD
27	Pb	Pb	B-NP	NN	O	28	NMOD
28	exposure	exposure	I-NP	NN	O	26	PMOD
29	.	.	O	.	O	1	P

1	Caffeine	Caffeine	B-NP	NN	O	3	NMOD
2	challenge	challenge	I-NP	NN	O	3	NMOD
3	test	test	I-NP	NN	O	8	NMOD
4	in	in	B-PP	IN	O	3	NMOD
5	panic	panic	B-NP	NN	O	6	NMOD
6	disorder	disorder	I-NP	NN	O	4	PMOD
7	and	and	O	CC	O	8	NMOD
8	depression	depression	B-NP	NN	O	0	ROOT
9	with	with	B-PP	IN	O	8	NMOD
10	panic	panic	B-NP	NN	O	11	NMOD
11	attacks	attack	I-NP	NNS	O	9	PMOD
12	.	.	O	.	O	8	P

1	Our	Our	B-NP	PRP$	O	2	NMOD
2	aim	aim	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	to	to	B-VP	TO	O	5	VMOD
5	observe	observe	I-VP	VB	O	3	PRD
6	if	if	B-SBAR	IN	O	5	VMOD
7	patients	patient	B-NP	NNS	O	38	SUB
8	with	with	B-PP	IN	O	7	NMOD
9	panic	panic	B-NP	NN	O	10	NMOD
10	disorder	disorder	I-NP	NN	O	15	NMOD
11	(	(	O	(	O	13	DEP
12	PD	PD	B-NP	NN	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	and	and	O	CC	O	15	NMOD
15	patients	patient	B-NP	NNS	O	8	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	major	major	B-NP	JJ	O	18	NMOD
18	depression	depression	I-NP	NN	O	16	PMOD
19	with	with	B-PP	IN	O	15	NMOD
20	panic	panic	B-NP	JJ	O	21	NMOD
21	attacks	attack	I-NP	NNS	O	19	PMOD
22	(	(	O	(	O	24	DEP
23	MDP	MDP	B-NP	NN	O	24	DEP
24	)	)	O	)	O	21	NMOD
25	(	(	O	(	O	37	DEP
26	Diagnostic	Diagnostic	B-NP	NNP	O	29	NMOD
27	and	and	O	CC	O	29	NMOD
28	Statistical	Statistical	B-NP	NNP	O	29	NMOD
29	Manual	Manual	I-NP	NNP	O	37	DEP
30	of	of	B-PP	IN	O	29	NMOD
31	Mental	Mental	B-NP	NNP	O	32	NMOD
32	Disorders	Disorders	I-NP	NNP	O	36	NMOD
33	,	,	O	,	O	36	P
34	Fourth	Fourth	B-NP	NNP	O	36	NMOD
35	Edition	Edition	I-NP	NNP	O	36	NMOD
36	criteria	criterion	I-NP	NNS	O	30	PMOD
37	)	)	O	)	O	15	NMOD
38	respond	respond	B-VP	VBP	O	6	SBAR
39	in	in	B-PP	IN	O	38	VMOD
40	a	a	B-NP	DT	O	42	NMOD
41	similar	similar	I-NP	JJ	O	42	NMOD
42	way	way	I-NP	NN	O	39	PMOD
43	to	to	B-PP	TO	O	42	NMOD
44	the	the	B-NP	DT	O	45	NMOD
45	induction	induction	I-NP	NN	O	43	PMOD
46	of	of	B-PP	IN	O	45	NMOD
47	panic	panic	B-NP	NN	O	48	NMOD
48	attacks	attack	I-NP	NNS	O	46	PMOD
49	by	by	B-PP	IN	O	45	NMOD
50	an	an	B-NP	DT	O	54	NMOD
51	oral	oral	I-NP	JJ	O	54	NMOD
52	caffeine	caffeine	I-NP	NN	O	54	NMOD
53	challenge	challenge	I-NP	NN	O	54	NMOD
54	test	test	I-NP	NN	O	49	PMOD
55	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	33	VMOD
2	a	a	B-NP	DT	O	5	NMOD
3	randomized	randomize	I-NP	VBN	O	5	NMOD
4	double-blind	double-blind	I-NP	JJ	O	5	NMOD
5	experiment	experiment	I-NP	NN	O	1	PMOD
6	performed	perform	B-VP	VBN	O	5	NMOD
7	in	in	B-PP	IN	O	6	VMOD
8	2	2	B-NP	CD	O	9	NMOD
9	occasions	occasion	I-NP	NNS	O	7	PMOD
10	7	7	B-NP	CD	O	11	NMOD
11	days	day	I-NP	NNS	O	24	SUB
12	apart	apart	B-ADVP	RB	O	24	VMOD
13	,	,	O	,	O	24	P
14	480	480	B-NP	CD	O	15	AMOD
15	mg	mg	I-NP	NN	O	16	NMOD
16	caffeine	caffeine	I-NP	NN	O	19	NMOD
17	and	and	O	CC	O	19	NMOD
18	a	a	B-NP	DT	O	19	NMOD
19	caffeine-free	caffeine-free	I-NP	JJ	O	24	SUB
20	(	(	O	(	O	22	DEP
21	placebo	placebo	B-NP	NN	O	22	DEP
22	)	)	O	)	O	19	NMOD
23	solution	solution	B-NP	NN	O	19	NMOD
24	were	be	B-VP	VBD	O	6	VMOD
25	administered	administer	I-VP	VBN	O	24	VC
26	in	in	B-PP	IN	O	25	VMOD
27	a	a	B-NP	DT	O	29	NMOD
28	coffee	coffee	I-NP	NN	O	29	NMOD
29	form	form	I-NP	NN	O	32	NMOD
30	and	and	I-NP	CC	O	32	NMOD
31	anxiety	anxiety	I-NP	NN	O	32	NMOD
32	scales	scale	I-NP	NNS	O	26	PMOD
33	were	be	B-VP	VBD	O	0	ROOT
34	applied	apply	I-VP	VBN	O	33	VC
35	before	before	B-PP	IN	O	34	VMOD
36	and	and	I-PP	CC	O	35	PMOD
37	after	after	I-PP	IN	O	35	PMOD
38	each	each	B-NP	DT	O	39	NMOD
39	test	test	I-NP	NN	O	35	PMOD
40	.	.	O	.	O	33	P

1	A	A	B-NP	DT	O	2	NMOD
2	total	total	I-NP	NN	O	42	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	58.6	58.6	B-NP	CD	O	5	NMOD
5	%	%	I-NP	NN	O	3	PMOD
6	(	(	O	(	O	10	DEP
7	n	n	B-NP	NN	O	10	DEP
8	=	=	B-VP	SYM	O	7	NMOD
9	17	17	B-NP	CD	O	8	AMOD
10	)	)	O	)	O	5	NMOD
11	of	of	B-PP	IN	O	5	NMOD
12	patients	patient	B-NP	NNS	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	PD	PD	B-NP	NN	O	13	PMOD
15	,	,	O	,	O	42	P
16	44.4	44.4	B-NP	CD	O	17	NMOD
17	%	%	I-NP	NN	O	42	NMOD
18	(	(	O	(	O	22	DEP
19	n	n	B-NP	NN	O	22	DEP
20	=	=	B-VP	SYM	O	19	NMOD
21	12	12	B-NP	CD	O	20	AMOD
22	)	)	O	)	O	17	NMOD
23	of	of	B-PP	IN	O	17	NMOD
24	patients	patient	B-NP	NNS	O	23	PMOD
25	with	with	B-PP	IN	O	24	NMOD
26	MDP	MDP	B-NP	NN	O	25	PMOD
27	,	,	O	,	O	42	P
28	12.0	12.0	B-NP	CD	O	29	NMOD
29	%	%	I-NP	NN	O	42	NMOD
30	(	(	O	(	O	34	DEP
31	n	n	B-NP	NN	O	34	DEP
32	=	=	B-VP	SYM	O	31	NMOD
33	3	3	B-NP	CD	O	32	AMOD
34	)	)	O	)	O	29	NMOD
35	of	of	B-PP	IN	O	29	NMOD
36	patients	patient	B-NP	NNS	O	35	PMOD
37	with	with	B-PP	IN	O	36	NMOD
38	MD	MD	B-NP	NN	O	37	PMOD
39	,	,	O	,	O	42	P
40	and	and	O	CC	O	42	NMOD
41	7.1	7.1	B-NP	CD	O	42	NMOD
42	%	%	I-NP	NN	O	50	SUB
43	(	(	O	(	O	46	DEP
44	n=	n=	B-NP	NN	O	46	DEP
45	2	2	I-NP	CD	O	44	NMOD
46	)	)	O	)	O	42	NMOD
47	of	of	B-PP	IN	O	42	NMOD
48	control	control	B-NP	JJ	O	49	NMOD
49	subjects	subject	I-NP	NNS	O	47	PMOD
50	had	have	B-VP	VBD	O	0	ROOT
51	a	a	B-NP	DT	O	53	NMOD
52	panic	panic	I-NP	JJ	O	53	NMOD
53	attack	attack	I-NP	NN	O	50	OBJ
54	after	after	B-PP	IN	O	50	VMOD
55	the	the	B-NP	DT	O	59	NMOD
56	480-mg	480-mg	I-NP	JJ	O	59	NMOD
57	caffeine	caffeine	I-NP	NN	O	59	NMOD
58	challenge	challenge	I-NP	NN	O	59	NMOD
59	test	test	I-NP	NN	O	54	PMOD
60	.	.	O	.	O	50	P

1	The	The	B-NP	DT	O	2	NMOD
2	patients	patient	I-NP	NNS	O	7	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	PD	PD	B-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	MDP	MDP	I-NP	NN	O	3	PMOD
7	were	be	B-VP	VBD	O	0	ROOT
8	more	more	B-ADJP	RBR	O	9	AMOD
9	sensitive	sensitive	I-ADJP	JJ	O	7	PRD
10	to	to	B-PP	TO	O	9	AMOD
11	caffeine	caffeine	B-NP	NN	O	10	PMOD
12	than	than	B-SBAR	IN	O	7	VMOD
13	were	be	B-VP	VBD	O	12	SBAR
14	patients	patient	B-NP	NNS	O	19	NMOD
15	with	with	B-PP	IN	O	14	NMOD
16	MD	MD	B-NP	NN	O	15	PMOD
17	and	and	O	CC	O	19	NMOD
18	healthy	healthy	B-NP	JJ	O	19	NMOD
19	volunteers	volunteer	I-NP	NNS	O	13	PRD
20	.	.	O	.	O	7	P

1	No	No	B-NP	DT	O	3	NMOD
2	panic	panic	I-NP	NN	O	3	NMOD
3	attack	attack	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	observed	observe	I-VP	VBN	O	4	VC
6	after	after	B-PP	IN	O	5	VMOD
7	the	the	B-NP	DT	O	10	NMOD
8	caffeine-free	caffeine-free	I-NP	JJ	O	10	NMOD
9	solution	solution	I-NP	NN	O	10	NMOD
10	intake	intake	I-NP	NN	O	6	PMOD
11	.	.	O	.	O	4	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	heart	heart	I-NP	NN	O	3	NMOD
3	failure	failure	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	21	VMOD
5	induced	induce	I-VP	VBN	O	4	VC
6	by	by	B-PP	IN	O	5	VMOD
7	propranolol	propranolol	B-NP	NN	O	10	NMOD
8	and	and	I-NP	CC	O	10	NMOD
9	volume	volume	I-NP	NN	O	10	NMOD
10	loading	loading	I-NP	NN	O	6	PMOD
11	after	after	B-PP	IN	O	5	VMOD
12	weaning	wean	B-VP	VBG	O	11	PMOD
13	from	from	B-PP	IN	O	12	VMOD
14	cardiopulmonary	cardiopulmonary	B-NP	JJ	O	15	NMOD
15	bypass	bypass	I-NP	NN	O	13	PMOD
16	;	;	O	:	O	21	P
17	an	an	B-NP	DT	O	18	NMOD
18	absence	absence	I-NP	NN	O	21	SUB
19	of	of	B-PP	IN	O	18	NMOD
20	MR	MR	B-NP	NN	B-protein	19	PMOD
21	was	be	B-VP	VBD	O	0	ROOT
22	confirmed	confirm	I-VP	VBN	O	21	VC
23	by	by	B-PP	IN	O	22	VMOD
24	echocardiography	echocardiography	B-NP	NN	O	23	PMOD
25	.	.	O	.	O	21	P

1	Piperacillin/tazobactam	Piperacillin/tazobactam	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	seizure	seizure	B-NP	NN	O	2	OBJ
4	rapidly	rapidly	B-VP	RB	O	5	VMOD
5	reversed	reverse	I-VP	VBN	O	3	NMOD
6	by	by	B-PP	IN	O	5	VMOD
7	high	high	B-NP	JJ	O	9	NMOD
8	flux	flux	I-NP	NN	O	9	NMOD
9	hemodialysis	hemodialysis	I-NP	NN	O	6	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	a	a	B-NP	DT	O	12	NMOD
12	patient	patient	I-NP	NN	O	10	PMOD
13	on	on	B-PP	IN	O	12	NMOD
14	peritoneal	peritoneal	B-NP	JJ	O	15	NMOD
15	dialysis	dialysis	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	2	P

1	Despite	Despite	B-PP	IN	O	14	VMOD
2	popular	popular	B-NP	JJ	O	3	NMOD
3	use	use	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	piperacillin	piperacillin	B-NP	NN	B-protein	4	PMOD
6	,	,	O	,	O	14	P
7	the	the	B-NP	DT	O	9	NMOD
8	dire	dire	I-NP	JJ	O	9	NMOD
9	neurotoxicity	neurotoxicity	I-NP	NN	O	14	SUB
10	associated	associate	B-VP	VBN	O	9	NMOD
11	with	with	B-PP	IN	O	10	VMOD
12	piperacillin	piperacillin	B-NP	NN	B-protein	11	PMOD
13	still	still	B-ADVP	RB	O	14	VMOD
14	goes	go	B-VP	VBZ	O	0	ROOT
15	unrecognized	unrecognized	B-ADJP	JJ	O	14	PRD
16	,	,	O	,	O	15	P
17	leading	lead	B-VP	VBG	O	15	AMOD
18	to	to	B-PP	TO	O	17	VMOD
19	a	a	B-NP	DT	O	20	NMOD
20	delay	delay	I-NP	NN	O	18	PMOD
21	in	in	B-PP	IN	O	20	NMOD
22	appropriate	appropriate	B-NP	JJ	O	23	NMOD
23	management	management	I-NP	NN	O	21	PMOD
24	.	.	O	.	O	14	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	57-year-old	57-year-old	I-NP	JJ	O	5	NMOD
5	woman	woman	I-NP	NN	O	2	OBJ
6	with	with	B-PP	IN	O	5	NMOD
7	end-stage	end-stage	B-NP	JJ	O	9	NMOD
8	renal	renal	I-NP	JJ	O	9	NMOD
9	disease	disease	I-NP	NN	O	6	PMOD
10	receiving	receive	B-VP	VBG	O	9	NMOD
11	continuous	continuous	B-NP	JJ	O	14	NMOD
12	ambulatory	ambulatory	I-NP	JJ	O	14	NMOD
13	peritoneal	peritoneal	I-NP	JJ	O	14	NMOD
14	dialysis	dialysis	I-NP	NN	O	10	OBJ
15	(	(	O	(	O	17	DEP
16	CAPD	CAPD	B-NP	NN	B-protein	17	DEP
17	)	)	O	)	O	14	NMOD
18	,	,	O	,	O	5	P
19	who	who	B-NP	WP	O	5	NMOD
20	developed	develop	B-VP	VBD	O	19	SBAR
21	slurred	slur	I-VP	VBN	O	20	VC
22	speech	speech	B-NP	NN	O	35	NMOD
23	,	,	O	,	O	35	P
24	tremor	tremor	B-NP	NN	O	35	NMOD
25	,	,	O	,	O	35	P
26	bizarre	bizarre	B-NP	JJ	O	27	NMOD
27	behavior	behavior	I-NP	NN	O	35	NMOD
28	,	,	O	,	O	35	P
29	progressive	progressive	B-NP	JJ	O	31	NMOD
30	mental	mental	I-NP	JJ	O	31	NMOD
31	confusion	confusion	I-NP	NN	O	35	NMOD
32	,	,	O	,	O	35	P
33	and	and	O	CC	O	35	NMOD
34	2	2	B-NP	CD	O	35	NMOD
35	episodes	episode	I-NP	NNS	O	21	OBJ
36	of	of	B-PP	IN	O	35	NMOD
37	generalized	generalize	B-NP	VBN	O	39	NMOD
38	tonic-clonic	tonic-clonic	I-NP	JJ	O	39	NMOD
39	seizure	seizure	I-NP	NN	O	36	PMOD
40	(	(	O	(	O	42	DEP
41	GTCS	GTCS	B-NP	NN	O	42	DEP
42	)	)	O	)	O	39	NMOD
43	after	after	B-PP	IN	O	21	VMOD
44	5	5	B-NP	CD	O	45	NMOD
45	doses	dose	I-NP	NNS	O	43	PMOD
46	of	of	B-PP	IN	O	45	NMOD
47	piperacillin/tazobactam	piperacillin/tazobactam	B-NP	NN	O	46	PMOD
48	(	(	O	(	O	52	DEP
49	2	2	B-NP	CD	O	51	NMOD
50	g/250	g/250	I-NP	NN	O	51	NMOD
51	mg	mg	I-NP	NN	O	52	DEP
52	)	)	O	)	O	45	NMOD
53	were	be	B-VP	VBD	O	19	SBAR
54	given	give	I-VP	VBN	O	53	VC
55	for	for	B-PP	IN	O	54	VMOD
56	bronchiectasis	bronchiectasis	B-NP	NN	O	55	PMOD
57	with	with	B-PP	IN	O	56	NMOD
58	secondary	secondary	B-NP	JJ	O	59	NMOD
59	infection	infection	I-NP	NN	O	57	PMOD
60	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	laboratory	laboratory	I-NP	NN	O	3	NMOD
3	data	datum	I-NP	NNS	O	4	SUB
4	revealed	reveal	B-VP	VBD	O	0	ROOT
5	normal	normal	B-NP	JJ	O	7	NMOD
6	plasma	plasma	I-NP	NN	O	7	NMOD
7	electrolyte	electrolyte	I-NP	NN	O	10	NMOD
8	and	and	I-NP	CC	O	10	NMOD
9	ammonia	ammonia	I-NP	NN	O	10	NMOD
10	levels	level	I-NP	NNS	O	12	NMOD
11	but	but	O	CC	O	12	NMOD
12	leukocytosis	leukocytosis	B-NP	NN	O	4	OBJ
13	.	.	O	.	O	4	P

1	Despite	Despite	B-PP	IN	O	11	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	use	use	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	antiepileptic	antiepileptic	B-NP	JJ	O	6	NMOD
6	agents	agent	I-NP	NNS	O	4	PMOD
7	,	,	O	,	O	11	P
8	another	another	B-NP	DT	O	10	NMOD
9	GTCS	GTCS	I-NP	NN	O	10	NMOD
10	episode	episode	I-NP	NN	O	11	SUB
11	recurred	recur	B-VP	VBD	O	0	ROOT
12	after	after	B-PP	IN	O	11	VMOD
13	the	the	B-NP	DT	O	15	NMOD
14	sixth	sixth	I-NP	JJ	O	15	NMOD
15	dose	dose	I-NP	NN	O	12	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	piperacillin/tazobactam	piperacillin/tazobactam	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	11	P

1	Piperacillin	Piperacillin	B-NP	NN	B-protein	2	SUB
2	induced	induce	B-VP	VBD	O	4	VMOD
3	encephalopathy	encephalopathy	B-NP	NN	O	2	OBJ
4	should	should	B-VP	MD	O	0	ROOT
5	be	be	I-VP	VB	O	4	VC
6	considered	consider	I-VP	VBN	O	5	VC
7	in	in	B-PP	IN	O	6	VMOD
8	any	any	B-NP	DT	O	10	NMOD
9	uremic	uremic	I-NP	JJ	O	10	NMOD
10	patients	patient	I-NP	NNS	O	7	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	unexplained	unexplained	B-NP	JJ	O	14	NMOD
13	neurological	neurological	I-NP	JJ	O	14	NMOD
14	manifestations	manifestation	I-NP	NNS	O	11	PMOD
15	.	.	O	.	O	4	P

1	Neuroprotective	Neuroprotective	B-NP	JJ	O	2	NMOD
2	effects	effect	I-NP	NNS	O	16	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	melatonin	melatonin	B-NP	NN	O	3	PMOD
5	upon	upon	B-PP	IN	O	2	NMOD
6	the	the	B-NP	DT	O	9	NMOD
7	offspring	offspring	I-NP	NN	O	9	NMOD
8	cerebellar	cerebellar	I-NP	JJ	O	9	NMOD
9	cortex	cortex	I-NP	NN	O	5	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	13	NMOD
12	rat	rat	I-NP	NN	O	13	NMOD
13	model	model	I-NP	NN	O	10	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	BCNU	BCNU	B-NP	NN	B-protein	14	PMOD
16	induced	induce	B-VP	VBD	O	0	ROOT
17	cortical	cortical	B-NP	JJ	O	18	NMOD
18	dysplasia	dysplasia	I-NP	NN	O	16	OBJ
19	.	.	O	.	O	16	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	designed	design	I-VP	VBN	O	3	VC
5	to	to	B-VP	TO	O	6	VMOD
6	evaluate	evaluate	I-VP	VB	O	3	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	alterations	alteration	I-NP	NNS	O	6	OBJ
9	in	in	B-PP	IN	O	8	NMOD
10	offspring	offspre	B-VP	VBG	O	9	PMOD
11	rat	rat	B-NP	NN	O	12	NMOD
12	cerebellum	cerebellum	I-NP	NN	O	10	OBJ
13	induced	induce	B-VP	VBN	O	12	NMOD
14	by	by	B-PP	IN	O	13	VMOD
15	maternal	maternal	B-NP	JJ	O	16	NMOD
16	exposure	exposure	I-NP	NN	O	14	PMOD
17	to	to	B-PP	TO	O	16	NMOD
18	carmustine-	carmustine-	B-NP	NN	O	17	PMOD
19	[	[	O	(	O	6	VMOD
20	1	1	B-NP	CD	O	42	VMOD
21	,	,	O	,	O	42	P
22	3-bis	3-bis	B-NP	NN	O	42	SUB
23	(	(	O	(	O	25	DEP
24	2-chloroethyl	2-chloroethyl	B-NP	NN	O	25	DEP
25	)	)	O	)	O	22	NMOD
26	-1-nitrosoure	-1-nitrosoure	B-ADJP	JJ	O	22	NMOD
27	]	]	O	)	O	30	NMOD
28	(	(	O	(	O	30	DEP
29	BCNU	BCNU	B-NP	NN	B-protein	30	DEP
30	)	)	O	)	O	26	AMOD
31	and	and	O	CC	O	33	VMOD
32	to	to	B-VP	TO	O	33	VMOD
33	investigate	investigate	I-VP	VB	O	22	NMOD
34	the	the	B-NP	DT	O	35	NMOD
35	effects	effect	I-NP	NNS	O	33	OBJ
36	of	of	B-PP	IN	O	35	NMOD
37	exogenous	exogenous	B-NP	JJ	O	38	NMOD
38	melatonin	melatonin	I-NP	NN	O	36	PMOD
39	upon	upon	B-PP	IN	O	35	NMOD
40	cerebellar	cerebellar	B-NP	JJ	B-protein	41	NMOD
41	BCNU	BCNU	I-NP	NN	I-protein	39	PMOD
42	induced	induce	B-VP	VBD	O	19	SBAR
43	cortical	cortical	B-NP	JJ	O	44	NMOD
44	dysplasia	dysplasia	I-NP	NN	O	42	OBJ
45	,	,	O	,	O	42	P
46	using	use	B-VP	VBG	O	42	VMOD
47	histological	histological	B-NP	JJ	O	49	AMOD
48	and	and	I-NP	CC	O	49	AMOD
49	biochemical	biochemical	I-NP	JJ	O	50	NMOD
50	analyses	analysis	I-NP	NNS	O	46	OBJ
51	.	.	O	.	O	3	P

1	Histopathologically	Histopathologically	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	typical	typical	B-NP	JJ	O	4	NMOD
4	findings	finding	I-NP	NNS	O	5	SUB
5	were	be	B-VP	VBD	O	23	VMOD
6	observed	observe	I-VP	VBN	O	5	VC
7	in	in	B-PP	IN	O	6	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	cerebella	cerebella	I-NP	NN	O	7	PMOD
10	from	from	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	13	NMOD
12	control	control	I-NP	NN	O	13	NMOD
13	groups	group	I-NP	NNS	O	10	PMOD
14	,	,	O	,	O	17	P
15	but	but	O	CC	O	17	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	findings	finding	I-NP	NNS	O	23	SUB
18	consistent	consistent	B-ADJP	JJ	O	17	NMOD
19	with	with	B-PP	IN	O	18	AMOD
20	early	early	B-NP	JJ	O	22	NMOD
21	embryonic	embryonic	I-NP	JJ	O	22	NMOD
22	development	development	I-NP	NN	O	19	PMOD
23	were	be	B-VP	VBD	O	0	ROOT
24	noted	note	I-VP	VBN	O	23	VC
25	in	in	B-PP	IN	O	24	VMOD
26	BCNU-exposed	BCNU-exposed	B-NP	JJ	O	29	NMOD
27	cortical	cortical	I-NP	JJ	O	29	NMOD
28	dysplasia	dysplasia	I-NP	NN	O	29	NMOD
29	group	group	I-NP	NN	O	25	PMOD
30	.	.	O	.	O	23	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	shows	show	B-VP	VBZ	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	MIP	MIP	B-NP	NN	B-protein	7	NMOD
6	synthase	synthase	I-NP	NN	I-protein	7	NMOD
7	inhibition	inhibition	I-NP	NN	O	8	SUB
8	does	do	B-VP	VBZ	O	4	SBAR
9	not	not	I-VP	RB	O	8	VMOD
10	replicate	replicate	I-VP	VB	O	8	VC
11	or	or	I-VP	CC	O	10	VMOD
12	augment	augment	I-VP	VB	O	10	VMOD
13	the	the	B-NP	DT	O	14	NMOD
14	effects	effect	I-NP	NNS	O	10	VMOD
15	of	of	B-PP	IN	O	14	NMOD
16	lithium	lithium	B-NP	NN	O	15	PMOD
17	in	in	B-PP	IN	O	10	VMOD
18	the	the	B-NP	DT	O	21	NMOD
19	inositol	inositol	I-NP	NN	O	21	NMOD
20	sensitive	sensitive	I-NP	JJ	O	21	NMOD
21	pilocarpine	pilocarpine	I-NP	NN	O	22	SUB
22	induced	induce	B-VP	VBD	O	17	SBAR
23	seizures	seizure	B-NP	NNS	O	24	NMOD
24	model	model	I-NP	NN	O	22	OBJ
25	.	.	O	.	O	3	P

1	He	He	B-NP	PRP	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	put	put	I-VP	VBN	O	2	VC
4	on	on	B-PP	IN	O	3	VMOD
5	aspirin	aspirin	B-NP	NN	O	4	PMOD
6	following	follow	B-PP	VBG	O	5	NMOD
7	surgery	surgery	B-NP	NN	O	6	PMOD
8	and	and	O	CC	O	2	VMOD
9	took	take	B-VP	VBD	O	2	VMOD
10	ibuprofen	ibuprofen	B-NP	NN	O	9	OBJ
11	for	for	B-PP	IN	O	10	NMOD
12	fever	fever	B-NP	NN	O	11	PMOD
13	for	for	B-PP	IN	O	12	NMOD
14	nearly	nearly	B-NP	RB	O	16	NMOD
15	a	a	I-NP	DT	O	16	NMOD
16	week	week	I-NP	NN	O	13	PMOD
17	prior	prior	B-ADVP	RB	O	18	PMOD
18	to	to	B-PP	TO	O	9	VMOD
19	presentation	presentation	B-NP	NN	O	18	PMOD
20	.	.	O	.	O	2	P

1	Rifampicin-associated	Rifampicin-associated	B-NP	JJ	O	4	NMOD
2	segmental	segmental	I-NP	JJ	O	4	NMOD
3	necrotizing	necrotizing	I-NP	JJ	O	4	NMOD
4	glomerulonephritis	glomerulonephritis	I-NP	NN	O	0	ROOT
5	in	in	B-PP	IN	O	4	NMOD
6	staphylococcal	staphylococcal	B-NP	JJ	O	7	NMOD
7	endocarditis	endocarditis	I-NP	NN	O	5	PMOD
8	.	.	O	.	O	4	P

1	Segmental	Segmental	B-NP	JJ	O	3	NMOD
2	necrotising	necrotising	I-NP	NN	O	3	NMOD
3	glomerulonephritis	glomerulonephritis	I-NP	NN	O	4	SUB
4	has	have	B-VP	VBZ	O	0	ROOT
5	been	be	I-VP	VBN	O	4	VC
6	reported	report	I-VP	VBN	O	5	VC
7	as	as	B-PP	IN	O	6	VMOD
8	complication	complication	B-NP	NN	O	7	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	rifampicin	rifampicin	B-NP	NN	O	11	NMOD
11	therapy	therapy	I-NP	NN	O	9	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	patients	patient	B-NP	NNS	O	12	PMOD
14	receiving	receive	B-VP	VBG	O	13	NMOD
15	treatment	treatment	B-NP	NN	O	14	OBJ
16	for	for	B-PP	IN	O	15	NMOD
17	tuberculosis	tuberculosis	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	4	P

1	Changing	Change	B-VP	VBG	O	12	SUB
2	epidemiology	epidemiology	B-NP	NN	O	1	OBJ
3	of	of	B-PP	IN	O	2	NMOD
4	infections	infection	B-NP	NNS	O	3	PMOD
5	such	such	B-PP	JJ	O	6	PMOD
6	as	as	I-PP	IN	O	4	NMOD
7	infective	infective	B-NP	JJ	O	8	NMOD
8	endocarditis	endocarditis	I-NP	NN	O	6	PMOD
9	(	(	O	(	O	11	DEP
10	IE	IE	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	has	have	B-VP	VBZ	O	0	ROOT
13	led	lead	I-VP	VBN	O	12	VC
14	to	to	B-PP	TO	O	13	VMOD
15	an	an	B-NP	DT	O	16	NMOD
16	increase	increase	I-NP	NN	O	14	PMOD
17	in	in	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	19	NMOD
19	use	use	I-NP	NN	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	rifampicin	rifampicin	B-NP	NN	O	20	PMOD
22	for	for	B-PP	IN	O	19	NMOD
23	Staphylococcal	Staphylococcal	B-NP	JJ	O	24	NMOD
24	infections	infection	I-NP	NNS	O	22	PMOD
25	.	.	O	.	O	12	P

1	Rate	Rate	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	YMDD	YMDD	B-NP	NN	B-protein	5	NMOD
4	motif	motif	I-NP	NN	I-protein	5	NMOD
5	mutants	mutant	I-NP	NNS	I-protein	2	PMOD
6	in	in	B-PP	IN	O	1	NMOD
7	lamivudine-untreated	lamivudine-untreated	B-NP	JJ	O	9	NMOD
8	Iranian	Iranian	I-NP	JJ	O	9	NMOD
9	patients	patient	I-NP	NNS	O	6	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	chronic	chronic	B-NP	JJ	O	15	NMOD
12	hepatitis	hepatitis	I-NP	NN	O	15	NMOD
13	B	B	I-NP	NN	O	15	NMOD
14	virus	virus	I-NP	NN	O	15	NMOD
15	infection	infection	I-NP	NN	O	10	PMOD
16	.	.	O	.	O	1	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Lamivudine	Lamivudine	B-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	1	NMOD
5	used	use	I-VP	VBN	O	4	VC
6	for	for	B-PP	IN	O	5	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	treatment	treatment	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	chronic	chronic	B-NP	JJ	O	13	NMOD
11	hepatitis	hepatitis	I-NP	NN	O	13	NMOD
12	B	B	I-NP	NN	O	13	NMOD
13	patients	patient	I-NP	NNS	O	9	PMOD
14	.	.	O	.	O	4	P

1	Recent	Recent	B-NP	JJ	O	2	NMOD
2	studies	study	I-NP	NNS	O	3	SUB
3	show	show	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	the	the	B-NP	DT	O	8	NMOD
6	YMDD	YMDD	I-NP	NN	B-protein	8	NMOD
7	motif	motif	I-NP	NN	I-protein	8	NMOD
8	mutants	mutant	I-NP	NNS	I-protein	15	SUB
9	(	(	O	(	O	14	DEP
10	resistant	resistant	B-NP	JJ	O	13	NMOD
11	hepatitis	hepatitis	I-NP	NN	O	13	NMOD
12	B	B	I-NP	NN	O	13	NMOD
13	virus	virus	I-NP	NN	O	14	DEP
14	)	)	O	)	O	8	NMOD
15	occur	occur	B-VP	VBP	O	4	SBAR
16	as	as	B-PP	IN	O	15	VMOD
17	natural	natural	B-NP	JJ	O	19	NMOD
18	genome	genome	I-NP	NN	O	19	NMOD
19	variability	variability	I-NP	NN	O	16	PMOD
20	in	in	B-PP	IN	O	19	NMOD
21	lamivudine-untreated	lamivudine-untreated	B-NP	JJ	O	25	NMOD
22	chronic	chronic	I-NP	JJ	O	25	NMOD
23	hepatitis	hepatitis	I-NP	NN	O	25	NMOD
24	B	B	I-NP	NN	O	25	NMOD
25	patients	patient	I-NP	NNS	O	20	PMOD
26	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	5	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	study	study	I-NP	NN	O	1	PMOD
4	we	we	B-NP	PRP	O	5	SUB
5	aimed	aim	B-VP	VBD	O	0	ROOT
6	to	to	I-VP	TO	O	7	VMOD
7	determine	determine	I-VP	VB	O	5	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	rate	rate	I-NP	NN	O	7	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	YMDD	YMDD	B-NP	NN	B-protein	13	NMOD
12	motif	motif	I-NP	NN	I-protein	13	NMOD
13	mutants	mutant	I-NP	NNS	I-protein	10	PMOD
14	in	in	B-PP	IN	O	9	NMOD
15	lamivudine-untreated	lamivudine-untreated	B-NP	JJ	O	19	NMOD
16	chronic	chronic	I-NP	JJ	O	19	NMOD
17	hepatitis	hepatitis	I-NP	NN	O	19	NMOD
18	B	B	I-NP	NN	O	19	NMOD
19	patients	patient	I-NP	NNS	O	14	PMOD
20	in	in	B-PP	IN	O	19	NMOD
21	Iran	Iran	B-NP	NNP	O	20	PMOD
22	.	.	O	.	O	5	P

1	PATIENTS	PATIENTS	B-NP	NNS	O	3	NMOD
2	AND	AND	I-NP	CC	O	3	NMOD
3	METHODS	METHODS	I-NP	NNS	O	0	ROOT
4	:	:	O	:	O	3	P
5	A	A	B-NP	DT	O	6	NMOD
6	total	total	I-NP	NN	O	20	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	77	77	B-NP	CD	O	12	NMOD
9	chronic	chronic	I-NP	JJ	O	12	NMOD
10	hepatitis	hepatitis	I-NP	NN	O	12	NMOD
11	B	B	I-NP	NN	O	12	NMOD
12	patients	patient	I-NP	NNS	O	7	PMOD
13	who	who	B-NP	WP	O	12	NMOD
14	had	have	B-VP	VBD	O	13	SBAR
15	not	not	I-VP	RB	O	14	VMOD
16	been	be	I-VP	VBN	O	14	VC
17	treated	treat	I-VP	VBN	O	16	VC
18	with	with	B-PP	IN	O	17	VMOD
19	lamivudine	lamivudine	B-NP	NN	O	18	PMOD
20	were	be	B-VP	VBD	O	3	NMOD
21	included	include	I-VP	VBN	O	20	VC
22	in	in	B-PP	IN	O	21	VMOD
23	the	the	B-NP	DT	O	24	NMOD
24	study	study	I-NP	NN	O	22	PMOD
25	.	.	O	.	O	3	P

1	Branch	Branch	B-NP	NN	O	4	NMOD
2	retinal	retinal	I-NP	JJ	O	4	NMOD
3	vein	vein	I-NP	NN	O	4	NMOD
4	occlusion	occlusion	I-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	fluoxetine	fluoxetine	I-NP	NN	O	0	ROOT
7	.	.	O	.	O	6	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	11	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	branch	branch	B-NP	NN	O	7	NMOD
5	retinal	retinal	I-NP	NN	O	7	NMOD
6	vein	vein	I-NP	NN	O	7	NMOD
7	occlusion	occlusion	I-NP	NN	O	3	PMOD
8	associated	associate	B-VP	VBN	O	7	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	fluoxetine	fluoxetine	B-NP	NN	O	9	PMOD
11	induced	induce	B-VP	VBD	O	14	VMOD
12	secondary	secondary	B-NP	JJ	O	13	NMOD
13	hypertension	hypertension	I-NP	NN	O	14	SUB
14	is	be	B-VP	VBZ	O	0	ROOT
15	described	describe	I-VP	VBN	O	14	VC
16	.	.	O	.	O	14	P

1	The	The	B-NP	DT	O	3	NMOD
2	differential	differential	I-NP	JJ	O	3	NMOD
3	effects	effect	I-NP	NNS	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	bupivacaine	bupivacaine	B-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	lidocaine	lidocaine	I-NP	NN	O	4	PMOD
8	on	on	B-PP	IN	O	3	NMOD
9	prostaglandin	prostaglandin	B-NP	NN	O	11	NMOD
10	E2	E2	I-NP	NN	O	11	NMOD
11	release	release	I-NP	NN	O	17	NMOD
12	,	,	O	,	O	17	P
13	cyclooxygenase	cyclooxygenase	B-NP	NN	B-protein	15	NMOD
14	gene	gene	I-NP	NN	O	15	NMOD
15	expression	expression	I-NP	NN	O	17	NMOD
16	and	and	O	CC	O	17	NMOD
17	pain	pain	B-NP	NN	O	8	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	a	a	B-NP	DT	O	22	NMOD
20	clinical	clinical	I-NP	JJ	O	22	NMOD
21	pain	pain	I-NP	NN	O	22	NMOD
22	model	model	I-NP	NN	O	18	PMOD
23	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	7	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	present	present	I-NP	JJ	O	4	NMOD
4	study	study	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	7	P
6	we	we	B-NP	PRP	O	7	SUB
7	describe	describe	B-VP	VBP	O	0	ROOT
8	the	the	B-NP	DT	O	10	NMOD
9	proinflammatory	proinflammatory	I-NP	JJ	O	10	NMOD
10	effects	effect	I-NP	NNS	O	7	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	bupivacaine	bupivacaine	B-NP	NN	O	11	PMOD
13	on	on	B-PP	IN	O	10	NMOD
14	local	local	B-NP	JJ	O	16	NMOD
15	prostaglandin	prostaglandin	I-NP	NN	O	16	NMOD
16	E2	E2	I-NP	NN	O	22	NMOD
17	(	(	O	(	O	19	DEP
18	PGE2	PGE2	B-NP	NN	O	19	DEP
19	)	)	O	)	O	16	NMOD
20	production	production	B-NP	NN	O	16	NMOD
21	and	and	O	CC	O	22	NMOD
22	cyclooxygenase	cyclooxygenase	B-NP	NN	B-protein	27	NMOD
23	(	(	O	(	O	25	DEP
24	COX	COX	B-NP	NN	O	25	DEP
25	)	)	O	)	O	22	NMOD
26	gene	gene	B-NP	NN	O	27	NMOD
27	expression	expression	I-NP	NN	O	13	PMOD
28	that	that	B-NP	WDT	O	27	NMOD
29	increases	increase	B-VP	VBZ	O	28	SBAR
30	postoperative	postoperative	B-NP	JJ	O	31	NMOD
31	pain	pain	I-NP	NN	O	29	OBJ
32	in	in	B-PP	IN	O	31	NMOD
33	human	human	B-NP	JJ	O	34	NMOD
34	subjects	subject	I-NP	NNS	O	32	PMOD
35	.	.	O	.	O	7	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	5	NMOD
4	bupivacaine/rofecoxib	bupivacaine/rofecoxib	I-NP	NN	O	5	NMOD
5	group	group	I-NP	NN	O	6	SUB
6	reported	report	B-VP	VBD	O	1	NMOD
7	significantly	significantly	B-NP	RB	O	8	AMOD
8	less	less	I-NP	JJR	O	9	NMOD
9	pain	pain	I-NP	NN	O	6	OBJ
10	,	,	O	,	O	6	P
11	as	as	B-SBAR	IN	O	6	VMOD
12	assessed	assess	B-VP	VBN	O	11	SBAR
13	by	by	B-PP	IN	O	12	VMOD
14	a	a	B-NP	DT	O	17	NMOD
15	visual	visual	I-NP	JJ	O	17	NMOD
16	analog	analog	I-NP	NN	O	17	NMOD
17	scale	scale	I-NP	NN	O	13	PMOD
18	,	,	O	,	O	6	P
19	compared	compare	B-PP	VBN	O	6	VMOD
20	with	with	B-PP	IN	O	19	PMOD
21	the	the	B-NP	DT	O	25	NMOD
22	other	other	I-NP	JJ	O	25	NMOD
23	three	three	I-NP	CD	O	25	NMOD
24	treatment	treatment	I-NP	NN	O	25	NMOD
25	groups	group	I-NP	NNS	O	20	PMOD
26	over	over	B-PP	IN	O	25	NMOD
27	the	the	B-NP	DT	O	30	NMOD
28	first	first	I-NP	JJ	O	30	NMOD
29	4	4	I-NP	CD	O	30	NMOD
30	h	h	I-NP	NN	O	26	PMOD
31	.	.	O	.	O	1	P

1	However	However	B-ADVP	RB	O	6	VMOD
2	,	,	O	,	O	6	P
3	the	the	B-NP	DT	O	5	NMOD
4	bupivacaine/placebo	bupivacaine/placebo	I-NP	NN	O	5	NMOD
5	group	group	I-NP	NN	O	6	SUB
6	reported	report	B-VP	VBD	O	0	ROOT
7	significantly	significantly	B-NP	RB	O	8	AMOD
8	more	more	I-NP	JJR	O	9	NMOD
9	pain	pain	I-NP	NN	O	15	NMOD
10	at	at	B-PP	IN	O	9	NMOD
11	24	24	B-NP	CD	O	12	NMOD
12	h	h	I-NP	NN	O	10	PMOD
13	and	and	I-NP	CC	O	15	NMOD
14	PGE2	PGE2	I-NP	NN	O	15	NMOD
15	levels	level	I-NP	NNS	O	21	SUB
16	during	during	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	20	NMOD
18	first	first	I-NP	JJ	O	20	NMOD
19	4	4	I-NP	CD	O	20	NMOD
20	h	h	I-NP	NN	O	16	PMOD
21	were	be	B-VP	VBD	O	6	VMOD
22	significantly	significantly	B-ADJP	RB	O	23	AMOD
23	higher	high	I-ADJP	JJR	O	21	PRD
24	than	than	B-PP	IN	O	23	AMOD
25	the	the	B-NP	DT	O	29	NMOD
26	other	other	I-NP	JJ	O	29	NMOD
27	three	three	I-NP	CD	O	29	NMOD
28	treatment	treatment	I-NP	NN	O	29	NMOD
29	groups	group	I-NP	NNS	O	24	PMOD
30	.	.	O	.	O	6	P

1	p75NTR	p75NTR	B-NP	NN	B-protein	2	NMOD
2	expression	expression	I-NP	NN	O	11	NMOD
3	in	in	B-PP	IN	O	2	NMOD
4	rat	rat	B-NP	NN	B-cell_type	8	NMOD
5	urinary	urinary	I-NP	JJ	I-cell_type	8	NMOD
6	bladder	bladder	I-NP	NN	I-cell_type	8	NMOD
7	sensory	sensory	I-NP	JJ	I-cell_type	8	NMOD
8	neurons	neuron	I-NP	NNS	I-cell_type	3	PMOD
9	and	and	O	CC	O	11	NMOD
10	spinal	spinal	B-NP	JJ	O	11	NMOD
11	cord	cord	I-NP	NN	O	0	ROOT
12	with	with	B-PP	IN	O	11	NMOD
13	cyclophosphamide	cyclophosphamide	B-NP	NN	O	15	NMOD
14	induced	induced	I-NP	JJ	O	15	NMOD
15	cystitis	cystitis	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	11	P

1	Previous	Previous	B-NP	JJ	O	2	NMOD
2	studies	study	I-NP	NNS	O	3	SUB
3	have	have	B-VP	VBP	O	0	ROOT
4	examined	examine	I-VP	VBN	O	3	VC
5	the	the	B-NP	DT	O	8	NMOD
6	expression	expression	B-NP	NN	O	8	NMOD
7	and	and	O	CC	O	8	NMOD
8	regulation	regulation	B-NP	NN	O	4	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	tyrosine	tyrosine	B-NP	NN	B-protein	12	NMOD
11	kinase	kinase	I-NP	NN	I-protein	12	NMOD
12	receptors	receptor	I-NP	NNS	I-protein	9	PMOD
13	(	(	O	(	O	15	DEP
14	Trks	Trk	B-NP	NNS	B-protein	15	DEP
15	)	)	O	)	O	12	NMOD
16	in	in	B-PP	IN	O	8	NMOD
17	micturition	micturition	B-NP	NN	O	18	NMOD
18	reflexes	reflex	I-NP	NNS	O	16	PMOD
19	with	with	B-PP	IN	O	18	NMOD
20	urinary	urinary	B-NP	JJ	O	22	NMOD
21	bladder	bladder	I-NP	NN	O	22	NMOD
22	inflammation	inflammation	I-NP	NN	O	19	PMOD
23	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	studies	study	I-NP	NNS	O	4	SUB
4	examine	examine	B-VP	VBP	O	0	ROOT
5	the	the	O	DT	O	8	NMOD
6	expression	expression	B-NP	NN	O	8	NMOD
7	and	and	O	CC	O	8	NMOD
8	regulation	regulation	B-NP	NN	O	4	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	another	another	B-NP	DT	O	11	NMOD
11	receptor	receptor	I-NP	NN	O	9	PMOD
12	known	know	B-VP	VBN	O	11	NMOD
13	to	to	B-VP	TO	O	14	VMOD
14	bind	bind	I-VP	VB	O	12	VMOD
15	NGF	NGF	B-NP	NN	B-protein	14	OBJ
16	,	,	O	,	O	17	P
17	p75	p75	B-NP	NN	B-protein	15	NMOD
18	(	(	O	(	O	20	DEP
19	NTR	NTR	B-NP	NN	B-protein	20	DEP
20	)	)	O	)	O	17	NMOD
21	,	,	O	,	O	17	P
22	after	after	B-PP	IN	O	17	NMOD
23	various	various	B-NP	JJ	O	24	NMOD
24	durations	duration	I-NP	NNS	O	22	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	bladder	bladder	B-NP	NN	O	27	NMOD
27	inflammation	inflammation	I-NP	NN	O	25	PMOD
28	induced	induce	B-VP	VBN	O	27	NMOD
29	by	by	B-PP	IN	O	28	VMOD
30	cyclophosphamide	cyclophosphamide	B-NP	NN	O	29	PMOD
31	(	(	O	(	O	33	DEP
32	CYP	CYP	B-NP	NN	B-protein	33	DEP
33	)	)	O	)	O	30	NMOD
34	.	.	O	.	O	4	P

1	CYP	CYP	B-NP	NN	B-protein	3	NMOD
2	induced	induced	I-NP	JJ	O	3	NMOD
3	cystitis	cystitis	I-NP	NN	O	4	SUB
4	increased	increase	B-VP	VBD	O	0	ROOT
5	(	(	O	(	O	4	VMOD
6	P	P	B-NP	NN	O	16	NMOD
7	<	<	B-VP	SYM	O	16	NMOD
8	or	or	O	CC	O	16	NMOD
9	=	=	B-VP	SYM	O	10	VMOD
10	0.001	0.001	B-NP	CD	O	11	DEP
11	)	)	O	)	O	16	NMOD
12	p75	p75	B-NP	NN	O	16	NMOD
13	(	(	O	(	O	15	DEP
14	NTR	NTR	B-NP	NN	B-protein	15	DEP
15	)	)	O	)	O	12	NMOD
16	expression	expression	B-NP	NN	O	5	PMOD
17	in	in	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	24	NMOD
19	superficial	superficial	I-NP	JJ	O	24	NMOD
20	lateral	lateral	I-NP	JJ	O	24	NMOD
21	and	and	I-NP	CC	O	24	NMOD
22	medial	medial	I-NP	JJ	O	24	NMOD
23	dorsal	dorsal	I-NP	JJ	O	24	NMOD
24	horn	horn	I-NP	NN	O	17	PMOD
25	in	in	B-PP	IN	O	24	NMOD
26	L1-L2	L1-L2	B-NP	NN	O	30	NMOD
27	and	and	O	CC	O	30	NMOD
28	L6-S1	L6-S1	B-NP	NN	B-protein	30	NMOD
29	spinal	spinal	I-NP	JJ	I-protein	30	NMOD
30	segments	segment	I-NP	NNS	I-protein	25	PMOD
31	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	2	NMOD
2	number	number	I-NP	NN	O	23	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	p75	p75	B-NP	NN	B-cell_line	12	NMOD
5	(	(	O	(	I-cell_line	12	NMOD
6	NTR	NTR	B-NP	NN	I-cell_line	12	NMOD
7	)	)	O	)	I-cell_line	12	NMOD
8	-immunoreactive	-immunoreactive	O	JJ	I-cell_line	12	NMOD
9	(	(	O	(	I-cell_line	11	DEP
10	-IR	-IR	B-ADJP	JJ	I-cell_line	11	DEP
11	)	)	O	)	I-cell_line	8	AMOD
12	cells	cell	B-NP	NNS	I-cell_line	3	PMOD
13	in	in	B-PP	IN	O	2	NMOD
14	the	the	B-NP	DT	O	18	NMOD
15	lumbosacral	lumbosacral	I-NP	JJ	O	18	NMOD
16	dorsal	dorsal	I-NP	JJ	O	18	NMOD
17	root	root	I-NP	NN	O	18	NMOD
18	ganglia	ganglia	I-NP	NNS	O	13	PMOD
19	(	(	O	(	O	21	DEP
20	DRG	DRG	B-NP	NN	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	also	also	B-ADVP	RB	O	23	VMOD
23	increased	increase	B-VP	VBD	O	0	ROOT
24	(	(	O	(	O	30	DEP
25	P	P	B-NP	NN	O	30	DEP
26	<	<	B-VP	SYM	O	28	AMOD
27	or	or	O	CC	O	28	AMOD
28	=	=	B-VP	SYM	O	25	NMOD
29	0.05	0.05	B-NP	CD	O	28	AMOD
30	)	)	O	)	O	23	VMOD
31	with	with	B-PP	IN	O	23	VMOD
32	CYP	CYP	B-NP	NN	B-protein	33	AMOD
33	induced	induce	I-NP	VBN	O	34	NMOD
34	cystitis	cystitis	I-NP	NN	O	31	PMOD
35	(	(	O	(	O	42	DEP
36	acute	acute	B-ADJP	JJ	O	41	NMOD
37	,	,	O	,	O	41	P
38	intermediate	intermediate	B-ADJP	JJ	O	41	NMOD
39	,	,	O	,	O	41	P
40	and	and	O	CC	O	41	NMOD
41	chronic	chronic	B-ADJP	JJ	O	42	DEP
42	)	)	O	)	O	34	NMOD
43	.	.	O	.	O	23	P

1	Quantitative	Quantitative	B-NP	JJ	O	3	AMOD
2	,	,	I-NP	,	O	3	P
3	real-time	real-time	I-NP	JJ	O	6	NMOD
4	polymerase	polymerase	I-NP	NN	O	6	NMOD
5	chain	chain	I-NP	NN	O	6	NMOD
6	reaction	reaction	I-NP	NN	O	8	SUB
7	also	also	B-ADVP	RB	O	8	VMOD
8	demonstrated	demonstrate	B-VP	VBD	O	0	ROOT
9	significant	significant	B-NP	JJ	O	10	NMOD
10	increases	increase	I-NP	NNS	O	8	OBJ
11	(	(	O	(	O	17	DEP
12	P	P	B-NP	NN	O	17	DEP
13	<	<	B-VP	SYM	O	15	AMOD
14	or	or	O	CC	O	15	AMOD
15	=	=	B-VP	SYM	O	12	NMOD
16	0.01	0.01	B-NP	CD	O	15	AMOD
17	)	)	O	)	O	10	NMOD
18	in	in	B-PP	IN	O	10	NMOD
19	p75	p75	B-NP	NN	B-RNA	23	NMOD
20	(	(	O	(	I-RNA	23	NMOD
21	NTR	NTR	B-NP	NN	I-RNA	23	NMOD
22	)	)	O	)	I-RNA	23	NMOD
23	mRNA	mRNA	B-NP	NN	I-RNA	18	PMOD
24	in	in	B-PP	IN	O	10	NMOD
25	DRG	DRG	B-NP	NN	O	24	PMOD
26	with	with	B-PP	IN	O	25	NMOD
27	intermediate	intermediate	B-NP	JJ	O	29	AMOD
28	and	and	I-NP	CC	O	29	AMOD
29	chronic	chronic	I-NP	JJ	O	26	PMOD
30	CYP	CYP	I-NP	NN	B-protein	32	NMOD
31	induced	induce	B-VP	VBD	O	32	NMOD
32	cystitis	cystitis	B-NP	NN	O	29	NMOD
33	.	.	O	.	O	8	P

1	The	The	B-NP	DT	O	3	NMOD
2	side	side	I-NP	JJ	O	3	NMOD
3	effects	effect	I-NP	NNS	O	6	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	azathioprine	azathioprine	B-NP	NN	O	4	PMOD
6	include	include	B-VP	VBP	O	0	ROOT
7	anemia	anemia	B-NP	NN	O	6	OBJ
8	,	,	O	,	O	7	P
9	which	which	B-NP	WDT	O	7	NMOD
10	has	have	B-VP	VBZ	O	9	SBAR
11	been	be	I-VP	VBN	O	10	VC
12	attributed	attribute	I-VP	VBN	O	11	VC
13	to	to	B-PP	TO	O	12	VMOD
14	bone	bone	B-NP	NN	O	16	NMOD
15	marrow	marrow	I-NP	NN	O	16	NMOD
16	suppression	suppression	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	6	P

1	Alternatively	Alternatively	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	anemia	anemia	B-NP	NN	O	4	SUB
4	could	could	B-VP	MD	O	0	ROOT
5	result	result	I-VP	VB	O	4	VC
6	from	from	B-PP	IN	O	5	VMOD
7	accelerated	accelerate	B-NP	VBN	O	12	NMOD
8	suicidal	suicidal	I-NP	JJ	O	10	NMOD
9	erythrocyte	erythrocyte	I-NP	NN	O	10	NMOD
10	death	death	I-NP	NN	O	12	NMOD
11	or	or	I-NP	CC	O	12	NMOD
12	eryptosis	eryptosis	I-NP	NN	O	6	PMOD
13	,	,	O	,	O	12	P
14	which	which	B-NP	WDT	O	12	NMOD
15	is	be	B-VP	VBZ	O	14	SBAR
16	characterized	characterize	I-VP	VBN	O	15	VC
17	by	by	B-PP	IN	O	16	VMOD
18	exposure	exposure	B-NP	NN	O	17	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	phosphatidylserine	phosphatidylserine	B-NP	NN	O	19	PMOD
21	(	(	O	(	O	23	DEP
22	PS	PS	B-NP	NN	O	23	DEP
23	)	)	O	)	O	20	NMOD
24	at	at	B-PP	IN	O	18	NMOD
25	the	the	B-NP	DT	O	27	NMOD
26	erythrocyte	erythrocyte	I-NP	NN	O	27	NMOD
27	surface	surface	I-NP	NN	O	24	PMOD
28	and	and	B-PP	CC	O	17	PMOD
29	by	by	B-PP	IN	O	17	PMOD
30	cell	cell	B-NP	NN	O	31	NMOD
31	shrinkage	shrinkage	I-NP	NN	O	29	PMOD
32	.	.	O	.	O	4	P

1	Four	Four	B-NP	CD	O	6	NMOD
2	(	(	O	(	O	5	DEP
3	10.8	10.8	B-NP	CD	O	4	NMOD
4	%	%	I-NP	NN	O	5	DEP
5	)	)	O	)	O	1	NMOD
6	patients	patient	B-NP	NNS	O	24	SUB
7	in	in	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	10	NMOD
9	conventional	conventional	I-NP	JJ	O	10	NMOD
10	group	group	I-NP	NN	O	7	PMOD
11	and	and	O	CC	O	24	VMOD
12	1	1	B-NP	CD	O	24	VMOD
13	(	(	O	(	O	16	DEP
14	2.7	2.7	B-NP	CD	O	15	NMOD
15	%	%	I-NP	NN	O	16	DEP
16	)	)	O	)	O	12	NMOD
17	in	in	B-PP	IN	O	12	NMOD
18	the	the	B-NP	DT	O	20	NMOD
19	unilateral	unilateral	I-NP	JJ	O	20	NMOD
20	group	group	I-NP	NN	O	17	PMOD
21	,	,	O	,	O	24	P
22	P=	P=	B-NP	NN	O	24	SUB
23	0.17	0.17	I-NP	CD	O	22	NMOD
24	required	require	B-VP	VBD	O	0	ROOT
25	epinephrine	epinephrine	B-NP	NN	O	26	NMOD
26	infusion	infusion	I-NP	NN	O	24	OBJ
27	to	to	B-VP	TO	O	28	VMOD
28	treat	treat	I-VP	VB	O	26	NMOD
29	hypotension	hypotension	B-NP	NN	O	28	OBJ
30	.	.	O	.	O	24	P

1	Clinically	Clinically	B-NP	RB	O	10	SUB
2	significant	significant	I-NP	JJ	O	3	NMOD
3	anemia	anemia	I-NP	NN	O	1	NMOD
4	(	(	O	(	O	9	DEP
5	hemoglobin	hemoglobin	B-NP	NN	B-protein	8	NMOD
6	<	<	O	SYM	O	8	NMOD
7	7	7	B-NP	CD	O	8	NMOD
8	g/dL	g/dL	I-NP	NN	O	9	DEP
9	)	)	O	)	O	3	NMOD
10	was	be	B-VP	VBD	O	0	ROOT
11	observed	observe	I-VP	VBN	O	10	VC
12	in	in	B-PP	IN	O	11	VMOD
13	5.4	5.4	B-NP	CD	O	14	NMOD
14	%	%	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	patients	patient	B-NP	NNS	O	24	NMOD
17	(	(	O	(	O	22	DEP
18	CD4	CD4	B-NP	NN	B-protein	21	NMOD
19	,	,	O	,	O	21	P
20	165	165	B-NP	CD	O	21	NMOD
21	cells/microL	cells/microL	I-NP	NN	O	22	DEP
22	)	)	O	)	O	16	NMOD
23	and	and	O	CC	O	24	NMOD
24	hepatitis	hepatitis	B-NP	NN	O	15	PMOD
25	(	(	O	(	O	24	NMOD
26	clinical	clinical	B-NP	JJ	O	27	NMOD
27	jaundice	jaundice	I-NP	NN	O	25	PMOD
28	with	with	B-PP	IN	O	27	NMOD
29	alanine	alanine	B-NP	NN	B-protein	30	NMOD
30	aminotransferase	aminotransferase	I-NP	NN	I-protein	33	NMOD
31	>	>	B-VP	SYM	O	33	P
32	5	5	B-NP	CD	O	33	AMOD
33	times	time	I-NP	NNS	O	35	NMOD
34	upper	upper	I-NP	JJ	O	35	NMOD
35	limits	limit	I-NP	NNS	O	28	PMOD
36	of	of	B-PP	IN	O	35	NMOD
37	normal	normal	B-NP	JJ	O	36	PMOD
38	)	)	O	)	O	37	NMOD
39	in	in	B-PP	IN	O	27	NMOD
40	3.5	3.5	B-NP	CD	O	41	NMOD
41	%	%	I-NP	NN	O	39	PMOD
42	of	of	B-PP	IN	O	41	NMOD
43	patients	patient	B-NP	NNS	O	42	PMOD
44	(	(	O	(	O	49	DEP
45	CD4	CD4	B-NP	NN	B-protein	48	NMOD
46	,	,	O	,	O	48	P
47	260	260	B-NP	CD	O	48	NMOD
48	cells/microL	cells/microL	I-NP	NN	O	49	DEP
49	)	)	O	)	O	43	NMOD
50	.	.	O	.	O	10	P

1	Among	Among	B-PP	IN	O	12	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	patients	patient	I-NP	NNS	O	1	PMOD
4	with	with	B-PP	IN	O	3	NMOD
5	1	1	B-NP	CD	O	6	NMOD
6	year	year	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	follow-up	follow-up	B-NP	NN	O	7	PMOD
9	,	,	O	,	O	12	P
10	NVP	NVP	B-NP	NN	O	11	NMOD
11	therapy	therapy	I-NP	NN	O	12	SUB
12	was	be	B-VP	VBD	O	0	ROOT
13	significantly	significantly	I-VP	RB	O	12	VMOD
14	associated	associate	I-VP	VBN	O	12	VC
15	with	with	B-PP	IN	O	14	VMOD
16	developing	develop	B-VP	VBG	O	15	PMOD
17	rash	rash	B-NP	NN	O	20	NMOD
18	and	and	I-NP	CC	O	20	NMOD
19	d4T	d4T	I-NP	NN	O	20	NMOD
20	therapy	therapy	I-NP	NN	O	16	OBJ
21	with	with	B-PP	IN	O	16	VMOD
22	developing	develop	B-VP	VBG	O	21	PMOD
23	peripheral	peripheral	B-NP	JJ	O	24	NMOD
24	neuropathy	neuropathy	I-NP	NN	O	22	OBJ
25	(	(	O	(	O	29	DEP
26	p	p	B-NP	NN	O	29	DEP
27	<	<	O	SYM	O	26	NMOD
28	0.05	0.05	B-NP	CD	O	27	AMOD
29	)	)	O	)	O	12	VMOD
30	.	.	O	.	O	12	P

1	Thalidomide	Thalidomide	B-NP	NN	O	4	NMOD
2	and	and	O	CC	O	4	NMOD
3	sensory	sensory	B-NP	JJ	O	4	NMOD
4	neurotoxicity	neurotoxicity	I-NP	NN	O	8	NMOD
5	:	:	O	:	O	4	P
6	a	a	B-NP	DT	O	8	NMOD
7	neurophysiological	neurophysiological	I-NP	JJ	O	8	NMOD
8	study	study	I-NP	NN	O	0	ROOT
9	.	.	O	.	O	8	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Recent	Recent	B-NP	JJ	O	4	NMOD
4	studies	study	I-NP	NNS	O	5	SUB
5	confirmed	confirm	B-VP	VBD	O	1	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	high	high	I-NP	JJ	O	8	NMOD
8	incidence	incidence	I-NP	NN	O	5	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	sensory	sensory	B-NP	JJ	O	12	NMOD
11	axonal	axonal	I-NP	JJ	O	12	NMOD
12	neuropathy	neuropathy	I-NP	NN	O	9	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	patients	patient	B-NP	NNS	O	13	PMOD
15	treated	treat	B-VP	VBN	O	14	NMOD
16	with	with	B-PP	IN	O	15	VMOD
17	different	different	B-NP	JJ	O	18	NMOD
18	doses	dose	I-NP	NNS	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	thalidomide	thalidomide	B-NP	NN	O	19	PMOD
21	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	3	NMOD
2	study	study	I-NP	NN	O	3	NMOD
3	's	's	B-NP	POS	O	4	NMOD
4	aims	aim	I-NP	NNS	O	5	SUB
5	were	be	B-VP	VBD	O	0	ROOT
6	to	to	I-VP	TO	O	7	VMOD
7	measure	measure	I-VP	VB	O	5	PRD
8	variations	variation	B-NP	NNS	O	7	OBJ
9	in	in	B-PP	IN	O	8	NMOD
10	sural	sural	B-NP	JJ	O	14	NMOD
11	nerve	nerve	I-NP	NN	O	14	NMOD
12	sensory	sensory	I-NP	JJ	O	14	NMOD
13	action	action	I-NP	NN	O	14	NMOD
14	potential	potential	I-NP	NN	O	18	NMOD
15	(	(	O	(	O	17	DEP
16	SAP	SAP	B-NP	NN	B-protein	17	DEP
17	)	)	O	)	O	14	NMOD
18	amplitude	amplitude	B-NP	NN	O	9	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	patients	patient	B-NP	NNS	O	19	PMOD
21	with	with	B-PP	IN	O	20	NMOD
22	refractory	refractory	B-NP	JJ	O	25	NMOD
23	cutaneous	cutaneous	I-NP	JJ	O	25	NMOD
24	lupus	lupus	I-NP	NN	O	25	NMOD
25	erythematosus	erythematosus	I-NP	NN	O	21	PMOD
26	(	(	O	(	O	28	DEP
27	CLE	CLE	B-NP	NN	O	28	DEP
28	)	)	O	)	O	25	NMOD
29	treated	treat	B-VP	VBN	O	25	NMOD
30	with	with	B-PP	IN	O	29	VMOD
31	thalidomide	thalidomide	B-NP	NN	O	30	PMOD
32	and	and	O	CC	O	7	VMOD
33	use	use	B-VP	VB	O	7	VMOD
34	these	these	B-NP	DT	O	35	NMOD
35	findings	finding	I-NP	NNS	O	33	OBJ
36	to	to	B-VP	TO	O	37	VMOD
37	identify	identify	I-VP	VB	O	33	VMOD
38	the	the	B-NP	DT	O	40	NMOD
39	neurotoxic	neurotoxic	I-NP	JJ	O	40	NMOD
40	potential	potential	I-NP	NN	O	46	NMOD
41	of	of	B-PP	IN	O	40	NMOD
42	thalidomide	thalidomide	B-NP	NN	O	41	PMOD
43	and	and	O	CC	O	46	NMOD
44	the	the	B-NP	DT	O	46	NMOD
45	recovery	recovery	I-NP	NN	O	46	NMOD
46	capacity	capacity	I-NP	NN	O	37	OBJ
47	of	of	B-PP	IN	O	46	NMOD
48	sensory	sensory	B-NP	JJ	O	49	NMOD
49	fibres	fibre	I-NP	NNS	O	47	PMOD
50	after	after	B-PP	IN	O	33	VMOD
51	discontinuation	discontinuation	B-NP	NN	O	50	PMOD
52	of	of	B-PP	IN	O	51	NMOD
53	treatment	treatment	B-NP	NN	O	52	PMOD
54	.	.	O	.	O	5	P

1	PATIENTS	PATIENTS	B-NP	NNS	O	3	NMOD
2	AND	AND	I-NP	CC	O	3	NMOD
3	METHODS	METHODS	I-NP	NNS	O	0	ROOT
4	:	:	O	:	O	3	P
5	Clinical	Clinical	B-NP	JJ	O	8	NMOD
6	and	and	I-NP	CC	O	8	NMOD
7	electrophysiological	electrophysiological	I-NP	JJ	O	8	NMOD
8	data	datum	I-NP	NNS	O	23	NMOD
9	in	in	B-PP	IN	O	8	NMOD
10	12	12	B-NP	CD	O	12	NMOD
11	female	female	I-NP	JJ	O	12	NMOD
12	patients	patient	I-NP	NNS	O	9	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	CLE	CLE	B-NP	NN	O	13	PMOD
15	during	during	B-PP	IN	O	8	NMOD
16	treatment	treatment	B-NP	NN	O	15	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	thalidomide	thalidomide	B-NP	NN	O	17	PMOD
19	and	and	O	CC	O	23	NMOD
20	up	up	B-NP	RB	O	23	NMOD
21	to	to	I-NP	TO	O	20	AMOD
22	47	47	I-NP	CD	O	20	AMOD
23	months	month	I-NP	NNS	O	24	PMOD
24	after	after	B-PP	IN	O	3	NMOD
25	discontinuation	discontinuation	B-NP	NN	O	24	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	treatment	treatment	B-NP	NN	O	26	PMOD
28	were	be	B-VP	VBD	O	24	SBAR
29	analysed	analyse	I-VP	VBN	O	28	VC
30	.	.	O	.	O	3	P

1	Amiodarone-related	Amiodarone-related	B-NP	JJ	O	3	NMOD
2	pulmonary	pulmonary	I-NP	JJ	O	3	NMOD
3	mass	mass	I-NP	NN	O	7	NMOD
4	and	and	O	CC	O	7	NMOD
5	unique	unique	B-NP	JJ	O	7	NMOD
6	membranous	membranous	I-NP	JJ	O	7	NMOD
7	glomerulonephritis	glomerulonephritis	I-NP	NN	O	17	NMOD
8	in	in	B-PP	IN	O	7	NMOD
9	a	a	B-NP	DT	O	10	NMOD
10	patient	patient	I-NP	NN	O	8	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	valvular	valvular	B-NP	JJ	O	14	NMOD
13	heart	heart	I-NP	NN	O	14	NMOD
14	disease	disease	I-NP	NN	O	11	PMOD
15	:	:	O	:	O	7	P
16	Diagnostic	Diagnostic	B-NP	JJ	O	17	NMOD
17	pitfall	pitfall	I-NP	NN	O	20	NMOD
18	and	and	O	CC	O	20	NMOD
19	new	new	B-NP	JJ	O	20	NMOD
20	findings	finding	I-NP	NNS	O	0	ROOT
21	.	.	O	.	O	20	P

1	Amiodarone	Amiodarone	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	14	VMOD
3	an	an	B-NP	DT	O	5	NMOD
4	anti-arrhythmic	anti-arrhythmic	I-NP	JJ	O	5	NMOD
5	drug	drug	I-NP	NN	O	2	PRD
6	for	for	B-PP	IN	O	5	NMOD
7	life-threatening	life-threatening	B-NP	JJ	O	8	NMOD
8	tachycardia	tachycardia	I-NP	NN	O	6	PMOD
9	,	,	O	,	O	14	P
10	but	but	O	CC	O	14	VMOD
11	various	various	B-NP	JJ	O	13	NMOD
12	adverse	adverse	I-NP	JJ	O	13	NMOD
13	effects	effect	I-NP	NNS	O	14	SUB
14	have	have	B-VP	VBP	O	0	ROOT
15	been	be	I-VP	VBN	O	14	VC
16	reported	report	I-VP	VBN	O	15	VC
17	.	.	O	.	O	14	P

1	Reported	Report	B-VP	VBN	O	0	ROOT
2	herein	herein	B-ADVP	RB	O	1	VMOD
3	is	be	B-VP	VBZ	O	1	VMOD
4	an	an	B-NP	DT	O	6	NMOD
5	autopsy	autopsy	I-NP	NN	O	6	NMOD
6	case	case	I-NP	NN	O	1	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	valvular	valvular	B-NP	JJ	O	10	NMOD
9	heart	heart	I-NP	NN	O	10	NMOD
10	disease	disease	I-NP	NN	O	7	PMOD
11	,	,	O	,	O	1	P
12	in	in	B-PP	IN	O	1	VMOD
13	a	a	B-NP	DT	O	14	NMOD
14	patient	patient	I-NP	NN	O	12	PMOD
15	who	who	B-NP	WP	O	14	NMOD
16	developed	develop	B-VP	VBD	O	15	SBAR
17	a	a	B-NP	DT	O	19	NMOD
18	lung	lung	I-NP	NN	O	19	NMOD
19	mass	mass	I-NP	NN	O	27	NMOD
20	(	(	O	(	O	25	DEP
21	1.5	1.5	B-NP	CD	O	22	NMOD
22	cm	cm	I-NP	NN	O	25	DEP
23	in	in	B-PP	IN	O	22	NMOD
24	diameter	diameter	B-NP	NN	O	23	PMOD
25	)	)	O	)	O	19	NMOD
26	and	and	O	CC	O	27	NMOD
27	proteinuria	proteinuria	B-NP	NN	O	16	OBJ
28	(	(	O	(	O	31	DEP
29	2.76	2.76	B-NP	CD	O	30	NMOD
30	g/day	g/day	I-NP	NN	O	31	DEP
31	)	)	O	)	O	27	NMOD
32	after	after	B-PP	IN	O	16	VMOD
33	treatment	treatment	B-NP	NN	O	32	PMOD
34	with	with	B-PP	IN	O	33	NMOD
35	amiodarone	amiodarone	B-NP	NN	O	34	PMOD
36	for	for	B-PP	IN	O	35	NMOD
37	a	a	B-NP	DT	O	39	NMOD
38	long	long	I-NP	JJ	O	39	NMOD
39	time	time	I-NP	NN	O	36	PMOD
40	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	3	NMOD
2	lung	lung	I-NP	NN	O	3	NMOD
3	mass	mass	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	22	VMOD
5	highly	highly	I-VP	RB	O	4	VMOD
6	suspected	suspect	I-VP	VBN	O	22	VMOD
7	to	to	I-VP	TO	O	8	VMOD
8	be	be	I-VP	VB	O	6	VMOD
9	lung	lung	B-NP	NN	O	10	NMOD
10	cancer	cancer	I-NP	NN	O	8	PRD
11	on	on	B-PP	IN	O	10	NMOD
12	CT	CT	B-NP	NN	O	16	NMOD
13	and	and	I-NP	CC	O	16	NMOD
14	positron	positron	I-NP	NN	O	16	NMOD
15	emission	emission	I-NP	NN	O	16	NMOD
16	tomography	tomography	I-NP	NN	O	11	PMOD
17	,	,	O	,	O	6	P
18	but	but	O	CC	O	6	VMOD
19	histologically	histologically	B-ADVP	RB	O	22	VMOD
20	the	the	B-NP	DT	O	21	NMOD
21	lesion	lesion	I-NP	NN	O	22	SUB
22	was	be	B-VP	VBD	O	0	ROOT
23	composed	compose	I-VP	VBN	O	22	VC
24	of	of	B-PP	IN	O	23	VMOD
25	lymphoplasmacytic	lymphoplasmacytic	B-NP	JJ	B-cell_type	26	NMOD
26	infiltrates	infiltrate	I-NP	NNS	I-cell_type	24	PMOD
27	in	in	B-PP	IN	O	26	NMOD
28	alveolar	alveolar	B-NP	JJ	B-cell_type	29	NMOD
29	walls	wall	I-NP	NNS	I-cell_type	32	NMOD
30	and	and	O	CC	O	32	NMOD
31	intra-alveolar	intra-alveolar	B-NP	JJ	O	32	NMOD
32	accumulation	accumulation	I-NP	NN	O	27	PMOD
33	of	of	B-PP	IN	O	32	NMOD
34	foamy	foamy	B-NP	JJ	B-cell_type	35	NMOD
35	macrophages	macrophage	I-NP	NNS	I-cell_type	33	PMOD
36	containing	contain	B-VP	VBG	O	35	NMOD
37	characteristic	characteristic	B-NP	JJ	O	39	NMOD
38	myelinoid	myelinoid	I-NP	JJ	O	39	NMOD
39	bodies	body	I-NP	NNS	O	36	OBJ
40	,	,	O	,	O	22	P
41	indicating	indicate	B-VP	VBG	O	22	VMOD
42	that	that	B-SBAR	IN	O	41	VMOD
43	it	it	B-NP	PRP	O	44	SUB
44	was	be	B-VP	VBD	O	42	SBAR
45	an	an	B-NP	DT	O	47	NMOD
46	amiodarone-related	amiodarone-related	I-NP	JJ	O	47	NMOD
47	lesion	lesion	I-NP	NN	O	44	PRD
48	.	.	O	.	O	22	P

1	Risk	Risk	B-NP	NN	O	21	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	coronary	coronary	B-NP	JJ	O	5	NMOD
4	artery	artery	I-NP	NN	O	5	NMOD
5	disease	disease	I-NP	NN	O	2	PMOD
6	associated	associate	B-VP	VBN	O	1	NMOD
7	with	with	B-PP	IN	O	6	VMOD
8	initial	initial	B-NP	JJ	O	10	NMOD
9	sulphonylurea	sulphonylurea	I-NP	NN	O	10	NMOD
10	treatment	treatment	I-NP	NN	O	7	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	patients	patient	B-NP	NNS	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	type	type	B-NP	NN	O	16	NMOD
15	2	2	I-NP	CD	O	16	NMOD
16	diabetes	diabete	I-NP	NNS	O	13	PMOD
17	:	:	O	:	O	1	P
18	a	a	B-NP	DT	O	21	NMOD
19	matched	matched	I-NP	JJ	O	21	NMOD
20	case-control	case-control	I-NP	JJ	O	21	NMOD
21	study	study	I-NP	NN	O	0	ROOT
22	.	.	O	.	O	21	P

1	AIMS	AIMS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	This	This	B-NP	DT	O	4	NMOD
4	study	study	I-NP	NN	O	5	SUB
5	sought	seek	B-VP	VBD	O	1	NMOD
6	to	to	I-VP	TO	O	7	VMOD
7	assess	assess	I-VP	VB	O	5	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	risk	risk	I-NP	NN	O	7	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	developing	develop	B-VP	VBG	O	10	PMOD
12	coronary	coronary	B-NP	JJ	O	14	NMOD
13	artery	artery	I-NP	NN	O	14	NMOD
14	disease	disease	I-NP	NN	O	11	OBJ
15	(	(	O	(	O	17	DEP
16	CAD	CAD	B-NP	NN	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	associated	associate	B-VP	VBN	O	14	NMOD
19	with	with	B-PP	IN	O	18	VMOD
20	initial	initial	B-NP	JJ	O	21	NMOD
21	treatment	treatment	I-NP	NN	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	type	type	B-NP	NN	O	25	NMOD
24	2	2	I-NP	CD	O	25	NMOD
25	diabetes	diabete	I-NP	NNS	O	22	PMOD
26	with	with	B-PP	IN	O	21	NMOD
27	different	different	B-NP	JJ	O	28	NMOD
28	sulphonylureas	sulphonylurea	I-NP	NNS	O	26	PMOD
29	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	hazard	hazard	I-NP	NN	O	15	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	developing	develop	B-VP	VBG	O	3	PMOD
5	CAD	CAD	B-NP	NN	O	4	OBJ
6	(	(	O	(	O	10	DEP
7	95	95	B-NP	CD	O	9	NMOD
8	%	%	I-NP	NN	O	9	NMOD
9	CI	CI	I-NP	NN	O	10	DEP
10	)	)	O	)	O	5	NMOD
11	associated	associate	B-VP	VBN	O	5	NMOD
12	with	with	B-PP	IN	O	11	VMOD
13	initial	initial	B-NP	JJ	O	14	NMOD
14	treatment	treatment	I-NP	NN	O	12	PMOD
15	increased	increase	B-VP	VBD	O	45	VMOD
16	by	by	B-PP	IN	O	15	VMOD
17	2.4-fold	2.4-fold	B-ADJP	JJ	O	16	PMOD
18	(	(	O	(	O	22	DEP
19	1.3-4.3	1.3-4.3	B-NP	CD	O	21	NMOD
20	,	,	O	,	O	21	P
21	P=0.004	P=0.004	B-NP	NN	O	22	DEP
22	)	)	O	)	O	17	NMOD
23	with	with	B-PP	IN	O	15	VMOD
24	glibenclamide	glibenclamide	B-NP	NN	O	23	PMOD
25	;	;	O	:	O	45	P
26	2-fold	2-fold	B-ADVP	RB	O	45	VMOD
27	(	(	O	(	O	31	DEP
28	0.9-4.6	0.9-4.6	B-NP	CD	O	30	NMOD
29	,	,	O	,	O	30	P
30	P=0.099	P=0.099	B-NP	NN	O	31	DEP
31	)	)	O	)	O	26	AMOD
32	with	with	B-PP	IN	O	26	PMOD
33	glipizide	glipizide	B-NP	NN	O	32	PMOD
34	;	;	O	:	O	45	P
35	2.9-fold	2.9-fold	B-ADVP	RB	O	45	VMOD
36	(	(	O	(	O	40	DEP
37	1.6-5.1	1.6-5.1	B-NP	CD	O	39	NMOD
38	,	,	O	,	O	39	P
39	P=0.000	P=0.000	B-NP	NN	O	40	DEP
40	)	)	O	)	O	35	AMOD
41	with	with	B-PP	IN	O	35	PMOD
42	either	either	O	CC	O	41	PMOD
43	,	,	O	,	O	35	P
44	and	and	O	CC	O	45	DEP
45	was	be	B-VP	VBD	O	0	ROOT
46	unchanged	unchanged	B-ADJP	JJ	O	45	PRD
47	with	with	B-PP	IN	O	46	AMOD
48	metformin	metformin	B-NP	NN	O	47	PMOD
49	.	.	O	.	O	45	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Initiating	Initiate	B-VP	VBG	O	1	NMOD
4	treatment	treatment	B-NP	NN	O	3	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	type	type	B-NP	NN	O	8	NMOD
7	2	2	I-NP	CD	O	8	NMOD
8	diabetes	diabete	I-NP	NNS	O	5	PMOD
9	with	with	B-PP	IN	O	4	NMOD
10	glibenclamide	glibenclamide	B-NP	NN	O	12	NMOD
11	or	or	I-NP	CC	O	12	NMOD
12	glipizide	glipizide	I-NP	NN	O	9	PMOD
13	is	be	B-VP	VBZ	O	1	NMOD
14	associated	associate	I-VP	VBN	O	13	VC
15	with	with	B-PP	IN	O	14	VMOD
16	increased	increase	B-NP	VBN	O	17	NMOD
17	risk	risk	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	CAD	CAD	B-NP	NN	B-protein	18	PMOD
20	in	in	B-PP	IN	O	17	NMOD
21	comparison	comparison	B-NP	NN	O	20	PMOD
22	to	to	B-PP	TO	O	21	NMOD
23	gliclazide	gliclazide	B-NP	NN	O	25	NMOD
24	or	or	I-NP	CC	O	25	NMOD
25	glimepiride	glimepiride	I-NP	NN	O	22	PMOD
26	.	.	O	.	O	1	P

1	Reduced	Reduce	B-NP	VBN	O	2	NMOD
2	progression	progression	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	adriamycin	adriamycin	B-NP	NN	O	5	NMOD
5	nephropathy	nephropathy	I-NP	NN	O	3	PMOD
6	in	in	B-PP	IN	O	2	NMOD
7	spontaneously	spontaneously	B-NP	RB	O	8	AMOD
8	hypertensive	hypertensive	I-NP	JJ	O	9	NMOD
9	rats	rat	I-NP	NNS	O	6	PMOD
10	treated	treat	B-VP	VBN	O	9	NMOD
11	by	by	B-PP	IN	O	10	VMOD
12	losartan	losartan	B-NP	NN	O	11	PMOD
13	.	.	O	.	O	2	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	aim	aim	I-NP	NN	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	study	study	I-NP	NN	O	5	PMOD
8	was	be	B-VP	VBD	O	1	NMOD
9	to	to	B-VP	TO	O	10	VMOD
10	investigate	investigate	I-VP	VB	O	8	PRD
11	the	the	B-NP	DT	O	13	NMOD
12	antihypertensive	antihypertensive	I-NP	JJ	O	13	NMOD
13	effects	effect	I-NP	NNS	O	10	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	angiotensin	angiotensin	B-NP	NN	B-protein	19	NMOD
16	II	II	I-NP	CD	I-protein	19	NMOD
17	type-1	type-1	I-NP	NN	I-protein	19	NMOD
18	receptor	receptor	I-NP	NN	I-protein	19	NMOD
19	blocker	blocker	I-NP	NN	O	25	NMOD
20	,	,	O	,	O	25	P
21	losartan	losartan	B-NP	NN	O	25	NMOD
22	,	,	O	,	O	25	P
23	and	and	O	CC	O	25	NMOD
24	its	its	B-NP	PRP$	O	25	NMOD
25	potential	potential	I-NP	NN	O	14	PMOD
26	in	in	B-PP	IN	O	10	VMOD
27	slowing	slow	B-VP	VBG	O	26	PMOD
28	down	down	B-PRT	RP	O	27	VMOD
29	renal	renal	B-NP	JJ	O	31	NMOD
30	disease	disease	I-NP	NN	O	31	NMOD
31	progression	progression	I-NP	NN	O	27	OBJ
32	in	in	B-PP	IN	O	31	NMOD
33	spontaneously	spontaneously	B-NP	RB	O	34	AMOD
34	hypertensive	hypertensive	I-NP	JJ	O	35	NMOD
35	rats	rat	I-NP	NNS	O	32	PMOD
36	(	(	O	(	O	38	DEP
37	SHR	SHR	B-NP	NN	B-protein	38	DEP
38	)	)	O	)	O	35	NMOD
39	with	with	B-PP	IN	O	31	NMOD
40	adriamycin	adriamycin	B-NP	NN	O	44	NMOD
41	(	(	O	(	O	43	DEP
42	ADR	ADR	B-NP	NN	O	43	DEP
43	)	)	O	)	O	40	NMOD
44	nephropathy	nephropathy	B-NP	NN	O	39	PMOD
45	.	.	O	.	O	8	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Short-term	Short-term	B-NP	JJ	O	5	NMOD
4	losartan	losartan	I-NP	NN	O	5	NMOD
5	treatment	treatment	I-NP	NN	O	1	NMOD
6	,	,	O	,	O	5	P
7	besides	besides	B-PP	IN	O	5	NMOD
8	antihypertensive	antihypertensive	B-NP	JJ	O	9	NMOD
9	effect	effect	I-NP	NN	O	7	PMOD
10	,	,	O	,	O	5	P
11	improved	improve	B-VP	VBD	O	1	NMOD
12	glomerular	glomerular	B-NP	JJ	O	14	NMOD
13	filtration	filtration	I-NP	NN	O	14	NMOD
14	rate	rate	I-NP	NN	O	17	NMOD
15	and	and	O	CC	O	17	NMOD
16	ameliorated	ameliorate	B-NP	VBN	O	17	NMOD
17	glomerulosclerosis	glomerulosclerosis	I-NP	NN	O	11	OBJ
18	resulting	result	B-VP	VBG	O	17	NMOD
19	in	in	B-PP	IN	O	18	VMOD
20	decreased	decrease	B-NP	VBN	O	21	NMOD
21	proteinuria	proteinuria	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	1	P

1	Prolonged	Prolonged	B-NP	JJ	O	2	NMOD
2	treatment	treatment	I-NP	NN	O	5	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	losartan	losartan	B-NP	NN	O	3	PMOD
5	showed	show	B-VP	VBD	O	0	ROOT
6	further	further	B-NP	JJ	O	7	NMOD
7	reduction	reduction	I-NP	NN	O	5	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	glomerulosclerosis	glomerulosclerosis	B-NP	NN	O	8	PMOD
10	associated	associate	B-VP	VBN	O	9	NMOD
11	with	with	B-PP	IN	O	10	VMOD
12	reduced	reduce	B-NP	VBN	O	13	NMOD
13	progression	progression	I-NP	NN	O	19	NMOD
14	of	of	B-PP	IN	O	13	NMOD
15	tubular	tubular	B-NP	JJ	O	16	NMOD
16	atrophy	atrophy	I-NP	NN	O	14	PMOD
17	and	and	O	CC	O	19	NMOD
18	interstitial	interstitial	B-NP	JJ	O	19	NMOD
19	fibrosis	fibrosis	I-NP	NN	O	11	PMOD
20	,	,	O	,	O	5	P
21	thus	thus	B-ADVP	RB	O	22	VMOD
22	preventing	prevent	B-VP	VBG	O	5	VMOD
23	heavy	heavy	B-NP	JJ	O	24	NMOD
24	proteinuria	proteinuria	I-NP	NN	O	28	NMOD
25	and	and	O	CC	O	28	NMOD
26	chronic	chronic	B-NP	JJ	O	28	NMOD
27	renal	renal	I-NP	JJ	O	28	NMOD
28	failure	failure	I-NP	NN	O	22	OBJ
29	.	.	O	.	O	5	P

1	Losartan	Losartan	B-NP	NNP	O	2	SUB
2	reduced	reduce	B-VP	VBD	O	0	ROOT
3	uraemia	uraemia	B-NP	NN	O	2	OBJ
4	and	and	O	CC	O	2	VMOD
5	increased	increase	B-VP	VBD	O	2	VMOD
6	urea	urea	B-NP	NN	O	7	NMOD
7	clearance	clearance	I-NP	NN	O	5	OBJ
8	in	in	B-PP	IN	O	7	NMOD
9	advanced	advance	B-NP	VBN	O	11	NMOD
10	ADR	ADR	I-NP	NN	O	11	NMOD
11	nephropathy	nephropathy	I-NP	NN	O	8	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	SHR	SHR	B-NP	NN	B-protein	12	PMOD
14	.	.	O	.	O	2	P

1	Histological	Histological	B-NP	JJ	O	2	NMOD
2	examination	examination	I-NP	NN	O	3	SUB
3	showed	show	B-VP	VBD	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	losartan	losartan	B-NP	NN	O	6	SUB
6	could	could	B-VP	MD	O	4	SBAR
7	prevent	prevent	I-VP	VB	O	6	VC
8	tubular	tubular	B-NP	JJ	O	9	NMOD
9	atrophy	atrophy	I-NP	NN	O	7	OBJ
10	,	,	O	,	O	3	P
11	interstitial	interstitial	B-NP	JJ	O	12	NMOD
12	infiltration	infiltration	I-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	fibrosis	fibrosis	I-NP	NN	O	3	VMOD
15	in	in	B-PP	IN	O	14	NMOD
16	ADR	ADR	B-NP	NN	O	17	NMOD
17	nephropathy	nephropathy	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	3	NMOD
2	biological	biological	I-NP	JJ	O	3	NMOD
3	properties	property	I-NP	NNS	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	7	NMOD
6	optical	optical	I-NP	JJ	O	7	NMOD
7	isomers	isomer	I-NP	NNS	O	4	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	propranolol	propranolol	B-NP	NN	O	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	their	their	B-NP	PRP$	O	12	NMOD
12	effects	effect	I-NP	NNS	O	8	PMOD
13	on	on	B-PP	IN	O	12	NMOD
14	cardiac	cardiac	B-NP	JJ	B-protein	15	NMOD
15	arrhythmias.	arrhythmias.	I-NP	NN	I-protein	13	PMOD
16	1	1	I-NP	CD	I-protein	15	NMOD
17	.	.	O	.	O	3	P

1	Both	Both	B-NP	DT	O	2	NMOD
2	isomers	isomer	I-NP	NNS	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	propranolol	propranolol	B-NP	NN	O	3	PMOD
5	were	be	B-VP	VBD	O	28	VMOD
6	capable	capable	B-ADJP	JJ	O	5	PRD
7	of	of	B-PP	IN	O	6	AMOD
8	preventing	prevent	B-VP	VBG	O	7	PMOD
9	adrenaline	adrenaline	B-NP	NN	O	8	OBJ
10	induced	induce	B-VP	VBD	O	5	VMOD
11	cardiac	cardiac	B-NP	JJ	O	12	NMOD
12	arrhythmias	arrhythmia	I-NP	NNS	O	10	OBJ
13	in	in	B-PP	IN	O	10	VMOD
14	cats	cat	B-NP	NNS	O	13	PMOD
15	anaesthetized	anaesthetize	B-VP	VBN	O	14	NMOD
16	with	with	B-PP	IN	O	15	VMOD
17	halothane	halothane	B-NP	NN	O	16	PMOD
18	,	,	O	,	O	28	P
19	but	but	O	CC	O	28	VMOD
20	the	the	B-NP	DT	O	22	NMOD
21	mean	mean	I-NP	JJ	O	22	NMOD
22	dose	dose	I-NP	NN	O	28	SUB
23	of	of	B-PP	IN	O	22	NMOD
24	(	(	O	(	O	26	DEP
25	-	-	O	SYM	O	26	DEP
26	)	)	O	)	O	27	NMOD
27	-propranolol	-propranolol	B-NP	NN	O	23	PMOD
28	was	be	B-VP	VBD	O	0	ROOT
29	0.09+/-0.02	0.09+/-0.02	B-NP	CD	O	30	NMOD
30	mg/kg	mg/kg	I-NP	NN	O	28	PRD
31	whereas	whereas	B-PP	IN	O	28	VMOD
32	that	that	B-NP	DT	O	38	SUB
33	of	of	B-PP	IN	O	32	NMOD
34	(	(	O	(	O	36	DEP
35	+	+	O	SYM	O	36	DEP
36	)	)	O	)	O	37	NMOD
37	-propranolol	-propranolol	B-NP	NN	O	33	PMOD
38	was	be	B-VP	VBD	O	31	SBAR
39	4.2+/-1.2	4.2+/-1.2	B-NP	CD	O	40	NMOD
40	mg/kg	mg/kg	I-NP	NN	O	38	PRD
41	.	.	O	.	O	28	P

1	Blockade	Blockade	B-NP	NN	O	7	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	arrhythmias	arrhythmia	B-NP	NNS	O	2	PMOD
4	with	with	B-PP	IN	O	3	NMOD
5	both	both	B-NP	DT	O	6	NMOD
6	isomers	isomer	I-NP	NNS	O	4	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	surmountable	surmountable	B-ADJP	JJ	O	7	PRD
9	by	by	B-PP	IN	O	8	AMOD
10	increasing	increase	B-VP	VBG	O	9	PMOD
11	the	the	B-NP	DT	O	12	NMOD
12	dose	dose	I-NP	NN	O	10	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	adrenaline.7	adrenaline.7	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	7	P

1	Both	Both	B-NP	DT	O	2	NMOD
2	isomers	isomer	I-NP	NNS	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	propranolol	propranolol	B-NP	NN	O	3	PMOD
5	were	be	B-VP	VBD	O	0	ROOT
6	also	also	B-ADVP	RB	O	5	VMOD
7	capable	capable	B-ADJP	JJ	O	5	PRD
8	of	of	B-PP	IN	O	7	AMOD
9	reversing	reverse	B-VP	VBG	O	8	PMOD
10	ventricular	ventricular	B-NP	JJ	O	11	NMOD
11	tachycardia	tachycardia	I-NP	NN	O	9	OBJ
12	caused	cause	B-VP	VBN	O	11	NMOD
13	by	by	B-PP	IN	O	12	VMOD
14	ouabain	ouabain	B-NP	NN	O	13	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	anaesthetized	anaesthetize	B-NP	VBN	O	19	NMOD
17	cats	cat	I-NP	NNS	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	dogs	dog	I-NP	NNS	O	15	PMOD
20	.	.	O	.	O	5	P

1	Topotecan	Topotecan	B-NP	NN	O	13	NMOD
2	in	in	B-PP	IN	O	1	NMOD
3	combination	combination	B-NP	NN	O	2	PMOD
4	with	with	B-PP	IN	O	3	NMOD
5	radiotherapy	radiotherapy	B-NP	NN	O	4	PMOD
6	in	in	B-PP	IN	O	5	NMOD
7	unresectable	unresectable	B-NP	JJ	O	8	NMOD
8	glioblastoma	glioblastoma	I-NP	NN	O	6	PMOD
9	:	:	O	:	O	1	P
10	a	a	B-NP	DT	O	13	NMOD
11	phase	phase	I-NP	NN	O	13	NMOD
12	2	2	I-NP	CD	O	13	NMOD
13	study	study	I-NP	NN	O	0	ROOT
14	.	.	O	.	O	13	P

1	Topotecan	Topotecan	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	an	an	B-NP	DT	O	5	NMOD
4	attractive	attractive	I-NP	JJ	O	5	NMOD
5	option	option	I-NP	NN	O	2	PRD
6	as	as	B-SBAR	IN	O	2	VMOD
7	it	it	B-NP	PRP	O	8	SUB
8	exhibits	exhibit	B-VP	VBZ	O	6	SBAR
9	growth	growth	B-NP	NN	O	10	NMOD
10	inhibition	inhibition	I-NP	NN	O	18	NMOD
11	of	of	B-PP	IN	O	10	NMOD
12	human	human	B-NP	JJ	O	13	NMOD
13	glioma	glioma	I-NP	NN	O	11	PMOD
14	as	as	B-CONJP	RB	O	18	NMOD
15	well	well	I-CONJP	RB	O	14	DEP
16	as	as	I-CONJP	IN	O	14	DEP
17	brain	brain	B-NP	NN	O	18	NMOD
18	penetration	penetration	I-NP	NN	O	8	OBJ
19	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	assessed	assess	B-VP	VBD	O	0	ROOT
5	the	the	B-NP	DT	O	6	NMOD
6	combination	combination	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	radiotherapy	radiotherapy	B-NP	NN	O	16	NMOD
9	(	(	O	(	O	14	DEP
10	60	60	B-NP	CD	O	13	NMOD
11	Gy/30	Gy/30	I-NP	NN	O	13	NMOD
12	fractions/40	fractions/40	I-NP	NN	O	13	NMOD
13	days	day	I-NP	NNS	O	14	DEP
14	)	)	O	)	O	8	NMOD
15	and	and	O	CC	O	16	NMOD
16	topotecan	topotecan	B-NP	NN	O	7	PMOD
17	(	(	O	(	O	34	DEP
18	0.9	0.9	B-NP	CD	O	19	NMOD
19	mg/m	mg/m	I-NP	NN	O	23	SUB
20	(	(	O	(	O	22	DEP
21	2	2	B-NP	CD	O	22	DEP
22	)	)	O	)	O	19	NMOD
23	/day	/day	B-VP	VBP	O	34	DEP
24	on	on	B-PP	IN	O	23	VMOD
25	days	day	B-NP	NNS	O	24	PMOD
26	1-5	1-5	B-NP	CD	O	25	NMOD
27	on	on	B-PP	IN	O	25	NMOD
28	weeks	week	B-NP	NNS	O	27	PMOD
29	1	1	I-NP	CD	O	28	NMOD
30	,	,	I-NP	,	O	28	P
31	3	3	I-NP	CD	O	28	NMOD
32	and	and	I-NP	CC	O	28	NMOD
33	5	5	I-NP	CD	O	28	NMOD
34	)	)	O	)	O	16	NMOD
35	in	in	B-PP	IN	O	16	NMOD
36	50	50	B-NP	CD	O	37	NMOD
37	adults	adult	I-NP	NNS	O	35	PMOD
38	with	with	B-PP	IN	O	37	NMOD
39	histologically	histologically	B-NP	RB	O	43	NMOD
40	proven	proven	I-NP	JJ	O	43	NMOD
41	and	and	I-NP	CC	O	43	NMOD
42	untreated	untreated	I-NP	JJ	O	43	NMOD
43	GBM	GBM	I-NP	NN	O	38	PMOD
44	.	.	O	.	O	4	P

1	Long-term	Long-term	B-NP	JJ	O	3	NMOD
2	lithium	lithium	I-NP	NN	O	3	NMOD
3	therapy	therapy	I-NP	NN	O	10	NMOD
4	leading	lead	B-VP	VBG	O	3	NMOD
5	to	to	B-PP	TO	O	4	VMOD
6	hyperparathyroidism	hyperparathyroidism	B-NP	NN	O	5	PMOD
7	:	:	O	:	O	3	P
8	a	a	B-NP	DT	O	10	NMOD
9	case	case	I-NP	NN	O	10	NMOD
10	report	report	I-NP	NN	O	0	ROOT
11	.	.	O	.	O	10	P

1	We	We	B-NP	PRP	O	2	SUB
2	examined	examine	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	lithium-treated	lithium-treated	I-NP	JJ	O	8	NMOD
8	patient	patient	I-NP	NN	O	12	NMOD
9	who	who	B-NP	WP	O	12	NMOD
10	had	have	B-VP	VBD	O	12	NMOD
11	recurrent	recurrent	B-NP	JJ	O	12	NMOD
12	hypercalcemia	hypercalcemia	I-NP	NN	O	5	PMOD
13	to	to	B-VP	TO	O	15	VMOD
14	better	well	I-VP	RBR	O	15	VMOD
15	understand	understand	I-VP	VB	O	4	NMOD
16	the	the	B-NP	DT	O	18	NMOD
17	disease	disease	I-NP	NN	O	18	NMOD
18	process	process	I-NP	NN	O	15	OBJ
19	.	.	O	.	O	2	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Primary	Primary	B-NP	JJ	O	4	NMOD
4	hyperparathyroidism	hyperparathyroidism	I-NP	NN	O	5	SUB
5	is	be	B-VP	VBZ	O	1	NMOD
6	a	a	B-NP	DT	O	7	NMOD
7	rare	rare	I-NP	JJ	O	12	NMOD
8	but	but	I-NP	CC	O	10	AMOD
9	potentially	potentially	I-NP	RB	O	10	AMOD
10	life-threatening	life-threatening	I-NP	JJ	O	12	NMOD
11	side	side	I-NP	NN	O	12	NMOD
12	effect	effect	I-NP	NN	O	5	PRD
13	of	of	B-PP	IN	O	12	NMOD
14	long-term	long-term	B-NP	JJ	O	16	NMOD
15	lithium	lithium	I-NP	NN	O	16	NMOD
16	therapy	therapy	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	1	P

1	PRACTICAL	PRACTICAL	B-NP	JJ	O	2	NMOD
2	IMPLICATIONS	IMPLICATIONS	I-NP	NNS	O	8	NMOD
3	:	:	O	:	O	2	P
4	As	As	B-NP	RB	O	6	AMOD
5	much	much	I-NP	RB	O	6	AMOD
6	as	as	I-NP	IN	O	8	NMOD
7	15	15	I-NP	CD	O	6	AMOD
8	%	%	I-NP	NN	O	12	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	lithium-treated	lithium-treated	B-NP	JJ	O	11	NMOD
11	patients	patient	I-NP	NNS	O	9	PMOD
12	become	become	B-VP	VBP	O	0	ROOT
13	hypercalcemic	hypercalcemic	B-ADJP	JJ	O	12	PRD
14	.	.	O	.	O	12	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	purpose	purpose	I-NP	NN	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	this	this	B-NP	DT	O	7	NMOD
7	study	study	I-NP	NN	O	5	PMOD
8	was	be	B-VP	VBD	O	1	NMOD
9	to	to	B-VP	TO	O	10	VMOD
10	compare	compare	I-VP	VB	O	8	PRD
11	surgical	surgical	B-NP	JJ	O	12	NMOD
12	conditions	condition	I-NP	NNS	O	10	OBJ
13	,	,	O	,	O	12	P
14	including	include	B-PP	VBG	O	12	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	amount	amount	I-NP	NN	O	25	NMOD
17	of	of	B-PP	IN	O	16	NMOD
18	intraoperative	intraoperative	B-NP	JJ	O	19	NMOD
19	bleeding	bleeding	I-NP	NN	O	17	PMOD
20	as	as	B-CONJP	RB	O	25	NMOD
21	well	well	I-CONJP	RB	O	20	DEP
22	as	as	I-CONJP	IN	O	20	DEP
23	intraoperative	intraoperative	B-NP	JJ	O	25	NMOD
24	blood	blood	I-NP	NN	O	25	NMOD
25	pressure	pressure	I-NP	NN	O	14	PMOD
26	,	,	O	,	O	25	P
27	during	during	B-PP	IN	O	25	NMOD
28	functional	functional	B-NP	JJ	O	31	NMOD
29	endoscopic	endoscopic	I-NP	JJ	O	31	NMOD
30	sinus	sinus	I-NP	NN	O	31	NMOD
31	surgery	surgery	I-NP	NN	O	27	PMOD
32	(	(	O	(	O	34	DEP
33	FESS	FESS	B-NP	NN	O	34	DEP
34	)	)	O	)	O	31	NMOD
35	using	use	B-VP	VBG	O	8	VMOD
36	flexible	flexible	B-NP	JJ	O	40	NMOD
37	reinforced	reinforced	I-NP	JJ	O	40	NMOD
38	laryngeal	laryngeal	I-NP	JJ	O	40	NMOD
39	mask	mask	I-NP	NN	O	40	NMOD
40	airway	airway	I-NP	NN	O	35	OBJ
41	(	(	O	(	O	43	DEP
42	FRLMA	FRLMA	B-NP	NN	O	43	DEP
43	)	)	O	)	O	40	NMOD
44	versus	versus	B-PP	IN	O	40	NMOD
45	endotracheal	endotracheal	B-NP	JJ	O	46	NMOD
46	tube	tube	I-NP	NN	O	44	PMOD
47	(	(	O	(	O	49	DEP
48	ETT	ETT	B-NP	NN	B-protein	49	DEP
49	)	)	O	)	O	46	NMOD
50	in	in	B-PP	IN	O	46	NMOD
51	maintaining	maintain	B-VP	VBG	O	50	PMOD
52	controlled	control	B-NP	VBN	O	54	NMOD
53	hypotension	hypotension	I-NP	NN	O	54	NMOD
54	anesthesia	anesthesia	I-NP	NN	O	51	OBJ
55	induced	induce	B-VP	VBN	O	54	NMOD
56	by	by	B-PP	IN	O	55	VMOD
57	propofol-remifentanil	propofol-remifentanil	B-NP	NN	O	60	NMOD
58	total	total	I-NP	JJ	O	60	NMOD
59	i.v.	i.v.	I-NP	JJ	O	60	NMOD
60	anesthesia	anesthesia	I-NP	NN	O	56	PMOD
61	(	(	O	(	O	63	DEP
62	TIVA	TIVA	B-NP	NN	B-protein	63	DEP
63	)	)	O	)	O	60	NMOD
64	.	.	O	.	O	8	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Sixty	Sixty	B-NP	CD	O	6	NMOD
4	normotensive	normotensive	I-NP	JJ	O	6	NMOD
5	American	American	I-NP	JJ	O	6	NMOD
6	Society	Society	I-NP	NN	O	21	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	Anesthesiologists	Anesthesiologist	B-NP	NNS	O	11	NMOD
9	I-II	I-II	I-NP	NN	O	11	NMOD
10	adult	adult	B-NP	JJ	O	11	NMOD
11	patients	patient	I-NP	NNS	O	7	PMOD
12	undergoing	undergo	B-VP	VBG	O	11	NMOD
13	FESS	FESS	B-NP	NN	O	12	OBJ
14	under	under	B-PP	IN	O	12	VMOD
15	controlled	control	B-NP	VBN	O	17	NMOD
16	hypotension	hypotension	I-NP	NN	O	17	NMOD
17	anesthesia	anesthesia	I-NP	NN	O	14	PMOD
18	caused	cause	B-VP	VBN	O	17	NMOD
19	by	by	B-PP	IN	O	18	VMOD
20	propofol-remifentanil-TIVA	propofol-remifentanil-TIVA	B-NP	NN	O	19	PMOD
21	were	be	B-VP	VBD	O	36	VMOD
22	randomly	randomly	I-VP	RB	O	21	VMOD
23	assigned	assign	I-VP	VBN	O	21	VC
24	into	into	B-PP	IN	O	23	VMOD
25	two	two	B-NP	CD	O	26	NMOD
26	groups	group	I-NP	NNS	O	24	PMOD
27	:	:	O	:	O	21	P
28	group	group	B-NP	NN	O	36	NMOD
29	I	I	I-NP	CD	O	28	NMOD
30	,	,	O	,	O	31	P
31	FRLMA	FRLMA	B-NP	NNP	O	36	NMOD
32	;	;	O	:	O	36	P
33	group	group	B-NP	NN	O	36	NMOD
34	II	II	I-NP	CD	O	33	NMOD
35	,	,	O	,	O	36	P
36	ETT	ETT	B-NP	NNP	O	1	NMOD
37	.	.	O	.	O	36	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Controlled	Controlled	B-NP	JJ	O	4	NMOD
4	hypotension	hypotension	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	1	NMOD
6	achieved	achieve	I-VP	VBN	O	5	VC
7	within	within	B-PP	IN	O	6	VMOD
8	a	a	B-NP	DT	O	10	NMOD
9	shorter	short	I-NP	JJR	O	10	NMOD
10	period	period	I-NP	NN	O	7	PMOD
11	using	use	B-VP	VBG	O	5	VMOD
12	laryngeal	laryngeal	B-NP	JJ	O	13	NMOD
13	mask	mask	I-NP	NN	O	11	OBJ
14	using	use	B-VP	VBG	O	13	NMOD
15	lower	low	B-NP	JJR	O	16	NMOD
16	rates	rate	I-NP	NNS	O	14	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	remifentanil	remifentanil	B-NP	NN	O	19	NMOD
19	infusion	infusion	I-NP	NN	O	23	NMOD
20	and	and	O	CC	O	23	NMOD
21	lower	low	B-NP	JJR	O	23	NMOD
22	total	total	I-NP	JJ	O	23	NMOD
23	dose	dose	I-NP	NN	O	17	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	remifentanil	remifentanil	B-NP	NN	O	24	PMOD
26	.	.	O	.	O	1	P

1	Nonalcoholic	Nonalcoholic	B-NP	JJ	O	4	NMOD
2	fatty	fatty	I-NP	JJ	O	4	NMOD
3	liver	liver	I-NP	NN	O	4	NMOD
4	disease	disease	I-NP	NN	O	0	ROOT
5	during	during	B-PP	IN	O	4	NMOD
6	valproate	valproate	B-NP	NN	O	7	NMOD
7	therapy	therapy	I-NP	NN	O	5	PMOD
8	.	.	O	.	O	4	P

1	Valproic	Valproic	B-NP	JJ	O	2	NMOD
2	acid	acid	I-NP	NN	O	6	SUB
3	(	(	O	(	O	5	DEP
4	VPA	VPA	B-NP	NN	B-protein	5	DEP
5	)	)	O	)	O	2	NMOD
6	is	be	B-VP	VBZ	O	20	VMOD
7	effective	effective	B-ADJP	JJ	O	6	PRD
8	for	for	B-PP	IN	O	7	AMOD
9	the	the	B-NP	DT	O	10	NMOD
10	treatment	treatment	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	many	many	B-NP	JJ	O	13	NMOD
13	types	type	I-NP	NNS	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	epilepsy	epilepsy	B-NP	NN	O	14	PMOD
16	,	,	O	,	O	20	P
17	but	but	O	CC	O	20	VMOD
18	its	its	B-NP	PRP$	O	19	NMOD
19	use	use	I-NP	NN	O	20	SUB
20	can	can	B-VP	MD	O	0	ROOT
21	be	be	I-VP	VB	O	20	VC
22	associated	associate	I-VP	VBN	O	21	VC
23	with	with	B-PP	IN	O	22	VMOD
24	an	an	B-NP	DT	O	25	NMOD
25	increase	increase	I-NP	NN	O	23	PMOD
26	in	in	B-PP	IN	O	25	NMOD
27	body	body	B-NP	NN	O	28	NMOD
28	weight	weight	I-NP	NN	O	26	PMOD
29	.	.	O	.	O	20	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	nonalcoholic	nonalcoholic	B-NP	JJ	O	9	NMOD
7	fatty	fatty	I-NP	JJ	O	9	NMOD
8	liver	liver	I-NP	NN	O	9	NMOD
9	disease	disease	I-NP	NN	O	5	PMOD
10	(	(	O	(	O	12	DEP
11	NAFLD	NAFLD	B-NP	NN	O	12	DEP
12	)	)	O	)	O	9	NMOD
13	arising	arise	B-VP	VBG	O	9	NMOD
14	in	in	B-PP	IN	O	13	VMOD
15	a	a	B-NP	DT	O	16	NMOD
16	child	child	I-NP	NN	O	14	PMOD
17	who	who	B-NP	WP	O	16	NMOD
18	developed	develop	B-VP	VBD	O	17	SBAR
19	obesity	obesity	B-NP	NN	O	18	OBJ
20	during	during	B-PP	IN	O	18	VMOD
21	VPA	VPA	B-NP	NN	B-protein	22	NMOD
22	treatment	treatment	I-NP	NN	O	20	PMOD
23	.	.	O	.	O	2	P

1	After	After	B-PP	IN	O	10	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	withdrawal	withdrawal	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	VPA	VPA	B-NP	NN	O	6	NMOD
6	therapy	therapy	I-NP	NN	O	4	PMOD
7	,	,	O	,	O	10	P
8	our	our	B-NP	PRP$	O	9	NMOD
9	patient	patient	I-NP	NN	O	10	SUB
10	showed	show	B-VP	VBD	O	35	VMOD
11	a	a	B-NP	DT	O	14	NMOD
12	significant	significant	I-NP	JJ	O	14	NMOD
13	weight	weight	I-NP	NN	O	14	NMOD
14	loss	loss	I-NP	NN	O	24	NMOD
15	,	,	O	,	O	24	P
16	a	a	B-NP	DT	O	17	NMOD
17	decrease	decrease	I-NP	NN	O	24	NMOD
18	of	of	B-PP	IN	O	17	NMOD
19	body	body	B-NP	NN	O	21	NMOD
20	mass	mass	I-NP	NN	O	21	NMOD
21	index	index	I-NP	NN	O	18	PMOD
22	,	,	O	,	O	24	P
23	and	and	O	CC	O	24	NMOD
24	normalization	normalization	B-NP	NN	O	10	OBJ
25	of	of	B-PP	IN	O	24	NMOD
26	metabolic	metabolic	B-NP	JJ	O	28	AMOD
27	and	and	I-NP	CC	O	28	AMOD
28	endocrine	endocrine	I-NP	JJ	O	29	NMOD
29	parameters	parameter	I-NP	NNS	O	25	PMOD
30	;	;	O	:	O	35	P
31	moreover	moreover	B-ADVP	RB	O	35	VMOD
32	,	,	O	,	O	35	P
33	ultrasound	ultrasound	B-NP	JJ	O	34	NMOD
34	measurements	measurement	I-NP	NNS	O	35	SUB
35	showed	show	B-VP	VBD	O	0	ROOT
36	a	a	B-NP	DT	O	38	NMOD
37	complete	complete	I-NP	JJ	O	38	NMOD
38	normalization	normalization	I-NP	NN	O	35	OBJ
39	.	.	O	.	O	35	P

1	Carbimazole	Carbimazole	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	ANCA	ANCA	B-NP	CC	O	5	NMOD
4	positive	positive	I-NP	JJ	O	5	NMOD
5	vasculitis	vasculitis	I-NP	NN	O	2	OBJ
6	.	.	O	.	O	2	P

1	Anti-thyroid	Anti-thyroid	B-NP	JJ	O	2	NMOD
2	drugs	drug	I-NP	NNS	O	11	SUB
3	,	,	O	,	O	2	P
4	like	like	B-PP	IN	O	2	NMOD
5	carbimazole	carbimazole	B-NP	NN	O	7	NMOD
6	and	and	O	CC	O	7	NMOD
7	propylthiouracil	propylthiouracil	B-NP	NN	O	4	PMOD
8	(	(	O	(	O	10	DEP
9	PTU	PTU	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	are	be	B-VP	VBP	O	0	ROOT
12	commonly	commonly	I-VP	RB	O	11	VMOD
13	prescribed	prescribe	I-VP	VBN	O	11	VC
14	for	for	B-PP	IN	O	13	VMOD
15	the	the	B-NP	DT	O	16	NMOD
16	treatment	treatment	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	hyperthyroidism	hyperthyroidism	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	11	P

1	Antineutrophil	Antineutrophil	B-NP	NN	B-protein	3	NMOD
2	cytoplasmic	cytoplasmic	I-NP	JJ	I-protein	3	NMOD
3	antibody	antibody	I-NP	NN	I-protein	9	NMOD
4	(	(	O	(	O	6	DEP
5	ANCA	ANCA	B-NP	NN	O	6	DEP
6	)	)	O	)	O	3	NMOD
7	--	--	O	:	O	3	P
8	associated	associate	B-NP	VBN	O	9	NMOD
9	vasculitis	vasculitis	I-NP	NN	O	10	SUB
10	is	be	B-VP	VBZ	O	0	ROOT
11	a	a	B-NP	DT	O	15	NMOD
12	potentially	potentially	I-NP	RB	O	13	AMOD
13	life-threatening	life-threatening	I-NP	JJ	O	15	NMOD
14	adverse	adverse	I-NP	JJ	O	15	NMOD
15	effect	effect	I-NP	NN	O	10	PRD
16	of	of	B-PP	IN	O	15	NMOD
17	antithyroidmedications	antithyroidmedication	B-NP	NNS	O	16	PMOD
18	.	.	O	.	O	10	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	patient	patient	I-NP	NN	O	14	SUB
5	with	with	B-PP	IN	O	4	NMOD
6	Graves	Graves	B-NP	NN	O	8	NMOD
7	'	'	B-NP	POS	O	8	NMOD
8	disease	disease	I-NP	NN	O	5	PMOD
9	who	who	B-NP	WP	O	4	NMOD
10	developed	develop	B-VP	VBD	O	9	SBAR
11	ANCA	ANCA	B-NP	NN	O	13	NMOD
12	positive	positive	I-NP	JJ	O	13	NMOD
13	carbimazole	carbimazole	I-NP	NN	O	10	OBJ
14	induced	induce	B-VP	VBD	O	2	VMOD
15	vasculitis	vasculitis	B-NP	NN	O	14	OBJ
16	.	.	O	.	O	2	P

1	Preventive	Preventive	B-NP	JJ	O	4	NMOD
2	Services	Services	I-NP	NNP	O	4	NMOD
3	Task	Task	I-NP	NNP	O	4	NMOD
4	Force	Force	I-NP	NNP	O	9	SUB
5	(	(	O	(	O	7	DEP
6	USPSTF	USPSTF	B-NP	NNP	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	strongly	strongly	B-VP	RB	O	9	VMOD
9	recommended	recommend	I-VP	VBD	O	0	ROOT
10	that	that	B-SBAR	IN	O	9	VMOD
11	clinicians	clinician	B-NP	NNS	O	12	SUB
12	discuss	discuss	B-VP	VBP	O	10	SBAR
13	aspirin	aspirin	B-NP	NN	O	12	OBJ
14	with	with	B-PP	IN	O	13	NMOD
15	adults	adult	B-NP	NNS	O	14	PMOD
16	who	who	B-NP	WP	O	13	NMOD
17	are	be	B-VP	VBP	O	16	SBAR
18	at	at	B-PP	IN	O	17	PRD
19	increased	increase	B-NP	VBN	O	20	NMOD
20	risk	risk	I-NP	NN	O	18	PMOD
21	for	for	B-PP	IN	O	20	NMOD
22	coronary	coronary	B-NP	JJ	O	24	NMOD
23	heart	heart	I-NP	NN	O	24	NMOD
24	disease	disease	I-NP	NN	O	21	PMOD
25	.	.	O	.	O	9	P

1	PURPOSE	PURPOSE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	determine	determine	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	8	NMOD
6	benefits	benefit	I-NP	NNS	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	harms	harm	I-NP	NNS	O	4	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	taking	take	B-VP	VBG	O	9	PMOD
11	aspirin	aspirin	B-NP	NN	O	10	OBJ
12	for	for	B-PP	IN	O	10	VMOD
13	the	the	B-NP	DT	O	15	NMOD
14	primary	primary	I-NP	JJ	O	15	NMOD
15	prevention	prevention	I-NP	NN	O	12	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	myocardial	myocardial	B-NP	JJ	O	18	NMOD
18	infarctions	infarction	I-NP	NNS	O	23	NMOD
19	,	,	O	,	O	23	P
20	strokes	stroke	B-NP	NNS	O	23	NMOD
21	,	,	O	,	O	23	P
22	and	and	O	CC	O	23	NMOD
23	death	death	B-NP	NN	O	16	PMOD
24	.	.	O	.	O	4	P

1	STUDY	STUDY	B-NP	NN	O	2	NMOD
2	SELECTION	SELECTION	I-NP	NN	O	5	SUB
3	:	:	O	:	O	2	P
4	English-language	English-language	B-NP	NN	O	5	AMOD
5	randomized	randomize	B-VP	VBN	O	35	VMOD
6	,	,	O	,	O	35	P
7	controlled	control	B-NP	VBN	O	8	NMOD
8	trials	trial	I-NP	NNS	O	35	SUB
9	(	(	O	(	O	11	DEP
10	RCTs	RCT	B-NP	NNS	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	;	;	O	:	O	35	P
13	case-control	case-control	B-NP	JJ	O	14	NMOD
14	studies	study	I-NP	NNS	O	35	SUB
15	;	;	O	:	O	35	P
16	meta-analyses	meta-analys	B-NP	NNS	O	35	SUB
17	;	;	O	:	O	35	P
18	and	and	O	CC	O	20	NMOD
19	systematic	systematic	B-NP	JJ	O	20	NMOD
20	reviews	review	I-NP	NNS	O	35	SUB
21	of	of	B-PP	IN	O	20	NMOD
22	aspirin	aspirin	B-NP	NN	O	24	NMOD
23	versus	versus	I-NP	CC	O	24	NMOD
24	control	control	I-NP	NN	O	21	PMOD
25	for	for	B-PP	IN	O	20	NMOD
26	the	the	B-NP	DT	O	28	NMOD
27	primary	primary	I-NP	JJ	O	28	NMOD
28	prevention	prevention	I-NP	NN	O	25	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	cardiovascular	cardiovascular	B-NP	JJ	O	31	NMOD
31	disease	disease	I-NP	NN	O	29	PMOD
32	(	(	O	(	O	34	DEP
33	CVD	CVD	B-NP	NN	O	34	DEP
34	)	)	O	)	O	31	NMOD
35	were	be	B-VP	VBD	O	0	ROOT
36	selected	select	I-VP	VBN	O	35	VC
37	to	to	I-VP	TO	O	38	VMOD
38	answer	answer	I-VP	VB	O	36	VMOD
39	the	the	B-NP	DT	O	41	NMOD
40	following	follow	I-NP	VBG	O	41	NMOD
41	questions	question	I-NP	NNS	O	38	OBJ
42	:	:	O	:	O	35	P
43	Does	Do	B-VP	VBZ	O	62	VMOD
44	aspirin	aspirin	B-NP	NN	O	48	NMOD
45	decrease	decrease	I-NP	NN	O	48	NMOD
46	coronary	coronary	I-NP	JJ	O	48	NMOD
47	heart	heart	I-NP	NN	O	48	NMOD
48	events	event	I-NP	NNS	O	58	SUB
49	,	,	O	,	O	58	P
50	strokes	stroke	B-NP	NNS	O	58	SUB
51	,	,	O	,	O	58	P
52	death	death	B-NP	NN	O	58	SUB
53	from	from	B-PP	IN	O	52	NMOD
54	coronary	coronary	B-NP	JJ	O	56	NMOD
55	heart	heart	I-NP	NN	O	56	NMOD
56	events	event	I-NP	NNS	O	53	PMOD
57	or	or	O	CC	O	58	VMOD
58	stroke	stroke	B-VP	VB	O	43	VMOD
59	,	,	O	,	O	62	P
60	or	or	O	CC	O	62	NMOD
61	all-cause	all-cause	B-NP	JJ	O	62	NMOD
62	mortality	mortality	I-NP	NN	O	35	VMOD
63	in	in	B-PP	IN	O	62	NMOD
64	adults	adult	B-NP	NNS	O	63	PMOD
65	without	without	B-PP	IN	O	62	NMOD
66	known	known	B-NP	JJ	O	67	NMOD
67	CVD	CVD	I-NP	NN	O	65	PMOD
68	.	.	O	.	O	35	P

1	Does	Do	O	VBZ	O	0	ROOT
2	aspirin	aspirin	B-NP	NN	O	5	NMOD
3	increase	increase	I-NP	NN	O	5	NMOD
4	gastrointestinal	gastrointestinal	I-NP	JJ	O	5	NMOD
5	bleeding	bleeding	I-NP	NN	O	8	NMOD
6	or	or	O	CC	O	8	NMOD
7	hemorrhagic	hemorrhagic	B-NP	JJ	O	8	NMOD
8	strokes	stroke	I-NP	NNS	O	1	OBJ
9	.	.	O	.	O	1	P

1	DATA	DATA	B-NP	NN	O	2	NMOD
2	SYNTHESIS	SYNTHESIS	I-NP	NN	O	5	NMOD
3	:	:	O	:	O	2	P
4	New	New	B-NP	JJ	O	5	NMOD
5	evidence	evidence	I-NP	NN	O	18	NMOD
6	from	from	B-PP	IN	O	5	NMOD
7	1	1	B-NP	CD	O	9	NMOD
8	good-quality	good-quality	I-NP	NN	O	9	NMOD
9	RCT	RCT	I-NP	NN	O	6	PMOD
10	,	,	O	,	O	18	P
11	1	1	B-NP	CD	O	13	NMOD
12	good-quality	good-quality	I-NP	NN	O	13	NMOD
13	meta-analysis	meta-analysis	I-NP	NN	O	18	NMOD
14	,	,	O	,	O	18	P
15	and	and	O	CC	O	18	NMOD
16	2	2	B-NP	CD	O	18	NMOD
17	fair-quality	fair-quality	I-NP	JJ	O	18	NMOD
18	subanalyses	subanalys	I-NP	NNS	O	21	SUB
19	of	of	B-PP	IN	O	18	NMOD
20	RCTs	RCT	B-NP	NNS	B-protein	19	PMOD
21	demonstrates	demonstrate	B-VP	VBZ	O	0	ROOT
22	that	that	B-SBAR	IN	O	21	VMOD
23	aspirin	aspirin	B-NP	NN	O	24	NMOD
24	use	use	I-NP	NN	O	25	SUB
25	reduces	reduce	B-VP	VBZ	O	22	SBAR
26	the	the	B-NP	DT	O	27	NMOD
27	number	number	I-NP	NN	O	25	OBJ
28	of	of	B-PP	IN	O	27	NMOD
29	CVD	CVD	B-NP	NN	O	30	NMOD
30	events	event	I-NP	NNS	O	28	PMOD
31	in	in	B-PP	IN	O	30	NMOD
32	patients	patient	B-NP	NNS	O	31	PMOD
33	without	without	B-PP	IN	O	32	NMOD
34	known	known	B-NP	JJ	O	35	NMOD
35	CVD	CVD	I-NP	NN	O	33	PMOD
36	.	.	O	.	O	21	P

1	Aspirin	Aspirin	B-NP	NN	O	2	SUB
2	does	do	B-VP	VBZ	O	0	ROOT
3	not	not	I-VP	RB	O	2	VMOD
4	seem	seem	I-VP	VB	O	2	VC
5	to	to	I-VP	TO	O	6	VMOD
6	affect	affect	I-VP	VB	O	4	VMOD
7	CVD	CVD	B-NP	NN	O	8	NMOD
8	mortality	mortality	I-NP	NN	O	11	NMOD
9	or	or	O	CC	O	11	NMOD
10	all-cause	all-cause	B-NP	JJ	O	11	NMOD
11	mortality	mortality	I-NP	NN	O	6	OBJ
12	in	in	B-PP	IN	O	11	NMOD
13	either	either	O	CC	O	16	NMOD
14	men	man	B-NP	NNS	O	16	NMOD
15	or	or	I-NP	CC	O	16	NMOD
16	women	woman	I-NP	NNS	O	12	PMOD
17	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	use	use	I-NP	NN	O	8	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	aspirin	aspirin	B-NP	NN	O	3	PMOD
5	for	for	B-PP	IN	O	2	NMOD
6	primary	primary	B-NP	JJ	O	7	NMOD
7	prevention	prevention	I-NP	NN	O	5	PMOD
8	increases	increase	B-VP	VBZ	O	0	ROOT
9	the	the	B-NP	DT	O	10	NMOD
10	risk	risk	I-NP	NN	O	8	OBJ
11	for	for	B-PP	IN	O	10	NMOD
12	major	major	B-NP	JJ	O	14	NMOD
13	bleeding	bleed	I-NP	VBG	O	14	NMOD
14	events	event	I-NP	NNS	O	11	PMOD
15	,	,	O	,	O	8	P
16	primarily	primarily	B-NP	RB	O	19	NMOD
17	gastrointestinal	gastrointestinal	I-NP	JJ	O	19	NMOD
18	bleeding	bleed	I-NP	VBG	O	19	NMOD
19	events	event	I-NP	NNS	O	8	VMOD
20	,	,	O	,	O	19	P
21	in	in	B-PP	IN	O	19	NMOD
22	both	both	B-NP	CC	O	25	NMOD
23	men	man	I-NP	NNS	O	25	NMOD
24	and	and	I-NP	CC	O	25	NMOD
25	women	woman	I-NP	NNS	O	21	PMOD
26	.	.	O	.	O	8	P

1	Men	Men	B-NP	NN	B-protein	2	SUB
2	have	have	B-VP	VBP	O	0	ROOT
3	an	an	B-NP	DT	O	5	NMOD
4	increased	increase	I-NP	VBN	O	5	NMOD
5	risk	risk	I-NP	NN	O	2	OBJ
6	for	for	B-PP	IN	O	5	NMOD
7	hemorrhagic	hemorrhagic	B-NP	JJ	O	8	NMOD
8	strokes	stroke	I-NP	NNS	O	6	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	aspirin	aspirin	B-NP	NN	O	11	NMOD
11	use	use	I-NP	NN	O	9	PMOD
12	.	.	O	.	O	2	P

1	LIMITATIONS	LIMITATIONS	B-NP	NNS	O	4	NMOD
2	:	:	O	:	O	1	P
3	New	New	B-NP	JJ	O	4	NMOD
4	evidence	evidence	I-NP	NN	O	13	SUB
5	on	on	B-PP	IN	O	4	NMOD
6	aspirin	aspirin	B-NP	NN	O	5	PMOD
7	for	for	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	10	NMOD
9	primary	primary	I-NP	JJ	O	10	NMOD
10	prevention	prevention	I-NP	NN	O	7	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	CVD	CVD	B-NP	NN	B-protein	11	PMOD
13	is	be	B-VP	VBZ	O	0	ROOT
14	limited	limit	B-ADJP	VBN	O	13	PRD
15	.	.	O	.	O	13	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Aspirin	Aspirin	B-NP	NN	O	4	SUB
4	reduces	reduce	B-VP	VBZ	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	risk	risk	I-NP	NN	O	4	OBJ
7	for	for	B-PP	IN	O	4	VMOD
8	myocardial	myocardial	B-NP	JJ	O	9	NMOD
9	infarction	infarction	I-NP	NN	O	7	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	men	man	B-NP	NNS	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	strokes	stroke	I-NP	NNS	O	10	PMOD
14	in	in	B-PP	IN	O	13	NMOD
15	women	woman	B-NP	NNS	O	14	PMOD
16	.	.	O	.	O	1	P

1	Reducing	Reduce	B-NP	VBG	O	2	NMOD
2	harm	harm	I-NP	NN	O	8	NMOD
3	associated	associate	B-VP	VBN	O	2	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	anticoagulation	anticoagulation	B-NP	NN	O	4	PMOD
6	:	:	O	:	O	2	P
7	practical	practical	B-NP	JJ	O	8	NMOD
8	considerations	consideration	I-NP	NNS	O	0	ROOT
9	of	of	B-PP	IN	O	8	NMOD
10	argatroban	argatroban	B-NP	JJ	O	11	NMOD
11	therapy	therapy	I-NP	NN	O	9	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	heparin	heparin	B-NP	NN	O	15	NMOD
14	induced	induced	I-NP	JJ	O	15	NMOD
15	thrombocytopenia	thrombocytopenia	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	8	P

1	Argatroban	Argatroban	B-NP	NNP	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	a	a	B-NP	DT	O	9	NMOD
4	hepatically	hepatically	I-NP	RB	O	5	AMOD
5	metabolized	metabolize	I-NP	VBN	O	7	AMOD
6	,	,	I-NP	,	O	7	P
7	direct	direct	I-NP	JJ	O	9	NMOD
8	thrombin	thrombin	I-NP	NN	B-protein	9	NMOD
9	inhibitor	inhibitor	I-NP	NN	O	2	PRD
10	used	use	B-VP	VBN	O	9	NMOD
11	for	for	B-PP	IN	O	10	VMOD
12	prophylaxis	prophylaxis	B-NP	NN	O	14	NMOD
13	or	or	I-NP	CC	O	14	NMOD
14	treatment	treatment	I-NP	NN	O	11	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	thrombosis	thrombosis	B-NP	NN	O	15	PMOD
17	in	in	B-PP	IN	O	14	NMOD
18	heparin	heparin	B-NP	NN	O	20	NMOD
19	induced	induce	I-NP	VBN	O	20	NMOD
20	thrombocytopenia	thrombocytopenia	I-NP	NN	O	17	PMOD
21	(	(	O	(	O	23	DEP
22	HIT	HIT	B-NP	NN	B-protein	23	DEP
23	)	)	O	)	O	20	NMOD
24	and	and	O	CC	O	17	PMOD
25	for	for	B-PP	IN	O	17	PMOD
26	patients	patient	B-NP	NNS	O	25	PMOD
27	with	with	B-PP	IN	O	26	NMOD
28	or	or	B-PP	CC	O	27	PMOD
29	at	at	B-PP	IN	O	27	PMOD
30	risk	risk	B-NP	NN	O	29	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	HIT	HIT	B-NP	NN	B-protein	31	PMOD
33	undergoing	undergo	B-VP	VBG	O	32	NMOD
34	percutaneous	percutaneous	B-NP	JJ	O	36	NMOD
35	coronary	coronary	I-NP	JJ	O	36	NMOD
36	intervention	intervention	I-NP	NN	O	33	OBJ
37	(	(	O	(	O	39	DEP
38	PCI	PCI	B-NP	NN	B-protein	39	DEP
39	)	)	O	)	O	36	NMOD
40	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	objective	objective	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	review	review	I-NP	NN	O	3	PMOD
6	is	be	B-VP	VBZ	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	summarize	summarize	I-VP	VB	O	6	PRD
9	practical	practical	B-NP	JJ	O	10	NMOD
10	considerations	consideration	I-NP	NNS	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	argatroban	argatroban	B-NP	JJ	O	13	NMOD
13	therapy	therapy	I-NP	NN	O	11	PMOD
14	in	in	B-PP	IN	O	13	NMOD
15	HIT	HIT	B-NP	NN	B-protein	14	PMOD
16	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	5	NMOD
2	US	US	I-NP	NNP	O	5	NMOD
3	FDA-recommended	FDA-recommended	I-NP	NNP	O	5	NMOD
4	argatroban	argatroban	I-NP	JJ	O	5	NMOD
5	dose	dose	I-NP	NN	O	8	SUB
6	in	in	B-PP	IN	O	5	NMOD
7	HIT	HIT	B-NP	NN	B-protein	6	PMOD
8	is	be	B-VP	VBZ	O	0	ROOT
9	2	2	B-NP	CD	O	10	NMOD
10	microg/kg/min	microg/kg/min	I-NP	NN	O	8	PRD
11	(	(	O	(	O	22	DEP
12	reduced	reduce	B-VP	VBN	O	22	DEP
13	in	in	B-PP	IN	O	12	VMOD
14	patients	patient	B-NP	NNS	O	13	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	hepatic	hepatic	B-NP	JJ	O	17	NMOD
17	impairment	impairment	I-NP	NN	O	15	PMOD
18	and	and	B-PP	CC	O	13	PMOD
19	in	in	B-PP	IN	O	13	PMOD
20	paediatric	paediatric	B-NP	JJ	O	21	NMOD
21	patients	patient	I-NP	NNS	O	19	PMOD
22	)	)	O	)	O	10	NMOD
23	,	,	O	,	O	10	P
24	adjusted	adjust	B-VP	VBN	O	10	NMOD
25	to	to	B-VP	TO	O	26	VMOD
26	achieve	achieve	I-VP	VB	O	24	VMOD
27	activated	activate	B-NP	VBN	O	36	NMOD
28	partial	partial	I-NP	JJ	O	30	NMOD
29	thromboplastin	thromboplastin	I-NP	NN	O	30	NMOD
30	times	time	I-NP	NNS	O	36	NMOD
31	(	(	O	(	O	33	DEP
32	aPTTs	aPTT	B-NP	NNS	O	33	DEP
33	)	)	O	)	O	30	NMOD
34	1.5-3	1.5-3	B-NP	CD	O	36	NMOD
35	times	time	I-NP	NNS	O	36	NMOD
36	baseline	baseline	I-NP	NN	O	26	OBJ
37	(	(	O	(	O	42	DEP
38	not	not	O	RB	O	42	DEP
39	>	>	O	SYM	O	41	NMOD
40	100	100	B-NP	CD	O	41	NMOD
41	seconds	second	I-NP	NNS	O	42	DEP
42	)	)	O	)	O	8	VMOD
43	.	.	O	.	O	8	P

1	For	For	B-PP	IN	O	5	VMOD
2	PCI	PCI	B-NP	NN	B-protein	1	PMOD
3	,	,	O	,	O	5	P
4	argatroban	argatroban	B-NP	NN	O	5	SUB
5	has	have	B-VP	VBZ	O	31	VMOD
6	not	not	I-VP	RB	O	5	VMOD
7	been	be	I-VP	VBN	O	5	VC
8	investigated	investigate	I-VP	VBN	O	7	VC
9	in	in	B-PP	IN	O	8	VMOD
10	hepatically	hepatically	B-NP	RB	O	11	AMOD
11	impaired	impaired	I-NP	JJ	O	12	NMOD
12	patients	patient	I-NP	NNS	O	9	PMOD
13	;	;	O	:	O	31	P
14	dose	dose	B-NP	NN	O	15	NMOD
15	adjustment	adjustment	I-NP	NN	O	16	SUB
16	is	be	B-VP	VBZ	O	31	VMOD
17	unnecessary	unnecessary	B-ADJP	JJ	O	16	PRD
18	for	for	B-PP	IN	O	17	AMOD
19	adult	adult	B-NP	JJ	O	20	NMOD
20	age	age	I-NP	NN	O	18	PMOD
21	,	,	O	,	O	31	P
22	sex	sex	B-NP	NN	O	30	NMOD
23	,	,	O	,	O	30	P
24	race/ethnicity	race/ethnicity	B-NP	NN	O	26	NMOD
25	or	or	I-NP	CC	O	26	NMOD
26	obesity	obesity	I-NP	NN	O	30	NMOD
27	,	,	O	,	O	30	P
28	and	and	O	CC	O	30	NMOD
29	lesser	less	B-NP	JJR	O	30	NMOD
30	doses	dose	I-NP	NNS	O	31	SUB
31	may	may	B-VP	MD	O	0	ROOT
32	be	be	I-VP	VB	O	31	VC
33	adequate	adequate	B-ADJP	JJ	O	32	PRD
34	with	with	B-PP	IN	O	33	AMOD
35	concurrent	concurrent	B-NP	JJ	O	38	NMOD
36	glycoprotein	glycoprotein	I-NP	NN	O	38	NMOD
37	IIb/IIIa	IIb/IIIa	I-NP	NN	O	38	NMOD
38	inhibition	inhibition	I-NP	NN	O	34	PMOD
39	.	.	O	.	O	31	P

1	Major	Major	B-NP	JJ	O	2	NMOD
2	bleeding	bleeding	I-NP	NN	O	5	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	argatroban	argatroban	B-NP	NN	O	3	PMOD
5	is	be	B-VP	VBZ	O	0	ROOT
6	0-10	0-10	B-NP	CD	O	7	NMOD
7	%	%	I-NP	NN	O	5	PRD
8	in	in	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	11	NMOD
10	non-interventional	non-interventional	I-NP	JJ	O	11	NMOD
11	setting	setting	I-NP	NN	O	8	PMOD
12	and	and	O	CC	O	15	AMOD
13	0-5.8	0-5.8	B-NP	CD	O	14	NMOD
14	%	%	I-NP	NN	O	15	NMOD
15	periprocedurally	periprocedurally	B-ADVP	RB	O	5	VMOD
16	.	.	O	.	O	5	P

1	Rhabdomyolysis	Rhabdomyolysis	B-NP	NN	O	5	NMOD
2	and	and	I-NP	CC	O	5	NMOD
3	brain	brain	I-NP	NN	O	5	NMOD
4	ischemic	ischemic	I-NP	JJ	O	5	NMOD
5	stroke	stroke	I-NP	NN	O	0	ROOT
6	in	in	B-PP	IN	O	5	NMOD
7	a	a	B-NP	DT	O	9	NMOD
8	heroin-dependent	heroin-dependent	I-NP	JJ	O	9	NMOD
9	male	male	I-NP	NN	O	6	PMOD
10	under	under	B-PP	IN	O	5	NMOD
11	methadone	methadone	B-NP	NN	O	13	NMOD
12	maintenance	maintenance	I-NP	NN	O	13	NMOD
13	therapy	therapy	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	5	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	A	A	B-NP	DT	O	5	NMOD
4	33-year-old	33-year-old	I-NP	JJ	O	5	NMOD
5	man	man	I-NP	NN	O	1	NMOD
6	presented	present	B-VP	VBN	O	5	NMOD
7	with	with	B-PP	IN	O	6	VMOD
8	rhabdomyolysis	rhabdomyolysis	B-NP	NN	O	12	NMOD
9	and	and	O	CC	O	12	NMOD
10	cerebral	cerebral	B-NP	JJ	O	12	NMOD
11	ischemic	ischemic	I-NP	JJ	O	12	NMOD
12	stroke	stroke	I-NP	NN	O	7	PMOD
13	after	after	B-PP	IN	O	12	NMOD
14	intravenous	intravenous	B-NP	JJ	O	15	NMOD
15	heroin	heroin	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	1	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	7	NMOD
2	:	:	O	:	O	1	P
3	Those	Those	B-NP	DT	O	7	NMOD
4	using	use	I-NP	VBG	O	7	NMOD
5	methadone	methadone	I-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	heroin	heroin	I-NP	NN	O	9	SUB
8	simultaneously	simultaneously	B-ADVP	RB	O	9	VMOD
9	may	may	B-VP	MD	O	0	ROOT
10	increase	increase	I-VP	VB	O	9	VC
11	risk	risk	B-NP	NN	O	10	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	rhabdomyolysis	rhabdomyolysis	B-NP	NN	O	16	NMOD
14	and	and	O	CC	O	16	NMOD
15	ischemic	ischemic	B-NP	JJ	O	16	NMOD
16	stroke	stroke	I-NP	NN	O	12	PMOD
17	.	.	O	.	O	9	P

1	Increased	Increase	B-NP	VBN	O	2	NMOD
2	vulnerability	vulnerability	I-NP	NN	O	0	ROOT
3	to	to	B-PP	TO	O	2	NMOD
4	6-hydroxydopamine	6-hydroxydopamine	B-NP	NN	O	5	NMOD
5	lesion	lesion	I-NP	NN	O	8	NMOD
6	and	and	O	CC	O	8	NMOD
7	reduced	reduce	B-NP	VBN	O	8	NMOD
8	development	development	I-NP	NN	O	3	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	dyskinesias	dyskinesia	B-NP	NNS	O	9	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	mice	mouse	B-NP	NNS	O	11	PMOD
13	lacking	lack	B-VP	VBG	O	12	NMOD
14	CB1	CB1	B-NP	NN	B-protein	16	NMOD
15	cannabinoid	cannabinoid	I-NP	NN	I-protein	16	NMOD
16	receptors	receptor	I-NP	NNS	I-protein	13	OBJ
17	.	.	O	.	O	2	P

1	Treatment	Treatment	B-NP	NN	O	8	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	L-DOPA+benserazide	L-DOPA+benserazide	B-NP	NN	O	2	PMOD
4	(	(	O	(	O	7	DEP
5	12	12	B-NP	CD	O	6	NMOD
6	weeks	week	I-NP	NNS	O	7	DEP
7	)	)	O	)	O	3	NMOD
8	resulted	result	B-VP	VBD	O	0	ROOT
9	in	in	B-PP	IN	O	8	VMOD
10	less	less	B-NP	RBR	O	11	AMOD
11	severe	severe	I-NP	JJ	O	12	NMOD
12	dyskinesias	dyskinesia	I-NP	NNS	O	9	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	CB1	CB1	B-NP	NN	B-protein	15	NMOD
15	KO	KO	I-NP	NN	I-protein	13	PMOD
16	than	than	B-PP	IN	O	8	VMOD
17	in	in	B-PP	IN	O	16	PMOD
18	WT	WT	B-NP	JJ	O	19	NMOD
19	mice	mouse	I-NP	NNS	O	17	PMOD
20	.	.	O	.	O	8	P

1	The	The	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	revealed	reveal	B-VP	VBD	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	the	the	B-NP	DT	O	6	NMOD
6	lack	lack	I-NP	NN	O	11	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	cannabinoid	cannabinoid	B-NP	NN	B-protein	10	NMOD
9	CB1	CB1	I-NP	NN	I-protein	10	NMOD
10	receptors	receptor	I-NP	NNS	I-protein	7	PMOD
11	increased	increase	B-VP	VBD	O	4	SBAR
12	the	the	B-NP	DT	O	13	NMOD
13	severity	severity	I-NP	NN	O	11	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	motor	motor	B-NP	NN	O	16	NMOD
16	impairment	impairment	I-NP	NN	O	19	NMOD
17	and	and	O	CC	O	19	NMOD
18	DA	DA	B-NP	NN	O	19	NMOD
19	lesion	lesion	I-NP	NN	O	14	PMOD
20	,	,	O	,	O	25	P
21	and	and	O	CC	O	25	NMOD
22	reduced	reduce	B-NP	VBN	O	25	NMOD
23	L-DOPA	L-DOPA	I-NP	NN	B-protein	25	NMOD
24	induced	induce	I-NP	VBN	O	25	NMOD
25	dyskinesias	dyskinesia	I-NP	NNS	O	11	VMOD
26	.	.	O	.	O	3	P

1	Animal	Animal	B-NP	NN	O	2	NMOD
2	model	model	I-NP	NN	O	9	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	mania	mania	B-NP	NN	O	3	PMOD
5	induced	induce	B-VP	VBN	O	4	NMOD
6	by	by	B-PP	IN	O	5	VMOD
7	ouabain	ouabain	B-NP	NN	O	6	PMOD
8	:	:	O	:	O	2	P
9	Evidence	Evidence	B-NP	NN	O	0	ROOT
10	of	of	B-PP	IN	O	9	NMOD
11	oxidative	oxidative	B-NP	JJ	O	12	NMOD
12	stress	stress	I-NP	NN	O	10	PMOD
13	in	in	B-PP	IN	O	9	NMOD
14	submitochondrial	submitochondrial	B-NP	JJ	O	15	NMOD
15	particles	particle	I-NP	NNS	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	19	NMOD
18	rat	rat	I-NP	NN	O	19	NMOD
19	brain	brain	I-NP	NN	O	16	PMOD
20	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	6	NMOD
2	intracerebroventricular	intracerebroventricular	I-NP	JJ	O	6	NMOD
3	(	(	O	(	O	5	DEP
4	ICV	ICV	B-NP	NN	O	5	DEP
5	)	)	O	)	O	2	AMOD
6	administration	administration	B-NP	NN	O	24	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	ouabain	ouabain	B-NP	NN	O	7	PMOD
9	(	(	O	(	O	21	DEP
10	a	a	B-NP	DT	O	11	NMOD
11	Na	Na	I-NP	NN	O	20	NMOD
12	(	(	O	(	O	14	DEP
13	+	+	O	SYM	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	/K	/K	B-NP	NN	B-protein	20	NMOD
16	(	(	O	(	I-protein	20	NMOD
17	+	+	O	SYM	I-protein	20	NMOD
18	)	)	O	)	I-protein	20	NMOD
19	-ATPase	-ATPase	B-NP	NN	I-protein	20	NMOD
20	inhibitor	inhibitor	I-NP	NN	O	21	DEP
21	)	)	O	)	O	8	NMOD
22	in	in	B-PP	IN	O	6	NMOD
23	rats	rat	B-NP	NNS	O	22	PMOD
24	has	have	B-VP	VBZ	O	0	ROOT
25	been	be	I-VP	VBN	O	24	VC
26	suggested	suggest	I-VP	VBN	O	25	VC
27	to	to	I-VP	TO	O	28	VMOD
28	mimic	mimic	I-VP	VB	O	26	VMOD
29	some	some	B-NP	DT	O	30	NMOD
30	symptoms	symptom	I-NP	NNS	O	28	OBJ
31	of	of	B-PP	IN	O	30	NMOD
32	human	human	B-NP	JJ	O	34	NMOD
33	bipolar	bipolar	I-NP	JJ	O	34	NMOD
34	mania	mania	I-NP	NN	O	31	PMOD
35	.	.	O	.	O	24	P

1	Our	Our	B-NP	PRP$	O	2	NMOD
2	findings	finding	I-NP	NNS	O	3	SUB
3	demonstrated	demonstrate	B-VP	VBD	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	ouabain	ouabain	B-NP	NN	O	17	SUB
6	at	at	B-PP	IN	O	5	NMOD
7	10	10	B-NP	CD	O	12	NMOD
8	(	(	O	(	O	10	DEP
9	-2	-2	B-NP	CD	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	and	and	O	CC	O	12	NMOD
12	10	10	B-NP	CD	O	16	NMOD
13	(	(	O	(	O	15	DEP
14	-3	-3	B-NP	CD	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	M	M	B-NP	NN	O	6	PMOD
17	induced	induce	B-VP	VBD	O	25	VMOD
18	hyperlocomotion	hyperlocomotion	B-NP	NN	O	17	OBJ
19	in	in	B-PP	IN	O	17	VMOD
20	rats	rat	B-NP	NNS	O	19	PMOD
21	,	,	O	,	O	25	P
22	and	and	O	CC	O	24	NMOD
23	this	this	B-NP	DT	O	24	NMOD
24	response	response	I-NP	NN	O	25	SUB
25	remained	remain	B-VP	VBD	O	4	SBAR
26	up	up	B-NP	RB	O	29	NMOD
27	to	to	I-NP	TO	O	26	AMOD
28	7	7	I-NP	CD	O	26	AMOD
29	days	day	I-NP	NNS	O	25	OBJ
30	following	follow	B-PP	VBG	O	25	VMOD
31	a	a	B-NP	DT	O	34	NMOD
32	single	single	I-NP	JJ	O	34	NMOD
33	ICV	ICV	I-NP	NN	O	34	NMOD
34	injection	injection	I-NP	NN	O	30	PMOD
35	.	.	O	.	O	3	P

1	Systemic	Systemic	B-NP	JJ	O	2	NMOD
2	anticoagulation	anticoagulation	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	unsafe	unsafe	B-NP	JJ	O	6	AMOD
5	and	and	I-NP	CC	O	6	AMOD
6	regional	regional	I-NP	JJ	O	8	NMOD
7	citrate	citrate	I-NP	NN	O	8	NMOD
8	anticoagulation	anticoagulation	I-NP	NN	O	3	PRD
9	in	in	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	absence	absence	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	a	a	B-NP	DT	O	15	NMOD
14	functional	functional	I-NP	JJ	O	15	NMOD
15	liver	liver	I-NP	NN	O	12	PMOD
16	carries	carry	B-VP	VBZ	O	3	VMOD
17	the	the	B-NP	DT	O	18	NMOD
18	risk	risk	I-NP	NN	O	16	OBJ
19	of	of	B-PP	IN	O	18	NMOD
20	citrate	citrate	B-NP	NN	O	21	NMOD
21	toxicity	toxicity	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	11	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	40-year-old	40-year-old	I-NP	JJ	O	8	NMOD
8	female	female	I-NP	NN	O	5	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	acetaminophen	acetaminophen	B-NP	NN	O	9	PMOD
11	induced	induce	B-VP	VBD	O	2	VMOD
12	fulminant	fulminant	B-NP	JJ	O	14	NMOD
13	liver	liver	I-NP	NN	O	14	NMOD
14	failure	failure	I-NP	NN	O	11	OBJ
15	with	with	B-PP	IN	O	14	NMOD
16	associated	associate	B-NP	VBN	O	17	NMOD
17	AKI	AKI	I-NP	NN	O	15	PMOD
18	who	who	B-NP	WP	O	17	NMOD
19	underwent	undergo	B-VP	VBD	O	18	SBAR
20	intraoperative	intraoperative	B-NP	JJ	O	22	NMOD
21	dialytic	dialytic	I-NP	JJ	O	22	NMOD
22	support	support	I-NP	NN	O	19	OBJ
23	during	during	B-PP	IN	O	19	VMOD
24	liver	liver	B-NP	NN	O	25	NMOD
25	transplantation	transplantation	I-NP	NN	O	23	PMOD
26	anticoagulated	anticoagulate	B-VP	VBN	O	25	NMOD
27	with	with	B-PP	IN	O	26	VMOD
28	citrate	citrate	B-NP	NN	O	29	NMOD
29	dialysate	dialysate	I-NP	NN	O	27	PMOD
30	during	during	B-PP	IN	O	26	VMOD
31	the	the	B-NP	DT	O	33	NMOD
32	entire	entire	I-NP	JJ	O	33	NMOD
33	procedure	procedure	I-NP	NN	O	30	PMOD
34	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	3	SUB
3	tolerated	tolerate	B-VP	VBD	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	procedure	procedure	I-NP	NN	O	3	OBJ
6	well	well	B-ADVP	RB	O	3	VMOD
7	without	without	B-PP	IN	O	3	VMOD
8	any	any	B-NP	DT	O	9	NMOD
9	signs	sign	I-NP	NNS	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	citrate	citrate	B-NP	NN	O	12	NMOD
12	toxicity	toxicity	I-NP	NN	O	10	PMOD
13	and	and	O	CC	O	3	VMOD
14	maintained	maintain	B-VP	VBD	O	3	VMOD
15	adequate	adequate	B-NP	JJ	O	16	NMOD
16	anticoagulation	anticoagulation	I-NP	NN	O	14	OBJ
17	for	for	B-PP	IN	O	16	NMOD
18	patency	patency	B-NP	NN	O	17	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	22	NMOD
21	dialysis	dialysis	I-NP	NN	O	22	NMOD
22	circuit	circuit	I-NP	NN	O	19	PMOD
23	.	.	O	.	O	3	P

1	Delirium	Delirium	B-NP	NN	O	12	NMOD
2	in	in	B-PP	IN	O	1	NMOD
3	a	a	B-NP	DT	O	4	NMOD
4	patient	patient	I-NP	NN	O	2	PMOD
5	with	with	B-PP	IN	O	4	NMOD
6	toxic	toxic	B-NP	JJ	O	9	NMOD
7	flecainide	flecainide	I-NP	NN	O	9	NMOD
8	plasma	plasma	I-NP	NN	O	9	NMOD
9	concentrations	concentration	I-NP	NNS	O	5	PMOD
10	:	:	O	:	O	1	P
11	the	the	B-NP	DT	O	12	NMOD
12	role	role	I-NP	NN	O	0	ROOT
13	of	of	B-PP	IN	O	12	NMOD
14	a	a	B-NP	DT	O	17	NMOD
15	pharmacokinetic	pharmacokinetic	I-NP	JJ	O	17	NMOD
16	drug	drug	I-NP	NN	O	17	NMOD
17	interaction	interaction	I-NP	NN	O	13	PMOD
18	with	with	B-PP	IN	O	17	NMOD
19	paroxetine	paroxetine	B-NP	NN	O	18	PMOD
20	.	.	O	.	O	12	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	9	SUB
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	describe	describe	I-VP	VB	O	1	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	flecainide	flecainide	B-NP	NN	O	7	PMOD
9	induced	induce	B-VP	VBD	O	0	ROOT
10	delirium	delirium	B-NP	NN	O	9	OBJ
11	associated	associate	B-VP	VBN	O	10	NMOD
12	with	with	B-PP	IN	O	11	VMOD
13	a	a	B-NP	DT	O	16	NMOD
14	pharmacokinetic	pharmacokinetic	I-NP	JJ	O	16	NMOD
15	drug	drug	I-NP	NN	O	16	NMOD
16	interaction	interaction	I-NP	NN	O	12	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	paroxetine	paroxetine	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	9	P

1	Flecainide	Flecainide	B-NP	NN	O	2	SUB
2	had	have	B-VP	VBD	O	0	ROOT
3	been	be	I-VP	VBN	O	2	VC
4	started	start	I-VP	VBN	O	3	VC
5	2	2	B-NP	CD	O	6	NMOD
6	weeks	week	I-NP	NNS	O	4	OBJ
7	prior	prior	B-ADJP	JJ	O	6	NMOD
8	for	for	B-PP	IN	O	7	AMOD
9	atrial	atrial	B-NP	JJ	O	10	NMOD
10	fibrillation	fibrillation	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	2	P

1	DISCUSSION	DISCUSSION	B-NP	NN	O	3	NMOD
2	:	:	O	:	O	1	P
3	Flecainide	Flecainide	B-NP	NN	O	7	NMOD
4	and	and	O	CC	O	7	NMOD
5	pharmacologically	pharmacologically	B-NP	RB	O	6	AMOD
6	similar	similar	I-NP	JJ	O	7	NMOD
7	agents	agent	I-NP	NNS	O	13	SUB
8	that	that	B-NP	WDT	O	7	NMOD
9	interact	interact	B-VP	VBP	O	8	SBAR
10	with	with	B-PP	IN	O	9	VMOD
11	sodium	sodium	B-NP	NN	B-protein	12	NMOD
12	channels	channel	I-NP	NNS	I-protein	10	PMOD
13	may	may	B-VP	MD	O	0	ROOT
14	cause	cause	I-VP	VB	O	13	VC
15	delirium	delirium	B-NP	NN	O	14	OBJ
16	in	in	B-PP	IN	O	14	VMOD
17	susceptible	susceptible	B-NP	JJ	O	18	NMOD
18	patients	patient	I-NP	NNS	O	16	PMOD
19	.	.	O	.	O	13	P

1	A	A	B-NP	DT	O	3	NMOD
2	MEDLINE	MEDLINE	I-NP	NNP	O	3	NMOD
3	search	search	I-NP	NN	O	8	SUB
4	(	(	O	(	O	7	DEP
5	1966-January	1966-January	B-NP	JJ	O	6	NMOD
6	2009	2009	I-NP	CD	O	7	DEP
7	)	)	O	)	O	3	NMOD
8	revealed	reveal	B-VP	VBD	O	0	ROOT
9	one	one	B-NP	CD	O	13	NMOD
10	in	in	I-NP	FW	O	11	AMOD
11	vivo	vivo	I-NP	FW	O	12	AMOD
12	pharmacokinetic	pharmacokinetic	I-NP	JJ	O	13	NMOD
13	study	study	I-NP	NN	O	8	OBJ
14	on	on	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	interaction	interaction	I-NP	NN	O	14	PMOD
17	between	between	B-PP	IN	O	16	NMOD
18	flecainide	flecainide	B-NP	NN	O	29	NMOD
19	,	,	O	,	O	29	P
20	a	a	B-NP	DT	O	22	NMOD
21	CYP2D6	CYP2D6	I-NP	NN	B-protein	22	NMOD
22	substrate	substrate	I-NP	NN	I-protein	29	NMOD
23	,	,	O	,	O	29	P
24	and	and	O	CC	O	29	NMOD
25	paroxetine	paroxetine	B-NP	NN	O	29	NMOD
26	,	,	O	,	O	29	P
27	a	a	B-NP	DT	O	29	NMOD
28	CYP2D6	CYP2D6	I-NP	NN	B-protein	29	NMOD
29	inhibitor	inhibitor	I-NP	NN	I-protein	36	NMOD
30	,	,	O	,	O	36	P
31	as	as	B-CONJP	RB	O	36	NMOD
32	well	well	I-CONJP	RB	O	31	DEP
33	as	as	I-CONJP	IN	O	31	DEP
34	3	3	B-NP	CD	O	36	NMOD
35	case	case	I-NP	NN	O	36	NMOD
36	reports	report	I-NP	NNS	O	17	PMOD
37	of	of	B-PP	IN	O	36	NMOD
38	flecainide	flecainide	B-NP	NN	O	40	NMOD
39	induced	induced	I-NP	JJ	O	40	NMOD
40	delirium	delirium	I-NP	NN	O	37	PMOD
41	.	.	O	.	O	8	P

1	According	Accord	B-PP	VBG	O	9	VMOD
2	to	to	B-PP	TO	O	1	PMOD
3	the	the	B-NP	DT	O	6	NMOD
4	Naranjo	Naranjo	I-NP	NNP	O	6	NMOD
5	probability	probability	I-NP	NN	O	6	NMOD
6	scale	scale	I-NP	NN	O	2	PMOD
7	,	,	O	,	O	9	P
8	flecainide	flecainide	B-NP	NN	O	9	SUB
9	was	be	B-VP	VBD	O	25	VMOD
10	the	the	B-NP	DT	O	12	NMOD
11	probable	probable	I-NP	JJ	O	12	NMOD
12	cause	cause	I-NP	NN	O	9	PRD
13	of	of	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	17	NMOD
15	patient	patient	I-NP	NN	O	17	NMOD
16	's	's	B-NP	POS	O	17	NMOD
17	delirium	delirium	I-NP	NN	O	13	PMOD
18	;	;	O	:	O	9	P
19	the	the	B-NP	DT	O	24	NMOD
20	Horn	Horn	I-NP	NNP	O	24	NMOD
21	Drug	Drug	I-NP	NNP	O	24	NMOD
22	Interaction	Interaction	I-NP	NNP	O	24	NMOD
23	Probability	Probability	I-NP	NNP	O	24	NMOD
24	Scale	Scale	I-NP	NNP	O	25	SUB
25	indicates	indicate	B-VP	VBZ	O	0	ROOT
26	a	a	B-NP	DT	O	30	NMOD
27	possible	possible	I-NP	JJ	O	30	NMOD
28	pharmacokinetic	pharmacokinetic	I-NP	JJ	O	30	NMOD
29	drug	drug	I-NP	NN	O	30	NMOD
30	interaction	interaction	I-NP	NN	O	25	OBJ
31	between	between	B-PP	IN	O	30	NMOD
32	flecainide	flecainide	B-NP	NN	O	34	NMOD
33	and	and	I-NP	CC	O	34	NMOD
34	paroxetine	paroxetine	I-NP	NN	O	31	PMOD
35	.	.	O	.	O	25	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	6	NMOD
2	:	:	O	:	O	1	P
3	Supratherapeutic	Supratherapeutic	B-NP	JJ	O	6	NMOD
4	flecainide	flecainide	I-NP	NN	O	6	NMOD
5	plasma	plasma	I-NP	NN	O	6	NMOD
6	concentrations	concentration	I-NP	NNS	O	7	SUB
7	may	may	B-VP	MD	O	0	ROOT
8	cause	cause	I-VP	VB	O	7	VC
9	delirium	delirium	B-NP	NN	O	8	OBJ
10	.	.	O	.	O	7	P

1	Efficacy	Efficacy	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	everolimus	everolimus	B-NP	NN	O	2	PMOD
4	(	(	O	(	O	6	DEP
5	RAD001	RAD001	B-NP	NN	B-protein	6	DEP
6	)	)	O	)	O	3	NMOD
7	in	in	B-PP	IN	O	1	NMOD
8	patients	patient	B-NP	NNS	O	7	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	advanced	advance	B-NP	VBN	O	11	NMOD
11	NSCLC	NSCLC	I-NP	NN	B-protein	9	PMOD
12	previously	previously	B-VP	RB	O	13	VMOD
13	treated	treat	I-VP	VBN	O	1	NMOD
14	with	with	B-PP	IN	O	13	VMOD
15	chemotherapy	chemotherapy	B-NP	NN	O	14	PMOD
16	alone	alone	B-ADVP	RB	O	15	NMOD
17	or	or	O	CC	O	14	PMOD
18	with	with	B-PP	IN	O	14	PMOD
19	chemotherapy	chemotherapy	B-NP	NN	O	22	NMOD
20	and	and	I-NP	CC	O	22	NMOD
21	EGFR	EGFR	I-NP	NN	B-protein	22	NMOD
22	inhibitors	inhibitor	I-NP	NNS	O	18	PMOD
23	.	.	O	.	O	1	P

1	RAD001	RAD001	B-NP	NN	B-protein	5	NMOD
2	,	,	O	,	O	5	P
3	an	an	B-NP	DT	O	5	NMOD
4	oral	oral	I-NP	JJ	O	5	NMOD
5	inhibitor	inhibitor	I-NP	NN	O	16	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	9	NMOD
8	mammalian	mammalian	I-NP	JJ	O	9	NMOD
9	target	target	I-NP	NN	O	6	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	rapamycin	rapamycin	B-NP	NN	O	10	PMOD
12	(	(	O	(	O	14	DEP
13	mTOR	mTOR	B-NP	NN	B-protein	14	DEP
14	)	)	O	)	O	11	NMOD
15	,	,	O	,	O	5	P
16	has	have	B-VP	VBZ	O	0	ROOT
17	shown	show	I-VP	VBN	O	16	VC
18	phase	phase	B-NP	NN	O	20	NMOD
19	I	I	I-NP	CD	O	20	NMOD
20	efficacy	efficacy	I-NP	NN	O	17	OBJ
21	in	in	B-PP	IN	O	20	NMOD
22	NSCLC	NSCLC	B-NP	NN	B-protein	21	PMOD
23	.	.	O	.	O	16	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Stage	Stage	B-NP	NN	O	4	NMOD
4	IIIb	IIIb	I-NP	NN	O	8	NMOD
5	or	or	O	CC	O	8	NMOD
6	IV	IV	B-NP	CD	O	8	NMOD
7	NSCLC	NSCLC	I-NP	NN	O	8	NMOD
8	patients	patient	I-NP	NNS	O	35	NMOD
9	,	,	O	,	O	8	P
10	with	with	B-PP	IN	O	8	NMOD
11	two	two	B-NP	CD	O	16	NMOD
12	or	or	I-NP	CC	O	16	NMOD
13	fewer	few	I-NP	JJR	O	14	AMOD
14	prior	prior	I-NP	JJ	O	16	NMOD
15	chemotherapy	chemotherapy	I-NP	NN	O	16	NMOD
16	regimens	regimen	I-NP	NNS	O	10	PMOD
17	,	,	O	,	O	35	P
18	one	one	B-NP	CD	O	19	NMOD
19	platinum	platinum	I-NP	NN	O	35	NMOD
20	based	base	B-VP	VBN	O	19	NMOD
21	(	(	O	(	O	24	DEP
22	stratum	stratum	B-NP	NN	O	24	DEP
23	1	1	I-NP	CD	O	22	NMOD
24	)	)	O	)	O	19	NMOD
25	or	or	O	CC	O	35	NMOD
26	both	both	O	CC	O	35	NMOD
27	chemotherapy	chemotherapy	B-NP	NN	O	35	NMOD
28	and	and	O	CC	O	35	NMOD
29	epidermal	epidermal	B-NP	JJ	O	35	NMOD
30	growth	growth	I-NP	NN	O	35	NMOD
31	factor	factor	I-NP	NN	O	35	NMOD
32	receptor	receptor	I-NP	NN	O	35	NMOD
33	tyrosine	tyrosine	I-NP	NN	O	35	NMOD
34	kinase	kinase	I-NP	NN	O	35	NMOD
35	inhibitors	inhibitor	I-NP	NNS	O	41	SUB
36	(	(	O	(	O	39	DEP
37	stratum	stratum	B-NP	NN	O	39	DEP
38	2	2	I-NP	CD	O	37	NMOD
39	)	)	O	)	O	35	NMOD
40	,	,	O	,	O	35	P
41	received	receive	B-VP	VBD	O	1	NMOD
42	RAD001	RAD001	B-NP	NN	O	44	NMOD
43	10	10	I-NP	CD	O	44	NMOD
44	mg/day	mg/day	I-NP	NN	O	41	OBJ
45	until	until	B-PP	IN	O	41	VMOD
46	progression	progression	B-NP	NN	O	49	NMOD
47	or	or	O	CC	O	49	NMOD
48	unacceptable	unacceptable	B-NP	JJ	O	49	NMOD
49	toxicity	toxicity	I-NP	NN	O	45	PMOD
50	.	.	O	.	O	1	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	RAD001	RAD001	B-NP	NN	O	5	NMOD
4	10	10	I-NP	CD	O	5	NMOD
5	mg/day	mg/day	I-NP	NN	O	6	SUB
6	was	be	B-VP	VBD	O	1	NMOD
7	well	well	I-VP	RB	O	6	VMOD
8	tolerated	tolerate	I-VP	VBN	O	6	VC
9	,	,	O	,	O	8	P
10	showing	show	B-VP	VBG	O	8	VMOD
11	modest	modest	B-NP	JJ	O	12	AMOD
12	clinical	clinical	I-NP	JJ	O	13	NMOD
13	activity	activity	I-NP	NN	O	10	OBJ
14	in	in	B-PP	IN	O	13	NMOD
15	pretreated	pretreate	B-NP	VBN	O	16	NMOD
16	NSCLC	NSCLC	I-NP	NN	B-protein	14	PMOD
17	.	.	O	.	O	1	P

1	Posttransplant	Posttransplant	B-NP	NN	O	2	NMOD
2	anemia	anemia	I-NP	NN	O	5	NMOD
3	:	:	O	:	O	2	P
4	the	the	B-NP	DT	O	5	NMOD
5	role	role	I-NP	NN	O	0	ROOT
6	of	of	B-PP	IN	O	5	NMOD
7	sirolimus	sirolimus	B-NP	NN	O	6	PMOD
8	.	.	O	.	O	5	P

1	Sirolimus	Sirolimus	B-NP	NNP	O	5	NMOD
2	,	,	O	,	O	5	P
3	a	a	B-NP	DT	O	5	NMOD
4	mammalian	mammalian	I-NP	JJ	O	5	NMOD
5	target	target	I-NP	NN	O	10	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	rapamycin	rapamycin	B-NP	NN	O	8	NMOD
8	inhibitor	inhibitor	I-NP	NN	O	6	PMOD
9	,	,	O	,	O	5	P
10	has	have	B-VP	VBZ	O	0	ROOT
11	been	be	I-VP	VBN	O	10	VC
12	implicated	implicate	I-VP	VBN	O	11	VC
13	as	as	B-PP	IN	O	12	VMOD
14	playing	play	B-VP	VBG	O	13	PMOD
15	a	a	B-NP	DT	O	17	NMOD
16	special	special	I-NP	JJ	O	17	NMOD
17	role	role	I-NP	NN	O	14	OBJ
18	in	in	B-PP	IN	O	14	VMOD
19	posttransplant	posttransplant	B-NP	NN	O	20	NMOD
20	anemia	anemia	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	10	P

1	Coronary	Coronary	B-NP	JJ	O	4	NMOD
2	computerized	computerized	I-NP	JJ	O	4	NMOD
3	tomography	tomography	I-NP	NN	O	4	NMOD
4	angiography	angiography	I-NP	NN	O	0	ROOT
5	for	for	B-PP	IN	O	4	NMOD
6	rapid	rapid	B-NP	JJ	O	7	NMOD
7	discharge	discharge	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	low-risk	low-risk	B-NP	JJ	O	10	NMOD
10	patients	patient	I-NP	NNS	O	8	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	cocaine-associated	cocaine-associated	B-NP	JJ	O	14	NMOD
13	chest	chest	I-NP	NN	O	14	NMOD
14	pain	pain	I-NP	NN	O	11	PMOD
15	.	.	O	.	O	4	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Most	Most	B-NP	JJS	O	4	NMOD
4	patients	patient	I-NP	NNS	O	16	SUB
5	presenting	present	B-VP	VBG	O	4	NMOD
6	to	to	B-PP	TO	O	5	VMOD
7	emergency	emergency	B-NP	NN	O	8	NMOD
8	departments	department	I-NP	NNS	O	6	PMOD
9	(	(	O	(	O	11	DEP
10	EDs	ED	B-NP	NNS	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	with	with	B-PP	IN	O	8	NMOD
13	cocaine-associated	cocaine-associated	B-NP	JJ	O	15	NMOD
14	chest	chest	I-NP	NN	O	15	NMOD
15	pain	pain	I-NP	NN	O	12	PMOD
16	are	be	B-VP	VBP	O	1	NMOD
17	admitted	admit	I-VP	VBN	O	16	VC
18	for	for	B-PP	IN	O	17	VMOD
19	at	at	B-NP	IN	O	22	NMOD
20	least	least	I-NP	JJS	O	19	AMOD
21	12	12	I-NP	CD	O	19	AMOD
22	hours	hour	I-NP	NNS	O	18	PMOD
23	and	and	O	CC	O	16	VMOD
24	receive	receive	B-VP	VB	O	16	VMOD
25	a	a	B-NP	DT	O	27	NMOD
26	``	``	I-NP	``	O	27	NMOD
27	rule	rule	I-NP	NN	O	24	OBJ
28	out	out	B-PP	IN	O	24	VMOD
29	acute	acute	B-NP	JJ	O	31	NMOD
30	coronary	coronary	I-NP	JJ	O	31	NMOD
31	syndrome	syndrome	I-NP	NN	O	33	NMOD
32	''	''	I-NP	''	O	31	NMOD
33	protocol	protocol	I-NP	NN	O	28	PMOD
34	,	,	O	,	O	16	P
35	often	often	B-ADVP	RB	O	16	VMOD
36	with	with	B-PP	IN	O	35	PMOD
37	noninvasive	noninvasive	B-NP	JJ	O	38	NMOD
38	testing	testing	I-NP	NN	O	36	PMOD
39	prior	prior	B-ADJP	JJ	O	35	AMOD
40	to	to	B-VP	TO	O	41	VMOD
41	discharge	discharge	I-VP	VB	O	16	VMOD
42	.	.	O	.	O	16	P

1	It	It	B-NP	PRP	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	unclear	unclear	B-ADJP	JJ	O	2	PRD
4	whether	whether	B-SBAR	IN	O	2	VMOD
5	a	a	B-NP	DT	O	8	NMOD
6	coronary	coronary	I-NP	JJ	O	8	NMOD
7	CTA	CTA	I-NP	NN	O	8	NMOD
8	strategy	strategy	I-NP	NN	O	9	SUB
9	would	would	B-VP	MD	O	4	SBAR
10	be	be	I-VP	VB	O	9	VC
11	efficacious	efficacious	B-ADJP	JJ	O	10	PRD
12	in	in	B-PP	IN	O	11	AMOD
13	cocaine-associated	cocaine-associated	B-NP	JJ	O	15	NMOD
14	chest	chest	I-NP	NN	O	15	NMOD
15	pain	pain	I-NP	NN	O	12	PMOD
16	,	,	O	,	O	2	P
17	as	as	B-SBAR	IN	O	2	VMOD
18	coronary	coronary	B-NP	JJ	O	19	NMOD
19	vasospasm	vasospasm	I-NP	NN	O	20	SUB
20	may	may	B-VP	MD	O	17	SBAR
21	account	account	I-VP	VB	O	20	VC
22	for	for	B-PP	IN	O	21	VMOD
23	some	some	B-NP	DT	O	22	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	the	the	B-NP	DT	O	26	NMOD
26	ischemia	ischemia	I-NP	NN	O	24	PMOD
27	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	studied	study	B-VP	VBD	O	0	ROOT
3	whether	whether	B-SBAR	IN	O	2	VMOD
4	a	a	B-NP	DT	O	7	NMOD
5	negative	negative	I-NP	JJ	O	7	NMOD
6	coronary	coronary	I-NP	JJ	O	7	NMOD
7	CTA	CTA	I-NP	NN	O	14	SUB
8	in	in	B-PP	IN	O	7	NMOD
9	patients	patient	B-NP	NNS	O	8	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	cocaine-associated	cocaine-associated	B-NP	JJ	O	13	NMOD
12	chest	chest	I-NP	NN	O	13	NMOD
13	pain	pain	I-NP	NN	O	10	PMOD
14	could	could	B-VP	MD	O	3	SBAR
15	identify	identify	I-VP	VB	O	14	VC
16	a	a	B-NP	DT	O	17	NMOD
17	subset	subset	I-NP	NN	O	15	OBJ
18	safe	safe	B-ADJP	JJ	O	17	NMOD
19	for	for	B-PP	IN	O	18	AMOD
20	discharge	discharge	B-NP	NN	O	19	PMOD
21	.	.	O	.	O	2	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	A	A	B-NP	DT	O	4	NMOD
4	total	total	I-NP	NN	O	12	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	59	59	B-NP	CD	O	7	NMOD
7	patients	patient	I-NP	NNS	O	5	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	cocaine-associated	cocaine-associated	B-NP	JJ	O	11	NMOD
10	chest	chest	I-NP	NN	O	11	NMOD
11	pain	pain	I-NP	NN	O	8	PMOD
12	were	be	B-VP	VBD	O	1	NMOD
13	evaluated	evaluate	I-VP	VBN	O	12	VC
14	.	.	O	.	O	1	P

1	METHOD	METHOD	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Case-based	Case-based	B-NP	JJ	O	4	NMOD
4	observations	observation	I-NP	NNS	O	1	OBJ
5	from	from	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	10	NMOD
7	medical	medical	I-NP	JJ	O	10	NMOD
8	intensive	intensive	I-NP	JJ	O	10	NMOD
9	care	care	I-NP	NN	O	10	NMOD
10	unit	unit	I-NP	NN	O	5	PMOD
11	(	(	O	(	O	13	DEP
12	MICU	MICU	B-NP	NN	B-DNA	13	DEP
13	)	)	O	)	O	10	NMOD
14	in	in	B-PP	IN	O	4	NMOD
15	a	a	B-NP	DT	O	18	NMOD
16	tertiary	tertiary	I-NP	JJ	O	18	NMOD
17	care	care	I-NP	NN	O	18	NMOD
18	facility	facility	I-NP	NN	O	14	PMOD
19	in	in	B-PP	IN	O	4	NMOD
20	a	a	B-NP	DT	O	22	NMOD
21	27-year-old	27-year-old	I-NP	JJ	O	22	NMOD
22	female	female	I-NP	NN	O	19	PMOD
23	with	with	B-PP	IN	O	22	NMOD
24	FHF	FHF	B-NP	NN	B-protein	23	PMOD
25	from	from	B-PP	IN	O	24	NMOD
26	acetaminophen	acetaminophen	B-NP	NN	O	30	NMOD
27	and	and	O	CC	O	30	NMOD
28	resultant	resultant	B-NP	JJ	O	30	NMOD
29	cerebral	cerebral	I-NP	JJ	O	30	NMOD
30	edema	edema	I-NP	NN	O	25	PMOD
31	.	.	O	.	O	1	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Our	Our	B-NP	PRP$	O	4	NMOD
4	patient	patient	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	1	NMOD
6	admitted	admit	I-VP	VBN	O	5	VC
7	to	to	B-PP	TO	O	6	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	MICU	MICU	I-NP	NN	B-DNA	7	PMOD
10	after	after	B-PP	IN	O	6	VMOD
11	being	be	B-VP	VBG	O	10	PMOD
12	found	find	I-VP	VBN	O	11	VC
13	unresponsive	unresponsive	B-ADJP	JJ	O	12	PRD
14	with	with	B-PP	IN	O	13	AMOD
15	presumed	presume	B-NP	VBN	O	16	NMOD
16	toxicity	toxicity	I-NP	NN	O	14	PMOD
17	from	from	B-PP	IN	O	16	NMOD
18	acetaminophen	acetaminophen	B-NP	NN	O	17	PMOD
19	which	which	B-NP	WDT	O	16	NMOD
20	was	be	B-VP	VBD	O	19	SBAR
21	ingested	ingest	I-VP	VBN	O	20	VC
22	over	over	B-PP	IN	O	21	VMOD
23	a	a	B-NP	DT	O	25	NMOD
24	2-day	2-day	I-NP	JJ	O	25	NMOD
25	period	period	I-NP	NN	O	22	PMOD
26	.	.	O	.	O	1	P

1	Initial	Initial	B-NP	JJ	O	2	NMOD
2	evaluation	evaluation	I-NP	NN	O	3	SUB
3	confirmed	confirm	B-VP	VBD	O	0	ROOT
4	FHF	FHF	B-NP	NN	B-protein	3	OBJ
5	from	from	B-PP	IN	O	3	VMOD
6	acetaminophen	acetaminophen	B-NP	NN	O	9	NMOD
7	and	and	O	CC	O	9	NMOD
8	cerebral	cerebral	B-NP	JJ	O	9	NMOD
9	edema	edema	I-NP	NN	O	5	PMOD
10	.	.	O	.	O	3	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	14	SUB
2	:	:	O	:	O	1	P
3	In	In	B-PP	IN	O	14	VMOD
4	patients	patient	B-NP	NNS	O	3	PMOD
5	with	with	B-PP	IN	O	4	NMOD
6	FHF	FHF	B-NP	NN	B-protein	9	NMOD
7	and	and	O	CC	O	9	NMOD
8	cerebral	cerebral	B-NP	JJ	O	9	NMOD
9	edema	edema	I-NP	NN	O	5	PMOD
10	from	from	B-PP	IN	O	9	NMOD
11	acetaminophen	acetaminophen	B-NP	NN	O	12	NMOD
12	overdose	overdose	I-NP	NN	O	10	PMOD
13	,	,	O	,	O	14	P
14	prolonged	prolong	B-VP	VBD	O	0	ROOT
15	therapeutic	therapeutic	B-NP	JJ	O	16	NMOD
16	hypothermia	hypothermia	I-NP	NN	O	17	SUB
17	could	could	B-VP	MD	O	14	VMOD
18	potentially	potentially	I-VP	RB	O	17	VMOD
19	be	be	I-VP	VB	O	17	VC
20	used	use	I-VP	VBN	O	19	VC
21	as	as	B-PP	IN	O	20	VMOD
22	a	a	B-NP	DT	O	23	NMOD
23	life	life	I-NP	NN	O	25	NMOD
24	saving	save	I-NP	VBG	O	25	NMOD
25	therapy	therapy	I-NP	NN	O	28	NMOD
26	and	and	O	CC	O	28	NMOD
27	a	a	B-NP	DT	O	28	NMOD
28	bridge	bridge	I-NP	NN	O	21	PMOD
29	to	to	B-PP	TO	O	28	NMOD
30	hepatic	hepatic	B-NP	JJ	O	32	AMOD
31	and	and	I-NP	CC	O	32	AMOD
32	neurological	neurological	I-NP	JJ	O	33	NMOD
33	recovery	recovery	I-NP	NN	O	29	PMOD
34	.	.	O	.	O	14	P

1	Binasal	Binasal	B-NP	JJ	O	4	NMOD
2	visual	visual	I-NP	JJ	O	4	NMOD
3	field	field	I-NP	NN	O	4	NMOD
4	defects	defect	I-NP	NNS	O	5	SUB
5	are	be	B-VP	VBP	O	0	ROOT
6	not	not	O	RB	O	5	VMOD
7	specific	specific	B-ADJP	JJ	O	5	PRD
8	to	to	B-PP	TO	O	7	AMOD
9	vigabatrin	vigabatrin	B-NP	NN	O	8	PMOD
10	.	.	O	.	O	5	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	investigated	investigate	B-VP	VBD	O	0	ROOT
4	the	the	B-NP	DT	O	6	NMOD
5	visual	visual	I-NP	JJ	O	6	NMOD
6	defects	defect	I-NP	NNS	O	3	OBJ
7	associated	associate	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	the	the	B-NP	DT	O	12	NMOD
10	antiepileptic	antiepileptic	I-NP	JJ	O	12	NMOD
11	drug	drug	I-NP	NN	O	12	NMOD
12	vigabatrin	vigabatrin	I-NP	NN	O	8	PMOD
13	(	(	O	(	O	15	DEP
14	VGB	VGB	B-NP	NN	B-protein	15	DEP
15	)	)	O	)	O	12	NMOD
16	.	.	O	.	O	3	P

1	Two	Two	B-NP	CD	O	3	AMOD
2	hundred	hundred	I-NP	CD	O	3	AMOD
3	four	four	I-NP	CD	O	4	NMOD
4	people	people	I-NP	NNS	O	7	SUB
5	with	with	B-PP	IN	O	4	NMOD
6	epilepsy	epilepsy	B-NP	NN	O	5	PMOD
7	were	be	B-VP	VBD	O	0	ROOT
8	grouped	group	I-VP	VBN	O	7	VC
9	on	on	B-PP	IN	O	8	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	basis	basis	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	antiepileptic	antiepileptic	B-NP	JJ	O	15	NMOD
14	drug	drug	I-NP	NN	O	15	NMOD
15	therapy	therapy	I-NP	NN	O	12	PMOD
16	(	(	O	(	O	26	DEP
17	current	current	B-ADJP	JJ	O	26	DEP
18	,	,	O	,	O	26	P
19	previous	previous	B-ADJP	JJ	O	26	DEP
20	,	,	O	,	O	26	P
21	or	or	O	CC	O	26	DEP
22	no	no	B-NP	DT	O	23	NMOD
23	exposure	exposure	I-NP	NN	O	26	DEP
24	to	to	B-PP	TO	O	23	NMOD
25	VGB	VGB	B-NP	NN	B-protein	24	PMOD
26	)	)	O	)	O	15	NMOD
27	.	.	O	.	O	7	P

1	Smoking	Smoking	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	crack	crack	B-NP	NN	O	4	NMOD
4	cocaine	cocaine	I-NP	NN	O	2	PMOD
5	as	as	B-PP	IN	O	1	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	risk	risk	I-NP	NN	O	8	NMOD
8	factor	factor	I-NP	NN	O	5	PMOD
9	for	for	B-PP	IN	O	8	NMOD
10	HIV	HIV	B-NP	NN	O	11	NMOD
11	infection	infection	I-NP	NN	O	9	PMOD
12	among	among	B-PP	IN	O	8	NMOD
13	people	people	B-NP	NNS	O	12	PMOD
14	who	who	B-NP	WP	O	8	NMOD
15	use	use	B-VP	VBP	O	14	SBAR
16	injection	injection	B-NP	NN	O	17	NMOD
17	drugs	drug	I-NP	NNS	O	15	OBJ
18	.	.	O	.	O	1	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Little	Little	B-ADJP	JJ	O	4	SUB
4	is	be	B-VP	VBZ	O	1	NMOD
5	known	know	I-VP	VBN	O	4	VC
6	about	about	B-PP	IN	O	5	VMOD
7	the	the	B-NP	DT	O	9	NMOD
8	possible	possible	I-NP	JJ	O	9	NMOD
9	role	role	I-NP	NN	O	6	PMOD
10	that	that	B-NP	WDT	O	9	NMOD
11	smoking	smoke	B-VP	VBG	O	10	SBAR
12	crack	crack	B-NP	NN	O	13	NMOD
13	cocaine	cocaine	I-NP	NN	O	11	OBJ
14	has	have	B-VP	VBZ	O	4	VMOD
15	on	on	B-PP	IN	O	14	VMOD
16	the	the	B-NP	DT	O	17	NMOD
17	incidence	incidence	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	HIV	HIV	B-NP	NN	O	20	NMOD
20	infection	infection	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	1	P

1	Given	Give	B-PP	VBN	O	10	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	increasing	increase	I-NP	VBG	O	4	NMOD
4	use	use	I-NP	NN	O	1	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	crack	crack	B-NP	NN	O	7	NMOD
7	cocaine	cocaine	I-NP	NN	O	5	PMOD
8	,	,	O	,	O	10	P
9	we	we	B-NP	PRP	O	10	SUB
10	sought	seek	B-VP	VBD	O	0	ROOT
11	to	to	I-VP	TO	O	12	VMOD
12	examine	examine	I-VP	VB	O	10	VMOD
13	whether	whether	B-SBAR	IN	O	12	VMOD
14	use	use	B-NP	NN	O	19	SUB
15	of	of	B-PP	IN	O	14	NMOD
16	this	this	B-NP	DT	O	18	NMOD
17	illicit	illicit	I-NP	JJ	O	18	NMOD
18	drug	drug	I-NP	NN	O	15	PMOD
19	has	have	B-VP	VBZ	O	13	SBAR
20	become	become	I-VP	VBN	O	19	VC
21	a	a	B-NP	DT	O	23	NMOD
22	risk	risk	I-NP	NN	O	23	NMOD
23	factor	factor	I-NP	NN	O	20	PRD
24	for	for	B-PP	IN	O	23	NMOD
25	HIV	HIV	B-NP	NN	O	26	NMOD
26	infection	infection	I-NP	NN	O	24	PMOD
27	.	.	O	.	O	10	P

1	To	To	B-VP	TO	O	2	VMOD
2	determine	determine	I-VP	VB	O	20	VMOD
3	whether	whether	B-SBAR	IN	O	2	VMOD
4	the	the	B-NP	DT	O	5	NMOD
5	risk	risk	I-NP	NN	O	15	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	HIV	HIV	B-NP	NN	O	8	NMOD
8	seroconversion	seroconversion	I-NP	NN	O	6	PMOD
9	among	among	B-PP	IN	O	5	NMOD
10	daily	daily	B-NP	JJ	O	11	NMOD
11	smokers	smoker	I-NP	NNS	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	crack	crack	B-NP	NN	O	14	NMOD
14	cocaine	cocaine	I-NP	NN	O	12	PMOD
15	changed	change	B-VP	VBD	O	3	SBAR
16	over	over	B-PP	IN	O	15	VMOD
17	time	time	B-NP	NN	O	16	PMOD
18	,	,	O	,	O	20	P
19	we	we	B-NP	PRP	O	20	SUB
20	used	use	B-VP	VBD	O	0	ROOT
21	Cox	Cox	B-NP	NNP	O	24	NMOD
22	proportional	proportional	I-NP	JJ	O	23	NMOD
23	hazards	hazard	I-NP	NNS	O	24	NMOD
24	regression	regression	I-NP	NN	O	20	OBJ
25	and	and	O	CC	O	20	VMOD
26	divided	divide	B-VP	VBD	O	20	VMOD
27	the	the	B-NP	DT	O	28	NMOD
28	study	study	I-NP	NN	O	26	OBJ
29	into	into	B-PP	IN	O	26	VMOD
30	3	3	B-NP	CD	O	31	NMOD
31	periods	period	I-NP	NNS	O	29	PMOD
32	:	:	O	:	O	20	P
33	May	May	B-NP	NNP	O	20	VMOD
34	1	1	I-NP	CD	O	33	NMOD
35	,	,	O	,	O	61	P
36	1996-Nov.	1996-Nov.	B-NP	NNP	O	61	NMOD
37	30	30	I-NP	CD	O	36	NMOD
38	,	,	I-NP	,	O	61	P
39	1999	1999	I-NP	CD	O	61	NMOD
40	(	(	O	(	O	43	DEP
41	period	period	B-NP	NN	B-protein	43	DEP
42	1	1	I-NP	CD	I-protein	41	NMOD
43	)	)	O	)	O	39	NMOD
44	,	,	O	,	O	61	P
45	Dec.	Dec.	B-NP	NNP	O	61	NMOD
46	1	1	I-NP	CD	O	45	NMOD
47	,	,	O	,	O	61	P
48	1999-Nov.	1999-Nov.	B-NP	NNP	O	61	NMOD
49	30	30	I-NP	CD	O	48	NMOD
50	,	,	I-NP	,	O	61	P
51	2002	2002	I-NP	CD	O	61	NMOD
52	(	(	O	(	O	55	DEP
53	period	period	B-NP	NN	B-protein	55	DEP
54	2	2	I-NP	CD	I-protein	53	NMOD
55	)	)	O	)	O	51	NMOD
56	,	,	O	,	O	61	P
57	and	and	O	CC	O	58	NMOD
58	Dec.	Dec.	B-NP	NNP	B-protein	61	NMOD
59	1	1	I-NP	CD	I-protein	58	NMOD
60	,	,	O	,	O	61	P
61	2002-Dec.	2002-Dec.	B-NP	JJ	O	33	VMOD
62	30	30	I-NP	CD	O	64	NMOD
63	,	,	I-NP	,	O	64	P
64	2005	2005	I-NP	CD	O	61	NMOD
65	(	(	O	(	O	68	DEP
66	period	period	B-NP	NN	O	68	DEP
67	3	3	I-NP	CD	O	66	NMOD
68	)	)	O	)	O	64	NMOD
69	.	.	O	.	O	20	P

1	After	After	B-PP	IN	O	8	VMOD
2	adjusting	adjust	B-VP	VBG	O	1	PMOD
3	for	for	B-PP	IN	O	2	VMOD
4	potential	potential	B-NP	JJ	O	5	NMOD
5	confounders	confounder	I-NP	NNS	O	3	PMOD
6	,	,	O	,	O	8	P
7	we	we	B-NP	PRP	O	8	SUB
8	found	find	B-VP	VBD	O	0	ROOT
9	that	that	B-SBAR	IN	O	8	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	risk	risk	I-NP	NN	O	24	SUB
12	of	of	B-PP	IN	O	11	NMOD
13	HIV	HIV	B-NP	NN	O	14	NMOD
14	seroconversion	seroconversion	I-NP	NN	O	12	PMOD
15	among	among	B-PP	IN	O	11	NMOD
16	participants	participant	B-NP	NNS	O	15	PMOD
17	who	who	B-NP	WP	O	11	NMOD
18	were	be	B-VP	VBD	O	20	NMOD
19	daily	daily	B-NP	JJ	O	20	NMOD
20	smokers	smoker	I-NP	NNS	O	17	OBJ
21	of	of	B-PP	IN	O	20	NMOD
22	crack	crack	B-NP	NN	O	23	NMOD
23	cocaine	cocaine	I-NP	NN	O	21	PMOD
24	increased	increase	B-VP	VBD	O	9	SBAR
25	over	over	B-PP	IN	O	24	VMOD
26	time	time	B-NP	NN	O	32	NMOD
27	(	(	O	(	O	32	NMOD
28	period	period	B-NP	NN	O	32	NMOD
29	1	1	I-NP	CD	O	28	NMOD
30	:	:	O	:	O	28	P
31	hazard	hazard	B-NP	NN	O	32	NMOD
32	ratio	ratio	I-NP	NN	O	25	PMOD
33	[	[	O	(	O	35	DEP
34	HR	HR	B-NP	NN	O	35	DEP
35	]	]	O	)	O	24	VMOD
36	1.03	1.03	B-NP	CD	O	24	VMOD
37	,	,	O	,	O	24	P
38	95	95	B-NP	CD	O	41	NMOD
39	%	%	I-NP	NN	O	41	NMOD
40	confidence	confidence	I-NP	NN	O	41	NMOD
41	interval	interval	I-NP	NN	O	67	NMOD
42	[	[	O	(	O	44	DEP
43	CI	CI	B-NP	NN	O	44	DEP
44	]	]	O	)	O	41	NMOD
45	0.57-1.85	0.57-1.85	B-NP	CD	O	41	NMOD
46	;	;	O	:	O	67	P
47	period	period	B-NP	NN	O	67	NMOD
48	2	2	I-NP	CD	O	47	NMOD
49	:	:	O	:	O	67	P
50	HR	HR	B-NP	NN	O	67	NMOD
51	1.68	1.68	I-NP	CD	O	50	NMOD
52	,	,	O	,	O	67	P
53	95	95	B-NP	CD	O	55	NMOD
54	%	%	I-NP	NN	O	55	NMOD
55	CI	CI	I-NP	NN	O	67	NMOD
56	1.01-2.80	1.01-2.80	I-NP	CD	O	55	NMOD
57	;	;	O	:	O	67	P
58	and	and	O	CC	O	62	NMOD
59	period	period	B-NP	NN	O	62	NMOD
60	3	3	I-NP	CD	O	59	NMOD
61	:	:	O	:	O	59	P
62	HR	HR	B-NP	NN	O	67	NMOD
63	2.74	2.74	I-NP	CD	O	62	NMOD
64	,	,	O	,	O	67	P
65	95	95	B-NP	CD	O	67	NMOD
66	%	%	I-NP	NN	O	67	NMOD
67	CI	CI	I-NP	NN	O	24	OBJ
68	1.06-7.11	1.06-7.11	I-NP	CD	O	67	NMOD
69	)	)	O	)	O	67	NMOD
70	.	.	O	.	O	8	P

1	INTERPRETATION	INTERPRETATION	B-NP	NN	O	3	NMOD
2	:	:	O	:	O	1	P
3	Smoking	Smoking	B-NP	NN	O	7	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	crack	crack	B-NP	NN	O	6	NMOD
6	cocaine	cocaine	I-NP	NN	O	4	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	found	find	I-VP	VBN	O	7	VC
9	to	to	I-VP	TO	O	10	VMOD
10	be	be	I-VP	VB	O	8	VMOD
11	an	an	B-NP	DT	O	14	NMOD
12	independent	independent	I-NP	JJ	O	14	NMOD
13	risk	risk	I-NP	NN	O	14	NMOD
14	factor	factor	I-NP	NN	O	10	PRD
15	for	for	B-PP	IN	O	14	NMOD
16	HIV	HIV	B-NP	NN	O	17	NMOD
17	seroconversion	seroconversion	I-NP	NN	O	15	PMOD
18	among	among	B-PP	IN	O	14	NMOD
19	people	people	B-NP	NNS	O	18	PMOD
20	who	who	B-NP	WP	O	14	NMOD
21	were	be	B-VP	VBD	O	20	SBAR
22	injection	injection	B-NP	NN	O	24	NMOD
23	drug	drug	I-NP	NN	O	24	NMOD
24	users	user	I-NP	NNS	O	21	PRD
25	.	.	O	.	O	7	P

1	Fluoxetine	Fluoxetine	B-NP	NN	O	2	SUB
2	improves	improve	B-VP	VBZ	O	0	ROOT
3	the	the	B-NP	DT	O	5	NMOD
4	memory	memory	I-NP	NN	O	5	NMOD
5	deficits	deficit	I-NP	NNS	O	2	OBJ
6	caused	cause	B-VP	VBN	O	5	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	the	the	B-NP	DT	O	11	NMOD
9	chemotherapy	chemotherapy	I-NP	NN	O	11	NMOD
10	agent	agent	I-NP	NN	O	11	NMOD
11	5-fluorouracil	5-fluorouracil	I-NP	NN	O	7	PMOD
12	.	.	O	.	O	2	P

1	Liver-specific	Liver-specific	B-NP	JJ	O	2	NMOD
2	ablation	ablation	I-NP	NN	O	8	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	integrin-linked	integrin-linked	B-NP	JJ	B-protein	5	NMOD
5	kinase	kinase	I-NP	NN	I-protein	3	PMOD
6	in	in	B-PP	IN	O	2	NMOD
7	mice	mouse	B-NP	NNS	O	6	PMOD
8	results	result	B-VP	VBZ	O	0	ROOT
9	in	in	B-PP	IN	O	8	VMOD
10	enhanced	enhance	B-NP	VBN	O	12	AMOD
11	and	and	I-NP	CC	O	12	AMOD
12	prolonged	prolong	I-NP	VBN	O	14	NMOD
13	cell	cell	I-NP	NN	O	14	NMOD
14	proliferation	proliferation	I-NP	NN	O	9	PMOD
15	and	and	O	CC	O	9	PMOD
16	hepatomegaly	hepatomegaly	B-ADVP	RB	O	17	PMOD
17	after	after	B-SBAR	IN	O	9	PMOD
18	phenobarbital	phenobarbital	B-NP	NN	O	19	NMOD
19	administration	administration	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	8	P

1	Decreased	Decrease	B-NP	VBN	O	2	NMOD
2	Expression	Expression	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	Na/K-ATPase	Na/K-ATPase	B-NP	NN	B-protein	12	NMOD
5	,	,	O	,	O	12	P
6	NHE3	NHE3	B-NP	NN	B-protein	12	NMOD
7	,	,	O	,	O	12	P
8	NBC1	NBC1	B-NP	NN	B-protein	12	NMOD
9	,	,	O	,	O	12	P
10	AQP1	AQP1	B-NP	NN	B-protein	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	OAT	OAT	I-NP	NN	B-protein	3	PMOD
13	in	in	B-PP	IN	O	2	NMOD
14	Gentamicin	Gentamicin	B-NP	NN	O	16	NMOD
15	induced	induced	I-NP	JJ	O	16	NMOD
16	Nephropathy	Nephropathy	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	aimed	aim	I-VP	VBN	O	4	VC
6	to	to	B-VP	TO	O	7	VMOD
7	determine	determine	I-VP	VB	O	5	VMOD
8	whether	whether	B-SBAR	IN	O	7	VMOD
9	there	there	B-NP	EX	O	10	SUB
10	is	be	B-VP	VBZ	O	8	SBAR
11	an	an	B-NP	DT	O	13	NMOD
12	altered	altered	I-NP	JJ	O	13	NMOD
13	regulation	regulation	I-NP	NN	O	10	PRD
14	of	of	B-PP	IN	O	13	NMOD
15	tubular	tubular	B-NP	JJ	B-protein	16	NMOD
16	transporters	transporter	I-NP	NNS	I-protein	14	PMOD
17	in	in	B-PP	IN	O	13	NMOD
18	gentamicin	gentamicin	B-NP	NN	O	20	NMOD
19	induced	induced	I-NP	JJ	O	20	NMOD
20	nephropathy	nephropathy	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	4	P

1	Longitudinal	Longitudinal	B-NP	JJ	O	2	NMOD
2	association	association	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	alcohol	alcohol	B-NP	NN	O	5	NMOD
5	use	use	I-NP	NN	O	3	PMOD
6	with	with	B-PP	IN	O	2	NMOD
7	HIV	HIV	B-NP	NN	O	9	NMOD
8	disease	disease	I-NP	NN	O	9	NMOD
9	progression	progression	I-NP	NN	O	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	psychological	psychological	B-NP	JJ	O	12	NMOD
12	health	health	I-NP	NN	O	6	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	women	woman	B-NP	NNS	O	13	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	HIV	HIV	B-NP	NN	O	15	PMOD
17	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	evaluated	evaluate	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	association	association	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	alcohol	alcohol	B-NP	NN	O	7	NMOD
7	consumption	consumption	I-NP	NN	O	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	depression	depression	I-NP	NN	O	5	PMOD
10	,	,	O	,	O	13	P
11	and	and	O	CC	O	13	NMOD
12	their	their	B-NP	PRP$	O	13	NMOD
13	effects	effect	I-NP	NNS	O	2	OBJ
14	on	on	B-PP	IN	O	13	NMOD
15	HIV	HIV	B-NP	NN	O	17	NMOD
16	disease	disease	I-NP	NN	O	17	NMOD
17	progression	progression	I-NP	NN	O	14	PMOD
18	among	among	B-PP	IN	O	17	NMOD
19	women	woman	B-NP	NNS	O	18	PMOD
20	with	with	B-PP	IN	O	19	NMOD
21	HIV	HIV	B-NP	NN	O	20	PMOD
22	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	participants	participant	I-NP	NNS	O	3	SUB
3	had	have	B-VP	VBD	O	0	ROOT
4	physical	physical	B-NP	JJ	O	5	NMOD
5	examination	examination	I-NP	NN	O	34	NMOD
6	,	,	O	,	O	34	P
7	medical	medical	B-NP	JJ	O	9	NMOD
8	record	record	I-NP	NN	O	9	NMOD
9	extraction	extraction	I-NP	NN	O	34	NMOD
10	,	,	O	,	O	34	P
11	and	and	O	CC	O	34	NMOD
12	venipuncture	venipuncture	B-NP	NN	O	34	NMOD
13	,	,	O	,	O	34	P
14	CD4+T-cell	CD4+T-cell	B-NP	NN	O	15	NMOD
15	counts	count	I-NP	NNS	O	16	NMOD
16	determination	determination	I-NP	NN	O	34	NMOD
17	,	,	O	,	O	34	P
18	measurement	measurement	B-NP	NN	O	34	NMOD
19	of	of	B-PP	IN	O	18	NMOD
20	depression	depression	B-NP	NN	O	21	NMOD
21	symptoms	symptom	I-NP	NNS	O	19	PMOD
22	(	(	O	(	O	31	DEP
23	using	use	B-VP	VBG	O	31	DEP
24	the	the	B-NP	DT	O	26	NMOD
25	self-report	self-report	I-NP	JJ	O	26	NMOD
26	Center	Center	I-NP	NNP	O	23	OBJ
27	for	for	B-PP	IN	O	26	NMOD
28	Epidemiological	Epidemiological	B-NP	NNP	O	30	NMOD
29	Studies-Depression	Studies-Depression	I-NP	NNP	O	30	NMOD
30	Scale	Scale	I-NP	NNP	O	27	PMOD
31	)	)	O	)	O	18	NMOD
32	,	,	O	,	O	34	P
33	and	and	O	CC	O	34	NMOD
34	alcohol	alcohol	B-NP	NN	O	35	SUB
35	use	use	B-VP	VBP	O	3	VMOD
36	assessment	assessment	B-NP	NN	O	35	OBJ
37	at	at	B-PP	IN	O	35	VMOD
38	enrollment	enrollment	B-NP	NN	O	37	PMOD
39	,	,	O	,	O	35	P
40	and	and	O	CC	O	35	VMOD
41	semiannually	semiannually	B-ADVP	RB	O	35	VMOD
42	until	until	B-PP	IN	O	35	VMOD
43	March	March	B-NP	NNP	O	42	PMOD
44	2000	2000	I-NP	CD	O	43	NMOD
45	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	association	association	I-NP	NN	O	8	SUB
3	between	between	B-PP	IN	O	2	NMOD
4	alcohol	alcohol	B-NP	NN	O	5	NMOD
5	consumption	consumption	I-NP	NN	O	7	NMOD
6	and	and	O	CC	O	7	NMOD
7	depression	depression	B-NP	NN	O	3	PMOD
8	was	be	B-VP	VBD	O	0	ROOT
9	significant	significant	B-ADJP	JJ	O	8	PRD
10	(	(	O	(	O	14	DEP
11	p	p	B-NP	NN	O	13	SUB
12	<	<	O	SYM	O	13	VMOD
13	0.001	0.001	B-NP	CD	O	14	DEP
14	)	)	O	)	O	8	VMOD
15	.	.	O	.	O	8	P

1	Our	Our	B-NP	PRP$	O	2	NMOD
2	findings	finding	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	alcohol	alcohol	B-NP	NN	O	6	NMOD
6	consumption	consumption	I-NP	NN	O	7	SUB
7	has	have	B-VP	VBZ	O	4	SBAR
8	a	a	B-NP	DT	O	10	NMOD
9	direct	direct	I-NP	JJ	O	10	NMOD
10	association	association	I-NP	NN	O	7	OBJ
11	with	with	B-PP	IN	O	10	NMOD
12	depression	depression	B-NP	NN	O	11	PMOD
13	.	.	O	.	O	3	P

1	Chemokine	Chemokine	B-NP	NN	B-protein	2	NMOD
2	CCL2	CCL2	I-NP	NN	O	6	NMOD
3	and	and	O	CC	O	6	NMOD
4	its	its	B-NP	PRP$	O	6	NMOD
5	receptor	receptor	I-NP	NN	O	6	NMOD
6	CCR2	CCR2	I-NP	NN	B-protein	7	SUB
7	are	be	B-VP	VBP	O	0	ROOT
8	increased	increase	I-VP	VBN	O	7	VC
9	in	in	B-PP	IN	O	8	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	hippocampus	hippocampus	I-NP	NN	O	9	PMOD
12	following	follow	B-PP	VBG	O	8	VMOD
13	pilocarpine	pilocarpine	B-NP	NN	O	16	NMOD
14	induced	induce	B-VP	VBD	O	16	NMOD
15	status	status	B-NP	NN	O	16	NMOD
16	epilepticus	epilepticus	I-NP	NN	O	12	PMOD
17	.	.	O	.	O	7	P

1	In	In	B-PP	IN	O	8	VMOD
2	this	this	B-NP	DT	O	4	NMOD
3	work	work	I-NP	NN	O	4	NMOD
4	CCR2	CCR2	I-NP	NN	B-protein	7	NMOD
5	and	and	O	CC	O	7	NMOD
6	CCL2	CCL2	B-NP	NN	B-protein	7	NMOD
7	expression	expression	I-NP	NN	O	1	PMOD
8	were	be	B-VP	VBD	O	0	ROOT
9	examined	examine	I-VP	VBN	O	8	VC
10	following	follow	B-PP	VBG	O	9	VMOD
11	status	status	B-NP	NN	O	12	NMOD
12	epilepticus	epilepticus	I-NP	NN	O	10	PMOD
13	(	(	O	(	O	15	DEP
14	SE	SE	B-NP	NN	B-protein	15	DEP
15	)	)	O	)	O	12	NMOD
16	induced	induce	B-VP	VBN	O	12	NMOD
17	by	by	B-PP	IN	O	16	VMOD
18	pilocarpine	pilocarpine	B-NP	NN	O	19	NMOD
19	injection	injection	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	8	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	SE	SE	B-NP	NN	B-protein	4	SUB
4	was	be	B-VP	VBD	O	1	NMOD
5	induced	induce	I-VP	VBN	O	4	VC
6	by	by	B-PP	IN	O	5	VMOD
7	pilocarpine	pilocarpine	B-NP	NN	O	8	NMOD
8	injection	injection	I-NP	NN	O	6	PMOD
9	.	.	O	.	O	1	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	data	datum	I-NP	NNS	O	5	SUB
5	show	show	B-VP	VBP	O	1	NMOD
6	that	that	B-SBAR	IN	O	5	VMOD
7	CCR2	CCR2	B-NP	NN	B-protein	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	CCL2	CCL2	I-NP	NN	B-protein	10	SUB
10	are	be	B-VP	VBP	O	6	SBAR
11	up-regulated	up-regulate	I-VP	VBN	O	10	VC
12	in	in	B-PP	IN	O	11	VMOD
13	the	the	B-NP	DT	O	14	NMOD
14	hippocampus	hippocampus	I-NP	NN	O	12	PMOD
15	after	after	B-PP	IN	O	14	NMOD
16	pilocarpine	pilocarpine	B-NP	NN	O	18	NMOD
17	induced	induced	I-NP	JJ	O	18	NMOD
18	SE	SE	I-NP	NN	O	15	PMOD
19	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	aimed	aim	B-VP	VBD	O	0	ROOT
5	to	to	I-VP	TO	O	6	VMOD
6	explore	explore	I-VP	VB	O	4	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	effect	effect	I-NP	NN	O	17	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	MT	MT	B-NP	NN	O	11	NMOD
11	induction	induction	I-NP	NN	O	9	PMOD
12	on	on	B-PP	IN	O	8	NMOD
13	carmustine	carmustine	B-NP	NN	O	12	PMOD
14	(	(	O	(	O	16	DEP
15	BCNU	BCNU	B-NP	NN	O	16	DEP
16	)	)	O	)	O	13	NMOD
17	induced	induce	B-VP	VBD	O	6	VMOD
18	hippocampal	hippocampal	B-NP	JJ	O	20	NMOD
19	cognitive	cognitive	I-NP	JJ	O	20	NMOD
20	dysfunction	dysfunction	I-NP	NN	O	17	OBJ
21	in	in	B-PP	IN	O	17	VMOD
22	rats	rat	B-NP	NNS	O	21	PMOD
23	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	3	NMOD
2	obtained	obtain	I-NP	VBN	O	3	NMOD
3	data	datum	I-NP	NNS	O	4	SUB
4	revealed	reveal	B-VP	VBD	O	0	ROOT
5	that	that	B-SBAR	IN	O	4	VMOD
6	BCNU	BCNU	B-NP	NN	O	7	NMOD
7	administration	administration	I-NP	NN	O	8	SUB
8	resulted	result	B-VP	VBD	O	5	SBAR
9	in	in	B-PP	IN	O	8	VMOD
10	deterioration	deterioration	B-NP	NN	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	learning	learning	B-NP	NN	O	15	NMOD
13	and	and	O	CC	O	15	NMOD
14	short-term	short-term	B-NP	JJ	O	15	NMOD
15	memory	memory	I-NP	NN	O	11	PMOD
16	(	(	O	(	O	18	DEP
17	STM	STM	B-NP	NN	B-protein	18	DEP
18	)	)	O	)	O	15	NMOD
19	,	,	O	,	O	8	P
20	as	as	B-SBAR	IN	O	8	VMOD
21	measured	measure	B-VP	VBN	O	20	SBAR
22	by	by	B-PP	IN	O	21	VMOD
23	using	use	B-VP	VBG	O	22	PMOD
24	radial	radial	B-NP	JJ	O	27	NMOD
25	arm	arm	I-NP	NN	O	27	NMOD
26	water	water	I-NP	NN	O	27	NMOD
27	maze	maze	I-NP	NN	O	23	OBJ
28	,	,	O	,	O	8	P
29	accompanied	accompany	B-VP	VBN	O	8	VMOD
30	with	with	B-PP	IN	O	29	VMOD
31	decreased	decrease	B-NP	VBN	O	34	NMOD
32	hippocampal	hippocampal	I-NP	JJ	B-protein	34	NMOD
33	glutathione	glutathione	I-NP	NN	I-protein	34	NMOD
34	reductase	reductase	I-NP	NN	I-protein	38	NMOD
35	(	(	O	(	O	37	DEP
36	GR	GR	B-NP	NN	B-protein	37	DEP
37	)	)	O	)	O	34	NMOD
38	activity	activity	B-NP	NN	O	45	NMOD
39	and	and	O	CC	O	45	NMOD
40	reduced	reduce	B-NP	VBN	O	41	NMOD
41	glutathione	glutathione	I-NP	NN	O	45	NMOD
42	(	(	O	(	O	44	DEP
43	GSH	GSH	B-NP	NN	O	44	DEP
44	)	)	O	)	O	41	NMOD
45	content	content	B-NP	NN	O	30	PMOD
46	.	.	O	.	O	4	P

1	Also	Also	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	BCNU	BCNU	B-NP	NN	O	4	NMOD
4	administration	administration	I-NP	NN	O	5	SUB
5	increased	increase	B-VP	VBD	O	0	ROOT
6	serum	serum	B-NP	NN	B-protein	9	NMOD
7	tumor	tumor	I-NP	NN	I-protein	9	NMOD
8	necrosis	necrosis	I-NP	NN	I-protein	9	NMOD
9	factor-alpha	factor-alpha	I-NP	NN	I-protein	17	NMOD
10	(	(	O	(	O	12	DEP
11	TNFalpha	TNFalpha	B-NP	NN	B-protein	12	DEP
12	)	)	O	)	O	9	NMOD
13	,	,	O	,	O	17	P
14	hippocampal	hippocampal	B-NP	JJ	O	15	NMOD
15	MT	MT	I-NP	NN	O	17	NMOD
16	and	and	O	CC	O	17	NMOD
17	malondialdehyde	malondialdehyde	B-NP	NN	O	21	NMOD
18	(	(	O	(	O	20	DEP
19	MDA	MDA	B-NP	NN	O	20	DEP
20	)	)	O	)	O	17	NMOD
21	contents	content	B-NP	NNS	O	26	NMOD
22	as	as	B-CONJP	RB	O	26	NMOD
23	well	well	I-CONJP	RB	O	22	DEP
24	as	as	I-CONJP	IN	O	22	DEP
25	caspase-3	caspase-3	B-NP	NN	B-protein	26	NMOD
26	activity	activity	I-NP	NN	O	5	OBJ
27	in	in	B-PP	IN	O	26	NMOD
28	addition	addition	B-NP	NN	O	27	PMOD
29	to	to	B-PP	TO	O	28	NMOD
30	histological	histological	B-NP	JJ	O	31	NMOD
31	alterations	alteration	I-NP	NNS	O	29	PMOD
32	.	.	O	.	O	5	P

1	Fatal	Fatal	B-NP	JJ	O	2	NMOD
2	carbamazepine	carbamazepine	I-NP	NN	O	3	SUB
3	induced	induce	B-VP	VBD	O	0	ROOT
4	fulminant	fulminant	B-NP	JJ	O	5	AMOD
5	eosinophilic	eosinophilic	I-NP	JJ	O	3	OBJ
6	(	(	O	(	O	8	DEP
7	hypersensitivity	hypersensitivity	B-NP	NN	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	myocarditis	myocarditis	B-NP	NN	O	5	NMOD
10	:	:	O	:	O	3	P
11	emphasis	emphasis	B-NP	NN	O	3	VMOD
12	on	on	B-PP	IN	O	11	NMOD
13	anatomical	anatomical	B-NP	JJ	O	15	AMOD
14	and	and	I-NP	CC	O	15	AMOD
15	histological	histological	I-NP	JJ	O	16	NMOD
16	characteristics	characteristic	I-NP	NNS	O	20	NMOD
17	,	,	O	,	O	20	P
18	mechanisms	mechanism	B-NP	NNS	O	20	NMOD
19	and	and	I-NP	CC	O	20	NMOD
20	genetics	genetic	I-NP	NNS	O	12	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	drug	drug	B-NP	NN	O	23	NMOD
23	hypersensitivity	hypersensitivity	I-NP	NN	O	26	NMOD
24	and	and	O	CC	O	26	NMOD
25	differential	differential	B-NP	JJ	O	26	NMOD
26	diagnosis	diagnosis	I-NP	NN	O	21	PMOD
27	.	.	O	.	O	3	P

1	A	A	B-NP	DT	O	0	ROOT
2	frequently	frequently	I-NP	RB	O	3	AMOD
3	fatal	fatal	I-NP	JJ	O	1	PRD
4	,	,	O	,	O	5	P
5	although	although	B-SBAR	IN	O	3	AMOD
6	exceptionally	exceptionally	B-NP	RB	O	7	AMOD
7	rare	rare	I-NP	JJ	O	9	NMOD
8	side	side	I-NP	NN	O	9	NMOD
9	effect	effect	I-NP	NN	O	12	SUB
10	of	of	B-PP	IN	O	9	NMOD
11	carbamazepine	carbamazepine	B-NP	NN	O	10	PMOD
12	is	be	B-VP	VBZ	O	5	SBAR
13	necrotizing	necrotize	I-VP	VBG	O	12	VC
14	eosinophilic	eosinophilic	B-NP	JJ	O	13	OBJ
15	(	(	O	(	O	17	DEP
16	hypersensitivity	hypersensitivity	B-NP	NN	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	myocarditis	myocarditis	B-NP	NN	O	14	NMOD
19	.	.	O	.	O	1	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	hypersensitivity	hypersensitivity	B-NP	NN	O	7	NMOD
7	myocarditis	myocarditis	I-NP	NN	O	5	PMOD
8	secondary	secondary	B-ADJP	JJ	O	7	NMOD
9	to	to	B-PP	TO	O	8	AMOD
10	administration	administration	B-NP	NN	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	carbamazepine	carbamazepine	B-NP	NN	O	11	PMOD
13	.	.	O	.	O	2	P

1	Neuropsychiatric	Neuropsychiatric	B-NP	JJ	O	2	NMOD
2	behaviors	behavior	I-NP	NNS	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	7	NMOD
5	MPTP	MPTP	I-NP	NN	O	7	NMOD
6	marmoset	marmoset	I-NP	NN	O	7	NMOD
7	model	model	I-NP	NN	O	3	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	Parkinson	Parkinson	B-NP	NNP	O	11	NMOD
10	's	's	B-NP	POS	O	11	NMOD
11	disease	disease	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	4	NMOD
2	levodopa-treated	levodopa-treated	I-NP	JJ	O	4	NMOD
3	MPTP-lesioned	MPTP-lesioned	I-NP	JJ	O	4	NMOD
4	marmoset	marmoset	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	0	ROOT
6	used	use	I-VP	VBN	O	5	VC
7	as	as	B-PP	IN	O	6	VMOD
8	a	a	B-NP	DT	O	9	NMOD
9	model	model	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	neuropsychiatric	neuropsychiatric	B-NP	JJ	B-cell_type	12	NMOD
12	symptoms	symptom	I-NP	NNS	I-cell_type	10	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	PD	PD	B-NP	NN	O	15	NMOD
15	patients	patient	I-NP	NNS	O	13	PMOD
16	.	.	O	.	O	5	P

1	Here	Here	B-ADVP	RB	O	3	VMOD
2	we	we	B-NP	PRP	O	3	SUB
3	compare	compare	B-VP	VBP	O	0	ROOT
4	the	the	B-NP	DT	O	6	NMOD
5	time	time	I-NP	NN	O	6	NMOD
6	course	course	I-NP	NN	O	14	NMOD
7	of	of	B-PP	IN	O	6	NMOD
8	levodopa	levodopa	B-NP	NN	O	7	PMOD
9	induced	induce	B-VP	VBD	O	14	NMOD
10	motor	motor	B-NP	NN	O	11	NMOD
11	fluctuations	fluctuation	I-NP	NNS	O	14	NMOD
12	and	and	O	CC	O	14	NMOD
13	neuropsychiatric-like	neuropsychiatric-like	B-NP	JJ	O	14	NMOD
14	behaviors	behavior	I-NP	NNS	O	3	OBJ
15	to	to	B-VP	TO	O	16	VMOD
16	determine	determine	I-VP	VB	O	3	VMOD
17	the	the	B-NP	DT	O	18	NMOD
18	relationship	relationship	I-NP	NN	O	16	OBJ
19	between	between	B-PP	IN	O	18	NMOD
20	duration	duration	B-NP	NN	O	19	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	treatment	treatment	B-NP	NN	O	24	NMOD
23	and	and	I-NP	CC	O	24	NMOD
24	onset	onset	I-NP	NN	O	21	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	symptoms	symptom	B-NP	NNS	O	25	PMOD
27	.	.	O	.	O	3	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Marmosets	Marmoset	B-NP	NNS	O	4	SUB
4	were	be	B-VP	VBD	O	1	NMOD
5	administered	administer	I-VP	VBN	O	4	VC
6	1-methyl-4-phenyl-1	1-methyl-4-phenyl-1	B-NP	NN	O	5	OBJ
7	,	,	O	,	O	8	P
8	2	2	B-NP	CD	O	6	NMOD
9	,	,	I-NP	,	O	8	NMOD
10	3	3	I-NP	CD	O	9	OBJ
11	,	,	O	,	O	12	P
12	6-tetrahydropyridine	6-tetrahydropyridine	B-NP	NN	O	10	NMOD
13	(	(	O	(	O	17	DEP
14	2.0	2.0	B-NP	CD	O	16	NMOD
15	mg/kg	mg/kg	I-NP	NN	O	16	NMOD
16	s.c.	s.c.	I-NP	NN	O	17	DEP
17	)	)	O	)	O	12	NMOD
18	for	for	B-PP	IN	O	12	NMOD
19	five	five	B-NP	CD	O	20	NMOD
20	days	day	I-NP	NNS	O	18	PMOD
21	,	,	O	,	O	12	P
22	resulting	result	B-VP	VBG	O	12	NMOD
23	in	in	B-PP	IN	O	22	VMOD
24	stable	stable	B-NP	JJ	O	25	NMOD
25	parkinsonism	parkinsonism	I-NP	NN	O	23	PMOD
26	.	.	O	.	O	1	P

1	Animals	Animal	B-NP	NNS	O	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	evaluated	evaluate	I-VP	VBN	O	2	VC
4	for	for	B-PP	IN	O	3	VMOD
5	parkinsonian	parkinsonian	B-NP	JJ	O	6	NMOD
6	disability	disability	I-NP	NN	O	10	AMOD
7	,	,	O	,	O	10	P
8	dyskinesia	dyskinesia	B-NP	NN	O	10	AMOD
9	and	and	O	CC	O	10	AMOD
10	on-time	on-time	B-ADJP	JJ	O	17	NMOD
11	(	(	O	(	O	14	DEP
12	motor	motor	B-NP	NN	O	13	NMOD
13	fluctuations	fluctuation	I-NP	NNS	O	14	DEP
14	)	)	O	)	O	10	NMOD
15	and	and	O	CC	O	17	NMOD
16	neuropsychiatric-like	neuropsychiatric-like	B-NP	JJ	O	17	NMOD
17	behaviors	behavior	I-NP	NNS	O	4	PMOD
18	on	on	B-PP	IN	O	17	NMOD
19	Day	Day	B-NP	NN	O	18	PMOD
20	0	0	I-NP	CD	O	19	NMOD
21	(	(	O	(	O	25	DEP
22	prior	prior	B-ADJP	JJ	O	23	PMOD
23	to	to	B-PP	TO	O	25	DEP
24	levodopa	levodopa	B-NP	NN	O	23	PMOD
25	)	)	O	)	O	17	NMOD
26	and	and	O	CC	O	4	PMOD
27	on	on	B-PP	IN	O	4	PMOD
28	Days	Day	B-NP	NNS	O	37	NMOD
29	1	1	I-NP	CD	O	28	NMOD
30	,	,	I-NP	,	O	28	P
31	7	7	I-NP	CD	O	28	NMOD
32	,	,	I-NP	,	O	28	P
33	13	13	I-NP	CD	O	28	NMOD
34	,	,	I-NP	,	O	37	P
35	27	27	I-NP	CD	O	37	NMOD
36	and	and	I-NP	CC	O	37	NMOD
37	30	30	I-NP	CD	O	27	PMOD
38	of	of	B-PP	IN	O	37	NMOD
39	treatment	treatment	B-NP	NN	O	38	PMOD
40	using	use	B-VP	VBG	O	2	VMOD
41	post	post	B-NP	NN	O	44	NMOD
42	hoc	hoc	I-NP	NN	O	44	NMOD
43	DVD	DVD	I-NP	NN	O	44	NMOD
44	analysis	analysis	I-NP	NN	O	40	OBJ
45	by	by	B-PP	IN	O	44	NMOD
46	a	a	B-NP	DT	O	48	NMOD
47	trained	trained	I-NP	JJ	O	48	NMOD
48	rater	rater	I-NP	NN	O	45	PMOD
49	,	,	O	,	O	44	P
50	blind	blind	B-ADJP	JJ	O	44	NMOD
51	to	to	B-PP	TO	O	50	AMOD
52	the	the	B-NP	DT	O	54	NMOD
53	treatment	treatment	I-NP	NN	O	54	NMOD
54	day	day	I-NP	NN	O	51	PMOD
55	.	.	O	.	O	2	P

1	As	As	B-SBAR	IN	O	5	VMOD
2	anticipated	anticipate	B-VP	VBN	O	1	SBAR
3	,	,	O	,	O	5	P
4	animals	animal	B-NP	NNS	O	5	SUB
5	exhibited	exhibit	B-VP	VBD	O	0	ROOT
6	a	a	B-NP	DT	O	8	NMOD
7	progressive	progressive	I-NP	JJ	O	8	NMOD
8	increase	increase	I-NP	NN	O	17	NMOD
9	in	in	B-PP	IN	O	8	NMOD
10	levodopa	levodopa	B-NP	NN	O	9	PMOD
11	induced	induce	B-VP	VBD	O	17	VMOD
12	motor	motor	B-NP	NN	O	13	NMOD
13	fluctuations	fluctuation	I-NP	NNS	O	17	NMOD
14	,	,	O	,	O	17	P
15	dyskinesia	dyskinesia	B-NP	NN	O	17	NMOD
16	and	and	I-NP	CC	O	17	NMOD
17	wearing-off	wearing-off	I-NP	NN	O	5	OBJ
18	,	,	O	,	O	17	P
19	that	that	B-NP	WDT	O	17	NMOD
20	correlated	correlate	B-VP	VBD	O	19	SBAR
21	with	with	B-PP	IN	O	20	VMOD
22	the	the	B-NP	DT	O	23	NMOD
23	duration	duration	I-NP	NN	O	21	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	levodopa	levodopa	B-NP	NN	O	26	NMOD
26	therapy	therapy	I-NP	NN	O	24	PMOD
27	.	.	O	.	O	5	P

1	In	In	B-PP	IN	O	5	VMOD
2	contrast	contrast	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	5	P
4	levodopa	levodopa	B-NP	NN	O	5	SUB
5	induced	induce	B-VP	VBD	O	8	VMOD
6	neuropsychiatric-like	neuropsychiatric-like	B-NP	JJ	B-protein	7	NMOD
7	behaviors	behavior	I-NP	NNS	I-protein	8	SUB
8	were	be	B-VP	VBD	O	0	ROOT
9	present	present	B-ADJP	JJ	O	8	PRD
10	on	on	B-PP	IN	O	9	AMOD
11	Day	Day	B-NP	NN	O	18	NMOD
12	1	1	I-NP	CD	O	11	NMOD
13	of	of	B-PP	IN	O	11	NMOD
14	levodopa	levodopa	B-NP	NN	O	15	NMOD
15	treatment	treatment	I-NP	NN	O	13	PMOD
16	and	and	O	CC	O	18	NMOD
17	their	their	B-NP	PRP$	O	18	NMOD
18	severity	severity	I-NP	NN	O	10	PMOD
19	did	do	B-VP	VBD	O	8	VMOD
20	not	not	I-VP	RB	O	19	VMOD
21	correlate	correlate	I-VP	VB	O	19	VC
22	with	with	B-PP	IN	O	21	VMOD
23	duration	duration	B-NP	NN	O	22	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	treatment	treatment	B-NP	NN	O	24	PMOD
26	.	.	O	.	O	8	P

1	Contrast	Contrast	B-NP	NN	O	3	NMOD
2	medium	medium	I-NP	NN	O	3	NMOD
3	nephrotoxicity	nephrotoxicity	I-NP	NN	O	0	ROOT
4	after	after	B-PP	IN	O	3	NMOD
5	renal	renal	B-NP	JJ	O	6	NMOD
6	artery	artery	I-NP	NN	O	9	NMOD
7	and	and	O	CC	O	9	NMOD
8	coronary	coronary	B-NP	JJ	O	9	NMOD
9	angioplasty	angioplasty	I-NP	NN	O	4	PMOD
10	.	.	O	.	O	3	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Renal	Renal	B-NP	JJ	O	4	NMOD
4	dysfunction	dysfunction	I-NP	NN	O	14	SUB
5	induced	induce	B-VP	VBN	O	4	NMOD
6	by	by	B-PP	IN	O	5	VMOD
7	iodinated	iodinate	B-NP	VBN	O	9	NMOD
8	contrast	contrast	I-NP	NN	O	9	NMOD
9	medium	medium	I-NP	NN	O	13	NMOD
10	(	(	O	(	O	12	DEP
11	CM	CM	B-NP	NN	O	12	DEP
12	)	)	O	)	O	9	NMOD
13	administration	administration	B-NP	NN	O	6	PMOD
14	can	can	B-VP	MD	O	1	NMOD
15	minimize	minimize	I-VP	VB	O	14	VC
16	the	the	B-NP	DT	O	17	NMOD
17	benefit	benefit	I-NP	NN	O	15	OBJ
18	of	of	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	21	NMOD
20	interventional	interventional	I-NP	JJ	O	21	NMOD
21	procedure	procedure	I-NP	NN	O	18	PMOD
22	in	in	B-PP	IN	O	21	NMOD
23	patients	patient	B-NP	NNS	O	22	PMOD
24	undergoing	undergo	B-VP	VBG	O	23	NMOD
25	renal	renal	B-NP	JJ	O	26	NMOD
26	angioplasty	angioplasty	I-NP	JJ	O	24	OBJ
27	(	(	O	(	O	29	DEP
28	PTRA	PTRA	B-NP	NN	B-protein	29	DEP
29	)	)	O	)	O	26	NMOD
30	.	.	O	.	O	1	P

1	PURPOSE	PURPOSE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	compare	compare	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	susceptibility	susceptibility	I-NP	NN	O	4	OBJ
7	to	to	B-PP	TO	O	6	NMOD
8	nephrotoxic	nephrotoxic	B-NP	JJ	O	9	NMOD
9	effect	effect	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	CM	CM	B-NP	NN	O	10	PMOD
12	in	in	B-PP	IN	O	9	NMOD
13	patients	patient	B-NP	NNS	O	12	PMOD
14	undergoing	undergo	B-VP	VBG	O	13	NMOD
15	PTRA	PTRA	B-NP	NN	B-protein	14	OBJ
16	with	with	B-PP	IN	O	14	VMOD
17	that	that	B-NP	DT	O	16	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	patients	patient	B-NP	NNS	O	18	PMOD
20	submitted	submit	B-VP	VBN	O	19	NMOD
21	to	to	B-PP	TO	O	20	VMOD
22	percutaneous	percutaneous	B-NP	JJ	O	24	NMOD
23	coronary	coronary	I-NP	JJ	O	24	NMOD
24	intervention	intervention	I-NP	NN	O	21	PMOD
25	(	(	O	(	O	27	DEP
26	PCI	PCI	B-NP	NN	B-protein	27	DEP
27	)	)	O	)	O	24	NMOD
28	.	.	O	.	O	4	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	11	SUB
2	:	:	O	:	O	1	P
3	In	In	B-PP	IN	O	1	NMOD
4	this	this	B-NP	DT	O	7	NMOD
5	preliminary	preliminary	I-NP	JJ	O	7	NMOD
6	study	study	I-NP	NN	O	7	NMOD
7	patients	patient	I-NP	NNS	O	3	PMOD
8	submitted	submit	B-VP	VBN	O	7	NMOD
9	to	to	B-PP	TO	O	8	VMOD
10	PTRA	PTRA	B-NP	NN	B-protein	9	PMOD
11	showed	show	B-VP	VBD	O	0	ROOT
12	a	a	B-NP	DT	O	14	NMOD
13	lower	low	I-NP	JJR	O	14	NMOD
14	susceptibility	susceptibility	I-NP	NN	O	11	OBJ
15	to	to	B-PP	TO	O	14	NMOD
16	renal	renal	B-NP	JJ	O	17	NMOD
17	damage	damage	I-NP	NN	O	15	PMOD
18	induced	induce	B-VP	VBN	O	17	NMOD
19	by	by	B-PP	IN	O	18	VMOD
20	CM	CM	B-NP	NN	O	21	NMOD
21	administration	administration	I-NP	NN	O	19	PMOD
22	than	than	B-PP	IN	O	18	VMOD
23	PCI	PCI	B-NP	NN	O	24	NMOD
24	patients	patient	I-NP	NNS	O	22	PMOD
25	.	.	O	.	O	11	P

1	Medical	Medical	B-NP	JJ	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	psychiatric	psychiatric	I-NP	JJ	O	4	NMOD
4	outcomes	outcome	I-NP	NNS	O	10	SUB
5	for	for	B-PP	IN	O	4	NMOD
6	patients	patient	B-NP	NNS	O	5	PMOD
7	transplanted	transplant	B-VP	VBN	O	6	NMOD
8	for	for	B-PP	IN	O	7	VMOD
9	acetaminophen	acetaminophen	B-NP	NN	O	8	PMOD
10	induced	induce	B-VP	VBD	O	0	ROOT
11	acute	acute	B-NP	JJ	O	13	NMOD
12	liver	liver	I-NP	NN	O	13	NMOD
13	failure	failure	I-NP	NN	O	10	OBJ
14	:	:	O	:	O	10	P
15	a	a	B-NP	DT	O	17	NMOD
16	case-control	case-control	I-NP	JJ	O	17	NMOD
17	study	study	I-NP	NN	O	10	VMOD
18	.	.	O	.	O	10	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Acetaminophen	Acetaminophen	B-NP	NN	O	5	NMOD
4	induced	induced	I-NP	JJ	O	5	NMOD
5	hepatotoxicity	hepatotoxicity	I-NP	NN	O	6	SUB
6	is	be	B-VP	VBZ	O	1	NMOD
7	the	the	B-NP	DT	O	10	NMOD
8	most	most	I-NP	RBS	O	9	AMOD
9	common	common	I-NP	JJ	O	10	NMOD
10	cause	cause	I-NP	NN	O	6	PRD
11	of	of	B-PP	IN	O	10	NMOD
12	acute	acute	B-NP	JJ	O	14	NMOD
13	liver	liver	I-NP	NN	O	14	NMOD
14	failure	failure	I-NP	NN	O	11	PMOD
15	(	(	O	(	O	17	DEP
16	ALF	ALF	B-NP	NN	B-protein	17	DEP
17	)	)	O	)	O	14	NMOD
18	in	in	B-PP	IN	O	6	VMOD
19	the	the	B-NP	DT	O	20	NMOD
20	UK	UK	I-NP	NNP	O	18	PMOD
21	.	.	O	.	O	6	P

1	AIMS	AIMS	B-NP	NNS	O	3	NMOD
2	AND	AND	I-NP	CC	O	3	NMOD
3	METHODS	METHODS	I-NP	NNS	O	0	ROOT
4	:	:	O	:	O	3	P
5	We	We	B-NP	PRP	O	6	SUB
6	compared	compare	B-VP	VBD	O	3	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	severity	severity	I-NP	NN	O	19	NMOD
9	of	of	B-PP	IN	O	8	NMOD
10	pretransplant	pretransplant	B-NP	NN	O	11	NMOD
11	illness	illness	I-NP	NN	O	9	PMOD
12	,	,	O	,	O	19	P
13	psychiatric	psychiatric	B-NP	JJ	O	14	NMOD
14	co-morbidity	co-morbidity	I-NP	NN	O	19	NMOD
15	,	,	O	,	O	19	P
16	medical	medical	B-NP	JJ	O	19	NMOD
17	and	and	I-NP	CC	O	19	NMOD
18	psychosocial	psychosocial	I-NP	JJ	O	19	NMOD
19	outcomes	outcome	I-NP	NNS	O	6	OBJ
20	of	of	B-PP	IN	O	19	NMOD
21	all	all	B-NP	DT	O	22	NMOD
22	patients	patient	I-NP	NNS	O	20	PMOD
23	who	who	B-NP	WP	O	22	NMOD
24	had	have	B-VP	VBD	O	23	SBAR
25	undergone	undergo	I-VP	VBN	O	24	VC
26	liver	liver	B-NP	NN	O	27	NMOD
27	transplantation	transplantation	I-NP	NN	O	25	OBJ
28	(	(	O	(	O	30	DEP
29	LT	LT	B-NP	NN	B-protein	30	DEP
30	)	)	O	)	O	27	NMOD
31	emergently	emergently	B-ADVP	RB	O	25	VMOD
32	between	between	B-PP	IN	O	31	AMOD
33	1999-2004	1999-2004	B-NP	CD	O	32	PMOD
34	for	for	B-PP	IN	O	33	NMOD
35	acetaminophen	acetaminophen	B-NP	NN	O	37	NMOD
36	induced	induce	I-NP	VBN	O	35	AMOD
37	ALF	ALF	I-NP	NN	B-protein	34	PMOD
38	(	(	O	(	O	40	DEP
39	n=36	n=36	B-NP	NN	O	40	DEP
40	)	)	O	)	O	37	NMOD
41	with	with	B-PP	IN	O	37	NMOD
42	age-	age-	B-NP	NN	O	45	NMOD
43	and	and	O	CC	O	45	NMOD
44	sex-matched	sex-matched	B-NP	JJ	O	45	NMOD
45	patients	patient	I-NP	NNS	O	41	PMOD
46	undergoing	undergo	B-VP	VBG	O	45	NMOD
47	emergent	emergent	B-NP	JJ	O	48	NMOD
48	LT	LT	I-NP	NN	O	46	OBJ
49	for	for	B-PP	IN	O	46	VMOD
50	non-acetaminophen	non-acetaminophen	B-NP	JJ	O	52	NMOD
51	induced	induce	I-NP	VBN	O	52	NMOD
52	ALF	ALF	I-NP	NN	B-protein	58	NMOD
53	(	(	O	(	O	55	DEP
54	n=35	n=35	B-NP	NN	B-protein	55	DEP
55	)	)	O	)	O	52	NMOD
56	and	and	O	CC	O	58	NMOD
57	elective	elective	B-NP	JJ	O	58	NMOD
58	LT	LT	I-NP	NN	O	49	PMOD
59	for	for	B-PP	IN	O	58	NMOD
60	chronic	chronic	B-NP	JJ	O	62	NMOD
61	liver	liver	I-NP	NN	O	62	NMOD
62	disease	disease	I-NP	NN	O	59	PMOD
63	(	(	O	(	O	67	DEP
64	CLD	CLD	B-NP	NN	O	66	NMOD
65	,	,	O	,	O	66	P
66	n=34	n=34	B-NP	NN	B-protein	67	DEP
67	)	)	O	)	O	62	NMOD
68	.	.	O	.	O	3	P

1	RESULTS	RESULTS	B-NP	NNS	O	9	SUB
2	:	:	O	:	O	1	P
3	Acetaminophen	Acetaminophen	B-NP	NN	O	1	NMOD
4	induced	induce	B-VP	VBD	O	3	SBAR
5	ALF	ALF	B-NP	NN	O	6	NMOD
6	patients	patient	I-NP	NNS	O	4	OBJ
7	undergoing	undergo	B-VP	VBG	O	6	NMOD
8	LT	LT	B-NP	NN	B-protein	7	OBJ
9	had	have	B-VP	VBD	O	0	ROOT
10	a	a	B-NP	DT	O	12	NMOD
11	greater	great	I-NP	JJR	O	12	NMOD
12	severity	severity	I-NP	NN	O	28	NMOD
13	of	of	B-PP	IN	O	12	NMOD
14	pre-LT	pre-LT	B-NP	JJ	O	15	NMOD
15	illness	illness	I-NP	NN	O	13	PMOD
16	reflected	reflect	B-VP	VBN	O	15	NMOD
17	by	by	B-PP	IN	O	16	VMOD
18	higher	high	B-NP	JJR	O	20	NMOD
19	Acute	Acute	I-NP	NNP	O	20	NMOD
20	Physiology	Physiology	I-NP	NNP	O	26	NMOD
21	and	and	O	CC	O	26	NMOD
22	Chronic	Chronic	B-NP	NNP	O	26	NMOD
23	Health	Health	I-NP	NNP	O	26	NMOD
24	Evaluation	Evaluation	I-NP	NN	O	26	NMOD
25	II	II	B-NP	CD	O	26	NMOD
26	scores	score	I-NP	NNS	O	17	PMOD
27	and	and	O	CC	O	28	NMOD
28	requirement	requirement	B-NP	NN	O	9	OBJ
29	for	for	B-PP	IN	O	28	NMOD
30	organ	organ	B-NP	NN	O	31	NMOD
31	support	support	I-NP	NN	O	29	PMOD
32	compared	compare	B-PP	VBN	O	9	VMOD
33	with	with	B-PP	IN	O	32	PMOD
34	the	the	B-NP	DT	O	37	NMOD
35	other	other	I-NP	JJ	O	37	NMOD
36	two	two	I-NP	CD	O	37	NMOD
37	groups	group	I-NP	NNS	O	33	PMOD
38	.	.	O	.	O	9	P

1	Twenty	Twenty	B-NP	CD	O	6	NMOD
2	(	(	O	(	O	5	DEP
3	56	56	B-NP	CD	O	4	NMOD
4	%	%	I-NP	NN	O	5	DEP
5	)	)	O	)	O	1	NMOD
6	acetaminophen	acetaminophen	B-NP	NN	O	7	SUB
7	induced	induce	B-VP	VBD	O	0	ROOT
8	ALF	ALF	B-NP	NN	O	9	NMOD
9	patients	patient	I-NP	NNS	O	7	OBJ
10	had	have	B-VP	VBD	O	7	VMOD
11	a	a	B-NP	DT	O	14	NMOD
12	formal	formal	I-NP	JJ	O	14	NMOD
13	psychiatric	psychiatric	I-NP	JJ	O	14	NMOD
14	diagnosis	diagnosis	I-NP	NN	O	10	OBJ
15	before	before	B-PP	IN	O	7	VMOD
16	LT	LT	B-NP	NN	B-protein	36	SUB
17	(	(	O	(	O	29	DEP
18	non-acetaminophen	non-acetaminophen	B-NP	JJ	O	26	VMOD
19	induced	induce	I-NP	VBN	O	20	NMOD
20	ALF=0/35	ALF=0/35	I-NP	NN	B-protein	18	NMOD
21	,	,	O	,	O	18	P
22	CLD=2/34	CLD=2/34	B-NP	NN	O	18	NMOD
23	;	;	O	:	O	18	P
24	P	P	B-NP	NN	O	18	NMOD
25	<	<	B-VP	SYM	O	26	VMOD
26	0.01	0.01	B-NP	CD	O	29	DEP
27	for	for	B-PP	IN	O	26	VMOD
28	all	all	O	DT	O	27	PMOD
29	)	)	O	)	O	16	NMOD
30	and	and	O	CC	O	36	VMOD
31	nine	nine	B-NP	CD	O	36	SUB
32	(	(	O	(	O	35	DEP
33	25	25	B-NP	CD	O	34	NMOD
34	%	%	I-NP	NN	O	35	DEP
35	)	)	O	)	O	31	NMOD
36	had	have	B-VP	VBD	O	15	SBAR
37	a	a	B-NP	DT	O	40	NMOD
38	previous	previous	I-NP	JJ	O	40	NMOD
39	suicide	suicide	I-NP	NN	O	40	NMOD
40	attempt	attempt	I-NP	NN	O	36	OBJ
41	.	.	O	.	O	7	P

1	During	During	B-PP	IN	O	10	VMOD
2	follow-up	follow-up	B-NP	NN	O	1	PMOD
3	(	(	O	(	O	7	DEP
4	median	median	B-NP	NN	O	6	NMOD
5	5	5	B-NP	CD	O	6	NMOD
6	years	year	I-NP	NNS	O	7	DEP
7	)	)	O	)	O	2	NMOD
8	,	,	O	,	O	10	P
9	there	there	B-NP	EX	O	10	SUB
10	were	be	B-VP	VBD	O	0	ROOT
11	no	no	B-NP	DT	O	13	NMOD
12	significant	significant	I-NP	JJ	O	13	NMOD
13	differences	difference	I-NP	NNS	O	10	PRD
14	in	in	B-PP	IN	O	10	VMOD
15	rejection	rejection	B-NP	NN	O	14	PMOD
16	(	(	O	(	O	20	DEP
17	acute	acute	B-ADJP	JJ	O	19	NMOD
18	and	and	O	CC	O	19	NMOD
19	chronic	chronic	B-ADJP	JJ	O	20	DEP
20	)	)	O	)	O	15	NMOD
21	,	,	O	,	O	10	P
22	graft	graft	B-NP	NN	O	23	NMOD
23	failure	failure	I-NP	NN	O	25	NMOD
24	or	or	I-NP	CC	O	25	NMOD
25	survival	survival	I-NP	NN	O	10	VMOD
26	between	between	B-PP	IN	O	25	NMOD
27	the	the	B-NP	DT	O	28	NMOD
28	groups	group	I-NP	NNS	O	26	PMOD
29	(	(	O	(	O	64	DEP
30	acetaminophen	acetaminophen	B-NP	NN	O	39	SUB
31	induced	induce	B-VP	VBD	O	39	VMOD
32	ALF	ALF	B-NP	NN	B-protein	34	NMOD
33	1	1	I-NP	CD	I-protein	34	NMOD
34	year	year	I-NP	NN	O	36	NMOD
35	87	87	B-NP	CD	O	36	NMOD
36	%	%	I-NP	NN	O	39	NMOD
37	,	,	O	,	O	39	P
38	5	5	B-NP	CD	O	39	NMOD
39	years	year	I-NP	NNS	O	41	NMOD
40	75	75	B-NP	CD	O	41	NMOD
41	%	%	I-NP	NN	O	63	NMOD
42	;	;	O	:	O	63	P
43	non-acetaminophen	non-acetaminophen	B-NP	JJ	O	47	NMOD
44	induced	induce	I-NP	VBN	O	47	NMOD
45	ALF	ALF	I-NP	NN	O	47	NMOD
46	88	88	B-NP	CD	O	47	NMOD
47	%	%	I-NP	NN	O	50	NMOD
48	,	,	O	,	O	50	P
49	78	78	B-NP	CD	O	50	NMOD
50	%	%	I-NP	NN	O	63	NMOD
51	;	;	O	:	O	63	P
52	CLD	CLD	B-NP	NN	O	54	NMOD
53	93	93	B-NP	CD	O	54	NMOD
54	%	%	I-NP	NN	O	57	NMOD
55	,	,	O	,	O	57	P
56	82	82	B-NP	CD	O	57	NMOD
57	%	%	I-NP	NN	O	63	NMOD
58	:	:	O	:	O	63	P
59	P	P	B-NP	NN	O	63	NMOD
60	>	>	O	SYM	O	63	NMOD
61	0.6	0.6	B-NP	CD	O	63	NMOD
62	log	log	I-NP	NN	O	63	NMOD
63	rank	rank	I-NP	NN	O	64	DEP
64	)	)	O	)	O	28	NMOD
65	.	.	O	.	O	10	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	acetaminophen	acetaminophen	I-NP	NN	O	3	SUB
3	induced	induce	B-VP	VBD	O	0	ROOT
4	ALF	ALF	B-NP	NN	O	5	NMOD
5	patients	patient	I-NP	NNS	O	6	SUB
6	reattempted	reattempte	B-VP	VBD	O	3	VMOD
7	suicide	suicide	B-NP	NN	O	6	OBJ
8	post-LT	post-LT	I-NP	JJ	O	7	AMOD
9	(	(	O	(	O	15	DEP
10	one	one	B-NP	CD	O	11	SUB
11	died	die	B-VP	VBD	O	15	DEP
12	8	8	B-NP	CD	O	13	NMOD
13	years	year	I-NP	NNS	O	11	OBJ
14	post-LT	post-LT	B-ADJP	JJ	O	13	NMOD
15	)	)	O	)	O	7	NMOD
16	.	.	O	.	O	3	P

1	Studies	Study	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	synergy	synergy	B-NP	NN	O	2	PMOD
4	between	between	B-PP	IN	O	3	NMOD
5	morphine	morphine	B-NP	NN	O	13	NMOD
6	and	and	O	CC	O	13	NMOD
7	a	a	B-NP	DT	O	11	NMOD
8	novel	novel	I-NP	JJ	O	11	NMOD
9	sodium	sodium	I-NP	NN	O	11	NMOD
10	channel	channel	I-NP	NN	O	11	NMOD
11	blocker	blocker	I-NP	NN	O	13	NMOD
12	,	,	O	,	O	13	P
13	CNSB002	CNSB002	B-NP	NN	B-protein	4	PMOD
14	,	,	O	,	O	1	P
15	in	in	B-PP	IN	O	1	NMOD
16	rat	rat	B-NP	NN	O	17	NMOD
17	models	model	I-NP	NNS	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	inflammatory	inflammatory	B-NP	JJ	O	22	NMOD
20	and	and	I-NP	CC	O	22	NMOD
21	neuropathic	neuropathic	I-NP	JJ	B-protein	22	NMOD
22	pain	pain	I-NP	NN	I-protein	18	PMOD
23	.	.	O	.	O	1	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	5	VMOD
2	:	:	O	:	O	5	P
3	This	This	B-NP	DT	O	4	NMOD
4	study	study	I-NP	NN	O	5	SUB
5	determined	determine	B-VP	VBD	O	0	ROOT
6	the	the	B-NP	DT	O	8	NMOD
7	antihyperalgesic	antihyperalgesic	I-NP	JJ	O	8	NMOD
8	effect	effect	I-NP	NN	O	5	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	CNSB002	CNSB002	B-NP	NN	B-protein	15	NMOD
11	,	,	O	,	O	15	P
12	a	a	B-NP	DT	O	15	NMOD
13	sodium	sodium	I-NP	NN	O	15	NMOD
14	channel	channel	I-NP	NN	O	15	NMOD
15	blocker	blocker	I-NP	NN	O	9	PMOD
16	with	with	B-PP	IN	O	8	NMOD
17	antioxidant	antioxidant	B-NP	JJ	O	18	NMOD
18	properties	property	I-NP	NNS	O	16	PMOD
19	given	give	B-VP	VBN	O	18	NMOD
20	alone	alone	B-ADVP	RB	O	19	VMOD
21	and	and	O	CC	O	20	DEP
22	in	in	B-PP	IN	O	20	DEP
23	combinations	combination	B-NP	NNS	O	22	PMOD
24	with	with	B-PP	IN	O	23	NMOD
25	morphine	morphine	B-NP	NN	O	24	PMOD
26	in	in	B-PP	IN	O	25	NMOD
27	rat	rat	B-NP	NN	O	28	NMOD
28	models	model	I-NP	NNS	O	26	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	inflammatory	inflammatory	B-NP	JJ	O	33	NMOD
31	and	and	I-NP	CC	O	33	NMOD
32	neuropathic	neuropathic	I-NP	JJ	B-protein	33	NMOD
33	pain	pain	I-NP	NN	I-protein	29	PMOD
34	.	.	O	.	O	5	P

1	DESIGN	DESIGN	B-NP	NN	O	5	NMOD
2	:	:	O	:	O	1	P
3	Dose	Dose	B-NP	NN	O	5	NMOD
4	response	response	I-NP	NN	O	5	NMOD
5	curves	curve	I-NP	NNS	O	20	SUB
6	for	for	B-PP	IN	O	5	NMOD
7	nonsedating	nonsedating	B-NP	JJ	O	8	NMOD
8	doses	dose	I-NP	NNS	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	morphine	morphine	B-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	CNSB002	CNSB002	I-NP	NN	B-protein	9	PMOD
13	given	give	B-VP	VBN	O	8	NMOD
14	intraperitoneally	intraperitoneally	B-ADVP	RB	O	13	VMOD
15	alone	alone	I-ADVP	RB	O	14	AMOD
16	and	and	I-ADVP	CC	O	14	AMOD
17	together	together	I-ADVP	RB	O	14	AMOD
18	in	in	B-PP	IN	O	14	DEP
19	combinations	combination	B-NP	NNS	O	18	PMOD
20	were	be	B-VP	VBD	O	0	ROOT
21	constructed	construct	I-VP	VBN	O	20	VC
22	for	for	B-PP	IN	O	21	VMOD
23	antihyperalgesic	antihyperalgesic	B-NP	JJ	O	24	NMOD
24	effect	effect	I-NP	NN	O	22	PMOD
25	using	use	B-VP	VBG	O	24	NMOD
26	paw	paw	B-NP	NN	O	27	NMOD
27	withdrawal	withdrawal	I-NP	NN	O	25	OBJ
28	from	from	B-PP	IN	O	27	NMOD
29	noxious	noxious	B-NP	JJ	O	30	NMOD
30	heat	heat	I-NP	NN	O	28	PMOD
31	in	in	B-PP	IN	O	25	VMOD
32	two	two	B-NP	CD	O	35	NMOD
33	rat	rat	I-NP	NN	O	35	NMOD
34	pain	pain	I-NP	NN	O	35	NMOD
35	models	model	I-NP	NNS	O	31	PMOD
36	:	:	O	:	O	20	P
37	carrageenan	carrageenan	B-NP	NN	O	20	VMOD
38	induced	induce	B-VP	VBD	O	37	NMOD
39	paw	paw	B-NP	NN	O	40	NMOD
40	inflammation	inflammation	I-NP	NN	O	42	NMOD
41	and	and	O	CC	O	42	NMOD
42	streptozotocin	streptozotocin	B-NP	NN	O	46	SUB
43	(	(	O	(	O	45	DEP
44	STZ	STZ	B-NP	NN	B-protein	45	DEP
45	)	)	O	)	O	42	NMOD
46	induced	induce	B-VP	VBD	O	38	VMOD
47	diabetic	diabetic	B-NP	JJ	O	48	NMOD
48	neuropathy	neuropathy	I-NP	NN	O	46	OBJ
49	.	.	O	.	O	20	P

1	The	The	B-NP	DT	O	2	NMOD
2	doses	dose	I-NP	NNS	O	14	SUB
3	calculated	calculate	B-VP	VBN	O	2	NMOD
4	to	to	I-VP	TO	O	5	VMOD
5	cause	cause	I-VP	VB	O	3	VMOD
6	50	50	B-NP	CD	O	7	AMOD
7	%	%	I-NP	NN	O	8	NMOD
8	reversal	reversal	I-NP	NN	O	5	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	hyperalgesia	hyperalgesia	B-NP	NN	O	9	PMOD
11	(	(	O	(	O	13	DEP
12	ED50	ED50	B-NP	NN	B-protein	13	DEP
13	)	)	O	)	O	10	NMOD
14	were	be	B-VP	VBD	O	0	ROOT
15	7.54	7.54	B-NP	CD	O	20	NMOD
16	(	(	O	(	O	18	DEP
17	1.81	1.81	B-NP	CD	O	18	DEP
18	)	)	O	)	O	15	NMOD
19	and	and	O	CC	O	20	NMOD
20	4.83	4.83	B-NP	CD	O	14	PRD
21	(	(	O	(	O	23	DEP
22	1.54	1.54	B-NP	CD	O	23	DEP
23	)	)	O	)	O	20	NMOD
24	in	in	B-PP	IN	O	20	NMOD
25	the	the	B-NP	DT	O	27	NMOD
26	carrageenan	carrageenan	I-NP	NN	O	27	NMOD
27	model	model	I-NP	NN	O	34	NMOD
28	and	and	O	CC	O	34	NMOD
29	44.18	44.18	B-NP	CD	O	34	NMOD
30	(	(	O	(	O	32	DEP
31	1.37	1.37	B-NP	CD	O	32	DEP
32	)	)	O	)	O	29	NMOD
33	and	and	O	CC	O	34	NMOD
34	9.14	9.14	B-NP	CD	O	24	PMOD
35	(	(	O	(	O	37	DEP
36	1.24	1.24	B-NP	CD	O	37	DEP
37	)	)	O	)	O	34	NMOD
38	in	in	B-PP	IN	O	20	NMOD
39	the	the	B-NP	DT	O	40	NMOD
40	STZ	STZ	I-NP	NN	B-protein	38	PMOD
41	induced	induce	B-VP	VBD	O	20	NMOD
42	neuropathy	neuropathy	B-NP	NN	O	43	NMOD
43	model	model	I-NP	NN	O	41	OBJ
44	for	for	B-PP	IN	O	43	NMOD
45	CNSB002	CNSB002	B-NP	NN	B-protein	47	NMOD
46	and	and	I-NP	CC	O	47	NMOD
47	morphine	morphine	I-NP	NN	O	44	PMOD
48	,	,	O	,	O	41	P
49	respectively	respectively	B-ADVP	RB	O	41	VMOD
50	(	(	O	(	O	56	DEP
51	mg/kg	mg/kg	B-NP	NN	O	55	NMOD
52	;	;	O	:	O	55	P
53	mean	mean	B-NP	NN	O	55	NMOD
54	,	,	I-NP	,	O	55	P
55	SEM	SEM	I-NP	NN	O	56	DEP
56	)	)	O	)	O	41	VMOD
57	.	.	O	.	O	14	P

1	The	The	B-NP	DT	O	3	NMOD
2	ED50	ED50	I-NP	NN	O	3	NMOD
3	values	value	I-NP	NNS	O	0	ROOT
4	for	for	B-PP	IN	O	3	NMOD
5	morphine	morphine	B-NP	NN	O	4	PMOD
6	when	when	B-ADVP	WRB	O	3	VMOD
7	given	give	B-VP	VBN	O	6	SBAR
8	in	in	B-PP	IN	O	7	VMOD
9	combination	combination	B-NP	NN	O	8	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	CNSB002	CNSB002	B-NP	NN	B-protein	10	PMOD
12	(	(	O	(	O	15	DEP
13	5	5	B-NP	CD	O	14	NMOD
14	mg/kg	mg/kg	I-NP	NN	O	15	DEP
15	)	)	O	)	O	11	NMOD
16	were	be	B-VP	VBD	O	6	SBAR
17	less	less	B-ADJP	JJR	O	16	PRD
18	than	than	B-PP	IN	O	17	AMOD
19	the	the	B-NP	DT	O	22	NMOD
20	maximum	maximum	I-NP	NN	O	22	NMOD
21	nonsedating	nonsedating	I-NP	JJ	O	22	NMOD
22	dose	dose	I-NP	NN	O	18	PMOD
23	:	:	O	:	O	6	DEP
24	0.56	0.56	B-NP	CD	O	23	PRD
25	(	(	O	(	O	27	DEP
26	1.55	1.55	B-NP	CD	O	27	DEP
27	)	)	O	)	O	24	NMOD
28	in	in	B-PP	IN	O	24	NMOD
29	the	the	B-NP	DT	O	31	NMOD
30	carrageenan	carrageenan	I-NP	NN	O	31	NMOD
31	model	model	I-NP	NN	O	28	PMOD
32	and	and	O	CC	O	33	NMOD
33	1.37	1.37	B-NP	CD	O	31	NMOD
34	(	(	O	(	O	36	DEP
35	1.23	1.23	B-NP	CD	O	36	DEP
36	)	)	O	)	O	33	NMOD
37	in	in	B-PP	IN	O	33	NMOD
38	the	the	B-NP	DT	O	40	NMOD
39	neuropathy	neuropathy	I-NP	NN	O	40	NMOD
40	model	model	I-NP	NN	O	37	PMOD
41	(	(	O	(	O	47	DEP
42	mg/kg	mg/kg	B-NP	NN	O	46	NMOD
43	;	;	O	:	O	46	P
44	mean	mean	B-NP	NN	O	46	NMOD
45	,	,	I-NP	,	O	46	P
46	SEM	SEM	I-NP	NN	O	47	DEP
47	)	)	O	)	O	40	NMOD
48	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	antinociception	antinociception	I-NP	NN	O	9	SUB
3	after	after	B-PP	IN	O	2	NMOD
4	morphine	morphine	B-NP	NN	O	3	PMOD
5	(	(	O	(	O	8	DEP
6	3.2	3.2	B-NP	CD	O	7	NMOD
7	mg/kg	mg/kg	I-NP	NN	O	8	DEP
8	)	)	O	)	O	4	NMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	increased	increase	I-VP	VBN	O	9	VC
11	by	by	B-PP	IN	O	10	VMOD
12	co-administration	co-administration	B-NP	NN	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	CNSB002	CNSB002	B-NP	NN	B-protein	13	PMOD
15	from	from	B-PP	IN	O	12	NMOD
16	28.0	28.0	B-NP	CD	O	18	AMOD
17	and	and	I-NP	CC	O	18	AMOD
18	31.7	31.7	I-NP	CD	O	19	NMOD
19	%	%	I-NP	NN	O	25	NMOD
20	to	to	I-NP	TO	O	25	NMOD
21	114.6	114.6	I-NP	CD	O	23	AMOD
22	and	and	I-NP	CC	O	23	AMOD
23	56.9	56.9	I-NP	CD	O	25	NMOD
24	%	%	I-NP	NN	O	23	AMOD
25	reversal	reversal	I-NP	NN	O	15	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	hyperalgesia	hyperalgesia	B-NP	NN	O	26	PMOD
28	in	in	B-PP	IN	O	10	VMOD
29	the	the	B-NP	DT	O	33	NMOD
30	inflammatory	inflammatory	I-NP	JJ	O	33	NMOD
31	and	and	I-NP	CC	O	33	NMOD
32	neuropathic	neuropathic	I-NP	JJ	O	33	NMOD
33	models	model	I-NP	NNS	O	28	PMOD
34	,	,	O	,	O	10	P
35	respectively	respectively	B-ADVP	RB	O	10	VMOD
36	(	(	O	(	O	10	VMOD
37	P	P	B-NP	NN	O	42	NMOD
38	<	<	O	SYM	O	37	NMOD
39	0.01	0.01	B-NP	CD	O	38	AMOD
40	;	;	O	:	O	42	P
41	one-way	one-way	B-NP	JJ	O	42	NMOD
42	analysis	analysis	I-NP	NN	O	36	PMOD
43	of	of	B-PP	IN	O	42	NMOD
44	variance-significantly	variance-significantly	B-NP	RB	O	45	AMOD
45	greater	great	I-NP	JJR	O	43	PMOD
46	than	than	B-PP	IN	O	45	AMOD
47	either	either	B-NP	DT	O	48	NMOD
48	drug	drug	I-NP	NN	O	46	PMOD
49	given	give	B-VP	VBN	O	48	NMOD
50	alone	alone	B-ADVP	RB	O	49	VMOD
51	)	)	O	)	O	45	NMOD
52	.	.	O	.	O	9	P

1	Heparin	Heparin	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	thrombocytopenia	thrombocytopenia	B-NP	NN	O	2	OBJ
4	:	:	O	:	O	2	P
5	a	a	B-NP	DT	O	7	NMOD
6	practical	practical	I-NP	JJ	O	7	NMOD
7	review	review	I-NP	NN	O	2	VMOD
8	.	.	O	.	O	2	P

1	Heparin	Heparin	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	thrombocytopenia	thrombocytopenia	B-NP	NN	O	7	SUB
4	(	(	O	(	O	6	DEP
5	HIT	HIT	B-NP	NN	O	6	DEP
6	)	)	O	)	O	3	NMOD
7	remains	remain	B-VP	VBZ	O	2	VMOD
8	under-recognized	under-recognized	B-ADJP	JJ	O	7	PRD
9	despite	despite	B-PP	IN	O	8	AMOD
10	its	its	B-NP	PRP$	O	13	NMOD
11	potentially	potentially	I-NP	RB	O	12	AMOD
12	devastating	devastate	I-NP	VBG	O	13	NMOD
13	outcomes	outcome	I-NP	NNS	O	9	PMOD
14	.	.	O	.	O	2	P

1	HIT	HIT	B-NP	NN	B-protein	2	SUB
2	must	must	B-VP	MD	O	0	ROOT
3	be	be	I-VP	VB	O	2	VC
4	acknowledged	acknowledge	I-VP	VBN	O	3	VC
5	for	for	B-PP	IN	O	4	VMOD
6	its	its	B-NP	PRP$	O	8	NMOD
7	intense	intense	I-NP	JJ	O	8	NMOD
8	predilection	predilection	I-NP	NN	O	5	PMOD
9	for	for	B-PP	IN	O	8	NMOD
10	thrombosis	thrombosis	B-NP	NN	O	9	PMOD
11	and	and	O	CC	O	2	VMOD
12	suspected	suspect	B-VP	VBN	O	2	VMOD
13	whenever	whenever	B-ADVP	WRB	O	12	VMOD
14	thrombosis	thrombosis	B-NP	NN	O	15	SUB
15	occurs	occur	B-VP	VBZ	O	13	SBAR
16	after	after	B-PP	IN	O	15	VMOD
17	heparin	heparin	B-NP	NN	O	18	NMOD
18	exposure	exposure	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	treatment	treatment	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	HIT	HIT	B-NP	NN	B-protein	3	PMOD
5	mandates	mandate	B-VP	VBZ	O	0	ROOT
6	an	an	B-NP	DT	O	8	NMOD
7	immediate	immediate	I-NP	JJ	O	8	NMOD
8	cessation	cessation	I-NP	NN	O	22	NMOD
9	of	of	B-PP	IN	O	8	NMOD
10	all	all	B-NP	DT	O	12	NMOD
11	heparin	heparin	I-NP	NN	O	12	NMOD
12	exposure	exposure	I-NP	NN	O	15	NMOD
13	and	and	O	CC	O	15	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	institution	institution	I-NP	NN	O	9	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	an	an	B-NP	DT	O	19	NMOD
18	antithrombotic	antithrombotic	I-NP	JJ	O	19	NMOD
19	therapy	therapy	I-NP	NN	O	16	PMOD
20	,	,	O	,	O	22	P
21	most	most	B-ADVP	RBS	O	22	AMOD
22	commonly	commonly	I-ADVP	RB	O	23	VMOD
23	using	use	B-VP	VBG	O	5	VMOD
24	a	a	B-NP	DT	O	27	NMOD
25	direct	direct	I-NP	JJ	O	27	NMOD
26	thrombin	thrombin	I-NP	NN	B-protein	27	NMOD
27	inhibitor	inhibitor	I-NP	NN	O	23	OBJ
28	.	.	O	.	O	5	P

1	Direct	Direct	B-NP	JJ	O	3	NMOD
2	thrombin	thrombin	I-NP	NN	B-protein	3	NMOD
3	inhibitors	inhibitor	I-NP	NNS	O	4	SUB
4	are	be	B-VP	VBP	O	0	ROOT
5	appropriate	appropriate	B-NP	JJ	O	7	AMOD
6	,	,	I-NP	,	O	7	P
7	evidence-based	evidence-based	I-NP	JJ	O	8	NMOD
8	alternatives	alternative	I-NP	NNS	O	4	PRD
9	to	to	B-PP	TO	O	8	NMOD
10	heparin	heparin	B-NP	NN	O	9	PMOD
11	in	in	B-PP	IN	O	8	NMOD
12	patients	patient	B-NP	NNS	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	a	a	B-NP	DT	O	15	NMOD
15	history	history	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	HIT	HIT	B-NP	NN	B-protein	16	PMOD
18	,	,	O	,	O	8	P
19	who	who	B-NP	WP	O	8	NMOD
20	need	need	B-VP	VBP	O	19	SBAR
21	to	to	I-VP	TO	O	22	VMOD
22	undergo	undergo	I-VP	VB	O	20	VMOD
23	percutaneous	percutaneous	B-NP	JJ	O	25	NMOD
24	coronary	coronary	I-NP	JJ	O	25	NMOD
25	intervention	intervention	I-NP	NN	O	22	OBJ
26	.	.	O	.	O	4	P

1	Abductor	Abductor	B-NP	NN	O	2	NMOD
2	paralysis	paralysis	I-NP	NN	O	0	ROOT
3	after	after	B-PP	IN	O	2	NMOD
4	botox	botox	B-NP	NN	O	5	NMOD
5	injection	injection	I-NP	NN	O	3	PMOD
6	for	for	B-PP	IN	O	5	NMOD
7	adductor	adductor	B-NP	NN	O	9	NMOD
8	spasmodic	spasmodic	I-NP	JJ	O	9	NMOD
9	dysphonia	dysphonia	I-NP	NN	O	6	PMOD
10	.	.	O	.	O	2	P

1	OBJECTIVES/HYPOTHESIS	OBJECTIVES/HYPOTHESIS	B-NP	NN	O	4	NMOD
2	:	:	O	:	O	1	P
3	Botulinum	Botulinum	B-NP	NN	O	4	NMOD
4	toxin	toxin	I-NP	NN	O	8	NMOD
5	(	(	O	(	O	7	DEP
6	Botox	Botox	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	injections	injection	B-NP	NNS	O	13	SUB
9	into	into	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	12	NMOD
11	thyroarytenoid	thyroarytenoid	I-NP	JJ	O	12	NMOD
12	muscles	muscle	I-NP	NNS	O	9	PMOD
13	are	be	B-VP	VBP	O	0	ROOT
14	the	the	B-NP	DT	O	16	NMOD
15	current	current	I-NP	JJ	O	16	NMOD
16	standard	standard	I-NP	NN	O	13	PRD
17	of	of	B-PP	IN	O	16	NMOD
18	care	care	B-NP	NN	O	17	PMOD
19	for	for	B-PP	IN	O	16	NMOD
20	adductor	adductor	B-NP	NN	O	22	NMOD
21	spasmodic	spasmodic	I-NP	JJ	O	22	NMOD
22	dysphonia	dysphonia	I-NP	NN	O	19	PMOD
23	(	(	O	(	O	25	DEP
24	ADSD	ADSD	B-NP	NN	O	25	DEP
25	)	)	O	)	O	22	NMOD
26	.	.	O	.	O	13	P

1	Here	Here	B-ADVP	RB	O	3	VMOD
2	we	we	B-NP	PRP	O	3	SUB
3	report	report	B-VP	VBP	O	0	ROOT
4	multiple	multiple	B-NP	JJ	O	5	NMOD
5	cases	case	I-NP	NNS	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	bilateral	bilateral	B-NP	JJ	O	9	NMOD
8	abductor	abductor	I-NP	NN	O	9	NMOD
9	paralysis	paralysis	I-NP	NN	O	6	PMOD
10	following	follow	B-PP	VBG	O	3	VMOD
11	Botox	Botox	B-NP	NN	O	12	NMOD
12	injections	injection	I-NP	NNS	O	10	PMOD
13	for	for	B-PP	IN	O	12	NMOD
14	ADSD	ADSD	B-NP	NN	B-protein	17	NMOD
15	,	,	O	,	O	17	P
16	a	a	B-NP	DT	O	17	NMOD
17	complication	complication	I-NP	NN	O	13	PMOD
18	previously	previously	B-ADJP	RB	O	19	AMOD
19	unreported	unreported	I-ADJP	JJ	O	17	NMOD
20	.	.	O	.	O	3	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Patients	Patient	B-NP	NNS	O	17	SUB
4	that	that	B-NP	WDT	O	3	NMOD
5	received	receive	B-VP	VBD	O	4	SBAR
6	Botox	Botox	B-NP	NN	O	7	NMOD
7	injections	injection	I-NP	NNS	O	5	OBJ
8	for	for	B-PP	IN	O	7	NMOD
9	spasmodic	spasmodic	B-NP	JJ	O	10	NMOD
10	dysphonia	dysphonia	I-NP	NN	O	8	PMOD
11	between	between	B-PP	IN	O	10	NMOD
12	January	January	B-NP	NNP	O	15	NMOD
13	2000	2000	I-NP	CD	O	12	NMOD
14	and	and	O	CC	O	15	NMOD
15	October	October	B-NP	NNP	O	11	PMOD
16	2009	2009	I-NP	CD	O	15	NMOD
17	were	be	B-VP	VBD	O	1	NMOD
18	evaluated	evaluate	I-VP	VBN	O	17	VC
19	.	.	O	.	O	1	P

1	For	For	B-PP	IN	O	21	VMOD
2	patients	patient	B-NP	NNS	O	1	PMOD
3	with	with	B-PP	IN	O	2	NMOD
4	bilateral	bilateral	B-NP	JJ	O	6	NMOD
5	abductor	abductor	I-NP	NN	O	6	NMOD
6	paralysis	paralysis	I-NP	NN	O	3	PMOD
7	,	,	O	,	O	21	P
8	age	age	B-NP	NN	O	21	NMOD
9	,	,	O	,	O	21	P
10	sex	sex	B-NP	NN	O	21	NMOD
11	,	,	O	,	O	21	P
12	paralytic	paralytic	B-NP	JJ	O	14	NMOD
13	Botox	Botox	I-NP	NN	O	14	NMOD
14	dose	dose	I-NP	NN	O	21	NMOD
15	,	,	O	,	O	21	P
16	prior	prior	B-NP	JJ	O	18	NMOD
17	Botox	Botox	I-NP	NN	O	18	NMOD
18	dose	dose	I-NP	NN	O	21	NMOD
19	,	,	O	,	O	21	P
20	and	and	O	CC	O	21	NMOD
21	course	course	B-NP	NN	O	24	SUB
22	following	follow	B-PP	VBG	O	21	NMOD
23	paralysis	paralysis	B-NP	NN	O	22	PMOD
24	were	be	B-VP	VBD	O	0	ROOT
25	noted	note	I-VP	VBN	O	24	VC
26	.	.	O	.	O	24	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	From	From	B-PP	IN	O	1	NMOD
4	a	a	B-NP	DT	O	5	NMOD
5	database	database	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	452	452	B-NP	CD	O	8	NMOD
8	patients	patient	I-NP	NNS	O	6	PMOD
9	receiving	receive	B-VP	VBG	O	8	NMOD
10	Botox	Botox	B-NP	NN	O	13	NMOD
11	,	,	O	,	O	13	P
12	352	352	B-NP	CD	O	13	NMOD
13	patients	patient	I-NP	NNS	O	9	OBJ
14	had	have	B-VP	VBD	O	1	NMOD
15	been	be	I-VP	VBN	O	14	VC
16	diagnosed	diagnose	I-VP	VBN	O	15	VC
17	with	with	B-PP	IN	O	16	VMOD
18	ADSD	ADSD	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	incidence	incidence	I-NP	NN	O	11	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	abductor	abductor	B-NP	NN	O	5	NMOD
5	paralysis	paralysis	I-NP	NN	O	3	PMOD
6	after	after	B-PP	IN	O	5	NMOD
7	Botox	Botox	B-NP	NN	O	8	NMOD
8	injection	injection	I-NP	NN	O	6	PMOD
9	for	for	B-PP	IN	O	8	NMOD
10	ADSD	ADSD	B-NP	NN	O	9	PMOD
11	was	be	B-VP	VBD	O	0	ROOT
12	0.34	0.34	B-NP	CD	O	13	NMOD
13	%	%	I-NP	NN	O	11	PRD
14	.	.	O	.	O	11	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Bilateral	Bilateral	B-NP	JJ	O	5	NMOD
4	abductor	abductor	I-NP	NN	O	5	NMOD
5	paralysis	paralysis	I-NP	NN	O	6	SUB
6	is	be	B-VP	VBZ	O	1	NMOD
7	a	a	B-NP	DT	O	9	NMOD
8	rare	rare	I-NP	JJ	O	9	NMOD
9	complication	complication	I-NP	NN	O	6	PRD
10	of	of	B-PP	IN	O	9	NMOD
11	Botox	Botox	B-NP	NN	O	12	NMOD
12	injections	injection	I-NP	NNS	O	10	PMOD
13	for	for	B-PP	IN	O	9	NMOD
14	ADSD	ADSD	B-NP	NN	O	13	PMOD
15	,	,	O	,	O	9	P
16	causing	cause	B-VP	VBG	O	9	NMOD
17	difficulty	difficulty	B-NP	NN	O	16	OBJ
18	with	with	B-PP	IN	O	16	VMOD
19	breathing	breathing	B-NP	NN	O	18	PMOD
20	upon	upon	B-PP	IN	O	16	VMOD
21	exertion	exertion	B-NP	NN	O	20	PMOD
22	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	3	NMOD
2	likely	likely	I-NP	JJ	O	3	NMOD
3	mechanism	mechanism	I-NP	NN	O	6	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	paralysis	paralysis	B-NP	NN	O	4	PMOD
6	is	be	B-VP	VBZ	O	0	ROOT
7	diffusion	diffusion	B-NP	NN	O	6	PRD
8	of	of	B-PP	IN	O	7	NMOD
9	Botox	Botox	B-NP	NNP	O	8	PMOD
10	around	around	B-PP	IN	O	7	NMOD
11	the	the	B-NP	DT	O	13	NMOD
12	muscular	muscular	I-NP	JJ	O	13	NMOD
13	process	process	I-NP	NN	O	10	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	arytenoid	arytenoid	I-NP	NN	O	14	PMOD
17	to	to	B-PP	TO	O	13	NMOD
18	the	the	B-NP	DT	O	21	NMOD
19	posterior	posterior	I-NP	JJ	O	21	NMOD
20	cricoarytenoid	cricoarytenoid	I-NP	JJ	O	21	NMOD
21	muscles	muscle	I-NP	NNS	O	17	PMOD
22	.	.	O	.	O	6	P

1	Mitochondrial	Mitochondrial	B-NP	JJ	O	2	NMOD
2	impairment	impairment	I-NP	NN	O	3	SUB
3	contributes	contribute	B-VP	VBZ	O	0	ROOT
4	to	to	B-PP	TO	O	3	VMOD
5	cocaine	cocaine	B-NP	NN	O	4	PMOD
6	induced	induce	B-VP	VBD	O	3	VMOD
7	cardiac	cardiac	B-NP	JJ	O	8	NMOD
8	dysfunction	dysfunction	I-NP	NN	O	6	OBJ
9	:	:	O	:	O	3	P
10	Prevention	Prevention	B-NP	NN	O	3	VMOD
11	by	by	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	15	NMOD
13	targeted	target	I-NP	VBN	O	15	NMOD
14	antioxidant	antioxidant	I-NP	NN	O	15	NMOD
15	MitoQ	MitoQ	I-NP	NNP	O	11	PMOD
16	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	goal	goal	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	assess	assess	I-VP	VB	O	6	PRD
9	mitochondrial	mitochondrial	B-NP	JJ	O	10	NMOD
10	function	function	I-NP	NN	O	13	NMOD
11	and	and	I-NP	CC	O	13	NMOD
12	ROS	ROS	I-NP	NN	O	13	NMOD
13	production	production	I-NP	NN	O	8	OBJ
14	in	in	B-PP	IN	O	13	NMOD
15	an	an	B-NP	DT	O	17	NMOD
16	experimental	experimental	I-NP	JJ	O	17	NMOD
17	model	model	I-NP	NN	O	14	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	cocaine	cocaine	B-NP	NN	O	18	PMOD
20	induced	induce	B-VP	VBD	O	8	VMOD
21	cardiac	cardiac	B-NP	JJ	O	22	NMOD
22	dysfunction	dysfunction	I-NP	NN	O	20	OBJ
23	.	.	O	.	O	6	P

1	This	This	B-NP	DT	O	3	NMOD
2	uncoupling	uncoupling	I-NP	JJ	O	3	NMOD
3	effect	effect	I-NP	NN	O	7	SUB
4	on	on	B-PP	IN	O	3	NMOD
5	oxidative	oxidative	B-NP	JJ	O	6	NMOD
6	phosphorylation	phosphorylation	I-NP	NN	O	4	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	not	not	O	RB	O	7	VMOD
9	detectable	detectable	B-ADJP	JJ	O	7	PRD
10	after	after	B-SBAR	IN	O	7	VMOD
11	short-term	short-term	B-NP	JJ	O	12	NMOD
12	exposure	exposure	I-NP	NN	O	10	PMOD
13	to	to	B-PP	TO	O	12	NMOD
14	cocaine	cocaine	B-NP	NN	O	13	PMOD
15	,	,	O	,	O	7	P
16	suggesting	suggest	B-VP	VBG	O	7	VMOD
17	that	that	B-SBAR	IN	O	16	VMOD
18	these	these	B-NP	DT	O	20	NMOD
19	mitochondrial	mitochondrial	I-NP	JJ	O	20	NMOD
20	abnormalities	abnormality	I-NP	NNS	O	21	SUB
21	were	be	B-VP	VBD	O	17	SBAR
22	a	a	O	DT	O	28	NMOD
23	late	late	O	JJ	O	28	NMOD
24	rather	rather	B-CONJP	RB	O	28	NMOD
25	than	than	I-CONJP	IN	O	24	DEP
26	a	a	B-NP	DT	O	28	NMOD
27	primary	primary	I-NP	JJ	O	28	NMOD
28	event	event	I-NP	NN	O	21	PRD
29	in	in	B-PP	IN	O	21	VMOD
30	the	the	B-NP	DT	O	32	NMOD
31	pathological	pathological	I-NP	JJ	O	32	NMOD
32	response	response	I-NP	NN	O	29	PMOD
33	to	to	B-PP	TO	O	32	NMOD
34	cocaine	cocaine	B-NP	NN	O	33	PMOD
35	.	.	O	.	O	7	P

1	MitoQ	MitoQ	B-NP	NNP	O	5	NMOD
2	,	,	O	,	O	5	P
3	a	a	B-NP	DT	O	5	NMOD
4	mitochondrial-targeted	mitochondrial-targeted	I-NP	JJ	O	5	NMOD
5	antioxidant	antioxidant	I-NP	NN	O	7	SUB
6	,	,	O	,	O	5	P
7	was	be	B-VP	VBD	O	0	ROOT
8	shown	show	I-VP	VBN	O	7	VC
9	to	to	I-VP	TO	O	11	VMOD
10	completely	completely	I-VP	RB	O	11	VMOD
11	prevent	prevent	I-VP	VB	O	8	VMOD
12	these	these	B-NP	DT	O	14	NMOD
13	mitochondrial	mitochondrial	I-NP	JJ	O	14	NMOD
14	abnormalities	abnormality	I-NP	NNS	O	19	NMOD
15	as	as	B-CONJP	RB	O	19	NMOD
16	well	well	I-CONJP	RB	O	15	DEP
17	as	as	I-CONJP	IN	O	15	DEP
18	cardiac	cardiac	B-NP	JJ	O	19	NMOD
19	dysfunction	dysfunction	I-NP	NN	O	11	OBJ
20	characterized	characterize	B-VP	VBN	O	19	NMOD
21	here	here	B-ADVP	RB	O	20	VMOD
22	by	by	B-PP	IN	O	20	VMOD
23	a	a	B-NP	DT	O	25	NMOD
24	diastolic	diastolic	I-NP	JJ	O	25	NMOD
25	dysfunction	dysfunction	I-NP	NN	O	22	PMOD
26	studied	study	B-VP	VBN	O	25	NMOD
27	with	with	B-PP	IN	O	26	VMOD
28	a	a	B-NP	DT	O	30	NMOD
29	conductance	conductance	I-NP	NN	O	30	NMOD
30	catheter	catheter	I-NP	NN	O	27	PMOD
31	to	to	B-VP	TO	O	32	VMOD
32	obtain	obtain	I-VP	VB	O	25	NMOD
33	pressure-volume	pressure-volume	B-NP	NN	O	34	NMOD
34	data	datum	I-NP	NNS	O	32	OBJ
35	.	.	O	.	O	7	P

1	Trimethoprim	Trimethoprim	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	immune	immune	B-NP	JJ	O	5	NMOD
4	hemolytic	hemolytic	I-NP	JJ	O	5	NMOD
5	anemia	anemia	I-NP	NN	O	2	OBJ
6	in	in	B-PP	IN	O	2	VMOD
7	a	a	B-NP	DT	O	10	NMOD
8	pediatric	pediatric	I-NP	JJ	O	10	NMOD
9	oncology	oncology	I-NP	NN	O	10	NMOD
10	patient	patient	I-NP	NN	O	6	PMOD
11	presenting	present	B-VP	VBG	O	10	NMOD
12	as	as	B-PP	IN	O	11	VMOD
13	an	an	B-NP	DT	O	17	NMOD
14	acute	acute	I-NP	JJ	O	17	NMOD
15	hemolytic	hemolytic	I-NP	JJ	O	17	NMOD
16	transfusion	transfusion	I-NP	NN	O	17	NMOD
17	reaction	reaction	I-NP	NN	O	12	PMOD
18	.	.	O	.	O	2	P

1	Blockade	Blockade	B-NP	NN	O	9	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	endothelial-mesenchymal	endothelial-mesenchymal	B-NP	JJ	O	4	NMOD
4	transition	transition	I-NP	NN	O	2	PMOD
5	by	by	B-PP	IN	O	1	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	Smad3	Smad3	I-NP	NN	B-protein	8	NMOD
8	inhibitor	inhibitor	I-NP	NN	O	5	PMOD
9	delays	delay	B-VP	VBZ	O	0	ROOT
10	the	the	B-NP	DT	O	12	NMOD
11	early	early	I-NP	JJ	O	12	NMOD
12	development	development	I-NP	NN	O	15	SUB
13	of	of	B-PP	IN	O	12	NMOD
14	streptozotocin	streptozotocin	B-NP	NN	O	13	PMOD
15	induced	induce	B-VP	VBD	O	9	VMOD
16	diabetic	diabetic	B-NP	JJ	O	17	NMOD
17	nephropathy	nephropathy	I-NP	NN	O	15	OBJ
18	.	.	O	.	O	9	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	7	NMOD
2	:	:	O	:	O	7	P
3	A	A	B-NP	DT	O	4	NMOD
4	multicenter	multicenter	I-NP	NN	O	7	NMOD
5	,	,	O	,	O	7	P
6	controlled	control	B-NP	VBN	O	7	NMOD
7	trial	trial	I-NP	NN	O	8	SUB
8	showed	show	B-VP	VBD	O	0	ROOT
9	that	that	B-SBAR	IN	O	8	VMOD
10	early	early	B-NP	JJ	O	11	NMOD
11	blockade	blockade	I-NP	NN	O	23	NMOD
12	of	of	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	15	NMOD
14	renin-angiotensin	renin-angiotensin	I-NP	NN	B-protein	15	NMOD
15	system	system	I-NP	NN	O	12	PMOD
16	in	in	B-PP	IN	O	11	NMOD
17	patients	patient	B-NP	NNS	O	16	PMOD
18	with	with	B-PP	IN	O	17	NMOD
19	type	type	B-NP	NN	O	21	NMOD
20	1	1	I-NP	CD	O	21	NMOD
21	diabetes	diabete	I-NP	NNS	O	18	PMOD
22	and	and	O	CC	O	23	NMOD
23	normoalbuminuria	normoalbuminuria	B-NP	NN	O	24	SUB
24	did	do	B-VP	VBD	O	9	SBAR
25	not	not	I-VP	RB	O	24	VMOD
26	retard	retard	I-VP	VB	O	24	VC
27	the	the	B-NP	DT	O	28	NMOD
28	progression	progression	I-NP	NN	O	26	OBJ
29	of	of	B-PP	IN	O	28	NMOD
30	nephropathy	nephropathy	B-NP	NN	O	29	PMOD
31	,	,	O	,	O	8	P
32	suggesting	suggest	B-VP	VBG	O	8	VMOD
33	that	that	B-SBAR	IN	O	32	VMOD
34	other	other	B-NP	JJ	O	37	NMOD
35	mechanism	mechanism	I-NP	NN	O	37	NMOD
36	(	(	I-NP	(	O	37	NMOD
37	s	s	I-NP	NNS	O	39	SUB
38	)	)	O	)	O	37	NMOD
39	are	be	B-VP	VBP	O	33	SBAR
40	involved	involve	I-VP	VBN	O	39	VC
41	in	in	B-PP	IN	O	40	VMOD
42	the	the	B-NP	DT	O	43	NMOD
43	pathogenesis	pathogenesis	I-NP	NN	O	41	PMOD
44	of	of	B-PP	IN	O	43	NMOD
45	early	early	B-NP	JJ	O	47	NMOD
46	diabetic	diabetic	I-NP	JJ	O	47	NMOD
47	nephropathy	nephropathy	I-NP	NN	O	44	PMOD
48	(	(	O	(	O	51	DEP
49	diabetic	diabetic	B-NP	JJ	O	50	NMOD
50	nephropathy	nephropathy	I-NP	NN	O	51	DEP
51	)	)	O	)	O	47	NMOD
52	.	.	O	.	O	8	P

1	We	We	B-NP	PRP	O	2	SUB
2	have	have	B-VP	VBP	O	0	ROOT
3	previously	previously	I-VP	RB	O	2	VMOD
4	demonstrated	demonstrate	I-VP	VBN	O	2	VC
5	that	that	B-SBAR	IN	O	4	VMOD
6	endothelial-mesenchymal-transition	endothelial-mesenchymal-transition	B-NP	NN	O	10	SUB
7	(	(	O	(	O	9	DEP
8	EndoMT	EndoMT	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	contributes	contribute	B-VP	VBZ	O	5	SBAR
11	to	to	B-PP	TO	O	10	VMOD
12	the	the	B-NP	DT	O	14	NMOD
13	early	early	I-NP	JJ	O	14	NMOD
14	development	development	I-NP	NN	O	11	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	renal	renal	B-NP	JJ	O	18	NMOD
17	interstitial	interstitial	I-NP	JJ	O	18	NMOD
18	fibrosis	fibrosis	I-NP	NN	O	15	PMOD
19	independently	independently	B-ADVP	RB	O	14	NMOD
20	of	of	B-PP	IN	O	14	NMOD
21	microalbuminuria	microalbuminuria	B-NP	NN	O	20	PMOD
22	in	in	B-PP	IN	O	10	VMOD
23	mice	mouse	B-NP	NNS	O	22	PMOD
24	with	with	B-PP	IN	O	23	NMOD
25	streptozotocin	streptozotocin	B-NP	NN	O	30	NMOD
26	(	(	O	(	O	28	DEP
27	STZ	STZ	B-NP	NN	B-protein	28	DEP
28	)	)	O	)	O	25	NMOD
29	induced	induce	B-NP	VBN	O	30	NMOD
30	diabetes	diabetes	I-NP	NN	O	24	PMOD
31	.	.	O	.	O	2	P

1	Blocking	Blocking	B-NP	NN	O	2	NMOD
2	studies	study	I-NP	NNS	O	17	SUB
3	using	use	B-VP	VBG	O	2	NMOD
4	receptor	receptor	B-NP	NN	O	3	OBJ
5	for	for	B-PP	IN	O	4	NMOD
6	AGE	AGE	B-NP	NN	O	7	NMOD
7	siRNA	siRNA	I-NP	NN	O	11	NMOD
8	and	and	O	CC	O	11	NMOD
9	a	a	B-NP	DT	O	11	NMOD
10	specific	specific	I-NP	JJ	O	11	NMOD
11	inhibitor	inhibitor	I-NP	NN	O	5	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	Smad3	Smad3	B-NP	NN	B-protein	12	PMOD
14	(	(	O	(	O	16	DEP
15	SIS3	SIS3	B-NP	NN	B-protein	16	DEP
16	)	)	O	)	O	13	NMOD
17	were	be	B-VP	VBD	O	0	ROOT
18	performed	perform	I-VP	VBN	O	17	VC
19	in	in	B-PP	IN	O	18	VMOD
20	MMECs	MMEC	B-NP	NNS	B-cell_type	19	PMOD
21	and	and	B-PP	CC	O	19	PMOD
22	in	in	B-PP	IN	O	19	PMOD
23	STZ	STZ	B-NP	NN	B-protein	26	NMOD
24	induced	induce	B-VP	VBD	O	23	AMOD
25	diabetic	diabetic	B-NP	JJ	O	26	NMOD
26	nephropathy	nephropathy	I-NP	NN	O	22	PMOD
27	in	in	B-PP	IN	O	18	VMOD
28	Tie2-Cre	Tie2-Cre	B-NP	NN	O	27	PMOD
29	;	;	O	:	O	17	P
30	Loxp-EGFP	Loxp-EGFP	B-NP	NN	O	31	NMOD
31	mice	mouse	I-NP	NNS	O	17	PRD
32	.	.	O	.	O	17	P

1	Immunoprecipitation/Western	Immunoprecipitation/Western	B-NP	NN	O	2	NMOD
2	blotting	blotting	I-NP	NN	O	3	SUB
3	showed	show	B-VP	VBD	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	Smad3	Smad3	B-NP	NN	B-protein	6	SUB
6	was	be	B-VP	VBD	O	4	SBAR
7	activated	activate	I-VP	VBN	O	6	VC
8	by	by	B-PP	IN	O	7	VMOD
9	AGEs	AGE	B-NP	NNS	O	8	PMOD
10	but	but	O	CC	O	6	VMOD
11	was	be	B-VP	VBD	O	6	VMOD
12	inhibited	inhibit	I-VP	VBN	O	11	VC
13	by	by	B-PP	IN	O	12	VMOD
14	SIS3	SIS3	B-NP	NN	B-protein	13	PMOD
15	in	in	B-PP	IN	O	12	VMOD
16	MMECs	MMEC	B-NP	NNS	B-cell_type	15	PMOD
17	and	and	B-PP	CC	O	15	PMOD
18	in	in	B-PP	IN	O	15	PMOD
19	STZ	STZ	B-NP	NN	B-protein	22	NMOD
20	induced	induce	B-VP	VBD	O	19	AMOD
21	diabetic	diabetic	B-NP	JJ	O	22	NMOD
22	nephropathy	nephropathy	I-NP	NN	O	18	PMOD
23	.	.	O	.	O	3	P

1	Cytostatic	Cytostatic	B-NP	JJ	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	anti-angiogenic	anti-angiogenic	I-NP	JJ	O	4	NMOD
4	effects	effect	I-NP	NNS	O	0	ROOT
5	of	of	B-PP	IN	O	4	NMOD
6	temsirolimus	temsirolimus	B-NP	NN	O	5	PMOD
7	in	in	B-PP	IN	O	4	NMOD
8	refractory	refractory	B-NP	JJ	O	11	NMOD
9	mantle	mantle	I-NP	NN	O	11	NMOD
10	cell	cell	I-NP	NN	O	11	NMOD
11	lymphoma	lymphoma	I-NP	NN	O	7	PMOD
12	.	.	O	.	O	4	P

1	However	However	B-ADVP	RB	O	8	VMOD
2	,	,	O	,	O	8	P
3	a	a	B-NP	DT	O	7	NMOD
4	38	38	I-NP	CD	O	5	AMOD
5	%	%	I-NP	NN	O	7	NMOD
6	remission	remission	I-NP	NN	O	7	NMOD
7	rate	rate	I-NP	NN	O	8	SUB
8	has	have	B-VP	VBZ	O	0	ROOT
9	been	be	I-VP	VBN	O	8	VC
10	recently	recently	I-VP	RB	O	9	VMOD
11	reported	report	I-VP	VBN	O	9	VC
12	in	in	B-PP	IN	O	11	VMOD
13	refractory	refractory	B-NP	JJ	O	14	NMOD
14	MCL	MCL	I-NP	NN	O	21	NMOD
15	treated	treat	B-VP	VBN	O	14	NMOD
16	with	with	B-PP	IN	O	15	VMOD
17	temsirolimus	temsirolimus	B-NP	NN	O	16	PMOD
18	,	,	O	,	O	21	P
19	a	a	B-NP	DT	O	21	NMOD
20	mTOR	mTOR	I-NP	NN	O	21	NMOD
21	inhibitor	inhibitor	I-NP	NN	O	12	PMOD
22	.	.	O	.	O	8	P

1	Here	Here	B-ADVP	RB	O	3	VMOD
2	we	we	B-NP	PRP	O	3	SUB
3	had	have	B-VP	VBD	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	opportunity	opportunity	I-NP	NN	O	3	OBJ
6	to	to	B-VP	TO	O	7	VMOD
7	study	study	I-VP	VB	O	5	NMOD
8	a	a	B-NP	DT	O	9	NMOD
9	case	case	I-NP	NN	O	18	NMOD
10	of	of	B-PP	IN	O	9	NMOD
11	refractory	refractory	B-NP	JJ	O	12	NMOD
12	MCL	MCL	I-NP	NN	O	10	PMOD
13	who	who	B-NP	WP	O	12	NMOD
14	had	have	B-VP	VBD	O	13	SBAR
15	tumor	tumor	B-NP	NN	O	16	NMOD
16	regression	regression	I-NP	NN	O	14	OBJ
17	two	two	B-NP	CD	O	9	NMOD
18	months	month	I-NP	NNS	O	19	PMOD
19	after	after	B-SBAR	IN	O	7	VMOD
20	temsirolimus	temsirolimus	B-NP	NN	O	21	NMOD
21	treatment	treatment	I-NP	NN	O	26	NMOD
22	,	,	O	,	O	26	P
23	and	and	O	CC	O	26	NMOD
24	a	a	B-NP	DT	O	26	NMOD
25	progression-free	progression-free	I-NP	JJ	O	26	NMOD
26	survival	survival	I-NP	NN	O	19	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	10	10	B-NP	CD	O	29	NMOD
29	months	month	I-NP	NNS	O	27	PMOD
30	.	.	O	.	O	3	P

1	Comparison	Comparison	B-NP	NN	O	6	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	5	NMOD
4	two	two	I-NP	CD	O	5	NMOD
5	biopsies	biopsy	I-NP	NNS	O	2	PMOD
6	showed	show	B-VP	VBD	O	0	ROOT
7	that	that	B-SBAR	IN	O	6	VMOD
8	temsirolimus	temsirolimus	B-NP	NN	O	9	SUB
9	inhibited	inhibit	B-VP	VBD	O	7	SBAR
10	tumor	tumor	B-NP	NN	B-cell_type	12	NMOD
11	cell	cell	I-NP	NN	I-cell_type	12	NMOD
12	proliferation	proliferation	I-NP	NN	O	9	OBJ
13	through	through	B-PP	IN	O	12	NMOD
14	cell	cell	B-NP	NN	O	16	NMOD
15	cycle	cycle	I-NP	NN	O	16	NMOD
16	arrest	arrest	I-NP	NN	O	13	PMOD
17	,	,	O	,	O	9	P
18	but	but	O	CC	O	9	VMOD
19	did	do	B-VP	VBD	O	9	VMOD
20	not	not	I-VP	RB	O	19	VMOD
21	induce	induce	I-VP	VB	O	19	VC
22	any	any	B-NP	DT	O	23	NMOD
23	change	change	I-NP	NN	O	21	OBJ
24	in	in	B-PP	IN	O	21	VMOD
25	the	the	B-NP	DT	O	26	NMOD
26	number	number	I-NP	NN	O	24	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	apoptotic	apoptotic	B-NP	JJ	B-cell_type	30	NMOD
29	tumor	tumor	I-NP	NN	I-cell_type	30	NMOD
30	cells	cell	I-NP	NNS	I-cell_type	27	PMOD
31	.	.	O	.	O	6	P

1	Apart	Apart	B-ADVP	RB	O	8	VMOD
2	from	from	B-PP	IN	O	1	AMOD
3	this	this	B-NP	DT	O	5	NMOD
4	cytostatic	cytostatic	I-NP	JJ	O	5	NMOD
5	effect	effect	I-NP	NN	O	2	PMOD
6	,	,	O	,	O	8	P
7	temsirolimus	temsirolimus	B-NP	NN	O	8	SUB
8	had	have	B-VP	VBD	O	0	ROOT
9	an	an	B-NP	DT	O	11	NMOD
10	antiangiogenic	antiangiogenic	I-NP	JJ	O	11	NMOD
11	effect	effect	I-NP	NN	O	8	OBJ
12	with	with	B-PP	IN	O	8	VMOD
13	decrease	decrease	B-NP	NN	O	12	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	tumor	tumor	B-NP	NN	O	17	NMOD
16	microvessel	microvessel	I-NP	NN	O	17	NMOD
17	density	density	I-NP	NN	O	14	PMOD
18	and	and	B-PP	CC	O	14	PMOD
19	of	of	B-PP	IN	O	14	PMOD
20	VEGF	VEGF	B-NP	NN	B-protein	21	NMOD
21	expression	expression	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	8	P

1	Moreover	Moreover	B-ADVP	RB	O	16	VMOD
2	,	,	O	,	O	16	P
3	numerous	numerous	B-NP	JJ	O	4	NMOD
4	patchy	patchy	I-NP	NN	O	8	NMOD
5	,	,	O	,	O	8	P
6	well-limited	well-limited	B-NP	JJ	O	8	NMOD
7	fibrotic	fibrotic	I-NP	JJ	O	8	NMOD
8	areas	area	I-NP	NNS	O	16	SUB
9	,	,	O	,	O	8	P
10	compatible	compatible	B-ADJP	JJ	O	8	NMOD
11	with	with	B-PP	IN	O	10	AMOD
12	post-necrotic	post-necrotic	B-NP	JJ	O	14	NMOD
13	tissue	tissue	I-NP	NN	O	14	NMOD
14	repair	repair	I-NP	NN	O	11	PMOD
15	,	,	O	,	O	8	P
16	were	be	B-VP	VBD	O	0	ROOT
17	found	find	I-VP	VBN	O	16	VC
18	after	after	B-PP	IN	O	17	VMOD
19	6-month	6-month	B-NP	JJ	O	21	NMOD
20	temsirolimus	temsirolimus	I-NP	NN	O	21	NMOD
21	therapy	therapy	I-NP	NN	O	18	PMOD
22	.	.	O	.	O	16	P

1	Thus	Thus	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	temsirolimus	temsirolimus	B-NP	NN	O	4	SUB
4	reduced	reduce	B-VP	VBD	O	0	ROOT
5	tumor	tumor	B-NP	NN	O	6	NMOD
6	burden	burden	I-NP	NN	O	4	OBJ
7	through	through	B-PP	IN	O	4	VMOD
8	associated	associate	B-NP	VBN	O	12	NMOD
9	cytostatic	cytostatic	I-NP	JJ	O	11	AMOD
10	and	and	I-NP	CC	O	11	AMOD
11	anti-angiogenic	anti-angiogenic	I-NP	JJ	O	12	NMOD
12	effects	effect	I-NP	NNS	O	7	PMOD
13	.	.	O	.	O	4	P

1	Syncope	Syncope	B-NP	NN	O	0	ROOT
2	caused	cause	B-VP	VBN	O	1	NMOD
3	by	by	B-PP	IN	O	2	VMOD
4	hyperkalemia	hyperkalemia	B-NP	NN	O	3	PMOD
5	during	during	B-PP	IN	O	2	VMOD
6	use	use	B-NP	NN	O	5	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	a	a	B-NP	DT	O	10	NMOD
9	combined	combined	I-NP	JJ	O	10	NMOD
10	therapy	therapy	I-NP	NN	O	7	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	17	NMOD
13	angiotensin-converting	angiotensin-converting	I-NP	JJ	B-protein	15	NMOD
14	enzyme	enzyme	I-NP	NN	I-protein	15	NMOD
15	inhibitor	inhibitor	I-NP	NN	O	17	NMOD
16	and	and	I-NP	CC	O	17	NMOD
17	spironolactone	spironolactone	I-NP	NN	O	11	PMOD
18	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	cause	cause	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	hyperkalemia	hyperkalemia	B-NP	NN	O	3	PMOD
5	was	be	B-VP	VBD	O	0	ROOT
6	considered	consider	I-VP	VBN	O	5	VC
7	to	to	I-VP	TO	O	8	VMOD
8	be	be	I-VP	VB	O	6	VMOD
9	several	several	B-NP	JJ	O	10	NMOD
10	doses	dose	I-NP	NNS	O	8	PRD
11	of	of	B-PP	IN	O	10	NMOD
12	spiranolactone	spiranolactone	B-NP	NN	O	16	NMOD
13	,	,	O	,	O	16	P
14	an	an	B-NP	DT	O	16	NMOD
15	aldosterone	aldosterone	I-NP	NN	O	16	NMOD
16	antagonist	antagonist	I-NP	NN	O	11	PMOD
17	,	,	O	,	O	8	P
18	in	in	B-PP	IN	O	8	VMOD
19	addition	addition	B-NP	NN	O	18	PMOD
20	to	to	B-PP	TO	O	19	NMOD
21	the	the	B-NP	DT	O	23	NMOD
22	long-term	long-term	I-NP	JJ	O	23	NMOD
23	intake	intake	I-NP	NN	O	20	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	ramipril	ramipril	B-NP	NN	O	29	NMOD
26	,	,	O	,	O	29	P
27	an	an	B-NP	DT	O	29	NMOD
28	ACE	ACE	I-NP	NN	O	29	NMOD
29	inhibitor	inhibitor	I-NP	NN	O	24	PMOD
30	.	.	O	.	O	5	P

1	Diffuse	Diffuse	B-NP	NN	O	3	NMOD
2	skeletal	skeletal	I-NP	JJ	O	3	NMOD
3	pain	pain	I-NP	NN	O	0	ROOT
4	after	after	B-PP	IN	O	3	NMOD
5	administration	administration	B-NP	NN	O	4	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	alendronate	alendronate	B-NP	NN	O	6	PMOD
8	.	.	O	.	O	3	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Osteoporosis	Osteoporosis	B-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	18	VMOD
5	caused	cause	I-VP	VBN	O	4	VC
6	by	by	B-PP	IN	O	5	VMOD
7	bone	bone	B-NP	NN	O	8	NMOD
8	resorption	resorption	I-NP	NN	O	6	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	excess	excess	B-NP	NN	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	bone	bone	B-NP	NN	O	13	NMOD
13	formation	formation	I-NP	NN	O	11	PMOD
14	,	,	O	,	O	18	P
15	and	and	O	CC	O	16	NMOD
16	bisphosphonates	bisphosphonate	B-NP	NNS	O	18	SUB
17	,	,	O	,	O	16	P
18	are	be	B-VP	VBP	O	1	NMOD
19	used	use	I-VP	VBN	O	18	VC
20	to	to	B-VP	TO	O	21	VMOD
21	inhibit	inhibit	I-VP	VB	O	19	VMOD
22	bone	bone	B-NP	NN	O	23	NMOD
23	resorption	resorption	I-NP	NN	O	21	OBJ
24	.	.	O	.	O	18	P

1	Alendronate	Alendronate	B-NP	NN	O	4	NMOD
2	,	,	O	,	O	4	P
3	a	a	B-NP	DT	O	4	NMOD
4	biphosphonate	biphosphonate	I-NP	NN	O	6	SUB
5	,	,	O	,	O	4	P
6	is	be	B-VP	VBZ	O	0	ROOT
7	effective	effective	B-ADJP	JJ	O	6	PRD
8	for	for	B-PP	IN	O	7	AMOD
9	both	both	O	CC	O	13	NMOD
10	the	the	B-NP	DT	O	13	NMOD
11	treatment	treatment	I-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	prevention	prevention	I-NP	NN	O	8	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	osteoporosis	osteoporosis	B-NP	NN	O	14	PMOD
16	in	in	B-PP	IN	O	13	NMOD
17	postmenopausal	postmenopausal	B-NP	JJ	O	18	NMOD
18	women	woman	I-NP	NNS	O	16	PMOD
19	.	.	O	.	O	6	P

1	We	We	B-NP	PRP	O	2	SUB
2	presented	present	B-VP	VBD	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	patient	patient	I-NP	NN	O	2	OBJ
5	admitted	admit	B-VP	VBN	O	4	NMOD
6	to	to	B-PP	TO	O	5	VMOD
7	our	our	B-NP	PRP$	O	9	NMOD
8	out-patient	out-patient	I-NP	JJ	O	9	NMOD
9	clinic	clinic	I-NP	NN	O	6	PMOD
10	with	with	B-PP	IN	O	5	VMOD
11	diffuse	diffuse	B-NP	JJ	O	12	AMOD
12	skeletal	skeletal	I-NP	JJ	O	13	NMOD
13	pain	pain	I-NP	NN	O	10	PMOD
14	after	after	B-PP	IN	O	13	NMOD
15	three	three	B-NP	CD	O	17	NMOD
16	consecutive	consecutive	I-NP	JJ	O	17	NMOD
17	administration	administration	I-NP	NN	O	14	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	alendronate	alendronate	B-NP	NN	O	18	PMOD
20	.	.	O	.	O	2	P

1	Cerebrospinal	Cerebrospinal	B-NP	JJ	O	3	NMOD
2	fluid	fluid	I-NP	NN	O	3	NMOD
3	penetration	penetration	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	high-dose	high-dose	B-NP	JJ	O	6	NMOD
6	daptomycin	daptomycin	I-NP	NN	O	4	PMOD
7	in	in	B-PP	IN	O	3	NMOD
8	suspected	suspect	B-NP	VBN	O	11	NMOD
9	Staphylococcus	Staphylococcus	I-NP	FW	O	11	NMOD
10	aureus	aureus	I-NP	FW	O	11	NMOD
11	meningitis	meningitis	I-NP	NN	O	7	PMOD
12	.	.	O	.	O	3	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	report	report	I-VP	VB	O	1	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	methicillin-sensitive	methicillin-sensitive	B-NP	JJ	O	10	NMOD
9	Staphylococcus	Staphylococcus	I-NP	FW	O	10	NMOD
10	aureus	aureus	I-NP	FW	O	14	NMOD
11	(	(	O	(	O	13	DEP
12	MSSA	MSSA	B-NP	NN	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	bacteremia	bacteremia	B-NP	NN	O	7	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	suspected	suspect	B-NP	VBN	O	18	NMOD
17	MSSA	MSSA	I-NP	NN	O	18	NMOD
18	meningitis	meningitis	I-NP	NN	O	15	PMOD
19	treated	treat	B-VP	VBN	O	18	NMOD
20	with	with	B-PP	IN	O	19	VMOD
21	high-dose	high-dose	B-NP	JJ	O	22	NMOD
22	daptomycin	daptomycin	I-NP	NN	O	20	PMOD
23	assessed	assess	B-VP	VBN	O	22	NMOD
24	with	with	B-PP	IN	O	23	VMOD
25	concurrent	concurrent	B-NP	JJ	O	26	NMOD
26	serum	serum	I-NP	NN	O	29	NMOD
27	and	and	O	CC	O	29	NMOD
28	cerebrospinal	cerebrospinal	B-NP	JJ	O	29	NMOD
29	fluid	fluid	I-NP	NN	O	33	NMOD
30	(	(	O	(	O	32	DEP
31	CSF	CSF	B-NP	NN	B-protein	32	DEP
32	)	)	O	)	O	29	NMOD
33	concentrations	concentration	B-NP	NNS	O	24	PMOD
34	.	.	O	.	O	1	P

1	On	On	B-PP	IN	O	7	VMOD
2	day	day	B-NP	NN	O	1	PMOD
3	8	8	I-NP	CD	O	2	NMOD
4	,	,	O	,	O	7	P
5	the	the	B-NP	DT	O	6	NMOD
6	patient	patient	I-NP	NN	O	7	SUB
7	developed	develop	B-VP	VBD	O	0	ROOT
8	acute	acute	B-NP	JJ	O	10	NMOD
9	renal	renal	I-NP	JJ	O	10	NMOD
10	failure	failure	I-NP	NN	O	7	OBJ
11	(	(	O	(	O	10	NMOD
12	serum	serum	B-NP	NN	O	15	NMOD
13	creatinine	creatinine	I-NP	NN	O	15	NMOD
14	1.9	1.9	B-NP	CD	O	15	NMOD
15	mg/dL	mg/dL	I-NP	NN	O	17	SUB
16	,	,	O	,	O	15	P
17	increased	increase	B-VP	VBD	O	11	SBAR
18	from	from	B-PP	IN	O	17	VMOD
19	1.2	1.2	B-NP	CD	O	20	NMOD
20	mg/dL	mg/dL	I-NP	NN	O	18	PMOD
21	the	the	B-NP	DT	O	23	NMOD
22	previous	previous	I-NP	JJ	O	23	NMOD
23	day	day	I-NP	NN	O	26	NMOD
24	and	and	O	CC	O	26	NMOD
25	0.8	0.8	B-NP	CD	O	26	NMOD
26	mg/dL	mg/dL	I-NP	NN	O	17	VMOD
27	on	on	B-PP	IN	O	26	NMOD
28	admission	admission	B-NP	NN	O	27	PMOD
29	)	)	O	)	O	26	NMOD
30	.	.	O	.	O	7	P

1	Nafcillin	Nafcillin	B-NP	NN	B-protein	2	SUB
2	was	be	B-VP	VBD	O	9	VMOD
3	discontinued	discontinue	I-VP	VBN	O	2	VC
4	and	and	O	CC	O	9	VMOD
5	daptomycin	daptomycin	B-NP	NN	O	9	SUB
6	9	9	I-NP	CD	O	5	NMOD
7	mg/kg	mg/kg	I-NP	NN	O	6	NMOD
8	daily	daily	I-NP	JJ	O	7	AMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	initiated	initiate	I-VP	VBN	O	9	VC
11	for	for	B-PP	IN	O	10	VMOD
12	suspected	suspect	B-NP	VBN	O	13	NMOD
13	meningitis	meningitis	I-NP	NN	O	11	PMOD
14	and	and	O	CC	O	9	VMOD
15	was	be	B-VP	VBD	O	9	VMOD
16	continued	continue	I-VP	VBN	O	15	VC
17	until	until	B-SBAR	IN	O	16	VMOD
18	the	the	B-NP	DT	O	21	NMOD
19	patient	patient	I-NP	NN	O	21	NMOD
20	's	's	B-NP	POS	O	21	NMOD
21	death	death	I-NP	NN	O	17	PMOD
22	on	on	B-PP	IN	O	21	NMOD
23	day	day	B-NP	NN	O	22	PMOD
24	16	16	I-NP	CD	O	23	NMOD
25	.	.	O	.	O	9	P

1	DISCUSSION	DISCUSSION	B-NP	NN	O	3	NMOD
2	:	:	O	:	O	1	P
3	Daptomycin	Daptomycin	B-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	initiated	initiate	I-VP	VBN	O	4	VC
6	in	in	B-PP	IN	O	5	VMOD
7	our	our	B-NP	PRP$	O	8	NMOD
8	patient	patient	I-NP	NN	O	6	PMOD
9	secondary	secondary	B-ADJP	JJ	O	8	NMOD
10	to	to	B-PP	TO	O	9	AMOD
11	possible	possible	B-NP	JJ	B-protein	12	NMOD
12	nafcillin	nafcillin	I-NP	NN	I-protein	10	PMOD
13	induced	induce	B-VP	VBD	O	4	VMOD
14	acute	acute	B-NP	JJ	O	16	NMOD
15	interstitial	interstitial	I-NP	JJ	O	16	NMOD
16	nephritis	nephritis	I-NP	NN	O	13	OBJ
17	and	and	O	CC	O	4	VMOD
18	relapsing	relapse	B-VP	VBG	O	4	VMOD
19	bacteremia	bacteremia	B-NP	NN	O	18	OBJ
20	.	.	O	.	O	4	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	High-dose	High-dose	B-NP	JJ	O	4	NMOD
4	daptomycin	daptomycin	I-NP	NN	O	5	SUB
5	may	may	B-VP	MD	O	1	NMOD
6	be	be	I-VP	VB	O	5	VC
7	an	an	B-NP	DT	O	9	NMOD
8	alternative	alternative	I-NP	JJ	O	9	NMOD
9	option	option	I-NP	NN	O	6	PRD
10	for	for	B-PP	IN	O	9	NMOD
11	MSSA	MSSA	B-NP	NN	O	12	NMOD
12	bacteremia	bacteremia	I-NP	NN	O	10	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	or	or	B-PP	CC	O	13	PMOD
15	without	without	B-PP	IN	O	13	PMOD
16	a	a	B-NP	DT	O	18	NMOD
17	CNS	CNS	I-NP	NN	B-protein	18	NMOD
18	source	source	I-NP	NN	O	13	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	patients	patient	B-NP	NNS	O	19	PMOD
21	who	who	B-NP	WP	O	20	NMOD
22	have	have	B-VP	VBP	O	21	SBAR
23	failed	fail	I-VP	VBN	O	22	VC
24	or	or	O	CC	O	23	VMOD
25	can	can	B-VP	MD	O	19	SBAR
26	not	not	I-VP	RB	O	25	VMOD
27	tolerate	tolerate	I-VP	VB	O	25	VC
28	standard	standard	B-NP	JJ	O	29	NMOD
29	therapy	therapy	I-NP	NN	O	27	OBJ
30	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	role	role	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	nitric	nitric	B-NP	JJ	O	5	NMOD
5	oxide	oxide	I-NP	NN	O	3	PMOD
6	in	in	B-PP	IN	O	2	NMOD
7	convulsions	convulsion	B-NP	NNS	O	6	PMOD
8	induced	induce	B-VP	VBN	O	7	NMOD
9	by	by	B-PP	IN	O	8	VMOD
10	lindane	lindane	B-NP	NN	O	9	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	rats	rat	B-NP	NNS	O	11	PMOD
13	.	.	O	.	O	2	P

1	It	It	B-NP	PRP	O	2	SUB
2	evokes	evoke	B-VP	VBZ	O	0	ROOT
3	convulsions	convulsion	B-NP	NNS	O	2	OBJ
4	mainly	mainly	B-ADVP	RB	O	5	PMOD
5	trough	trough	B-PP	IN	O	3	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	blockage	blockage	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	GABA	GABA	B-NP	NN	B-protein	13	NMOD
10	(	(	O	(	I-protein	13	NMOD
11	A	A	B-NP	NN	I-protein	13	NMOD
12	)	)	O	)	I-protein	13	NMOD
13	receptors	receptor	B-NP	NNS	I-protein	8	PMOD
14	.	.	O	.	O	2	P

1	Nitric	Nitric	B-NP	JJ	O	2	NMOD
2	oxide	oxide	I-NP	NN	O	8	NMOD
3	(	(	O	(	O	5	DEP
4	NO	NO	B-NP	NN	O	5	DEP
5	)	)	O	)	O	2	NMOD
6	,	,	O	,	O	8	P
7	gaseous	gaseous	B-NP	JJ	O	8	NMOD
8	neurotransmitter	neurotransmitter	I-NP	NN	O	10	SUB
9	,	,	O	,	O	8	P
10	has	have	B-VP	VBZ	O	0	ROOT
11	contradictor	contradictor	B-NP	NN	O	12	NMOD
12	role	role	I-NP	NN	O	10	OBJ
13	in	in	B-PP	IN	O	10	VMOD
14	epileptogenesis	epileptogenesis	B-NP	NN	O	13	PMOD
15	due	due	B-PP	JJ	O	14	NMOD
16	to	to	B-PP	TO	O	15	AMOD
17	opposite	opposite	B-NP	JJ	O	18	NMOD
18	effects	effect	I-NP	NNS	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	L-arginine	L-arginine	B-NP	NN	O	22	NMOD
21	,	,	O	,	O	22	P
22	precursor	precursor	B-NP	NN	O	19	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	NO	NO	B-NP	NN	O	25	NMOD
25	syntheses	synthesis	I-NP	NNS	O	23	PMOD
26	(	(	O	(	O	28	DEP
27	NOS	NOS	B-NP	NN	B-protein	28	DEP
28	)	)	O	)	O	25	NMOD
29	,	,	O	,	O	10	VMOD
30	and	and	O	CC	O	31	NMOD
31	L-NAME	L-NAME	B-NP	NN	B-protein	29	SUB
32	(	(	O	(	O	35	DEP
33	NOS	NOS	B-NP	NN	O	34	NMOD
34	inhibitor	inhibitor	I-NP	NN	O	35	DEP
35	)	)	O	)	O	31	NMOD
36	observed	observe	B-VP	VBN	O	31	NMOD
37	in	in	B-PP	IN	O	36	VMOD
38	different	different	B-NP	JJ	O	40	NMOD
39	epilepsy	epilepsy	I-NP	NN	O	40	NMOD
40	models	model	I-NP	NNS	O	37	PMOD
41	.	.	O	.	O	10	P

1	The	The	B-NP	DT	O	2	NMOD
2	aim	aim	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	current	current	I-NP	JJ	O	6	NMOD
6	study	study	I-NP	NN	O	3	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	to	to	B-VP	TO	O	9	VMOD
9	determine	determine	I-VP	VB	O	7	PRD
10	the	the	B-NP	DT	O	11	NMOD
11	effects	effect	I-NP	NNS	O	22	SUB
12	of	of	B-PP	IN	O	11	NMOD
13	NO	NO	B-NP	NN	O	12	PMOD
14	on	on	B-PP	IN	O	11	NMOD
15	the	the	B-NP	DT	O	19	NMOD
16	behavioral	behavioral	I-NP	NN	O	19	NMOD
17	and	and	I-NP	CC	O	19	NMOD
18	EEG	EEG	I-NP	NN	O	19	NMOD
19	characteristics	characteristic	I-NP	NNS	O	14	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	lindane	lindane	B-NP	NN	O	20	PMOD
22	induced	induce	B-VP	VBD	O	9	VMOD
23	epilepsy	epilepsy	B-NP	NN	O	22	OBJ
24	in	in	B-PP	IN	O	23	NMOD
25	male	male	B-NP	JJ	O	28	NMOD
26	Wistar	Wistar	I-NP	NNP	O	28	NMOD
27	albino	albino	I-NP	NNP	O	28	NMOD
28	rats	rat	I-NP	NNS	O	24	PMOD
29	.	.	O	.	O	7	P

1	The	The	B-NP	DT	O	2	NMOD
2	administration	administration	I-NP	NN	O	19	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	L-arginine	L-arginine	B-NP	NN	O	3	PMOD
5	(	(	O	(	O	14	DEP
6	600	600	B-NP	CD	O	11	NMOD
7	,	,	I-NP	,	O	11	P
8	800	800	I-NP	CD	O	11	NMOD
9	and	and	I-NP	CC	O	11	NMOD
10	1000	1000	I-NP	CD	O	11	NMOD
11	mg/kg	mg/kg	I-NP	NN	O	14	DEP
12	,	,	O	,	O	11	P
13	i.p.	i.p.	B-ADVP	RB	O	11	NMOD
14	)	)	O	)	O	2	NMOD
15	in	in	B-PP	IN	O	2	NMOD
16	dose-dependent	dose-dependent	B-NP	JJ	O	17	NMOD
17	manner	manner	I-NP	NN	O	15	PMOD
18	significantly	significantly	B-ADVP	RB	O	19	VMOD
19	increased	increase	B-VP	VBD	O	0	ROOT
20	convulsion	convulsion	B-NP	NN	O	21	NMOD
21	incidence	incidence	I-NP	NN	O	23	NMOD
22	and	and	I-NP	CC	O	23	NMOD
23	severity	severity	I-NP	NN	O	19	OBJ
24	and	and	O	CC	O	19	VMOD
25	shortened	shorten	B-VP	VBD	O	19	VMOD
26	latency	latency	B-NP	NN	O	27	NMOD
27	time	time	I-NP	NN	O	25	OBJ
28	to	to	B-PP	TO	O	27	NMOD
29	first	first	B-NP	JJ	O	30	NMOD
30	convulsion	convulsion	I-NP	NN	O	28	PMOD
31	elicited	elicit	B-VP	VBN	O	30	NMOD
32	by	by	B-PP	IN	O	31	VMOD
33	lower	low	B-NP	JJR	O	35	NMOD
34	lindane	lindane	I-NP	NN	O	35	NMOD
35	dose	dose	I-NP	NN	O	32	PMOD
36	(	(	O	(	O	41	DEP
37	4	4	B-NP	CD	O	38	NMOD
38	mg/kg	mg/kg	I-NP	NN	O	41	DEP
39	,	,	O	,	O	38	P
40	i.p.	i.p.	B-ADVP	RB	O	38	NMOD
41	)	)	O	)	O	35	NMOD
42	.	.	O	.	O	19	P

1	On	On	B-PP	IN	O	18	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	contrary	contrary	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	18	P
5	pretreatment	pretreatment	B-NP	NN	O	18	SUB
6	with	with	B-PP	IN	O	5	NMOD
7	L-NAME	L-NAME	B-NP	NN	B-protein	6	PMOD
8	(	(	O	(	O	17	DEP
9	500	500	B-NP	CD	O	14	NMOD
10	,	,	I-NP	,	O	14	P
11	700	700	I-NP	CD	O	14	NMOD
12	and	and	I-NP	CC	O	14	NMOD
13	900	900	I-NP	CD	O	14	NMOD
14	mg/kg	mg/kg	I-NP	NN	O	17	DEP
15	,	,	O	,	O	14	P
16	i.p.	i.p.	B-ADVP	RB	O	14	NMOD
17	)	)	O	)	O	7	NMOD
18	decreased	decrease	B-VP	VBD	O	0	ROOT
19	convulsion	convulsion	B-NP	NN	O	20	NMOD
20	incidence	incidence	I-NP	NN	O	22	NMOD
21	and	and	I-NP	CC	O	22	NMOD
22	severity	severity	I-NP	NN	O	18	OBJ
23	and	and	O	CC	O	18	VMOD
24	prolonged	prolong	B-VP	VBD	O	18	VMOD
25	latency	latency	B-NP	NN	O	26	NMOD
26	time	time	I-NP	NN	O	24	OBJ
27	to	to	B-PP	TO	O	24	VMOD
28	convulsion	convulsion	B-NP	NN	O	27	PMOD
29	following	follow	B-PP	VBG	O	24	VMOD
30	injection	injection	B-NP	NN	O	29	PMOD
31	with	with	B-PP	IN	O	30	NMOD
32	a	a	B-NP	DT	O	34	NMOD
33	convulsive	convulsive	I-NP	JJ	O	34	NMOD
34	dose	dose	I-NP	NN	O	31	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	lindane	lindane	B-NP	NN	O	35	PMOD
37	(	(	O	(	O	42	DEP
38	8	8	B-NP	CD	O	39	NMOD
39	mg/kg	mg/kg	I-NP	NN	O	42	DEP
40	,	,	O	,	O	39	P
41	i.p.	i.p.	B-ADVP	RB	O	39	NMOD
42	)	)	O	)	O	34	NMOD
43	.	.	O	.	O	18	P

1	Long-term	Long-term	B-NP	JJ	O	4	NMOD
2	oral	oral	I-NP	JJ	O	4	NMOD
3	galactose	galactose	I-NP	NN	O	4	NMOD
4	treatment	treatment	I-NP	NN	O	5	SUB
5	prevents	prevent	B-VP	VBZ	O	0	ROOT
6	cognitive	cognitive	B-NP	JJ	O	7	NMOD
7	deficits	deficit	I-NP	NNS	O	5	OBJ
8	in	in	B-PP	IN	O	5	VMOD
9	male	male	B-NP	JJ	O	11	NMOD
10	Wistar	Wistar	I-NP	NNP	O	11	NMOD
11	rats	rat	I-NP	NNS	O	8	PMOD
12	treated	treat	B-VP	VBN	O	11	NMOD
13	intracerebroventricularly	intracerebroventricularly	B-ADVP	RB	O	12	VMOD
14	with	with	B-PP	IN	O	12	VMOD
15	streptozotocin	streptozotocin	B-NP	NN	O	14	PMOD
16	.	.	O	.	O	5	P

1	Basic	Basic	B-NP	JJ	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	clinical	clinical	I-NP	JJ	O	4	NMOD
4	research	research	I-NP	NN	O	5	SUB
5	has	have	B-VP	VBZ	O	0	ROOT
6	demonstrated	demonstrate	I-VP	VBN	O	5	VC
7	that	that	B-SBAR	IN	O	6	VMOD
8	dementia	dementia	B-NP	NN	O	18	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	sporadic	sporadic	B-NP	JJ	O	13	NMOD
11	Alzheimer	Alzheimer	I-NP	NNP	O	13	NMOD
12	's	's	B-NP	POS	O	13	NMOD
13	disease	disease	I-NP	NN	O	17	NMOD
14	(	(	O	(	O	16	DEP
15	sAD	sAD	B-NP	NN	O	16	DEP
16	)	)	O	)	O	13	NMOD
17	type	type	B-NP	NN	O	9	PMOD
18	is	be	B-VP	VBZ	O	7	SBAR
19	associated	associate	I-VP	VBN	O	18	VC
20	with	with	B-PP	IN	O	19	VMOD
21	dysfunction	dysfunction	B-NP	NN	O	20	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	28	NMOD
24	insulin-receptor	insulin-receptor	I-NP	NN	B-protein	28	NMOD
25	(	(	O	(	O	27	DEP
26	IR	IR	B-NP	NN	O	27	DEP
27	)	)	O	)	O	24	NMOD
28	system	system	B-NP	NN	O	22	PMOD
29	followed	follow	B-VP	VBN	O	21	NMOD
30	by	by	B-PP	IN	O	29	VMOD
31	decreased	decrease	B-NP	VBN	O	33	NMOD
32	glucose	glucose	I-NP	NN	O	33	NMOD
33	transport	transport	I-NP	NN	O	30	PMOD
34	via	via	B-PP	IN	O	21	NMOD
35	glucose	glucose	B-NP	NN	B-protein	37	NMOD
36	transporter	transporter	I-NP	NN	I-protein	37	NMOD
37	GLUT4	GLUT4	I-NP	NN	I-protein	34	PMOD
38	and	and	O	CC	O	18	VMOD
39	decreased	decrease	B-VP	VBD	O	18	VMOD
40	glucose	glucose	B-NP	NN	O	41	NMOD
41	metabolism	metabolism	I-NP	NN	O	39	OBJ
42	in	in	B-PP	IN	O	41	NMOD
43	brain	brain	B-NP	NN	B-cell_type	44	NMOD
44	cells	cell	I-NP	NNS	I-cell_type	42	PMOD
45	.	.	O	.	O	5	P

1	Exclusively	Exclusively	B-NP	RB	O	2	AMOD
2	parenteral	parenteral	I-NP	JJ	O	4	NMOD
3	daily	daily	I-NP	JJ	O	4	NMOD
4	injections	injection	I-NP	NNS	O	7	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	galactose	galactose	B-NP	NN	O	5	PMOD
7	induce	induce	B-VP	VBP	O	31	VMOD
8	memory	memory	B-NP	NN	O	9	NMOD
9	deterioration	deterioration	I-NP	NN	O	7	OBJ
10	in	in	B-PP	IN	O	9	NMOD
11	rodents	rodent	B-NP	NNS	O	10	PMOD
12	and	and	O	CC	O	7	VMOD
13	are	be	B-VP	VBP	O	7	VMOD
14	used	use	I-VP	VBN	O	13	VC
15	to	to	B-VP	TO	O	16	VMOD
16	generate	generate	I-VP	VB	O	14	VMOD
17	animal	animal	B-NP	NN	O	19	NMOD
18	aging	aging	I-NP	NN	O	19	NMOD
19	model	model	I-NP	NN	O	16	OBJ
20	,	,	O	,	O	31	P
21	but	but	O	CC	O	31	VMOD
22	the	the	B-NP	DT	O	23	NMOD
23	effects	effect	I-NP	NNS	O	31	SUB
24	of	of	B-PP	IN	O	23	NMOD
25	oral	oral	B-NP	JJ	O	27	NMOD
26	galactose	galactose	I-NP	NN	O	27	NMOD
27	treatment	treatment	I-NP	NN	O	24	PMOD
28	on	on	B-PP	IN	O	23	NMOD
29	cognitive	cognitive	B-NP	JJ	O	30	NMOD
30	functions	function	I-NP	NNS	O	28	PMOD
31	have	have	B-VP	VBP	O	0	ROOT
32	never	never	I-VP	RB	O	31	VMOD
33	been	be	I-VP	VBN	O	31	VC
34	tested	test	I-VP	VBN	O	33	VC
35	.	.	O	.	O	31	P

1	We	We	B-NP	PRP	O	2	SUB
2	have	have	B-VP	VBP	O	0	ROOT
3	investigated	investigate	I-VP	VBN	O	2	VC
4	the	the	B-NP	DT	O	5	NMOD
5	effects	effect	I-NP	NNS	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	continuous	continuous	B-NP	JJ	O	10	NMOD
8	daily	daily	I-NP	JJ	O	10	NMOD
9	oral	oral	I-NP	JJ	O	10	NMOD
10	galactose	galactose	I-NP	NN	O	15	NMOD
11	(	(	O	(	O	14	DEP
12	200	200	B-NP	CD	O	13	NMOD
13	mg/kg/day	mg/kg/day	I-NP	NN	O	14	DEP
14	)	)	O	)	O	10	NMOD
15	treatment	treatment	B-NP	NN	O	6	PMOD
16	on	on	B-PP	IN	O	5	NMOD
17	cognitive	cognitive	B-NP	JJ	O	18	NMOD
18	deficits	deficit	I-NP	NNS	O	16	PMOD
19	in	in	B-PP	IN	O	5	NMOD
20	streptozotocin	streptozotocin	B-NP	NN	O	26	NMOD
21	induced	induce	B-VP	VBN	O	20	AMOD
22	(	(	O	(	O	24	DEP
23	STZ-icv	STZ-icv	O	JJ	O	24	DEP
24	)	)	O	)	O	20	NMOD
25	rat	rat	B-NP	NN	O	26	NMOD
26	model	model	I-NP	NN	O	19	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	sAD	sAD	B-NP	NN	O	27	PMOD
29	,	,	O	,	O	5	P
30	tested	test	B-VP	VBN	O	5	NMOD
31	by	by	B-PP	IN	O	30	VMOD
32	Morris	Morris	B-NP	NNP	O	34	NMOD
33	Water	Water	I-NP	NNP	O	34	NMOD
34	Maze	Maze	I-NP	NNP	O	38	NMOD
35	and	and	O	CC	O	38	NMOD
36	Passive	Passive	B-NP	NNP	O	38	NMOD
37	Avoidance	Avoidance	I-NP	NNP	O	38	NMOD
38	test	test	I-NP	NN	O	31	PMOD
39	,	,	O	,	O	5	P
40	respectively	respectively	B-ADVP	RB	O	5	NMOD
41	.	.	O	.	O	2	P

1	One	One	B-NP	CD	O	2	NMOD
2	month	month	I-NP	NN	O	15	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	oral	oral	B-NP	JJ	O	6	NMOD
5	galactose	galactose	I-NP	NN	O	6	NMOD
6	treatment	treatment	I-NP	NN	O	3	PMOD
7	initiated	initiate	B-VP	VBN	O	6	NMOD
8	immediately	immediately	B-ADVP	RB	O	7	VMOD
9	after	after	B-PP	IN	O	7	VMOD
10	the	the	B-NP	DT	O	12	NMOD
11	STZ-icv	STZ-icv	I-NP	JJ	O	12	NMOD
12	administration	administration	I-NP	NN	O	9	PMOD
13	,	,	O	,	O	2	P
14	successfully	successfully	B-VP	RB	O	15	VMOD
15	prevented	prevent	I-VP	VBD	O	0	ROOT
16	development	development	B-NP	NN	O	20	SUB
17	of	of	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	19	NMOD
19	STZ-icv	STZ-icv	I-NP	NN	O	17	PMOD
20	induced	induce	B-VP	VBD	O	15	VMOD
21	cognitive	cognitive	B-NP	JJ	O	22	NMOD
22	deficits	deficit	I-NP	NNS	O	20	OBJ
23	.	.	O	.	O	15	P
